NCBI_Build	Hugo_Symbol	Tumor_Sample_Barcode	HGVSp_Short	HGVSp	Chromosome	Start_Position	End_Position	Reference_Allele	Tumor_Seq_Allele1	Tumor_Seq_Allele2	POS	ID	REF	ALT	QUAL	FILTER	NM_Transcript	Allele	Consequence	IMPACT	SYMBOL	Gene	Feature_type	Feature	BIOTYPE	EXON	INTRON	HGVSc	cDNA_position	CDS_position	Protein_position	Amino_acids	Codons	Existing_variation	DISTANCE	STRAND	FLAGS	VARIANT_CLASS	SYMBOL_SOURCE	HGNC_ID	CANONICAL	MANE	MANE_SELECT	MANE_PLUS_CLINICAL	TSL	APPRIS	CCDS	ENSP	SWISSPROT	TREMBL	UNIPARC	UNIPROT_ISOFORM	SOURCE	GENE_PHENO	SIFT	PolyPhen	DOMAINS	miRNA	HGVS_OFFSET	AF	AFR_AF	AMR_AF	EAS_AF	EUR_AF	SAS_AF	gnomADe_AF	gnomADe_AFR_AF	gnomADe_AMR_AF	gnomADe_ASJ_AF	gnomADe_EAS_AF	gnomADe_FIN_AF	gnomADe_MID_AF	gnomADe_NFE_AF	gnomADe_REMAINING_AF	gnomADe_SAS_AF	gnomADg_AF	gnomADg_AFR_AF	gnomADg_AMI_AF	gnomADg_AMR_AF	gnomADg_ASJ_AF	gnomADg_EAS_AF	gnomADg_FIN_AF	gnomADg_MID_AF	gnomADg_NFE_AF	gnomADg_REMAINING_AF	gnomADg_SAS_AF	MAX_AF	MAX_AF_POPS	CLIN_SIG	SOMATIC	PHENO	PUBMED	MOTIF_NAME	MOTIF_POS	HIGH_INF_POS	MOTIF_SCORE_CHANGE	TRANSCRIPTION_FACTORS	SpliceAI_cutoff	SpliceAI_pred_DP_AG	SpliceAI_pred_DP_AL	SpliceAI_pred_DP_DG	SpliceAI_pred_DP_DL	SpliceAI_pred_DS_AG	SpliceAI_pred_DS_AL	SpliceAI_pred_DS_DG	SpliceAI_pred_DS_DL	SpliceAI_pred_SYMBOL	REVEL	LOEUF	ClinVar	ClinVar_AF_ESP	ClinVar_AF_EXAC	ClinVar_AF_TGP	ClinVar_ALLELEID	ClinVar_CLNDN	ClinVar_CLNDNINCL	ClinVar_CLNDISDB	ClinVar_CLNDISDBINCL	ClinVar_CLNHGVS	ClinVar_CLNREVSTAT	ClinVar_CLNSIG	ClinVar_CLNSIGCONF	ClinVar_CLNSIGINCL	ClinVar_CLNSIGSCV	ClinVar_CLNVC	ClinVar_CLNVCSO	ClinVar_CLNVI	ClinVar_DBVARID	ClinVar_GENEINFO	ClinVar_MC	ClinVar_ONCDN	ClinVar_ONCDNINCL	ClinVar_ONCDISDB	ClinVar_ONCDISDBINCL	ClinVar_ONC	ClinVar_ONCINCL	ClinVar_ONCREVSTAT	ClinVar_ONCSCV	ClinVar_ONCCONF	ClinVar_ORIGIN	ClinVar_RS	ClinVar_SCIDN	ClinVar_SCIDNINCL	ClinVar_SCIDISDB	ClinVar_SCIDISDBINCL	ClinVar_SCIREVSTAT	ClinVar_SCI	ClinVar_SCIINCL	ClinVar_SCISCV	CIViC	CIViC_GN	CIViC_VT	CIViC_CSQ	CancerHotspots	CancerHotspots_HOTSPOT	CancerHotspots_HOTSPOT_GENE	CancerHotspots_HOTSPOT_HGVSp	CancerHotspots_HOTSPOT3D	CancerHotspots_HOTSPOT3D_GENE	CancerHotspots_HOTSPOT3D_HGVSp	CancerHotspots_HOTSPOTNC	CancerHotspots_HOTSPOTNC_GENE	CancerHotspots_HOTSPOTNC_HGVSc	BND_DEPTH	CIEND	CIGAR	CIPOS	DP	DUPHOMLEN	DUPHOMSEQ	DUPSVLEN	END	FractionInformativeReads	HOMLEN	HOMSEQ	IMPRECISE	LEFT_SVINSSEQ	MATEID	MATE_BND_DEPTH	MQ	ONCOKB_DATA_VERSION	ONCOKB_EFFECT	ONCOKB_EFFECT_DESC	ONCOKB_GENE_EXIST	ONCOKB_GENE_SUMMARY	ONCOKB_HOTSPOT	ONCOKB_LAST_UPDATE	ONCOKB_ONCOGENIC	ONCOKB_QUERY_TYPE	ONCOKB_TUMOR_TYPE_SUMMARY	ONCOKB_VARIANT_EXIST	ONCOKB_VARIANT_SUMMARY	OriginalContig	OriginalStart	RIGHT_SVINSSEQ	ReverseComplementedAlleles	SVLEN	SVTYPE	hotspot	ONCOKB_geneExist	ONCOKB_variantExist	ONCOKB_alleleExist	ONCOKB_oncogenic	ONCOKB_highestSensitiveLevel	ONCOKB_highestResistanceLevel	ONCOKB_highestDiagnosticImplicationLevel	ONCOKB_highestPrognosticImplicationLevel	ONCOKB_highestFdaLevel	ONCOKB_otherSignificantSensitiveLevels	ONCOKB_otherSignificantResistanceLevels	ONCOKB_VUS	ONCOKB_hotspot	ONCOKB_exon	ONCOKB_geneSummary	ONCOKB_variantSummary	ONCOKB_tumorTypeSummary	ONCOKB_prognosticSummary	ONCOKB_diagnosticSummary	ONCOKB_diagnosticImplications	ONCOKB_prognosticImplications	ONCOKB_treatments	ONCOKB_dataVersion	ONCOKB_lastUpdate	ONCOKB_query.id	ONCOKB_query.referenceGenome	ONCOKB_query.hugoSymbol	ONCOKB_query.entrezGeneId	ONCOKB_query.alteration	ONCOKB_query.alterationType	ONCOKB_query.svType	ONCOKB_query.tumorType	ONCOKB_query.consequence	ONCOKB_query.proteinStart	ONCOKB_query.proteinEnd	ONCOKB_query.hgvs	ONCOKB_query.hgvsInfo	ONCOKB_query.canonicalTranscript	ONCOKB_mutationEffect.knownEffect	ONCOKB_mutationEffect.description	ONCOKB_mutationEffect.citations.pmids	ONCOKB_mutationEffect.citations.abstracts	ONCOKB_JSON	ANNOTATED	GENE_IN_ONCOKB	VARIANT_IN_ONCOKB	MUTATION_EFFECT	MUTATION_EFFECT_CITATIONS	ONCOGENIC	LEVEL_1	LEVEL_2	LEVEL_3A	LEVEL_3B	LEVEL_4	LEVEL_R1	LEVEL_R2	HIGHEST_LEVEL	HIGHEST_SENSITIVE_LEVEL	HIGHEST_RESISTANCE_LEVEL	TX_CITATIONS	LEVEL_Dx1	LEVEL_Dx2	LEVEL_Dx3	HIGHEST_DX_LEVEL	DX_CITATIONS	LEVEL_Px1	LEVEL_Px2	LEVEL_Px3	HIGHEST_PX_LEVEL	PX_CITATIONS	AD	F1R2	F2R1	GT	MB	OBC	OBPa	OBParc	OBPsnp	PR	PS	SB	SQ	SR	VAF
MAF Standard Metadata	MAF Standard Metadata	VCF	VEP	VEP	VCF	VCF	Computed	VCF	VCF	VCF	VCF	VCF	VCF	VCF	VCF	VCF	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP		VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP	gnomAD/1000G	gnomAD/1000G	gnomAD/1000G	gnomAD/1000G	gnomAD/1000G	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Exomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	gnomAD Genomes	VEP	VEP	ClinVar	ClinVar	ClinVar	ClinVar	VEP	VEP	VEP	VEP	VEP	SpliceAI	SpliceAI	SpliceAI	SpliceAI	SpliceAI	SpliceAI	SpliceAI	SpliceAI	SpliceAI	SpliceAI	REVEL	gnomAD constraint metrics	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	ClinVar	CIViC	CIViC	CIViC	CIViC	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Cancer Hotspots	Manta	Manta	Manta	Manta	VCF Standard	UNKNOWN	UNKNOWN	Manta	Manta	Manta	Manta	Manta	Manta	Manta	Manta	Manta	VCF Standard	OncoKB	OncoKB	UNKNOWN	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	Manta	Manta	Manta	Manta	Manta	Manta	Cancer Hotspots	UNKNOWN	UNKNOWN	UNKNOWN	UNKNOWN	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	UNKNOWN	UNKNOWN	UNKNOWN	OncoKB	OncoKB	UNKNOWN	UNKNOWN	UNKNOWN	OncoKB	OncoKB	UNKNOWN	UNKNOWN	OncoKB	UNKNOWN	UNKNOWN	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	Pipeline	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	OncoKB	VCF FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	FORMAT	
GRCh38	MTOR	D12_12345_1234556_Thyroid_S9	p.Leu2303=	ENSP00000354558.4:p.Leu2303=	chr1	11121270	11121270.0	C	T	T	11121270	.	C	T	.	PASS	NM_004958	T	synonymous_variant	LOW	MTOR	ENSG00000198793	Transcript	ENST00000361445	protein_coding	49/58		c.6909G>A	7030	6909	2303	L	ctG/ctA	rs11121691&COSV63870864		-1		SNV	HGNC	HGNC:3942	YES	MANE_Select	NM_004958.4		1	P1	CCDS127.1	ENSP00000354558	P42345.237		UPI000012ABD3			1			PDB-ENSP_mappings:3jbz.A&PDB-ENSP_mappings:4jsn.A&PDB-ENSP_mappings:4jsn.B&PDB-ENSP_mappings:4jsp.A&PDB-ENSP_mappings:4jsp.B&PDB-ENSP_mappings:4jsv.A&PDB-ENSP_mappings:4jsv.B&PDB-ENSP_mappings:4jsx.A&PDB-ENSP_mappings:4jsx.B&PDB-ENSP_mappings:4jt5.A&PDB-ENSP_mappings:4jt5.B&PDB-ENSP_mappings:4jt6.A&PDB-ENSP_mappings:4jt6.B&PDB-ENSP_mappings:5flc.B&PDB-ENSP_mappings:5flc.F&PDB-ENSP_mappings:5h64.A&PDB-ENSP_mappings:5h64.a&PDB-ENSP_mappings:5wbu.A&PDB-ENSP_mappings:5wbu.B&PDB-ENSP_mappings:5wby.A&PDB-ENSP_mappings:5wby.B&PDB-ENSP_mappings:5zcs.A&PDB-ENSP_mappings:5zcs.B&PDB-ENSP_mappings:6bcu.A&PDB-ENSP_mappings:6bcu.B&PDB-ENSP_mappings:6bcx.A&PDB-ENSP_mappings:6bcx.B&PDB-ENSP_mappings:6sb0.A&PDB-ENSP_mappings:6sb0.B&PDB-ENSP_mappings:6sb2.A&PDB-ENSP_mappings:6sb2.B&PDB-ENSP_mappings:6zwm.A&PDB-ENSP_mappings:6zwm.B&PDB-ENSP_mappings:6zwo.B&PDB-ENSP_mappings:7owg.B&PDB-ENSP_mappings:7pe7.A&PDB-ENSP_mappings:7pe7.B&PDB-ENSP_mappings:7pe8.A&PDB-ENSP_mappings:7pe9.A&PDB-ENSP_mappings:7pea.A&PDB-ENSP_mappings:7pea.B&PDB-ENSP_mappings:7peb.A&PDB-ENSP_mappings:7pec.A&PDB-ENSP_mappings:7tzo.A&PDB-ENSP_mappings:7tzo.B&PDB-ENSP_mappings:7uxc.A&PDB-ENSP_mappings:7uxh.A&PDB-ENSP_mappings:7uxh.C&PDB-ENSP_mappings:8era.A&PDB-ENSP_mappings:9f44.A&PDB-ENSP_mappings:9f44.B&PDB-ENSP_mappings:9f45.A&PDB-ENSP_mappings:9f45.B&SMART:SM00146&PROSITE_profiles:PS50290&Gene3D:1.10.1070.11&Pfam:PF00454&Superfamily:SSF56112&PANTHER:PTHR11139&CDD:cd05169&AFDB-ENSP_mappings:AF-P42345-F1			0.2206	0.4365	0.1542	0.0565	0.2356	0.1299	0.2303	0.4525	0.1272	0.3253	0.06073	0.2246	0.2495	0.2364	0.2343	0.167	0.2782	0.431	0.1934	0.1819	0.3289	0.06421	0.2272	0.2245	0.239	0.2491	0.1598	0.4525	gnomADe_AFR	benign	0&1	1&1	27462867&33997407&29434720&24996771&30585697&36239337						FAIL	-2	25	-21	-24	0.00	0.00	0.00	0.00	MTOR		2.6800e-01	516652	0.30209	0.21844	0.22065	497964	not_specified&not_provided&Macrocephaly-intellectual_disability-neurodevelopmental_disorder-small_thorax_syndrome		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0014716&MedGen:C4225259&OMIM:616638&Orphanet:457485		NC_000001.11:g.11121270C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000729955&SCV001717501&SCV002014272&SCV005283633	single_nucleotide_variant	SO:0001483	ClinGen:CA588984		MTOR:2475	SO:0001819&synonymous_variant										1	11121691																											833					0.996							247.07	v6.1	Unknown		True	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	False	01/16/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:L2303= mutant UNKNOWN.	False	The MTOR ENSP00000354558.4:l2303= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	11181327						True	False	False	Unknown								False	False		MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	The MTOR ENSP00000354558.4:l2303= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:L2303= mutant UNKNOWN.						v6.1	01/16/2019		GRCh38	MTOR	2475.0	ENSP00000354558.4:L2303=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MTOR"",""entrezGeneId"":2475,""alteration"":""ENSP00000354558.4:L2303="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types."",""variantSummary"":""The MTOR ENSP00000354558.4:l2303= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:L2303= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/16/2019""}"	True	True	False	Unknown		Unknown																						418,412	217,179	201,233	0/1	209,209,213,199	ACA	0.00	0.00	0.00			224,194,224,188	49.67		0.4963855421686747
GRCh38	MTOR	D12_12345_1234556_Thyroid_S9	p.Ser1851=	ENSP00000354558.4:p.Ser1851=	chr1	11130589	11130589.0	G	A	A	11130589	.	G	A	.	PASS	NM_004958	A	synonymous_variant	LOW	MTOR	ENSG00000198793	Transcript	ENST00000361445	protein_coding	39/58		c.5553C>T	5674	5553	1851	S	agC/agT	rs2275527&COSV63871083		-1		SNV	HGNC	HGNC:3942	YES	MANE_Select	NM_004958.4		1	P1	CCDS127.1	ENSP00000354558	P42345.237		UPI000012ABD3			1			PDB-ENSP_mappings:3jbz.A&PDB-ENSP_mappings:4jsn.A&PDB-ENSP_mappings:4jsn.B&PDB-ENSP_mappings:4jsp.A&PDB-ENSP_mappings:4jsp.B&PDB-ENSP_mappings:4jsv.A&PDB-ENSP_mappings:4jsv.B&PDB-ENSP_mappings:4jsx.A&PDB-ENSP_mappings:4jsx.B&PDB-ENSP_mappings:4jt5.A&PDB-ENSP_mappings:4jt5.B&PDB-ENSP_mappings:4jt6.A&PDB-ENSP_mappings:4jt6.B&PDB-ENSP_mappings:5flc.B&PDB-ENSP_mappings:5flc.F&PDB-ENSP_mappings:5h64.A&PDB-ENSP_mappings:5h64.a&PDB-ENSP_mappings:5wbu.A&PDB-ENSP_mappings:5wbu.B&PDB-ENSP_mappings:5wby.A&PDB-ENSP_mappings:5wby.B&PDB-ENSP_mappings:5zcs.A&PDB-ENSP_mappings:5zcs.B&PDB-ENSP_mappings:6bcu.A&PDB-ENSP_mappings:6bcu.B&PDB-ENSP_mappings:6bcx.A&PDB-ENSP_mappings:6bcx.B&PDB-ENSP_mappings:6sb0.A&PDB-ENSP_mappings:6sb0.B&PDB-ENSP_mappings:6sb2.A&PDB-ENSP_mappings:6sb2.B&PDB-ENSP_mappings:6zwm.A&PDB-ENSP_mappings:6zwm.B&PDB-ENSP_mappings:6zwo.B&PDB-ENSP_mappings:7owg.B&PDB-ENSP_mappings:7pe7.A&PDB-ENSP_mappings:7pe7.B&PDB-ENSP_mappings:7pe8.A&PDB-ENSP_mappings:7pe9.A&PDB-ENSP_mappings:7pea.A&PDB-ENSP_mappings:7pea.B&PDB-ENSP_mappings:7peb.A&PDB-ENSP_mappings:7pec.A&PDB-ENSP_mappings:7tzo.A&PDB-ENSP_mappings:7tzo.B&PDB-ENSP_mappings:7uxc.A&PDB-ENSP_mappings:7uxh.A&PDB-ENSP_mappings:7uxh.C&PDB-ENSP_mappings:8era.A&PDB-ENSP_mappings:9f44.A&PDB-ENSP_mappings:9f44.B&PDB-ENSP_mappings:9f45.A&PDB-ENSP_mappings:9f45.B&Low_complexity_(Seg):seg&PROSITE_profiles:PS51189&Pfam:PF02259&PANTHER:PTHR11139&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P42345-F1			0.2286	0.4486	0.1542	0.0794	0.2356	0.1309	0.2316	0.4637	0.1278	0.3261	0.097	0.2249	0.2497	0.2364	0.2359	0.1671	0.2818	0.442	0.1912	0.1832	0.3292	0.08607	0.2263	0.2295	0.2386	0.2524	0.1583	0.4637	gnomADe_AFR	benign	0&1	1&1	15720714&33997407&26504747&35861070						FAIL	2	24	2	8	0.00	0.00	0.00	0.00	MTOR		2.6800e-01	380311	0.30594	0.22152	0.22863	364358	not_provided&Macrocephaly-intellectual_disability-neurodevelopmental_disorder-small_thorax_syndrome&not_specified		MedGen:C3661900&MONDO:MONDO:0014716&MedGen:C4225259&OMIM:616638&Orphanet:457485&MedGen:CN169374		NC_000001.11:g.11130589G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000518229&SCV001717502&SCV002014275&SCV005283766	single_nucleotide_variant	SO:0001483	ClinGen:CA589312		MTOR:2475	SO:0001819&synonymous_variant										1	2275527																											1264					0.995							247.28	v6.1	Unknown		True	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	False	01/16/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:S1851= mutant UNKNOWN.	False	The MTOR ENSP00000354558.4:s1851= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	11190646						True	False	False	Unknown								False	False		MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	The MTOR ENSP00000354558.4:s1851= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:S1851= mutant UNKNOWN.						v6.1	01/16/2019		GRCh38	MTOR	2475.0	ENSP00000354558.4:S1851=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MTOR"",""entrezGeneId"":2475,""alteration"":""ENSP00000354558.4:S1851="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types."",""variantSummary"":""The MTOR ENSP00000354558.4:s1851= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:S1851= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/16/2019""}"	True	True	False	Unknown		Unknown																						661,597	322,282	339,315	0/1	327,334,288,309	CGC	0.00	0.00	0.00			350,311,331,266	33.8		0.47456279809220986
GRCh38	MTOR	D12_12345_1234556_Thyroid_S9	p.Asn999=	ENSP00000354558.4:p.Asn999=	chr1	11228701	11228701.0	G	A	A	11228701	.	G	A	.	PASS	NM_004958	A	synonymous_variant	LOW	MTOR	ENSG00000198793	Transcript	ENST00000361445	protein_coding	19/58		c.2997C>T	3118	2997	999	N	aaC/aaT	rs1064261&COSV63873449		-1		SNV	HGNC	HGNC:3942	YES	MANE_Select	NM_004958.4		1	P1	CCDS127.1	ENSP00000354558	P42345.237		UPI000012ABD3			1			PDB-ENSP_mappings:5h64.A&PDB-ENSP_mappings:5h64.a&PDB-ENSP_mappings:5zcs.A&PDB-ENSP_mappings:5zcs.B&PDB-ENSP_mappings:6bcu.A&PDB-ENSP_mappings:6bcu.B&PDB-ENSP_mappings:6bcx.A&PDB-ENSP_mappings:6bcx.B&PDB-ENSP_mappings:6sb0.A&PDB-ENSP_mappings:6sb0.B&PDB-ENSP_mappings:6sb2.A&PDB-ENSP_mappings:6sb2.B&PDB-ENSP_mappings:6zwm.A&PDB-ENSP_mappings:6zwm.B&PDB-ENSP_mappings:6zwo.B&PDB-ENSP_mappings:7owg.B&PDB-ENSP_mappings:7pe7.A&PDB-ENSP_mappings:7pe7.B&PDB-ENSP_mappings:7pe8.A&PDB-ENSP_mappings:7pe9.A&PDB-ENSP_mappings:7pea.A&PDB-ENSP_mappings:7pea.B&PDB-ENSP_mappings:7peb.A&PDB-ENSP_mappings:7pec.A&PDB-ENSP_mappings:7tzo.A&PDB-ENSP_mappings:7tzo.B&PDB-ENSP_mappings:7uxc.A&PDB-ENSP_mappings:7uxh.A&PDB-ENSP_mappings:7uxh.C&PDB-ENSP_mappings:8era.A&PDB-ENSP_mappings:9f44.A&PDB-ENSP_mappings:9f44.B&PDB-ENSP_mappings:9f45.A&PDB-ENSP_mappings:9f45.B&SMART:SM01346&Pfam:PF11865&Gene3D:1.25.10.10&Superfamily:SSF48371&PANTHER:PTHR11139&AFDB-ENSP_mappings:AF-P42345-F1			0.7005	0.3351	0.8141	0.9187	0.7237	0.865	0.7359	0.3652	0.852	0.6569	0.8995	0.7472	0.7331	0.7314	0.7295	0.8236	0.649	0.3863	0.755	0.7808	0.6554	0.9115	0.745	0.7517	0.7279	0.6996	0.8311	0.9187	EAS	benign	0&1	1&1	27462867&35090889&15720714&27051587&30487748&33172148&21606320&26317520&33997407&28977864&37047730&33145270&36790512&36496178&37209192&25654238&36882608&38002079						FAIL	-11	32	21	-33	0.00	0.00	0.00	0.00	MTOR		2.6800e-01	1170840	0.61756	0.74289	0.70048	1153195	Macrocephaly-intellectual_disability-neurodevelopmental_disorder-small_thorax_syndrome&not_specified&not_provided		MONDO:MONDO:0014716&MedGen:C4225259&OMIM:616638&Orphanet:457485&MedGen:CN169374&MedGen:C3661900		NC_000001.11:g.11228701G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001733267&SCV001843486&SCV002014278&SCV005286047	single_nucleotide_variant	SO:0001483	ClinGen:CA590341		MTOR:2475	SO:0001819&synonymous_variant										1	1064261																											920					0.997							246.63	v6.1	Unknown		True	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	False	01/16/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:N999= mutant UNKNOWN.	False	The MTOR ENSP00000354558.4:n999= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	11288758						True	False	False	Unknown								False	False		MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	The MTOR ENSP00000354558.4:n999= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:N999= mutant UNKNOWN.						v6.1	01/16/2019		GRCh38	MTOR	2475.0	ENSP00000354558.4:N999=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MTOR"",""entrezGeneId"":2475,""alteration"":""ENSP00000354558.4:N999="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types."",""variantSummary"":""The MTOR ENSP00000354558.4:n999= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:N999= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/16/2019""}"	True	True	False	Unknown		Unknown																						478,439	223,169	255,270	0/1	243,235,224,215	CGT	0.00	0.00	0.00			258,220,230,209	37.13		0.4787350054525627
GRCh38	SPEN	D12_12345_1234556_Thyroid_S9	p.A970V	ENSP00000364912.3:p.Ala970Val	chr1	15929149	15929149.0	C	T	T	15929149	.	C	T	.	PASS	NM_015001	T	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	11/15		c.2909C>T	3270	2909	970	A/V	gCa/gTa	rs848208&COSV65357982		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	tolerated(0.53)	benign(0.183)	MobiDB_lite:mobidb-lite			0.1208	0.0212	0.2392	0.2222	0.0984	0.09	0.112	0.03468	0.3115	0.07856	0.2576	0.1672	0.07143	0.1012	0.1067	0.09401	0.1061	0.03953	0.1206	0.2308	0.08727	0.2112	0.1691	0.06122	0.1021	0.1137	0.09801	0.3115	gnomADe_AMR	benign	0&1	1&1	36653681&36513072						FAIL	49	3	-2	7	0.00	0.00	0.00	0.00	SPEN	0.099	9.4000e-02	1233038	0.08089	0.13089	0.12081	1223450	not_provided&SPEN-related_disorder		MedGen:C3661900&.		NC_000001.11:g.15929149C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001846487&SCV005282606	single_nucleotide_variant	SO:0001483	ClinGen:CA619359		SPEN:23013	SO:0001583&missense_variant										1	848208																											438					0.989							241.9	v6.1	Unknown		True	SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	False	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A970V mutant UNKNOWN.	False	The SPEN ENSP00000364912.3:a970v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16255644						True	False	False	Unknown								False	False		SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	The SPEN ENSP00000364912.3:a970v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A970V mutant UNKNOWN.						v6.1	05/11/2017		GRCh38	SPEN	23013.0	ENSP00000364912.3:A970V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPEN"",""entrezGeneId"":23013,""alteration"":""ENSP00000364912.3:A970V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer."",""variantSummary"":""The SPEN ENSP00000364912.3:a970v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A970V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/11/2017""}"	True	True	False	Unknown		Unknown																						262,171	98,82	164,89	0/1	133,129,91,80	GCA	0.00	0.00	0.00			133,129,74,97	11.84		0.394919168591224
GRCh38	SPEN	D12_12345_1234556_Thyroid_S9	p.L1091P	ENSP00000364912.3:p.Leu1091Pro	chr1	15929512	15929512.0	T	C	C	15929512	.	T	C	.	PASS	NM_015001	C	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	11/15		c.3272T>C	3633	3272	1091	L/P	cTa/cCa	rs848209&COSV65359297		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	tolerated(1)	benign(0)	MobiDB_lite:mobidb-lite			0.6490	0.9758	0.7118	0.3214	0.5577	0.5941	0.585	0.9309	0.7481	0.6124	0.3299	0.6068	0.6147	0.5717	0.5921	0.6267	0.6773	0.917	0.5407	0.709	0.6218	0.3063	0.6096	0.5714	0.5727	0.6439	0.62	0.9758	AFR	benign	0&1	1&1	26848890&32327693						FAIL	-35	3	13	5	0.00	0.00	0.00	0.00	SPEN	0.060	9.4000e-02	1333155	0.68776	0.61536	0.64896	1323912	not_provided&SPEN-related_disorder&Radio-Tartaglia_syndrome		MedGen:C3661900&.&MONDO:MONDO:0859143&MedGen:C5543339&OMIM:619312&Orphanet:662234		NC_000001.11:g.15929512T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002057600&SCV005282607	single_nucleotide_variant	SO:0001483	ClinGen:CA619413		SPEN:23013	SO:0001583&missense_variant										1	848209																											200					0.96							233.3	v6.1	Unknown		True	SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	False	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:L1091P mutant UNKNOWN.	False	The SPEN ENSP00000364912.3:l1091p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16256007						True	False	False	Unknown								False	False		SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	The SPEN ENSP00000364912.3:l1091p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:L1091P mutant UNKNOWN.						v6.1	05/11/2017		GRCh38	SPEN	23013.0	ENSP00000364912.3:L1091P			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPEN"",""entrezGeneId"":23013,""alteration"":""ENSP00000364912.3:L1091P"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer."",""variantSummary"":""The SPEN ENSP00000364912.3:l1091p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:L1091P mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/11/2017""}"	True	True	False	Unknown		Unknown																						0,192	0,95	0,97	0/1	0,0,101,91	CTA	.	.	.			0,0,98,94	64.73		1.0
GRCh38	SPEN	D12_12345_1234556_Thyroid_S9	p.N2360D	ENSP00000364912.3:p.Asn2360Asp	chr1	15933318	15933318.0	A	G	G	15933318	.	A	G	.	PASS	NM_015001	G	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	11/15		c.7078A>G	7439	7078	2360	N/D	Aac/Gac	rs848210&COSV65359302		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	tolerated(0.74)	benign(0)	Pfam:PF20809&MobiDB_lite:mobidb-lite			0.6490	0.9758	0.7118	0.3214	0.5577	0.5941	0.5851	0.9309	0.7484	0.6129	0.3299	0.6069	0.6151	0.5718	0.5922	0.6267	0.6772	0.9169	0.5409	0.709	0.6219	0.3059	0.6086	0.5714	0.5727	0.6439	0.6202	0.9758	AFR	benign	0&1	1&1	32869539&28296976&31358993						FAIL	-20	7	12	-37	0.00	0.00	0.00	0.00	SPEN	0.099	9.4000e-02	1268492	0.68960		0.64896	1258399	SPEN-related_disorder&Radio-Tartaglia_syndrome&not_provided		.&MONDO:MONDO:0859143&MedGen:C5543339&OMIM:619312&Orphanet:662234&MedGen:C3661900		NC_000001.11:g.15933318A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001897446&SCV002057601&SCV005282610	single_nucleotide_variant	SO:0001483	ClinGen:CA620037		SPEN:23013	SO:0001583&missense_variant										1	848210																											877					0.997							246.85	v6.1	Unknown		True	SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	False	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:N2360D mutant UNKNOWN.	False	The SPEN ENSP00000364912.3:n2360d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16259813						True	False	False	Unknown								False	False		SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	The SPEN ENSP00000364912.3:n2360d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:N2360D mutant UNKNOWN.						v6.1	05/11/2017		GRCh38	SPEN	23013.0	ENSP00000364912.3:N2360D			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPEN"",""entrezGeneId"":23013,""alteration"":""ENSP00000364912.3:N2360D"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer."",""variantSummary"":""The SPEN ENSP00000364912.3:n2360d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:N2360D mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/11/2017""}"	True	True	False	Unknown		Unknown																						0,874	0,425	0,449	0/1	0,0,453,421	CAA	.	.	.			0,0,418,456	64.73		1.0
GRCh38	SPEN	D12_12345_1234556_Thyroid_S9	p.Ala2727=	ENSP00000364912.3:p.Ala2727=	chr1	15934421	15934421.0	C	T	T	15934421	.	C	T	.	PASS	NM_015001	T	synonymous_variant	LOW	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	11/15		c.8181C>T	8542	8181	2727	A	gcC/gcT	rs848211&COSV65357526		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1			Pfam:PF20808&Low_complexity_(Seg):seg			0.1212	0.0212	0.2406	0.2232	0.0984	0.09	0.1121	0.03641	0.3116	0.07855	0.2602	0.1685	0.0716	0.1011	0.1068	0.09404	0.1069	0.04114	0.1206	0.232	0.08737	0.2143	0.1711	0.06122	0.1021	0.1153	0.09818	0.3116	gnomADe_AMR	benign	0&1	1&1							FAIL	-49	14	33	49	0.00	0.00	0.00	0.00	SPEN		9.4000e-02	1342068	0.08142	0.13113	0.12121	1333466	not_provided		MedGen:C3661900		NC_000001.11:g.15934421C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002098233&SCV005282611	single_nucleotide_variant	SO:0001483	ClinGen:CA620225		SPEN:23013	SO:0001819&synonymous_variant										1	848211																											1073					0.999							247.83	v6.1	Unknown		True	SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	False	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A2727= mutant UNKNOWN.	False	The SPEN ENSP00000364912.3:a2727= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16260916						True	False	False	Unknown								False	False		SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	The SPEN ENSP00000364912.3:a2727= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A2727= mutant UNKNOWN.						v6.1	05/11/2017		GRCh38	SPEN	23013.0	ENSP00000364912.3:A2727=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPEN"",""entrezGeneId"":23013,""alteration"":""ENSP00000364912.3:A2727="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer."",""variantSummary"":""The SPEN ENSP00000364912.3:a2727= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A2727= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/11/2017""}"	True	True	False	Unknown		Unknown																						534,538	266,276	268,262	0/1	272,262,245,293	CCG	0.00	0.00	0.00			260,274,261,277	58.36		0.5018656716417911
GRCh38	SPEN	D12_12345_1234556_Thyroid_S9	p.Ser3223=	ENSP00000364912.3:p.Ser3223=	chr1	15935909	15935909.0	C	T	T	15935909	.	C	T	.	PASS	NM_015001	T	synonymous_variant	LOW	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	11/15		c.9669C>T	10030	9669	3223	S	agC/agT	rs61749277&COSV107487023		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1			MobiDB_lite:mobidb-lite			0.1212	0.0212	0.2392	0.2242	0.0984	0.09	0.112	0.03472	0.3112	0.07852	0.2604	0.1658	0.07182	0.1011	0.1063	0.09405	0.1058	0.03953	0.1209	0.2297	0.08703	0.2144	0.1678	0.06122	0.102	0.1125	0.09714	0.3112	gnomADe_AMR	benign	0&1	1&1							FAIL	-2	16	-2	-15	0.00	0.00	0.08	0.00	SPEN		9.4000e-02	3060127	0.07623	0.13094	0.12121	3218032	SPEN-related_disorder		.		NC_000001.11:g.15935909C>T	no_assertion_criteria_provided	Benign			SCV004798699	single_nucleotide_variant	SO:0001483	ClinGen:CA620535		SPEN:23013	SO:0001819&synonymous_variant										1	61749277																											788					0.995							245.63	v6.1	Unknown		True	SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	False	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:S3223= mutant UNKNOWN.	False	The SPEN ENSP00000364912.3:s3223= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16262404						True	False	False	Unknown								False	False		SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	The SPEN ENSP00000364912.3:s3223= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:S3223= mutant UNKNOWN.						v6.1	05/11/2017		GRCh38	SPEN	23013.0	ENSP00000364912.3:S3223=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPEN"",""entrezGeneId"":23013,""alteration"":""ENSP00000364912.3:S3223="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer."",""variantSummary"":""The SPEN ENSP00000364912.3:s3223= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:S3223= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/11/2017""}"	True	True	False	Unknown		Unknown																						413,371	198,187	215,184	0/1	216,197,213,158	GCA	0.00	0.00	0.00			199,214,173,198	33.14		0.4732142857142857
GRCh38	SPEN	D12_12345_1234556_Thyroid_S9	p.S3466G	ENSP00000364912.3:p.Ser3466Gly	chr1	15937532	15937532.0	A	G	G	15937532	.	A	G	.	PASS	NM_015001	G	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	12/15		c.10396A>G	10757	10396	3466	S/G	Agc/Ggc	rs187821820		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	tolerated(0.34)	benign(0.029)	MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.0002	0	0.0014	0	0	0	0.0003455	0.0001195	2.236e-05	0	0	0	0	0.0004254	0.000447	0	0.0004799	0.000217	0.02741	0.000458	0	0	0	0	0.0004705	0	0	0.02741	gnomADg_AMI										FAIL	13	2	13	-45	0.10	0.02	0.00	0.00	SPEN	0.026	9.4000e-02																																																											1041					0.982							246	v6.1	Unknown		True	SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	False	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:S3466G mutant UNKNOWN.	False	The SPEN ENSP00000364912.3:s3466g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16264027						True	False	False	Unknown								False	False		SPEN encodes a tumor suppressor that regulates transcription of ER-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	The SPEN ENSP00000364912.3:s3466g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:S3466G mutant UNKNOWN.						v6.1	05/11/2017		GRCh38	SPEN	23013.0	ENSP00000364912.3:S3466G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPEN"",""entrezGeneId"":23013,""alteration"":""ENSP00000364912.3:S3466G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer."",""variantSummary"":""The SPEN ENSP00000364912.3:s3466g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:S3466G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/11/2017""}"	True	True	False	Unknown		Unknown																						514,508	319,293	195,215	0/1	259,255,258,250	CAG	.	.	.			264,250,279,229	53.62		0.49706457925636005
GRCh38	PAX7	D12_12345_1234556_Thyroid_S9			chr1	18748486	18748486.0	C	T	T	18748486	.	C	T	.	PASS	NM_001135254	T	3_prime_UTR_variant	MODIFIER	PAX7	ENSG00000009709	Transcript	ENST00000420770	protein_coding	9/9		c.*3557C>T	5833					rs12121503		1		SNV	HGNC	HGNC:8621	YES	MANE_Select	NM_001135254.2		1	P1	CCDS44074.1	ENSP00000403389	P23759.221		UPI0000E1E6AE	P23759-3		1						0.0535	0.0008	0.0879	0.1022	0.0596	0.044	0.06551	0.01125	0.06518	0.08929	0.07273	0	0.04772	0.06675	0.0634	0.02616	0.05122	0.01244	0.1075	0.06755	0.08554	0.08568	0.07082	0.05782	0.06303	0.04967	0.0521	0.1075	gnomADg_AMI										FAIL	37	-50	-49	35	0.00	0.00	0.00	0.00	PAX7		5.0400e-01																																																											462					0.996							244.81													chr1	19074980																																																	True	True	False	Unknown		Unknown																						220,240	99,112	121,128	0/1	107,113,131,109	ACG	0.00	0.00	0.00			118,102,125,115	52.72		0.5217391304347826
GRCh38	PAX7	D12_12345_1234556_Thyroid_S9			chr1	18748731	18748731.0	A	G	G	18748731	.	A	G	.	PASS	NM_001135254	G	3_prime_UTR_variant	MODIFIER	PAX7	ENSG00000009709	Transcript	ENST00000420770	protein_coding	9/9		c.*3802A>G	6078					rs851114		1		SNV	HGNC	HGNC:8621	YES	MANE_Select	NM_001135254.2		1	P1	CCDS44074.1	ENSP00000403389	P23759.221		UPI0000E1E6AE	P23759-3		1						0.6502	0.8495	0.5706	0.5218	0.5666	0.6554	0.6031	0.8237	0.5559	0.6827	0.526	0.4394	0.6496	0.5944	0.6221	0.6608	0.6424	0.8111	0.5692	0.5682	0.6783	0.5655	0.4832	0.7381	0.5856	0.644	0.6389	0.8495	AFR				38608796						FAIL	20	18	50	-21	0.00	0.00	0.00	0.00	PAX7		5.0400e-01																																																											610					0.979							238.87													chr1	19075225																																																	True	True	False	Unknown		Unknown																						2,595	0,252	2,343	0/1	1,1,317,278	CAC	.	.	.			1,1,206,389	64.73		0.9966499162479062
GRCh38	PAX7	D12_12345_1234556_Thyroid_S9			chr1	18748833	18748833.0	C	A	A	18748833	.	C	A	.	PASS	NM_001135254	A	3_prime_UTR_variant	MODIFIER	PAX7	ENSG00000009709	Transcript	ENST00000420770	protein_coding	9/9		c.*3904C>A	6180					rs34660444		1		SNV	HGNC	HGNC:8621	YES	MANE_Select	NM_001135254.2		1	P1	CCDS44074.1	ENSP00000403389	P23759.221		UPI0000E1E6AE	P23759-3		1						0.0535	0.0008	0.0879	0.1022	0.0596	0.044	0.06465	0.01436	0.05856	0.09146	0.07262	0	0.04717	0.06493	0.0607	0.02991	0.05134	0.0125	0.1075	0.06753	0.08554	0.08537	0.07116	0.05782	0.06313	0.04967	0.05339	0.1075	gnomADg_AMI										FAIL	2	-1	-26	0	0.00	0.00	0.00	0.00	PAX7		5.0400e-01																																																											248					0.996							245.49													chr1	19075327																																																	True	True	False	Unknown		Unknown																						119,128	55,55	64,73	0/1	58,61,78,50	GCG	0.00	0.00	0.00			46,73,43,85	43.71		0.5182186234817814
GRCh38	ID3	D12_12345_1234556_Thyroid_S9	p.T105A	ENSP00000363689.5:p.Thr105Ala	chr1	23559007	23559007.0	T	C	C	23559007	.	T	C	.	PASS	NM_002167	C	missense_variant	MODERATE	ID3	ENSG00000117318	Transcript	ENST00000374561	protein_coding	2/3		c.313A>G	388	313	105	T/A	Act/Gct	rs11574&CM102358&COSV107485314		-1		SNV	HGNC	HGNC:5362	YES	MANE_Select	NM_002167.5		1	P1	CCDS237.1	ENSP00000363689	Q02535.209		UPI000016A132			1	tolerated(0.89)	benign(0)	AFDB-ENSP_mappings:AF-Q02535-F1			0.8904	0.9894	0.7392	0.9692	0.7575	0.9192	0.7713	0.9572	0.7064	0.8992	0.9788	0.6884	0.9307	0.7488	0.8036	0.9058	0.821	0.9491	0.8187	0.7661	0.9064	0.9738	0.6878	0.9218	0.7524	0.8409	0.9111	0.9894	AFR		0&1&1	0&1&1	20185798&20133430&21499051&23733655&29442437&33271747&35209718&35977879&34668636&24603695&28528328&31126344&24115031&36090536&23042815&35634348&26082558&26555048&29143670&28785583&21801865						FAIL	12	8	42	8	0.00	0.05	0.00	0.00	ID3	0.044	8.6500e-01																																																											1007					0.999							246.77	v6.1	Unknown		True	ID3 encodes a helix-loop-helix protein involved in transcription. Mutations and overexpression of ID3 are found in a variety of cancers.	False	01/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ID3 ENSP00000363689.5:T105A mutant UNKNOWN.	False	The ID3 ENSP00000363689.5:t105a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	23885498						True	False	False	Unknown								False	False		ID3 encodes a helix-loop-helix protein involved in transcription. Mutations and overexpression of ID3 are found in a variety of cancers.	The ID3 ENSP00000363689.5:t105a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ID3 ENSP00000363689.5:T105A mutant UNKNOWN.						v6.1	01/17/2017		GRCh38	ID3	3399.0	ENSP00000363689.5:T105A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ID3"",""entrezGeneId"":3399,""alteration"":""ENSP00000363689.5:T105A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ID3 encodes a helix-loop-helix protein involved in transcription. Mutations and overexpression of ID3 are found in a variety of cancers."",""variantSummary"":""The ID3 ENSP00000363689.5:t105a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ID3 ENSP00000363689.5:T105A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/17/2017""}"	True	True	False	Unknown		Unknown																						0,1006	0,468	0,538	0/1	0,0,529,477	GTG	.	.	.			0,0,533,473	64.73		1.0
GRCh38	TRNAU1AP	D12_12345_1234556_Thyroid_S9			chr1	28571798		T	<INS>	<INS>	28571798	MantaINS:4235:0:0:0:1:0	T	<INS>	.	PASS		insertion	downstream_gene_variant	MODIFIER	TRNAU1AP	ENSG00000180098	Transcript	ENST00000495215	protein_coding_CDS_not_defined										4467	1		insertion	HGNC	HGNC:30813					3																																																																																																																								0,1		0,1							1	A		AGGGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGA																chr1	28898310				INS																																													True	False	False	Unknown		Unknown																															0,1				0,4	
GRCh38	STK40	D12_12345_1234556_Thyroid_S9	p.Ser150=	ENSP00000362224.4:p.Ser150=	chr1	36355326	36355326.0	G	A	A	36355326	.	G	A	.	PASS	NM_001282547	A	synonymous_variant	LOW	STK40	ENSG00000196182	Transcript	ENST00000373132	protein_coding	5/11		c.450C>T	660	450	150	S	agC/agT	rs11263875&COSV63736402		-1		SNV	HGNC	HGNC:21373	YES	MANE_Select	NM_001282547.2		1	A1	CCDS407.1	ENSP00000362224	Q8N2I9.172		UPI0000073E73	Q8N2I9-1					PDB-ENSP_mappings:5l2q.A&PDB-ENSP_mappings:5l2q.B&PDB-ENSP_mappings:5l2q.C&PDB-ENSP_mappings:5l2q.D&Superfamily:SSF56112&PANTHER:PTHR22961&PROSITE_profiles:PS50011&SMART:SM00220&CDD:cd13974&Gene3D:1.10.510.10&Pfam:PF00069&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q8N2I9-F1			0.0845	0.0514	0.098	0.0407	0.1163	0.1319	0.1121	0.05726	0.07797	0.1869	0.03924	0.08588	0.2129	0.1147	0.1197	0.1339	0.09804	0.06024	0.1035	0.08713	0.1913	0.0469	0.08495	0.2329	0.1211	0.1197	0.1302	0.2329	gnomADg_MID		0&1	0&1							FAIL	-31	-7	6	-1	0.02	0.00	0.00	0.00	STK40		4.1600e-01																																																											967					0.999							248.7	v6.1	Unknown		True	STK40 encodes a serine/threonine kinase involved in regulation of NF-B- and p53-mediated transcription. Altered expression of STK40 is found in ovarian and esophageal cancers, among others.	False	01/18/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with STK40 ENSP00000362224.4:S150= mutant UNKNOWN.	False	The STK40 ENSP00000362224.4:s150= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	36820927						True	False	False	Unknown								False	False		STK40 encodes a serine/threonine kinase involved in regulation of NF-B- and p53-mediated transcription. Altered expression of STK40 is found in ovarian and esophageal cancers, among others.	The STK40 ENSP00000362224.4:s150= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with STK40 ENSP00000362224.4:S150= mutant UNKNOWN.						v6.1	01/18/2017		GRCh38	STK40	83931.0	ENSP00000362224.4:S150=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""STK40"",""entrezGeneId"":83931,""alteration"":""ENSP00000362224.4:S150="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""STK40 encodes a serine/threonine kinase involved in regulation of NF-\u03baB- and p53-mediated transcription. Altered expression of STK40 is found in ovarian and esophageal cancers, among others."",""variantSummary"":""The STK40 ENSP00000362224.4:s150= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with STK40 ENSP00000362224.4:S150= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/18/2017""}"	True	True	False	Unknown		Unknown																						489,477	225,233	264,244	0/1	233,256,243,234	CGC	0.00	0.00	0.00			241,248,243,234	49.9		0.4937888198757764
GRCh38	MUTYH	D12_12345_1234556_Thyroid_S9			chr1	45339894	45339894.0	G	C	C	45339894	.	G	C	.	PASS	NM_001128425	C	intron_variant	MODIFIER	MUTYH	ENSG00000132781	Transcript	ENST00000710952	protein_coding		1/15	c.36+325C>G						rs3219468		-1		SNV	HGNC	HGNC:7527		MANE_Plus_Clinical		NM_001128425.2				ENSP00000518552		E5KP25.104	UPI0001761701			1						0.9944	0.9992	0.9856	1	0.9841	0.999	0.9872	0.9977	0.9909	0.9953	0.9999	0.9912	0.9979	0.9854	0.9895	0.9963	0.9903	0.9966	0.9868	0.9876	0.9942	0.9996	0.9938	0.9932	0.9852	0.9886	0.9971	1	EAS	benign		1	22473953&22876359&35582231						FAIL	5	-2	5	-2	0.00	0.00	0.10	0.01	MUTYH			1244445			0.99441	1236974	Hereditary_cancer-predisposing_syndrome&not_provided		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900		NC_000001.11:g.45339894G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001861759&SCV005281470	single_nucleotide_variant	SO:0001483	ClinGen:CA059389		MUTYH:4595	SO:0001627&intron_variant										1	3219468																											512					1							246.95													chr1	45805566																																																	True	True	False	Unknown		Unknown																						0,512	0,292	0,220	0/1	0,0,275,237	CGC	.	.	.			0,0,375,137	64.73		1.0
GRCh38	PIK3R3	D12_12345_1234556_Thyroid_S9	p.Ser297=	ENSP00000262741.5:p.Ser297=	chr1	46055845	46055845.0	G	A	A	46055845	.	G	A	.	PASS	NM_003629	A	synonymous_variant	LOW	PIK3R3	ENSG00000117461	Transcript	ENST00000262741	protein_coding	7/10		c.891C>T	1568	891	297	S	agC/agT	rs785468&COSV53105695&COSV53111169		-1		SNV	HGNC	HGNC:8981	YES	MANE_Select	NM_003629.4		1	P1	CCDS529.1	ENSP00000262741	Q92569.199		UPI000013D318	Q92569-1					Pfam:PF16454&Gene3D:1.10.287.1490&Prints:PR00678&AFDB-ENSP_mappings:AF-Q92569-F1			0.6380	0.5893	0.6254	0.6885	0.7336	0.5624	0.6959	0.595	0.6562	0.7017	0.6852	0.7331	0.6323	0.7059	0.6873	0.616	0.6733	0.6053	0.6987	0.6688	0.7083	0.6661	0.7433	0.6054	0.7084	0.6594	0.6079	0.7433	gnomADg_FIN		0&1&1	0&1&1	36535266						FAIL	-22	0	-48	-50	0.00	0.00	0.00	0.00	PIK3R3		1.5350e+00																																																											200					0.95							237.79	v6.1	Unknown		True	PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers.	False	03/22/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:S297= mutant UNKNOWN.	False	The PIK3R3 ENSP00000262741.5:s297= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	46521517						True	False	False	Unknown								False	False		PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers.	The PIK3R3 ENSP00000262741.5:s297= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:S297= mutant UNKNOWN.						v6.1	03/22/2017		GRCh38	PIK3R3	8503.0	ENSP00000262741.5:S297=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3R3"",""entrezGeneId"":8503,""alteration"":""ENSP00000262741.5:S297="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers."",""variantSummary"":""The PIK3R3 ENSP00000262741.5:s297= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:S297= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/22/2017""}"	True	True	False	Unknown		Unknown																						85,105	43,61	42,44	0/1	40,45,52,53	TGC	0.00	0.00	0.00			54,31,58,47	46.85		0.5526315789473685
GRCh38	PIK3R3	D12_12345_1234556_Thyroid_S9	p.N283K	ENSP00000262741.5:p.Asn283Lys	chr1	46055887	46055887.0	A	T	T	46055887	.	A	T	.	PASS	NM_003629	T	missense_variant	MODERATE	PIK3R3	ENSG00000117461	Transcript	ENST00000262741	protein_coding	7/10		c.849T>A	1526	849	283	N/K	aaT/aaA	rs785467&COSV53106348		-1		SNV	HGNC	HGNC:8981	YES	MANE_Select	NM_003629.4		1	P1	CCDS529.1	ENSP00000262741	Q92569.199		UPI000013D318	Q92569-1			tolerated_low_confidence(1)		Coiled-coils_(Ncoils):Coil&Pfam:PF16454&Gene3D:1.10.287.1490&AFDB-ENSP_mappings:AF-Q92569-F1			0.6821	0.7474	0.6412	0.6885	0.7346	0.5624	0.7002	0.7452	0.666	0.7058	0.6854	0.7332	0.6391	0.706	0.6979	0.6166	0.7153	0.7503	0.6993	0.6847	0.7127	0.6678	0.7443	0.6199	0.7091	0.6825	0.6099	0.7503	gnomADg_AFR		0&1	0&1	15986317&18853455&36535266						FAIL	16	2	11	47	0.00	0.00	0.00	0.00	PIK3R3	0.129	1.5350e+00																																																											187					0.963							244.07	v6.1	Unknown		True	PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers.	False	03/22/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:N283K mutant UNKNOWN.	False	The PIK3R3 ENSP00000262741.5:n283k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	46521559						True	False	False	Unknown								False	False		PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers.	The PIK3R3 ENSP00000262741.5:n283k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:N283K mutant UNKNOWN.						v6.1	03/22/2017		GRCh38	PIK3R3	8503.0	ENSP00000262741.5:N283K			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3R3"",""entrezGeneId"":8503,""alteration"":""ENSP00000262741.5:N283K"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers."",""variantSummary"":""The PIK3R3 ENSP00000262741.5:n283k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:N283K mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/22/2017""}"	True	True	False	Unknown		Unknown																						85,95	43,50	42,45	0/1	43,42,49,46	GAT	.	.	.			49,36,58,37	42.62		0.5277777777777778
GRCh38	CDKN2C	D12_12345_1234556_Thyroid_S9			chr1	50972230	50972230.0	G	A	A	50972230	.	G	A	.	PASS	NM_078626	A	intron_variant	MODIFIER	CDKN2C	ENSG00000123080	Transcript	ENST00000371761	protein_coding		1/1	c.130-1663G>A						rs2487827		1		SNV	HGNC	HGNC:1789	YES	MANE_Select	NM_078626.3		1	P1	CCDS555.1	ENSP00000360826	P42773.211	Q6ICV4.167	UPI0000047FD9			1						0.9984	0.9947	0.9986	1	1	1											0.9971	0.9899	1	0.999	1	1	1	1	1	0.9991	1	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_SAS										FAIL	-26	0	37	0	0.01	0.00	0.01	0.00	CDKN2C		9.4000e-01																																																											78					0.962							245.86													chr1	51437902																																																	True	True	False	Unknown		Unknown																						0,75	0,34	0,41	0/1	0,0,39,36	GGG	0.00	0.00	0.00			0,0,38,37	64.54		1.0
GRCh38	EPS15	D12_12345_1234556_Thyroid_S9			chr1	51507777		G	[chr8:76145776[G	[chr8:76145776[G	51507777	MantaBND:4529:0:1:0:0:0:1	G	[chr8:76145776[G	.	PASS		.G	feature_truncation&intron_variant&NMD_transcript_variant	HIGH	EPS15	ENSG00000085832	Transcript	ENST00000706293	nonsense_mediated_decay		1/15									-1		chromosome_breakpoint	HGNC	HGNC:3419								ENSP00000516337		A0A994J7R8.8	UPI0021EC1A68			1																																																																																																														0			0,5							5	ATGTA			MantaBND:4529:0:1:0:0:0:0	2														chr1	51973449				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	SSBP3	D12_12345_1234556_Thyroid_S9			chr1	54252518	54252540.0	CGGGACAGGTGGCCACTAGGAGA	C	C	54252518	.	CGGGACAGGTGGCCACTAGGAGA	C	.	PASS	NM_145716	-	intron_variant	MODIFIER	SSBP3	ENSG00000157216	Transcript	ENST00000610401	protein_coding		7/17	c.508-680_508-659del						rs146044344		-1		deletion	HGNC	HGNC:15674	YES	MANE_Select	NM_145716.4		5	P1	CCDS591.1	ENSP00000479674	Q9BWW4.179	A0A087WVT6.57	UPI0000135F96	Q9BWW4-1								0.5835	0.705	0.5346	0.3323	0.5388	0.7587											0.5934	0.6989	0.5705	0.5318	0.5113	0.3227	0.5479	0.5034	0.5669	0.55	0.7336	0.7587	SAS																					1.7500e-01																																																											645					0.859							238.24													chr1	54718191																																																	True	False	False	Unknown		Unknown																						336,218	137,111	199,107	0/1	172,164,109,109	GCG						175,161,110,108	10.65		0.3935018050541516
GRCh38	ROR1-AS1	D12_12345_1234556_Thyroid_S9			chr1	64153710		A	[chr3:150798607[A	[chr3:150798607[A	64153710	MantaBND:4637:0:1:0:0:0:1	A	[chr3:150798607[A	.	PASS		.A	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	ROR1-AS1	ENSG00000223949	Transcript	ENST00000818568	lncRNA		1/2									-1		chromosome_breakpoint	HGNC	HGNC:40508																																																																																																																												0			0,9							9	AACAGAAAG			MantaBND:4637:0:1:0:0:0:0	1														chr1	64619393				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	JAK1	D12_12345_1234556_Thyroid_S9	p.Lys1032=	ENSP00000343204.4:p.Lys1032=	chr1	64837976	64837976.0	C	T	T	64837976	.	C	T	.	PASS	NM_002227	T	synonymous_variant	LOW	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	22/25		c.3096G>A	3390	3096	1032	K	aaG/aaA	rs12129819&COSV53805030		-1		SNV	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			Gene3D:1.10.510.10&PDB-ENSP_mappings:3eyg.A&PDB-ENSP_mappings:3eyh.A&PDB-ENSP_mappings:4e4l.A&PDB-ENSP_mappings:4e4l.B&PDB-ENSP_mappings:4e4l.D&PDB-ENSP_mappings:4e4l.E&PDB-ENSP_mappings:4e4n.A&PDB-ENSP_mappings:4e4n.B&PDB-ENSP_mappings:4e5w.A&PDB-ENSP_mappings:4e5w.B&PDB-ENSP_mappings:4ehz.A&PDB-ENSP_mappings:4ehz.B&PDB-ENSP_mappings:4ehz.C&PDB-ENSP_mappings:4ehz.D&PDB-ENSP_mappings:4ei4.A&PDB-ENSP_mappings:4ei4.B&PDB-ENSP_mappings:4fk6.A&PDB-ENSP_mappings:4fk6.B&PDB-ENSP_mappings:4i5c.A&PDB-ENSP_mappings:4i5c.B&PDB-ENSP_mappings:4ivb.A&PDB-ENSP_mappings:4ivb.B&PDB-ENSP_mappings:4ivc.A&PDB-ENSP_mappings:4ivc.B&PDB-ENSP_mappings:4ivd.A&PDB-ENSP_mappings:4ivd.B&PDB-ENSP_mappings:4k6z.A&PDB-ENSP_mappings:4k77.A&PDB-ENSP_mappings:4k77.B&PDB-ENSP_mappings:5e1e.A&PDB-ENSP_mappings:5e1e.B&PDB-ENSP_mappings:5hx8.A&PDB-ENSP_mappings:5hx8.B&PDB-ENSP_mappings:5khw.A&PDB-ENSP_mappings:5khw.B&PDB-ENSP_mappings:5khx.A&PDB-ENSP_mappings:5wo4.A&PDB-ENSP_mappings:5wo4.B&PDB-ENSP_mappings:6aah.A&PDB-ENSP_mappings:6aah.B&PDB-ENSP_mappings:6bbu.A&PDB-ENSP_mappings:6c7y.A&PDB-ENSP_mappings:6dbn.A&PDB-ENSP_mappings:6elr.A&PDB-ENSP_mappings:6elr.B&PDB-ENSP_mappings:6ggh.A&PDB-ENSP_mappings:6ggh.B&PDB-ENSP_mappings:6hzu.A&PDB-ENSP_mappings:6hzu.B&PDB-ENSP_mappings:6n77.A&PDB-ENSP_mappings:6n77.B&PDB-ENSP_mappings:6n78.A&PDB-ENSP_mappings:6n79.A&PDB-ENSP_mappings:6n7a.A&PDB-ENSP_mappings:6n7a.B&PDB-ENSP_mappings:6n7b.A&PDB-ENSP_mappings:6n7c.A&PDB-ENSP_mappings:6n7c.B&PDB-ENSP_mappings:6n7d.A&PDB-ENSP_mappings:6rsb.A&PDB-ENSP_mappings:6rsb.B&PDB-ENSP_mappings:6rsc.A&PDB-ENSP_mappings:6rsc.B&PDB-ENSP_mappings:6rsd.A&PDB-ENSP_mappings:6rsd.B&PDB-ENSP_mappings:6rse.A&PDB-ENSP_mappings:6rse.B&PDB-ENSP_mappings:6rsh.A&PDB-ENSP_mappings:6rsh.B&PDB-ENSP_mappings:6sm8.A&PDB-ENSP_mappings:6sm8.B&PDB-ENSP_mappings:6smb.A&PDB-ENSP_mappings:6smb.B&PDB-ENSP_mappings:6tpe.A&PDB-ENSP_mappings:6tpe.B&PDB-ENSP_mappings:6tpf.A&PDB-ENSP_mappings:6tpf.B&PDB-ENSP_mappings:6w8l.A&PDB-ENSP_mappings:8exj.D&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF07714&PIRSF:PIRSF000636&PROSITE_profiles:PS50011&PANTHER:PTHR45807&SMART:SM00219&Superfamily:SSF56112&CDD:cd05079			0.0385	0.0219	0.0548	0	0.1153	0.0102	0.09158	0.03229	0.05718	0.09401	7.557e-05	0.1121	0.08287	0.1035	0.08189	0.01456	0.07615	0.03404	0.1099	0.07941	0.09343	0.0001926	0.1133	0.08844	0.104	0.08617	0.01222	0.1153	EUR	benign	0&1	1&1	23670291&36669486&26242990						FAIL	-2	-1	-2	-44	0.00	0.00	0.00	0.00	JAK1		1.6800e-01	1168338	0.08060	0.07574	0.03854	1153650	not_provided		MedGen:C3661900		NC_000001.11:g.64837976C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001727222&SCV005287336	single_nucleotide_variant	SO:0001483	ClinGen:CA892528		JAK1:3716	SO:0001819&synonymous_variant										1	12129819																											96					1							247.26	v6.1	Unknown		True	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	False	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:K1032= mutant UNKNOWN.	False	The JAK1 ENSP00000343204.4:k1032= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65303659						True	False	False	Unknown								False	False		JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	The JAK1 ENSP00000343204.4:k1032= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:K1032= mutant UNKNOWN.						v6.1	02/04/2019		GRCh38	JAK1	3716.0	ENSP00000343204.4:K1032=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""JAK1"",""entrezGeneId"":3716,""alteration"":""ENSP00000343204.4:K1032="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers."",""variantSummary"":""The JAK1 ENSP00000343204.4:k1032= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:K1032= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/04/2019""}"	True	True	False	Unknown		Unknown																						51,45	26,27	25,18	0/1	31,20,26,19	CCT	0.00	0.00	0.00			26,25,22,23	32.12		0.46875
GRCh38	JAK1	D12_12345_1234556_Thyroid_S9	p.Pro733=	ENSP00000343204.4:p.Pro733=	chr1	64844806	64844806.0	T	C	C	64844806	.	T	C	.	PASS	NM_002227	C	synonymous_variant	LOW	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	16/25		c.2199A>G	2493	2199	733	P	ccA/ccG	rs2230588&COSV61087119		-1		SNV	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			Gene3D:1.10.510.10&PDB-ENSP_mappings:4l00.A&PDB-ENSP_mappings:4l00.B&PDB-ENSP_mappings:4l01.A&PDB-ENSP_mappings:4l01.B&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF07714&PIRSF:PIRSF000636&Prints:PR01823&PROSITE_profiles:PS50011&PANTHER:PTHR45807&SMART:SM00219&Superfamily:SSF56112&CDD:cd05077			0.3726	0.6604	0.3199	0.2996	0.2525	0.2198	0.2523	0.6278	0.3489	0.3531	0.2957	0.276	0.2667	0.2325	0.2726	0.231	0.3583	0.6149	0.17	0.3073	0.3574	0.2948	0.2865	0.2347	0.2419	0.3458	0.2287	0.6604	AFR	benign	0&1	1&1	25741868&20588308&19434718&15657875&23670291&36355252&26242990						FAIL	23	14	-36	14	0.00	0.00	0.00	0.02	JAK1		1.6800e-01	1169782	0.34920	0.29354	0.37260	1153651	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000001.11:g.64844806T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001730890&SCV004102156&SCV005287338	single_nucleotide_variant	SO:0001483	ClinGen:CA892728		JAK1:3716	SO:0001819&synonymous_variant										1	2230588																											1018					0.997							248.67	v6.1	Unknown		True	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	False	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:P733= mutant UNKNOWN.	False	The JAK1 ENSP00000343204.4:p733= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65310489						True	False	False	Unknown								False	False		JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	The JAK1 ENSP00000343204.4:p733= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:P733= mutant UNKNOWN.						v6.1	02/04/2019		GRCh38	JAK1	3716.0	ENSP00000343204.4:P733=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""JAK1"",""entrezGeneId"":3716,""alteration"":""ENSP00000343204.4:P733="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers."",""variantSummary"":""The JAK1 ENSP00000343204.4:p733= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:P733= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/04/2019""}"	True	True	False	Unknown		Unknown																						517,498	260,240	257,258	0/1	271,246,266,232	ATG	.	.	.			244,273,230,268	48.16		0.49064039408866994
GRCh38	JAK1	D12_12345_1234556_Thyroid_S9	p.Ser683=	ENSP00000343204.4:p.Ser683=	chr1	64845579	64845579.0	G	A	A	64845579	.	G	A	.	PASS	NM_002227	A	synonymous_variant	LOW	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	15/25		c.2049C>T	2343	2049	683	S	agC/agT	rs2230587&COSV61087573		-1		SNV	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			Gene3D:1.10.510.10&PDB-ENSP_mappings:4l00.A&PDB-ENSP_mappings:4l00.B&PDB-ENSP_mappings:4l01.A&PDB-ENSP_mappings:4l01.B&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF07714&PIRSF:PIRSF000636&PROSITE_profiles:PS50011&PANTHER:PTHR45807&SMART:SM00219&Superfamily:SSF56112&CDD:cd05077			0.1983	0.2035	0.2046	0.3165	0.1153	0.1503	0.1293	0.1993	0.1765	0.1314	0.2953	0.1266	0.1156	0.1163	0.1463	0.1589	0.1513	0.1966	0.1919	0.1562	0.1347	0.314	0.1298	0.102	0.1142	0.1404	0.1559	0.3165	EAS	benign	0&1	1&1	25741868&17727713&19434718&23670291&27049718&32750333&36355252&26242990						FAIL	34	44	2	-30	0.00	0.00	0.00	0.00	JAK1		1.6800e-01	1169783	0.13555	0.15068	0.19828	1153653	not_specified&JAK1-related_disorder&not_provided		MedGen:CN169374&.&MedGen:C3661900		NC_000001.11:g.64845579G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001730891&SCV004102449&SCV005287340	single_nucleotide_variant	SO:0001483	ClinGen:CA892761		JAK1:3716	SO:0001819&synonymous_variant										1	2230587																											717					0.989							248.07	v6.1	Unknown		True	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	False	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:S683= mutant UNKNOWN.	False	The JAK1 ENSP00000343204.4:s683= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65311262						True	False	False	Unknown								False	False		JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	The JAK1 ENSP00000343204.4:s683= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:S683= mutant UNKNOWN.						v6.1	02/04/2019		GRCh38	JAK1	3716.0	ENSP00000343204.4:S683=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""JAK1"",""entrezGeneId"":3716,""alteration"":""ENSP00000343204.4:S683="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers."",""variantSummary"":""The JAK1 ENSP00000343204.4:s683= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:S683= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/04/2019""}"	True	True	False	Unknown		Unknown																						351,358	190,199	161,159	0/1	164,187,181,177	CGC	0.00	0.00	0.00			155,196,172,186	52.7		0.5049365303244006
GRCh38	JAK1	D12_12345_1234556_Thyroid_S9	p.Ala193=	ENSP00000343204.4:p.Ala193=	chr1	64869379	64869379.0	A	G	G	64869379	.	A	G	.	PASS	NM_002227	G	synonymous_variant	LOW	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	6/25		c.579T>C	873	579	193	A	gcT/gcC	rs45598436&COSV61087391		-1		SNV	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			PDB-ENSP_mappings:5ixd.A&PDB-ENSP_mappings:5ixi.A&PDB-ENSP_mappings:5l04.A&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF18377&PIRSF:PIRSF000636&PROSITE_profiles:PS50057&PANTHER:PTHR45807&SMART:SM00295&Superfamily:SSF47031&CDD:cd14473			0.0391	0.028	0.0504	0	0.1133	0.0102	0.09259	0.03708	0.05767	0.0946	7.557e-05	0.1122	0.08394	0.1046	0.08302	0.0146	0.07755	0.03783	0.1096	0.07911	0.09481	0.0001933	0.1132	0.08503	0.1048	0.08507	0.01268	0.1133	EUR	benign	0&1	1&1	23670291&26242990						FAIL	7	-34	16	-17	0.00	0.00	0.00	0.00	JAK1		1.6800e-01	1168339	0.08048	0.07644	0.03914	1153660	not_provided		MedGen:C3661900		NC_000001.11:g.64869379A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001727223&SCV005287348	single_nucleotide_variant	SO:0001483	ClinGen:CA893130		JAK1:3716	SO:0001819&synonymous_variant										1	45598436																											549					0.995							247.98	v6.1	Unknown		True	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	False	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:A193= mutant UNKNOWN.	False	The JAK1 ENSP00000343204.4:a193= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65335062						True	False	False	Unknown								False	False		JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	The JAK1 ENSP00000343204.4:a193= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:A193= mutant UNKNOWN.						v6.1	02/04/2019		GRCh38	JAK1	3716.0	ENSP00000343204.4:A193=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""JAK1"",""entrezGeneId"":3716,""alteration"":""ENSP00000343204.4:A193="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers."",""variantSummary"":""The JAK1 ENSP00000343204.4:a193= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:A193= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/04/2019""}"	True	True	False	Unknown		Unknown																						258,288	129,156	129,132	0/1	134,124,136,152	CAG	.	.	.			147,111,152,136	57.08		0.5274725274725275
GRCh38	NEGR1	D12_12345_1234556_Thyroid_S9	p.Y347S	ENSP00000350364.4:p.Tyr347Ser	chr1	71407471	71407471.0	T	G	G	71407471	.	T	G	.	PASS	NM_173808	G	missense_variant	MODERATE	NEGR1	ENSG00000172260	Transcript	ENST00000357731	protein_coding	7/7		c.1040A>C	1085	1040	347	Y/S	tAc/tCc	rs41289154&COSV60833851&COSV60866382		-1		SNV	HGNC	HGNC:17302	YES	MANE_Select	NM_173808.3		1	P1	CCDS661.1	ENSP00000350364	Q7Z3B1.174		UPI00000477EE	Q7Z3B1-1			deleterious(0)	possibly_damaging(0.62)	Phobius:TRANSMEMBRANE&AFDB-ENSP_mappings:AF-Q7Z3B1-F1			0.0114	0.0008	0.0115	0	0.0398	0.0082	0.03339	0.004523	0.00956	0.02286	7.565e-05	0.08827	0.009031	0.03645	0.0285	0.00701	0.02661	0.005396	0.03399	0.01502	0.02191	0.0001933	0.08491	0.02041	0.03697	0.01517	0.007469	0.08827	gnomADe_FIN		0&1&1	0&1&1	24081230&30402368						FAIL	-8	8	42	8	0.00	0.01	0.02	0.00	NEGR1	0.282	4.2900e-01																																																											72					0.944							238.67	v6.1	Unknown		True	NEGR1, a cell adhesion protein, is altered by deletion and mutation in various cancer types.	False	08/28/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NEGR1 ENSP00000350364.4:Y347S mutant UNKNOWN.	False	The NEGR1 ENSP00000350364.4:y347s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	71873154						True	False	False	Unknown								False	False		NEGR1, a cell adhesion protein, is altered by deletion and mutation in various cancer types.	The NEGR1 ENSP00000350364.4:y347s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NEGR1 ENSP00000350364.4:Y347S mutant UNKNOWN.						v6.1	08/28/2019		GRCh38	NEGR1	257194.0	ENSP00000350364.4:Y347S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NEGR1"",""entrezGeneId"":257194,""alteration"":""ENSP00000350364.4:Y347S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NEGR1, a cell adhesion protein, is altered by deletion and mutation in various cancer types."",""variantSummary"":""The NEGR1 ENSP00000350364.4:y347s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NEGR1 ENSP00000350364.4:Y347S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/28/2019""}"	True	True	False	Unknown		Unknown																						37,31	17,19	20,12	0/1	17,20,15,16	GTA	.	.	.			15,22,21,10	30.52		0.45588235294117646
GRCh38	NEGR1	D12_12345_1234556_Thyroid_S9	p.Thr296=	ENSP00000350364.4:p.Thr296=	chr1	71592869	71592869.0	G	A	A	71592869	.	G	A	.	PASS	NM_173808	A	synonymous_variant	LOW	NEGR1	ENSG00000172260	Transcript	ENST00000357731	protein_coding	6/7		c.888C>T	933	888	296	T	acC/acT	rs1413368&COSV108130367		-1		SNV	HGNC	HGNC:17302	YES	MANE_Select	NM_173808.3		1	P1	CCDS661.1	ENSP00000350364	Q7Z3B1.174		UPI00000477EE	Q7Z3B1-1					PDB-ENSP_mappings:6dld.B&PDB-ENSP_mappings:6dld.D&PDB-ENSP_mappings:6u6t.A&PDB-ENSP_mappings:6u6t.B&SMART:SM00409&SMART:SM00408&PROSITE_profiles:PS50835&Gene3D:2.60.40.10&Pfam:PF13927&PANTHER:PTHR42757&Superfamily:SSF48726&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q7Z3B1-F1			0.8496	0.6634	0.928	0.8472	0.996	0.8978	0.9771	0.6736	0.9231	0.9894	0.8289	0.9962	0.9576	0.9984	0.9605	0.9134	0.8948	0.6858	1	0.9131	0.9876	0.8552	0.9962	0.9524	0.9974	0.9195	0.9065	1	gnomADg_AMI		0&1	0&1							FAIL	-23	20	-49	-17	0.00	0.00	0.00	0.00	NEGR1		4.2900e-01																																																											93					1							245.34	v6.1	Unknown		True	NEGR1, a cell adhesion protein, is altered by deletion and mutation in various cancer types.	False	08/28/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NEGR1 ENSP00000350364.4:T296= mutant UNKNOWN.	False	The NEGR1 ENSP00000350364.4:t296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	72058552						True	False	False	Unknown								False	False		NEGR1, a cell adhesion protein, is altered by deletion and mutation in various cancer types.	The NEGR1 ENSP00000350364.4:t296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NEGR1 ENSP00000350364.4:T296= mutant UNKNOWN.						v6.1	08/28/2019		GRCh38	NEGR1	257194.0	ENSP00000350364.4:T296=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NEGR1"",""entrezGeneId"":257194,""alteration"":""ENSP00000350364.4:T296="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NEGR1, a cell adhesion protein, is altered by deletion and mutation in various cancer types."",""variantSummary"":""The NEGR1 ENSP00000350364.4:t296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NEGR1 ENSP00000350364.4:T296= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/28/2019""}"	True	True	False	Unknown		Unknown																						0,93	0,39	0,54	0/1	0,0,53,40	AGG	0.00	0.00	0.00			0,0,43,50	64.65		1.0
GRCh38	BCL10	D12_12345_1234556_Thyroid_S9			chr1	85280884		G	<INS>	<INS>	85280884	MantaINS:4851:0:0:0:6:0	G	<INS>	.	PASS	NM_003921	insertion	upstream_gene_variant	MODIFIER	BCL10	ENSG00000142867	Transcript	ENST00000648566	protein_coding										4253	-1		insertion	HGNC	HGNC:989	YES	MANE_Select	NM_003921.5			P1	CCDS704.1	ENSP00000498104	O95999.204		UPI000012682F			1																																																																																																															0,72		0,72							72	TCCTTCTTGCTTTCTAATGCATCATAATTCTTTCATTAGTAAACTAATTTTCCTCTTTCTGCTAAATCACAG		TCCTTCTTGCTTTCTAATGCATCATAATTCTTTCATTAGTAAACTAATTTTCCTCTTTCTGCTAAATCACAGAGTTGAAACTTTCTTTTGATTGAGCAGTTTGG																chr1	85746567	ATCATGTCGTCTGCAAACAGGGACAATTTGACTTCCTCTTTTCCTAATTGAATACCCTTTATT			INS																																													True	True	False	Unknown		Unknown																															1,2				0,3	
GRCh38	TGFBR3	D12_12345_1234556_Thyroid_S9			chr1	91772335	91772353.0	A	AATCCCATTTTTGTTTAGG	AATCCCATTTTTGTTTAGG	91772335	.	A	AATCCCATTTTTGTTTAGG	.	PASS		ATCCCATTTTTGTTTAGG	intron_variant&NMD_transcript_variant	MODIFIER	TGFBR3	ENSG00000069702	Transcript	ENST00000533089	nonsense_mediated_decay		4/19	c.*78-1383_*78-1366dup						rs17878444		-1		insertion	HGNC	HGNC:11774					1			ENSP00000433477		E9PKY4.62	UPI0001F7811B			1						0.4028	0.5764	0.4121	0.1151	0.3837	0.4775											0.413	0.5351	0.2692	0.4111	0.391	0.1291	0.347	0.5136	0.3696	0.4064	0.4741	0.5764	AFR				23690203&22124616&36292568																																																																												90					0.933							232.18													chr1	92237892																																																	True	False	False	Unknown		Unknown																						53,31	25,16	28,15	0/1	22,31,15,16	AAA						26,27,10,21	25.35		0.36904761904761907
GRCh38	NRAS	D12_12345_1234556_Thyroid_S9	p.Q61R	ENSP00000358548.4:p.Gln61Arg	chr1	114713908	114713908.0	T	C	C	114713908	.	T	C	.	PASS	NM_002524	C	missense_variant	MODERATE	NRAS	ENSG00000213281	Transcript	ENST00000369535	protein_coding	3/7		c.182A>G	313	182	61	Q/R	cAa/cGa	rs11554290&COSV54736340&COSV54736624&COSV54738969&COSV54747786		-1		SNV	HGNC	HGNC:7989	YES	MANE_Select	NM_002524.5		1	P1	CCDS877.1	ENSP00000358548	P01111.251	Q5U091.171	UPI0000001254			1	deleterious_low_confidence(0.02)		PDB-ENSP_mappings:3con.A&PDB-ENSP_mappings:5uhv.A&PDB-ENSP_mappings:6e6h.A&PDB-ENSP_mappings:6mpp.B&PDB-ENSP_mappings:6wgh.A&PDB-ENSP_mappings:6wgh.B&PDB-ENSP_mappings:6zio.A&PDB-ENSP_mappings:6zio.B&PDB-ENSP_mappings:6zir.A&PDB-ENSP_mappings:6ziz.A&PDB-ENSP_mappings:6ziz.B&PDB-ENSP_mappings:7f68.A&PDB-ENSP_mappings:8tbi.A&PDB-ENSP_mappings:8tbi.B&PDB-ENSP_mappings:8vm2.A&PDB-ENSP_mappings:8vm2.B&PDB-ENSP_mappings:8vm2.C&SMART:SM00173&SMART:SM00175&SMART:SM00174&Superfamily:SSF52540&CDD:cd04138&PANTHER:PTHR24070&PROSITE_profiles:PS51419&PROSITE_profiles:PS51420&PROSITE_profiles:PS51421&Pfam:PF00071&NCBIFAM:TIGR00231&Gene3D:3.40.50.300&Prints:PR00449&AFDB-ENSP_mappings:AF-P01111-F1																																likely_pathogenic&pathogenic&uncertain_significance	0&1&1&1&1	1&1&1&1&1	24033266&1654209&2278970&2674680&3122217&6587382&8120410&12460918&12727991&14508525&16273091&16291983&16434492&17699718&18390968&18633438&18948947&19075190&19880792&20130576&20149136&20179705&20406486&20619739&20736745&21107323&21305640&21576590&21729679&21829508&22407852&22499344&22761467&22773810&23392294&23414587&23515407&23538902&23569304&23614898&24006476&24370118&25032700&25157968&26619011&29525983&31752122&35117297&29721857&38684670						FAIL	6	-42	-6	-1	0.00	0.00	0.00	0.00	NRAS	0.888	5.5000e-01	13900				28939	Vascular_malformation&Colorectal_cancer&Large_congenital_melanocytic_nevus&Neurocutaneous_melanocytosis&not_provided&Linear_nevus_sebaceous_syndrome&Non-small_cell_lung_carcinoma&Noonan_syndrome_6&Epidermal_nevus&Thyroid_cancer&_nonmedullary&_2		MONDO:MONDO:0024291&MedGen:C0158570&MONDO:MONDO:0005575&MedGen:C0346629&OMIM:114500&Human_Phenotype_Ontology:HP:0005600&Human_Phenotype_Ontology:HP:0005604&MONDO:MONDO:0044792&MedGen:C1842036&OMIM:137550&Orphanet:626&MONDO:MONDO:0009578&MedGen:C0544862&OMIM:249400&Orphanet:2481&MedGen:C3661900&Human_Phenotype_Ontology:HP:0010817&MONDO:MONDO:0008097&MedGen:C4552097&OMIM:163200&Orphanet:2612&Human_Phenotype_Ontology:HP:0030358&MONDO:MONDO:0005233&MeSH:D002289&MedGen:C0007131&MONDO:MONDO:0013186&MedGen:C2750732&OMIM:613224&Orphanet:648&Human_Phenotype_Ontology:HP:0010816&MONDO:MONDO:0008093&MedGen:C0334082&OMIM:162900&Orphanet:79414&MONDO:MONDO:0008566&MedGen:C4225426&OMIM:188470		NC_000001.11:g.114713908T>C	criteria_provided&_multiple_submitters&_no_conflicts	Pathogenic			SCV000061232&SCV000490986&SCV002525697&SCV004176931&SCV004810324&SCV005902174&SCV006279548	single_nucleotide_variant	SO:0001483	ClinGen:CA123618&OMIM:164790.0002&UniProtKB:P01111																																																																																																																																															65,19	31,12	34,7	0/1	34,31,9,10	TTG	.	.	.			26,39,6,13	51.5		0.2261904761904762
GRCh38	NRAS	D12_12345_1234556_Thyroid_S9			chr1	114714900	114714900.0	C	T	T	114714900	.	C	T	.	PASS	NM_002524	T	intron_variant	MODIFIER	NRAS	ENSG00000213281	Transcript	ENST00000369535	protein_coding		2/6	c.112-922G>A						rs6671984&COSV54761004		-1		SNV	HGNC	HGNC:7989	YES	MANE_Select	NM_002524.5		1	P1	CCDS877.1	ENSP00000358548	P01111.251	Q5U091.171	UPI0000001254			1						0.8752	0.9803	0.8213	0.999	0.67	0.8548											0.7634	0.9348	0.63	0.8232	0.6638	0.9981	0.6953	0.7143	0.6402	0.7528	0.8334	0.999	EAS		0&1	0&1							FAIL	-4	1	-19	1	0.00	0.00	0.00	0.00	NRAS		5.5000e-01																																																											273					0.996							244.62													chr1	115257521																																																	True	True	False	Unknown		Unknown																						0,272	0,125	0,147	0/1	0,0,144,128	ACA	0.00	0.00	0.00			0,0,175,97	64.73		1.0
GRCh38	TENT5C	D12_12345_1234556_Thyroid_S9	p.His67=	ENSP00000358458.3:p.His67=	chr1	117623069	117623069.0	C	T	T	117623069	.	C	T	.	PASS	NM_017709	T	synonymous_variant	LOW	TENT5C	ENSG00000183508	Transcript	ENST00000369448	protein_coding	2/2		c.201C>T	334	201	67	H	caC/caT	rs1630312&COSV65616400&COSV65616610		1		SNV	HGNC	HGNC:24712	YES	MANE_Select	NM_017709.4		1	P1	CCDS896.1	ENSP00000358458	Q5VWP2.131		UPI0000070C6C			1			PDB-ENSP_mappings:6w36.A&PDB-ENSP_mappings:6w38.A&PDB-ENSP_mappings:6w3i.A&PDB-ENSP_mappings:6w3j.A&PDB-ENSP_mappings:8eqb.B&PDB-ENSP_mappings:8eqb.E&PDB-ENSP_mappings:8eqb.H&PDB-ENSP_mappings:8eqb.K&AFDB-ENSP_mappings:AF-Q5VWP2-F1&Pfam:PF07984&PANTHER:PTHR12974&SMART:SM01153			0.2071	0.1974	0.281	0.0923	0.2873	0.2035	0.2947	0.2147	0.2097	0.2082	0.1445	0.3616	0.2119	0.3136	0.2706	0.203	0.2689	0.2192	0.1088	0.2599	0.2154	0.1045	0.3508	0.2245	0.3104	0.2658	0.2102	0.3616	gnomADe_FIN		0&1&1	1&1&1	24728327																	4.4800e-01																																																											1354					0.999							246.88	v6.1	Unknown		True	TENT5C, a non-canonical poly(A) polymerase, is most frequently altered by mutation and deletion in multiple myelomas.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TENT5C ENSP00000358458.3:H67= mutant UNKNOWN.	False	The TENT5C ENSP00000358458.3:h67= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	118165691						True	False	False	Unknown								False	False		TENT5C, a non-canonical poly(A) polymerase, is most frequently altered by mutation and deletion in multiple myelomas.	The TENT5C ENSP00000358458.3:h67= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TENT5C ENSP00000358458.3:H67= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	TENT5C	54855.0	ENSP00000358458.3:H67=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""TENT5C"",""entrezGeneId"":54855,""alteration"":""ENSP00000358458.3:H67="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""TENT5C, a non-canonical poly(A) polymerase, is most frequently altered by mutation and deletion in multiple myelomas."",""variantSummary"":""The TENT5C ENSP00000358458.3:h67= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TENT5C ENSP00000358458.3:H67= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						693,660	348,332	345,328	0/1	361,332,342,318	ACG	0.00	0.00	0.00			360,333,306,354	49.14		0.4878048780487805
GRCh38	NOTCH2	D12_12345_1234556_Thyroid_S9	p.Gly2447=	ENSP00000256646.2:p.Gly2447=	chr1	119915381	119915381.0	A	T	T	119915381	.	A	T	.	PASS	NM_024408	T	synonymous_variant	LOW	NOTCH2	ENSG00000134250	Transcript	ENST00000256646	protein_coding	34/34		c.7341T>A	7597	7341	2447	G	ggT/ggA	rs6685892&COSV56683182		-1		SNV	HGNC	HGNC:7882	YES	MANE_Select	NM_024408.4		1	P1	CCDS908.1	ENSP00000256646	Q04721.252		UPI000013CF1D			1			AFDB-ENSP_mappings:AF-Q04721-F1&Phobius:CYTOPLASMIC_DOMAIN&PIRSF:PIRSF002279&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.1925	0.3775	0.1182	0.0476	0.1103	0.229	0.1148	0.3323	0.09163	0.07147	0.02209	0.1336	0.0857	0.1073	0.1203	0.1824	0.168	0.3256	0.05921	0.1065	0.08357	0.03141	0.1346	0.08163	0.1063	0.1556	0.1891	0.3775	AFR	benign	0&1	1&1	25741868&34737607&29593342						FAIL	28	-8	-10	34	0.00	0.00	0.00	0.00	NOTCH2		1.5100e-01	261705	0.17853	0.12930	0.19249	249377	not_provided&Hajdu-Cheney_syndrome&not_specified		MedGen:C3661900&MONDO:MONDO:0007057&MedGen:C0917715&OMIM:102500&Orphanet:955&MedGen:CN169374		NC_000001.11:g.119915381A>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000314297&SCV000339995&SCV001722438&SCV001940886&SCV005281105	single_nucleotide_variant	SO:0001483	ClinGen:CA1039283		NOTCH2:4853	SO:0001819&synonymous_variant										1	6685892																											919					0.998							248.58	v6.1	Unknown		True	NOTCH2 encodes a transmembrane receptor that regulates many aspects of development by affecting cell-fate determination.	False	05/05/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH2 ENSP00000256646.2:G2447= mutant UNKNOWN.	False	The NOTCH2 ENSP00000256646.2:g2447= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	120458004						True	False	False	Unknown								False	False		NOTCH2 encodes a transmembrane receptor that regulates many aspects of development by affecting cell-fate determination.	The NOTCH2 ENSP00000256646.2:g2447= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH2 ENSP00000256646.2:G2447= mutant UNKNOWN.						v6.1	05/05/2017		GRCh38	NOTCH2	4853.0	ENSP00000256646.2:G2447=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH2"",""entrezGeneId"":4853,""alteration"":""ENSP00000256646.2:G2447="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH2 encodes a transmembrane receptor that regulates many aspects of development by affecting cell-fate determination."",""variantSummary"":""The NOTCH2 ENSP00000256646.2:g2447= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH2 ENSP00000256646.2:G2447= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/05/2017""}"	True	True	False	Unknown		Unknown																						486,431	222,223	264,208	0/1	234,252,214,217	CAC	.	.	.			262,224,216,215	30.39		0.47001090512540894
GRCh38	NOTCH2	D12_12345_1234556_Thyroid_S9			chr1	119935375	119935375.0	C	A	A	119935375	.	C	A	.	PASS	NM_024408	A	intron_variant	MODIFIER	NOTCH2	ENSG00000134250	Transcript	ENST00000256646	protein_coding		22/33	c.3655+97G>T						rs2453056&COSV104375007		-1		SNV	HGNC	HGNC:7882	YES	MANE_Select	NM_024408.4		1	P1	CCDS908.1	ENSP00000256646	Q04721.252		UPI000013CF1D			1						0.3013	0.6021	0.1945	0.1101	0.1312	0.3425	0.1474	0.5274	0.1802	0.1124	0.06797	0.1661	0.1626	0.125	0.1657	0.2947	0.2445	0.5134	0.06374	0.172	0.1184	0.09737	0.1657	0.1599	0.1259	0.2287	0.3014	0.6021	AFR	benign	0&1	1&1	29434720						FAIL	-21	0	2	-39	0.00	0.00	0.00	0.00	NOTCH2		1.5100e-01	1179326			0.30132	1168765	not_provided		MedGen:C3661900		NC_000001.11:g.119935375C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001753026&SCV005283304	single_nucleotide_variant	SO:0001483	ClinGen:CA1040001		NOTCH2:4853	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant										1	2453056																											114					0.974							243.05													chr1	120477998																																																	True	True	False	Unknown		Unknown																						51,60	24,32	27,28	0/1	31,20,28,32	TCC	0.00	0.00	0.00			26,25,24,36	40.36		0.5405405405405406
GRCh38	RIT1	D12_12345_1234556_Thyroid_S9			chr1	155910782	155910782.0	C	G	G	155910782	.	C	G	.	PASS	NM_006912	G	5_prime_UTR_variant	MODIFIER	RIT1	ENSG00000143622	Transcript	ENST00000368323	protein_coding	2/6		c.-21G>C	130					rs493446&COSV107467725		-1		SNV	HGNC	HGNC:10023	YES	MANE_Select	NM_006912.6		1	P3	CCDS1123.1	ENSP00000357306	Q92963.196		UPI0000070A64	Q92963-1		1						0.7800	0.4334	0.9078	0.9405	0.8926	0.8763	0.9113	0.5274	0.9405	0.8774	0.9448	0.8941	0.8291	0.9279	0.8913	0.8561	0.8116	0.5424	0.7785	0.9073	0.875	0.9393	0.8896	0.8163	0.9246	0.8444	0.866	0.9448	gnomADe_EAS	benign	0&1	1&1	25741868&24033266						FAIL	-3	22	23	-41	0.00	0.01	0.00	0.03	RIT1		5.2300e-01	227047	0.79525	0.87745	0.77995	228267	not_specified&Noonan_syndrome_8&not_provided		MedGen:CN169374&MONDO:MONDO:0014143&MedGen:C3809233&OMIM:615355&Orphanet:648&MedGen:C3661900		NC_000001.11:g.155910782C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000269747&SCV000307147&SCV000698731&SCV001836493&SCV002033634&SCV005282251&SCV006065249	single_nucleotide_variant	SO:0001483	ClinGen:CA1151916		RIT1:6016	SO:0001583&missense_variant&SO:0001623&5_prime_UTR_variant&SO:0001627&intron_variant										1	493446																											951					0.999							247.79													chr1	155880573																																																	True	True	False	Unknown		Unknown																						0,950	0,478	0,472	0/1	0,0,490,460	TCG	.	.	.			0,0,446,504	64.73		1.0
GRCh38	NTRK1	D12_12345_1234556_Thyroid_S9			chr1	156815825	156815825.0	G	A	A	156815825	.	G	A	.	PASS		A	5_prime_UTR_variant	MODIFIER	NTRK1	ENSG00000198400	Transcript	ENST00000674537	protein_coding	1/18		c.-217G>A	190					rs1800601&COSV63884607		1		SNV	HGNC	HGNC:8031								ENSP00000502725		A0A6Q8PHG5.19	UPI001635BE7D			1						0.6370	0.444	0.6657	0.8135	0.6948	0.636	0.6792	0.4906	0.6934	0.6894	0.8167	0.6502	0.7194	0.6819	0.6825	0.6571	0.6352	0.5057	0.7978	0.6955	0.6831	0.8187	0.6614	0.7143	0.6765	0.6431	0.647	0.8187	gnomADg_EAS	benign	0&1	1&1	35484167&20219210&30595370																	9.1700e-01	380853	0.61771	0.66741	0.63698	364541	not_provided&X-linked_lymphoproliferative_disease_due_to_SH2D1A_deficiency&Hereditary_insensitivity_to_pain_with_anhidrosis&not_specified		MedGen:C3661900&MONDO:MONDO:0024551&MedGen:C5399825&OMIM:308240&Orphanet:2442&Orphanet:538931&MONDO:MONDO:0009746&MedGen:C0020074&OMIM:256800&Orphanet:642&MedGen:CN169374		NC_000001.11:g.156815825G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000519553&SCV001754583&SCV004015454&SCV005282787	single_nucleotide_variant	SO:0001483	ClinGen:CA1167403		NTRK1:4914&SH2D2A:9047	SO:0001623&5_prime_UTR_variant&SO:0001627&intron_variant										1	1800601																											805					0.994							244.8													chr1	156785617																																																	True	True	False	Unknown		Unknown																						0,800	0,408	0,392	0/1	0,0,420,380	CGG	0.00	0.00	0.00			0,0,436,364	64.73		1.0
GRCh38	NTRK1	D12_12345_1234556_Thyroid_S9	p.Ala629=	ENSP00000431418.1:p.Ala629=	chr1	156879203	156879203.0	C	T	T	156879203	.	C	T	.	PASS	NM_002529	T	synonymous_variant	LOW	NTRK1	ENSG00000198400	Transcript	ENST00000524377	protein_coding	15/17		c.1887C>T	1957	1887	629	A	gcC/gcT	rs6337&COSV62325231		1		SNV	HGNC	HGNC:8031	YES	MANE_Select	NM_002529.4		1	P4	CCDS1161.1	ENSP00000431418	P04629.274		UPI000013D5D3	P04629-1		1			PDB-ENSP_mappings:4aoj.A&PDB-ENSP_mappings:4aoj.B&PDB-ENSP_mappings:4aoj.C&PDB-ENSP_mappings:4f0i.A&PDB-ENSP_mappings:4f0i.B&PDB-ENSP_mappings:4gt5.A&PDB-ENSP_mappings:4pmm.A&PDB-ENSP_mappings:4pmp.A&PDB-ENSP_mappings:4pms.A&PDB-ENSP_mappings:4pmt.A&PDB-ENSP_mappings:4yne.A&PDB-ENSP_mappings:4yps.A&PDB-ENSP_mappings:5h3q.A&PDB-ENSP_mappings:5i8a.A&PDB-ENSP_mappings:5jfs.A&PDB-ENSP_mappings:5jfv.A&PDB-ENSP_mappings:5jfw.A&PDB-ENSP_mappings:5jfx.A&PDB-ENSP_mappings:5kmi.A&PDB-ENSP_mappings:5kmj.A&PDB-ENSP_mappings:5kmk.A&PDB-ENSP_mappings:5kml.A&PDB-ENSP_mappings:5kmm.A&PDB-ENSP_mappings:5kmn.A&PDB-ENSP_mappings:5kmo.A&PDB-ENSP_mappings:5kvt.A&PDB-ENSP_mappings:5wr7.A&PDB-ENSP_mappings:6d1y.A&PDB-ENSP_mappings:6d1z.A&PDB-ENSP_mappings:6d20.A&PDB-ENSP_mappings:6d22.A&PDB-ENSP_mappings:6dkb.A&PDB-ENSP_mappings:6dkg.A&PDB-ENSP_mappings:6dki.A&PDB-ENSP_mappings:6dkw.A&PDB-ENSP_mappings:6dkw.B&PDB-ENSP_mappings:6iqn.A&PDB-ENSP_mappings:6iqn.B&PDB-ENSP_mappings:6j5l.A&PDB-ENSP_mappings:6npt.A&PDB-ENSP_mappings:6nsp.A&PDB-ENSP_mappings:6nss.A&PDB-ENSP_mappings:6pl1.A&PDB-ENSP_mappings:6pl2.A&PDB-ENSP_mappings:6pl3.A&PDB-ENSP_mappings:6pl4.A&PDB-ENSP_mappings:6pma.A&PDB-ENSP_mappings:6pmb.A&PDB-ENSP_mappings:6pmc.A&PDB-ENSP_mappings:6pme.A&PDB-ENSP_mappings:6pme.B&PDB-ENSP_mappings:6pme.C&PDB-ENSP_mappings:7vkm.A&PDB-ENSP_mappings:7vkn.A&PDB-ENSP_mappings:7vko.A&PDB-ENSP_mappings:7xaf.A&PDB-ENSP_mappings:7xbi.A&PDB-ENSP_mappings:8j5w.A&PDB-ENSP_mappings:8j5x.A&PDB-ENSP_mappings:8j61.A&PDB-ENSP_mappings:8j63.A&Low_complexity_(Seg):seg&CDD:cd05092&PANTHER:PTHR24416&SMART:SM00219&Superfamily:SSF56112&Phobius:CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50011&Gene3D:1.10.510.10&Pfam:PF07714&AFDB-ENSP_mappings:AF-P04629-F1			0.3341	0.1384	0.5735	0.0437	0.7127	0.3384	0.6671	0.193	0.5778	0.7503	0.04571	0.7333	0.603	0.7257	0.6204	0.3985	0.5328	0.214	0.711	0.5584	0.7501	0.05056	0.7306	0.6735	0.724	0.5536	0.3708	0.7503	gnomADe_ASJ	benign	0&1	1&1	26384852&20003389&33986442&16373086						FAIL	13	40	-50	12	0.00	0.00	0.00	0.04	NTRK1		9.5400e-01	138564	0.55683	0.57236	0.33407	142267	Hereditary_insensitivity_to_pain_with_anhidrosis&not_specified&not_provided		MONDO:MONDO:0009746&MedGen:C0020074&OMIM:256800&Orphanet:642&MedGen:CN169374&MedGen:C3661900		NC_000001.11:g.156879203C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000349062&SCV000614366&SCV001720533&SCV001748595&SCV004016468&SCV005282814	single_nucleotide_variant	SO:0001483	ClinGen:CA292613		NTRK1:4914	SO:0001819&synonymous_variant										1	6337																											865					0.995							248.34	v6.1	Unknown		True	NTRK1, a receptor tyrosine kinase, is altered by gene fusions in various cancer types.	False	02/09/2021	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK1 ENSP00000431418.1:A629= mutant UNKNOWN.	False	The NTRK1 ENSP00000431418.1:a629= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	156848995						True	False	False	Unknown								False	False		NTRK1, a receptor tyrosine kinase, is altered by gene fusions in various cancer types.	The NTRK1 ENSP00000431418.1:a629= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK1 ENSP00000431418.1:A629= mutant UNKNOWN.						v6.1	02/09/2021		GRCh38	NTRK1	4914.0	ENSP00000431418.1:A629=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NTRK1"",""entrezGeneId"":4914,""alteration"":""ENSP00000431418.1:A629="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NTRK1, a receptor tyrosine kinase, is altered by gene fusions in various cancer types."",""variantSummary"":""The NTRK1 ENSP00000431418.1:a629= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK1 ENSP00000431418.1:A629= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/09/2021""}"	True	True	False	Unknown		Unknown																						1,860	1,410	0,450	0/1	0,1,436,424	CCG	0.00	0.00	0.00			0,1,418,442	64.73		0.9988385598141696
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Ala2365=	ENSP00000495214.1:p.Ala2365=	chr1	158612856	158612856.0	T	C	C	158612856	.	T	C	.	PASS	NM_003126	C	synonymous_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	51/52		c.7095A>G	7293	7095	2365	A	gcA/gcG	rs2251969&COSV63755039		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1			Gene3D:1.10.238.10&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF08726&SMART:SM01184&Superfamily:SSF47473			0.5048	0.4183	0.5202	0.6319	0.5626	0.4202	0.544	0.4273	0.5448	0.5777	0.5987	0.6302	0.5297	0.5493	0.5483	0.4297	0.5214	0.4229	0.5548	0.5439	0.5701	0.6232	0.6383	0.6062	0.553	0.5422	0.4327	0.6383	gnomADg_FIN	benign	0&1	1&1	25741868&24077844&24895341						FAIL	7	-4	-35	-4	0.00	0.00	0.00	0.02	SPTA1		5.9100e-01	258958	0.50948	0.53849	0.50479	249424	not_specified&Hereditary_spherocytosis_type_3&not_provided&Pyropoikilocytosis&_hereditary&Elliptocytosis_2		MedGen:CN169374&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MedGen:C3661900&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288		NC_000001.11:g.158612856T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309440&SCV000349153&SCV000349154&SCV000349155&SCV000605266&SCV001864201&SCV002057656&SCV002057657&SCV002057658&SCV002390490&SCV005282858	single_nucleotide_variant	SO:0001483	ClinGen:CA1181731		SPTA1:6708	SO:0001819&synonymous_variant										1	2251969																											73					0.986							247.14	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158582646						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:A2365=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:A2365="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						31,41	16,21	15,20	0/1	17,14,16,25	CTG	.	.	.			16,15,20,21	39.77		0.5694444444444444
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.I2265T	ENSP00000495214.1:p.Ile2265Thr	chr1	158614301	158614301.0	A	G	G	158614301	.	A	G	.	PASS	NM_003126	G	missense_variant	MODERATE	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	49/52		c.6794T>C	6992	6794	2265	I/T	aTc/aCc	rs952094&COSV63754417		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1	tolerated_low_confidence(1)		Gene3D:1.10.238.10&AFDB-ENSP_mappings:AF-P02549-F1			0.5062	0.4228	0.5202	0.6319	0.5636	0.4202	0.5406	0.4215	0.5406	0.5756	0.5984	0.6301	0.5308	0.5457	0.5458	0.4243	0.5206	0.423	0.5529	0.5442	0.5698	0.6211	0.6326	0.6122	0.5522	0.5441	0.4321	0.6326	gnomADg_FIN	benign	0&1	1&1	25741868&29905378						FAIL	-6	5	-7	-48	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01	258957	0.50681	0.53735	0.50619	249425	not_specified&Hereditary_spherocytosis_type_3&Elliptocytosis_2&Pyropoikilocytosis&_hereditary&not_provided		MedGen:CN169374&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:C3661900		NC_000001.11:g.158614301A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309439&SCV000349180&SCV000349181&SCV000349182&SCV000605267&SCV001915902&SCV002057659&SCV002057660&SCV002057661&SCV002403200&SCV005282859	single_nucleotide_variant	SO:0001483	ClinGen:CA1181833&UniProtKB:P02549																																																																																																																																															36,38	19,17	17,21	0/1	16,20,16,22	GAT	.	.	.			13,23,17,21	35.72		0.5135135135135135
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Q2146R	ENSP00000495214.1:p.Gln2146Arg	chr1	158619315	158619315.0	T	C	C	158619315	.	T	C	.	PASS	NM_003126	C	missense_variant	MODERATE	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	45/52		c.6437A>G	6635	6437	2146	Q/R	cAa/cGa	rs138055271&COSV63750926		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1	deleterious_low_confidence(0)		Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176&CDD:cd00176&Low_complexity_(Seg):seg			0.0052	0	0.0101	0	0.0169	0.002	0.01114	0.002061	0.006574	0.004439	2.519e-05	0.008667	0.01664	0.01293	0.01103	0.002353	0.008461	0.00267	0.01425	0.00895	0.003746	0	0.006306	0.01701	0.01333	0.01278	0.001864	0.01701	gnomADg_MID	benign&uncertain_significance&likely_benign&uncertain_significance&_benign&_likely_benign	0&1	1&1	25741868&37596262						FAIL	19	-2	-19	19	0.04	0.00	0.00	0.00	SPTA1		5.9100e-01	258953	0.00868	0.00852	0.00519	249429	not_provided&Hereditary_spherocytosis_type_3&Elliptocytosis_2&Pyropoikilocytosis&_hereditary&not_specified		MedGen:C3661900&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:CN169374		NC_000001.11:g.158619315T>C	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(3)&Benign(4)&Likely_benign(1)		SCV000309435&SCV000349216&SCV000349217&SCV000349218&SCV000884580&SCV001113578&SCV001713867&SCV004009891	single_nucleotide_variant	SO:0001483	ClinGen:CA1181979		SPTA1:6708	SO:0001583&missense_variant										1	138055271																											177					0.904							223.1	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158589105						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:Q2146R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:Q2146R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						81,79	50,49	31,30	0/1	41,40,36,43	TTG	.	.	.			42,39,38,41	36.75		0.49375
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.K1693Q	ENSP00000495214.1:p.Lys1693Gln	chr1	158638145	158638145.0	T	G	G	158638145	.	T	G	.	PASS	NM_003126	G	missense_variant	MODERATE	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	36/52		c.5077A>C	5275	5077	1693	K/Q	Aag/Cag	rs857725&CM1212304&COSV63750569		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1	tolerated_low_confidence(0.18)		Gene3D:1.20.58.60&PDB-ENSP_mappings:5j4o.A&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176			0.2456	0.1036	0.3026	0.4365	0.2763	0.1687	0.2682	0.1188	0.3587	0.2348	0.4081	0.3404	0.2801	0.2675	0.2763	0.1821	0.2389	0.1213	0.3253	0.3163	0.2359	0.4519	0.3294	0.2789	0.2649	0.2609	0.1859	0.4519	gnomADg_EAS	benign	0&1&1	1&1&1	25741868&35124268&20858683&34059833&32327693&22560525&32888493&34014839&34887591&34594039&28212192&39280063						FAIL	49	27	-14	7	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01	258943	0.21836	0.27368	0.24561	249439	not_provided&Hereditary_spherocytosis_type_3&Pyropoikilocytosis&_hereditary&Elliptocytosis_2&not_specified		MedGen:C3661900&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&MedGen:CN169374		NC_000001.11:g.158638145T>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309425&SCV000349318&SCV000349319&SCV000349320&SCV000605259&SCV002347007&SCV005282881	single_nucleotide_variant	SO:0001483	ClinGen:CA1182432&UniProtKB:P02549																																																																																																																																															35,36	18,20	17,16	0/1	24,11,16,20	TTG	.	.	.			15,20,16,20	35.05		0.5070422535211268
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.C1568R	ENSP00000495214.1:p.Cys1568Arg	chr1	158642446	158642446.0	A	G	G	158642446	.	A	G	.	PASS	NM_003126	G	missense_variant	MODERATE	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	33/52		c.4702T>C	4900	4702	1568	C/R	Tgt/Cgt	rs863931&COSV63754161		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1	tolerated_low_confidence(1)		Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176			0.5940	0.6853	0.5605	0.6359	0.5865	0.4591	0.5677	0.6763	0.5678	0.6392	0.6073	0.6395	0.6278	0.5632	0.5856	0.4832	0.6034	0.6657	0.554	0.5819	0.6311	0.6323	0.6475	0.6871	0.5688	0.6093	0.4784	0.6871	gnomADg_MID	benign	0&1	1&1	25741868&29905378						FAIL	39	-25	-35	40	0.00	0.00	0.00	0.01	SPTA1		5.9100e-01	258942	0.59956		0.59405	249440	Hereditary_spherocytosis_type_3&Elliptocytosis_2&Pyropoikilocytosis&_hereditary&not_provided&not_specified		MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:C3661900&MedGen:CN169374		NC_000001.11:g.158642446A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309424&SCV000349333&SCV000349334&SCV000349335&SCV000605271&SCV001889478&SCV002057686&SCV002057687&SCV002057688&SCV002365730&SCV005282887	single_nucleotide_variant	SO:0001483	ClinGen:CA1182595&UniProtKB:P02549																																																																																																																																															52,85	27,52	25,33	0/1	28,24,43,42	CAC	.	.	.			19,33,48,37	45.46		0.6204379562043796
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.S1163A	ENSP00000495214.1:p.Ser1163Ala	chr1	158649938	158649938.0	A	C	C	158649938	.	A	C	.	PASS	NM_003126	C	missense_variant	MODERATE	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	25/52		c.3487T>G	3685	3487	1163	S/A	Tcc/Gcc	rs2482965&COSV107461993		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1	tolerated_low_confidence(0.44)		Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176			0.9946	0.9796	1	1	1	1	0.9995	0.9808	0.9989	1	1	1	0.9995	1	0.9989	1	0.9942	0.9797	1	0.9977	1	1	1	0.9966	1	0.9986	1	1	AMR&EAS&EUR&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_NFE&gnomADe_SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_NFE&gnomADg_SAS	benign	0&1	1&1	25741868						FAIL	9	-21	-4	-21	0.00	0.01	0.00	0.00	SPTA1		5.9100e-01	258929	0.99397	0.99826	0.99461	249451	Hereditary_spherocytosis_type_3&Pyropoikilocytosis&_hereditary&not_provided&Elliptocytosis_2&not_specified		MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:C3661900&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&MedGen:CN169374		NC_000001.11:g.158649938A>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309411&SCV000349390&SCV000349391&SCV000349392&SCV000605261&SCV001915723&SCV002056488&SCV002056489&SCV002057695&SCV002475955&SCV005282894	single_nucleotide_variant	SO:0001483	ClinGen:CA1183031&UniProtKB:P02549																																																																																																																																															0,108	0,61	0,47	0/1	0,0,45,63	GAA	.	.	.			0,0,44,64	64.69		1.0
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Leu1116=	ENSP00000495214.1:p.Leu1116=	chr1	158652494	158652494.0	C	T	T	158652494	.	C	T	.	PASS	NM_003126	T	synonymous_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	23/52		c.3348G>A	3546	3348	1116	L	ctG/ctA	rs773776083&COSV63751111		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1			Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176									4.788e-05	0	0	0	0	0	0	5.755e-05	9.934e-05	0	1.971e-05	2.413e-05	0	0	0	0	0	0	2.94e-05	0	0	9.934e-05	gnomADe_REMAINING		0&1	0&1							FAIL	-4	2	12	-27	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01																																																											127					0.953							227.66	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158622284						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:L1116=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:L1116="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						118,3	67,0	51,3	0/1	66,52,1,2	GCA	0.00	0.00	1.00			63,55,2,1	8.25		0.024793388429752067
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Leu958=	ENSP00000495214.1:p.Leu958=	chr1	158656588	158656588.0	C	T	T	158656588	.	C	T	.	PASS	NM_003126	T	synonymous_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	20/52		c.2874G>A	3072	2874	958	L	ctG/ctA	rs857691&COSV63748240		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1			Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176			0.4235	0.7935	0.3588	0.4087	0.2495	0.1636	0.2681	0.7218	0.3702	0.2363	0.3806	0.3316	0.2794	0.2507	0.2997	0.1599	0.3947	0.706	0.3	0.353	0.2439	0.4349	0.3203	0.2911	0.2491	0.3609	0.1671	0.7935	AFR	benign	0&1	1&1	25741868&26047609&20858683&29844224&28898252						FAIL	-24	34	-9	-24	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01	258926	0.38696	0.30927	0.42352	249454	not_specified&Pyropoikilocytosis&_hereditary&not_provided&Hereditary_spherocytosis_type_3&Elliptocytosis_2		MedGen:CN169374&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:C3661900&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288		NC_000001.11:g.158656588C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309407&SCV000349436&SCV000349437&SCV000349438&SCV000605274&SCV001888333&SCV002471331&SCV005282897	single_nucleotide_variant	SO:0001483	ClinGen:CA1183252		SPTA1:6708	SO:0001819&synonymous_variant										1	857691																											84					0.988							243.94	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158626378						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:L958=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:L958="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						43,40	26,18	17,22	0/1	16,27,22,18	GCA	0.00	0.00	0.00			17,26,20,20	33.28		0.4819277108433735
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Leu831=	ENSP00000495214.1:p.Leu831=	chr1	158661381	158661381.0	A	C	C	158661381	.	A	C	.	PASS	NM_003126	C	synonymous_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	18/52		c.2493T>G	2691	2493	831	L	ctT/ctG	rs2518493&COSV63748244		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1			Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176			0.2436	0.1407	0.3026	0.4087	0.2525	0.1616	0.2534	0.1633	0.338	0.2202	0.3807	0.3356	0.2102	0.2523	0.2614	0.1569	0.2414	0.1733	0.3	0.2926	0.2266	0.4351	0.3235	0.2381	0.2494	0.2524	0.1611	0.4351	gnomADg_EAS	benign	0&1	1&1	25741868&20858683						FAIL	28	23	0	28	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01	258922	0.22536		0.24361	249458	not_provided&Hereditary_spherocytosis_type_3&not_specified&Pyropoikilocytosis&_hereditary&Elliptocytosis_2		MedGen:C3661900&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MedGen:CN169374&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288		NC_000001.11:g.158661381A>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309403&SCV000349469&SCV000349470&SCV000349471&SCV000605275&SCV002388130&SCV005282900	single_nucleotide_variant	SO:0001483	ClinGen:CA1183374		SPTA1:6708	SO:0001819&synonymous_variant										1	2518493																											94					0.989							242.32	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158631171						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:L831=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:L831="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						40,53	21,27	19,26	0/1	22,18,25,28	GAA	.	.	.			15,25,23,30	41.72		0.5698924731182796
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Y653C	ENSP00000495214.1:p.Tyr653Cys	chr1	158667938	158667938.0	T	C	C	158667938	.	T	C	.	PASS	NM_003126	C	missense_variant	MODERATE	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	15/52		c.1958A>G	2156	1958	653	Y/C	tAt/tGt	rs148912436&COSV63748984		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1	deleterious_low_confidence(0)		Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&PANTHER:PTHR11915&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176			0.0054	0	0.0115	0	0.0149	0.0041	0.01015	0.001852	0.007313	0.007921	2.52e-05	0.00867	0.01544	0.0115	0.01055	0.003084	0.008018	0.00243	0.01429	0.01131	0.007493	0	0.006494	0.01701	0.0117	0.01183	0.002697	0.01701	gnomADg_MID	benign/likely_benign&benign&uncertain_significance&likely_benign	0&1	1&1	25741868&27863252&33462484&32888494&34201899						FAIL	34	-36	1	-13	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01	258918	0.00787	0.00811	0.00539	249461	Hereditary_spherocytosis_type_3&Elliptocytosis_2&Pyropoikilocytosis&_hereditary&not_specified&not_provided		MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:CN169374&MedGen:C3661900		NC_000001.11:g.158667938T>C	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(2)&Benign(4)&Likely_benign(1)		SCV000309399&SCV000349517&SCV000349518&SCV000349519&SCV000884581&SCV001100230&SCV004009892	single_nucleotide_variant	SO:0001483	ClinGen:CA1183560		SPTA1:6708	SO:0001583&missense_variant										1	148912436																											116					0.983							242.05	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158637728						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:Y653C			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:Y653C"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						54,60	27,32	27,28	0/1	24,30,32,28	ATA	.	.	.			23,31,28,32	39.03		0.5263157894736842
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Ala314=	ENSP00000495214.1:p.Ala314=	chr1	158677705	158677705.0	A	T	T	158677705	.	A	T	.	PASS	NM_003126	T	synonymous_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	7/52		c.942T>A	1140	942	314	A	gcT/gcA	rs325996&COSV108215570		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1			Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Coiled-coils_(Ncoils):Coil&Pfam:PF00435&PANTHER:PTHR11915&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176&CDD:cd00176			0.9569	0.8442	0.9914	1	0.996	1	0.9932	0.8616	0.9903	0.9989	1	0.986	0.9884	0.9971	0.9881	0.9993	0.9581	0.8643	0.9704	0.9838	0.998	1	0.9834	0.983	0.997	0.9688	0.9983	1	EAS&SAS&gnomADe_EAS&gnomADg_EAS	benign	0&1	1&1	25741868						FAIL	-2	-16	-15	21	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01	258962	0.95805	0.98497	0.95687	249465	Hereditary_spherocytosis_type_3&Elliptocytosis_2&Pyropoikilocytosis&_hereditary&not_provided&not_specified		MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:C3661900&MedGen:CN169374		NC_000001.11:g.158677705A>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309444&SCV000349586&SCV000349587&SCV000349588&SCV000605262&SCV001895222&SCV002056493&SCV002056494&SCV002056495&SCV002471334&SCV005282906	single_nucleotide_variant	SO:0001483	ClinGen:CA1183972		SPTA1:6708	SO:0001819&synonymous_variant										1	325996																											77					0.961							241.21	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158647495						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:A314=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:A314="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						0,74	0,36	0,38	0/1	0,0,37,37	CAG	.	.	.			0,0,45,29	64.53		1.0
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Ser305=	ENSP00000495214.1:p.Ser305=	chr1	158677732	158677732.0	A	G	G	158677732	.	A	G	.	PASS	NM_003126	G	synonymous_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	7/52		c.915T>C	1113	915	305	S	agT/agC	rs703121&COSV63750610		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1			Gene3D:1.20.58.60&AFDB-ENSP_mappings:AF-P02549-F1&Pfam:PF00435&PANTHER:PTHR11915&SMART:SM00150&Superfamily:SSF46966&CDD:cd00176&CDD:cd00176			0.4539	0.2262	0.5058	0.5833	0.6153	0.4254	0.5755	0.2645	0.5476	0.5749	0.5465	0.633	0.568	0.5937	0.5683	0.46	0.4993	0.2818	0.4593	0.5456	0.5752	0.569	0.6284	0.5306	0.5956	0.534	0.4453	0.633	gnomADe_FIN	benign	0&1	1&1	25741868&24895341						FAIL	13	-42	-42	2	0.00	0.00	0.01	0.00	SPTA1		5.9100e-01	258961	0.47773	0.54491	0.45387	249466	not_specified&not_provided&Hereditary_spherocytosis_type_3&Elliptocytosis_2&Pyropoikilocytosis&_hereditary		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867		NC_000001.11:g.158677732A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309443&SCV000349589&SCV000349590&SCV000349591&SCV000605272&SCV001888478&SCV002056496&SCV002056497&SCV002056499&SCV002343127&SCV005282908	single_nucleotide_variant	SO:0001483	ClinGen:CA1183977		SPTA1:6708	SO:0001819&synonymous_variant										1	703121																											86					0.953							238.97	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158647522						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:S305=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:S305="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						40,42	15,26	25,16	0/1	23,17,13,29	GAC	.	.	.			24,16,21,21	36.03		0.5121951219512195
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9	p.Val42=	ENSP00000495214.1:p.Val42=	chr1	158685246	158685246.0	G	A	A	158685246	.	G	A	.	PASS	NM_003126	A	synonymous_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding	2/52		c.126C>T	324	126	42	V	gtC/gtT	rs435080&COSV108215571		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1			Gene3D:1.20.5.170&PDB-ENSP_mappings:1owa.A&PDB-ENSP_mappings:3lbx.A&AFDB-ENSP_mappings:AF-P02549-F1&Superfamily:SSF46966&CDD:cd00176			0.9698	0.888	0.9957	1	1	1	0.9973	0.9097	0.9938	1	1	1	0.9905	0.9999	0.9936	0.9996	0.9739	0.91	1	0.9887	1	1	1	0.9932	0.9998	0.9773	0.999	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN	benign	0&1	1&1	25741868						FAIL	25	8	25	-10	0.00	0.00	0.03	0.01	SPTA1		5.9100e-01	258916	0.97319	0.99197	0.96985	249471	not_specified&Hereditary_spherocytosis_type_3&not_provided&Pyropoikilocytosis&_hereditary&Elliptocytosis_2		MedGen:CN169374&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MedGen:C3661900&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288		NC_000001.11:g.158685246G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309397&SCV000349649&SCV000349650&SCV000349651&SCV000605264&SCV001898317&SCV002056510&SCV002056511&SCV002056512&SCV002470245&SCV005282916	single_nucleotide_variant	SO:0001483	ClinGen:CA1184248		SPTA1:6708	SO:0001819&synonymous_variant										1	435080																											123					0.959							235.81	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr1	158655036						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	SPTA1		ENSP00000495214.1:V42=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SPTA1"",""entrezGeneId"":null,""alteration"":""ENSP00000495214.1:V42="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						0,118	0,56	0,62	0/1	0,0,74,44	CGA	0.00	0.00	0.00			0,0,72,46	64.71		1.0
GRCh38	SPTA1	D12_12345_1234556_Thyroid_S9			chr1	158686491	158686491.0	T	C	C	158686491	.	T	C	.	PASS	NM_003126	C	splice_donor_region_variant&intron_variant	LOW	SPTA1	ENSG00000163554	Transcript	ENST00000643759	protein_coding		1/51	c.24+3A>G						rs2564858		-1		SNV	HGNC	HGNC:11272	YES	MANE_Select	NM_003126.4			P1	CCDS41423.1	ENSP00000495214	P02549.253		UPI0000458906	P02549-1		1						0.9698	0.888	0.9957	1	1	1	0.9973	0.909	0.9938	1	1	1	0.9907	0.9999	0.9935	0.9996	0.9737	0.9095	1	0.9885	1	1	1	0.9932	0.9998	0.9777	0.999	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN	benign		1	25741868						FAIL	46	8	46	3	0.00	0.00	0.00	0.00	SPTA1		5.9100e-01	258920	0.97313	0.99195	0.96985	249472	not_provided&Hereditary_spherocytosis_type_3&Elliptocytosis_2&Pyropoikilocytosis&_hereditary&not_specified		MedGen:C3661900&MONDO:MONDO:0010053&MedGen:C2678338&OMIM:270970&Orphanet:822&MONDO:MONDO:0007533&MedGen:C1851741&OMIM:130600&Orphanet:288&Human_Phenotype_Ontology:HP:0004805&Human_Phenotype_Ontology:HP:0004839&MONDO:MONDO:0009948&MedGen:C0520739&OMIM:266140&Orphanet:98867&MedGen:CN169374		NC_000001.11:g.158686491T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000309401&SCV000349658&SCV000349659&SCV000349660&SCV000605265&SCV002056516&SCV002056517&SCV002056518&SCV002333731&SCV005282919	single_nucleotide_variant	SO:0001483	ClinGen:CA1184294		SPTA1:6708	SO:0001627&intron_variant										1	2564858																											70					1							241.02													chr1	158656281																																																	True	False	False	Unknown		Unknown																						0,70	0,33	0,37	0/1	0,0,36,34	TTA	.	.	.			0,0,47,23	64.49		1.0
GRCh38	DDR2	D12_12345_1234556_Thyroid_S9	p.Leu420=	ENSP00000356898.3:p.Leu420=	chr1	162767326	162767326.0	C	G	G	162767326	.	C	G	.	PASS	NM_006182	G	synonymous_variant	LOW	DDR2	ENSG00000162733	Transcript	ENST00000367921	protein_coding	11/18		c.1260C>G	1619	1260	420	L	ctC/ctG	rs2298258&COSV63369342		1		SNV	HGNC	HGNC:2731	YES	MANE_Select	NM_006182.4		1	P1	CCDS1241.1	ENSP00000356898	Q16832.220		UPI000013E1B4			1			AFDB-ENSP_mappings:AF-Q16832-F1&PANTHER:PTHR24416&Transmembrane_helices:TMhelix&Phobius:TRANSMEMBRANE&Low_complexity_(Seg):seg			0.3484	0.5023	0.353	0.4077	0.1461	0.2843	0.1775	0.4882	0.395	0.1057	0.4347	0.08129	0.1875	0.1487	0.1955	0.2647	0.2602	0.4751	0.2105	0.3179	0.09937	0.4115	0.07419	0.2109	0.1431	0.2374	0.2692	0.5023	AFR	benign&likely_benign	0&1	1&1	25741868&25658585						FAIL	1	6	41	-45	0.00	0.00	0.00	0.00	DDR2		3.7500e-01	259929	0.25727	0.22417	0.34844	249492	not_provided&Spondyloepimetaphyseal_dysplasia-short_limb-abnormal_calcification_syndrome&Squamous_cell_lung_carcinoma&Warburg-cinotti_syndrome&not_specified		MedGen:C3661900&MONDO:MONDO:0010077&MedGen:C1849011&OMIM:271665&Orphanet:93358&Human_Phenotype_Ontology:HP:0030359&MONDO:MONDO:0005097&MedGen:C0149782&MONDO:MONDO:0032579&MedGen:C5193019&OMIM:618175&MedGen:CN169374		NC_000001.11:g.162767326C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000311395&SCV000350330&SCV001726039&SCV001751763&SCV001876601&SCV001876602&SCV005285850	single_nucleotide_variant	SO:0001483	ClinGen:CA1217466		DDR2:4921	SO:0001819&synonymous_variant										3	2298258																											112					0.955							245.35	v6.1	Unknown		True	DDR2, a receptor tyrosine kinase, is mutated at low frequencies in various cancers.	False	04/20/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DDR2 ENSP00000356898.3:L420= mutant UNKNOWN.	False	The DDR2 ENSP00000356898.3:l420= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	162737116						True	False	False	Unknown								False	False		DDR2, a receptor tyrosine kinase, is mutated at low frequencies in various cancers.	The DDR2 ENSP00000356898.3:l420= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DDR2 ENSP00000356898.3:L420= mutant UNKNOWN.						v6.1	04/20/2017		GRCh38	DDR2	4921.0	ENSP00000356898.3:L420=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DDR2"",""entrezGeneId"":4921,""alteration"":""ENSP00000356898.3:L420="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DDR2, a receptor tyrosine kinase, is mutated at low frequencies in various cancers."",""variantSummary"":""The DDR2 ENSP00000356898.3:l420= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DDR2 ENSP00000356898.3:L420= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/20/2017""}"	True	True	False	Unknown		Unknown																						63,44	29,26	34,18	0/1	33,30,21,23	TCT	.	.	.			33,30,21,23	23.87		0.411214953271028
GRCh38	CCDC190	D12_12345_1234556_Thyroid_S9			chr1	162841035	162841039.0	C	CCAGT	CCAGT	162841035	.	C	CCAGT	.	PASS		CAGT	intron_variant&non_coding_transcript_variant	MODIFIER	CCDC190	ENSG00000185860	Transcript	ENST00000524691	protein_coding_CDS_not_defined		1/1	n.152+14593_152+14596dup						rs3047269		-1		insertion	HGNC	HGNC:28736					1															0.4479	0.2897	0.4986	0.3889	0.5577	0.5736	0.3846				0			0.4167			0.4936	0.3344	0.6958	0.5133	0.5529	0.3881	0.6188	0.524	0.5643	0.4938	0.5583	0.6958	gnomADg_AMI				33801242																																																																												584					0.974							245.89													chr1	162810825																																																	True	False	False	Unknown		Unknown																						277,292	147,150	130,142	0/1	153,124,157,135	CCC						171,106,193,99	51.93		0.5131810193321616
GRCh38		D12_12345_1234556_Thyroid_S9			chr1	173441341		C	[chr7:138726154[C	[chr7:138726154[C	173441341	MantaBND:2404:0:1:0:0:0:1	C	[chr7:138726154[C	.	PASS		.C	downstream_gene_variant	MODIFIER		ENSG00000301462	Transcript	ENST00000778987	lncRNA										885	1		chromosome_breakpoint			YES																																																																																																																											2			0,4							4	TCCC			MantaBND:2404:0:1:0:0:0:0	1														chr1	173410480				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr1	194909217	194909225.0	G	GATTAAATA	GATTAAATA	194909217	.	G	GATTAAATA	.	PASS		ATTAAATA	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000285718	Transcript	ENST00000670710	lncRNA		2/2	n.216+11241_216+11242insTATTTAAT						rs2307924		-1		insertion																						0.5016	0.702	0.415	0.3026	0.5	0.499											0.5253	0.6651	0.354	0.4423	0.4814	0.3158	0.5613	0.4793	0.4767	0.5071	0.4908	0.702	AFR				23690203&36292568																																																																												29					1							241.79													chr1	194878347																																																	True	False	False	Unknown		Unknown																						0,29	0,14	0,15	0/1	0,0,17,12	TGC						0,0,10,19	61.54		1.0
GRCh38	PIK3C2B	D12_12345_1234556_Thyroid_S9	p.Pro199=	ENSP00000507222.1:p.Pro199=	chr1	204469206	204469206.0	C	T	T	204469206	.	C	T	.	PASS	NM_001377334	T	synonymous_variant	LOW	PIK3C2B	ENSG00000133056	Transcript	ENST00000684373	protein_coding	2/33		c.597G>A	1131	597	199	P	ccG/ccA	rs1124777&COSV108216577		-1		SNV	HGNC	HGNC:8972	YES	MANE_Select	NM_001377334.1			P1	CCDS1446.1	ENSP00000507222	O00750.225	A2RUF7.156	UPI00002056D1						AFDB-ENSP_mappings:AF-O00750-F1			0.7280	0.2413	0.8948	0.8194	0.9841	0.91	0.9539	0.336	0.8597	0.9609	0.8109	0.9679	0.9189	0.9853	0.9228	0.9166	0.7906	0.3643	0.9923	0.871	0.9579	0.7856	0.9651	0.8776	0.9833	0.8349	0.916	0.9923	gnomADg_AMI		0&1	0&1							FAIL	-2	-14	-1	-39	0.00	0.00	0.00	0.00	PIK3C2B		5.5700e-01																																																											1030					0.997							245.18	v6.1	Unknown		True	PIK3C2B, a lipid phosphoinositide, is infrequently altered in cancer.	False	12/08/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2B ENSP00000507222.1:P199= mutant UNKNOWN.	False	The PIK3C2B ENSP00000507222.1:p199= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	204438334						True	False	False	Unknown								False	False		PIK3C2B, a lipid phosphoinositide, is infrequently altered in cancer.	The PIK3C2B ENSP00000507222.1:p199= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2B ENSP00000507222.1:P199= mutant UNKNOWN.						v6.1	12/08/2023		GRCh38	PIK3C2B	5287.0	ENSP00000507222.1:P199=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3C2B"",""entrezGeneId"":5287,""alteration"":""ENSP00000507222.1:P199="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3C2B, a lipid phosphoinositide, is infrequently altered in cancer."",""variantSummary"":""The PIK3C2B ENSP00000507222.1:p199= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2B ENSP00000507222.1:P199= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/08/2023""}"	True	True	False	Unknown		Unknown																						0,1027	0,499	0,528	0/1	0,0,498,529	CCG	0.00	0.00	0.00			0,0,496,531	64.73		1.0
GRCh38	PIK3C2B	D12_12345_1234556_Thyroid_S9	p.Leu96=	ENSP00000507222.1:p.Leu96=	chr1	204469515	204469515.0	G	T	T	204469515	.	G	T	.	PASS	NM_001377334	T	synonymous_variant	LOW	PIK3C2B	ENSG00000133056	Transcript	ENST00000684373	protein_coding	2/33		c.288C>A	822	288	96	L	ctC/ctA	rs1553921&COSV100915003		-1		SNV	HGNC	HGNC:8972	YES	MANE_Select	NM_001377334.1			P1	CCDS1446.1	ENSP00000507222	O00750.225	A2RUF7.156	UPI00002056D1						AFDB-ENSP_mappings:AF-O00750-F1&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.7272	0.2368	0.8963	0.8194	0.9841	0.911	0.9538	0.3338	0.8591	0.9607	0.8109	0.9679	0.918	0.9852	0.9224	0.9161	0.7898	0.3622	0.9923	0.871	0.9577	0.7846	0.9648	0.8801	0.9833	0.8351	0.9156	0.9923	gnomADg_AMI		0&1	0&1							FAIL	1	-10	41	-10	0.00	0.02	0.00	0.00	PIK3C2B		5.5700e-01																																																											1125					0.989							245.93	v6.1	Unknown		True	PIK3C2B, a lipid phosphoinositide, is infrequently altered in cancer.	False	12/08/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2B ENSP00000507222.1:L96= mutant UNKNOWN.	False	The PIK3C2B ENSP00000507222.1:l96= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	204438643						True	False	False	Unknown								False	False		PIK3C2B, a lipid phosphoinositide, is infrequently altered in cancer.	The PIK3C2B ENSP00000507222.1:l96= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2B ENSP00000507222.1:L96= mutant UNKNOWN.						v6.1	12/08/2023		GRCh38	PIK3C2B	5287.0	ENSP00000507222.1:L96=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3C2B"",""entrezGeneId"":5287,""alteration"":""ENSP00000507222.1:L96="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3C2B, a lipid phosphoinositide, is infrequently altered in cancer."",""variantSummary"":""The PIK3C2B ENSP00000507222.1:l96= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2B ENSP00000507222.1:L96= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/08/2023""}"	True	True	False	Unknown		Unknown																						0,1113	0,507	0,606	0/1	0,0,578,535	AGA	0.00	0.00	0.00			0,0,538,575	64.73		1.0
GRCh38	MDM4	D12_12345_1234556_Thyroid_S9			chr1	204525155	204525155.0	C	T	T	204525155	.	C	T	.	PASS	NM_002393	T	intron_variant	MODIFIER	MDM4	ENSG00000198625	Transcript	ENST00000367182	protein_coding		1/10	c.-35-329C>T						rs3789052		1		SNV	HGNC	HGNC:6974	YES	MANE_Select	NM_002393.5		1	P1	CCDS1447.1	ENSP00000356150	O15151.223		UPI000007467F	O15151-1		1						0.3073	0.0643	0.5072	0.3006	0.4592	0.3446											0.3815	0.1269	0.604	0.4732	0.4403	0.2954	0.5813	0.3776	0.4875	0.3911	0.3572	0.604	gnomADg_AMI										FAIL	37	-24	-37	44	0.00	0.00	0.00	0.00	MDM4		1.4600e-01																																																											66					0.97							246.06													chr1	204494283																																																	True	True	False	Unknown		Unknown																						0,64	0,30	0,34	0/1	0,0,33,31	CCT	0.00	0.00	0.00			0,0,37,27	64.4		1.0
GRCh38	MDM4	D12_12345_1234556_Thyroid_S9			chr1	204542474	204542474.0	C	A	A	204542474	.	C	A	.	PASS	NM_002393	A	intron_variant	MODIFIER	MDM4	ENSG00000198625	Transcript	ENST00000367182	protein_coding		7/10	c.512-310C>A						rs10900595		1		SNV	HGNC	HGNC:6974	YES	MANE_Select	NM_002393.5		1	P1	CCDS1447.1	ENSP00000356150	O15151.223		UPI000007467F	O15151-1		1						0.5958	0.354	0.6398	0.7103	0.7266	0.6391											0.6289	0.4099	0.7961	0.6353	0.6511	0.6862	0.8323	0.6769	0.7194	0.6274	0.6578	0.8323	gnomADg_FIN										FAIL	18	9	-50	-6	0.00	0.00	0.00	0.00	MDM4		1.4600e-01																																																											90					0.9							232.55													chr1	204511602																																																	True	True	False	Unknown		Unknown																						0,81	0,43	0,38	0/1	0,0,40,41	GCA	0.00	0.00	0.00			0,0,50,31	64.59		1.0
GRCh38	MDM4	D12_12345_1234556_Thyroid_S9			chr1	204544128	204544128.0	A	G	G	204544128	.	A	G	.	PASS	NM_002393	G	intron_variant	MODIFIER	MDM4	ENSG00000198625	Transcript	ENST00000367182	protein_coding		8/10	c.673-407A>G						rs4252725		1		SNV	HGNC	HGNC:6974	YES	MANE_Select	NM_002393.5		1	P1	CCDS1447.1	ENSP00000356150	O15151.223		UPI000007467F	O15151-1		1						0.5513	0.2579	0.6167	0.7024	0.6918	0.6012											0.5888	0.3289	0.7818	0.6083	0.6141	0.6797	0.8116	0.6054	0.6965	0.593	0.6015	0.8116	gnomADg_FIN										FAIL	1	20	-5	-41	0.00	0.00	0.00	0.00	MDM4		1.4600e-01																																																											113					0.956							242.99													chr1	204513256																																																	True	True	False	Unknown		Unknown																						0,108	0,56	0,52	0/1	0,0,61,47	AAC	.	.	.			0,0,55,53	64.69		1.0
GRCh38	MDM4	D12_12345_1234556_Thyroid_S9			chr1	204555926	204555927.0	GT	G	G	204555926	.	GT	G	.	PASS	NM_002393	-	3_prime_UTR_variant	MODIFIER	MDM4	ENSG00000198625	Transcript	ENST00000367182	protein_coding	11/11		c.*6255del	7857					rs34656478		1		deletion	HGNC	HGNC:6974	YES	MANE_Select	NM_002393.5		1	P1	CCDS1447.1	ENSP00000356150	O15151.223		UPI000007467F	O15151-1		1					10	0.5439	0.2368	0.6138	0.7024	0.6889	0.5971	0.5991	0.3143	0.5355	0.5863	0.6764	0.5	0.5508	0.6103	0.561	0.5404	0.5757	0.3049	0.7758	0.5991	0.6186	0.6804	0.8019	0.5966	0.6843	0.5806	0.5998	0.8019	gnomADg_FIN										FAIL	-5	18	16	-5	0.00	0.00	0.00	0.00	MDM4		1.4600e-01																																																											368					0.875							246.54													chr1	204525054																																																	True	True	False	Unknown		Unknown																						24,298	9,153	15,145	0/1	14,10,128,170	TGT						7,17,133,165	47.02		0.9254658385093167
GRCh38	IKBKE	D12_12345_1234556_Thyroid_S9	p.Ile67=	ENSP00000464030.1:p.Ile67=	chr1	206474444	206474444.0	T	C	C	206474444	.	T	C	.	PASS	NM_014002	C	synonymous_variant	LOW	IKBKE	ENSG00000263528	Transcript	ENST00000581977	protein_coding	4/22		c.201T>C	546	201	67	I	atT/atC	rs1539243&COSV108214656		1		SNV	HGNC	HGNC:14552	YES	MANE_Select	NM_014002.4		1	P1	CCDS30996.1	ENSP00000464030	Q14164.222		UPI0000033727	Q14164-1					Gene3D:3.30.200.20&AFDB-ENSP_mappings:AF-Q14164-F1&Pfam:PF00069&PROSITE_profiles:PS50011&PANTHER:PTHR22969&SMART:SM00220&Superfamily:SSF56112			0.8992	0.8797	0.9207	0.9732	0.835	0.8998	0.8456	0.8739	0.9255	0.7803	0.961	0.8275	0.8609	0.8378	0.8508	0.8673	0.8565	0.872	0.8904	0.8919	0.7765	0.9761	0.8263	0.8503	0.836	0.8666	0.8834	0.9761	gnomADg_EAS		0&1	0&1	22546513&19786281&21179067&30386510&29434720&23428251&25798331&33158196&31435520&29159863						FAIL	-50	7	27	31	0.00	0.00	0.00	0.01	IKBKE		6.5900e-01																																																											1003					0.999							245.43	v6.1	Unknown		True	IKBKE, an intracellular kinase, is altered by mutation and overexpression in various cancer types.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IKBKE ENSP00000464030.1:I67= mutant UNKNOWN.	False	The IKBKE ENSP00000464030.1:i67= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	206647787						True	False	False	Unknown								False	False		IKBKE, an intracellular kinase, is altered by mutation and overexpression in various cancer types.	The IKBKE ENSP00000464030.1:i67= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IKBKE ENSP00000464030.1:I67= mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	IKBKE	9641.0	ENSP00000464030.1:I67=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IKBKE"",""entrezGeneId"":9641,""alteration"":""ENSP00000464030.1:I67="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IKBKE, an intracellular kinase, is altered by mutation and overexpression in various cancer types."",""variantSummary"":""The IKBKE ENSP00000464030.1:i67= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IKBKE ENSP00000464030.1:I67= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						0,1002	0,476	0,526	0/1	0,0,494,508	TTG	.	.	.			0,0,464,538	64.73		1.0
GRCh38	IKBKE	D12_12345_1234556_Thyroid_S9	p.Gln195=	ENSP00000464030.1:p.Gln195=	chr1	206476722	206476722.0	A	G	G	206476722	.	A	G	.	PASS	NM_014002	G	synonymous_variant	LOW	IKBKE	ENSG00000263528	Transcript	ENST00000581977	protein_coding	7/22		c.585A>G	930	585	195	Q	caA/caG	rs41296034&COSV65625162		1		SNV	HGNC	HGNC:14552	YES	MANE_Select	NM_014002.4		1	P1	CCDS30996.1	ENSP00000464030	Q14164.222		UPI0000033727	Q14164-1					Gene3D:1.10.510.10&AFDB-ENSP_mappings:AF-Q14164-F1&Pfam:PF00069&PROSITE_profiles:PS50011&PANTHER:PTHR22969&SMART:SM00220&Superfamily:SSF56112			0.0180	0.0038	0.0202	0	0.0686	0.002	0.07855	0.01213	0.01715	0.02797	7.557e-05	0.04446	0.004854	0.09536	0.06244	0.008335	0.04884	0.01484	0.04515	0.02482	0.02333	0.0003854	0.03949	0.003401	0.0852	0.0345	0.006424	0.09536	gnomADe_NFE		0&1	0&1							FAIL	-44	33	12	-34	0.01	0.00	0.00	0.00	IKBKE		6.5900e-01																																																											994					1							246.91	v6.1	Unknown		True	IKBKE, an intracellular kinase, is altered by mutation and overexpression in various cancer types.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IKBKE ENSP00000464030.1:Q195= mutant UNKNOWN.	False	The IKBKE ENSP00000464030.1:q195= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	206650065						True	False	False	Unknown								False	False		IKBKE, an intracellular kinase, is altered by mutation and overexpression in various cancer types.	The IKBKE ENSP00000464030.1:q195= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IKBKE ENSP00000464030.1:Q195= mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	IKBKE	9641.0	ENSP00000464030.1:Q195=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IKBKE"",""entrezGeneId"":9641,""alteration"":""ENSP00000464030.1:Q195="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IKBKE, an intracellular kinase, is altered by mutation and overexpression in various cancer types."",""variantSummary"":""The IKBKE ENSP00000464030.1:q195= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IKBKE ENSP00000464030.1:Q195= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						487,507	252,279	235,228	0/1	251,236,248,259	AAA	.	.	.			250,237,260,247	61.51		0.5100603621730382
GRCh38	PARP1	D12_12345_1234556_Thyroid_S9	p.V762A	ENSP00000355759.5:p.Val762Ala	chr1	226367601	226367601.0	A	G	G	226367601	.	A	G	.	PASS	NM_001618	G	missense_variant	MODERATE	PARP1	ENSG00000143799	Transcript	ENST00000366794	protein_coding	17/23		c.2285T>C	2449	2285	762	V/A	gTg/gCg	rs1136410&CM042761&COSV64689246		-1		SNV	HGNC	HGNC:270	YES	MANE_Select	NM_001618.4		1	P1	CCDS1554.1	ENSP00000355759	P09874.269		UPI000013D92D			1	deleterious(0.01)	probably_damaging(0.95)	PDB-ENSP_mappings:1uk0.A&PDB-ENSP_mappings:1uk0.B&PDB-ENSP_mappings:1uk1.A&PDB-ENSP_mappings:1uk1.B&PDB-ENSP_mappings:1wok.A&PDB-ENSP_mappings:1wok.B&PDB-ENSP_mappings:1wok.C&PDB-ENSP_mappings:1wok.D&PDB-ENSP_mappings:2rcw.A&PDB-ENSP_mappings:2rd6.A&PDB-ENSP_mappings:3gjw.A&PDB-ENSP_mappings:3gn7.A&PDB-ENSP_mappings:3l3l.A&PDB-ENSP_mappings:3l3m.A&PDB-ENSP_mappings:4dqy.C&PDB-ENSP_mappings:4dqy.F&PDB-ENSP_mappings:4gv7.A&PDB-ENSP_mappings:4gv7.B&PDB-ENSP_mappings:4gv7.C&PDB-ENSP_mappings:4gv7.D&PDB-ENSP_mappings:4hhy.A&PDB-ENSP_mappings:4hhy.B&PDB-ENSP_mappings:4hhy.C&PDB-ENSP_mappings:4hhy.D&PDB-ENSP_mappings:4hhz.A&PDB-ENSP_mappings:4hhz.B&PDB-ENSP_mappings:4hhz.C&PDB-ENSP_mappings:4hhz.D&PDB-ENSP_mappings:4l6s.A&PDB-ENSP_mappings:4l6s.B&PDB-ENSP_mappings:4opx.C&PDB-ENSP_mappings:4opx.F&PDB-ENSP_mappings:4oqa.C&PDB-ENSP_mappings:4oqa.F&PDB-ENSP_mappings:4oqb.C&PDB-ENSP_mappings:4oqb.F&PDB-ENSP_mappings:4pjt.A&PDB-ENSP_mappings:4pjt.B&PDB-ENSP_mappings:4pjt.C&PDB-ENSP_mappings:4pjt.D&PDB-ENSP_mappings:4r5w.A&PDB-ENSP_mappings:4r5w.B&PDB-ENSP_mappings:4r6e.A&PDB-ENSP_mappings:4r6e.B&PDB-ENSP_mappings:4r6e.C&PDB-ENSP_mappings:4r6e.D&PDB-ENSP_mappings:4rv6.A&PDB-ENSP_mappings:4rv6.B&PDB-ENSP_mappings:4rv6.C&PDB-ENSP_mappings:4rv6.D&PDB-ENSP_mappings:4und.A&PDB-ENSP_mappings:4und.B&PDB-ENSP_mappings:4uxb.A&PDB-ENSP_mappings:4uxb.B&PDB-ENSP_mappings:4xhu.A&PDB-ENSP_mappings:4xhu.C&PDB-ENSP_mappings:4zzz.A&PDB-ENSP_mappings:4zzz.B&PDB-ENSP_mappings:5a00.A&PDB-ENSP_mappings:5ha9.A&PDB-ENSP_mappings:5ha9.B&PDB-ENSP_mappings:5kpn.A&PDB-ENSP_mappings:5kpn.B&PDB-ENSP_mappings:5kpo.A&PDB-ENSP_mappings:5kpo.B&PDB-ENSP_mappings:5kpp.A&PDB-ENSP_mappings:5kpp.B&PDB-ENSP_mappings:5kpq.A&PDB-ENSP_mappings:5kpq.B&PDB-ENSP_mappings:5wrq.A&PDB-ENSP_mappings:5wrq.B&PDB-ENSP_mappings:5wry.A&PDB-ENSP_mappings:5wry.B&PDB-ENSP_mappings:5wrz.A&PDB-ENSP_mappings:5wrz.B&PDB-ENSP_mappings:5ws0.A&PDB-ENSP_mappings:5ws0.B&PDB-ENSP_mappings:5ws1.A&PDB-ENSP_mappings:5ws1.B&PDB-ENSP_mappings:5wtc.A&PDB-ENSP_mappings:5wtc.B&PDB-ENSP_mappings:5xsr.A&PDB-ENSP_mappings:5xst.A&PDB-ENSP_mappings:5xsu.A&PDB-ENSP_mappings:5xsu.B&PDB-ENSP_mappings:5xsu.C&PDB-ENSP_mappings:5xsu.D&PDB-ENSP_mappings:6ghk.A&PDB-ENSP_mappings:6ghk.B&PDB-ENSP_mappings:6vkk.A&PDB-ENSP_mappings:6vkk.B&PDB-ENSP_mappings:6vkk.C&PDB-ENSP_mappings:6vkk.D&PDB-ENSP_mappings:6vko.A&PDB-ENSP_mappings:6vko.B&PDB-ENSP_mappings:6vko.C&PDB-ENSP_mappings:6vko.D&PDB-ENSP_mappings:6vkq.A&PDB-ENSP_mappings:6vkq.B&PDB-ENSP_mappings:6vkq.C&PDB-ENSP_mappings:6vkq.D&PDB-ENSP_mappings:6xvw.A&PDB-ENSP_mappings:6xvw.B&PDB-ENSP_mappings:7aaa.A&PDB-ENSP_mappings:7aaa.B&PDB-ENSP_mappings:7aab.A&PDB-ENSP_mappings:7aab.B&PDB-ENSP_mappings:7aac.A&PDB-ENSP_mappings:7aac.B&PDB-ENSP_mappings:7aad.A&PDB-ENSP_mappings:7aad.B&PDB-ENSP_mappings:7cmw.A&PDB-ENSP_mappings:7cmw.B&PDB-ENSP_mappings:7kk2.A&PDB-ENSP_mappings:7kk2.B&PDB-ENSP_mappings:7kk3.A&PDB-ENSP_mappings:7kk3.B&PDB-ENSP_mappings:7kk3.C&PDB-ENSP_mappings:7kk3.D&PDB-ENSP_mappings:7kk4.A&PDB-ENSP_mappings:7kk4.B&PDB-ENSP_mappings:7kk5.A&PDB-ENSP_mappings:7kk5.B&PDB-ENSP_mappings:7kk5.C&PDB-ENSP_mappings:7kk5.D&PDB-ENSP_mappings:7kk6.A&PDB-ENSP_mappings:7kk6.B&PDB-ENSP_mappings:7onr.A&PDB-ENSP_mappings:7onr.B&PDB-ENSP_mappings:7ons.A&PDB-ENSP_mappings:7ons.B&PDB-ENSP_mappings:7ont.A&PDB-ENSP_mappings:7ont.B&PDB-ENSP_mappings:7s68.B&PDB-ENSP_mappings:7s6h.B&PDB-ENSP_mappings:7s6h.D&PDB-ENSP_mappings:7s6m.B&PDB-ENSP_mappings:7s6m.D&PDB-ENSP_mappings:7s81.C&PDB-ENSP_mappings:7s81.H&PDB-ENSP_mappings:7s81.K&PDB-ENSP_mappings:7s81.P&PDB-ENSP_mappings:8g0h.B&PDB-ENSP_mappings:8g0h.D&PDB-ENSP_mappings:8he7.A&PDB-ENSP_mappings:8he7.B&PDB-ENSP_mappings:8hlr.A&PDB-ENSP_mappings:8hlr.B&PDB-ENSP_mappings:8jnz.A&PDB-ENSP_mappings:8jnz.B&PIRSF:PIRSF000489&Pfam:PF02877&Gene3D:1.20.142.10&PANTHER:PTHR10459&CDD:cd01437&PROSITE_profiles:PS51060&Superfamily:SSF47587&AFDB-ENSP_mappings:AF-P09874-F1			0.1969	0.0371	0.3516	0.4365	0.1541	0.1002	0.1692	0.0486	0.4016	0.1562	0.4204	0.2333	0.1486	0.1567	0.1692	0.1066	0.1573	0.05387	0.07237	0.303	0.1584	0.4287	0.234	0.1293	0.1594	0.1656	0.1124	0.4365	EAS	benign	0&1&1	1&1&1	31818908&21976407&21767974&31413734&33112558&33147530&33528729&30337837&25111588&33893823&23139751&19249341&26648684&34691999&18191955&17267408&21989229&31288058&32103589&21606320&16465622&16857995&17203305&17220334&18701435&19109789&19124499&19318434&19822020&20150366&20211558&20353610&20486200&20559012&21037106&21129811&21385363&21420246&21700777&21810555&22127734&22687647&22740911&22792228&22850545&22969958&23608917&23633189&23644255&23720673&24172093&24203816&24340057&24500421&25106941&25179837&25231222&25493225&25911198&26921778&27055523&27099827&27285066&27323894&27415837&27588484&27840165&27866211&28765340&28956850&29399184&29484706&29662639&29667179&30183716&31489712&31584889&31609976&31762827&31983162&33108038&33284833&33706586&34406176&28206966&32355298&31374908&22868256&28749454&29937070&35117636&35600838&25837821&25178586&34944636&22430443&33534415&31415677&29577582&34295994&29156789&31171785&36006023&27105872&26491355&36632296&37182709&36581511&27959887&25998844&27209488&28423490&26388025&2259190						FAIL	34	33	-31	2	0.00	0.00	0.00	0.00	PARP1	0.180	4.5400e-01	1261945	0.12333	0.20178	0.19688	1250560	not_provided		MedGen:C3661900		NC_000001.11:g.226367601A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001887752&SCV005281323	single_nucleotide_variant	SO:0001483	ClinGen:CA1422514		PARP1:142	SO:0001583&missense_variant										1	1136410																											700					0.999							247.49	v6.1	Unknown		True	PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:V762A mutant UNKNOWN.	False	The PARP1 ENSP00000355759.5:v762a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	226555302						True	False	False	Unknown								False	False		PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	The PARP1 ENSP00000355759.5:v762a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:V762A mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PARP1	142.0	ENSP00000355759.5:V762A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PARP1"",""entrezGeneId"":142,""alteration"":""ENSP00000355759.5:V762A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma."",""variantSummary"":""The PARP1 ENSP00000355759.5:v762a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:V762A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						342,357	168,169	174,188	0/1	175,167,173,184	CAC	.	.	.			151,191,145,212	55.54		0.5107296137339056
GRCh38	PARP1	D12_12345_1234556_Thyroid_S9	p.Lys352=	ENSP00000355759.5:p.Lys352=	chr1	226383139	226383139.0	T	C	C	226383139	.	T	C	.	PASS	NM_001618	C	synonymous_variant	LOW	PARP1	ENSG00000143799	Transcript	ENST00000366794	protein_coding	8/23		c.1056A>G	1220	1056	352	K	aaA/aaG	rs1805415&COSV64689254		-1		SNV	HGNC	HGNC:270	YES	MANE_Select	NM_001618.4		1	P1	CCDS1554.1	ENSP00000355759	P09874.269		UPI000013D92D			1			PDB-ENSP_mappings:2jvn.A&PDB-ENSP_mappings:2riq.A&PDB-ENSP_mappings:4dqy.B&PDB-ENSP_mappings:4dqy.E&PDB-ENSP_mappings:4opx.A&PDB-ENSP_mappings:4opx.D&PDB-ENSP_mappings:4oqa.A&PDB-ENSP_mappings:4oqa.D&PDB-ENSP_mappings:4oqb.A&PDB-ENSP_mappings:4oqb.D&PDB-ENSP_mappings:7s68.A&PDB-ENSP_mappings:7s6h.A&PDB-ENSP_mappings:7s6h.C&PDB-ENSP_mappings:7s6m.A&PDB-ENSP_mappings:7s6m.C&PDB-ENSP_mappings:7s81.B&PDB-ENSP_mappings:7s81.G&PDB-ENSP_mappings:7s81.J&PDB-ENSP_mappings:7s81.O&PDB-ENSP_mappings:8g0h.A&PDB-ENSP_mappings:8g0h.C&PIRSF:PIRSF000489&PANTHER:PTHR10459&PROSITE_profiles:PS52007&AFDB-ENSP_mappings:AF-P09874-F1			0.7893	0.9123	0.6455	0.5635	0.8459	0.8998	0.8295	0.8982	0.5959	0.8434	0.5802	0.7665	0.8488	0.8436	0.8274	0.8933	0.8275	0.8923	0.9275	0.6922	0.8412	0.5712	0.7668	0.8673	0.8408	0.8256	0.888	0.9275	gnomADg_AMI		0&1	0&1	19249341&17267408&33284833&27153553&17560163&20113831						FAIL	17	-23	1	9	0.00	0.03	0.00	0.00	PARP1		4.5400e-01																																																											842					0.999							221.01	v6.1	Unknown		True	PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:K352= mutant UNKNOWN.	False	The PARP1 ENSP00000355759.5:k352= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	226570840						True	False	False	Unknown								False	False		PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	The PARP1 ENSP00000355759.5:k352= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:K352= mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PARP1	142.0	ENSP00000355759.5:K352=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PARP1"",""entrezGeneId"":142,""alteration"":""ENSP00000355759.5:K352="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma."",""variantSummary"":""The PARP1 ENSP00000355759.5:k352= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:K352= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						430,411	188,185	242,226	0/1	228,202,218,193	GTT	.	.	.			132,298,126,285	44.08		0.4887039239001189
GRCh38	PARP1	D12_12345_1234556_Thyroid_S9	p.Ala284=	ENSP00000355759.5:p.Ala284=	chr1	226385663	226385663.0	A	G	G	226385663	.	A	G	.	PASS	NM_001618	G	synonymous_variant	LOW	PARP1	ENSG00000143799	Transcript	ENST00000366794	protein_coding	7/23		c.852T>C	1016	852	284	A	gcT/gcC	rs1805414&CM071915&COSV64689261		-1		SNV	HGNC	HGNC:270	YES	MANE_Select	NM_001618.4		1	P1	CCDS1554.1	ENSP00000355759	P09874.269		UPI000013D92D			1			PDB-ENSP_mappings:2jvn.A&PDB-ENSP_mappings:2riq.A&PDB-ENSP_mappings:4dqy.B&PDB-ENSP_mappings:4dqy.E&PDB-ENSP_mappings:4opx.A&PDB-ENSP_mappings:4opx.D&PDB-ENSP_mappings:4oqa.A&PDB-ENSP_mappings:4oqa.D&PDB-ENSP_mappings:4oqb.A&PDB-ENSP_mappings:4oqb.D&PDB-ENSP_mappings:7s68.A&PDB-ENSP_mappings:7s6h.A&PDB-ENSP_mappings:7s6h.C&PDB-ENSP_mappings:7s6m.A&PDB-ENSP_mappings:7s6m.C&PDB-ENSP_mappings:7s81.B&PDB-ENSP_mappings:7s81.G&PDB-ENSP_mappings:7s81.J&PDB-ENSP_mappings:7s81.O&PDB-ENSP_mappings:8g0h.A&PDB-ENSP_mappings:8g0h.C&Gene3D:1.10.20.130&PIRSF:PIRSF000489&Pfam:PF21728&PANTHER:PTHR10459&PROSITE_profiles:PS52007&SMART:SM01335&AFDB-ENSP_mappings:AF-P09874-F1			0.5166	0.5582	0.5029	0.7946	0.329	0.3763	0.3585	0.5587	0.5378	0.3297	0.7933	0.4033	0.3339	0.3265	0.3772	0.3691	0.4246	0.5431	0.2148	0.4584	0.3282	0.8066	0.4011	0.3129	0.3315	0.3957	0.3799	0.8066	gnomADg_EAS		0&1&1	0&1&1	18805967&21767974&27746584&29662639&30183716&31609976&31762827&33284833&19604089&21695249&23803078&37329186&32352035&17560163&20113831&38892180						FAIL	17	-37	-46	1	0.00	0.00	0.00	0.00	PARP1		4.5400e-01																																																											769					0.999							235.78	v6.1	Unknown		True	PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:A284= mutant UNKNOWN.	False	The PARP1 ENSP00000355759.5:a284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	226573364						True	False	False	Unknown								False	False		PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	The PARP1 ENSP00000355759.5:a284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:A284= mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PARP1	142.0	ENSP00000355759.5:A284=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PARP1"",""entrezGeneId"":142,""alteration"":""ENSP00000355759.5:A284="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma."",""variantSummary"":""The PARP1 ENSP00000355759.5:a284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:A284= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						389,379	200,191	189,188	0/1	200,189,199,180	CAG	.	.	.			135,254,125,254	46.55		0.4934895833333333
GRCh38	PARP1	D12_12345_1234556_Thyroid_S9	p.Asp81=	ENSP00000355759.5:p.Asp81=	chr1	226402257	226402257.0	G	A	A	226402257	.	G	A	.	PASS	NM_001618	A	synonymous_variant	LOW	PARP1	ENSG00000143799	Transcript	ENST00000366794	protein_coding	2/23		c.243C>T	407	243	81	D	gaC/gaT	rs1805404&COSV64687027		-1		SNV	HGNC	HGNC:270	YES	MANE_Select	NM_001618.4		1	P1	CCDS1554.1	ENSP00000355759	P09874.269		UPI000013D92D			1			PDB-ENSP_mappings:2dmj.A&PDB-ENSP_mappings:2l30.A&PDB-ENSP_mappings:2n8a.A&PDB-ENSP_mappings:3od8.A&PDB-ENSP_mappings:3od8.B&PDB-ENSP_mappings:3od8.C&PDB-ENSP_mappings:3od8.D&PDB-ENSP_mappings:3od8.E&PDB-ENSP_mappings:3od8.F&PDB-ENSP_mappings:3od8.G&PDB-ENSP_mappings:3od8.H&PDB-ENSP_mappings:3oda.A&PDB-ENSP_mappings:3oda.B&PDB-ENSP_mappings:3oda.C&PDB-ENSP_mappings:3oda.D&PDB-ENSP_mappings:3oda.E&PDB-ENSP_mappings:3oda.F&PDB-ENSP_mappings:3oda.G&PDB-ENSP_mappings:3oda.H&PDB-ENSP_mappings:4av1.A&PDB-ENSP_mappings:4av1.B&PDB-ENSP_mappings:4av1.C&PDB-ENSP_mappings:4av1.D&PDB-ENSP_mappings:4dqy.A&PDB-ENSP_mappings:4dqy.D&PDB-ENSP_mappings:4opx.A&PDB-ENSP_mappings:4opx.D&PDB-ENSP_mappings:4oqa.A&PDB-ENSP_mappings:4oqa.D&PDB-ENSP_mappings:4oqb.A&PDB-ENSP_mappings:4oqb.D&PDB-ENSP_mappings:7s68.A&PDB-ENSP_mappings:7s6h.A&PDB-ENSP_mappings:7s6h.C&PDB-ENSP_mappings:7s6m.A&PDB-ENSP_mappings:7s6m.C&PDB-ENSP_mappings:7s81.A&PDB-ENSP_mappings:7s81.F&PDB-ENSP_mappings:7s81.I&PDB-ENSP_mappings:7s81.N&PDB-ENSP_mappings:8g0h.A&PDB-ENSP_mappings:8g0h.C&PIRSF:PIRSF000489&Pfam:PF00645&Gene3D:3.30.1740.10&PROSITE_profiles:PS50064&SMART:SM01336&Superfamily:SSF57716&AFDB-ENSP_mappings:AF-P09874-F1			0.2183	0.115	0.3573	0.4365	0.1541	0.1002	0.1713	0.1281	0.405	0.1562	0.4205	0.2333	0.1531	0.1566	0.1753	0.107	0.1792	0.131	0.07237	0.3099	0.158	0.4291	0.2333	0.1327	0.1593	0.1777	0.113	0.4365	EAS		0&1	1&1	17267408&20486200&30183716&31609976&33284833&27462201&31415677&37216007&36292754&32888493&23576132&20113831&38892180						FAIL	-4	-11	33	-43	0.00	0.00	0.00	0.00	PARP1		4.5400e-01																																																											1013					0.994							186.4	v6.1	Unknown		True	PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:D81= mutant UNKNOWN.	False	The PARP1 ENSP00000355759.5:d81= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	226589958						True	False	False	Unknown								False	False		PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma.	The PARP1 ENSP00000355759.5:d81= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:D81= mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PARP1	142.0	ENSP00000355759.5:D81=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PARP1"",""entrezGeneId"":142,""alteration"":""ENSP00000355759.5:D81="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PARP1 encodes a nuclear protein modifier enzyme involved in the DNA repair pathway. PARP1 inhibition has been shown to be effective in germline BRCA-deficient tumors, triple-negative breast cancer (TNBC), chronic lymphocytic leukemia, and ovarian serous papillary carcinoma."",""variantSummary"":""The PARP1 ENSP00000355759.5:d81= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PARP1 ENSP00000355759.5:D81= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						486,521	253,288	233,233	0/1	248,238,273,248	GGT	0.00	0.00	0.00			269,217,266,255	63.2		0.5173783515392254
GRCh38	H3-4	D12_12345_1234556_Thyroid_S9	p.Ile63=	ENSP00000355657.2:p.Ile63=	chr1	228425137	228425137.0	G	T	T	228425137	.	G	T	.	PASS	NM_003493	T	synonymous_variant	LOW	H3-4	ENSG00000168148	Transcript	ENST00000366696	protein_coding	1/1		c.189C>A	224	189	63	I	atC/atA	rs2230656&COSV64210568		-1		SNV	HGNC	HGNC:4778	YES	MANE_Select	NM_003493.3			P1	CCDS1572.1	ENSP00000355657	Q16695.217		UPI000000D7E2			1			PDB-ENSP_mappings:3a6n.A&PDB-ENSP_mappings:3a6n.E&PDB-ENSP_mappings:8z50.B&Superfamily:SSF47113&SMART:SM00428&Gene3D:1.10.20.10&Pfam:PF00125&Prints:PR00622&PANTHER:PTHR11426&AFDB-ENSP_mappings:AF-Q16695-F1			0.6903	0.3116	0.8977	0.6895	0.8847	0.8558	0.8689	0.3891	0.9201	0.8841	0.6655	0.8078	0.818	0.8935	0.8445	0.8578	0.7369	0.4072	0.8516	0.8658	0.8761	0.6631	0.8017	0.8129	0.8864	0.7933	0.8474	0.9201	gnomADe_AMR		0&1	0&1	30066433&29405169																	1.9020e+00																																																											1141					1							225.4	v6.1	Unknown		True	H3-4, a histone variant, is infrequently altered by mutation in various cancer types.	False	08/07/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3-4 ENSP00000355657.2:I63= mutant UNKNOWN.	False	The H3-4 ENSP00000355657.2:i63= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	228612838						True	False	False	Unknown								False	False		H3-4, a histone variant, is infrequently altered by mutation in various cancer types.	The H3-4 ENSP00000355657.2:i63= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3-4 ENSP00000355657.2:I63= mutant UNKNOWN.						v6.1	08/07/2019		GRCh38	H3-4	8290.0	ENSP00000355657.2:I63=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""H3-4"",""entrezGeneId"":8290,""alteration"":""ENSP00000355657.2:I63="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""H3-4, a histone variant, is infrequently altered by mutation in various cancer types."",""variantSummary"":""The H3-4 ENSP00000355657.2:i63= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3-4 ENSP00000355657.2:I63= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/07/2019""}"	True	True	False	Unknown		Unknown																						0,1141	0,557	0,584	0/1	0,0,572,569	GGA	0.00	0.00	0.00			0,0,544,597	64.73		1.0
GRCh38	CHRM3-AS2	D12_12345_1234556_Thyroid_S9			chr1	239718626	239718626.0	A	G	G	239718626	.	A	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER	CHRM3-AS2	ENSG00000233355	Transcript	ENST00000833734	lncRNA		1/2	n.73-4362T>C						rs891700		-1		SNV	HGNC	HGNC:43725																				0.5064	0.5008	0.5706	0.4732	0.5159	0.4928											0.5078	0.4952	0.5637	0.5647	0.5528	0.4707	0.4469	0.5306	0.5107	0.5162	0.5187	0.5706	AMR				26522768&26691610&29121662&33406744&34721519&19083859&27294018&29615764&19948332&38522119																																																																												114					0.719							222.4													chr1	239881926																																																	True	False	False	Unknown		Unknown																						42,40	22,20	20,20	0/1	24,18,18,22	TAC	.	.	.			18,24,16,24	33.68		0.4878048780487805
GRCh38		D12_12345_1234556_Thyroid_S9			chr1	242643495	242643495.0	T	C	C	242643495	.	T	C	.	PASS		C	intergenic_variant	MODIFIER														rs1413212				SNV																						0.6346	0.6074	0.732	0.502	0.7366	0.6339											0.6864	0.624	0.7918	0.7037	0.6886	0.4965	0.7683	0.7143	0.7261	0.6717	0.6159	0.7918	gnomADg_AMI				26691610&29121662&33406744&34721519&32195283&19083859&27294018&19948332																																																																												80					0.963							237.79													chr1	242806797																																																	True	False	False	Unknown		Unknown																						36,41	20,21	16,20	0/1	22,14,24,17	GTC	.	.	.			18,18,16,25	37.42		0.5324675324675324
GRCh38		D12_12345_1234556_Thyroid_S9			chr1	247648781	247648784.0	C	CATG	CATG	247648781	.	C	CATG	.	PASS		ATG	downstream_gene_variant	MODIFIER		ENSG00000235749	Transcript	ENST00000746712	lncRNA									rs2307579	2591	1		insertion																						0.5972	0.469	0.7046	0.8026	0.507	0.5757											0.5291	0.4788	0.4791	0.6489	0.5375	0.8048	0.4768	0.5646	0.5168	0.5374	0.5709	0.8048	gnomADg_EAS				33801242																																																																												71					0.986							244.18													chr1	247812083																																																	True	False	False	Unknown		Unknown																						0,70	0,35	0,35	0/1	0,0,34,36	ACA						0,0,39,31	63.24		1.0
GRCh38	LINC02645	D12_12345_1234556_Thyroid_S9			chr10	2364437	2364437.0	T	C	C	2364437	.	T	C	.	PASS		C	downstream_gene_variant	MODIFIER	LINC02645	ENSG00000234170	Transcript	ENST00000666064	lncRNA									rs826472	4124	-1		SNV	HGNC	HGNC:54129	YES																			0.7514	0.8737	0.7666	0.8145	0.5954	0.6708											0.7035	0.8362	0.417	0.7099	0.5889	0.8271	0.7052	0.6473	0.625	0.6708	0.6621	0.8737	AFR				26691610&29121662&33406744&21611176&30483616&16400611&35784409&19948332&19083752																																																																												112					0.982							240.88													chr10	2406631																																																	True	False	False	Unknown		Unknown																						48,62	25,32	23,30	0/1	15,33,27,35	ATC	.	.	.			20,28,27,35	42.24		0.5636363636363636
GRCh38		D12_12345_1234556_Thyroid_S9			chr10	3331986	3331986.0	C	T	T	3331986	.	C	T	.	PASS		T	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000286610	Transcript	ENST00000783531	lncRNA		1/2	n.965+13130C>T						rs735155		1		SNV																						0.5387	0.3147	0.4568	0.8234	0.4901	0.6564											0.4404	0.3216	0.3143	0.4904	0.5458	0.819	0.4915	0.5816	0.4462	0.4838	0.6278	0.8234	EAS				26522768&26691610&29121662&33406744&24149050&24551080&19083859&27294018&19948332																																																																												1035					1							247.6													chr10	3374178																																																	True	False	False	Unknown		Unknown																						541,494	280,262	261,232	0/1	272,269,242,252	GCC	0.00	0.00	0.00			299,242,276,218	36.48		0.47729468599033814
GRCh38		D12_12345_1234556_Thyroid_S9			chr10	5945195	5945198.0	TAAC	T	T	5945195	.	TAAC	T	.	PASS		-	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR10_B36T3	enhancer									rs41293961				deletion																						0.3335	0.4561	0.2291	0.2897	0.3668	0.2526											0.3745	0.4559	0.4427	0.2603	0.3364	0.2974	0.4077	0.1939	0.3623	0.3231	0.2676	0.4561	AFR																																																																																563					0.993							246.7													chr10	5987158																																																	True	False	False	Unknown		Unknown																						366,193	203,113	163,80	0|1	195,171,106,87	TTA					5987158	236,130,120,73	3.64		0.34525939177101966
GRCh38		D12_12345_1234556_Thyroid_S9			chr10	5945208	5945208.0	C	T	T	5945208	.	C	T	.	PASS		T	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR10_B36T3	enhancer									rs687805				SNV																						0.2640	0.4887	0.1484	0.1806	0.2783	0.1135											0.308	0.45	0.3714	0.1816	0.215	0.1586	0.2656	0.1293	0.2866	0.2453	0.136	0.4887	AFR																																																																																540					0.998							246.83													chr10	5987171																																																	True	False	False	Unknown		Unknown																						362,177	197,104	165,73	0|1	185,177,88,89	CCG	0.00	0.00	0.00		5987158	228,134,99,78	4.8		0.32838589981447125
GRCh38		D12_12345_1234556_Thyroid_S9			chr10	8809944		A	[chr2:75653285[A	[chr2:75653285[A	8809944	MantaBND:6716:0:1:0:0:0:1	A	[chr2:75653285[A	.	PASS		.A	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH		ENSG00000308749	Transcript	ENST00000836254	lncRNA		3/3									1		chromosome_breakpoint			YES																																																																																																																											1			0,12							12	AGGAAGGGAAAC			MantaBND:6716:0:1:0:0:0:0	0														chr10	8851907				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	TRDMT1	D12_12345_1234556_Thyroid_S9			chr10	17151347	17151347.0	A	G	G	17151347	.	A	G	.	PASS		G	intron_variant&NMD_transcript_variant	MODIFIER	TRDMT1	ENSG00000107614	Transcript	ENST00000495022	nonsense_mediated_decay		8/8	c.*740+2160T>C						rs3780962		-1		SNV	HGNC	HGNC:2977					2			ENSP00000417594	O14717.192	A0A0U1SZ86.44	UPI000002A830	O14717-4								0.5022	0.5136	0.3905	0.4901	0.501	0.5798	0.5344	0.5188	0.4094	0.6154	0.4997	0.5326	0.5715	0.5332	0.5381	0.5843	0.5211	0.5235	0.2906	0.4381	0.5793	0.489	0.5501	0.483	0.5336	0.5043	0.5705	0.6154	gnomADe_ASJ			1	23771752&26691610&29121662&33406744&34721519&33857205&27294018&29797257&30595370&38605929						FAIL	32	-4	-38	-4	0.00	0.00	0.00	0.00	TRDMT1																																																													120					0.983							232.4													chr10	17193346																																																	True	False	False	Unknown		Unknown																						56,62	17,27	39,35	0/1	32,24,33,29	TAA	.	.	.			27,29,22,40	39.23		0.5254237288135594
GRCh38	ANKRD26	D12_12345_1234556_Thyroid_S9	p.Gln893=	ENSP00000365255.4:p.Gln893=	chr10	27037204	27037204.0	T	C	C	27037204	.	T	C	.	PASS	NM_014915	C	synonymous_variant	LOW	ANKRD26	ENSG00000107890	Transcript	ENST00000376087	protein_coding	23/34		c.2679A>G	2847	2679	893	Q	caA/caG	rs61730098		-1		SNV	HGNC	HGNC:29186	YES	MANE_Select	NM_014915.3		5	A2	CCDS41499.1	ENSP00000365255	Q9UPS8.173		UPI000006FC41	Q9UPS8-1		1			MobiDB_lite:mobidb-lite&Pfam:PF14915&PANTHER:PTHR24147&AFDB-ENSP_mappings:AF-Q9UPS8-F1			0.0006	0	0	0	0.002	0.001	0.002893	0.0003885	0.000246	0.0002297	0	0.003483	0	0.003441	0.001541	0.001078	0.002094	0.0006735	0	0.000392	0	0	0.002918	0	0.003632	0.000947	0.001034	0.003632	gnomADg_NFE	benign/likely_benign		1	25741868						FAIL	17	-18	-18	-26	0.00	0.00	0.00	0.00	ANKRD26		7.2800e-01	260463	0.00263	0.00230	0.00060	253728	not_specified&not_provided&Thrombocytopenia_2&Inborn_genetic_diseases		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0008555&MedGen:C1861185&OMIM:188000&Orphanet:268322&MeSH:D030342&MedGen:C0950123		NC_000010.11:g.27037204T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000312251&SCV000593193&SCV001100896&SCV001265257&SCV001791974&SCV002506025&SCV002539229&SCV005074403&SCV005444467	single_nucleotide_variant	SO:0001483	ClinGen:CA5448172		ANKRD26:22852	SO:0001819&synonymous_variant										1	61730098																											80					1							241.36	v6.1	Unknown		True	ANKRD26, an ankyrin repeat protein, is altered by mutation in various hematological malignancies.	False	12/01/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD26 ENSP00000365255.4:Q893= mutant UNKNOWN.	False	The ANKRD26 ENSP00000365255.4:q893= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	27326133						True	False	False	Unknown								False	False		ANKRD26, an ankyrin repeat protein, is altered by mutation in various hematological malignancies.	The ANKRD26 ENSP00000365255.4:q893= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD26 ENSP00000365255.4:Q893= mutant UNKNOWN.						v6.1	12/01/2025		GRCh38	ANKRD26	22852.0	ENSP00000365255.4:Q893=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ANKRD26"",""entrezGeneId"":22852,""alteration"":""ENSP00000365255.4:Q893="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ANKRD26, an ankyrin repeat protein, is altered by mutation in various hematological malignancies."",""variantSummary"":""The ANKRD26 ENSP00000365255.4:q893= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD26 ENSP00000365255.4:Q893= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/01/2025""}"	True	True	False	Unknown		Unknown																						44,36	22,15	22,21	0/1	20,24,20,16	TTT	.	.	.			26,18,19,17	29.94		0.45
GRCh38	ANKRD26	D12_12345_1234556_Thyroid_S9			chr10	27038070	27038070.0	T	C	C	27038070	.	T	C	.	PASS	NM_014915	C	splice_polypyrimidine_tract_variant&intron_variant	LOW	ANKRD26	ENSG00000107890	Transcript	ENST00000376087	protein_coding		21/33	c.2376-16A>G						rs7096505		-1		SNV	HGNC	HGNC:29186	YES	MANE_Select	NM_014915.3		5	A2	CCDS41499.1	ENSP00000365255	Q9UPS8.173		UPI000006FC41	Q9UPS8-1		1						0.8652	0.8684	0.7262	0.9891	0.8101	0.8885	0.8188	0.8615	0.731	0.8325	0.9848	0.9025	0.8008	0.8063	0.8273	0.8766	0.8349	0.8618	0.7989	0.7596	0.8365	0.9891	0.9098	0.7755	0.8092	0.8195	0.8914	0.9891	EAS&gnomADg_EAS	benign		1	25741868						FAIL	12	-16	5	-45	0.29	0.03	0.00	0.00	ANKRD26		7.2800e-01	260461	0.82887	0.84081	0.86522	253730	not_provided&Thrombocytopenia_2&not_specified		MedGen:C3661900&MONDO:MONDO:0008555&MedGen:C1861185&OMIM:188000&Orphanet:268322&MedGen:CN169374		NC_000010.11:g.27038070T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000312249&SCV001861967&SCV002050141&SCV002539263&SCV003781697&SCV005322612	single_nucleotide_variant	SO:0001483	ClinGen:CA5448233		ANKRD26:22852	SO:0001627&intron_variant										1	7096505																											196					0.964							218.43													chr10	27326999																																																	True	True	False	Unknown		Unknown																						0,189	0,102	0,87	0/1	0,0,88,101	GTT	.	.	.			0,0,71,118	64.72		1.0
GRCh38	ANKRD26	D12_12345_1234556_Thyroid_S9	p.Q20R	ENSP00000365255.4:p.Gln20Arg	chr10	27100268	27100268.0	T	C	C	27100268	.	T	C	.	PASS	NM_014915	C	missense_variant	MODERATE	ANKRD26	ENSG00000107890	Transcript	ENST00000376087	protein_coding	1/34		c.59A>G	227	59	20	Q/R	cAg/cGg	rs7897309&COSV65793917		-1		SNV	HGNC	HGNC:29186	YES	MANE_Select	NM_014915.3		5	A2	CCDS41499.1	ENSP00000365255	Q9UPS8.173		UPI000006FC41	Q9UPS8-1		1	tolerated(1)	benign(0)	Low_complexity_(Seg):seg&MobiDB_lite:mobidb-lite&PANTHER:PTHR24147&AFDB-ENSP_mappings:AF-Q9UPS8-F1			0.9447	0.9871	0.9337	0.999	0.8628	0.9233	0.8673	0.9751	0.9291	0.8753	0.9997	0.9248	0.8657	0.8494	0.8788	0.918	0.9031	0.9723	0.8289	0.9016	0.8715	0.9994	0.9312	0.8503	0.8513	0.8879	0.9225	0.9997	gnomADe_EAS	benign	0&1	1&1	25741868						FAIL	34	-2	-8	43	0.00	0.00	0.00	0.00	ANKRD26	0.005	7.2800e-01	260472	0.89346	0.89774	0.94469	253739	Thrombocytopenia_2&not_specified&not_provided		MONDO:MONDO:0008555&MedGen:C1861185&OMIM:188000&Orphanet:268322&MedGen:CN169374&MedGen:C3661900		NC_000010.11:g.27100268T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000312260&SCV000362083&SCV001757151&SCV002048227&SCV002539718&SCV003337244&SCV005316304	single_nucleotide_variant	SO:0001483	ClinGen:CA5449084		ANKRD26:22852&LOC130003554:130003554	SO:0001583&missense_variant										1	7897309																											966					0.998							247.65	v6.1	Unknown		True	ANKRD26, an ankyrin repeat protein, is altered by mutation in various hematological malignancies.	False	12/01/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD26 ENSP00000365255.4:Q20R mutant UNKNOWN.	False	The ANKRD26 ENSP00000365255.4:q20r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	27389197						True	False	False	Unknown								False	False		ANKRD26, an ankyrin repeat protein, is altered by mutation in various hematological malignancies.	The ANKRD26 ENSP00000365255.4:q20r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD26 ENSP00000365255.4:Q20R mutant UNKNOWN.						v6.1	12/01/2025		GRCh38	ANKRD26	22852.0	ENSP00000365255.4:Q20R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ANKRD26"",""entrezGeneId"":22852,""alteration"":""ENSP00000365255.4:Q20R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ANKRD26, an ankyrin repeat protein, is altered by mutation in various hematological malignancies."",""variantSummary"":""The ANKRD26 ENSP00000365255.4:q20r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD26 ENSP00000365255.4:Q20R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/01/2025""}"	True	True	False	Unknown		Unknown																						0,964	0,532	0,432	0/1	0,0,472,492	CTG	.	.	.			0,0,470,494	64.73		1.0
GRCh38	KIF5B	D12_12345_1234556_Thyroid_S9			chr10	32009912	32009912.0	C	T	T	32009912	.	C	T	.	PASS	NM_004521	T	3_prime_UTR_variant	MODIFIER	KIF5B	ENSG00000170759	Transcript	ENST00000302418	protein_coding	26/26		c.*1625G>A	4969					rs13470		-1		SNV	HGNC	HGNC:6324	YES	MANE_Select	NM_004521.3		1	P1	CCDS7171.1	ENSP00000307078	P33176.224	V9HW29.75	UPI000012DE68			1						0.1546	0.1936	0.1614	0.005	0.2316	0.1718											0.2123	0.2029	0.1791	0.1868	0.2343	0.007725	0.1834	0.2313	0.2454	0.2159	0.1777	0.2454	gnomADg_NFE										FAIL	-35	-1	4	-1	0.01	0.00	0.00	0.00	KIF5B		4.3300e-01																																																											106					0.981							244.76													chr10	32298840																																																	True	False	False	Unknown		Unknown																						58,46	34,25	24,21	0/1	30,28,24,22	ACT	0.00	0.00	0.00			38,20,19,27	28.77		0.4423076923076923
GRCh38	KIF5B	D12_12345_1234556_Thyroid_S9			chr10	32011485	32011486.0	G	GT	GT	32011485	.	G	GT	.	PASS	NM_004521	T	3_prime_UTR_variant	MODIFIER	KIF5B	ENSG00000170759	Transcript	ENST00000302418	protein_coding	26/26		c.*51dup	3395-3396					rs145356849		-1		insertion	HGNC	HGNC:6324	YES	MANE_Select	NM_004521.3		1	P1	CCDS7171.1	ENSP00000307078	P33176.224	V9HW29.75	UPI000012DE68			1						0.1440	0.1536	0.1614	0.005	0.2316	0.1718	0.1915					0.1848			0.5		0.2	0.1611	0.1802	0.1822	0.2346	0.00771	0.1822	0.2279	0.2449	0.2035	0.1789	0.5	gnomADe_REMAINING										FAIL	31	20	-3	13	0.01	0.00	0.00	0.00	KIF5B		4.3300e-01																																																											83					0.892							241.91													chr10	32300413																																																	True	False	False	Unknown		Unknown																						35,39	20,18	15,21	0/1	18,17,16,23	TGT						17,18,13,26	35.54		0.527027027027027
GRCh38	KIF5B	D12_12345_1234556_Thyroid_S9			chr10	32023041	32023041.0	A	G	G	32023041	.	A	G	.	PASS	NM_004521	G	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	KIF5B	ENSG00000170759	Transcript	ENST00000302418	protein_coding		15/25	c.1726-5T>C						rs176924		-1		SNV	HGNC	HGNC:6324	YES	MANE_Select	NM_004521.3		1	P1	CCDS7171.1	ENSP00000307078	P33176.224	V9HW29.75	UPI000012DE68			1						0.9671	0.8797	0.9914	1	1	1	0.9974	0.9043	0.9947	0.9999	1	1	0.9991	0.9999	0.9948	0.9999	0.9737	0.9087	1	0.9907	1	1	1	1	0.9998	0.9777	0.9996	1	EAS&EUR&SAS&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID	benign		1	21695249						FAIL	-8	-5	-30	-8	0.03	0.00	0.00	0.00	KIF5B		4.3300e-01	1302449	0.96771		0.96705	1292730	not_provided		MedGen:C3661900		NC_000010.11:g.32023041A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001987426&SCV005317061	single_nucleotide_variant	SO:0001483	ClinGen:CA5463051		KIF5B:3799	SO:0001627&intron_variant										1	176924																											98					0.98							233.84													chr10	32311969																																																	True	False	False	Unknown		Unknown																						0,96	0,56	0,40	0/1	0,0,48,48	TAA	.	.	.			0,0,46,50	64.66		1.0
GRCh38	KIF5B	D12_12345_1234556_Thyroid_S9	p.E347K	ENSP00000307078.4:p.Glu347Lys	chr10	32034762	32034762.0	C	T	T	32034762	.	C	T	.	PASS	NM_004521	T	missense_variant	MODERATE	KIF5B	ENSG00000170759	Transcript	ENST00000302418	protein_coding	11/26		c.1039G>A	1491	1039	347	E/K	Gaa/Aaa	rs767638980		-1		SNV	HGNC	HGNC:6324	YES	MANE_Select	NM_004521.3		1	P1	CCDS7171.1	ENSP00000307078	P33176.224	V9HW29.75	UPI000012DE68			1	deleterious_low_confidence(0.01)	possibly_damaging(0.547)	PDB-ENSP_mappings:1mkj.A&PDB-ENSP_mappings:3j8x.K&PDB-ENSP_mappings:3j8y.K&PDB-ENSP_mappings:4hna.K&PDB-ENSP_mappings:7rik.A&PDB-ENSP_mappings:8ixa.S&PDB-ENSP_mappings:8ixa.T&PDB-ENSP_mappings:8ixa.U&PDB-ENSP_mappings:8ixa.V&PDB-ENSP_mappings:8ixa.W&PDB-ENSP_mappings:8ixa.X&PDB-ENSP_mappings:8ixa.Y&PDB-ENSP_mappings:8ixa.Z&PDB-ENSP_mappings:8ixa.a&PDB-ENSP_mappings:8ixb.g&PDB-ENSP_mappings:8ixb.k&PDB-ENSP_mappings:8ixb.l&PDB-ENSP_mappings:8ixb.m&PDB-ENSP_mappings:8ixd.S&PDB-ENSP_mappings:8ixd.T&PDB-ENSP_mappings:8ixd.U&PDB-ENSP_mappings:8ixd.V&PDB-ENSP_mappings:8ixd.W&PDB-ENSP_mappings:8ixd.X&PDB-ENSP_mappings:8ixd.Y&PDB-ENSP_mappings:8ixd.Z&PDB-ENSP_mappings:8ixd.a&PDB-ENSP_mappings:8ixe.h&PDB-ENSP_mappings:8ixe.l&PDB-ENSP_mappings:8ixe.p&PDB-ENSP_mappings:8ixe.q&PDB-ENSP_mappings:8ixf.S&PDB-ENSP_mappings:8ixf.T&PDB-ENSP_mappings:8ixf.U&PDB-ENSP_mappings:8ixf.V&PDB-ENSP_mappings:8ixf.W&PDB-ENSP_mappings:8ixf.X&PDB-ENSP_mappings:8ixf.Y&PDB-ENSP_mappings:8ixf.Z&PDB-ENSP_mappings:8ixf.a&PDB-ENSP_mappings:8ixg.h&PDB-ENSP_mappings:8ixg.l&PDB-ENSP_mappings:8ixg.p&PDB-ENSP_mappings:8ixg.q&Low_complexity_(Seg):seg&Coiled-coils_(Ncoils):Coil&Superfamily:SSF52540&PANTHER:PTHR47968&Gene3D:6.10.250.1590&AFDB-ENSP_mappings:AF-P33176-F1									2.06e-06	3.028e-05	0	0	0	0	0	1.802e-06	0	0	0	0	0	0	0	0	0	0	0	0	0	3.028e-05	gnomADe_AFR										FAIL	-7	26	11	-12	0.00	0.00	0.00	0.00	KIF5B	0.630	4.3300e-01																																																											225					0.791							229.78	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr10	32323690						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	KIF5B		ENSP00000307078.4:E347K			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KIF5B"",""entrezGeneId"":null,""alteration"":""ENSP00000307078.4:E347K"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						168,10	72,8	96,2	0/1	90,78,1,9	TCT	0.00	0.00	1.00			70,98,3,7	11.76		0.056179775280898875
GRCh38	KIF5B	D12_12345_1234556_Thyroid_S9			chr10	32056210	32056210.0	A	G	G	32056210	.	A	G	.	PASS	NM_004521	G	5_prime_UTR_variant	MODIFIER	KIF5B	ENSG00000170759	Transcript	ENST00000302418	protein_coding	1/26		c.-237T>C	216					rs211300		-1		SNV	HGNC	HGNC:6324	YES	MANE_Select	NM_004521.3		1	P1	CCDS7171.1	ENSP00000307078	P33176.224	V9HW29.75	UPI000012DE68			1						0.1540	0.1914	0.1614	0.005	0.2316	0.1718	0.2192	0.2064	0.2028	0.2298	0.003994	0.1879	0.2845	0.2453	0.2124	0.203	0.2124	0.2033	0.1791	0.1865	0.2346	0.007782	0.1829	0.2329	0.2453	0.2133	0.1801	0.2845	gnomADe_MID				18984674						FAIL	-44	-32	-32	2	0.00	0.00	0.00	0.00	KIF5B		4.3300e-01																																																											1043					0.996							246.25													chr10	32345138																																																	True	False	False	Unknown		Unknown																						496,543	255,280	241,263	0/1	245,251,270,273	CAG	.	.	.			268,228,295,248	62.8		0.5226179018286814
GRCh38	KIF5B	D12_12345_1234556_Thyroid_S9			chr10	32056417	32056417.0	T	C	C	32056417	.	T	C	.	PASS	NM_004521	C	5_prime_UTR_variant	MODIFIER	KIF5B	ENSG00000170759	Transcript	ENST00000302418	protein_coding	1/26		c.-444A>G	9					rs12251445&COSV56656531&CR092629		-1		SNV	HGNC	HGNC:6324	YES	MANE_Select	NM_004521.3		1	P1	CCDS7171.1	ENSP00000307078	P33176.224	V9HW29.75	UPI000012DE68			1						0.3005	0.2572	0.3084	0.4137	0.2326	0.3067	0.1767	0.25	0.1852	0.1923	0.3	0.1416	0.2708	0.1607	0.1646	0.2235	0.2597	0.2618	0.2588	0.3091	0.2671	0.3852	0.2086	0.2808	0.2407	0.2649	0.3239	0.4137	EAS		0&1&1	0&1&1	18984674						FAIL	-1	-13	-1	29	0.00	0.00	0.00	0.00	KIF5B		4.3300e-01																																																											339					1							248.85													chr10	32345345																																																	True	False	False	Unknown		Unknown																						185,154	88,70	97,84	0/1	85,100,79,75	GTT	.	.	.			30,155,29,125	27.79		0.45427728613569324
GRCh38	RET	D12_12345_1234556_Thyroid_S9			chr10	43081462	43081462.0	G	T	T	43081462	.	G	T	.	PASS	NM_020975	T	intron_variant	MODIFIER	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding		1/19	c.73+4131G>T						rs1864407		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1						0.9948	0.9985	0.9914	1	0.9861	0.9959											0.9825	0.9965	0.9682	0.9881	0.9715	1	0.9623	0.9966	0.9743	0.983	0.9954	1	EAS&gnomADg_EAS										FAIL	-32	-5	13	-5	0.00	0.00	0.00	0.00	RET		2.4000e-01																																																											793					0.994							246.2													chr10	43576910																																																	True	True	False	Unknown		Unknown																						401,387	164,186	237,201	0/1	190,211,206,181	GGG	0.00	0.00	0.00			209,192,215,172	45.43		0.49111675126903553
GRCh38	RET	D12_12345_1234556_Thyroid_S9	p.Ala45=	ENSP00000347942.3:p.Ala45=	chr10	43100520	43100520.0	A	G	G	43100520	.	A	G	.	PASS	NM_020975	G	synonymous_variant	LOW	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding	2/20		c.135A>G	325	135	45	A	gcA/gcG	rs1800858&CM020759&COSV60686024		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1			PDB-ENSP_mappings:2x2u.A&PDB-ENSP_mappings:4ux8.A&PDB-ENSP_mappings:4ux8.B&PDB-ENSP_mappings:6gl7.E&PDB-ENSP_mappings:6gl7.F&PDB-ENSP_mappings:6q2j.E&PDB-ENSP_mappings:6q2j.F&PDB-ENSP_mappings:6q2n.E&PDB-ENSP_mappings:6q2n.F&PDB-ENSP_mappings:6q2o.E&PDB-ENSP_mappings:6q2o.F&PDB-ENSP_mappings:6q2r.E&PDB-ENSP_mappings:6q2r.F&PDB-ENSP_mappings:6q2r.Y&PDB-ENSP_mappings:6q2r.Z&PDB-ENSP_mappings:6q2s.E&PDB-ENSP_mappings:6q2s.F&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF17756&PIRSF:PIRSF000631&Gene3D:2.60.40.60&AFDB-ENSP_mappings:AF-P07949-F1			0.7536	0.9803	0.7493	0.5268	0.7435	0.6943	0.7409	0.953	0.758	0.7065	0.5658	0.6468	0.7183	0.7463	0.74	0.7318	0.7853	0.9492	0.8344	0.7565	0.701	0.5485	0.6377	0.7143	0.7423	0.7718	0.7084	0.9803	AFR	benign&likely_benign	0&1&1	1&1&1	30409984&17267408&32708070&20532249&34950210&19138047&18091754&15759212&22312249&24897126&29131865&8001158&10090908&10521317&10528857&10922382&11950855&16091499&18284634&20123584&20454948&21349203&23059849&23084198&23527089&26102504&31644668&34981673&35359901&22648184&32364585&23840513&37189693&24651702&26191299&30072953&33827484&32411094&27174043&16443855&22584707&35078996&28930629&18436345&37835559&37490568						FAIL	-2	-36	17	4	0.00	0.00	0.00	0.00	RET		2.4000e-01	167589		0.73653	0.75359	174942	not_specified&Hereditary_cancer-predisposing_syndrome&not_provided&Hirschsprung_disease&_susceptibility_to&_1&Multiple_endocrine_neoplasia_type_2B&Multiple_endocrine_neoplasia&_type_2&Multiple_endocrine_neoplasia_type_2A&Pheochromocytoma		MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MONDO:MONDO:0007723&MedGen:C3888239&OMIM:142623&Orphanet:388&MONDO:MONDO:0008082&MeSH:D018814&MedGen:C0025269&OMIM:162300&Orphanet:247709&Orphanet:653&MONDO:MONDO:0019003&MedGen:C4048306&Orphanet:653&MONDO:MONDO:0008234&MeSH:D018813&MedGen:C0025268&OMIM:171400&Orphanet:247698&Orphanet:653&Human_Phenotype_Ontology:HP:0002666&MONDO:MONDO:0008233&MedGen:C0031511&OMIM:171300&Orphanet:29072		NC_000010.11:g.43100520A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000203415&SCV000205133&SCV001000072&SCV002033558&SCV002033559&SCV002033560&SCV002761949&SCV004357213&SCV005317093&SCV005442085&SCV006311177	single_nucleotide_variant	SO:0001483	ClinGen:CA009515		RET:5979	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	1800858																											902					0.998							246.11	v6.1	Unknown		True	RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:A45= mutant UNKNOWN.	False	The RET ENSP00000347942.3:a45= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	43595968						True	False	False	Unknown								False	False		RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors.	The RET ENSP00000347942.3:a45= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:A45= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	RET	5979.0	ENSP00000347942.3:A45=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RET"",""entrezGeneId"":5979,""alteration"":""ENSP00000347942.3:A45="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors."",""variantSummary"":""The RET ENSP00000347942.3:a45= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:A45= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						442,458	246,223	196,235	0/1	215,227,226,232	CAG	.	.	.			231,211,253,205	59.39		0.5088888888888888
GRCh38	RET	D12_12345_1234556_Thyroid_S9	p.Ala432=	ENSP00000347942.3:p.Ala432=	chr10	43111239	43111239.0	A	G	G	43111239	.	A	G	.	PASS	NM_020975	G	synonymous_variant	LOW	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding	7/20		c.1296A>G	1486	1296	432	A	gcA/gcG	rs1800860&CM033447&COSV60686810		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1			PDB-ENSP_mappings:4ux8.A&PDB-ENSP_mappings:4ux8.B&PDB-ENSP_mappings:6gl7.E&PDB-ENSP_mappings:6gl7.F&PDB-ENSP_mappings:6q2j.E&PDB-ENSP_mappings:6q2j.F&PDB-ENSP_mappings:6q2n.E&PDB-ENSP_mappings:6q2n.F&PDB-ENSP_mappings:6q2o.E&PDB-ENSP_mappings:6q2o.F&PDB-ENSP_mappings:6q2r.E&PDB-ENSP_mappings:6q2r.F&PDB-ENSP_mappings:6q2r.Y&PDB-ENSP_mappings:6q2r.Z&PDB-ENSP_mappings:6q2s.E&PDB-ENSP_mappings:6q2s.F&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000631&Pfam:PF17813&AFDB-ENSP_mappings:AF-P07949-F1			0.7752	0.8903	0.6239	0.8006	0.7237	0.7536	0.6955	0.8725	0.5614	0.6715	0.8109	0.6932	0.7966	0.6873	0.7118	0.7396	0.7426	0.8614	0.6425	0.6774	0.6896	0.8113	0.6954	0.8265	0.6896	0.7637	0.746	0.8903	AFR	benign	0&1&1	1&1&1	25741868&23757202&32708070&25310821&20532249&21821672&24897126&29131865&20454948&21349203&23084198&34981673&12872262&16424056&18820179&22035350&27533506&33342844&32364585&23840513&37189693&24651702&33827484&32411094&22584707&34006365&27442016&31263477&28930629&37490568						FAIL	-32	-2	40	-3	0.00	0.00	0.00	0.00	RET		2.4000e-01	95995	0.74858	0.70607	0.77516	101890	Multiple_endocrine_neoplasia&Hereditary_cancer-predisposing_syndrome&not_provided&not_specified&Multiple_endocrine_neoplasia&_type_2&Hirschsprung_disease&_susceptibility_to&_1&Multiple_endocrine_neoplasia_type_2B&Multiple_endocrine_neoplasia_type_2A&Pheochromocytoma&Renal_hypodysplasia/aplasia_1		MONDO:MONDO:0017169&MedGen:C0027662&OMIM:PS131100&Orphanet:276161&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0019003&MedGen:C4048306&Orphanet:653&MONDO:MONDO:0007723&MedGen:C3888239&OMIM:142623&Orphanet:388&MONDO:MONDO:0008082&MeSH:D018814&MedGen:C0025269&OMIM:162300&Orphanet:247709&Orphanet:653&MONDO:MONDO:0008234&MeSH:D018813&MedGen:C0025268&OMIM:171400&Orphanet:247698&Orphanet:653&Human_Phenotype_Ontology:HP:0002666&MONDO:MONDO:0008233&MedGen:C0031511&OMIM:171300&Orphanet:29072&MONDO:MONDO:0024519&MedGen:C1619700&OMIM:191830&Orphanet:411709		NC_000010.11:g.43111239A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000113983&SCV000185998&SCV000200116&SCV000313712&SCV000362295&SCV000362296&SCV000362297&SCV000362298&SCV000658401&SCV001158791&SCV002033565&SCV002033566&SCV002033567&SCV002761957&SCV004017333&SCV004357229&SCV005319276&SCV005881270&SCV006099383&SCV006311175	single_nucleotide_variant	SO:0001483	ClinGen:CA007516		RET:5979	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	1800860																											873					0.999							246.81	v6.1	Unknown		True	RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:A432= mutant UNKNOWN.	False	The RET ENSP00000347942.3:a432= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	43606687						True	False	False	Unknown								False	False		RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors.	The RET ENSP00000347942.3:a432= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:A432= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	RET	5979.0	ENSP00000347942.3:A432=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RET"",""entrezGeneId"":5979,""alteration"":""ENSP00000347942.3:A432="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors."",""variantSummary"":""The RET ENSP00000347942.3:a432= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:A432= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						428,444	204,219	224,225	0/1	227,201,234,210	CAT	.	.	.			235,193,247,197	58.76		0.5091743119266054
GRCh38	RET	D12_12345_1234556_Thyroid_S9			chr10	43113205	43113205.0	G	A	A	43113205	.	G	A	.	PASS	NM_020975	A	intron_variant	MODIFIER	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding		9/19	c.1759+242G>A						rs78601594		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1						0.0509	0.0643	0.0331	0	0.0586	0.09											0.05201	0.06821	0.09978	0.04125	0.0502	0.0009656	0.03191	0.06463	0.04789	0.06144	0.0911	0.09978	gnomADg_AMI	benign		1							FAIL	8	1	40	19	0.00	0.00	0.00	0.00	RET		2.4000e-01	1242352			0.05092	1231895	not_provided		MedGen:C3661900		NC_000010.11:g.43113205G>A	criteria_provided&_single_submitter	Benign			SCV001858563	single_nucleotide_variant	SO:0001483	ClinGen:CA13352289		RET:5979	SO:0001627&intron_variant										1	78601594																											799					0.995							247.74													chr10	43608653																																																	True	True	False	Unknown		Unknown																						394,401	171,180	223,221	0/1	198,196,202,199	AGA	0.00	0.00	0.00			203,191,197,204	54.19		0.5044025157232704
GRCh38	RET	D12_12345_1234556_Thyroid_S9			chr10	43113359	43113359.0	G	T	T	43113359	.	G	T	.	PASS	NM_020975	T	intron_variant	MODIFIER	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding		9/19	c.1760-197G>T						rs112675631		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1						0.0637	0.1112	0.036	0	0.0586	0.09											0.06202	0.1026	0.09978	0.04496	0.05127	0.0007722	0.03165	0.07823	0.04806	0.0715	0.0913	0.1112	AFR										FAIL	19	-35	22	-42	0.00	0.00	0.00	0.00	RET		2.4000e-01																																																											789					0.997							248.77													chr10	43608807																																																	True	True	False	Unknown		Unknown																						388,399	175,203	213,196	0/1	202,186,212,187	GGC	0.00	0.00	0.00			201,187,202,197	55.67		0.5069885641677255
GRCh38	RET	D12_12345_1234556_Thyroid_S9			chr10	43114918	43114918.0	G	A	A	43114918	.	G	A	.	PASS	NM_020975	A	intron_variant	MODIFIER	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding		11/19	c.2136+182G>A						rs1864400&COSV60687565		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1						0.7498	0.9365	0.7795	0.4742	0.825	0.683											0.8244	0.908	0.92	0.8021	0.7682	0.4973	0.8139	0.7925	0.8147	0.8137	0.709	0.9365	AFR	benign	0&1	1&1	25310821&32851260						FAIL	-9	25	-9	24	0.00	0.00	0.00	0.00	RET		2.4000e-01	1226080			0.74980	1214761	not_provided		MedGen:C3661900		NC_000010.11:g.43114918G>A	criteria_provided&_single_submitter	Benign			SCV001834563	single_nucleotide_variant	SO:0001483	ClinGen:CA13152660		RET:5979	SO:0001627&intron_variant										1	1864400																											842					0.996							246.94													chr10	43610366																																																	True	True	False	Unknown		Unknown																						435,404	214,183	221,221	0/1	211,224,187,217	TGT	0.00	0.00	0.00			210,225,190,214	39.09		0.48152562574493446
GRCh38	RET	D12_12345_1234556_Thyroid_S9			chr10	43116260	43116260.0	A	G	G	43116260	.	A	G	.	PASS	NM_020975	G	intron_variant	MODIFIER	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding		11/19	c.2137-324A>G						rs741968		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1						0.7530	0.9402	0.7824	0.4742	0.829	0.6881											0.8303	0.9139	0.92	0.8047	0.7683	0.4965	0.8216	0.7911	0.8226	0.8191	0.7128	0.9402	AFR	benign		1	25310821						FAIL	-45	3	20	3	0.00	0.00	0.00	0.00	RET		2.4000e-01	1267407			0.75300	1257744	not_provided		MedGen:C3661900		NC_000010.11:g.43116260A>G	criteria_provided&_single_submitter	Benign			SCV001894388	single_nucleotide_variant	SO:0001483	ClinGen:CA13152662		RET:5979	SO:0001627&intron_variant										1	741968																											858					0.999							247.7													chr10	43611708																																																	True	True	False	Unknown		Unknown																						417,440	205,203	212,237	0/1	211,206,212,228	CAG	.	.	.			207,210,221,219	60.6		0.5134189031505251
GRCh38	RET	D12_12345_1234556_Thyroid_S9	p.Ser836=	ENSP00000347942.3:p.Ser836=	chr10	43119646	43119646.0	C	T	T	43119646	.	C	T	.	PASS	NM_020975	T	synonymous_variant	LOW	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding	14/20		c.2508C>T	2698	2508	836	S	agC/agT	rs1800862&CM012798&COSV60687774		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1			PDB-ENSP_mappings:2ivs.A&PDB-ENSP_mappings:2ivs.B&PDB-ENSP_mappings:2ivt.A&PDB-ENSP_mappings:2ivu.A&PDB-ENSP_mappings:2ivv.A&PDB-ENSP_mappings:2x2k.A&PDB-ENSP_mappings:2x2l.A&PDB-ENSP_mappings:2x2m.A&PDB-ENSP_mappings:2x2m.B&PDB-ENSP_mappings:4cki.A&PDB-ENSP_mappings:4ckj.A&PDB-ENSP_mappings:5amn.A&PDB-ENSP_mappings:5fm2.A&PDB-ENSP_mappings:5fm3.A&PDB-ENSP_mappings:6fek.A&PDB-ENSP_mappings:6i82.A&PDB-ENSP_mappings:6i82.B&PDB-ENSP_mappings:6i83.A&PDB-ENSP_mappings:6ne7.A&PDB-ENSP_mappings:6nec.A&PDB-ENSP_mappings:6nec.C&PDB-ENSP_mappings:6nja.A&PDB-ENSP_mappings:6vhg.A&PDB-ENSP_mappings:7du8.A&PDB-ENSP_mappings:7du8.B&PDB-ENSP_mappings:7du9.A&PDB-ENSP_mappings:7du9.B&PDB-ENSP_mappings:7dua.A&PDB-ENSP_mappings:7dua.B&PDB-ENSP_mappings:7ju5.A&PDB-ENSP_mappings:7ju5.B&PDB-ENSP_mappings:7ju6.A&PDB-ENSP_mappings:7ju6.B&PDB-ENSP_mappings:7nzn.A&PDB-ENSP_mappings:7run.A&PDB-ENSP_mappings:7run.B&Low_complexity_(Seg):seg&PROSITE_profiles:PS50011&SMART:SM00219&Phobius:CYTOPLASMIC_DOMAIN&CDD:cd05045&Superfamily:SSF56112&PIRSF:PIRSF000631&Pfam:PF07714&Gene3D:1.10.510.10&PANTHER:PTHR24416&AFDB-ENSP_mappings:AF-P07949-F1			0.0359	0.0129	0.0303	0	0.0586	0.0849	0.04906	0.02465	0.02505	0.05382	0.001058	0.03661	0.07326	0.04938	0.04687	0.09493	0.03931	0.02439	0.1	0.03652	0.05271	0.0009653	0.03188	0.06463	0.04767	0.05345	0.08754	0.1	gnomADg_AMI	benign&likely_benign&benign/likely_benign	0&1&1	1&1&1	25741868&24033266&32708070&26829565&20532249&34950210&19138047&22312249&24897126&25330015&28946813&32228166&34769224&23059849&23527089&34981673&10022819&22111543&16118333&11589684&30283335&31717449&33827484&32411094&27174043&32458635&22584707&37835559						FAIL	-12	0	-2	5	0.00	0.00	0.00	0.00	RET		2.4000e-01	24946	0.04245	0.04666	0.03594	36287	not_provided&Multiple_endocrine_neoplasia_type_2B&Multiple_endocrine_neoplasia_type_2A&Multiple_endocrine_neoplasia&Familial_medullary_thyroid_carcinoma&Multiple_endocrine_neoplasia&_type_2&not_specified&Renal_hypodysplasia/aplasia_1&Hereditary_cancer-predisposing_syndrome&Pheochromocytoma&Hirschsprung_disease&_susceptibility_to&_1		MedGen:C3661900&MONDO:MONDO:0008082&MeSH:D018814&MedGen:C0025269&OMIM:162300&Orphanet:247709&Orphanet:653&MONDO:MONDO:0008234&MeSH:D018813&MedGen:C0025268&OMIM:171400&Orphanet:247698&Orphanet:653&MONDO:MONDO:0017169&MedGen:C0027662&OMIM:PS131100&Orphanet:276161&MONDO:MONDO:0007958&MedGen:C1833921&OMIM:155240&Orphanet:653&Orphanet:99361&MONDO:MONDO:0019003&MedGen:C4048306&Orphanet:653&MedGen:CN169374&MONDO:MONDO:0024519&MedGen:C1619700&OMIM:191830&Orphanet:411709&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&Human_Phenotype_Ontology:HP:0002666&MONDO:MONDO:0008233&MedGen:C0031511&OMIM:171300&Orphanet:29072&MONDO:MONDO:0007723&MedGen:C3888239&OMIM:142623&Orphanet:388		NC_000010.11:g.43119646C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000171360&SCV000200118&SCV000226158&SCV000258171&SCV000313720&SCV000362356&SCV000362357&SCV000362358&SCV000362359&SCV000556205&SCV000605018&SCV000842756&SCV001176664&SCV002550389&SCV004017338&SCV004357251&SCV005220646&SCV005881264&SCV005914600&SCV006096080	single_nucleotide_variant	SO:0001483	ClinGen:CA008829		RET:5979	SO:0001819&synonymous_variant										1	1800862																											890					0.997							248.12	v6.1	Unknown		True	RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:S836= mutant UNKNOWN.	False	The RET ENSP00000347942.3:s836= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	43615094						True	False	False	Unknown								False	False		RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors.	The RET ENSP00000347942.3:s836= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:S836= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	RET	5979.0	ENSP00000347942.3:S836=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RET"",""entrezGeneId"":5979,""alteration"":""ENSP00000347942.3:S836="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors."",""variantSummary"":""The RET ENSP00000347942.3:s836= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RET ENSP00000347942.3:S836= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						452,435	235,216	217,219	0/1	240,212,224,211	GCT	0.00	0.00	0.00			211,241,231,204	45.62		0.4904171364148816
GRCh38	RET	D12_12345_1234556_Thyroid_S9			chr10	43126769	43126769.0	T	C	C	43126769	.	T	C	.	PASS	NM_020975	C	intron_variant	MODIFIER	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding		19/19	c.3187+47T>C						rs2075912&COSV60689472&CS032426		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1						0.7550	0.9425	0.781	0.4762	0.828	0.6953	0.812	0.9141	0.7962	0.768	0.4939	0.8067	0.7914	0.8284	0.7977	0.743	0.8309	0.9149	0.92	0.8054	0.7648	0.4996	0.8219	0.7925	0.823	0.822	0.7111	0.9425	AFR	benign	0&1&1	1&1&1	25741868&24033266&27798940&29131865&20454948&34981673&22648184&37189693&32411094&31247956						FAIL	-21	-47	19	-47	0.00	0.00	0.00	0.03	RET		2.4000e-01	165056	0.85333	0.80309	0.75499	174666	RET-related_disorder&Hereditary_cancer-predisposing_syndrome&not_specified&Multiple_endocrine_neoplasia&_type_2&not_provided&Multiple_endocrine_neoplasia_type_2B&Multiple_endocrine_neoplasia_type_2A&Pheochromocytoma		.&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0019003&MedGen:C4048306&Orphanet:653&MedGen:C3661900&MONDO:MONDO:0008082&MeSH:D018814&MedGen:C0025269&OMIM:162300&Orphanet:247709&Orphanet:653&MONDO:MONDO:0008234&MeSH:D018813&MedGen:C0025268&OMIM:171400&Orphanet:247698&Orphanet:653&Human_Phenotype_Ontology:HP:0002666&MONDO:MONDO:0008233&MedGen:C0031511&OMIM:171300&Orphanet:29072		NC_000010.11:g.43126769T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000200120&SCV001729634&SCV002033571&SCV002033574&SCV002033575&SCV002761349&SCV004017337&SCV005319285&SCV005881267&SCV006099417&SCV006311170	single_nucleotide_variant	SO:0001483	ClinGen:CA007687		RET:5979	SO:0001627&intron_variant										1	2075912																											461					0.987							243.45													chr10	43622217																																																	True	True	False	Unknown		Unknown																						248,207	129,117	119,90	0/1	122,126,104,103	TTT	.	.	.			111,137,94,113	26.36		0.45494505494505494
GRCh38	RET	D12_12345_1234556_Thyroid_S9			chr10	43127485	43127485.0	T	C	C	43127485	.	T	C	.	PASS	NM_020975	C	intron_variant	MODIFIER	RET	ENSG00000165731	Transcript	ENST00000355710	protein_coding		19/19	c.3188-627T>C						rs2565200&COSV60689476		1		SNV	HGNC	HGNC:9967	YES	MANE_Select	NM_020975.6		5	P4	CCDS7200.1	ENSP00000347942	P07949.278		UPI00001336E1	P07949-1		1						0.7654	0.9781	0.7882	0.4762	0.828	0.6953	0.8251	0.9551	0.7942	0.7715	0.4853	0.8333	0.7859	0.8305	0.7987	0.746	0.8396	0.9458	0.92	0.8078	0.7648	0.4998	0.8218	0.7891	0.8231	0.8243	0.7107	0.9781	AFR		0&1	0&1	20532249&24897126&27798940&29131865&37189693						FAIL	45	14	9	-39	0.00	0.00	0.00	0.00	RET		2.4000e-01																																																											327					0.988							246.95													chr10	43622933																																																	True	True	False	Unknown		Unknown																						159,164	82,84	77,80	0/1	89,70,80,84	TTG	.	.	.			58,101,58,106	43.49		0.5077399380804953
GRCh38		D12_12345_1234556_Thyroid_S9			chr10	52682621	52682624.0	GTAC	G	G	52682621	.	GTAC	G	.	PASS		-	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000296123	Transcript	ENST00000736559	lncRNA		1/1	n.177-28984_177-28982del						rs1160886		1		deletion			YES																		4	0.3924	0.3048	0.3963	0.5288	0.3966	0.363											0.3717	0.3021	0.5644	0.4039	0.3594	0.5445	0.4374	0.3425	0.3812	0.3909	0.3714	0.5644	gnomADg_AMI				33801242																																																																												95					0.937							241.99													chr10	54442381																																																	True	False	False	Unknown		Unknown																						50,39	17,19	33,20	0/1	28,22,23,16	AGT						23,27,15,24	27.24		0.43820224719101125
GRCh38	ARID5B	D12_12345_1234556_Thyroid_S9	p.C258G	ENSP00000279873.7:p.Cys258Gly	chr10	62050926	62050926.0	T	G	G	62050926	.	T	G	.	PASS	NM_032199	G	missense_variant	MODERATE	ARID5B	ENSG00000150347	Transcript	ENST00000279873	protein_coding	5/10		c.772T>G	783	772	258	C/G	Tgc/Ggc	rs146939872		1		SNV	HGNC	HGNC:17362	YES	MANE_Select	NM_032199.3		1	P3	CCDS31208.1	ENSP00000279873	Q14865.203		UPI00001606F0	Q14865-1			tolerated(0.06)	benign(0.003)	AFDB-ENSP_mappings:AF-Q14865-F1&PANTHER:PTHR13964&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg									1.642e-05	0.0004182	4.472e-05	0	0	0	0	7.194e-06	0	0	0.0001839	0.0006513	0	6.542e-05	0	0	0	0	0	0	0	0.0006513	gnomADg_AFR										FAIL	-38	-19	-23	-24	0.00	0.00	0.00	0.00	ARID5B	0.115	2.1100e-01																																																											88					0.966							238.95	v6.1	Unknown		True	ARID5B, a tumor suppressor involved in transcriptional regulation, is altered at low frequencies in various cancer types.	False	10/03/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID5B ENSP00000279873.7:C258G mutant UNKNOWN.	False	The ARID5B ENSP00000279873.7:c258g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	63810685						True	False	False	Unknown								False	False		ARID5B, a tumor suppressor involved in transcriptional regulation, is altered at low frequencies in various cancer types.	The ARID5B ENSP00000279873.7:c258g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID5B ENSP00000279873.7:C258G mutant UNKNOWN.						v6.1	10/03/2018		GRCh38	ARID5B	84159.0	ENSP00000279873.7:C258G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ARID5B"",""entrezGeneId"":84159,""alteration"":""ENSP00000279873.7:C258G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ARID5B, a tumor suppressor involved in transcriptional regulation, is altered at low frequencies in various cancer types."",""variantSummary"":""The ARID5B ENSP00000279873.7:c258g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID5B ENSP00000279873.7:C258G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/03/2018""}"	True	True	False	Unknown		Unknown																						42,43	22,23	20,20	0/1	18,24,22,21	ATG	.	.	.			20,22,24,19	35.61		0.5058823529411764
GRCh38	TET1	D12_12345_1234556_Thyroid_S9	p.D162G	ENSP00000362748.4:p.Asp162Gly	chr10	68572823	68572823.0	A	G	G	68572823	.	A	G	.	PASS	NM_030625	G	missense_variant	MODERATE	TET1	ENSG00000138336	Transcript	ENST00000373644	protein_coding	2/12		c.485A>G	1013	485	162	D/G	gAc/gGc	rs10823229&COSV65381629		1		SNV	HGNC	HGNC:29484	YES	MANE_Select	NM_030625.3		1	P1	CCDS7281.1	ENSP00000362748	Q8NFU7.163		UPI000013D114	Q8NFU7-1		1	deleterious(0.01)	benign(0.019)	PANTHER:PTHR23358&AFDB-ENSP_mappings:AF-Q8NFU7-F1			0.2586	0.0227	0.2622	0.3919	0.3877	0.3047	0.3734	0.06299	0.2411	0.4986	0.3629	0.2945	0.3637	0.3936	0.3733	0.3184	0.2857	0.0739	0.455	0.296	0.502	0.3793	0.2809	0.4252	0.3894	0.3357	0.3085	0.502	gnomADg_ASJ		0&1	1&1	36224396						FAIL	0	24	-1	35	0.00	0.00	0.00	0.00	TET1	0.087	1.5100e-01																																																											127					0.992							242.58	v6.1	Unknown		True	TET1 encodes a tumor suppressor and DNA demethylase involved in the epigenetic regulation of gene expression. TET1 is infrequently mutated in solid tumors.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TET1 ENSP00000362748.4:D162G mutant UNKNOWN.	False	The TET1 ENSP00000362748.4:d162g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	70332580						True	False	False	Unknown								False	False		TET1 encodes a tumor suppressor and DNA demethylase involved in the epigenetic regulation of gene expression. TET1 is infrequently mutated in solid tumors.	The TET1 ENSP00000362748.4:d162g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TET1 ENSP00000362748.4:D162G mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	TET1	80312.0	ENSP00000362748.4:D162G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""TET1"",""entrezGeneId"":80312,""alteration"":""ENSP00000362748.4:D162G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""TET1 encodes a tumor suppressor and DNA demethylase involved in the epigenetic regulation of gene expression. TET1 is infrequently mutated in solid tumors."",""variantSummary"":""The TET1 ENSP00000362748.4:d162g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TET1 ENSP00000362748.4:D162G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						0,126	0,80	0,46	0/1	0,0,67,59	GAC	.	.	.			0,0,61,65	64.71		1.0
GRCh38	TET1	D12_12345_1234556_Thyroid_S9	p.I1123M	ENSP00000362748.4:p.Ile1123Met	chr10	68646098	68646098.0	A	G	G	68646098	.	A	G	.	PASS	NM_030625	G	missense_variant	MODERATE	TET1	ENSG00000138336	Transcript	ENST00000373644	protein_coding	4/12		c.3369A>G	3897	3369	1123	I/M	atA/atG	rs3998860&COSV65385549		1		SNV	HGNC	HGNC:29484	YES	MANE_Select	NM_030625.3		1	P1	CCDS7281.1	ENSP00000362748	Q8NFU7.163		UPI000013D114	Q8NFU7-1		1	deleterious(0.05)	benign(0.011)	MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&PANTHER:PTHR23358&AFDB-ENSP_mappings:AF-Q8NFU7-F1			0.6933	0.4508	0.7781	0.8502	0.8091	0.68	0.8097	0.4883	0.7305	0.8896	0.8353	0.7976	0.8575	0.8256	0.8086	0.7399	0.7212	0.4928	0.911	0.7538	0.8965	0.8375	0.7974	0.8163	0.8187	0.7595	0.7278	0.911	gnomADg_AMI		0&1	0&1	26648445&22666496&26356709&26880370&37347215&38320344						FAIL	-29	7	-38	-41	0.00	0.00	0.00	0.00	TET1	0.060	1.5100e-01																																																											238					0.895							215.54	v6.1	Unknown		True	TET1 encodes a tumor suppressor and DNA demethylase involved in the epigenetic regulation of gene expression. TET1 is infrequently mutated in solid tumors.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TET1 ENSP00000362748.4:I1123M mutant UNKNOWN.	False	The TET1 ENSP00000362748.4:i1123m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	70405855						True	False	False	Unknown								False	False		TET1 encodes a tumor suppressor and DNA demethylase involved in the epigenetic regulation of gene expression. TET1 is infrequently mutated in solid tumors.	The TET1 ENSP00000362748.4:i1123m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TET1 ENSP00000362748.4:I1123M mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	TET1	80312.0	ENSP00000362748.4:I1123M			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""TET1"",""entrezGeneId"":80312,""alteration"":""ENSP00000362748.4:I1123M"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""TET1 encodes a tumor suppressor and DNA demethylase involved in the epigenetic regulation of gene expression. TET1 is infrequently mutated in solid tumors."",""variantSummary"":""The TET1 ENSP00000362748.4:i1123m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TET1 ENSP00000362748.4:I1123M mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						0,213	0,111	0,102	0/1	0,0,117,96	TAC	.	.	.			0,0,129,84	64.73		1.0
GRCh38	LRMDA	D12_12345_1234556_Thyroid_S9			chr10	76253482		G	[chr13:102955140[G	[chr13:102955140[G	76253482	MantaBND:11326:0:1:0:0:0:0	G	[chr13:102955140[G	.	PASS	NM_001305581	.G	feature_truncation&intron_variant	HIGH	LRMDA	ENSG00000148655	Transcript	ENST00000611255	protein_coding		5/6									1		chromosome_breakpoint	HGNC	HGNC:23405	YES	MANE_Select	NM_001305581.2		5	P1	CCDS76319.1	ENSP00000480240		A0A087WWI0.60	UPI00001A5016			1																																																																																																														1			0,8							8	GAGAGAGA			MantaBND:11326:0:1:0:0:0:1	0														chr10	78013240				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr10	83610901		A	[chr21:27305418[A	[chr21:27305418[A	83610901	MantaBND:11363:0:1:0:0:0:1	A	[chr21:27305418[A	.	PASS																																																																																																																																																				0			0,5							5	AAGAT			MantaBND:11363:0:1:0:0:0:0	6														chr10	85370657				BND																																													True	False	False	Unknown		Unknown																															1,1				3,2	
GRCh38	PTEN	D12_12345_1234556_Thyroid_S9			chr10	87892783		G	<INS>	<INS>	87892783	MantaINS:6692:1:1:2:8:0	G	<INS>	.	PASS	NM_000314	insertion	intron_variant	MODIFIER	PTEN	ENSG00000171862	Transcript	ENST00000371953	protein_coding		1/8									1		insertion	HGNC	HGNC:9588	YES	MANE_Select	NM_000314.8		1	P1	CCDS31238.1	ENSP00000361021	P60484.218	F6KD01.101	UPI00001328C5	P60484-1		1																																																																																																															0,67		0,67							67	GGCTGGTGTGAAAGGTCTGTCAGAAAATCATGAGATTAGATTGAGGTACCTCAAAAAATGAGAGCTG		GGCTGGTGTGAAAGGTCTGTCAGAAAATCATGAGATTAGATTGAGGTACCTCAAAAAATGAGAGCTGCTATTCATGTGCAGGTTTTTGTGTGGACATGTTTTCACCATATTTGAGTAAATAC																chr10	89652540	AGGTGTGAAGAAGCTGGCTGTGCAAGTGCTAGAAAAGCTGGCACCTGGATTCTGT			INS																																													True	True	False	Unknown		Unknown																															1,1				0,1	
GRCh38	PTEN	D12_12345_1234556_Thyroid_S9			chr10	87945672	87945672.0	G	C	C	87945672	.	G	C	.	PASS	NM_000314	C	intron_variant	MODIFIER	PTEN	ENSG00000171862	Transcript	ENST00000371953	protein_coding		5/8	c.493-6446G>C						rs2735343		1		SNV	HGNC	HGNC:9588	YES	MANE_Select	NM_000314.8		1	P1	CCDS31238.1	ENSP00000361021	P60484.218	F6KD01.101	UPI00001328C5	P60484-1		1						0.4227	0.4924	0.4409	0.501	0.3698	0.2894	0.351	0.476	0.4605	0.3834	0.4958	0.3411	0.3644	0.3345	0.3719	0.3004	0.3905	0.4715	0.2703	0.4492	0.3759	0.5054	0.3448	0.4384	0.3347	0.4095	0.2944	0.5054	gnomADg_EAS				18805939&22562547&27246533&24959314&32637184&21093899&27344223&32484847&30799775&16385451&21633361&26541596&22336889&27677222&29221206&16331670&28303061&33403820&24132918&24391010&36585213&35582142&20381115&37867611						FAIL	46	-48	-42	44	0.02	0.00	0.01	0.00	PTEN		6.8500e-01																																																											53					0.981							243.39													chr10	89705429																																																	True	True	False	Unknown		Unknown																						24,28	12,13	12,15	0/1	9,15,16,12	CGC	.	.	.			11,13,15,13	35.94		0.5384615384615384
GRCh38	FAS	D12_12345_1234556_Thyroid_S9	p.Thr214=	ENSP00000498466.1:p.Thr214=	chr10	89012072	89012072.0	T	C	C	89012072	.	T	C	.	PASS	NM_000043	C	synonymous_variant	LOW	FAS	ENSG00000026103	Transcript	ENST00000652046	protein_coding	7/9		c.642T>C	721	642	214	T	acT/acC	rs2234978&CM045201&COSV108108887		1		SNV	HGNC	HGNC:11920	YES	MANE_Select	NM_000043.6			A2	CCDS7393.1	ENSP00000498466	P25445.269		UPI000003060C	P25445-1		1			AFDB-ENSP_mappings:AF-P25445-F1&Phobius:CYTOPLASMIC_DOMAIN&PANTHER:PTHR46874			0.7754	0.6475	0.7911	0.9573	0.7028	0.8241	0.7271	0.6771	0.8474	0.7374	0.9622	0.7866	0.73	0.7044	0.739	0.82	0.7273	0.6809	0.636	0.7988	0.7477	0.9736	0.7942	0.7313	0.7035	0.7417	0.8187	0.9736	gnomADg_EAS	benign	0&1&1	1&1&1	25741868&27417569&24033266&22295056&27834829&20959405&27009330&21858107&22347493&20694011&31228212&25103824&23378343&21436341&20813889&19669200&21625619&29657992&26690594&34566427&33507988&22983578&31804351&16271851&37924126						FAIL	-20	14	13	-20	0.00	0.00	0.02	0.03	FAS		3.7200e-01	254734	0.69522	0.75613	0.77536	253905	not_provided&Autoimmune_lymphoproliferative_syndrome_type_1&not_specified		MedGen:C3661900&MONDO:MONDO:0011158&MedGen:C1328840&OMIM:601859&Orphanet:3261&MedGen:CN169374		NC_000010.11:g.89012072T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000301609&SCV000365905&SCV000539137&SCV001724243&SCV001843579&SCV001933314&SCV004102278&SCV005319924	single_nucleotide_variant	SO:0001483	ClinGen:CA5593176		FAS:355	SO:0001619&non-coding_transcript_variant&SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	2234978																											293					0.973							239.98	v6.1	Unknown		True	FAS, a death receptor that initiates apoptosis, is recurrently altered by mutation or downregulation in a diverse range of human cancers.	False	12/01/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAS ENSP00000498466.1:T214= mutant UNKNOWN.	False	The FAS ENSP00000498466.1:t214= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	90771829						True	False	False	Unknown								False	False		FAS, a death receptor that initiates apoptosis, is recurrently altered by mutation or downregulation in a diverse range of human cancers.	The FAS ENSP00000498466.1:t214= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAS ENSP00000498466.1:T214= mutant UNKNOWN.						v6.1	12/01/2025		GRCh38	FAS	355.0	ENSP00000498466.1:T214=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAS"",""entrezGeneId"":355,""alteration"":""ENSP00000498466.1:T214="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAS, a death receptor that initiates apoptosis, is recurrently altered by mutation or downregulation in a diverse range of human cancers."",""variantSummary"":""The FAS ENSP00000498466.1:t214= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAS ENSP00000498466.1:T214= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/01/2025""}"	True	True	False	Unknown		Unknown																						0,285	0,133	0,152	0/1	0,0,122,163	CTT	.	.	.			0,0,150,135	64.73		1.0
GRCh38	FGF8	D12_12345_1234556_Thyroid_S9			chr10	101770141	101770153.0	TAAAAAAAAAAAA	T	T	101770141	.	TAAAAAAAAAAAA	T	.	PASS	NM_033163	-	3_prime_UTR_variant	MODIFIER	FGF8	ENSG00000107831	Transcript	ENST00000320185	protein_coding	6/6		c.*176_*187del	1125-1136					rs11322844		-1		deletion	HGNC	HGNC:3686	YES	MANE_Select	NM_033163.5		1	A2	CCDS7516.1	ENSP00000321797	P55075.201		UPI000002A991	P55075-4		1												0.05438	0.01039	0.04811	0.01884	9.228e-05	0.04508	0.01042	0.07001	0.04422	0.02914	0.04379	0.01376	0.278	0.05045	0.01621	0.0007112	0.06071	0.01327	0.06048	0.0373	0.01696	0.278	gnomADg_AMI	benign		1																		7.6500e-01	1269222				1260365	not_provided		MedGen:C3661900		NC_000010.11:g.101770153_101770164del	criteria_provided&_single_submitter	Benign			SCV001900040	Deletion	SO:0000159	ClinGen:CA212179429		FGF8:2253	SO:0001624&3_prime_UTR_variant										1	11322844																											399					0.917							235.29													chr10	103529898																																																	True	True	False	Unknown		Unknown																						183,183	92,94	91,89	0/1	100,83,99,84	TTA						129,54,132,51	48.69		0.5
GRCh38	FGF8	D12_12345_1234556_Thyroid_S9			chr10	101777535	101777535.0	C	T	T	101777535	.	C	T	.	PASS	NM_033163	T	upstream_gene_variant	MODIFIER	FGF8	ENSG00000107831	Transcript	ENST00000320185	protein_coding									rs1010812994	1421	-1		SNV	HGNC	HGNC:3686	YES	MANE_Select	NM_033163.5		1	A2	CCDS7516.1	ENSP00000321797	P55075.201		UPI000002A991	P55075-4		1																						5.911e-05	0	0	6.543e-05	0	0	0	0	0.0001029	0.0004776	0	0.0004776	gnomADg_REMAINING																																																																																808					0.996							246.61													chr10	103537292																																																	True	True	False	Unknown		Unknown																						417,388	212,212	205,176	0/1	214,203,200,188	ACT	0.00	0.00	0.00			199,218,152,236	39.31		0.48198757763975153
GRCh38	SMC3	D12_12345_1234556_Thyroid_S9			chr10	110583571	110583571.0	A	G	G	110583571	.	A	G	.	PASS	NM_005445	G	intron_variant	MODIFIER	SMC3	ENSG00000108055	Transcript	ENST00000361804	protein_coding		11/28	c.969+23A>G						rs79429105&COSV62419930		1		SNV	HGNC	HGNC:2468	YES	MANE_Select	NM_005445.4		1	P1	CCDS31285.1	ENSP00000354720	Q9UQE7.219		UPI0000135A8D			1						0.0202	0.0015	0.0086	0	0.0328	0.0613	0.0206	0.004249	0.01247	0.04667	0.0001009	0.02524	0.05299	0.01824	0.02488	0.05519	0.01645	0.003584	0.001096	0.01738	0.05219	0.0003855	0.02714	0.03061	0.01902	0.02081	0.05634	0.0613	SAS	benign	0&1	1&1							FAIL	-23	18	17	-23	0.00	0.00	0.04	0.00	SMC3		1.3200e-01	1227950	0.01607		0.02017	1215342	not_provided		MedGen:C3661900		NC_000010.11:g.110583571A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001837383&SCV005317176	single_nucleotide_variant	SO:0001483	ClinGen:CA5687848		SMC3:9126	SO:0001627&intron_variant										1	79429105																											154					0.961							227.08													chr10	112343329																																																	True	True	False	Unknown		Unknown																						73,75	30,37	43,38	0/1	35,38,37,38	GAA	.	.	.			38,35,37,38	38.07		0.5067567567567568
GRCh38	SMC3	D12_12345_1234556_Thyroid_S9			chr10	110596573	110596573.0	G	A	A	110596573	.	G	A	.	PASS	NM_005445	A	intron_variant	MODIFIER	SMC3	ENSG00000108055	Transcript	ENST00000361804	protein_coding		19/28	c.2116+23G>A						rs7075340		1		SNV	HGNC	HGNC:2468	YES	MANE_Select	NM_005445.4		1	P1	CCDS31285.1	ENSP00000354720	Q9UQE7.219		UPI0000135A8D			1						0.9573	0.8956	0.9625	0.9692	0.9861	0.9949	0.9885	0.9233	0.9284	0.9881	0.9571	0.9895	0.9906	0.9935	0.9834	0.9967	0.9682	0.9245	0.9682	0.9488	0.9893	0.967	0.9889	0.983	0.9932	0.9655	0.9948	0.9967	gnomADe_SAS	benign		1	25741868&17273969						FAIL	7	1	-23	-13	0.00	0.00	0.11	0.00	SMC3		1.3200e-01	259768	0.97262	0.97925	0.95727	253691	not_specified&not_provided&Cornelia_de_Lange_syndrome_3		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0012555&MedGen:C1853099&OMIM:610759&Orphanet:199		NC_000010.11:g.110596573G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000311069&SCV000976048&SCV002057464&SCV005317184	single_nucleotide_variant	SO:0001483	ClinGen:CA5688113		SMC3:9126	SO:0001627&intron_variant										1	7075340																											82					0.951							238.95													chr10	112356331																																																	True	True	False	Unknown		Unknown																						0,78	0,37	0,41	0/1	0,0,37,41	AGT	0.00	0.00	0.00			0,0,24,54	64.57		1.0
GRCh38	SMC3	D12_12345_1234556_Thyroid_S9	p.Ser1013=	ENSP00000354720.5:p.Ser1013=	chr10	110602112	110602112.0	A	G	G	110602112	.	A	G	.	PASS	NM_005445	G	synonymous_variant	LOW	SMC3	ENSG00000108055	Transcript	ENST00000361804	protein_coding	25/29		c.3039A>G	3161	3039	1013	S	tcA/tcG	rs2419565&COSV62418881		1		SNV	HGNC	HGNC:2468	YES	MANE_Select	NM_005445.4		1	P1	CCDS31285.1	ENSP00000354720	Q9UQE7.219		UPI0000135A8D			1			Gene3D:3.40.50.300&PDB-ENSP_mappings:6wg3.B&PDB-ENSP_mappings:6wge.B&PDB-ENSP_mappings:7w1m.B&AFDB-ENSP_mappings:AF-Q9UQE7-F1&Pfam:PF02463&PIRSF:PIRSF005719&PANTHER:PTHR43977&Superfamily:SSF52540			0.9868	0.9531	0.9986	1	0.997	1	0.9985	0.9641	0.9978	0.9892	1	1	0.996	0.9997	0.9966	0.9998	0.9895	0.9649	1	0.9959	0.9902	1	1	0.9932	0.9996	0.992	0.9994	1	EAS&SAS&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN	benign	0&1	1&1	25741868&18414213&17273969						FAIL	-50	2	18	-43	0.00	0.00	0.00	0.00	SMC3		1.3200e-01	159985	0.98985		0.98682	168840	not_specified&not_provided&Inborn_genetic_diseases&Cornelia_de_Lange_syndrome_3		MedGen:CN169374&MedGen:C3661900&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0012555&MedGen:C1853099&OMIM:610759&Orphanet:199		NC_000010.11:g.110602112A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000195044&SCV000311073&SCV000360321&SCV000728758&SCV000843977&SCV000846098&SCV001729160&SCV002057465&SCV005317192	single_nucleotide_variant	SO:0001483	ClinGen:CA173529		SMC3:9126	SO:0001819&synonymous_variant										1	2419565																											125					0.792							81.2	v6.1	Unknown		True	SMC3, an ATPase that functions as a subunit of the cohesin complex, is recurrently mutated in Cornelia de Lange syndromes, hematologic malignancies, and solid tumors.	False	11/25/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMC3 ENSP00000354720.5:S1013= mutant UNKNOWN.	False	The SMC3 ENSP00000354720.5:s1013= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	112361870						True	False	False	Unknown								False	False		SMC3, an ATPase that functions as a subunit of the cohesin complex, is recurrently mutated in Cornelia de Lange syndromes, hematologic malignancies, and solid tumors.	The SMC3 ENSP00000354720.5:s1013= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMC3 ENSP00000354720.5:S1013= mutant UNKNOWN.						v6.1	11/25/2018		GRCh38	SMC3	9126.0	ENSP00000354720.5:S1013=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SMC3"",""entrezGeneId"":9126,""alteration"":""ENSP00000354720.5:S1013="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SMC3, an ATPase that functions as a subunit of the cohesin complex, is recurrently mutated in Cornelia de Lange syndromes, hematologic malignancies, and solid tumors."",""variantSummary"":""The SMC3 ENSP00000354720.5:s1013= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMC3 ENSP00000354720.5:S1013= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/25/2018""}"	True	True	False	Unknown		Unknown																						0,99	0,42	0,57	0/1	0,0,57,42	CAA	.	.	.			0,0,38,61	64.67		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121479598	121479598.0	G	A	A	121479598	.	G	A	.	PASS	NM_000141	A	3_prime_UTR_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding	18/18		c.*259C>T	3358					rs1047057&COSV60638447		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.4143	0.0938	0.6873	0.3512	0.5099	0.6207	0.5523	0.1434	0.7323	0.561	0.3909	0.5011	0.4802	0.5644	0.525	0.5962	0.444	0.1568	0.4923	0.6335	0.5886	0.3728	0.4925	0.4966	0.5543	0.4773	0.6002	0.7323	gnomADe_AMR	benign	0&1	1&1	26959740&22253485&24943593&27223085&27511275&26069105&30258940&23532954&37358427&38785976																	2.7800e-01	298991	0.43452	0.53105	0.41434	309584	not_specified&Craniosynostosis_syndrome&not_provided&Isolated_Coronal_Synostosis&Beare-Stevenson_cutis_gyrata_syndrome&Crouzon_syndrome&Saethre-Chotzen_syndrome		MedGen:CN169374&Human_Phenotype_Ontology:HP:0001363&Human_Phenotype_Ontology:HP:0001365&Human_Phenotype_Ontology:HP:0004494&Human_Phenotype_Ontology:HP:0005448&Human_Phenotype_Ontology:HP:0005457&Human_Phenotype_Ontology:HP:0005467&Human_Phenotype_Ontology:HP:0008492&MONDO:MONDO:0015469&MeSH:D003398&MedGen:C0010278&OMIM:PS123100&Orphanet:1531&MedGen:C3661900&MedGen:CN043619&MONDO:MONDO:0007412&MedGen:C1852406&OMIM:123790&Orphanet:1555&Human_Phenotype_Ontology:HP:0004439&MONDO:MONDO:0007405&MeSH:D003394&MedGen:C0010273&OMIM:123500&Orphanet:207&MONDO:MONDO:0007042&MedGen:C0175699&OMIM:101400&Orphanet:794		NC_000010.11:g.121479598G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000360786&SCV000360787&SCV000360788&SCV000360790&SCV000360793&SCV000516266&SCV000842034&SCV005322882	single_nucleotide_variant	SO:0001483	ClinGen:CA5720419		FGFR2:2263	SO:0001619&non-coding_transcript_variant&SO:0001624&3_prime_UTR_variant&SO:0001819&synonymous_variant										1	1047057																											546					0.995							245.22													chr10	123239112																																																	True	True	False	Unknown		Unknown																						318,225	153,107	165,118	0/1	156,162,99,126	AGT	0.00	0.00	0.00			173,145,117,108	12.04		0.4143646408839779
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121480773	121480773.0	T	C	C	121480773	.	T	C	.	PASS	NM_000141	C	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2302-752A>G						rs1649163		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.9776	0.9213	0.9885	1	1	1											0.9785	0.9257	1	0.9915	1	1	1	0.9932	0.9997	0.9858	0.9996	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN										FAIL	27	-39	-14	-9	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											508					0.994							244.86													chr10	123240287																																																	True	True	False	Unknown		Unknown																						0,505	0,246	0,259	0/1	0,0,265,240	TTT	.	.	.			0,0,316,189	64.73		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481111	121481111.0	A	G	G	121481111	.	A	G	.	PASS	NM_000141	G	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2302-1090T>C						rs1649202		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.5527	0.7837	0.3012	0.6558	0.4871	0.3804											0.5232	0.7318	0.5088	0.3504	0.4115	0.6338	0.507	0.4829	0.4443	0.5052	0.4017	0.7837	AFR				23121717						FAIL	26	-40	-46	18	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											432					0.986							240.01													chr10	123240625																																																	True	True	False	Unknown		Unknown																						190,236	94,107	96,129	0|1	88,102,115,121	CAA	.	.	.		123240625	102,88,120,116	45.98		0.5539906103286385
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481131	121481131.0	C	T	T	121481131	.	C	T	.	PASS	NM_000141	T	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2302-1110G>A						rs3135821&COSV60640875		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.1767	0.0567	0.0793	0.4276	0.1034	0.2249											0.1034	0.0675	0.1355	0.07916	0.1228	0.4173	0.06899	0.1701	0.1004	0.1276	0.2349	0.4276	EAS		0&1	0&1							FAIL	6	-17	-2	-32	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											425					0.991							238.02													chr10	123240645																																																	True	True	False	Unknown		Unknown																						197,224	98,99	99,125	0|1	109,88,113,111	CCC	0.00	0.00	0.00		123240625	80,117,110,114	47.09		0.5320665083135392
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481818	121481818.0	G	A	A	121481818	.	G	A	.	PASS	NM_000141	A	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2302-1797C>T						rs1649164		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.9724	0.9017	0.9885	1	1	1	0.994	0.8892	0.9847	0.9997	0.9995	1	0.9967	0.9988	0.9877	0.9983	0.9748	0.9102	1	0.9904	1	1	0.9998	0.9896	0.9997	0.9811	0.9996	1	EAS&EUR&SAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS										FAIL	18	-43	18	-15	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											443					0.876							207.88													chr10	123241332																																																	True	True	False	Unknown		Unknown																						0,388	0,204	0,184	0/1	0,0,196,192	CGG	0.00	0.00	0.00			0,0,230,158	64.73		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481834	121481834.0	A	T	T	121481834	.	A	T	.	PASS	NM_000141	T	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2302-1813T>A						rs1649165		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.4329	0.5983	0.2003	0.6419	0.2565	0.3405	0.07045	0.1375	0.05203	0.04629	0.245	0.05426	0.01724	0.05135	0.06767	0.1514	0.3523	0.5614	0.3655	0.2143	0.2471	0.5887	0.1458	0.2963	0.2741	0.3387	0.3199	0.6419	EAS										FAIL	8	48	8	2	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											359					0.852							188.4													chr10	123241348																																																	True	True	False	Unknown		Unknown																						224,82	118,39	106,43	0|1	117,107,43,39	TAT	.	.	.		123241348	115,109,52,30	4.8		0.2679738562091503
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481840	121481840.0	A	T	T	121481840	.	A	T	.	PASS	NM_000141	T	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2302-1819T>A						rs1799603		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1												0.3387	0.4322	0.2156	0.3323	0.2273	0.5204	0.3384	0.3528	0.3359	0.2971	0.496	0.6721	0.5058	0.3236	0.3903	0.6035	0.5006	0.4737	0.4417	0.487	0.3705	0.6721	gnomADg_AFR	benign		1							FAIL	42	2	7	2	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	1275991				1268620	not_provided		MedGen:C3661900		NC_000010.11:g.121481840A>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001907844&SCV005322883	single_nucleotide_variant	SO:0001483	ClinGen:CA13276730		FGFR2:2263	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant										1	1799603																											343					0.843							182.44													chr10	123241354																																																	True	True	False	Unknown		Unknown																						214,75	111,36	103,39	0|1	109,105,35,40	TAT	.	.	.		123241348	92,122,44,31	4.79		0.25951557093425603
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481859	121481859.0	C	T	T	121481859	.	C	T	.	PASS	NM_000141	T	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2302-1838G>A						rs3135817		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.4315	0.1664	0.6585	0.3542	0.5129	0.6247	0.644	0.349	0.759	0.6776	0.6304	0.541	0.6275	0.6526	0.6282	0.7919	0.5345	0.2904	0.5564	0.6836	0.6506	0.5198	0.5528	0.6391	0.5955	0.5578	0.6716	0.7919	gnomADe_SAS	benign		1							FAIL	11	23	11	4	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	667903			0.43151	664070	not_provided		MedGen:C3661900		NC_000010.11:g.121481859C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000968270&SCV005322887	single_nucleotide_variant	SO:0001483	ClinGen:CA13206482		FGFR2:2263	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant										1	3135817																											298					0.782							162.96													chr10	123241373																																																	True	True	False	Unknown		Unknown																						53,180	28,93	25,87	0/1	30,23,88,92	ACG	0.00	0.00	0.00			9,44,71,109	41.91		0.7725321888412017
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481869	121481869.0	C	T	T	121481869	.	C	T	.	PASS	NM_000141	T	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+1829G>A						rs1649166		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.4361	0.5998	0.2305	0.6389	0.2525	0.3405	0.1331	0.2891	0.09511	0.1076	0.4099	0.03657	0.1514	0.1029	0.1359	0.1383	0.323	0.5225	0.328	0.2384	0.2269	0.6038	0.1531	0.2664	0.2409	0.3181	0.3096	0.6389	EAS	benign		1							FAIL	13	1	-27	44	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	670716			0.43610	664618	not_provided		MedGen:C3661900		NC_000010.11:g.121481869C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000971609&SCV005322888	single_nucleotide_variant	SO:0001483	ClinGen:CA13206483		FGFR2:2263	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant										1	1649166																											256					0.848							148.95													chr10	123241383																																																	True	True	False	Unknown		Unknown																						154,63	80,36	74,27	0/1	76,78,36,27	GCT	0.00	0.00	1.00			50,104,11,52	11.76		0.2903225806451613
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121481982	121481982.0	T	C	C	121481982	.	T	C	.	PASS	NM_000141	C	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+1716A>G						rs1649167		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.9864	0.9516	0.9942	1	1	1	0.9982	0.9545	0.9965	1	1	1	0.9974	0.9999	0.9968	0.9998	0.9877	0.9576	1	0.9942	1	0.9998	1	0.9966	0.9999	0.9938	0.9996	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN	benign		1							FAIL	32	-14	5	24	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	667902			0.98642	664912	not_provided		MedGen:C3661900		NC_000010.11:g.121481982T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000968269&SCV005322889	single_nucleotide_variant	SO:0001483	ClinGen:CA214952777		FGFR2:2263	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant										1	1649167																											90					0.956							147.24													chr10	123241496																																																	True	True	False	Unknown		Unknown																						1,85	1,46	0,39	0/1	1,0,47,38	GTG	.	.	.			1,0,44,41	51.99		0.9883720930232558
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121482280	121482280.0	C	T	T	121482280	.	C	T	.	PASS	NM_000141	T	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+1418G>A						rs2556537&COSV60647364		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.4427	0.6513	0.2046	0.6468	0.2465	0.3211	0.276	0.6054	0.16	0.2619	0.6004	0.2402	0.3385	0.2495	0.3052	0.3137	0.3607	0.6048	0.3297	0.2319	0.2507	0.6245	0.2339	0.2789	0.2518	0.3406	0.3191	0.6513	AFR	benign	0&1	1&1	27223085						FAIL	43	5	-41	-28	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	1263215			0.44269	1251833	not_provided		MedGen:C3661900		NC_000010.11:g.121482280C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001888191&SCV005322891	single_nucleotide_variant	SO:0001483	ClinGen:CA13206484		FGFR2:2263	SO:0001627&intron_variant										1	2556537																											298					0.973							242.53													chr10	123241794																																																	True	True	False	Unknown		Unknown																						159,131	82,64	77,67	0/1	79,80,74,57	TCC	0.00	0.00	0.00			68,91,53,78	27.02		0.4517241379310345
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121482512	121482512.0	T	C	C	121482512	.	T	C	.	PASS	NM_000141	C	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+1186A>G						rs3135814		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.8009	0.5431	0.8588	0.994	0.7555	0.956											0.7525	0.5868	0.7945	0.8531	0.8327	0.9824	0.6821	0.8163	0.8054	0.7859	0.9367	0.994	EAS	benign		1							FAIL	47	-40	6	-9	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	667901			0.80092	664913	not_provided		MedGen:C3661900		NC_000010.11:g.121482512T>C	criteria_provided&_single_submitter	Benign			SCV000968268	single_nucleotide_variant	SO:0001483	ClinGen:CA15655088		FGFR2:2263	SO:0001627&intron_variant										1	3135814																											130					0.977							241.46													chr10	123242026																																																	True	True	False	Unknown		Unknown																						0,127	0,67	0,60	0/1	0,0,62,65	CTT	.	.	.			0,0,64,63	64.71		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121482985	121482985.0	C	T	T	121482985	.	C	T	.	PASS	NM_000141	T	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+713G>A						rs1564849422		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1																																												FAIL	-26	-37	-31	-37	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											204					0.975							154.14													chr10	123242499																																																	True	True	False	Unknown		Unknown																						195,4	93,3	102,1	0|1	94,101,1,3	ACA	0.00	0.00	1.00		123242499	120,75,2,2	4.44		0.020100502512562814
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121483207	121483207.0	A	G	G	121483207	.	A	G	.	PASS	NM_000141	G	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+491T>C						rs3135812&COSV60641202		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.0098	0.0008	0.0173	0	0.0348	0.001											0.02483	0.006517	0.1009	0.02574	0.04207	0.0001926	0.02184	0.01361	0.0377	0.03261	0.001866	0.1009	gnomADg_AMI		0&1	0&1	18285324						FAIL	34	-10	-20	12	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											221					0.986							245.79													chr10	123242721																																																	True	True	False	Unknown		Unknown																						122,96	59,53	63,43	0|1	58,64,57,39	CAT	.	.	.		123242721	53,69,44,52	19.04		0.44036697247706424
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121483210	121483210.0	T	C	C	121483210	.	T	C	.	PASS	NM_000141	C	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+488A>G						rs3135811		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.7991	0.5439	0.8501	0.994	0.7515	0.956											0.7515	0.5864	0.7923	0.8504	0.8296	0.9825	0.6827	0.8163	0.804	0.7836	0.9375	0.994	EAS										FAIL	31	40	-23	9	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											219					0.982							246.06													chr10	123242724																																																	True	True	False	Unknown		Unknown																						0,215	0,111	0,104	0|1	0,0,107,108	ATA	.	.	.		123242721	0,0,95,120	57.73		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121483266	121483266.0	G	C	C	121483266	.	G	C	.	PASS	NM_000141	C	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+432C>G						rs3135810		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.8586	0.6974	0.8804	0.998	0.8151	0.9622											0.8201	0.7255	0.8136	0.8866	0.8832	0.9965	0.7429	0.8639	0.8479	0.8397	0.9537	0.998	EAS										FAIL	4	-25	40	-47	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											162					0.994							243.21													chr10	123242780																																																	True	True	False	Unknown		Unknown																						0,161	0,93	0,68	0/1	0,0,91,70	AGA	.	.	.			0,0,77,84	64.72		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121483683	121483683.0	G	A	A	121483683	.	G	A	.	PASS	NM_000141	A	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		17/17	c.2301+15C>T						rs2278202&COSV60638466		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.4231	0.1082	0.6888	0.3333	0.5398	0.6329	0.5802	0.1691	0.7476	0.6005	0.3664	0.5093	0.5178	0.5947	0.5512	0.628	0.4665	0.1823	0.523	0.6468	0.6161	0.3441	0.4968	0.5544	0.5832	0.4924	0.6238	0.7476	gnomADe_AMR	benign	0&1	1&1	25741868&20887964&18285324&31772679&30258940&23121717						FAIL	-4	-7	15	-27	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	255317	0.45441	0.56138	0.42312	253699	Isolated_Coronal_Synostosis&not_provided&Saethre-Chotzen_syndrome&FGFR2-related_craniosynostosis&Beare-Stevenson_cutis_gyrata_syndrome&Crouzon_syndrome&Craniosynostosis_syndrome&not_specified		MedGen:CN043619&MedGen:C3661900&MONDO:MONDO:0007042&MedGen:C0175699&OMIM:101400&Orphanet:794&MedGen:CN231480&MONDO:MONDO:0007412&MedGen:C1852406&OMIM:123790&Orphanet:1555&Human_Phenotype_Ontology:HP:0004439&MONDO:MONDO:0007405&MeSH:D003394&MedGen:C0010273&OMIM:123500&Orphanet:207&Human_Phenotype_Ontology:HP:0001363&Human_Phenotype_Ontology:HP:0001365&Human_Phenotype_Ontology:HP:0004494&Human_Phenotype_Ontology:HP:0005448&Human_Phenotype_Ontology:HP:0005457&Human_Phenotype_Ontology:HP:0005467&Human_Phenotype_Ontology:HP:0008492&MONDO:MONDO:0015469&MeSH:D003398&MedGen:C0010278&OMIM:PS123100&Orphanet:1531&MedGen:CN169374		NC_000010.11:g.121483683G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000302600&SCV000360840&SCV000360841&SCV000360844&SCV000360846&SCV000360848&SCV000516265&SCV002407467&SCV005322892	single_nucleotide_variant	SO:0001483	ClinGen:CA5720511		FGFR2:2263	SO:0001627&intron_variant										1	2278202																											99					0.99							241.96													chr10	123243197																																																	True	True	False	Unknown		Unknown																						50,48	22,24	28,24	0/1	26,24,22,26	AGA	0.00	0.00	0.00			22,28,22,26	34.48		0.4897959183673469
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121503194	121503194.0	G	A	A	121503194	.	G	A	.	PASS	NM_000141	A	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		10/17	c.1439+596C>T						rs2912755		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.8223	0.4561	0.8761	0.9881	0.9682	0.9581											0.8356	0.5209	0.9759	0.8606	0.9461	0.9824	0.9641	0.9422	0.9727	0.8645	0.9618	0.9881	EAS										FAIL	-29	42	11	0	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											779					0.996							245.39													chr10	123262708																																																	True	True	False	Unknown		Unknown																						0,776	0,407	0,369	0/1	0,0,363,413	CGT	0.00	0.00	0.00			0,0,266,510	64.73		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9			chr10	121521401	121521401.0	T	C	C	121521401	.	T	C	.	PASS	NM_000141	C	intron_variant	MODIFIER	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding		6/17	c.749-1232A>G						rs2981444		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1						0.8854	0.5961	0.9496	1	0.996	0.999											0.8972	0.6471	1	0.956	0.9977	1	1	0.9898	0.9978	0.9243	0.9977	1	EAS&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN										FAIL	-1	-12	-1	-3	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01																																																											81					0.988							240.87													chr10	123280915																																																	True	True	False	Unknown		Unknown																						0,80	0,31	0,49	0/1	0,0,33,47	TTT	.	.	.			0,0,46,34	64.58		1.0
GRCh38	FGFR2	D12_12345_1234556_Thyroid_S9	p.Val232=	ENSP00000351276.6:p.Val232=	chr10	121538644	121538644.0	T	C	C	121538644	.	T	C	.	PASS	NM_000141	C	synonymous_variant	LOW	FGFR2	ENSG00000066468	Transcript	ENST00000358487	protein_coding	6/18		c.696A>G	1329	696	232	V	gtA/gtG	rs1047100&COSV100335254		-1		SNV	HGNC	HGNC:3689	YES	MANE_Select	NM_000141.5		1	A2	CCDS31298.1	ENSP00000351276	P21802.275		UPI000012A72A	P21802-1		1			PDB-ENSP_mappings:1djs.A&PDB-ENSP_mappings:1e0o.B&PDB-ENSP_mappings:1e0o.D&PDB-ENSP_mappings:1ev2.E&PDB-ENSP_mappings:1ev2.F&PDB-ENSP_mappings:1ev2.G&PDB-ENSP_mappings:1ev2.H&PDB-ENSP_mappings:1ii4.E&PDB-ENSP_mappings:1ii4.F&PDB-ENSP_mappings:1ii4.G&PDB-ENSP_mappings:1ii4.H&PDB-ENSP_mappings:1iil.E&PDB-ENSP_mappings:1iil.F&PDB-ENSP_mappings:1iil.G&PDB-ENSP_mappings:1iil.H&PDB-ENSP_mappings:1nun.B&PDB-ENSP_mappings:1wvz.A&PDB-ENSP_mappings:2fdb.P&PDB-ENSP_mappings:2fdb.R&PDB-ENSP_mappings:3caf.A&PDB-ENSP_mappings:3cu1.A&PDB-ENSP_mappings:3cu1.C&PDB-ENSP_mappings:3dar.A&PDB-ENSP_mappings:3dar.B&PDB-ENSP_mappings:3euu.A&PDB-ENSP_mappings:3euu.B&PDB-ENSP_mappings:3oj2.C&PDB-ENSP_mappings:3oj2.D&PDB-ENSP_mappings:3ojm.B&PDB-ENSP_mappings:4j23.A&PDB-ENSP_mappings:4wv1.C&PDB-ENSP_mappings:4wv1.F&PANTHER:PTHR24416&Superfamily:SSF48726&SMART:SM00408&SMART:SM00409&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd05857&PIRSF:PIRSF000628&Gene3D:2.60.40.10&Pfam:PF07679&PROSITE_profiles:PS50835&AFDB-ENSP_mappings:AF-P21802-F1			0.7953	0.7322	0.7997	0.9355	0.7903	0.7382	0.7778	0.7559	0.799	0.8186	0.9039	0.7536	0.8239	0.7747	0.7934	0.7456	0.769	0.7517	0.7785	0.7833	0.8288	0.9076	0.7509	0.8253	0.7667	0.7802	0.7438	0.9355	EAS	benign	0&1	1&1	25741868&33195260&22253485&21108794&19937600&16385451&20887964&11781872&22993671&18285324&29998616&24385678&31772679&30258940&31968564&23127126&23300950&31438887&35267517&24265722						FAIL	17	-2	-48	-50	0.00	0.00	0.00	0.00	FGFR2		2.7800e-01	255319	0.76672		0.79533	253704	not_specified&Isolated_Coronal_Synostosis&Saethre-Chotzen_syndrome&FGFR2-related_craniosynostosis&not_provided&Beare-Stevenson_cutis_gyrata_syndrome&Crouzon_syndrome&Craniosynostosis_syndrome		MedGen:CN169374&MedGen:CN043619&MONDO:MONDO:0007042&MedGen:C0175699&OMIM:101400&Orphanet:794&MedGen:CN231480&MedGen:C3661900&MONDO:MONDO:0007412&MedGen:C1852406&OMIM:123790&Orphanet:1555&Human_Phenotype_Ontology:HP:0004439&MONDO:MONDO:0007405&MeSH:D003394&MedGen:C0010273&OMIM:123500&Orphanet:207&Human_Phenotype_Ontology:HP:0001363&Human_Phenotype_Ontology:HP:0001365&Human_Phenotype_Ontology:HP:0004494&Human_Phenotype_Ontology:HP:0005448&Human_Phenotype_Ontology:HP:0005457&Human_Phenotype_Ontology:HP:0005467&Human_Phenotype_Ontology:HP:0008492&MONDO:MONDO:0015469&MeSH:D003398&MedGen:C0010278&OMIM:PS123100&Orphanet:1531		NC_000010.11:g.121538644T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000302604&SCV000360959&SCV000360960&SCV000360961&SCV000360962&SCV000360964&SCV000516264&SCV001729161&SCV005322905	single_nucleotide_variant	SO:0001483	ClinGen:CA5721070		FGFR2:2263	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	1047100																											149					0.987							242.54	v6.1	Unknown		True	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types.	False	04/20/2020	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR2 ENSP00000351276.6:V232= mutant UNKNOWN.	False	The FGFR2 ENSP00000351276.6:v232= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr10	123298158						True	False	False	Unknown								False	False		FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types.	The FGFR2 ENSP00000351276.6:v232= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR2 ENSP00000351276.6:V232= mutant UNKNOWN.						v6.1	04/20/2020		GRCh38	FGFR2	2263.0	ENSP00000351276.6:V232=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGFR2"",""entrezGeneId"":2263,""alteration"":""ENSP00000351276.6:V232="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types."",""variantSummary"":""The FGFR2 ENSP00000351276.6:v232= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR2 ENSP00000351276.6:V232= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/20/2020""}"	True	True	False	Unknown		Unknown																						64,83	27,35	37,48	0/1	42,22,42,41	CTA	.	.	.			35,29,44,39	45.51		0.564625850340136
GRCh38		D12_12345_1234556_Thyroid_S9			chr10	130900156	130900156.0	T	C	C	130900156	.	T	C	.	PASS		C	intergenic_variant	MODIFIER														rs964681				SNV																						0.3415	0.2375	0.3314	0.3016	0.4334	0.4356											0.3747	0.287	0.444	0.3731	0.4003	0.3197	0.4289	0.4184	0.4177	0.3917	0.4256	0.444	gnomADg_AMI				26522768&26691610&29121662&33406744&33857205&16400611&19083859&31745634&27294018&19948332																																																																												833					0.996							246.19													chr10	132698419																																																	True	False	False	Unknown		Unknown																						0,830	0,389	0,441	0/1	0,0,432,398	ATG	.	.	.			0,0,393,437	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr11	268180	268182.0	C	CCT	CCT	268180	.	C	CCT	.	PASS		CT	downstream_gene_variant	MODIFIER		ENSG00000293500	Transcript	ENST00000835503	lncRNA									rs10688868	3607	-1		insertion																						0.6687	0.7413	0.6974	0.502	0.6998	0.6902											0.7126	0.7576	0.8037	0.7043	0.6024	0.4895	0.7583	0.5411	0.7042	0.7006	0.6856	0.8037	gnomADg_AMI				33801242																																																																												968					0.986							243.87													chr11	268180																																																	True	False	False	Unknown		Unknown																						504,450	284,252	220,198	0/1	267,237,227,223	CCT						253,251,245,205	30.41		0.4716981132075472
GRCh38		D12_12345_1234556_Thyroid_S9			chr11	5687798	5687798.0	C	T	T	5687798	.	C	T	.	PASS		T	downstream_gene_variant	MODIFIER		ENSG00000295362	Transcript	ENST00000729541	lncRNA									rs1498553	2429	-1		SNV																						0.5062	0.5242	0.5202	0.4593	0.5398	0.4857											0.526	0.5227	0.5615	0.5298	0.5216	0.4769	0.5646	0.5308	0.529	0.5024	0.4743	0.5646	gnomADg_FIN				26691610&29121662&33406744&33857205&24066097&30483616&18446592&27294018&29615764																																																																												158					0.968							232.78													chr11	5709028																																																	True	False	False	Unknown		Unknown																						78,75	40,44	38,31	0/1	35,43,43,32	ACG	0.00	0.00	0.00			33,45,40,35	35.82		0.49019607843137253
GRCh38	LMO1	D12_12345_1234556_Thyroid_S9	p.Phe151=	ENSP00000338207.3:p.Phe151=	chr11	8224634	8224634.0	A	G	G	8224634	.	A	G	.	PASS	NM_002315	G	synonymous_variant	LOW	LMO1	ENSG00000166407	Transcript	ENST00000335790	protein_coding	4/4		c.453T>C	969	453	151	F	ttT/ttC	rs1042359&COSV59956747		-1		SNV	HGNC	HGNC:6641	YES	MANE_Select	NM_002315.3		1	A1	CCDS44534.1	ENSP00000338207	P25800.196		UPI0000133883	P25800-1		1			AFDB-ENSP_mappings:AF-P25800-F1			0.1793	0.3759	0.1225	0.0585	0.1431	0.1155	0.1587	0.3463	0.09284	0.1055	0.06512	0.1608	0.1359	0.1658	0.1519	0.0912	0.1992	0.3379	0.2242	0.1344	0.1118	0.05543	0.1527	0.1565	0.1607	0.1635	0.08772	0.3759	AFR		0&1	0&1	31205537&29760797&33870932						FAIL	35	-40	-14	-9	0.01	0.01	0.00	0.00	LMO1		9.4600e-01																																																											821					1							246.56	v6.1	Unknown		True	LMO1, a transcriptional regulator of the cell cycle and metastasis, is altered in the germline of some patients predisposed to neuroblastoma.	False	08/20/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LMO1 ENSP00000338207.3:F151= mutant UNKNOWN.	False	The LMO1 ENSP00000338207.3:f151= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	8246181						True	False	False	Unknown								False	False		LMO1, a transcriptional regulator of the cell cycle and metastasis, is altered in the germline of some patients predisposed to neuroblastoma.	The LMO1 ENSP00000338207.3:f151= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LMO1 ENSP00000338207.3:F151= mutant UNKNOWN.						v6.1	08/20/2018		GRCh38	LMO1	4004.0	ENSP00000338207.3:F151=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LMO1"",""entrezGeneId"":4004,""alteration"":""ENSP00000338207.3:F151="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LMO1, a transcriptional regulator of the cell cycle and metastasis, is altered in the germline of some patients predisposed to neuroblastoma."",""variantSummary"":""The LMO1 ENSP00000338207.3:f151= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LMO1 ENSP00000338207.3:F151= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/20/2018""}"	True	True	False	Unknown		Unknown																						387,434	187,204	200,230	0/1	210,177,225,209	CAA	.	.	.			206,181,209,225	59.93		0.5286236297198539
GRCh38	LINC02752	D12_12345_1234556_Thyroid_S9			chr11	11074674	11074674.0	C	T	T	11074674	.	C	T	.	PASS		T	intron_variant&non_coding_transcript_variant	MODIFIER	LINC02752	ENSG00000254401	Transcript	ENST00000647635	lncRNA		1/6	n.159-43162C>T						rs901398		1		SNV	HGNC	HGNC:54272	YES																			0.6639	0.621	0.6311	0.7054	0.6869	0.6789											0.672	0.6369	0.5747	0.6735	0.6998	0.7125	0.6708	0.7483	0.6876	0.6873	0.6949	0.7483	gnomADg_MID				26691610&29121662&33406744&34721519&33857205&19083859&27294018&19948332																																																																												631					0.997							246.09													chr11	11096221																																																	True	False	False	Unknown		Unknown																						0,629	0,317	0,312	0/1	0,0,320,309	CCG	0.00	0.00	0.00			0,0,356,273	64.73		1.0
GRCh38	MEN1	D12_12345_1234556_Thyroid_S9	p.T541A	ENSP00000394933.3:p.Thr541Ala	chr11	64804546	64804546.0	T	C	C	64804546	.	T	C	.	PASS	NM_001370259	C	missense_variant	MODERATE	MEN1	ENSG00000133895	Transcript	ENST00000450708	protein_coding	10/10		c.1621A>G	1682	1621	541	T/A	Aca/Gca	rs2959656&CM085535&COSV53639974		-1		SNV	HGNC	HGNC:7010	YES	MANE_Select	NM_001370259.2		5	P4	CCDS31600.1	ENSP00000394933	O00255.223		UPI0000228E6B	O00255-2		1	tolerated(1)	benign(0)	PDB-ENSP_mappings:3u84.A&PDB-ENSP_mappings:3u84.B&PDB-ENSP_mappings:3u85.A&PDB-ENSP_mappings:3u86.A&PDB-ENSP_mappings:3u88.A&PDB-ENSP_mappings:3u88.B&PDB-ENSP_mappings:4gpq.A&PDB-ENSP_mappings:4gq3.A&PDB-ENSP_mappings:4gq4.A&PDB-ENSP_mappings:4gq6.A&PDB-ENSP_mappings:4i80.A&PDB-ENSP_mappings:4og3.A&PDB-ENSP_mappings:4og4.A&PDB-ENSP_mappings:4og5.A&PDB-ENSP_mappings:4og6.A&PDB-ENSP_mappings:4og7.A&PDB-ENSP_mappings:4og8.A&PDB-ENSP_mappings:4x5y.A&PDB-ENSP_mappings:4x5z.A&PDB-ENSP_mappings:5db0.A&PDB-ENSP_mappings:5db1.A&PDB-ENSP_mappings:5db2.A&PDB-ENSP_mappings:5db3.A&PDB-ENSP_mappings:5dd9.A&PDB-ENSP_mappings:5dda.A&PDB-ENSP_mappings:5ddb.A&PDB-ENSP_mappings:5ddc.A&PDB-ENSP_mappings:5ddd.A&PDB-ENSP_mappings:5dde.A&PDB-ENSP_mappings:5ddf.A&PDB-ENSP_mappings:6b41.A&PDB-ENSP_mappings:6bxy.A&PDB-ENSP_mappings:6by8.A&PDB-ENSP_mappings:6e1a.A&PDB-ENSP_mappings:6o5i.A&PDB-ENSP_mappings:6opj.A&PDB-ENSP_mappings:6pkc.A&PDB-ENSP_mappings:6pkc.B&PDB-ENSP_mappings:6s2k.A&PDB-ENSP_mappings:6s2k.B&PDB-ENSP_mappings:6wnh.A&PDB-ENSP_mappings:7m4t.A&PDB-ENSP_mappings:7o9t.A&PDB-ENSP_mappings:7o9x.A&PDB-ENSP_mappings:7o9z.A&PDB-ENSP_mappings:7oa9.A&PDB-ENSP_mappings:8gpn.K&PDB-ENSP_mappings:8ig0.A&PDB-ENSP_mappings:8ig0.B&PDB-ENSP_mappings:8ig0.C&PDB-ENSP_mappings:8ig0.D&AFDB-ENSP_mappings:AF-O00255-F1&PANTHER:PTHR12693&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.8345	0.6664	0.902	0.6964	0.9911	0.9949	0.9773	0.7003	0.8842	0.9955	0.733	0.9825	0.983	0.9971	0.9594	0.9935	0.8974	0.7134	0.9934	0.9027	0.9968	0.701	0.9834	0.9694	0.996	0.9252	0.9857	0.9971	gnomADe_NFE	benign	0&1&1	1&1&1	25741868&24033266&24728327&23757202&32708070&22703879&26307114&564891&9215689&18775714&27185868&28899949&33240400&28969599&30214228&34750164						FAIL	-42	-4	-42	13	0.00	0.00	0.00	0.00	MEN1		2.0600e-01	134640	0.90843	0.93778	0.83446	138379	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Multiple_endocrine_neoplasia&_type_1		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0007540&MeSH:D018761&MedGen:C0025267&OMIM:131100&Orphanet:652		NC_000011.10:g.64804546T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000203003&SCV000539614&SCV001000095&SCV002506314&SCV004359140&SCV004836523&SCV005319087&SCV005895470&SCV006311041	single_nucleotide_variant	SO:0001483	ClinGen:CA060856		MEN1:4221	SO:0001583&missense_variant										1	2959656																											944					0.996							246.32	v6.1	Unknown		True	MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:T541A mutant UNKNOWN.	False	The MEN1 ENSP00000394933.3:t541a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	64572018						True	False	False	Unknown								False	False		MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	The MEN1 ENSP00000394933.3:t541a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:T541A mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	MEN1	4221.0	ENSP00000394933.3:T541A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MEN1"",""entrezGeneId"":4221,""alteration"":""ENSP00000394933.3:T541A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers."",""variantSummary"":""The MEN1 ENSP00000394933.3:t541a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:T541A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						0,940	0,459	0,481	0/1	0,0,461,479	GTG	.	.	.			0,0,438,502	64.73		1.0
GRCh38	MEN1	D12_12345_1234556_Thyroid_S9	p.His433=	ENSP00000394933.3:p.His433=	chr11	64805085	64805085.0	A	G	G	64805085	.	A	G	.	PASS	NM_001370259	G	synonymous_variant	LOW	MEN1	ENSG00000133895	Transcript	ENST00000450708	protein_coding	9/10		c.1299T>C	1360	1299	433	H	caT/caC	rs540012&COSV108102490		-1		SNV	HGNC	HGNC:7010	YES	MANE_Select	NM_001370259.2		5	P4	CCDS31600.1	ENSP00000394933	O00255.223		UPI0000228E6B	O00255-2		1			PDB-ENSP_mappings:3u84.A&PDB-ENSP_mappings:3u84.B&PDB-ENSP_mappings:3u85.A&PDB-ENSP_mappings:3u86.A&PDB-ENSP_mappings:3u88.A&PDB-ENSP_mappings:3u88.B&PDB-ENSP_mappings:4gpq.A&PDB-ENSP_mappings:4gq3.A&PDB-ENSP_mappings:4gq4.A&PDB-ENSP_mappings:4gq6.A&PDB-ENSP_mappings:4i80.A&PDB-ENSP_mappings:4og3.A&PDB-ENSP_mappings:4og4.A&PDB-ENSP_mappings:4og5.A&PDB-ENSP_mappings:4og6.A&PDB-ENSP_mappings:4og7.A&PDB-ENSP_mappings:4og8.A&PDB-ENSP_mappings:5db0.A&PDB-ENSP_mappings:5db1.A&PDB-ENSP_mappings:5db2.A&PDB-ENSP_mappings:5db3.A&PDB-ENSP_mappings:5dd9.A&PDB-ENSP_mappings:5dda.A&PDB-ENSP_mappings:5ddb.A&PDB-ENSP_mappings:5ddc.A&PDB-ENSP_mappings:5ddd.A&PDB-ENSP_mappings:5dde.A&PDB-ENSP_mappings:5ddf.A&PDB-ENSP_mappings:6b41.A&PDB-ENSP_mappings:6bxh.A&PDB-ENSP_mappings:6bxy.A&PDB-ENSP_mappings:6by8.A&PDB-ENSP_mappings:6e1a.A&PDB-ENSP_mappings:6o5i.A&PDB-ENSP_mappings:6opj.A&PDB-ENSP_mappings:6pkc.A&PDB-ENSP_mappings:6pkc.B&PDB-ENSP_mappings:6s2k.A&PDB-ENSP_mappings:6s2k.B&PDB-ENSP_mappings:6wnh.A&PDB-ENSP_mappings:7m4t.A&PDB-ENSP_mappings:7o9t.A&PDB-ENSP_mappings:7o9x.A&PDB-ENSP_mappings:7o9z.A&PDB-ENSP_mappings:7oa9.A&PDB-ENSP_mappings:7uj4.A&PDB-ENSP_mappings:7uj4.B&PDB-ENSP_mappings:8e90.A&PDB-ENSP_mappings:8e90.B&PDB-ENSP_mappings:8gpn.K&PDB-ENSP_mappings:8ig0.A&PDB-ENSP_mappings:8ig0.B&PDB-ENSP_mappings:8ig0.C&PDB-ENSP_mappings:8ig0.D&AFDB-ENSP_mappings:AF-O00255-F1&Pfam:PF05053&PANTHER:PTHR12693&CDD:cd14456			0.9760	0.9115	0.9957	1	1	1	0.9978	0.9191	0.9968	1	0.9999	1	0.997	1	0.9951	0.9998	0.978	0.923	1	0.9927	1	1	1	1	0.9998	0.9839	1	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_FIN&gnomADe_NFE&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_SAS	benign	0&1	1&1	32708070&26307114&28899949&28969599&34750164						FAIL	-2	-28	4	0	0.00	0.00	0.00	0.07	MEN1		2.0600e-01	167288	0.97615	0.99275	0.97604	177834	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Multiple_endocrine_neoplasia&_type_1		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0007540&MeSH:D018761&MedGen:C0025267&OMIM:131100&Orphanet:652		NC_000011.10:g.64805085A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000203004&SCV000712183&SCV001000096&SCV004359143&SCV005319089&SCV005895473&SCV006311043	single_nucleotide_variant	SO:0001483	ClinGen:CA060368		MEN1:4221	SO:0001819&synonymous_variant										1	540012																											920					1							246.76	v6.1	Unknown		True	MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:H433= mutant UNKNOWN.	False	The MEN1 ENSP00000394933.3:h433= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	64572557						True	False	False	Unknown								False	False		MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	The MEN1 ENSP00000394933.3:h433= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:H433= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	MEN1	4221.0	ENSP00000394933.3:H433=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MEN1"",""entrezGeneId"":4221,""alteration"":""ENSP00000394933.3:H433="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers."",""variantSummary"":""The MEN1 ENSP00000394933.3:h433= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:H433= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						0,920	0,456	0,464	0/1	0,0,434,486	CAT	.	.	.			0,0,478,442	64.73		1.0
GRCh38	MEN1	D12_12345_1234556_Thyroid_S9	p.Asp418=	ENSP00000394933.3:p.Asp418=	chr11	64805130	64805130.0	G	A	A	64805130	.	G	A	.	PASS	NM_001370259	A	synonymous_variant	LOW	MEN1	ENSG00000133895	Transcript	ENST00000450708	protein_coding	9/10		c.1254C>T	1315	1254	418	D	gaC/gaT	rs2071313&CD005470&CD982777&COSV53640840&CX066452		-1		SNV	HGNC	HGNC:7010	YES	MANE_Select	NM_001370259.2		5	P4	CCDS31600.1	ENSP00000394933	O00255.223		UPI0000228E6B	O00255-2		1			PDB-ENSP_mappings:3u84.A&PDB-ENSP_mappings:3u84.B&PDB-ENSP_mappings:3u85.A&PDB-ENSP_mappings:3u86.A&PDB-ENSP_mappings:3u88.A&PDB-ENSP_mappings:3u88.B&PDB-ENSP_mappings:4gpq.A&PDB-ENSP_mappings:4gq3.A&PDB-ENSP_mappings:4gq4.A&PDB-ENSP_mappings:4gq6.A&PDB-ENSP_mappings:4i80.A&PDB-ENSP_mappings:4og3.A&PDB-ENSP_mappings:4og4.A&PDB-ENSP_mappings:4og5.A&PDB-ENSP_mappings:4og6.A&PDB-ENSP_mappings:4og7.A&PDB-ENSP_mappings:4og8.A&PDB-ENSP_mappings:4x5y.A&PDB-ENSP_mappings:4x5z.A&PDB-ENSP_mappings:5db0.A&PDB-ENSP_mappings:5db1.A&PDB-ENSP_mappings:5db2.A&PDB-ENSP_mappings:5db3.A&PDB-ENSP_mappings:5dd9.A&PDB-ENSP_mappings:5dda.A&PDB-ENSP_mappings:5ddb.A&PDB-ENSP_mappings:5ddc.A&PDB-ENSP_mappings:5ddd.A&PDB-ENSP_mappings:5dde.A&PDB-ENSP_mappings:5ddf.A&PDB-ENSP_mappings:6b41.A&PDB-ENSP_mappings:6bxh.A&PDB-ENSP_mappings:6bxy.A&PDB-ENSP_mappings:6by8.A&PDB-ENSP_mappings:6e1a.A&PDB-ENSP_mappings:6o5i.A&PDB-ENSP_mappings:6opj.A&PDB-ENSP_mappings:6pkc.A&PDB-ENSP_mappings:6pkc.B&PDB-ENSP_mappings:6s2k.A&PDB-ENSP_mappings:6s2k.B&PDB-ENSP_mappings:6wnh.A&PDB-ENSP_mappings:7m4t.A&PDB-ENSP_mappings:7o9t.A&PDB-ENSP_mappings:7o9x.A&PDB-ENSP_mappings:7o9z.A&PDB-ENSP_mappings:7oa9.A&PDB-ENSP_mappings:7uj4.A&PDB-ENSP_mappings:7uj4.B&PDB-ENSP_mappings:8e90.A&PDB-ENSP_mappings:8e90.B&PDB-ENSP_mappings:8gpn.K&PDB-ENSP_mappings:8ig0.A&PDB-ENSP_mappings:8ig0.B&PDB-ENSP_mappings:8ig0.C&PDB-ENSP_mappings:8ig0.D&AFDB-ENSP_mappings:AF-O00255-F1&Pfam:PF05053&PANTHER:PTHR12693&CDD:cd14456			0.3079	0.0348	0.2997	0.372	0.4056	0.5164	0.4047	0.07557	0.3343	0.3406	0.3815	0.4358	0.4395	0.413	0.3895	0.4814	0.3182	0.08927	0.2686	0.3248	0.3524	0.3789	0.4524	0.4252	0.4164	0.3468	0.4907	0.5164	SAS	benign	0&1&1&1&1	1&1&1&1&1	25741868&23757202&17267408&26307114&27366707&9215689&12050235&28899949&30286710&28969599						FAIL	-27	38	-1	-45	0.00	0.00	0.00	0.00	MEN1		2.0600e-01	96249	0.30402	0.39335	0.30791	102143	Hyperparathyroidism&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Multiple_endocrine_neoplasia&_type_1		Human_Phenotype_Ontology:HP:0000843&MONDO:MONDO:0001741&MedGen:C0020502&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0007540&MeSH:D018761&MedGen:C0025267&OMIM:131100&Orphanet:652		NC_000011.10:g.64805130G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000114295&SCV000303131&SCV000373095&SCV000373096&SCV000579618&SCV000604198&SCV000628032&SCV000711427&SCV001476546&SCV001939553&SCV004015819&SCV004359145&SCV005319091&SCV005895472&SCV006311044	single_nucleotide_variant	SO:0001483	ClinGen:CA009098		MEN1:4221	SO:0001819&synonymous_variant										1	2071313																											890					0.997							247.72	v6.1	Unknown		True	MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:D418= mutant UNKNOWN.	False	The MEN1 ENSP00000394933.3:d418= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	64572602						True	False	False	Unknown								False	False		MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	The MEN1 ENSP00000394933.3:d418= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:D418= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	MEN1	4221.0	ENSP00000394933.3:D418=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MEN1"",""entrezGeneId"":4221,""alteration"":""ENSP00000394933.3:D418="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers."",""variantSummary"":""The MEN1 ENSP00000394933.3:d418= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:D418= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						442,445	216,218	226,227	0/1	201,241,209,236	CGT	0.00	0.00	0.00			223,219,232,213	54.45		0.5016910935738444
GRCh38	MEN1	D12_12345_1234556_Thyroid_S9	p.Ser145=	ENSP00000394933.3:p.Ser145=	chr11	64809675	64809675.0	G	A	A	64809675	.	G	A	.	PASS	NM_001370259	A	synonymous_variant	LOW	MEN1	ENSG00000133895	Transcript	ENST00000450708	protein_coding	2/10		c.435C>T	496	435	145	S	agC/agT	rs61736636&COSV56341605&COSV56345622		-1		SNV	HGNC	HGNC:7010	YES	MANE_Select	NM_001370259.2		5	P4	CCDS31600.1	ENSP00000394933	O00255.223		UPI0000228E6B	O00255-2		1			PDB-ENSP_mappings:3u84.A&PDB-ENSP_mappings:3u84.B&PDB-ENSP_mappings:3u85.A&PDB-ENSP_mappings:3u86.A&PDB-ENSP_mappings:3u88.A&PDB-ENSP_mappings:3u88.B&PDB-ENSP_mappings:4gpq.A&PDB-ENSP_mappings:4gq3.A&PDB-ENSP_mappings:4gq4.A&PDB-ENSP_mappings:4gq6.A&PDB-ENSP_mappings:4i80.A&PDB-ENSP_mappings:4og3.A&PDB-ENSP_mappings:4og4.A&PDB-ENSP_mappings:4og5.A&PDB-ENSP_mappings:4og6.A&PDB-ENSP_mappings:4og7.A&PDB-ENSP_mappings:4og8.A&PDB-ENSP_mappings:4x5y.A&PDB-ENSP_mappings:4x5z.A&PDB-ENSP_mappings:5db0.A&PDB-ENSP_mappings:5db1.A&PDB-ENSP_mappings:5db2.A&PDB-ENSP_mappings:5db3.A&PDB-ENSP_mappings:5dd9.A&PDB-ENSP_mappings:5dda.A&PDB-ENSP_mappings:5ddb.A&PDB-ENSP_mappings:5ddc.A&PDB-ENSP_mappings:5ddd.A&PDB-ENSP_mappings:5dde.A&PDB-ENSP_mappings:5ddf.A&PDB-ENSP_mappings:6b41.A&PDB-ENSP_mappings:6bxh.A&PDB-ENSP_mappings:6bxy.A&PDB-ENSP_mappings:6by8.A&PDB-ENSP_mappings:6e1a.A&PDB-ENSP_mappings:6o5i.A&PDB-ENSP_mappings:6opj.A&PDB-ENSP_mappings:6pkc.A&PDB-ENSP_mappings:6pkc.B&PDB-ENSP_mappings:6s2k.A&PDB-ENSP_mappings:6s2k.B&PDB-ENSP_mappings:6wnh.A&PDB-ENSP_mappings:7m4t.A&PDB-ENSP_mappings:7o9t.A&PDB-ENSP_mappings:7o9x.A&PDB-ENSP_mappings:7o9z.A&PDB-ENSP_mappings:7oa9.A&PDB-ENSP_mappings:7uj4.A&PDB-ENSP_mappings:7uj4.B&PDB-ENSP_mappings:8e90.A&PDB-ENSP_mappings:8e90.B&PDB-ENSP_mappings:8gpn.K&PDB-ENSP_mappings:8ig0.A&PDB-ENSP_mappings:8ig0.B&PDB-ENSP_mappings:8ig0.C&PDB-ENSP_mappings:8ig0.D&AFDB-ENSP_mappings:AF-O00255-F1&Pfam:PF05053&PANTHER:PTHR12693&CDD:cd14456			0.0106	0.0038	0.0043	0	0.0378	0.0072	0.03627	0.006033	0.009817	0.007156	7.557e-05	0.0634	0.013	0.04168	0.02858	0.007652	0.02673	0.00758	0.04057	0.01144	0.00576	0.000193	0.0655	0	0.0407	0.01186	0.007042	0.0655	gnomADg_FIN	benign	0&1&1	1&1&1	25741868&23757202&11807402&10843194&9215689&28899949						FAIL	0	-5	-21	-10	0.00	0.00	0.02	0.00	MEN1		2.0600e-01	96252	0.02639	0.02862	0.01058	102146	Hyperparathyroidism&Hereditary_cancer-predisposing_syndrome&Multiple_endocrine_neoplasia&_type_1&not_provided&not_specified		Human_Phenotype_Ontology:HP:0000843&MONDO:MONDO:0001741&MedGen:C0020502&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0007540&MeSH:D018761&MedGen:C0025267&OMIM:131100&Orphanet:652&MedGen:C3661900&MedGen:CN169374		NC_000011.10:g.64809675G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000114299&SCV000153866&SCV000303132&SCV000373102&SCV000373103&SCV000579619&SCV000604199&SCV000842747&SCV001910760&SCV002530069&SCV002549980&SCV002774017&SCV004015821&SCV004359153&SCV005319094&SCV005895498&SCV006055684	single_nucleotide_variant	SO:0001483	ClinGen:CA009422		MEN1:4221	SO:0001819&synonymous_variant										1	61736636																											714					0.993							247.03	v6.1	Unknown		True	MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:S145= mutant UNKNOWN.	False	The MEN1 ENSP00000394933.3:s145= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	64577147						True	False	False	Unknown								False	False		MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers.	The MEN1 ENSP00000394933.3:s145= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:S145= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	MEN1	4221.0	ENSP00000394933.3:S145=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MEN1"",""entrezGeneId"":4221,""alteration"":""ENSP00000394933.3:S145="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MEN1, a transcriptional repressor, is altered by mutation and deletion in various cancer types, including parathyroid and endocrine cancers."",""variantSummary"":""The MEN1 ENSP00000394933.3:s145= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MEN1 ENSP00000394933.3:S145= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						361,348	185,154	176,194	0/1	199,162,174,174	AGC	0.00	0.00	0.00			201,160,214,134	44.14		0.4908321579689704
GRCh38	RPS6KB2	D12_12345_1234556_Thyroid_S9	p.Phe269=	ENSP00000308413.5:p.Phe269=	chr11	67433348	67433348.0	C	T	T	67433348	.	C	T	.	PASS	NM_003952	T	synonymous_variant	LOW	RPS6KB2	ENSG00000175634	Transcript	ENST00000312629	protein_coding	10/15		c.807C>T	859	807	269	F	ttC/ttT	rs4930427&COSV57047270		1		SNV	HGNC	HGNC:10437	YES	MANE_Select	NM_003952.3		1	P1	CCDS41677.1	ENSP00000308413	Q9UBS0.219		UPI00001FAD74	Q9UBS0-1					Gene3D:1.10.510.10&Gene3D:3.30.200.20&AFDB-ENSP_mappings:AF-Q9UBS0-F1&Pfam:PF00069&PIRSF:PIRSF000605&PROSITE_profiles:PS50011&PANTHER:PTHR24351&SMART:SM00220&Superfamily:SSF56112&CDD:cd05584			0.3560	0.3283	0.5389	0.3264	0.4225	0.226	0.4134	0.325	0.5512	0.3108	0.3068	0.3735	0.3567	0.4315	0.3958	0.2642	0.38	0.3184	0.3637	0.445	0.317	0.292	0.3718	0.2687	0.4247	0.369	0.2456	0.5512	gnomADe_AMR		0&1	0&1	20019842						FAIL	8	-8	8	43	0.04	0.00	0.00	0.00	RPS6KB2		1.1010e+00																																																											703					0.996							246.12	v6.1	Unknown		True	RPS6KB2 encodes a serine/threonine kinase involved in protein translation, cell proliferation and survival. Copy number alterations and mutations of RPS6KB2 are found in various cancers and are associated with poor prognosis.	False	01/18/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPS6KB2 ENSP00000308413.5:F269= mutant UNKNOWN.	False	The RPS6KB2 ENSP00000308413.5:f269= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	67200819						True	False	False	Unknown								False	False		RPS6KB2 encodes a serine/threonine kinase involved in protein translation, cell proliferation and survival. Copy number alterations and mutations of RPS6KB2 are found in various cancers and are associated with poor prognosis.	The RPS6KB2 ENSP00000308413.5:f269= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPS6KB2 ENSP00000308413.5:F269= mutant UNKNOWN.						v6.1	01/18/2017		GRCh38	RPS6KB2	6199.0	ENSP00000308413.5:F269=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RPS6KB2"",""entrezGeneId"":6199,""alteration"":""ENSP00000308413.5:F269="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RPS6KB2 encodes a serine/threonine kinase involved in protein translation, cell proliferation and survival. Copy number alterations and mutations of RPS6KB2 are found in various cancers and are associated with poor prognosis."",""variantSummary"":""The RPS6KB2 ENSP00000308413.5:f269= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPS6KB2 ENSP00000308413.5:F269= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/18/2017""}"	True	True	False	Unknown		Unknown																						0,700	0,358	0,342	0/1	0,0,371,329	TCA	0.00	0.00	0.00			0,0,389,311	64.73		1.0
GRCh38	RPS6KB2	D12_12345_1234556_Thyroid_S9	p.A420V	ENSP00000308413.5:p.Ala420Val	chr11	67434685	67434685.0	C	T	T	67434685	.	C	T	.	PASS	NM_003952	T	missense_variant	MODERATE	RPS6KB2	ENSG00000175634	Transcript	ENST00000312629	protein_coding	14/15		c.1259C>T	1311	1259	420	A/V	gCc/gTc	rs13859&CM1212310&COSV57048502		1		SNV	HGNC	HGNC:10437	YES	MANE_Select	NM_003952.3		1	P1	CCDS41677.1	ENSP00000308413	Q9UBS0.219		UPI00001FAD74	Q9UBS0-1			deleterious_low_confidence(0.01)	benign(0.009)	AFDB-ENSP_mappings:AF-Q9UBS0-F1&PIRSF:PIRSF000605&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.4868	0.8079	0.5692	0.3264	0.4225	0.226	0.4256	0.7526	0.5728	0.3175	0.3055	0.3697	0.3775	0.4323	0.4221	0.2639	0.5043	0.7439	0.3648	0.499	0.3224	0.2926	0.3721	0.3469	0.4274	0.4583	0.2481	0.8079	AFR		0&1&1	0&1&1	20019842&38427583						FAIL	-43	9	-2	-13	0.00	0.00	0.00	0.00	RPS6KB2	0.158	1.1010e+00																																																											656					1							247.57	v6.1	Unknown		True	RPS6KB2 encodes a serine/threonine kinase involved in protein translation, cell proliferation and survival. Copy number alterations and mutations of RPS6KB2 are found in various cancers and are associated with poor prognosis.	False	01/18/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPS6KB2 ENSP00000308413.5:A420V mutant UNKNOWN.	False	The RPS6KB2 ENSP00000308413.5:a420v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	67202156						True	False	False	Unknown								False	False		RPS6KB2 encodes a serine/threonine kinase involved in protein translation, cell proliferation and survival. Copy number alterations and mutations of RPS6KB2 are found in various cancers and are associated with poor prognosis.	The RPS6KB2 ENSP00000308413.5:a420v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPS6KB2 ENSP00000308413.5:A420V mutant UNKNOWN.						v6.1	01/18/2017		GRCh38	RPS6KB2	6199.0	ENSP00000308413.5:A420V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RPS6KB2"",""entrezGeneId"":6199,""alteration"":""ENSP00000308413.5:A420V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RPS6KB2 encodes a serine/threonine kinase involved in protein translation, cell proliferation and survival. Copy number alterations and mutations of RPS6KB2 are found in various cancers and are associated with poor prognosis."",""variantSummary"":""The RPS6KB2 ENSP00000308413.5:a420v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPS6KB2 ENSP00000308413.5:A420V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/18/2017""}"	True	True	False	Unknown		Unknown																						0,656	0,352	0,304	0/1	0,0,324,332	GCC	0.00	0.00	0.00			0,0,256,400	64.73		1.0
GRCh38	CCND1	D12_12345_1234556_Thyroid_S9	p.Pro241=	ENSP00000227507.2:p.Pro241=	chr11	69648142	69648142.0	G	A	A	69648142	.	G	A	.	PASS	NM_053056	A	splice_region_variant&synonymous_variant	LOW	CCND1	ENSG00000110092	Transcript	ENST00000227507	protein_coding	4/5		c.723G>A	881	723	241	P	ccG/ccA	rs9344&COSV57118864&CS004528		1		SNV	HGNC	HGNC:1582	YES	MANE_Select	NM_053056.3		1	P1	CCDS8191.1	ENSP00000227507	P24385.240	Q6FI00.158	UPI0000001285			1			Gene3D:1.10.472.10&PDB-ENSP_mappings:2w96.A&PDB-ENSP_mappings:2w99.A&PDB-ENSP_mappings:2w9f.A&PDB-ENSP_mappings:2w9z.A&PDB-ENSP_mappings:6p8e.A&PDB-ENSP_mappings:6p8f.A&PDB-ENSP_mappings:6p8g.A&PDB-ENSP_mappings:6p8h.A&AFDB-ENSP_mappings:AF-P24385-F1&Pfam:PF02984&PANTHER:PTHR10177&SMART:SM01332&Superfamily:SSF47954&CDD:cd20576			0.4135	0.1876	0.3487	0.5714	0.497	0.5164	0.4494	0.2153	0.3792	0.4439	0.5227	0.4808	0.5147	0.4489	0.4554	0.5229	0.3923	0.2187	0.3947	0.403	0.4461	0.5475	0.4699	0.4795	0.4585	0.4286	0.5238	0.5714	EAS	risk_factor&benign	0&1&1	1&1&1	31818908&20844743&21992066&24944790&21514219&23946381&25928231&21976407&25214541&21819567&18174243&19258477&27897268&30337837&30793520&31516756&21723269&22117530&24491308&26884752&31935498&22215955&24357096&28264017&16465622&27415837&30139066&26445852&27536357&14724163&18547414&19826048&21282454&21989330&23072573&28266606&19124506&28596683&25611573&19543528&31629678&28380465&35205374&19336552&35990252&33466296&19442035&24264314&22517515&29732392&19372140&21454829&19941161&31935283&18507837&34182776&18822177&19585495&19750108&34227093&22367361&23625573&34441352&28025584&28445979&28508326&19183483&34254644&23125009&29113352&16783567&19287456&19302219&20680537&21161398&21268129&21273603&21594903&21890746&21965784&22399638&23311506&23354566&23567490&25436006&25809706&26459309&27137881&28357079&29970717&30361291&30389156&30428594&30972946&32373934&32737004&34182479&34593429&35984915&32625092&32983964&34124820&36632296&36764694&19383379&32885146&31450905&36534235&27229157&22606291&27009395&32581388&31541294&3284844						FAIL	0	-18	4	0	0.00	0.00	0.00	0.00	CCND1		6.0900e-01	13755	0.38674	0.45513	0.41354	28794	not_provided&MULTIPLE_MYELOMA&_t(11%3B14)_TYPE&_SUSCEPTIBILITY_TO&VON_HIPPEL-LINDAU_SYNDROME&_MODIFIER_OF&CCND1-related_disorder&Colorectal_cancer&_susceptibility_to		MedGen:C3661900&.&MedGen:C3805838&.&MedGen:C1858438		NC_000011.10:g.69648142G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001890546&SCV005321526	single_nucleotide_variant	SO:0001483	ClinGen:CA123434&OMIM:168461.0001		CCND1:595	SO:0001819&synonymous_variant										1	9344																											816					0.999							248.11	v6.1	Unknown		True	CCND1, a regulator of the cell cycle, is amplified in various cancer types including breast, head and neck, and bladder cancers.	False	02/07/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCND1 ENSP00000227507.2:P241= mutant UNKNOWN.	False	The CCND1 ENSP00000227507.2:p241= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	69462910						True	False	False	Unknown								False	False		CCND1, a regulator of the cell cycle, is amplified in various cancer types including breast, head and neck, and bladder cancers.	The CCND1 ENSP00000227507.2:p241= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCND1 ENSP00000227507.2:P241= mutant UNKNOWN.						v6.1	02/07/2019		GRCh38	CCND1	595.0	ENSP00000227507.2:P241=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CCND1"",""entrezGeneId"":595,""alteration"":""ENSP00000227507.2:P241="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CCND1, a regulator of the cell cycle, is amplified in various cancer types including breast, head and neck, and bladder cancers."",""variantSummary"":""The CCND1 ENSP00000227507.2:p241= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCND1 ENSP00000227507.2:P241= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/07/2019""}"	True	True	False	Unknown		Unknown																						430,385	218,186	212,199	0/1	216,214,177,208	CGG	0.00	0.00	0.00			190,240,158,227	32.58		0.4723926380368098
GRCh38	CCND1	D12_12345_1234556_Thyroid_S9			chr11	69648710	69648711.0	AG	A	A	69648710	.	AG	A	.	PASS	NM_053056	-	intron_variant	MODIFIER	CCND1	ENSG00000110092	Transcript	ENST00000227507	protein_coding		4/4	c.723+571del						rs3212879		1		deletion	HGNC	HGNC:1582	YES	MANE_Select	NM_053056.3		1	P1	CCDS8191.1	ENSP00000227507	P24385.240	Q6FI00.158	UPI0000001285			1					2	0.4962	0.1725	0.4179	0.8403	0.5716	0.5573											0.4479	0.2162	0.5735	0.4438	0.4325	0.8482	0.5747	0.4762	0.5302	0.4721	0.5652	0.8482	gnomADg_EAS				18174243&19258477&19124506&19543528&18507837&38994482						FAIL	-19	31	2	42	0.00	0.00	0.01	0.00	CCND1		6.0900e-01																																																											526					0.971							247.71													chr11	69463478																																																	True	True	False	Unknown		Unknown																						272,239	125,114	147,125	0/1	145,127,115,124	AAG						132,140,108,131	29.85		0.46771037181996084
GRCh38	CCND1	D12_12345_1234556_Thyroid_S9			chr11	69651969	69651969.0	C	G	G	69651969	.	C	G	.	PASS	NM_053056	G	3_prime_UTR_variant	MODIFIER	CCND1	ENSG00000110092	Transcript	ENST00000227507	protein_coding	5/5		c.*687C>G	1733					rs678653		1		SNV	HGNC	HGNC:1582	YES	MANE_Select	NM_053056.3		1	P1	CCDS8191.1	ENSP00000227507	P24385.240	Q6FI00.158	UPI0000001285			1						0.5254	0.171	0.438	0.8671	0.6581	0.5777	0.6347	0.2401	0.4747	0.5486	0.8785	0.7857	0.5878	0.6335	0.5891	0.6046	0.5255	0.2299	0.6623	0.4931	0.5585	0.8764	0.753	0.5102	0.6419	0.5484	0.5986	0.8785	gnomADe_EAS			1	21976407&26959740&18174243&19258477&25124382&19124506&21869864&19372140&18507837&34182776&29113352&21268129&21273603&21965784&22399638&23354566&25809706&30361291&34182479&34593429&26979757&22406644&34078296&25202078&23761956&37280435						FAIL	-12	-20	17	-20	0.00	0.00	0.00	0.00	CCND1		6.0900e-01																																																											781					0.999							247.38													chr11	69466737																																																	True	True	False	Unknown		Unknown																						0,780	0,424	0,356	0/1	0,0,406,374	GCC	.	.	.			0,0,518,262	64.73		1.0
GRCh38	CCND1	D12_12345_1234556_Thyroid_S9			chr11	69652779	69652781.0	T	TAC	TAC	69652779	.	T	TAC	.	PASS	NM_053056	AC	3_prime_UTR_variant	MODIFIER	CCND1	ENSG00000110092	Transcript	ENST00000227507	protein_coding	5/5		c.*1521_*1522dup	2543-2544					rs10640302		1		insertion	HGNC	HGNC:1582	YES	MANE_Select	NM_053056.3		1	P1	CCDS8191.1	ENSP00000227507	P24385.240	Q6FI00.158	UPI0000001285			1					25	0.7949	0.5832	0.8386	0.9038	0.8658	0.865	0.4963	0.3895	0.4967	0.4978	0.5049	0.5286	0.4854	0.503	0.4934	0.5	0.7814	0.5	0.9297	0.843	0.8389	0.9719	0.9335	0.8369	0.8927	0.7716	0.8675	0.9719	gnomADg_EAS																					6.0900e-01																																																											146					0.644							214.72													chr11	69467547																																																	True	True	False	Unknown		Unknown																						30,64	20,33	10,31	0/1	18,12,36,28	ATA						20,10,37,27	41.43		0.6808510638297872
GRCh38	FGF19	D12_12345_1234556_Thyroid_S9			chr11	69700766	69700771.0	C	CCCAGG	CCCAGG	69700766	.	C	CCCAGG	.	PASS	NM_005117	CCAGG	intron_variant	MODIFIER	FGF19	ENSG00000162344	Transcript	ENST00000294312	protein_coding		2/2	c.337-1195_337-1191dup						rs149065170		-1		insertion	HGNC	HGNC:3675	YES	MANE_Select	NM_005117.3		1	P1	CCDS8193.1	ENSP00000294312	O95750.202	A0A7U3L4E7.12	UPI0000037216									0.8666	0.8835	0.9049	0.874	0.8549	0.8211											0.8796	0.8867	0.9408	0.9007	0.9097	0.9108	0.8778	0.8014	0.8689	0.8817	0.842	0.9408	gnomADg_AMI																					1.8560e+00																																																											1037					0.816							242.27													chr11	69515534																																																	True	True	False	Unknown		Unknown																						21,825	11,392	10,433	0/1	11,10,392,433	CCC						9,12,443,382	61.69		0.975177304964539
GRCh38	FGF19	D12_12345_1234556_Thyroid_S9			chr11	69708824	69708824.0	A	G	G	69708824	.	A	G	.	PASS	NM_005117	G	upstream_gene_variant	MODIFIER	FGF19	ENSG00000162344	Transcript	ENST00000294312	protein_coding									rs4980680	4802	-1		SNV	HGNC	HGNC:3675	YES	MANE_Select	NM_005117.3		1	P1	CCDS8193.1	ENSP00000294312	O95750.202	A0A7U3L4E7.12	UPI0000037216									0.8484	0.8041	0.8977	0.9107	0.834	0.8241											0.8472	0.816	0.8736	0.8864	0.908	0.9217	0.8716	0.8027	0.8456	0.848	0.8348	0.9217	gnomADg_EAS																																																																																745					0.996							248.42													chr11	69523592																																																	True	True	False	Unknown		Unknown																						0,742	0,373	0,369	0/1	0,0,376,366	AAC	.	.	.			0,0,415,327	64.73		1.0
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69769667	69769667.0	C	T	T	69769667	.	C	T	.	PASS	NM_002007	T	downstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs9330206	1355	-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.9882	0.9569	0.9971	1	1	1											0.9906	0.9676	1	0.9965	0.9994	1	1	1	0.9998	0.9939	1	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_SAS																																																																																332					0.991							235.71													chr11	69584435																																																	True	True	False	Unknown		Unknown																						0,329	0,169	0,160	0/1	0,0,127,202	ACA	0.00	0.00	0.00			0,0,87,242	64.73		1.0
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69774374	69774374.0	G	A	A	69774374	.	G	A	.	PASS	NM_002007	A	intron_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding		1/2	c.341-247C>T						rs2070678		-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.1821	0.1029	0.1988	0.1667	0.2654	0.2076											0.2277	0.1365	0.2478	0.2304	0.2319	0.1709	0.259	0.2603	0.2824	0.232	0.2141	0.2824	gnomADg_NFE										FAIL	-19	39	4	-36	0.00	0.00	0.03	0.11	FGF4		1.3970e+00																																																											613					1							244													chr11	69589142																																																	True	True	False	Unknown		Unknown																						0,613	0,335	0,278	0/1	0,0,322,291	CGG	0.00	0.00	0.00			0,0,246,367	64.73		1.0
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69774540	69774540.0	A	G	G	69774540	.	A	G	.	PASS	NM_002007	G	intron_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding		1/2	c.340+205T>C						rs9666457		-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.7802	0.5908	0.8775	0.7976	0.8897	0.8364											0.8158	0.6403	0.9814	0.8833	0.8556	0.7796	0.8884	0.8973	0.892	0.8436	0.8369	0.9814	gnomADg_AMI										FAIL	-24	19	-24	2	0.00	0.00	0.00	0.03	FGF4		1.3970e+00																																																											430					1							247.38													chr11	69589308																																																	True	True	False	Unknown		Unknown																						1,429	1,213	0,216	0/1	0,1,209,220	GAC	.	.	.			0,1,213,216	64.73		0.9976744186046511
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69775624	69775625.0	GT	G	G	69775624	.	GT	G	.	PASS	NM_002007	-	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs11332593	284	-1		deletion	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.0968	0.0832	0.0749	0.0367	0.1779	0.1094											0.1292	0.09524	0.1086	0.0923	0.1351	0.04075	0.1439	0.1531	0.1632	0.1311	0.1212	0.1779	EUR																																																																																781					0.954							245.52													chr11	69590392																																																	True	True	False	Unknown		Unknown																						2,743	1,392	1,351	0/1	0,2,375,368	AGT						1,1,396,347	63.48		0.9973154362416108
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69777016	69777017.0	T	TC	TC	69777016	.	T	TC	.	PASS	NM_002007	C	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs34023759	1675	-1		insertion	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.4445	0.3971	0.4942	0.6855	0.3499	0.3221											0.3728	0.3792	0.2967	0.4456	0.2764	0.6918	0.3877	0.2279	0.3361	0.3431	0.3388	0.6918	gnomADg_EAS																																																																																684					0.971							245.94													chr11	69591784																																																	True	True	False	Unknown		Unknown																						343,321	185,179	158,142	0/1	179,164,160,161	TTC						199,144,152,169	37.86		0.48343373493975905
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69777372	69777372.0	A	T	T	69777372	.	A	T	.	PASS	NM_002007	T	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs4084210	2031	-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.8744	0.6672	0.9467	0.9603	0.9602	0.9264											0.8893	0.709	0.9879	0.9472	0.9531	0.9473	0.9668	0.9558	0.9607	0.9092	0.9386	0.9879	gnomADg_AMI																																																																																851					0.998							247.84													chr11	69592140																																																	True	True	False	Unknown		Unknown																						0,849	0,455	0,394	0/1	0,0,429,420	AAG	.	.	.			0,0,423,426	64.73		1.0
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69777946	69777946.0	T	C	C	69777946	.	T	C	.	PASS	NM_002007	C	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs4121890	2605	-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.8744	0.6672	0.9467	0.9603	0.9602	0.9264											0.8892	0.7089	0.9879	0.9471	0.9531	0.9468	0.9667	0.9558	0.9607	0.9093	0.9387	0.9879	gnomADg_AMI																																																																																639					0.997							246.38													chr11	69592714																																																	True	True	False	Unknown		Unknown																						0,637	0,302	0,335	0/1	0,0,320,317	CTA	.	.	.			0,0,247,390	64.73		1.0
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69777980	69777980.0	A	T	T	69777980	.	A	T	.	PASS	NM_002007	T	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs3886167	2639	-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.4449	0.3994	0.4942	0.6845	0.3499	0.3221											0.3734	0.3807	0.2961	0.4453	0.2768	0.6934	0.3888	0.2279	0.3361	0.3431	0.3392	0.6934	gnomADg_EAS																																																																																525					0.994							247.59													chr11	69592748																																																	True	True	False	Unknown		Unknown																						279,243	146,112	133,131	0/1	140,139,130,113	TAT	.	.	.			97,182,93,150	29.39		0.46551724137931033
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69778046	69778046.0	A	G	G	69778046	.	A	G	.	PASS	NM_002007	G	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs9330207	2705	-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.8792	0.6679	0.9467	0.9613	0.9602	0.9489											0.891	0.7129	0.9879	0.9481	0.9531	0.947	0.9665	0.9555	0.9608	0.9103	0.9539	0.9879	gnomADg_AMI																																																																																297					0.99							231.73													chr11	69592814																																																	True	True	False	Unknown		Unknown																						0,294	0,147	0,147	0/1	0,0,154,140	GAG	.	.	.			0,0,101,193	64.73		1.0
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69778048	69778048.0	A	G	G	69778048	.	A	G	.	PASS	NM_002007	G	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs12417716	2707	-1		SNV	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1								0.0659	0.084	0.062	0.0248	0.0954	0.0562											0.08254	0.08694	0.05804	0.06469	0.05067	0.02798	0.06065	0.06993	0.09378	0.08301	0.06967	0.0954	EUR																																																																																284					0.993							231.22													chr11	69592816																																																	True	True	False	Unknown		Unknown																						134,148	67,73	67,75	0/1	63,71,82,66	GAC	.	.	.			44,90,55,93	46.35		0.524822695035461
GRCh38	FGF4	D12_12345_1234556_Thyroid_S9			chr11	69778841	69778842.0	C	CA	CA	69778841	.	C	CA	.	PASS	NM_002007	A	upstream_gene_variant	MODIFIER	FGF4	ENSG00000075388	Transcript	ENST00000168712	protein_coding									rs779885648	3500	-1		insertion	HGNC	HGNC:3682	YES	MANE_Select	NM_002007.4		1	P1	CCDS8194.1	ENSP00000168712	P08620.205	A0A7U3JW12.12	UPI0000040662	P08620-1																								0.106	0.1356	0.06484	0.08051	0.07138	0.0336	0.08282	0.0916	0.1058	0.1083	0.08308	0.1356	gnomADg_AFR																																																																																178					0.803							236.96													chr11	69593609																																																	True	True	False	Unknown		Unknown																						82,61	35,29	47,32	0/1	37,45,34,27	CCA						42,40,32,29	20.16		0.42657342657342656
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69808637	69808637.0	G	C	C	69808637	.	G	C	.	PASS	NM_005247	C	downstream_gene_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding									rs12577876	1331	-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.1989	0.0189	0.1974	0.4077	0.2406	0.1851											0.1913	0.04729	0.4769	0.1786	0.1893	0.3964	0.3624	0.2041	0.2371	0.178	0.1844	0.4769	gnomADg_AMI																																																																																732					0.997							248.61													chr11	69623405																																																	True	True	False	Unknown		Unknown																						365,365	213,193	152,172	0/1	195,170,165,200	TGC	.	.	.			199,166,189,176	49.98		0.5
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9	p.Thr136=	ENSP00000334122.2:p.Thr136=	chr11	69810617	69810617.0	C	T	T	69810617	.	C	T	.	PASS	NM_005247	T	synonymous_variant	LOW	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding	3/3		c.408G>A	891	408	136	T	acG/acA	rs35420992&COSV61926295		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1			SMART:SM00442&Pfam:PF00167&Gene3D:2.80.10.50&PANTHER:PTHR11486&Phobius:CYTOPLASMIC_DOMAIN&CDD:cd00058&Superfamily:SSF50353&AFDB-ENSP_mappings:AF-P11487-F1			0.0521	0.0386	0.0274	0.0159	0.0954	0.0808	0.09685	0.04165	0.03317	0.03763	0.01693	0.1163	0.04631	0.1059	0.08097	0.09213	0.07752	0.04355	0.07895	0.04248	0.03744	0.01602	0.1097	0.04422	0.1072	0.07143	0.09085	0.1163	gnomADe_FIN	benign	0&1	1&1	25741868						FAIL	-2	-9	-7	-50	0.00	0.00	0.00	0.00	FGF3		1.8150e+00	259688	0.08405	0.08507	0.05212	254313	not_provided&not_specified		MedGen:C3661900&MedGen:CN169374		NC_000011.10:g.69810617C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000310932&SCV001873512&SCV002364929&SCV005321532	single_nucleotide_variant	SO:0001483	ClinGen:CA6157075		FGF3:2248	SO:0001819&synonymous_variant										1	35420992																											946					1							247.82	v6.1	Unknown		True	FGF3, a fibroblast growth factor, is altered by amplification in various cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF3 ENSP00000334122.2:T136= mutant UNKNOWN.	False	The FGF3 ENSP00000334122.2:t136= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	69625385						True	False	False	Unknown								False	False		FGF3, a fibroblast growth factor, is altered by amplification in various cancer types.	The FGF3 ENSP00000334122.2:t136= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF3 ENSP00000334122.2:T136= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	FGF3	2248.0	ENSP00000334122.2:T136=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGF3"",""entrezGeneId"":2248,""alteration"":""ENSP00000334122.2:T136="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGF3, a fibroblast growth factor, is altered by amplification in various cancer types."",""variantSummary"":""The FGF3 ENSP00000334122.2:t136= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF3 ENSP00000334122.2:T136= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						470,476	234,249	236,227	0/1	219,251,257,219	CCG	0.00	0.00	0.00			221,249,218,258	56.71		0.5031712473572939
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69810962	69810962.0	G	A	A	69810962	.	G	A	.	PASS	NM_005247	A	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.325-262C>T						rs2071395		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.4581	0.388	0.3718	0.623	0.4901	0.411											0.4652	0.3824	0.6864	0.3622	0.4732	0.6139	0.61	0.5136	0.5059	0.4446	0.4137	0.6864	gnomADg_AMI	benign		1							FAIL	-49	41	2	-37	0.00	0.00	0.00	0.01	FGF3		1.8150e+00	1249252			0.45807	1238343	not_provided		MedGen:C3661900		NC_000011.10:g.69810962G>A	criteria_provided&_single_submitter	Benign			SCV001865557	single_nucleotide_variant	SO:0001483	ClinGen:CA13444102		FGF3:2248	SO:0001627&intron_variant										1	2071395																											726					0.993							246.02													chr11	69625730																																																	True	True	False	Unknown		Unknown																						0,721	0,395	0,326	0/1	0,0,341,380	TGC	0.00	0.00	0.00			0,0,309,412	64.73		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69811704	69811704.0	A	G	G	69811704	.	A	G	.	PASS	NM_005247	G	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.325-1004T>C						rs1893047		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.5455	0.6195	0.4121	0.6329	0.5487	0.4468											0.5501	0.5771	0.7418	0.412	0.5328	0.6206	0.6564	0.5612	0.5486	0.5194	0.4574	0.7418	gnomADg_AMI				34366884&23549991&32249341&22074045&31574782&33492380&35629331&37176653&38840172						FAIL	30	-15	-36	24	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											655					1							248.33													chr11	69626472																																																	True	True	False	Unknown		Unknown																						0,655	0,296	0,359	0/1	0,0,331,324	CAT	.	.	.			0,0,340,315	64.73		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69812150	69812150.0	C	T	T	69812150	.	C	T	.	PASS	NM_005247	T	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.325-1450G>A						rs10908228		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.2087	0.0499	0.1974	0.4167	0.2406	0.184											0.1966	0.06634	0.4769	0.1808	0.1865	0.4003	0.3621	0.2055	0.2368	0.1809	0.1838	0.4769	gnomADg_AMI				23121717						FAIL	-2	24	-2	-46	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											917					0.997							245.63													chr11	69626918																																																	True	True	False	Unknown		Unknown																						440,474	183,218	257,256	0/1	209,231,234,240	GCA	0.00	0.00	0.00			224,216,236,238	62.49		0.5185995623632386
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69812240	69812240.0	C	G	G	69812240	.	C	G	.	PASS	NM_005247	G	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.325-1540G>C						rs12049848		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.4930	0.5159	0.3718	0.629	0.4911	0.41											0.4893	0.4676	0.6836	0.3725	0.4746	0.6137	0.6075	0.5308	0.5055	0.4604	0.4141	0.6836	gnomADg_AMI										FAIL	-22	39	-22	-40	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											828					0.998							246.78													chr11	69627008																																																	True	True	False	Unknown		Unknown																						0,826	0,366	0,460	0|1	0,0,451,375	GCA	.	.	.		69627008	0,0,407,419	56.31		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69812247	69812247.0	A	G	G	69812247	.	A	G	.	PASS	NM_005247	G	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.325-1547T>C						rs12049856		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.5449	0.6203	0.4121	0.631	0.5487	0.4448											0.5484	0.5747	0.7394	0.4119	0.5323	0.6162	0.654	0.5612	0.5474	0.5172	0.4563	0.7394	gnomADg_AMI										FAIL	48	-29	6	39	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											834					0.999							246.44													chr11	69627015																																																	True	True	False	Unknown		Unknown																						1,832	1,370	0,462	0|1	0,1,441,391	GAG	.	.	.		69627008	0,1,403,429	56.31		0.9987995198079231
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69814248	69814248.0	A	G	G	69814248	.	A	G	.	PASS	NM_005247	G	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.324+2072T>C						rs11263588		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.5441	0.618	0.4107	0.631	0.5487	0.4448											0.5487	0.575	0.7418	0.4111	0.5329	0.6186	0.6551	0.5612	0.5476	0.5195	0.4568	0.7418	gnomADg_AMI										FAIL	32	-19	-18	26	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											785					0.989							241.27													chr11	69629016																																																	True	True	False	Unknown		Unknown																						1,775	0,324	1,451	0/1	1,0,347,428	CAG	.	.	.			0,1,410,365	64.73		0.9987113402061856
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69814356	69814356.0	C	T	T	69814356	.	C	T	.	PASS	NM_005247	T	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.324+1964G>A						rs11263589		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.3173	0.3048	0.2305	0.4246	0.337	0.2648											0.3233	0.2795	0.556	0.2423	0.2292	0.4115	0.4718	0.2619	0.3451	0.2875	0.2744	0.556	gnomADg_AMI										FAIL	23	-46	-12	5	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											827					0.996							246.36													chr11	69629124																																																	True	True	False	Unknown		Unknown																						0,824	0,324	0,500	0/1	0,0,431,393	GCC	0.00	0.00	0.00			0,0,413,411	64.73		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69815565	69815565.0	G	A	A	69815565	.	G	A	.	PASS	NM_005247	A	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.324+755C>T						rs75043912		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.0429	0.0038	0.0259	0.0159	0.0964	0.0808											0.07032	0.01841	0.07895	0.0393	0.03718	0.01601	0.1095	0.04422	0.1074	0.06906	0.08974	0.1095	gnomADg_FIN										FAIL	-25	11	6	-23	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											556					0.998							246.87													chr11	69630333																																																	True	True	False	Unknown		Unknown																						303,252	140,113	163,139	0/1	155,148,141,111	CGC	0.00	0.00	0.00			124,179,98,154	24.45		0.4540540540540541
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69815736	69815736.0	G	A	A	69815736	.	G	A	.	PASS	NM_005247	A	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		2/2	c.324+584C>T						rs12575712		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.2009	0.0272	0.196	0.4087	0.2406	0.184											0.1923	0.05173	0.4781	0.1794	0.1859	0.3967	0.3624	0.2075	0.2367	0.1785	0.1844	0.4781	gnomADg_AMI										FAIL	-17	-1	-3	-34	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											638					1							246.98													chr11	69630504																																																	True	True	False	Unknown		Unknown																						304,334	163,159	141,175	0/1	160,144,155,179	AGT	0.00	0.00	0.00			181,123,192,142	58.71		0.5235109717868338
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69816963	69816963.0	G	A	A	69816963	.	G	A	.	PASS	NM_005247	A	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		1/2	c.221-540C>T						rs12574452		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.3191	0.3124	0.2305	0.4246	0.336	0.2648											0.3246	0.284	0.5582	0.2424	0.2294	0.4124	0.4723	0.2653	0.3449	0.2865	0.2748	0.5582	gnomADg_AMI				34366884&29228018&23549991&33979311&35629331&28162885						FAIL	-11	50	19	50	0.00	0.00	0.00	0.00	FGF3		1.8150e+00																																																											650					0.998							247.76													chr11	69631731																																																	True	True	False	Unknown		Unknown																						0,649	0,314	0,335	0/1	0,0,343,306	AGA	0.00	0.00	0.00			0,0,350,299	64.73		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69817481	69817481.0	T	A	A	69817481	.	T	A	.	PASS	NM_005247	A	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		1/2	c.221-1058A>T						rs12363691		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.3201	0.3124	0.2305	0.4296	0.336	0.2648	0.2458	0.25	0	0.5	1		0	0.2449	0		0.3223	0.2834	0.557	0.2423	0.2297	0.4169	0.4661	0.2653	0.3408	0.2862	0.2755	1	gnomADe_EAS										FAIL	41	-2	45	3	0.02	0.00	0.00	0.12	FGF3		1.8150e+00																																																											671					0.999							245.02													chr11	69632249																																																	True	True	False	Unknown		Unknown																						0,670	0,313	0,357	0/1	0,0,302,368	CTA	.	.	.			0,0,315,355	64.73		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69818269	69818269.0	G	A	A	69818269	.	G	A	.	PASS	NM_005247	A	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		1/2	c.220+445C>T						rs60563122		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.3265	0.3116	0.2392	0.4296	0.3439	0.2843											0.3315	0.2851	0.5614	0.2525	0.2754	0.4187	0.4726	0.3571	0.3521	0.3008	0.2959	0.5614	gnomADg_AMI										FAIL	-11	24	13	39	0.00	0.00	0.02	0.00	FGF3		1.8150e+00																																																											577					1							245.16													chr11	69633037																																																	True	True	False	Unknown		Unknown																						0,577	0,268	0,309	0/1	0,0,309,268	AGG	0.00	0.00	0.00			0,0,320,257	64.73		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69818542	69818542.0	C	A	A	69818542	.	C	A	.	PASS	NM_005247	A	intron_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding		1/2	c.220+172G>T						rs61177401		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.1174	0.2572	0.0432	0.0159	0.1034	0.1002											0.1337	0.2156	0.08333	0.07188	0.08847	0.01581	0.1101	0.1531	0.1153	0.1186	0.1111	0.2572	AFR	benign		1							FAIL	-5	-19	43	48	0.02	0.00	0.00	0.00	FGF3		1.8150e+00	1225751			0.11741	1215724	not_provided		MedGen:C3661900		NC_000011.10:g.69818542C>A	criteria_provided&_single_submitter	Benign			SCV001832943	single_nucleotide_variant	SO:0001483	ClinGen:CA13571613		FGF3:2248&LOC109115964:109115964	SO:0001627&intron_variant										1	61177401																											625					0.997							245.13													chr11	69633310																																																	True	True	False	Unknown		Unknown																						303,320	164,177	139,143	0/1	149,154,160,160	GCA	0.00	0.00	0.00			126,177,137,183	54.66		0.5136436597110754
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9	p.Ala23=	ENSP00000334122.2:p.Ala23=	chr11	69818865	69818865.0	C	A	A	69818865	.	C	A	.	PASS	NM_005247	A	synonymous_variant	LOW	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding	1/3		c.69G>T	552	69	23	A	gcG/gcT	rs41538178		-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1			Low_complexity_(Seg):seg&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P11487-F1			0.0743	0.1188	0.0346	0.0159	0.0954	0.0808	0.1018	0.1186	0.04571	0.04152	0.02031	0.1211	0.04652	0.107	0.08779	0.09474	0.09844	0.1149	0.07912	0.05132	0.04037	0.01583	0.1093	0.04452	0.1079	0.0865	0.09085	0.1211	gnomADe_FIN	benign		1	25741868						FAIL	39	13	-2	3	0.00	0.00	0.00	0.00	FGF3		1.8150e+00	259690		0.08261	0.07428	254315	not_provided&not_specified		MedGen:C3661900&MedGen:CN169374		NC_000011.10:g.69818865C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000310934&SCV000331732&SCV001848746&SCV002454514&SCV005321540	single_nucleotide_variant	SO:0001483	ClinGen:CA6157189		FGF3:2248&LOC109115964:109115964	SO:0001819&synonymous_variant										1	41538178																											119					1							243.3	v6.1	Unknown		True	FGF3, a fibroblast growth factor, is altered by amplification in various cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF3 ENSP00000334122.2:A23= mutant UNKNOWN.	False	The FGF3 ENSP00000334122.2:a23= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	69633633						True	False	False	Unknown								False	False		FGF3, a fibroblast growth factor, is altered by amplification in various cancer types.	The FGF3 ENSP00000334122.2:a23= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF3 ENSP00000334122.2:A23= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	FGF3	2248.0	ENSP00000334122.2:A23=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGF3"",""entrezGeneId"":2248,""alteration"":""ENSP00000334122.2:A23="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGF3, a fibroblast growth factor, is altered by amplification in various cancer types."",""variantSummary"":""The FGF3 ENSP00000334122.2:a23= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF3 ENSP00000334122.2:A23= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						48,71	28,35	20,36	0/1	22,26,43,28	GCG	0.00	0.00	0.00			24,24,31,40	45.91		0.5966386554621849
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69819948	69819948.0	G	C	C	69819948	.	G	C	.	PASS	NM_005247	C	upstream_gene_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding									rs12362498	532	-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.3277	0.3207	0.2406	0.4286	0.3439	0.2781											0.3326	0.2892	0.5604	0.2532	0.2746	0.4177	0.4733	0.3605	0.3523	0.3012	0.2936	0.5604	gnomADg_AMI																																																																																669					0.988							240.8													chr11	69634716																																																	True	True	False	Unknown		Unknown																						0,661	0,292	0,369	0/1	0,0,315,346	AGA	.	.	.			0,0,340,321	64.73		1.0
GRCh38	FGF3	D12_12345_1234556_Thyroid_S9			chr11	69820654	69820654.0	C	T	T	69820654	.	C	T	.	PASS	NM_005247	T	upstream_gene_variant	MODIFIER	FGF3	ENSG00000186895	Transcript	ENST00000334134	protein_coding									rs58187256	1238	-1		SNV	HGNC	HGNC:3681	YES	MANE_Select	NM_005247.4		1	P1	CCDS8195.1	ENSP00000334122	P11487.186	A0A7U3JVY0.12	UPI0000040661			1						0.2534	0.354	0.1758	0.2153	0.2575	0.2076											0.2716	0.3144	0.2363	0.1913	0.2998	0.2148	0.2493	0.3299	0.2742	0.2673	0.217	0.354	AFR																																																																																744					1							246.34													chr11	69635422																																																	True	True	False	Unknown		Unknown																						376,368	196,194	180,174	0/1	169,207,206,162	GCG	0.00	0.00	0.00			191,185,194,174	46.97		0.4946236559139785
GRCh38	EMSY	D12_12345_1234556_Thyroid_S9			chr11	76516138	76516138.0	G	A	A	76516138	.	G	A	.	PASS	NM_001300942	A	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	EMSY	ENSG00000158636	Transcript	ENST00000695367	protein_coding		11/21	c.1559-4G>A						rs2508740		1		SNV	HGNC	HGNC:18071	YES	MANE_Select	NM_001300942.2				CCDS73349.1	ENSP00000511840	Q7Z589.185		UPI000191704B	Q7Z589-7								0.6362	0.3828	0.755	0.8006	0.6213	0.7403	0.623	0.421	0.7696	0.5345	0.8142	0.6381	0.5859	0.6111	0.6157	0.7189	0.5796	0.4304	0.4901	0.6811	0.5421	0.8201	0.6324	0.6361	0.6132	0.5773	0.733	0.8201	gnomADg_EAS	benign		1	16029503&26119467&33213402&28738860&29707144&25817017																		3058884	0.54991	0.64385	0.63618	3200500	EMSY-related_disorder		.		NC_000011.10:g.76516138G>A	no_assertion_criteria_provided	Benign			SCV004793435	single_nucleotide_variant	SO:0001483	ClinGen:CA6193942		EMSY:56946	SO:0001627&intron_variant										1	2508740																											81					0.988							238.6													chr11	76227182																																																	True	True	False	Unknown		Unknown																						38,42	21,17	17,25	0/1	20,18,24,18	TGT	0.00	0.00	0.00			27,11,25,17	37.01		0.525
GRCh38	EMSY	D12_12345_1234556_Thyroid_S9	p.Thr1231=	ENSP00000511840.1:p.Thr1231=	chr11	76546171	76546171.0	T	C	C	76546171	.	T	C	.	PASS	NM_001300942	C	synonymous_variant	LOW	EMSY	ENSG00000158636	Transcript	ENST00000695367	protein_coding	21/22		c.3693T>C	3843	3693	1231	T	acT/acC	rs3753051&COSV58258432		1		SNV	HGNC	HGNC:18071	YES	MANE_Select	NM_001300942.2				CCDS73349.1	ENSP00000511840	Q7Z589.185		UPI000191704B	Q7Z589-7					AFDB-ENSP_mappings:AF-Q7Z589-F1&PANTHER:PTHR16500&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.2069	0.1815	0.1729	0.1379	0.3131	0.227	0.3018	0.2034	0.1585	0.3909	0.1385	0.3256	0.2998	0.3182	0.2935	0.2417	0.2699	0.2092	0.4604	0.2058	0.3826	0.128	0.3379	0.2313	0.3161	0.2781	0.2298	0.4604	gnomADg_AMI	benign	0&1	1&1	16029503&33213402&28738860&29707144&33290408																		3060664	0.28628		0.20687	3197081	EMSY-related_disorder		.		NC_000011.10:g.76546171T>C	no_assertion_criteria_provided	Benign			SCV004796551	single_nucleotide_variant	SO:0001483	ClinGen:CA6194412		EMSY:56946	SO:0001819&synonymous_variant										1	3753051																											684					0.996							244.86	v6.1	Unknown		True	EMSY, a BRCA2-associated transcriptional repressor protein, is altered by amplification in breast cancer and ovarian cancer.	False	12/08/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EMSY ENSP00000511840.1:T1231= mutant UNKNOWN.	False	The EMSY ENSP00000511840.1:t1231= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	76257215						True	False	False	Unknown								False	False		EMSY, a BRCA2-associated transcriptional repressor protein, is altered by amplification in breast cancer and ovarian cancer.	The EMSY ENSP00000511840.1:t1231= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EMSY ENSP00000511840.1:T1231= mutant UNKNOWN.						v6.1	12/08/2023		GRCh38	EMSY	56946.0	ENSP00000511840.1:T1231=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EMSY"",""entrezGeneId"":56946,""alteration"":""ENSP00000511840.1:T1231="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EMSY, a BRCA2-associated transcriptional repressor protein, is altered by amplification in breast cancer and ovarian cancer."",""variantSummary"":""The EMSY ENSP00000511840.1:t1231= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EMSY ENSP00000511840.1:T1231= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/08/2023""}"	True	True	False	Unknown		Unknown																						300,381	163,205	137,176	0/1	156,144,191,190	CTG	.	.	.			139,161,195,186	45.95		0.5594713656387665
GRCh38	PAK1	D12_12345_1234556_Thyroid_S9			chr11	77349124	77349125.0	CA	C	C	77349124	.	CA	C	.	PASS	NM_002576	-	intron_variant	MODIFIER	PAK1	ENSG00000149269	Transcript	ENST00000356341	protein_coding		9/14	c.885+114del						rs34167967		-1		deletion	HGNC	HGNC:8590	YES	MANE_Select	NM_002576.5		1	P1	CCDS8250.1	ENSP00000348696	Q13153.244		UPI000013ED74	Q13153-1		1												0.1344	0.1385	0.1681	0.1305	0.1619	0.1483	0.1365	0.1309	0.1347	0.1159	0.002032	0.001523	0.01791	0.001232	0.008041	0.0008881	0.007616	0	0.001541	0.004399	0.0002917	0.1681	gnomADe_AMR										FAIL	-27	18	26	19	0.00	0.00	0.00	0.00	PAK1		7.0500e-01																																																											340					0.835							217.26													chr11	77060169																																																	True	True	False	Unknown		Unknown																						227,57	109,29	118,28	0/1	116,111,31,26	CCA						132,95,31,26	4.43		0.2007042253521127
GRCh38	PAK1	D12_12345_1234556_Thyroid_S9			chr11	77351432		C	<INS>	<INS>	77351432	MantaINS:12739:0:0:0:4:0	C	<INS>	.	PASS	NM_002576	insertion	intron_variant	MODIFIER	PAK1	ENSG00000149269	Transcript	ENST00000356341	protein_coding		8/14									-1		insertion	HGNC	HGNC:8590	YES	MANE_Select	NM_002576.5		1	P1	CCDS8250.1	ENSP00000348696	Q13153.244		UPI000013ED74	Q13153-1		1																																																																																																															0,60		0,60							60	ATGTACATTTCTGCTACATTCTTAATATCTCAATTTCACTACCTAAAGGAAATACCATCC		ATGTACATTTCTGCTACATTCTTAATATCTCAATTTCACTACCTAAAGGAAATACCATCCAACATTTAAAAGTCTGACAGGGGAGGAGGAGCTAACAAAGACAACTGAGGAAGTGC																chr11	77062477	GTTTTGAATTTACTGGCTGTCCCTTATGAGTTCACAGTTAGATTGGACTGTCCTCA			INS																																													True	True	False	Unknown		Unknown																															1,2				3,1	
GRCh38	PAK1	D12_12345_1234556_Thyroid_S9			chr11	77395669		A	<INS>	<INS>	77395669	MantaINS:1336:1:1:0:7:0	A	<INS>	.	PASS	NM_002576	insertion	intron_variant	MODIFIER	PAK1	ENSG00000149269	Transcript	ENST00000356341	protein_coding		1/14									-1		insertion	HGNC	HGNC:8590	YES	MANE_Select	NM_002576.5		1	P1	CCDS8250.1	ENSP00000348696	Q13153.244		UPI000013ED74	Q13153-1		1																																																																																																															0,29		0,29							29	ATCTTACTCATCCATCAAGGCCAAACCCT		ATCTTACTCATCCATCAAGGCCAAACCCTGCCTCCACTTGCCTTGTGATATTCTATTACCTTGTAAAGTACTTGATGTCTGTGACCCACACC																chr11	77106714	CACCTTTCAGTGGCGTCCCTATGGGTTAAAATTCAAATTCCTTAACATGAATTACAAGGACCTGTAGGATCTGG			INS																																													True	True	False	Unknown		Unknown																															14,6				57,4	
GRCh38	PAK1	D12_12345_1234556_Thyroid_S9			chr11	77452768		A	<INS>	<INS>	77452768	MantaINS:1481:5:5:1:4:0	A	<INS>	.	PASS	NM_002576	insertion	intron_variant	MODIFIER	PAK1	ENSG00000149269	Transcript	ENST00000356341	protein_coding		1/14									-1		insertion	HGNC	HGNC:8590	YES	MANE_Select	NM_002576.5		1	P1	CCDS8250.1	ENSP00000348696	Q13153.244		UPI000013ED74	Q13153-1		1																																																																																																															0,24		0,24							24	CAGGGTTGGCACATCTAATAACAA		CAGGGTTGGCACATCTAATAACAACCCAAGTAGGAGTAAAGAGTGTGTTCATGGTAGGTCCCTTTTCCTGTAGAAACTAGGAGGGACTAGGGAGAGTCTGCAAGGGGAAGAGTGTGT																chr11	77163813	CTTAAACGTTAGACCTAAAACCATAAAAACCCTAGAAGAAAACCTAAGCATTACCATT			INS																																													True	True	False	Unknown		Unknown																															17,1				83,2	
GRCh38	PGR	D12_12345_1234556_Thyroid_S9	p.Gly393=	ENSP00000325120.5:p.Gly393=	chr11	101127892	101127892.0	G	A	A	101127892	.	G	A	.	PASS	NM_000926	A	synonymous_variant	LOW	PGR	ENSG00000082175	Transcript	ENST00000325455	protein_coding	1/8		c.1179C>T	1922	1179	393	G	ggC/ggT	rs1379130&COSV108004167		-1		SNV	HGNC	HGNC:8910	YES	MANE_Select	NM_000926.4		1	P1	CCDS8310.1	ENSP00000325120	P06401.265		UPI0000046E22	P06401-1		1			Low_complexity_(Seg):seg&Pfam:PF02161&PANTHER:PTHR48092&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P06401-F1			0.1438	0.034	0.2406	0.006	0.3211	0.183	0.313	0.07023	0.236	0.2261	0.002356	0.3817	0.308	0.3427	0.2768	0.2164	0.2456	0.07769	0.2804	0.2477	0.2146	0.006168	0.3851	0.3028	0.3467	0.2459	0.1993	0.3851	gnomADg_FIN		0&1	0&1	19846565&20148360&15718480&19555469&31616008&36702635						FAIL	2	45	2	-43	0.00	0.00	0.05	0.00	PGR		5.5400e-01																																																											827					0.995							246.96	v6.1	Unknown		True	PGR encodes the progesterone receptor which mediates the effects of progesterone, playing a central role in reproductive events. PGR expression is common in breast and endometrial tumors and is predictive for response to endocrine therapy.	False	01/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PGR ENSP00000325120.5:G393= mutant UNKNOWN.	False	The PGR ENSP00000325120.5:g393= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	100998623						True	False	False	Unknown								False	False		PGR encodes the progesterone receptor which mediates the effects of progesterone, playing a central role in reproductive events. PGR expression is common in breast and endometrial tumors and is predictive for response to endocrine therapy.	The PGR ENSP00000325120.5:g393= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PGR ENSP00000325120.5:G393= mutant UNKNOWN.						v6.1	01/17/2017		GRCh38	PGR	5241.0	ENSP00000325120.5:G393=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PGR"",""entrezGeneId"":5241,""alteration"":""ENSP00000325120.5:G393="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PGR encodes the progesterone receptor which mediates the effects of progesterone, playing a central role in reproductive events. PGR expression is common in breast and endometrial tumors and is predictive for response to endocrine therapy."",""variantSummary"":""The PGR ENSP00000325120.5:g393= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PGR ENSP00000325120.5:G393= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/17/2017""}"	True	True	False	Unknown		Unknown																						421,402	183,206	238,196	0/1	183,238,203,199	CGC	0.00	0.00	0.00			153,268,183,219	43.98		0.488456865127582
GRCh38	BIRC3	D12_12345_1234556_Thyroid_S9			chr11	102322797		A	<INS>	<INS>	102322797	MantaINS:3237:1:1:0:10:0	A	<INS>	.	PASS	NM_001165	insertion	feature_elongation&5_prime_UTR_variant	HIGH	BIRC3	ENSG00000023445	Transcript	ENST00000263464	protein_coding	2/9			1050							1		insertion	HGNC	HGNC:591	YES	MANE_Select	NM_001165.5		1	P1	CCDS8315.1	ENSP00000263464	Q13489.226		UPI0000001C60			1																																																																																																																											TTAGCCAGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCT																chr11	102193528				INS																																													True	True	False	Unknown		Unknown																															0,3				41,0	
GRCh38	GRIA4	D12_12345_1234556_Thyroid_S9			chr11	105634970		C	[chr4:68924370[C	[chr4:68924370[C	105634970	MantaBND:768:0:1:0:0:0:0	C	[chr4:68924370[C	.	PASS		.C	feature_truncation&intron_variant	HIGH	GRIA4	ENSG00000152578	Transcript	ENST00000706777	protein_coding		3/16									1		chromosome_breakpoint	HGNC	HGNC:4574						P3	CCDS41706.1	ENSP00000516542		G3V164.111	UPI0000E5924E			1																																																																																																														0			0,8							8	CTTTGTCT			MantaBND:768:0:1:0:0:0:1	1														chr11	105505697				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	SDHD	D12_12345_1234556_Thyroid_S9			chr11	112093136	112093136.0	A	G	G	112093136	.	A	G	.	PASS	NM_003002	G	intron_variant	MODIFIER	SDHD	ENSG00000204370	Transcript	ENST00000375549	protein_coding		3/3	c.315-1669A>G						rs592626&COSV108227245		1		SNV	HGNC	HGNC:10683	YES	MANE_Select	NM_003002.4		1	P1	CCDS31678.1	ENSP00000364699	O14521.225	A0A0S2Z4J3.42	UPI0000129396	O14521-1		1						0.9455	0.8079	0.9755	0.999	0.999	1	0.9939	0.7989	0.9872	0.9993	1	1	0.9888	0.9992	0.9891	0.9991	0.9515	0.8333	1	0.9766	0.9997	0.999	0.9999	0.9932	0.9991	0.9628	0.9985	1	SAS&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI	benign	0&1	1&1							FAIL	50	-9	25	2	0.00	0.00	0.00	0.00	SDHD		5.8100e-01	1247534		0.99672	0.94549	1234913	not_provided&Hereditary_cancer-predisposing_syndrome		MedGen:C3661900&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000011.10:g.112093136A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001864908&SCV005231597&SCV006099484	single_nucleotide_variant	SO:0001483	ClinGen:CA071120		SDHD:6392	SO:0001583&missense_variant&SO:0001627&intron_variant										1	592626																											135					1							191.5													chr11	111963860																																																	True	True	False	Unknown		Unknown																						0,135	0,63	0,72	0/1	0,0,58,77	CAG	.	.	.			0,0,70,65	64.72		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr11	115336457	115336457.0	C	G	G	115336457	.	C	G	.	PASS		G	upstream_gene_variant	MODIFIER		ENSG00000287897	Transcript	ENST00000661109	lncRNA									rs10488710	3039	-1		SNV			YES																			0.6324	0.6142	0.5922	0.63	0.6491	0.6708											0.6291	0.6015	0.4627	0.6331	0.5127	0.6144	0.6725	0.585	0.6436	0.6233	0.6903	0.6903	gnomADg_SAS				23771752&26691610&28341840&29121662&30735000&33406744&34721519&30483659&32451905&33546406																																																																												96					0.958							239.22													chr11	115207176																																																	True	False	False	Unknown		Unknown																						1,91	0,43	1,48	0/1	0,1,45,46	ACT	.	.	.			1,0,49,42	61.65		0.9891304347826086
GRCh38	CHEK1	D12_12345_1234556_Thyroid_S9			chr11	125620870	125620870.0	A	T	T	125620870	.	A	T	.	PASS	NM_001114122	T	upstream_gene_variant	MODIFIER	CHEK1	ENSG00000149554	Transcript	ENST00000438015	protein_coding									rs74957637&COSV101205309	4293	1		SNV	HGNC	HGNC:1925	YES	MANE_Select	NM_001114122.3		5	P1	CCDS8459.1	ENSP00000388648	O14757.249		UPI000013DBA3	O14757-1		1												0.03847	0.007069	0.03046	0.06137	0.06165	0.01312	0.07274	0.0395	0.03675	0.03411	0.03431	0.00793	0.02771	0.03399	0.06585	0.07314	0.009758	0.068	0.04659	0.05113	0.04297	0.07314	gnomADg_EAS		0&1	0&1																																																																													175					0.583							221.08													chr11	125490765																																																	True	True	False	Unknown		Unknown																						31,71	18,36	13,35	0/1	22,9,38,33	GAT	.	.	.			19,12,39,32	39.67		0.696078431372549
GRCh38	CHEK1	D12_12345_1234556_Thyroid_S9			chr11	125650830	125650832.0	CAG	C	C	125650830	.	CAG	C	.	PASS	NM_001114122	-	intron_variant	MODIFIER	CHEK1	ENSG00000149554	Transcript	ENST00000438015	protein_coding		11/12	c.1234-2912_1234-2911del						rs36103357		1		deletion	HGNC	HGNC:1925	YES	MANE_Select	NM_001114122.3		5	P1	CCDS8459.1	ENSP00000388648	O14757.249		UPI000013DBA3	O14757-1		1					3	0.3562	0.3926	0.2349	0.4315	0.3121	0.3609											0.3178	0.372	0.1206	0.2451	0.3075	0.4211	0.2858	0.3197	0.2995	0.3052	0.3495	0.4315	EAS										FAIL	5	46	-18	19	0.00	0.00	0.00	0.00	CHEK1		8.3100e-01																																																											231					0.957							245.86													chr11	125520725																																																	True	True	False	Unknown		Unknown																						117,104	60,62	57,42	0/1	54,63,52,52	ACA						49,68,40,64	31.78		0.47058823529411764
GRCh38	CHEK1	D12_12345_1234556_Thyroid_S9	p.I471V	ENSP00000388648.1:p.Ile471Val	chr11	125655300	125655300.0	A	G	G	125655300	.	A	G	.	PASS	NM_001114122	G	missense_variant	MODERATE	CHEK1	ENSG00000149554	Transcript	ENST00000438015	protein_coding	13/13		c.1411A>G	2281	1411	471	I/V	Att/Gtt	rs506504&COSV104594243		1		SNV	HGNC	HGNC:1925	YES	MANE_Select	NM_001114122.3		5	P1	CCDS8459.1	ENSP00000388648	O14757.249		UPI000013DBA3	O14757-1		1	tolerated(1)	benign(0)	PDB-ENSP_mappings:5wi2.A&PDB-ENSP_mappings:5wi2.B&AFDB-ENSP_mappings:AF-O14757-F1			0.9858	0.997	0.9726	1	0.9672	0.9847	0.9659	0.9948	0.9828	0.9608	0.9998	0.9666	0.9573	0.9621	0.9679	0.9799	0.9747	0.9931	0.9759	0.974	0.9562	0.9998	0.9681	0.9354	0.964	0.963	0.978	1	EAS	benign	0&1	1&1	18805967&29458332						FAIL	-1	-7	-1	47	0.00	0.00	0.00	0.00	CHEK1	0.053	8.3100e-01	496139	0.97385	0.97260	0.98582	487497	CHEK1-related_disorder&not_provided		.&MedGen:C3661900		NC_000011.10:g.125655300A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000697846&SCV005231114	single_nucleotide_variant	SO:0001483	ClinGen:CA6349680		CHEK1:1111	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	506504																											156					1							238.99	v6.1	Unknown		True	CHEK1, an intracellular kinase, is overexpressed in various solid and hematologic malignancies.	False	10/04/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHEK1 ENSP00000388648.1:I471V mutant UNKNOWN.	False	The CHEK1 ENSP00000388648.1:i471v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr11	125525195						True	False	False	Unknown								False	False		CHEK1, an intracellular kinase, is overexpressed in various solid and hematologic malignancies.	The CHEK1 ENSP00000388648.1:i471v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHEK1 ENSP00000388648.1:I471V mutant UNKNOWN.						v6.1	10/04/2018		GRCh38	CHEK1	1111.0	ENSP00000388648.1:I471V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CHEK1"",""entrezGeneId"":1111,""alteration"":""ENSP00000388648.1:I471V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CHEK1, an intracellular kinase, is overexpressed in various solid and hematologic malignancies."",""variantSummary"":""The CHEK1 ENSP00000388648.1:i471v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHEK1 ENSP00000388648.1:I471V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/04/2018""}"	True	True	False	Unknown		Unknown																						0,156	0,73	0,83	0/1	0,0,82,74	GAT	.	.	.			0,0,59,97	64.72		1.0
GRCh38	CHEK1	D12_12345_1234556_Thyroid_S9			chr11	125666986	125666987.0	G	GT	GT	125666986	.	G	GT	.	PASS		T	intron_variant	MODIFIER	CHEK1	ENSG00000149554	Transcript	ENST00000711049	protein_coding		12/12	c.*28-8931dup						rs34905634		1		insertion	HGNC	HGNC:1925								ENSP00000518558		E7EPP6.106	UPI0001AE6D14			1					11	0.3482	0.3888	0.2291	0.4097	0.3072	0.3569											0.3292	0.3874	0.1267	0.2554	0.3215	0.4343	0.2872	0.3158	0.309	0.3271	0.3628	0.4343	gnomADg_EAS																																																																																195					0.549							221.79													chr11	125536881																																																	True	True	False	Unknown		Unknown																						64,43	30,25	34,18	0/1	45,19,20,23	TGT						25,39,14,29	28.3		0.40186915887850466
GRCh38	CHEK1	D12_12345_1234556_Thyroid_S9			chr11	125675540	125675540.0	C	T	T	125675540	.	C	T	.	PASS		T	intron_variant	MODIFIER	CHEK1	ENSG00000149554	Transcript	ENST00000711049	protein_coding		12/12	c.*28-388C>T						rs17141326		1		SNV	HGNC	HGNC:1925								ENSP00000518558		E7EPP6.106	UPI0001AE6D14			1						0.1378	0.0499	0.2781	0.1746	0.1163	0.1411											0.1143	0.05412	0.1978	0.2303	0.06142	0.1795	0.1056	0.1088	0.123	0.122	0.1109	0.2781	AMR																																																																																211					0.924							228.1													chr11	125545435																																																	True	True	False	Unknown		Unknown																						102,93	47,46	55,47	0/1	47,55,52,41	CCT	0.00	0.00	0.00			50,52,47,46	34.15		0.47692307692307695
GRCh38		D12_12345_1234556_Thyroid_S9			chr11	126418977	126418979.0	C	CCT	CCT	126418977	.	C	CCT	.	PASS		CT	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR11_93T6RJ	enhancer									rs33972805				insertion																						0.6398	0.6929	0.5173	0.8919	0.5467	0.4908											0.5719	0.6446	0.436	0.5629	0.5908	0.8911	0.4562	0.5308	0.5287	0.5716	0.5087	0.8919	EAS			1	34605444&32888493&33801242																																																																												114					0.956							239.53													chr11	126288872																																																	True	False	False	Unknown		Unknown																						56,53	28,28	28,25	0/1	20,36,23,30	CCG						34,22,28,25	33.68		0.48623853211009177
GRCh38	ETS1	D12_12345_1234556_Thyroid_S9			chr11	128460625	128460625.0	T	C	C	128460625	.	T	C	.	PASS	NM_001143820	C	3_prime_UTR_variant	MODIFIER	ETS1	ENSG00000134954	Transcript	ENST00000392668	protein_coding	10/10		c.*1736A>G	3279					rs4937333&COSV107401136		-1		SNV	HGNC	HGNC:3488	YES	MANE_Select	NM_001143820.2		1		CCDS44767.1	ENSP00000376436	P14921.240		UPI00001BDB62	P14921-3		1						0.4411	0.2315	0.3689	0.5397	0.5169	0.5961	0.5141				0.5074			0.75	0.5		0.4584	0.2887	0.5143	0.4264	0.5807	0.5645	0.5899	0.6156	0.5253	0.4901	0.5518	0.75	gnomADe_NFE	benign	0&1	1&1	32382553&22087647&20169177&22517515&19825846&26241881&31275358&31873148&24708692&23926020&27863252&32888493&28845756&24023622&32888494&33569643&38064665																	3.9300e-01	1276850			0.44109	1266720	not_provided		MedGen:C3661900		NC_000011.10:g.128460625T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001910540&SCV005233432	single_nucleotide_variant	SO:0001483	ClinGen:CA15678207		ETS1:2113	SO:0001624&3_prime_UTR_variant										1	4937333																											197					0.985							234.12													chr11	128330520																																																	True	True	False	Unknown		Unknown																						111,83	57,41	54,42	0/1	59,52,41,42	TTC	.	.	.			53,58,35,48	23.65		0.42783505154639173
GRCh38	ETS1	D12_12345_1234556_Thyroid_S9			chr11	128522042	128522042.0	C	T	T	128522042	.	C	T	.	PASS	NM_001143820	T	intron_variant	MODIFIER	ETS1	ENSG00000134954	Transcript	ENST00000392668	protein_coding		3/9	c.215-31466G>A						rs61907765&COSV106101302&COSV60092503		-1		SNV	HGNC	HGNC:3488	YES	MANE_Select	NM_001143820.2		1		CCDS44767.1	ENSP00000376436	P14921.240		UPI00001BDB62	P14921-3		1						0.0901	0.0106	0.1859	0.003	0.2366	0.0685	0.1946	0.02817	0.1789	0.2121	0.005691	0.2298	0.1462	0.2122	0.1799	0.09366	0.1531	0.03756	0.3758	0.1743	0.2016	0.005204	0.2291	0.1701	0.217	0.1648	0.08814	0.3758	gnomADg_AMI		0&1&1	1&1&1	22057235&25920553&25388004&30572963&35347089&28845756&38348734						FAIL	-29	10	26	-24	0.00	0.00	0.00	0.00	ETS1		3.9300e-01																																																											932					0.988							246.19													chr11	128391937																																																	True	True	False	Unknown		Unknown																						479,442	232,200	247,242	0/1	236,243,240,202	ACT	0.00	0.00	0.00			231,248,186,256	38.17		0.4799131378935939
GRCh38	FLI1	D12_12345_1234556_Thyroid_S9			chr11	128812565	128812565.0	C	A	A	128812565	.	C	A	.	PASS	NM_002017	A	3_prime_UTR_variant	MODIFIER	FLI1	ENSG00000151702	Transcript	ENST00000527786	protein_coding	9/9		c.*1577C>A	3123					rs682695		1		SNV	HGNC	HGNC:3749	YES	MANE_Select	NM_002017.5		1	P1	CCDS44768.1	ENSP00000433488	Q01543.236		UPI000012A972	Q01543-1		1						0.2081	0.1051	0.2233	0.244	0.2893	0.2157	0.2906	0.1115	0.2111	0.213	0.3374	0.2045	0.2601	0.311	0.261	0.2172	0.2516	0.1262	0.3978	0.2197	0.2047	0.2525	0.3369	0.1815	0.3241	0.2524	0.233	0.3978	gnomADg_AMI				23940558						FAIL	24	-33	-23	15	0.00	0.00	0.00	0.00	FLI1		3.6700e-01																																																											377					0.958							230.25													chr11	128682460																																																	True	True	False	Unknown		Unknown																						209,152	122,82	87,70	0/1	107,102,72,80	TCA	0.00	0.00	0.00			108,101,80,72	15.71		0.42105263157894735
GRCh38	FLI1	D12_12345_1234556_Thyroid_S9			chr11	128812711	128812711.0	G	T	T	128812711	.	G	T	.	PASS	NM_002017	T	3_prime_UTR_variant	MODIFIER	FLI1	ENSG00000151702	Transcript	ENST00000527786	protein_coding	9/9		c.*1723G>T	3269					rs1148066		1		SNV	HGNC	HGNC:3749	YES	MANE_Select	NM_002017.5		1	P1	CCDS44768.1	ENSP00000433488	Q01543.236		UPI000012A972	Q01543-1		1						0.2081	0.1051	0.2233	0.244	0.2893	0.2157	0.2778	0.1023	0.2039	0.2041	0.3281	0.2727	0.2438	0.296	0.2496	0.2152	0.2515	0.1261	0.3967	0.2196	0.2044	0.2536	0.3364	0.1837	0.3241	0.2528	0.2326	0.3967	gnomADg_AMI										FAIL	24	-33	4	0	0.00	0.00	0.00	0.00	FLI1		3.6700e-01																																																											438					0.998							245.11													chr11	128682606																																																	True	True	False	Unknown		Unknown																						258,179	127,103	131,76	0/1	131,127,101,78	TGG	0.00	0.00	0.00			146,112,99,80	12.26		0.4096109839816934
GRCh38	FLI1	D12_12345_1234556_Thyroid_S9			chr11	128812821	128812853.0	A	ACTCAATTTTGAAATCTGCAAAGTATTCATTAG	ACTCAATTTTGAAATCTGCAAAGTATTCATTAG	128812821	.	A	ACTCAATTTTGAAATCTGCAAAGTATTCATTAG	.	PASS	NM_002017	CTCAATTTTGAAATCTGCAAAGTATTCATTAG	3_prime_UTR_variant	MODIFIER	FLI1	ENSG00000151702	Transcript	ENST00000527786	protein_coding	9/9		c.*1833_*1834insCTCAATTTTGAAATCTGCAAAGTATTCATTAG	3379-3380					rs1565514831		1		insertion	HGNC	HGNC:3749	YES	MANE_Select	NM_002017.5		1	P1	CCDS44768.1	ENSP00000433488	Q01543.236		UPI000012A972	Q01543-1		1												0.001436	0.001146	0.001346	0.0009053	0.00111	0	0	0.001683	0.001185	0	0.0003413	0.0001476	0	0.000623	0.0003007	0.000209	0.0005417	0	0.0003127	0.0005139	0.001353	0.001683	gnomADe_NFE																					3.6700e-01																																																											365					0.929							231.22													chr11	128682716																																																	True	True	False	Unknown		Unknown																						246,93	123,50	123,43	0|1	118,128,42,51	CAG					128682716	97,149,31,62	3.64		0.2743362831858407
GRCh38	FLI1	D12_12345_1234556_Thyroid_S9			chr11	128812824	128812833.0	A	AAAATGGAGG	AAAATGGAGG	128812824	.	A	AAAATGGAGG	.	PASS	NM_002017	AAATGGAGG	3_prime_UTR_variant	MODIFIER	FLI1	ENSG00000151702	Transcript	ENST00000527786	protein_coding	9/9		c.*1836_*1837insAAATGGAGG	3382-3383					rs1316655200		1		insertion	HGNC	HGNC:3749	YES	MANE_Select	NM_002017.5		1	P1	CCDS44768.1	ENSP00000433488	Q01543.236		UPI000012A972	Q01543-1		1												0.0002847	0.0004425	0	0	0	0	0	0.0004375	0	0	0.0001044	6.315e-05	0	0.0002146	0.0004587	0	0	0	9.707e-05	0	0.0003501	0.0004587	gnomADg_ASJ																					3.6700e-01																																																											364					0.734							230.24													chr11	128682719																																																	True	True	False	Unknown		Unknown																						252,15	126,9	126,6	0|1	130,122,7,8	GAC					128682716	100,152,1,14	3.44		0.056179775280898875
GRCh38	KDM5A	D12_12345_1234556_Thyroid_S9	p.Ser1383=	ENSP00000382688.2:p.Ser1383=	chr12	297126	297126.0	G	A	A	297126	.	G	A	.	PASS	NM_001042603	A	synonymous_variant	LOW	KDM5A	ENSG00000073614	Transcript	ENST00000399788	protein_coding	25/28		c.4149C>T	4378	4149	1383	S	tcC/tcT	rs2229351&COSV66993162		-1		SNV	HGNC	HGNC:9886	YES	MANE_Select	NM_001042603.3		1	P1	CCDS41736.1	ENSP00000382688	P29375.220		UPI0000DB2E73	P29375-1		1			AFDB-ENSP_mappings:AF-P29375-F1			0.3526	0.3306	0.3199	0.5109	0.2326	0.3661	0.2836	0.3209	0.351	0.2474	0.5193	0.3419	0.251	0.2645	0.2943	0.3431	0.2957	0.3176	0.1732	0.3028	0.2411	0.5078	0.3458	0.2211	0.2576	0.2694	0.3632	0.5193	gnomADe_EAS		0&1	0&1							FAIL	16	14	-6	-9	0.00	0.00	0.00	0.00	KDM5A		2.7000e-01																																																											57					0.895							241.93	v6.1	Unknown		True	KDM5A, a histone methyltransferase, is altered by chromosomal rearrangement and amplification in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KDM5A ENSP00000382688.2:S1383= mutant UNKNOWN.	False	The KDM5A ENSP00000382688.2:s1383= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	406292						True	False	False	Unknown								False	False		KDM5A, a histone methyltransferase, is altered by chromosomal rearrangement and amplification in various cancer types.	The KDM5A ENSP00000382688.2:s1383= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KDM5A ENSP00000382688.2:S1383= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	KDM5A	5927.0	ENSP00000382688.2:S1383=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KDM5A"",""entrezGeneId"":5927,""alteration"":""ENSP00000382688.2:S1383="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KDM5A, a histone methyltransferase, is altered by chromosomal rearrangement and amplification in various cancer types."",""variantSummary"":""The KDM5A ENSP00000382688.2:s1383= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KDM5A ENSP00000382688.2:S1383= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						26,25	11,10	15,15	0/1	16,10,15,10	CGG	0.00	0.00	0.00			13,13,18,7	32.81		0.49019607843137253
GRCh38	KDM5A	D12_12345_1234556_Thyroid_S9	p.M865T	ENSP00000382688.2:p.Met865Thr	chr12	318409	318409.0	A	G	G	318409	.	A	G	.	PASS	NM_001042603	G	missense_variant	MODERATE	KDM5A	ENSG00000073614	Transcript	ENST00000399788	protein_coding	19/28		c.2594T>C	2823	2594	865	M/T	aTg/aCg	rs11062385&COSV66991468		-1		SNV	HGNC	HGNC:9886	YES	MANE_Select	NM_001042603.3		1	P1	CCDS41736.1	ENSP00000382688	P29375.220		UPI0000DB2E73	P29375-1		1	tolerated(0.25)		Coiled-coils_(Ncoils):Coil&PANTHER:PTHR10694&Pfam:PF08429&AFDB-ENSP_mappings:AF-P29375-F1			0.3530	0.3321	0.3199	0.5109	0.2326	0.3661	0.2835	0.3212	0.3508	0.2503	0.5193	0.3421	0.251	0.2642	0.2943	0.3432	0.2958	0.3178	0.1732	0.3027	0.2441	0.5099	0.3448	0.2211	0.2575	0.2694	0.3638	0.5193	gnomADe_EAS	benign	0&1	1&1	17952073&34691999&29030403&21562575						FAIL	42	-32	-12	42	0.00	0.00	0.00	0.00	KDM5A	0.054	2.7000e-01	1255235	0.27340		0.35304	1245167	not_provided		MedGen:C3661900		NC_000012.12:g.318409A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001871613&SCV005234081	single_nucleotide_variant	SO:0001483	ClinGen:CA6379023		KDM5A:5927	SO:0001583&missense_variant										1	11062385																											157					0.955							238.58	v6.1	Unknown		True	KDM5A, a histone methyltransferase, is altered by chromosomal rearrangement and amplification in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KDM5A ENSP00000382688.2:M865T mutant UNKNOWN.	False	The KDM5A ENSP00000382688.2:m865t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	427575						True	False	False	Unknown								False	False		KDM5A, a histone methyltransferase, is altered by chromosomal rearrangement and amplification in various cancer types.	The KDM5A ENSP00000382688.2:m865t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KDM5A ENSP00000382688.2:M865T mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	KDM5A	5927.0	ENSP00000382688.2:M865T			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KDM5A"",""entrezGeneId"":5927,""alteration"":""ENSP00000382688.2:M865T"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KDM5A, a histone methyltransferase, is altered by chromosomal rearrangement and amplification in various cancer types."",""variantSummary"":""The KDM5A ENSP00000382688.2:m865t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KDM5A ENSP00000382688.2:M865T mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						70,80	42,39	28,41	0/1	39,31,38,42	CAT	.	.	.			45,25,49,31	41.78		0.5333333333333333
GRCh38	WNK1	D12_12345_1234556_Thyroid_S9			chr12	779154	779154.0	G	A	A	779154	.	G	A	.	PASS		A	intron_variant	MODIFIER	WNK1	ENSG00000060237	Transcript	ENST00000537687	protein_coding		1/27	c.759+24830G>A						rs2107612&COSV60024787		1		SNV	HGNC	HGNC:14540					5	A2		ENSP00000444465	Q9H4A3.225		UPI0001D411C7	Q9H4A3-6		1						0.7117	0.5756	0.7406	0.87	0.7207	0.7025											0.7049	0.6302	0.7912	0.7369	0.632	0.8717	0.7533	0.6463	0.7258	0.6823	0.7154	0.8717	gnomADg_EAS		0&1	0&1	29121662&33406744&34721519&21611176&32195283&25763762&19083859&19347040&21520334&27294018&19948332						FAIL	2	17	-8	25	0.00	0.00	0.00	0.00	WNK1		2.5900e-01																																																											100					0.97							243.53													chr12	888320																																																	True	False	False	Unknown		Unknown																						51,46	25,26	26,20	0/1	19,32,28,18	TGC	0.00	0.00	0.00			25,26,20,26	32.76		0.4742268041237113
GRCh38	FGF23	D12_12345_1234556_Thyroid_S9	p.T239M	ENSP00000237837.1:p.Thr239Met	chr12	4370383	4370383.0	G	A	A	4370383	.	G	A	.	PASS	NM_020638	A	missense_variant	MODERATE	FGF23	ENSG00000118972	Transcript	ENST00000237837	protein_coding	3/3		c.716C>T	846	716	239	T/M	aCg/aTg	rs7955866&CM123510&COSV52976898		-1		SNV	HGNC	HGNC:3680	YES	MANE_Select	NM_020638.3		1	P1	CCDS8526.1	ENSP00000237837	Q9GZV9.217		UPI000003ED58			1	tolerated_low_confidence(0.15)	benign(0)	PDB-ENSP_mappings:7ysh.B&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q9GZV9-F1			0.1474	0.0885	0.219	0.2302	0.1193	0.1196	0.118	0.08704	0.2014	0.067	0.1626	0.1214	0.06709	0.1161	0.116	0.1096	0.1158	0.08152	0.09649	0.199	0.0625	0.2067	0.1246	0.05102	0.1133	0.1203	0.1108	0.2302	EAS	benign	0&1&1	1&1&1	21565945&21050253&35205271&34490035&29336609&25445451&20394945&11062477&22419710&24053368&25257970&36907780&32879300&36699452&36719157&32039214&33462484&30900415&37284066&26543054&33142950&37228872&37761831						FAIL	-41	41	38	-41	0.00	0.00	0.00	0.00	FGF23	0.189	1.6080e+00	308803	0.10534	0.12388	0.14736	330952	Autosomal_dominant_hypophosphatemic_rickets&not_specified&not_provided&Tumoral_calcinosis&_hyperphosphatemic&_familial&_2		MONDO:MONDO:0008660&MedGen:C0342642&OMIM:193100&Orphanet:89937&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0060714&MedGen:C4693863&OMIM:617993		NC_000012.12:g.4370383G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000378837&SCV000378838&SCV000613286&SCV000711884&SCV001718213&SCV001829983&SCV005234768	single_nucleotide_variant	SO:0001483	ClinGen:CA6395616&UniProtKB:Q9GZV9																																																																																																																																															454,404	245,203	209,201	0/1	241,213,208,196	CGT	0.00	0.00	0.00			266,188,241,163	31.18		0.47086247086247085
GRCh38	FGF23	D12_12345_1234556_Thyroid_S9			chr12	4373807	4373807.0	T	C	C	4373807	.	T	C	.	PASS	NM_020638	C	intron_variant	MODIFIER	FGF23	ENSG00000118972	Transcript	ENST00000237837	protein_coding		1/2	c.212-1110A>G						rs10744644		-1		SNV	HGNC	HGNC:3680	YES	MANE_Select	NM_020638.3		1	P1	CCDS8526.1	ENSP00000237837	Q9GZV9.217		UPI000003ED58			1						0.9373	0.885	0.9568	0.9435	0.9771	0.9468											0.9488	0.8901	0.9451	0.9533	0.9793	0.9609	0.9748	0.9762	0.9771	0.9461	0.9488	0.9793	gnomADg_ASJ										FAIL	-34	47	-43	47	0.00	0.00	0.00	0.00	FGF23		1.6080e+00																																																											51					0.922							238.84													chr12	4482973																																																	True	True	False	Unknown		Unknown																						0,47	0,25	0,22	0/1	0,0,24,23	CTA	.	.	.			0,0,20,27	63.95		1.0
GRCh38	FGF23	D12_12345_1234556_Thyroid_S9			chr12	4374636	4374636.0	C	T	T	4374636	.	C	T	.	PASS	NM_020638	T	intron_variant	MODIFIER	FGF23	ENSG00000118972	Transcript	ENST00000237837	protein_coding		1/2	c.212-1939G>A						rs10774226		-1		SNV	HGNC	HGNC:3680	YES	MANE_Select	NM_020638.3		1	P1	CCDS8526.1	ENSP00000237837	Q9GZV9.217		UPI000003ED58			1						0.5459	0.5847	0.5058	0.4395	0.6948	0.4785											0.6572	0.6131	0.7582	0.5826	0.7829	0.4775	0.6701	0.7958	0.7105	0.671	0.5243	0.7958	gnomADg_MID										FAIL	7	10	11	16	0.00	0.00	0.00	0.00	FGF23		1.6080e+00																																																											187					0.898							164.07													chr12	4483802																																																	True	True	False	Unknown		Unknown																						77,91	35,34	42,57	0/1	41,36,43,48	GCG	0.00	0.00	0.00			59,18,68,23	43.93		0.5416666666666666
GRCh38	FGF23	D12_12345_1234556_Thyroid_S9			chr12	4374649	4374650.0	C	CA	CA	4374649	.	C	CA	.	PASS	NM_020638	A	intron_variant	MODIFIER	FGF23	ENSG00000118972	Transcript	ENST00000237837	protein_coding		1/2	c.212-1953dup						rs55658971		-1		insertion	HGNC	HGNC:3680	YES	MANE_Select	NM_020638.3		1	P1	CCDS8526.1	ENSP00000237837	Q9GZV9.217		UPI000003ED58			1						0.4325	0.2776	0.5389	0.6101	0.4354	0.3804											0.5213	0.3819	0.5656	0.6046	0.5555	0.7945	0.5369	0.5868	0.5541	0.5325	0.4995	0.7945	gnomADg_EAS										FAIL	-3	-27	2	3	0.00	0.00	0.00	0.00	FGF23		1.6080e+00																																																											280					0.85							203.79													chr12	4483815																																																	True	True	False	Unknown		Unknown																						146,92	58,38	88,54	0/1	77,69,49,43	TCA						89,57,53,39	10.98		0.3865546218487395
GRCh38	FGF23	D12_12345_1234556_Thyroid_S9			chr12	4375293	4375293.0	C	T	T	4375293	.	C	T	.	PASS	NM_020638	T	intron_variant	MODIFIER	FGF23	ENSG00000118972	Transcript	ENST00000237837	protein_coding		1/2	c.212-2596G>A						rs7976548		-1		SNV	HGNC	HGNC:3680	YES	MANE_Select	NM_020638.3		1	P1	CCDS8526.1	ENSP00000237837	Q9GZV9.217		UPI000003ED58			1						0.1460	0.0832	0.2161	0.2361	0.1113	0.1237											0.1171	0.07964	0.09211	0.1974	0.0602	0.2152	0.1448	0.05102	0.1134	0.1184	0.1203	0.2361	EAS										FAIL	-16	31	28	-32	0.00	0.00	0.00	0.00	FGF23		1.6080e+00																																																											1042					0.999							248.1													chr12	4484459																																																	True	True	False	Unknown		Unknown																						491,550	240,250	251,300	0/1	246,245,270,280	TCA	0.00	0.00	0.00			229,262,274,276	60.05		0.5283381364073007
GRCh38	FGF23	D12_12345_1234556_Thyroid_S9			chr12	4380069	4380069.0	T	C	C	4380069	.	T	C	.	PASS	NM_020638	C	upstream_gene_variant	MODIFIER	FGF23	ENSG00000118972	Transcript	ENST00000237837	protein_coding									rs3812822	357	-1		SNV	HGNC	HGNC:3680	YES	MANE_Select	NM_020638.3		1	P1	CCDS8526.1	ENSP00000237837	Q9GZV9.217		UPI000003ED58			1						0.1597	0.1293	0.2233	0.2371	0.1153	0.1217											0.1321	0.1207	0.09649	0.2098	0.06113	0.2156	0.1448	0.05102	0.1188	0.1319	0.116	0.2371	EAS	benign		1	29336609&32848883																		1181562			0.15974	1172428	not_provided		MedGen:C3661900		NC_000012.12:g.4380069T>C	criteria_provided&_single_submitter	Benign			SCV001756701	single_nucleotide_variant	SO:0001483	ClinGen:CA231763636		FGF23:8074											1	3812822																											366					0.989							248.19													chr12	4489235																																																	True	True	False	Unknown		Unknown																						169,193	91,108	78,85	0/1	92,77,87,106	TTT	.	.	.			80,89,64,129	51.77		0.5331491712707183
GRCh38	FGF6	D12_12345_1234556_Thyroid_S9			chr12	4439673	4439673.0	G	T	T	4439673	.	G	T	.	PASS	NM_020996	T	intron_variant	MODIFIER	FGF6	ENSG00000111241	Transcript	ENST00000228837	protein_coding		2/2	c.450+4460C>A						rs1354268606		-1		SNV	HGNC	HGNC:3684	YES	MANE_Select	NM_020996.3		1	P1	CCDS8527.1	ENSP00000228837	P10767.203	A0A7U3JW05.9	UPI00000411BF																									3.363e-05	0	0	0	0	0	0.000303	0	2.986e-05	0	0	0.000303	gnomADg_FIN										FAIL	-13	-3	-13	-3	0.00	0.00	0.00	0.00	FGF6		1.1690e+00																																																											348					0.845							236.85													chr12	4548839																																																	True	True	False	Unknown		Unknown																						274,20	141,9	133,11	0/1	166,108,9,11	TGT	0.00	0.00	1.00			155,119,10,10	11.8		0.06802721088435375
GRCh38	FGF6	D12_12345_1234556_Thyroid_S9			chr12	4440089	4440089.0	G	A	A	4440089	.	G	A	.	PASS	NM_020996	A	intron_variant	MODIFIER	FGF6	ENSG00000111241	Transcript	ENST00000228837	protein_coding		2/2	c.450+4044C>T						rs2270437		-1		SNV	HGNC	HGNC:3684	YES	MANE_Select	NM_020996.3		1	P1	CCDS8527.1	ENSP00000228837	P10767.203	A0A7U3JW05.9	UPI00000411BF									0.5138	0.2814	0.6758	0.5942	0.6809	0.4581											0.5545	0.3142	0.6678	0.662	0.68	0.6228	0.6271	0.6054	0.6547	0.6058	0.4981	0.6809	EUR										FAIL	-17	21	36	-15	0.00	0.00	0.00	0.00	FGF6		1.1690e+00																																																											464					0.998							248.08													chr12	4549255																																																	True	True	False	Unknown		Unknown																						0,463	0,218	0,245	0/1	0,0,255,208	CGC	0.00	0.00	0.00			0,0,182,281	64.73		1.0
GRCh38	FGF6	D12_12345_1234556_Thyroid_S9	p.Ala63=	ENSP00000228837.2:p.Ala63=	chr12	4445382	4445382.0	G	C	C	4445382	.	G	C	.	PASS	NM_020996	C	synonymous_variant	LOW	FGF6	ENSG00000111241	Transcript	ENST00000228837	protein_coding	1/3		c.189C>G	434	189	63	A	gcC/gcG	rs7358740&COSV57404741		-1		SNV	HGNC	HGNC:3684	YES	MANE_Select	NM_020996.3		1	P1	CCDS8527.1	ENSP00000228837	P10767.203	A0A7U3JW05.9	UPI00000411BF						Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P10767-F1			0.9032	0.652	0.9669	1	0.998	1	0.991	0.6995	0.9806	0.9982	1	0.9998	0.9801	0.9993	0.9796	0.9992	0.9154	0.7089	1	0.9642	0.9977	1	0.9999	0.9795	0.9986	0.9365	0.9988	1	EAS&SAS&gnomADe_EAS&gnomADg_AMI&gnomADg_EAS		0&1	0&1							FAIL	10	33	10	-24	0.00	0.00	0.01	0.00	FGF6		1.1690e+00																																																											1112					0.999							245.58	v6.1	Unknown		True	FGF6, a fibroblast growth factor, is infrequently altered in cancer.	False	11/17/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF6 ENSP00000228837.2:A63= mutant UNKNOWN.	False	The FGF6 ENSP00000228837.2:a63= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	4554548						True	False	False	Unknown								False	False		FGF6, a fibroblast growth factor, is infrequently altered in cancer.	The FGF6 ENSP00000228837.2:a63= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF6 ENSP00000228837.2:A63= mutant UNKNOWN.						v6.1	11/17/2023		GRCh38	FGF6	2251.0	ENSP00000228837.2:A63=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGF6"",""entrezGeneId"":2251,""alteration"":""ENSP00000228837.2:A63="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGF6, a fibroblast growth factor, is infrequently altered in cancer."",""variantSummary"":""The FGF6 ENSP00000228837.2:a63= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF6 ENSP00000228837.2:A63= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/17/2023""}"	True	True	False	Unknown		Unknown																						0,1111	0,597	0,514	0/1	0,0,557,554	CGG	.	.	.			0,0,561,550	64.73		1.0
GRCh38	FGF6	D12_12345_1234556_Thyroid_S9			chr12	4448431	4448431.0	C	A	A	4448431	.	C	A	.	PASS	NM_020996	A	upstream_gene_variant	MODIFIER	FGF6	ENSG00000111241	Transcript	ENST00000228837	protein_coding									rs2909379	2616	-1		SNV	HGNC	HGNC:3684	YES	MANE_Select	NM_020996.3		1	P1	CCDS8527.1	ENSP00000228837	P10767.203	A0A7U3JW05.9	UPI00000411BF									0.2458	0.1188	0.2594	0.2034	0.2962	0.3998											0.2668	0.1454	0.4064	0.2717	0.3329	0.18	0.3519	0.3435	0.3196	0.269	0.3793	0.4064	gnomADg_AMI			1	36224396																																																																												113					0.982							235.52													chr12	4557597																																																	True	True	False	Unknown		Unknown																						63,48	31,25	32,23	0/1	31,32,23,25	ACC	0.00	0.00	0.00			31,32,32,16	27.17		0.43243243243243246
GRCh38	CHD4	D12_12345_1234556_Thyroid_S9	p.G1293E	ENSP00000440542.2:p.Gly1293Glu	chr12	6587385	6587385.0	C	T	T	6587385	.	C	T	.	PASS	NM_001273	T	missense_variant&splice_region_variant	MODERATE	CHD4	ENSG00000111642	Transcript	ENST00000544040	protein_coding	25/40		c.3878G>A	4036	3878	1293	G/E	gGg/gAg			-1		SNV	HGNC	HGNC:1919	YES	MANE_Select	NM_001273.5		5	P4	CCDS8552.1	ENSP00000440542	Q14839.243		UPI000013C8EF	Q14839-1		1	deleterious_low_confidence(0)	benign(0.018)	PDB-ENSP_mappings:6ryr.W&PDB-ENSP_mappings:6ryu.V&PDB-ENSP_mappings:6ryu.W&AFDB-ENSP_mappings:AF-Q14839-F1&Coiled-coils_(Ncoils):Coil&PANTHER:PTHR45623&SMART:SM01147&Low_complexity_(Seg):seg																																									FAIL	44	20	-1	20	0.00	0.00	0.00	0.00	CHD4	0.404	1.9200e-01																																																											155					0.942							232.28	v6.1	Unknown		True	CHD4, a helicase, is infrequently altered in cancer.	False	05/31/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD4 ENSP00000440542.2:G1293E mutant UNKNOWN.	False	The CHD4 ENSP00000440542.2:g1293e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	6696551						True	False	False	Unknown								False	False		CHD4, a helicase, is infrequently altered in cancer.	The CHD4 ENSP00000440542.2:g1293e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD4 ENSP00000440542.2:G1293E mutant UNKNOWN.						v6.1	05/31/2023		GRCh38	CHD4	1108.0	ENSP00000440542.2:G1293E			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CHD4"",""entrezGeneId"":1108,""alteration"":""ENSP00000440542.2:G1293E"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CHD4, a helicase, is infrequently altered in cancer."",""variantSummary"":""The CHD4 ENSP00000440542.2:g1293e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD4 ENSP00000440542.2:G1293E mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/31/2023""}"	True	True	False	Unknown		Unknown																						143,3	82,1	61,2	0/1	77,66,2,1	CCC	0.00	0.00	1.00			90,53,2,1	5.16		0.02054794520547945
GRCh38	CHD4	D12_12345_1234556_Thyroid_S9	p.E139D	ENSP00000440542.2:p.Glu139Asp	chr12	6601981	6601981.0	C	A	A	6601981	.	C	A	.	PASS	NM_001273	A	missense_variant	MODERATE	CHD4	ENSG00000111642	Transcript	ENST00000544040	protein_coding	4/40		c.417G>T	575	417	139	E/D	gaG/gaT	rs1639122&COSV58895130		-1		SNV	HGNC	HGNC:1919	YES	MANE_Select	NM_001273.5		5	P4	CCDS8552.1	ENSP00000440542	Q14839.243		UPI000013C8EF	Q14839-1		1	tolerated_low_confidence(1)	benign(0)	PDB-ENSP_mappings:6ryr.W&PDB-ENSP_mappings:6ryu.V&PDB-ENSP_mappings:6ryu.W&AFDB-ENSP_mappings:AF-Q14839-F1&PANTHER:PTHR45623&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.5531	0.9009	0.3617	0.4821	0.4066	0.4427	0.4209	0.7808	0.373	0.2636	0.4144	0.4823	0.2757	0.4155	0.4227	0.402	0.5326	0.8404	0.3477	0.4072	0.2686	0.444	0.4962	0.2705	0.4165	0.4405	0.4104	0.9009	AFR	benign	0&1	1&1	32390946&25407497&18340469&28619829&32888493&32888494&30595370						FAIL	-21	43	-47	-23	0.00	0.00	0.01	0.00	CHD4	0.217	1.9200e-01	1209824	0.54874		0.55312	1199805	Thalidomide_response&not_provided&Sifrim-Hitz-Weiss_syndrome		MedGen:CN297989&MedGen:C3661900&MONDO:MONDO:0014946&MedGen:C4310688&OMIM:617159&Orphanet:653712		NC_000012.12:g.6601981C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001806645&SCV002410642&SCV005237357	single_nucleotide_variant	SO:0001483	ClinGen:CA6412525		CHD4:1108	SO:0001583&missense_variant										1	1639122																											407					0.855							244.2	v6.1	Unknown		True	CHD4, a helicase, is infrequently altered in cancer.	False	05/31/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD4 ENSP00000440542.2:E139D mutant UNKNOWN.	False	The CHD4 ENSP00000440542.2:e139d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	6711147						True	False	False	Unknown								False	False		CHD4, a helicase, is infrequently altered in cancer.	The CHD4 ENSP00000440542.2:e139d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD4 ENSP00000440542.2:E139D mutant UNKNOWN.						v6.1	05/31/2023		GRCh38	CHD4	1108.0	ENSP00000440542.2:E139D			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CHD4"",""entrezGeneId"":1108,""alteration"":""ENSP00000440542.2:E139D"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CHD4, a helicase, is infrequently altered in cancer."",""variantSummary"":""The CHD4 ENSP00000440542.2:e139d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD4 ENSP00000440542.2:E139D mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/31/2023""}"	True	True	False	Unknown		Unknown																						211,137	119,76	92,61	0/1	107,104,67,70	CCT	0.00	0.00	0.00			151,60,92,45	11.8		0.3936781609195402
GRCh38	GNB3	D12_12345_1234556_Thyroid_S9			chr12	6836750	6836750.0	C	G	G	6836750	.	C	G	.	PASS		G	upstream_gene_variant	MODIFIER	GNB3	ENSG00000111664	Transcript	ENST00000675241	protein_coding									rs2269355	3461	1	cds_end_NF	SNV	HGNC	HGNC:4400								ENSP00000501677		A0A6Q8PF84.16	UPI000016A2CE			1																						0.4666	0.5266	0.5209	0.4819	0.5055	0.5721	0.3344	0.5	0.4296	0.4981	0.5454	0.5721	gnomADg_EAS				26522768&26691610&29121662&33406744&34721519&33857205&19876010&35627269&27294018&35784409&38605929																																																																												850					0.998							247.07													chr12	6945914																																																	True	False	False	Unknown		Unknown																						416,432	220,212	196,220	0/1	186,230,219,213	TCC	.	.	.			222,194,245,187	58.68		0.5094339622641509
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9	p.Thr86=	ENSP00000379658.3:p.Thr86=	chr12	11839234	11839234.0	G	A	A	11839234	.	G	A	.	PASS	NM_001987	A	synonymous_variant	LOW	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding	3/8		c.258G>A	712	258	86	T	acG/acA	rs11611479&COSV67147941		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1			PDB-ENSP_mappings:1ji7.A&PDB-ENSP_mappings:1ji7.B&PDB-ENSP_mappings:1ji7.C&PDB-ENSP_mappings:1lky.A&PDB-ENSP_mappings:1lky.B&PDB-ENSP_mappings:1lky.C&PDB-ENSP_mappings:1lky.D&PDB-ENSP_mappings:1lky.E&PDB-ENSP_mappings:1lky.F&PDB-ENSP_mappings:2qar.A&PDB-ENSP_mappings:2qar.B&PDB-ENSP_mappings:2qar.D&PDB-ENSP_mappings:2qar.E&PDB-ENSP_mappings:2qb0.A&PDB-ENSP_mappings:2qb0.C&PDB-ENSP_mappings:2qb1.A&PDB-ENSP_mappings:2qb1.B&PDB-ENSP_mappings:5l0p.A&PDB-ENSP_mappings:7ju2.A&PDB-ENSP_mappings:7ju2.B&PDB-ENSP_mappings:7n1o.A&PDB-ENSP_mappings:7n2b.A&PDB-ENSP_mappings:7n2b.B&PDB-ENSP_mappings:7t8j.A&PDB-ENSP_mappings:7tdy.A&PDB-ENSP_mappings:7tw7.A&PDB-ENSP_mappings:7tw8.A&PDB-ENSP_mappings:7tw9.A&PDB-ENSP_mappings:7u4w.A&PDB-ENSP_mappings:7u4z.A&PDB-ENSP_mappings:8bwu.A&PDB-ENSP_mappings:8e1f.A&PDB-ENSP_mappings:8e1f.B&PDB-ENSP_mappings:8e1f.C&PDB-ENSP_mappings:8e1f.D&PDB-ENSP_mappings:8frj.A&PDB-ENSP_mappings:8frk.A&PDB-ENSP_mappings:8ft6.A&PDB-ENSP_mappings:8ft8.A&PDB-ENSP_mappings:8fz3.A&PDB-ENSP_mappings:8fz3.B&PDB-ENSP_mappings:8fz3.C&PDB-ENSP_mappings:8fz3.D&PDB-ENSP_mappings:8fzu.A&PDB-ENSP_mappings:8fzu.B&PDB-ENSP_mappings:8fzu.C&PDB-ENSP_mappings:8fzv.A&PDB-ENSP_mappings:8fzv.B&PDB-ENSP_mappings:8fzv.C&PDB-ENSP_mappings:8tha.A&PDB-ENSP_mappings:9cpl.A&PDB-ENSP_mappings:9feh.A&Superfamily:SSF47769&PANTHER:PTHR11849&Gene3D:1.10.150.50&Pfam:PF02198&CDD:cd08535&PROSITE_profiles:PS51433&SMART:SM00251&AFDB-ENSP_mappings:AF-P41212-F1			0.2129	0.23	0.111	0.2192	0.1093	0.362	0.128	0.1999	0.09475	0.1315	0.1811	0.09625	0.138	0.1128	0.1395	0.2978	0.144	0.1955	0.1776	0.1073	0.1256	0.2215	0.09442	0.119	0.1105	0.1362	0.3285	0.362	SAS	benign	0&1	1&1	34641967						FAIL	2	-18	6	-18	0.00	0.00	0.00	0.00	ETV6		4.4000e-01	1272565	0.13086	0.15193	0.21286	1262030	not_provided&Inborn_genetic_diseases		MedGen:C3661900&MeSH:D030342&MedGen:C0950123		NC_000012.12:g.11839234G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001903171&SCV002049324&SCV003237167&SCV005233592&SCV005587785	single_nucleotide_variant	SO:0001483	ClinGen:CA6454187		ETV6:2120&LOC126861451:126861451	SO:0001819&synonymous_variant										1	11611479																											274					0.985							246.27	v6.1	Unknown		True	ETV6, a transcription factor, is frequently altered by chromosomal rearrangement in hematologic malignancies.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV6 ENSP00000379658.3:T86= mutant UNKNOWN.	False	The ETV6 ENSP00000379658.3:t86= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	11992168						True	False	False	Unknown								False	False		ETV6, a transcription factor, is frequently altered by chromosomal rearrangement in hematologic malignancies.	The ETV6 ENSP00000379658.3:t86= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV6 ENSP00000379658.3:T86= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	ETV6	2120.0	ENSP00000379658.3:T86=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ETV6"",""entrezGeneId"":2120,""alteration"":""ENSP00000379658.3:T86="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ETV6, a transcription factor, is frequently altered by chromosomal rearrangement in hematologic malignancies."",""variantSummary"":""The ETV6 ENSP00000379658.3:t86= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV6 ENSP00000379658.3:T86= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						145,125	79,69	66,56	0/1	83,62,74,51	CGT	0.00	0.00	0.00			61,84,52,73	31.21		0.46296296296296297
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11854409	11854409.0	G	C	C	11854409	.	G	C	.	PASS	NM_001987	C	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+848G>C						rs2710266		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3269	0.0998	0.3285	0.1935	0.5169	0.5746											0.4013	0.1567	0.6347	0.3801	0.5026	0.1796	0.5133	0.568	0.5314	0.4372	0.5884	0.6347	gnomADg_AMI										FAIL	7	-44	-34	39	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											732					1							228.51													chr12	12007343																																																	True	True	False	Unknown		Unknown																						0,732	0,353	0,379	0/1	0,0,340,392	CGC	.	.	.			0,0,279,453	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11855139	11855140.0	CA	C	C	11855139	.	CA	C	.	PASS	NM_001987	-	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+1595del						rs34202702		1		deletion	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1					16	0.3580	0.177	0.3271	0.2192	0.5298	0.591											0.3947	0.1578	0.5914	0.3774	0.4973	0.184	0.4693	0.554	0.516	0.425	0.5837	0.5914	gnomADg_AMI										FAIL	38	22	-4	-27	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											83					0.723							89.58													chr12	12008073																																																	True	True	False	Unknown		Unknown																						20,40	11,12	9,28	0/1	12,8,17,23	ACA						11,9,21,19	20.48		0.6666666666666666
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11857802	11857802.0	C	T	T	11857802	.	C	T	.	PASS	NM_001987	T	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+4241C>T						rs2255953		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.6470	0.5182	0.6873	0.4405	0.7694	0.8793											0.7029	0.547	0.8651	0.7358	0.8228	0.4231	0.6726	0.8571	0.795	0.7386	0.8657	0.8793	SAS				24714607&25234806						FAIL	21	-29	-16	33	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											88					0.943							241.3													chr12	12010736																																																	True	True	False	Unknown		Unknown																						0,83	0,43	0,40	0/1	0,0,42,41	TCC	0.00	0.00	0.00			0,0,36,47	64.6		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11858405	11858406.0	T	TA	TA	11858405	.	T	TA	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+4844_463+4845insA						rs35490088		1		insertion	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3365	0.0908	0.3314	0.2431	0.5179	0.5818											0.3599	0.1449	0.5705	0.3418	0.4432	0.2282	0.4005	0.493	0.4706	0.3965	0.544	0.5818	SAS										FAIL	-43	29	29	-10	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											51					0.725							230.51													chr12	12011339																																																	True	True	False	Unknown		Unknown																						4,33	1,21	3,12	0|1	1,3,20,13	ATT					12011339	2,2,20,13	50.43		0.8918918918918919
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11858406	11858407.0	T	TA	TA	11858406	.	T	TA	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+4845_463+4846insA						rs200339462		1		insertion	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3365	0.0908	0.3314	0.2431	0.5179	0.5818											0.3569	0.1352	0.5772	0.343	0.4469	0.2279	0.4042	0.5036	0.4757	0.3935	0.5405	0.5818	SAS										FAIL	-44	28	28	-11	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											49					0.653							226.01													chr12	12011340																																																	True	True	False	Unknown		Unknown																						0,32	0,20	0,12	0|1	0,0,20,12	TTT					12011339	0,0,20,12	54.24		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11858586	11858586.0	G	A	A	11858586	.	G	A	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+5025G>A						rs17819115		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.2949	0.0265	0.2954	0.1825	0.495	0.5675											0.368	0.09324	0.6382	0.3399	0.4594	0.1709	0.4619	0.4626	0.518	0.3949	0.5783	0.6382	gnomADg_AMI										FAIL	2	-25	2	12	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											130					0.954							235.14													chr12	12011520																																																	True	True	False	Unknown		Unknown																						0,124	0,66	0,58	0/1	0,0,60,64	CGG	0.00	0.00	0.00			0,0,58,66	64.71		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11858832	11858833.0	AG	A	A	11858832	.	AG	A	.	PASS	NM_001987	-	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+5273del						rs201629816		1		deletion	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1					1																	0.3757	0.1248	0.6353	0.3456	0.4608	0.1619	0.4569	0.4694	0.5155	0.4051	0.5752	0.6353	gnomADg_AMI										FAIL	50	-26	21	-26	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											117					0.983							242.39													chr12	12011766																																																	True	True	False	Unknown		Unknown																						0,115	0,61	0,54	0|1	0,0,54,61	GAG					12011766	0,0,66,49	56.46		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11858836	11858838.0	GAA	G	G	11858836	.	GAA	G	.	PASS	NM_001987	-	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+5276_463+5277del						rs66946835		1		deletion	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1																						0.3749	0.124	0.6339	0.345	0.4608	0.1623	0.4564	0.4694	0.5153	0.4049	0.5754	0.6339	gnomADg_AMI										FAIL	50	-30	17	-30	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											123					0.992							243.17													chr12	12011770																																																	True	True	False	Unknown		Unknown																						0,122	0,63	0,59	0|1	0,0,60,62	AGA					12011766	0,0,73,49	56.46		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11859172	11859172.0	T	C	C	11859172	.	T	C	.	PASS	NM_001987	C	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+5611T>C						rs10845413		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.9207	0.7806	0.9323	0.999	0.9483	0.9928											0.9059	0.8036	0.9651	0.94	0.9639	0.9982	0.9399	0.9797	0.9328	0.9135	0.9926	0.999	EAS										FAIL	-6	15	28	-16	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											106					0.943							65.99													chr12	12012106																																																	True	True	False	Unknown		Unknown																						0,100	0,56	0,44	0/1	0,0,47,53	TTG	.	.	.			0,0,3,97	64.67		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11859747	11859747.0	T	C	C	11859747	.	T	C	.	PASS	NM_001987	C	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+6186T>C						rs2723804		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3462	0.1127	0.3357	0.245	0.5219	0.593											0.4054	0.1565	0.6546	0.3902	0.5159	0.2309	0.4693	0.589	0.5391	0.45	0.602	0.6546	gnomADg_AMI										FAIL	-2	34	3	-2	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											217					0.977							245.26													chr12	12012681																																																	True	True	False	Unknown		Unknown																						0,212	0,94	0,118	0/1	0,0,109,103	GTA	.	.	.			0,0,117,95	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11859867	11859867.0	A	G	G	11859867	.	A	G	.	PASS	NM_001987	G	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+6306A>G						rs2855706		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.9659	0.8812	0.9798	1	1	1											0.9705	0.898	1	0.9869	1	1	1	0.9932	0.9998	0.9787	1	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_SAS										FAIL	-21	34	-43	-16	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											315					0.994							246.1													chr12	12012801																																																	True	True	False	Unknown		Unknown																						0,313	0,153	0,160	0/1	0,0,175,138	CAT	.	.	.			0,0,185,128	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11860255	11860255.0	A	G	G	11860255	.	A	G	.	PASS	NM_001987	G	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+6694A>G						rs2723803		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3261	0.0847	0.3271	0.1964	0.5209	0.5849											0.396	0.1421	0.6538	0.3835	0.5107	0.1863	0.468	0.5918	0.5327	0.4444	0.5963	0.6538	gnomADg_AMI										FAIL	1	19	-1	19	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											1003					1							246.95													chr12	12013189																																																	True	True	False	Unknown		Unknown																						0,1003	0,508	0,495	0/1	0,0,494,509	AAT	.	.	.			0,0,467,536	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11860358	11860358.0	G	A	A	11860358	.	G	A	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+6797G>A						rs2855707		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3249	0.0855	0.3271	0.1944	0.5169	0.5838											0.3957	0.1424	0.6546	0.383	0.5101	0.1829	0.4688	0.5918	0.5323	0.4425	0.5933	0.6546	gnomADg_AMI										FAIL	2	-16	4	0	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											812					1							245.28													chr12	12013292																																																	True	True	False	Unknown		Unknown																						0,812	0,413	0,399	0/1	0,0,434,378	CGG	0.00	0.00	0.00			0,0,393,419	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11860638	11860638.0	G	A	A	11860638	.	G	A	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+7077G>A						rs2855708		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.6272	0.5136	0.6499	0.4415	0.7266	0.8538											0.6652	0.5387	0.8571	0.698	0.7879	0.4235	0.6114	0.8503	0.7375	0.7085	0.8453	0.8571	gnomADg_AMI				27145994&24714607&25234806						FAIL	2	0	47	0	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											256					0.941							239.45													chr12	12013572																																																	True	True	False	Unknown		Unknown																						0,241	0,111	0,130	0/1	0,0,133,108	CGG	0.00	0.00	0.00			0,0,81,160	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11861051	11861051.0	C	A	A	11861051	.	C	A	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+7490C>A						rs2855709		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3662	0.1581	0.3775	0.1935	0.5636	0.6145											0.4536	0.2171	0.6612	0.4288	0.5513	0.1837	0.528	0.6054	0.591	0.4896	0.6218	0.6612	gnomADg_AMI										FAIL	2	9	-4	-26	0.00	0.01	0.00	0.00	ETV6		4.4000e-01																																																											269					0.993							245.72													chr12	12013985																																																	True	True	False	Unknown		Unknown																						0,267	0,142	0,125	0/1	0,0,140,127	CCC	0.00	0.00	0.00			0,0,159,108	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11861490	11861490.0	G	A	A	11861490	.	G	A	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.463+7929G>A						rs2238129		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3259	0.0855	0.33	0.1935	0.5139	0.591											0.3959	0.1435	0.6336	0.3831	0.5144	0.1814	0.4687	0.5884	0.5314	0.4393	0.5995	0.6336	gnomADg_AMI										FAIL	2	12	-50	12	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											1026					0.999							246.87													chr12	12014424																																																	True	True	False	Unknown		Unknown																						0,1025	0,558	0,467	0/1	0,0,509,516	CGG	0.00	0.00	0.00			0,0,496,529	64.73		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11862467	11862467.0	G	A	A	11862467	.	G	A	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-6957G>A						rs2710269		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3684	0.1679	0.3818	0.1925	0.5666	0.6074											0.4563	0.2257	0.6612	0.4306	0.5507	0.1838	0.5282	0.602	0.5916	0.4962	0.6142	0.6612	gnomADg_AMI										FAIL	2	10	2	10	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											126					0.889							229.98													chr12	12015401																																																	True	True	False	Unknown		Unknown																						0,112	0,60	0,52	0/1	0,0,55,57	GGG	0.00	0.00	0.00			0,0,59,53	64.7		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11863074	11863074.0	G	A	A	11863074	.	G	A	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-6350G>A						rs2238130		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.8437	0.6505	0.8876	0.9048	0.9125	0.9397											0.8396	0.6826	0.9319	0.9011	0.9191	0.9089	0.8699	0.9558	0.8972	0.8672	0.9462	0.9558	gnomADg_MID										FAIL	2	-24	3	20	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											127					0.961							234.47													chr12	12016008																																																	True	True	False	Unknown		Unknown																						0,122	0,53	0,69	0/1	0,0,57,65	CGG	0.00	0.00	0.00			0,0,60,62	64.71		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11863111	11863111.0	C	T	T	11863111	.	C	T	.	PASS	NM_001987	T	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-6313C>T						rs2416944		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3075	0.0741	0.2997	0.1756	0.494	0.5726											0.3768	0.1296	0.6154	0.3446	0.4591	0.1614	0.4595	0.4762	0.5151	0.4038	0.5842	0.6154	gnomADg_AMI										FAIL	-17	-46	-17	36	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											115					0.957							241.33													chr12	12016045																																																	True	True	False	Unknown		Unknown																						1,109	1,52	0,57	0/1	0,1,51,58	ACT	0.00	0.00	0.00			0,1,48,61	64.68		0.990909090909091
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11863249	11863249.0	G	T	T	11863249	.	G	T	.	PASS	NM_001987	T	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-6175G>T						rs928936		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.2877	0.1021	0.2608	0.1716	0.4185	0.5429											0.3206	0.1402	0.4692	0.3007	0.4248	0.1547	0.3387	0.4932	0.4209	0.3592	0.5288	0.5429	SAS										FAIL	46	-32	-19	-1	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											123					0.984							237.34													chr12	12016183																																																	True	True	False	Unknown		Unknown																						0,121	0,51	0,70	0/1	0,0,55,66	TGT	0.00	0.00	0.00			0,0,55,66	64.71		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11864351	11864351.0	T	C	C	11864351	.	T	C	.	PASS	NM_001987	C	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-5073T>C						rs2723843		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.9946	0.9811	0.9971	1	1	1											0.9951	0.9835	1	0.9986	1	1	0.9996	1	0.9997	0.9957	0.9996	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_MID										FAIL	-49	-50	38	-50	0.00	0.00	0.00	0.01	ETV6		4.4000e-01																																																											162					0.988							244.21													chr12	12017285																																																	True	True	False	Unknown		Unknown																						0,160	0,81	0,79	0/1	0,0,79,81	ATG	.	.	.			0,0,72,88	64.72		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11865108	11865108.0	A	G	G	11865108	.	A	G	.	PASS	NM_001987	G	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-4316A>G						rs2710270		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.9942	0.9803	0.9957	1	1	1											0.9953	0.9834	1	0.9986	1	1	1	1	0.9999	0.9967	1	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_SAS										FAIL	-8	-2	-40	1	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											52					0.962							82.94													chr12	12018042																																																	True	True	False	Unknown		Unknown																						0,50	0,23	0,27	0/1	0,0,29,21	CAG	.	.	.			0,0,20,30	64.07		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11867180	11867180.0	C	T	T	11867180	.	C	T	.	PASS	NM_001987	T	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-2244C>T						rs2723805		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.5162	0.5393	0.4467	0.3313	0.6252	0.6125											0.5982	0.5655	0.7181	0.4947	0.5806	0.3089	0.616	0.585	0.6582	0.6071	0.6195	0.7181	gnomADg_AMI										FAIL	11	10	-29	10	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											91					0.956							231.48													chr12	12020114																																																	True	True	False	Unknown		Unknown																						0,87	0,37	0,50	0/1	0,0,42,45	ACC	0.00	0.00	0.00			0,0,44,43	64.63		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11867236	11867236.0	C	T	T	11867236	.	C	T	.	PASS	NM_001987	T	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-2188C>T						rs7973930		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3952	0.298	0.3804	0.2202	0.5497	0.5583											0.4758	0.3369	0.6495	0.4228	0.4954	0.202	0.5	0.4728	0.579	0.4929	0.5699	0.6495	gnomADg_AMI										FAIL	16	-46	19	-37	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											94					0.968							238.15													chr12	12020170																																																	True	True	False	Unknown		Unknown																						0,91	0,56	0,35	0/1	0,0,48,43	CCC	0.00	0.00	0.00			0,0,41,50	64.64		1.0
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11868438	11868439.0	C	CT	CT	11868438	.	C	CT	.	PASS	NM_001987	T	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-969dup						rs71057775		1		insertion	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1					17																	0.3474	0.2145	0.5354	0.2944	0.4117	0.1276	0.2961	0.3917	0.4343	0.3714	0.518	0.5354	gnomADg_AMI										FAIL	21	45	-25	-26	0.00	0.01	0.00	0.00	ETV6		4.4000e-01																																																											459					0.715							192.03													chr12	12021372																																																	True	True	False	Unknown		Unknown																						205,123	97,77	108,46	0/1	109,96,72,51	TCT						83,122,46,77	10.55		0.375
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11868723	11868723.0	T	C	C	11868723	.	T	C	.	PASS	NM_001987	C	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-701T>C						rs10772510		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3373	0.1672	0.389	0.1369	0.505	0.5644											0.4127	0.2277	0.67	0.4091	0.4666	0.1312	0.446	0.4728	0.5233	0.4395	0.5837	0.67	gnomADg_AMI										FAIL	-12	12	21	-11	0.00	0.00	0.00	0.00	ETV6		4.4000e-01																																																											375					0.976							246.25													chr12	12021657																																																	True	True	False	Unknown		Unknown																						3,363	2,178	1,185	0/1	1,2,186,177	ATG	.	.	.			0,3,173,190	42.72		0.9918032786885246
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11869164	11869164.0	A	T	T	11869164	.	A	T	.	PASS	NM_001987	T	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-260A>T						rs12578955		1		SNV	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1						0.3389	0.1672	0.3905	0.1369	0.5119	0.5644											0.4143	0.2259	0.6689	0.4085	0.4593	0.1297	0.4662	0.4792	0.5251	0.4396	0.5833	0.6689	gnomADg_AMI	benign		1							FAIL	6	-47	-2	13	0.00	0.00	0.00	0.00	ETV6		4.4000e-01	1243723			0.33886	1233211	not_provided		MedGen:C3661900		NC_000012.12:g.11869164A>T	criteria_provided&_single_submitter	Benign			SCV001859930	single_nucleotide_variant	SO:0001483	ClinGen:CA13580005		ETV6:2120	SO:0001627&intron_variant										1	12578955																											139					1							99.3													chr12	12022098																																																	True	True	False	Unknown		Unknown																						1,138	1,67	0,71	0/1	1,0,68,70	GAG	.	.	.			1,0,129,9	61.16		0.9928057553956835
GRCh38	ETV6	D12_12345_1234556_Thyroid_S9			chr12	11869241	11869242.0	G	GA	GA	11869241	.	G	GA	.	PASS	NM_001987	A	intron_variant	MODIFIER	ETV6	ENSG00000139083	Transcript	ENST00000396373	protein_coding		4/7	c.464-169dup						rs11302289		1		insertion	HGNC	HGNC:3495	YES	MANE_Select	NM_001987.5		1	P1	CCDS8643.1	ENSP00000379658	P41212.230	A0A0S2Z3C9.48	UPI000000DA45			1					14	0.3974	0.3411	0.4467	0.2262	0.5139	0.4949											0.4792	0.3531	0.7023	0.5008	0.5311	0.1425	0.4612	0.6204	0.5573	0.5154	0.6009	0.7023	gnomADg_AMI	benign		1							FAIL	0	1	0	-21	0.00	0.00	0.00	0.00	ETV6		4.4000e-01	1232639				1224346	not_provided		MedGen:C3661900		NC_000012.12:g.11869255dup	criteria_provided&_single_submitter	Benign			SCV001845128	Duplication	SO:1000035	ClinGen:CA232607488		ETV6:2120	SO:0001627&intron_variant										1	11302289																											440					0.855							209.48													chr12	12022175																																																	True	True	False	Unknown		Unknown																						151,225	64,104	87,121	0/1	73,78,115,110	AGA						92,59,132,93	40.66		0.598404255319149
GRCh38	GUCY2C-AS1	D12_12345_1234556_Thyroid_S9			chr12	14757061	14757063.0	GAT	G	G	14757061	.	GAT	G	.	PASS		-	intron_variant&non_coding_transcript_variant	MODIFIER	GUCY2C-AS1	ENSG00000214772	Transcript	ENST00000786474	lncRNA		2/4	n.115-24851_115-24850del						rs1610919		1		deletion	HGNC	HGNC:56054																			1	0.5014	0.5552	0.6138	0.3085	0.5457	0.502											0.5361	0.5557	0.6189	0.5977	0.5084	0.3074	0.4717	0.534	0.5398	0.5294	0.5135	0.6189	gnomADg_AMI				33801242																																																																												99					0.939							238.46													chr12	14909995																																																	True	False	False	Unknown		Unknown																						0,93	0,47	0,46	0/1	0,0,48,45	TGA						0,0,38,55	63.4		1.0
GRCh38	PIK3C2G	D12_12345_1234556_Thyroid_S9	p.P952L	ENSP00000445381.1:p.Pro952Leu	chr12	18496123	18496123.0	C	T	T	18496123	.	C	T	.	PASS	NM_001288772	T	missense_variant	MODERATE	PIK3C2G	ENSG00000139144	Transcript	ENST00000538779	protein_coding	21/33		c.2855C>T	2993	2855	952	P/L	cCg/cTg	rs12312266&COSV56807152		1		SNV	HGNC	HGNC:8973	YES	MANE_Select	NM_001288772.2		5	P1	CCDS73452.1	ENSP00000445381	O75747.205		UPI00020655D2	O75747-1			tolerated(0.05)	probably_damaging(0.985)	Gene3D:3.30.1010.10&AFDB-ENSP_mappings:AF-O75747-F1&PROSITE_profiles:PS50290&PANTHER:PTHR10048&Superfamily:SSF56112&CDD:cd05177			0.3744	0.5008	0.366	0.3046	0.2425	0.4172	0.2462	0.4698	0.3039	0.247	0.3293	0.1948	0.2776	0.2275	0.2606	0.3711	0.3111	0.4752	0.1319	0.3031	0.2406	0.3045	0.1852	0.2585	0.2338	0.3205	0.3827	0.5008	AFR		0&1	0&1	30545124						FAIL	19	-22	36	31	0.00	0.00	0.00	0.00	PIK3C2G	0.592	1.2330e+00																																																											83					0.94							244.96	v6.1	Unknown		True	PIK3C2G encodes a kinase involved in cell proliferation, oncogenic transformation and protein trafficking signaling pathways. Inactivating mutations of PIK3C2G are found in melanomas and lung and gastrointestinal cancers.	False	01/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2G ENSP00000445381.1:P952L mutant UNKNOWN.	False	The PIK3C2G ENSP00000445381.1:p952l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	18649057						True	False	False	Unknown								False	False		PIK3C2G encodes a kinase involved in cell proliferation, oncogenic transformation and protein trafficking signaling pathways. Inactivating mutations of PIK3C2G are found in melanomas and lung and gastrointestinal cancers.	The PIK3C2G ENSP00000445381.1:p952l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2G ENSP00000445381.1:P952L mutant UNKNOWN.						v6.1	01/17/2017		GRCh38	PIK3C2G	5288.0	ENSP00000445381.1:P952L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3C2G"",""entrezGeneId"":5288,""alteration"":""ENSP00000445381.1:P952L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3C2G encodes a kinase involved in cell proliferation, oncogenic transformation and protein trafficking signaling pathways. Inactivating mutations of PIK3C2G are found in melanomas and lung and gastrointestinal cancers."",""variantSummary"":""The PIK3C2G ENSP00000445381.1:p952l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3C2G ENSP00000445381.1:P952L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/17/2017""}"	True	True	False	Unknown		Unknown																						35,43	20,27	15,16	0/1	20,15,19,24	CCG	0.00	0.00	0.00			11,24,19,24	38.96		0.5512820512820513
GRCh38	KRAS	D12_12345_1234556_Thyroid_S9	p.Asp173=	ENSP00000308495.3:p.Asp173=	chr12	25209843	25209843.0	A	G	G	25209843	.	A	G	.	PASS	NM_004985	G	synonymous_variant	LOW	KRAS	ENSG00000133703	Transcript	ENST00000311936	protein_coding	5/5		c.519T>C	709	519	173	D	gaT/gaC	rs1137282&COSV55562336		-1		SNV	HGNC	HGNC:6407	YES	MANE_Select	NM_004985.5		1	P4	CCDS8702.1	ENSP00000308495	P01116.262		UPI0000001252	P01116-2		1			AFDB-ENSP_mappings:AF-P01116-F1&PROSITE_profiles:PS51419&PROSITE_profiles:PS51421&PANTHER:PTHR24070&Superfamily:SSF52540&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.1755	0.18	0.1931	0.0923	0.2187	0.1984	0.2071	0.1769	0.1746	0.162	0.1159	0.1618	0.2366	0.2171	0.2013	0.1928	0.1952	0.1753	0.3956	0.1963	0.1697	0.09815	0.1497	0.2415	0.2199	0.2061	0.1929	0.3956	gnomADg_AMI	benign&likely_benign	0&1	1&1	25741868&31637880&24033266&26959740&29048575&23757202&18805939&21085059&20827186&29282362&30826992&28150169&21688344&31564912&24853176&25408372&26432889&36632296&24186849&30463544&37232746&29142307&30860980&35477782&38664609&37463056&38384455&39170526						FAIL	40	-34	-1	-44	0.00	0.00	0.00	0.00	KRAS		2.6400e-01	41449	0.20077	0.19690	0.17552	49887	Cardiovascular_phenotype&not_specified&not_provided&RASopathy&Noonan_syndrome		MedGen:CN230736&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MONDO:MONDO:0018997&MeSH:D009634&MedGen:C0028326&OMIM:PS163950&Orphanet:648		NC_000012.12:g.25209843A>G	reviewed_by_expert_panel	Benign			SCV000616402	single_nucleotide_variant	SO:0001483	ClinGen:CA135582		KRAS:3845	SO:0001624&3_prime_UTR_variant&SO:0001819&synonymous_variant										1	1137282																											154					0.916							213.09	v6.1	Unknown		True	KRAS, a GTPase which functions as an upstream regulator of the MAPK pathway, is frequently mutated in various cancer types including lung, colorectal and pancreatic cancers.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS ENSP00000308495.3:D173= mutant UNKNOWN.	False	The KRAS ENSP00000308495.3:d173= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	25362777						True	False	False	Unknown								False	False		KRAS, a GTPase which functions as an upstream regulator of the MAPK pathway, is frequently mutated in various cancer types including lung, colorectal and pancreatic cancers.	The KRAS ENSP00000308495.3:d173= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS ENSP00000308495.3:D173= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	KRAS	3845.0	ENSP00000308495.3:D173=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KRAS"",""entrezGeneId"":3845,""alteration"":""ENSP00000308495.3:D173="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KRAS, a GTPase which functions as an upstream regulator of the MAPK pathway, is frequently mutated in various cancer types including lung, colorectal and pancreatic cancers."",""variantSummary"":""The KRAS ENSP00000308495.3:d173= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS ENSP00000308495.3:D173= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						1,140	1,76	0,64	0/1	1,0,71,69	CAT	.	.	.			1,0,69,71	60.85		0.9929078014184397
GRCh38	KRAS	D12_12345_1234556_Thyroid_S9			chr12	25217315	25217315.0	T	G	G	25217315	.	T	G	.	PASS	NM_004985	G	intron_variant	MODIFIER	KRAS	ENSG00000133703	Transcript	ENST00000311936	protein_coding		4/4	c.451-7404A>C						rs4246231		-1		SNV	HGNC	HGNC:6407	YES	MANE_Select	NM_004985.5		1	P4	CCDS8702.1	ENSP00000308495	P01116.262		UPI0000001252	P01116-2		1						0.9972	0.9909	0.9971	1	1	1											0.9984	0.9947	1	0.9985	1	1	1	1	1	0.9976	1	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_SAS										FAIL	11	-35	39	-28	0.00	0.00	0.00	0.00	KRAS		2.6400e-01																																																											70					0.971							243.45													chr12	25370249																																																	True	True	False	Unknown		Unknown																						0,68	0,36	0,32	0/1	0,0,30,38	ATT	.	.	.			0,0,22,46	64.46		1.0
GRCh38	KRAS	D12_12345_1234556_Thyroid_S9			chr12	25236573	25236573.0	A	G	G	25236573	.	A	G	.	PASS	NM_004985	G	intron_variant	MODIFIER	KRAS	ENSG00000133703	Transcript	ENST00000311936	protein_coding		2/4	c.111+8701T>C						rs4495968		-1		SNV	HGNC	HGNC:6407	YES	MANE_Select	NM_004985.5		1	P4	CCDS8702.1	ENSP00000308495	P01116.262		UPI0000001252	P01116-2		1						0.9287	0.8328	0.9769	1	0.9841	0.8937											0.9455	0.8548	1	0.9687	0.9389	1	0.9959	0.9388	0.9855	0.9514	0.9065	1	EAS&gnomADg_AMI&gnomADg_EAS				18805939						FAIL	33	-6	-49	-31	0.00	0.00	0.00	0.00	KRAS		2.6400e-01																																																											128					0.938							243.27													chr12	25389507																																																	True	True	False	Unknown		Unknown																						0,120	0,70	0,50	0/1	0,0,62,58	TAT	.	.	.			0,0,74,46	64.71		1.0
GRCh38	KRAS	D12_12345_1234556_Thyroid_S9			chr12	25240358	25240358.0	C	T	T	25240358	.	C	T	.	PASS	NM_004985	T	intron_variant	MODIFIER	KRAS	ENSG00000133703	Transcript	ENST00000311936	protein_coding		2/4	c.111+4916G>A						rs11047916		-1		SNV	HGNC	HGNC:6407	YES	MANE_Select	NM_004985.5		1	P4	CCDS8702.1	ENSP00000308495	P01116.262		UPI0000001252	P01116-2		1						0.0032	0.0008	0.0014	0	0.0099	0.0041											0.00654	0.002094	0.05702	0.0017	0.00432	0	0.02216	0.006803	0.00807	0.005198	0.003932	0.05702	gnomADg_AMI										FAIL	19	5	39	-50	0.00	0.00	0.00	0.00	KRAS		2.6400e-01																																																											117					0.991							244.51													chr12	25393292																																																	True	True	False	Unknown		Unknown																						63,53	27,30	36,23	0/1	28,35,28,25	ACT	0.00	0.00	0.00			30,33,29,24	30.7		0.45689655172413796
GRCh38	KRAS	D12_12345_1234556_Thyroid_S9			chr12	25248028	25248028.0	G	C	C	25248028	.	G	C	.	PASS	NM_004985	C	intron_variant	MODIFIER	KRAS	ENSG00000133703	Transcript	ENST00000311936	protein_coding		1/4	c.-11-2633C>G						rs4397950		-1		SNV	HGNC	HGNC:6407	YES	MANE_Select	NM_004985.5		1	P4	CCDS8702.1	ENSP00000308495	P01116.262		UPI0000001252	P01116-2		1						0.3466	0.4614	0.3876	0.1845	0.3847	0.2904											0.3916	0.4539	0.4923	0.3983	0.2874	0.2024	0.4319	0.3931	0.3701	0.3708	0.3146	0.4923	gnomADg_AMI										FAIL	5	32	-24	32	0.00	0.00	0.00	0.00	KRAS		2.6400e-01																																																											314					0.984							245.31													chr12	25400962																																																	True	True	False	Unknown		Unknown																						0,309	0,160	0,149	0/1	0,0,158,151	TGG	.	.	.			0,0,209,100	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr12	31804372	31804372.0	A	G	G	31804372	.	A	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000306285	Transcript	ENST00000816773	lncRNA		1/2	n.309+303T>C						rs3844102		-1		SNV			YES																			0.4748	0.6339	0.428	0.3264	0.4632	0.4581											0.4776	0.6102	0.3326	0.4127	0.4484	0.3237	0.4623	0.415	0.4294	0.4715	0.4757	0.6339	AFR																																																																																87					0.966							237.84													chr12	31957306																																																	True	False	False	Unknown		Unknown																						0,84	0,45	0,39	0|1	0,0,41,43	AAA	.	.	.		31957306	0,0,56,28	57.61		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr12	31804387	31804387.0	C	T	T	31804387	.	C	T	.	PASS		T	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000306285	Transcript	ENST00000816773	lncRNA		1/2	n.309+288G>A						rs3850977		-1		SNV			YES																			0.4748	0.6339	0.428	0.3264	0.4632	0.4581											0.4775	0.6099	0.3355	0.4124	0.4484	0.3235	0.4624	0.415	0.4295	0.4724	0.4763	0.6339	AFR																																																																																103					0.932							234.67													chr12	31957321																																																	True	False	False	Unknown		Unknown																						0,96	0,51	0,45	0|1	0,0,42,54	TCA	0.00	0.00	0.00		31957306	0,0,57,39	57.66		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr12	31804447	31804447.0	G	A	A	31804447	.	G	A	.	PASS		A	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000306285	Transcript	ENST00000816773	lncRNA		1/2	n.309+228C>T						rs10844014		-1		SNV			YES																			0.2726	0.5113	0.2594	0.0575	0.2535	0.2004											0.3027	0.4845	0.1619	0.2254	0.2578	0.05782	0.335	0.2653	0.2345	0.3043	0.1997	0.5113	AFR																																																																																170					0.888							235.04													chr12	31957381																																																	True	False	False	Unknown		Unknown																						0,151	0,66	0,85	0/1	0,0,67,84	TGA	0.00	0.00	0.00			0,0,66,85	64.72		1.0
GRCh38	SYT10	D12_12345_1234556_Thyroid_S9			chr12	33392156		T	[chr4:19932371[T	[chr4:19932371[T	33392156	MantaBND:181:0:1:0:0:0:0	T	[chr4:19932371[T	.	PASS		.T	feature_truncation&intron_variant&NMD_transcript_variant	HIGH	SYT10	ENSG00000110975	Transcript	ENST00000539102	nonsense_mediated_decay		5/8									-1		chromosome_breakpoint	HGNC	HGNC:19266					1			ENSP00000444577		F5GZB8.65	UPI000204AAC7																																																																																																																	1			0,4							4	TGTG			MantaBND:181:0:1:0:0:0:1	0														chr12	33545091				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	MUC19	D12_12345_1234556_Thyroid_S9			chr12	40469250	40469250.0	A	G	G	40469250	.	A	G	.	PASS		G	intron_variant	MODIFIER	MUC19	ENSG00000205592	Transcript	ENST00000454784	protein_coding_LoF		51/172	c.5701+3212A>G						rs2920816		1		SNV	HGNC	HGNC:14362	YES				5	P1		ENSP00000508949												0.3480	0.326	0.4006	0.3075	0.3917	0.3374											0.383	0.3637	0.4283	0.4099	0.4271	0.3269	0.2941	0.4116	0.4049	0.4013	0.3587	0.4283	gnomADg_AMI				29121662&33406744&30483659&32451905&30483616&31745634&35318655&33546406&38522119																																																																												149					0.993							248.68													chr12	40863052																																																	True	False	False	Unknown		Unknown																						76,72	30,37	46,35	0/1	36,40,39,33	GAT	.	.	.			24,52,30,42	35.18		0.4864864864864865
GRCh38	KMT2D	D12_12345_1234556_Thyroid_S9	p.H4724Y	ENSP00000301067.7:p.His4724Tyr	chr12	49029142	49029142.0	G	A	A	49029142	.	G	A	.	PASS	NM_003482	A	missense_variant	MODERATE	KMT2D	ENSG00000167548	Transcript	ENST00000301067	protein_coding	45/55		c.14170C>T	15389	14170	4724	H/Y	Cat/Tat	rs1275148461		-1		SNV	HGNC	HGNC:7133	YES	MANE_Select	NM_003482.4		5	A2	CCDS44873.1	ENSP00000301067	O14686.213		UPI0000EE84D6	O14686-1		1	deleterious_low_confidence(0.03)	unknown(0)	PANTHER:PTHR45888&MobiDB_lite:mobidb-lite									6.842e-07	0	0	0	0	0	0	0	1.657e-05	0												1.657e-05	gnomADe_REMAINING										FAIL	-13	47	-16	-12	0.00	0.00	0.00	0.00	KMT2D	0.335	1.4100e-01																																																											1035					1							248.43	v6.1	Unknown		True	KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	False	02/16/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:H4724Y mutant UNKNOWN.	False	The KMT2D ENSP00000301067.7:h4724y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	49422925						True	False	False	Unknown								False	False		KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	The KMT2D ENSP00000301067.7:h4724y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:H4724Y mutant UNKNOWN.						v6.1	02/16/2018		GRCh38	KMT2D	8085.0	ENSP00000301067.7:H4724Y			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2D"",""entrezGeneId"":8085,""alteration"":""ENSP00000301067.7:H4724Y"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer."",""variantSummary"":""The KMT2D ENSP00000301067.7:h4724y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:H4724Y mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/16/2018""}"	True	True	False	Unknown		Unknown																						993,42	514,20	479,22	0/1	514,479,21,21	TGA	0.00	0.00	1.00			507,486,23,19	11.8		0.04057971014492753
GRCh38	KMT2D	D12_12345_1234556_Thyroid_S9	p.Pro4170=	ENSP00000301067.7:p.Pro4170=	chr12	49032195	49032195.0	T	C	C	49032195	.	T	C	.	PASS	NM_003482	C	synonymous_variant	LOW	KMT2D	ENSG00000167548	Transcript	ENST00000301067	protein_coding	40/55		c.12510A>G	13729	12510	4170	P	ccA/ccG	rs3741622&COSV56407671		-1		SNV	HGNC	HGNC:7133	YES	MANE_Select	NM_003482.4		5	A2	CCDS44873.1	ENSP00000301067	O14686.213		UPI0000EE84D6	O14686-1		1			PANTHER:PTHR45888&MobiDB_lite:mobidb-lite			0.2754	0.0234	0.2363	0.4454	0.3022	0.4407	0.3467	0.05791	0.2333	0.232	0.398	0.3653	0.2333	0.3574	0.3332	0.3958	0.2665	0.0754	0.3311	0.2579	0.2191	0.4246	0.358	0.2007	0.3498	0.2621	0.4239	0.4454	EAS	benign	0&1	1&1	25741868&24033266&18414213&23757202						FAIL	4	-31	4	11	0.00	0.00	0.00	0.00	KMT2D		1.4100e-01	94158	0.25065	0.31922	0.27536	100058	Kabuki_syndrome&not_provided&Kabuki_syndrome_1&not_specified		MONDO:MONDO:0016512&MedGen:C0796004&OMIM:PS147920&Orphanet:2322&MedGen:C3661900&MONDO:MONDO:0007843&MedGen:CN030661&OMIM:147920&Orphanet:2322&MedGen:CN169374		NC_000012.12:g.49032195T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000112016&SCV000193383&SCV000309600&SCV000539483&SCV000604075&SCV000842769&SCV001721835&SCV001939562&SCV004233326&SCV005235740	single_nucleotide_variant	SO:0001483	ClinGen:CA147663		KMT2D:8085	SO:0001819&synonymous_variant										1	3741622																											880					1							247.89	v6.1	Unknown		True	KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	False	02/16/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:P4170= mutant UNKNOWN.	False	The KMT2D ENSP00000301067.7:p4170= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	49425978						True	False	False	Unknown								False	False		KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	The KMT2D ENSP00000301067.7:p4170= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:P4170= mutant UNKNOWN.						v6.1	02/16/2018		GRCh38	KMT2D	8085.0	ENSP00000301067.7:P4170=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2D"",""entrezGeneId"":8085,""alteration"":""ENSP00000301067.7:P4170="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer."",""variantSummary"":""The KMT2D ENSP00000301067.7:p4170= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:P4170= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/16/2018""}"	True	True	False	Unknown		Unknown																						435,445	232,211	203,234	0/1	204,231,223,222	GTG	.	.	.			199,236,213,232	57.03		0.5056818181818182
GRCh38	KMT2D	D12_12345_1234556_Thyroid_S9	p.Gln3612=	ENSP00000301067.7:p.Gln3612=	chr12	49033869	49033869.0	C	T	T	49033869	.	C	T	.	PASS	NM_003482	T	synonymous_variant	LOW	KMT2D	ENSG00000167548	Transcript	ENST00000301067	protein_coding	40/55		c.10836G>A	12055	10836	3612	Q	caG/caA	rs3782357&COSV56407688		-1		SNV	HGNC	HGNC:7133	YES	MANE_Select	NM_003482.4		5	A2	CCDS44873.1	ENSP00000301067	O14686.213		UPI0000EE84D6	O14686-1		1			Coiled-coils_(Ncoils):Coil&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.4435	0.5726	0.2911	0.4444	0.3489	0.4734	0.3897	0.5425	0.2845	0.2596	0.3957	0.4122	0.2812	0.3874	0.3918	0.4351	0.4239	0.5361	0.3549	0.3423	0.247	0.4244	0.4133	0.2789	0.3851	0.382	0.4574	0.5726	AFR	benign	0&1	1&1	25741868&24033266&18414213&23757202&37305557						FAIL	-24	-1	-9	1	0.00	0.00	0.00	0.00	KMT2D		1.4100e-01	94142	0.42173	0.46163	0.44349	100042	Kabuki_syndrome&not_specified&Kabuki_syndrome_1&not_provided		MONDO:MONDO:0016512&MedGen:C0796004&OMIM:PS147920&Orphanet:2322&MedGen:CN169374&MONDO:MONDO:0007843&MedGen:CN030661&OMIM:147920&Orphanet:2322&MedGen:C3661900		NC_000012.12:g.49033869C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000112000&SCV000193371&SCV000309597&SCV000539484&SCV000604078&SCV000842766&SCV001721836&SCV001849438&SCV004233275&SCV005235743	single_nucleotide_variant	SO:0001483	ClinGen:CA147659		KMT2D:8085	SO:0001819&synonymous_variant										1	3782357																											1018					0.927							241.71	v6.1	Unknown		True	KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	False	02/16/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:Q3612= mutant UNKNOWN.	False	The KMT2D ENSP00000301067.7:q3612= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	49427652						True	False	False	Unknown								False	False		KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	The KMT2D ENSP00000301067.7:q3612= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:Q3612= mutant UNKNOWN.						v6.1	02/16/2018		GRCh38	KMT2D	8085.0	ENSP00000301067.7:Q3612=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2D"",""entrezGeneId"":8085,""alteration"":""ENSP00000301067.7:Q3612="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer."",""variantSummary"":""The KMT2D ENSP00000301067.7:q3612= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:Q3612= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/16/2018""}"	True	True	False	Unknown		Unknown																						482,462	213,205	269,257	0/1	226,256,231,231	GCT	0.00	0.00	0.00			225,257,202,260	46.37		0.4894067796610169
GRCh38	KMT2D	D12_12345_1234556_Thyroid_S9	p.Gly2493=	ENSP00000301067.7:p.Gly2493=	chr12	49040291	49040291.0	C	A	A	49040291	.	C	A	.	PASS	NM_003482	A	synonymous_variant	LOW	KMT2D	ENSG00000167548	Transcript	ENST00000301067	protein_coding	32/55		c.7479G>T	8698	7479	2493	G	ggG/ggT	rs10747559&CD1312975&COSV56407715		-1		SNV	HGNC	HGNC:7133	YES	MANE_Select	NM_003482.4		5	A2	CCDS44873.1	ENSP00000301067	O14686.213		UPI0000EE84D6	O14686-1		1			MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.4355	0.4796	0.3271	0.4514	0.3966	0.4765	0.4206	0.4745	0.3002	0.2951	0.4007	0.4347	0.366	0.4246	0.4199	0.4502	0.429	0.4697	0.4051	0.366	0.2809	0.4323	0.4277	0.3367	0.4246	0.4061	0.4667	0.4796	AFR	benign	0&1&1	1&1&1	25741868&24033266&18414213&23757202						FAIL	-11	-49	-31	34	0.00	0.00	0.02	0.00	KMT2D		1.4100e-01	94248	0.41650		0.43550	100148	not_specified&Kabuki_syndrome&not_provided&Kabuki_syndrome_1		MedGen:CN169374&MONDO:MONDO:0016512&MedGen:C0796004&OMIM:PS147920&Orphanet:2322&MedGen:C3661900&MONDO:MONDO:0007843&MedGen:CN030661&OMIM:147920&Orphanet:2322		NC_000012.12:g.49040291C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000112106&SCV000193473&SCV000309630&SCV000539485&SCV000604079&SCV000842776&SCV001721837&SCV001940582&SCV001981143&SCV004233180&SCV005235754	single_nucleotide_variant	SO:0001483	ClinGen:CA147705		KMT2D:8085	SO:0001819&synonymous_variant										1	10747559																											773					1							248.86	v6.1	Unknown		True	KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	False	02/16/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:G2493= mutant UNKNOWN.	False	The KMT2D ENSP00000301067.7:g2493= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	49434074						True	False	False	Unknown								False	False		KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	The KMT2D ENSP00000301067.7:g2493= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:G2493= mutant UNKNOWN.						v6.1	02/16/2018		GRCh38	KMT2D	8085.0	ENSP00000301067.7:G2493=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2D"",""entrezGeneId"":8085,""alteration"":""ENSP00000301067.7:G2493="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer."",""variantSummary"":""The KMT2D ENSP00000301067.7:g2493= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:G2493= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/16/2018""}"	True	True	False	Unknown		Unknown																						367,406	160,205	207,201	0/1	180,187,194,212	ACC	0.00	0.00	0.00			173,194,185,221	60.57		0.5252263906856404
GRCh38	KMT2D	D12_12345_1234556_Thyroid_S9	p.Ile942=	ENSP00000301067.7:p.Ile942=	chr12	49050762	49050762.0	G	A	A	49050762	.	G	A	.	PASS	NM_003482	A	synonymous_variant	LOW	KMT2D	ENSG00000167548	Transcript	ENST00000301067	protein_coding	12/55		c.2826C>T	4045	2826	942	I	atC/atT	rs2241726&COSV56407742		-1		SNV	HGNC	HGNC:7133	YES	MANE_Select	NM_003482.4		5	A2	CCDS44873.1	ENSP00000301067	O14686.213		UPI0000EE84D6	O14686-1		1			MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.4036	0.4297	0.2911	0.4306	0.3479	0.4775	0.3856	0.4294	0.2723	0.2574	0.3775	0.4123	0.2748	0.387	0.383	0.4434	0.3912	0.4249	0.3538	0.3268	0.2475	0.4101	0.4122	0.2671	0.3846	0.358	0.4639	0.4775	SAS	benign	0&1	1&1	25741868&24033266&18414213&23757202&33863951&36224396						FAIL	-8	28	-8	-26	0.01	0.04	0.00	0.00	KMT2D		1.4100e-01	94206	0.38541	0.37957	0.40355	100106	Kabuki_syndrome&Kabuki_syndrome_1&not_specified&not_provided		MONDO:MONDO:0016512&MedGen:C0796004&OMIM:PS147920&Orphanet:2322&MONDO:MONDO:0007843&MedGen:CN030661&OMIM:147920&Orphanet:2322&MedGen:CN169374&MedGen:C3661900		NC_000012.12:g.49050762G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000112064&SCV000193434&SCV000309617&SCV000539486&SCV000604080&SCV001721838&SCV001900875&SCV004233282&SCV005235775	single_nucleotide_variant	SO:0001483	ClinGen:CA147686		KMT2D:8085	SO:0001819&synonymous_variant										1	2241726																											750					0.991							245.01	v6.1	Unknown		True	KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	False	02/16/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:I942= mutant UNKNOWN.	False	The KMT2D ENSP00000301067.7:i942= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	49444545						True	False	False	Unknown								False	False		KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	The KMT2D ENSP00000301067.7:i942= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:I942= mutant UNKNOWN.						v6.1	02/16/2018		GRCh38	KMT2D	8085.0	ENSP00000301067.7:I942=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2D"",""entrezGeneId"":8085,""alteration"":""ENSP00000301067.7:I942="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer."",""variantSummary"":""The KMT2D ENSP00000301067.7:i942= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:I942= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/16/2018""}"	True	True	False	Unknown		Unknown																						392,351	184,156	208,195	0/1	209,183,185,166	TGA	0.00	0.00	0.00			165,227,142,209	32.48		0.47240915208613726
GRCh38	KMT2D	D12_12345_1234556_Thyroid_S9	p.Ala792_Gln809del	ENSP00000301067.7:p.Ala792_Gln809del	chr12	49051255	49051309.0	TCTGGGGGGACAGGTGCAATTCCTCAGGCTGAGGGGACAGATGTGGTCCCTCAGC	T	T	49051255	.	TCTGGGGGGACAGGTGCAATTCCTCAGGCTGAGGGGACAGATGTGGTCCCTCAGC	T	.	PASS	NM_003482	-	inframe_deletion	MODERATE	KMT2D	ENSG00000167548	Transcript	ENST00000301067	protein_coding	11/55		c.2374_2427del	3593-3646	2374-2427	792-809	AEGPHLSPQPEELHLSPQ/-	GCTGAGGGACCACATCTGTCCCCTCAGCCTGAGGAATTGCACCTGTCCCCCCAG/-			-1		deletion	HGNC	HGNC:7133	YES	MANE_Select	NM_003482.4		5	A2	CCDS44873.1	ENSP00000301067	O14686.213		UPI0000EE84D6	O14686-1		1			MobiDB_lite:mobidb-lite																																																				1.4100e-01																																																											1370					0.913							244.96	v6.1	Unknown		True	KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	False	02/16/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:A792_Q809del altered UNKNOWN.	False	The KMT2D ENSP00000301067.7:a792_q809del alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	49445038						True	False	False	Unknown								False	False		KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.	The KMT2D ENSP00000301067.7:a792_q809del alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:A792_Q809del altered UNKNOWN.						v6.1	02/16/2018		GRCh38	KMT2D	8085.0	ENSP00000301067.7:A792_Q809del			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2D"",""entrezGeneId"":8085,""alteration"":""ENSP00000301067.7:A792_Q809del"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer."",""variantSummary"":""The KMT2D ENSP00000301067.7:a792_q809del alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2D ENSP00000301067.7:A792_Q809del altered UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/16/2018""}"	True	True	False	Unknown		Unknown																						1210,41	570,22	640,19	0/1	661,549,20,21	GTC						621,589,19,22	10.64		0.032773780975219824
GRCh38	ERBB3	D12_12345_1234556_Thyroid_S9			chr12	56080595	56080595.0	T	C	C	56080595	.	T	C	.	PASS	NM_001982	C	intron_variant	MODIFIER	ERBB3	ENSG00000065361	Transcript	ENST00000267101	protein_coding		1/27	c.82+213T>C						rs3741499		1		SNV	HGNC	HGNC:3431	YES	MANE_Select	NM_001982.4		1	P1	CCDS31833.1	ENSP00000267101	P21860.249		UPI000012A113	P21860-1		1						0.6995	0.5681	0.7565	0.7907	0.664	0.7791											0.6529	0.5681	0.5055	0.7326	0.625	0.7841	0.6944	0.7517	0.6645	0.664	0.7711	0.7907	EAS	benign		1	28738846&36914875&30643251&33082346&17275115&30038396						FAIL	7	5	-44	26	0.00	0.00	0.00	0.00	ERBB3		6.9500e-01	1293095			0.69948	1282901	not_provided		MedGen:C3661900		NC_000012.12:g.56080595T>C	criteria_provided&_single_submitter	Benign			SCV001943694	single_nucleotide_variant	SO:0001483	ClinGen:CA13590107		ERBB3:2065	SO:0001627&intron_variant										1	3741499																											776					0.995							248.62													chr12	56474379																																																	True	True	False	Unknown		Unknown																						401,371	191,196	210,175	0/1	195,206,192,179	CTC	.	.	.			193,208,193,178	38.07		0.4805699481865285
GRCh38	ERBB3	D12_12345_1234556_Thyroid_S9			chr12	56087129	56087129.0	C	T	T	56087129	.	C	T	.	PASS	NM_001982	T	intron_variant	MODIFIER	ERBB3	ENSG00000065361	Transcript	ENST00000267101	protein_coding		4/27	c.548-448C>T						rs1868511688		1		SNV	HGNC	HGNC:3431	YES	MANE_Select	NM_001982.4		1	P1	CCDS31833.1	ENSP00000267101	P21860.249		UPI000012A113	P21860-1		1																						0	0	0	0	0	0	0	0	0	0	0	0	gnomADg_AFR&gnomADg_AMI&gnomADg_AMR&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_REMAINING&gnomADg_SAS										FAIL	-8	-20	-30	-8	0.00	0.00	0.00	0.00	ERBB3		6.9500e-01																																																											283					0.947							196.89													chr12	56480913																																																	True	True	False	Unknown		Unknown																						261,7	139,5	122,2	0/1	153,108,5,2	CCC	0.00	0.00	1.00			177,84,3,4	11.72		0.026119402985074626
GRCh38	ERBB3	D12_12345_1234556_Thyroid_S9	p.Arg1116=	ENSP00000267101.4:p.Arg1116=	chr12	56101207	56101207.0	G	A	A	56101207	.	G	A	.	PASS	NM_001982	A	synonymous_variant	LOW	ERBB3	ENSG00000065361	Transcript	ENST00000267101	protein_coding	27/28		c.3348G>A	3484	3348	1116	R	agG/agA	rs2271189&COSV57251880		1		SNV	HGNC	HGNC:3431	YES	MANE_Select	NM_001982.4		1	P1	CCDS31833.1	ENSP00000267101	P21860.249		UPI000012A113	P21860-1		1			Low_complexity_(Seg):seg&MobiDB_lite:mobidb-lite&Phobius:CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000619&AFDB-ENSP_mappings:AF-P21860-F1			0.2522	0.0734	0.3718	0.2887	0.4036	0.2157	0.3799	0.1167	0.356	0.3687	0.3205	0.3875	0.2606	0.4019	0.3597	0.2587	0.3082	0.1236	0.5044	0.3397	0.3806	0.3116	0.3753	0.3116	0.4004	0.3142	0.2501	0.5044	gnomADg_AMI	benign	0&1	1&1	27331016&21850031&19995212&25530448&23741632&26413465&20718829&27776352&17275115						FAIL	3	0	-18	-5	0.00	0.00	0.00	0.00	ERBB3		6.9500e-01	1248586	0.31009	0.34166	0.25220	1238955	Visceral_neuropathy&_familial&not_provided&Lethal_congenital_contracture_syndrome_2		MONDO:MONDO:0023961&MedGen:C0266834&OMIM:PS243180&MedGen:C3661900&MONDO:MONDO:0011868&MedGen:C1843478&OMIM:607598&Orphanet:137776		NC_000012.12:g.56101207G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001867998&SCV001876090&SCV001876091&SCV005233037	single_nucleotide_variant	SO:0001483	ClinGen:CA6622919		ERBB3:2065	SO:0001819&synonymous_variant										1	2271189																											1085					0.994							246.88	v6.1	Unknown		True	ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types.	False	02/14/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB3 ENSP00000267101.4:R1116= mutant UNKNOWN.	False	The ERBB3 ENSP00000267101.4:r1116= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	56494991						True	False	False	Unknown								False	False		ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types.	The ERBB3 ENSP00000267101.4:r1116= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB3 ENSP00000267101.4:R1116= mutant UNKNOWN.						v6.1	02/14/2018		GRCh38	ERBB3	2065.0	ENSP00000267101.4:R1116=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERBB3"",""entrezGeneId"":2065,""alteration"":""ENSP00000267101.4:R1116="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types."",""variantSummary"":""The ERBB3 ENSP00000267101.4:r1116= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB3 ENSP00000267101.4:R1116= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/14/2018""}"	True	True	False	Unknown		Unknown																						548,531	283,251	265,280	0/1	306,242,280,251	GGA	0.00	0.00	0.00			291,257,282,249	50.25		0.49212233549582945
GRCh38	ERBB3	D12_12345_1234556_Thyroid_S9	p.L1177I	ENSP00000267101.4:p.Leu1177Ile	chr12	56101555	56101555.0	C	A	A	56101555	.	C	A	.	PASS	NM_001982	A	missense_variant	MODERATE	ERBB3	ENSG00000065361	Transcript	ENST00000267101	protein_coding	28/28		c.3529C>A	3665	3529	1177	L/I	Ctt/Att	rs55699040&COSV104386542		1		SNV	HGNC	HGNC:3431	YES	MANE_Select	NM_001982.4		1	P1	CCDS31833.1	ENSP00000267101	P21860.249		UPI000012A113	P21860-1		1	tolerated(0.32)	benign(0.07)	Low_complexity_(Seg):seg&Phobius:CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000619&AFDB-ENSP_mappings:AF-P21860-F1			0.0012	0	0.0043	0	0.003	0	0.003971	0.0008961	0.001252	0.001071	2.519e-05	0.0005803	0	0.004948	0.0025	6.956e-05	0.002779	0.001397	0	0.001439	0.001441	0	0.0004714	0	0.004852	0.001422	0	0.004948	gnomADe_NFE	uncertain_significance&_likely_benign	0&1	1&1	32293552&23741632&33809641						FAIL	-26	10	8	-27	0.04	0.00	0.00	0.00	ERBB3	0.219	6.9500e-01	715634	0.00392		0.00120	725198	not_provided		MedGen:C3661900		NC_000012.12:g.56101555C>A	criteria_provided&_multiple_submitters&_no_conflicts	Likely_benign			SCV001031752&SCV001249021	single_nucleotide_variant	SO:0001483	ClinGen:CA6623004		ERBB3:2065	SO:0001583&missense_variant										1	55699040																											450					0.998							245.49	v6.1	Unknown		True	ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types.	False	02/14/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB3 ENSP00000267101.4:L1177I mutant UNKNOWN.	False	The ERBB3 ENSP00000267101.4:l1177i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	56495339						True	False	False	Unknown								False	False		ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types.	The ERBB3 ENSP00000267101.4:l1177i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB3 ENSP00000267101.4:L1177I mutant UNKNOWN.						v6.1	02/14/2018		GRCh38	ERBB3	2065.0	ENSP00000267101.4:L1177I			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERBB3"",""entrezGeneId"":2065,""alteration"":""ENSP00000267101.4:L1177I"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types."",""variantSummary"":""The ERBB3 ENSP00000267101.4:l1177i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB3 ENSP00000267101.4:L1177I mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/14/2018""}"	True	True	False	Unknown		Unknown																						237,212	116,107	121,105	0/1	115,122,102,110	CCT	0.00	0.00	0.00			142,95,139,73	33.19		0.47216035634743875
GRCh38	NAB2	D12_12345_1234556_Thyroid_S9			chr12	57092864	57092864.0	A	G	G	57092864	.	A	G	.	PASS	NM_005967	G	intron_variant	MODIFIER	NAB2	ENSG00000166886	Transcript	ENST00000300131	protein_coding		3/6	c.1092-53A>G						rs324019&COSV55665401		1		SNV	HGNC	HGNC:7627	YES	MANE_Select	NM_005967.4		1	P3	CCDS8930.1	ENSP00000300131	Q15742.188		UPI000012FC41	Q15742-1		1						0.5675	0.7337	0.6167	0.374	0.5964	0.4775	0.6005	0.708	0.635	0.6385	0.3247	0.5456	0.6453	0.6131	0.6089	0.5209	0.6226	0.7006	0.4385	0.6318	0.63	0.3792	0.5317	0.7109	0.6149	0.6354	0.512	0.7337	AFR		0&1	1&1	24973796&27903959						FAIL	7	2	-44	-47	0.00	0.00	0.00	0.00	NAB2		4.0300e-01																																																											839					0.996							246.61													chr12	57486647																																																	True	True	False	Unknown		Unknown																						401,435	207,245	194,190	0/1	194,207,218,217	CAG	.	.	.			216,185,204,231	61.71		0.5203349282296651
GRCh38	NAB2	D12_12345_1234556_Thyroid_S9			chr12	57093946	57093946.0	T	G	G	57093946	.	T	G	.	PASS	NM_005967	G	intron_variant	MODIFIER	NAB2	ENSG00000166886	Transcript	ENST00000300131	protein_coding		6/6	c.1468+348T>G						rs324018&COSV100272473		1		SNV	HGNC	HGNC:7627	YES	MANE_Select	NM_005967.4		1	P3	CCDS8930.1	ENSP00000300131	Q15742.188		UPI000012FC41	Q15742-1		1						0.5773	0.7678	0.6239	0.373	0.5954	0.4785											0.6333	0.7355	0.4407	0.6354	0.638	0.3778	0.5318	0.7109	0.6157	0.6456	0.5123	0.7678	AFR		0&1	0&1							FAIL	47	-28	-27	-2	0.00	0.00	0.00	0.00	NAB2		4.0300e-01																																																											896					0.992							246.25													chr12	57487729																																																	True	True	False	Unknown		Unknown																						435,454	187,172	248,282	0/1	218,217,236,218	GTA	.	.	.			204,231,230,224	59.9		0.5106861642294713
GRCh38	NAB2	D12_12345_1234556_Thyroid_S9			chr12	57094031	57094031.0	A	C	C	57094031	.	A	C	.	PASS	NM_005967	C	intron_variant	MODIFIER	NAB2	ENSG00000166886	Transcript	ENST00000300131	protein_coding		6/6	c.1468+433A>C						rs324017&COSV100272476		1		SNV	HGNC	HGNC:7627	YES	MANE_Select	NM_005967.4		1	P3	CCDS8930.1	ENSP00000300131	Q15742.188		UPI000012FC41	Q15742-1		1						0.6873	0.826	0.7305	0.5357	0.7167	0.5951											0.7233	0.7994	0.5433	0.7304	0.7252	0.5264	0.655	0.7655	0.7099	0.7335	0.6195	0.826	AFR		0&1	1&1	31995602&35538198&34883503&35396580&29805045&31761296&36726730&30804566&31094488&33686288&28166306&33117014&30050107&30804565&26198764&37518996&38383296&36123897						FAIL	-18	2	31	-30	0.01	0.00	0.00	0.00	NAB2		4.0300e-01																																																											926					0.987							246.23													chr12	57487814																																																	True	True	False	Unknown		Unknown																						457,457	183,192	274,265	0/1	231,226,244,213	CAG	.	.	.			247,210,223,234	53.95		0.5
GRCh38	NAB2	D12_12345_1234556_Thyroid_S9			chr12	57094050	57094050.0	C	T	T	57094050	.	C	T	.	PASS	NM_005967	T	intron_variant	MODIFIER	NAB2	ENSG00000166886	Transcript	ENST00000300131	protein_coding		6/6	c.1468+452C>T						rs141407717&COSV100272900&COSV55666835		1		SNV	HGNC	HGNC:7627	YES	MANE_Select	NM_005967.4		1	P3	CCDS8930.1	ENSP00000300131	Q15742.188		UPI000012FC41	Q15742-1		1						0.0046	0.0008	0.0043	0.001	0.0149	0.0031											0.01219	0.002848	0	0.005077	0.004622	0.0001971	0.03868	0	0.01754	0.01237	0.003154	0.03868	gnomADg_FIN		0&1&1	0&1&1							FAIL	-49	-37	44	47	0.00	0.00	0.00	0.01	NAB2		4.0300e-01																																																											952					0.988							246.84													chr12	57487833																																																	True	True	False	Unknown		Unknown																						475,466	206,191	269,275	0/1	250,225,251,215	CCG	0.00	0.00	0.00			227,248,246,220	50.73		0.4952178533475027
GRCh38	GLI1	D12_12345_1234556_Thyroid_S9	p.Glu192=	ENSP00000228682.2:p.Glu192=	chr12	57465648	57465648.0	G	A	A	57465648	.	G	A	.	PASS	NM_005269	A	synonymous_variant	LOW	GLI1	ENSG00000111087	Transcript	ENST00000228682	protein_coding	6/12		c.576G>A	1020	576	192	E	gaG/gaA	rs2228225&COSV57357787		1		SNV	HGNC	HGNC:4317	YES	MANE_Select	NM_005269.3		1	P1	CCDS8940.1	ENSP00000228682	P08151.242		UPI000012B607	P08151-1		1			AFDB-ENSP_mappings:AF-P08151-F1&PANTHER:PTHR45718			0.3630	0.1611	0.3934	0.3046	0.6233	0.407	0.5859	0.2253	0.3361	0.5788	0.4	0.5154	0.6489	0.6306	0.5488	0.4321	0.4751	0.2379	0.4879	0.4348	0.5798	0.3232	0.5165	0.6837	0.6297	0.5185	0.427	0.6837	gnomADg_MID	benign	0&1	1&1	20838396&21984931&19071955&23826113						FAIL	-35	27	13	40	0.01	0.00	0.01	0.00	GLI1		7.0400e-01	1277191	0.49762	0.49985	0.36302	1265771	Polydactyly_of_a_biphalangeal_thumb&GLI1-related_disorder&not_provided&Polydactyly&_postaxial&_type_A8		Human_Phenotype_Ontology:HP:0001177&Human_Phenotype_Ontology:HP:0005629&Human_Phenotype_Ontology:HP:0005634&Human_Phenotype_Ontology:HP:0006182&Human_Phenotype_Ontology:HP:0009604&MONDO:MONDO:0008269&MedGen:C1395852&OMIM:174400&Orphanet:93339&.&MedGen:C3661900&MONDO:MONDO:0029130&MedGen:C4748277&OMIM:618123		NC_000012.12:g.57465648G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001906827&SCV001933805&SCV001933806&SCV005235428	single_nucleotide_variant	SO:0001483	ClinGen:CA6648521		GLI1:2735	SO:0001819&synonymous_variant										1	2228225																											851					0.998							246.64	v6.1	Unknown		True	GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types.	False	09/19/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:E192= mutant UNKNOWN.	False	The GLI1 ENSP00000228682.2:e192= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	57859431						True	False	False	Unknown								False	False		GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types.	The GLI1 ENSP00000228682.2:e192= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:E192= mutant UNKNOWN.						v6.1	09/19/2024		GRCh38	GLI1	2735.0	ENSP00000228682.2:E192=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GLI1"",""entrezGeneId"":2735,""alteration"":""ENSP00000228682.2:E192="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types."",""variantSummary"":""The GLI1 ENSP00000228682.2:e192= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:E192= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/19/2024""}"	True	True	False	Unknown		Unknown																						0,849	0,401	0,448	0/1	0,0,436,413	AGG	0.00	0.00	0.00			0,0,436,413	64.73		1.0
GRCh38	GLI1	D12_12345_1234556_Thyroid_S9	p.G933D	ENSP00000228682.2:p.Gly933Asp	chr12	57471538	57471538.0	G	A	A	57471538	.	G	A	.	PASS	NM_005269	A	missense_variant	MODERATE	GLI1	ENSG00000111087	Transcript	ENST00000228682	protein_coding	12/12		c.2798G>A	3242	2798	933	G/D	gGt/gAt	rs2228224&COSV105849091&COSV57357796		1		SNV	HGNC	HGNC:4317	YES	MANE_Select	NM_005269.3		1	P1	CCDS8940.1	ENSP00000228682	P08151.242		UPI000012B607	P08151-1		1	tolerated(0.28)		AFDB-ENSP_mappings:AF-P08151-F1&PANTHER:PTHR45718&MobiDB_lite:mobidb-lite			0.3640	0.1626	0.3934	0.3036	0.6252	0.409	0.5865	0.2279	0.3361	0.6034	0.4001	0.5154	0.6499	0.6306	0.5504	0.432	0.4767	0.2406	0.4868	0.4349	0.6096	0.3231	0.5165	0.6837	0.6298	0.5204	0.4269	0.6837	gnomADg_MID	benign	0&1&1	1&1&1	21085059&26263974&30334169&22677152&19071955&23826113&28286483&34939981&20864405&36143291&21119888&37711539						FAIL	7	8	7	-1	0.00	0.00	0.00	0.00	GLI1	0.060	7.0400e-01	1240928	0.49815	0.50266	0.36402	1230466	Polydactyly&_postaxial&_type_A8&Polydactyly_of_a_biphalangeal_thumb&GLI1-related_disorder&not_provided		MONDO:MONDO:0029130&MedGen:C4748277&OMIM:618123&Human_Phenotype_Ontology:HP:0001177&Human_Phenotype_Ontology:HP:0005629&Human_Phenotype_Ontology:HP:0005634&Human_Phenotype_Ontology:HP:0006182&Human_Phenotype_Ontology:HP:0009604&MONDO:MONDO:0008269&MedGen:C1395852&OMIM:174400&Orphanet:93339&.&MedGen:C3661900		NC_000012.12:g.57471538G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001857976&SCV001933808&SCV001933809&SCV005235433	single_nucleotide_variant	SO:0001483	ClinGen:CA6649048		GLI1:2735	SO:0001583&missense_variant										1	2228224																											890					0.991							247.06	v6.1	Unknown		True	GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types.	False	09/19/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:G933D mutant UNKNOWN.	False	The GLI1 ENSP00000228682.2:g933d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	57865321						True	False	False	Unknown								False	False		GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types.	The GLI1 ENSP00000228682.2:g933d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:G933D mutant UNKNOWN.						v6.1	09/19/2024		GRCh38	GLI1	2735.0	ENSP00000228682.2:G933D			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GLI1"",""entrezGeneId"":2735,""alteration"":""ENSP00000228682.2:G933D"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types."",""variantSummary"":""The GLI1 ENSP00000228682.2:g933d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:G933D mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/19/2024""}"	True	True	False	Unknown		Unknown																						0,882	0,452	0,430	0/1	0,0,452,430	GGT	0.00	0.00	0.00			0,0,466,416	64.73		1.0
GRCh38	GLI1	D12_12345_1234556_Thyroid_S9	p.E1100Q	ENSP00000228682.2:p.Glu1100Gln	chr12	57472038	57472038.0	G	C	C	57472038	.	G	C	.	PASS	NM_005269	C	missense_variant	MODERATE	GLI1	ENSG00000111087	Transcript	ENST00000228682	protein_coding	12/12		c.3298G>C	3742	3298	1100	E/Q	Gaa/Caa	rs2228226&CM087618&COSV57357806		1		SNV	HGNC	HGNC:4317	YES	MANE_Select	NM_005269.3		1	P1	CCDS8940.1	ENSP00000228682	P08151.242		UPI000012B607	P08151-1		1	tolerated(1)		AFDB-ENSP_mappings:AF-P08151-F1&PANTHER:PTHR45718			0.5863	0.7882	0.4755	0.3958	0.674	0.498	0.6593	0.7796	0.4154	0.6853	0.4565	0.5683	0.7491	0.6826	0.6459	0.5133	0.6691	0.772	0.7303	0.535	0.6887	0.3907	0.5647	0.7877	0.6824	0.6711	0.5137	0.7882	AFR	benign	0&1&1	1&1&1	18817904&26715268&30334169&35403607&19071955&20445566&24470513&25352360&32629623&35457572&23727413&23826113&34939981&33462484&26613581&36143291&33381468&21119888						FAIL	17	1	26	15	0.00	0.00	0.00	0.00	GLI1	0.083	7.0400e-01	1285295	0.71183	0.60610	0.58626	1275138	not_provided&Polydactyly&_postaxial&_type_A8&Polydactyly_of_a_biphalangeal_thumb		MedGen:C3661900&MONDO:MONDO:0029130&MedGen:C4748277&OMIM:618123&Human_Phenotype_Ontology:HP:0001177&Human_Phenotype_Ontology:HP:0005629&Human_Phenotype_Ontology:HP:0005634&Human_Phenotype_Ontology:HP:0006182&Human_Phenotype_Ontology:HP:0009604&MONDO:MONDO:0008269&MedGen:C1395852&OMIM:174400&Orphanet:93339		NC_000012.12:g.57472038G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001933810&SCV001933811&SCV005235434	single_nucleotide_variant	SO:0001483	ClinGen:CA6649119		GLI1:2735	SO:0001583&missense_variant										1	2228226																											563					1							246.71	v6.1	Unknown		True	GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types.	False	09/19/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:E1100Q mutant UNKNOWN.	False	The GLI1 ENSP00000228682.2:e1100q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	57865821						True	False	False	Unknown								False	False		GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types.	The GLI1 ENSP00000228682.2:e1100q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:E1100Q mutant UNKNOWN.						v6.1	09/19/2024		GRCh38	GLI1	2735.0	ENSP00000228682.2:E1100Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GLI1"",""entrezGeneId"":2735,""alteration"":""ENSP00000228682.2:E1100Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GLI1, a transcription factor, is altered by mutation, amplification or overexpression in various cancer types."",""variantSummary"":""The GLI1 ENSP00000228682.2:e1100q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GLI1 ENSP00000228682.2:E1100Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/19/2024""}"	True	True	False	Unknown		Unknown																						1,562	1,272	0,290	0/1	0,1,290,272	AGA	.	.	.			0,1,174,388	64.73		0.9982238010657194
GRCh38	CDK4	D12_12345_1234556_Thyroid_S9			chr12	57745470	57745471.0	C	CA	CA	57745470	.	C	CA	.	PASS	NM_000075	A	downstream_gene_variant	MODIFIER	CDK4	ENSG00000135446	Transcript	ENST00000257904	protein_coding									rs35187428	2256	-1		insertion	HGNC	HGNC:1773	YES	MANE_Select	NM_000075.4		1	P1	CCDS8953.1	ENSP00000257904	P11802.259		UPI0000113582	P11802-1		1						0.3385	0.0378	0.255	0.6488	0.3141	0.5092	0.3549	0.07773	0.2944	0.2918	0.7243	0.3479	0.2036	0.3176	0.3158	0.4911	0.266	0.0786	0.3857	0.256	0.2896	0.6631	0.3759	0.1463	0.3178	0.2355	0.4979	0.7243	gnomADe_EAS																																																																																778					0.985							246.95													chr12	58139253																																																	True	True	False	Unknown		Unknown																						391,375	190,190	201,185	0/1	213,178,194,181	TCA						192,199,189,186	42.75		0.489556135770235
GRCh38	CDK4	D12_12345_1234556_Thyroid_S9			chr12	57749071	57749071.0	C	A	A	57749071	.	C	A	.	PASS	NM_000075	A	intron_variant	MODIFIER	CDK4	ENSG00000135446	Transcript	ENST00000257904	protein_coding		7/7	c.819+111G>T						rs2069506		-1		SNV	HGNC	HGNC:1773	YES	MANE_Select	NM_000075.4		1	P1	CCDS8953.1	ENSP00000257904	P11802.259		UPI0000113582	P11802-1		1						0.3363	0.0393	0.255	0.6458	0.3091	0.5041	0.3393	0.0729	0.334	0.2886	0.7073	0.3529	0.1914	0.321	0.3203	0.4868	0.2648	0.08179	0.3849	0.2563	0.2893	0.6555	0.3732	0.1463	0.3145	0.2353	0.4915	0.7073	gnomADe_EAS	benign		1	18174243&19258477&18281541						FAIL	4	0	2	9	0.00	0.00	0.00	0.00	CDK4		6.1000e-01	1182049			0.33626	1172462	not_provided		MedGen:C3661900		NC_000012.12:g.57749071C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001757367&SCV005228947	single_nucleotide_variant	SO:0001483	ClinGen:CA15730372		CDK4:1019&TSPAN31:6302	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant										1	2069506																											895					0.992							245.82													chr12	58142854																																																	True	True	False	Unknown		Unknown																						467,421	262,228	205,193	0/1	228,239,215,206	GCC	0.00	0.00	0.00			245,222,198,223	33.48		0.4740990990990991
GRCh38	CDK4	D12_12345_1234556_Thyroid_S9			chr12	57753436	57753436.0	G	A	A	57753436	.	G	A	.	PASS	NM_000075	A	upstream_gene_variant	MODIFIER	CDK4	ENSG00000135446	Transcript	ENST00000257904	protein_coding									rs3211602	1126	-1		SNV	HGNC	HGNC:1773	YES	MANE_Select	NM_000075.4		1	P1	CCDS8953.1	ENSP00000257904	P11802.259		UPI0000113582	P11802-1		1						0.0038	0	0.0029	0.001	0.0149	0.001											0.01199	0.002166	0.006579	0.004381	0.004608	0.0003851	0.05042	0	0.01557	0.01089	0.005804	0.05042	gnomADg_FIN																																																																																155					0.981							224.61													chr12	58147219																																																	True	True	False	Unknown		Unknown																						84,68	46,34	38,34	0/1	35,49,34,34	TGA	0.00	0.00	0.00			39,45,34,34	28.86		0.4473684210526316
GRCh38	CDK4	D12_12345_1234556_Thyroid_S9			chr12	57754938	57754939.0	T	TG	TG	57754938	.	T	TG	.	PASS	NM_000075	G	upstream_gene_variant	MODIFIER	CDK4	ENSG00000135446	Transcript	ENST00000257904	protein_coding									rs63680463	2628	-1		insertion	HGNC	HGNC:1773	YES	MANE_Select	NM_000075.4		1	P1	CCDS8953.1	ENSP00000257904	P11802.259		UPI0000113582	P11802-1		1						0.9998	1	1	1	1	0.999											0.9999	0.9999	1	1	1	1	0.9998	1	0.9999	1	0.9996	1	AFR&AMR&EAS&EUR&gnomADg_AMI&gnomADg_AMR&gnomADg_ASJ&gnomADg_EAS&gnomADg_MID&gnomADg_REMAINING																																																																																471					0.945							244.26													chr12	58148721																																																	True	True	False	Unknown		Unknown																						1,444	1,258	0,186	0/1	0,1,215,229	CTG						0,1,127,317	63.48		0.9977528089887641
GRCh38	MDM2	D12_12345_1234556_Thyroid_S9			chr12	68820911	68820911.0	G	A	A	68820911	.	G	A	.	PASS	NM_002392	A	intron_variant	MODIFIER	MDM2	ENSG00000135679	Transcript	ENST00000258149	protein_coding		5/10	c.358+537G>A						rs1201644		1		SNV	HGNC	HGNC:6973	YES	MANE_Select	NM_002392.6		1		CCDS8986.2	ENSP00000258149	Q00987.274		UPI00006CA35C	Q00987-11		1						0.4776	0.795	0.3559	0.2768	0.4831	0.3364											0.5298	0.7571	0.5396	0.3588	0.3304	0.2944	0.4573	0.432	0.4861	0.4805	0.3112	0.795	AFR				17360557						FAIL	41	-26	-15	-1	0.00	0.04	0.00	0.06	MDM2		3.2500e-01																																																											177					0.994							245.51													chr12	69214691																																																	True	True	False	Unknown		Unknown																						0,176	0,88	0,88	0/1	0,0,96,80	GGT	0.00	0.00	0.00			0,0,100,76	64.72		1.0
GRCh38	MDM2	D12_12345_1234556_Thyroid_S9			chr12	68821745	68821745.0	A	T	T	68821745	.	A	T	.	PASS	NM_002392	T	intron_variant	MODIFIER	MDM2	ENSG00000135679	Transcript	ENST00000258149	protein_coding		5/10	c.358+1371A>T						rs1206251		1		SNV	HGNC	HGNC:6973	YES	MANE_Select	NM_002392.6		1		CCDS8986.2	ENSP00000258149	Q00987.274		UPI00006CA35C	Q00987-11		1						0.2450	0.0923	0.2349	0.2579	0.4095	0.2761											0.3148	0.1471	0.521	0.2335	0.2625	0.2793	0.4423	0.2687	0.4236	0.3107	0.2449	0.521	gnomADg_AMI										FAIL	-25	-44	-2	-1	0.00	0.00	0.00	0.00	MDM2		3.2500e-01																																																											309					0.984							239.4													chr12	69215525																																																	True	True	False	Unknown		Unknown																						0,304	0,150	0,154	0/1	0,0,164,140	AAA	.	.	.			0,0,180,124	63.98		1.0
GRCh38	MDM2	D12_12345_1234556_Thyroid_S9			chr12	68822015	68822015.0	T	C	C	68822015	.	T	C	.	PASS	NM_002392	C	intron_variant	MODIFIER	MDM2	ENSG00000135679	Transcript	ENST00000258149	protein_coding		5/10	c.358+1641T>C						rs12821879		1		SNV	HGNC	HGNC:6973	YES	MANE_Select	NM_002392.6		1		CCDS8986.2	ENSP00000258149	Q00987.274		UPI00006CA35C	Q00987-11		1						0.1687	0.0182	0.196	0.1548	0.3539	0.1769											0.2487	0.06491	0.4035	0.1928	0.2114	0.172	0.3557	0.1939	0.3696	0.2332	0.1612	0.4035	gnomADg_AMI										FAIL	-41	27	13	1	0.00	0.00	0.00	0.00	MDM2		3.2500e-01																																																											401					0.988							234.63													chr12	69215795																																																	True	True	False	Unknown		Unknown																						195,201	100,109	95,92	0/1	91,104,105,96	CTG	.	.	.			114,81,107,94	45.49		0.5075757575757576
GRCh38	MDM2	D12_12345_1234556_Thyroid_S9			chr12	68832689	68832690.0	C	CT	CT	68832689	.	C	CT	.	PASS	NM_002392	T	intron_variant	MODIFIER	MDM2	ENSG00000135679	Transcript	ENST00000258149	protein_coding		8/10	c.685-3129dup						rs570742144		1		insertion	HGNC	HGNC:6973	YES	MANE_Select	NM_002392.6		1		CCDS8986.2	ENSP00000258149	Q00987.274		UPI00006CA35C	Q00987-11		1					11	0.2804	0.2141	0.2594	0.2579	0.4066	0.2781											0.3403	0.2355	0.527	0.2443	0.2628	0.2797	0.4281	0.2604	0.4256	0.3313	0.2445	0.527	gnomADg_AMI										FAIL	12	15	7	-34	0.00	0.01	0.00	0.00	MDM2		3.2500e-01																																																											435					0.841							212.79													chr12	69226469																																																	True	True	False	Unknown		Unknown																						65,301	34,160	31,141	0/1	28,37,134,167	ACT						21,44,139,162	53.12		0.8224043715846995
GRCh38	MDM2	D12_12345_1234556_Thyroid_S9			chr12	68836955	68836956.0	C	CT	CT	68836955	.	C	CT	.	PASS	NM_002392	T	intron_variant	MODIFIER	MDM2	ENSG00000135679	Transcript	ENST00000258149	protein_coding		10/10	c.918+224dup						rs35125243		1		insertion	HGNC	HGNC:6973	YES	MANE_Select	NM_002392.6		1		CCDS8986.2	ENSP00000258149	Q00987.274		UPI00006CA35C	Q00987-11		1					18	0.8207	0.6104	0.8156	0.9335	0.9046	0.9059											0.3487	0.1958	0.5876	0.2562	0.3152	0.3041	0.4397	0.3144	0.4548	0.3423	0.2706	0.9335	EAS										FAIL	25	-15	25	-16	0.02	0.00	0.00	0.00	MDM2		3.2500e-01																																																											203					0.571							225.19													chr12	69230735																																																	True	True	False	Unknown		Unknown																						72,44	32,24	40,20	0/1	43,29,17,27	ACT						35,37,15,29	26.42		0.3793103448275862
GRCh38	MDM2	D12_12345_1234556_Thyroid_S9			chr12	68838200	68838200.0	G	A	A	68838200	.	G	A	.	PASS	NM_002392	A	intron_variant	MODIFIER	MDM2	ENSG00000135679	Transcript	ENST00000258149	protein_coding		10/10	c.919-1074G>A						rs3730646		1		SNV	HGNC	HGNC:6973	YES	MANE_Select	NM_002392.6		1		CCDS8986.2	ENSP00000258149	Q00987.274		UPI00006CA35C	Q00987-11		1						0.2328	0.0628	0.2262	0.2579	0.3946	0.2751											0.2943	0.1127	0.5243	0.2208	0.2539	0.2812	0.4215	0.2449	0.4061	0.2914	0.2405	0.5243	gnomADg_AMI										FAIL	2	-28	4	-1	0.00	0.00	0.00	0.00	MDM2		3.2500e-01																																																											82					0.963							242.24													chr12	69231980																																																	True	True	False	Unknown		Unknown																						0,79	0,44	0,35	0/1	0,0,36,43	TGT	0.00	0.00	0.00			0,0,33,46	64.58		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr12	94282129	94282134.0	CAAAGT	C	C	94282129	.	CAAAGT	C	.	PASS		-	upstream_gene_variant	MODIFIER		ENSG00000258172	Transcript	ENST00000815690	lncRNA									rs61124555	4916	-1		deletion			YES																			0.4868	0.5635	0.4352	0.4236	0.4155	0.5583	0.4493	0.5403	0.4099	0.5054	0.378	0.3951	0.5558	0.4388	0.462	0.5519	0.4614	0.533	0.3466	0.4213	0.5127	0.4172	0.3956	0.479	0.4331	0.469	0.5455	0.5635	AFR																																																																																188					0.883							235.76													chr12	94675905																																																	True	False	False	Unknown		Unknown																						96,70	48,29	48,41	0/1	56,40,37,33	ACA						42,54,32,38	21.71		0.42168674698795183
GRCh38		D12_12345_1234556_Thyroid_S9			chr12	94596576		G	G[chr16:19781918[	G[chr16:19781918[	94596576	MantaBND:15841:0:1:0:0:0:0	G	G[chr16:19781918[	.	PASS		G.	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR12_BNQTT														chromosome_breakpoint																																																																																																																														0			0,4							4	CTTA			MantaBND:15841:0:1:0:0:0:1	3														chr12	94990352				BND																																													True	False	False	Unknown		Unknown																															0,0				0,3	
GRCh38		D12_12345_1234556_Thyroid_S9			chr12	105934476	105934476.0	T	C	C	105934476	.	T	C	.	PASS		C	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR12_BR2M5	promoter									rs2111980				SNV																						0.4421	0.2874	0.4683	0.379	0.5616	0.5746											0.4848	0.3248	0.5471	0.4884	0.4971	0.404	0.6196	0.4864	0.5626	0.4607	0.5346	0.6196	gnomADg_FIN				26522768&26691610&29121662&33406744&21611176&32195283&19083859&33640735&27294018&19948332																																																																												873					0.992							246.35													chr12	106328254																																																	True	False	False	Unknown		Unknown																						421,445	209,225	212,220	0/1	210,211,222,223	TTG	.	.	.			202,219,198,247	60.75		0.5138568129330254
GRCh38	SH2B3	D12_12345_1234556_Thyroid_S9	p.W262R	ENSP00000345492.2:p.Trp262Arg	chr12	111446804	111446804.0	T	C	C	111446804	.	T	C	.	PASS	NM_005475	C	missense_variant	MODERATE	SH2B3	ENSG00000111252	Transcript	ENST00000341259	protein_coding	3/8		c.784T>C	1166	784	262	W/R	Tgg/Cgg	rs3184504&CM084630&COSV57981059		1		SNV	HGNC	HGNC:29605	YES	MANE_Select	NM_005475.3		1	P1	CCDS9153.1	ENSP00000345492	Q9UQQ2.178		UPI000012E798			1	tolerated(1)	benign(0)	PANTHER:PTHR10872&Gene3D:2.30.29.30&SMART:SM00233&Superfamily:SSF50729&CDD:cd01231&AFDB-ENSP_mappings:AF-Q9UQQ2-F1			0.8526	0.9811	0.7464	0.997	0.5358	0.9315	0.5705	0.9352	0.7739	0.3494	0.9994	0.5989	0.6681	0.5143	0.5983	0.8923	0.6763	0.9178	0.5429	0.7066	0.3297	0.9981	0.6018	0.6259	0.5132	0.6502	0.9055	0.9994	gnomADe_EAS	benign	0&1&1	1&1&1	20610812&19430483&20224392&22504314&21507254&24987407&20190752&19430479&35088123&26870082&19862010&20805105&25542012&19913121&20440292&21369780&21378990&21860704&21875899&22144573&22151179&22588700&23468967&24932356&26847647&26892960&26958643&27189168&27313952&28686695&31845553&24219970&26293461&26950853&28209224&19956433&20729558&20971364&22216278&22363065&22848412&24931982&27294088&20453842&20933377&22355377&34919578&28739976&21383967&20948529&21045733&21572416&20560212&22139419&22057235&25920553&22493691&19820697&31456518&21060006&22277159&26974007&32929287&22046141&21378095&23303523&21253569&21852963&27532455&28107422&30065929&26843707&19430480&20587799&20885991&26904692&22144904&17554260&18556337&18978792&19073967&19951419&21266329&21270831&21595938&21829393&21873553&21980299&22315323&22328738&24274136&24773525&25075402&25422107&28646072&30291855&30888520&30967432&34199962&35470158&36034444&18252225&21153663&21738479&18311140&18713140&19648293&19693089&20647273&20854658&22087237&29182645&21909115&3276999						FAIL	-49	50	50	-7	0.04	0.00	0.03	0.00	SH2B3	0.158	1.3500e+00	1265448	0.63402	0.66255	0.85264	1254915	not_provided&Primary_familial_polycythemia_due_to_EPO_receptor_mutation&Thrombocythemia_1&Primary_myelofibrosis		MedGen:C3661900&MONDO:MONDO:0007572&MedGen:C4551637&OMIM:133100&Orphanet:90042&MONDO:MONDO:0008554&MedGen:C3277671&OMIM:187950&MONDO:MONDO:0009692&MeSH:D055728&MedGen:C0001815&OMIM:254450&Orphanet:824		NC_000012.12:g.111446804T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001891065&SCV002795933&SCV004562829&SCV005231468	single_nucleotide_variant	SO:0001483	ClinGen:CA6789733		SH2B3:10019	SO:0001583&missense_variant										1	3184504									699	SH2B3	RS3184504	C&Missense_Variant&Polymorphic_Sequence_Variant&SH2B3&10019&transcript&ENST00000341259.2&ENST00000341259.2:c.784T>C&&RS3184504&699&ARG262TRP&R262W&TRP262ARG&https://civicdb.org/links/variants/699&SH2B3_RS3184504&680&ARG262TRP&R262W&TRP262ARG&https://civicdb.org/links/molecular-profiles/680&NC_000012.11:g.111884608T>C&NM_005475.2:c.784T>C&ENST00000341259.2:c.784T>C&CA6789733&NONE_FOUND&10.0&evidence&1744&https://civicdb.org/links/evidence/1744&26621817_(PUBMED)&COMMON_GERMLINE&accepted&PREDISPOSITION&SUPPORTS&Colorectal_Cancer&&&&B&2&&&&&															918					0.999							246.98	v6.1	Unknown		True	SH2B3 is an adaptor protein that regulates growth factor and cytokine signaling. Mutations are found in hematopoietic disorders including leukemias and myeloid disease.	False	11/03/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SH2B3 ENSP00000345492.2:W262R mutant UNKNOWN.	False	The SH2B3 ENSP00000345492.2:w262r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	111884608					True	True	False	False	Unknown								False	False		SH2B3 is an adaptor protein that regulates growth factor and cytokine signaling. Mutations are found in hematopoietic disorders including leukemias and myeloid disease.	The SH2B3 ENSP00000345492.2:w262r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SH2B3 ENSP00000345492.2:W262R mutant UNKNOWN.						v6.1	11/03/2025		GRCh38	SH2B3	10019.0	ENSP00000345492.2:W262R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SH2B3"",""entrezGeneId"":10019,""alteration"":""ENSP00000345492.2:W262R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SH2B3 is an adaptor protein that regulates growth factor and cytokine signaling. Mutations are found in hematopoietic disorders including leukemias and myeloid disease."",""variantSummary"":""The SH2B3 ENSP00000345492.2:w262r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SH2B3 ENSP00000345492.2:W262R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/03/2025""}"	True	True	False	Unknown		Unknown																						452,465	224,233	228,232	0/1	243,209,237,228	GTG	.	.	.			221,231,223,242	76.29		0.5070883315158125
GRCh38	HNF1A	D12_12345_1234556_Thyroid_S9	p.Gly288=	ENSP00000257555.5:p.Gly288=	chr12	120994314	120994314.0	G	C	C	120994314	.	G	C	.	PASS	NM_000545	C	synonymous_variant	LOW	HNF1A	ENSG00000135100	Transcript	ENST00000257555	protein_coding	4/10		c.864G>C	1090	864	288	G	ggG/ggC	rs56348580&CD1413687&CM067044&COSV104568481&COSV57458899&COSV57459764&COSV57467482&CX1310026		1		SNV	HGNC	HGNC:11621	YES	MANE_Select	NM_000545.8		1	P4	CCDS9209.1	ENSP00000257555		A0A0A0MQU7.60	UPI000013CF6C			1			Low_complexity_(Seg):seg&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&PANTHER:PTHR11568&Gene3D:1.10.10.60&Pfam:PF04812&AFDB-ENSP_mappings:AF-P20823-F1			0.1811	0.1778	0.415	0.005	0.3032	0.0757	0.2836	0.2029	0.4254	0.3119	0.001137	0.2745	0.2413	0.3053	0.2696	0.1033	0.2624	0.2065	0.2297	0.367	0.3111	0.003486	0.2655	0.2828	0.3009	0.2792	0.1005	0.4254	gnomADe_AMR	benign&uncertain_significance	0&1&1&1&1&1&1&1	1&1&1&1&1&1&1&1	25741868&18414213&23127113&12627330&17573900&20132997&21224407&18513305&8945470&36257325&35108381&32541925&34864818&37268885&30297969&35663783&32193382&30814848&29371776&34226521&38529400&39175569						FAIL	11	-40	-10	-3	0.00	0.00	0.00	0.00	HNF1A		4.7700e-01	129236	0.23577	0.27878	0.18111	134682	Maturity_onset_diabetes_mellitus_in_young&not_provided&not_specified&Nonpapillary_renal_cell_carcinoma&Maturity-onset_diabetes_of_the_young_type_3&Type_2_diabetes_mellitus		Human_Phenotype_Ontology:HP:0004904&MONDO:MONDO:0018911&MedGen:C0342276&OMIM:PS125850&Orphanet:552&MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0007763&MedGen:CN074294&OMIM:144700&Orphanet:422526&MONDO:MONDO:0010894&MedGen:C1838100&OMIM:600496&Orphanet:552&Human_Phenotype_Ontology:HP:0005965&Human_Phenotype_Ontology:HP:0005978&Human_Phenotype_Ontology:HP:0100652&MONDO:MONDO:0005148&MeSH:D003924&MedGen:C0011860&OMIM:125853		NC_000012.12:g.120994314G>C	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(1)&Benign(10)		SCV000151407&SCV000168823&SCV000230121&SCV000305109&SCV000376714&SCV000613635&SCV001725506&SCV002505646&SCV002682517&SCV004015753&SCV005880767	single_nucleotide_variant	SO:0001483	ClinGen:CA153103		HNF1A:6927	SO:0001819&synonymous_variant										3	56348580													rs56348580	1	HNF1A	p.G288G											903					0.99							246.3	v6.1	Unknown		True	HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers.	False	08/08/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:G288= mutant UNKNOWN.	False	The HNF1A ENSP00000257555.5:g288= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	121432117					True	True	False	False	Unknown								False	False		HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers.	The HNF1A ENSP00000257555.5:g288= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:G288= mutant UNKNOWN.						v6.1	08/08/2019		GRCh38	HNF1A	6927.0	ENSP00000257555.5:G288=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HNF1A"",""entrezGeneId"":6927,""alteration"":""ENSP00000257555.5:G288="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers."",""variantSummary"":""The HNF1A ENSP00000257555.5:g288= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:G288= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/08/2019""}"	True	True	False	Unknown		Unknown																						0,894	0,482	0,412	0/1	0,0,467,427	GGC	.	.	.			0,0,453,441	81.97		1.0
GRCh38	HNF1A	D12_12345_1234556_Thyroid_S9	p.Thr515=	ENSP00000257555.5:p.Thr515=	chr12	120999311	120999311.0	G	A	A	120999311	.	G	A	.	PASS	NM_000545	A	synonymous_variant	LOW	HNF1A	ENSG00000135100	Transcript	ENST00000257555	protein_coding	8/10		c.1545G>A	1771	1545	515	T	acG/acA	rs55834942&COSV56566403&COSV56567209		1		SNV	HGNC	HGNC:11621	YES	MANE_Select	NM_000545.8		1	P4	CCDS9209.1	ENSP00000257555		A0A0A0MQU7.60	UPI000013CF6C			1			PANTHER:PTHR11568&Pfam:PF04812&AFDB-ENSP_mappings:AF-P20823-F1			0.0629	0.0121	0.1095	0.001	0.1988	0.0225	0.1737	0.02879	0.09221	0.2178	0.0002267	0.2269	0.1664	0.1945	0.1672	0.04295	0.1314	0.032	0.1184	0.1158	0.2156	0.001159	0.2217	0.1735	0.1933	0.1504	0.038	0.2269	gnomADe_FIN	benign&uncertain_significance	0&1&1	1&1&1	25741868&19672314&8945470&31384417&35663783&27398621&29371776&38152129&39175569						FAIL	2	16	1	16	0.01	0.08	0.00	0.00	HNF1A		4.7700e-01	129232	0.14065		0.06290	134678	not_provided&Maturity-onset_diabetes_of_the_young_type_3&Insulin-resistant_diabetes_mellitus&not_specified&Maturity_onset_diabetes_mellitus_in_young&Nonpapillary_renal_cell_carcinoma		MedGen:C3661900&MONDO:MONDO:0010894&MedGen:C1838100&OMIM:600496&Orphanet:552&Human_Phenotype_Ontology:HP:0000831&MedGen:C0854110&MedGen:CN169374&Human_Phenotype_Ontology:HP:0004904&MONDO:MONDO:0018911&MedGen:C0342276&OMIM:PS125850&Orphanet:552&MONDO:MONDO:0007763&MedGen:CN074294&OMIM:144700&Orphanet:422526		NC_000012.12:g.120999311G>A	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(1)&Benign(8)		SCV000168827&SCV000305101&SCV000376723&SCV000613603&SCV001731230&SCV002505509&SCV002709313&SCV004015754&SCV005880771	single_nucleotide_variant	SO:0001483	ClinGen:CA153091		HNF1A:6927	SO:0001819&synonymous_variant										3	55834942																											1029					0.998							246.87	v6.1	Unknown		True	HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers.	False	08/08/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:T515= mutant UNKNOWN.	False	The HNF1A ENSP00000257555.5:t515= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	121437114						True	False	False	Unknown								False	False		HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers.	The HNF1A ENSP00000257555.5:t515= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:T515= mutant UNKNOWN.						v6.1	08/08/2019		GRCh38	HNF1A	6927.0	ENSP00000257555.5:T515=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HNF1A"",""entrezGeneId"":6927,""alteration"":""ENSP00000257555.5:T515="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers."",""variantSummary"":""The HNF1A ENSP00000257555.5:t515= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:T515= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/08/2019""}"	True	True	False	Unknown		Unknown																						0,1027	0,585	0,442	0/1	0,0,551,476	CGG	0.00	0.00	0.00			0,0,547,480	64.73		1.0
GRCh38	HNF1A	D12_12345_1234556_Thyroid_S9	p.S574G	ENSP00000257555.5:p.Ser574Gly	chr12	120999579	120999579.0	A	G	G	120999579	.	A	G	.	PASS	NM_000545	G	missense_variant	MODERATE	HNF1A	ENSG00000135100	Transcript	ENST00000257555	protein_coding	9/10		c.1720A>G	1946	1720	574	S/G	Agc/Ggc	rs1169305&CM020516&COSV56568164		1		SNV	HGNC	HGNC:11621	YES	MANE_Select	NM_000545.8		1	P4	CCDS9209.1	ENSP00000257555		A0A0A0MQU7.60	UPI000013CF6C			1	tolerated(0.53)	benign(0)	PANTHER:PTHR11568&Pfam:PF04813&AFDB-ENSP_mappings:AF-P20823-F1			0.9852	0.9463	0.9957	1	1	1	0.9986	0.9526	0.9973	1	0.9998	1	0.9979	0.9999	0.9974	0.9999	0.9871	0.9553	1	0.9954	1	1	1	1	0.9998	0.9905	1	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_SAS	likely_pathogenic&benign	0&1&1	1&1&1	24033266&24728327&29334895&25887915&32708070&28453780&27035118&11938027&12355088&19228875&34668636&35663783&36407475						FAIL	-13	18	50	48	0.01	0.00	0.00	0.00	HNF1A	0.157	4.7700e-01	36810		0.99585	0.98522	45471	Symphalangism_affecting_the_proximal_phalanx_of_the_4th_finger&Monogenic_diabetes&Reduced_delayed_hypersensitivity&Diabetes_mellitus_type_1&Type_1_diabetes_mellitus_20&Hepatic_adenomas&_familial&Maturity-onset_diabetes_of_the_young_type_3&Type_2_diabetes_mellitus&Nonpapillary_renal_cell_carcinoma&Maturity_onset_diabetes_mellitus_in_young&not_specified&not_provided&Breast_carcinoma		Human_Phenotype_Ontology:HP:0009314&MedGen:C4024448&MONDO:MONDO:0015967&MedGen:C3888631&Orphanet:183625&Human_Phenotype_Ontology:HP:0002972&Human_Phenotype_Ontology:HP:0005434&MedGen:C1843386&Human_Phenotype_Ontology:HP:0100651&MONDO:MONDO:0005147&MedGen:C0011854&OMIM:222100&MONDO:MONDO:0012919&MedGen:C2675866&OMIM:612520&MONDO:MONDO:0007718&MedGen:C1840646&OMIM:142330&MONDO:MONDO:0010894&MedGen:C1838100&OMIM:600496&Orphanet:552&Human_Phenotype_Ontology:HP:0005965&Human_Phenotype_Ontology:HP:0005978&Human_Phenotype_Ontology:HP:0100652&MONDO:MONDO:0005148&MeSH:D003924&MedGen:C0011860&OMIM:125853&MONDO:MONDO:0007763&MedGen:CN074294&OMIM:144700&Orphanet:422526&Human_Phenotype_Ontology:HP:0004904&MONDO:MONDO:0018911&MedGen:C0342276&OMIM:PS125850&Orphanet:552&MedGen:CN169374&MedGen:C3661900&Human_Phenotype_Ontology:HP:0003002&MONDO:MONDO:0004989&MedGen:C0678222		NC_000012.12:g.120999579A>G	reviewed_by_expert_panel	Benign			SCV002520640	single_nucleotide_variant	SO:0001483	ClinGen:CA214285		HNF1A:6927	SO:0001583&missense_variant										1	1169305																											776					0.996							248.31	v6.1	Unknown		True	HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers.	False	08/08/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:S574G mutant UNKNOWN.	False	The HNF1A ENSP00000257555.5:s574g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	121437382						True	False	False	Unknown								False	False		HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers.	The HNF1A ENSP00000257555.5:s574g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:S574G mutant UNKNOWN.						v6.1	08/08/2019		GRCh38	HNF1A	6927.0	ENSP00000257555.5:S574G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HNF1A"",""entrezGeneId"":6927,""alteration"":""ENSP00000257555.5:S574G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HNF1A, a transcription factor, is altered by mutation in various cancer types. Germline mutations of HNF1A are associated with Maturity Onset Diabetes of Young (MODY3) and hepatic adenomas familial (HEPAF), while somatic inactivating mutations are found in a diverse range of cancers."",""variantSummary"":""The HNF1A ENSP00000257555.5:s574g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HNF1A ENSP00000257555.5:S574G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/08/2019""}"	True	True	False	Unknown		Unknown																						0,773	0,448	0,325	0/1	0,0,366,407	CAG	.	.	.			0,0,341,432	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr12	130277151	130277151.0	A	G	G	130277151	.	A	G	.	PASS		G	intergenic_variant	MODIFIER														rs10773760				SNV																						0.3514	0.2852	0.3718	0.3294	0.4235	0.3753											0.3893	0.306	0.5352	0.3813	0.4414	0.3447	0.4268	0.4524	0.4356	0.4198	0.3632	0.5352	gnomADg_AMI				26691610&29121662&33406744&27294018																																																																												864					1							247.38													chr12	130761696																																																	True	False	False	Unknown		Unknown																						422,442	212,231	210,211	0/1	199,223,219,223	AAG	.	.	.			167,255,180,262	59.74		0.5115740740740741
GRCh38	POLE	D12_12345_1234556_Thyroid_S9	p.Ser2084=	ENSP00000322570.5:p.Ser2084=	chr12	132632393	132632393.0	T	C	C	132632393	.	T	C	.	PASS	NM_006231	C	synonymous_variant	LOW	POLE	ENSG00000177084	Transcript	ENST00000320574	protein_coding	45/49		c.6252A>G	6279	6252	2084	S	tcA/tcG	rs5745022&COSV105207645		-1		SNV	HGNC	HGNC:9177	YES	MANE_Select	NM_006231.4		1	P1	CCDS9278.1	ENSP00000322570	Q07864.223		UPI00001FBF97			1			PDB-ENSP_mappings:7pfo.B&PDB-ENSP_mappings:7plo.B&AFDB-ENSP_mappings:AF-Q07864-F1&Phobius:CYTOPLASMIC_DOMAIN&PANTHER:PTHR10670			0.6991	0.7844	0.7464	0.7788	0.5656	0.6053	0.6031	0.7662	0.7843	0.5324	0.8061	0.5744	0.6197	0.5856	0.6117	0.6097	0.6591	0.7665	0.5912	0.7368	0.5256	0.8031	0.5788	0.6327	0.5883	0.6414	0.6259	0.8061	gnomADe_EAS	benign	0&1	1&1	28339009&27217144						FAIL	47	-2	44	-5	0.09	0.00	0.00	0.00	POLE		7.5000e-01	380217	0.64270	0.63814	0.69908	371896	Intrauterine_growth_retardation&_metaphyseal_dysplasia&_adrenal_hypoplasia_congenita&_genital_anomalies&_and_immunodeficiency&Facial_dysmorphism-immunodeficiency-livedo-short_stature_syndrome&Hereditary_cancer-predisposing_syndrome&not_provided&Colorectal_cancer&_susceptibility_to&_12&not_specified		MONDO:MONDO:0032684&MedGen:C5193036&OMIM:618336&MONDO:MONDO:0014058&MedGen:C3554576&OMIM:615139&Orphanet:352712&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MONDO:MONDO:0014038&MedGen:C3554460&OMIM:615083&Orphanet:220460&MedGen:CN169374		NC_000012.12:g.132632393T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000518001&SCV000581371&SCV000698682&SCV000711959&SCV000806829&SCV001000927&SCV001470787&SCV002031635&SCV002031636&SCV004016674&SCV005237204	single_nucleotide_variant	SO:0001483	ClinGen:CA6892242		POLE:5426	SO:0001819&synonymous_variant										1	5745022																											905					0.997							246.33	v6.1	Unknown		True	POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:S2084= mutant UNKNOWN.	False	The POLE ENSP00000322570.5:s2084= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	133208979						True	False	False	Unknown								False	False		POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer.	The POLE ENSP00000322570.5:s2084= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:S2084= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	POLE	5426.0	ENSP00000322570.5:S2084=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""POLE"",""entrezGeneId"":5426,""alteration"":""ENSP00000322570.5:S2084="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer."",""variantSummary"":""The POLE ENSP00000322570.5:s2084= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:S2084= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						0,902	0,406	0,496	0/1	0,0,427,475	CTG	.	.	.			0,0,441,461	64.73		1.0
GRCh38	POLE	D12_12345_1234556_Thyroid_S9	p.Ala1510=	ENSP00000322570.5:p.Ala1510=	chr12	132643245	132643245.0	T	C	C	132643245	.	T	C	.	PASS	NM_006231	C	synonymous_variant	LOW	POLE	ENSG00000177084	Transcript	ENST00000320574	protein_coding	35/49		c.4530A>G	4557	4530	1510	A	gcA/gcG	rs5744944&COSV57686501		-1		SNV	HGNC	HGNC:9177	YES	MANE_Select	NM_006231.4		1	P1	CCDS9278.1	ENSP00000322570	Q07864.223		UPI00001FBF97			1			PDB-ENSP_mappings:7pfo.B&PDB-ENSP_mappings:7plo.B&AFDB-ENSP_mappings:AF-Q07864-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR10670			0.6052	0.761	0.5317	0.6736	0.4304	0.5562	0.4563	0.7158	0.5719	0.3893	0.6971	0.4272	0.5109	0.4302	0.4707	0.5462	0.5354	0.7154	0.3235	0.5543	0.3819	0.701	0.4327	0.4966	0.434	0.5303	0.5584	0.761	AFR	benign	0&1	1&1	24033266&27217144						FAIL	47	37	-21	-25	0.01	0.00	0.00	0.00	POLE		7.5000e-01	380214	0.52237	0.50320	0.60523	372706	Facial_dysmorphism-immunodeficiency-livedo-short_stature_syndrome&Colorectal_cancer&_susceptibility_to&_12&Intrauterine_growth_retardation&_metaphyseal_dysplasia&_adrenal_hypoplasia_congenita&_genital_anomalies&_and_immunodeficiency&not_specified&Hereditary_cancer-predisposing_syndrome&not_provided		MONDO:MONDO:0014058&MedGen:C3554576&OMIM:615139&Orphanet:352712&MONDO:MONDO:0014038&MedGen:C3554460&OMIM:615083&Orphanet:220460&MONDO:MONDO:0032684&MedGen:C5193036&OMIM:618336&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900		NC_000012.12:g.132643245T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000517998&SCV000540082&SCV000581370&SCV000698676&SCV000806785&SCV001470785&SCV001730162&SCV002031644&SCV002031645&SCV004016677&SCV005237223&SCV006055398	single_nucleotide_variant	SO:0001483	ClinGen:CA6892815		POLE:5426	SO:0001819&synonymous_variant										1	5744944																											771					0.999							247.74	v6.1	Unknown		True	POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:A1510= mutant UNKNOWN.	False	The POLE ENSP00000322570.5:a1510= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	133219831						True	False	False	Unknown								False	False		POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer.	The POLE ENSP00000322570.5:a1510= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:A1510= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	POLE	5426.0	ENSP00000322570.5:A1510=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""POLE"",""entrezGeneId"":5426,""alteration"":""ENSP00000322570.5:A1510="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer."",""variantSummary"":""The POLE ENSP00000322570.5:a1510= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:A1510= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						0,770	0,375	0,395	0/1	0,0,366,404	ATG	.	.	.			0,0,445,325	64.73		1.0
GRCh38	POLE	D12_12345_1234556_Thyroid_S9	p.Thr1052=	ENSP00000322570.5:p.Thr1052=	chr12	132659414	132659414.0	C	T	T	132659414	.	C	T	.	PASS	NM_006231	T	synonymous_variant	LOW	POLE	ENSG00000177084	Transcript	ENST00000320574	protein_coding	26/49		c.3156G>A	3183	3156	1052	T	acG/acA	rs5744857&COSV105207436		-1		SNV	HGNC	HGNC:9177	YES	MANE_Select	NM_006231.4		1	P1	CCDS9278.1	ENSP00000322570	Q07864.223		UPI00001FBF97			1			Gene3D:1.10.132.60&PDB-ENSP_mappings:7pfo.B&PDB-ENSP_mappings:7plo.B&PDB-ENSP_mappings:9f6d.A&PDB-ENSP_mappings:9f6e.A&PDB-ENSP_mappings:9f6f.A&PDB-ENSP_mappings:9f6i.A&PDB-ENSP_mappings:9f6j.A&PDB-ENSP_mappings:9f6k.A&PDB-ENSP_mappings:9f6l.A&AFDB-ENSP_mappings:AF-Q07864-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF22634&PANTHER:PTHR10670&Superfamily:SSF56672&CDD:cd05535			0.6054	0.7602	0.5317	0.6736	0.4314	0.5573	0.4565	0.7157	0.572	0.3897	0.6973	0.4271	0.5184	0.4304	0.471	0.5461	0.5356	0.7154	0.3242	0.5546	0.3832	0.7011	0.4327	0.4966	0.4342	0.5308	0.5578	0.7602	AFR	benign	0&1	1&1	27217144&22493747&20503108						FAIL	-14	29	-9	-14	0.00	0.01	0.00	0.00	POLE		7.5000e-01	380212	0.52245	0.50285	0.60543	372744	Intrauterine_growth_retardation&_metaphyseal_dysplasia&_adrenal_hypoplasia_congenita&_genital_anomalies&_and_immunodeficiency&Hereditary_cancer-predisposing_syndrome&Facial_dysmorphism-immunodeficiency-livedo-short_stature_syndrome&not_provided&Colorectal_cancer&_susceptibility_to&_12&not_specified		MONDO:MONDO:0032684&MedGen:C5193036&OMIM:618336&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0014058&MedGen:C3554576&OMIM:615139&Orphanet:352712&MedGen:C3661900&MONDO:MONDO:0014038&MedGen:C3554460&OMIM:615083&Orphanet:220460&MedGen:CN169374		NC_000012.12:g.132659414C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000517995&SCV000581372&SCV000698670&SCV000711960&SCV000806758&SCV001473381&SCV001730163&SCV002031650&SCV002031651&SCV004016680&SCV005237242&SCV006053622	single_nucleotide_variant	SO:0001483	ClinGen:CA6893345		POLE:5426	SO:0001819&synonymous_variant										1	5744857																											1023					1							247.59	v6.1	Unknown		True	POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:T1052= mutant UNKNOWN.	False	The POLE ENSP00000322570.5:t1052= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr12	133236000						True	False	False	Unknown								False	False		POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer.	The POLE ENSP00000322570.5:t1052= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:T1052= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	POLE	5426.0	ENSP00000322570.5:T1052=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""POLE"",""entrezGeneId"":5426,""alteration"":""ENSP00000322570.5:T1052="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high mutation rates, most frequently in endometrial and colorectal cancer."",""variantSummary"":""The POLE ENSP00000322570.5:t1052= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with POLE ENSP00000322570.5:T1052= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						0,1023	0,501	0,522	0/1	0,0,520,503	ACG	0.00	0.00	0.00			0,0,446,577	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr13	20327590		G	<INS>	<INS>	20327590	MantaINS:16564:0:0:0:5:0	G	<INS>	.	PASS		insertion	intergenic_variant	MODIFIER																		insertion																																																																																																																															0,23		0,23							23	GCCAACAATACATACCTGCACCC		GCCAACAATACATACCTGCACCCAATACAGGAGCACCCAGATTCATAAAGCAAGTCCTTAGTGACCTACAAAGAGACTTAGACTCCCACACAAT																chr13	20901729	ACATTTTCCACTTCTATTGCACTCTGTCATGAAACTCAATGACCACAGTAGTTCCTTGTTCAAAA			INS																																													True	False	False	Unknown		Unknown																															4,3				29,3	
GRCh38	LATS2	D12_12345_1234556_Thyroid_S9	p.Pro516=	ENSP00000372035.4:p.Pro516=	chr13	20988232	20988232.0	C	T	T	20988232	.	C	T	.	PASS	NM_014572	T	synonymous_variant	LOW	LATS2	ENSG00000150457	Transcript	ENST00000382592	protein_coding	4/8		c.1548G>A	1993	1548	516	P	ccG/ccA	rs59928188&COSV66878728		-1		SNV	HGNC	HGNC:6515	YES	MANE_Select	NM_014572.3		1	P1	CCDS9294.1	ENSP00000372035	Q9NRM7.205		UPI000013DBF5			1			AFDB-ENSP_mappings:AF-Q9NRM7-F1&Low_complexity_(Seg):seg			0.0437	0.0605	0.0331	0.0665	0.0358	0.0133	0.03143	0.05449	0.03179	0.01539	0.05726	0.04169	0.0362	0.03121	0.03055	0.01284	0.03939	0.05138	0.003289	0.03587	0.01643	0.05876	0.04221	0.03401	0.03456	0.03214	0.01531	0.0665	EAS		0&1	0&1	38135866						FAIL	-13	-30	13	-41	0.00	0.00	0.00	0.00	LATS2		4.9300e-01																																																											853					0.999							248.51	v6.1	Unknown		True	LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:P516= mutant UNKNOWN.	False	The LATS2 ENSP00000372035.4:p516= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	21562371						True	False	False	Unknown								False	False		LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types.	The LATS2 ENSP00000372035.4:p516= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:P516= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	LATS2	26524.0	ENSP00000372035.4:P516=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LATS2"",""entrezGeneId"":26524,""alteration"":""ENSP00000372035.4:P516="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types."",""variantSummary"":""The LATS2 ENSP00000372035.4:p516= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:P516= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						439,413	235,204	204,209	0/1	209,230,209,204	GCG	0.00	0.00	0.00			173,266,170,243	41.78		0.4847417840375587
GRCh38	LATS2	D12_12345_1234556_Thyroid_S9	p.G363S	ENSP00000372035.4:p.Gly363Ser	chr13	20988693	20988693.0	C	T	T	20988693	.	C	T	.	PASS	NM_014572	T	missense_variant	MODERATE	LATS2	ENSG00000150457	Transcript	ENST00000382592	protein_coding	4/8		c.1087G>A	1532	1087	363	G/S	Ggc/Agc	rs2770928&COSV66873754		-1		SNV	HGNC	HGNC:6515	YES	MANE_Select	NM_014572.3		1	P1	CCDS9294.1	ENSP00000372035	Q9NRM7.205		UPI000013DBF5			1	tolerated(0.29)	benign(0.003)	AFDB-ENSP_mappings:AF-Q9NRM7-F1			0.8502	0.6876	0.9135	0.997	0.8767	0.8466	0.8806	0.707	0.9375	0.9329	0.9994	0.8213	0.8914	0.884	0.8828	0.8286	0.837	0.7174	0.9189	0.898	0.9363	0.9983	0.8186	0.9144	0.88	0.8674	0.8302	0.9994	gnomADe_EAS		0&1	1&1	33230300&34594039						FAIL	-21	-5	11	0	0.00	0.00	0.00	0.00	LATS2	0.107	4.9300e-01																																																											926					1							247.34	v6.1	Unknown		True	LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:G363S mutant UNKNOWN.	False	The LATS2 ENSP00000372035.4:g363s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	21562832						True	False	False	Unknown								False	False		LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types.	The LATS2 ENSP00000372035.4:g363s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:G363S mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	LATS2	26524.0	ENSP00000372035.4:G363S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LATS2"",""entrezGeneId"":26524,""alteration"":""ENSP00000372035.4:G363S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types."",""variantSummary"":""The LATS2 ENSP00000372035.4:g363s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:G363S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						458,468	214,204	244,264	0/1	243,215,241,227	CCC	0.00	0.00	0.00			263,195,245,223	57.83		0.5053995680345572
GRCh38	LATS2	D12_12345_1234556_Thyroid_S9	p.Lys27=	ENSP00000372035.4:p.Lys27=	chr13	21045946	21045946.0	T	C	C	21045946	.	T	C	.	PASS	NM_014572	C	synonymous_variant	LOW	LATS2	ENSG00000150457	Transcript	ENST00000382592	protein_coding	2/8		c.81A>G	526	81	27	K	aaA/aaG	rs7317471&COSV66880211		-1		SNV	HGNC	HGNC:6515	YES	MANE_Select	NM_014572.3		1	P1	CCDS9294.1	ENSP00000372035	Q9NRM7.205		UPI000013DBF5			1			AFDB-ENSP_mappings:AF-Q9NRM7-F1&MobiDB_lite:mobidb-lite			0.8075	0.6286	0.8501	0.8839	0.828	0.9192	0.8485	0.6533	0.9021	0.7168	0.9053	0.894	0.8131	0.8485	0.8267	0.8998	0.8006	0.6616	0.8081	0.8469	0.7179	0.8994	0.8915	0.7925	0.8496	0.8056	0.9079	0.9192	SAS		0&1	0&1	27110123&32423384&36033517&38135866						FAIL	36	-25	14	7	0.00	0.00	0.00	0.00	LATS2		4.9300e-01																																																											928					0.997							246.29	v6.1	Unknown		True	LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:K27= mutant UNKNOWN.	False	The LATS2 ENSP00000372035.4:k27= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	21620085						True	False	False	Unknown								False	False		LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types.	The LATS2 ENSP00000372035.4:k27= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:K27= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	LATS2	26524.0	ENSP00000372035.4:K27=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LATS2"",""entrezGeneId"":26524,""alteration"":""ENSP00000372035.4:K27="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LATS2, an intracellular kinase involved in Hippo signaling, is recurrently altered by mutation in various cancer types."",""variantSummary"":""The LATS2 ENSP00000372035.4:k27= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LATS2 ENSP00000372035.4:K27= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						1,924	1,485	0,439	0/1	0,1,458,466	GTT	.	.	.			0,1,373,551	64.73		0.9989189189189189
GRCh38	FGF9	D12_12345_1234556_Thyroid_S9			chr13	21692998	21692998.0	C	A	A	21692998	.	C	A	.	PASS	NM_002010	A	intron_variant	MODIFIER	FGF9	ENSG00000102678	Transcript	ENST00000382353	protein_coding		2/2	c.382-8192C>A						rs7991329		1		SNV	HGNC	HGNC:3687	YES	MANE_Select	NM_002010.3		1	P1	CCDS9298.1	ENSP00000371790	P31371.222	A0A7U3L6D0.13	UPI00000374AF			1						0.8129	0.5688	0.8761	0.9504	0.8499	0.9182											0.7801	0.6075	0.8432	0.8663	0.8414	0.9574	0.8204	0.8639	0.8321	0.8038	0.9058	0.9574	gnomADg_EAS										FAIL	16	1	3	16	0.00	0.00	0.00	0.00	FGF9		4.1800e-01																																																											166					0.964							242.32													chr13	22267137																																																	True	True	False	Unknown		Unknown																						0,160	0,83	0,77	0/1	0,0,73,87	ACA	0.00	0.00	0.00			0,0,70,90	64.72		1.0
GRCh38	FGF9	D12_12345_1234556_Thyroid_S9			chr13	21699151	21699151.0	C	T	T	21699151	.	C	T	.	PASS	NM_002010	T	intron_variant	MODIFIER	FGF9	ENSG00000102678	Transcript	ENST00000382353	protein_coding		2/2	c.382-2039C>T						rs7332774		1		SNV	HGNC	HGNC:3687	YES	MANE_Select	NM_002010.3		1	P1	CCDS9298.1	ENSP00000371790	P31371.222	A0A7U3L6D0.13	UPI00000374AF			1						0.7442	0.32	0.8444	0.9593	0.8439	0.9223											0.7147	0.3887	0.8432	0.8387	0.8373	0.9629	0.8159	0.8367	0.8276	0.7578	0.9052	0.9629	gnomADg_EAS										FAIL	7	-47	-37	12	0.00	0.00	0.00	0.00	FGF9		4.1800e-01																																																											571					0.996							247.29													chr13	22273290																																																	True	True	False	Unknown		Unknown																						0,569	0,277	0,292	0/1	0,0,289,280	ACA	0.00	0.00	0.00			0,0,395,174	64.73		1.0
GRCh38	FGF9	D12_12345_1234556_Thyroid_S9			chr13	21700177	21700177.0	G	C	C	21700177	.	G	C	.	PASS	NM_002010	C	intron_variant	MODIFIER	FGF9	ENSG00000102678	Transcript	ENST00000382353	protein_coding		2/2	c.382-1013G>C						rs1022924		1		SNV	HGNC	HGNC:3687	YES	MANE_Select	NM_002010.3		1	P1	CCDS9298.1	ENSP00000371790	P31371.222	A0A7U3L6D0.13	UPI00000374AF			1						0.9034	0.8048	0.9049	1	0.8728	0.9673											0.8603	0.8141	0.8629	0.9023	0.8879	0.999	0.8275	0.8844	0.865	0.8629	0.9592	1	EAS										FAIL	-2	-43	19	34	0.00	0.00	0.00	0.00	FGF9		4.1800e-01																																																											102					0.951							241.45													chr13	22274316																																																	True	True	False	Unknown		Unknown																						0,97	0,51	0,46	0/1	0,0,52,45	AGC	.	.	.			0,0,30,67	64.67		1.0
GRCh38	FGF9	D12_12345_1234556_Thyroid_S9	p.Ser149=	ENSP00000371790.5:p.Ser149=	chr13	21701255	21701255.0	A	G	G	21701255	.	A	G	.	PASS	NM_002010	G	synonymous_variant	LOW	FGF9	ENSG00000102678	Transcript	ENST00000382353	protein_coding	3/3		c.447A>G	1287	447	149	S	tcA/tcG	rs9509841&COSV108224303		1		SNV	HGNC	HGNC:3687	YES	MANE_Select	NM_002010.3		1	P1	CCDS9298.1	ENSP00000371790	P31371.222	A0A7U3L6D0.13	UPI00000374AF			1			PDB-ENSP_mappings:1g82.A&PDB-ENSP_mappings:1g82.B&PDB-ENSP_mappings:1g82.C&PDB-ENSP_mappings:1g82.D&PDB-ENSP_mappings:1ihk.A&PDB-ENSP_mappings:5w59.A&CDD:cd00058&Prints:PR00262&Prints:PR00263&PANTHER:PTHR11486&Pfam:PF00167&Gene3D:2.80.10.50&Superfamily:SSF50353&SMART:SM00442&AFDB-ENSP_mappings:AF-P31371-F1			0.8325	0.6339	0.8847	0.9603	0.8449	0.9192	0.8327	0.6571	0.9149	0.8463	0.9761	0.8061	0.858	0.8256	0.8276	0.899	0.7943	0.6628	0.8429	0.8707	0.8429	0.9635	0.8157	0.8741	0.829	0.8155	0.9051	0.9761	gnomADe_EAS	benign	0&1	1&1	29998616&19460469						FAIL	-36	-16	14	-16	0.00	0.00	0.00	0.00	FGF9		4.1800e-01	311424	0.77403		0.83247	333908	Multiple_synostoses_syndrome_3&not_specified&not_provided		MONDO:MONDO:0013064&MedGen:C2751826&OMIM:612961&Orphanet:3237&MedGen:CN169374&MedGen:C3661900		NC_000013.11:g.21701255A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000383184&SCV001933447&SCV002388934&SCV005230812	single_nucleotide_variant	SO:0001483	ClinGen:CA6909498		FGF9:2254	SO:0001819&synonymous_variant										1	9509841																											86					0.988							237.35	v6.1	Unknown		True	FGF9, a fibroblast growth factor, is altered by amplification in colorectal cancer.	False	05/10/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF9 ENSP00000371790.5:S149= mutant UNKNOWN.	False	The FGF9 ENSP00000371790.5:s149= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	22275394						True	False	False	Unknown								False	False		FGF9, a fibroblast growth factor, is altered by amplification in colorectal cancer.	The FGF9 ENSP00000371790.5:s149= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF9 ENSP00000371790.5:S149= mutant UNKNOWN.						v6.1	05/10/2024		GRCh38	FGF9	2254.0	ENSP00000371790.5:S149=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGF9"",""entrezGeneId"":2254,""alteration"":""ENSP00000371790.5:S149="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGF9, a fibroblast growth factor, is altered by amplification in colorectal cancer."",""variantSummary"":""The FGF9 ENSP00000371790.5:s149= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGF9 ENSP00000371790.5:S149= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""05/10/2024""}"	True	True	False	Unknown		Unknown																						0,85	0,41	0,44	0/1	0,0,42,43	CAT	.	.	.			0,0,56,29	64.61		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr13	21800561	21800561.0	G	A	A	21800561	.	G	A	.	PASS		A	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000302249	Transcript	ENST00000785196	lncRNA		1/1	n.238+5292G>A						rs1886510		1		SNV																						0.2606	0.0946	0.4568	0.1558	0.5249	0.182											0.398	0.1671	0.6923	0.4668	0.3839	0.1484	0.4958	0.3503	0.5368	0.3929	0.2213	0.6923	gnomADg_AMI			1	26691610&29121662&33406744&34721519&19083859&24362753&27294018&36134022&32450446&19948332																																																																												119					0.983							245.76													chr13	22374700																																																	True	False	False	Unknown		Unknown																						0,117	0,58	0,59	0/1	0,0,74,43	CGA	0.00	0.00	0.00			0,0,51,66	64.7		1.0
GRCh38	SPATA13	D12_12345_1234556_Thyroid_S9			chr13	24094909		A	[chr2:240268330[A	[chr2:240268330[A	24094909	MantaBND:8048:0:1:0:0:0:0	A	[chr2:240268330[A	.	PASS		.A	feature_truncation&intron_variant	HIGH	SPATA13	ENSG00000182957	Transcript	ENST00000424834	protein_coding		3/14									1		chromosome_breakpoint	HGNC	HGNC:23222					1		CCDS53857.1	ENSP00000398560	Q96N96.180		UPI000165C148	Q96N96-6																																																																																																																1			0,5							5	GTGTT			MantaBND:8048:0:1:0:0:0:1	3														chr13	24669048				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38	FLT3	D12_12345_1234556_Thyroid_S9			chr13	28036046	28036046.0	A	G	G	28036046	.	A	G	.	PASS	NM_004119	G	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	FLT3	ENSG00000122025	Transcript	ENST00000241453	protein_coding		10/23	c.1310-3T>C						rs2491231&COSV54043781		-1		SNV	HGNC	HGNC:3765	YES	MANE_Select	NM_004119.3		1	P1	CCDS31953.1	ENSP00000241453	P36888.218		UPI00001FC90B	P36888-1		1						0.5633	0.1944	0.7161	0.7351	0.7724	0.5613	0.7533	0.2561	0.7098	0.7179	0.6901	0.8055	0.6567	0.784	0.7309	0.6028	0.6163	0.2734	0.7055	0.6611	0.7239	0.7297	0.796	0.6207	0.7728	0.6455	0.5941	0.8055	gnomADe_FIN	benign	0&1	1&1	29434720&30867801&35152189&36780540&36077746&32612806						FAIL	-3	-24	-31	-3	0.04	0.00	0.00	0.00	FLT3		4.6800e-01	1291994	0.61641	0.69932	0.56330	1281808	not_provided		MedGen:C3661900		NC_000013.11:g.28036046A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001943259&SCV005233965	single_nucleotide_variant	SO:0001483	ClinGen:CA6928705		FLT3:2322	SO:0001627&intron_variant										1	2491231																											88					0.977							245.67													chr13	28610183																																																	True	True	False	Unknown		Unknown																						0,86	0,41	0,45	0/1	0,0,43,43	TAT	.	.	.			0,0,34,52	64.62		1.0
GRCh38	FLT3	D12_12345_1234556_Thyroid_S9	p.Asp96=	ENSP00000241453.7:p.Asp96=	chr13	28061947	28061947.0	G	A	A	28061947	.	G	A	.	PASS	NM_004119	A	synonymous_variant	LOW	FLT3	ENSG00000122025	Transcript	ENST00000241453	protein_coding	3/24		c.288C>T	354	288	96	D	gaC/gaT	rs7338903&COSV54043799		-1		SNV	HGNC	HGNC:3765	YES	MANE_Select	NM_004119.3		1	P1	CCDS31953.1	ENSP00000241453	P36888.218		UPI00001FC90B	P36888-1		1			PDB-ENSP_mappings:3qs7.E&PDB-ENSP_mappings:3qs7.F&PDB-ENSP_mappings:3qs7.G&PDB-ENSP_mappings:3qs7.H&PDB-ENSP_mappings:3qs9.E&PDB-ENSP_mappings:3qs9.F&PDB-ENSP_mappings:3qs9.G&PDB-ENSP_mappings:3qs9.H&PDB-ENSP_mappings:7qdp.E&PDB-ENSP_mappings:7qdp.F&PDB-ENSP_mappings:7qdp.G&PDB-ENSP_mappings:7qdp.H&PDB-ENSP_mappings:7zv9.B&PDB-ENSP_mappings:7zv9.D&PDB-ENSP_mappings:7zv9.F&PDB-ENSP_mappings:7zv9.H&PDB-ENSP_mappings:7zv9.J&PDB-ENSP_mappings:7zv9.L&PDB-ENSP_mappings:7zv9.N&PDB-ENSP_mappings:7zv9.P&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000615&AFDB-ENSP_mappings:AF-P36888-F1			0.9581	0.8707	0.9726	0.996	0.9891	0.9949	0.9871	0.906	0.9894	0.9951	0.9994	0.9958	0.9853	0.9879	0.9843	0.9952	0.9648	0.9033	0.9956	0.9806	0.9963	0.9985	0.9959	0.9898	0.9871	0.9706	0.994	0.9994	gnomADe_EAS	benign	0&1	1&1							FAIL	-37	10	16	10	0.00	0.00	0.00	0.00	FLT3		4.6800e-01	1280165	0.95994	0.98274	0.95807	1270029	not_provided		MedGen:C3661900		NC_000013.11:g.28061947G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001913016&SCV005235894	single_nucleotide_variant	SO:0001483	ClinGen:CA6928958		FLT3:2322	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	7338903																											759					1							246.27	v6.1	Unknown		True	FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.	False	04/09/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT3 ENSP00000241453.7:D96= mutant UNKNOWN.	False	The FLT3 ENSP00000241453.7:d96= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	28636084						True	False	False	Unknown								False	False		FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.	The FLT3 ENSP00000241453.7:d96= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT3 ENSP00000241453.7:D96= mutant UNKNOWN.						v6.1	04/09/2017		GRCh38	FLT3	2322.0	ENSP00000241453.7:D96=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FLT3"",""entrezGeneId"":2322,""alteration"":""ENSP00000241453.7:D96="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies."",""variantSummary"":""The FLT3 ENSP00000241453.7:d96= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT3 ENSP00000241453.7:D96= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/09/2017""}"	True	True	False	Unknown		Unknown																						0,759	0,388	0,371	0/1	0,0,397,362	CGT	0.00	0.00	0.00			0,0,444,315	64.73		1.0
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9	p.Tyr1213=	ENSP00000282397.4:p.Tyr1213=	chr13	28308924	28308924.0	G	A	A	28308924	.	G	A	.	PASS	NM_002019	A	synonymous_variant	LOW	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding	28/30		c.3639C>T	3924	3639	1213	Y	taC/taT	rs7993418&COSV56717614		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1			Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P17948-F1			0.7308	0.2769	0.8285	1	0.7952	0.9315	0.7977	0.3366	0.8667	0.8494	0.9993	0.7859	0.7119	0.7953	0.7864	0.882	0.6861	0.3564	0.7259	0.816	0.8542	0.9967	0.7945	0.6871	0.7916	0.7334	0.8962	1	EAS		0&1	0&1	28926193&22808003&32555399&27117754&27175586&27843601&35893809&33916610&35075138&27147901&23511629&22608783&23421954&27417418&34298648&36919054&34108518&31462894&37240136&36601631&35625740&36559251&23026828&32836220&37862026&37425411&38087190&38341189						FAIL	3	-1	-27	0	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											309					0.994							203.76	v6.1	Unknown		True	FLT1, a receptor tyrosine kinase involved in cell survival and tumor angiogenesis, is infrequently altered in cancer.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT1 ENSP00000282397.4:Y1213= mutant UNKNOWN.	False	The FLT1 ENSP00000282397.4:y1213= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	28883061						True	False	False	Unknown								False	False		FLT1, a receptor tyrosine kinase involved in cell survival and tumor angiogenesis, is infrequently altered in cancer.	The FLT1 ENSP00000282397.4:y1213= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT1 ENSP00000282397.4:Y1213= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	FLT1	2321.0	ENSP00000282397.4:Y1213=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FLT1"",""entrezGeneId"":2321,""alteration"":""ENSP00000282397.4:Y1213="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FLT1, a receptor tyrosine kinase involved in cell survival and tumor angiogenesis, is infrequently altered in cancer."",""variantSummary"":""The FLT1 ENSP00000282397.4:y1213= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT1 ENSP00000282397.4:Y1213= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						176,131	85,65	91,66	0/1	92,84,67,64	CGT	0.00	0.00	0.00			83,93,65,66	19.4		0.42671009771986973
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28368313	28368313.0	T	C	C	28368313	.	T	C	.	PASS	NM_002019	C	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		14/29	c.2117-10628A>G						rs9508020		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.9483	0.826	0.9798	1	0.9881	0.9969	0.9868	0.852	0.9828	0.9848	0.9999	0.9984	0.9797	0.9899	0.9829	0.9993	0.9517	0.8523	0.9956	0.9762	0.9891	0.9998	0.9978	0.9898	0.9897	0.9602	0.9985	1	EAS										FAIL	8	2	38	-1	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											179					0.989							143.28													chr13	28942450																																																	True	True	False	Unknown		Unknown																						0,177	0,85	0,92	0/1	0,0,85,92	CTG	.	.	.			0,0,83,94	64.72		1.0
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28386331	28386331.0	A	C	C	28386331	.	A	C	.	PASS	NM_002019	C	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1970-1300T>G						rs7319123		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.9657	0.8767	0.987	1	1	1	0.9974	0.8972	0.9897	1	0.9999	1	0.9902	0.9998	0.9931	0.9998	0.9709	0.9006	1	0.986	1	1	1	0.983	0.9996	0.9773	0.9996	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN										FAIL	44	10	1	-4	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											87					1							247.56													chr13	28960468																																																	True	True	False	Unknown		Unknown																						1,86	1,51	0,35	0/1	0,1,39,47	AAT	.	.	.			0,1,38,48	64.58		0.9885057471264368
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28386456	28386456.0	T	A	A	28386456	.	T	A	.	PASS	NM_002019	A	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1970-1425A>T						rs3751397		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.4141	0.1649	0.5303	0.5298	0.5179	0.4427	0.527	0.1977	0.4964	0.5353	0.5615	0.4472	0.4934	0.5362	0.503	0.4849	0.4324	0.2151	0.6099	0.4816	0.5649	0.5361	0.4508	0.568	0.5288	0.4759	0.4805	0.6099	gnomADg_AMI				33246355&23794399&28323906						FAIL	-43	0	2	-38	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											100					0.95							241.36													chr13	28960593																																																	True	True	False	Unknown		Unknown																						46,49	17,31	29,18	0/1	27,19,28,21	ATC	.	.	.			20,26,20,29	37		0.5157894736842106
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28387702	28387702.0	C	T	T	28387702	.	C	T	.	PASS	NM_002019	T	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+2094G>A						rs7325639		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.9423	0.823	0.9726	1	0.9901	0.9734	0.9621	0.8097	0.9592	0.9684	0.9769	0.9824	0.9581	0.9658	0.9563	0.959	0.9504	0.8495	0.9956	0.9766	0.9919	1	0.9978	0.9722	0.9897	0.9606	0.9796	1	EAS&gnomADg_EAS										FAIL	37	-44	46	34	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											216					0.699							225.53													chr13	28961839																																																	True	True	False	Unknown		Unknown																						2,149	1,74	1,75	0/1	1,1,90,59	TCC	0.00	0.00	0.00			0,2,77,72	45.17		0.9867549668874173
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28388454	28388455.0	GT	G	G	28388454	.	GT	G	.	PASS	NM_002019	-	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+1341del						rs61707719		-1		deletion	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.3720	0.2988	0.2435	0.4792	0.3996	0.4233	0.372	0.2958	0.2521	0.3505	0.4041	0.4735	0.3711	0.3736	0.3691	0.3923	0.3704	0.3072	0.3841	0.3012	0.3569	0.4551	0.4969	0.331	0.3957	0.3712	0.4231	0.4969	gnomADg_FIN										FAIL	-18	13	42	1	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											95					0.705							235.11													chr13	28962591																																																	True	True	False	Unknown		Unknown																						39,28	26,17	13,11	0/1	23,16,10,18	AGT						20,19,19,9	21.01		0.417910447761194
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28388529	28388529.0	T	C	C	28388529	.	T	C	.	PASS	NM_002019	C	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+1267A>G						rs7337610		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.4856	0.2474	0.5403	0.5129	0.6143	0.6084	0.6169	0.2821	0.5063	0.6303	0.5533	0.5497	0.6284	0.6262	0.5988	0.6448	0.5163	0.3021	0.6857	0.5221	0.6589	0.5323	0.5497	0.6724	0.6198	0.5497	0.6311	0.6857	gnomADg_AMI			1	30696427&33246355&29808027&19741061&23794399&28323906&34989438&37178326						FAIL	-1	-44	1	-43	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											103					0.883							232.24													chr13	28962666																																																	True	True	False	Unknown		Unknown																						41,50	19,23	22,27	0/1	25,16,18,32	ATT	.	.	.			21,20,21,29	39.82		0.5494505494505495
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28388549	28388549.0	T	C	C	28388549	.	T	C	.	PASS	NM_002019	C	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+1247A>G						rs17086617&COSV56740576		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.2839	0.1657	0.1758	0.4732	0.3171	0.2914	0.2972	0.1711	0.1989	0.3121	0.4249	0.4031	0.2894	0.2989	0.2955	0.2719	0.2704	0.1761	0.2896	0.218	0.2932	0.4482	0.4024	0.2295	0.3038	0.2682	0.2819	0.4732	EAS		0&1	1&1	33246355&36474045						FAIL	5	17	1	36	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											105					0.905							237.15													chr13	28962686																																																	True	True	False	Unknown		Unknown																						54,41	30,15	24,26	0/1	23,31,25,16	ATT	.	.	.			25,29,17,24	27.46		0.43157894736842106
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28388620	28388620.0	A	T	T	28388620	.	A	T	.	PASS	NM_002019	T	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+1176T>A						rs9551465		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.4000	0.1203	0.4841	0.5089	0.5308	0.4714	0.5275	0.1562	0.4424	0.5691	0.5517	0.4299	0.5247	0.5372	0.5069	0.503	0.4196	0.1751	0.5954	0.4474	0.596	0.5263	0.4605	0.5788	0.5298	0.4555	0.4909	0.596	gnomADg_ASJ			1	33246355&34413389&35285134						FAIL	7	-17	7	-35	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											111					0.919							235.89													chr13	28962757																																																	True	True	False	Unknown		Unknown																						50,52	25,19	25,33	0/1	28,22,23,29	TAA	.	.	.			27,23,26,26	36.72		0.5098039215686274
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28389146	28389147.0	TA	T	T	28389146	.	TA	T	.	PASS	NM_002019	-	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+649del						rs5802479		-1		deletion	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.5577	0.7005	0.5245	0.5159	0.4851	0.5061	0.4863	0.4871	0.47	0.4748	0.4748	0.5104	0.4774	0.4868	0.4827	0.49	0.5189	0.6094	0.4097	0.5311	0.4087	0.4767	0.553	0.3986	0.469	0.5099	0.4924	0.7005	AFR										FAIL	-8	-2	42	46	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											161					0.708							245.38													chr13	28963283																																																	True	True	False	Unknown		Unknown																						55,59	25,27	30,32	0/1	29,26,29,30	GTA						31,24,37,22	37.31		0.5175438596491229
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28389539	28389539.0	G	A	A	28389539	.	G	A	.	PASS	NM_002019	A	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+257C>T						rs2296284&COSV56740584		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.2772	0.1551	0.1628	0.4633	0.3082	0.2996	0.295	0.1677	0.1883	0.308	0.4103	0.4072	0.2689	0.2938	0.295	0.2806	0.2638	0.1682	0.289	0.2056	0.2904	0.4416	0.4012	0.2041	0.2972	0.2628	0.2896	0.4633	EAS		0&1	0&1	33246355						FAIL	-35	2	48	-28	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											935					0.996							248.51													chr13	28963676																																																	True	True	False	Unknown		Unknown																						446,485	234,256	212,229	0/1	209,237,223,262	CGG	0.00	0.00	0.00			223,223,240,245	62.51		0.5209452201933404
GRCh38	FLT1	D12_12345_1234556_Thyroid_S9			chr13	28389565	28389565.0	G	A	A	28389565	.	G	A	.	PASS	NM_002019	A	intron_variant	MODIFIER	FLT1	ENSG00000102755	Transcript	ENST00000282397	protein_coding		13/29	c.1969+231C>T						rs2296283		-1		SNV	HGNC	HGNC:3763	YES	MANE_Select	NM_002019.4		1	P1	CCDS9330.1	ENSP00000282397	P17948.254	L7RSL3.81	UPI000013DCDD	P17948-1		1						0.4016	0.121	0.487	0.5099	0.5348	0.4714	0.5285	0.1657	0.4539	0.5781	0.556	0.459	0.5289	0.5427	0.5086	0.5016	0.4241	0.1764	0.6031	0.4528	0.5975	0.5279	0.4655	0.5884	0.5364	0.4588	0.495	0.6031	gnomADg_AMI				33246355&19741061&28323906&32929141&25330801						FAIL	-5	39	18	22	0.00	0.00	0.00	0.00	FLT1		3.7900e-01																																																											878					0.993							249.13													chr13	28963702																																																	True	True	False	Unknown		Unknown																						429,443	223,229	206,214	0/1	189,240,205,238	GGG	0.00	0.00	0.00			161,268,177,266	58.26		0.5080275229357798
GRCh38	ALOX5AP	D12_12345_1234556_Thyroid_S9			chr13	30754245	30754259.0	G	GAGAGAGAAAGCTGA	GAGAGAGAAAGCTGA	30754245	.	G	GAGAGAGAAAGCTGA	.	PASS		AGAGAGAAAGCTGA	intron_variant	MODIFIER	ALOX5AP	ENSG00000132965	Transcript	ENST00000617770	protein_coding		4/5	c.413-1697_413-1696insAGAGAAAGCTGAAG						rs17238892		1		insertion	HGNC	HGNC:436					1		CCDS73558.1	ENSP00000479870		A0A087WW23.66	UPI0000E00F64			1					2	0.4521	0.4826	0.4741	0.3492	0.5606	0.3896											0.505	0.4648	0.6413	0.4945	0.4936	0.3748	0.5553	0.4014	0.5402	0.4915	0.4129	0.6413	gnomADg_AMI				23690203&23138099&36292568																	8.1800e-01																																																											250					0.972							164.78													chr13	31328382																																																	True	False	False	Unknown		Unknown																						0,243	0,129	0,114	0/1	0,0,129,114	AGA						0,0,171,72	63.48		1.0
GRCh38	BRCA2	D12_12345_1234556_Thyroid_S9			chr13	32328875	32328877.0	A	AGT	AGT	32328875	.	A	AGT	.	PASS	NM_000059	GT	intron_variant	MODIFIER	BRCA2	ENSG00000139618	Transcript	ENST00000380152	protein_coding		7/26	c.632-551_632-550dup						rs397843915		1		insertion	HGNC	HGNC:1101	YES	MANE_Select	NM_000059.4		5	A2	CCDS9344.1	ENSP00000369497	P51587.244		UPI00001FCBCC			1					18	0.1220	0.059	0.0879	0.1528	0.1968	0.1227											0.1434	0.07707	0.2775	0.1127	0.1344	0.1392	0.1842	0.2138	0.1854	0.1523	0.1062	0.2775	gnomADg_AMI			1																		8.0300e-01	264864				259430	Breast-ovarian_cancer&_familial&_susceptibility_to&_2		MONDO:MONDO:0012933&MedGen:C2675520&OMIM:612555&Orphanet:145		NC_000013.11:g.32328876GT[10]	reviewed_by_expert_panel	Benign			SCV000321170	Microsatellite	SO:0000289	ClinGen:CA10588084		BRCA2:675	SO:0001627&intron_variant										1	397843915																											134					0.604							231.71													chr13	32903012																																																	True	True	False	Unknown		Unknown																						38,43	21,25	17,18	0/1	14,24,23,20	AAG						13,25,23,20	37.23		0.5308641975308642
GRCh38	BRCA2	D12_12345_1234556_Thyroid_S9	p.N372H	ENSP00000369497.3:p.Asn372His	chr13	32332592	32332592.0	A	C	C	32332592	.	A	C	.	PASS	NM_000059	C	missense_variant	MODERATE	BRCA2	ENSG00000139618	Transcript	ENST00000380152	protein_coding	10/27		c.1114A>C	1313	1114	372	N/H	Aat/Cat	rs144848&CM002750&COSV66448817		1		SNV	HGNC	HGNC:1101	YES	MANE_Select	NM_000059.4		5	A2	CCDS9344.1	ENSP00000369497	P51587.244		UPI00001FCBCC			1	deleterious(0.04)	benign(0.003)	PIRSF:PIRSF002397&PANTHER:PTHR11289&MobiDB_lite:mobidb-lite			0.2494	0.084	0.2997	0.2847	0.2952	0.3538	0.2805	0.1253	0.302	0.3532	0.2363	0.232	0.3008	0.2814	0.276	0.3494	0.2379	0.1252	0.295	0.304	0.3603	0.2581	0.2215	0.2603	0.2764	0.2666	0.3577	0.3603	gnomADg_ASJ	benign&uncertain_significance	0&1&1	1&1&1	25741868&24728327&21514219&20003265&33126731&22253860&16857995&18547414&18830263&21296624&19902366&22703879&29458332&19276285&24062231&18974877&18086758&18431743&19500380&18579371&15113441&29209986&28418863&22532573&19138047&21987080&25178586&22875147&29963112&22430443&30677706&22513257&12466288&17428325&35637613&21161372&11062481&11927503&14555511&15235023&17767707&19644020&20135345&23961350&24323938&26979245&27478808&28415599&33499154&34008499&23767878&23451180&18694767&33643918&34295994&23313170&25802882&26496279&24052750&35870994&19383379&25653542&28418854&35908255&19012493&32284662&29891014&29921024&29657992&31938277&29884136&18059179&29785135&35456488&37204320&23964347&31131559&33162799&35510381&34242281&34367235&28076423&32579544&33357097&22065914&33507988&29997359&24289560&31962039&26052455&25923920&34758846&18062861&17182175&37804357&38156855&38019249&39135053						FAIL	-14	26	47	-30	0.00	0.00	0.00	0.00	BRCA2	0.041	8.0300e-01	9329		0.27793	0.24940	24368	Hereditary_breast_ovarian_cancer_syndrome&Breast_ductal_adenocarcinoma&Breast_carcinoma&BRCA2-related_cancer_predisposition&not_provided&Familial_cancer_of_breast&Glioma_susceptibility_3&Pancreatic_cancer&_susceptibility_to&_2&Prostate_cancer&Wilms_tumor_1&Medulloblastoma&Fanconi_anemia_complementation_group_D1&Breast-ovarian_cancer&_familial&_susceptibility_to&_2&Hereditary_cancer-predisposing_syndrome&not_specified		MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MONDO:MONDO:0005590&MedGen:C1527349&Human_Phenotype_Ontology:HP:0003002&MONDO:MONDO:0004989&MedGen:C0678222&MONDO:MONDO:0700269&MedGen:CN377758&MedGen:C3661900&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0013093&MedGen:C2751641&OMIM:613029&Orphanet:182067&Orphanet:360&MONDO:MONDO:0013235&MedGen:C3150546&OMIM:613347&Orphanet:1333&Human_Phenotype_Ontology:HP:0012125&MONDO:MONDO:0008315&MedGen:C0376358&Orphanet:1331&MONDO:MONDO:0008679&MedGen:CN033288&OMIM:194070&Orphanet:654&Human_Phenotype_Ontology:HP:0002885&MONDO:MONDO:0007959&MeSH:D008527&MedGen:C0025149&OMIM:155255&Orphanet:616&MONDO:MONDO:0011584&MedGen:C1838457&OMIM:605724&Orphanet:319462&MONDO:MONDO:0012933&MedGen:C2675520&OMIM:612555&Orphanet:145&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374		NC_000013.11:g.32332592A>C	reviewed_by_expert_panel	Benign			SCV000245002	single_nucleotide_variant	SO:0001483	ClinGen:CA010835&OMIM:600185.0013		BRCA2:675	SO:0001583&missense_variant										1	144848																											129					0.969							243.45	v6.1	Unknown		True	BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:N372H mutant UNKNOWN.	False	The BRCA2 ENSP00000369497.3:n372h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	32906729						True	False	False	Unknown								False	False		BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	The BRCA2 ENSP00000369497.3:n372h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:N372H mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	BRCA2	675.0	ENSP00000369497.3:N372H			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BRCA2"",""entrezGeneId"":675,""alteration"":""ENSP00000369497.3:N372H"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types."",""variantSummary"":""The BRCA2 ENSP00000369497.3:n372h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:N372H mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	True	Likely Neutral	18451181;15695382	Likely Neutral																						70,55	35,22	35,33	0/1	31,39,34,21	AAA	.	.	.			30,40,23,32	28.05		0.44
GRCh38	BRCA2	D12_12345_1234556_Thyroid_S9	p.Val1269=	ENSP00000369497.3:p.Val1269=	chr13	32338162	32338162.0	T	C	C	32338162	.	T	C	.	PASS	NM_000059	C	synonymous_variant	LOW	BRCA2	ENSG00000139618	Transcript	ENST00000380152	protein_coding	11/27		c.3807T>C	4006	3807	1269	V	gtT/gtC	rs543304&CM173525&COSV66455922		1		SNV	HGNC	HGNC:1101	YES	MANE_Select	NM_000059.4		5	A2	CCDS9344.1	ENSP00000369497	P51587.244		UPI00001FCBCC			1			PIRSF:PIRSF002397&PANTHER:PTHR11289			0.1681	0.1846	0.1527	0.1726	0.1998	0.1196	0.1763	0.1978	0.1716	0.1385	0.1507	0.1852	0.2351	0.1825	0.1739	0.1022	0.181	0.191	0.2796	0.1577	0.1326	0.1605	0.1913	0.2363	0.186	0.1861	0.1096	0.2796	gnomADg_AMI	benign	0&1&1	1&1&1	25741868&24033266&18830263&19902366&22188678&25178586&22430443&21161372&21597964&19644020&27478808&20104584&20807450&12474142&18431501&19471317&23767878&33643918&24824029&34295994&30256453&28944232&35908255&35899106&29884136&27273131&32327675&35300046&24711893&28076423&31962039						FAIL	-46	16	39	-45	0.00	0.00	0.00	0.00	BRCA2		8.0300e-01	126022	0.19111	0.18984	0.16813	131560	Breast-ovarian_cancer&_familial&_susceptibility_to&_2&not_specified&Hereditary_cancer-predisposing_syndrome&Fanconi_anemia_complementation_group_D1&Familial_cancer_of_breast&not_provided&Hereditary_breast_ovarian_cancer_syndrome		MONDO:MONDO:0012933&MedGen:C2675520&OMIM:612555&Orphanet:145&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0011584&MedGen:C1838457&OMIM:605724&Orphanet:319462&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145		NC_000013.11:g.32338162T>C	reviewed_by_expert_panel	Benign			SCV000245028	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core_(BIC)_(BRCA2):4035&base_change%3DT_to_C&ClinGen:CA018842		BRCA2:675	SO:0001819&synonymous_variant										1	543304																											107					0.953							239.31	v6.1	Unknown		True	BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V1269= mutant UNKNOWN.	False	The BRCA2 ENSP00000369497.3:v1269= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	32912299						True	False	False	Unknown								False	False		BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	The BRCA2 ENSP00000369497.3:v1269= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V1269= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	BRCA2	675.0	ENSP00000369497.3:V1269=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BRCA2"",""entrezGeneId"":675,""alteration"":""ENSP00000369497.3:V1269="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types."",""variantSummary"":""The BRCA2 ENSP00000369497.3:v1269= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V1269= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						55,47	31,23	24,24	0/1	29,26,24,23	TTG	.	.	.			25,30,28,19	31.21		0.46078431372549017
GRCh38	BRCA2	D12_12345_1234556_Thyroid_S9	p.Leu1521=	ENSP00000369497.3:p.Leu1521=	chr13	32338918	32338918.0	A	G	G	32338918	.	A	G	.	PASS	NM_000059	G	synonymous_variant	LOW	BRCA2	ENSG00000139618	Transcript	ENST00000380152	protein_coding	11/27		c.4563A>G	4762	4563	1521	L	ctA/ctG	rs206075&CD1612287&COSV101203861		1		SNV	HGNC	HGNC:1101	YES	MANE_Select	NM_000059.4		5	A2	CCDS9344.1	ENSP00000369497	P51587.244		UPI00001FCBCC			1			PDB-ENSP_mappings:1n0w.B&PIRSF:PIRSF002397&PROSITE_profiles:PS50138&PANTHER:PTHR11289			0.9740	0.9039	0.9971	1	0.999	1	0.9977	0.922	0.9954	1	1	1	0.9934	0.9998	0.9952	0.9998	0.9786	0.926	1	0.9925	1	0.9998	1	0.9762	0.9997	0.9849	0.9994	1	EAS&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN	benign	0&1&1	1&1&1	25741868&24033266&18414213&32708070&27478808&1517275&1684755&9971877&12552570&15744044&16847550&19941162&20104584&22034289&23767878&33643918&28944232&35908255&32327675&35300046&28076423&29997359&35686104&31962039						FAIL	17	21	-29	-10	0.00	0.00	0.00	0.00	BRCA2		8.0300e-01	132779	0.97577		0.97404	136527	Fanconi_anemia_complementation_group_D1&Breast-ovarian_cancer&_familial&_susceptibility_to&_2&not_provided&Malignant_tumor_of_breast&Hereditary_breast_ovarian_cancer_syndrome&not_specified&Familial_cancer_of_breast&BRCA2-related_disorder&Hereditary_cancer-predisposing_syndrome		MONDO:MONDO:0011584&MedGen:C1838457&OMIM:605724&Orphanet:319462&MONDO:MONDO:0012933&MedGen:C2675520&OMIM:612555&Orphanet:145&MedGen:C3661900&MONDO:MONDO:0007254&MedGen:C0006142&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MedGen:CN169374&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MedGen:CN239275&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000013.11:g.32338918A>G	reviewed_by_expert_panel	Benign			SCV000245032	single_nucleotide_variant	SO:0001483	ClinGen:CA020461		BRCA2:675	SO:0001819&synonymous_variant										1	206075																											92					1							238.88	v6.1	Unknown		True	BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:L1521= mutant UNKNOWN.	False	The BRCA2 ENSP00000369497.3:l1521= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	32913055						True	False	False	Unknown								False	False		BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	The BRCA2 ENSP00000369497.3:l1521= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:L1521= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	BRCA2	675.0	ENSP00000369497.3:L1521=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BRCA2"",""entrezGeneId"":675,""alteration"":""ENSP00000369497.3:L1521="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types."",""variantSummary"":""The BRCA2 ENSP00000369497.3:l1521= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:L1521= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						0,92	0,43	0,49	0/1	0,0,46,46	TAT	.	.	.			0,0,43,49	64.65		1.0
GRCh38	BRCA2	D12_12345_1234556_Thyroid_S9	p.Val2171=	ENSP00000369497.3:p.Val2171=	chr13	32340868	32340868.0	G	C	C	32340868	.	G	C	.	PASS	NM_000059	C	synonymous_variant	LOW	BRCA2	ENSG00000139618	Transcript	ENST00000380152	protein_coding	11/27		c.6513G>C	6712	6513	2171	V	gtG/gtC	rs206076&COSV66458663		1		SNV	HGNC	HGNC:1101	YES	MANE_Select	NM_000059.4		5	A2	CCDS9344.1	ENSP00000369497	P51587.244		UPI00001FCBCC			1			PIRSF:PIRSF002397&PANTHER:PTHR11289			0.9736	0.9024	0.9971	1	0.999	1	0.9977	0.9205	0.9952	1	1	1	0.9924	0.9998	0.9949	0.9997	0.9785	0.9255	1	0.9925	1	0.9998	1	0.9728	0.9997	0.9849	0.9994	1	EAS&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN	benign	0&1	1&1	25741868&18414213&27478808&9971877&15744044&16847550&20127978&21156238&33643918&35908255&32284662&32327675&35300046&28076423&29997359&35686104&31962039						FAIL	-31	40	-11	-22	0.00	0.00	0.00	0.00	BRCA2		8.0300e-01	132780	0.97547		0.97364	136528	Familial_cancer_of_breast&Breast-ovarian_cancer&_familial&_susceptibility_to&_2&not_specified&Hereditary_cancer-predisposing_syndrome&Hereditary_breast_ovarian_cancer_syndrome&Fanconi_anemia_complementation_group_D1&not_provided&Malignant_tumor_of_breast		MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0012933&MedGen:C2675520&OMIM:612555&Orphanet:145&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MONDO:MONDO:0011584&MedGen:C1838457&OMIM:605724&Orphanet:319462&MedGen:C3661900&MONDO:MONDO:0007254&MedGen:C0006142		NC_000013.11:g.32340868G>C	reviewed_by_expert_panel	Benign			SCV000245036	single_nucleotide_variant	SO:0001483	ClinGen:CA024126		BRCA2:675	SO:0001819&synonymous_variant										1	206076																											102					0.99							237.13	v6.1	Unknown		True	BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V2171= mutant UNKNOWN.	False	The BRCA2 ENSP00000369497.3:v2171= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	32915005						True	False	False	Unknown								False	False		BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	The BRCA2 ENSP00000369497.3:v2171= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V2171= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	BRCA2	675.0	ENSP00000369497.3:V2171=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BRCA2"",""entrezGeneId"":675,""alteration"":""ENSP00000369497.3:V2171="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types."",""variantSummary"":""The BRCA2 ENSP00000369497.3:v2171= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V2171= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						0,101	0,54	0,47	0/1	0,0,61,40	TGT	.	.	.			0,0,40,61	64.68		1.0
GRCh38	BRCA2	D12_12345_1234556_Thyroid_S9	p.V2466A	ENSP00000369497.3:p.Val2466Ala	chr13	32355250	32355250.0	T	C	C	32355250	.	T	C	.	PASS	NM_000059	C	missense_variant	MODERATE	BRCA2	ENSG00000139618	Transcript	ENST00000380152	protein_coding	14/27		c.7397T>C	7596	7397	2466	V/A	gTa/gCa	rs169547&CM960194&COSV66451785		1		SNV	HGNC	HGNC:1101	YES	MANE_Select	NM_000059.4		5	A2	CCDS9344.1	ENSP00000369497	P51587.244		UPI00001FCBCC			1	tolerated(1)	benign(0)	PIRSF:PIRSF002397&PANTHER:PTHR11289			0.9758	0.9107	0.9971	1	0.999	1	0.9979	0.9299	0.9957	1	1	1	0.9948	0.9998	0.9957	0.9998	0.9806	0.9328	1	0.993	1	0.9998	1	0.9762	0.9997	0.9853	0.9996	1	EAS&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN	benign&uncertain_significance	0&1&1	1&1&1	25741868&24033266&24728327&32708070&29458332&27900359&34203389&23961350&27478808&8665505&27698805&31203256&33643918&25802882&26092435&28944232&35908255&33240400&35456488&32327675&35300046&31131559&28076423&26358132&29997359&35686104&31962039&25923920&37804357						FAIL	-3	43	38	-2	0.00	0.00	0.00	0.00	BRCA2	0.091	8.0300e-01	133738	0.97770	0.99372	0.97584	137477	BRCA2-related_cancer_predisposition&Breast_ductal_adenocarcinoma&not_specified&not_provided&Hereditary_breast_ovarian_cancer_syndrome&Breast-ovarian_cancer&_familial&_susceptibility_to&_2		MONDO:MONDO:0700269&MedGen:CN377758&MONDO:MONDO:0005590&MedGen:C1527349&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MONDO:MONDO:0012933&MedGen:C2675520&OMIM:612555&Orphanet:145		NC_000013.11:g.32355250T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000202300&SCV000268811&SCV000602752&SCV001000149&SCV001139178&SCV002025816&SCV002097591&SCV004844403&SCV005236526&SCV006311479	single_nucleotide_variant	SO:0001483	ClinGen:CA157623		BRCA2:675	SO:0001583&missense_variant										1	169547																											154					0.942							235.38	v6.1	Unknown		True	BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V2466A mutant UNKNOWN.	False	The BRCA2 ENSP00000369497.3:v2466a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	32929387						True	False	False	Unknown								False	False		BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	The BRCA2 ENSP00000369497.3:v2466a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V2466A mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	BRCA2	675.0	ENSP00000369497.3:V2466A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BRCA2"",""entrezGeneId"":675,""alteration"":""ENSP00000369497.3:V2466A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types."",""variantSummary"":""The BRCA2 ENSP00000369497.3:v2466a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRCA2 ENSP00000369497.3:V2466A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	True	Likely Neutral	29394989	Likely Neutral																						0,145	0,81	0,64	0/1	0,0,70,75	GTA	.	.	.			0,0,72,73	64.72		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr13	44306016	44306020.0	C	CCTGT	CCTGT	44306016	.	C	CCTGT	.	PASS		CTGT	downstream_gene_variant	MODIFIER		ENSG00000298636	Transcript	ENST00000757030	lncRNA									rs2135608739&rs2135608740&rs2135608744&rs2135608746&rs2308171	3130	1		insertion			YES																			0.7444	0.3888	0.8285	0.9345	0.8002	0.9121											0.7055	0.4674	0.8267	0.8055	0.8452	0.9387	0.7708	0.7363	0.7762	0.7733	0.8914	0.9387	gnomADg_EAS&gnomADg_EAS&gnomADg_EAS&gnomADg_EAS&gnomADg_EAS				33801242																																																																												222					0.977							244.64													chr13	44880152																																																	True	False	False	Unknown		Unknown																						118,99	57,40	61,59	0/1	52,66,43,56	GCC						73,45,60,39	28.56		0.45622119815668205
GRCh38	RB1	D12_12345_1234556_Thyroid_S9	p.Pro23=	ENSP00000267163.4:p.Pro23=	chr13	48303981	48303981.0	G	A	A	48303981	.	G	A	.	PASS	NM_000321	A	synonymous_variant	LOW	RB1	ENSG00000139687	Transcript	ENST00000267163	protein_coding	1/27		c.69G>A	231	69	23	P	ccG/ccA	rs746662122		1		SNV	HGNC	HGNC:9884	YES	MANE_Select	NM_000321.3		1	P1	CCDS31973.1	ENSP00000267163	P06400.280		UPI0000001C79			1			Low_complexity_(Seg):seg&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P06400-F1									6.721e-06	0	6.689e-05	0	3.202e-05	0	0.0002506	2.831e-06	0	2.678e-05												0.0002506	gnomADe_MID	likely_benign		1							FAIL	22	37	16	-6	0.00	0.00	0.00	0.00	RB1		2.3900e-01	486297				477618	Hereditary_cancer-predisposing_syndrome&Retinoblastoma&not_provided		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&Human_Phenotype_Ontology:HP:0009919&MONDO:MONDO:0008380&MeSH:D012175&MedGen:C0035335&OMIM:180200&Orphanet:790&MedGen:C3661900		NC_000013.11:g.48303981G>A	criteria_provided&_multiple_submitters&_no_conflicts	Likely_benign			SCV000674735&SCV001601462&SCV004846300&SCV006330171	single_nucleotide_variant	SO:0001483	ClinGen:CA483711616		RB1:5925	SO:0001819&synonymous_variant										1	746662122																											262					1							245.06	v6.1	Unknown		True	RB1, a regulator of the cell cycle, is inactivated by mutation, deletion or allelic loss in various cancer types, including retinoblastoma and lung cancer.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RB1 ENSP00000267163.4:P23= mutant UNKNOWN.	False	The RB1 ENSP00000267163.4:p23= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	48878117						True	False	False	Unknown								False	False		RB1, a regulator of the cell cycle, is inactivated by mutation, deletion or allelic loss in various cancer types, including retinoblastoma and lung cancer.	The RB1 ENSP00000267163.4:p23= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RB1 ENSP00000267163.4:P23= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	RB1	5925.0	ENSP00000267163.4:P23=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RB1"",""entrezGeneId"":5925,""alteration"":""ENSP00000267163.4:P23="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RB1, a regulator of the cell cycle, is inactivated by mutation, deletion or allelic loss in various cancer types, including retinoblastoma and lung cancer."",""variantSummary"":""The RB1 ENSP00000267163.4:p23= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RB1 ENSP00000267163.4:P23= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						258,4	135,3	123,1	0/1	132,126,3,1	CGC	0.00	0.00	1.00			161,97,2,2	10.7		0.015267175572519083
GRCh38	RB1	D12_12345_1234556_Thyroid_S9			chr13	48348923		C	<INS>	<INS>	48348923	MantaINS:14610:1:1:0:3:0	C	<INS>	.	PASS	NM_000321	insertion	intron_variant	MODIFIER	RB1	ENSG00000139687	Transcript	ENST00000267163	protein_coding		5/26									1		insertion	HGNC	HGNC:9884	YES	MANE_Select	NM_000321.3		1	P1	CCDS31973.1	ENSP00000267163	P06400.280		UPI0000001C79			1																																																																																																															0,104		0,104							104	TGTTTTTTTTCTGCTTTCTATTTGTTTAATAGGATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTAGCTAAAGGTAA		TGTTTTTTTTCTGCTTTCTATTTGTTTAATAGGATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTAGCTAAAGGTAATTTCCTTATATATCACATGAGAGGTCTGG																chr13	48923059	TCTTTGATGAGTCTTCTCACTTTCTAAGTCCCTGAGTGCTTGGGTTTGTTTTT			INS																																													True	True	False	Unknown		Unknown																															0,0				0,4	
GRCh38	RB1	D12_12345_1234556_Thyroid_S9			chr13	48480024		C	<INS>	<INS>	48480024	MantaINS:16687:0:0:2:4:0	C	<INS>	.	PASS	NM_000321	insertion	feature_elongation&coding_sequence_variant	HIGH	RB1	ENSG00000139687	Transcript	ENST00000267163	protein_coding	27/27			2903	2741	914					1		insertion	HGNC	HGNC:9884	YES	MANE_Select	NM_000321.3		1	P1	CCDS31973.1	ENSP00000267163	P06400.280		UPI0000001C79			1			MobiDB_lite:mobidb-lite&Pfam:PF08934&SMART:SM01369&AFDB-ENSP_mappings:AF-P06400-F1																																																																																																												0,50		0,50							50	AGAAAATGAATGATAGCATGGATACCTCAAACAAGGAAGAGAAATGAGGA		AGAAAATGAATGATAGCATGGATACCTCAAACAAGGAAGAGAAATGAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGA																chr13	49054160	CAGATAAATACATACATACATACATACATACATACATACATACATACATACATACATAAAAGAAAGACAAAAAGAAAAGAAAG			INS																																													True	True	False	Unknown		Unknown																															1,2				10,3	
GRCh38	DIS3	D12_12345_1234556_Thyroid_S9	p.Thr589=	ENSP00000366997.4:p.Thr589=	chr13	72768901	72768901.0	C	T	T	72768901	.	C	T	.	PASS	NM_014953	T	synonymous_variant	LOW	DIS3	ENSG00000083520	Transcript	ENST00000377767	protein_coding	14/21		c.1767G>A	1835	1767	589	T	acG/acA	rs2196979&COSV66705551		-1		SNV	HGNC	HGNC:20604	YES	MANE_Select	NM_014953.5		1	P1	CCDS9447.1	ENSP00000366997	Q9Y2L1.224		UPI0000141B79	Q9Y2L1-1					PDB-ENSP_mappings:6d6q.K&PDB-ENSP_mappings:6d6r.K&PDB-ENSP_mappings:6h25.J&AFDB-ENSP_mappings:AF-Q9Y2L1-F1&Pfam:PF00773&PANTHER:PTHR23355&SMART:SM00955&Superfamily:SSF50249			0.7702	0.8185	0.7637	0.748	0.6859	0.819	0.7206	0.8175	0.8096	0.7332	0.7802	0.6743	0.7782	0.707	0.7307	0.7992	0.7489	0.8163	0.598	0.7903	0.7437	0.7595	0.6936	0.7143	0.7052	0.7311	0.8044	0.819	SAS		0&1	0&1	38152368						FAIL	-11	11	-15	1	0.00	0.00	0.00	0.00	DIS3		1.0760e+00																																																											134					0.97							241.39	v6.1	Unknown		True	DIS3, the catalytic subunit of the RNA exosome complex, is recurrently mutated in several cancer types including multiple myeloma.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DIS3 ENSP00000366997.4:T589= mutant UNKNOWN.	False	The DIS3 ENSP00000366997.4:t589= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	73343039						True	False	False	Unknown								False	False		DIS3, the catalytic subunit of the RNA exosome complex, is recurrently mutated in several cancer types including multiple myeloma.	The DIS3 ENSP00000366997.4:t589= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DIS3 ENSP00000366997.4:T589= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	DIS3	22894.0	ENSP00000366997.4:T589=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DIS3"",""entrezGeneId"":22894,""alteration"":""ENSP00000366997.4:T589="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DIS3, the catalytic subunit of the RNA exosome complex, is recurrently mutated in several cancer types including multiple myeloma."",""variantSummary"":""The DIS3 ENSP00000366997.4:t589= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DIS3 ENSP00000366997.4:T589= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						66,64	38,36	28,28	0/1	30,36,28,36	ACG	0.00	0.00	0.00			30,36,20,44	35.61		0.49230769230769234
GRCh38	DIS3	D12_12345_1234556_Thyroid_S9	p.N269S	ENSP00000366997.4:p.Asn269Ser	chr13	72775941	72775941.0	T	C	C	72775941	.	T	C	.	PASS	NM_014953	C	missense_variant	MODERATE	DIS3	ENSG00000083520	Transcript	ENST00000377767	protein_coding	5/21		c.806A>G	874	806	269	N/S	aAt/aGt	rs4883918&COSV66705534		-1		SNV	HGNC	HGNC:20604	YES	MANE_Select	NM_014953.5		1	P1	CCDS9447.1	ENSP00000366997	Q9Y2L1.224		UPI0000141B79	Q9Y2L1-1			tolerated(0.23)	benign(0)	Gene3D:2.40.50.690&PDB-ENSP_mappings:6d6q.K&PDB-ENSP_mappings:6d6r.K&PDB-ENSP_mappings:6h25.J&AFDB-ENSP_mappings:AF-Q9Y2L1-F1&Pfam:PF17216&PANTHER:PTHR23355&Superfamily:SSF50249			0.3271	0.0825	0.4741	0.4534	0.2634	0.4888	0.3203	0.09729	0.5478	0.2279	0.5232	0.3	0.2465	0.307	0.3113	0.4312	0.2704	0.1084	0.2324	0.4285	0.2291	0.4923	0.311	0.2585	0.2995	0.2842	0.4627	0.5478	gnomADe_AMR		0&1	1&1	34290314&38152368						FAIL	-1	-6	1	-16	0.00	0.00	0.00	0.00	DIS3	0.059	1.0760e+00																																																											65					0.923							242.32	v6.1	Unknown		True	DIS3, the catalytic subunit of the RNA exosome complex, is recurrently mutated in several cancer types including multiple myeloma.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DIS3 ENSP00000366997.4:N269S mutant UNKNOWN.	False	The DIS3 ENSP00000366997.4:n269s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	73350079						True	False	False	Unknown								False	False		DIS3, the catalytic subunit of the RNA exosome complex, is recurrently mutated in several cancer types including multiple myeloma.	The DIS3 ENSP00000366997.4:n269s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DIS3 ENSP00000366997.4:N269S mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	DIS3	22894.0	ENSP00000366997.4:N269S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DIS3"",""entrezGeneId"":22894,""alteration"":""ENSP00000366997.4:N269S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DIS3, the catalytic subunit of the RNA exosome complex, is recurrently mutated in several cancer types including multiple myeloma."",""variantSummary"":""The DIS3 ENSP00000366997.4:n269s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DIS3 ENSP00000366997.4:N269S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						37,23	22,14	15,9	0/1	21,16,10,13	ATT	.	.	.			16,21,15,8	22.92		0.38333333333333336
GRCh38		D12_12345_1234556_Thyroid_S9			chr13	80677564		T	]chrX:71547210]T	]chrX:71547210]T	80677564	MantaBND:2462:0:1:0:0:0:0	T	]chrX:71547210]T	.	PASS		.T	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH		ENSG00000298571	Transcript	ENST00000756623	lncRNA		3/3									1		chromosome_breakpoint																																																																																																																														2			0,9							9	GATTTTCTC			MantaBND:2462:0:1:0:0:0:1	0														chr13	81251699				BND																																													True	False	False	Unknown		Unknown																															0,2				0,2	
GRCh38	UBAC2	D12_12345_1234556_Thyroid_S9			chr13	99385979	99385979.0	A	G	G	99385979	.	A	G	.	PASS		G	non_coding_transcript_exon_variant	MODIFIER	UBAC2	ENSG00000134882	Transcript	ENST00000494576	protein_coding_CDS_not_defined	6/6		n.1400A>G	1400					rs1058083		1		SNV	HGNC	HGNC:20486					2									1						0.6112	0.5703	0.5634	0.6171	0.6501	0.6544	0.7137	0.75	0.8571	1	0.75	0.7299		0.6701	0.75	0.8	0.6285	0.5711	0.6011	0.5941	0.6311	0.6145	0.7519	0.6769	0.6529	0.6029	0.6432	1	gnomADe_ASJ			1	23771752&26522768&26691610&29121662&33406744&34721519&32451905&27294018&32002491&36224396&33546406&16360294&19646946																																																																												762					0.991							223.89													chr13	100038233																																																	True	False	False	Unknown		Unknown																						371,384	184,191	187,193	0/1	186,185,182,202	CAG	.	.	.			259,112,229,155	55.72		0.5086092715231788
GRCh38	FGF14	D12_12345_1234556_Thyroid_S9			chr13	102199828		G	<INS>	<INS>	102199828	MantaINS:3248:1:1:1:10:0	G	<INS>	.	PASS		insertion	intron_variant	MODIFIER	FGF14	ENSG00000102466	Transcript	ENST00000706494	protein_coding		3/6									-1		insertion	HGNC	HGNC:3671								ENSP00000516417		A0A9L9PX77.6	UPI0003E5E74E			1																																																																																																															0,63		0,63							63	CGTGTTTCTCTCCCTATCTGAGACCCCATCTTCTTCTGCACCTCAAACCCACTTCCTCCAAGC		CGTGTTTCTCTCCCTATCTGAGACCCCATCTTCTTCTGCACCTCAAACCCACTTCCTCCAAGCCCTGCCCACTTTTACCTACTCGGTTTCTCTCCAGTTGCTCTGTTTTCTCCATATGC																chr13	102852178	ATTCCATTCAATTCCATCCCATTCCATTGCATTCCATTCTATTGCGTTCCATTCCATTCCATTCCACT			INS																																													True	True	False	Unknown		Unknown																															2,1				0,2	
GRCh38	FGF14	D12_12345_1234556_Thyroid_S9			chr13	102239616	102239616.0	T	A	A	102239616	.	T	A	.	PASS		A	intron_variant	MODIFIER	FGF14	ENSG00000102466	Transcript	ENST00000706494	protein_coding		3/6	c.-60+126829A>T						rs3904750&COSV65938263		-1		SNV	HGNC	HGNC:3671								ENSP00000516417		A0A9L9PX77.6	UPI0003E5E74E			1						0.8407	0.9917	0.8141	0.8165	0.7734	0.7495											0.8196	0.9547	0.7325	0.8171	0.7641	0.807	0.7995	0.8741	0.7498	0.8306	0.7536	0.9917	AFR		0&1	0&1																																																																													96					0.802							238.4													chr13	102891966																																																	True	True	False	Unknown		Unknown																						4,73	0,41	4,32	0/1	2,2,35,38	ATA	.	.	.			2,2,39,34	61.91		0.948051948051948
GRCh38	FGF14	D12_12345_1234556_Thyroid_S9			chr13	102283380	102283380.0	A	G	G	102283380	.	A	G	.	PASS		G	intron_variant	MODIFIER	FGF14	ENSG00000102466	Transcript	ENST00000706494	protein_coding		3/6	c.-60+83065T>C						rs2105105		-1		SNV	HGNC	HGNC:3671								ENSP00000516417		A0A9L9PX77.6	UPI0003E5E74E			1						0.5699	0.6399	0.6095	0.4355	0.5805	0.5746											0.5899	0.6453	0.5702	0.6122	0.596	0.4283	0.5683	0.6735	0.5688	0.6055	0.5468	0.6735	gnomADg_MID																																																																																87					0.966							243.21													chr13	102935730																																																	True	True	False	Unknown		Unknown																						0,84	0,41	0,43	0/1	0,0,43,41	TAG	.	.	.			0,0,36,48	64.61		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr13	102295799	102295799.0	C	T	T	102295799	.	C	T	.	PASS		T	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR13_93HL9H	enhancer									rs1932792				SNV																						0.7488	0.7292	0.7695	0.8234	0.7068	0.727											0.7153	0.7251	0.7324	0.7586	0.7285	0.8175	0.7283	0.7959	0.688	0.7505	0.7076	0.8234	EAS																																																																																73					0.904							233.88													chr13	102948149																																																	True	False	False	Unknown		Unknown																						0,66	0,27	0,39	0/1	0,0,34,32	ACG	0.00	0.00	0.00			0,0,35,31	64.43		1.0
GRCh38	FGF14	D12_12345_1234556_Thyroid_S9			chr13	102302782		C	[chr10:78013248[C	[chr10:78013248[C	102302782	MantaBND:11326:0:1:0:0:0:1	C	[chr10:78013248[C	.	PASS		.C	feature_truncation&intron_variant	HIGH	FGF14	ENSG00000102466	Transcript	ENST00000706494	protein_coding		3/6									-1		chromosome_breakpoint	HGNC	HGNC:3671								ENSP00000516417		A0A9L9PX77.6	UPI0003E5E74E			1																																																																																																														0			0,8							8	TCTCTCCA			MantaBND:11326:0:1:0:0:0:0	1														chr13	102955132				BND																																													True	True	False	Unknown		Unknown																															0,1				0,2	
GRCh38	ERCC5	D12_12345_1234556_Thyroid_S9	p.His46=	ENSP00000498881.2:p.His46=	chr13	102852167	102852167.0	T	C	C	102852167	.	T	C	.	PASS	NM_000123	C	synonymous_variant	LOW	ERCC5	ENSG00000134899	Transcript	ENST00000652225	protein_coding	2/15		c.138T>C	373	138	46	H	caT/caC	rs1047768&COSV63245576		1		SNV	HGNC	HGNC:3437	YES	MANE_Select	NM_000123.4			P1	CCDS32004.1	ENSP00000498881	P28715.243		UPI000006D0C3	P28715-1		1			Gene3D:3.40.50.1010&PDB-ENSP_mappings:6tur.AAA&PDB-ENSP_mappings:6tur.BBB&PDB-ENSP_mappings:6tur.CCC&PDB-ENSP_mappings:6tur.DDD&PDB-ENSP_mappings:6tus.A&PDB-ENSP_mappings:6tus.B&PDB-ENSP_mappings:6tuw.A&PDB-ENSP_mappings:6tux.A&PDB-ENSP_mappings:6tux.B&AFDB-ENSP_mappings:AF-P28715-F1&Pfam:PF00752&PANTHER:PTHR16171&SMART:SM00485&Superfamily:SSF88723&NCBIFAM:TIGR00600&CDD:cd09868			0.4930	0.6778	0.3991	0.25	0.5845	0.4663	0.5741	0.6685	0.3098	0.5766	0.2236	0.6133	0.5232	0.5988	0.5656	0.501	0.5837	0.6649	0.5813	0.4258	0.5905	0.2489	0.6231	0.4762	0.5959	0.5706	0.4948	0.6778	AFR	benign	0&1	1&1	25741868&19661089&34862210&28827732&31516756&28499365&19536092&23175176&28717179&28415781&22493747&25452763&26967386&29581776&19442035&25391773&26339355&29669843&30609649&28115302&35693108&23407396&24487794&31988591&27019310&22761669&28520216&33575466&29434449&28351583&17299578&24615519&26820236&27235448&27698911&29416691&36033436&20233728&27929383&28416771&29072052&30139812&31558863&33393424&28342452&29950854&31528641&35069899&35955506&22108238&30161024&19157633&27396427&36632296&30883028&23966156&27051028&34078296&30255276&23720401&21908578&35628498&31031852&20531418&29394274&23679317&30464628&25520562&26045839&27248474&32629971&23621222&24353725&33117169&33116759&35852645&27974699&27340861&23626689&37610496&38541204&39234108						FAIL	-49	14	-49	-42	0.04	0.00	0.00	0.00	ERCC5		7.6600e-01	129009	0.61179	0.52910	0.49301	134455	not_specified&not_provided&Xeroderma_pigmentosum&_group_G		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0010216&MedGen:C0268141&OMIM:278780		NC_000013.11:g.102852167T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000302357&SCV000382083&SCV000745520&SCV001852626&SCV002485266&SCV005233341&SCV005880452	single_nucleotide_variant	SO:0001483	ClinGen:CA152762		ERCC5:2073&BIVM-ERCC5:100533467	SO:0001819&synonymous_variant										1	1047768																											165					0.958							232.94	v6.1	Unknown		True	ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:H46= mutant UNKNOWN.	False	The ERCC5 ENSP00000498881.2:h46= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	103504517						True	False	False	Unknown								False	False		ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	The ERCC5 ENSP00000498881.2:h46= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:H46= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	ERCC5	2073.0	ENSP00000498881.2:H46=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERCC5"",""entrezGeneId"":2073,""alteration"":""ENSP00000498881.2:H46="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers."",""variantSummary"":""The ERCC5 ENSP00000498881.2:h46= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:H46= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						0,158	0,81	0,77	0/1	0,0,87,71	ATG	.	.	.			0,0,98,60	64.72		1.0
GRCh38	ERCC5	D12_12345_1234556_Thyroid_S9	p.E158D	ENSP00000498881.2:p.Glu158Asp	chr13	102856058	102856058.0	A	T	T	102856058	.	A	T	.	PASS	NM_000123	T	missense_variant	MODERATE	ERCC5	ENSG00000134899	Transcript	ENST00000652225	protein_coding	5/15		c.474A>T	709	474	158	E/D	gaA/gaT			1		SNV	HGNC	HGNC:3437	YES	MANE_Select	NM_000123.4			P1	CCDS32004.1	ENSP00000498881	P28715.243		UPI000006D0C3	P28715-1		1	tolerated(0.12)	benign(0.059)	Gene3D:3.40.50.1010&PDB-ENSP_mappings:6tur.AAA&PDB-ENSP_mappings:6tur.BBB&PDB-ENSP_mappings:6tur.CCC&PDB-ENSP_mappings:6tur.DDD&PDB-ENSP_mappings:6tus.A&PDB-ENSP_mappings:6tus.B&PDB-ENSP_mappings:6tuw.A&PDB-ENSP_mappings:6tux.A&PDB-ENSP_mappings:6tux.B&AFDB-ENSP_mappings:AF-P28715-F1&PANTHER:PTHR16171&Superfamily:SSF88723&NCBIFAM:TIGR00600&Low_complexity_(Seg):seg																																									FAIL	-1	-6	-1	20	0.06	0.06	0.00	0.00	ERCC5		7.6600e-01																																																											143					0.93							232.61	v6.1	Unknown		True	ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:E158D mutant UNKNOWN.	False	The ERCC5 ENSP00000498881.2:e158d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	103508408						True	False	False	Unknown								False	False		ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	The ERCC5 ENSP00000498881.2:e158d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:E158D mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	ERCC5	2073.0	ENSP00000498881.2:E158D			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERCC5"",""entrezGeneId"":2073,""alteration"":""ENSP00000498881.2:E158D"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers."",""variantSummary"":""The ERCC5 ENSP00000498881.2:e158d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:E158D mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						130,3	63,1	67,2	0/1	70,60,2,1	AAG	.	.	.			65,65,2,1	9.88		0.022556390977443608
GRCh38	ERCC5	D12_12345_1234556_Thyroid_S9	p.G1053R	ENSP00000498881.2:p.Gly1053Arg	chr13	102875499	102875499.0	G	C	C	102875499	.	G	C	.	PASS	NM_000123	C	missense_variant	MODERATE	ERCC5	ENSG00000134899	Transcript	ENST00000652225	protein_coding	15/15		c.3157G>C	3392	3157	1053	G/R	Gga/Cga	rs9514066&COSV100863566		1		SNV	HGNC	HGNC:3437	YES	MANE_Select	NM_000123.4			P1	CCDS32004.1	ENSP00000498881	P28715.243		UPI000006D0C3	P28715-1		1	deleterious(0.03)	possibly_damaging(0.465)	AFDB-ENSP_mappings:AF-P28715-F1&PANTHER:PTHR16171			0.9982	0.9932	1	1	1	1	0.9998	0.9941	0.9994	1	0.9999	1	1	1	0.9994	1	0.998	0.9932	1	0.999	1	0.9998	1	0.9966	0.9999	0.9986	0.9998	1	AMR&EAS&EUR&SAS&gnomADe_ASJ&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN	not_provided&benign	0&1	1&1	24728327&32708070&34944636&31242667						FAIL	12	1	-7	18	0.00	0.00	0.00	0.00	ERCC5		7.6600e-01	134172	0.99746		0.99820	137911	not_specified&not_provided&Xeroderma_pigmentosum&_group_G		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0010216&MedGen:C0268141&OMIM:278780		NC_000013.11:g.102875499G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001139380&SCV002409477&SCV005233364	single_nucleotide_variant	SO:0001483	ClinGen:CA158990		ERCC5:2073&BIVM-ERCC5:100533467	SO:0001583&missense_variant										1	9514066																											132					0.879							234.17	v6.1	Unknown		True	ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:G1053R mutant UNKNOWN.	False	The ERCC5 ENSP00000498881.2:g1053r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	103527849						True	False	False	Unknown								False	False		ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	The ERCC5 ENSP00000498881.2:g1053r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:G1053R mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	ERCC5	2073.0	ENSP00000498881.2:G1053R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERCC5"",""entrezGeneId"":2073,""alteration"":""ENSP00000498881.2:G1053R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers."",""variantSummary"":""The ERCC5 ENSP00000498881.2:g1053r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:G1053R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						0,116	0,65	0,51	0/1	0,0,64,52	AGG	.	.	.			0,0,47,69	64.7		1.0
GRCh38	ERCC5	D12_12345_1234556_Thyroid_S9	p.G1080R	ENSP00000498881.2:p.Gly1080Arg	chr13	102875580	102875580.0	G	C	C	102875580	.	G	C	.	PASS	NM_000123	C	missense_variant	MODERATE	ERCC5	ENSG00000134899	Transcript	ENST00000652225	protein_coding	15/15		c.3238G>C	3473	3238	1080	G/R	Gga/Cga	rs9514067&COSV107450835		1		SNV	HGNC	HGNC:3437	YES	MANE_Select	NM_000123.4			P1	CCDS32004.1	ENSP00000498881	P28715.243		UPI000006D0C3	P28715-1		1	tolerated(0.54)	benign(0)	AFDB-ENSP_mappings:AF-P28715-F1&PANTHER:PTHR16171&MobiDB_lite:mobidb-lite			0.9972	0.9932	1	1	1	0.9949	0.9998	0.994	0.9994	1	0.9999	1	1	1	0.9993	0.9996	0.998	0.9932	1	0.999	1	1	1	1	0.9999	0.9986	0.9986	1	AMR&EAS&EUR&gnomADe_ASJ&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID	not_provided&benign	0&1	1&1	24033266&24728327&32708070&15082767&33922147						FAIL	6	1	15	0	0.00	0.00	0.00	0.00	ERCC5		7.6600e-01	134173	0.99746		0.99720	137912	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000013.11:g.102875580G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002349351&SCV005233365	single_nucleotide_variant	SO:0001483	ClinGen:CA158994		ERCC5:2073&BIVM-ERCC5:100533467	SO:0001583&missense_variant										1	9514067																											115					0.991							243.8	v6.1	Unknown		True	ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:G1080R mutant UNKNOWN.	False	The ERCC5 ENSP00000498881.2:g1080r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	103527930						True	False	False	Unknown								False	False		ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers.	The ERCC5 ENSP00000498881.2:g1080r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:G1080R mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	ERCC5	2073.0	ENSP00000498881.2:G1080R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERCC5"",""entrezGeneId"":2073,""alteration"":""ENSP00000498881.2:G1080R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERCC5 is a tumor suppressor and an endonuclease involved in DNA repair. Germline mutations of ERCC5 are associated with xeroderma pigmentosum and Cockayne's syndrome, which predispose to certain cancers."",""variantSummary"":""The ERCC5 ENSP00000498881.2:g1080r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERCC5 ENSP00000498881.2:G1080R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						0,114	0,51	0,63	0/1	0,0,56,58	AGG	.	.	.			0,0,45,69	64.7		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr13	106286062	106286062.0	A	T	T	106286062	.	A	T	.	PASS		T	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000286780	Transcript	ENST00000669705	lncRNA		1/2	n.70-26411T>A						rs354439		-1		SNV			YES																			0.5162	0.6596	0.3386	0.4563	0.4085	0.6207											0.4636	0.6207	0.4593	0.3629	0.5625	0.438	0.3368	0.5884	0.3957	0.4569	0.618	0.6596	AFR				26522768&26691610&29121662&33406744&34721519&30483659&19083859&19228012&31745634&27294018&19948332&19083839																																																																												97					0.887							233.17													chr13	106938411																																																	True	False	False	Unknown		Unknown																						55,31	23,14	32,17	0/1	28,27,16,15	AAA	.	.	.			32,23,13,18	16.91		0.36046511627906974
GRCh38	IRS2	D12_12345_1234556_Thyroid_S9	p.G1057D	ENSP00000365016.3:p.Gly1057Asp	chr13	109782884	109782884.0	C	T	T	109782884	.	C	T	.	PASS	NM_003749	T	missense_variant	MODERATE	IRS2	ENSG00000185950	Transcript	ENST00000375856	protein_coding	1/2		c.3170G>A	3700	3170	1057	G/D	gGc/gAc	rs1805097&CM003938&COSV65478662		-1		SNV	HGNC	HGNC:6126	YES	MANE_Select	NM_003749.3		1	P1	CCDS9510.1	ENSP00000365016	Q9Y4H2.200		UPI000006E4A8			1	tolerated(0.35)		AFDB-ENSP_mappings:AF-Q9Y4H2-F1&PANTHER:PTHR10614&MobiDB_lite:mobidb-lite			0.2833	0.0938	0.4107	0.3929	0.3161	0.3027	0.3325	0.1176	0.4597	0.4072	0.4081	0.3378	0.2599	0.3346	0.3245	0.2819	0.2872	0.1247	0.2791	0.4042	0.3904	0.3849	0.3314	0.2808	0.3406	0.2938	0.2891	0.4597	gnomADe_AMR	benign&risk_factor	0&1&1	1&1&1	18603647&28690685&18611262&18992263&19124510&29622662&28369940&18398040&25557790&27144430&34784930&35596833&28708046&26381944&21771880&11030756&11600548&19818665&19887537&28212577&35124585&36730981&29764441&25061488&33921825&25310961&32724448&37234924&36013453&23216712&34222068&19091018&37173295&36776603&38965376						FAIL	7	0	-38	48	0.00	0.00	0.00	0.00	IRS2	0.052	9.4000e-01	8820		0.38205	0.28335	23859	IRS2-related_disorder&Type_2_diabetes_mellitus		.&Human_Phenotype_Ontology:HP:0005965&Human_Phenotype_Ontology:HP:0005978&Human_Phenotype_Ontology:HP:0100652&MONDO:MONDO:0005148&MeSH:D003924&MedGen:C0011860&OMIM:125853		NC_000013.11:g.109782884C>T	no_assertion_criteria_provided	Benign&risk_factor			SCV000029586&SCV004799340	single_nucleotide_variant	SO:0001483	ClinGen:CA119944&OMIM:600797.0001&UniProtKB:Q9Y4H2																																																																																																																																															228,229	106,99	122,130	0/1	118,110,122,107	GCC	0.00	0.00	0.00			60,168,70,159	62.72		0.5010940919037199
GRCh38	IRS2	D12_12345_1234556_Thyroid_S9	p.Cys816=	ENSP00000365016.3:p.Cys816=	chr13	109783606	109783606.0	A	G	G	109783606	.	A	G	.	PASS	NM_003749	G	synonymous_variant	LOW	IRS2	ENSG00000185950	Transcript	ENST00000375856	protein_coding	1/2		c.2448T>C	2978	2448	816	C	tgT/tgC	rs4773092&COSV65478656		-1		SNV	HGNC	HGNC:6126	YES	MANE_Select	NM_003749.3		1	P1	CCDS9510.1	ENSP00000365016	Q9Y4H2.200		UPI000006E4A8			1			AFDB-ENSP_mappings:AF-Q9Y4H2-F1&PANTHER:PTHR10614			0.5639	0.59	0.7089	0.4514	0.5905	0.5143	0.5846	0.6042	0.6873	0.6168	0.4905	0.6091	0.4249	0.5895	0.5689	0.5033	0.595	0.606	0.5077	0.6517	0.6207	0.448	0.6037	0.469	0.5935	0.5587	0.5006	0.7089	AMR	benign	0&1	1&1	18611262&19124510&27483248&21771880&23706954&28303061&36528847&23033454						FAIL	36	-12	-17	2	0.00	0.00	0.00	0.00	IRS2		9.4000e-01	3059034	0.60178	0.58709	0.56390	3196750	IRS2-related_disorder		.		NC_000013.11:g.109783606A>G	no_assertion_criteria_provided	Benign			SCV004795964	single_nucleotide_variant	SO:0001483	ClinGen:CA7046350		IRS2:8660	SO:0001819&synonymous_variant										1	4773092																											716					1							247.84	v6.1	Unknown		True	IRS2, a signaling molecule involved in insulin signaling, is altered by amplification and mutation in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IRS2 ENSP00000365016.3:C816= mutant UNKNOWN.	False	The IRS2 ENSP00000365016.3:c816= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	110435953						True	False	False	Unknown								False	False		IRS2, a signaling molecule involved in insulin signaling, is altered by amplification and mutation in various cancer types.	The IRS2 ENSP00000365016.3:c816= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IRS2 ENSP00000365016.3:C816= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	IRS2	8660.0	ENSP00000365016.3:C816=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IRS2"",""entrezGeneId"":8660,""alteration"":""ENSP00000365016.3:C816="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IRS2, a signaling molecule involved in insulin signaling, is altered by amplification and mutation in various cancer types."",""variantSummary"":""The IRS2 ENSP00000365016.3:c816= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IRS2 ENSP00000365016.3:C816= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						344,372	152,180	192,192	0/1	150,194,176,196	CAC	.	.	.			172,172,202,170	59.57		0.5195530726256983
GRCh38	IRS2	D12_12345_1234556_Thyroid_S9	p.Ser723=	ENSP00000365016.3:p.Ser723=	chr13	109783885	109783885.0	G	A	A	109783885	.	G	A	.	PASS	NM_003749	A	synonymous_variant	LOW	IRS2	ENSG00000185950	Transcript	ENST00000375856	protein_coding	1/2		c.2169C>T	2699	2169	723	S	agC/agT	rs3742210&COSV65479217		-1		SNV	HGNC	HGNC:6126	YES	MANE_Select	NM_003749.3		1	P1	CCDS9510.1	ENSP00000365016	Q9Y4H2.200		UPI000006E4A8			1			AFDB-ENSP_mappings:AF-Q9Y4H2-F1&PANTHER:PTHR10614&MobiDB_lite:mobidb-lite			0.5595	0.5794	0.7104	0.4514	0.5875	0.5082	0.5805	0.5896	0.6853	0.6167	0.4904	0.6025	0.4244	0.5858	0.5659	0.4961	0.5886	0.5926	0.5077	0.6494	0.6205	0.4474	0.5937	0.4692	0.5899	0.5536	0.4954	0.7104	AMR	benign	0&1	1&1	21771880						FAIL	15	-21	6	-49	0.00	0.00	0.00	0.00	IRS2		9.4000e-01	3060213	0.63954	0.55375	0.55950	3200529	IRS2-related_disorder		.		NC_000013.11:g.109783885G>A	no_assertion_criteria_provided	Benign			SCV004798853	single_nucleotide_variant	SO:0001483	ClinGen:CA7046412		IRS2:8660	SO:0001819&synonymous_variant										1	3742210																											411					0.998							247.31	v6.1	Unknown		True	IRS2, a signaling molecule involved in insulin signaling, is altered by amplification and mutation in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IRS2 ENSP00000365016.3:S723= mutant UNKNOWN.	False	The IRS2 ENSP00000365016.3:s723= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr13	110436232						True	False	False	Unknown								False	False		IRS2, a signaling molecule involved in insulin signaling, is altered by amplification and mutation in various cancer types.	The IRS2 ENSP00000365016.3:s723= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IRS2 ENSP00000365016.3:S723= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	IRS2	8660.0	ENSP00000365016.3:S723=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IRS2"",""entrezGeneId"":8660,""alteration"":""ENSP00000365016.3:S723="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IRS2, a signaling molecule involved in insulin signaling, is altered by amplification and mutation in various cancer types."",""variantSummary"":""The IRS2 ENSP00000365016.3:s723= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IRS2 ENSP00000365016.3:S723= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						207,203	100,99	107,104	0/1	103,104,100,103	CGC	0.00	0.00	0.00			72,135,50,153	41.3		0.4951219512195122
GRCh38		D12_12345_1234556_Thyroid_S9			chr13	113232110	113232379.0	C	<INS>	<INS>	113232110	MantaDUP:TANDEM:16836:0:1:0:0:0	C	<INS>	.	PASS		insertion	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR13_85BTXS														insertion																																																																																																																															0,7		0,7		7	CCACCAC	269										v6.1	Likely Gain-of-function	Amplification of CUL4 typically results in the overexpression of the protein. CUL4 amplification has been identified in lung cancer, prostate cancer, breast cancer and ovarian cancer (PMID: 34119472, 22422151, 24305877). In vitro studies with H460, A549, LNCAP, C4-2, CWR22, 22RV1, MCF10A and MDA-MB-468 cells overexpressing CUL4 demonstrate that amplification is activating as measured by increased cellular proliferation, induced epithelial-mesenchymal transition and malignant cellular transformation compared to vector controls (PMID: 28576144, 25413624, 28223829). Preclinical studies with ovarian cancer cells and lung cancer cells overexpressing CUL4 demonstrate resistance to cisplatin, doxorubicin, docetaxel, gemcitabine and erlotinib as measured by decreased cellular apoptosis and sustained cellular proliferation (PMID: 25413624, 26503734, 30718461).	True	CUL4, a ubiquitin ligase component of an E3 ubiquitin-protein ligase complex, is infrequently altered in cancer.	False	07/19/2023	Likely Oncogenic	CNA	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUL4A-amplified UNKNOWN.	True	CUL4A amplification is likely oncogenic.	chr13	113886424			269	INS		True	True	False	Likely Oncogenic								False	False		CUL4, a ubiquitin ligase component of an E3 ubiquitin-protein ligase complex, is infrequently altered in cancer.	CUL4A amplification is likely oncogenic.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUL4A-amplified UNKNOWN.						v6.1	07/19/2023		GRCh38	CUL4A	8451.0	Amplification			UNKNOWN							Likely Gain-of-function	Amplification of CUL4 typically results in the overexpression of the protein. CUL4 amplification has been identified in lung cancer, prostate cancer, breast cancer and ovarian cancer (PMID: 34119472, 22422151, 24305877). In vitro studies with H460, A549, LNCAP, C4-2, CWR22, 22RV1, MCF10A and MDA-MB-468 cells overexpressing CUL4 demonstrate that amplification is activating as measured by increased cellular proliferation, induced epithelial-mesenchymal transition and malignant cellular transformation compared to vector controls (PMID: 28576144, 25413624, 28223829). Preclinical studies with ovarian cancer cells and lung cancer cells overexpressing CUL4 demonstrate resistance to cisplatin, doxorubicin, docetaxel, gemcitabine and erlotinib as measured by decreased cellular apoptosis and sustained cellular proliferation (PMID: 25413624, 26503734, 30718461).	['28223829', '30718461', '24305877', '28576144', '26503734', '34119472', '25413624', '22422151']		"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CUL4A"",""entrezGeneId"":8451,""alteration"":""Amplification"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":true,""alleleExist"":false,""oncogenic"":""Likely Oncogenic"",""mutationEffect"":{""knownEffect"":""Likely Gain-of-function"",""description"":""Amplification of CUL4 typically results in the overexpression of the protein. CUL4 amplification has been identified in lung cancer, prostate cancer, breast cancer and ovarian cancer (PMID: 34119472, 22422151, 24305877). In vitro studies with H460, A549, LNCAP, C4-2, CWR22, 22RV1, MCF10A and MDA-MB-468 cells overexpressing CUL4 demonstrate that amplification is activating as measured by increased cellular proliferation, induced epithelial-mesenchymal transition and malignant cellular transformation compared to vector controls (PMID: 28576144, 25413624, 28223829). Preclinical studies with ovarian cancer cells and lung cancer cells overexpressing CUL4 demonstrate resistance to cisplatin, doxorubicin, docetaxel, gemcitabine and erlotinib as measured by decreased cellular apoptosis and sustained cellular proliferation (PMID: 25413624, 26503734, 30718461)."",""citations"":{""pmids"":[""28223829"",""30718461"",""24305877"",""28576144"",""26503734"",""34119472"",""25413624"",""22422151""],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CUL4, a ubiquitin ligase component of an E3 ubiquitin-protein ligase complex, is infrequently altered in cancer."",""variantSummary"":""CUL4A amplification is likely oncogenic."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUL4A-amplified UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/19/2023""}"	True	False	False	Unknown		Unknown																															23,3				27,26	
GRCh38	LAMP1	D12_12345_1234556_Thyroid_S9	p.Arg186=	ENSP00000333298.4:p.Arg186=	chr13	113310861	113310861.0	C	A	A	113310861	.	C	A	.	PASS	NM_005561	A	synonymous_variant	LOW	LAMP1	ENSG00000185896	Transcript	ENST00000332556	protein_coding	4/9		c.556C>A	752	556	186	R	Cgg/Agg	rs9577503&COSV107406208&COSV108126582		1		SNV	HGNC	HGNC:6499	YES	MANE_Select	NM_005561.4		1	P1	CCDS41909.1	ENSP00000333298	P11279.218		UPI0000072D40	P11279-1					Gene3D:2.40.160.110&PDB-ENSP_mappings:8ath.A&PDB-ENSP_mappings:8ath.B&PDB-ENSP_mappings:8fy5.C&PDB-ENSP_mappings:8fy5.D&PDB-ENSP_mappings:8fyf.C&PDB-ENSP_mappings:8fyf.D&AFDB-ENSP_mappings:AF-P11279-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS51407&PANTHER:PTHR11506&MobiDB_lite:mobidb-lite			0.9792	0.9281	0.9914	1	0.997	1	0.9969	0.9145	0.9922	0.9978	1	1	0.991	0.9993	0.993	0.9997	0.9751	0.9178	1	0.9829	0.9991	1	1	0.983	0.9992	0.9715	0.9996	1	EAS&SAS&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN		0&1&1	0&1&1							FAIL	2	-27	2	6	0.00	0.00	0.00	0.02	LAMP1		3.3800e-01																																																											743					1							247.87	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr13	113965176						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	LAMP1		ENSP00000333298.4:R186=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LAMP1"",""entrezGeneId"":null,""alteration"":""ENSP00000333298.4:R186="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						0,743	0,382	0,361	0/1	0,0,352,391	CCG	0.00	0.00	0.00			0,0,305,438	64.73		1.0
GRCh38	LAMP1	D12_12345_1234556_Thyroid_S9			chr13	113323251	113323251.0	A	T	T	113323251	.	A	T	.	PASS	NM_005561	T	3_prime_UTR_variant	MODIFIER	LAMP1	ENSG00000185896	Transcript	ENST00000332556	protein_coding	9/9		c.*830A>T	2280					rs3945894		1		SNV	HGNC	HGNC:6499	YES	MANE_Select	NM_005561.4		1	P1	CCDS41909.1	ENSP00000333298	P11279.218		UPI0000072D40	P11279-1								0.9878	0.9569	0.9957	1	0.999	1	1					1					0.9898	0.9667	1	0.993	1	1	0.9998	0.9898	0.9996	0.9868	0.9996	1	EAS&SAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS										FAIL	10	2	-18	-28	0.00	0.00	0.00	0.00	LAMP1		3.3800e-01																																																											821					0.955							235.03													chr13	113977566																																																	True	False	False	Unknown		Unknown																						10,774	3,376	7,398	0/1	4,6,384,390	TAT	.	.	.			3,7,342,432	64.73		0.9872448979591837
GRCh38	BCL2L2	D12_12345_1234556_Thyroid_S9	p.Pro41=	ENSP00000250405.6:p.Pro41=	chr14	23307890	23307890.0	G	A	A	23307890	.	G	A	.	PASS	NM_004050	A	synonymous_variant	LOW	BCL2L2	ENSG00000129473	Transcript	ENST00000250405	protein_coding	3/4		c.123G>A	281	123	41	P	ccG/ccA	rs2231301&COSV51635377		1		SNV	HGNC	HGNC:995	YES	MANE_Select	NM_004050.5		1	P1	CCDS9591.1	ENSP00000250405	Q92843.218		UPI000013CCB8	Q92843-1					PDB-ENSP_mappings:1mk3.A&PDB-ENSP_mappings:1o0l.A&PDB-ENSP_mappings:1zy3.A&PDB-ENSP_mappings:2y6w.A&PDB-ENSP_mappings:2y6w.B&PDB-ENSP_mappings:4cim.A&PDB-ENSP_mappings:4cim.B&PDB-ENSP_mappings:4cim.P&PDB-ENSP_mappings:4cim.Q&Low_complexity_(Seg):seg&PANTHER:PTHR11256&Prints:PR01865&Superfamily:SSF56854&Gene3D:1.10.437.10&CDD:cd06845&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q92843-F1			0.2490	0.0454	0.3069	0.4752	0.2336	0.2658	0.2344	0.07256	0.3435	0.2132	0.5029	0.3239	0.2076	0.2201	0.2364	0.2535	0.2051	0.0756	0.4159	0.2708	0.2101	0.505	0.3301	0.1973	0.2207	0.2088	0.2541	0.505	gnomADg_EAS		0&1	1&1	28552196						FAIL	23	-50	23	32	0.00	0.00	0.00	0.00	BCL2L2		8.8300e-01																																																											1037					0.996							248.52	v6.1	Unknown		True	BCL2L2, a regulator of apoptosis, is infrequently altered in cancer.	False	09/13/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L2 ENSP00000250405.6:P41= mutant UNKNOWN.	False	The BCL2L2 ENSP00000250405.6:p41= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	23777099						True	False	False	Unknown								False	False		BCL2L2, a regulator of apoptosis, is infrequently altered in cancer.	The BCL2L2 ENSP00000250405.6:p41= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L2 ENSP00000250405.6:P41= mutant UNKNOWN.						v6.1	09/13/2024		GRCh38	BCL2L2	599.0	ENSP00000250405.6:P41=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCL2L2"",""entrezGeneId"":599,""alteration"":""ENSP00000250405.6:P41="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCL2L2, a regulator of apoptosis, is infrequently altered in cancer."",""variantSummary"":""The BCL2L2 ENSP00000250405.6:p41= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L2 ENSP00000250405.6:P41= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/13/2024""}"	True	True	False	Unknown		Unknown																						492,541	260,278	232,263	0/1	260,232,268,273	CGC	0.00	0.00	0.00			240,252,259,282	62.21		0.5237173281703775
GRCh38	BCL2L2	D12_12345_1234556_Thyroid_S9	p.Q133R	ENSP00000250405.6:p.Gln133Arg	chr14	23308165	23308165.0	A	G	G	23308165	.	A	G	.	PASS	NM_004050	G	missense_variant	MODERATE	BCL2L2	ENSG00000129473	Transcript	ENST00000250405	protein_coding	3/4		c.398A>G	556	398	133	Q/R	cAg/cGg	rs910332&COSV51636472		1		SNV	HGNC	HGNC:995	YES	MANE_Select	NM_004050.5		1	P1	CCDS9591.1	ENSP00000250405	Q92843.218		UPI000013CCB8	Q92843-1			tolerated(0.13)		PDB-ENSP_mappings:1mk3.A&PDB-ENSP_mappings:1o0l.A&PDB-ENSP_mappings:1zy3.A&PDB-ENSP_mappings:2y6w.A&PDB-ENSP_mappings:2y6w.B&PDB-ENSP_mappings:4cim.A&PDB-ENSP_mappings:4cim.B&PROSITE_profiles:PS50062&SMART:SM00337&PANTHER:PTHR11256&Prints:PR01865&Prints:PR01862&Superfamily:SSF56854&Pfam:PF00452&Gene3D:1.10.437.10&CDD:cd06845&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q92843-F1			0.9994	1	1	1	0.997	1	0.9963	0.9995	0.9994	0.9997	1	0.9994	0.9988	0.9954	0.9979	0.9992	0.9982	0.9992	1	0.9997	1	1	0.9997	1	0.9967	0.9981	0.9983	1	AFR&AMR&EAS&SAS&gnomADe_EAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_MID		0&1	0&1							FAIL	-28	2	34	29	0.00	0.00	0.00	0.00	BCL2L2	0.050	8.8300e-01																																																											848					1							246.95	v6.1	Unknown		True	BCL2L2, a regulator of apoptosis, is infrequently altered in cancer.	False	09/13/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L2 ENSP00000250405.6:Q133R mutant UNKNOWN.	False	The BCL2L2 ENSP00000250405.6:q133r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	23777374						True	False	False	Unknown								False	False		BCL2L2, a regulator of apoptosis, is infrequently altered in cancer.	The BCL2L2 ENSP00000250405.6:q133r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L2 ENSP00000250405.6:Q133R mutant UNKNOWN.						v6.1	09/13/2024		GRCh38	BCL2L2	599.0	ENSP00000250405.6:Q133R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCL2L2"",""entrezGeneId"":599,""alteration"":""ENSP00000250405.6:Q133R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCL2L2, a regulator of apoptosis, is infrequently altered in cancer."",""variantSummary"":""The BCL2L2 ENSP00000250405.6:q133r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L2 ENSP00000250405.6:Q133R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/13/2024""}"	True	True	False	Unknown		Unknown																						0,848	0,379	0,469	0/1	0,0,433,415	CAG	.	.	.			0,0,336,512	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr14	25381626	25381626.0	T	A	A	25381626	.	T	A	.	PASS		A	intergenic_variant	MODIFIER														rs1454361				SNV																						0.4129	0.298	0.4366	0.4494	0.4851	0.4397											0.426	0.3275	0.3549	0.4403	0.3736	0.4748	0.4861	0.4759	0.4709	0.4354	0.4562	0.4861	gnomADg_FIN				26691610&29121662&33406744&30483659&32195283&30483616&19083859&27294018&35300118&19948332																																																																												98					0.918							241.6													chr14	25850832																																																	True	False	False	Unknown		Unknown																						0,90	0,40	0,50	0/1	0,0,42,48	ATG	.	.	.			0,0,40,50	64.64		1.0
GRCh38	LINC02300	D12_12345_1234556_Thyroid_S9			chr14	28567531	28567531.0	T	C	C	28567531	.	T	C	.	PASS		C	intron_variant&non_coding_transcript_variant	MODIFIER	LINC02300	ENSG00000258175	Transcript	ENST00000757289	lncRNA		2/4	n.342-7228A>G						rs176294		-1		SNV	HGNC	HGNC:53219	YES																			0.6801	0.621	0.7853	0.7113	0.7147	0.6176											0.6975	0.6163	0.5386	0.7771	0.7525	0.7124	0.7114	0.6747	0.7285	0.7174	0.6403	0.7853	AMR																																																																																104					0.962							242.45													chr14	29036737																																																	True	False	False	Unknown		Unknown																						46,54	28,32	18,22	0/1	25,21,28,26	ATG	.	.	.			29,17,38,16	39.59		0.54
GRCh38	EGLN3	D12_12345_1234556_Thyroid_S9			chr14	34372347		C	[chr2:86268489[C	[chr2:86268489[C	34372347	MantaBND:3118:0:1:0:0:0:1	C	[chr2:86268489[C	.	PASS		.C	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	EGLN3	ENSG00000129521	Transcript	ENST00000551935	protein_coding_CDS_not_defined		1/4									-1		chromosome_breakpoint	HGNC	HGNC:14661					4																																																																																																																							2			0,11							11	ACACACACACG			MantaBND:3118:0:1:0:0:0:0	6														chr14	34841553				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38	NFKBIA	D12_12345_1234556_Thyroid_S9	p.Ala102=	ENSP00000216797.6:p.Ala102=	chr14	35403720	35403720.0	G	A	A	35403720	.	G	A	.	PASS	NM_020529	A	synonymous_variant	LOW	NFKBIA	ENSG00000100906	Transcript	ENST00000216797	protein_coding	2/6		c.306C>T	411	306	102	A	gcC/gcT	rs1050851&COSV53751737		-1		SNV	HGNC	HGNC:7797	YES	MANE_Select	NM_020529.3		1	P1	CCDS9656.1	ENSP00000216797	P25963.241		UPI000004F0A9			1			Gene3D:1.25.40.20&PDB-ENSP_mappings:1ikn.D&PDB-ENSP_mappings:1nfi.E&PDB-ENSP_mappings:1nfi.F&AFDB-ENSP_mappings:AF-P25963-F1&PANTHER:PTHR46680&SMART:SM00248&Superfamily:SSF48403			0.1016	0.0204	0.1383	0.0188	0.2217	0.1472	0.2091	0.0526	0.1041	0.1909	0.02333	0.1694	0.2099	0.23	0.1993	0.1773	0.1547	0.05368	0.1352	0.1367	0.1899	0.01705	0.1702	0.2177	0.2264	0.1491	0.1604	0.23	gnomADe_NFE	benign	0&1	1&1	25741868&24033266&19223558&26477820&21424379&29407193&28266732&29980729&30429237&33848569&37062025&31519222&30862128&34300206&26053036&38143267						FAIL	-16	49	18	-30	0.00	0.00	0.02	0.00	NFKBIA		5.0000e-01	313115	0.17077	0.17343	0.10164	320475	Ectodermal_dysplasia_and_immunodeficiency_2&not_provided&not_specified		MONDO:MONDO:0012806&MedGen:C2677481&OMIM:612132&Orphanet:238468&Orphanet:98813&MedGen:C3661900&MedGen:CN169374		NC_000014.9:g.35403720G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000386630&SCV000539896&SCV000604539&SCV001726422&SCV001890052&SCV004102367&SCV005297459	single_nucleotide_variant	SO:0001483	ClinGen:CA7155528		NFKBIA:4792	SO:0001819&synonymous_variant										1	1050851																											821					0.999							247.41	v6.1	Unknown		True	NFBI, a negative regulator of NF-B, is altered by mutation and deletion in various cancer types.	False	08/28/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NFKBIA ENSP00000216797.6:A102= mutant UNKNOWN.	False	The NFKBIA ENSP00000216797.6:a102= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	35872926						True	False	False	Unknown								False	False		NFBI, a negative regulator of NF-B, is altered by mutation and deletion in various cancer types.	The NFKBIA ENSP00000216797.6:a102= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NFKBIA ENSP00000216797.6:A102= mutant UNKNOWN.						v6.1	08/28/2019		GRCh38	NFKBIA	4792.0	ENSP00000216797.6:A102=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NFKBIA"",""entrezGeneId"":4792,""alteration"":""ENSP00000216797.6:A102="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NF\u03baBI\u03b1, a negative regulator of NF-\u03baB, is altered by mutation and deletion in various cancer types."",""variantSummary"":""The NFKBIA ENSP00000216797.6:a102= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NFKBIA ENSP00000216797.6:A102= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/28/2019""}"	True	True	False	Unknown		Unknown																						418,402	220,183	198,219	0/1	199,219,202,200	AGG	0.00	0.00	0.00			219,199,201,201	45.17		0.4902439024390244
GRCh38		D12_12345_1234556_Thyroid_S9			chr14	38162307		A	[chr16:53337110[A	[chr16:53337110[A	38162307	MantaBND:3134:0:1:0:0:0:0	A	[chr16:53337110[A	.	PASS		.A	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH		ENSG00000259048	Transcript	ENST00000554687	lncRNA		2/4									-1		chromosome_breakpoint			YES				4																																																																																																																							0			0,13							13	AAAAAAAAAAAAG			MantaBND:3134:0:1:0:0:0:1	2														chr14	38631512				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	STYX	D12_12345_1234556_Thyroid_S9			chr14	52750005	52750005.0	G	C	C	52750005	.	G	C	.	PASS		C	intron_variant&non_coding_transcript_variant	MODIFIER	STYX	ENSG00000198252	Transcript	ENST00000556861	protein_coding_CDS_not_defined		1/1	n.119+18293G>C						rs722290		1		SNV	HGNC	HGNC:11447					3															0.4986	0.475	0.4669	0.5119	0.4891	0.5491											0.4887	0.4547	0.4615	0.4701	0.4645	0.5071	0.6049	0.4252	0.4917	0.4773	0.5547	0.6049	gnomADg_FIN				19127300&26691610&29121662&33406744&34721519&31745634						FAIL	3	-6	3	1	0.00	0.00	0.00	0.00	STYX																																																													71					0.986							221.71													chr14	53216723																																																	True	False	False	Unknown		Unknown																						34,36	16,21	18,15	0/1	19,15,22,14	TGA	.	.	.			15,19,21,15	35.56		0.5142857142857142
GRCh38		D12_12345_1234556_Thyroid_S9			chr14	57583363	57583367.0	C	CTGAT	CTGAT	57583363	.	C	CTGAT	.	PASS		TGAT	downstream_gene_variant	MODIFIER		ENSG00000259039	Transcript	ENST00000655475	lncRNA									rs2308163	1366	1		insertion																						0.6727	0.6717	0.5159	0.877	0.5954	0.6544											0.6198	0.6657	0.6637	0.5402	0.4801	0.8733	0.7045	0.6224	0.5832	0.6213	0.6306	0.877	EAS				23690203&36292568&35251118																																																																												73					0.863							241.26													chr14	58050081																																																	True	False	False	Unknown		Unknown																						0,63	0,37	0,26	0/1	0,0,31,32	ACT						0,0,27,36	63.14		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr14	68594542	68594542.0	C	G	G	68594542	.	C	G	.	PASS		G	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR14_BHLJW	enhancer									rs28908468&COSV104699664				SNV																						0.0194	0.0045	0.0259	0	0.0427	0.0307	0.03468	0.004102	0.01282	0.01957	9.548e-05	0.06087	0.02697	0.03694	0.03513	0.03447	0.02788	0.006428	0.02522	0.01961	0.02277	0	0.07173	0.02721	0.03785	0.03548	0.03263	0.07173	gnomADg_FIN	drug_response&benign	0&1	1&1	29458332&27149063&33240314																		523174	0.02650	0.05084	0.01937	513784	not_provided&Hereditary_breast_ovarian_cancer_syndrome&Poly_(ADP-Ribose)_polymerase_inhibitor_response		MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MedGen:CN322715		NC_000014.9:g.68594542C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001945320&SCV002504905&SCV005291480&SCV005909748	single_nucleotide_variant	SO:0001483	ClinGen:CA7241422		RAD51B:5890	SO:0001583&missense_variant&SO:0001627&intron_variant										5	28908468																											282					1							231.22													chr14	69061259																																																	True	False	False	Unknown		Unknown																						145,137	82,69	63,68	0/1	61,84,66,71	CCA	.	.	.			58,87,70,67	36.76		0.4858156028368794
GRCh38	TSHR	D12_12345_1234556_Thyroid_S9			chr14	81108615	81108615.0	A	G	G	81108615	.	A	G	.	PASS	NM_000369	G	intron_variant	MODIFIER	TSHR	ENSG00000165409	Transcript	ENST00000298171	protein_coding		8/9	c.692+163A>G						rs3783942&COSV53318816		1		SNV	HGNC	HGNC:12373	YES	MANE_Select	NM_000369.5		1	P1	CCDS9872.1	ENSP00000298171		A0A0A0MTJ0.68	UPI000013E4A2			1						0.6112	0.6369	0.6268	0.3889	0.671	0.7331	0.6539	0.628	0.6492	0.7475	0.3791	0.6684	0.7186	0.6554	0.6513	0.7324	0.6369	0.6258	0.4287	0.6242	0.75	0.354	0.6724	0.7226	0.6519	0.6564	0.7282	0.75	gnomADg_ASJ	benign	0&1	1&1	20437249						FAIL	-3	31	14	-3	0.01	0.00	0.00	0.00	TSHR		1.0120e+00	1284491	0.64378	0.64681	0.61122	1274345	Hypothyroidism_due_to_TSH_receptor_mutations&Familial_gestational_hyperthyroidism&Familial_hyperthyroidism_due_to_mutations_in_TSH_receptor&not_provided&not_specified		MONDO:MONDO:0010142&MedGen:C3493776&OMIM:275200&Orphanet:90673&MONDO:MONDO:0011309&MedGen:C1863959&OMIM:603373&Orphanet:99819&MONDO:MONDO:0012203&MedGen:C1836706&OMIM:609152&Orphanet:424&MedGen:C3661900&MedGen:CN169374		NC_000014.9:g.81108615A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001938918&SCV002102084&SCV002102095&SCV002102106&SCV005295227	single_nucleotide_variant	SO:0001483	ClinGen:CA7294278		TSHR:7253&TSHR-AS1:101928462	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	3783942																											127					0.984							246.45													chr14	81574959																																																	True	True	False	Unknown		Unknown																						60,65	36,39	24,26	0/1	27,33,36,29	TAC	.	.	.			21,39,32,33	38.86		0.52
GRCh38	TSHR	D12_12345_1234556_Thyroid_S9			chr14	81108661	81108661.0	C	A	A	81108661	.	C	A	.	PASS	NM_000369	A	intron_variant	MODIFIER	TSHR	ENSG00000165409	Transcript	ENST00000298171	protein_coding		8/9	c.692+209C>A						rs3783941&COSV53335435		1		SNV	HGNC	HGNC:12373	YES	MANE_Select	NM_000369.5		1	P1	CCDS9872.1	ENSP00000298171		A0A0A0MTJ0.68	UPI000013E4A2			1						0.6102	0.6354	0.6239	0.3889	0.671	0.7321	0.6537	0.624	0.6487	0.7475	0.3788	0.6684	0.718	0.6554	0.6511	0.7324	0.635	0.6204	0.4275	0.6242	0.7503	0.3526	0.6689	0.7226	0.6517	0.6564	0.7278	0.7503	gnomADg_ASJ	benign	0&1	1&1	17952073&24728327&22654555&22654554&28410400&21124799&28421036&20437249&37680843						FAIL	2	-49	-49	6	0.00	0.01	0.00	0.00	TSHR		1.0120e+00	135403	0.64247		0.61022	139142	Familial_hyperthyroidism_due_to_mutations_in_TSH_receptor&not_specified&Familial_gestational_hyperthyroidism&Hypothyroidism_due_to_TSH_receptor_mutations&not_provided		MONDO:MONDO:0012203&MedGen:C1836706&OMIM:609152&Orphanet:424&MedGen:CN169374&MONDO:MONDO:0011309&MedGen:C1863959&OMIM:603373&Orphanet:99819&MONDO:MONDO:0010142&MedGen:C3493776&OMIM:275200&Orphanet:90673&MedGen:C3661900		NC_000014.9:g.81108661C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001839859&SCV002102117&SCV002102128&SCV002102139&SCV005295228	single_nucleotide_variant	SO:0001483	ClinGen:CA162658		TSHR:7253&TSHR-AS1:101928462	SO:0001583&missense_variant&SO:0001627&intron_variant										1	3783941																											109					1							247.68													chr14	81575005																																																	True	True	False	Unknown		Unknown																						57,52	27,27	30,25	0/1	27,30,27,25	ACG	0.00	0.00	0.00			29,28,24,28	33.15		0.47706422018348627
GRCh38	TSHR	D12_12345_1234556_Thyroid_S9	p.E727D	ENSP00000298171.2:p.Glu727Asp	chr14	81144239	81144239.0	G	C	C	81144239	.	G	C	.	PASS	NM_000369	C	missense_variant	MODERATE	TSHR	ENSG00000165409	Transcript	ENST00000298171	protein_coding	10/10		c.2181G>C	2241	2181	727	E/D	gaG/gaC	rs1991517&CM994612&COSV107314885		1		SNV	HGNC	HGNC:12373	YES	MANE_Select	NM_000369.5		1	P1	CCDS9872.1	ENSP00000298171		A0A0A0MTJ0.68	UPI000013E4A2			1	tolerated(0.68)	benign(0)	PDB-ENSP_mappings:7t9i.R&PDB-ENSP_mappings:7t9n.R&PDB-ENSP_mappings:7utz.R&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P16473-F1			0.8968	0.9425	0.8631	0.8472	0.8956	0.911	0.9113	0.936	0.8691	0.9059	0.8484	0.8481	0.9336	0.9176	0.9096	0.9126	0.9075	0.9402	0.8651	0.8616	0.9009	0.8381	0.8432	0.932	0.9132	0.9175	0.9125	0.9425	AFR	benign/likely_benign&benign	0&1&1	1&1&1	25741868&20357209&24728327&22147956&32550104&32930933&34950210&19138047&28410400&23344678&27456991&15911145&36835420&35008368&30304112&28421036&24052734&32733377&25531179&34539639&22313426&20437249&15579207&37680843&37641720						FAIL	10	-11	-12	-21	0.00	0.00	0.00	0.00	TSHR	0.073	1.0120e+00	135400	0.92334	0.90038	0.89677	139139	Familial_gestational_hyperthyroidism&Hypothyroidism_due_to_TSH_receptor_mutations&Familial_hyperthyroidism_due_to_mutations_in_TSH_receptor&not_provided&not_specified		MONDO:MONDO:0011309&MedGen:C1863959&OMIM:603373&Orphanet:99819&MONDO:MONDO:0010142&MedGen:C3493776&OMIM:275200&Orphanet:90673&MONDO:MONDO:0012203&MedGen:C1836706&OMIM:609152&Orphanet:424&MedGen:C3661900&MedGen:CN169374		NC_000014.9:g.81144239G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000303881&SCV000389156&SCV000389157&SCV001759705&SCV002102151&SCV002102162&SCV002102173&SCV004522579&SCV005217816	single_nucleotide_variant	SO:0001483	ClinGen:CA162649		TSHR:7253&TSHR-AS1:101928462	SO:0001583&missense_variant										1	1991517																											193					0.995							241.59	v6.1	Unknown		True	TSHR (thyroid stimulating hormone receptor) is mutated in various cancers, including skin cancer.	False	01/02/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TSHR ENSP00000298171.2:E727D mutant UNKNOWN.	False	The TSHR ENSP00000298171.2:e727d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	81610583						True	False	False	Unknown								False	False		TSHR (thyroid stimulating hormone receptor) is mutated in various cancers, including skin cancer.	The TSHR ENSP00000298171.2:e727d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TSHR ENSP00000298171.2:E727D mutant UNKNOWN.						v6.1	01/02/2018		GRCh38	TSHR	7253.0	ENSP00000298171.2:E727D			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""TSHR"",""entrezGeneId"":7253,""alteration"":""ENSP00000298171.2:E727D"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""TSHR (thyroid stimulating hormone receptor) is mutated in various cancers, including skin cancer."",""variantSummary"":""The TSHR ENSP00000298171.2:e727d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TSHR ENSP00000298171.2:E727D mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/02/2018""}"	True	True	False	Unknown		Unknown																						0,192	0,96	0,96	0/1	0,0,100,92	AGA	.	.	.			0,0,88,104	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr14	98379194	98379194.0	C	T	T	98379194	.	C	T	.	PASS		T	intergenic_variant	MODIFIER														rs873196				SNV																						0.7766	0.8275	0.7709	0.8611	0.6233	0.7822											0.6788	0.7761	0.7066	0.7104	0.6719	0.8555	0.6765	0.6497	0.5935	0.6895	0.7563	0.8611	EAS				26522768&26691610&29121662&33406744&34721519&21611176&32451905&28155888&19083859&27294018&33950286&19948332																																																																												471					0.998							244.16													chr14	98845531																																																	True	False	False	Unknown		Unknown																						252,218	119,120	133,98	0/1	132,120,110,108	CCT	0.00	0.00	0.00			159,93,142,76	29.8		0.46382978723404256
GRCh38	HSP90AA1	D12_12345_1234556_Thyroid_S9	p.Asn360=	ENSP00000216281.8:p.Asn360=	chr14	102084466	102084466.0	G	A	A	102084466	.	G	A	.	PASS	NM_005348	A	synonymous_variant	LOW	HSP90AA1	ENSG00000080824	Transcript	ENST00000216281	protein_coding	6/11		c.1080C>T	1139	1080	360	N	aaC/aaT	rs4947&COSV53488817		-1		SNV	HGNC	HGNC:5253	YES	MANE_Select	NM_005348.4		1	P1	CCDS9967.1	ENSP00000216281	P07900.277	K9JA46.87	UPI0000163B5F	P07900-1		1			Gene3D:3.30.230.80&PDB-ENSP_mappings:3q6m.A&PDB-ENSP_mappings:3q6m.B&PDB-ENSP_mappings:3q6m.C&PDB-ENSP_mappings:3q6n.A&PDB-ENSP_mappings:3q6n.B&PDB-ENSP_mappings:3q6n.C&PDB-ENSP_mappings:3q6n.D&PDB-ENSP_mappings:3q6n.E&PDB-ENSP_mappings:3q6n.F&PDB-ENSP_mappings:6ksq.A&PDB-ENSP_mappings:7krj.A&PDB-ENSP_mappings:7krj.B&PDB-ENSP_mappings:7kw7.A&PDB-ENSP_mappings:7kw7.B&PDB-ENSP_mappings:7l7i.A&PDB-ENSP_mappings:7l7i.B&PDB-ENSP_mappings:7l7j.A&PDB-ENSP_mappings:7l7j.B&PDB-ENSP_mappings:7rxz.A&PDB-ENSP_mappings:7rxz.B&PDB-ENSP_mappings:7rxz.C&PDB-ENSP_mappings:7rxz.D&PDB-ENSP_mappings:7rxz.E&PDB-ENSP_mappings:7rxz.F&PDB-ENSP_mappings:7ry0.A&PDB-ENSP_mappings:7ry0.B&PDB-ENSP_mappings:7ry1.A&PDB-ENSP_mappings:7ry1.B&PDB-ENSP_mappings:7ry1.C&PDB-ENSP_mappings:8ffv.A&PDB-ENSP_mappings:8ffv.B&PDB-ENSP_mappings:8ffw.A&PDB-ENSP_mappings:8ffw.B&AFDB-ENSP_mappings:AF-P07900-F1&HAMAP:MF_00505&Pfam:PF00183&PIRSF:PIRSF002583&PANTHER:PTHR11528&Superfamily:SSF54211			0.6845	0.2837	0.8415	0.8026	0.841	0.8323	0.826	0.3208	0.8309	0.8282	0.7788	0.7954	0.7977	0.8438	0.8063	0.8454	0.6935	0.3462	0.9309	0.8043	0.8372	0.7896	0.778	0.7295	0.8385	0.7105	0.8393	0.9309	gnomADg_AMI		0&1	0&1	27026916&39185521						FAIL	-21	15	44	-8	0.00	0.13	0.00	0.00	HSP90AA1		3.6200e-01																																																											191					0.979							107.04	v6.1	Unknown		True	HSP90AA1, a heat shock protein, is infrequently altered in cancer.	False	10/31/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000216281.8:N360= mutant UNKNOWN.	False	The HSP90AA1 ENSP00000216281.8:n360= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	102550803						True	False	False	Unknown								False	False		HSP90AA1, a heat shock protein, is infrequently altered in cancer.	The HSP90AA1 ENSP00000216281.8:n360= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000216281.8:N360= mutant UNKNOWN.						v6.1	10/31/2023		GRCh38	HSP90AA1	3320.0	ENSP00000216281.8:N360=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HSP90AA1"",""entrezGeneId"":3320,""alteration"":""ENSP00000216281.8:N360="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HSP90AA1, a heat shock protein, is infrequently altered in cancer."",""variantSummary"":""The HSP90AA1 ENSP00000216281.8:n360= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000216281.8:N360= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/31/2023""}"	True	True	False	Unknown		Unknown																						0,187	0,106	0,81	0/1	0,0,88,99	TGT	0.00	0.00	0.00			0,0,83,104	64.72		1.0
GRCh38	HSP90AA1	D12_12345_1234556_Thyroid_S9	p.E249ArgfsTer	ENSP00000216281.8:p.Glu249ArgfsTer68	chr14	102084916	102084917.0	TC	T	T	102084916	.	TC	T	.	PASS	NM_005348	-	frameshift_variant	HIGH	HSP90AA1	ENSG00000080824	Transcript	ENST00000216281	protein_coding	5/11		c.745del	804	745	249	E/X	Gag/ag	COSV53490469		-1		deletion	HGNC	HGNC:5253	YES	MANE_Select	NM_005348.4		1	P1	CCDS9967.1	ENSP00000216281	P07900.277	K9JA46.87	UPI0000163B5F	P07900-1		1			PDB-ENSP_mappings:7krj.A&PDB-ENSP_mappings:7krj.B&PDB-ENSP_mappings:7kw7.A&PDB-ENSP_mappings:7kw7.B&PDB-ENSP_mappings:7l7i.A&PDB-ENSP_mappings:7l7i.B&PDB-ENSP_mappings:7l7j.A&PDB-ENSP_mappings:7l7j.B&PDB-ENSP_mappings:7lsz.A&PDB-ENSP_mappings:7lt0.A&PDB-ENSP_mappings:7ur3.A&PDB-ENSP_mappings:8ffv.A&PDB-ENSP_mappings:8ffv.B&PDB-ENSP_mappings:8ffw.A&PDB-ENSP_mappings:8ffw.B&AFDB-ENSP_mappings:AF-P07900-F1&Coiled-coils_(Ncoils):Coil&HAMAP:MF_00505&Pfam:PF00183&PIRSF:PIRSF002583&PANTHER:PTHR11528&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg																																	1	1							FAIL	-50	-33	32	-34	0.00	0.00	0.00	0.00	HSP90AA1		3.6200e-01																																																											391					0.621							101.51	v6.1	Unknown		True	HSP90AA1, a heat shock protein, is infrequently altered in cancer.	False	10/31/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000216281.8:E249Rfs*68 mutant UNKNOWN.	False	The HSP90AA1 ENSP00000216281.8:e249rfs*68 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	102551253						True	False	False	Unknown								False	False		HSP90AA1, a heat shock protein, is infrequently altered in cancer.	The HSP90AA1 ENSP00000216281.8:e249rfs*68 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000216281.8:E249Rfs*68 mutant UNKNOWN.						v6.1	10/31/2023		GRCh38	HSP90AA1	3320.0	ENSP00000216281.8:E249Rfs*68			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HSP90AA1"",""entrezGeneId"":3320,""alteration"":""ENSP00000216281.8:E249Rfs*68"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HSP90AA1, a heat shock protein, is infrequently altered in cancer."",""variantSummary"":""The HSP90AA1 ENSP00000216281.8:e249rfs*68 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000216281.8:E249Rfs*68 mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/31/2023""}"	True	True	False	Unknown		Unknown																						235,8	124,3	111,5	0/1	117,118,4,4	CTC						122,113,3,5	10.41		0.03292181069958848
GRCh38	HSP90AA1	D12_12345_1234556_Thyroid_S9	p.Thr93=	ENSP00000489370.1:p.Thr93=	chr14	102101959	102101959.0	G	A	A	102101959	.	G	A	.	PASS		A	synonymous_variant	LOW	HSP90AA1	ENSG00000080824	Transcript	ENST00000558600	protein_coding	2/2		c.279C>T	574	279	93	T	acC/acT	rs10873531&COSV58234662		-1	cds_end_NF	SNV	HGNC	HGNC:5253					4			ENSP00000489370		A0A0U1RR69.37	UPI000719A1B9			1			AFDB-ENSP_mappings:AF-A0A0U1RR69-F1			0.6645	0.2776	0.853	0.7708	0.8807	0.7219	0.8461	0.3269	0.8381	0.7996	0.758	0.8719	0.7796	0.8731	0.8184	0.7654	0.7117	0.3538	0.9308	0.8072	0.8134	0.7582	0.8685	0.7449	0.8683	0.7311	0.758	0.9308	gnomADg_AMI		0&1	0&1	28266732&34178482&27026916&33167063&36467365																	1.5290e+00																																																											561					0.989							247.62	v6.1	Unknown		True	HSP90AA1, a heat shock protein, is infrequently altered in cancer.	False	10/31/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000335153.7:T94= mutant UNKNOWN.	False	The HSP90AA1 ENSP00000335153.7:t94= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	102568296						True	False	False	Unknown								False	False		HSP90AA1, a heat shock protein, is infrequently altered in cancer.	The HSP90AA1 ENSP00000335153.7:t94= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000335153.7:T94= mutant UNKNOWN.						v6.1	10/31/2023		GRCh38	HSP90AA1	3320.0	ENSP00000335153.7:T94=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HSP90AA1"",""entrezGeneId"":3320,""alteration"":""ENSP00000335153.7:T94="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HSP90AA1, a heat shock protein, is infrequently altered in cancer."",""variantSummary"":""The HSP90AA1 ENSP00000335153.7:t94= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000335153.7:T94= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/31/2023""}"	True	True	False	Unknown		Unknown																						0,555	0,255	0,300	0/1	0,0,253,302	CGG	0.00	0.00	0.00			0,0,303,252	64.73		1.0
GRCh38	HSP90AA1	D12_12345_1234556_Thyroid_S9	p.M70L	ENSP00000489370.1:p.Met70Leu	chr14	102102030	102102030.0	T	A	A	102102030	.	T	A	.	PASS		A	missense_variant	MODERATE	HSP90AA1	ENSG00000080824	Transcript	ENST00000558600	protein_coding	2/2		c.208A>T	503	208	70	M/L	Atg/Ttg	rs8005905&COSV58233514		-1	cds_end_NF	SNV	HGNC	HGNC:5253					4			ENSP00000489370		A0A0U1RR69.37	UPI000719A1B9			1	tolerated_low_confidence(1)	benign(0)	AFDB-ENSP_mappings:AF-A0A0U1RR69-F1			0.8011	0.5946	0.9207	0.8194	0.8976	0.8773	0.8856	0.6438	0.9105	0.8584	0.8015	0.8786	0.8434	0.8973	0.8723	0.8795	0.8231	0.6614	0.932	0.8807	0.8724	0.808	0.8746	0.8129	0.894	0.822	0.8788	0.932	gnomADg_AMI		0&1	0&1	27437086&28266732&34178482&33747278																	1.5290e+00																																																											612					0.99							247.64	v6.1	Unknown		True	HSP90AA1, a heat shock protein, is infrequently altered in cancer.	False	10/31/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000335153.7:M71L mutant UNKNOWN.	False	The HSP90AA1 ENSP00000335153.7:m71l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr14	102568367						True	False	False	Unknown								False	False		HSP90AA1, a heat shock protein, is infrequently altered in cancer.	The HSP90AA1 ENSP00000335153.7:m71l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000335153.7:M71L mutant UNKNOWN.						v6.1	10/31/2023		GRCh38	HSP90AA1	3320.0	ENSP00000335153.7:M71L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HSP90AA1"",""entrezGeneId"":3320,""alteration"":""ENSP00000335153.7:M71L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HSP90AA1, a heat shock protein, is infrequently altered in cancer."",""variantSummary"":""The HSP90AA1 ENSP00000335153.7:m71l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HSP90AA1 ENSP00000335153.7:M71L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/31/2023""}"	True	True	False	Unknown		Unknown																						0,606	0,294	0,312	0/1	0,0,313,293	ATC	.	.	.			0,0,297,309	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr14	104806606		T	<INS>	<INS>	104806606	MantaINS:3765:0:0:0:5:0	T	<INS>	.	PASS		insertion	downstream_gene_variant	MODIFIER		ENSG00000279140	Transcript	ENST00000803114	lncRNA										2722	-1		insertion																																																																																																																															0,11		0,11							11	CACCTCCACCA		CACCTCCACCAGCATCACCACCTCCACCACCATCACCTCCACTTTTACCTCCACCAGCATCACCACCATCACCTCCACTTTTACCTCCACCTCCACTACCACCATCACCACCTCCTCCACCTCCACCATTGCCTCCACCTCCATCATCACCTCCACCTCCAGCACCATCACCTCCACCTCTACCACCATTACCTCCACCATCACCTCCACCTCTACCATCACTACCAACCACAAACACCTCCACCTTCACAACCAACAACGCAACCTCATCCA																chr14	105272943	TACCTACATCGCTACCTCCTCCACCTCCACCATTACCTC			INS																																													True	False	False	Unknown		Unknown																															0,1				0,20	
GRCh38	GREM1	D12_12345_1234556_Thyroid_S9			chr15	32731285	32731285.0	C	A	A	32731285	.	C	A	.	PASS	NM_013372	A	3_prime_UTR_variant	MODIFIER	GREM1	ENSG00000166923	Transcript	ENST00000651154	protein_coding	2/2		c.*40C>A	754					rs12915554&COSV55715058		1		SNV	HGNC	HGNC:2001	YES	MANE_Select	NM_013372.7			P1	CCDS10029.1	ENSP00000498748	O60565.179	A6XAA7.130	UPI0000073D48	O60565-1		1						0.1787	0.0499	0.3199	0.0258	0.3569	0.227	0.3282	0.09292	0.307	0.3771	0.02297	0.2943	0.3347	0.3559	0.3166	0.2382	0.264	0.1033	0.3662	0.3135	0.3939	0.02927	0.2858	0.3503	0.3583	0.2763	0.2387	0.3939	gnomADg_ASJ	benign	0&1	1&1	31637880&19577778&20150533&31650875&28977865&22561515&35627259&35739095&36287119&35330456						FAIL	-38	-29	-27	-29	0.00	0.00	0.00	0.01	GREM1		8.5600e-01	1282623	0.27325	0.29164	0.17871	1271192	Hereditary_cancer-predisposing_syndrome&not_provided		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900		NC_000015.10:g.32731285C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001913588&SCV005293549&SCV006311039	single_nucleotide_variant	SO:0001483	ClinGen:CA7456195		GREM1:26585	SO:0001624&3_prime_UTR_variant										1	12915554																											619					1							247.44													chr15	33023486																																																	True	True	False	Unknown		Unknown																						327,292	155,134	172,158	0/1	170,157,147,145	GCC	0.00	0.00	0.00			128,199,109,183	32.56		0.4717285945072698
GRCh38	NUTM1	D12_12345_1234556_Thyroid_S9			chr15	34346343	34346343.0	G	A	A	34346343	.	G	A	.	PASS	NM_001284292	A	intron_variant	MODIFIER	NUTM1	ENSG00000184507	Transcript	ENST00000537011	protein_coding		2/7	c.100+308G>A						rs402784		1		SNV	HGNC	HGNC:29919	YES	MANE_Select	NM_001284292.2		2	A2	CCDS61585.1	ENSP00000444896	Q86Y26.134		UPI0002064E63	Q86Y26-4		1						0.6619	0.9576	0.6124	0.6409	0.4751	0.5112											0.5971	0.8811	0.5432	0.5755	0.5133	0.6548	0.5045	0.5272	0.4517	0.5492	0.5186	0.9576	AFR										FAIL	-43	38	1	29	0.01	0.00	0.02	0.00	NUTM1		5.3100e-01																																																											445					0.935							232.62													chr15	34638544																																																	True	True	False	Unknown		Unknown																						222,194	108,82	114,112	0/1	97,125,89,105	GGG	0.00	0.00	0.00			111,111,99,95	31.19		0.46634615384615385
GRCh38	NUTM1	D12_12345_1234556_Thyroid_S9			chr15	34346709	34346709.0	C	A	A	34346709	.	C	A	.	PASS	NM_001284292	A	intron_variant	MODIFIER	NUTM1	ENSG00000184507	Transcript	ENST00000537011	protein_coding		2/7	c.100+674C>A						rs2935162		1		SNV	HGNC	HGNC:29919	YES	MANE_Select	NM_001284292.2		2	A2	CCDS61585.1	ENSP00000444896	Q86Y26.134		UPI0002064E63	Q86Y26-4		1																						0.382	0.1038	0.4426	0.3819	0.4623	0.3347	0.4464	0.4395	0.5366	0.4051	0.4475	0.5366	gnomADg_NFE										FAIL	29	-1	2	-41	0.00	0.00	0.00	0.00	NUTM1		5.3100e-01																																																											306					1							211.38													chr15	34638910																																																	True	True	False	Unknown		Unknown																						168,138	82,71	86,67	0/1	80,88,70,68	CCC	0.00	0.00	0.00			82,86,67,71	27.13		0.45098039215686275
GRCh38	NUTM1	D12_12345_1234556_Thyroid_S9			chr15	34346814	34346814.0	C	T	T	34346814	.	C	T	.	PASS	NM_001284292	T	intron_variant	MODIFIER	NUTM1	ENSG00000184507	Transcript	ENST00000537011	protein_coding		2/7	c.100+779C>T						rs383086		1		SNV	HGNC	HGNC:29919	YES	MANE_Select	NM_001284292.2		2	A2	CCDS61585.1	ENSP00000444896	Q86Y26.134		UPI0002064E63	Q86Y26-4		1						0.3393	0.0461	0.3876	0.3621	0.5229	0.4888											0.4249	0.1356	0.466	0.4646	0.4754	0.3679	0.5307	0.4917	0.5501	0.4535	0.493	0.5501	gnomADg_NFE										FAIL	-36	-44	-2	10	0.00	0.00	0.00	0.00	NUTM1		5.3100e-01																																																											226					0.996							174.15													chr15	34639015																																																	True	True	False	Unknown		Unknown																						130,95	56,47	74,48	0/1	60,70,46,49	GCG	0.00	0.00	0.00			86,44,54,41	20.66		0.4222222222222222
GRCh38	NUTM1	D12_12345_1234556_Thyroid_S9			chr15	34347262	34347263.0	C	CT	CT	34347262	.	C	CT	.	PASS	NM_001284292	T	intron_variant	MODIFIER	NUTM1	ENSG00000184507	Transcript	ENST00000537011	protein_coding		2/7	c.101-694dup						rs55955824		1		insertion	HGNC	HGNC:29919	YES	MANE_Select	NM_001284292.2		2	A2	CCDS61585.1	ENSP00000444896	Q86Y26.134		UPI0002064E63	Q86Y26-4		1					13																	0.4228	0.1852	0.4599	0.4323	0.4938	0.3553	0.4806	0.4893	0.5496	0.456	0.4832	0.5496	gnomADg_NFE										FAIL	21	-24	-34	-35	0.00	0.00	0.00	0.00	NUTM1		5.3100e-01																																																											603					0.841							230.5													chr15	34639463																																																	True	True	False	Unknown		Unknown																						313,194	154,100	159,94	0/1	157,156,105,89	TCT						176,137,109,85	10.79		0.3826429980276134
GRCh38	NUTM1	D12_12345_1234556_Thyroid_S9			chr15	34347853	34347859.0	AAAAAAT	A	A	34347853	.	AAAAAAT	A	.	PASS	NM_001284292	-	intron_variant	MODIFIER	NUTM1	ENSG00000184507	Transcript	ENST00000537011	protein_coding		2/7	c.101-80_101-75del						rs150911418		1		deletion	HGNC	HGNC:29919	YES	MANE_Select	NM_001284292.2		2	A2	CCDS61585.1	ENSP00000444896	Q86Y26.134		UPI0002064E63	Q86Y26-4		1					35	0.9383	0.7965	0.9582	0.9911	0.999	0.999	0.985	0.798	0.9617	0.9939	0.9482	0.9885	0.9792	0.9969	0.9751	0.9968	0.9383	0.7977	0.9989	0.9628	0.9927	0.9678	0.9922	0.9793	0.9977	0.9498	0.9964	0.999	EUR&SAS																					5.3100e-01																																																											366					0.861							161.22													chr15	34640054																																																	True	True	False	Unknown		Unknown																						2,313	0,142	2,171	0/1	0,2,169,144	CAA						2,0,156,157	61.94		0.9936507936507937
GRCh38	NUTM1	D12_12345_1234556_Thyroid_S9	p.P50L	ENSP00000444896.1:p.Pro50Leu	chr15	34348017	34348017.0	C	T	T	34348017	.	C	T	.	PASS	NM_001284292	T	missense_variant	MODERATE	NUTM1	ENSG00000184507	Transcript	ENST00000537011	protein_coding	3/8		c.149C>T	531	149	50	P/L	cCg/cTg	rs374230&COSV107328912		1		SNV	HGNC	HGNC:29919	YES	MANE_Select	NM_001284292.2		2	A2	CCDS61585.1	ENSP00000444896	Q86Y26.134		UPI0002064E63	Q86Y26-4		1	tolerated(1)	benign(0)	Low_complexity_(Seg):seg&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Pfam:PF12881&PANTHER:PTHR22879&AFDB-ENSP_mappings:AF-Q86Y26-F1			0.8778	0.5613	0.9597	1	0.996	1	0.9878	0.5986	0.978	0.9882	1	1	0.9742	0.999	0.9711	0.9991	0.8901	0.6195	1	0.96	0.9911	1	1	0.9762	0.9982	0.9171	0.9981	1	EAS&SAS&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN		0&1	0&1							FAIL	9	-48	0	14	0.00	0.02	0.00	0.00	NUTM1	0.019	5.3100e-01																																																											881					0.975							243.71	v6.1	Unknown		True	NUTM1, a gene of unknown function, is recurrently altered by chromosomal rearrangement in NUT midline carcinoma.	False	01/22/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NUTM1 ENSP00000444896.1:P50L mutant UNKNOWN.	False	The NUTM1 ENSP00000444896.1:p50l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	34640218						True	False	False	Unknown								False	False		NUTM1, a gene of unknown function, is recurrently altered by chromosomal rearrangement in NUT midline carcinoma.	The NUTM1 ENSP00000444896.1:p50l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NUTM1 ENSP00000444896.1:P50L mutant UNKNOWN.						v6.1	01/22/2019		GRCh38	NUTM1	256646.0	ENSP00000444896.1:P50L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NUTM1"",""entrezGeneId"":256646,""alteration"":""ENSP00000444896.1:P50L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NUTM1, a gene of unknown function, is recurrently altered by chromosomal rearrangement in NUT midline carcinoma."",""variantSummary"":""The NUTM1 ENSP00000444896.1:p50l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NUTM1 ENSP00000444896.1:P50L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/22/2019""}"	True	True	False	Unknown		Unknown																						1,858	0,520	1,338	0/1	1,0,459,399	CCG	0.00	0.00	0.00			0,1,475,383	64.73		0.9988358556461001
GRCh38	NUTM1	D12_12345_1234556_Thyroid_S9	p.Asp103=	ENSP00000444896.1:p.Asp103=	chr15	34348177	34348177.0	T	C	C	34348177	.	T	C	.	PASS	NM_001284292	C	synonymous_variant	LOW	NUTM1	ENSG00000184507	Transcript	ENST00000537011	protein_coding	3/8		c.309T>C	691	309	103	D	gaT/gaC	rs430083&COSV60995641		1		SNV	HGNC	HGNC:29919	YES	MANE_Select	NM_001284292.2		2	A2	CCDS61585.1	ENSP00000444896	Q86Y26.134		UPI0002064E63	Q86Y26-4		1			Pfam:PF12881&PANTHER:PTHR22879&AFDB-ENSP_mappings:AF-Q86Y26-F1			0.9397	0.7821	0.9798	1	1	1	0.995	0.8313	0.991	0.9978	0.9999	1	0.9906	0.9996	0.9887	0.9997	0.9529	0.8373	1	0.984	0.9974	1	1	0.983	0.999	0.9616	0.9996	1	EAS&EUR&SAS&gnomADe_FIN&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN		0&1	0&1							FAIL	-21	-16	36	-16	0.00	0.00	0.00	0.02	NUTM1		5.3100e-01																																																											991					0.995							247.98	v6.1	Unknown		True	NUTM1, a gene of unknown function, is recurrently altered by chromosomal rearrangement in NUT midline carcinoma.	False	01/22/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NUTM1 ENSP00000444896.1:D103= mutant UNKNOWN.	False	The NUTM1 ENSP00000444896.1:d103= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	34640378						True	False	False	Unknown								False	False		NUTM1, a gene of unknown function, is recurrently altered by chromosomal rearrangement in NUT midline carcinoma.	The NUTM1 ENSP00000444896.1:d103= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NUTM1 ENSP00000444896.1:D103= mutant UNKNOWN.						v6.1	01/22/2019		GRCh38	NUTM1	256646.0	ENSP00000444896.1:D103=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NUTM1"",""entrezGeneId"":256646,""alteration"":""ENSP00000444896.1:D103="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NUTM1, a gene of unknown function, is recurrently altered by chromosomal rearrangement in NUT midline carcinoma."",""variantSummary"":""The NUTM1 ENSP00000444896.1:d103= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NUTM1 ENSP00000444896.1:D103= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/22/2019""}"	True	True	False	Unknown		Unknown																						0,986	0,520	0,466	0/1	0,0,498,488	ATG	.	.	.			0,0,502,484	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr15	39021201	39021201.0	C	G	G	39021201	.	C	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000259278	Transcript	ENST00000824826	lncRNA		1/1	n.125+1877C>G						rs1821380		1		SNV																						0.3966	0.3631	0.4755	0.4038	0.4334	0.3405											0.4199	0.3914	0.5417	0.4361	0.3834	0.3824	0.4016	0.4388	0.4437	0.4356	0.3531	0.5417	gnomADg_AMI				23771752&26691610&29121662&33406744&24406457&31745634&27294018&33546406&15639604																																																																												135					0.911							234.79													chr15	39313402																																																	True	False	False	Unknown		Unknown																						67,56	30,29	37,27	0/1	37,30,24,32	TCC	.	.	.			30,37,33,23	30.29		0.45528455284552843
GRCh38	MGA	D12_12345_1234556_Thyroid_S9	p.T716S	ENSP00000515495.1:p.Thr716Ser	chr15	41699117	41699117.0	A	T	T	41699117	.	A	T	.	PASS	NM_001400225	T	missense_variant	MODERATE	MGA	ENSG00000174197	Transcript	ENST00000703841	protein_coding	5/24		c.2146A>T	2334	2146	716	T/S	Act/Tct	rs2178004&COSV107271798		1		SNV	HGNC	HGNC:14010	YES	MANE_Select	NM_001400225.1			A2	CCDS91982.1	ENSP00000515495		A0A994J6L2.8	UPI00001D7772				tolerated_low_confidence(1)	benign(0)	PANTHER:PTHR11267			0.7594	0.5083	0.8256	0.8909	0.835	0.8384	0.8184	0.5439	0.8473	0.8811	0.8926	0.8644	0.8605	0.8179	0.8251	0.827	0.7559	0.5577	0.8487	0.8223	0.8911	0.8888	0.8638	0.8435	0.8211	0.7749	0.8229	0.8926	gnomADe_EAS		0&1	1&1	36581621																																																																												269					0.974							233.25	v6.1	Unknown		True	MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	False	03/08/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:T716S mutant UNKNOWN.	False	The MGA ENSP00000515495.1:t716s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	41991315						True	False	False	Unknown								False	False		MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	The MGA ENSP00000515495.1:t716s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:T716S mutant UNKNOWN.						v6.1	03/08/2018		GRCh38	MGA	23269.0	ENSP00000515495.1:T716S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MGA"",""entrezGeneId"":23269,""alteration"":""ENSP00000515495.1:T716S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers."",""variantSummary"":""The MGA ENSP00000515495.1:t716s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:T716S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/08/2018""}"	True	True	False	Unknown		Unknown																						136,126	71,63	65,63	0/1	67,69,69,57	GAC	.	.	.			80,56,74,52	35.47		0.48091603053435117
GRCh38	MGA	D12_12345_1234556_Thyroid_S9	p.E1120*	ENSP00000515495.1:p.Glu1120Ter	chr15	41713424	41713424.0	G	T	T	41713424	.	G	T	.	PASS	NM_001400225	T	stop_gained	HIGH	MGA	ENSG00000174197	Transcript	ENST00000703841	protein_coding	9/24		c.3358G>T	3546	3358	1120	E/*	Gag/Tag			1		SNV	HGNC	HGNC:14010	YES	MANE_Select	NM_001400225.1			A2	CCDS91982.1	ENSP00000515495		A0A994J6L2.8	UPI00001D7772						Low_complexity_(Seg):seg&Coiled-coils_(Ncoils):Coil																																																																																																															223					0.834							229.14	v6.1	Unknown		True	MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	False	03/08/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:E1120* mutant UNKNOWN.	False	The MGA ENSP00000515495.1:e1120* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	42005622						True	False	False	Unknown								False	False		MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	The MGA ENSP00000515495.1:e1120* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:E1120* mutant UNKNOWN.						v6.1	03/08/2018		GRCh38	MGA	23269.0	ENSP00000515495.1:E1120*			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MGA"",""entrezGeneId"":23269,""alteration"":""ENSP00000515495.1:E1120*"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers."",""variantSummary"":""The MGA ENSP00000515495.1:e1120* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:E1120* mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/08/2018""}"	True	True	False	Likely Loss-of-function	23039309	Likely Oncogenic																						182,4	95,1	87,3	0/1	103,79,4,0	GGA	0.00	0.00	1.00			108,74,1,3	8.96		0.021505376344086023
GRCh38	MGA	D12_12345_1234556_Thyroid_S9	p.Asp1296=	ENSP00000515495.1:p.Asp1296=	chr15	41734566	41734566.0	C	T	T	41734566	.	C	T	.	PASS	NM_001400225	T	synonymous_variant	LOW	MGA	ENSG00000174197	Transcript	ENST00000703841	protein_coding	12/24		c.3888C>T	4076	3888	1296	D	gaC/gaT	rs1918314&COSV54961870		1		SNV	HGNC	HGNC:14010	YES	MANE_Select	NM_001400225.1			A2	CCDS91982.1	ENSP00000515495		A0A994J6L2.8	UPI00001D7772						MobiDB_lite:mobidb-lite			0.7482	0.5386	0.8242	0.8919	0.8161	0.7597	0.8	0.5545	0.8385	0.867	0.8925	0.8344	0.8197	0.8042	0.8059	0.7312	0.745	0.5656	0.7385	0.8175	0.877	0.8877	0.8322	0.8231	0.8067	0.7618	0.7363	0.8925	gnomADe_EAS		0&1	0&1																																																																													115					0.983							243.87	v6.1	Unknown		True	MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	False	03/08/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:D1296= mutant UNKNOWN.	False	The MGA ENSP00000515495.1:d1296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	42026764						True	False	False	Unknown								False	False		MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	The MGA ENSP00000515495.1:d1296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:D1296= mutant UNKNOWN.						v6.1	03/08/2018		GRCh38	MGA	23269.0	ENSP00000515495.1:D1296=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MGA"",""entrezGeneId"":23269,""alteration"":""ENSP00000515495.1:D1296="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers."",""variantSummary"":""The MGA ENSP00000515495.1:d1296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:D1296= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/08/2018""}"	True	True	False	Unknown		Unknown																						65,48	28,27	37,21	0/1	31,34,26,22	ACT	0.00	0.00	0.00			28,37,21,27	25.88		0.4247787610619469
GRCh38	MGA	D12_12345_1234556_Thyroid_S9	p.K1673E	ENSP00000515495.1:p.Lys1673Glu	chr15	41742830	41742830.0	A	G	G	41742830	.	A	G	.	PASS	NM_001400225	G	missense_variant	MODERATE	MGA	ENSG00000174197	Transcript	ENST00000703841	protein_coding	15/24		c.5017A>G	5205	5017	1673	K/E	Aaa/Gaa	rs150585920&COSV104588892		1		SNV	HGNC	HGNC:14010	YES	MANE_Select	NM_001400225.1			A2	CCDS91982.1	ENSP00000515495		A0A994J6L2.8	UPI00001D7772				deleterious_low_confidence(0)	benign(0.062)				0.0006	0	0	0	0.003	0	0.00136	0.0001493	0.0002236	7.652e-05	0	0.000356	0	0.001698	0.0007122	0.0002435	0.0007618	0.0002648	0	0.0004576	0	0	0.0005647	0	0.001353	0	0	0.003	EUR		0&1	0&1																																																																													263					0.985							242.94	v6.1	Unknown		True	MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	False	03/08/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:K1673E mutant UNKNOWN.	False	The MGA ENSP00000515495.1:k1673e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	42035028						True	False	False	Unknown								False	False		MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	The MGA ENSP00000515495.1:k1673e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:K1673E mutant UNKNOWN.						v6.1	03/08/2018		GRCh38	MGA	23269.0	ENSP00000515495.1:K1673E			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MGA"",""entrezGeneId"":23269,""alteration"":""ENSP00000515495.1:K1673E"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers."",""variantSummary"":""The MGA ENSP00000515495.1:k1673e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:K1673E mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/08/2018""}"	True	True	False	Unknown		Unknown																						129,130	70,65	59,65	0/1	68,61,69,61	TAA	.	.	.			51,78,62,68	40.22		0.5019305019305019
GRCh38	MGA	D12_12345_1234556_Thyroid_S9	p.Lys2018=	ENSP00000515495.1:p.Lys2018=	chr15	41749514	41749514.0	G	A	A	41749514	.	G	A	.	PASS	NM_001400225	A	synonymous_variant	LOW	MGA	ENSG00000174197	Transcript	ENST00000703841	protein_coding	17/24		c.6054G>A	6242	6054	2018	K	aaG/aaA	rs2695163&COSV54949153		1		SNV	HGNC	HGNC:14010	YES	MANE_Select	NM_001400225.1			A2	CCDS91982.1	ENSP00000515495		A0A994J6L2.8	UPI00001D7772						MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.7009	0.3699	0.8055	0.8909	0.8161	0.7597	0.7961	0.4168	0.8349	0.8671	0.8921	0.8343	0.8179	0.8038	0.7977	0.7322	0.7075	0.436	0.7379	0.8033	0.8769	0.8872	0.8322	0.8197	0.806	0.7358	0.7365	0.8921	gnomADe_EAS		0&1	0&1																																																																													101					0.832							230.31	v6.1	Unknown		True	MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	False	03/08/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:K2018= mutant UNKNOWN.	False	The MGA ENSP00000515495.1:k2018= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	42041712						True	False	False	Unknown								False	False		MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers.	The MGA ENSP00000515495.1:k2018= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:K2018= mutant UNKNOWN.						v6.1	03/08/2018		GRCh38	MGA	23269.0	ENSP00000515495.1:K2018=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MGA"",""entrezGeneId"":23269,""alteration"":""ENSP00000515495.1:K2018="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MGA, a tumor suppressor and transcription factor, is altered by mutation, deletion or chromosomal translocation in a diverse range of cancers."",""variantSummary"":""The MGA ENSP00000515495.1:k2018= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MGA ENSP00000515495.1:K2018= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/08/2018""}"	True	True	False	Unknown		Unknown																						43,41	25,25	18,16	0/1	24,19,23,18	AGA	0.00	0.00	0.00			18,25,29,12	33.93		0.4880952380952381
GRCh38	FGF7	D12_12345_1234556_Thyroid_S9			chr15	49427756	49427756.0	A	C	C	49427756	.	A	C	.	PASS	NM_002009	C	intron_variant	MODIFIER	FGF7	ENSG00000140285	Transcript	ENST00000267843	protein_coding		2/3	c.286+3173A>C						rs10519224		1		SNV	HGNC	HGNC:3685	YES	MANE_Select	NM_002009.4		1	P1	CCDS10131.1	ENSP00000267843	P21781.196	A0A7U3JVY2.11	UPI0000040660	P21781-1								0.1911	0.0371	0.219	0.1696	0.3668	0.2209											0.2771	0.08969	0.5176	0.269	0.4362	0.1851	0.3417	0.2483	0.3832	0.285	0.2156	0.5176	gnomADg_AMI				22796760						FAIL	-2	-33	-11	33	0.00	0.00	0.00	0.00	FGF7		6.4300e-01																																																											122					0.959							238.6													chr15	49719953																																																	True	True	False	Unknown		Unknown																						0,117	0,55	0,62	0/1	0,0,52,65	GAT	.	.	.			0,0,72,45	64.7		1.0
GRCh38	LINC02490	D12_12345_1234556_Thyroid_S9			chr15	53189317	53189319.0	T	TAA	TAA	53189317	.	T	TAA	.	PASS		AA	intron_variant&non_coding_transcript_variant	MODIFIER	LINC02490	ENSG00000259237	Transcript	ENST00000780990	lncRNA		1/1	n.251-4309_251-4308dup						rs2308020		1		insertion	HGNC	HGNC:53471																			3	0.3411	0.2262	0.3905	0.497	0.2893	0.3538											0.3103	0.2568	0.1744	0.3836	0.3197	0.4992	0.3741	0.3099	0.2997	0.3108	0.3741	0.4992	gnomADg_EAS				33801242																																																																												57					1							238.72													chr15	53481514																																																	True	False	False	Unknown		Unknown																						27,30	10,17	17,13	0/1	20,7,19,11	GTA						9,18,14,16	34.33		0.5263157894736842
GRCh38		D12_12345_1234556_Thyroid_S9			chr15	53324712	53324712.0	C	T	T	53324712	.	C	T	.	PASS		T	intergenic_variant	MODIFIER														rs8037429				SNV																						0.4501	0.4054	0.4769	0.3889	0.5348	0.4673											0.4942	0.423	0.6963	0.4851	0.5554	0.4216	0.551	0.4694	0.5314	0.4938	0.482	0.6963	gnomADg_AMI				29121662&33406744&34721519&24997319&19083859&24847187&22851934&19948332																																																																												84					0.976							245.1													chr15	53616909																																																	True	False	False	Unknown		Unknown																						39,43	19,27	20,16	0/1	16,23,25,18	ACG	0.00	0.00	0.00			20,19,23,20	37.08		0.524390243902439
GRCh38		D12_12345_1234556_Thyroid_S9			chr15	54918507	54918507.0	C	T	T	54918507	.	C	T	.	PASS		T	intergenic_variant	MODIFIER														rs1528460				SNV																						0.4758	0.0514	0.5965	0.5843	0.7336	0.5869											0.5382	0.1553	0.5263	0.6105	0.6815	0.6079	0.7846	0.5719	0.6993	0.5773	0.5991	0.7846	gnomADg_FIN				26691610&28341840&29121662&33406744&34721519&21611176&19083859&23612573&33850175&19948332																																																																												68					0.985							244.86													chr15	55210705																																																	True	False	False	Unknown		Unknown																						35,32	14,19	21,13	0/1	22,13,21,11	ACT	0.00	0.00	0.00			17,18,20,12	32.46		0.47761194029850745
GRCh38	DNAAF4	D12_12345_1234556_Thyroid_S9			chr15	55428931		A	[chr3:76051004[A	[chr3:76051004[A	55428931	MantaBND:14821:0:1:0:0:0:0	A	[chr3:76051004[A	.	PASS		.A	feature_truncation&intron_variant&NMD_transcript_variant	HIGH	DNAAF4	ENSG00000256061	Transcript	ENST00000524160	nonsense_mediated_decay		7/8									-1		chromosome_breakpoint	HGNC	HGNC:21493					2			ENSP00000428097		B4DY92.101	UPI00017A819C			1																																																																																																														3			0,5							5	ATTTG			MantaBND:14821:0:1:0:0:0:1	2														chr15	55721129				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	SMAD3	D12_12345_1234556_Thyroid_S9	p.Leu103=	ENSP00000332973.4:p.Leu103=	chr15	67164997	67164997.0	A	G	G	67164997	.	A	G	.	PASS	NM_005902	G	synonymous_variant	LOW	SMAD3	ENSG00000166949	Transcript	ENST00000327367	protein_coding	2/9		c.309A>G	862	309	103	L	ctA/ctG	rs1065080&COSV59284976		1		SNV	HGNC	HGNC:6769	YES	MANE_Select	NM_005902.4		1	P1	CCDS10222.1	ENSP00000332973	P84022.210		UPI0000023A91	P84022-1		1			PDB-ENSP_mappings:1mhd.A&PDB-ENSP_mappings:1mhd.B&PDB-ENSP_mappings:1ozj.A&PDB-ENSP_mappings:1ozj.B&Gene3D:3.90.520.10&PDB-ENSP_mappings:5od6.A&PDB-ENSP_mappings:5od6.B&PDB-ENSP_mappings:5odg.A&PDB-ENSP_mappings:5odg.B&PDB-ENSP_mappings:6zmn.A&PDB-ENSP_mappings:6zmn.B&AFDB-ENSP_mappings:AF-P84022-F1&Pfam:PF03165&PROSITE_profiles:PS51075&PANTHER:PTHR13703&SMART:SM00523&Superfamily:SSF56366&CDD:cd10491			0.8341	0.8669	0.9135	0.7619	0.8608	0.7802	0.875	0.8646	0.9402	0.8481	0.8077	0.8609	0.8675	0.8825	0.8647	0.804	0.8705	0.8621	0.886	0.9098	0.8399	0.7724	0.8629	0.8912	0.8818	0.8842	0.7936	0.9402	gnomADe_AMR	benign	0&1	1&1	25741868&24033266&31786580&27386823&18095113&35002714&31183679&31860681&31818039&32160291&37685308						FAIL	-22	16	48	16	0.00	0.00	0.00	0.00	SMAD3		3.7300e-01	139217	0.88000	0.86352	0.83407	142920	Familial_thoracic_aortic_aneurysm_and_aortic_dissection&Thoracic_aortic_aneurysm&not_specified&not_provided&Aneurysm-osteoarthritis_syndrome		MONDO:MONDO:0019625&MedGen:C4707243&OMIM:PS607086&Orphanet:91387&Human_Phenotype_Ontology:HP:0012727&MONDO:MONDO:0005396&MedGen:C0162872&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0013426&MedGen:C3151087&OMIM:613795&Orphanet:284984		NC_000015.10:g.67164997A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000171761&SCV000269835&SCV000311291&SCV000317696&SCV000332954&SCV000393479&SCV000393480&SCV000605214&SCV000740518&SCV000910495&SCV001139639&SCV001362471&SCV001729738&SCV002043353&SCV002057751&SCV004815332&SCV005293037	single_nucleotide_variant	SO:0001483	ClinGen:CA019603		SMAD3:4088	SO:0001623&5_prime_UTR_variant&SO:0001819&synonymous_variant										1	1065080																											986					0.998							248.77	v6.1	Unknown		True	SMAD3, a transcription factor in the TGF pathway, is infrequently altered in cancer.	False	12/01/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMAD3 ENSP00000332973.4:L103= mutant UNKNOWN.	False	The SMAD3 ENSP00000332973.4:l103= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	67457335						True	False	False	Unknown								False	False		SMAD3, a transcription factor in the TGF pathway, is infrequently altered in cancer.	The SMAD3 ENSP00000332973.4:l103= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMAD3 ENSP00000332973.4:L103= mutant UNKNOWN.						v6.1	12/01/2025		GRCh38	SMAD3	4088.0	ENSP00000332973.4:L103=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SMAD3"",""entrezGeneId"":4088,""alteration"":""ENSP00000332973.4:L103="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SMAD3, a transcription factor in the TGF\u00df pathway, is infrequently altered in cancer."",""variantSummary"":""The SMAD3 ENSP00000332973.4:l103= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMAD3 ENSP00000332973.4:L103= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/01/2025""}"	True	True	False	Unknown		Unknown																						0,984	0,498	0,486	0/1	0,0,457,527	TAC	.	.	.			0,0,467,517	64.73		1.0
GRCh38	NTRK3	D12_12345_1234556_Thyroid_S9			chr15	87978049	87978049.0	C	G	G	87978049	.	C	G	.	PASS	NM_001012338	G	intron_variant	MODIFIER	NTRK3	ENSG00000140538	Transcript	ENST00000629765	protein_coding		14/19	c.1586-37296G>C						rs28521337&COSV58124966&CR094224		-1		SNV	HGNC	HGNC:8033	YES	MANE_Select	NM_001012338.3		1		CCDS32322.1	ENSP00000485864	Q16288.237	X5D2R1.76	UPI000006DC82	Q16288-1		1						0.6995	0.8918	0.6153	0.8145	0.5258	0.5593	0.575	0.8437	0.6092	0.4714	0.7873	0.543	0.4793	0.5175	0.5693	0.5243	0.6255	0.8319	0.5604	0.606	0.4671	0.8031	0.5334	0.5442	0.5208	0.6071	0.5361	0.8918	AFR		0&1&1	0&1&1	25106527&23150170&21995669&18367154&19370765&21143953&24653674						FAIL	-8	45	-2	5	0.00	0.00	0.00	0.00	NTRK3		3.4700e-01																																																											753					0.996							247.8													chr15	88521280																																																	True	True	False	Unknown		Unknown																						389,361	199,175	190,186	0/1	191,198,177,184	TCA	.	.	.			205,184,193,168	38.38		0.48133333333333334
GRCh38	NTRK3	D12_12345_1234556_Thyroid_S9			chr15	87978108	87978108.0	G	A	A	87978108	.	G	A	.	PASS	NM_001012338	A	intron_variant	MODIFIER	NTRK3	ENSG00000140538	Transcript	ENST00000629765	protein_coding		14/19	c.1586-37355C>T						rs556313499		-1		SNV	HGNC	HGNC:8033	YES	MANE_Select	NM_001012338.3		1		CCDS32322.1	ENSP00000485864	Q16288.237	X5D2R1.76	UPI000006DC82	Q16288-1		1												0.0004548	0.0002674	0	0	0	0	0	0.0006584	0.0004566	0	0.0005979	0.0003376	0.002193	0.0002617	0	0	0	0	0.001029	0.000478	0	0.002193	gnomADg_AMI										FAIL	-14	46	-4	46	0.00	0.00	0.00	0.00	NTRK3		3.4700e-01																																																											783					0.997							247.54													chr15	88521339																																																	True	True	False	Unknown		Unknown																						404,377	205,178	199,199	0/1	190,214,191,186	TGA	0.00	0.00	0.00			181,223,178,199	39.73		0.4827144686299616
GRCh38	NTRK3	D12_12345_1234556_Thyroid_S9	p.Asn226=	ENSP00000485864.1:p.Asn226=	chr15	88136554	88136554.0	G	A	A	88136554	.	G	A	.	PASS	NM_001012338	A	synonymous_variant	LOW	NTRK3	ENSG00000140538	Transcript	ENST00000629765	protein_coding	8/20		c.678C>T	992	678	226	N	aaC/aaT	rs1863480&COSV58135005		-1		SNV	HGNC	HGNC:8033	YES	MANE_Select	NM_001012338.3		1		CCDS32322.1	ENSP00000485864	Q16288.237	X5D2R1.76	UPI000006DC82	Q16288-1		1			SMART:SM00409&PANTHER:PTHR24416&Gene3D:2.60.40.10&Pfam:PF00047&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50835&Superfamily:SSF48726&AFDB-ENSP_mappings:AF-Q16288-F1			0.9982	0.9992	0.9986	1	0.993	1	0.9955	0.9993	0.9975	0.9994	1	0.9967	0.9979	0.9947	0.9962	0.9984	0.9972	0.9994	1	0.9972	0.998	1	0.9974	1	0.9954	0.9976	0.9985	1	EAS&SAS&gnomADe_EAS&gnomADg_AMI&gnomADg_EAS&gnomADg_MID		0&1	0&1							FAIL	44	39	18	4	0.00	0.00	0.00	0.00	NTRK3		3.4700e-01																																																											888					0.995							247.56	v6.1	Unknown		True	NTRK3, a receptor tyrosine kinase, is altered by gene fusion in various cancer types.	False	02/17/2021	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK3 ENSP00000485864.1:N226= mutant UNKNOWN.	False	The NTRK3 ENSP00000485864.1:n226= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	88679785						True	False	False	Unknown								False	False		NTRK3, a receptor tyrosine kinase, is altered by gene fusion in various cancer types.	The NTRK3 ENSP00000485864.1:n226= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK3 ENSP00000485864.1:N226= mutant UNKNOWN.						v6.1	02/17/2021		GRCh38	NTRK3	4916.0	ENSP00000485864.1:N226=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NTRK3"",""entrezGeneId"":4916,""alteration"":""ENSP00000485864.1:N226="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NTRK3, a receptor tyrosine kinase, is altered by gene fusion in various cancer types."",""variantSummary"":""The NTRK3 ENSP00000485864.1:n226= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK3 ENSP00000485864.1:N226= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/17/2021""}"	True	True	False	Unknown		Unknown																						0,884	0,417	0,467	0/1	0,0,418,466	CGT	0.00	0.00	0.00			0,0,439,445	64.73		1.0
GRCh38	FANCI	D12_12345_1234556_Thyroid_S9	p.A86V	ENSP00000310842.8:p.Ala86Val	chr15	89260812	89260812.0	C	T	T	89260812	.	C	T	.	PASS	NM_001113378	T	missense_variant	MODERATE	FANCI	ENSG00000140525	Transcript	ENST00000310775	protein_coding	4/38		c.257C>T	331	257	86	A/V	gCg/gTg	rs17803620&COSV55527083		1		SNV	HGNC	HGNC:25568	YES	MANE_Select	NM_001113378.2		1	P1	CCDS45346.1	ENSP00000310842	Q9NVI1.177		UPI00001FEB1D	Q9NVI1-3		1	tolerated(0.17)	benign(0.054)	PDB-ENSP_mappings:6vaa.A&PDB-ENSP_mappings:6vad.A&PDB-ENSP_mappings:6vae.A&PDB-ENSP_mappings:6vaf.A&PDB-ENSP_mappings:7ay1.A&PDB-ENSP_mappings:7zf1.A&PDB-ENSP_mappings:8a9j.A&PDB-ENSP_mappings:8a9k.A&Pfam:PF14675&CDD:cd11720&PANTHER:PTHR21818&AFDB-ENSP_mappings:AF-Q9NVI1-F1			0.2598	0.0393	0.3458	0.3036	0.3787	0.3292	0.3722	0.07342	0.3555	0.3815	0.3061	0.4535	0.329	0.38	0.3618	0.3838	0.2984	0.08789	0.391	0.3088	0.3686	0.3178	0.4693	0.3027	0.3863	0.3052	0.3753	0.4693	gnomADg_FIN	benign	0&1	1&1	25741868&32888494						FAIL	31	-34	0	31	0.00	0.01	0.00	0.21	FANCI	0.152	9.5900e-01	257484	0.28627		0.25978	255379	not_specified&Fanconi_anemia_complementation_group_I&Fanconi_anemia&not_provided		MedGen:CN169374&MONDO:MONDO:0012186&MedGen:C1836861&OMIM:609053&Orphanet:84&MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MedGen:C3661900		NC_000015.10:g.89260812C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306642&SCV000394175&SCV000603583&SCV001000389&SCV001833509&SCV001933187&SCV004017692&SCV005294814	single_nucleotide_variant	SO:0001483	ClinGen:CA7722545&UniProtKB:Q9NVI1																																																																																																																																															119,123	51,48	68,75	0/1	51,68,57,66	GCG	0.00	0.00	0.00			69,50,78,45	41.33		0.5082644628099173
GRCh38	FANCI	D12_12345_1234556_Thyroid_S9	p.C742S	ENSP00000310842.8:p.Cys742Ser	chr15	89292997	89292997.0	G	C	C	89292997	.	G	C	.	PASS	NM_001113378	C	missense_variant	MODERATE	FANCI	ENSG00000140525	Transcript	ENST00000310775	protein_coding	22/38		c.2225G>C	2299	2225	742	C/S	tGt/tCt	rs2283432&COSV55522176		1		SNV	HGNC	HGNC:25568	YES	MANE_Select	NM_001113378.2		1	P1	CCDS45346.1	ENSP00000310842	Q9NVI1.177		UPI00001FEB1D	Q9NVI1-3		1	tolerated(0.05)	benign(0.007)	PDB-ENSP_mappings:6vaa.A&PDB-ENSP_mappings:6vad.A&PDB-ENSP_mappings:6vae.A&PDB-ENSP_mappings:6vaf.A&PDB-ENSP_mappings:7ay1.A&PDB-ENSP_mappings:7zf1.A&PDB-ENSP_mappings:8a9j.A&PDB-ENSP_mappings:8a9k.A&Pfam:PF14680&CDD:cd11720&PANTHER:PTHR21818&AFDB-ENSP_mappings:AF-Q9NVI1-F1			0.2650	0.0393	0.3473	0.3135	0.3837	0.3395	0.3763	0.07403	0.3589	0.3829	0.3125	0.4552	0.3299	0.384	0.3657	0.3925	0.3018	0.08867	0.391	0.3167	0.3696	0.325	0.4687	0.3027	0.3903	0.3076	0.3849	0.4687	gnomADg_FIN	benign	0&1	1&1	25741868&24194833&30591675						FAIL	-42	-12	23	-1	0.01	0.00	0.00	0.00	FANCI	0.075	9.5900e-01	257482	0.28994		0.26498	255384	not_provided&Fanconi_anemia_complementation_group_I&Fanconi_anemia&not_specified		MedGen:C3661900&MONDO:MONDO:0012186&MedGen:C1836861&OMIM:609053&Orphanet:84&MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MedGen:CN169374		NC_000015.10:g.89292997G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306640&SCV000394208&SCV000603584&SCV001000390&SCV001869707&SCV001933242&SCV004017698&SCV005294838	single_nucleotide_variant	SO:0001483	ClinGen:CA7723319&UniProtKB:Q9NVI1																																																																																																																																															60,68	30,36	30,32	0|1	35,25,35,33	TGT	.	.	.		89836228	29,31,41,27	33.33		0.53125
GRCh38	FANCI	D12_12345_1234556_Thyroid_S9	p.Gly1302=	ENSP00000310842.8:p.Gly1302=	chr15	89315371	89315371.0	T	C	C	89315371	.	T	C	.	PASS	NM_001113378	C	synonymous_variant	LOW	FANCI	ENSG00000140525	Transcript	ENST00000310775	protein_coding	37/38		c.3906T>C	3980	3906	1302	G	ggT/ggC	rs1138465&COSV51519356		1		SNV	HGNC	HGNC:25568	YES	MANE_Select	NM_001113378.2		1	P1	CCDS45346.1	ENSP00000310842	Q9NVI1.177		UPI00001FEB1D	Q9NVI1-3		1			PDB-ENSP_mappings:6vaa.A&PDB-ENSP_mappings:6vad.A&PDB-ENSP_mappings:6vae.A&PDB-ENSP_mappings:6vaf.A&PDB-ENSP_mappings:7ay1.A&PDB-ENSP_mappings:7zf1.A&PDB-ENSP_mappings:8a9j.A&PDB-ENSP_mappings:8a9k.A&PANTHER:PTHR21818&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-Q9NVI1-F1			0.4123	0.4667	0.3934	0.4256	0.3996	0.3517	0.3972	0.4452	0.3872	0.3934	0.4112	0.4952	0.3835	0.3899	0.4045	0.4073	0.4166	0.4446	0.3879	0.3733	0.3782	0.4336	0.5099	0.3586	0.3978	0.3939	0.4018	0.5099	gnomADg_FIN	benign&likely_benign	0&1	1&1	25741868						FAIL	-22	-2	18	-2	0.00	0.00	0.00	0.00	FANCI		9.5900e-01	257489	0.40960	0.41226	0.41234	255389	not_specified&Fanconi_anemia_complementation_group_I&Fanconi_anemia&not_provided&POLG-Related_Spectrum_Disorders		MedGen:CN169374&MONDO:MONDO:0012186&MedGen:C1836861&OMIM:609053&Orphanet:84&MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MedGen:C3661900&MedGen:C4763519		NC_000015.10:g.89315371T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000306649&SCV000394231&SCV000483522&SCV000603585&SCV001000392&SCV001275858&SCV001906819&SCV001933275&SCV004017701&SCV005213927	single_nucleotide_variant	SO:0001483	ClinGen:CA7723952		POLG:5428&FANCI:55215	SO:0001819&synonymous_variant										1	1138465																											249					0.996							243.3	v6.1	Unknown		True	FANCI, a DNA repair protein in the Fanconi Anemia complementation group, is infrequently altered in various cancers.	False	09/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCI ENSP00000310842.8:G1302= mutant UNKNOWN.	False	The FANCI ENSP00000310842.8:g1302= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	89858602						True	False	False	Unknown								False	False		FANCI, a DNA repair protein in the Fanconi Anemia complementation group, is infrequently altered in various cancers.	The FANCI ENSP00000310842.8:g1302= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCI ENSP00000310842.8:G1302= mutant UNKNOWN.						v6.1	09/11/2024		GRCh38	FANCI	55215.0	ENSP00000310842.8:G1302=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FANCI"",""entrezGeneId"":55215,""alteration"":""ENSP00000310842.8:G1302="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FANCI, a DNA repair protein in the Fanconi Anemia complementation group, is infrequently altered in various cancers."",""variantSummary"":""The FANCI ENSP00000310842.8:g1302= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCI ENSP00000310842.8:G1302= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/11/2024""}"	True	True	False	Unknown		Unknown																						120,128	60,57	60,71	0/1	60,60,63,65	GTG	.	.	.			58,62,66,62	43.13		0.5161290322580645
GRCh38	FANCI	D12_12345_1234556_Thyroid_S9			chr15	89321085	89321089.0	G	GCTAC	GCTAC	89321085	.	G	GCTAC	.	PASS	NM_001113378	CTAC	downstream_gene_variant	MODIFIER	FANCI	ENSG00000140525	Transcript	ENST00000310775	protein_coding									rs2307433	3954	1		insertion	HGNC	HGNC:25568	YES	MANE_Select	NM_001113378.2		1	P1	CCDS45346.1	ENSP00000310842	Q9NVI1.177		UPI00001FEB1D	Q9NVI1-3		1						0.5583	0.8396	0.4784	0.4315	0.4692	0.4571	0.4747	0.8003	0.4515	0.4959	0.4119	0.5192	0.4877	0.4634	0.4925	0.4869	0.5611	0.7876	0.5199	0.4716	0.483	0.4331	0.5226	0.4762	0.4706	0.5241	0.4824	0.8396	AFR			1	23690203&22124616&16080118&31865639&32986753&31998787&36672794&36292568																		619386				610835	not_provided&not_specified&Progressive_sclerosing_poliodystrophy		MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0008758&MedGen:C0205710&OMIM:203700&Orphanet:726		NC_000015.10:g.89321087_89321088insACCT	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000887080&SCV001847495&SCV005087535	Insertion	SO:0000667	ClinGen:CA7724368		POLG:5428	SO:0001627&intron_variant										1	2307433																											757					0.975							246.98													chr15	89864316																																																	True	True	False	Unknown		Unknown																						359,379	188,197	171,182	0/1	200,159,178,201	TGC						185,174,202,177	56.58		0.513550135501355
GRCh38	CHD2	D12_12345_1234556_Thyroid_S9			chr15	92943038		T	<INS>	<INS>	92943038	MantaINS:1701:1:1:1:9:0	T	<INS>	.	PASS	NM_001271	insertion	feature_elongation&coding_sequence_variant	HIGH	CHD2	ENSG00000173575	Transcript	ENST00000394196	protein_coding	9/39			1595	1023	341					1		insertion	HGNC	HGNC:1917	YES	MANE_Select	NM_001271.4		5	P1	CCDS10374.2	ENSP00000377747	O14647.204		UPI0000E8A85C	O14647-1		1			Gene3D:2.40.50.40&AFDB-ENSP_mappings:AF-O14647-F1&PROSITE_profiles:PS50013&PANTHER:PTHR45623&SMART:SM00298&Superfamily:SSF54160&CDD:cd18666&Low_complexity_(Seg):seg																																																																																																												0,49		0,49							49	CAAGAAAAAAGAGGACGAAATCAAACAATGGTATATTTTCCATCATGGA		CAAGAAAAAAGAGGACGAAATCAAACAATGGTATATTTTCCATCATGGAATAAAGAAATGTATTTGCAGCCTGAAAGAAGGAAAGTAACAAATGAGTGGTTGCAGGAGGACACTTTTTCTGTCGAGGTCACTAAACAAAACATTGTCT																chr15	93486268	ATCTACAAAGAACTCAAACAAATTTA			INS																																													True	True	False	Unknown		Unknown																															9,0				25,6	
GRCh38	CHD2	D12_12345_1234556_Thyroid_S9			chr15	92953409		A	<INS>	<INS>	92953409	MantaINS:1051:1:1:1:10:0	A	<INS>	.	PASS	NM_001271	insertion	feature_elongation&coding_sequence_variant	HIGH	CHD2	ENSG00000173575	Transcript	ENST00000394196	protein_coding	14/39			2128	1556	519					1		insertion	HGNC	HGNC:1917	YES	MANE_Select	NM_001271.4		5	P1	CCDS10374.2	ENSP00000377747	O14647.204		UPI0000E8A85C	O14647-1		1			Gene3D:3.40.50.10810&AFDB-ENSP_mappings:AF-O14647-F1&Pfam:PF00176&PROSITE_profiles:PS51192&PANTHER:PTHR45623&SMART:SM00487&Superfamily:SSF52540&CDD:cd18054																																																																																																												0,58		0,58							58	CCATATCATTCCTCTCCTACCTGTTCCACCAACACCAGCTGTATGGCCCCTTTCTTAT		CCATATCATTCCTCTCCTACCTGTTCCACCAACACCAGCTGTATGGCCCCTTTCTTATTTGTCCCCTTCCATGTCCTGTTTCTGTCATATCAGAATGCCCTTTTCTCAATCCT																chr15	93496639	TTTATTCCATTCCATTCCATTCCATTCCATTCCATTCCATTCTATTCAAGTGCATTCCATTCCATT			INS																																													True	True	False	Unknown		Unknown																															6,2				5,6	
GRCh38	CHD2	D12_12345_1234556_Thyroid_S9	p.Glu683=	ENSP00000377747.4:p.Glu683=	chr15	92967373	92967373.0	A	G	G	92967373	.	A	G	.	PASS	NM_001271	G	synonymous_variant	LOW	CHD2	ENSG00000173575	Transcript	ENST00000394196	protein_coding	17/39		c.2049A>G	2621	2049	683	E	gaA/gaG	rs4777755&COSV108240537		1		SNV	HGNC	HGNC:1917	YES	MANE_Select	NM_001271.4		5	P1	CCDS10374.2	ENSP00000377747	O14647.204		UPI0000E8A85C	O14647-1		1			Gene3D:3.40.50.10810&AFDB-ENSP_mappings:AF-O14647-F1&Pfam:PF00176&PANTHER:PTHR45623&Superfamily:SSF52540&CDD:cd18054			0.8265	0.5756	0.8948	0.999	0.8529	0.9121	0.843	0.6186	0.9162	0.9071	0.9984	0.76	0.9216	0.8389	0.8433	0.8996	0.784	0.6132	0.9353	0.8866	0.9083	0.9977	0.7547	0.9014	0.8341	0.8259	0.9087	0.999	EAS	benign	0&1	1&1	25741868																	1.7400e-01	257706	0.76559	0.84194	0.82648	255443	Developmental_and_epileptic_encephalopathy_94&not_specified&Inborn_genetic_diseases&not_provided		MONDO:MONDO:0014150&MedGen:C3809278&OMIM:615369&Orphanet:1942&Orphanet:2382&MedGen:CN169374&MeSH:D030342&MedGen:C0950123&MedGen:C3661900		NC_000015.10:g.92967373A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000307170&SCV000519221&SCV000841512&SCV000846125&SCV001729742&SCV001806391&SCV005087803&SCV005297494	single_nucleotide_variant	SO:0001483	ClinGen:CA7747919		CHD2:1106	SO:0001819&synonymous_variant										1	4777755																											156					0.962							240.7	v6.1	Unknown		True	CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia.	False	07/18/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:E683= mutant UNKNOWN.	False	The CHD2 ENSP00000377747.4:e683= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	93510603						True	False	False	Unknown								False	False		CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia.	The CHD2 ENSP00000377747.4:e683= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:E683= mutant UNKNOWN.						v6.1	07/18/2023		GRCh38	CHD2	1106.0	ENSP00000377747.4:E683=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CHD2"",""entrezGeneId"":1106,""alteration"":""ENSP00000377747.4:E683="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia."",""variantSummary"":""The CHD2 ENSP00000377747.4:e683= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:E683= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/18/2023""}"	True	True	False	Unknown		Unknown																						75,75	40,28	35,47	0/1	36,39,42,33	AAA	.	.	.			41,34,39,36	37.27		0.5
GRCh38	CHD2	D12_12345_1234556_Thyroid_S9	p.Gln906=	ENSP00000377747.4:p.Gln906=	chr15	92978374	92978374.0	A	G	G	92978374	.	A	G	.	PASS	NM_001271	G	synonymous_variant	LOW	CHD2	ENSG00000173575	Transcript	ENST00000394196	protein_coding	21/39		c.2718A>G	3290	2718	906	Q	caA/caG	rs11074121&COSV108240538		1		SNV	HGNC	HGNC:1917	YES	MANE_Select	NM_001271.4		5	P1	CCDS10374.2	ENSP00000377747	O14647.204		UPI0000E8A85C	O14647-1		1			Gene3D:3.40.50.300&AFDB-ENSP_mappings:AF-O14647-F1&PROSITE_profiles:PS51194&PANTHER:PTHR45623&Superfamily:SSF52540&CDD:cd18793			0.8091	0.5182	0.889	0.999	0.8479	0.91	0.8386	0.5647	0.9124	0.9068	0.9984	0.7594	0.9194	0.8353	0.8376	0.8991	0.7669	0.5593	0.9353	0.881	0.9078	0.9979	0.7535	0.9014	0.8307	0.8175	0.9082	0.999	EAS	benign	0&1	1&1	25741868																	1.7400e-01	257708	0.74765	0.83525	0.80911	255445	Developmental_and_epileptic_encephalopathy_94&not_specified&Inborn_genetic_diseases&not_provided		MONDO:MONDO:0014150&MedGen:C3809278&OMIM:615369&Orphanet:1942&Orphanet:2382&MedGen:CN169374&MeSH:D030342&MedGen:C0950123&MedGen:C3661900		NC_000015.10:g.92978374A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000307173&SCV000516752&SCV000841513&SCV000846115&SCV001729743&SCV001806392&SCV005087970&SCV005297499	single_nucleotide_variant	SO:0001483	ClinGen:CA7748040		CHD2:1106	SO:0001819&synonymous_variant										1	11074121																											633					0.995							246.05	v6.1	Unknown		True	CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia.	False	07/18/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:Q906= mutant UNKNOWN.	False	The CHD2 ENSP00000377747.4:q906= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	93521604						True	False	False	Unknown								False	False		CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia.	The CHD2 ENSP00000377747.4:q906= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:Q906= mutant UNKNOWN.						v6.1	07/18/2023		GRCh38	CHD2	1106.0	ENSP00000377747.4:Q906=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CHD2"",""entrezGeneId"":1106,""alteration"":""ENSP00000377747.4:Q906="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia."",""variantSummary"":""The CHD2 ENSP00000377747.4:q906= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:Q906= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/18/2023""}"	True	True	False	Unknown		Unknown																						298,332	137,174	161,158	0/1	158,140,144,188	AAA	.	.	.			125,173,150,182	58.93		0.526984126984127
GRCh38	CHD2	D12_12345_1234556_Thyroid_S9	p.Arg1060=	ENSP00000377747.4:p.Arg1060=	chr15	92984443	92984443.0	G	A	A	92984443	.	G	A	.	PASS	NM_001271	A	synonymous_variant	LOW	CHD2	ENSG00000173575	Transcript	ENST00000394196	protein_coding	25/39		c.3180G>A	3752	3180	1060	R	cgG/cgA	rs1005206801		1		SNV	HGNC	HGNC:1917	YES	MANE_Select	NM_001271.4		5	P1	CCDS10374.2	ENSP00000377747	O14647.204		UPI0000E8A85C	O14647-1		1			AFDB-ENSP_mappings:AF-O14647-F1&Coiled-coils_(Ncoils):Coil&PANTHER:PTHR45623&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg									4.793e-06	0	0	0	0	0	0	6.299e-06	0	0	6.59e-06	0	0	6.562e-05	0	0	0	0	0	0	0	6.562e-05	gnomADg_AMR	likely_benign		1																		1.7400e-01	668448				656329	not_provided&CHD2-related_disorder&Developmental_and_epileptic_encephalopathy_94		MedGen:C3661900&.&MONDO:MONDO:0014150&MedGen:C3809278&OMIM:615369&Orphanet:1942&Orphanet:2382		NC_000015.10:g.92984443G>A	criteria_provided&_multiple_submitters&_no_conflicts	Likely_benign			SCV000968986&SCV001658277	single_nucleotide_variant	SO:0001483	ClinGen:CA274859075		CHD2:1106	SO:0001819&synonymous_variant										1	1005206801																											164					0.878							230.28	v6.1	Unknown		True	CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia.	False	07/18/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:R1060= mutant UNKNOWN.	False	The CHD2 ENSP00000377747.4:r1060= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	93527673						True	False	False	Unknown								False	False		CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia.	The CHD2 ENSP00000377747.4:r1060= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:R1060= mutant UNKNOWN.						v6.1	07/18/2023		GRCh38	CHD2	1106.0	ENSP00000377747.4:R1060=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CHD2"",""entrezGeneId"":1106,""alteration"":""ENSP00000377747.4:R1060="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CHD2, a chromodomain helicase, is frequently altered in chronic lymphocytic leukemia."",""variantSummary"":""The CHD2 ENSP00000377747.4:r1060= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CHD2 ENSP00000377747.4:R1060= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/18/2023""}"	True	True	False	Unknown		Unknown																						141,3	71,1	70,2	0/1	75,66,2,1	GGC	0.00	0.00	1.00			71,70,0,3	7.75		0.020833333333333332
GRCh38	IGF1R	D12_12345_1234556_Thyroid_S9	p.Asn638=	ENSP00000497069.1:p.Asn638=	chr15	98916049	98916049.0	C	T	T	98916049	.	C	T	.	PASS	NM_000875	T	synonymous_variant	LOW	IGF1R	ENSG00000140443	Transcript	ENST00000650285	protein_coding	9/21		c.1914C>T	2957	1914	638	N	aaC/aaT	rs45506098&COSV51406833		1		SNV	HGNC	HGNC:5465	YES	MANE_Select	NM_000875.5			P4	CCDS10378.1	ENSP00000497069	P08069.253		UPI000012D3EA			1			PDB-ENSP_mappings:5u8q.A&PDB-ENSP_mappings:5u8r.A&PDB-ENSP_mappings:6jk8.A&PDB-ENSP_mappings:6jk8.B&PDB-ENSP_mappings:6vwg.A&PDB-ENSP_mappings:6vwg.B&PDB-ENSP_mappings:6vwh.A&PDB-ENSP_mappings:6vwh.B&PDB-ENSP_mappings:6vwi.A&PDB-ENSP_mappings:6vwi.B&PDB-ENSP_mappings:6vwj.A&PDB-ENSP_mappings:6vwj.B&PDB-ENSP_mappings:7s0q.A&PDB-ENSP_mappings:7s8v.A&PDB-ENSP_mappings:7u23.E&PDB-ENSP_mappings:7u23.F&PDB-ENSP_mappings:7v3p.A&PDB-ENSP_mappings:7v3p.B&PDB-ENSP_mappings:7xgd.A&PDB-ENSP_mappings:7xgd.B&PDB-ENSP_mappings:7xlc.A&PDB-ENSP_mappings:7xlc.B&PDB-ENSP_mappings:7yrr.A&PDB-ENSP_mappings:7yrr.B&PDB-ENSP_mappings:8tan.A&PDB-ENSP_mappings:8tan.B&Gene3D:2.60.40.10&PIRSF:PIRSF000620&PANTHER:PTHR24416&Superfamily:SSF49265&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00060&CDD:cd00063&AFDB-ENSP_mappings:AF-P08069-F1			0.0048	0.0008	0.0072	0	0.0159	0.002	0.009682	0.001255	0.008139	0.01098	0	0.01314	0.005895	0.01088	0.009438	0.0007072	0.007496	0.001876	0	0.00895	0.01152	0.0007716	0.01101	0	0.01083	0.01135	0.001035	0.0159	EUR	benign	0&1	1&1	20625407						FAIL	34	-35	-30	10	0.00	0.03	0.00	0.00	IGF1R		3.9300e-01	199042	0.00724	0.00729	0.00479	196202	not_specified&not_provided&Growth_delay_due_to_insulin-like_growth_factor_I_resistance		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0010038&MedGen:C1849157&OMIM:270450&Orphanet:73273		NC_000015.10:g.98916049C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000232994&SCV001094635&SCV001274004&SCV004130976&SCV005297569	single_nucleotide_variant	SO:0001483	ClinGen:CA203721		IGF1R:3480	SO:0001819&synonymous_variant										1	45506098																											731					0.997							247.84	v6.1	Unknown		True	IGF1R, an insulin growth factor receptor, is altered by mutation in various cancer types.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IGF1R ENSP00000497069.1:N638= mutant UNKNOWN.	False	The IGF1R ENSP00000497069.1:n638= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	99459278						True	False	False	Unknown								False	False		IGF1R, an insulin growth factor receptor, is altered by mutation in various cancer types.	The IGF1R ENSP00000497069.1:n638= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IGF1R ENSP00000497069.1:N638= mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	IGF1R	3480.0	ENSP00000497069.1:N638=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IGF1R"",""entrezGeneId"":3480,""alteration"":""ENSP00000497069.1:N638="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IGF1R, an insulin growth factor receptor, is altered by mutation in various cancer types."",""variantSummary"":""The IGF1R ENSP00000497069.1:n638= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IGF1R ENSP00000497069.1:N638= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						382,347	207,205	175,142	0/1	187,195,167,180	ACG	0.00	0.00	0.00			238,144,195,152	34.98		0.47599451303155005
GRCh38	IGF1R	D12_12345_1234556_Thyroid_S9	p.Glu1043=	ENSP00000497069.1:p.Glu1043=	chr15	98934996	98934996.0	G	A	A	98934996	.	G	A	.	PASS	NM_000875	A	synonymous_variant	LOW	IGF1R	ENSG00000140443	Transcript	ENST00000650285	protein_coding	16/21		c.3129G>A	4172	3129	1043	E	gaG/gaA	rs2229765&CM031698&COSV51291816		1		SNV	HGNC	HGNC:5465	YES	MANE_Select	NM_000875.5			P4	CCDS10378.1	ENSP00000497069	P08069.253		UPI000012D3EA			1			PDB-ENSP_mappings:1jqh.A&PDB-ENSP_mappings:1jqh.B&PDB-ENSP_mappings:1jqh.C&PDB-ENSP_mappings:1k3a.A&PDB-ENSP_mappings:1m7n.A&PDB-ENSP_mappings:1m7n.B&PDB-ENSP_mappings:1p4o.A&PDB-ENSP_mappings:1p4o.B&PDB-ENSP_mappings:2oj9.A&PDB-ENSP_mappings:2zm3.A&PDB-ENSP_mappings:2zm3.B&PDB-ENSP_mappings:2zm3.C&PDB-ENSP_mappings:2zm3.D&PDB-ENSP_mappings:3d94.A&PDB-ENSP_mappings:3f5p.A&PDB-ENSP_mappings:3f5p.B&PDB-ENSP_mappings:3f5p.C&PDB-ENSP_mappings:3f5p.D&PDB-ENSP_mappings:3f5p.E&PDB-ENSP_mappings:3f5p.F&PDB-ENSP_mappings:3f5p.G&PDB-ENSP_mappings:3f5p.H&PDB-ENSP_mappings:3f5p.I&PDB-ENSP_mappings:3f5p.J&PDB-ENSP_mappings:3f5p.K&PDB-ENSP_mappings:3f5p.L&PDB-ENSP_mappings:3f5p.M&PDB-ENSP_mappings:3f5p.R&PDB-ENSP_mappings:3f5p.S&PDB-ENSP_mappings:3f5p.T&PDB-ENSP_mappings:3i81.A&PDB-ENSP_mappings:3lvp.A&PDB-ENSP_mappings:3lvp.B&PDB-ENSP_mappings:3lvp.C&PDB-ENSP_mappings:3lvp.D&PDB-ENSP_mappings:3lw0.A&PDB-ENSP_mappings:3lw0.B&PDB-ENSP_mappings:3lw0.C&PDB-ENSP_mappings:3lw0.D&PDB-ENSP_mappings:3nw5.A&PDB-ENSP_mappings:3nw6.A&PDB-ENSP_mappings:3nw7.A&PDB-ENSP_mappings:3o23.A&PDB-ENSP_mappings:3qqu.A&PDB-ENSP_mappings:3qqu.B&PDB-ENSP_mappings:3qqu.C&PDB-ENSP_mappings:3qqu.D&PDB-ENSP_mappings:4d2r.A&PDB-ENSP_mappings:5fxq.A&PDB-ENSP_mappings:5fxr.A&PDB-ENSP_mappings:5fxs.A&PDB-ENSP_mappings:5hzn.A&PDB-ENSP_mappings:5hzn.B&PDB-ENSP_mappings:5hzn.C&PDB-ENSP_mappings:5hzn.D&PDB-ENSP_mappings:5hzn.E&PDB-ENSP_mappings:5hzn.F&PDB-ENSP_mappings:5hzn.G&PDB-ENSP_mappings:5hzn.H&PDB-ENSP_mappings:6jk8.A&PDB-ENSP_mappings:6jk8.B&PDB-ENSP_mappings:8pyi.AAA&PDB-ENSP_mappings:8pyi.BBB&PDB-ENSP_mappings:8pyi.CCC&PDB-ENSP_mappings:8pyi.DDD&PDB-ENSP_mappings:8pyi.EEE&PDB-ENSP_mappings:8pyi.FFF&PDB-ENSP_mappings:8pyi.GGG&PDB-ENSP_mappings:8pyi.HHH&PDB-ENSP_mappings:8pyj.AAA&PDB-ENSP_mappings:8pyk.AAA&PDB-ENSP_mappings:8pyl.AAA&PDB-ENSP_mappings:8pym.AAA&PDB-ENSP_mappings:8pyn.AAA&Gene3D:3.30.200.20&PIRSF:PIRSF000620&Pfam:PF07714&PANTHER:PTHR24416&Superfamily:SSF56112&PROSITE_profiles:PS50011&Phobius:CYTOPLASMIC_DOMAIN&SMART:SM00219&CDD:cd05032&AFDB-ENSP_mappings:AF-P08069-F1			0.3357	0.2557	0.3646	0.3462	0.4294	0.316	0.4329	0.2948	0.3429	0.4729	0.3111	0.4217	0.3622	0.4559	0.4116	0.3082	0.3908	0.2985	0.3978	0.3787	0.4645	0.3377	0.4131	0.4048	0.4521	0.379	0.3156	0.4729	gnomADe_ASJ	benign	0&1&1	1&1&1	22303384&20935157&21791631&18249219&35207726&24895547&26445852&27536357&19124510&19124506&28050343&20569235&27144430&27376028&21304894&29434720&28119888&20302654&26535220&24194259&22115178&20580999&25117571&19877134&29126188&18761080&28213921&21047277&32150843&22156437&27405474&12843179&18477064&19460140&20625407&22909219&25189651&27213344&34501407&21340542&32554381&28765617&24350933&26623053&35076986&36656337&33144411&34527927&36013453&24037648&33300568&34208601&25592580&34103530&19536170&24392142&37834454&37763773&38136416&37665017&38555553&38892441						FAIL	-25	-42	3	-5	0.00	0.00	0.00	0.00	IGF1R		3.9300e-01	194610	0.40268	0.39719	0.33566	191773	Growth_delay_due_to_insulin-like_growth_factor_I_resistance&not_specified&not_provided		MONDO:MONDO:0010038&MedGen:C1849157&OMIM:270450&Orphanet:73273&MedGen:CN169374&MedGen:C3661900		NC_000015.10:g.98934996G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000226442&SCV000394496&SCV002353884&SCV005297571	single_nucleotide_variant	SO:0001483	ClinGen:CA201258		IGF1R:3480	SO:0001819&synonymous_variant										1	2229765																											870					0.999							247.89	v6.1	Unknown		True	IGF1R, an insulin growth factor receptor, is altered by mutation in various cancer types.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IGF1R ENSP00000497069.1:E1043= mutant UNKNOWN.	False	The IGF1R ENSP00000497069.1:e1043= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr15	99478225						True	False	False	Unknown								False	False		IGF1R, an insulin growth factor receptor, is altered by mutation in various cancer types.	The IGF1R ENSP00000497069.1:e1043= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IGF1R ENSP00000497069.1:E1043= mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	IGF1R	3480.0	ENSP00000497069.1:E1043=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IGF1R"",""entrezGeneId"":3480,""alteration"":""ENSP00000497069.1:E1043="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IGF1R, an insulin growth factor receptor, is altered by mutation in various cancer types."",""variantSummary"":""The IGF1R ENSP00000497069.1:e1043= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IGF1R ENSP00000497069.1:E1043= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						446,423	208,184	238,239	0/1	247,199,211,212	AGA	0.00	0.00	0.00			205,241,222,201	43.3		0.48676639815880324
GRCh38	AXIN1	D12_12345_1234556_Thyroid_S9	p.Asp254=	ENSP00000262320.3:p.Asp254=	chr16	346264	346264.0	A	G	G	346264	.	A	G	.	PASS	NM_003502	G	synonymous_variant	LOW	AXIN1	ENSG00000103126	Transcript	ENST00000262320	protein_coding	2/11		c.762T>C	1198	762	254	D	gaT/gaC	rs1805105&COSV51987760		-1		SNV	HGNC	HGNC:903	YES	MANE_Select	NM_003502.4		1	A1	CCDS10405.1	ENSP00000262320	O15169.242	A0A0S2Z4R0.57	UPI000012669E	O15169-1		1			MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&PANTHER:PTHR46102&AFDB-ENSP_mappings:AF-O15169-F1			0.6390	0.9024	0.5375	0.2897	0.6173	0.7372	0.646	0.8731	0.4549	0.5128	0.3432	0.6091	0.5593	0.6565	0.6314	0.7389	0.6836	0.8607	0.7319	0.5636	0.5063	0.312	0.613	0.5612	0.6477	0.6237	0.7467	0.9024	AFR	benign	0&1	1&1	24033266&20844743&23940558&23777469&32453708&26968103&31723073&25355064&30929455&31143301&33096676&30810360&29053018&25802106&36421790&33725943&36510340&18514389&38135866&38880668						FAIL	8	-17	-10	17	0.00	0.00	0.00	0.00	AXIN1		5.6300e-01	402405	0.71413	0.62184	0.63898	390297	not_provided&not_specified		MedGen:C3661900&MedGen:CN169374		NC_000016.10:g.346264A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000538384&SCV005294267	single_nucleotide_variant	SO:0001483	ClinGen:CA7774452		AXIN1:8312	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	1805105																											1102					0.994							247.02	v6.1	Unknown		True	AXIN1, a tumor suppressor involved in WNT signaling, is mutated at low frequencies in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AXIN1 ENSP00000262320.3:D254= mutant UNKNOWN.	False	The AXIN1 ENSP00000262320.3:d254= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr16	396264						True	False	False	Unknown								False	False		AXIN1, a tumor suppressor involved in WNT signaling, is mutated at low frequencies in various cancer types.	The AXIN1 ENSP00000262320.3:d254= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AXIN1 ENSP00000262320.3:D254= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	AXIN1	8312.0	ENSP00000262320.3:D254=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""AXIN1"",""entrezGeneId"":8312,""alteration"":""ENSP00000262320.3:D254="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""AXIN1, a tumor suppressor involved in WNT signaling, is mutated at low frequencies in various cancer types."",""variantSummary"":""The AXIN1 ENSP00000262320.3:d254= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AXIN1 ENSP00000262320.3:D254= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,1095	0,604	0,491	0/1	0,0,566,529	CAT	.	.	.			0,0,521,574	64.73		1.0
GRCh38	SLX4	D12_12345_1234556_Thyroid_S9	p.Asn1500=	ENSP00000294008.3:p.Asn1500=	chr16	3589138	3589138.0	A	G	G	3589138	.	A	G	.	PASS	NM_032444	G	synonymous_variant	LOW	SLX4	ENSG00000188827	Transcript	ENST00000294008	protein_coding	12/15		c.4500T>C	5149	4500	1500	N	aaT/aaC	rs3810812&COSV53564459		-1		SNV	HGNC	HGNC:23845	YES	MANE_Select	NM_032444.4		5	P1	CCDS10506.2	ENSP00000294008	Q8IY92.174		UPI000050D2C5	Q8IY92-1		1			AFDB-ENSP_mappings:AF-Q8IY92-F1&PANTHER:PTHR21541&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.7396	0.9289	0.647	0.7103	0.5169	0.8088	0.5441	0.8922	0.6565	0.4821	0.7375	0.5174	0.5614	0.5074	0.5597	0.7584	0.6386	0.8749	0.5418	0.6194	0.4882	0.716	0.5151	0.6199	0.5121	0.616	0.7735	0.9289	AFR	benign	0&1	1&1	25741868&32708070&22401137						FAIL	4	26	-19	28	0.00	0.00	0.00	0.00	SLX4		8.9600e-01	262053	0.62660	0.61159	0.73962	255709	Fanconi_anemia_complementation_group_P&Fanconi_anemia&not_provided&not_specified		MONDO:MONDO:0013499&MedGen:C3469542&OMIM:613951&Orphanet:84&MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MedGen:C3661900&MedGen:CN169374		NC_000016.10:g.3589138A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000314943&SCV000396827&SCV000605192&SCV001000173&SCV001863940&SCV002057718&SCV004015456&SCV005295844	single_nucleotide_variant	SO:0001483	ClinGen:CA7865620		SLX4:84464	SO:0001819&synonymous_variant										1	3810812																											1110					0.995							247.61	v6.1	Unknown		True	SLX4, a protein involved in DNA damage repair, is mutated in the germline of the FANCP subtype of Fanconi anemia patients.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SLX4 ENSP00000294008.3:N1500= mutant UNKNOWN.	False	The SLX4 ENSP00000294008.3:n1500= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr16	3639139						True	False	False	Unknown								False	False		SLX4, a protein involved in DNA damage repair, is mutated in the germline of the FANCP subtype of Fanconi anemia patients.	The SLX4 ENSP00000294008.3:n1500= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SLX4 ENSP00000294008.3:N1500= mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	SLX4	84464.0	ENSP00000294008.3:N1500=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SLX4"",""entrezGeneId"":84464,""alteration"":""ENSP00000294008.3:N1500="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SLX4, a protein involved in DNA damage repair, is mutated in the germline of the FANCP subtype of Fanconi anemia patients."",""variantSummary"":""The SLX4 ENSP00000294008.3:n1500= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SLX4 ENSP00000294008.3:N1500= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						571,534	253,262	318,272	0/1	283,288,262,272	TAT	.	.	.			307,264,256,278	42.18		0.4832579185520362
GRCh38	ANKRD11	D12_12345_1234556_Thyroid_S9	p.A971V	ENSP00000301030.4:p.Ala971Val	chr16	89283630	89283630.0	G	A	A	89283630	.	G	A	.	PASS	NM_013275	A	missense_variant	MODERATE	ANKRD11	ENSG00000167522	Transcript	ENST00000301030	protein_coding	9/13		c.2912C>T	3373	2912	971	A/V	gCg/gTg	rs2279348&COSV56354485		-1		SNV	HGNC	HGNC:21316	YES	MANE_Select	NM_013275.6		5	P1	CCDS32513.1	ENSP00000301030	Q6UB99.164		UPI00004569E1			1	tolerated(0.21)	benign(0)	AFDB-ENSP_mappings:AF-Q6UB99-F1&PANTHER:PTHR24145&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.5335	0.6248	0.6009	0.1627	0.6819	0.592	0.7011	0.6352	0.5838	0.8385	0.2394	0.5915	0.7046	0.7342	0.678	0.6105	0.6602	0.637	0.8136	0.6204	0.8493	0.195	0.5779	0.7109	0.7239	0.6643	0.5966	0.8493	gnomADg_ASJ	benign	0&1	1&1	25537509						FAIL	2	-47	2	-23	0.00	0.00	0.00	0.00	ANKRD11	0.026	1.3200e-01	587797	0.69701	0.63785	0.53355	580427	not_provided&KBG_syndrome&Inborn_genetic_diseases&not_specified		MedGen:C3661900&MONDO:MONDO:0007846&MedGen:C0220687&OMIM:148050&Orphanet:2332&MeSH:D030342&MedGen:C0950123&MedGen:CN169374		NC_000016.10:g.89283630G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000846119&SCV001717602&SCV001775336&SCV001858405&SCV005253181	single_nucleotide_variant	SO:0001483	ClinGen:CA8242477		ANKRD11:29123	SO:0001583&missense_variant										1	2279348																											1267					0.996							246.32	v6.1	Unknown		True	ANKRD11, a tumor suppressor and chromatin regulator, is inactivated by mutation or deletion in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD11 ENSP00000301030.4:A971V mutant UNKNOWN.	False	The ANKRD11 ENSP00000301030.4:a971v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr16	89350038						True	False	False	Unknown								False	False		ANKRD11, a tumor suppressor and chromatin regulator, is inactivated by mutation or deletion in various cancer types.	The ANKRD11 ENSP00000301030.4:a971v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD11 ENSP00000301030.4:A971V mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ANKRD11	29123.0	ENSP00000301030.4:A971V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ANKRD11"",""entrezGeneId"":29123,""alteration"":""ENSP00000301030.4:A971V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ANKRD11, a tumor suppressor and chromatin regulator, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The ANKRD11 ENSP00000301030.4:a971v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD11 ENSP00000301030.4:A971V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,1262	0,729	0,533	0/1	0,0,610,652	CGC	0.00	0.00	0.00			0,0,685,577	64.73		1.0
GRCh38	ANKRD11	D12_12345_1234556_Thyroid_S9	p.Thr924=	ENSP00000301030.4:p.Thr924=	chr16	89283770	89283770.0	G	A	A	89283770	.	G	A	.	PASS	NM_013275	A	synonymous_variant	LOW	ANKRD11	ENSG00000167522	Transcript	ENST00000301030	protein_coding	9/13		c.2772C>T	3233	2772	924	T	acC/acT	rs2279349&COSV56354791		-1		SNV	HGNC	HGNC:21316	YES	MANE_Select	NM_013275.6		5	P1	CCDS32513.1	ENSP00000301030	Q6UB99.164		UPI00004569E1			1			AFDB-ENSP_mappings:AF-Q6UB99-F1&PANTHER:PTHR24145&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.7636	0.8646	0.7118	0.6161	0.8201	0.7577	0.8306	0.8607	0.6759	0.9251	0.6471	0.7921	0.8877	0.846	0.8271	0.7786	0.8237	0.8604	0.8827	0.7272	0.9283	0.6252	0.7899	0.8904	0.8409	0.8205	0.7697	0.9283	gnomADg_ASJ	benign	0&1	1&1							FAIL	-40	47	-9	-13	0.00	0.00	0.00	0.00	ANKRD11		1.3200e-01	1169489	0.85219	0.79806	0.76358	1157895	not_specified&KBG_syndrome&not_provided		MedGen:CN169374&MONDO:MONDO:0007846&MedGen:C0220687&OMIM:148050&Orphanet:2332&MedGen:C3661900		NC_000016.10:g.89283770G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001730016&SCV001775337&SCV001843704&SCV005253182	single_nucleotide_variant	SO:0001483	ClinGen:CA8242516		ANKRD11:29123	SO:0001819&synonymous_variant										1	2279349																											1156					0.998							241.43	v6.1	Unknown		True	ANKRD11, a tumor suppressor and chromatin regulator, is inactivated by mutation or deletion in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD11 ENSP00000301030.4:T924= mutant UNKNOWN.	False	The ANKRD11 ENSP00000301030.4:t924= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr16	89350178						True	False	False	Unknown								False	False		ANKRD11, a tumor suppressor and chromatin regulator, is inactivated by mutation or deletion in various cancer types.	The ANKRD11 ENSP00000301030.4:t924= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD11 ENSP00000301030.4:T924= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ANKRD11	29123.0	ENSP00000301030.4:T924=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ANKRD11"",""entrezGeneId"":29123,""alteration"":""ENSP00000301030.4:T924="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ANKRD11, a tumor suppressor and chromatin regulator, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The ANKRD11 ENSP00000301030.4:t924= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ANKRD11 ENSP00000301030.4:T924= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,1154	0,663	0,491	0/1	0,0,591,563	CGG	0.00	0.00	0.00			0,0,548,606	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr17	3016099	3016099.0	A	G	G	3016099	.	A	G	.	PASS		G	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR17_84DMF	enhancer									rs9905977&COSV54587360				SNV																						0.6741	0.7504	0.7133	0.5903	0.6988	0.6043											0.7043	0.7407	0.7599	0.7141	0.6332	0.5915	0.7149	0.6122	0.6974	0.6767	0.6114	0.7599	gnomADg_AMI		0&1	0&1	26522768&26691610&29121662&33406744&33857205																																																																												876					1							248.03													chr17	2919393																																																	True	False	False	Unknown		Unknown																						456,420	255,219	201,201	0/1	229,227,210,210	CAT	.	.	.			242,214,215,205	37.83		0.4794520547945205
GRCh38		D12_12345_1234556_Thyroid_S9			chr17	5803303	5803303.0	A	G	G	5803303	.	A	G	.	PASS		G	downstream_gene_variant	MODIFIER		ENSG00000300067	Transcript	ENST00000768618	lncRNA									rs740910&COSV73784208	3376	1		SNV			YES																			0.1739	0.0197	0.3804	0.0565	0.3121	0.2147											0.2331	0.06599	0.3531	0.3646	0.3073	0.06597	0.206	0.2055	0.3179	0.2493	0.2186	0.3804	AMR		0&1	0&1	26691610&29121662&33406744&34721519&19083859&36134022&19948332																																																																												86					0.907							240.44													chr17	5706623																																																	True	False	False	Unknown		Unknown																						38,40	19,19	19,21	0/1	25,13,22,18	TAT	.	.	.			20,18,19,21	35.88		0.5128205128205128
GRCh38	GPS2	D12_12345_1234556_Thyroid_S9	p.Leu111=	ENSP00000370104.2:p.Leu111=	chr17	7314144	7314144.0	T	C	C	7314144	.	T	C	.	PASS	NM_004489	C	synonymous_variant	LOW	GPS2	ENSG00000132522	Transcript	ENST00000380728	protein_coding	5/11		c.333A>G	430	333	111	L	ctA/ctG	rs2292064&COSV59747661		-1		SNV	HGNC	HGNC:4550	YES	MANE_Select	NM_004489.5		1	P1	CCDS11100.1	ENSP00000370104	Q13227.183		UPI0000000DD1	Q13227-1					AFDB-ENSP_mappings:AF-Q13227-F1&Pfam:PF15991&PANTHER:PTHR22654			0.5749	0.4592	0.6484	0.6796	0.5179	0.6299	0.5423	0.4726	0.6807	0.4412	0.6787	0.6022	0.4144	0.5304	0.5365	0.5929	0.5249	0.4679	0.5428	0.589	0.428	0.6714	0.5992	0.4048	0.5223	0.5142	0.6069	0.6807	gnomADe_AMR		0&1	0&1	20407468&22006096						FAIL	15	-22	-40	-22	0.00	0.00	0.00	0.00	GPS2		6.4500e-01																																																											665					0.983							198.75	v6.1	Unknown		True	GPS2, a transcriptional cofactor involved in MAPK signaling, is altered by mutation and translocation in a variety of cancer types including medulloblastoma and glioblastoma.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GPS2 ENSP00000370104.2:L111= mutant UNKNOWN.	False	The GPS2 ENSP00000370104.2:l111= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	7217463						True	False	False	Unknown								False	False		GPS2, a transcriptional cofactor involved in MAPK signaling, is altered by mutation and translocation in a variety of cancer types including medulloblastoma and glioblastoma.	The GPS2 ENSP00000370104.2:l111= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GPS2 ENSP00000370104.2:L111= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	GPS2	2874.0	ENSP00000370104.2:L111=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GPS2"",""entrezGeneId"":2874,""alteration"":""ENSP00000370104.2:L111="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GPS2, a transcriptional cofactor involved in MAPK signaling, is altered by mutation and translocation in a variety of cancer types including medulloblastoma and glioblastoma."",""variantSummary"":""The GPS2 ENSP00000370104.2:l111= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GPS2 ENSP00000370104.2:L111= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						0,654	0,312	0,342	0/1	0,0,316,338	TTA	.	.	.			0,0,264,390	64.73		1.0
GRCh38	TP53	D12_12345_1234556_Thyroid_S9			chr17	7668836	7668838.0	GAA	G	G	7668836	.	GAA	G	.	PASS	NM_000546	-	3_prime_UTR_variant	MODIFIER	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding	11/11		c.*771_*772del	2095-2096					rs200757381		-1		deletion	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1												0.1284	0.1548	0.148	0.1227	0.1098	0.1538	0.1206	0.1302	0.1367	0.1132	0.002435	0.001839	0	0.00277	0.00299	0.02152	0.004037	0.004273	0.001324	0.001212	0.002046	0.1548	gnomADe_AFR	uncertain_significance		1	36035419						FAIL	35	-37	35	-25	0.00	0.04	0.00	0.00	TP53		4.4900e-01																																																											494					0.603							204.19													chr17	7572154																																																	True	True	False	Unknown		Unknown																						231,67	94,32	137,35	0/1	140,91,35,32	AGA						73,158,32,35	9.77		0.22483221476510068
GRCh38	TP53	D12_12345_1234556_Thyroid_S9			chr17	7674797	7674797.0	T	C	C	7674797	.	T	C	.	PASS	NM_000546	C	intron_variant	MODIFIER	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding		6/10	c.672+62A>G						rs1625895		-1		SNV	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1						0.8337	0.6846	0.9092	0.9762	0.8569	0.8108	0.8675	0.7089	0.921	0.8348	0.9724	0.8874	0.6975	0.8735	0.859	0.7927	0.8305	0.713	0.8322	0.8846	0.8401	0.9664	0.8899	0.6905	0.8726	0.8344	0.7986	0.9762	EAS	benign		1	25741868&27917368&18854777&34953598&16465622&18640487&19826048&19426493&19276375&28415781&33942220&24818791&21402718&25340731&19276285&30867801&25233467&30801535&19505915&35865244&29892419&21838531&12466288&17151932&17428325&36039053&17908995&18798306&19193430&28678827&34295994&17301252&17449902&17624591&19423538&21810023&23029260&23360829&29167767&30796655&31205533&31788124&32888145&34190520&35351459&25430047&30048458&31624379&31686737&33985476&25925845&35571038&27503997&37083525&23412385&37116145&34967580&21342648&33544795&32423484&25842861&34848757&31143958&21869887&32214837&32552660&33462484&22829776&25394431&20445773&32445942&33318152&36856940&36224396&29030886&30944658&16039051&18314326&19386249&37829618&37763132&38743086&38835350&39062026						FAIL	-49	9	21	-1	0.00	0.00	0.00	0.01	TP53		4.4900e-01	256603			0.83367	256462	not_provided&Hereditary_cancer-predisposing_syndrome&Li-Fraumeni_syndrome_1&not_specified		MedGen:C3661900&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&Gene:553989&MedGen:C1835398&OMIM:151623&Orphanet:524&MedGen:CN169374		NC_000017.11:g.7674797T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000305118&SCV000605413&SCV001848557&SCV002582423&SCV002583085&SCV005248519	single_nucleotide_variant	SO:0001483	ClinGen:CA001948		TP53:7157	SO:0001627&intron_variant										1	1625895																											750					0.997							246.86													chr17	7578115																																																	True	True	False	Unknown		Unknown																						0,748	0,408	0,340	0/1	0,0,379,369	CTG	.	.	.			0,0,419,329	64.73		1.0
GRCh38	TP53	D12_12345_1234556_Thyroid_S9			chr17	7675327	7675327.0	C	T	T	7675327	.	C	T	.	PASS	NM_000546	T	intron_variant	MODIFIER	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding		4/10	c.376-91G>A						rs2909430&COSV52668782		-1		SNV	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1						0.8429	0.7141	0.9121	0.9762	0.8579	0.8149	0.8673	0.727	0.9191	0.8338	0.9724	0.8901	0.7163	0.8726	0.8609	0.7927	0.8373	0.7365	0.8322	0.8873	0.8405	0.9667	0.8895	0.6939	0.8726	0.8392	0.7998	0.9762	EAS	benign	0&1	1&1	27917368&23761422&27246533&19276375&18678618&33942220&24818791&21402718&24218030&19276285&28542283&25233467&19888426&29963112&28976792&15450681&17301252&17449902&19423538&22962577&28364582&28373458&31205533&31788124&32882831&34591432&35351459&25925845&26503811&35923699&21342648&32899294&36164436&20352120&37239075&24177593&36733806&36581621&37763132						FAIL	-31	11	9	23	0.00	0.00	0.01	0.00	TP53		4.4900e-01	440348			0.84285	433983	not_specified&Li-Fraumeni_syndrome_1&Hereditary_cancer-predisposing_syndrome&not_provided		MedGen:CN169374&Gene:553989&MedGen:C1835398&OMIM:151623&Orphanet:524&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900		NC_000017.11:g.7675327C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000605414&SCV001885745&SCV002011124&SCV002582426&SCV002583087&SCV005251481	single_nucleotide_variant	SO:0001483	ClinGen:CA14459943		TP53:7157	SO:0001627&intron_variant										1	2909430																											774					0.991							247.18													chr17	7578645																																																	True	True	False	Unknown		Unknown																						0,767	0,351	0,416	0/1	0,0,405,362	GCG	0.00	0.00	0.00			0,0,367,400	64.73		1.0
GRCh38	TP53	D12_12345_1234556_Thyroid_S9			chr17	7675393	7675396.0	CTTT	C	C	7675393	.	CTTT	C	.	PASS	NM_000546	-	intron_variant	MODIFIER	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding		4/10	c.376-160_376-158del						rs5819162		-1		deletion	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1												0.493	0.4452	0.4814	0.4775	0.5037	0.4903	0.4517	0.4963	0.4899	0.47	0.8086	0.7061	0.8259	0.8195	0.8094	0.9586	0.8438	0.6856	0.8523	0.8097	0.7797	0.9586	gnomADg_EAS	benign&likely_benign		1							FAIL	-37	-1	-43	42	0.00	0.00	0.00	0.00	TP53		4.4900e-01	803309				791833	Squamous_cell_carcinoma_of_the_head_and_neck&Hereditary_cancer-predisposing_syndrome&not_provided&Li-Fraumeni_syndrome_1		MONDO:MONDO:0010150&MeSH:D000077195&MedGen:C1168401&OMIM:275355&Orphanet:67037&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&Gene:553989&MedGen:C1835398&OMIM:151623&Orphanet:524		NC_000017.11:g.7675409_7675411del	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV001140265&SCV001888470&SCV002582249&SCV002582909	Deletion	SO:0000159	ClinGen:CA287488787		TP53:7157	SO:0001627&intron_variant										1	5819162																											424					0.632							203.87													chr17	7578711																																																	True	True	False	Unknown		Unknown																						31,237	13,125	18,112	0/1	15,16,142,95	TCT						19,12,96,141	39.71		0.8843283582089553
GRCh38	TP53	D12_12345_1234556_Thyroid_S9			chr17	7675519	7675519.0	A	G	G	7675519	.	A	G	.	PASS	NM_000546	G	intron_variant	MODIFIER	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding		4/10	c.376-283T>C						rs1794287&CR104657		-1		SNV	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1						0.8496	0.7224	0.9222	0.9752	0.8738	0.816	0.8779	0.7381	0.915	0.8406	0.9731	0.8952	0.7667	0.8856	0.8691	0.8032	0.8472	0.7439	0.8554	0.8927	0.8498	0.9668	0.8927	0.7103	0.8866	0.8512	0.8072	0.9752	EAS	benign	0&1	1&1	32882831&20127977&29928384&37239075						FAIL	37	-3	-11	34	0.00	0.00	0.00	0.00	TP53		4.4900e-01	695142			0.84964	685438	Hereditary_cancer-predisposing_syndrome&not_provided&Li-Fraumeni_syndrome_1&Li-Fraumeni_syndrome		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&Gene:553989&MedGen:C1835398&OMIM:151623&Orphanet:524&MONDO:MONDO:0018875&MedGen:C0085390&OMIM:PS151623&Orphanet:524		NC_000017.11:g.7675519A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001729822&SCV001891624&SCV002582427&SCV002583089&SCV005251487	single_nucleotide_variant	SO:0001483	ClinGen:CA16534634		TP53:7157	SO:0001627&intron_variant										1	1794287																											370					0.992							167.39													chr17	7578837																																																	True	True	False	Unknown		Unknown																						1,366	1,183	0,183	0/1	0,1,161,205	TAA	.	.	.			0,1,126,240	64.73		0.997275204359673
GRCh38	TP53	D12_12345_1234556_Thyroid_S9	p.P72R	ENSP00000269305.4:p.Pro72Arg	chr17	7676154	7676154.0	G	C	C	7676154	.	G	C	.	PASS	NM_000546	C	missense_variant	MODERATE	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding	4/11		c.215C>G	357	215	72	P/R	cCc/cGc	rs1042522&CM961374&COSV52666208&COSV53098660		-1		SNV	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1	tolerated(0.14)	benign(0.047)	PDB-ENSP_mappings:2gs0.B&PDB-ENSP_mappings:2ly4.B&PDB-ENSP_mappings:6rz3.A&PDB-ENSP_mappings:6xre.M&PDB-ENSP_mappings:7xzz.K&PDB-ENSP_mappings:7xzz.L&PDB-ENSP_mappings:7xzz.M&PDB-ENSP_mappings:7xzz.N&PDB-ENSP_mappings:8f2h.A&PDB-ENSP_mappings:8f2h.B&PDB-ENSP_mappings:8f2i.A&PDB-ENSP_mappings:8r1f.C&PDB-ENSP_mappings:8r1g.C&PDB-ENSP_mappings:8r1g.F&Low_complexity_(Seg):seg&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&PANTHER:PTHR11447&AFDB-ENSP_mappings:AF-P04637-F1			0.5429	0.3313	0.683	0.5863	0.7147	0.5082	0.7163	0.3758	0.7143	0.7194	0.6049	0.7326	0.6035	0.7477	0.6953	0.5066	0.6268	0.3866	0.67	0.6995	0.7206	0.5756	0.7357	0.6463	0.745	0.6521	0.5231	0.7477	gnomADe_NFE	benign&pathogenic	0&1&1&1	1&1&1&1	25741868&30409984&34131278&23267696&26451011&31818908&24033266&24728327&24944790&21708280&21514219&23946381&28652652&30551681&34540891&22879966&22992668&23820649&27277665&27716216&25214541&25719551&20599859&28827732&30337837&30793520&30988702&26690118&20003265&35566612&26873362&23757202&33262486&30781715&24491308&32287273&32338278&18805939&18854777&30616520&30937706&18191955&23168575&18298806&22215955&22655231&24084248&29193749&27871254&26870349&16465622&16857995&19822020&27415837&27588484&29484706&19911060&20855462&25479941&33941312&18640487&19470478&21779510&24654968&26382048&26867771&30956778&34618298&21589938&23906684&18978339&30139066&30807515&32651972&28881764&18547414&18715757&18830263&19826048&23072573&32257953&20638924&20847277&21897271&27618021&28348449&32295184&19426493&19657586&20452958&21841506&24820515&27246533&21533266&24534481&31821471&19276375&18678618&32708070&22703879&28415781&29458332&26900293&33942220&24818791&27376129&25203442&32492903&34077778&21402718&28324443&24218030&25412941&2219465						FAIL	45	-18	3	40	0.00	0.00	0.00	0.05	TP53	0.368	4.4900e-01	12351		0.65996	0.54293	27390	Hepatocellular_carcinoma&Bone_osteosarcoma&Glioma_susceptibility_1&Bone_marrow_failure_syndrome_5&Li-Fraumeni_syndrome_1&Basal_cell_carcinoma&_susceptibility_to&_7&Familial_cancer_of_breast&Colorectal_cancer&Carcinoma_of_pancreas&Choroid_plexus_papilloma&Nasopharyngeal_carcinoma&Adrenocortical_carcinoma&_hereditary&Lip_and_oral_cavity_carcinoma&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_breast_ovarian_cancer_syndrome&Acute_myeloid_leukemia&TP53_POLYMORPHISM&Li-Fraumeni_syndrome		Human_Phenotype_Ontology:HP:0001402&Human_Phenotype_Ontology:HP:0002899&Human_Phenotype_Ontology:HP:0003007&Human_Phenotype_Ontology:HP:0006750&MONDO:MONDO:0007256&MedGen:C2239176&OMIM:114550&Orphanet:88673&MONDO:MONDO:0002629&MedGen:C0585442&OMIM:259500&Orphanet:668&MONDO:MONDO:0024498&MedGen:C2750850&OMIM:137800&MONDO:MONDO:0032573&MedGen:C4748488&OMIM:618165&Gene:553989&MedGen:C1835398&OMIM:151623&Orphanet:524&MONDO:MONDO:0013876&MedGen:C3553606&OMIM:614740&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0005575&MedGen:C0346629&OMIM:114500&MONDO:MONDO:0005192&MeSH:C562463&MedGen:C0235974&Orphanet:1333&Orphanet:217074&Human_Phenotype_Ontology:HP:0200022&MONDO:MONDO:0009837&MedGen:C0205770&OMIM:260500&Orphanet:251899&Orphanet:2807&MONDO:MONDO:0015459&MedGen:C2931822&OMIM:607107&Orphanet:150&MONDO:MONDO:0008734&MedGen:C1859972&OMIM:202300&Orphanet:1501&MONDO:MONDO:0023644&MedGen:C0220641&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&Human_Phenotype_Ontology:HP:0001914&Human_Phenotype_Ontology:HP:0004808&Human_Phenotype_Ontology:HP:0004843&Human_Phenotype_Ontology:HP:0005516&Human_Phenotype_Ontology:HP:0006724&Human_Phenotype_Ontology:HP:0006728&MONDO:MONDO:0018874&MeSH:D015470&MedGen:C0023467&OMIM:601626&Orphanet:519&.&MONDO:MONDO:0018875&MedGen:C0085390&OMIM:PS151623&Orphanet:524		NC_000017.11:g.7676154G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000111071&SCV000187242&SCV000292072&SCV000305114&SCV000407071&SCV000605416&SCV000611723&SCV000629789&SCV001440886&SCV001940208&SCV002505076&SCV002515178&SCV002582428&SCV002583090&SCV002804833&SCV004823832&SCV005251488&SCV006059726&SCV006301172&SCV006311208	single_nucleotide_variant	SO:0001483	ClinGen:CA000072&OMIM:191170.0005&PharmGKB_Clinical_Annotation:655386635&UniProtKB:P04637																																																																																																																																															0,1141	0,497	0,644	0/1	0,0,598,543	GGG	.	.	.			0,0,532,609	81.98		1.0
GRCh38	TP53	D12_12345_1234556_Thyroid_S9			chr17	7676325	7676341.0	CCCCCAGCCCTCCAGGT	C	C	7676325	.	CCCCCAGCCCTCCAGGT	C	.	PASS	NM_000546	-	intron_variant	MODIFIER	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding		3/10	c.96+41_97-54del						rs59758982		-1		deletion	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1						0.5865	0.5182	0.6095	0.6815	0.6223	0.5276	0.8509	0.7218	0.9113	0.8186	0.9699	0.8836	0.6861	0.8537	0.8462	0.7818	0.8269	0.733	0.8293	0.8757	0.8248	0.9634	0.8874	0.6897	0.8564	0.8252	0.7903	0.9699	gnomADe_EAS			1	32000721&19471604&32888145&31772679&36123588&31316092&30816478&38743086																	4.4900e-01	440349				433984	Li-Fraumeni_syndrome_1&not_provided&not_specified&Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome		Gene:553989&MedGen:C1835398&OMIM:151623&Orphanet:524&MedGen:C3661900&MedGen:CN169374&MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000017.11:g.7676335TCCAGGTCCCCAGCCC[1]	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000605417&SCV001849336&SCV002042838&SCV002582432&SCV002583094&SCV006311209	Microsatellite	SO:0000289	ClinGen:CA000510		TP53:7157	SO:0001627&intron_variant										1	59758982																											853					0.749							237.28													chr17	7579643																																																	True	True	False	Unknown		Unknown																						63,576	43,296	20,280	0/1	44,19,265,311	CCC						52,11,173,403	40.66		0.9014084507042254
GRCh38	TP53	D12_12345_1234556_Thyroid_S9			chr17	7676483	7676483.0	G	C	C	7676483	.	G	C	.	PASS	NM_000546	C	intron_variant	MODIFIER	TP53	ENSG00000141510	Transcript	ENST00000269305	protein_coding		2/10	c.74+38C>G						rs1642785&COSV52668860&CR1413385		-1		SNV	HGNC	HGNC:11998	YES	MANE_Select	NM_000546.6		1	P1	CCDS11118.1	ENSP00000269305	P04637.307	K7PPA8.92	UPI000002ED67	P04637-1		1						0.5849	0.4924	0.6931	0.5823	0.7117	0.5051	0.7085	0.5034	0.7188	0.7119	0.6045	0.7228	0.6032	0.7346	0.6963	0.5043	0.6598	0.5147	0.6692	0.7106	0.7153	0.5729	0.726	0.6327	0.7395	0.6762	0.521	0.7395	gnomADg_NFE	benign	0&1&1	1&1&1	25741868&27608007&19276375&21402718&21437228&18798306&32000721&17096406&19423538&21115003&22829934&22962577&23552518&27223485&27619989&28364582&30796655&31762593&32888145&34591432&34683108&25269805&25896519&25925845&32592449&24336192&24171036&24936644&36536332&27907203&32899294&34207603&36233089&23013791&36349164&17133269&23570263&24716831&32629971&32585821&25313908&27566557&34655190&30816478&18248785&37763132&38074116&38360742						FAIL	50	-39	32	38	0.00	0.00	0.00	0.00	TP53		4.4900e-01	137691	0.66695		0.58486	141394	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_breast_ovarian_cancer_syndrome&Li-Fraumeni_syndrome_1&Li-Fraumeni_syndrome		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&Gene:553989&MedGen:C1835398&OMIM:151623&Orphanet:524&MONDO:MONDO:0018875&MedGen:C0085390&OMIM:PS151623&Orphanet:524		NC_000017.11:g.7676483G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000305120&SCV000605415&SCV000686765&SCV001729823&SCV002505088&SCV002582433&SCV002583095&SCV004015622&SCV004026699&SCV005251493&SCV006311213	single_nucleotide_variant	SO:0001483	ClinGen:CA000385		TP53:7157	SO:0001623&5_prime_UTR_variant&SO:0001627&intron_variant										1	1642785																											824					0.966							245.65													chr17	7579801																																																	True	True	False	Unknown		Unknown																						62,734	34,366	28,368	0/1	28,34,367,367	TGG	.	.	.			0,62,597,137	41.91		0.9221105527638191
GRCh38	AURKB	D12_12345_1234556_Thyroid_S9	p.M298T	ENSP00000463999.1:p.Met298Thr	chr17	8205013	8205013.0	A	G	G	8205013	.	A	G	.	PASS	NM_004217	G	missense_variant	MODERATE	AURKB	ENSG00000178999	Transcript	ENST00000585124	protein_coding	9/9		c.893T>C	964	893	298	M/T	aTg/aCg	rs1059476&COSV60243948		-1		SNV	HGNC	HGNC:11390	YES	MANE_Select	NM_004217.4		1	P4	CCDS11134.1	ENSP00000463999	Q96GD4.236		UPI000013FD00	Q96GD4-1			tolerated_low_confidence(0.27)	benign(0)	PDB-ENSP_mappings:4af3.A&Superfamily:SSF56112&Pfam:PF00069&Gene3D:1.10.510.10&SMART:SM00220&PROSITE_profiles:PS50011&PANTHER:PTHR24350&AFDB-ENSP_mappings:AF-Q96GD4-F1			0.7360	0.6407	0.8141	0.5516	0.8827	0.8487	0.8667	0.6921	0.8011	0.7342	0.5976	0.907	0.7696	0.8872	0.8336	0.8629	0.8131	0.7042	0.8267	0.8024	0.7119	0.5625	0.9071	0.7619	0.8883	0.7915	0.862	0.9071	gnomADg_FIN		0&1	0&1	28977903&25586992&24722014&16762494						FAIL	-1	31	-33	32	0.00	0.00	0.00	0.00	AURKB		9.5700e-01																																																											907					0.996							230.28	v6.1	Unknown		True	AURKB, an intracellular kinase, is infrequently altered in cancer.	False	10/23/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKB ENSP00000463999.1:M298T mutant UNKNOWN.	False	The AURKB ENSP00000463999.1:m298t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	8108331						True	False	False	Unknown								False	False		AURKB, an intracellular kinase, is infrequently altered in cancer.	The AURKB ENSP00000463999.1:m298t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKB ENSP00000463999.1:M298T mutant UNKNOWN.						v6.1	10/23/2017		GRCh38	AURKB	9212.0	ENSP00000463999.1:M298T			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""AURKB"",""entrezGeneId"":9212,""alteration"":""ENSP00000463999.1:M298T"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""AURKB, an intracellular kinase, is infrequently altered in cancer."",""variantSummary"":""The AURKB ENSP00000463999.1:m298t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKB ENSP00000463999.1:M298T mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/23/2017""}"	True	True	False	Unknown		Unknown																						477,426	229,185	248,241	0|1	264,213,227,199	CAT	.	.	.		8108331	220,257,166,260	24.92		0.4717607973421927
GRCh38	AURKB	D12_12345_1234556_Thyroid_S9	p.Ser295=	ENSP00000463999.1:p.Ser295=	chr17	8205021	8205021.0	G	A	A	8205021	.	G	A	.	PASS	NM_004217	A	synonymous_variant	LOW	AURKB	ENSG00000178999	Transcript	ENST00000585124	protein_coding	9/9		c.885C>T	956	885	295	S	tcC/tcT	rs2241909&COSV60243958		-1		SNV	HGNC	HGNC:11390	YES	MANE_Select	NM_004217.4		1	P4	CCDS11134.1	ENSP00000463999	Q96GD4.236		UPI000013FD00	Q96GD4-1					PDB-ENSP_mappings:4af3.A&Superfamily:SSF56112&Pfam:PF00069&Gene3D:1.10.510.10&SMART:SM00220&PROSITE_profiles:PS50011&PANTHER:PTHR24350&AFDB-ENSP_mappings:AF-Q96GD4-F1			0.6208	0.5545	0.696	0.5179	0.66	0.7229	0.6584	0.5653	0.6929	0.516	0.5669	0.7478	0.5863	0.6595	0.6385	0.7102	0.6357	0.5698	0.6148	0.6573	0.4905	0.5239	0.7544	0.6096	0.6629	0.6286	0.7221	0.7544	gnomADg_FIN		0&1	0&1	25586992&27270838&30288111&31521144&34465813&16762494						FAIL	-19	23	24	-41	0.00	0.00	0.00	0.00	AURKB		9.5700e-01																																																											846					0.994							235.85	v6.1	Unknown		True	AURKB, an intracellular kinase, is infrequently altered in cancer.	False	10/23/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKB ENSP00000463999.1:S295= mutant UNKNOWN.	False	The AURKB ENSP00000463999.1:s295= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	8108339						True	False	False	Unknown								False	False		AURKB, an intracellular kinase, is infrequently altered in cancer.	The AURKB ENSP00000463999.1:s295= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKB ENSP00000463999.1:S295= mutant UNKNOWN.						v6.1	10/23/2017		GRCh38	AURKB	9212.0	ENSP00000463999.1:S295=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""AURKB"",""entrezGeneId"":9212,""alteration"":""ENSP00000463999.1:S295="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""AURKB, an intracellular kinase, is infrequently altered in cancer."",""variantSummary"":""The AURKB ENSP00000463999.1:s295= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKB ENSP00000463999.1:S295= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/23/2017""}"	True	True	False	Unknown		Unknown																						444,397	210,173	234,224	0|1	245,199,224,173	CGG	0.00	0.00	0.00		8108331	181,263,146,251	25.22		0.47205707491082044
GRCh38		D12_12345_1234556_Thyroid_S9			chr17	10232618	10232622.0	C	CATGT	CATGT	10232618	.	C	CATGT	.	PASS		ATGT	intergenic_variant	MODIFIER														rs3051300				insertion																						0.6745	0.7935	0.6931	0.6438	0.5746	0.635											0.6192	0.7426	0.4215	0.6748	0.5043	0.6528	0.5296	0.6473	0.5516	0.6142	0.6175	0.7935	AFR				33801242																																																																												99					0.99							243.02													chr17	10135935																																																	True	False	False	Unknown		Unknown																						47,51	20,19	27,32	0/1	27,20,26,25	CCA						22,25,32,19	36.32		0.5204081632653061
GRCh38		D12_12345_1234556_Thyroid_S9			chr17	11293661		T	T[chr20:31150747[	T[chr20:31150747[	11293661	MantaBND:16034:0:1:0:0:0:1	T	T[chr20:31150747[	.	PASS		T.	downstream_gene_variant	MODIFIER		ENSG00000264727	Transcript	ENST00000577346	lncRNA										2851	1		chromosome_breakpoint			YES																																																																																																																											0			0,4							4	GGGG			MantaBND:16034:0:1:0:0:0:0	3														chr17	11196978				BND																																													True	False	False	Unknown		Unknown																															0,0				0,6	
GRCh38	NCOR1	D12_12345_1234556_Thyroid_S9			chr17	16070530	16070530.0	A	T	T	16070530	.	A	T	.	PASS	NM_006311	T	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	NCOR1	ENSG00000141027	Transcript	ENST00000268712	protein_coding		30/45	c.4153-5T>A						rs12942295&COSV51966361		-1		SNV	HGNC	HGNC:7672	YES	MANE_Select	NM_006311.4		1	P3	CCDS11175.1	ENSP00000268712	O75376.235		UPI000013D7D5	O75376-1		1						0.3516	0.3064	0.4481	0.1528	0.5328	0.363	0.5075	0.3411	0.3835	0.6203	0.1338	0.5512	0.5538	0.5357	0.4973	0.3883	0.4623	0.3435	0.5242	0.4638	0.6303	0.1441	0.5633	0.5959	0.5384	0.4867	0.3751	0.6303	gnomADg_ASJ	benign	0&1	1&1							FAIL	-36	-5	-5	-35	0.00	0.01	0.00	0.00	NCOR1		2.9200e-01	3059996	0.47447	0.45774	0.35164	3217902	NCOR1-related_disorder		.		NC_000017.11:g.16070530A>T	no_assertion_criteria_provided	Benign			SCV004799104	single_nucleotide_variant	SO:0001483	ClinGen:CA8408568		NCOR1:9611	SO:0001627&intron_variant										1	12942295																											269					0.996							248.33													chr17	15973844																																																	True	True	False	Unknown		Unknown																						121,147	64,68	57,79	0/1	59,62,72,75	AAG	.	.	.			26,95,43,104	50.6		0.5485074626865671
GRCh38	NCOR1	D12_12345_1234556_Thyroid_S9			chr17	16080529	16080531.0	CAT	C	C	16080529	.	CAT	C	.	PASS	NM_006311	-	intron_variant	MODIFIER	NCOR1	ENSG00000141027	Transcript	ENST00000268712	protein_coding		24/45	c.3299-22_3299-21del						rs147790941		-1		deletion	HGNC	HGNC:7672	YES	MANE_Select	NM_006311.4		1	P3	CCDS11175.1	ENSP00000268712	O75376.235		UPI000013D7D5	O75376-1		1						0.0070	0	0.0072	0	0.0278	0.002	0.02544	0.003585	0.006373	0.01362	5.039e-05	0.01972	0.005201	0.03001	0.02075	0.008359	0.0172	0.004673	0.07785	0.00909	0.01125	0	0.01803	0.0102	0.02811	0.01231	0.008929	0.07785	gnomADg_AMI										FAIL	16	-20	-20	-40	0.01	0.04	0.00	0.00	NCOR1		2.9200e-01																																																											95					0.937							238.25													chr17	15983843																																																	True	True	False	Unknown		Unknown																						51,38	15,18	36,20	0/1	32,19,16,22	ACA						20,31,22,16	25.7		0.42696629213483145
GRCh38	NCOR1	D12_12345_1234556_Thyroid_S9	p.S172L	ENSP00000268712.2:p.Ser172Leu	chr17	16165082	16165082.0	G	A	A	16165082	.	G	A	.	PASS	NM_006311	A	missense_variant	MODERATE	NCOR1	ENSG00000141027	Transcript	ENST00000268712	protein_coding	5/46		c.515C>T	758	515	172	S/L	tCa/tTa	rs150910818&COSV51959131		-1		SNV	HGNC	HGNC:7672	YES	MANE_Select	NM_006311.4		1	P3	CCDS11175.1	ENSP00000268712	O75376.235		UPI000013D7D5	O75376-1		1	deleterious_low_confidence(0.01)	benign(0.007)	AFDB-ENSP_mappings:AF-O75376-F1&Pfam:PF15784&PANTHER:PTHR13992&MobiDB_lite:mobidb-lite																																	0&1	0&1							FAIL	-20	-35	-24	-35	0.00	0.00	0.00	0.01	NCOR1	0.174	2.9200e-01																																																											134					0.731							63.48	v6.1	Unknown		True	NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types.	False	10/01/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:S172L mutant UNKNOWN.	False	The NCOR1 ENSP00000268712.2:s172l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	16068396						True	False	False	Unknown								False	False		NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types.	The NCOR1 ENSP00000268712.2:s172l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:S172L mutant UNKNOWN.						v6.1	10/01/2019		GRCh38	NCOR1	9611.0	ENSP00000268712.2:S172L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NCOR1"",""entrezGeneId"":9611,""alteration"":""ENSP00000268712.2:S172L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types."",""variantSummary"":""The NCOR1 ENSP00000268712.2:s172l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:S172L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/01/2019""}"	True	True	False	Unknown		Unknown																						66,32	36,17	30,15	0/1	37,29,17,15	TGA	0.00	0.00	0.00			37,29,28,4	10.73		0.32653061224489793
GRCh38	NCOR1	D12_12345_1234556_Thyroid_S9	p.G150R	ENSP00000268712.2:p.Gly150Arg	chr17	16165149	16165149.0	C	T	T	16165149	.	C	T	.	PASS	NM_006311	T	missense_variant	MODERATE	NCOR1	ENSG00000141027	Transcript	ENST00000268712	protein_coding	5/46		c.448G>A	691	448	150	G/R	Gga/Aga	rs74453660&COSV51959167		-1		SNV	HGNC	HGNC:7672	YES	MANE_Select	NM_006311.4		1	P3	CCDS11175.1	ENSP00000268712	O75376.235		UPI000013D7D5	O75376-1		1	deleterious_low_confidence(0.02)	possibly_damaging(0.681)	AFDB-ENSP_mappings:AF-O75376-F1&Pfam:PF15784&PANTHER:PTHR13992&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite									6.931e-06	3.1e-05	0	0	0	0	0	8.127e-06	0	0	4.601e-05	0.0001689	0	0	0	0	0	0	0	0	0	0.0001689	gnomADg_AFR		0&1	0&1							FAIL	-2	12	-2	-3	0.00	0.00	0.00	0.00	NCOR1	0.053	2.9200e-01																																																											241					0.672							66.04	v6.1	Unknown		True	NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types.	False	10/01/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:G150R mutant UNKNOWN.	False	The NCOR1 ENSP00000268712.2:g150r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	16068463						True	False	False	Unknown								False	False		NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types.	The NCOR1 ENSP00000268712.2:g150r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:G150R mutant UNKNOWN.						v6.1	10/01/2019		GRCh38	NCOR1	9611.0	ENSP00000268712.2:G150R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NCOR1"",""entrezGeneId"":9611,""alteration"":""ENSP00000268712.2:G150R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types."",""variantSummary"":""The NCOR1 ENSP00000268712.2:g150r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:G150R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/01/2019""}"	True	True	False	Unknown		Unknown																						126,36	69,18	57,18	0/1	57,69,17,19	CCG	0.00	0.00	1.00			64,62,15,21	9.53		0.2222222222222222
GRCh38	NCOR1	D12_12345_1234556_Thyroid_S9			chr17	16181671	16181675.0	A	AACAC	AACAC	16181671	.	A	AACAC	.	PASS	NM_006311	ACAC	intron_variant	MODIFIER	NCOR1	ENSG00000141027	Transcript	ENST00000268712	protein_coding		3/45	c.242+4879_242+4882dup						rs1305047		-1		insertion	HGNC	HGNC:7672	YES	MANE_Select	NM_006311.4		1	P3	CCDS11175.1	ENSP00000268712	O75376.235		UPI000013D7D5	O75376-1		1						0.3369	0.3245	0.4524	0.1101	0.5258	0.3108											0.4628	0.3682	0.5177	0.4552	0.6103	0.09606	0.5705	0.585	0.5329	0.4787	0.3416	0.6103	gnomADg_ASJ				21359226&23690203&22124616&24416183&36292568&35251118																	2.9200e-01																																																											49					0.939							242.75													chr17	16084985																																																	True	True	False	Unknown		Unknown																						30,16	12,8	18,8	0/1	15,15,5,11	TAA						13,17,5,11	19.28		0.34782608695652173
GRCh38	NCOR1	D12_12345_1234556_Thyroid_S9	p.G5V	ENSP00000268712.2:p.Gly5Val	chr17	16194556	16194556.0	C	A	A	16194556	.	C	A	.	PASS	NM_006311	A	missense_variant	MODERATE	NCOR1	ENSG00000141027	Transcript	ENST00000268712	protein_coding	2/46		c.14G>T	257	14	5	G/V	gGt/gTt	rs76145228&COSV51961729		-1		SNV	HGNC	HGNC:7672	YES	MANE_Select	NM_006311.4		1	P3	CCDS11175.1	ENSP00000268712	O75376.235		UPI000013D7D5	O75376-1		1	deleterious_low_confidence(0)	possibly_damaging(0.839)	AFDB-ENSP_mappings:AF-O75376-F1&PANTHER:PTHR13992&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite																																	0&1	0&1							FAIL	-18	0	35	1	0.00	0.00	0.00	0.00	NCOR1	0.259	2.9200e-01																																																											216					0.764							92.64	v6.1	Unknown		True	NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types.	False	10/01/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:G5V mutant UNKNOWN.	False	The NCOR1 ENSP00000268712.2:g5v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	16097870						True	False	False	Unknown								False	False		NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types.	The NCOR1 ENSP00000268712.2:g5v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:G5V mutant UNKNOWN.						v6.1	10/01/2019		GRCh38	NCOR1	9611.0	ENSP00000268712.2:G5V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NCOR1"",""entrezGeneId"":9611,""alteration"":""ENSP00000268712.2:G5V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NCOR1, a transcriptional co-repressor, is altered by chromosomal translocation and mutation in various cancer types."",""variantSummary"":""The NCOR1 ENSP00000268712.2:g5v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NCOR1 ENSP00000268712.2:G5V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/01/2019""}"	True	True	False	Unknown		Unknown																						108,57	51,23	57,34	0/1	59,49,29,28	ACC	0.00	0.00	0.00			38,70,27,30	11.14		0.34545454545454546
GRCh38	NF1	D12_12345_1234556_Thyroid_S9	p.Leu234=	ENSP00000351015.4:p.Leu234=	chr17	31181757	31181757.0	G	A	A	31181757	.	G	A	.	PASS	NM_001042492	A	synonymous_variant	LOW	NF1	ENSG00000196712	Transcript	ENST00000358273	protein_coding	7/58		c.702G>A	1035	702	234	L	ctG/ctA	rs1801052&CD148107&COSV62193259		1		SNV	HGNC	HGNC:7765	YES	MANE_Select	NM_001042492.3		1	A1	CCDS42292.1	ENSP00000351015	P21359.256		UPI000012FFAE	P21359-1		1			PDB-ENSP_mappings:7moc.A&PDB-ENSP_mappings:7moc.B&PDB-ENSP_mappings:7mp5.A&PDB-ENSP_mappings:7mp5.B&PDB-ENSP_mappings:7mp6.A&PDB-ENSP_mappings:7mp6.B&PDB-ENSP_mappings:7pgp.F&PDB-ENSP_mappings:7pgp.N&PDB-ENSP_mappings:7pgq.F&PDB-ENSP_mappings:7pgq.N&PDB-ENSP_mappings:7pgr.F&PDB-ENSP_mappings:7pgr.N&PDB-ENSP_mappings:7pgs.F&PDB-ENSP_mappings:7pgs.N&PDB-ENSP_mappings:7pgt.F&PDB-ENSP_mappings:7pgt.N&PDB-ENSP_mappings:7pgu.F&PDB-ENSP_mappings:7pgu.N&PDB-ENSP_mappings:7r03.A&PDB-ENSP_mappings:7r03.B&PDB-ENSP_mappings:7r04.A&PDB-ENSP_mappings:7r04.B&PDB-ENSP_mappings:8e20.A&PDB-ENSP_mappings:8e20.B&PDB-ENSP_mappings:8edl.A&PDB-ENSP_mappings:8edm.A&PDB-ENSP_mappings:8edm.B&PDB-ENSP_mappings:8edn.A&PANTHER:PTHR10194			0.5118	0.2307	0.5288	0.5506	0.7157	0.6299	0.6751	0.2857	0.5161	0.7751	0.5553	0.6566	0.7676	0.6989	0.669	0.6374	0.5718	0.3039	0.7198	0.5651	0.7682	0.5616	0.6603	0.7774	0.7044	0.6318	0.6261	0.7774	gnomADg_MID	benign	0&1&1	1&1&1	25741868&24033266&17668375&21354044&31048186&38419798						FAIL	7	-47	34	28	0.00	0.00	0.00	0.00	NF1		4.4900e-01	183825	0.57440	0.62280	0.51178	184518	Cardiovascular_phenotype&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Neurofibromatosis&_familial_spinal&Neurofibromatosis-Noonan_syndrome&Neurofibromatosis&_type_1&Caf-au-lait_macules_with_pulmonary_stenosis		MedGen:CN230736&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0008078&MedGen:C1834235&OMIM:162210&Orphanet:636&MONDO:MONDO:0011035&MedGen:C2931482&OMIM:601321&Orphanet:638&MONDO:MONDO:0018975&MedGen:C0027831&OMIM:162200&Orphanet:636&MONDO:MONDO:0008672&MedGen:C0553586&OMIM:193520&Orphanet:3444		NC_000017.11:g.31181757G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000213085&SCV000269460&SCV000306287&SCV000401693&SCV000401694&SCV000401695&SCV000401696&SCV000515325&SCV000604468&SCV000628753&SCV000696403&SCV002026733&SCV002530180&SCV002667074&SCV004016063&SCV005253759&SCV005880969&SCV006311109	single_nucleotide_variant	SO:0001483	ClinGen:CA186628		NF1:4763	SO:0001819&synonymous_variant										1	1801052																											142					0.986							241.63	v6.1	Unknown		True	NF1, a negative regulator of RAS, is inactivated by mutation or deletion in various solid and hematologic malignancies.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NF1 ENSP00000351015.4:L234= mutant UNKNOWN.	False	The NF1 ENSP00000351015.4:l234= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	29508775						True	False	False	Unknown								False	False		NF1, a negative regulator of RAS, is inactivated by mutation or deletion in various solid and hematologic malignancies.	The NF1 ENSP00000351015.4:l234= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NF1 ENSP00000351015.4:L234= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	NF1	4763.0	ENSP00000351015.4:L234=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NF1"",""entrezGeneId"":4763,""alteration"":""ENSP00000351015.4:L234="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NF1, a negative regulator of RAS, is inactivated by mutation or deletion in various solid and hematologic malignancies."",""variantSummary"":""The NF1 ENSP00000351015.4:l234= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NF1 ENSP00000351015.4:L234= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						0,140	0,68	0,72	0/1	0,0,69,71	TGT	0.00	0.00	0.00			0,0,89,51	64.72		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr17	32629736		A	[chr17:62343113[A	[chr17:62343113[A	32629736	MantaBND:16135:0:1:0:0:0:1	A	[chr17:62343113[A	.	PASS		.A	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH		ENSG00000264458	Transcript	ENST00000582272	lncRNA		1/2									1		chromosome_breakpoint			YES				3																																																																																																																							2			0,13							13	AAAAAAAAAAAAG			MantaBND:16135:0:1:0:0:0:0	1														chr17	30956754				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	PGAP3	D12_12345_1234556_Thyroid_S9			chr17	39691546	39691547.0	T	TA	TA	39691546	.	T	TA	.	PASS		A	intron_variant	MODIFIER	PGAP3	ENSG00000161395	Transcript	ENST00000584856	protein_coding		1/2	c.-36+4959dup						rs557885708		-1	cds_end_NF	insertion	HGNC	HGNC:23719					4			ENSP00000463785		J3QQL0.55	UPI000268AFB5			1						0.5437	0.4637	0.5115	0.3988	0.674	0.6902											0.5137	0.2877	0.6963	0.4449	0.596	0.3418	0.5818	0.5328	0.5959	0.5056	0.6341	0.6963	gnomADg_AMI																					1.3290e+00																																																											123					0.61							166.11													chr17	37847799																																																	True	False	False	Unknown		Unknown																						45,30	16,16	29,14	0/1	28,17,13,17	TTA						21,24,9,21	14.28		0.4
GRCh38	ERBB2	D12_12345_1234556_Thyroid_S9			chr17	39699581	39699581.0	C	A	A	39699581	.	C	A	.	PASS	NM_004448	A	upstream_gene_variant	MODIFIER	ERBB2	ENSG00000141736	Transcript	ENST00000269571	protein_coding									rs4252596&COSV54064965	483	1		SNV	HGNC	HGNC:3430	YES	MANE_Select	NM_004448.4		1	P1	CCDS32642.1	ENSP00000269571	P04626.275	X5DNK3.71	UPI000003F55F	P04626-1		1						0.0659	0.0038	0.0519	0.002	0.1183	0.1718	0.1229	0.01808	0.04731	0.1699	0.0006165	0.07309	0.117	0.1279	0.1193	0.1955	0.08724	0.02131	0.03399	0.0631	0.1699	0.001928	0.06801	0.1156	0.1327	0.07576	0.1787	0.1955	gnomADe_SAS	not_provided	0&1	1&1	24728327&25710561&22199994&23912956&17132159&15743501&28424560&17117180																		135519		0.17616	0.06589	139258	not_specified		MedGen:CN169374		NC_000017.11:g.39699581C>A	no_classification_provided	not_provided			SCV000083930	single_nucleotide_variant	SO:0001483	ClinGen:CA162974		ERBB2:2064	SO:0001583&missense_variant&SO:0001627&intron_variant										1	4252596																											320					0.997							246.14													chr17	37855834																																																	True	True	False	Unknown		Unknown																						176,143	87,66	89,77	0/1	83,93,66,77	GCC	0.00	0.00	0.00			98,78,57,86	26.2		0.4482758620689655
GRCh38	ERBB2	D12_12345_1234556_Thyroid_S9	p.P1170A	ENSP00000269571.4:p.Pro1170Ala	chr17	39727784	39727784.0	C	G	G	39727784	.	C	G	.	PASS	NM_004448	G	missense_variant	MODERATE	ERBB2	ENSG00000141736	Transcript	ENST00000269571	protein_coding	27/27		c.3508C>G	3683	3508	1170	P/A	Ccc/Gcc	rs1058808&CM087578&COSV54064104		1		SNV	HGNC	HGNC:3430	YES	MANE_Select	NM_004448.4		1	P1	CCDS32642.1	ENSP00000269571	P04626.275	X5DNK3.71	UPI000003F55F	P04626-1		1	deleterious(0)	possibly_damaging(0.484)	AFDB-ENSP_mappings:AF-P04626-F1&Phobius:CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000619&MobiDB_lite:mobidb-lite			0.4521	0.1921	0.4784	0.4018	0.673	0.6094	0.6544	0.2205	0.5653	0.6849	0.4428	0.6766	0.7015	0.6749	0.6279	0.6945	0.5224	0.2281	0.7708	0.5319	0.6761	0.395	0.6815	0.6088	0.6627	0.5407	0.661	0.7708	gnomADg_AMI	not_provided&benign	0&1&1	1&1&1	25537509&24728327&16595073&25710561&17267408&25803781&32780457&32293552&22188591&17598910&26919099&26201965&28763429&33834328&23200760&31888550&34944636&29853740&22199994&34721579&30214282&28422721&27267075&27698805&15743501&19055823&19336545&19438491&26323365&26464710&30719131&31116314&18510993&29247589&24676663&25653542&33110473&28424560&35761855&35261178&30689737&37336194&30646946&36312261&25885598&36993286&28735727&17117180&34103634&27776352&36765720&37735578&35972693&38676836&38275400&38374091&38756376						FAIL	40	19	-1	-2	0.00	0.01	0.00	0.00	ERBB2	0.254	5.1800e-01	134082	0.51353	0.60698	0.45208	137821	not_provided&not_specified		MedGen:C3661900&MedGen:CN169374		NC_000017.11:g.39727784C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001729186&SCV005247491	single_nucleotide_variant	SO:0001483	ClinGen:CA158663		ERBB2:2064	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant&SO:0001624&3_prime_UTR_variant										1	1058808																											992					1							246.79	v6.1	Unknown		True	ERBB2, a receptor tyrosine kinase, is altered by mutation, amplification and/or overexpression in various cancer types, most frequently in breast, esophagogastric and endometrial cancers.	False	11/06/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB2 ENSP00000269571.4:P1170A mutant UNKNOWN.	False	The ERBB2 ENSP00000269571.4:p1170a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	37884037						True	False	False	Unknown								False	False		ERBB2, a receptor tyrosine kinase, is altered by mutation, amplification and/or overexpression in various cancer types, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 ENSP00000269571.4:p1170a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB2 ENSP00000269571.4:P1170A mutant UNKNOWN.						v6.1	11/06/2019		GRCh38	ERBB2	2064.0	ENSP00000269571.4:P1170A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERBB2"",""entrezGeneId"":2064,""alteration"":""ENSP00000269571.4:P1170A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERBB2, a receptor tyrosine kinase, is altered by mutation, amplification and/or overexpression in various cancer types, most frequently in breast, esophagogastric and endometrial cancers."",""variantSummary"":""The ERBB2 ENSP00000269571.4:p1170a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB2 ENSP00000269571.4:P1170A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/06/2019""}"	True	True	True	Likely Neutral	19336545;29533785	Likely Neutral																						0,992	0,527	0,465	0/1	0,0,501,491	GCC	.	.	.			0,0,460,532	64.73		1.0
GRCh38	STAT5A	D12_12345_1234556_Thyroid_S9	p.Asp634=	ENSP00000468749.1:p.Asp634=	chr17	42307719	42307719.0	C	T	T	42307719	.	C	T	.	PASS	NM_001288718	T	synonymous_variant	LOW	STAT5A	ENSG00000126561	Transcript	ENST00000590949	protein_coding	15/19		c.1902C>T	2013	1902	634	D	gaC/gaT	rs1135669&COSV61806332&COSV61808409		1		SNV	HGNC	HGNC:11366	YES	MANE_Select	NM_001288718.2		1	P4	CCDS11424.1	ENSP00000468749	P42229.224	A0A384N5W4.33	UPI0000136075	P42229-1					Gene3D:3.30.505.10&PDB-ENSP_mappings:7tva.A&PDB-ENSP_mappings:7tva.B&PDB-ENSP_mappings:7tvb.A&PDB-ENSP_mappings:7ubt.A&PDB-ENSP_mappings:7uc6.A&PDB-ENSP_mappings:7uc7.A&AFDB-ENSP_mappings:AF-P42229-F1&Pfam:PF00017&PROSITE_profiles:PS50001&PANTHER:PTHR11801&SMART:SM00252&Superfamily:SSF55550&CDD:cd10421			0.2410	0.1967	0.0908	0.371	0.1889	0.3272	0.1843	0.2101	0.09077	0.2558	0.3534	0.1831	0.2358	0.1701	0.2008	0.292	0.1871	0.2018	0.2127	0.1144	0.2718	0.3581	0.1812	0.1973	0.1681	0.2048	0.3153	0.371	EAS		0&1&1	0&1&1	18520591&23940558&28400551&36355252						FAIL	-5	-42	4	8	0.00	0.02	0.00	0.00	STAT5A		3.6400e-01																																																											877					0.999							246.1	v6.1	Unknown		True	STAT5A encodes a transcription factor involved in the JAK signaling cascade. Mutations of STAT5A are found in prostate and breast cancers and leukemias, among others.	False	01/18/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with STAT5A ENSP00000468749.1:D634= mutant UNKNOWN.	False	The STAT5A ENSP00000468749.1:d634= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	40459737						True	False	False	Unknown								False	False		STAT5A encodes a transcription factor involved in the JAK signaling cascade. Mutations of STAT5A are found in prostate and breast cancers and leukemias, among others.	The STAT5A ENSP00000468749.1:d634= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with STAT5A ENSP00000468749.1:D634= mutant UNKNOWN.						v6.1	01/18/2017		GRCh38	STAT5A	6776.0	ENSP00000468749.1:D634=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""STAT5A"",""entrezGeneId"":6776,""alteration"":""ENSP00000468749.1:D634="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""STAT5A encodes a transcription factor involved in the JAK signaling cascade. Mutations of STAT5A are found in prostate and breast cancers and leukemias, among others."",""variantSummary"":""The STAT5A ENSP00000468749.1:d634= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with STAT5A ENSP00000468749.1:D634= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/18/2017""}"	True	True	False	Unknown		Unknown																						462,414	247,207	215,207	0/1	249,213,207,207	ACT	0.00	0.00	0.00			236,226,204,210	32.24		0.4726027397260274
GRCh38	STAT3	D12_12345_1234556_Thyroid_S9			chr17	42331452		G	<INS>	<INS>	42331452	MantaINS:11982:0:0:1:4:0	G	<INS>	.	PASS	NM_139276	insertion	intron_variant	MODIFIER	STAT3	ENSG00000168610	Transcript	ENST00000264657	protein_coding		11/23									-1		insertion	HGNC	HGNC:11364	YES	MANE_Select	NM_139276.3		1	A1	CCDS32656.1	ENSP00000264657	P40763.245		UPI0000031047	P40763-1		1																																																								3752089				3875409	Hyper-IgE_recurrent_infection_syndrome_1&_autosomal_dominant&STAT3_gain_of_function		MONDO:MONDO:0007818&MedGen:C2936739&OMIM:147060&Orphanet:2314&MedGen:C4288261		NC_000017.11:g.42331453C>T	criteria_provided&_single_submitter	Likely_benign			SCV005854892	single_nucleotide_variant	SO:0001483			STAT3:6774	SO:0001627&intron_variant										1																									0,90		0,90							90	CTAAGATAGGAGTACTTACTTGTCAATGCACACTTTAATTTTAAGCTGATAATTCAACTCAGGGAATTTGACCAGCAACCTATTTAAAAA		CTAAGATAGGAGTACTTACTTGTCAATGCACACTTTAATTTTAAGCTGATAATTCAACTCAGGGAATTTGACCAGCAACCTATTTAAAAAAAAAAAAAAAAAAAAAAGAATGGTGTTAACTTAATTG																chr17	40483470	CAGTCCACTCCATTCCATTCCATTCCTTTTCATTACATTCCATTCCACTCCACTAAATTCCATTCCTCATTTGAAAAACAGAA			INS																																													True	True	False	Unknown		Unknown																															0,0				21,2	
GRCh38	BRCA1	D12_12345_1234556_Thyroid_S9			chr17	43084735	43084744.0	GGTCTGCAGC	G	G	43084735	.	GGTCTGCAGC	G	.	PASS	NM_007294	-	intron_variant	MODIFIER	BRCA1	ENSG00000012048	Transcript	ENST00000357654	protein_coding		11/22	c.4186-2169_4186-2161del								-1		deletion	HGNC	HGNC:1100	YES	MANE_Select	NM_007294.4		1	P4	CCDS11453.1	ENSP00000350283	P38398.277		UPI0000126AC8	P38398-1		1																																																							8.8500e-01																																																											116					0.983							245.35													chr17	41236752																																																	True	True	False	Unknown		Unknown																						111,3	62,3	49,0	0/1	60,51,2,1	AGG						61,50,2,1	8.82		0.02631578947368421
GRCh38	ETV4	D12_12345_1234556_Thyroid_S9			chr17	43530602	43530604.0	ACG	A	A	43530602	.	ACG	A	.	PASS	NM_001079675	-	intron_variant	MODIFIER	ETV4	ENSG00000175832	Transcript	ENST00000319349	protein_coding		8/12	c.812-423_812-422del						rs200376976		-1		deletion	HGNC	HGNC:3493	YES	MANE_Select	NM_001079675.5		1	P1	CCDS11465.1	ENSP00000321835	P43268.192		UPI0000000236	P43268-1		1						0.9553	0.9773	0.9078	0.9881	0.9175	0.9642											0.3988	0.3806	0.4024	0.4269	0.4243	0.4376	0.3642	0.3374	0.4071	0.4241	0.3378	0.9881	EAS			1							FAIL	11	27	8	27	0.00	0.00	0.00	0.00	ETV4		8.2100e-01	1260653				1253141	not_provided		MedGen:C3661900		NC_000017.11:g.43530603CG[3]	criteria_provided&_single_submitter	Benign			SCV001887349	Microsatellite	SO:0000289	ClinGen:CA290848228		DHX8:1659&ETV4:2118	SO:0001627&intron_variant										1	200376976																											1063					0.807							225.41													chr17	41607970																																																	True	True	False	Unknown		Unknown																						549,309	249,147	300,162	0/1	281,268,162,147	CAC						291,258,168,141	10.64		0.36013986013986016
GRCh38	ETV4	D12_12345_1234556_Thyroid_S9			chr17	43530609	43530617.0	CGTGTGTGT	C	C	43530609	.	CGTGTGTGT	C	.	PASS	NM_001079675	-	intron_variant	MODIFIER	ETV4	ENSG00000175832	Transcript	ENST00000319349	protein_coding		8/12	c.812-436_812-429del						rs58803566		-1		deletion	HGNC	HGNC:3493	YES	MANE_Select	NM_001079675.5		1	P1	CCDS11465.1	ENSP00000321835	P43268.192		UPI0000000236	P43268-1		1																						0.2681	0.1521	0.2768	0.2573	0.3546	0.3692	0.3167	0.3571	0.304	0.2865	0.2945	0.3692	gnomADg_EAS			1																		8.2100e-01	1295940				1285735	not_provided		MedGen:C3661900		NC_000017.11:g.43530611TG[9]	criteria_provided&_single_submitter	Benign			SCV001947913	Microsatellite	SO:0000289	ClinGen:CA290848246		DHX8:1659&ETV4:2118	SO:0001627&intron_variant										1	58803566																											1064					0.877							225.13													chr17	41607977																																																	True	True	False	Unknown		Unknown																						548,385	255,170	293,215	0|1	294,254,190,195	GCG					41607977	287,261,207,178	28.68		0.41264737406216506
GRCh38	ETV4	D12_12345_1234556_Thyroid_S9			chr17	43530619	43530619.0	T	C	C	43530619	.	T	C	.	PASS	NM_001079675	C	intron_variant	MODIFIER	ETV4	ENSG00000175832	Transcript	ENST00000319349	protein_coding		8/12	c.812-438A>G						rs199966014		-1		SNV	HGNC	HGNC:3493	YES	MANE_Select	NM_001079675.5		1	P1	CCDS11465.1	ENSP00000321835	P43268.192		UPI0000000236	P43268-1		1																						0.2104	0.1015	0.233	0.2014	0.2889	0.3176	0.2726	0.3061	0.2522	0.2268	0.2607	0.3176	gnomADg_EAS										FAIL	46	-24	46	47	0.00	0.00	0.00	0.00	ETV4		8.2100e-01																																																											977					0.915							222.92													chr17	41607987																																																	True	True	False	Unknown		Unknown																						516,378	236,167	280,211	0|1	275,241,187,191	GTG	.	.	.		41607977	263,253,196,182	4.82		0.4228187919463087
GRCh38	RPTOR	D12_12345_1234556_Thyroid_S9	p.Thr842=	ENSP00000307272.3:p.Thr842=	chr17	80922729	80922729.0	C	T	T	80922729	.	C	T	.	PASS	NM_020761	T	synonymous_variant	LOW	RPTOR	ENSG00000141564	Transcript	ENST00000306801	protein_coding	22/34		c.2526C>T	3318	2526	842	T	acC/acT	rs2271603&COSV60802444		1		SNV	HGNC	HGNC:30287	YES	MANE_Select	NM_020761.3		1	P1	CCDS11773.1	ENSP00000307272	Q8N122.203		UPI000007000F	Q8N122-1					PDB-ENSP_mappings:5h64.B&PDB-ENSP_mappings:5h64.b&PDB-ENSP_mappings:6bcu.W&PDB-ENSP_mappings:6bcu.Y&PDB-ENSP_mappings:6bcx.W&PDB-ENSP_mappings:6bcx.Y&PDB-ENSP_mappings:6sb0.N&PDB-ENSP_mappings:6sb0.Y&PDB-ENSP_mappings:6sb2.N&PDB-ENSP_mappings:6sb2.Y&PDB-ENSP_mappings:6u62.A&PDB-ENSP_mappings:7owg.Y&PDB-ENSP_mappings:7pea.E&PDB-ENSP_mappings:7pea.F&PDB-ENSP_mappings:7peb.E&PDB-ENSP_mappings:7pec.E&PDB-ENSP_mappings:7ux2.A&PDB-ENSP_mappings:7uxc.C&PDB-ENSP_mappings:7uxh.E&PDB-ENSP_mappings:7uxh.U&PDB-ENSP_mappings:8era.Y&PDB-ENSP_mappings:9f42.E&PDB-ENSP_mappings:9f43.E&PDB-ENSP_mappings:9f44.E&PDB-ENSP_mappings:9f44.F&PDB-ENSP_mappings:9f45.E&PDB-ENSP_mappings:9f45.F&Superfamily:SSF48371&PANTHER:PTHR12848&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q8N122-F1			0.2454	0.1536	0.2911	0.1964	0.3241	0.3067	0.3011	0.1682	0.2673	0.4131	0.1644	0.3072	0.3446	0.3082	0.2958	0.3021	0.276	0.1724	0.5419	0.305	0.4162	0.1836	0.3259	0.3605	0.3177	0.2871	0.3176	0.5419	gnomADg_AMI		0&1	0&1							FAIL	19	-5	7	0	0.00	0.00	0.00	0.00	RPTOR		2.0500e-01																																																											598					0.993							245.81	v6.1	Unknown		True	RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis.	False	03/01/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:T842= mutant UNKNOWN.	False	The RPTOR ENSP00000307272.3:t842= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	78896529						True	False	False	Unknown								False	False		RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis.	The RPTOR ENSP00000307272.3:t842= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:T842= mutant UNKNOWN.						v6.1	03/01/2017		GRCh38	RPTOR	57521.0	ENSP00000307272.3:T842=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RPTOR"",""entrezGeneId"":57521,""alteration"":""ENSP00000307272.3:T842="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis."",""variantSummary"":""The RPTOR ENSP00000307272.3:t842= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:T842= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/01/2017""}"	True	True	False	Unknown		Unknown																						300,294	165,171	135,123	0/1	144,156,153,141	CCG	0.00	0.00	0.00			163,137,174,120	44.62		0.494949494949495
GRCh38	RPTOR	D12_12345_1234556_Thyroid_S9	p.Asn1077=	ENSP00000307272.3:p.Asn1077=	chr17	80947317	80947317.0	C	T	T	80947317	.	C	T	.	PASS	NM_020761	T	synonymous_variant	LOW	RPTOR	ENSG00000141564	Transcript	ENST00000306801	protein_coding	27/34		c.3231C>T	4023	3231	1077	N	aaC/aaT	rs4969231&COSV60802469		1		SNV	HGNC	HGNC:30287	YES	MANE_Select	NM_020761.3		1	P1	CCDS11773.1	ENSP00000307272	Q8N122.203		UPI000007000F	Q8N122-1					PDB-ENSP_mappings:5h64.B&PDB-ENSP_mappings:5h64.b&PDB-ENSP_mappings:6bcu.W&PDB-ENSP_mappings:6bcu.Y&PDB-ENSP_mappings:6bcx.W&PDB-ENSP_mappings:6bcx.Y&PDB-ENSP_mappings:6sb0.N&PDB-ENSP_mappings:6sb0.Y&PDB-ENSP_mappings:6sb2.N&PDB-ENSP_mappings:6sb2.Y&PDB-ENSP_mappings:6u62.A&PDB-ENSP_mappings:7owg.Y&PDB-ENSP_mappings:7pea.E&PDB-ENSP_mappings:7pea.F&PDB-ENSP_mappings:7peb.E&PDB-ENSP_mappings:7pec.E&PDB-ENSP_mappings:7ux2.A&PDB-ENSP_mappings:7uxc.C&PDB-ENSP_mappings:7uxh.E&PDB-ENSP_mappings:7uxh.U&PDB-ENSP_mappings:8era.Y&PDB-ENSP_mappings:9f42.E&PDB-ENSP_mappings:9f43.E&PDB-ENSP_mappings:9f44.E&PDB-ENSP_mappings:9f44.F&PDB-ENSP_mappings:9f45.E&PDB-ENSP_mappings:9f45.F&Gene3D:2.130.10.10&Superfamily:SSF50978&PANTHER:PTHR12848&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00320&AFDB-ENSP_mappings:AF-Q8N122-F1			0.1977	0.0219	0.2795	0.2044	0.3052	0.2597	0.2921	0.06392	0.2611	0.3742	0.1585	0.2672	0.3245	0.3065	0.2814	0.2624	0.237	0.07084	0.5925	0.288	0.3682	0.1895	0.283	0.3299	0.3094	0.2481	0.2648	0.5925	gnomADg_AMI		0&1	0&1							FAIL	7	-24	-34	34	0.00	0.00	0.00	0.00	RPTOR		2.0500e-01																																																											904					0.998							247.19	v6.1	Unknown		True	RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis.	False	03/01/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:N1077= mutant UNKNOWN.	False	The RPTOR ENSP00000307272.3:n1077= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	78921117						True	False	False	Unknown								False	False		RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis.	The RPTOR ENSP00000307272.3:n1077= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:N1077= mutant UNKNOWN.						v6.1	03/01/2017		GRCh38	RPTOR	57521.0	ENSP00000307272.3:N1077=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RPTOR"",""entrezGeneId"":57521,""alteration"":""ENSP00000307272.3:N1077="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis."",""variantSummary"":""The RPTOR ENSP00000307272.3:n1077= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:N1077= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/01/2017""}"	True	True	False	Unknown		Unknown																						475,427	210,201	265,226	0/1	237,238,204,223	ACG	0.00	0.00	0.00			258,217,242,185	33.1		0.47339246119733924
GRCh38	RPTOR	D12_12345_1234556_Thyroid_S9	p.Arg1203=	ENSP00000307272.3:p.Arg1203=	chr17	80961397	80961397.0	C	T	T	80961397	.	C	T	.	PASS	NM_020761	T	synonymous_variant	LOW	RPTOR	ENSG00000141564	Transcript	ENST00000306801	protein_coding	31/34		c.3609C>T	4401	3609	1203	R	cgC/cgT	rs9899178&COSV60810915		1		SNV	HGNC	HGNC:30287	YES	MANE_Select	NM_020761.3		1	P1	CCDS11773.1	ENSP00000307272	Q8N122.203		UPI000007000F	Q8N122-1					PDB-ENSP_mappings:5h64.B&PDB-ENSP_mappings:5h64.b&PDB-ENSP_mappings:6bcu.W&PDB-ENSP_mappings:6bcu.Y&PDB-ENSP_mappings:6bcx.W&PDB-ENSP_mappings:6bcx.Y&PDB-ENSP_mappings:6sb0.N&PDB-ENSP_mappings:6sb0.Y&PDB-ENSP_mappings:6sb2.N&PDB-ENSP_mappings:6sb2.Y&PDB-ENSP_mappings:6u62.A&PDB-ENSP_mappings:7owg.Y&PDB-ENSP_mappings:7pea.E&PDB-ENSP_mappings:7pea.F&PDB-ENSP_mappings:7peb.E&PDB-ENSP_mappings:7pec.E&PDB-ENSP_mappings:7ux2.A&PDB-ENSP_mappings:7uxc.C&PDB-ENSP_mappings:7uxh.E&PDB-ENSP_mappings:7uxh.U&PDB-ENSP_mappings:8era.Y&PDB-ENSP_mappings:9f42.E&PDB-ENSP_mappings:9f43.E&PDB-ENSP_mappings:9f44.E&PDB-ENSP_mappings:9f44.F&PDB-ENSP_mappings:9f45.E&PDB-ENSP_mappings:9f45.F&Gene3D:2.130.10.10&Superfamily:SSF50978&PANTHER:PTHR12848&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00320&AFDB-ENSP_mappings:AF-Q8N122-F1			0.3095	0.0862	0.3415	0.5546	0.3479	0.2965	0.3603	0.1152	0.3664	0.3633	0.6051	0.3727	0.3331	0.362	0.3496	0.3213	0.2984	0.1279	0.2654	0.3411	0.3657	0.5694	0.3656	0.2415	0.3573	0.3108	0.319	0.6051	gnomADe_EAS		0&1	0&1	28977864						FAIL	26	-2	17	8	0.00	0.00	0.00	0.00	RPTOR		2.0500e-01																																																											656					0.995							247.54	v6.1	Unknown		True	RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis.	False	03/01/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:R1203= mutant UNKNOWN.	False	The RPTOR ENSP00000307272.3:r1203= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr17	78935197						True	False	False	Unknown								False	False		RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis.	The RPTOR ENSP00000307272.3:r1203= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:R1203= mutant UNKNOWN.						v6.1	03/01/2017		GRCh38	RPTOR	57521.0	ENSP00000307272.3:R1203=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RPTOR"",""entrezGeneId"":57521,""alteration"":""ENSP00000307272.3:R1203="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RPTOR encodes a scaffolding protein in the mTORC1 complex that regulates protein synthesis."",""variantSummary"":""The RPTOR ENSP00000307272.3:r1203= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RPTOR ENSP00000307272.3:R1203= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/01/2017""}"	True	True	False	Unknown		Unknown																						327,326	157,164	170,162	0/1	146,181,156,170	GCG	0.00	0.00	0.00			202,125,208,118	47.84		0.4992343032159265
GRCh38	B3GNTL1	D12_12345_1234556_Thyroid_S9			chr17	83046582		T	[chr2:167285750[T	[chr2:167285750[T	83046582	MantaBND:7436:0:1:0:0:0:1	T	[chr2:167285750[T	.	PASS		.T	feature_truncation&intron_variant	HIGH	B3GNTL1	ENSG00000175711	Transcript	ENST00000576599	protein_coding		2/12									-1		chromosome_breakpoint	HGNC	HGNC:21727					2			ENSP00000461127		I3L4B6.81	UPI0000E5A125																																																																																																																	4			0,7							7	GTTGATG			MantaBND:7436:0:1:0:0:0:0	0														chr17	81004458				BND																																													True	False	False	Unknown		Unknown																															0,1				3,2	
GRCh38	YES1	D12_12345_1234556_Thyroid_S9	p.Leu482=	ENSP00000324740.4:p.Leu482=	chr18	724612	724612.0	A	G	G	724612	.	A	G	.	PASS	NM_005433	G	synonymous_variant	LOW	YES1	ENSG00000176105	Transcript	ENST00000314574	protein_coding	12/12		c.1444T>C	1581	1444	482	L	Tta/Cta	rs537141&COSV58847929		-1		SNV	HGNC	HGNC:12841	YES	MANE_Select	NM_005433.4		1	P1	CCDS11824.1	ENSP00000324740	P07947.252		UPI0000062316						Gene3D:1.10.510.10&AFDB-ENSP_mappings:AF-P07947-F1&Pfam:PF07714&PROSITE_profiles:PS50011&PANTHER:PTHR24418&SMART:SM00219&Superfamily:SSF56112&CDD:cd05069			0.9898	0.9637	0.9971	1	1	0.999	0.9991	0.9699	0.9983	1	1	1	0.9979	0.9999	0.9983	1	0.992	0.9719	1	0.9976	1	1	1	0.9966	0.9999	0.9967	0.9998	1	EAS&EUR&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN		0&1	0&1							FAIL	20	-42	-8	-4	0.00	0.00	0.00	0.00	YES1		7.5100e-01																																																											97					0.948							209.04	v6.1	Unknown		True	YES1 encodes a tyrosine kinase involved in regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling and differentiation. Overexpression of YES1 is found in colorectal, hepatocellular, breast and esophageal cancers and melanomas.	False	03/09/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with YES1 ENSP00000324740.4:L482= mutant UNKNOWN.	False	The YES1 ENSP00000324740.4:l482= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr18	724612						True	False	False	Unknown								False	False		YES1 encodes a tyrosine kinase involved in regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling and differentiation. Overexpression of YES1 is found in colorectal, hepatocellular, breast and esophageal cancers and melanomas.	The YES1 ENSP00000324740.4:l482= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with YES1 ENSP00000324740.4:L482= mutant UNKNOWN.						v6.1	03/09/2017		GRCh38	YES1	7525.0	ENSP00000324740.4:L482=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""YES1"",""entrezGeneId"":7525,""alteration"":""ENSP00000324740.4:L482="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""YES1 encodes a tyrosine kinase involved in regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling and differentiation. Overexpression of YES1 is found in colorectal, hepatocellular, breast and esophageal cancers and melanomas."",""variantSummary"":""The YES1 ENSP00000324740.4:l482= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with YES1 ENSP00000324740.4:L482= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/09/2017""}"	True	True	False	Unknown		Unknown																						0,92	0,45	0,47	0/1	0,0,44,48	AAT	.	.	.			0,0,51,41	64.65		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr18	59893374	59893374.0	T	G	G	59893374	.	T	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000310295	Transcript	ENST00000848866	lncRNA		1/2	n.218+6642A>C						rs1544252		-1		SNV			YES																			0.3738	0.1914	0.4452	0.6399	0.2266	0.4468											0.2714	0.2183	0.2868	0.4073	0.3013	0.6437	0.2118	0.2007	0.238	0.2794	0.4755	0.6437	gnomADg_EAS																																																																																253					0.996							243.89													chr18	57560606																																																	True	False	False	Unknown		Unknown																						127,125	74,64	53,61	0/1	70,57,74,51	GTT	.	.	.			71,56,71,54	38.83		0.49603174603174605
GRCh38	PMAIP1	D12_12345_1234556_Thyroid_S9			chr18	59901369	59901369.0	C	T	T	59901369	.	C	T	.	PASS	NM_021127	T	intron_variant	MODIFIER	PMAIP1	ENSG00000141682	Transcript	ENST00000316660	protein_coding		1/1	c.58+1134C>T						rs7240119		1		SNV	HGNC	HGNC:9108	YES	MANE_Select	NM_021127.3		1	P1	CCDS11975.1	ENSP00000326119	Q13794.171	A0A0S2Z490.36	UPI0000049C57	Q13794-1								0.5192	0.5287	0.4784	0.504	0.4592	0.6125											0.4776	0.5094	0.4339	0.4861	0.5724	0.495	0.3612	0.5952	0.46	0.5052	0.5827	0.6125	SAS										FAIL	29	-23	-50	8	0.00	0.00	0.00	0.00	PMAIP1		1.8550e+00																																																											165					0.982							235.07													chr18	57568601																																																	True	True	False	Unknown		Unknown																						84,78	43,30	41,48	0/1	48,36,35,43	ACG	0.00	0.00	0.00			35,49,31,47	34.63		0.48148148148148145
GRCh38	BCL2	D12_12345_1234556_Thyroid_S9	p.Thr7=	ENSP00000329623.3:p.Thr7=	chr18	63318646	63318646.0	T	C	C	63318646	.	T	C	.	PASS	NM_000633	C	synonymous_variant	LOW	BCL2	ENSG00000171791	Transcript	ENST00000333681	protein_coding	2/3		c.21A>G	903	21	7	T	acA/acG	rs1801018&COSV61374121		-1		SNV	HGNC	HGNC:990	YES	MANE_Select	NM_000633.3		1	P1	CCDS11981.1	ENSP00000329623	P10415.271		UPI000000D90E	P10415-1		1			PDB-ENSP_mappings:1g5m.A&PDB-ENSP_mappings:1gjh.A&PDB-ENSP_mappings:1ysw.A&PDB-ENSP_mappings:2o21.A&PDB-ENSP_mappings:2o22.A&PDB-ENSP_mappings:2xa0.A&PDB-ENSP_mappings:2xa0.B&PDB-ENSP_mappings:4aq3.A&PDB-ENSP_mappings:4aq3.B&PDB-ENSP_mappings:4aq3.C&PDB-ENSP_mappings:4aq3.D&PDB-ENSP_mappings:4aq3.E&PDB-ENSP_mappings:4aq3.F&PDB-ENSP_mappings:4ieh.A&PDB-ENSP_mappings:4lvt.A&PDB-ENSP_mappings:4lvt.B&PDB-ENSP_mappings:4lxd.A&PDB-ENSP_mappings:4man.A&PDB-ENSP_mappings:4man.B&PDB-ENSP_mappings:5agw.A&PDB-ENSP_mappings:5agw.B&PDB-ENSP_mappings:5agx.A&PDB-ENSP_mappings:5agx.B&PDB-ENSP_mappings:5fcg.A&PDB-ENSP_mappings:5jsn.A&PDB-ENSP_mappings:5jsn.C&PDB-ENSP_mappings:5vau.A&PDB-ENSP_mappings:5vau.B&PDB-ENSP_mappings:5vau.C&PDB-ENSP_mappings:5vau.D&PDB-ENSP_mappings:5vax.A&PDB-ENSP_mappings:5vax.B&PDB-ENSP_mappings:5vax.C&PDB-ENSP_mappings:5vax.D&PDB-ENSP_mappings:5vay.A&PDB-ENSP_mappings:5vay.B&PDB-ENSP_mappings:5vay.C&PDB-ENSP_mappings:5vay.D&PDB-ENSP_mappings:6iwb.B&PDB-ENSP_mappings:6iwb.D&PDB-ENSP_mappings:6o0k.A&PDB-ENSP_mappings:6o0l.A&PDB-ENSP_mappings:6o0l.C&PDB-ENSP_mappings:6o0m.A&PDB-ENSP_mappings:6o0o.A&PDB-ENSP_mappings:6o0o.C&PDB-ENSP_mappings:6o0p.A&PDB-ENSP_mappings:7lhb.A&PDB-ENSP_mappings:7lhb.B&PDB-ENSP_mappings:7lhb.C&PDB-ENSP_mappings:7y90.A&PDB-ENSP_mappings:7ya5.A&PDB-ENSP_mappings:8fy1.D&PDB-ENSP_mappings:8fy2.D&PDB-ENSP_mappings:8hog.A&PDB-ENSP_mappings:8hoh.A&PDB-ENSP_mappings:8hoi.A&PDB-ENSP_mappings:8hoi.B&PDB-ENSP_mappings:8hoi.C&PDB-ENSP_mappings:8hoi.D&PDB-ENSP_mappings:8htr.A&PDB-ENSP_mappings:8hts.A&PDB-ENSP_mappings:8iql.A&PDB-ENSP_mappings:8iql.C&PDB-ENSP_mappings:8u27.A&Prints:PR01863&SMART:SM00265&PANTHER:PTHR11256&Superfamily:SSF56854&NCBIFAM:TIGR00865&Gene3D:1.10.437.10&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P10415-F1			0.2432	0.0318	0.389	0.0923	0.4751	0.3425	0.4064	0.06796	0.414	0.3469	0.1052	0.4586	0.3898	0.4309	0.3713	0.3682	0.3182	0.08052	0.523	0.3913	0.3493	0.1013	0.4567	0.3946	0.4344	0.3496	0.3463	0.523	gnomADg_AMI	benign	0&1	1&1	28738859&23021489&22586632&19384415&17267408&21085059&19276283&27822610&22347493&32487238&34050209&22568453&21949582&20504155&24321200&26132559&26311051&20610805&28106544&19141860&19520430&26344465&28417194&28445963&27462919&32570722&36294746&23977251&31842912&36902139&24049550&23364242&28154089&35800369&29799308&20592475&24621205&36197420&31044156						FAIL	21	-2	-29	-2	0.00	0.00	0.00	0.01	BCL2		3.6800e-01	3060318	0.31045	0.36882	0.24321	3200634	BCL2-related_disorder		.		NC_000018.10:g.63318646T>C	no_assertion_criteria_provided	Benign			SCV004799526	single_nucleotide_variant	SO:0001483	ClinGen:CA8985929		BCL2:596	SO:0001819&synonymous_variant										1	1801018																											1068					0.994							246.33	v6.1	Unknown		True	BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 ENSP00000329623.3:T7= mutant UNKNOWN.	False	The BCL2 ENSP00000329623.3:t7= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr18	60985879						True	False	False	Unknown								False	False		BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas.	The BCL2 ENSP00000329623.3:t7= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 ENSP00000329623.3:T7= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	BCL2	596.0	ENSP00000329623.3:T7=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCL2"",""entrezGeneId"":596,""alteration"":""ENSP00000329623.3:T7="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas."",""variantSummary"":""The BCL2 ENSP00000329623.3:t7= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 ENSP00000329623.3:T7= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						537,525	293,276	244,249	0/1	262,275,294,231	CTG	.	.	.			304,233,299,226	51.9		0.4943502824858757
GRCh38		D12_12345_1234556_Thyroid_S9			chr18	71476488	71476543.0	C	CAGAGAGAAGGAAGAACAGTGTGGTGTGGTGGCACACCTGAGAGCCACACTGGGA	CAGAGAGAAGGAAGAACAGTGTGGTGTGGTGGCACACCTGAGAGCCACACTGGGA	71476488	MantaINS:18133:0:0:0:1:0	C	CAGAGAGAAGGAAGAACAGTGTGGTGTGGTGGCACACCTGAGAGCCACACTGGGA	.	PASS		AGAGAGAAGGAAGAACAGTGTGGTGTGGTGGCACACCTGAGAGCCACACTGGGA	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000298599	Transcript	ENST00000756738	lncRNA		1/1	n.119+44342_119+44343insAGAGAAGGAAGAACAGTGTGGTGTGGTGGCACACCTGAGAGCCACACTGGGAAG						rs1568175018		1		insertion																					2																	0.5805	0.5798	0.6948	0.5875	0.6211	0.5536	0.5758	0.7179	0.5756	0.6119	0.5978	0.7179	gnomADg_MID																																																																														1M54I	0,2					71476488		2	AG																		chr18	69143724			54	INS																																													True	False	False	Unknown		Unknown																															0,0				0,11	
GRCh38	C18orf63	D12_12345_1234556_Thyroid_S9			chr18	74342287		G	[chr8:72168764[G	[chr8:72168764[G	74342287	MantaBND:13411:0:1:0:0:0:0	G	[chr8:72168764[G	.	PASS	NM_001174123	.G	feature_truncation&coding_sequence_variant	HIGH	C18orf63	ENSG00000206043	Transcript	ENST00000579455	protein_coding	10/14			1059	756	252					1		chromosome_breakpoint	HGNC	HGNC:40037	YES	MANE_Select	NM_001174123.2		1	P1	CCDS54189.1	ENSP00000464330	Q68DL7.107		UPI00006C192C						AFDB-ENSP_mappings:AF-Q68DL7-F1&Pfam:PF15813&PANTHER:PTHR28495																																																																																																											1			0,12							12	CAACATCTATTT			MantaBND:13411:0:1:0:0:0:1	2														chr18	72009522				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr18	77720430	77720430.0	C	T	T	77720430	.	C	T	.	PASS		T	downstream_gene_variant	MODIFIER		ENSG00000293804	Transcript	ENST00000719122	lncRNA									rs1024116	398	1		SNV			YES																			0.3333	0.2663	0.5476	0.0933	0.5378	0.3088											0.4714	0.316	0.5921	0.5261	0.5986	0.1002	0.5343	0.5442	0.5727	0.4844	0.343	0.5986	gnomADg_ASJ				26691610&29121662&33406744&33857205&19083859&24362753&27294018&22851935&19948332																																																																												84					0.952							247.63													chr18	75432386																																																	True	False	False	Unknown		Unknown																						36,44	21,13	15,31	0/1	14,22,18,26	GCA	0.00	0.00	0.00			17,19,23,21	39.02		0.55
GRCh38	TCF3	D12_12345_1234556_Thyroid_S9	p.Gly436=	ENSP00000468487.1:p.Gly436=	chr19	1619334	1619334.0	G	A	A	1619334	.	G	A	.	PASS	NM_001136139	A	synonymous_variant	LOW	TCF3	ENSG00000071564	Transcript	ENST00000588136	protein_coding	15/20		c.1308C>T	1663	1308	436	G	ggC/ggT	rs1140828&COSV53645352		-1		SNV	HGNC	HGNC:11633		MANE_Plus_Clinical		NM_001136139.4	2	P3	CCDS45899.1	ENSP00000468487	P15923.251		UPI000002B52E	P15923-2		1			AFDB-ENSP_mappings:AF-P15923-F1&PANTHER:PTHR11793			0.2354	0.1702	0.2435	0.2897	0.3032	0.1922	0.3195	0.1814	0.2292	0.3025	0.2957	0.3807	0.2073	0.3376	0.302	0.1906	0.2805	0.1826	0.3352	0.2619	0.3061	0.2765	0.3891	0.2313	0.3329	0.2677	0.1906	0.3891	gnomADg_FIN	benign	0&1	1&1	38135866						PASS	2	25	2	-18	0.00	0.00	0.58	0.08	TCF3		1.2510e+00	1169440	0.26764	0.30777	0.23542	1158420	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000019.10:g.1619334G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001729882&SCV001940345&SCV004233437&SCV005307734	single_nucleotide_variant	SO:0001483	ClinGen:CA9049943		TCF3:6929	SO:0001819&synonymous_variant										1	1140828																											727					0.997							247.17	v6.1	Unknown		True	TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types.	False	01/17/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 ENSP00000468487.1:G436= mutant UNKNOWN.	False	The TCF3 ENSP00000468487.1:g436= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	1619333						True	False	False	Unknown								False	False		TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types.	The TCF3 ENSP00000468487.1:g436= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 ENSP00000468487.1:G436= mutant UNKNOWN.						v6.1	01/17/2019		GRCh38	TCF3	6929.0	ENSP00000468487.1:G436=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""TCF3"",""entrezGeneId"":6929,""alteration"":""ENSP00000468487.1:G436="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types."",""variantSummary"":""The TCF3 ENSP00000468487.1:g436= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 ENSP00000468487.1:G436= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/17/2019""}"	True	True	False	Unknown		Unknown																						373,352	195,186	178,166	0|1	177,196,153,199	CGC	0.00	0.00	0.00		1619333	217,156,205,147	34.21		0.48551724137931035
GRCh38	TCF3	D12_12345_1234556_Thyroid_S9	p.Ser434=	ENSP00000468487.1:p.Ser434=	chr19	1619340	1619340.0	T	C	C	1619340	.	T	C	.	PASS	NM_001136139	C	synonymous_variant	LOW	TCF3	ENSG00000071564	Transcript	ENST00000588136	protein_coding	15/20		c.1302A>G	1657	1302	434	S	tcA/tcG	rs8140&COSV53648484		-1		SNV	HGNC	HGNC:11633		MANE_Plus_Clinical		NM_001136139.4	2	P3	CCDS45899.1	ENSP00000468487	P15923.251		UPI000002B52E	P15923-2		1			AFDB-ENSP_mappings:AF-P15923-F1&PANTHER:PTHR11793			0.6238	0.7723	0.5187	0.8839	0.3658	0.4949	0.4297	0.7378	0.5124	0.4185	0.8595	0.4348	0.3233	0.4001	0.4498	0.4502	0.5221	0.7204	0.3403	0.5302	0.4215	0.8799	0.4458	0.3435	0.3968	0.4796	0.4727	0.8839	EAS	benign	0&1	1&1	38135866						FAIL	-20	20	-24	20	0.00	0.00	0.01	0.04	TCF3		1.2510e+00	1167431	0.49017		0.62380	1158421	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000019.10:g.1619340T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001724925&SCV001882641&SCV004233056&SCV005307745	single_nucleotide_variant	SO:0001483	ClinGen:CA9049945		TCF3:6929	SO:0001819&synonymous_variant										1	8140																											753					0.997							247.26	v6.1	Unknown		True	TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types.	False	01/17/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 ENSP00000468487.1:S434= mutant UNKNOWN.	False	The TCF3 ENSP00000468487.1:s434= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	1619339						True	False	False	Unknown								False	False		TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types.	The TCF3 ENSP00000468487.1:s434= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 ENSP00000468487.1:S434= mutant UNKNOWN.						v6.1	01/17/2019		GRCh38	TCF3	6929.0	ENSP00000468487.1:S434=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""TCF3"",""entrezGeneId"":6929,""alteration"":""ENSP00000468487.1:S434="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types."",""variantSummary"":""The TCF3 ENSP00000468487.1:s434= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 ENSP00000468487.1:S434= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/17/2019""}"	True	True	False	Unknown		Unknown																						394,357	209,185	185,172	0|1	185,209,160,197	GTG	.	.	.		1619333	230,164,216,141	27.59		0.47536617842876167
GRCh38	DOT1L	D12_12345_1234556_Thyroid_S9	p.Ser826=	ENSP00000381657.3:p.Ser826=	chr19	2217024	2217024.0	C	T	T	2217024	.	C	T	.	PASS	NM_032482	T	synonymous_variant	LOW	DOT1L	ENSG00000104885	Transcript	ENST00000398665	protein_coding	21/28		c.2478C>T	2730	2478	826	S	agC/agT	rs141523228&COSV67112286		1		SNV	HGNC	HGNC:24948	YES	MANE_Select	NM_032482.3		1	P2	CCDS42460.1	ENSP00000381657	Q8TEK3.202		UPI000002A839	Q8TEK3-2		1			AFDB-ENSP_mappings:AF-Q8TEK3-F1&PIRSF:PIRSF037123&MobiDB_lite:mobidb-lite			0.0136	0	0.0086	0	0.0378	0.0245	0.02587	0.003555	0.01423	0.0467	0.0001008	0.04027	0.01907	0.02667	0.02465	0.02827	0.02002	0.004353	0	0.01882	0.04902	0	0.04444	0.003401	0.02589	0.02363	0.02613	0.04902	gnomADg_ASJ		0&1	0&1							FAIL	40	-32	-7	-24	0.00	0.00	0.00	0.00	DOT1L		3.2100e-01																																																											767					0.997							248.46	v6.1	Unknown		True	DOT1L, a histone methyltransferase, is infrequently mutated in various cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DOT1L ENSP00000381657.3:S826= mutant UNKNOWN.	False	The DOT1L ENSP00000381657.3:s826= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	2217023						True	False	False	Unknown								False	False		DOT1L, a histone methyltransferase, is infrequently mutated in various cancer types.	The DOT1L ENSP00000381657.3:s826= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DOT1L ENSP00000381657.3:S826= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	DOT1L	84444.0	ENSP00000381657.3:S826=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DOT1L"",""entrezGeneId"":84444,""alteration"":""ENSP00000381657.3:S826="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DOT1L, a histone methyltransferase, is infrequently mutated in various cancer types."",""variantSummary"":""The DOT1L ENSP00000381657.3:s826= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DOT1L ENSP00000381657.3:S826= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						388,377	208,176	180,201	0/1	185,203,202,175	GCC	0.00	0.00	0.00			163,225,175,202	46.46		0.4928104575163399
GRCh38	DOT1L	D12_12345_1234556_Thyroid_S9	p.G1386S	ENSP00000381657.3:p.Gly1386Ser	chr19	2226677	2226677.0	G	A	A	2226677	.	G	A	.	PASS	NM_032482	A	missense_variant	MODERATE	DOT1L	ENSG00000104885	Transcript	ENST00000398665	protein_coding	27/28		c.4156G>A	4408	4156	1386	G/S	Ggc/Agc	rs3815308&COSV67107860		1		SNV	HGNC	HGNC:24948	YES	MANE_Select	NM_032482.3		1	P2	CCDS42460.1	ENSP00000381657	Q8TEK3.202		UPI000002A839	Q8TEK3-2		1	tolerated_low_confidence(0.37)	benign(0.007)	AFDB-ENSP_mappings:AF-Q8TEK3-F1&PIRSF:PIRSF037123&MobiDB_lite:mobidb-lite			0.2256	0.0356	0.3069	0.1825	0.4692	0.2188	0.4111	0.08007	0.3052	0.4306	0.2276	0.3548	0.4618	0.4458	0.3858	0.255	0.318	0.09239	0.4989	0.339	0.4404	0.1824	0.3385	0.4388	0.4533	0.3622	0.2414	0.4989	gnomADg_AMI		0&1	1&1	34373545&36773049&29059683&37511413						FAIL	2	6	8	0	0.00	0.00	0.00	0.00	DOT1L	0.064	3.2100e-01																																																											834					0.996							247.27	v6.1	Unknown		True	DOT1L, a histone methyltransferase, is infrequently mutated in various cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DOT1L ENSP00000381657.3:G1386S mutant UNKNOWN.	False	The DOT1L ENSP00000381657.3:g1386s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	2226676						True	False	False	Unknown								False	False		DOT1L, a histone methyltransferase, is infrequently mutated in various cancer types.	The DOT1L ENSP00000381657.3:g1386s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DOT1L ENSP00000381657.3:G1386S mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	DOT1L	84444.0	ENSP00000381657.3:G1386S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DOT1L"",""entrezGeneId"":84444,""alteration"":""ENSP00000381657.3:G1386S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DOT1L, a histone methyltransferase, is infrequently mutated in various cancer types."",""variantSummary"":""The DOT1L ENSP00000381657.3:g1386s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DOT1L ENSP00000381657.3:G1386S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						419,412	203,187	216,225	0/1	213,206,218,194	CGG	0.00	0.00	0.00			209,210,203,209	49.26		0.49578820697954273
GRCh38	MAP2K2	D12_12345_1234556_Thyroid_S9	p.Ile220=	ENSP00000262948.4:p.Ile220=	chr19	4101064	4101064.0	G	T	T	4101064	.	G	T	.	PASS	NM_030662	T	synonymous_variant	LOW	MAP2K2	ENSG00000126934	Transcript	ENST00000262948	protein_coding	6/11		c.660C>A	907	660	220	I	atC/atA	rs10250&COSV53562256		-1		SNV	HGNC	HGNC:6842	YES	MANE_Select	NM_030662.4		1	P1	CCDS12120.1	ENSP00000262948	P36507.246		UPI000012F489			1			PDB-ENSP_mappings:1s9i.A&PDB-ENSP_mappings:1s9i.B&SMART:SM00220&Gene3D:1.10.510.10&Pfam:PF00069&PROSITE_profiles:PS50011&PANTHER:PTHR47448&Superfamily:SSF56112&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd06649&AFDB-ENSP_mappings:AF-P36507-F1			0.4333	0.2443	0.5562	0.625	0.4761	0.3599	0.4735	0.2579	0.5706	0.5372	0.5637	0.4609	0.4031	0.4784	0.472	0.3981	0.4286	0.274	0.4538	0.5314	0.5283	0.5941	0.4615	0.4354	0.4788	0.4569	0.3871	0.625	EAS	benign	0&1	1&1	25741868&24033266&34203389&18060073&35116533&31669095&28168209&34482832&34732054						FAIL	-2	45	18	-45	0.00	0.10	0.05	0.02	MAP2K2		8.5800e-01	40816	0.41794	0.54717	0.43331	49286	RASopathy&not_provided&Cardiovascular_phenotype&not_specified&Cardiofaciocutaneous_syndrome_4		MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:C3661900&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340		NC_000019.10:g.4101064G>T	reviewed_by_expert_panel	Benign			SCV000616574	single_nucleotide_variant	SO:0001483	ClinGen:CA137959		MAP2K2:5605	SO:0001819&synonymous_variant										1	10250																											710					0.93							121.49	v6.1	Unknown		True	MAP2K2, an intracellular kinase, is altered by mutation in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K2 ENSP00000262948.4:I220= mutant UNKNOWN.	False	The MAP2K2 ENSP00000262948.4:i220= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	4101062						True	False	False	Unknown								False	False		MAP2K2, an intracellular kinase, is altered by mutation in various cancer types.	The MAP2K2 ENSP00000262948.4:i220= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K2 ENSP00000262948.4:I220= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	MAP2K2	5605.0	ENSP00000262948.4:I220=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAP2K2"",""entrezGeneId"":5605,""alteration"":""ENSP00000262948.4:I220="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MAP2K2, an intracellular kinase, is altered by mutation in various cancer types."",""variantSummary"":""The MAP2K2 ENSP00000262948.4:i220= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K2 ENSP00000262948.4:I220= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						0,660	0,316	0,344	0/1	0,0,343,317	CGA	0.00	0.00	0.00			0,0,343,317	64.73		1.0
GRCh38	MAP2K2	D12_12345_1234556_Thyroid_S9	p.Val64=	ENSP00000262948.4:p.Val64=	chr19	4117530	4117530.0	G	A	A	4117530	.	G	A	.	PASS	NM_030662	A	synonymous_variant	LOW	MAP2K2	ENSG00000126934	Transcript	ENST00000262948	protein_coding	2/11		c.192C>T	439	192	64	V	gtC/gtT	rs8157&COSV53562298		-1		SNV	HGNC	HGNC:6842	YES	MANE_Select	NM_030662.4		1	P1	CCDS12120.1	ENSP00000262948	P36507.246		UPI000012F489			1			PDB-ENSP_mappings:1s9i.A&PDB-ENSP_mappings:1s9i.B&Gene3D:3.30.200.20&PANTHER:PTHR47448&Superfamily:SSF56112&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P36507-F1			0.0583	0.0825	0.0317	0.0228	0.0596	0.0798	0.06237	0.07605	0.03039	0.05368	0.01421	0.07838	0.05426	0.06339	0.0594	0.07806	0.06383	0.07677	0.01425	0.04047	0.04925	0.01928	0.07112	0.06803	0.06455	0.05955	0.06974	0.0825	AFR	benign	0&1	1&1	25741868&24033266						FAIL	3	11	3	-39	0.00	0.00	0.03	0.00	MAP2K2		8.5800e-01	40770	0.06312	0.06190	0.05831	49240	RASopathy&not_provided&Cardiovascular_phenotype&not_specified&Cardiofaciocutaneous_syndrome_4		MONDO:MONDO:0021060&MedGen:C5555857&Orphanet:536391&MedGen:C3661900&MedGen:CN230736&MedGen:CN169374&MONDO:MONDO:0014114&MedGen:C3809007&OMIM:615280&Orphanet:1340		NC_000019.10:g.4117530G>A	reviewed_by_expert_panel	Benign			SCV000616588	single_nucleotide_variant	SO:0001483	ClinGen:CA137916		MAP2K2:5605	SO:0001819&synonymous_variant										1	8157																											952					0.997							97.9	v6.1	Unknown		True	MAP2K2, an intracellular kinase, is altered by mutation in various cancer types.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K2 ENSP00000262948.4:V64= mutant UNKNOWN.	False	The MAP2K2 ENSP00000262948.4:v64= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	4117528						True	False	False	Unknown								False	False		MAP2K2, an intracellular kinase, is altered by mutation in various cancer types.	The MAP2K2 ENSP00000262948.4:v64= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K2 ENSP00000262948.4:V64= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	MAP2K2	5605.0	ENSP00000262948.4:V64=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAP2K2"",""entrezGeneId"":5605,""alteration"":""ENSP00000262948.4:V64="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MAP2K2, an intracellular kinase, is altered by mutation in various cancer types."",""variantSummary"":""The MAP2K2 ENSP00000262948.4:v64= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K2 ENSP00000262948.4:V64= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						474,475	249,272	225,203	0/1	243,231,250,225	CGA	0.00	0.00	0.00			224,250,227,248	49.39		0.5005268703898841
GRCh38	PTPRS-AS1	D12_12345_1234556_Thyroid_S9			chr19	5174019	5174019.0	A	G	G	5174019	.	A	G	.	PASS		G	upstream_gene_variant	MODIFIER	PTPRS-AS1	ENSG00000267550	Transcript	ENST00000592429	lncRNA									rs2620822	4100	1		SNV	HGNC	HGNC:56210	YES																			0.6723	0.7436	0.6153	0.6786	0.6163	0.6677	0.6051	0.7054	0.5879	0.5001	0.6315	0.6403	0.6245	0.603	0.6189	0.6077	0.6398	0.7144	0.5863	0.6098	0.504	0.6658	0.6399	0.5753	0.6072	0.6443	0.6332	0.7436	AFR																																																																																72					1							121.82													chr19	5174030																																																	True	False	False	Unknown		Unknown																						0,72	0,25	0,47	0/1	0,0,33,39	CAG	.	.	.			0,0,58,14	64.4		1.0
GRCh38	PTPRS	D12_12345_1234556_Thyroid_S9	p.Asp1763=	ENSP00000262963.8:p.Asp1763=	chr19	5210751	5210751.0	G	A	A	5210751	.	G	A	.	PASS	NM_002850	A	synonymous_variant	LOW	PTPRS	ENSG00000105426	Transcript	ENST00000262963	protein_coding	34/38		c.5289C>T	5532	5289	1763	D	gaC/gaT	rs1143699&COSV108077583		-1		SNV	HGNC	HGNC:9681	YES	MANE_Select	NM_002850.4		5		CCDS45930.1	ENSP00000262963	Q13332.220	G8JL96.86	UPI000059D63E	Q13332-1					PDB-ENSP_mappings:2fh7.A&Gene3D:3.90.190.10&PDB-ENSP_mappings:4bpc.A&AFDB-ENSP_mappings:AF-Q13332-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF00102&PROSITE_profiles:PS50055&SMART:SM00194&Superfamily:SSF52799&CDD:cd14627			0.1006	0.2216	0.0807	0	0.0994	0.0562	0.0979	0.1974	0.05297	0.0895	0.0002771	0.08229	0.07108	0.1051	0.0965	0.04942	0.1196	0.1912	0.08462	0.08221	0.08324	0.0005785	0.08192	0.119	0.1066	0.1121	0.05008	0.2216	AFR		0&1	0&1	17893260&36755664						FAIL	1	50	-5	-39	0.00	0.01	0.00	0.01	PTPRS		3.7800e-01																																																											1204					0.998							246.45	v6.1	Unknown		True	PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:D1763= mutant UNKNOWN.	False	The PTPRS ENSP00000262963.8:d1763= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	5210762						True	False	False	Unknown								False	False		PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	The PTPRS ENSP00000262963.8:d1763= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:D1763= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PTPRS	5802.0	ENSP00000262963.8:D1763=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRS"",""entrezGeneId"":5802,""alteration"":""ENSP00000262963.8:D1763="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others."",""variantSummary"":""The PTPRS ENSP00000262963.8:d1763= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:D1763= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						0,1201	0,644	0,557	0|1	0,0,580,621	AGT	0.00	0.00	0.00		5210762	0,0,585,616	57.73		1.0
GRCh38	PTPRS	D12_12345_1234556_Thyroid_S9	p.Leu1757=	ENSP00000262963.8:p.Leu1757=	chr19	5210771	5210771.0	G	A	A	5210771	.	G	A	.	PASS	NM_002850	A	synonymous_variant	LOW	PTPRS	ENSG00000105426	Transcript	ENST00000262963	protein_coding	34/38		c.5269C>T	5512	5269	1757	L	Ctg/Ttg	rs1143698&COSV53614029		-1		SNV	HGNC	HGNC:9681	YES	MANE_Select	NM_002850.4		5		CCDS45930.1	ENSP00000262963	Q13332.220	G8JL96.86	UPI000059D63E	Q13332-1					PDB-ENSP_mappings:2fh7.A&Gene3D:3.90.190.10&PDB-ENSP_mappings:4bpc.A&AFDB-ENSP_mappings:AF-Q13332-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF00102&PROSITE_profiles:PS50055&SMART:SM00194&Superfamily:SSF52799&CDD:cd14627			0.3351	0.5545	0.3516	0.0992	0.2714	0.3354	0.2729	0.4934	0.2946	0.2717	0.1102	0.2723	0.2654	0.2709	0.2777	0.274	0.3294	0.4761	0.1659	0.3125	0.267	0.1132	0.2839	0.2925	0.2761	0.3198	0.2861	0.5545	AFR		0&1	0&1							FAIL	27	6	6	30	0.00	0.01	0.00	0.00	PTPRS		3.7800e-01																																																											1126					0.998							245.79	v6.1	Unknown		True	PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:L1757= mutant UNKNOWN.	False	The PTPRS ENSP00000262963.8:l1757= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	5210782						True	False	False	Unknown								False	False		PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	The PTPRS ENSP00000262963.8:l1757= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:L1757= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PTPRS	5802.0	ENSP00000262963.8:L1757=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRS"",""entrezGeneId"":5802,""alteration"":""ENSP00000262963.8:L1757="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others."",""variantSummary"":""The PTPRS ENSP00000262963.8:l1757= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:L1757= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						0,1124	0,596	0,528	0|1	0,0,525,599	AGC	0.00	0.00	0.00		5210762	0,0,521,603	57.73		1.0
GRCh38	PTPRS	D12_12345_1234556_Thyroid_S9	p.V1649M	ENSP00000262963.8:p.Val1649Met	chr19	5212075	5212075.0	C	T	T	5212075	.	C	T	.	PASS	NM_002850	T	missense_variant	MODERATE	PTPRS	ENSG00000105426	Transcript	ENST00000262963	protein_coding	32/38		c.4945G>A	5188	4945	1649	V/M	Gtg/Atg	rs139009302		-1		SNV	HGNC	HGNC:9681	YES	MANE_Select	NM_002850.4		5		CCDS45930.1	ENSP00000262963	Q13332.220	G8JL96.86	UPI000059D63E	Q13332-1			deleterious_low_confidence(0)	probably_damaging(0.996)	PDB-ENSP_mappings:2fh7.A&Gene3D:3.90.190.10&PDB-ENSP_mappings:4bpc.A&AFDB-ENSP_mappings:AF-Q13332-F1&Phobius:CYTOPLASMIC_DOMAIN&PANTHER:PTHR46957&SMART:SM00194&Superfamily:SSF52799&Superfamily:SSF52799&CDD:cd14625			0.0006	0	0	0	0.003	0	0.0004885	0.0001195	0.0001118	0	0	0.0006765	0	0.0005836	0.0003146	1.159e-05	0.0002822	0.0002164	0	6.532e-05	0	0	0.0007527	0	0.0003674	0	0	0.003	EUR										FAIL	-19	45	-1	-19	0.00	0.00	0.00	0.00	PTPRS	0.244	3.7800e-01																																																											1069					1							246.64	v6.1	Unknown		True	PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:V1649M mutant UNKNOWN.	False	The PTPRS ENSP00000262963.8:v1649m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	5212086						True	False	False	Unknown								False	False		PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	The PTPRS ENSP00000262963.8:v1649m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:V1649M mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PTPRS	5802.0	ENSP00000262963.8:V1649M			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRS"",""entrezGeneId"":5802,""alteration"":""ENSP00000262963.8:V1649M"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others."",""variantSummary"":""The PTPRS ENSP00000262963.8:v1649m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:V1649M mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						543,526	287,261	256,265	0/1	261,282,249,277	ACG	0.00	0.00	0.00			275,268,250,276	49.86		0.4920486435921422
GRCh38	PTPRS	D12_12345_1234556_Thyroid_S9	p.Pro1579=	ENSP00000262963.8:p.Pro1579=	chr19	5212369	5212369.0	C	T	T	5212369	.	C	T	.	PASS	NM_002850	T	synonymous_variant	LOW	PTPRS	ENSG00000105426	Transcript	ENST00000262963	protein_coding	31/38		c.4737G>A	4980	4737	1579	P	ccG/ccA	rs1064300&COSV53608907		-1		SNV	HGNC	HGNC:9681	YES	MANE_Select	NM_002850.4		5		CCDS45930.1	ENSP00000262963	Q13332.220	G8JL96.86	UPI000059D63E	Q13332-1					PDB-ENSP_mappings:2fh7.A&Gene3D:3.90.190.10&PDB-ENSP_mappings:4bpc.A&AFDB-ENSP_mappings:AF-Q13332-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF00102&PROSITE_profiles:PS50055&PROSITE_profiles:PS50056&PANTHER:PTHR46957&SMART:SM00194&SMART:SM00404&Superfamily:SSF52799&CDD:cd14625			0.3175	0.4372	0.415	0.0556	0.3469	0.3262	0.3186	0.4022	0.3819	0.3921	0.0675	0.3965	0.3495	0.3188	0.3183	0.294	0.3452	0.3908	0.2982	0.3731	0.3873	0.06925	0.4118	0.3707	0.3226	0.3607	0.3038	0.4372	AFR		0&1	0&1							FAIL	-5	16	-28	-32	0.00	0.00	0.00	0.00	PTPRS		3.7800e-01																																																											990					0.999							246.3	v6.1	Unknown		True	PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:P1579= mutant UNKNOWN.	False	The PTPRS ENSP00000262963.8:p1579= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	5212380						True	False	False	Unknown								False	False		PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	The PTPRS ENSP00000262963.8:p1579= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:P1579= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PTPRS	5802.0	ENSP00000262963.8:P1579=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRS"",""entrezGeneId"":5802,""alteration"":""ENSP00000262963.8:P1579="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others."",""variantSummary"":""The PTPRS ENSP00000262963.8:p1579= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:P1579= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						0,989	0,467	0,522	0/1	0,0,529,460	GCG	0.00	0.00	0.00			0,0,493,496	64.73		1.0
GRCh38	PTPRS	D12_12345_1234556_Thyroid_S9	p.C1457R	ENSP00000262963.8:p.Cys1457Arg	chr19	5214686	5214686.0	A	G	G	5214686	.	A	G	.	PASS	NM_002850	G	missense_variant	MODERATE	PTPRS	ENSG00000105426	Transcript	ENST00000262963	protein_coding	29/38		c.4369T>C	4612	4369	1457	C/R	Tgt/Cgt	rs4807697&COSV107304190		-1		SNV	HGNC	HGNC:9681	YES	MANE_Select	NM_002850.4		5		CCDS45930.1	ENSP00000262963	Q13332.220	G8JL96.86	UPI000059D63E	Q13332-1			tolerated_low_confidence(1)	benign(0)	PDB-ENSP_mappings:2fh7.A&Gene3D:3.90.190.10&PDB-ENSP_mappings:4bpc.A&AFDB-ENSP_mappings:AF-Q13332-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF00102&PROSITE_profiles:PS50055&PANTHER:PTHR46957&SMART:SM00194&Superfamily:SSF52799&CDD:cd14625			0.9990	1	0.9986	1	0.997	0.999	0.9981	0.9996	0.9995	1	1	1	0.9993	0.9976	0.9985	0.9992	0.9987	0.9993	1	0.9988	1	0.9998	1	1	0.9979	0.9986	0.9992	1	AFR&EAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN&gnomADg_MID		0&1	0&1							FAIL	-6	-27	-10	2	0.04	0.16	0.00	0.00	PTPRS	0.184	3.7800e-01																																																											1013					1							246.38	v6.1	Unknown		True	PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:C1457R mutant UNKNOWN.	False	The PTPRS ENSP00000262963.8:c1457r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	5214697						True	False	False	Unknown								False	False		PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	The PTPRS ENSP00000262963.8:c1457r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:C1457R mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PTPRS	5802.0	ENSP00000262963.8:C1457R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRS"",""entrezGeneId"":5802,""alteration"":""ENSP00000262963.8:C1457R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others."",""variantSummary"":""The PTPRS ENSP00000262963.8:c1457r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:C1457R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						0,1013	0,512	0,501	0/1	0,0,485,528	CAC	.	.	.			0,0,446,567	64.73		1.0
GRCh38	PTPRS	D12_12345_1234556_Thyroid_S9			chr19	5223302	5223302.0	G	A	A	5223302	.	G	A	.	PASS	NM_002850	A	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	PTPRS	ENSG00000105426	Transcript	ENST00000262963	protein_coding		17/37	c.2495-5C>T						rs150239914		-1		SNV	HGNC	HGNC:9681	YES	MANE_Select	NM_002850.4		5		CCDS45930.1	ENSP00000262963	Q13332.220	G8JL96.86	UPI000059D63E	Q13332-1								0.0106	0.0023	0.0274	0	0.0298	0.001	0.0236	0.004268	0.01944	0.02545	2.988e-05	0.01596	0.005882	0.02656	0.02348	0.001862	0.01742	0.006254	0	0.02541	0.02362	0.0001932	0.02117	0.006803	0.02403	0.0232	0.00207	0.0298	EUR										FAIL	-5	-37	8	-27	0.00	0.00	0.00	0.00	PTPRS		3.7800e-01																																																											408					0.998							249.7													chr19	5223313																																																	True	True	False	Unknown		Unknown																						196,211	98,110	98,101	0/1	93,103,100,111	CGG	0.00	0.00	0.00			47,149,59,152	49.44		0.5184275184275184
GRCh38	PTPRS	D12_12345_1234556_Thyroid_S9	p.Ala87=	ENSP00000262963.8:p.Ala87=	chr19	5273560	5273560.0	T	G	G	5273560	.	T	G	.	PASS	NM_002850	G	synonymous_variant	LOW	PTPRS	ENSG00000105426	Transcript	ENST00000262963	protein_coding	4/38		c.261A>C	504	261	87	A	gcA/gcC	rs1141371&COSV53618155		-1		SNV	HGNC	HGNC:9681	YES	MANE_Select	NM_002850.4		5		CCDS45930.1	ENSP00000262963	Q13332.220	G8JL96.86	UPI000059D63E	Q13332-1					Gene3D:2.60.40.10&PDB-ENSP_mappings:2yd2.A&PDB-ENSP_mappings:2yd3.A&PDB-ENSP_mappings:2yd9.A&PDB-ENSP_mappings:4pbx.A&AFDB-ENSP_mappings:AF-Q13332-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF07679&PROSITE_profiles:PS50835&SMART:SM00408&SMART:SM00409&Superfamily:SSF48726			0.1635	0.2943	0.1527	0.002	0.2266	0.0961	0.2077	0.2636	0.1276	0.323	0.0007053	0.1526	0.2802	0.2221	0.2114	0.1303	0.2157	0.2656	0.1689	0.1735	0.3182	0.001738	0.1381	0.3367	0.2237	0.2403	0.1256	0.3367	gnomADg_MID	benign	0&1	1&1	20111712						FAIL	23	-2	-50	-2	0.00	0.00	0.02	0.00	PTPRS		3.7800e-01	1263463	0.23774		0.16354	1252080	not_provided		MedGen:C3661900		NC_000019.10:g.5273560T>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001889354&SCV005309655	single_nucleotide_variant	SO:0001483	ClinGen:CA9110794		PTPRS:5802	SO:0001819&synonymous_variant										1	1141371																											959					0.997							246.3	v6.1	Unknown		True	PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:A87= mutant UNKNOWN.	False	The PTPRS ENSP00000262963.8:a87= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	5273571						True	False	False	Unknown								False	False		PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others.	The PTPRS ENSP00000262963.8:a87= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:A87= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PTPRS	5802.0	ENSP00000262963.8:A87=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRS"",""entrezGeneId"":5802,""alteration"":""ENSP00000262963.8:A87="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRS encodes a tyrosine phosphatase involved in regulation of synapse structure, function and plasticity in the central nervous system. Mutations, altered expression and microdeletions of PTPRS are found in colorectal, head and neck and ovarian cancers, among others."",""variantSummary"":""The PTPRS ENSP00000262963.8:a87= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRS ENSP00000262963.8:A87= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						504,452	278,234	226,218	0/1	243,261,224,228	CTG	.	.	.			215,289,210,242	32.43		0.47280334728033474
GRCh38	INSR	D12_12345_1234556_Thyroid_S9	p.His1085=	ENSP00000303830.4:p.His1085=	chr19	7125286	7125286.0	G	A	A	7125286	.	G	A	.	PASS	NM_000208	A	synonymous_variant	LOW	INSR	ENSG00000171105	Transcript	ENST00000302850	protein_coding	17/22		c.3255C>T	3778	3255	1085	H	caC/caT	rs1799817&CM092295&COSV57158382		-1		SNV	HGNC	HGNC:6091	YES	MANE_Select	NM_000208.4		1	A2	CCDS12176.1	ENSP00000303830	P06213.288		UPI000020324D	P06213-1		1			PDB-ENSP_mappings:1gag.A&PDB-ENSP_mappings:1i44.A&PDB-ENSP_mappings:1ir3.A&PDB-ENSP_mappings:1irk.A&PDB-ENSP_mappings:1p14.A&PDB-ENSP_mappings:1rqq.A&PDB-ENSP_mappings:1rqq.B&PDB-ENSP_mappings:2auh.A&PDB-ENSP_mappings:2b4s.B&PDB-ENSP_mappings:2b4s.D&PDB-ENSP_mappings:2z8c.A&Gene3D:3.30.200.20&PDB-ENSP_mappings:3bu3.A&PDB-ENSP_mappings:3bu5.A&PDB-ENSP_mappings:3bu6.A&PDB-ENSP_mappings:3ekk.A&PDB-ENSP_mappings:3ekn.A&PDB-ENSP_mappings:3eta.A&PDB-ENSP_mappings:3eta.B&PDB-ENSP_mappings:4ibm.A&PDB-ENSP_mappings:4ibm.B&PDB-ENSP_mappings:4xlv.A&PDB-ENSP_mappings:5e1s.A&PDB-ENSP_mappings:5hhw.A&PDB-ENSP_mappings:6pxv.A&PDB-ENSP_mappings:6pxv.C&PDB-ENSP_mappings:6pxw.A&PDB-ENSP_mappings:6pxw.B&PDB-ENSP_mappings:7bw7.A&PDB-ENSP_mappings:7bw7.C&PDB-ENSP_mappings:7bw8.A&PDB-ENSP_mappings:7bw8.C&PDB-ENSP_mappings:7bwa.A&PDB-ENSP_mappings:7bwa.C&PDB-ENSP_mappings:7pg0.A&PDB-ENSP_mappings:7pg0.B&PDB-ENSP_mappings:7pg2.A&PDB-ENSP_mappings:7pg2.B&PDB-ENSP_mappings:7pg3.A&PDB-ENSP_mappings:7pg3.B&PDB-ENSP_mappings:7pg4.A&PDB-ENSP_mappings:7pg4.B&PDB-ENSP_mappings:8dwn.A&PDB-ENSP_mappings:8u4b.A&PDB-ENSP_mappings:8u4b.B&PDB-ENSP_mappings:8u4c.A&PDB-ENSP_mappings:8u4c.B&PDB-ENSP_mappings:8u4e.A&PDB-ENSP_mappings:8u4e.B&PDB-ENSP_mappings:8vjb.A&PDB-ENSP_mappings:8vjb.B&PDB-ENSP_mappings:8vjc.A&PDB-ENSP_mappings:8vjc.B&AFDB-ENSP_mappings:AF-P06213-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF07714&PIRSF:PIRSF000620&PROSITE_profiles:PS50011&PANTHER:PTHR24416&SMART:SM00219&Superfamily:SSF56112&CDD:cd05061			0.2925	0.23	0.232	0.4464	0.2157	0.3405	0.1985	0.2269	0.2516	0.1486	0.3692	0.1838	0.2274	0.1815	0.2138	0.3125	0.2095	0.2289	0.114	0.2274	0.1572	0.4016	0.1832	0.2721	0.1789	0.2063	0.3231	0.4464	EAS	benign	0&1&1	1&1&1	18603647&34563259&20436251&21474949&18212354&29622662&19387820&30596735&33748128&34403018&25557790&36011374&21082232&21637951&17348446&34784930&26252243&21824047&31211453&32050935&26077721&18455362&21645371&22775283&31837364&33033446&36013384&25927028&36631836&35327342&24639745&35972046&25622255&29264459&35355907&34912452&25600292&27141540&33206859&35627115&35740328&34949963&36449775&31435596&25867326&33746952&17658524&16473310&38389245&38136416						FAIL	0	17	0	-3	0.00	0.00	0.01	0.00	INSR		5.5600e-01	194701	0.19084	0.22732	0.29253	191864	Rabson-Mendenhall_syndrome&Insulin-resistant_diabetes_mellitus_AND_acanthosis_nigricans&Leprechaunism_syndrome&not_specified&not_provided		MONDO:MONDO:0009874&MedGen:C0271695&OMIM:262190&Orphanet:769&MONDO:MONDO:0012520&MedGen:C0342278&OMIM:610549&Orphanet:2297&MONDO:MONDO:0009517&MedGen:C0265344&OMIM:246200&Orphanet:508&MedGen:CN169374&MedGen:C3661900		NC_000019.10:g.7125286G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000226561&SCV000415450&SCV000415451&SCV000415452&SCV000604049&SCV001892014&SCV002407518&SCV005312521	single_nucleotide_variant	SO:0001483	ClinGen:CA201311		INSR:3643	SO:0001819&synonymous_variant										1	1799817																											1000					0.999							245.08	v6.1	Unknown		True	INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:H1085= mutant UNKNOWN.	False	The INSR ENSP00000303830.4:h1085= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	7125297						True	False	False	Unknown								False	False		INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome.	The INSR ENSP00000303830.4:h1085= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:H1085= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	INSR	3643.0	ENSP00000303830.4:H1085=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""INSR"",""entrezGeneId"":3643,""alteration"":""ENSP00000303830.4:H1085="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome."",""variantSummary"":""The INSR ENSP00000303830.4:h1085= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:H1085= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						517,482	262,242	255,240	0/1	280,237,259,223	CGT	0.00	0.00	0.00			287,230,289,193	40.92		0.4824824824824825
GRCh38	INSR	D12_12345_1234556_Thyroid_S9	p.Phe669=	ENSP00000303830.4:p.Phe669=	chr19	7163054	7163054.0	G	A	A	7163054	.	G	A	.	PASS	NM_000208	A	synonymous_variant	LOW	INSR	ENSG00000171105	Transcript	ENST00000302850	protein_coding	9/22		c.2007C>T	2530	2007	669	F	ttC/ttT	rs2962&COSV57158641		-1		SNV	HGNC	HGNC:6091	YES	MANE_Select	NM_000208.4		1	A2	CCDS12176.1	ENSP00000303830	P06213.288		UPI000020324D	P06213-1		1			Gene3D:2.60.40.10&PDB-ENSP_mappings:4zxb.E&PDB-ENSP_mappings:6ce7.A&PDB-ENSP_mappings:6ce7.B&PDB-ENSP_mappings:6ce9.A&PDB-ENSP_mappings:6ce9.B&PDB-ENSP_mappings:6ceb.A&PDB-ENSP_mappings:6ceb.B&PDB-ENSP_mappings:6hn4.E&PDB-ENSP_mappings:6hn4.F&PDB-ENSP_mappings:6hn5.E&PDB-ENSP_mappings:6hn5.F&PDB-ENSP_mappings:6pxv.A&PDB-ENSP_mappings:6pxv.C&PDB-ENSP_mappings:6pxw.A&PDB-ENSP_mappings:6pxw.B&PDB-ENSP_mappings:6sof.A&PDB-ENSP_mappings:6sof.C&PDB-ENSP_mappings:7bw7.A&PDB-ENSP_mappings:7bw7.C&PDB-ENSP_mappings:7bw8.A&PDB-ENSP_mappings:7bw8.C&PDB-ENSP_mappings:7bwa.A&PDB-ENSP_mappings:7bwa.C&PDB-ENSP_mappings:7md4.A&PDB-ENSP_mappings:7md4.B&PDB-ENSP_mappings:7md5.A&PDB-ENSP_mappings:7md5.B&PDB-ENSP_mappings:7mqo.E&PDB-ENSP_mappings:7mqo.F&PDB-ENSP_mappings:7mqr.E&PDB-ENSP_mappings:7mqr.F&PDB-ENSP_mappings:7mqs.E&PDB-ENSP_mappings:7mqs.F&PDB-ENSP_mappings:7pg0.A&PDB-ENSP_mappings:7pg0.B&PDB-ENSP_mappings:7pg2.A&PDB-ENSP_mappings:7pg2.B&PDB-ENSP_mappings:7pg3.A&PDB-ENSP_mappings:7pg3.B&PDB-ENSP_mappings:7pg4.A&PDB-ENSP_mappings:7pg4.B&PDB-ENSP_mappings:7qid.A&PDB-ENSP_mappings:7qid.C&PDB-ENSP_mappings:7s0q.B&PDB-ENSP_mappings:7s8v.B&PDB-ENSP_mappings:7u6d.B&PDB-ENSP_mappings:7u6d.C&PDB-ENSP_mappings:7u6e.E&PDB-ENSP_mappings:7u6e.F&PDB-ENSP_mappings:7yq3.E&PDB-ENSP_mappings:7yq3.F&PDB-ENSP_mappings:7yq4.E&PDB-ENSP_mappings:7yq4.F&PDB-ENSP_mappings:7yq5.E&PDB-ENSP_mappings:7yq5.F&PDB-ENSP_mappings:7yq6.E&PDB-ENSP_mappings:7yq6.F&PDB-ENSP_mappings:8guy.E&PDB-ENSP_mappings:8guy.F&PDB-ENSP_mappings:8u4b.A&PDB-ENSP_mappings:8u4b.B&PDB-ENSP_mappings:8u4c.A&PDB-ENSP_mappings:8u4c.B&PDB-ENSP_mappings:8u4e.A&PDB-ENSP_mappings:8u4e.B&PDB-ENSP_mappings:8vjb.A&PDB-ENSP_mappings:8vjb.B&PDB-ENSP_mappings:8vjc.A&PDB-ENSP_mappings:8vjc.B&AFDB-ENSP_mappings:AF-P06213-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000620&PROSITE_profiles:PS50853&PANTHER:PTHR24416&SMART:SM00060&Superfamily:SSF49265			0.0633	0.1112	0.036	0.0337	0.0746	0.0368	0.07042	0.1106	0.04403	0.06601	0.02177	0.06346	0.05055	0.07429	0.07207	0.04675	0.08068	0.1125	0.211	0.05253	0.06048	0.02558	0.06819	0.02721	0.0764	0.06416	0.04293	0.211	gnomADg_AMI	benign	0&1	1&1	34563259&27589061&24194259&20493471&25622255&25600292						FAIL	-22	20	11	-22	0.00	0.00	0.00	0.00	INSR		5.5600e-01	330466	0.08765	0.06668	0.06330	334664	Leprechaunism_syndrome&Rabson-Mendenhall_syndrome&not_provided&Insulin-resistant_diabetes_mellitus_AND_acanthosis_nigricans		MONDO:MONDO:0009517&MedGen:C0265344&OMIM:246200&Orphanet:508&MONDO:MONDO:0009874&MedGen:C0271695&OMIM:262190&Orphanet:769&MedGen:C3661900&MONDO:MONDO:0012520&MedGen:C0342278&OMIM:610549&Orphanet:2297		NC_000019.10:g.7163054G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000415526&SCV000415527&SCV000415528&SCV000884038&SCV002380574&SCV005312543	single_nucleotide_variant	SO:0001483	ClinGen:CA9135706		INSR:3643	SO:0001819&synonymous_variant										1	2962																											739					0.996							247.36	v6.1	Unknown		True	INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:F669= mutant UNKNOWN.	False	The INSR ENSP00000303830.4:f669= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	7163065						True	False	False	Unknown								False	False		INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome.	The INSR ENSP00000303830.4:f669= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:F669= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	INSR	3643.0	ENSP00000303830.4:F669=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""INSR"",""entrezGeneId"":3643,""alteration"":""ENSP00000303830.4:F669="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome."",""variantSummary"":""The INSR ENSP00000303830.4:f669= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:F669= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						394,342	204,176	190,166	0/1	190,204,170,172	CGA	0.00	0.00	0.00			204,190,182,160	27.72		0.46467391304347827
GRCh38	INSR	D12_12345_1234556_Thyroid_S9	p.Asp546=	ENSP00000303830.4:p.Asp546=	chr19	7166377	7166377.0	G	A	A	7166377	.	G	A	.	PASS	NM_000208	A	synonymous_variant	LOW	INSR	ENSG00000171105	Transcript	ENST00000302850	protein_coding	8/22		c.1638C>T	2161	1638	546	D	gaC/gaT	rs2229429&COSV57158665		-1		SNV	HGNC	HGNC:6091	YES	MANE_Select	NM_000208.4		1	A2	CCDS12176.1	ENSP00000303830	P06213.288		UPI000020324D	P06213-1		1			Gene3D:2.60.40.10&PDB-ENSP_mappings:4zxb.E&PDB-ENSP_mappings:5kqv.E&PDB-ENSP_mappings:5kqv.F&PDB-ENSP_mappings:6ce7.A&PDB-ENSP_mappings:6ce7.B&PDB-ENSP_mappings:6ce9.A&PDB-ENSP_mappings:6ce9.B&PDB-ENSP_mappings:6ceb.A&PDB-ENSP_mappings:6ceb.B&PDB-ENSP_mappings:6hn4.E&PDB-ENSP_mappings:6hn4.F&PDB-ENSP_mappings:6hn5.E&PDB-ENSP_mappings:6hn5.F&PDB-ENSP_mappings:6pxv.A&PDB-ENSP_mappings:6pxv.C&PDB-ENSP_mappings:6pxw.A&PDB-ENSP_mappings:6pxw.B&PDB-ENSP_mappings:6sof.A&PDB-ENSP_mappings:6sof.C&PDB-ENSP_mappings:7bw7.A&PDB-ENSP_mappings:7bw7.C&PDB-ENSP_mappings:7bw8.A&PDB-ENSP_mappings:7bw8.C&PDB-ENSP_mappings:7bwa.A&PDB-ENSP_mappings:7bwa.C&PDB-ENSP_mappings:7md4.A&PDB-ENSP_mappings:7md4.B&PDB-ENSP_mappings:7md5.A&PDB-ENSP_mappings:7md5.B&PDB-ENSP_mappings:7mqo.E&PDB-ENSP_mappings:7mqo.F&PDB-ENSP_mappings:7mqr.E&PDB-ENSP_mappings:7mqr.F&PDB-ENSP_mappings:7mqs.E&PDB-ENSP_mappings:7mqs.F&PDB-ENSP_mappings:7pg0.A&PDB-ENSP_mappings:7pg0.B&PDB-ENSP_mappings:7pg2.A&PDB-ENSP_mappings:7pg2.B&PDB-ENSP_mappings:7pg3.A&PDB-ENSP_mappings:7pg3.B&PDB-ENSP_mappings:7pg4.A&PDB-ENSP_mappings:7pg4.B&PDB-ENSP_mappings:7qid.A&PDB-ENSP_mappings:7qid.C&PDB-ENSP_mappings:7s0q.B&PDB-ENSP_mappings:7s8v.B&PDB-ENSP_mappings:7u6d.B&PDB-ENSP_mappings:7u6d.C&PDB-ENSP_mappings:7u6e.E&PDB-ENSP_mappings:7u6e.F&PDB-ENSP_mappings:7yq3.E&PDB-ENSP_mappings:7yq3.F&PDB-ENSP_mappings:7yq4.E&PDB-ENSP_mappings:7yq4.F&PDB-ENSP_mappings:7yq5.E&PDB-ENSP_mappings:7yq5.F&PDB-ENSP_mappings:7yq6.E&PDB-ENSP_mappings:7yq6.F&PDB-ENSP_mappings:8guy.E&PDB-ENSP_mappings:8guy.F&PDB-ENSP_mappings:8u4b.A&PDB-ENSP_mappings:8u4b.B&PDB-ENSP_mappings:8u4c.A&PDB-ENSP_mappings:8u4c.B&PDB-ENSP_mappings:8u4e.A&PDB-ENSP_mappings:8u4e.B&PDB-ENSP_mappings:8vjb.A&PDB-ENSP_mappings:8vjb.B&PDB-ENSP_mappings:8vjc.A&PDB-ENSP_mappings:8vjc.B&AFDB-ENSP_mappings:AF-P06213-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000620&PANTHER:PTHR24416&SMART:SM00060&Superfamily:SSF49265			0.2566	0.4834	0.1441	0.0655	0.1909	0.2945	0.1989	0.4418	0.1387	0.2276	0.06008	0.137	0.246	0.1947	0.2134	0.2703	0.2552	0.4331	0.4407	0.1805	0.222	0.06482	0.134	0.2279	0.1951	0.2605	0.2693	0.4834	AFR	benign	0&1	1&1	24033266&25266237&35742925&27840822&25622255&36982665&37927197						FAIL	-27	17	-7	-33	0.00	0.01	0.00	0.00	INSR		5.5600e-01	330470	0.27764		0.25659	344495	not_specified&Rabson-Mendenhall_syndrome&Insulin-resistant_diabetes_mellitus_AND_acanthosis_nigricans&not_provided&Leprechaunism_syndrome		MedGen:CN169374&MONDO:MONDO:0009874&MedGen:C0271695&OMIM:262190&Orphanet:769&MONDO:MONDO:0012520&MedGen:C0342278&OMIM:610549&Orphanet:2297&MedGen:C3661900&MONDO:MONDO:0009517&MedGen:C0265344&OMIM:246200&Orphanet:508		NC_000019.10:g.7166377G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000415541&SCV000415542&SCV000415543&SCV000539388&SCV000604038&SCV001862340&SCV002372604&SCV005312557	single_nucleotide_variant	SO:0001483	ClinGen:CA9135776		INSR:3643	SO:0001819&synonymous_variant										1	2229429																											890					0.992							246.61	v6.1	Unknown		True	INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome.	False	08/21/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:D546= mutant UNKNOWN.	False	The INSR ENSP00000303830.4:d546= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	7166388						True	False	False	Unknown								False	False		INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome.	The INSR ENSP00000303830.4:d546= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:D546= mutant UNKNOWN.						v6.1	08/21/2019		GRCh38	INSR	3643.0	ENSP00000303830.4:D546=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""INSR"",""entrezGeneId"":3643,""alteration"":""ENSP00000303830.4:D546="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""INSR, a receptor tyrosine kinase involved in insulin signaling, is altered by chromosomal rearrangement in colorectal cancers. Germline mutations of INSR are associated with Donohue syndrome."",""variantSummary"":""The INSR ENSP00000303830.4:d546= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INSR ENSP00000303830.4:D546= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/21/2019""}"	True	True	False	Unknown		Unknown																						464,419	238,230	226,189	0/1	253,211,199,220	CGT	0.00	0.00	0.00			217,247,180,239	33.8		0.47451868629671573
GRCh38	INSR	D12_12345_1234556_Thyroid_S9	p.A2G	ENSP00000303830.4:p.Ala2Gly	chr19	7293887	7293887.0	G	C	C	7293887	.	G	C	.	PASS	NM_000208	C	missense_variant	MODERATE	INSR	ENSG00000171105	Transcript	ENST00000302850	protein_coding	1/22		c.5C>G	528	5	2	A/G	gCc/gGc	rs7508518&COSV105137469		-1		SNV	HGNC	HGNC:6091	YES	MANE_Select	NM_000208.4		1	A2	CCDS12176.1	ENSP00000303830	P06213.288		UPI000020324D	P06213-1		1	tolerated_low_confidence(1)	unknown(0)	PDB-ENSP_mappings:7pg0.A&PDB-ENSP_mappings:7pg0.B&PDB-ENSP_mappings:7pg2.A&PDB-ENSP_mappings:7pg2.B&PDB-ENSP_mappings:7pg3.A&PDB-ENSP_mappings:7pg3.B&PDB-ENSP_mappings:7pg4.A&PDB-ENSP_mappings:7pg4.B&PDB-ENSP_mappings:8u4b.A&PDB-ENSP_mappings:8u4b.B&PDB-ENSP_mappings:8u4c.A&PDB-ENSP_mappings:8u4c.B&PDB-ENSP_mappings:8u4e.A&PDB-ENSP_mappings:8u4e.B&PDB-ENSP_mappings:8vjb.A&PDB-ENSP_mappings:8vjb.B&PDB-ENSP_mappings:8vjc.A&PDB-ENSP_mappings:8vjc.B&AFDB-ENSP_mappings:AF-P06213-F1&Phobius:SIGNAL_PEPTIDE&Phobius:SIGNAL_PEPTIDE_N_REGION&Cleavage_site_(Signalp):SignalP-noTM			1.0000	1	1	1	1	1	1	1	0.9999	1	0.9996	1	1	1	1	1	1	1	1	0.9999	1	0.999	1	1	1	1	1	1	AFR&AMR&EAS&EUR&SAS&gnomADe_AFR&gnomADe_ASJ&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_REMAINING&gnomADe_SAS&gnomADg_AFR&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_REMAINING&gnomADg_SAS	benign	0&1	1&1	25741868&24033266&27840822&17560154						FAIL	-48	6	1	2	0.00	0.00	0.00	0.00	INSR	0.163	5.5600e-01	193063		1.00000	1.00000	190228	not_provided&Rabson-Mendenhall_syndrome&Insulin-resistant_diabetes_mellitus_AND_acanthosis_nigricans&Leprechaunism_syndrome&not_specified		MedGen:C3661900&MONDO:MONDO:0009874&MedGen:C0271695&OMIM:262190&Orphanet:769&MONDO:MONDO:0012520&MedGen:C0342278&OMIM:610549&Orphanet:2297&MONDO:MONDO:0009517&MedGen:C0265344&OMIM:246200&Orphanet:508&MedGen:CN169374		NC_000019.10:g.7293887G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000224169&SCV000247622&SCV000415592&SCV000415593&SCV000415594&SCV000539389&SCV001140965&SCV001473485&SCV001756311&SCV001981412&SCV001981423&SCV002401291&SCV005312584	single_nucleotide_variant	SO:0001483	ClinGen:CA200288&UniProtKB:P06213																																																																																																																																															0,8	0,5	0,3	0/1	0,0,5,3	GGC	.	.	.			0,0,4,4	54.7		1.0
GRCh38	DNMT1	D12_12345_1234556_Thyroid_S9	p.Thr594=	ENSP00000352516.3:p.Thr594=	chr19	10154636	10154636.0	T	C	C	10154636	.	T	C	.	PASS	NM_001130823	C	synonymous_variant	LOW	DNMT1	ENSG00000130816	Transcript	ENST00000359526	protein_coding	21/41		c.1782A>G	1836	1782	594	T	acA/acG	rs721186&COSV108162363		-1		SNV	HGNC	HGNC:2976	YES	MANE_Select	NM_001130823.3		1		CCDS45958.1	ENSP00000352516	P26358.245		UPI000002A823	P26358-2		1			PANTHER:PTHR10629&PIRSF:PIRSF037404&Gene3D:1.10.10.2230&AFDB-ENSP_mappings:AF-P26358-F1			0.9958	0.9985	0.9914	1	0.9871	1	0.9877	0.998	0.9915	0.986	1	0.9895	0.9929	0.9859	0.9882	0.9988	0.9909	0.9972	0.9868	0.9927	0.9844	1	0.992	1	0.9854	0.9915	0.999	1	EAS&SAS&gnomADe_EAS&gnomADg_EAS&gnomADg_MID	benign	0&1	1&1	25741868&22440650&27156515&22942708&21347319&27087738&23365052&27789275						FAIL	-1	-25	0	46	0.00	0.00	0.00	0.00	DNMT1		1.5000e-01	257537	0.98970		0.99581	256732	not_specified&Hereditary_sensory_neuropathy-deafness-dementia_syndrome&Autosomal_dominant_cerebellar_ataxia&_deafness_and_narcolepsy&not_provided		MedGen:CN169374&MONDO:MONDO:0013584&MedGen:C3279885&OMIM:614116&Orphanet:456318&MONDO:MONDO:0011397&MedGen:C3807295&OMIM:604121&Orphanet:314404&MedGen:C3661900		NC_000019.10:g.10154636T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306765&SCV000410240&SCV001717269&SCV001751557&SCV001875655&SCV001875658&SCV005309710	single_nucleotide_variant	SO:0001483	ClinGen:CA9188220		DNMT1:1786	SO:0001819&synonymous_variant										1	721186																											1133					0.997							247.56	v6.1	Unknown		True	DNMT1, a DNA methyltransferase, is infrequently altered in various cancer types.	False	10/19/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNMT1 ENSP00000352516.3:T594= mutant UNKNOWN.	False	The DNMT1 ENSP00000352516.3:t594= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	10265312						True	False	False	Unknown								False	False		DNMT1, a DNA methyltransferase, is infrequently altered in various cancer types.	The DNMT1 ENSP00000352516.3:t594= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNMT1 ENSP00000352516.3:T594= mutant UNKNOWN.						v6.1	10/19/2018		GRCh38	DNMT1	1786.0	ENSP00000352516.3:T594=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DNMT1"",""entrezGeneId"":1786,""alteration"":""ENSP00000352516.3:T594="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DNMT1, a DNA methyltransferase, is infrequently altered in various cancer types."",""variantSummary"":""The DNMT1 ENSP00000352516.3:t594= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNMT1 ENSP00000352516.3:T594= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/19/2018""}"	True	True	False	Unknown		Unknown																						0,1130	0,618	0,512	0/1	0,0,548,582	GTG	.	.	.			0,0,568,562	64.73		1.0
GRCh38	DNMT1	D12_12345_1234556_Thyroid_S9	p.Pro463=	ENSP00000352516.3:p.Pro463=	chr19	10156401	10156401.0	T	C	C	10156401	.	T	C	.	PASS	NM_001130823	C	synonymous_variant	LOW	DNMT1	ENSG00000130816	Transcript	ENST00000359526	protein_coding	18/41		c.1389A>G	1443	1389	463	P	ccA/ccG	rs2228611&COSV61577791		-1		SNV	HGNC	HGNC:2976	YES	MANE_Select	NM_001130823.3		1		CCDS45958.1	ENSP00000352516	P26358.245		UPI000002A823	P26358-2		1			PIRSF:PIRSF037404&Pfam:PF12047&AFDB-ENSP_mappings:AF-P26358-F1			0.5339	0.5204	0.4539	0.6488	0.4612	0.5654	0.5038	0.5097	0.4824	0.5543	0.622	0.5238	0.5617	0.4948	0.5121	0.5372	0.5105	0.5089	0.5595	0.4932	0.5557	0.6747	0.5155	0.534	0.4973	0.4914	0.5466	0.6747	gnomADg_EAS	benign	0&1	1&1	25741868&31516756&27156515&22103680&23049933&24859147&23666104&30111769&22942708&27292127&27554481&27699015&28940947&32118373&28323001&32258570&30852420&28855605&21170044&27314012&27281235&21247820&29313974&27087738&30950914&20920981&22382075&25493477&26211580&27237591&28414276&28473984&29400588&31713648&34697715&35581658&33854407&36980848&25597172&36551737&28706507&26941097&27789275&33270668&34774787&35046699&37372315&34603340&24070238&24631383&35129543&34893161&23957506&25646071&35620052&30687383&23638630&23079992&33024276&37833704&38504781&38275400&38296839&39125744&38970134&39075736&39094898						FAIL	25	-2	-20	-10	0.02	0.00	0.00	0.00	DNMT1		1.5000e-01	257536	0.49116	0.51876	0.53395	256733	not_provided&Hereditary_sensory_neuropathy-deafness-dementia_syndrome&Autosomal_dominant_cerebellar_ataxia&_deafness_and_narcolepsy&not_specified		MedGen:C3661900&MONDO:MONDO:0013584&MedGen:C3279885&OMIM:614116&Orphanet:456318&MONDO:MONDO:0011397&MedGen:C3807295&OMIM:604121&Orphanet:314404&MedGen:CN169374		NC_000019.10:g.10156401T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306762&SCV000410244&SCV001717270&SCV001847127&SCV001875659&SCV001875660&SCV005309715	single_nucleotide_variant	SO:0001483	ClinGen:CA9188313		DNMT1:1786	SO:0001819&synonymous_variant										1	2228611																											473					1							246.89	v6.1	Unknown		True	DNMT1, a DNA methyltransferase, is infrequently altered in various cancer types.	False	10/19/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNMT1 ENSP00000352516.3:P463= mutant UNKNOWN.	False	The DNMT1 ENSP00000352516.3:p463= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	10267077						True	False	False	Unknown								False	False		DNMT1, a DNA methyltransferase, is infrequently altered in various cancer types.	The DNMT1 ENSP00000352516.3:p463= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNMT1 ENSP00000352516.3:P463= mutant UNKNOWN.						v6.1	10/19/2018		GRCh38	DNMT1	1786.0	ENSP00000352516.3:P463=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DNMT1"",""entrezGeneId"":1786,""alteration"":""ENSP00000352516.3:P463="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DNMT1, a DNA methyltransferase, is infrequently altered in various cancer types."",""variantSummary"":""The DNMT1 ENSP00000352516.3:p463= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNMT1 ENSP00000352516.3:P463= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/19/2018""}"	True	True	False	Unknown		Unknown																						251,222	119,94	132,128	0/1	125,126,103,119	ATG	.	.	.			153,98,153,69	32.06		0.4693446088794926
GRCh38	DNMT1	D12_12345_1234556_Thyroid_S9			chr19	10177292		C	<INS>	<INS>	10177292	MantaINS:8219:0:0:0:6:0	C	<INS>	.	PASS	NM_001130823	insertion	feature_elongation&coding_sequence_variant	HIGH	DNMT1	ENSG00000130816	Transcript	ENST00000359526	protein_coding	6/41			622	568	190					-1		insertion	HGNC	HGNC:2976	YES	MANE_Select	NM_001130823.3		1		CCDS45958.1	ENSP00000352516	P26358.245		UPI000002A823	P26358-2		1			PIRSF:PIRSF037404&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P26358-F1																																																																																																												0,51		0,51							51	CCTTTGCAAAATGAGATGTGATGGTGGTTTGCCTGGTGCTTTTCCTTGTAA		CCTTTGCAAAATGAGATGTGATGGTGGTTTGCCTGGTGCTTTTCCTTGTAAGTTTGTTTAAGTTCCTTGTAGATTCTGGATATTAGACTTTTGTCAGATGGATAGATTGCAAAAATTTT																chr19	10287968	TCAAGAAAGTTCCATTCCAGTCCATTGCTTTCGAGTCCATTCCATTCCACTCTAGTCTATTCCACTCCATT			INS																																													True	True	False	Unknown		Unknown																															3,3				13,7	
GRCh38	SMARCA4	D12_12345_1234556_Thyroid_S9	p.His508=	ENSP00000343896.4:p.His508=	chr19	10994932	10994932.0	T	C	C	10994932	.	T	C	.	PASS	NM_003072	C	synonymous_variant	LOW	SMARCA4	ENSG00000127616	Transcript	ENST00000344626	protein_coding	9/35		c.1524T>C	1700	1524	508	H	caT/caC	rs7935&COSV60787320		1		SNV	HGNC	HGNC:11100	YES	MANE_Select	NM_003072.5		1	P1	CCDS12253.1	ENSP00000343896	P51532.248	A7E2E1.142	UPI000006F973	P51532-1		1			Gene3D:1.20.5.170&PDB-ENSP_mappings:6lth.I&PDB-ENSP_mappings:6ltj.I&PDB-ENSP_mappings:7vdt.A&PDB-ENSP_mappings:7vdv.A&PDB-ENSP_mappings:7y8r.I&AFDB-ENSP_mappings:AF-P51532-F1&Coiled-coils_(Ncoils):Coil&Pfam:PF07529&PROSITE_profiles:PS51204&PANTHER:PTHR10799&SMART:SM00573			0.3115	0.3109	0.2133	0.2639	0.3519	0.3896	0.3522	0.3047	0.197	0.3439	0.2262	0.3608	0.3859	0.3581	0.345	0.4326	0.3248	0.304	0.3205	0.2382	0.3502	0.2436	0.3681	0.3707	0.3487	0.3215	0.4127	0.4326	gnomADe_SAS	benign	0&1	1&1	25741868&18414213&23300646&23276717						FAIL	-40	13	39	48	0.00	0.00	0.00	0.00	SMARCA4		2.2600e-01	126359	0.32831	0.33535	0.31150	131891	Coffin-Siris_syndrome&Hereditary_cancer-predisposing_syndrome&not_specified&Intellectual_disability&_autosomal_dominant_16&not_provided&Rhabdoid_tumor_predisposition_syndrome_2		MONDO:MONDO:0015452&MedGen:C0265338&OMIM:PS135900&Orphanet:1465&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0013821&MedGen:C3553249&OMIM:614609&Orphanet:1465&MedGen:C3661900&MONDO:MONDO:0013224&MedGen:C2750074&OMIM:613325&Orphanet:231108&Orphanet:69077		NC_000019.10:g.10994932T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000147861&SCV000306741&SCV000410474&SCV000518004&SCV000663856&SCV001729834&SCV002057056&SCV005312041&SCV006311195	single_nucleotide_variant	SO:0001483	ClinGen:CA151110		SMARCA4:6597	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	7935																											976					0.99							247.56	v6.1	Unknown		True	SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT).	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:H508= mutant UNKNOWN.	False	The SMARCA4 ENSP00000343896.4:h508= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	11105608						True	False	False	Unknown								False	False		SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT).	The SMARCA4 ENSP00000343896.4:h508= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:H508= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	SMARCA4	6597.0	ENSP00000343896.4:H508=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SMARCA4"",""entrezGeneId"":6597,""alteration"":""ENSP00000343896.4:H508="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT)."",""variantSummary"":""The SMARCA4 ENSP00000343896.4:h508= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:H508= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						474,492	223,238	251,254	0/1	226,248,251,241	ATG	.	.	.			241,233,255,237	60.95		0.5093167701863354
GRCh38	SMARCA4	D12_12345_1234556_Thyroid_S9	p.Leu796=	ENSP00000343896.4:p.Leu796=	chr19	11013062	11013062.0	C	T	T	11013062	.	C	T	.	PASS	NM_003072	T	synonymous_variant	LOW	SMARCA4	ENSG00000127616	Transcript	ENST00000344626	protein_coding	16/35		c.2388C>T	2564	2388	796	L	ctC/ctT	rs28997580&COSV104418424		1		SNV	HGNC	HGNC:11100	YES	MANE_Select	NM_003072.5		1	P1	CCDS12253.1	ENSP00000343896	P51532.248	A7E2E1.142	UPI000006F973	P51532-1		1			Gene3D:3.40.50.10810&PDB-ENSP_mappings:6lth.I&PDB-ENSP_mappings:6ltj.I&PDB-ENSP_mappings:7vdt.A&PDB-ENSP_mappings:7vdv.A&PDB-ENSP_mappings:7y8r.I&AFDB-ENSP_mappings:AF-P51532-F1&Pfam:PF00176&PROSITE_profiles:PS51192&PANTHER:PTHR10799&SMART:SM00487&Superfamily:SSF52540&CDD:cd18062			0.0172	0	0	0.002	0.005	0.0808	0.00996	0.001135	0.002907	0.0008035	0.0005542	0.003575	0.006415	0.008653	0.009785	0.04531	0.006636	0.001587	0	0.002874	0.000288	0.0007725	0.002917	0.01361	0.008747	0.006155	0.05236	0.0808	SAS	benign	0&1	1&1	37895183						FAIL	7	-47	49	50	0.00	0.00	0.00	0.00	SMARCA4		2.2600e-01	220858	0.00492	0.01160	0.01717	222772	Coffin-Siris_syndrome&Otosclerosis_12&Rhabdoid_tumor_predisposition_syndrome_2&Intellectual_disability&_autosomal_dominant_16&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided		MONDO:MONDO:0015452&MedGen:C0265338&OMIM:PS135900&Orphanet:1465&MONDO:MONDO:0968980&MedGen:C5935610&OMIM:620792&MONDO:MONDO:0013224&MedGen:C2750074&OMIM:613325&Orphanet:231108&Orphanet:69077&MONDO:MONDO:0013821&MedGen:C3553249&OMIM:614609&Orphanet:1465&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900		NC_000019.10:g.11013062C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000261746&SCV000410485&SCV000518035&SCV000663869&SCV001157010&SCV002046795&SCV002057070&SCV005312055&SCV006053959&SCV006311194	single_nucleotide_variant	SO:0001483	ClinGen:CA350424		SMARCA4:6597	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	28997580																											1060					0.996							246.91	v6.1	Unknown		True	SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT).	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:L796= mutant UNKNOWN.	False	The SMARCA4 ENSP00000343896.4:l796= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	11123738						True	False	False	Unknown								False	False		SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT).	The SMARCA4 ENSP00000343896.4:l796= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:L796= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	SMARCA4	6597.0	ENSP00000343896.4:L796=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SMARCA4"",""entrezGeneId"":6597,""alteration"":""ENSP00000343896.4:L796="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT)."",""variantSummary"":""The SMARCA4 ENSP00000343896.4:l796= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:L796= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						523,533	266,312	257,221	0/1	264,259,277,256	TCA	0.00	0.00	0.00			297,226,290,243	59.91		0.5047348484848485
GRCh38	SMARCA4	D12_12345_1234556_Thyroid_S9	p.Asp1351=	ENSP00000343896.4:p.Asp1351=	chr19	11035015	11035015.0	C	T	T	11035015	.	C	T	.	PASS	NM_003072	T	synonymous_variant	LOW	SMARCA4	ENSG00000127616	Transcript	ENST00000344626	protein_coding	29/35		c.4053C>T	4229	4053	1351	D	gaC/gaT	rs28997582&COSV60798637		1		SNV	HGNC	HGNC:11100	YES	MANE_Select	NM_003072.5		1	P1	CCDS12253.1	ENSP00000343896	P51532.248	A7E2E1.142	UPI000006F973	P51532-1		1			PDB-ENSP_mappings:6lth.I&PDB-ENSP_mappings:6ltj.I&PDB-ENSP_mappings:7vdt.A&PDB-ENSP_mappings:7vdv.A&PDB-ENSP_mappings:7y8r.I&AFDB-ENSP_mappings:AF-P51532-F1&Pfam:PF14619&PANTHER:PTHR10799&SMART:SM01314			0.0471	0.0045	0.0346	0.0437	0.0666	0.0971	0.0647	0.01103	0.03183	0.06674	0.02625	0.08825	0.06662	0.06503	0.0634	0.1019	0.04831	0.01292	0.008772	0.03351	0.07007	0.03416	0.09217	0.06803	0.06262	0.05824	0.1036	0.1036	gnomADg_SAS	benign	0&1	1&1	25741868&18414213&39134668						FAIL	-5	31	6	22	0.00	0.00	0.00	0.00	SMARCA4		2.2600e-01	126362	0.04613	0.07271	0.04712	131894	Coffin-Siris_syndrome&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Intellectual_disability&_autosomal_dominant_16&Rhabdoid_tumor_predisposition_syndrome_2		MONDO:MONDO:0015452&MedGen:C0265338&OMIM:PS135900&Orphanet:1465&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0013821&MedGen:C3553249&OMIM:614609&Orphanet:1465&MONDO:MONDO:0013224&MedGen:C2750074&OMIM:613325&Orphanet:231108&Orphanet:69077		NC_000019.10:g.11035015C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000147864&SCV000306743&SCV000410501&SCV000518008&SCV000663862&SCV001723417&SCV002057097&SCV005312072&SCV006324579	single_nucleotide_variant	SO:0001483	ClinGen:CA151115		SMARCA4:6597	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	28997582																											1061					0.997							246.25	v6.1	Unknown		True	SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT).	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:D1351= mutant UNKNOWN.	False	The SMARCA4 ENSP00000343896.4:d1351= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	11145691						True	False	False	Unknown								False	False		SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT).	The SMARCA4 ENSP00000343896.4:d1351= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:D1351= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	SMARCA4	6597.0	ENSP00000343896.4:D1351=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SMARCA4"",""entrezGeneId"":6597,""alteration"":""ENSP00000343896.4:D1351="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT)."",""variantSummary"":""The SMARCA4 ENSP00000343896.4:d1351= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMARCA4 ENSP00000343896.4:D1351= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						522,536	246,240	276,296	0/1	265,257,257,279	ACG	0.00	0.00	0.00			283,239,273,263	61.01		0.5066162570888468
GRCh38	DNAJB1	D12_12345_1234556_Thyroid_S9			chr19	14516238	14516238.0	G	A	A	14516238	.	G	A	.	PASS	NM_006145	A	intron_variant	MODIFIER	DNAJB1	ENSG00000132002	Transcript	ENST00000254322	protein_coding		2/2	c.793-68C>T						rs4926222&COSV54317084		-1		SNV	HGNC	HGNC:5270	YES	MANE_Select	NM_006145.3		1	P1	CCDS12312.1	ENSP00000254322	P25685.230	Q6FHS4.150	UPI0000000C3A	P25685-1		1						0.7510	0.9198	0.7334	0.3532	0.8678	0.8252	0.8301	0.9131	0.7012	0.9014	0.3361	0.8528	0.8719	0.8491	0.8153	0.8195	0.8404	0.9074	0.9637	0.7499	0.8968	0.3384	0.8453	0.9014	0.8548	0.8226	0.8126	0.9637	gnomADg_AMI		0&1	0&1	19254810&21611153&37681004						FAIL	1	-35	18	-41	0.00	0.00	0.00	0.00	DNAJB1		9.5300e-01																																																											1039					0.999							247.09													chr19	14627050																																																	True	True	False	Unknown		Unknown																						0,1038	0,557	0,481	0/1	0,0,528,510	CGT	0.00	0.00	0.00			0,0,531,507	64.73		1.0
GRCh38	DNAJB1	D12_12345_1234556_Thyroid_S9			chr19	14517430	14517430.0	G	A	A	14517430	.	G	A	.	PASS	NM_006145	A	intron_variant	MODIFIER	DNAJB1	ENSG00000132002	Transcript	ENST00000254322	protein_coding		1/2	c.212-384C>T						rs755892		-1		SNV	HGNC	HGNC:5270	YES	MANE_Select	NM_006145.3		1	P1	CCDS12312.1	ENSP00000254322	P25685.230	Q6FHS4.150	UPI0000000C3A	P25685-1		1						0.2107	0.0681	0.2464	0.2312	0.3996	0.1626	0.297	0.08285	0.1453	0.4039	0.1698	0.2654	0.3158	0.3343	0.2917	0.144	0.2947	0.118	0.3113	0.2695	0.4752	0.2262	0.3553	0.3973	0.4008	0.3161	0.1814	0.4752	gnomADg_ASJ				19254810						FAIL	-18	-9	8	49	0.01	0.00	0.00	0.00	DNAJB1		9.5300e-01																																																											594					0.976							241.94													chr19	14628242																																																	True	True	False	Unknown		Unknown																						275,305	138,152	137,153	0/1	143,132,167,138	AGA	0.00	0.00	0.00			142,133,150,155	57.61		0.5258620689655172
GRCh38	DNAJB1	D12_12345_1234556_Thyroid_S9			chr19	14517712	14517712.0	C	T	T	14517712	.	C	T	.	PASS	NM_006145	T	intron_variant	MODIFIER	DNAJB1	ENSG00000132002	Transcript	ENST00000254322	protein_coding		1/2	c.211+427G>A						rs743511		-1		SNV	HGNC	HGNC:5270	YES	MANE_Select	NM_006145.3		1	P1	CCDS12312.1	ENSP00000254322	P25685.230	Q6FHS4.150	UPI0000000C3A	P25685-1		1						0.1841	0.034	0.2695	0.0456	0.2913	0.3589	0.2225	0.06757	0.2386	0.2146	0.03416	0.3115	0.1786	0.2392	0.2315	0.3036	0.2104	0.06278	0.4449	0.2463	0.2454	0.04136	0.3486	0.2945	0.2701	0.2024	0.3336	0.4449	gnomADg_AMI				19254810						FAIL	-48	5	-5	-9	0.00	0.00	0.00	0.00	DNAJB1		9.5300e-01																																																											595					0.997							245.79													chr19	14628524																																																	True	True	False	Unknown		Unknown																						308,285	172,150	136,135	0/1	151,157,129,156	TCG	0.00	0.00	0.00			107,201,88,197	37.21		0.4806070826306914
GRCh38	DNAJB1	D12_12345_1234556_Thyroid_S9	p.Asp4=	ENSP00000254322.1:p.Asp4=	chr19	14518338	14518338.0	G	A	A	14518338	.	G	A	.	PASS	NM_006145	A	synonymous_variant	LOW	DNAJB1	ENSG00000132002	Transcript	ENST00000254322	protein_coding	1/3		c.12C>T	60	12	4	D	gaC/gaT	rs3962158&COSV54316981		-1		SNV	HGNC	HGNC:5270	YES	MANE_Select	NM_006145.3		1	P1	CCDS12312.1	ENSP00000254322	P25685.230	Q6FHS4.150	UPI0000000C3A	P25685-1		1			PDB-ENSP_mappings:1hdj.A&PDB-ENSP_mappings:4wb7.A&PDB-ENSP_mappings:4wb7.B&PDB-ENSP_mappings:6byr.A&PDB-ENSP_mappings:6byr.C&PDB-ENSP_mappings:6wjf.A&PDB-ENSP_mappings:6wjf.B&PDB-ENSP_mappings:6wjg.A&PDB-ENSP_mappings:6wjg.B&PDB-ENSP_mappings:6z5n.A&PDB-ENSP_mappings:8fe2.A&PDB-ENSP_mappings:8fe2.B&PDB-ENSP_mappings:8fe5.A&PDB-ENSP_mappings:8fe5.B&PDB-ENSP_mappings:8fec.A&PDB-ENSP_mappings:8fec.B&Superfamily:SSF46565&Gene3D:1.10.287.110&Pfam:PF00226&SMART:SM00271&PANTHER:PTHR24078&CDD:cd06257&PROSITE_profiles:PS50076&AFDB-ENSP_mappings:AF-P25685-F1			0.3429	0.4493	0.3343	0.1071	0.3211	0.4703	0.3213	0.4227	0.3925	0.3409	0.08455	0.3923	0.3587	0.3126	0.3209	0.4273	0.3451	0.4195	0.4746	0.332	0.3303	0.09237	0.3874	0.3897	0.3087	0.3197	0.4326	0.4746	gnomADg_AMI		0&1	0&1	17601350&21611153&21757428						FAIL	-10	20	8	-11	0.00	0.00	0.00	0.00	DNAJB1		9.5300e-01																																																											542					0.996							196.84	v6.1	Unknown		True	DNAJB1, a subunit of the heat shock factor 40 (HSP40) complex, is recurrently altered by chromosomal rearrangement in fibrolamellar hepatocellular carcinoma.	False	02/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNAJB1 ENSP00000254322.1:D4= mutant UNKNOWN.	False	The DNAJB1 ENSP00000254322.1:d4= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	14629150						True	False	False	Unknown								False	False		DNAJB1, a subunit of the heat shock factor 40 (HSP40) complex, is recurrently altered by chromosomal rearrangement in fibrolamellar hepatocellular carcinoma.	The DNAJB1 ENSP00000254322.1:d4= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNAJB1 ENSP00000254322.1:D4= mutant UNKNOWN.						v6.1	02/22/2018		GRCh38	DNAJB1	3337.0	ENSP00000254322.1:D4=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DNAJB1"",""entrezGeneId"":3337,""alteration"":""ENSP00000254322.1:D4="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DNAJB1, a subunit of the heat shock factor 40 (HSP40) complex, is recurrently altered by chromosomal rearrangement in fibrolamellar hepatocellular carcinoma."",""variantSummary"":""The DNAJB1 ENSP00000254322.1:d4= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNAJB1 ENSP00000254322.1:D4= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/22/2018""}"	True	True	False	Unknown		Unknown																						270,270	146,154	124,116	0/1	121,149,116,154	AGT	0.00	0.00	0.00			97,173,92,178	45.94		0.5
GRCh38	NOTCH3	D12_12345_1234556_Thyroid_S9	p.A2223V	ENSP00000263388.1:p.Ala2223Val	chr19	15160960	15160960.0	G	A	A	15160960	.	G	A	.	PASS	NM_000435	A	missense_variant	MODERATE	NOTCH3	ENSG00000074181	Transcript	ENST00000263388	protein_coding	33/33		c.6668C>T	6758	6668	2223	A/V	gCg/gTg	rs1044009&COSV54625824		-1		SNV	HGNC	HGNC:7883	YES	MANE_Select	NM_000435.3		1	P1	CCDS12326.1	ENSP00000263388	Q9UM47.229		UPI000013D3FA			1	tolerated(0.15)	benign(0.001)	SMART:SM01334&Phobius:CYTOPLASMIC_DOMAIN&PIRSF:PIRSF002279&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-Q9UM47-F1			0.6294	0.5	0.6196	0.5724	0.7714	0.7239	0.7608	0.5143	0.5599	0.7606	0.6013	0.8115	0.6765	0.7848	0.7247	0.7134	0.6918	0.535	0.8531	0.6212	0.7504	0.5827	0.8147	0.6837	0.7852	0.6918	0.723	0.8531	gnomADg_AMI	benign	0&1	1&1	25741868&29458332&22517515&25957329&34575036&22006983&31288479&27370894&22664156&35144616&24086431&30104866&32545847&22153900&36570541&34039391&30510423&37228872&19054571&38790158						FAIL	2	27	2	-50	0.00	0.00	0.00	0.00	NOTCH3	0.143	5.6600e-01	256152	0.73490	0.75907	0.62939	256792	Cerebral_arteriopathy&_autosomal_dominant&_with_subcortical_infarcts_and_leukoencephalopathy&_type_1&Lateral_meningocele_syndrome&not_specified&not_provided		MONDO:MONDO:0000914&MedGen:C4551768&OMIM:125310&Orphanet:136&MONDO:MONDO:0007537&MedGen:C1851710&OMIM:130720&Orphanet:2789&MedGen:CN169374&MedGen:C3661900		NC_000019.10:g.15160960G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000304275&SCV000341666&SCV000410938&SCV001158967&SCV001730417&SCV001893991&SCV002026877&SCV002026878&SCV005315421	single_nucleotide_variant	SO:0001483	ClinGen:CA9262326&UniProtKB:Q9UM47																																																																																																																																															0,958	0,468	0,490	0/1	0,0,482,476	CGC	0.00	0.00	0.00			0,0,464,494	64.73		1.0
GRCh38	NOTCH3	D12_12345_1234556_Thyroid_S9			chr19	15167246	15167246.0	A	G	G	15167246	.	A	G	.	PASS	NM_000435	G	splice_donor_region_variant&intron_variant	LOW	NOTCH3	ENSG00000074181	Transcript	ENST00000263388	protein_coding		29/32	c.5362+3T>C						rs1548555		-1		SNV	HGNC	HGNC:7883	YES	MANE_Select	NM_000435.3		1	P1	CCDS12326.1	ENSP00000263388	Q9UM47.229		UPI000013D3FA			1						0.8700	0.9856	0.7622	0.8016	0.8817	0.8487	0.8918	0.98	0.7217	0.8718	0.8268	0.887	0.8466	0.9029	0.8788	0.8531	0.9016	0.9758	0.8849	0.7812	0.8776	0.8048	0.8834	0.8733	0.8992	0.8802	0.8513	0.9856	AFR	benign		1	25741868&21103979						FAIL	48	38	16	3	0.00	0.00	0.04	0.00	NOTCH3		5.6600e-01	256140	0.92365	0.87407	0.87001	256803	Lateral_meningocele_syndrome&not_specified&not_provided&Cerebral_arteriopathy&_autosomal_dominant&_with_subcortical_infarcts_and_leukoencephalopathy&_type_1		MONDO:MONDO:0007537&MedGen:C1851710&OMIM:130720&Orphanet:2789&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0000914&MedGen:C4551768&OMIM:125310&Orphanet:136		NC_000019.10:g.15167246A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000304263&SCV000410961&SCV001158969&SCV001721997&SCV001938295&SCV002026894&SCV002026895&SCV005315446	single_nucleotide_variant	SO:0001483	ClinGen:CA9262657		NOTCH3:4854	SO:0001627&intron_variant										1	1548555																											642					0.988							247.43													chr19	15278057																																																	True	True	False	Unknown		Unknown																						0,634	0,328	0,306	0/1	0,0,325,309	TAA	.	.	.			0,0,403,231	64.73		1.0
GRCh38	NOTCH3	D12_12345_1234556_Thyroid_S9	p.Pro1521=	ENSP00000263388.1:p.Pro1521=	chr19	15174241	15174241.0	T	C	C	15174241	.	T	C	.	PASS	NM_000435	C	synonymous_variant	LOW	NOTCH3	ENSG00000074181	Transcript	ENST00000263388	protein_coding	25/33		c.4563A>G	4653	4563	1521	P	ccA/ccG	rs1044006&COSV54629991		-1		SNV	HGNC	HGNC:7883	YES	MANE_Select	NM_000435.3		1	P1	CCDS12326.1	ENSP00000263388	Q9UM47.229		UPI000013D3FA			1			PDB-ENSP_mappings:4zlp.A&PDB-ENSP_mappings:4zlp.B&PDB-ENSP_mappings:5czv.A&PDB-ENSP_mappings:5czx.A&PDB-ENSP_mappings:5czx.B&PDB-ENSP_mappings:6xsw.C&PDB-ENSP_mappings:6xsw.F&PDB-ENSP_mappings:6xsw.J&PDB-ENSP_mappings:6xsw.X&Low_complexity_(Seg):seg&SMART:SM01338&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF002279&Gene3D:3.30.70.3310&Pfam:PF06816&AFDB-ENSP_mappings:AF-Q9UM47-F1			0.8718	0.9879	0.7637	0.8006	0.8817	0.8548	0.8923	0.9813	0.7243	0.8706	0.8268	0.8858	0.8461	0.9026	0.8791	0.8591	0.9019	0.9766	0.8849	0.7818	0.8759	0.8052	0.8832	0.8776	0.8991	0.8801	0.8567	0.9879	AFR	benign	0&1	1&1	25741868&22006983&27370894&24086431&22153900&36570541&34039391&19576955&38785976						FAIL	13	-2	-13	-2	0.00	0.00	0.00	0.00	NOTCH3		5.6600e-01	256138	0.92614	0.88124	0.87181	256805	not_provided&Lateral_meningocele_syndrome&not_specified&Cerebral_arteriopathy&_autosomal_dominant&_with_subcortical_infarcts_and_leukoencephalopathy&_type_1		MedGen:C3661900&MONDO:MONDO:0007537&MedGen:C1851710&OMIM:130720&Orphanet:2789&MedGen:CN169374&MONDO:MONDO:0000914&MedGen:C4551768&OMIM:125310&Orphanet:136		NC_000019.10:g.15174241T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000304261&SCV000410964&SCV001158970&SCV001721998&SCV001753973&SCV002026899&SCV002026900&SCV005315451	single_nucleotide_variant	SO:0001483	ClinGen:CA9262893		NOTCH3:4854	SO:0001819&synonymous_variant										1	1044006																											1049					0.998							246.76	v6.1	Unknown		True	NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:P1521= mutant UNKNOWN.	False	The NOTCH3 ENSP00000263388.1:p1521= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	15285052						True	False	False	Unknown								False	False		NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	The NOTCH3 ENSP00000263388.1:p1521= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:P1521= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	NOTCH3	4854.0	ENSP00000263388.1:P1521=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH3"",""entrezGeneId"":4854,""alteration"":""ENSP00000263388.1:P1521="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers."",""variantSummary"":""The NOTCH3 ENSP00000263388.1:p1521= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:P1521= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						0,1047	0,512	0,535	0/1	0,0,548,499	CTG	.	.	.			0,0,545,502	64.73		1.0
GRCh38	NOTCH3	D12_12345_1234556_Thyroid_S9	p.Pro914=	ENSP00000263388.1:p.Pro914=	chr19	15181626	15181626.0	T	C	C	15181626	.	T	C	.	PASS	NM_000435	C	synonymous_variant	LOW	NOTCH3	ENSG00000074181	Transcript	ENST00000263388	protein_coding	17/33		c.2742A>G	2832	2742	914	P	ccA/ccG	rs1043997&COSV54638490		-1		SNV	HGNC	HGNC:7883	YES	MANE_Select	NM_000435.3		1	P1	CCDS12326.1	ENSP00000263388	Q9UM47.229		UPI000013D3FA			1			CDD:cd00054&SMART:SM00181&SMART:SM00179&Superfamily:SSF57184&PROSITE_patterns:PS01186&PROSITE_patterns:PS00022&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50026&PIRSF:PIRSF002279&Pfam:PF12661&Gene3D:2.10.25.10&AFDB-ENSP_mappings:AF-Q9UM47-F1			0.7390	0.5582	0.7104	0.8284	0.841	0.8067	0.8527	0.6004	0.6885	0.8351	0.8502	0.8487	0.7842	0.8717	0.8208	0.807	0.7725	0.606	0.7418	0.7233	0.8399	0.8256	0.8461	0.8163	0.8642	0.7706	0.8041	0.8717	gnomADe_NFE	benign	0&1	1&1	25741868&26889213&22006983&25953367&24086431&26036933&22735669&22153900&36570541&30859180&29544907&19576955						FAIL	-11	-2	-28	-50	0.00	0.01	0.00	0.00	NOTCH3		5.6600e-01	256130	0.79049	0.80193	0.73902	256812	not_specified&not_provided&Lateral_meningocele_syndrome&Cerebral_arteriopathy&_autosomal_dominant&_with_subcortical_infarcts_and_leukoencephalopathy&_type_1		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0007537&MedGen:C1851710&OMIM:130720&Orphanet:2789&MONDO:MONDO:0000914&MedGen:C4551768&OMIM:125310&Orphanet:136		NC_000019.10:g.15181626T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000304252&SCV000410987&SCV001157011&SCV001721999&SCV001830146&SCV002026907&SCV002026908&SCV005308374	single_nucleotide_variant	SO:0001483	ClinGen:CA9263290		NOTCH3:4854	SO:0001819&synonymous_variant										1	1043997																											916					0.999							247.04	v6.1	Unknown		True	NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:P914= mutant UNKNOWN.	False	The NOTCH3 ENSP00000263388.1:p914= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	15292437						True	False	False	Unknown								False	False		NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	The NOTCH3 ENSP00000263388.1:p914= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:P914= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	NOTCH3	4854.0	ENSP00000263388.1:P914=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH3"",""entrezGeneId"":4854,""alteration"":""ENSP00000263388.1:P914="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers."",""variantSummary"":""The NOTCH3 ENSP00000263388.1:p914= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:P914= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						0,915	0,458	0,457	0/1	0,0,469,446	CTG	.	.	.			0,0,482,433	64.73		1.0
GRCh38	NOTCH3	D12_12345_1234556_Thyroid_S9	p.Cys846=	ENSP00000263388.1:p.Cys846=	chr19	15184323	15184323.0	G	A	A	15184323	.	G	A	.	PASS	NM_000435	A	synonymous_variant	LOW	NOTCH3	ENSG00000074181	Transcript	ENST00000263388	protein_coding	16/33		c.2538C>T	2628	2538	846	C	tgC/tgT	rs1043996&COSV54643242		-1		SNV	HGNC	HGNC:7883	YES	MANE_Select	NM_000435.3		1	P1	CCDS12326.1	ENSP00000263388	Q9UM47.229		UPI000013D3FA			1			CDD:cd00054&SMART:SM00181&SMART:SM00179&Superfamily:SSF57184&PROSITE_patterns:PS01186&PROSITE_patterns:PS00022&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50026&PIRSF:PIRSF002279&Gene3D:2.10.25.10&AFDB-ENSP_mappings:AF-Q9UM47-F1			0.5200	0.1997	0.562	0.5933	0.6928	0.6697	0.6936	0.2438	0.51	0.6755	0.6131	0.7577	0.6116	0.7208	0.6575	0.6464	0.5716	0.2633	0.6272	0.5563	0.6688	0.5986	0.7614	0.6122	0.7184	0.595	0.6628	0.7614	gnomADg_FIN	benign	0&1	1&1	25741868&34640639&28568708&22006983&27370894&24086431&22153900&36570541&34039391&19576955						FAIL	19	46	19	-28	0.00	0.01	0.00	0.01	NOTCH3		5.6600e-01	256129	0.56643	0.64274	0.51997	256813	Lateral_meningocele_syndrome&not_specified&not_provided&Cerebral_arteriopathy&_autosomal_dominant&_with_subcortical_infarcts_and_leukoencephalopathy&_type_1		MONDO:MONDO:0007537&MedGen:C1851710&OMIM:130720&Orphanet:2789&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0000914&MedGen:C4551768&OMIM:125310&Orphanet:136		NC_000019.10:g.15184323G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000304251&SCV000410992&SCV000677222&SCV001157012&SCV001730418&SCV001827691&SCV002026910&SCV002026911&SCV005308379	single_nucleotide_variant	SO:0001483	ClinGen:CA9263344		NOTCH3:4854	SO:0001819&synonymous_variant										1	1043996																											720					0.999							247.12	v6.1	Unknown		True	NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:C846= mutant UNKNOWN.	False	The NOTCH3 ENSP00000263388.1:c846= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	15295134						True	False	False	Unknown								False	False		NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	The NOTCH3 ENSP00000263388.1:c846= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:C846= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	NOTCH3	4854.0	ENSP00000263388.1:C846=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH3"",""entrezGeneId"":4854,""alteration"":""ENSP00000263388.1:C846="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers."",""variantSummary"":""The NOTCH3 ENSP00000263388.1:c846= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:C846= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						0,719	0,379	0,340	0/1	0,0,346,373	CGC	0.00	0.00	0.00			0,0,418,301	64.73		1.0
GRCh38	NOTCH3	D12_12345_1234556_Thyroid_S9	p.Ala202=	ENSP00000263388.1:p.Ala202=	chr19	15192033	15192033.0	T	C	C	15192033	.	T	C	.	PASS	NM_000435	C	synonymous_variant	LOW	NOTCH3	ENSG00000074181	Transcript	ENST00000263388	protein_coding	4/33		c.606A>G	696	606	202	A	gcA/gcG	rs1043994&COSV99656519		-1		SNV	HGNC	HGNC:7883	YES	MANE_Select	NM_000435.3		1	P1	CCDS12326.1	ENSP00000263388	Q9UM47.229		UPI000013D3FA			1			SMART:SM00181&SMART:SM00179&Superfamily:SSF57196&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50026&PIRSF:PIRSF002279&Gene3D:2.10.25.10&Pfam:PF00008&AFDB-ENSP_mappings:AF-Q9UM47-F1			0.8558	0.9191	0.7435	0.871	0.8519	0.8384	0.8731	0.9077	0.7075	0.8717	0.8801	0.8661	0.8254	0.8824	0.8603	0.8405	0.8701	0.9068	0.8662	0.7631	0.8775	0.8657	0.8628	0.8469	0.8763	0.8442	0.8339	0.9191	AFR	benign	0&1	1&1	25741868&27266621&34257585&31293107&26889213&16426270&22006983&22373597&25953367&30806291&31288479&24086431&26036933&19018300&22735669&25120811&22153900&32084158&36570541&29544907&19576955&37717975&37873835						FAIL	-33	20	5	26	0.00	0.00	0.00	0.00	NOTCH3		5.6600e-01	256148	0.88928	0.85812	0.85583	256825	not_specified&Lateral_meningocele_syndrome&not_provided&Cerebral_arteriopathy&_autosomal_dominant&_with_subcortical_infarcts_and_leukoencephalopathy&_type_1		MedGen:CN169374&MONDO:MONDO:0007537&MedGen:C1851710&OMIM:130720&Orphanet:2789&MedGen:C3661900&MONDO:MONDO:0000914&MedGen:C4551768&OMIM:125310&Orphanet:136		NC_000019.10:g.15192033T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000304271&SCV000411014&SCV001157013&SCV001722001&SCV001907352&SCV002026914&SCV002026915&SCV005308390	single_nucleotide_variant	SO:0001483	ClinGen:CA9263852		NOTCH3:4854	SO:0001819&synonymous_variant										1	1043994																											878					1							248.01	v6.1	Unknown		True	NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:A202= mutant UNKNOWN.	False	The NOTCH3 ENSP00000263388.1:a202= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	15302844						True	False	False	Unknown								False	False		NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers.	The NOTCH3 ENSP00000263388.1:a202= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:A202= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	NOTCH3	4854.0	ENSP00000263388.1:A202=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH3"",""entrezGeneId"":4854,""alteration"":""ENSP00000263388.1:A202="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH3 encodes a Type I transmembrane protein of the Notch family. Missense and nonsense mutations in NOTCH3 have been identified in various cancers."",""variantSummary"":""The NOTCH3 ENSP00000263388.1:a202= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH3 ENSP00000263388.1:A202= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						0,878	0,440	0,438	0/1	0,0,426,452	GTG	.	.	.			0,0,438,440	64.73		1.0
GRCh38	BRD4	D12_12345_1234556_Thyroid_S9	p.Leu1107=	ENSP00000506350.1:p.Leu1107=	chr19	15239783	15239783.0	G	A	A	15239783	.	G	A	.	PASS	NM_001379291	A	synonymous_variant	LOW	BRD4	ENSG00000141867	Transcript	ENST00000679869	protein_coding	16/20		c.3321C>T	3605	3321	1107	L	ctC/ctT	rs11669901&COSV54583814		-1		SNV	HGNC	HGNC:13575	YES	MANE_Select	NM_001379291.1			P1	CCDS12328.1	ENSP00000506350	O60885.214		UPI0000126ACE	O60885-1		1			PANTHER:PTHR22880&AFDB-ENSP_mappings:AF-O60885-F1			0.1320	0.1362	0.1009	0.0615	0.1879	0.1636	0.1676	0.1376	0.09671	0.1854	0.05555	0.1926	0.2258	0.1722	0.1656	0.1842	0.1577	0.136	0.1799	0.1362	0.1659	0.06078	0.1955	0.1973	0.1748	0.1668	0.1752	0.2258	gnomADe_MID	benign	0&1	1&1	36453946						FAIL	-45	11	-3	11	0.02	0.02	0.00	0.00	BRD4		1.9100e-01	1600450	0.16131	0.16294	0.13199	1632009	not_provided		MedGen:C3661900		NC_000019.10:g.15239783G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002404427&SCV005308406	single_nucleotide_variant	SO:0001483	ClinGen:CA9264714		BRD4:23476	SO:0001819&synonymous_variant										1	11669901																											864					1							247.2	v6.1	Unknown		True	BRD4, a transcriptional coactivator, is altered by amplification or chromosomal rearrangement in various cancer types.	False	02/14/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRD4 ENSP00000506350.1:L1107= mutant UNKNOWN.	False	The BRD4 ENSP00000506350.1:l1107= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	15350594						True	False	False	Unknown								False	False		BRD4, a transcriptional coactivator, is altered by amplification or chromosomal rearrangement in various cancer types.	The BRD4 ENSP00000506350.1:l1107= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRD4 ENSP00000506350.1:L1107= mutant UNKNOWN.						v6.1	02/14/2018		GRCh38	BRD4	23476.0	ENSP00000506350.1:L1107=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BRD4"",""entrezGeneId"":23476,""alteration"":""ENSP00000506350.1:L1107="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BRD4, a transcriptional coactivator, is altered by amplification or chromosomal rearrangement in various cancer types."",""variantSummary"":""The BRD4 ENSP00000506350.1:l1107= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRD4 ENSP00000506350.1:L1107= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/14/2018""}"	True	True	False	Unknown		Unknown																						433,431	207,203	226,228	0/1	224,209,232,199	CGA	0.00	0.00	0.00			224,209,220,211	51.84		0.4988425925925926
GRCh38	PIK3R2	D12_12345_1234556_Thyroid_S9	p.S234R	ENSP00000222254.6:p.Ser234Arg	chr19	18161380	18161380.0	A	C	C	18161380	.	A	C	.	PASS	NM_005027	C	missense_variant	MODERATE	PIK3R2	ENSG00000105647	Transcript	ENST00000222254	protein_coding	6/16		c.700A>C	1255	700	234	S/R	Agc/Cgc	rs2241088&COSV55848697		1		SNV	HGNC	HGNC:8980	YES	MANE_Select	NM_005027.4		1	P1	CCDS12371.1	ENSP00000222254	O00459.224		UPI000006EF95			1	tolerated(0.23)	benign(0)	PDB-ENSP_mappings:2xs6.A&SMART:SM00324&Gene3D:1.10.555.10&Pfam:PF00620&PROSITE_profiles:PS50238&Superfamily:SSF48350&AFDB-ENSP_mappings:AF-O00459-F1			0.9239	0.9773	0.8847	0.9117	0.9404	0.8753	0.9286	0.9715	0.8866	0.9238	0.9282	0.8842	0.8999	0.9311	0.9269	0.8667	0.9318	0.9711	0.9825	0.8919	0.9312	0.9105	0.8747	0.9384	0.9296	0.9359	0.8782	0.9825	gnomADg_AMI	benign	0&1	1&1							FAIL	12	-18	-13	26	0.00	0.01	0.00	0.00	PIK3R2	0.009	7.6000e-01	497079		0.89606	0.92392	488503	not_specified&not_provided&Megalencephaly-polymicrogyria-polydactyly-hydrocephalus_syndrome_1		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0011313&MedGen:C4012727&OMIM:603387&Orphanet:83473		NC_000019.10:g.18161380A>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000701262&SCV001718716&SCV002029903&SCV005314108	single_nucleotide_variant	SO:0001483	ClinGen:CA9306807		PIK3R2:5296&LOC130063979:130063979	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	2241088																											20					1							234.96	v6.1	Unknown		True	PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer.	False	04/24/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S234R mutant UNKNOWN.	False	The PIK3R2 ENSP00000222254.6:s234r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	18272190						True	False	False	Unknown								False	False		PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer.	The PIK3R2 ENSP00000222254.6:s234r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S234R mutant UNKNOWN.						v6.1	04/24/2017		GRCh38	PIK3R2	5296.0	ENSP00000222254.6:S234R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3R2"",""entrezGeneId"":5296,""alteration"":""ENSP00000222254.6:S234R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer."",""variantSummary"":""The PIK3R2 ENSP00000222254.6:s234r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S234R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/24/2017""}"	True	True	False	Unknown		Unknown																						0,20	0,12	0,8	0/1	0,0,12,8	CAG	.	.	.			0,0,10,10	61.59		1.0
GRCh38	PIK3R2	D12_12345_1234556_Thyroid_S9	p.S313P	ENSP00000222254.6:p.Ser313Pro	chr19	18162237	18162237.0	T	C	C	18162237	.	T	C	.	PASS	NM_005027	C	missense_variant	MODERATE	PIK3R2	ENSG00000105647	Transcript	ENST00000222254	protein_coding	8/16		c.937T>C	1492	937	313	S/P	Tcc/Ccc	rs1011320&COSV104547622		1		SNV	HGNC	HGNC:8980	YES	MANE_Select	NM_005027.4		1	P1	CCDS12371.1	ENSP00000222254	O00459.224		UPI000006EF95			1	tolerated(1)	benign(0)	MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-O00459-F1			0.9535	0.9697	0.9597	0.9633	0.9473	0.9233	0.9494	0.9652	0.971	0.9486	0.9632	0.9516	0.9077	0.9499	0.9503	0.9193	0.9554	0.9673	0.9825	0.9626	0.9499	0.965	0.9559	0.9354	0.9478	0.9597	0.9215	0.9825	gnomADg_AMI	benign	0&1	1&1	27141497&18650832&27980660						FAIL	42	-35	-13	49	0.00	0.00	0.00	0.00	PIK3R2	0.024	7.6000e-01	803546	0.95515	0.95006	0.95347	791917	not_provided&Megalencephaly-polymicrogyria-polydactyly-hydrocephalus_syndrome_1&not_specified		MedGen:C3661900&MONDO:MONDO:0011313&MedGen:C4012727&OMIM:603387&Orphanet:83473&MedGen:CN169374		NC_000019.10:g.18162237T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001141037&SCV001718717&SCV002029904&SCV005314110	single_nucleotide_variant	SO:0001483	ClinGen:CA9306874		PIK3R2:5296	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	1011320																											513					1							244.86	v6.1	Unknown		True	PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer.	False	04/24/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S313P mutant UNKNOWN.	False	The PIK3R2 ENSP00000222254.6:s313p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	18273047						True	False	False	Unknown								False	False		PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer.	The PIK3R2 ENSP00000222254.6:s313p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S313P mutant UNKNOWN.						v6.1	04/24/2017		GRCh38	PIK3R2	5296.0	ENSP00000222254.6:S313P			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3R2"",""entrezGeneId"":5296,""alteration"":""ENSP00000222254.6:S313P"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer."",""variantSummary"":""The PIK3R2 ENSP00000222254.6:s313p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S313P mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/24/2017""}"	True	True	False	Unknown		Unknown																						0,513	0,259	0,254	0/1	0,0,245,268	CTC	.	.	.			0,0,319,194	64.73		1.0
GRCh38	PIK3R2	D12_12345_1234556_Thyroid_S9	p.Ser637=	ENSP00000222254.6:p.Ser637=	chr19	18168828	18168828.0	T	C	C	18168828	.	T	C	.	PASS	NM_005027	C	synonymous_variant	LOW	PIK3R2	ENSG00000105647	Transcript	ENST00000222254	protein_coding	15/16		c.1911T>C	2466	1911	637	S	agT/agC	rs273269&COSV55849419		1		SNV	HGNC	HGNC:8980	YES	MANE_Select	NM_005027.4		1	P1	CCDS12371.1	ENSP00000222254	O00459.224		UPI000006EF95			1			PANTHER:PTHR10155&SMART:SM00252&Gene3D:3.30.505.10&Pfam:PF00017&PROSITE_profiles:PS50001&Prints:PR00678&CDD:cd09930&Superfamily:SSF55550&AFDB-ENSP_mappings:AF-O00459-F1			0.8624	0.7821	0.8501	0.9365	0.8946	0.8701	0.887	0.7844	0.8667	0.8714	0.9377	0.9126	0.8506	0.8898	0.8874	0.8682	0.8584	0.7839	0.9198	0.8527	0.8758	0.9306	0.9172	0.8707	0.8877	0.867	0.8698	0.9377	gnomADe_EAS	benign	0&1	1&1	29434720						FAIL	-17	-46	1	-46	0.00	0.00	0.00	0.06	PIK3R2		7.6000e-01	518294	0.85107	0.88000	0.86242	508919	not_provided&not_specified&Megalencephaly-polymicrogyria-polydactyly-hydrocephalus_syndrome_1		MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0011313&MedGen:C4012727&OMIM:603387&Orphanet:83473		NC_000019.10:g.18168828T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000745290&SCV001718718&SCV001839261&SCV002029905&SCV005314117	single_nucleotide_variant	SO:0001483	ClinGen:CA9307182		PIK3R2:5296	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	273269																											940					0.996							247.49	v6.1	Unknown		True	PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer.	False	04/24/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S637= mutant UNKNOWN.	False	The PIK3R2 ENSP00000222254.6:s637= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	18279638						True	False	False	Unknown								False	False		PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer.	The PIK3R2 ENSP00000222254.6:s637= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S637= mutant UNKNOWN.						v6.1	04/24/2017		GRCh38	PIK3R2	5296.0	ENSP00000222254.6:S637=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3R2"",""entrezGeneId"":5296,""alteration"":""ENSP00000222254.6:S637="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3R2 encodes a regulatory subunit of PI3-kinase, a component of the pro-oncogenic PI3-kinase/AKT/mTOR signaling pathway. PIK3R2 is mutated at low frequencies in a diverse range of cancer."",""variantSummary"":""The PIK3R2 ENSP00000222254.6:s637= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R2 ENSP00000222254.6:S637= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/24/2017""}"	True	True	False	Unknown		Unknown																						0,936	0,448	0,488	0/1	0,0,467,469	GTG	.	.	.			0,0,457,479	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr19	27972429	27972429.0	G	A	A	27972429	.	G	A	.	PASS		A	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR19_B7JTZ	enhancer									rs719366				SNV																						0.7372	0.8502	0.7075	0.7669	0.6481	0.6667											0.6809	0.8151	0.7225	0.7143	0.7255	0.7686	0.4801	0.6905	0.6152	0.6872	0.647	0.8502	AFR				26522768&26691610&29121662&33406744&19083859&31745634&27294018&19948332&38522119																																																																												228					0.886							233.83													chr19	28463337																																																	True	False	False	Unknown		Unknown																						116,86	68,36	48,50	0/1	61,55,43,43	TGC	0.00	0.00	0.00			67,49,39,47	22.84		0.42574257425742573
GRCh38	CCNE1	D12_12345_1234556_Thyroid_S9			chr19	29813679	29813680.0	A	AT	AT	29813679	.	A	AT	.	PASS	NM_001238	T	intron_variant	MODIFIER	CCNE1	ENSG00000105173	Transcript	ENST00000262643	protein_coding		4/11	c.180+651dup						rs5827671		1		insertion	HGNC	HGNC:1589	YES	MANE_Select	NM_001238.4		1	P1	CCDS12419.1	ENSP00000262643	P24864.230		UPI0000001C33	P24864-1		1					9	0.2179	0.1725	0.245	0.1022	0.3549	0.2382											0.3169	0.2039	0.3488	0.2684	0.3853	0.1032	0.4284	0.2687	0.3964	0.3213	0.2482	0.4284	gnomADg_FIN										FAIL	-16	36	-16	-13	0.00	0.02	0.01	0.00	CCNE1		3.6600e-01																																																											246					0.846							240.6													chr19	30304586																																																	True	True	False	Unknown		Unknown																						124,84	68,42	56,42	0/1	61,63,49,35	CAT						69,55,55,29	23.23		0.40384615384615385
GRCh38	CCNE1	D12_12345_1234556_Thyroid_S9	p.Ser405=	ENSP00000262643.3:p.Ser405=	chr19	29823759	29823759.0	C	T	T	29823759	.	C	T	.	PASS	NM_001238	T	synonymous_variant	LOW	CCNE1	ENSG00000105173	Transcript	ENST00000262643	protein_coding	12/12		c.1215C>T	1401	1215	405	S	agC/agT	rs7257694&COSV52904337		1		SNV	HGNC	HGNC:1589	YES	MANE_Select	NM_001238.4		1	P1	CCDS12419.1	ENSP00000262643	P24864.230		UPI0000001C33	P24864-1		1			AFDB-ENSP_mappings:AF-P24864-F1&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.1929	0.0825	0.2378	0.1012	0.3549	0.2382	0.37	0.1041	0.2477	0.3753	0.09911	0.4192	0.3104	0.3995	0.3491	0.2662	0.2901	0.115	0.3451	0.2592	0.372	0.1003	0.4291	0.2653	0.3949	0.2972	0.2467	0.4291	gnomADg_FIN		0&1	1&1	35124268&31772679&34837083&35762941						FAIL	43	-42	-17	-44	0.00	0.00	0.00	0.00	CCNE1		3.6600e-01																																																											878					0.998							247.21	v6.1	Unknown		True	CCNE1, a regulator of the cell cycle, is amplified in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCNE1 ENSP00000262643.3:S405= mutant UNKNOWN.	False	The CCNE1 ENSP00000262643.3:s405= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	30314666						True	False	False	Unknown								False	False		CCNE1, a regulator of the cell cycle, is amplified in various cancer types.	The CCNE1 ENSP00000262643.3:s405= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCNE1 ENSP00000262643.3:S405= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	CCNE1	898.0	ENSP00000262643.3:S405=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CCNE1"",""entrezGeneId"":898,""alteration"":""ENSP00000262643.3:S405="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CCNE1, a regulator of the cell cycle, is amplified in various cancer types."",""variantSummary"":""The CCNE1 ENSP00000262643.3:s405= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCNE1 ENSP00000262643.3:S405= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						475,401	244,215	231,186	0/1	245,230,201,200	GCG	0.00	0.00	0.00			232,243,181,220	21.7		0.4577625570776256
GRCh38	KMT2B	D12_12345_1234556_Thyroid_S9			chr19	35723730	35723731.0	A	AG	AG	35723730	.	A	AG	.	PASS	NM_014727	G	splice_acceptor_variant	HIGH	KMT2B	ENSG00000272333	Transcript	ENST00000420124	protein_coding		7/36	c.3059dup						rs11373774		1		insertion	HGNC	HGNC:15840	YES	MANE_Select	NM_014727.3		1	P2	CCDS46055.1	ENSP00000398837	Q9UMN6.231		UPI00001376B5			1					2																														benign&likely_benign		1	25741868																	1.2700e-01	975260				964061	Dystonia_28&_childhood-onset&Intellectual_disability&not_provided		MONDO:MONDO:0015004&MedGen:C4310633&OMIM:617284&Orphanet:589618&Human_Phenotype_Ontology:HP:0000730&Human_Phenotype_Ontology:HP:0001249&Human_Phenotype_Ontology:HP:0001267&Human_Phenotype_Ontology:HP:0001286&Human_Phenotype_Ontology:HP:0002122&Human_Phenotype_Ontology:HP:0002192&Human_Phenotype_Ontology:HP:0002316&Human_Phenotype_Ontology:HP:0002382&Human_Phenotype_Ontology:HP:0002386&Human_Phenotype_Ontology:HP:0002402&Human_Phenotype_Ontology:HP:0002458&Human_Phenotype_Ontology:HP:0002482&Human_Phenotype_Ontology:HP:0002499&Human_Phenotype_Ontology:HP:0002543&Human_Phenotype_Ontology:HP:0003767&Human_Phenotype_Ontology:HP:0006833&Human_Phenotype_Ontology:HP:0007154&Human_Phenotype_Ontology:HP:0007176&Human_Phenotype_Ontology:HP:0007180&MONDO:MONDO:0001071&MeSH:D008607&MedGen:C3714756&MedGen:C3661900		NC_000019.10:g.35723732dup	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001981137&SCV002410570	Duplication	SO:1000035	ClinGen:CA307786350		KMT2B:9757											5	11373774																											671					0.993							245.17													chr19	36214632																																																	True	True	False	Unknown		Unknown																						1,665	0,330	1,335	0/1	0,1,329,336	CAG						1,0,386,279	63.48		0.9984984984984985
GRCh38	KMT2B	D12_12345_1234556_Thyroid_S9	p.P1829L	ENSP00000398837.2:p.Pro1829Leu	chr19	35731956	35731956.0	C	T	T	35731956	.	C	T	.	PASS	NM_014727	T	missense_variant	MODERATE	KMT2B	ENSG00000272333	Transcript	ENST00000420124	protein_coding	27/37		c.5486C>T	5502	5486	1829	P/L	cCt/cTt	rs16970649&COSV55866349		1		SNV	HGNC	HGNC:15840	YES	MANE_Select	NM_014727.3		1	P2	CCDS46055.1	ENSP00000398837	Q9UMN6.231		UPI00001376B5			1	tolerated(0.09)	benign(0)	PIRSF:PIRSF010354&MobiDB_lite:mobidb-lite			0.1002	0.0794	0.0994	0.0883	0.1203	0.1207	0.1009	0.08686	0.1044	0.06235	0.08099	0.1808	0.05517	0.09888	0.08895	0.1127	0.1019	0.08367	0.1886	0.09219	0.06888	0.08826	0.1838	0.03401	0.1047	0.08009	0.1074	0.1886	gnomADg_AMI	benign	0&1	1&1	28672935						FAIL	-48	6	-5	-37	0.01	0.00	0.00	0.00	KMT2B	0.212	1.2700e-01	1278107	0.08992	0.11005	0.10024	1267985	KMT2B-related_disorder&not_provided		.&MedGen:C3661900		NC_000019.10:g.35731956C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001910852&SCV002471902&SCV005307885	single_nucleotide_variant	SO:0001483	ClinGen:CA9385435		KMT2B:9757	SO:0001583&missense_variant										1	16970649																											714					0.999							247.94	v6.1	Unknown		True	KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	False	11/25/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:P1829L mutant UNKNOWN.	False	The KMT2B ENSP00000398837.2:p1829l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	36222857						True	False	False	Unknown								False	False		KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	The KMT2B ENSP00000398837.2:p1829l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:P1829L mutant UNKNOWN.						v6.1	11/25/2019		GRCh38	KMT2B	9757.0	ENSP00000398837.2:P1829L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2B"",""entrezGeneId"":9757,""alteration"":""ENSP00000398837.2:P1829L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types."",""variantSummary"":""The KMT2B ENSP00000398837.2:p1829l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:P1829L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/25/2019""}"	True	True	False	Unknown		Unknown																						366,347	197,184	169,163	0/1	190,176,175,172	CCT	0.00	0.00	0.00			203,163,192,155	41.73		0.48667601683029454
GRCh38	KMT2B	D12_12345_1234556_Thyroid_S9			chr19	35732210	35732210.0	C	A	A	35732210	.	C	A	.	PASS	NM_014727	A	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	KMT2B	ENSG00000272333	Transcript	ENST00000420124	protein_coding		27/36	c.5666-5C>A						rs61351824&COSV55864477		1		SNV	HGNC	HGNC:15840	YES	MANE_Select	NM_014727.3		1	P2	CCDS46055.1	ENSP00000398837	Q9UMN6.231		UPI00001376B5			1						0.1030	0.087	0.1037	0.0883	0.1213	0.1207	0.1019	0.09485	0.1075	0.0626	0.08027	0.1812	0.05641	0.09988	0.09038	0.1126	0.105	0.092	0.1883	0.09549	0.06896	0.08849	0.1833	0.03425	0.1056	0.08333	0.1075	0.1883	gnomADg_AMI	benign	0&1	1&1							FAIL	41	9	28	9	0.02	0.02	0.00	0.00	KMT2B		1.2700e-01	1248123			0.10304	1239780	not_provided&KMT2B-related_disorder		MedGen:C3661900&.		NC_000019.10:g.35732210C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001866557&SCV002428506&SCV005307888	single_nucleotide_variant	SO:0001483	ClinGen:CA9385504		KMT2B:9757	SO:0001627&intron_variant										1	61351824																											372					0.997							247.35													chr19	36223111																																																	True	True	False	Unknown		Unknown																						171,200	88,100	83,100	0/1	90,81,98,102	CCA	0.00	0.00	0.00			81,90,100,100	53.56		0.5390835579514824
GRCh38	KMT2B	D12_12345_1234556_Thyroid_S9	p.Ala2099=	ENSP00000398837.2:p.Ala2099=	chr19	35732846	35732846.0	A	G	G	35732846	.	A	G	.	PASS	NM_014727	G	synonymous_variant	LOW	KMT2B	ENSG00000272333	Transcript	ENST00000420124	protein_coding	28/37		c.6297A>G	6313	6297	2099	A	gcA/gcG	rs73590585		1		SNV	HGNC	HGNC:15840	YES	MANE_Select	NM_014727.3		1	P2	CCDS46055.1	ENSP00000398837	Q9UMN6.231		UPI00001376B5			1			PIRSF:PIRSF010354&Low_complexity_(Seg):seg			0.1050	0.0885	0.1066	0.0903	0.1252	0.1207	0.1045	0.09642	0.1096	0.06251	0.08277	0.1843	0.05781	0.1027	0.09265	0.1143	0.1074	0.09386	0.189	0.09715	0.06884	0.09274	0.1891	0.03425	0.1082	0.08475	0.1096	0.1891	gnomADg_FIN	benign		1							FAIL	9	2	-30	42	0.00	0.00	0.00	0.00	KMT2B		1.2700e-01	1227002	0.08778	0.13103	0.10503	1216974	KMT2B-related_disorder&not_provided		.&MedGen:C3661900		NC_000019.10:g.35732846A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001833313&SCV002375811&SCV005307889	single_nucleotide_variant	SO:0001483	ClinGen:CA9385658		KMT2B:9757	SO:0001819&synonymous_variant										1	73590585																											781					0.995							248.26	v6.1	Unknown		True	KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	False	11/25/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:A2099= mutant UNKNOWN.	False	The KMT2B ENSP00000398837.2:a2099= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	36223747						True	False	False	Unknown								False	False		KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	The KMT2B ENSP00000398837.2:a2099= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:A2099= mutant UNKNOWN.						v6.1	11/25/2019		GRCh38	KMT2B	9757.0	ENSP00000398837.2:A2099=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2B"",""entrezGeneId"":9757,""alteration"":""ENSP00000398837.2:A2099="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types."",""variantSummary"":""The KMT2B ENSP00000398837.2:a2099= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:A2099= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/25/2019""}"	True	True	False	Unknown		Unknown																						403,374	193,178	210,196	0/1	200,203,193,181	CAG	.	.	.			184,219,163,211	38.62		0.48133848133848134
GRCh38	KMT2B	D12_12345_1234556_Thyroid_S9	p.Gly2237=	ENSP00000398837.2:p.Gly2237=	chr19	35733260	35733260.0	C	A	A	35733260	.	C	A	.	PASS	NM_014727	A	synonymous_variant	LOW	KMT2B	ENSG00000272333	Transcript	ENST00000420124	protein_coding	28/37		c.6711C>A	6727	6711	2237	G	ggC/ggA	rs112013670&COSV55872136		1		SNV	HGNC	HGNC:15840	YES	MANE_Select	NM_014727.3		1	P2	CCDS46055.1	ENSP00000398837	Q9UMN6.231		UPI00001376B5			1			PIRSF:PIRSF010354&PANTHER:PTHR45838&Low_complexity_(Seg):seg			0.1044	0.087	0.1037	0.0883	0.1223	0.1268	0.09973	0.09312	0.108	0.06177	0.07921	0.1813	0.05645	0.09707	0.08787	0.1149	0.1032	0.08966	0.1811	0.09518	0.06871	0.08552	0.1795	0.03401	0.1043	0.08063	0.108	0.1813	gnomADe_FIN	benign	0&1	1&1							FAIL	-1	32	33	-2	0.06	0.00	0.00	0.00	KMT2B		1.2700e-01	673318	0.08108	0.12882	0.10443	656525	KMT2B-related_disorder&not_provided		.&MedGen:C3661900		NC_000019.10:g.35733260C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000974343&SCV002370568&SCV005307890	single_nucleotide_variant	SO:0001483	ClinGen:CA9385739		KMT2B:9757	SO:0001819&synonymous_variant										1	112013670																											487					0.994							237.27	v6.1	Unknown		True	KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	False	11/25/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:G2237= mutant UNKNOWN.	False	The KMT2B ENSP00000398837.2:g2237= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	36224161						True	False	False	Unknown								False	False		KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	The KMT2B ENSP00000398837.2:g2237= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:G2237= mutant UNKNOWN.						v6.1	11/25/2019		GRCh38	KMT2B	9757.0	ENSP00000398837.2:G2237=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2B"",""entrezGeneId"":9757,""alteration"":""ENSP00000398837.2:G2237="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types."",""variantSummary"":""The KMT2B ENSP00000398837.2:g2237= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:G2237= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/25/2019""}"	True	True	False	Unknown		Unknown																						257,227	142,120	115,107	0/1	111,146,97,130	GCC	0.00	0.00	0.00			70,187,78,149	31.69		0.4690082644628099
GRCh38	KMT2B	D12_12345_1234556_Thyroid_S9	p.D2364G	ENSP00000398837.2:p.Asp2364Gly	chr19	35733804	35733804.0	A	G	G	35733804	.	A	G	.	PASS	NM_014727	G	missense_variant	MODERATE	KMT2B	ENSG00000272333	Transcript	ENST00000420124	protein_coding	30/37		c.7091A>G	7107	7091	2364	D/G	gAt/gGt	rs231591&COSV55857349		1		SNV	HGNC	HGNC:15840	YES	MANE_Select	NM_014727.3		1	P2	CCDS46055.1	ENSP00000398837	Q9UMN6.231		UPI00001376B5			1	tolerated(0.64)	benign(0)	PIRSF:PIRSF010354&PANTHER:PTHR45838&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.6204	0.848	0.428	0.505	0.4811	0.7117	0.4937	0.807	0.4314	0.5309	0.5128	0.5003	0.5182	0.4709	0.4977	0.6697	0.5728	0.7925	0.4075	0.4599	0.558	0.5031	0.5041	0.5136	0.4757	0.557	0.6879	0.848	AFR	benign	0&1	1&1							FAIL	0	-31	-1	13	0.00	0.06	0.00	0.00	KMT2B	0.185	1.2700e-01	1262833	0.57916	0.53313	0.62041	1252742	not_provided&Dystonia_28&_childhood-onset		MedGen:C3661900&MONDO:MONDO:0015004&MedGen:C4310633&OMIM:617284&Orphanet:589618		NC_000019.10:g.35733804A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001886466&SCV001981140&SCV002410571&SCV005307894	single_nucleotide_variant	SO:0001483	ClinGen:CA9385853		KMT2B:9757	SO:0001583&missense_variant										1	231591																											821					0.998							246.2	v6.1	Unknown		True	KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	False	11/25/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:D2364G mutant UNKNOWN.	False	The KMT2B ENSP00000398837.2:d2364g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr19	36224705						True	False	False	Unknown								False	False		KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types.	The KMT2B ENSP00000398837.2:d2364g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:D2364G mutant UNKNOWN.						v6.1	11/25/2019		GRCh38	KMT2B	9757.0	ENSP00000398837.2:D2364G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2B"",""entrezGeneId"":9757,""alteration"":""ENSP00000398837.2:D2364G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2B, a histone methyltransferase, is mutated at low frequencies in various cancer types."",""variantSummary"":""The KMT2B ENSP00000398837.2:d2364g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2B ENSP00000398837.2:D2364G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/25/2019""}"	True	True	False	Unknown		Unknown																						1,818	1,450	0,368	0/1	0,1,387,431	GAT	.	.	.			0,1,431,387	64.73		0.9987789987789988
GRCh38		D12_12345_1234556_Thyroid_S9			chr19	39069167	39069167.0	A	C	C	39069167	.	A	C	.	PASS		C	intergenic_variant	MODIFIER														rs576261				SNV																						0.4389	0.4357	0.4597	0.4157	0.4573	0.4335											0.4459	0.4261	0.4956	0.4452	0.4354	0.4235	0.4879	0.4286	0.4558	0.4553	0.4054	0.4956	gnomADg_AMI				26691610&29121662&30735000&33406744&34721519&33857205&32451905&27294018&32823826&33546406																																																																												646					0.955							211.06													chr19	39559807																																																	True	False	False	Unknown		Unknown																						319,298	165,162	154,136	0/1	170,149,152,146	AAC	.	.	.			162,157,162,136	38.69		0.4829821717990275
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	114974	114974.0	C	T	T	114974	.	C	T	.	PASS		T	intergenic_variant	MODIFIER														rs876724				SNV																						0.2724	0.1399	0.2233	0.4315	0.34	0.2526											0.2694	0.1628	0.2248	0.2731	0.3013	0.4245	0.3603	0.2857	0.3076	0.2654	0.2573	0.4315	EAS				26691610&28341840&29121662&33406744&20150382&29046953&16451622&19083859&27294018&37239431&19948332&19948333																																																																												388					0.987							245.23													chr2	114974																																																	True	False	False	Unknown		Unknown																						206,177	110,77	96,100	0/1	106,100,83,94	ACA	0.00	0.00	0.00			108,98,81,96	29.86		0.4621409921671018
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	115035	115035.0	C	T	T	115035	.	C	T	.	PASS		T	intergenic_variant	MODIFIER														rs300773				SNV																						0.7825	0.8101	0.6427	0.9067	0.829	0.6687											0.8096	0.8249	0.8626	0.7155	0.8144	0.8907	0.8726	0.7687	0.8148	0.7818	0.6803	0.9067	EAS				31830721																																																																												276					0.986							245.94													chr2	115035																																																	True	False	False	Unknown		Unknown																						0,272	0,132	0,140	0/1	0,0,133,139	ACA	0.00	0.00	0.00			0,0,99,173	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	3046019		G	<INS>	<INS>	3046019	MantaINS:6102:0:0:0:5:0	G	<INS>	.	PASS		insertion	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000296612	Transcript	ENST00000740785	lncRNA		1/2									1		insertion																																																																																																																															0,2		0,2							2	TG		TGCGTGTATGTATGCTGTGTATGTGTGCTGTGTATGTGTATGTGTGTGGATTTGTGGTGTGTATGTGTGT																chr2	3049791	CATGTGTGTGGTGTGTATGTGTGGTATGTATTTGTGCTGTGTGTATGCATGTGTCTGTATGTATGTGTGGTATGTGTATGGTGTGTATGTGTGTGGTGTGTGTGCATGTGTATGTGTGGTGTGTATGTGTATGGTATATGTGTATGTGTGTGGATATGTGGTGTGTGTGTACGTGTGTATGTAGGTGTGGTGTGCA			INS																																													True	False	False	Unknown		Unknown																															0,0				0,25	
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	9945593	9945593.0	G	A	A	9945593	.	G	A	.	PASS		A	upstream_gene_variant	MODIFIER		ENSG00000287305	Transcript	ENST00000826148	lncRNA									rs1109037	4792	-1		SNV																						0.4395	0.4221	0.4856	0.4395	0.4642	0.4049											0.4751	0.4299	0.5154	0.4896	0.4867	0.4399	0.4282	0.4116	0.5133	0.4772	0.4061	0.5154	gnomADg_AMI				23771752&26691610&29121662&33406744&34721519&31745634&32699278&37239431																																																																												667					0.997							245.93													chr2	10085722																																																	True	False	False	Unknown		Unknown																						337,328	173,179	164,149	0/1	153,184,178,150	CGG	0.00	0.00	0.00			223,114,179,149	44.76		0.4932330827067669
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	9945657	9945657.0	G	A	A	9945657	.	G	A	.	PASS		A	upstream_gene_variant	MODIFIER		ENSG00000287305	Transcript	ENST00000826148	lncRNA									rs1109038	4856	-1		SNV																						0.2923	0.1263	0.4236	0.3919	0.3469	0.2648											0.3124	0.1726	0.5066	0.4054	0.3751	0.429	0.2996	0.3527	0.3657	0.3201	0.2846	0.5066	gnomADg_AMI																																																																																711					0.999							246.95													chr2	10085786																																																	True	False	False	Unknown		Unknown																						381,329	198,169	183,160	0/1	190,191,148,181	GGG	0.00	0.00	0.00			177,204,156,173	27.09		0.46338028169014084
GRCh38	MYCN	D12_12345_1234556_Thyroid_S9			chr2	15943403	15943404.0	C	CT	CT	15943403	.	C	CT	.	PASS	NM_005378	T	intron_variant	MODIFIER	MYCN	ENSG00000134323	Transcript	ENST00000281043	protein_coding		2/2	c.790+564dup						rs111360717		1		insertion	HGNC	HGNC:7559	YES	MANE_Select	NM_005378.6		5	P1	CCDS1687.1	ENSP00000281043	P04198.236		UPI000012FAF8			1					15	0.6711	0.7791	0.67	0.7411	0.5666	0.5613											0.6156	0.7754	0.6674	0.5994	0.531	0.7443	0.6238	0.4432	0.5263	0.5747	0.5717	0.7791	AFR										FAIL	-35	-48	20	24	0.00	0.00	0.00	0.00	MYCN		3.1100e-01																																																											388					0.802							220.18													chr2	16083525																																																	True	True	False	Unknown		Unknown																						132,179	58,90	74,89	0/1	61,71,96,83	TCT						83,49,91,88	40.66		0.5755627009646302
GRCh38	MYCN	D12_12345_1234556_Thyroid_S9			chr2	15944472	15944472.0	T	C	C	15944472	.	T	C	.	PASS	NM_005378	C	intron_variant	MODIFIER	MYCN	ENSG00000134323	Transcript	ENST00000281043	protein_coding		2/2	c.791-1021T>C						rs3755135		1		SNV	HGNC	HGNC:7559	YES	MANE_Select	NM_005378.6		5	P1	CCDS1687.1	ENSP00000281043	P04198.236		UPI000012FAF8			1						0.5927	0.6611	0.5663	0.7817	0.3559	0.5675											0.4433	0.6045	0.2659	0.4914	0.3905	0.7933	0.335	0.3878	0.3228	0.4375	0.5441	0.7933	gnomADg_EAS										FAIL	-27	19	18	-37	0.00	0.00	0.00	0.00	MYCN		3.1100e-01																																																											109					0.945							239.52													chr2	16084594																																																	True	True	False	Unknown		Unknown																						48,55	24,33	24,22	0/1	29,19,24,31	GTT	.	.	.			19,29,26,29	39.1		0.5339805825242718
GRCh38	MYCN	D12_12345_1234556_Thyroid_S9			chr2	15946347	15946347.0	C	T	T	15946347	.	C	T	.	PASS	NM_005378	T	3_prime_UTR_variant	MODIFIER	MYCN	ENSG00000134323	Transcript	ENST00000281043	protein_coding	3/3		c.*250C>T	1956					rs922&COSV55258890		1		SNV	HGNC	HGNC:7559	YES	MANE_Select	NM_005378.6		5	P1	CCDS1687.1	ENSP00000281043	P04198.236		UPI000012FAF8			1						0.2328	0.0144	0.3501	0.3958	0.2475	0.2618	0.2391	0.04477	0.3515	0.2631	0.4182	0.2533	0.1838	0.219	0.2214	0.2455	0.1908	0.04402	0.1505	0.2903	0.2669	0.4176	0.2684	0.1463	0.2212	0.1912	0.2561	0.4182	gnomADe_EAS	benign	0&1	1&1	29997440&32888493&21654684&32888494						FAIL	-5	-16	-5	1	0.00	0.00	0.00	0.00	MYCN		3.1100e-01	1276196			0.23283	1268824	not_provided		MedGen:C3661900		NC_000002.12:g.15946347C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001908083&SCV005243105	single_nucleotide_variant	SO:0001483	ClinGen:CA11058727		MYCN:4613	SO:0001624&3_prime_UTR_variant										1	922																											826					0.996							206.92													chr2	16086469																																																	True	True	False	Unknown		Unknown																						422,401	222,211	200,190	0/1	198,224,202,199	ACG	0.00	0.00	0.00			162,260,138,263	43.06		0.48724179829890646
GRCh38	MYCN	D12_12345_1234556_Thyroid_S9			chr2	15949237	15949237.0	T	C	C	15949237	.	T	C	.	PASS	NM_005378	C	downstream_gene_variant	MODIFIER	MYCN	ENSG00000134323	Transcript	ENST00000281043	protein_coding									rs55912884	2233	1		SNV	HGNC	HGNC:7559	YES	MANE_Select	NM_005378.6		5	P1	CCDS1687.1	ENSP00000281043	P04198.236		UPI000012FAF8			1						0.5903	0.6762	0.572	0.7728	0.3588	0.5368											0.4459	0.6149	0.2637	0.4932	0.3957	0.7841	0.336	0.3878	0.3237	0.4369	0.5243	0.7841	gnomADg_EAS																																																																																267					0.996							246.38													chr2	16089359																																																	True	True	False	Unknown		Unknown																						133,133	71,60	62,73	0/1	74,59,71,62	CTG	.	.	.			90,43,78,55	40.04		0.5
GRCh38	MAP4K3	D12_12345_1234556_Thyroid_S9			chr2	39345794	39345794.0	T	C	C	39345794	.	T	C	.	PASS		C	intron_variant&NMD_transcript_variant	MODIFIER	MAP4K3	ENSG00000011566	Transcript	ENST00000437968	nonsense_mediated_decay		2/3	c.*53-2342A>G						rs6753323		-1		SNV	HGNC	HGNC:6865					5			ENSP00000410183		F8WBC3.77	UPI00004DEC3D									0.8413	0.7746	0.8127	0.8849	0.9264	0.819											0.8781	0.8134	0.8209	0.827	0.9135	0.8704	0.9739	0.8639	0.9176	0.883	0.8183	0.9739	gnomADg_FIN										FAIL	-46	-44	-9	3	0.00	0.00	0.00	0.00	MAP4K3																																																													38					1							108.34													chr2	39572935																																																	True	False	False	Unknown		Unknown																						20,18	13,8	7,10	0/1	13,7,8,10	GTG	.	.	.			20,0,16,2	28.86		0.47368421052631576
GRCh38	MAP4K3	D12_12345_1234556_Thyroid_S9			chr2	39345921	39345925.0	CAAAA	C	C	39345921	.	CAAAA	C	.	PASS		-	intron_variant&NMD_transcript_variant	MODIFIER	MAP4K3	ENSG00000011566	Transcript	ENST00000437968	nonsense_mediated_decay		2/3	c.*53-2473_*53-2470del						rs66729858		-1		deletion	HGNC	HGNC:6865					5			ENSP00000410183		F8WBC3.77	UPI00004DEC3D																									6.312e-05	0	0	0	0	0	0	0	0.0001359	0	0	0.0001359	gnomADg_NFE										FAIL	-3	-7	7	-7	0.00	0.00	0.00	0.00	MAP4K3																																																													248					0.556							148.15													chr2	39573062																																																	True	False	False	Unknown		Unknown																						117,21	46,15	71,6	0/1	78,39,13,8	TCA						65,52,11,10	6.78		0.15217391304347827
GRCh38	EML4	D12_12345_1234556_Thyroid_S9			chr2	42169582	42169582.0	A	G	G	42169582	.	A	G	.	PASS	NM_019063	G	5_prime_UTR_variant	MODIFIER	EML4	ENSG00000143924	Transcript	ENST00000318522	protein_coding	1/23		c.-30A>G	230					rs7233&COSV59296770		1		SNV	HGNC	HGNC:1316	YES	MANE_Select	NM_019063.5		1		CCDS1807.1	ENSP00000320663	Q9HC35.203		UPI0000140350	Q9HC35-1		1						0.6989	0.7262	0.8242	0.4335	0.67	0.8763	0.6823	0.7313	0.8267	0.7724	0.4541	0.6239	0.8085	0.6709	0.6894	0.8311	0.6947	0.7324	0.6009	0.7671	0.7661	0.447	0.6115	0.8527	0.6739	0.7167	0.8259	0.8763	SAS		0&1	0&1	27029813						FAIL	-13	3	50	-29	0.00	0.00	0.00	0.00	EML4		6.8000e-01																																																											1043					0.995							247.53													chr2	42396722																																																	True	True	False	Unknown		Unknown																						513,525	261,273	252,252	0/1	246,267,262,263	TAA	.	.	.			258,255,254,271	60.16		0.5057803468208093
GRCh38	EML4	D12_12345_1234556_Thyroid_S9	p.K283E	ENSP00000320663.5:p.Lys283Glu	chr2	42282878	42282878.0	A	G	G	42282878	.	A	G	.	PASS	NM_019063	G	missense_variant	MODERATE	EML4	ENSG00000143924	Transcript	ENST00000318522	protein_coding	8/23		c.847A>G	1106	847	283	K/E	Aaa/Gaa	rs6736913&COSV59293461		1		SNV	HGNC	HGNC:1316	YES	MANE_Select	NM_019063.5		1		CCDS1807.1	ENSP00000320663	Q9HC35.203		UPI0000140350	Q9HC35-1		1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.130.10.10&Gene3D:2.130.10.10&Pfam:PF03451&PANTHER:PTHR13720&Superfamily:SSF50998&AFDB-ENSP_mappings:AF-Q9HC35-F1			0.9962	0.9992	0.9928	1	0.9881	0.999	0.9841	0.998	0.9957	0.9989	1	0.9849	0.9988	0.9809	0.9878	0.9979	0.9896	0.9966	0.9978	0.991	0.9994	1	0.9844	1	0.9838	0.9905	0.9992	1	EAS&gnomADe_EAS&gnomADg_EAS&gnomADg_MID	benign	0&1	1&1	27029813&34944636&34668636&30281099&35192695&31654503&33462484&34852643&36330403&32042192&37521845&36653534						FAIL	-41	7	-1	7	0.00	0.01	0.00	0.00	EML4	0.197	6.8000e-01	1227684	0.98762	0.99047	0.99621	1215076	not_provided		MedGen:C3661900		NC_000002.12:g.42282878A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001836193&SCV005238306	single_nucleotide_variant	SO:0001483	ClinGen:CA1628657		EML4:27436	SO:0001583&missense_variant										1	6736913																											155					0.987							244.63	v6.1	Unknown		True	EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer.	False	04/21/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:K283E mutant UNKNOWN.	False	The EML4 ENSP00000320663.5:k283e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	42510018						True	False	False	Unknown								False	False		EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer.	The EML4 ENSP00000320663.5:k283e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:K283E mutant UNKNOWN.						v6.1	04/21/2025		GRCh38	EML4	27436.0	ENSP00000320663.5:K283E			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EML4"",""entrezGeneId"":27436,""alteration"":""ENSP00000320663.5:K283E"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer."",""variantSummary"":""The EML4 ENSP00000320663.5:k283e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:K283E mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/21/2025""}"	True	True	False	Unknown		Unknown																						0,153	0,84	0,69	0/1	0,0,86,67	GAA	.	.	.			0,0,73,80	64.72		1.0
GRCh38	EML4	D12_12345_1234556_Thyroid_S9	p.I382V	ENSP00000320663.5:p.Ile382Val	chr2	42288248	42288248.0	A	G	G	42288248	.	A	G	.	PASS	NM_019063	G	missense_variant	MODERATE	EML4	ENSG00000143924	Transcript	ENST00000318522	protein_coding	11/23		c.1144A>G	1403	1144	382	I/V	Att/Gtt	rs10202624&COSV59293527		1		SNV	HGNC	HGNC:1316	YES	MANE_Select	NM_019063.5		1		CCDS1807.1	ENSP00000320663	Q9HC35.203		UPI0000140350	Q9HC35-1		1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.130.10.10&Gene3D:2.130.10.10&Pfam:PF23409&PANTHER:PTHR13720&Superfamily:SSF50998&AFDB-ENSP_mappings:AF-Q9HC35-F1			0.8536	0.9705	0.6369	0.8036	0.8986	0.8548	0.8888	0.9426	0.5452	0.8877	0.7949	0.8636	0.8976	0.9063	0.8826	0.8786	0.8861	0.9423	0.8575	0.6924	0.8874	0.7981	0.8483	0.8878	0.9096	0.875	0.8722	0.9705	AFR		0&1	0&1	34668636						FAIL	-21	-14	-1	-14	0.00	0.01	0.00	0.00	EML4	0.165	6.8000e-01																																																											97					0.969							236.46	v6.1	Unknown		True	EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer.	False	04/21/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:I382V mutant UNKNOWN.	False	The EML4 ENSP00000320663.5:i382v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	42515388						True	False	False	Unknown								False	False		EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer.	The EML4 ENSP00000320663.5:i382v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:I382V mutant UNKNOWN.						v6.1	04/21/2025		GRCh38	EML4	27436.0	ENSP00000320663.5:I382V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EML4"",""entrezGeneId"":27436,""alteration"":""ENSP00000320663.5:I382V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer."",""variantSummary"":""The EML4 ENSP00000320663.5:i382v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:I382V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/21/2025""}"	True	True	False	Unknown		Unknown																						0,94	0,43	0,51	0/1	0,0,50,44	TAT	.	.	.			0,0,43,51	64.66		1.0
GRCh38	EML4	D12_12345_1234556_Thyroid_S9	p.K398R	ENSP00000320663.5:p.Lys398Arg	chr2	42288297	42288297.0	A	G	G	42288297	.	A	G	.	PASS	NM_019063	G	missense_variant	MODERATE	EML4	ENSG00000143924	Transcript	ENST00000318522	protein_coding	11/23		c.1193A>G	1452	1193	398	K/R	aAg/aGg	rs28651764&COSV59293537		1		SNV	HGNC	HGNC:1316	YES	MANE_Select	NM_019063.5		1		CCDS1807.1	ENSP00000320663	Q9HC35.203		UPI0000140350	Q9HC35-1		1	tolerated_low_confidence(0.26)	benign(0.007)	Gene3D:2.130.10.10&Gene3D:2.130.10.10&Pfam:PF23409&PANTHER:PTHR13720&Superfamily:SSF50998&SMART:SM00320&AFDB-ENSP_mappings:AF-Q9HC35-F1			0.2726	0.1679	0.1657	0.5784	0.3131	0.1329	0.2984	0.1603	0.1569	0.2259	0.5495	0.3277	0.172	0.3115	0.2893	0.1624	0.2742	0.1807	0.4121	0.2194	0.2356	0.5648	0.3315	0.1327	0.3205	0.2613	0.179	0.5784	EAS		0&1	0&1	34668636						FAIL	1	2	-17	25	0.00	0.00	0.00	0.01	EML4	0.059	6.8000e-01																																																											119					0.95							240.11	v6.1	Unknown		True	EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer.	False	04/21/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:K398R mutant UNKNOWN.	False	The EML4 ENSP00000320663.5:k398r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	42515437						True	False	False	Unknown								False	False		EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer.	The EML4 ENSP00000320663.5:k398r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:K398R mutant UNKNOWN.						v6.1	04/21/2025		GRCh38	EML4	27436.0	ENSP00000320663.5:K398R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EML4"",""entrezGeneId"":27436,""alteration"":""ENSP00000320663.5:K398R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EML4, a microtubule-associated protein, is frequently altered by chromosomal rearrangement in non-small cell lung cancer."",""variantSummary"":""The EML4 ENSP00000320663.5:k398r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EML4 ENSP00000320663.5:K398R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/21/2025""}"	True	True	False	Unknown		Unknown																						57,56	30,28	27,28	0/1	29,28,30,26	AAG	.	.	.			26,31,28,28	35.57		0.49557522123893805
GRCh38	EML4	D12_12345_1234556_Thyroid_S9			chr2	42328882	42328882.0	A	T	T	42328882	.	A	T	.	PASS	NM_019063	T	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	EML4	ENSG00000143924	Transcript	ENST00000318522	protein_coding		21/22	c.2342-4A>T						rs2286700&COSV59293699		1		SNV	HGNC	HGNC:1316	YES	MANE_Select	NM_019063.5		1		CCDS1807.1	ENSP00000320663	Q9HC35.203		UPI0000140350	Q9HC35-1		1						0.2268	0.062	0.1427	0.5704	0.2734	0.1074	0.2694	0.08225	0.1474	0.2166	0.5516	0.2943	0.1742	0.2799	0.2612	0.1452	0.2226	0.09108	0.3198	0.1917	0.2231	0.5597	0.2952	0.1258	0.2773	0.2216	0.1496	0.5704	EAS		0&1	0&1							FAIL	19	-32	16	-1	0.00	0.00	0.00	0.00	EML4		6.8000e-01																																																											62					0.984							242.18													chr2	42556022																																																	True	True	False	Unknown		Unknown																						35,26	11,10	24,16	0/1	18,17,12,14	CAA	.	.	.			14,21,18,8	27.66		0.4262295081967213
GRCh38	EML4	D12_12345_1234556_Thyroid_S9			chr2	42332148	42332148.0	A	G	G	42332148	.	A	G	.	PASS	NM_019063	G	3_prime_UTR_variant	MODIFIER	EML4	ENSG00000143924	Transcript	ENST00000318522	protein_coding	23/23		c.*1941A>G	5146					rs13375&COSV59304620		1		SNV	HGNC	HGNC:1316	YES	MANE_Select	NM_019063.5		1		CCDS1807.1	ENSP00000320663	Q9HC35.203		UPI0000140350	Q9HC35-1		1						0.2091	0.3714	0.1499	0.1706	0.1392	0.1431	0.1537	0.3318	0.1501	0.1476	0.1876	0.1068	0.1082	0.1344	0.1497	0.1498	0.1938	0.3308	0.06579	0.1486	0.147	0.1907	0.1266	0.06803	0.14	0.1711	0.1454	0.3714	AFR		0&1	0&1							FAIL	7	-13	-1	-32	0.00	0.00	0.00	0.00	EML4		6.8000e-01																																																											82					1							238.94													chr2	42559288																																																	True	True	False	Unknown		Unknown																						39,43	22,22	17,21	0/1	21,18,20,23	GAA	.	.	.			24,15,21,22	37.41		0.524390243902439
GRCh38	EPCAM	D12_12345_1234556_Thyroid_S9	p.M115T	ENSP00000263735.4:p.Met115Thr	chr2	47373967	47373967.0	T	C	C	47373967	.	T	C	.	PASS	NM_002354	C	missense_variant	MODERATE	EPCAM	ENSG00000119888	Transcript	ENST00000263735	protein_coding	3/9		c.344T>C	539	344	115	M/T	aTg/aCg	rs1126497&CM1110060&COSV55392922		1		SNV	HGNC	HGNC:11529	YES	MANE_Select	NM_002354.3		1	P1	CCDS1833.1	ENSP00000263735	P16422.217		UPI000013D450			1	tolerated(1)	benign(0)	Gene3D:4.10.800.10&PDB-ENSP_mappings:4mzv.A&PDB-ENSP_mappings:6i07.C&PDB-ENSP_mappings:6i07.D&AFDB-ENSP_mappings:AF-P16422-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00086&PROSITE_patterns:PS00484&PROSITE_profiles:PS51162&PANTHER:PTHR14168&SMART:SM00211&Superfamily:SSF57610&CDD:cd00191			0.6661	0.8888	0.5159	0.8323	0.4692	0.5031	0.4674	0.8493	0.4743	0.3677	0.7898	0.5922	0.3828	0.4385	0.4956	0.4797	0.5771	0.8311	0.3538	0.4938	0.3635	0.816	0.5912	0.3605	0.4425	0.5247	0.4979	0.8888	AFR	benign	0&1&1	1&1&1	25741868&24033266&22938532&28652652&29458332&20683652&22322561&26115884&27900359&26318430&35070966&31511551&30089705&34967580&33240400&24304228&22781090&24718422&28366820&34573430&37563730						FAIL	-25	31	25	6	0.00	0.00	0.00	0.02	EPCAM	0.183	1.3410e+00	183700	0.56674	0.51979	0.66613	181861	not_specified&Hereditary_cancer-predisposing_syndrome&not_provided&Lynch_syndrome_8&Congenital_diarrhea_5_with_tufting_enteropathy&Lynch_syndrome_1		MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MONDO:MONDO:0013196&MedGen:C2750471&OMIM:613244&Orphanet:144&MONDO:MONDO:0013184&MedGen:C2750737&OMIM:613217&Orphanet:92050&MONDO:MONDO:0007356&MedGen:C2936783&OMIM:120435&Orphanet:144		NC_000002.12:g.47373967T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212678&SCV000308851&SCV000539105&SCV000611714&SCV000625718&SCV001838969&SCV001876051&SCV004017450&SCV005241299&SCV006311501	single_nucleotide_variant	SO:0001483	ClinGen:CA186167&UniProtKB:P16422																																																																																																																																															244,326	115,158	129,168	0/1	126,118,161,165	ATG	.	.	.			127,117,153,173	43.69		0.5719298245614035
GRCh38	MSH2	D12_12345_1234556_Thyroid_S9	p.S498R	ENSP00000233146.2:p.Ser498Arg	chr2	47463138	47463138.0	T	G	G	47463138	.	T	G	.	PASS	NM_000251	G	missense_variant	MODERATE	MSH2	ENSG00000095002	Transcript	ENST00000233146	protein_coding	9/16		c.1494T>G	1530	1494	498	S/R	agT/agG	rs2104092927		1		SNV	HGNC	HGNC:7325	YES	MANE_Select	NM_000251.3		1	P1	CCDS1834.1	ENSP00000233146	P43246.249		UPI00000405F6	P43246-1		1	tolerated(0.31)	benign(0.005)	PDB-ENSP_mappings:2o8b.A&PDB-ENSP_mappings:2o8c.A&PDB-ENSP_mappings:2o8d.A&PDB-ENSP_mappings:2o8e.A&PDB-ENSP_mappings:2o8f.A&PDB-ENSP_mappings:3thw.A&PDB-ENSP_mappings:3thx.A&PDB-ENSP_mappings:3thy.A&PDB-ENSP_mappings:3thz.A&PDB-ENSP_mappings:8ag6.A&PDB-ENSP_mappings:8olx.A&PDB-ENSP_mappings:8om5.A&PDB-ENSP_mappings:8om9.A&PDB-ENSP_mappings:8oma.A&PDB-ENSP_mappings:8omo.A&PDB-ENSP_mappings:8omq.A&Coiled-coils_(Ncoils):Coil&Superfamily:SSF48334&PANTHER:PTHR11361&SMART:SM00533&Pfam:PF05192&Pfam:PF05190&Gene3D:1.10.1420.10&PIRSF:PIRSF005813&AFDB-ENSP_mappings:AF-P43246-F1																																		1							FAIL	0	5	36	16	0.00	0.00	0.00	0.00	MSH2	0.537	6.7200e-01																																																											97					0.959							240.4	v6.1	Unknown		True	MSH2, a DNA mismatch repair protein, is frequently mutated in colorectal, small bowel, and endometrial cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MSH2 ENSP00000233146.2:S498R mutant UNKNOWN.	False	The MSH2 ENSP00000233146.2:s498r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	47690277						True	False	False	Unknown								False	False		MSH2, a DNA mismatch repair protein, is frequently mutated in colorectal, small bowel, and endometrial cancers.	The MSH2 ENSP00000233146.2:s498r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MSH2 ENSP00000233146.2:S498R mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	MSH2	4436.0	ENSP00000233146.2:S498R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MSH2"",""entrezGeneId"":4436,""alteration"":""ENSP00000233146.2:S498R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MSH2, a DNA mismatch repair protein, is frequently mutated in colorectal, small bowel, and endometrial cancers."",""variantSummary"":""The MSH2 ENSP00000233146.2:s498r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MSH2 ENSP00000233146.2:S498R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	True	Unknown		Unknown																						90,3	41,0	49,3	0/1	46,44,2,1	GTG	.	.	.			41,49,1,2	9.23		0.03225806451612903
GRCh38	MSH6	D12_12345_1234556_Thyroid_S9	p.G39E	ENSP00000234420.5:p.Gly39Glu	chr2	47783349	47783349.0	G	A	A	47783349	.	G	A	.	PASS	NM_000179	A	missense_variant	MODERATE	MSH6	ENSG00000116062	Transcript	ENST00000234420	protein_coding	1/10		c.116G>A	205	116	39	G/E	gGg/gAg	rs1042821&CM092149&COSV52274018		1		SNV	HGNC	HGNC:7329	YES	MANE_Select	NM_000179.3		1	P4	CCDS1836.1	ENSP00000234420	P52701.253		UPI00000405F8	P52701-1		1	tolerated(0.6)	possibly_damaging(0.569)	PDB-ENSP_mappings:8ag6.B&AFDB-ENSP_mappings:AF-P52701-F1&PIRSF:PIRSF037677&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.2009	0.2103	0.1398	0.2758	0.1819	0.1738	0.1835	0.2172	0.1104	0.2999	0.283	0.1322	0.251	0.1782	0.1993	0.2123	0.1888	0.2151	0.2527	0.1453	0.307	0.2458	0.1245	0.2192	0.18	0.1837	0.2067	0.307	gnomADg_ASJ	benign&benign/likely_benign	0&1&1	1&1&1	25741868&24033266&25491747&26811195&30337837&23757202&22623965&18701435&21700777&23720673&21036793&22703879&29458332&19781088&20149637&26900293&29616133&32957448&19389263&10507723&10537275&10699937&15805151&24689082&1958276&8838326&16203774&16270383&16771955&17108146&17205513&18355840&18523027&19582761&19685280&22949387&25023197&26027715&27900359&31374908&35868444&25938433&32756484&28749454&22294770&24383517&28481244&32773772&37296718&21286719&29365312&37035153&31031852&32053874&30214228&35541922&23436172&18851982						FAIL	18	-20	1	-25	0.00	0.00	0.00	0.00	MSH6	0.163	8.4100e-01	36581	0.17965		0.20088	45243	Hereditary_nonpolyposis_colorectal_neoplasms&Hereditary_cancer-predisposing_syndrome&not_provided&not_specified&Lynch_syndrome&Lynch_syndrome_5&Carcinoma_of_colon&Breast_carcinoma&Lynch_syndrome_1		MeSH:D003123&MedGen:C0009405&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0005835&MedGen:C4552100&Orphanet:144&MONDO:MONDO:0013710&MedGen:C1833477&OMIM:614350&Orphanet:144&MONDO:MONDO:0002032&MedGen:C0699790&Human_Phenotype_Ontology:HP:0003002&MONDO:MONDO:0004989&MedGen:C0678222&MONDO:MONDO:0007356&MedGen:C2936783&OMIM:120435&Orphanet:144		NC_000002.12:g.47783349G>A	reviewed_by_expert_panel	Benign			SCV000107840	single_nucleotide_variant	SO:0001483	ClinGen:CA008209&UniProtKB:P52701																																																																																																																																															261,255	140,130	121,125	0/1	132,129,131,124	GGG	0.00	0.00	0.00			83,178,78,177	42.83		0.4941860465116279
GRCh38	FANCL	D12_12345_1234556_Thyroid_S9	p.Ser327=	ENSP00000233741.5:p.Ser327=	chr2	58161561	58161561.0	A	G	G	58161561	.	A	G	.	PASS	NM_018062	G	synonymous_variant	LOW	FANCL	ENSG00000115392	Transcript	ENST00000233741	protein_coding	12/14		c.981T>C	993	981	327	S	tcT/tcC	rs848291&COSV52073421		-1		SNV	HGNC	HGNC:20748	YES	MANE_Select	NM_018062.4		1	P4	CCDS1860.1	ENSP00000233741	Q9NW38.194		UPI000013C98C	Q9NW38-1		1			PDB-ENSP_mappings:4ccg.X&PDB-ENSP_mappings:4ccg.Y&PDB-ENSP_mappings:7kzp.L&PDB-ENSP_mappings:7kzp.M&PDB-ENSP_mappings:7kzq.L&PDB-ENSP_mappings:7kzq.M&PDB-ENSP_mappings:7kzr.L&PDB-ENSP_mappings:7kzr.M&PDB-ENSP_mappings:7kzs.L&PDB-ENSP_mappings:7kzs.M&PDB-ENSP_mappings:7kzt.L&PDB-ENSP_mappings:7kzt.M&PDB-ENSP_mappings:7kzv.L&PDB-ENSP_mappings:7kzv.M&Superfamily:SSF57850&PANTHER:PTHR13206&Gene3D:3.30.40.10&Pfam:PF11793&CDD:cd16490&SMART:SM01197&AFDB-ENSP_mappings:AF-Q9NW38-F1			0.7065	0.947	0.6412	0.5883	0.6173	0.6411	0.6211	0.9155	0.6731	0.5468	0.5712	0.653	0.557	0.6084	0.6347	0.6634	0.6923	0.8978	0.4978	0.6451	0.5413	0.575	0.6374	0.6088	0.608	0.6556	0.6698	0.947	AFR	benign	0&1	1&1	25741868&19488044&36143969						FAIL	13	-4	-39	15	0.00	0.00	0.01	0.00	FANCL		1.4440e+00	257495	0.70409	0.64866	0.70647	250750	Fanconi_anemia&Fanconi_anemia_complementation_group_L&not_provided&not_specified		MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MONDO:MONDO:0013566&MedGen:C3469528&OMIM:614083&Orphanet:84&MedGen:C3661900&MedGen:CN169374		NC_000002.12:g.58161561A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306655&SCV000431330&SCV000603590&SCV000999959&SCV001908246&SCV001933287&SCV002795267&SCV004015678&SCV005244229	single_nucleotide_variant	SO:0001483	ClinGen:CA1670366		FANCL:55120	SO:0001819&synonymous_variant										1	848291																											105					0.952							237.85	v6.1	Unknown		True	FANCL, an E3 ubiquitin ligase involved in DNA repair, is infrequently altered in cancer. Germline mutations of FANCL are associated with the cancer predisposition syndrome Fanconi Anemia.	False	06/05/2020	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCL ENSP00000233741.5:S327= mutant UNKNOWN.	False	The FANCL ENSP00000233741.5:s327= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	58388696						True	False	False	Unknown								False	False		FANCL, an E3 ubiquitin ligase involved in DNA repair, is infrequently altered in cancer. Germline mutations of FANCL are associated with the cancer predisposition syndrome Fanconi Anemia.	The FANCL ENSP00000233741.5:s327= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCL ENSP00000233741.5:S327= mutant UNKNOWN.						v6.1	06/05/2020		GRCh38	FANCL	55120.0	ENSP00000233741.5:S327=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FANCL"",""entrezGeneId"":55120,""alteration"":""ENSP00000233741.5:S327="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FANCL, an E3 ubiquitin ligase involved in DNA repair, is infrequently altered in cancer. Germline mutations of FANCL are associated with the cancer predisposition syndrome Fanconi Anemia."",""variantSummary"":""The FANCL ENSP00000233741.5:s327= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCL ENSP00000233741.5:S327= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/05/2020""}"	True	True	False	Unknown		Unknown																						56,44	29,27	27,17	0/1	28,28,23,21	GAG	.	.	.			25,31,22,22	28.51		0.44
GRCh38	XPO1	D12_12345_1234556_Thyroid_S9			chr2	61522608		T	<INS>	<INS>	61522608	MantaINS:1365:1:1:0:3:0	T	<INS>	.	PASS	NM_003400	insertion	intergenic_variant	MODIFIER	XPO1	ENSG00000082898	Transcript	ENST00000401558	protein_coding		4/24									-1		insertion	HGNC	HGNC:12825	YES	MANE_Select	NM_003400.4		1	P1	CCDS33205.1	ENSP00000384863	O14980.221		UPI0000001C23			1																																																																																																															0,46		0,46							46	ACCTTCGCACTGGTTCCTTGGAAGAATCTTCCACCTTGTTTTTATC		ACCTTCGCACTGGTTCCTTGGAAGAATCTTCCACCTTGTTTTTATCCTCTTTTATTTCCTTGAGCAGTGGTTTGTAGTTCTCCTTGAAGAGGTCCTTCACAT																chr2	61749743	ATTTCTCAATTTTACTCTAATTTTCTAACCTCAAACTTAAAACACATCATTTCCCTCTTTATTTTCCC			INS																																													True	True	False	Unknown		Unknown																															3,4				18,5	
GRCh38	EXOC6B	D12_12345_1234556_Thyroid_S9			chr2	72260119		A	[chr4:79453484[A	[chr4:79453484[A	72260119	MantaBND:893:0:1:0:0:0:1	A	[chr4:79453484[A	.	PASS		.A	feature_truncation&intron_variant	HIGH	EXOC6B	ENSG00000144036	Transcript	ENST00000634650	protein_coding		20/22									-1		chromosome_breakpoint	HGNC	HGNC:17085					5	A1	CCDS82468.1	ENSP00000489442		A0A0U1RRB6.44	UPI000387CC09			1																																																																																																														3			0,5							5	GCAGT			MantaBND:893:0:1:0:0:0:0	0														chr2	72487248				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	75426147		T	[chr10:8851919[T	[chr10:8851919[T	75426147	MantaBND:6716:0:1:0:0:0:0	T	[chr10:8851919[T	.	PASS																																																																																																																																																				0			0,12							12	TTCCCTTCCTTC			MantaBND:6716:0:1:0:0:0:1	1														chr2	75653273				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	86041355		G	[chr14:34841564[G	[chr14:34841564[G	86041355	MantaBND:3118:0:1:0:0:0:0	G	[chr14:34841564[G	.	PASS		.G	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR2_939647														chromosome_breakpoint																																																																																																																														6			0,11							11	TGTGTGTGTGC			MantaBND:3118:0:1:0:0:0:1	2														chr2	86268478				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38	ZNF2	D12_12345_1234556_Thyroid_S9			chr2	95183613	95183615.0	ATT	A	A	95183613	.	ATT	A	.	PASS		-	downstream_gene_variant	MODIFIER	ZNF2	ENSG00000275111	Transcript	ENST00000622059	protein_coding									rs761092352	1159	1		deletion	HGNC	HGNC:12991					2		CCDS62957.1	ENSP00000483131	Q9BSG1.183		UPI000390744E	Q9BSG1-4														0							0	0		0.0002179	0.0006636	0	0	0	0	0	0.01042	0.0001048	0	0	0.01042	gnomADg_MID																																																																																458					0.548							193.1													chr2	95849361																																																	True	False	False	Unknown		Unknown																						217,34	126,18	91,16	0/1	122,95,17,17	TAT						67,150,9,25	7.58		0.13545816733067728
GRCh38	INPP4A	D12_12345_1234556_Thyroid_S9	p.Thr86=	ENSP00000386777.4:p.Thr86=	chr2	98533483	98533483.0	G	A	A	98533483	.	G	A	.	PASS	NM_001134225	A	synonymous_variant	LOW	INPP4A	ENSG00000040933	Transcript	ENST00000409851	protein_coding	5/25		c.258G>A	651	258	86	T	acG/acA	rs2278211&COSV50812687		1		SNV	HGNC	HGNC:6074	YES	MANE_Select	NM_001134225.2		1		CCDS46371.1	ENSP00000386777	Q96PE3.152		UPI000013C579	Q96PE3-3		1			Gene3D:2.60.40.150&AFDB-ENSP_mappings:AF-Q96PE3-F1&PROSITE_profiles:PS50004&PANTHER:PTHR12187&Superfamily:SSF49562&CDD:cd04048			0.2304	0.0749	0.304	0.2956	0.2674	0.2832	0.2534	0.1124	0.2863	0.3543	0.2638	0.2035	0.2866	0.255	0.2595	0.2595	0.2203	0.1175	0.1118	0.2698	0.34	0.2863	0.2102	0.3095	0.2589	0.2676	0.2641	0.3543	gnomADe_ASJ		0&1	0&1							FAIL	12	-26	-27	12	0.00	0.00	0.00	0.06	INPP4A		4.1100e-01																																																											495					1							246.19	v6.1	Unknown		True	INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:T86= mutant UNKNOWN.	False	The INPP4A ENSP00000386777.4:t86= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	99149946						True	False	False	Unknown								False	False		INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma.	The INPP4A ENSP00000386777.4:t86= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:T86= mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	INPP4A	3631.0	ENSP00000386777.4:T86=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""INPP4A"",""entrezGeneId"":3631,""alteration"":""ENSP00000386777.4:T86="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma."",""variantSummary"":""The INPP4A ENSP00000386777.4:t86= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:T86= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						301,194	143,89	158,105	0/1	151,150,82,112	CGG	0.00	0.00	0.00			135,166,79,115	11.8		0.39191919191919194
GRCh38	INPP4A	D12_12345_1234556_Thyroid_S9	p.T599A	ENSP00000386777.4:p.Thr599Ala	chr2	98555781	98555781.0	A	G	G	98555781	.	A	G	.	PASS	NM_001134225	G	missense_variant	MODERATE	INPP4A	ENSG00000040933	Transcript	ENST00000409851	protein_coding	16/25		c.1795A>G	2188	1795	599	T/A	Act/Gct	rs2278206&CM084964&COSV50818983		1		SNV	HGNC	HGNC:6074	YES	MANE_Select	NM_001134225.2		1		CCDS46371.1	ENSP00000386777	Q96PE3.152		UPI000013C579	Q96PE3-3		1	tolerated_low_confidence(1)	benign(0)	AFDB-ENSP_mappings:AF-Q96PE3-F1&PANTHER:PTHR12187&Low_complexity_(Seg):seg			0.2843	0.2375	0.3069	0.3155	0.2654	0.319	0.2532	0.2494	0.2975	0.3162	0.2882	0.2039	0.3131	0.2482	0.2681	0.2817	0.2563	0.2539	0.1678	0.2763	0.3035	0.303	0.2096	0.3435	0.2517	0.2942	0.2922	0.3435	gnomADg_MID		0&1&1	1&1&1	30541564&36224396						FAIL	27	2	27	-42	0.00	0.00	0.16	0.00	INPP4A	0.049	4.1100e-01																																																											1207					0.99							243.67	v6.1	Unknown		True	INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:T599A mutant UNKNOWN.	False	The INPP4A ENSP00000386777.4:t599a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	99172244						True	False	False	Unknown								False	False		INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma.	The INPP4A ENSP00000386777.4:t599a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:T599A mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	INPP4A	3631.0	ENSP00000386777.4:T599A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""INPP4A"",""entrezGeneId"":3631,""alteration"":""ENSP00000386777.4:T599A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma."",""variantSummary"":""The INPP4A ENSP00000386777.4:t599a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:T599A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						632,563	375,330	257,233	0/1	335,297,275,288	CAC	.	.	.			300,332,286,277	30.18		0.4711297071129707
GRCh38	INPP4A	D12_12345_1234556_Thyroid_S9	p.Ser892=	ENSP00000386777.4:p.Ser892=	chr2	98577033	98577033.0	C	T	T	98577033	.	C	T	.	PASS	NM_001134225	T	synonymous_variant	LOW	INPP4A	ENSG00000040933	Transcript	ENST00000409851	protein_coding	24/25		c.2676C>T	3069	2676	892	S	agC/agT	rs2230388&COSV50785142		1		SNV	HGNC	HGNC:6074	YES	MANE_Select	NM_001134225.2		1		CCDS46371.1	ENSP00000386777	Q96PE3.152		UPI000013C579	Q96PE3-3		1			AFDB-ENSP_mappings:AF-Q96PE3-F1&PANTHER:PTHR12187			0.2564	0.1589	0.2968	0.2937	0.2714	0.3057	0.256	0.1707	0.2937	0.3143	0.2725	0.215	0.3121	0.2548	0.2627	0.2766	0.2359	0.1741	0.1743	0.2681	0.3012	0.2904	0.2208	0.3503	0.257	0.2744	0.2837	0.3503	gnomADg_MID		0&1	0&1							FAIL	-2	-9	-24	20	0.00	0.00	0.00	0.00	INPP4A		4.1100e-01																																																											1117					1							247.18	v6.1	Unknown		True	INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:S892= mutant UNKNOWN.	False	The INPP4A ENSP00000386777.4:s892= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	99193496						True	False	False	Unknown								False	False		INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma.	The INPP4A ENSP00000386777.4:s892= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:S892= mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	INPP4A	3631.0	ENSP00000386777.4:S892=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""INPP4A"",""entrezGeneId"":3631,""alteration"":""ENSP00000386777.4:S892="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""INPP4A, a lipid phosphatase involved in PI3K signaling, is altered in various cancer types including mesothelioma and asbestos-exposed lung adenocarcinoma."",""variantSummary"":""The INPP4A ENSP00000386777.4:s892= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INPP4A ENSP00000386777.4:S892= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						564,553	278,281	286,272	0/1	283,281,293,260	GCG	0.00	0.00	0.00			305,259,283,270	53.44		0.495076096687556
GRCh38	TMEM182	D12_12345_1234556_Thyroid_S9			chr2	102765427		G	[chr4:19039928[G	[chr4:19039928[G	102765427	MantaBND:182:0:1:0:0:0:1	G	[chr4:19039928[G	.	PASS		.G	feature_truncation&intron_variant	HIGH	TMEM182	ENSG00000170417	Transcript	ENST00000640575	protein_coding		3/5									1		chromosome_breakpoint	HGNC	HGNC:26391					5			ENSP00000492657		A0A1W2PS41.31	UPI00108D2398																																																																																																																	1			0,5							5	GTAGG			MantaBND:182:0:1:0:0:0:0	4														chr2	103381886				BND																																													True	False	False	Unknown		Unknown																															1,1				4,2	
GRCh38	RANBP2	D12_12345_1234556_Thyroid_S9	p.Ser850=	ENSP00000283195.6:p.Ser850=	chr2	108758496	108758496.0	A	G	G	108758496	.	A	G	.	PASS	NM_006267	G	synonymous_variant	LOW	RANBP2	ENSG00000153201	Transcript	ENST00000283195	protein_coding	18/29		c.2550A>G	2675	2550	850	S	tcA/tcG	rs826549&COSV51697984		1		SNV	HGNC	HGNC:9848	YES	MANE_Select	NM_006267.5		1	P1	CCDS2079.1	ENSP00000283195	P49792.248		UPI0000207FB9			1			PDB-ENSP_mappings:7r5j.00&PDB-ENSP_mappings:7r5j.01&PDB-ENSP_mappings:7r5j.02&PDB-ENSP_mappings:7r5j.03&PDB-ENSP_mappings:7r5j.04&PDB-ENSP_mappings:7r5k.00&PDB-ENSP_mappings:7r5k.01&PDB-ENSP_mappings:7r5k.02&PDB-ENSP_mappings:7r5k.03&PDB-ENSP_mappings:7r5k.04&PANTHER:PTHR23138									0.2476	0.7078	0.1628	0.2457	0.09687	0.1916	0.2878	0.2378	0.2668	0.3287	0.3534	0.6858	0.2692	0.2452	0.2465	0.06977	0.18	0.2857	0.2359	0.3189	0.335	0.7078	gnomADe_AFR	benign	0&1	1&1							FAIL	-19	2	0	-19	0.05	0.00	0.00	0.00	RANBP2		2.3100e-01	380029	0.30829	0.26040		365325	not_specified&not_provided&Familial_acute_necrotizing_encephalopathy		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0011953&MedGen:C2675556&OMIM:608033&Orphanet:88619		NC_000002.12:g.108758496A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000517691&SCV000767780&SCV005246496	single_nucleotide_variant	SO:0001483	ClinGen:CA1822735		RANBP2:5903	SO:0001819&synonymous_variant										1	826549																											151					0.795							70.17	v6.1	Unknown		True	RANBP2, a RAN-binding protein, is altered by mutation and chromosomal rearrangement in various cancers.	False	12/11/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RANBP2 ENSP00000283195.6:S850= mutant UNKNOWN.	False	The RANBP2 ENSP00000283195.6:s850= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	109374952						True	False	False	Unknown								False	False		RANBP2, a RAN-binding protein, is altered by mutation and chromosomal rearrangement in various cancers.	The RANBP2 ENSP00000283195.6:s850= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RANBP2 ENSP00000283195.6:S850= mutant UNKNOWN.						v6.1	12/11/2023		GRCh38	RANBP2	5903.0	ENSP00000283195.6:S850=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RANBP2"",""entrezGeneId"":5903,""alteration"":""ENSP00000283195.6:S850="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RANBP2, a RAN-binding protein, is altered by mutation and chromosomal rearrangement in various cancers."",""variantSummary"":""The RANBP2 ENSP00000283195.6:s850= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RANBP2 ENSP00000283195.6:S850= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/11/2023""}"	True	True	False	Unknown		Unknown																						86,34	35,17	51,17	0/1	48,38,12,22	CAG	.	.	.			33,53,7,27	11.26		0.2833333333333333
GRCh38	RANBP2	D12_12345_1234556_Thyroid_S9	p.Glu2751=	ENSP00000283195.6:p.Glu2751=	chr2	108773007	108773007.0	G	A	A	108773007	.	G	A	.	PASS	NM_006267	A	synonymous_variant	LOW	RANBP2	ENSG00000153201	Transcript	ENST00000283195	protein_coding	23/29		c.8253G>A	8378	8253	2751	E	gaG/gaA	rs826580&COSV108045973		1		SNV	HGNC	HGNC:9848	YES	MANE_Select	NM_006267.5		1	P1	CCDS2079.1	ENSP00000283195	P49792.248		UPI0000207FB9			1			PDB-ENSP_mappings:7r5j.00&PDB-ENSP_mappings:7r5j.01&PDB-ENSP_mappings:7r5j.02&PDB-ENSP_mappings:7r5j.03&PDB-ENSP_mappings:7r5j.04&PDB-ENSP_mappings:7r5k.00&PDB-ENSP_mappings:7r5k.01&PDB-ENSP_mappings:7r5k.02&PDB-ENSP_mappings:7r5k.03&PDB-ENSP_mappings:7r5k.04&Pfam:PF12185			0.9872	0.9531	0.9986	1	0.999	1	0.9987	0.9581	0.9975	1	1	1	0.9986	0.9999	0.9974	0.9999	0.9882	0.9588	1	0.9963	1	0.9998	1	0.9966	0.9999	0.9915	1	1	EAS&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_FIN&gnomADg_SAS	benign	0&1	1&1							FAIL	-37	14	39	-39	0.00	0.00	0.00	0.00	RANBP2		2.3100e-01	1169866	0.98416	0.99590	0.98722	1153780	not_provided&Familial_acute_necrotizing_encephalopathy		MedGen:C3661900&MONDO:MONDO:0011953&MedGen:C2675556&OMIM:608033&Orphanet:88619		NC_000002.12:g.108773007G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001731068&SCV005246515	single_nucleotide_variant	SO:0001483	ClinGen:CA1823786		RANBP2:5903	SO:0001819&synonymous_variant										1	826580																											236					0.992							246.04	v6.1	Unknown		True	RANBP2, a RAN-binding protein, is altered by mutation and chromosomal rearrangement in various cancers.	False	12/11/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RANBP2 ENSP00000283195.6:E2751= mutant UNKNOWN.	False	The RANBP2 ENSP00000283195.6:e2751= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	109389463						True	False	False	Unknown								False	False		RANBP2, a RAN-binding protein, is altered by mutation and chromosomal rearrangement in various cancers.	The RANBP2 ENSP00000283195.6:e2751= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RANBP2 ENSP00000283195.6:E2751= mutant UNKNOWN.						v6.1	12/11/2023		GRCh38	RANBP2	5903.0	ENSP00000283195.6:E2751=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RANBP2"",""entrezGeneId"":5903,""alteration"":""ENSP00000283195.6:E2751="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RANBP2, a RAN-binding protein, is altered by mutation and chromosomal rearrangement in various cancers."",""variantSummary"":""The RANBP2 ENSP00000283195.6:e2751= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RANBP2 ENSP00000283195.6:E2751= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/11/2023""}"	True	True	False	Unknown		Unknown																						0,234	0,105	0,129	0/1	0,0,108,126	AGG	0.00	0.00	0.00			0,0,133,101	64.73		1.0
GRCh38	BCL2L11	D12_12345_1234556_Thyroid_S9			chr2	111126229	111126229.0	T	A	A	111126229	.	T	A	.	PASS	NM_138621	A	intron_variant	MODIFIER	BCL2L11	ENSG00000153094	Transcript	ENST00000393256	protein_coding		2/3	c.394+2090T>A						rs150409667		1		SNV	HGNC	HGNC:994	YES	MANE_Select	NM_138621.5		1	P1	CCDS2089.1	ENSP00000376943	O43521.213		UPI0000033ABA	O43521-1								0.0054	0	0.0086	0	0.0139	0.0072											0.01286	0.003775	0.02961	0.0132	0.01412	0.0003893	0.004327	0.0102	0.02046	0.01843	0.008699	0.02961	gnomADg_AMI										FAIL	-22	-18	31	-29	0.00	0.00	0.00	0.00	BCL2L11		1.2300e+00																																																											128					0.953							235.2													chr2	111883806																																																	True	True	False	Unknown		Unknown																						60,62	35,28	25,34	0/1	23,37,34,28	GTT	.	.	.			26,34,28,34	37.23		0.5081967213114754
GRCh38	BCL2L11	D12_12345_1234556_Thyroid_S9			chr2	111127015	111127016.0	CT	C	C	111127015	.	CT	C	.	PASS	NM_138621	-	intron_variant	MODIFIER	BCL2L11	ENSG00000153094	Transcript	ENST00000393256	protein_coding		2/3	c.394+2880del						rs59854799		1		deletion	HGNC	HGNC:994	YES	MANE_Select	NM_138621.5		1	P1	CCDS2089.1	ENSP00000376943	O43521.213		UPI0000033ABA	O43521-1							3	0.5643	0.8548	0.353	0.6012	0.5368	0.3119											0.5932	0.8167	0.5592	0.4044	0.4086	0.5918	0.5454	0.3299	0.5386	0.5379	0.3228	0.8548	AFR										FAIL	7	26	50	-30	0.00	0.00	0.00	0.00	BCL2L11		1.2300e+00																																																											128					0.914							240.58													chr2	111884592																																																	True	True	False	Unknown		Unknown																						0,117	0,62	0,55	0/1	0,0,67,50	CCT						0,0,66,51	63.45		1.0
GRCh38	BCL2L11	D12_12345_1234556_Thyroid_S9			chr2	111127253	111127272.0	TTAAAGTGTAGTCAGTACAC	T	T	111127253	.	TTAAAGTGTAGTCAGTACAC	T	.	PASS	NM_138621	-	intron_variant	MODIFIER	BCL2L11	ENSG00000153094	Transcript	ENST00000393256	protein_coding		2/3	c.394+3133_394+3151del						rs572516992		1		deletion	HGNC	HGNC:994	YES	MANE_Select	NM_138621.5		1	P1	CCDS2089.1	ENSP00000376943	O43521.213		UPI0000033ABA	O43521-1							18	0.0030	0	0.0072	0	0.0089	0.001											0.008188	0.002095	0	0.01151	0.008641	0.0001955	0.002921	0.0102	0.01276	0.01708	0.002905	0.01708	gnomADg_REMAINING																					1.2300e+00																																																											137					0.715							235.4													chr2	111884830																																																	True	True	False	Unknown		Unknown																						63,35	28,22	35,13	0/1	28,35,15,20	ATT						33,30,18,17	15.04		0.35714285714285715
GRCh38	BCL2L11	D12_12345_1234556_Thyroid_S9			chr2	111128285	111128285.0	A	G	G	111128285	.	A	G	.	PASS	NM_138621	G	intron_variant	MODIFIER	BCL2L11	ENSG00000153094	Transcript	ENST00000393256	protein_coding		2/3	c.394+4146A>G						rs561830110		1		SNV	HGNC	HGNC:994	YES	MANE_Select	NM_138621.5		1	P1	CCDS2089.1	ENSP00000376943	O43521.213		UPI0000033ABA	O43521-1								0.0002	0	0	0	0.001	0											0.0003154	7.222e-05	0	0.001046	0	0	0	0	0.0004263	0	0	0.001046	gnomADg_AMR										FAIL	-23	3	9	3	0.00	0.00	0.00	0.00	BCL2L11		1.2300e+00																																																											103					0.951							231.72													chr2	111885862																																																	True	True	False	Unknown		Unknown																						45,53	24,20	21,33	0/1	22,23,29,24	TAA	.	.	.			29,16,28,25	39.54		0.5408163265306123
GRCh38	BCL2L11	D12_12345_1234556_Thyroid_S9			chr2	111128755	111128755.0	C	T	T	111128755	.	C	T	.	PASS	NM_138621	T	intron_variant	MODIFIER	BCL2L11	ENSG00000153094	Transcript	ENST00000393256	protein_coding		2/3	c.394+4616C>T						rs13429049&COSV58029793		1		SNV	HGNC	HGNC:994	YES	MANE_Select	NM_138621.5		1	P1	CCDS2089.1	ENSP00000376943	O43521.213		UPI0000033ABA	O43521-1								0.1975	0.205	0.134	0.1756	0.2972	0.1524	0.2868	0.1898	0.1445	0.2293	0.1643	0.3195	0.1733	0.3086	0.262	0.1665	0.2505	0.2023	0.3651	0.1782	0.2347	0.1669	0.3279	0.1565	0.2972	0.2332	0.1618	0.3651	gnomADg_AMI		0&1	1&1	26988918&30598549&30048462						FAIL	10	-32	3	-5	0.00	0.00	0.00	0.00	BCL2L11		1.2300e+00																																																											185					0.903							203.16													chr2	111886332																																																	True	True	False	Unknown		Unknown																						86,81	51,48	35,33	0/1	41,45,39,42	CCT	0.00	0.00	0.00			40,46,46,35	35.16		0.48502994011976047
GRCh38	BCL2L11	D12_12345_1234556_Thyroid_S9			chr2	111130177	111130177.0	T	G	G	111130177	.	T	G	.	PASS	NM_138621	G	intron_variant	MODIFIER	BCL2L11	ENSG00000153094	Transcript	ENST00000393256	protein_coding		2/3	c.394+6038T>G						rs113135335		1		SNV	HGNC	HGNC:994	YES	MANE_Select	NM_138621.5		1	P1	CCDS2089.1	ENSP00000376943	O43521.213		UPI0000033ABA	O43521-1								0.0515	0.056	0.0576	0	0.1173	0.0266	0.07286	0.04553	0.02573	0.08585	0	0.09444	0.04379	0.09832	0.07903	0.02221	0.0858	0.06656	0.02412	0.05811	0.09902	0.001161	0.09971	0.04422	0.1129	0.08428	0.02204	0.1173	EUR			1	32541925&31669095&32888493						FAIL	-45	24	-14	24	0.04	0.00	0.00	0.00	BCL2L11		1.2300e+00																																																											30					0.967							133.39													chr2	111887754																																																	True	True	False	Unknown		Unknown																						7,22	3,10	4,12	0/1	3,4,16,6	CTC	.	.	.			3,4,12,10	32.61		0.7586206896551724
GRCh38	BCL2L11	D12_12345_1234556_Thyroid_S9	p.Ile155=	ENSP00000376943.2:p.Ile155=	chr2	111150114	111150114.0	T	C	C	111150114	.	T	C	.	PASS	NM_138621	C	synonymous_variant	LOW	BCL2L11	ENSG00000153094	Transcript	ENST00000393256	protein_coding	3/4		c.465T>C	753	465	155	I	atT/atC	rs724710&COSV58033046		1		SNV	HGNC	HGNC:994	YES	MANE_Select	NM_138621.5		1	P1	CCDS2089.1	ENSP00000376943	O43521.213		UPI0000033ABA	O43521-1					PDB-ENSP_mappings:2k7w.B&PDB-ENSP_mappings:2nl9.B&PDB-ENSP_mappings:2v6q.B&PDB-ENSP_mappings:2vm6.B&PDB-ENSP_mappings:2wh6.B&PDB-ENSP_mappings:2yq6.B&PDB-ENSP_mappings:2yq7.B&PDB-ENSP_mappings:3d7v.B&PDB-ENSP_mappings:3fdl.B&PDB-ENSP_mappings:3io8.B&PDB-ENSP_mappings:3io8.D&PDB-ENSP_mappings:3io9.B&PDB-ENSP_mappings:3kj0.B&PDB-ENSP_mappings:3kj1.B&PDB-ENSP_mappings:3kj2.B&PDB-ENSP_mappings:4a1u.B&PDB-ENSP_mappings:4a1w.P&PDB-ENSP_mappings:4a1w.Q&PDB-ENSP_mappings:4a1w.R&PDB-ENSP_mappings:4a1w.S&PDB-ENSP_mappings:4b4s.B&PDB-ENSP_mappings:4d2m.B&PDB-ENSP_mappings:4d2m.D&PDB-ENSP_mappings:4qvf.B&PDB-ENSP_mappings:4uf3.B&PDB-ENSP_mappings:4yj4.B&PDB-ENSP_mappings:4zie.C&PDB-ENSP_mappings:4zif.B&PDB-ENSP_mappings:4zih.B&PDB-ENSP_mappings:5agw.C&PDB-ENSP_mappings:5agw.D&PDB-ENSP_mappings:5agx.C&PDB-ENSP_mappings:5agx.D&PDB-ENSP_mappings:5c3g.B&PDB-ENSP_mappings:5vwv.B&PDB-ENSP_mappings:5vww.C&PDB-ENSP_mappings:5vww.D&PDB-ENSP_mappings:5vwx.B&PDB-ENSP_mappings:5vwx.D&PDB-ENSP_mappings:5vwy.B&PDB-ENSP_mappings:5vwz.B&PDB-ENSP_mappings:5vwz.D&PDB-ENSP_mappings:5vx0.B&PDB-ENSP_mappings:5vx0.D&PDB-ENSP_mappings:5vx2.B&PDB-ENSP_mappings:5vx2.D&PDB-ENSP_mappings:5vx3.B&PDB-ENSP_mappings:5vx3.D&PDB-ENSP_mappings:5vx3.F&PDB-ENSP_mappings:5vx3.H&PDB-ENSP_mappings:5wos.B&PDB-ENSP_mappings:6qfi.B&PDB-ENSP_mappings:6rjp.C&PDB-ENSP_mappings:6rjp.D&PDB-ENSP_mappings:6tqq.B&PDB-ENSP_mappings:6ua3.B&PDB-ENSP_mappings:6uab.B&PDB-ENSP_mappings:6vbx.B&PDB-ENSP_mappings:6x8o.A&PDB-ENSP_mappings:6x8o.B&PDB-ENSP_mappings:6x8o.C&PDB-ENSP_mappings:6x8o.D&PDB-ENSP_mappings:8t5e.B&Pfam:PF08945&PIRSF:PIRSF037827&PANTHER:PTHR12044&AFDB-ENSP_mappings:AF-O43521-F1			0.6925	0.8011	0.5029	0.8502	0.668	0.5429	0.6745	0.7946	0.4491	0.6115	0.899	0.6579	0.5295	0.6852	0.6693	0.5463	0.6923	0.7875	0.6784	0.5439	0.6095	0.8606	0.6591	0.5136	0.6759	0.661	0.5537	0.899	gnomADe_EAS		0&1	0&1	20855536&26991123&29296778&29282361&30677473&32848787&35406404&23908358&24223824&24743263&27929201&37469404&38675222&38408093						FAIL	-43	30	29	30	0.00	0.00	0.00	0.00	BCL2L11		1.2300e+00																																																											170					0.982							239.94	v6.1	Unknown		True	BCL2L11, a tumor suppressor and pro-apoptotic protein, is altered by mutation in various cancer types.	False	06/20/2020	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L11 ENSP00000376943.2:I155= mutant UNKNOWN.	False	The BCL2L11 ENSP00000376943.2:i155= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	111907691						True	False	False	Unknown								False	False		BCL2L11, a tumor suppressor and pro-apoptotic protein, is altered by mutation in various cancer types.	The BCL2L11 ENSP00000376943.2:i155= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L11 ENSP00000376943.2:I155= mutant UNKNOWN.						v6.1	06/20/2020		GRCh38	BCL2L11	10018.0	ENSP00000376943.2:I155=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCL2L11"",""entrezGeneId"":10018,""alteration"":""ENSP00000376943.2:I155="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCL2L11, a tumor suppressor and pro-apoptotic protein, is altered by mutation in various cancer types."",""variantSummary"":""The BCL2L11 ENSP00000376943.2:i155= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2L11 ENSP00000376943.2:I155= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/20/2020""}"	True	True	False	Unknown		Unknown																						0,167	0,82	0,85	0/1	0,0,82,85	TTG	.	.	.			0,0,73,94	64.72		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	111636699		T	[chr5:1306089[T	[chr5:1306089[T	111636699	MantaBND:6898:0:1:0:0:0:0	T	[chr5:1306089[T	.	PASS		.T	upstream_gene_variant	MODIFIER		ENSG00000295159	Transcript	ENST00000728314	lncRNA										2542	-1		chromosome_breakpoint																																																																																																																														2			0,10							10	CAAAACCCAT			MantaBND:6898:0:1:0:0:0:1	2														chr2	112394276				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113220285	113220285.0	T	G	G	113220285	.	T	G	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1190-107A>C						rs4849175		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.9910	0.9667	0.9986	1	1	1	0.9989	0.9674	0.9982	1	1	1	0.9989	1	0.9975	0.9999	0.9916	0.9713	1	0.9952	1	1	1	1	0.9999	0.9938	0.9996	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_NFE&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID	benign		1							FAIL	-36	-28	-12	9	0.00	0.00	0.00	0.00	PAX8		4.1500e-01	1271887			0.99101	1259216	not_provided		MedGen:C3661900		NC_000002.12:g.113220285T>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001896898&SCV005242606	single_nucleotide_variant	SO:0001483	ClinGen:CA53712484		PAX8:7849	SO:0001627&intron_variant										1	4849175																											1152					0.994							244.89													chr2	113977862																																																	True	True	False	Unknown		Unknown																						0,1145	0,490	0,655	0/1	0,0,602,543	TTG	.	.	.			0,0,527,618	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113221073	113221073.0	C	T	T	113221073	.	C	T	.	PASS	NM_003466	T	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1190-895G>A						rs7578633		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3622	0.2769	0.3674	0.3333	0.3936	0.4714											0.3517	0.3001	0.3507	0.3571	0.3244	0.3342	0.4431	0.3163	0.3641	0.3544	0.4436	0.4714	SAS			1	31884074&36329257&35361970						FAIL	-46	-28	36	-16	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											123					0.984							245.72													chr2	113978650																																																	True	True	False	Unknown		Unknown																						0,121	0,65	0,56	0/1	0,0,61,60	TCT	0.00	0.00	0.00			0,0,49,72	64.71		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113221363	113221363.0	C	G	G	113221363	.	C	G	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1190-1185G>C						rs11123170		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3626	0.2784	0.3674	0.3333	0.3936	0.4714											0.352	0.3013	0.3505	0.3572	0.3246	0.3351	0.4414	0.3185	0.3642	0.3548	0.4427	0.4714	SAS			1	18846218&30415941&24943591&31152163&28575649&28201750&24298061&22797727&31920969&38116116						FAIL	48	-50	-37	-4	0.00	0.00	0.18	0.00	PAX8		4.1500e-01																																																											100					0.94							237.99													chr2	113978940																																																	True	True	False	Unknown		Unknown																						0,94	0,52	0,42	0/1	0,0,35,59	CCC	.	.	.			0,0,43,51	64.66		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113223068	113223068.0	C	G	G	113223068	.	C	G	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1190-2890G>C						rs12472361		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.1330	0.0166	0.232	0.0734	0.2306	0.181											0.1752	0.05451	0.1645	0.2006	0.1922	0.08188	0.2256	0.1735	0.2406	0.1953	0.1814	0.2406	gnomADg_NFE										FAIL	-15	-1	42	-1	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											110					0.991							244.82													chr2	113980645																																																	True	True	False	Unknown		Unknown																						0,109	0,46	0,63	0/1	0,0,60,49	TCT	.	.	.			0,0,57,52	64.69		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113223445	113223445.0	G	A	A	113223445	.	G	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1190-3267C>T						rs6707386		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3622	0.2769	0.3674	0.3333	0.3936	0.4714											0.3519	0.3002	0.3505	0.3572	0.3262	0.3352	0.442	0.3163	0.3644	0.3553	0.4444	0.4714	SAS			1	31578528						FAIL	2	-16	2	-10	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											136					0.949							232.4													chr2	113981022																																																	True	True	False	Unknown		Unknown																						0,129	0,61	0,68	0/1	0,0,81,48	TGC	0.00	0.00	0.00			0,0,61,68	64.71		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113223560	113223560.0	T	C	C	113223560	.	T	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1190-3382A>G						rs6755040		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3842	0.3585	0.3703	0.3333	0.3936	0.4714											0.3716	0.3686	0.3484	0.3637	0.3263	0.3352	0.4418	0.3163	0.3648	0.3686	0.447	0.4714	SAS										FAIL	17	-39	14	-6	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											129					0.93							233.07													chr2	113981137																																																	True	True	False	Unknown		Unknown																						0,120	0,59	0,61	0/1	0,0,48,72	GTC	.	.	.			0,0,61,59	64.71		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113224233	113224233.0	A	G	G	113224233	.	A	G	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+2922T>C						rs6755639		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.5214	0.6831	0.4597	0.3462	0.5378	0.5102											0.5543	0.6725	0.6396	0.4798	0.4551	0.3503	0.6074	0.3836	0.517	0.5175	0.484	0.6831	AFR										FAIL	8	-4	11	35	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											683					0.975							228.08													chr2	113981810																																																	True	True	False	Unknown		Unknown																						1,665	0,311	1,354	0/1	1,0,332,333	GAA	.	.	.			0,1,388,277	64.73		0.9984984984984985
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113224462	113224462.0	A	G	G	113224462	.	A	G	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+2693T>C						rs2863241		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.9916	0.969	0.9986	1	1	1											0.9926	0.9748	1	0.9964	0.9997	0.9998	0.9999	0.9966	0.9999	0.9943	0.9996	1	EAS&EUR&SAS&gnomADg_AMI										FAIL	-29	-17	50	2	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											280					0.986							146.99													chr2	113982039																																																	True	True	False	Unknown		Unknown																						3,273	1,112	2,161	0/1	1,2,148,125	CAC	.	.	.			1,2,125,148	51.49		0.9891304347826086
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113224566	113224566.0	G	A	A	113224566	.	G	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+2589C>T						rs3978694		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1																						0.3561	0.3272	0.3509	0.3479	0.327	0.3322	0.4119	0.3165	0.3637	0.3582	0.4465	0.4465	gnomADg_SAS										FAIL	-6	-23	-1	6	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											492					0.624							196.71													chr2	113982143																																																	True	True	False	Unknown		Unknown																						129,178	51,79	78,99	0/1	66,63,99,79	AGG	0.00	0.00	0.00			82,47,84,94	47		0.5798045602605864
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113224839	113224854.0	TATAAAATAAAATAAA	T	T	113224839	.	TATAAAATAAAATAAA	T	.	PASS	NM_003466	-	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+2301_1189+2315del						rs56177103		-1		deletion	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1																						0.6341	0.3741	0.5751	0.7378	0.7397	0.7239	0.6547	0.8239	0.741	0.6698	0.7307	0.8239	gnomADg_MID																					4.1500e-01																																																											165					0.588							148.67													chr2	113982416																																																	True	True	False	Unknown		Unknown																						2,95	2,47	0,48	0/1	1,1,50,45	ATA						1,1,36,59	43		0.979381443298969
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113225007	113225007.0	T	C	C	113225007	.	T	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+2148A>G						rs4849177		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3844	0.3585	0.3703	0.3333	0.3936	0.4724											0.3711	0.3685	0.3477	0.3634	0.3254	0.3352	0.4393	0.3163	0.3642	0.3679	0.446	0.4724	SAS			1	36929174&34680286						FAIL	5	-40	5	37	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											132					0.879							239.55													chr2	113982584																																																	True	True	False	Unknown		Unknown																						0,116	0,63	0,53	0|1	0,0,66,50	CTT	.	.	.		113982584	0,0,51,65	57.7		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113225031	113225031.0	G	A	A	113225031	.	G	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+2124C>T						rs4849178		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.1340	0.0166	0.232	0.0774	0.2296	0.183											0.1748	0.05456	0.1626	0.2006	0.1904	0.0842	0.2257	0.1667	0.2398	0.194	0.1816	0.2398	gnomADg_NFE										FAIL	-19	7	37	13	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											124					0.927							240.36													chr2	113982608																																																	True	True	False	Unknown		Unknown																						0,115	0,66	0,49	0|1	0,0,60,55	CGT	0.00	0.00	0.00		113982584	0,0,47,68	57.7		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113226669	113226672.0	G	GTCA	GTCA	113226669	.	G	GTCA	.	PASS	NM_003466	TCA	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+483_1189+485dup						rs34633676		-1		insertion	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1												0.3322	0.2234	0.3272	0.2814	0.2913	0.362	0.3299	0.3348	0.3232	0.3738	0.3383	0.2585	0.3484	0.3493	0.3243	0.3296	0.4356	0.3027	0.3638	0.3386	0.4398	0.4398	gnomADg_SAS																					4.1500e-01																																																											241					0.743							213.61													chr2	113984246																																																	True	True	False	Unknown		Unknown																						5,174	3,87	2,87	0/1	2,3,91,83	CGT						4,1,104,70	62.03		0.9720670391061452
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113226726	113226726.0	T	C	C	113226726	.	T	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		10/11	c.1189+429A>G						rs11123172&COSV105840654		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3848	0.3585	0.3703	0.3333	0.3936	0.4744	0.3636	0.3549	0.3663	0.3073	0.3342	0.4333	0.3796	0.3622	0.3584	0.4306	0.3714	0.3684	0.3498	0.3633	0.327	0.3346	0.441	0.3116	0.3648	0.3694	0.4462	0.4744	SAS		0&1	0&1							FAIL	3	-28	-28	-15	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											266					0.977							233.78													chr2	113984303																																																	True	True	False	Unknown		Unknown																						1,259	1,127	0,132	0/1	1,0,141,118	GTA	.	.	.			1,0,145,114	64.7		0.9961538461538462
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113227593	113227593.0	C	T	T	113227593	.	C	T	.	PASS	NM_003466	T	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1088-337G>A						rs4849179		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3836	0.3563	0.3703	0.3333	0.3936	0.4714											0.3708	0.366	0.3513	0.3631	0.3261	0.3346	0.4415	0.3151	0.3647	0.3677	0.4452	0.4714	SAS	benign		1	23344678&33556002&25375650						FAIL	-23	44	7	-44	0.00	0.00	0.00	0.00	PAX8		4.1500e-01	1260851			0.38359	1253339	not_provided		MedGen:C3661900		NC_000002.12:g.113227593C>T	criteria_provided&_single_submitter	Benign			SCV001888429	single_nucleotide_variant	SO:0001483	ClinGen:CA15191428		PAX8:7849	SO:0001627&intron_variant										1	4849179																											295					0.99							242.18													chr2	113985170																																																	True	True	False	Unknown		Unknown																						2,290	2,140	0,150	0|1	0,2,146,144	TCT	0.00	0.00	0.00		113985170	0,2,116,174	57.72		0.9931506849315068
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113227609	113227609.0	C	G	G	113227609	.	C	G	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1088-353G>C						rs4849180		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.1350	0.0197	0.232	0.0774	0.2306	0.183											0.1766	0.05934	0.1648	0.2016	0.192	0.08555	0.226	0.1644	0.2403	0.1952	0.1816	0.2403	gnomADg_NFE	benign		1							FAIL	-17	28	-9	-48	0.00	0.00	0.00	0.00	PAX8		4.1500e-01	1266961			0.13498	1254284	not_provided		MedGen:C3661900		NC_000002.12:g.113227609C>G	criteria_provided&_single_submitter	Benign			SCV001892990	single_nucleotide_variant	SO:0001483	ClinGen:CA11289733		PAX8:7849	SO:0001627&intron_variant										1	4849180																											235					0.987							245.05													chr2	113985186																																																	True	True	False	Unknown		Unknown																						0,232	0,110	0,122	0|1	0,0,120,112	GCA	.	.	.		113985170	0,0,90,142	57.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113229052	113229052.0	C	T	T	113229052	.	C	T	.	PASS	NM_003466	T	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1088-1796G>A						rs35222158		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.1340	0.0197	0.232	0.0734	0.2306	0.182											0.1765	0.05936	0.1637	0.2012	0.1919	0.0824	0.2264	0.1712	0.2404	0.1954	0.1815	0.2404	gnomADg_NFE										FAIL	-2	5	27	-42	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											232					0.983							240.37													chr2	113986629																																																	True	True	False	Unknown		Unknown																						0,228	0,110	0,118	0/1	0,0,114,114	CCG	0.00	0.00	0.00			0,0,102,126	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113230915	113230915.0	G	A	A	113230915	.	G	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1088-3659C>T						rs10175462		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3836	0.3555	0.3703	0.3333	0.3936	0.4724											0.3706	0.3658	0.3505	0.3634	0.3245	0.3349	0.4415	0.3151	0.3645	0.367	0.4453	0.4724	SAS			1	33905146&35205332&32887889&36152065&34683414&34680286&33462484&33794208&38392296&37217238						FAIL	-9	-15	27	-9	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											188					0.957							227.15													chr2	113988492																																																	True	True	False	Unknown		Unknown																						0,180	0,95	0,85	0/1	0,0,97,83	AGG	0.00	0.00	0.00			0,0,92,88	64.72		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113231545	113231546.0	A	AG	AG	113231545	.	A	AG	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+3848dup						rs5833488		-1		insertion	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3996	0.416	0.3732	0.3333	0.3936	0.4703											0.3861	0.4193	0.3505	0.3691	0.326	0.3339	0.4412	0.3265	0.3648	0.3783	0.446	0.4703	SAS										FAIL	33	44	-40	-22	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											740					0.965							245.02													chr2	113989122																																																	True	True	False	Unknown		Unknown																						0,714	0,327	0,387	0/1	0,0,344,370	TAG						0,0,367,347	63.48		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113231659	113231659.0	C	T	T	113231659	.	C	T	.	PASS	NM_003466	T	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+3735G>A						rs2863242		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.1336	0.0166	0.232	0.0744	0.2306	0.183											0.175	0.05449	0.1645	0.2009	0.1912	0.08221	0.2266	0.1678	0.2402	0.1952	0.1823	0.2402	gnomADg_NFE				31860065						FAIL	-30	-25	-6	0	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											671					0.99							244.04													chr2	113989236																																																	True	True	False	Unknown		Unknown																						0,664	0,329	0,335	0/1	0,0,362,302	CCT	0.00	0.00	0.00			0,0,341,323	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113231690	113231690.0	T	C	C	113231690	.	T	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+3704A>G						rs2863243		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3832	0.3555	0.3703	0.3333	0.3936	0.4703											0.3708	0.3661	0.3484	0.3635	0.326	0.3344	0.4411	0.3163	0.3647	0.3678	0.4464	0.4703	SAS				26075790						FAIL	-1	-2	0	-37	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											656					0.988							233.96													chr2	113989267																																																	True	True	False	Unknown		Unknown																						1,647	0,332	1,315	0/1	0,1,351,296	CTT	.	.	.			1,0,338,309	64.73		0.9984567901234568
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113231750	113231750.0	T	C	C	113231750	.	T	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+3644A>G						rs7563094		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3830	0.3555	0.3703	0.3333	0.3926	0.4703											0.3707	0.3656	0.3505	0.3633	0.3262	0.3346	0.4414	0.3163	0.3647	0.3673	0.4461	0.4703	SAS										FAIL	24	-7	-38	-10	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											402					0.935							181.14													chr2	113989327																																																	True	True	False	Unknown		Unknown																						0,376	0,195	0,181	0/1	0,0,176,200	ATG	.	.	.			0,0,121,255	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113232665	113232665.0	T	C	C	113232665	.	T	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+2729A>G						rs2166421		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.1320	0.0106	0.232	0.0744	0.2306	0.183											0.173	0.04649	0.1645	0.2005	0.1919	0.0825	0.2262	0.1735	0.2405	0.1932	0.1819	0.2405	gnomADg_NFE										FAIL	-1	23	5	-6	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											841					0.999							245.83													chr2	113990242																																																	True	True	False	Unknown		Unknown																						0,840	0,398	0,442	0|1	0,0,423,417	ATT	.	.	.		113990242	0,0,393,447	57.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113232684	113232684.0	G	A	A	113232684	.	G	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+2710C>T						rs7421852		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3594	0.2685	0.3674	0.3323	0.3926	0.4703											0.3501	0.295	0.3484	0.3575	0.3262	0.3303	0.4415	0.3163	0.3642	0.3542	0.4423	0.4703	SAS										FAIL	4	-49	-25	-17	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											814					0.999							246.83													chr2	113990261																																																	True	True	False	Unknown		Unknown																						0,813	0,375	0,438	0|1	0,0,414,399	GGG	0.00	0.00	0.00		113990242	0,0,398,415	57.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113232816	113232816.0	C	A	A	113232816	.	C	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+2578G>T						rs10206269		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3596	0.2693	0.3674	0.3323	0.3926	0.4703											0.3496	0.2942	0.3488	0.3569	0.3259	0.3289	0.4409	0.3151	0.3641	0.3561	0.4383	0.4703	SAS										FAIL	9	-1	9	-6	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											864					0.993							245.68													chr2	113990393																																																	True	True	False	Unknown		Unknown																						0,858	0,487	0,371	0/1	0,0,438,420	GCT	0.00	0.00	0.00			0,0,459,399	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113233330	113233331.0	G	GA	GA	113233330	.	G	GA	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+2063dup						rs35244828		-1		insertion	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.7837	0.7269	0.7738	0.7946	0.8191	0.82											0.9582	0.8733	1	0.977	0.9914	0.9953	0.9802	0.9888	0.9926	0.9685	0.9921	1	gnomADg_AMI										FAIL	-16	-9	-23	28	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											451					0.692							233.57													chr2	113990907																																																	True	True	False	Unknown		Unknown																						114,198	47,108	67,90	0/1	60,54,111,87	GGA						67,47,129,69	40.66		0.6346153846153846
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113233684	113233684.0	C	A	A	113233684	.	C	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+1710G>T						rs10779887		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.9832	0.9372	0.9986	1	1	1											0.9692	0.9053	0.9757	0.9852	0.9968	0.9992	0.9973	0.9965	0.9934	0.9775	0.997	1	EAS&EUR&SAS										FAIL	-10	-34	40	45	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											410					0.88							176.83													chr2	113991261																																																	True	True	False	Unknown		Unknown																						54,307	28,154	26,153	0/1	24,30,167,140	ACA	0.00	0.00	0.00			42,12,220,87	51.45		0.850415512465374
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113234393	113234393.0	A	G	G	113234393	.	A	G	.	PASS	NM_003466	G	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+1001T>C						rs4849181		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3832	0.3578	0.3703	0.3323	0.3926	0.4693											0.3711	0.3678	0.3487	0.3631	0.3262	0.3299	0.4414	0.3163	0.3648	0.3688	0.4445	0.4693	SAS										FAIL	46	12	-32	25	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											912					0.998							247.73													chr2	113991970																																																	True	True	False	Unknown		Unknown																						0,910	0,475	0,435	0/1	0,0,429,481	TAC	.	.	.			0,0,446,464	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113234624	113234624.0	G	A	A	113234624	.	G	A	.	PASS	NM_003466	A	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+770C>T						rs4849182		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.1352	0.0197	0.232	0.0784	0.2306	0.183											0.1764	0.05918	0.1645	0.2009	0.1919	0.08526	0.2252	0.1667	0.2404	0.1953	0.181	0.2404	gnomADg_NFE										FAIL	-13	43	11	-37	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											254					0.992							149.73													chr2	113992201																																																	True	True	False	Unknown		Unknown																						0,252	0,143	0,109	0/1	0,0,131,121	CGA	0.00	0.00	0.00			0,0,100,152	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113234797	113234797.0	G	C	C	113234797	.	G	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+597C>G						rs4849183		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.5202	0.6831	0.4597	0.3472	0.5368	0.5041											0.5536	0.6701	0.6396	0.4807	0.4539	0.3453	0.6075	0.3741	0.517	0.517	0.4832	0.6831	AFR										FAIL	31	-17	-30	10	0.00	0.00	0.00	0.00	PAX8		4.1500e-01																																																											504					0.994							198.36													chr2	113992374																																																	True	True	False	Unknown		Unknown																						0,501	0,248	0,253	0/1	0,0,268,233	GGG	.	.	.			0,0,277,224	64.73		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113235223	113235225.0	TCC	T	T	113235223	.	TCC	T	.	PASS	NM_003466	-	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		9/11	c.1087+169_1087+170del						rs35724515		-1		deletion	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3570	0.264	0.3689	0.3323	0.3926	0.4632	0.3696	0.287	0.3566	0.3059	0.3369	0.4306	0.3844	0.3672	0.3598	0.4202	0.3488	0.2913	0.3473	0.3574	0.3244	0.3267	0.4398	0.3129	0.3644	0.3534	0.438	0.4632	SAS	benign		1	34739318&34680286&33794208						FAIL	29	38	-26	3	0.05	0.00	0.00	0.00	PAX8		4.1500e-01	1272059				1259387	not_provided		MedGen:C3661900		NC_000002.12:g.113235226_113235227del	criteria_provided&_single_submitter	Benign			SCV001897111	Deletion	SO:0000159	ClinGen:CA53716222		PAX8:7849&LOC129934613:129934613	SO:0001627&intron_variant										1	35724515																											912					0.953							245.24													chr2	113992800																																																	True	True	False	Unknown		Unknown																						0,869	0,453	0,416	0/1	0,0,426,443	TTC						0,0,450,419	63.48		1.0
GRCh38	PAX8	D12_12345_1234556_Thyroid_S9			chr2	113235767	113235767.0	A	C	C	113235767	.	A	C	.	PASS	NM_003466	C	intron_variant	MODIFIER	PAX8	ENSG00000125618	Transcript	ENST00000429538	protein_coding		8/11	c.899-185T>G						rs7589901		-1		SNV	HGNC	HGNC:8622	YES	MANE_Select	NM_003466.4		1	P1	CCDS46398.1	ENSP00000395498	Q06710.214	R9W7C9.80	UPI0000071DEC	Q06710-1		1						0.3546	0.264	0.3631	0.3323	0.3837	0.4642	0.3663	0.2862	0.3538	0.3042	0.3376	0.4208	0.3766	0.3636	0.3551	0.4177	0.3452	0.2893	0.3487	0.3529	0.3228	0.329	0.4265	0.3163	0.3607	0.3493	0.439	0.4642	SAS	benign		1	25375650						FAIL	18	-3	4	40	0.01	0.00	0.00	0.00	PAX8		4.1500e-01	1227992			0.35463	1215384	not_provided		MedGen:C3661900		NC_000002.12:g.113235767A>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001837438&SCV005242610	single_nucleotide_variant	SO:0001483	ClinGen:CA11159467		PAX8:7849&PAX8-AS1:654433	SO:0001627&intron_variant										1	7589901																											975					1							246.32													chr2	113993344																																																	True	True	False	Unknown		Unknown																						0,975	0,440	0,535	0/1	0,0,499,476	TAG	.	.	.			0,0,494,481	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr2	123351637	123351637.0	A	G	G	123351637	.	A	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000305007	Transcript	ENST00000807628	lncRNA		1/6	n.107-1473T>C						rs993934		-1		SNV			YES																			0.4147	0.3396	0.3141	0.4802	0.4205	0.5143											0.3865	0.3264	0.4582	0.3392	0.4077	0.4715	0.525	0.4354	0.3963	0.3828	0.4898	0.525	gnomADg_FIN				26691610&29121662&33406744&34721519																																																																												75					1							243.78													chr2	124109213																																																	True	False	False	Unknown		Unknown																						41,34	18,15	23,19	0/1	20,21,20,14	CAT	.	.	.			23,18,15,19	30.3		0.4533333333333333
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Thr4349=	ENSP00000374135.3:p.Thr4349=	chr2	140274519	140274519.0	C	T	T	140274519	.	C	T	.	PASS	NM_018557	T	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	85/91		c.13047G>A	13334	13047	4349	T	acG/acA	rs1386356&COSV67186048		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_patterns:PS00022&PROSITE_profiles:PS50026&SMART:SM00181			0.4862	0.1558	0.5735	0.6508	0.665	0.5174	0.6601	0.2235	0.5374	0.5253	0.6687	0.6806	0.5394	0.6886	0.6267	0.5801	0.5354	0.2385	0.7247	0.5365	0.5361	0.6739	0.7019	0.5408	0.6756	0.5465	0.5535	0.7247	gnomADg_AMI	benign	0&1	1&1							FAIL	-11	21	44	-19	0.00	0.00	0.00	0.01	LRP1B		4.1900e-01	3060762	0.53199	0.60372	0.48622	3197178	LRP1B-related_disorder		.		NC_000002.12:g.140274519C>T	no_assertion_criteria_provided	Benign			SCV004796131	single_nucleotide_variant	SO:0001483	ClinGen:CA1892642		LRP1B:53353	SO:0001819&synonymous_variant										1	1386356																											114					0.912							228.28	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:T4349= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:t4349= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141032088						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:t4349= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:T4349= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:T4349=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:T4349="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:t4349= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:T4349= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						60,44	27,30	33,14	0/1	40,20,22,22	GCG	0.00	0.00	0.00			31,29,20,24	25.93		0.4230769230769231
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Q3140R	ENSP00000374135.3:p.Gln3140Arg	chr2	140485349	140485349.0	T	C	C	140485349	.	T	C	.	PASS	NM_018557	C	missense_variant	MODERATE	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	59/91		c.9419A>G	9706	9419	3140	Q/R	cAa/cGa	rs34488772&COSV67182511		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1	tolerated_low_confidence(0.49)	benign(0)	Gene3D:2.120.10.30&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF16472&PROSITE_profiles:PS51120&SMART:SM00135&Superfamily:SSF57184&Superfamily:SSF63825			0.0393	0.084	0.0144	0.001	0.0497	0.0256	0.04412	0.08212	0.02378	0.06403	0.0004798	0.09316	0.03244	0.04338	0.04831	0.03076	0.05665	0.07988	0.06718	0.0327	0.06603	0.001933	0.09785	0.02721	0.04767	0.04352	0.02591	0.09785	gnomADg_FIN	benign	0&1	1&1							FAIL	-6	-3	-6	47	0.00	0.00	0.04	0.00	LRP1B	0.221	4.1900e-01	3055298	0.05459	0.04776	0.03934	3206455	LRP1B-related_disorder		.		NC_000002.12:g.140485349T>C	no_assertion_criteria_provided	Benign			SCV004778792	single_nucleotide_variant	SO:0001483	ClinGen:CA1893657		LRP1B:53353	SO:0001583&missense_variant										1	34488772																											66					1							244.88	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Q3140R mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:q3140r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141242918						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:q3140r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Q3140R mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:Q3140R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:Q3140R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:q3140r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Q3140R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						34,32	14,13	20,19	0/1	11,23,14,18	TTG	.	.	.			19,15,17,15	33.03		0.48484848484848486
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Leu3075=	ENSP00000374135.3:p.Leu3075=	chr2	140487635	140487635.0	T	C	C	140487635	.	T	C	.	PASS	NM_018557	C	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	58/91		c.9225A>G	9512	9225	3075	L	ttA/ttG	rs74789055&COSV67182516		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:2.120.10.30&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF16472&SMART:SM00135&Superfamily:SSF57184&Superfamily:SSF63825			0.0216	0.0197	0.0101	0.001	0.0487	0.0256	0.04166	0.02315	0.01864	0.06211	0.0004821	0.09317	0.0281	0.04257	0.04215	0.0303	0.04029	0.0245	0.06798	0.02435	0.06401	0.001928	0.09804	0.02041	0.0472	0.03359	0.02589	0.09804	gnomADg_FIN	benign	0&1	1&1							FAIL	36	-18	-18	-26	0.00	0.00	0.00	0.00	LRP1B		4.1900e-01	3057183	0.03563	0.04221	0.02157	3196213	LRP1B-related_disorder		.		NC_000002.12:g.140487635T>C	no_assertion_criteria_provided	Benign			SCV004794300	single_nucleotide_variant	SO:0001483	ClinGen:CA1893714		LRP1B:53353	SO:0001819&synonymous_variant										1	74789055																											120					1							242.98	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:L3075= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:l3075= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141245204						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:l3075= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:L3075= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:L3075=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:L3075="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:l3075= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:L3075= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						59,61	30,27	29,34	0/1	33,26,27,34	TTA	.	.	.			30,29,39,22	37.28		0.5083333333333333
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Cys2910=	ENSP00000374135.3:p.Cys2910=	chr2	140501807	140501807.0	G	A	A	140501807	.	G	A	.	PASS	NM_018557	A	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	55/91		c.8730C>T	9017	8730	2910	C	tgC/tgT	rs35164907&COSV67182519		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:4.10.400.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00057&PROSITE_patterns:PS01209&PROSITE_profiles:PS50068&PANTHER:PTHR22722&SMART:SM00192&Superfamily:SSF57424&CDD:cd00112			0.1262	0.0613	0.1167	0.0198	0.2465	0.2065	0.2514	0.07687	0.1274	0.2217	0.01845	0.3002	0.1319	0.2725	0.2305	0.219	0.1962	0.08678	0.1963	0.1369	0.2239	0.01724	0.3078	0.161	0.2706	0.1825	0.2131	0.3078	gnomADg_FIN	benign	0&1	1&1							FAIL	27	24	25	-25	0.00	0.06	0.00	0.00	LRP1B		4.1900e-01	3060548	0.20667	0.21544	0.12620	3200863	LRP1B-related_disorder		.		NC_000002.12:g.140501807G>A	no_assertion_criteria_provided	Benign			SCV004796727	single_nucleotide_variant	SO:0001483	ClinGen:CA1893881		LRP1B:53353	SO:0001819&synonymous_variant										1	35164907																											118					0.949							235.05	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:C2910= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:c2910= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141259376						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:c2910= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:C2910= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:C2910=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:C2910="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:c2910= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:C2910= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						62,50	26,26	36,24	0/1	26,36,19,31	CGC	0.00	0.00	0.00			32,30,29,21	29.24		0.44642857142857145
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Tyr2842=	ENSP00000374135.3:p.Tyr2842=	chr2	140503099	140503099.0	A	G	G	140503099	.	A	G	.	PASS	NM_018557	G	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	54/91		c.8526T>C	8813	8526	2842	Y	taT/taC	rs4444457&COSV67186049		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:4.10.400.10&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00192&Superfamily:SSF57424			0.5431	0.466	0.451	0.7222	0.5388	0.5327	0.5626	0.4951	0.4624	0.4177	0.7342	0.5821	0.3719	0.5677	0.5457	0.5519	0.5334	0.4945	0.4659	0.4552	0.4275	0.7351	0.6084	0.3776	0.5547	0.4877	0.5539	0.7351	gnomADg_EAS	benign	0&1	1&1							FAIL	-17	29	-10	-7	0.00	0.00	0.00	0.00	LRP1B		4.1900e-01	3059780	0.53275	0.54899	0.54313	3217686	LRP1B-related_disorder		.		NC_000002.12:g.140503099A>G	no_assertion_criteria_provided	Benign			SCV004798122	single_nucleotide_variant	SO:0001483	ClinGen:CA1893949		LRP1B:53353	SO:0001819&synonymous_variant										1	4444457																											72					0.931							237.77	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Y2842= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:y2842= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141260668						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:y2842= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Y2842= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:Y2842=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:Y2842="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:y2842= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Y2842= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						38,29	21,17	17,12	0/1	20,18,14,15	GAT	.	.	.			17,21,12,17	28.22		0.43283582089552236
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Gln2677=	ENSP00000374135.3:p.Gln2677=	chr2	140517007	140517007.0	T	C	C	140517007	.	T	C	.	PASS	NM_018557	C	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	50/91		c.8031A>G	8318	8031	2677	Q	caA/caG	rs4954672&COSV67186053		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:4.10.400.10&Phobius:NON_CYTOPLASMIC_DOMAIN			0.6424	0.6921	0.7363	0.4167	0.7475	0.6329	0.7356	0.6886	0.7402	0.8353	0.4251	0.6922	0.843	0.7532	0.7378	0.6598	0.7237	0.6994	0.7319	0.7547	0.8323	0.4112	0.6656	0.8673	0.7619	0.7666	0.6494	0.8673	gnomADg_MID	benign	0&1	1&1							FAIL	4	47	-1	4	0.12	0.01	0.00	0.00	LRP1B		4.1900e-01	3060585	0.74669	0.71500	0.64237	3200900	LRP1B-related_disorder		.		NC_000002.12:g.140517007T>C	no_assertion_criteria_provided	Benign			SCV004796398	single_nucleotide_variant	SO:0001483	ClinGen:CA1894110		LRP1B:53353	SO:0001819&synonymous_variant										1	4954672																											87					0.977							245.56	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Q2677= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:q2677= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141274576						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:q2677= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Q2677= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:Q2677=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:Q2677="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:q2677= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:Q2677= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						50,35	22,13	28,22	0/1	26,24,19,16	TTT	.	.	.			22,28,13,22	25.04		0.4117647058823529
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9			chr2	140776093	140776093.0	T	C	C	140776093	.	T	C	.	PASS	NM_018557	C	splice_donor_5th_base_variant&intron_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding		33/90	c.5500+5A>G						rs996361		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1						0.8552	0.7458	0.8977	0.999	0.8658	0.8139	0.8758	0.7554	0.9213	0.8801	0.9994	0.9054	0.7817	0.8781	0.8666	0.8044	0.8532	0.7713	0.8505	0.8778	0.881	0.9992	0.9088	0.7619	0.8793	0.8523	0.8211	0.9994	gnomADe_EAS	benign		1							FAIL	16	45	5	45	0.00	0.00	0.00	0.00	LRP1B		4.1900e-01	3060361	0.83838	0.87319	0.85523	3200677	LRP1B-related_disorder		.		NC_000002.12:g.140776093T>C	no_assertion_criteria_provided	Benign			SCV004799599	single_nucleotide_variant	SO:0001483	ClinGen:CA1894900		LRP1B:53353	SO:0001627&intron_variant										1	996361																											75					0.973							247.26													chr2	141533662																																																	True	True	False	Unknown		Unknown																						0,73	0,29	0,44	0/1	0,0,31,42	ATT	.	.	.			0,0,49,24	64.52		1.0
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Ser1752=	ENSP00000374135.3:p.Ser1752=	chr2	140813760	140813760.0	T	C	C	140813760	.	T	C	.	PASS	NM_018557	C	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	32/91		c.5256A>G	5543	5256	1752	S	tcA/tcG	rs3749010&COSV67186059		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:2.120.10.30&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00135&Superfamily:SSF63825			0.8452	0.6974	0.7709	0.9871	0.8748	0.9213	0.8866	0.7204	0.7844	0.8699	0.9708	0.8922	0.8228	0.8922	0.8755	0.9056	0.8405	0.7292	0.8235	0.7959	0.8741	0.9864	0.8942	0.8163	0.8923	0.8488	0.911	0.9871	EAS	benign	0&1	1&1							FAIL	34	3	34	46	0.02	0.00	0.00	0.00	LRP1B		4.1900e-01	3060696	0.83700		0.84525	3197113	LRP1B-related_disorder		.		NC_000002.12:g.140813760T>C	no_assertion_criteria_provided	Benign			SCV004796615	single_nucleotide_variant	SO:0001483	ClinGen:CA1894954		LRP1B:53353	SO:0001819&synonymous_variant										1	3749010																											83					0.964							237.53	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:S1752= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:s1752= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141571329						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:s1752= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:S1752= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:S1752=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:S1752="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:s1752= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:S1752= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						0,80	0,41	0,39	0/1	0,0,44,36	CTG	.	.	.			0,0,39,41	64.58		1.0
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Asp872=	ENSP00000374135.3:p.Asp872=	chr2	140994023	140994023.0	G	A	A	140994023	.	G	A	.	PASS	NM_018557	A	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	16/91		c.2616C>T	2903	2616	872	D	gaC/gaT	rs13007735&COSV63341570&COSV63341855		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:4.10.400.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00057&Prints:PR00261&PROSITE_patterns:PS01209&PROSITE_profiles:PS50068&SMART:SM00192&Superfamily:SSF57424&Low_complexity_(Seg):seg			0.5096	0.6059	0.3847	0.6141	0.3748	0.499	0.3396	0.5597	0.3856	0.4824	0.6168	0.2474	0.4484	0.3119	0.3681	0.4459	0.4023	0.5546	0.2901	0.3707	0.4796	0.5974	0.2446	0.415	0.3191	0.4153	0.4643	0.6168	gnomADe_EAS	benign	0&1&1	1&1&1	28195579						FAIL	1	-28	47	-28	0.00	0.00	0.00	0.01	LRP1B		4.1900e-01	3060015	0.39874	0.38797	0.50958	3217921	LRP1B-related_disorder		.		NC_000002.12:g.140994023G>A	no_assertion_criteria_provided	Benign			SCV004799135	single_nucleotide_variant	SO:0001483	ClinGen:CA1895693		LRP1B:53353	SO:0001819&synonymous_variant										1	13007735																											112					0.938							235.51	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:D872= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:d872= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141751592						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:d872= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:D872= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:D872=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:D872="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:d872= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:D872= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						0,105	0,49	0,56	0/1	0,0,48,57	CGT	0.00	0.00	0.00			0,0,56,49	64.69		1.0
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Arg686=	ENSP00000374135.3:p.Arg686=	chr2	141015828	141015828.0	C	A	A	141015828	.	C	A	.	PASS	NM_018557	A	synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	13/91		c.2058G>T	2345	2058	686	R	cgG/cgT	rs78806080&COSV67229593		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:2.120.10.30&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00058&PROSITE_profiles:PS51120&SMART:SM00135&Superfamily:SSF63825			0.0340	0	0.0274	0.002	0.0736	0.0767	0.06042	0.01022	0.03292	0.06187	0.0003536	0.03503	0.07856	0.06494	0.05338	0.08248	0.04417	0.01168	0.1099	0.04251	0.05366	0.0003893	0.0266	0.04422	0.06669	0.04451	0.0778	0.1099	gnomADg_AMI	benign	0&1	1&1							FAIL	-22	-4	2	-37	0.00	0.00	0.00	0.01	LRP1B		4.1900e-01	3055701	0.04606	0.05282	0.03395	3221816	LRP1B-related_disorder		.		NC_000002.12:g.141015828C>A	no_assertion_criteria_provided	Benign			SCV004792568	single_nucleotide_variant	SO:0001483	ClinGen:CA1895849		LRP1B:53353	SO:0001819&synonymous_variant										1	78806080																											209					0.957							234.07	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:R686= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:r686= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141773397						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:r686= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:R686= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:R686=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:R686="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:r686= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:R686= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						85,115	43,63	42,52	0/1	44,41,61,54	GCC	0.00	0.00	0.00			42,43,69,46	49.4		0.575
GRCh38	LRP1B	D12_12345_1234556_Thyroid_S9	p.Val413=	ENSP00000374135.3:p.Val413=	chr2	141059052	141059052.0	A	G	G	141059052	.	A	G	.	PASS	NM_018557	G	splice_region_variant&synonymous_variant	LOW	LRP1B	ENSG00000168702	Transcript	ENST00000389484	protein_coding	9/91		c.1239T>C	1526	1239	413	V	gtT/gtC	rs1525579&COSV67186066		-1		SNV	HGNC	HGNC:6693	YES	MANE_Select	NM_018557.3		1	P1	CCDS2182.1	ENSP00000374135	Q9NZR2.188		UPI00001B045B			1			Gene3D:2.120.10.30&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00135&Superfamily:SSF57184&Superfamily:SSF63825			0.9453	0.8011	0.9841	1	1	1	0.9954	0.8176	0.9922	1	1	1	0.9957	0.9999	0.9903	0.9996	0.9502	0.826	1	0.984	1	1	1	0.9932	0.9995	0.9645	0.9994	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN	benign	0&1	1&1							FAIL	2	-32	-13	3	0.01	0.00	0.00	0.00	LRP1B		4.1900e-01	3059050	0.94048	0.98431	0.94529	3196766	LRP1B-related_disorder		.		NC_000002.12:g.141059052A>G	no_assertion_criteria_provided	Benign			SCV004795993	single_nucleotide_variant	SO:0001483	ClinGen:CA1896062		LRP1B:53353	SO:0001819&synonymous_variant										1	1525579																											44					0.955							243.29	v6.1	Unknown		True	LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	False	02/24/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:V413= mutant UNKNOWN.	False	The LRP1B ENSP00000374135.3:v413= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	141816621						True	False	False	Unknown								False	False		LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer.	The LRP1B ENSP00000374135.3:v413= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:V413= mutant UNKNOWN.						v6.1	02/24/2023		GRCh38	LRP1B	53353.0	ENSP00000374135.3:V413=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LRP1B"",""entrezGeneId"":53353,""alteration"":""ENSP00000374135.3:V413="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LRP1B, a low-density lipoprotein receptor, is infrequently altered in cancer."",""variantSummary"":""The LRP1B ENSP00000374135.3:v413= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LRP1B ENSP00000374135.3:V413= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/24/2023""}"	True	True	False	Unknown		Unknown																						0,42	0,19	0,23	0/1	0,0,22,20	TAA	.	.	.			0,0,13,29	63.73		1.0
GRCh38	ACVR1	D12_12345_1234556_Thyroid_S9	p.Glu230=	ENSP00000405004.1:p.Glu230=	chr2	157770468	157770468.0	C	T	T	157770468	.	C	T	.	PASS	NM_001111067	T	synonymous_variant	LOW	ACVR1	ENSG00000115170	Transcript	ENST00000434821	protein_coding	7/11		c.690G>A	1407	690	230	E	gaG/gaA	rs1146031&COSV99717424		-1		SNV	HGNC	HGNC:171	YES	MANE_Select	NM_001111067.4		1	P4	CCDS2206.1	ENSP00000405004	Q04771.225	D3DPA4.120	UPI000000163F			1			PDB-ENSP_mappings:3h9r.A&PDB-ENSP_mappings:3mtf.A&PDB-ENSP_mappings:3mtf.B&PDB-ENSP_mappings:3oom.A&PDB-ENSP_mappings:3q4u.A&PDB-ENSP_mappings:3q4u.B&PDB-ENSP_mappings:3q4u.C&PDB-ENSP_mappings:3q4u.D&PDB-ENSP_mappings:4bgg.A&PDB-ENSP_mappings:4bgg.B&PDB-ENSP_mappings:4bgg.C&PDB-ENSP_mappings:4bgg.D&PDB-ENSP_mappings:4c02.A&PDB-ENSP_mappings:4dym.A&PDB-ENSP_mappings:5oxg.A&PDB-ENSP_mappings:5oxg.B&PDB-ENSP_mappings:5oxg.C&PDB-ENSP_mappings:5oxg.D&PDB-ENSP_mappings:5oy6.A&PDB-ENSP_mappings:5oy6.B&PDB-ENSP_mappings:5oy6.C&PDB-ENSP_mappings:5oy6.D&PDB-ENSP_mappings:5s75.A&PDB-ENSP_mappings:5s75.B&PDB-ENSP_mappings:5s76.A&PDB-ENSP_mappings:5s76.B&PDB-ENSP_mappings:5s77.A&PDB-ENSP_mappings:5s77.B&PDB-ENSP_mappings:5s78.A&PDB-ENSP_mappings:5s78.B&PDB-ENSP_mappings:5s79.A&PDB-ENSP_mappings:5s79.B&PDB-ENSP_mappings:5s7a.A&PDB-ENSP_mappings:5s7a.B&PDB-ENSP_mappings:5s7b.A&PDB-ENSP_mappings:5s7b.B&PDB-ENSP_mappings:5s7c.A&PDB-ENSP_mappings:5s7c.B&PDB-ENSP_mappings:5s7d.A&PDB-ENSP_mappings:5s7d.B&PDB-ENSP_mappings:5s7e.A&PDB-ENSP_mappings:5s7e.B&PDB-ENSP_mappings:5s7f.A&PDB-ENSP_mappings:5s7f.B&PDB-ENSP_mappings:5s7g.A&PDB-ENSP_mappings:5s7g.B&PDB-ENSP_mappings:5s7h.A&PDB-ENSP_mappings:5s7h.B&PDB-ENSP_mappings:5s7i.A&PDB-ENSP_mappings:5s7i.B&PDB-ENSP_mappings:5s7j.A&PDB-ENSP_mappings:5s7j.B&PDB-ENSP_mappings:5s7k.A&PDB-ENSP_mappings:5s7k.B&PDB-ENSP_mappings:5s7l.A&PDB-ENSP_mappings:5s7l.B&PDB-ENSP_mappings:5s7m.A&PDB-ENSP_mappings:5s7m.B&PDB-ENSP_mappings:5s7n.A&PDB-ENSP_mappings:5s7n.B&PDB-ENSP_mappings:5s7o.A&PDB-ENSP_mappings:5s7o.B&PDB-ENSP_mappings:5s7p.A&PDB-ENSP_mappings:5s7p.B&PDB-ENSP_mappings:5s7q.A&PDB-ENSP_mappings:5s7q.B&PDB-ENSP_mappings:5s7r.A&PDB-ENSP_mappings:5s7r.B&PDB-ENSP_mappings:5s7s.A&PDB-ENSP_mappings:5s7s.B&PDB-ENSP_mappings:5s7t.A&PDB-ENSP_mappings:5s7t.B&PDB-ENSP_mappings:5s7u.A&PDB-ENSP_mappings:5s7u.B&PDB-ENSP_mappings:5s7v.A&PDB-ENSP_mappings:5s7v.B&PDB-ENSP_mappings:5s7w.A&PDB-ENSP_mappings:5s7w.B&PDB-ENSP_mappings:5s7x.A&PDB-ENSP_mappings:5s7x.B&PDB-ENSP_mappings:5s7y.A&PDB-ENSP_mappings:5s7y.B&PDB-ENSP_mappings:5s7z.A&PDB-ENSP_mappings:5s7z.B&PDB-ENSP_mappings:5s80.A&PDB-ENSP_mappings:5s80.B&PDB-ENSP_mappings:5s81.A&PDB-ENSP_mappings:5s81.B&PDB-ENSP_mappings:5s82.A&PDB-ENSP_mappings:5s82.B&PDB-ENSP_mappings:5s83.A&PDB-ENSP_mappings:5s83.B&PDB-ENSP_mappings:5s84.A&PDB-ENSP_mappings:5s84.B&PDB-ENSP_mappings:5s85.A&PDB-ENSP_mappings:5s85.B&PDB-ENSP_mappings:5s86.A&PDB-ENSP_mappings:5s86.B&PDB-ENSP_mappings:5s87.A&PDB-ENSP_mappings:5s87.B&PDB-ENSP_mappings:5s88.A&PDB-ENSP_mappings:5s88.B&PDB-ENSP_mappings:5s89.A&PDB-ENSP_mappings:5s89.B&PDB-ENSP_mappings:5s8a.A&PDB-ENSP_mappings:5s8a.B&PDB-ENSP_mappings:5s8b.A&PDB-ENSP_mappings:5s8b.B&PDB-ENSP_mappings:5s9k.A&PDB-ENSP_mappings:5s9k.B&PDB-ENSP_mappings:6acr.A&PDB-ENSP_mappings:6acr.B&PDB-ENSP_mappings:6eix.A&PDB-ENSP_mappings:6gi6.A&PDB-ENSP_mappings:6gin.A&PDB-ENSP_mappings:6gin.B&PDB-ENSP_mappings:6gip.A&PDB-ENSP_mappings:6i1s.A&PDB-ENSP_mappings:6jux.A&PDB-ENSP_mappings:6srh.A&PDB-ENSP_mappings:6srh.B&PDB-ENSP_mappings:6szm.A&PDB-ENSP_mappings:6szm.B&PDB-ENSP_mappings:6t6d.A&PDB-ENSP_mappings:6t6d.B&PDB-ENSP_mappings:6t6d.C&PDB-ENSP_mappings:6t6d.D&PDB-ENSP_mappings:6t8n.A&PDB-ENSP_mappings:6t8n.B&PDB-ENSP_mappings:6tn8.A&PDB-ENSP_mappings:6unq.A&PDB-ENSP_mappings:6unr.A&PDB-ENSP_mappings:6uns.A&PDB-ENSP_mappings:6uns.B&PDB-ENSP_mappings:6z36.A&PDB-ENSP_mappings:6z36.B&PDB-ENSP_mappings:6zgc.A&PDB-ENSP_mappings:6zgc.B&PDB-ENSP_mappings:6zgc.C&PDB-ENSP_mappings:6zgc.D&PDB-ENSP_mappings:7a21.A&PDB-ENSP_mappings:7a21.B&PDB-ENSP_mappings:7c3g.A&PDB-ENSP_mappings:7c3g.B&PDB-ENSP_mappings:7nns.B&PDB-ENSP_mappings:8c7w.A&PDB-ENSP_mappings:8c7z.A&PDB-ENSP_mappings:8pod.A&PDB-ENSP_mappings:8r7g.A&PDB-ENSP_mappings:8r7g.B&PDB-ENSP_mappings:8r7g.C&PDB-ENSP_mappings:8r7g.D&Gene3D:3.30.200.20&Pfam:PF00069&PROSITE_profiles:PS50011&Superfamily:SSF56112&SMART:SM00220&CDD:cd14142&Phobius:CYTOPLASMIC_DOMAIN&PANTHER:PTHR23255&PROSITE_patterns:PS00107&AFDB-ENSP_mappings:AF-Q04771-F1			0.9139	0.7421	0.9582	0.9712	0.9861	0.9816	0.9822	0.7574	0.9818	0.9813	0.962	0.9833	0.945	0.9914	0.9692	0.9717	0.9215	0.7586	0.9934	0.9633	0.9787	0.9687	0.9859	0.949	0.9897	0.9308	0.9734	0.9934	gnomADg_AMI	benign	0&1	1&1	25741868&19299629&18781190&32960377&23644028&25379134						FAIL	46	-40	37	46	0.00	0.00	0.00	0.00	ACVR1		8.3500e-01	257466	0.91150	0.96419	0.91394	250303	not_provided&Progressive_myositis_ossificans&not_specified		MedGen:C3661900&MONDO:MONDO:0007606&MedGen:C0016037&OMIM:135100&Orphanet:337&MedGen:CN169374		NC_000002.12:g.157770468C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306605&SCV000417322&SCV001768971&SCV001868593&SCV002410098&SCV005238979	single_nucleotide_variant	SO:0001483	ClinGen:CA1919082		ACVR1:90	SO:0001819&synonymous_variant										1	1146031																											129					0.845							242.15	v6.1	Unknown		True	ACVR1, a receptor protein, is mutated in various cancer types including diffuse intrinsic pontine glioma (DIPG).	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ACVR1 ENSP00000405004.1:E230= mutant UNKNOWN.	False	The ACVR1 ENSP00000405004.1:e230= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	158626980						True	False	False	Unknown								False	False		ACVR1, a receptor protein, is mutated in various cancer types including diffuse intrinsic pontine glioma (DIPG).	The ACVR1 ENSP00000405004.1:e230= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ACVR1 ENSP00000405004.1:E230= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ACVR1	90.0	ENSP00000405004.1:E230=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ACVR1"",""entrezGeneId"":90,""alteration"":""ENSP00000405004.1:E230="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ACVR1, a receptor protein, is mutated in various cancer types including diffuse intrinsic pontine glioma (DIPG)."",""variantSummary"":""The ACVR1 ENSP00000405004.1:e230= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ACVR1 ENSP00000405004.1:E230= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,109	0,65	0,44	0/1	0,0,63,46	TCT	0.00	0.00	0.00			0,0,63,46	64.69		1.0
GRCh38	ACVR1	D12_12345_1234556_Thyroid_S9	p.Ala90=	ENSP00000405004.1:p.Ala90=	chr2	157780398	157780398.0	G	A	A	157780398	.	G	A	.	PASS	NM_001111067	A	synonymous_variant	LOW	ACVR1	ENSG00000115170	Transcript	ENST00000434821	protein_coding	4/11		c.270C>T	987	270	90	A	gcC/gcT	rs2227861&COSV99717425		-1		SNV	HGNC	HGNC:171	YES	MANE_Select	NM_001111067.4		1	P4	CCDS2206.1	ENSP00000405004	Q04771.225	D3DPA4.120	UPI000000163F			1			PDB-ENSP_mappings:7yru.A&Gene3D:2.10.60.10&Pfam:PF01064&Prints:PR00653&Superfamily:SSF57302&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR23255&AFDB-ENSP_mappings:AF-Q04771-F1			0.6510	0.1838	0.7666	0.9067	0.7793	0.8047	0.7619	0.242	0.8182	0.8051	0.9176	0.7829	0.7566	0.7633	0.7522	0.8266	0.6379	0.271	0.6831	0.7578	0.8017	0.9229	0.7789	0.7483	0.7671	0.666	0.827	0.9229	gnomADg_EAS	benign	0&1	1&1	25741868&19299629&18781190&33562470&37146293						FAIL	-49	1	29	-23	0.00	0.00	0.03	0.00	ACVR1		8.3500e-01	257464	0.60472	0.75017	0.65096	250304	not_provided&Progressive_myositis_ossificans&not_specified		MedGen:C3661900&MONDO:MONDO:0007606&MedGen:C0016037&OMIM:135100&Orphanet:337&MedGen:CN169374		NC_000002.12:g.157780398G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306603&SCV000417328&SCV001755838&SCV001768972&SCV002409440&SCV005238982	single_nucleotide_variant	SO:0001483	ClinGen:CA1919198		ACVR1:90	SO:0001819&synonymous_variant										1	2227861																											1085					0.998							248.13	v6.1	Unknown		True	ACVR1, a receptor protein, is mutated in various cancer types including diffuse intrinsic pontine glioma (DIPG).	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ACVR1 ENSP00000405004.1:A90= mutant UNKNOWN.	False	The ACVR1 ENSP00000405004.1:a90= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	158636910						True	False	False	Unknown								False	False		ACVR1, a receptor protein, is mutated in various cancer types including diffuse intrinsic pontine glioma (DIPG).	The ACVR1 ENSP00000405004.1:a90= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ACVR1 ENSP00000405004.1:A90= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ACVR1	90.0	ENSP00000405004.1:A90=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ACVR1"",""entrezGeneId"":90,""alteration"":""ENSP00000405004.1:A90="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ACVR1, a receptor protein, is mutated in various cancer types including diffuse intrinsic pontine glioma (DIPG)."",""variantSummary"":""The ACVR1 ENSP00000405004.1:a90= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ACVR1 ENSP00000405004.1:A90= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						572,511	283,260	289,251	0/1	274,298,271,240	CGG	0.00	0.00	0.00			301,271,242,269	31.48		0.47183748845798706
GRCh38	SCN7A	D12_12345_1234556_Thyroid_S9			chr2	166429233		A	[chr17:81004465[A	[chr17:81004465[A	166429233	MantaBND:7436:0:1:0:0:0:0	A	[chr17:81004465[A	.	PASS	NM_002976	.A	feature_truncation&coding_sequence_variant	HIGH	SCN7A	ENSG00000136546	Transcript	ENST00000643258	protein_coding	17/26			3042	2633	878					-1		chromosome_breakpoint	HGNC	HGNC:10594	YES	MANE_Select	NM_002976.4			P1	CCDS46442.1	ENSP00000496114	Q01118.205		UPI0000209019						PDB-ENSP_mappings:7tj8.A&PDB-ENSP_mappings:7tj9.A&AFDB-ENSP_mappings:AF-Q01118-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF06512&PANTHER:PTHR10037																																																																																																											0			0,7							7	TCAACAG			MantaBND:7436:0:1:0:0:0:1	4														chr2	167285743				BND																																													True	False	False	Unknown		Unknown																															0,1				3,2	
GRCh38	ABCB11	D12_12345_1234556_Thyroid_S9			chr2	168943763	168943767.0	A	ACGTG	ACGTG	168943763	.	A	ACGTG	.	PASS	NM_003742	CGTG	intron_variant	MODIFIER	ABCB11	ENSG00000073734	Transcript	ENST00000650372	protein_coding		21/27	c.2610+841_2610+842insCACG						rs2307959		-1		insertion	HGNC	HGNC:42	YES	MANE_Select	NM_003742.4			P1	CCDS46444.1	ENSP00000497931	O95342.208		UPI0000163BFA			1						0.5214	0.2769	0.5634	0.6478	0.5348	0.6779											0.4943	0.3227	0.7604	0.5574	0.6196	0.6252	0.566	0.5272	0.5412	0.5196	0.6622	0.7604	gnomADg_AMI				21359226&23690203&22124616&24416183&36292568																	7.3900e-01																																																											61					0.902							243.68													chr2	169800273																																																	True	False	False	Unknown		Unknown																						0,55	0,26	0,29	0/1	0,0,33,22	GAC						0,0,24,31	62.96		1.0
GRCh38	SESTD1	D12_12345_1234556_Thyroid_S9			chr2	179255107		C	[chr7:137408835[C	[chr7:137408835[C	179255107	MantaBND:7511:0:1:0:0:0:0	C	[chr7:137408835[C	.	PASS		.C	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	SESTD1	ENSG00000187231	Transcript	ENST00000452991	protein_coding_CDS_not_defined		1/4									-1		chromosome_breakpoint	HGNC	HGNC:18379					3																																																																																																																							5			0,11							11	TGTCTCTCTCC			MantaBND:7511:0:1:0:0:0:1	2														chr2	180119834				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	CERKL	D12_12345_1234556_Thyroid_S9			chr2	181548532	181548532.0	A	G	G	181548532	.	A	G	.	PASS		G	intron_variant	MODIFIER	CERKL	ENSG00000188452	Transcript	ENST00000684145	protein_coding		7/11	c.377+13T>C						rs12997453&COSV59207851		-1		SNV	HGNC	HGNC:21699								ENSP00000508396		G0XYE7.52	UPI00001C1122			1						0.6484	0.6127	0.6282	0.621	0.5447	0.8456	0.5889	0.6111	0.603	0.6107	0.6159	0.4888	0.7165	0.5703	0.5976	0.8363	0.5939	0.6075	0.3835	0.613	0.6089	0.633	0.506	0.6633	0.5763	0.614	0.8301	0.8456	SAS	benign	0&1	1&1	25741868&23771752&26522768&26691610&29121662&33406744&33857205&27294018&29797257&16360294						FAIL	33	40	9	13	0.00	0.00	0.01	0.00	CERKL		1.4370e+00	257149	0.59313	0.62394	0.64836	250436	not_provided&Retinitis_pigmentosa_26&Retinitis_pigmentosa&not_specified		MedGen:C3661900&MONDO:MONDO:0012024&MedGen:C1842127&OMIM:608380&Orphanet:791&Human_Phenotype_Ontology:HP:0000547&MONDO:MONDO:0019200&MeSH:D012174&MedGen:C0035334&OMIM:268000&OMIM:PS268000&Orphanet:791&MedGen:CN169374		NC_000002.12:g.181548532A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000305949&SCV000425444&SCV001720503&SCV001761730&SCV001864949&SCV005241501	single_nucleotide_variant	SO:0001483	ClinGen:CA2010561		CERKL:375298	SO:0001627&intron_variant										1	12997453																											105					0.99							243.5													chr2	182413259																																																	True	False	False	Unknown		Unknown																						63,41	25,19	38,22	0/1	36,27,18,23	GAG	.	.	.			30,33,16,25	21.09		0.3942307692307692
GRCh38	PMS1	D12_12345_1234556_Thyroid_S9	p.Tyr90=	ENSP00000406490.3:p.Tyr90=	chr2	189795906	189795906.0	C	T	T	189795906	.	C	T	.	PASS	NM_000534	T	synonymous_variant	LOW	PMS1	ENSG00000064933	Transcript	ENST00000441310	protein_coding	3/13		c.270C>T	434	270	90	Y	taC/taT	rs149723996		1		SNV	HGNC	HGNC:9121	YES	MANE_Select	NM_000534.5		1	P1	CCDS2302.1	ENSP00000406490	P54277.209		UPI00000405F5	P54277-1		1			Gene3D:3.30.565.10&AFDB-ENSP_mappings:AF-P54277-F1&Pfam:PF13589&PANTHER:PTHR10073&Superfamily:SSF55874&NCBIFAM:TIGR00585&CDD:cd16926									0.0001382	5.976e-05	2.236e-05	0.0006124	0	1.872e-05	0	0.0001548	0.0001656	0	9.205e-05	0	0	6.549e-05	0.0005764	0	0	0	0.0001617	0	0	0.0006124	gnomADe_ASJ										FAIL	17	-30	-39	50	0.00	0.00	0.00	0.01	PMS1		1.0850e+00																																																											215					0.981							240.26	v6.1	Unknown		True	PMS1 is involved in DNA mismatch repair.	False	12/05/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PMS1 ENSP00000406490.3:Y90= mutant UNKNOWN.	False	The PMS1 ENSP00000406490.3:y90= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	190660632						True	False	False	Unknown								False	False		PMS1 is involved in DNA mismatch repair.	The PMS1 ENSP00000406490.3:y90= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PMS1 ENSP00000406490.3:Y90= mutant UNKNOWN.						v6.1	12/05/2017		GRCh38	PMS1	5378.0	ENSP00000406490.3:Y90=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PMS1"",""entrezGeneId"":5378,""alteration"":""ENSP00000406490.3:Y90="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PMS1 is involved in DNA mismatch repair."",""variantSummary"":""The PMS1 ENSP00000406490.3:y90= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PMS1 ENSP00000406490.3:Y90= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/05/2017""}"	True	True	False	Unknown		Unknown																						208,3	109,3	99,0	0/1	116,92,2,1	ACG	0.00	0.00	1.00			117,91,2,1	3.11		0.014218009478672985
GRCh38	STAT4	D12_12345_1234556_Thyroid_S9			chr2	191058115	191058115.0	G	A	A	191058115	.	G	A	.	PASS	NM_003151	A	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	STAT4	ENSG00000138378	Transcript	ENST00000392320	protein_coding		12/23	c.1113-4C>T						rs3024866&COSV61831638		-1		SNV	HGNC	HGNC:11365	YES	MANE_Select	NM_003151.4		1	P1	CCDS2310.1	ENSP00000376134	Q14765.215		UPI00000015F2			1						0.4964	0.1437	0.5187	0.5188	0.7435	0.68	0.712	0.1983	0.5167	0.6688	0.5556	0.6937	0.6211	0.7493	0.6768	0.6589	0.5685	0.2193	0.8128	0.5526	0.6865	0.5297	0.7002	0.6224	0.7491	0.6002	0.6754	0.8128	gnomADg_AMI	benign	0&1	1&1	24033266&23326239&17932559&18579578&19019891&19644876&23360093&28420002&26569609&29556239&33333988&34791504&26064250&26242990&38202017						FAIL	-13	-4	23	14	0.00	0.03	0.00	0.00	STAT4		5.0300e-01	403495	0.57012	0.64154	0.49641	389452	not_provided&not_specified		MedGen:C3661900&MedGen:CN169374		NC_000002.12:g.191058115G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000540461&SCV001730123&SCV005244393	single_nucleotide_variant	SO:0001483	ClinGen:CA2030670		STAT4:6775	SO:0001627&intron_variant										1	3024866																											196					1							247.65													chr2	191922841																																																	True	True	False	Unknown		Unknown																						100,96	45,60	55,36	0/1	45,55,42,54	GGA	0.00	0.00	0.00			48,52,46,50	36.63		0.4897959183673469
GRCh38	SF3B1	D12_12345_1234556_Thyroid_S9	p.Val1219=	ENSP00000335321.6:p.Val1219=	chr2	197393071	197393071.0	T	C	C	197393071	.	T	C	.	PASS	NM_012433	C	synonymous_variant	LOW	SF3B1	ENSG00000115524	Transcript	ENST00000335508	protein_coding	24/25		c.3657A>G	3686	3657	1219	V	gtA/gtG	rs4685&COSV59206298		-1		SNV	HGNC	HGNC:10768	YES	MANE_Select	NM_012433.4		1	P1	CCDS33356.1	ENSP00000335321	O75533.219		UPI000013D493	O75533-1		1			Gene3D:1.25.10.10&PDB-ENSP_mappings:5ife.C&PDB-ENSP_mappings:5o9z.v&PDB-ENSP_mappings:5z56.1&PDB-ENSP_mappings:5z57.1&PDB-ENSP_mappings:5z58.1&PDB-ENSP_mappings:5zya.C&PDB-ENSP_mappings:6ah0.1&PDB-ENSP_mappings:6ahd.1&PDB-ENSP_mappings:6en4.C&PDB-ENSP_mappings:6ff4.u&PDB-ENSP_mappings:6ff7.u&PDB-ENSP_mappings:6qx9.B1&PDB-ENSP_mappings:6y50.u&PDB-ENSP_mappings:6y53.u&PDB-ENSP_mappings:6y5q.u&PDB-ENSP_mappings:7abg.u&PDB-ENSP_mappings:7abh.u&PDB-ENSP_mappings:7abi.u&PDB-ENSP_mappings:7b0i.C&PDB-ENSP_mappings:7b91.C&PDB-ENSP_mappings:7b92.C&PDB-ENSP_mappings:7b9c.C&PDB-ENSP_mappings:7dvq.1&PDB-ENSP_mappings:7evn.C&PDB-ENSP_mappings:7evo.1&PDB-ENSP_mappings:7omf.C&PDB-ENSP_mappings:7onb.C&PDB-ENSP_mappings:7opi.C&PDB-ENSP_mappings:7q3l.A&PDB-ENSP_mappings:7q4o.A&PDB-ENSP_mappings:7q4p.A&PDB-ENSP_mappings:7qtt.C&PDB-ENSP_mappings:7vpx.1&PDB-ENSP_mappings:8ch6.C&PDB-ENSP_mappings:8h6e.2G&PDB-ENSP_mappings:8h6j.2G&PDB-ENSP_mappings:8h6k.2G&PDB-ENSP_mappings:8h6l.2G&PDB-ENSP_mappings:8hk1.1&PDB-ENSP_mappings:8i0p.1&PDB-ENSP_mappings:8i0r.1&PDB-ENSP_mappings:8i0s.1&PDB-ENSP_mappings:8i0t.1&PDB-ENSP_mappings:8i0u.1&PDB-ENSP_mappings:8i0v.1&PDB-ENSP_mappings:8qo9.B1&PDB-ENSP_mappings:8qxd.B1&PDB-ENSP_mappings:8qzs.B1&PDB-ENSP_mappings:8r08.B1&PDB-ENSP_mappings:8r09.B1&PDB-ENSP_mappings:8r0a.B1&PDB-ENSP_mappings:8r0b.B1&PDB-ENSP_mappings:8rm5.B1&PDB-ENSP_mappings:8y7e.1&AFDB-ENSP_mappings:AF-O75533-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR12097&Superfamily:SSF48371			0.7185	0.8835	0.6311	0.5218	0.7256	0.7526	0.6757	0.847	0.5182	0.75	0.6358	0.579	0.8563	0.6736	0.6858	0.7546	0.7097	0.8362	0.7138	0.6489	0.75	0.5539	0.5711	0.8639	0.6735	0.7265	0.7476	0.8835	AFR	benign	0&1	1&1	35637532&34159505&33479212&34560273&27922606&34910505&36893272						FAIL	40	-28	-18	15	0.00	0.00	0.00	0.00	SF3B1		1.0000e-01	1250652	0.73597	0.67169	0.71845	1239739	not_provided&SF3B1-related_disorder		MedGen:C3661900&.		NC_000002.12:g.197393071T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001866130&SCV005237936	single_nucleotide_variant	SO:0001483	ClinGen:CA2042343		SF3B1:23451	SO:0001819&synonymous_variant										1	4685																											103					0.971							239.07	v6.1	Unknown		True	SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:V1219= mutant UNKNOWN.	False	The SF3B1 ENSP00000335321.6:v1219= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	198257795						True	False	False	Unknown								False	False		SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	The SF3B1 ENSP00000335321.6:v1219= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:V1219= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	SF3B1	23451.0	ENSP00000335321.6:V1219=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SF3B1"",""entrezGeneId"":23451,""alteration"":""ENSP00000335321.6:V1219="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies."",""variantSummary"":""The SF3B1 ENSP00000335321.6:v1219= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:V1219= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						0,100	0,53	0,47	0/1	0,0,55,45	ATA	.	.	.			0,0,52,48	64.67		1.0
GRCh38	SF3B1	D12_12345_1234556_Thyroid_S9	p.Ala1072=	ENSP00000335321.6:p.Ala1072=	chr2	197398035	197398035.0	A	G	G	197398035	.	A	G	.	PASS	NM_012433	G	synonymous_variant	LOW	SF3B1	ENSG00000115524	Transcript	ENST00000335508	protein_coding	22/25		c.3216T>C	3245	3216	1072	A	gcT/gcC	rs111736429&COSV59214083		-1		SNV	HGNC	HGNC:10768	YES	MANE_Select	NM_012433.4		1	P1	CCDS33356.1	ENSP00000335321	O75533.219		UPI000013D493	O75533-1		1			Gene3D:1.25.10.10&PDB-ENSP_mappings:5ife.C&PDB-ENSP_mappings:5o9z.v&PDB-ENSP_mappings:5z56.1&PDB-ENSP_mappings:5z57.1&PDB-ENSP_mappings:5z58.1&PDB-ENSP_mappings:5zya.C&PDB-ENSP_mappings:6ah0.1&PDB-ENSP_mappings:6ahd.1&PDB-ENSP_mappings:6en4.C&PDB-ENSP_mappings:6ff4.u&PDB-ENSP_mappings:6ff7.u&PDB-ENSP_mappings:6qx9.B1&PDB-ENSP_mappings:6y50.u&PDB-ENSP_mappings:6y53.u&PDB-ENSP_mappings:6y5q.u&PDB-ENSP_mappings:7abg.u&PDB-ENSP_mappings:7abh.u&PDB-ENSP_mappings:7abi.u&PDB-ENSP_mappings:7b0i.C&PDB-ENSP_mappings:7b91.C&PDB-ENSP_mappings:7b92.C&PDB-ENSP_mappings:7b9c.C&PDB-ENSP_mappings:7dvq.1&PDB-ENSP_mappings:7evn.C&PDB-ENSP_mappings:7evo.1&PDB-ENSP_mappings:7omf.C&PDB-ENSP_mappings:7onb.C&PDB-ENSP_mappings:7opi.C&PDB-ENSP_mappings:7q3l.A&PDB-ENSP_mappings:7q4o.A&PDB-ENSP_mappings:7q4p.A&PDB-ENSP_mappings:7qtt.C&PDB-ENSP_mappings:7vpx.1&PDB-ENSP_mappings:8ch6.C&PDB-ENSP_mappings:8h6e.2G&PDB-ENSP_mappings:8h6j.2G&PDB-ENSP_mappings:8h6k.2G&PDB-ENSP_mappings:8h6l.2G&PDB-ENSP_mappings:8hk1.1&PDB-ENSP_mappings:8i0p.1&PDB-ENSP_mappings:8i0r.1&PDB-ENSP_mappings:8i0s.1&PDB-ENSP_mappings:8i0t.1&PDB-ENSP_mappings:8i0u.1&PDB-ENSP_mappings:8i0v.1&PDB-ENSP_mappings:8qo9.B1&PDB-ENSP_mappings:8qxd.B1&PDB-ENSP_mappings:8qzs.B1&PDB-ENSP_mappings:8r08.B1&PDB-ENSP_mappings:8r09.B1&PDB-ENSP_mappings:8r0a.B1&PDB-ENSP_mappings:8r0b.B1&PDB-ENSP_mappings:8rm5.B1&PDB-ENSP_mappings:8y7e.1&AFDB-ENSP_mappings:AF-O75533-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR12097&Superfamily:SSF48371			0.0024	0.0015	0.0014	0	0.006	0.0031	0.006876	0.001285	0.001767	0.001722	2.521e-05	0.003165	0.006593	0.007992	0.005583	0.005253	0.00457	0.001323	0.005482	0.002809	0.001728	0	0.001979	0.006803	0.007835	0.001896	0.005602	0.007992	gnomADe_NFE	benign	0&1	1&1							FAIL	25	-9	-50	2	0.00	0.00	0.00	0.00	SF3B1		1.0000e-01	715640	0.00561	0.00448	0.00240	719505	not_provided		MedGen:C3661900		NC_000002.12:g.197398035A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV001031760&SCV005237938&SCV005330206	single_nucleotide_variant	SO:0001483	ClinGen:CA2042408		SF3B1:23451	SO:0001819&synonymous_variant										1	111736429																											211					0.995							244.23	v6.1	Unknown		True	SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:A1072= mutant UNKNOWN.	False	The SF3B1 ENSP00000335321.6:a1072= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	198262759						True	False	False	Unknown								False	False		SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	The SF3B1 ENSP00000335321.6:a1072= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:A1072= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	SF3B1	23451.0	ENSP00000335321.6:A1072=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SF3B1"",""entrezGeneId"":23451,""alteration"":""ENSP00000335321.6:A1072="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies."",""variantSummary"":""The SF3B1 ENSP00000335321.6:a1072= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:A1072= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						114,96	64,48	50,48	0/1	57,57,51,45	TAG	.	.	.			35,79,47,49	30.13		0.45714285714285713
GRCh38	SF3B1	D12_12345_1234556_Thyroid_S9	p.Gly877=	ENSP00000335321.6:p.Gly877=	chr2	197400802	197400802.0	A	G	G	197400802	.	A	G	.	PASS	NM_012433	G	synonymous_variant	LOW	SF3B1	ENSG00000115524	Transcript	ENST00000335508	protein_coding	18/25		c.2631T>C	2660	2631	877	G	ggT/ggC	rs788018&COSV59206309		-1		SNV	HGNC	HGNC:10768	YES	MANE_Select	NM_012433.4		1	P1	CCDS33356.1	ENSP00000335321	O75533.219		UPI000013D493	O75533-1		1			Gene3D:1.25.10.10&PDB-ENSP_mappings:5ife.C&PDB-ENSP_mappings:5o9z.v&PDB-ENSP_mappings:5z56.1&PDB-ENSP_mappings:5z57.1&PDB-ENSP_mappings:5z58.1&PDB-ENSP_mappings:5zya.C&PDB-ENSP_mappings:6ah0.1&PDB-ENSP_mappings:6ahd.1&PDB-ENSP_mappings:6en4.C&PDB-ENSP_mappings:6ff4.u&PDB-ENSP_mappings:6ff7.u&PDB-ENSP_mappings:6qx9.B1&PDB-ENSP_mappings:6y50.u&PDB-ENSP_mappings:6y53.u&PDB-ENSP_mappings:6y5q.u&PDB-ENSP_mappings:7abg.u&PDB-ENSP_mappings:7abh.u&PDB-ENSP_mappings:7abi.u&PDB-ENSP_mappings:7b0i.C&PDB-ENSP_mappings:7b91.C&PDB-ENSP_mappings:7b92.C&PDB-ENSP_mappings:7b9c.C&PDB-ENSP_mappings:7dvq.1&PDB-ENSP_mappings:7evn.C&PDB-ENSP_mappings:7evo.1&PDB-ENSP_mappings:7omf.C&PDB-ENSP_mappings:7onb.C&PDB-ENSP_mappings:7opi.C&PDB-ENSP_mappings:7q3l.A&PDB-ENSP_mappings:7q4o.A&PDB-ENSP_mappings:7q4p.A&PDB-ENSP_mappings:7qtt.C&PDB-ENSP_mappings:7vpx.1&PDB-ENSP_mappings:8ch6.C&PDB-ENSP_mappings:8h6e.2G&PDB-ENSP_mappings:8h6j.2G&PDB-ENSP_mappings:8h6k.2G&PDB-ENSP_mappings:8h6l.2G&PDB-ENSP_mappings:8hk1.1&PDB-ENSP_mappings:8i0p.1&PDB-ENSP_mappings:8i0r.1&PDB-ENSP_mappings:8i0s.1&PDB-ENSP_mappings:8i0t.1&PDB-ENSP_mappings:8i0u.1&PDB-ENSP_mappings:8i0v.1&PDB-ENSP_mappings:8qo9.B1&PDB-ENSP_mappings:8qxd.B1&PDB-ENSP_mappings:8qzs.B1&PDB-ENSP_mappings:8r08.B1&PDB-ENSP_mappings:8r09.B1&PDB-ENSP_mappings:8r0a.B1&PDB-ENSP_mappings:8r0b.B1&PDB-ENSP_mappings:8rm5.B1&PDB-ENSP_mappings:8y7e.1&AFDB-ENSP_mappings:AF-O75533-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR12097&Superfamily:SSF48371			0.7167	0.8812	0.6326	0.5099	0.7276	0.7556	0.6758	0.8452	0.5175	0.7459	0.6307	0.5793	0.8557	0.674	0.6854	0.7554	0.709	0.8341	0.7138	0.6486	0.7464	0.5487	0.5712	0.8639	0.6737	0.7254	0.7471	0.8812	AFR	benign	0&1	1&1	25553291&36823318&28185911						FAIL	-3	-14	8	2	0.00	0.00	0.00	0.04	SF3B1		1.0000e-01	1228123	0.73508	0.67084	0.71665	1218088	SF3B1-related_disorder&not_provided		.&MedGen:C3661900		NC_000002.12:g.197400802A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001833469&SCV005237939	single_nucleotide_variant	SO:0001483	ClinGen:CA2042526		SF3B1:23451	SO:0001819&synonymous_variant										1	788018																											133					0.955							242.73	v6.1	Unknown		True	SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:G877= mutant UNKNOWN.	False	The SF3B1 ENSP00000335321.6:g877= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	198265526						True	False	False	Unknown								False	False		SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	The SF3B1 ENSP00000335321.6:g877= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:G877= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	SF3B1	23451.0	ENSP00000335321.6:G877=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SF3B1"",""entrezGeneId"":23451,""alteration"":""ENSP00000335321.6:G877="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies."",""variantSummary"":""The SF3B1 ENSP00000335321.6:g877= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:G877= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						0,127	0,74	0,53	0/1	0,0,81,46	TAC	.	.	.			0,0,78,49	64.71		1.0
GRCh38	SF3B1	D12_12345_1234556_Thyroid_S9	p.Lys141=	ENSP00000335321.6:p.Lys141=	chr2	197418581	197418581.0	T	C	C	197418581	.	T	C	.	PASS	NM_012433	C	synonymous_variant	LOW	SF3B1	ENSG00000115524	Transcript	ENST00000335508	protein_coding	5/25		c.423A>G	452	423	141	K	aaA/aaG	rs788023&COSV59205521		-1		SNV	HGNC	HGNC:10768	YES	MANE_Select	NM_012433.4		1	P1	CCDS33356.1	ENSP00000335321	O75533.219		UPI000013D493	O75533-1		1			PDB-ENSP_mappings:5ife.C&PDB-ENSP_mappings:5o9z.v&PDB-ENSP_mappings:5z56.1&PDB-ENSP_mappings:5z57.1&PDB-ENSP_mappings:5z58.1&PDB-ENSP_mappings:5zya.C&PDB-ENSP_mappings:6ah0.1&PDB-ENSP_mappings:6ahd.1&PDB-ENSP_mappings:6ff4.u&PDB-ENSP_mappings:6ff7.u&PDB-ENSP_mappings:6qx9.B1&PDB-ENSP_mappings:6y50.u&PDB-ENSP_mappings:6y53.u&PDB-ENSP_mappings:6y5q.u&PDB-ENSP_mappings:7abg.u&PDB-ENSP_mappings:7abh.u&PDB-ENSP_mappings:7abi.u&PDB-ENSP_mappings:7dvq.1&PDB-ENSP_mappings:7evo.1&PDB-ENSP_mappings:7onb.C&PDB-ENSP_mappings:7q3l.A&PDB-ENSP_mappings:7q4o.A&PDB-ENSP_mappings:7q4p.A&PDB-ENSP_mappings:7qtt.C&PDB-ENSP_mappings:7vpx.1&PDB-ENSP_mappings:8ch6.C&PDB-ENSP_mappings:8h6e.2G&PDB-ENSP_mappings:8h6j.2G&PDB-ENSP_mappings:8h6k.2G&PDB-ENSP_mappings:8h6l.2G&PDB-ENSP_mappings:8hk1.1&PDB-ENSP_mappings:8i0p.1&PDB-ENSP_mappings:8i0r.1&PDB-ENSP_mappings:8i0s.1&PDB-ENSP_mappings:8i0t.1&PDB-ENSP_mappings:8i0u.1&PDB-ENSP_mappings:8i0v.1&PDB-ENSP_mappings:8qo9.B1&PDB-ENSP_mappings:8qxd.B1&PDB-ENSP_mappings:8qzs.B1&PDB-ENSP_mappings:8r08.B1&PDB-ENSP_mappings:8r09.B1&PDB-ENSP_mappings:8r0a.B1&PDB-ENSP_mappings:8r0b.B1&PDB-ENSP_mappings:8rm5.B1&PDB-ENSP_mappings:8y7e.1&AFDB-ENSP_mappings:AF-O75533-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR12097&MobiDB_lite:mobidb-lite			0.7206	0.8903	0.6326	0.5179	0.7276	0.7556	0.6764	0.8559	0.5171	0.746	0.6322	0.5792	0.8563	0.6744	0.6863	0.7556	0.7122	0.8455	0.7138	0.6487	0.7458	0.5507	0.5711	0.8639	0.6738	0.7293	0.7482	0.8903	AFR	benign	0&1	1&1	28185911						FAIL	7	-27	-1	-39	0.00	0.00	0.00	0.00	SF3B1		1.0000e-01	1327755	0.73935	0.67248	0.72065	1318374	not_provided&SF3B1-related_disorder		MedGen:C3661900&.		NC_000002.12:g.197418581T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002032598&SCV005237945	single_nucleotide_variant	SO:0001483	ClinGen:CA2042918		SF3B1:23451	SO:0001819&synonymous_variant										1	788023																											100					0.94							235.67	v6.1	Unknown		True	SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:K141= mutant UNKNOWN.	False	The SF3B1 ENSP00000335321.6:k141= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	198283305						True	False	False	Unknown								False	False		SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.	The SF3B1 ENSP00000335321.6:k141= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:K141= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	SF3B1	23451.0	ENSP00000335321.6:K141=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SF3B1"",""entrezGeneId"":23451,""alteration"":""ENSP00000335321.6:K141="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies."",""variantSummary"":""The SF3B1 ENSP00000335321.6:k141= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1 ENSP00000335321.6:K141= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						0,94	0,47	0,47	0/1	0,0,43,51	TTT	.	.	.			0,0,42,52	64.66		1.0
GRCh38	CASP8	D12_12345_1234556_Thyroid_S9			chr2	201258272	201258272.0	A	G	G	201258272	.	A	G	.	PASS	NM_001372051	G	upstream_gene_variant	MODIFIER	CASP8	ENSG00000064012	Transcript	ENST00000673742	protein_coding									rs3769823&COSV51848843	2264	1		SNV	HGNC	HGNC:1509	YES	MANE_Select	NM_001372051.1			P1	CCDS2342.1	ENSP00000501268	Q14790.260		UPI000003AEFE	Q14790-1		1						0.6464	0.5862	0.5922	0.6964	0.6918	0.6677	0.6955	0.5649	0.5437	0.5837	0.6994	0.6499	0.6212	0.7133	0.6744	0.6758	0.6476	0.577	0.7495	0.5638	0.5853	0.7069	0.6455	0.7007	0.7055	0.6122	0.6817	0.7495	gnomADg_AMI	benign	0&1	1&1	25741868&24033266&19531679&28738859&31872004&28738811&22665367&26795348&26758508&18823309&22323360&28542283&31118947&25431829&28177523&30116257&32889700&32115800&29739929&35357426&36378845&29083408&36047776&36819030&32808324&33893285&36423637&31821614&26635288&31504207&37808664&38892172&38965614						FAIL	1	21	16	-4	0.00	0.00	0.00	0.02	CASP8			402492	0.66947	0.66730	0.64637	389468	not_provided&not_specified&Autoimmune_lymphoproliferative_syndrome_type_2B		MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0011804&MedGen:C1846545&OMIM:607271&Orphanet:275517		NC_000002.12:g.201258272A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000538592&SCV001726755&SCV001892133&SCV004101865&SCV005238019	single_nucleotide_variant	SO:0001483	ClinGen:CA2053387		CASP8:841&LOC128772255:128772255	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant&SO:0001623&5_prime_UTR_variant&SO:0001627&intron_variant										1	3769823																											833					0.995							244.02													chr2	202122995																																																	True	True	False	Unknown		Unknown																						0,829	0,400	0,429	0/1	0,0,387,442	AAA	.	.	.			0,0,480,349	64.73		1.0
GRCh38	IDH1	D12_12345_1234556_Thyroid_S9			chr2	208237148		C	<INS>	<INS>	208237148	MantaINS:6401:1:1:0:4:0	C	<INS>	.	PASS	NM_005896	insertion	feature_elongation&coding_sequence_variant	HIGH	IDH1	ENSG00000138413	Transcript	ENST00000345146	protein_coding	10/10			1398	1175	392					-1		insertion	HGNC	HGNC:5382	YES	MANE_Select	NM_005896.4		1	P1	CCDS2381.1	ENSP00000260985	O75874.233	A0A024R3Y6.24	UPI000012D1B4			1			PDB-ENSP_mappings:1t09.A&PDB-ENSP_mappings:1t09.B&PDB-ENSP_mappings:1t0l.A&PDB-ENSP_mappings:1t0l.B&PDB-ENSP_mappings:1t0l.C&PDB-ENSP_mappings:1t0l.D&Gene3D:3.40.718.10&PDB-ENSP_mappings:3inm.A&PDB-ENSP_mappings:3inm.B&PDB-ENSP_mappings:3inm.C&PDB-ENSP_mappings:3map.A&PDB-ENSP_mappings:3map.B&PDB-ENSP_mappings:3mar.A&PDB-ENSP_mappings:3mar.B&PDB-ENSP_mappings:3mas.A&PDB-ENSP_mappings:3mas.B&PDB-ENSP_mappings:4i3k.A&PDB-ENSP_mappings:4i3k.B&PDB-ENSP_mappings:4i3l.A&PDB-ENSP_mappings:4i3l.B&PDB-ENSP_mappings:4kzo.A&PDB-ENSP_mappings:4kzo.B&PDB-ENSP_mappings:4kzo.C&PDB-ENSP_mappings:4l03.A&PDB-ENSP_mappings:4l03.B&PDB-ENSP_mappings:4l03.C&PDB-ENSP_mappings:4l04.A&PDB-ENSP_mappings:4l04.B&PDB-ENSP_mappings:4l04.C&PDB-ENSP_mappings:4l04.D&PDB-ENSP_mappings:4l04.E&PDB-ENSP_mappings:4l04.F&PDB-ENSP_mappings:4l06.A&PDB-ENSP_mappings:4l06.B&PDB-ENSP_mappings:4l06.C&PDB-ENSP_mappings:4l06.D&PDB-ENSP_mappings:4l06.E&PDB-ENSP_mappings:4l06.F&PDB-ENSP_mappings:4umx.A&PDB-ENSP_mappings:4umx.B&PDB-ENSP_mappings:4umy.A&PDB-ENSP_mappings:4umy.B&PDB-ENSP_mappings:4xrx.A&PDB-ENSP_mappings:4xrx.B&PDB-ENSP_mappings:4xs3.A&PDB-ENSP_mappings:4xs3.B&PDB-ENSP_mappings:5de1.A&PDB-ENSP_mappings:5de1.B&PDB-ENSP_mappings:5k10.A&PDB-ENSP_mappings:5k10.B&PDB-ENSP_mappings:5k11.A&PDB-ENSP_mappings:5k11.B&PDB-ENSP_mappings:5l57.A&PDB-ENSP_mappings:5l58.A&PDB-ENSP_mappings:5lge.A&PDB-ENSP_mappings:5lge.B&PDB-ENSP_mappings:5lge.C&PDB-ENSP_mappings:5lge.D&PDB-ENSP_mappings:5sun.A&PDB-ENSP_mappings:5sun.B&PDB-ENSP_mappings:5svf.A&PDB-ENSP_mappings:5svf.B&PDB-ENSP_mappings:5svf.C&PDB-ENSP_mappings:5svf.D&PDB-ENSP_mappings:5tqh.A&PDB-ENSP_mappings:5tqh.B&PDB-ENSP_mappings:5tqh.C&PDB-ENSP_mappings:5tqh.D&PDB-ENSP_mappings:5yfm.A&PDB-ENSP_mappings:5yfm.B&PDB-ENSP_mappings:5yfm.C&PDB-ENSP_mappings:5yfn.A&PDB-ENSP_mappings:5yfn.B&PDB-ENSP_mappings:6adg.A&PDB-ENSP_mappings:6adg.B&PDB-ENSP_mappings:6adg.C&PDB-ENSP_mappings:6b0z.A&PDB-ENSP_mappings:6b0z.B&PDB-ENSP_mappings:6b0z.C&PDB-ENSP_mappings:6b0z.D&PDB-ENSP_mappings:6bkx.A&PDB-ENSP_mappings:6bkx.B&PDB-ENSP_mappings:6bkx.C&PDB-ENSP_mappings:6bky.A&PDB-ENSP_mappings:6bky.B&PDB-ENSP_mappings:6bky.C&PDB-ENSP_mappings:6bky.D&PDB-ENSP_mappings:6bky.E&PDB-ENSP_mappings:6bky.F&PDB-ENSP_mappings:6bkz.A&PDB-ENSP_mappings:6bkz.B&PDB-ENSP_mappings:6bl0.A&PDB-ENSP_mappings:6bl0.B&PDB-ENSP_mappings:6bl0.C&PDB-ENSP_mappings:6bl1.A&PDB-ENSP_mappings:6bl1.B&PDB-ENSP_mappings:6bl1.C&PDB-ENSP_mappings:6bl2.A&PDB-ENSP_mappings:6bl2.B&PDB-ENSP_mappings:6bl2.C&PDB-ENSP_mappings:6io0.A&PDB-ENSP_mappings:6io0.B&PDB-ENSP_mappings:6o2y.A&PDB-ENSP_mappings:6o2y.B&PDB-ENSP_mappings:6o2y.C&PDB-ENSP_mappings:6o2z.A&PDB-ENSP_mappings:6o2z.B&PDB-ENSP_mappings:6pay.A&PDB-ENSP_mappings:6pay.B&PDB-ENSP_mappings:6pay.C&PDB-ENSP_mappings:6pay.D&PDB-ENSP_mappings:6q6f.A&PDB-ENSP_mappings:6q6f.B&PDB-ENSP_mappings:6u4j.A&PDB-ENSP_mappings:6u4j.B&PDB-ENSP_mappings:6vei.A&PDB-ENSP_mappings:6vei.B&PDB-ENSP_mappings:6vg0.A&PDB-ENSP_mappings:6vg0.B&PDB-ENSP_mappings:6vg0.C&PDB-ENSP_mappings:7pjm.A&PDB-ENSP_mappings:7pjm.B&PDB-ENSP_mappings:7pjm.C&PDB-ENSP_mappings:7pjn.A&PDB-ENSP_mappings:7pjn.B&PDB-ENSP_mappings:7pjn.C&PDB-ENSP_mappings:7pjn.D&PDB-ENSP_mappings:8bay.A&PDB-ENSP_mappings:8bay.B&PDB-ENSP_mappings:8bay.C&PDB-ENSP_mappings:8hb9.AAA&PDB-ENSP_mappings:8hb9.BBB&PDB-ENSP_mappings:8hb9.CCC&PDB-ENSP_mappings:8hb9.DDD&PDB-ENSP_mappings:8t7d.A&PDB-ENSP_mappings:8t7d.B&PDB-ENSP_mappings:8t7d.C&PDB-ENSP_mappings:8t7d.D&PDB-ENSP_mappings:8t7n.A&PDB-ENSP_mappings:8t7n.B&PDB-ENSP_mappings:8t7o.A&PDB-ENSP_mappings:8t7o.B&PDB-ENSP_mappings:8vh9.A&PDB-ENSP_mappings:8vh9.B&PDB-ENSP_mappings:8vha.A&PDB-ENSP_mappings:8vha.B&PDB-ENSP_mappings:8vha.C&PDB-ENSP_mappings:8vha.D&PDB-ENSP_mappings:8vhb.A&PDB-ENSP_mappings:8vhb.B&PDB-ENSP_mappings:8vhb.C&PDB-ENSP_mappings:8vhb.D&PDB-ENSP_mappings:8vhc.A&PDB-ENSP_mappings:8vhc.B&PDB-ENSP_mappings:8vhd.A&PDB-ENSP_mappings:8vhd.B&PDB-ENSP_mappings:8vhd.C&PDB-ENSP_mappings:8vhd.D&PDB-ENSP_mappings:8vhe.A&PDB-ENSP_mappings:8vhe.B&PDB-ENSP_mappings:8vhe.C&PDB-ENSP_mappings:8vhe.D&AFDB-ENSP_mappings:AF-O75874-F1&PIRSF:PIRSF000108&PANTHER:PTHR11822&SMART:SM01329&Superfamily:SSF53659&NCBIFAM:TIGR00127																																																																																																												0,31		0,31							31	AAGTAGTCAGAACGTTGCACACTAACGGGAA		AAGTAGTCAGAACGTTGCACACTAACGGGAAAACAAAAAAAAAGCATAGTTATTCATATATAATGGGGACTTTTGCTTTCAATGAGGAAT																chr2	209101872	ATCACTAAAAAGAAATGAGCTACCAAGCCACTAAAAAACATGGAGGAACCTCAAATGCACATAGTT			INS																																													True	True	False	Unknown		Unknown																															8,2				10,2	
GRCh38	IDH1	D12_12345_1234556_Thyroid_S9	p.V178I	ENSP00000260985.2:p.Val178Ile	chr2	208243593	208243593.0	C	T	T	208243593	.	C	T	.	PASS	NM_005896	T	missense_variant	MODERATE	IDH1	ENSG00000138413	Transcript	ENST00000345146	protein_coding	6/10		c.532G>A	755	532	178	V/I	Gtt/Att	rs34218846&CM1512658&COSV61616229		-1		SNV	HGNC	HGNC:5382	YES	MANE_Select	NM_005896.4		1	P1	CCDS2381.1	ENSP00000260985	O75874.233	A0A024R3Y6.24	UPI000012D1B4			1	tolerated_low_confidence(0.15)	probably_damaging(0.97)	PDB-ENSP_mappings:1t09.A&PDB-ENSP_mappings:1t09.B&PDB-ENSP_mappings:1t0l.A&PDB-ENSP_mappings:1t0l.B&PDB-ENSP_mappings:1t0l.C&PDB-ENSP_mappings:1t0l.D&Gene3D:3.40.718.10&PDB-ENSP_mappings:3inm.A&PDB-ENSP_mappings:3inm.B&PDB-ENSP_mappings:3inm.C&PDB-ENSP_mappings:3map.A&PDB-ENSP_mappings:3map.B&PDB-ENSP_mappings:3mar.A&PDB-ENSP_mappings:3mar.B&PDB-ENSP_mappings:3mas.A&PDB-ENSP_mappings:3mas.B&PDB-ENSP_mappings:4i3k.A&PDB-ENSP_mappings:4i3k.B&PDB-ENSP_mappings:4i3l.A&PDB-ENSP_mappings:4i3l.B&PDB-ENSP_mappings:4kzo.A&PDB-ENSP_mappings:4kzo.B&PDB-ENSP_mappings:4kzo.C&PDB-ENSP_mappings:4l03.A&PDB-ENSP_mappings:4l03.B&PDB-ENSP_mappings:4l03.C&PDB-ENSP_mappings:4l04.A&PDB-ENSP_mappings:4l04.B&PDB-ENSP_mappings:4l04.C&PDB-ENSP_mappings:4l04.D&PDB-ENSP_mappings:4l04.E&PDB-ENSP_mappings:4l04.F&PDB-ENSP_mappings:4l06.A&PDB-ENSP_mappings:4l06.B&PDB-ENSP_mappings:4l06.C&PDB-ENSP_mappings:4l06.D&PDB-ENSP_mappings:4l06.E&PDB-ENSP_mappings:4l06.F&PDB-ENSP_mappings:4umx.A&PDB-ENSP_mappings:4umx.B&PDB-ENSP_mappings:4umy.A&PDB-ENSP_mappings:4umy.B&PDB-ENSP_mappings:4xrx.A&PDB-ENSP_mappings:4xrx.B&PDB-ENSP_mappings:4xs3.A&PDB-ENSP_mappings:4xs3.B&PDB-ENSP_mappings:5de1.A&PDB-ENSP_mappings:5de1.B&PDB-ENSP_mappings:5k10.A&PDB-ENSP_mappings:5k10.B&PDB-ENSP_mappings:5k11.A&PDB-ENSP_mappings:5k11.B&PDB-ENSP_mappings:5l57.A&PDB-ENSP_mappings:5l58.A&PDB-ENSP_mappings:5lge.A&PDB-ENSP_mappings:5lge.B&PDB-ENSP_mappings:5lge.C&PDB-ENSP_mappings:5lge.D&PDB-ENSP_mappings:5sun.A&PDB-ENSP_mappings:5sun.B&PDB-ENSP_mappings:5svf.A&PDB-ENSP_mappings:5svf.B&PDB-ENSP_mappings:5svf.C&PDB-ENSP_mappings:5svf.D&PDB-ENSP_mappings:5tqh.A&PDB-ENSP_mappings:5tqh.B&PDB-ENSP_mappings:5tqh.C&PDB-ENSP_mappings:5tqh.D&PDB-ENSP_mappings:5yfm.A&PDB-ENSP_mappings:5yfm.B&PDB-ENSP_mappings:5yfm.C&PDB-ENSP_mappings:5yfn.A&PDB-ENSP_mappings:5yfn.B&PDB-ENSP_mappings:6adg.A&PDB-ENSP_mappings:6adg.B&PDB-ENSP_mappings:6adg.C&PDB-ENSP_mappings:6b0z.A&PDB-ENSP_mappings:6b0z.B&PDB-ENSP_mappings:6b0z.C&PDB-ENSP_mappings:6b0z.D&PDB-ENSP_mappings:6bkx.A&PDB-ENSP_mappings:6bkx.B&PDB-ENSP_mappings:6bkx.C&PDB-ENSP_mappings:6bky.A&PDB-ENSP_mappings:6bky.B&PDB-ENSP_mappings:6bky.C&PDB-ENSP_mappings:6bky.D&PDB-ENSP_mappings:6bky.E&PDB-ENSP_mappings:6bky.F&PDB-ENSP_mappings:6bkz.A&PDB-ENSP_mappings:6bkz.B&PDB-ENSP_mappings:6bl0.A&PDB-ENSP_mappings:6bl0.B&PDB-ENSP_mappings:6bl0.C&PDB-ENSP_mappings:6bl1.A&PDB-ENSP_mappings:6bl1.B&PDB-ENSP_mappings:6bl1.C&PDB-ENSP_mappings:6bl2.A&PDB-ENSP_mappings:6bl2.B&PDB-ENSP_mappings:6bl2.C&PDB-ENSP_mappings:6io0.A&PDB-ENSP_mappings:6io0.B&PDB-ENSP_mappings:6o2y.A&PDB-ENSP_mappings:6o2y.B&PDB-ENSP_mappings:6o2y.C&PDB-ENSP_mappings:6o2z.A&PDB-ENSP_mappings:6o2z.B&PDB-ENSP_mappings:6pay.A&PDB-ENSP_mappings:6pay.B&PDB-ENSP_mappings:6pay.C&PDB-ENSP_mappings:6pay.D&PDB-ENSP_mappings:6q6f.A&PDB-ENSP_mappings:6q6f.B&PDB-ENSP_mappings:6u4j.A&PDB-ENSP_mappings:6u4j.B&PDB-ENSP_mappings:6vei.A&PDB-ENSP_mappings:6vei.B&PDB-ENSP_mappings:6vg0.A&PDB-ENSP_mappings:6vg0.B&PDB-ENSP_mappings:6vg0.C&PDB-ENSP_mappings:7pjm.A&PDB-ENSP_mappings:7pjm.B&PDB-ENSP_mappings:7pjm.C&PDB-ENSP_mappings:7pjn.A&PDB-ENSP_mappings:7pjn.B&PDB-ENSP_mappings:7pjn.C&PDB-ENSP_mappings:7pjn.D&PDB-ENSP_mappings:8bay.A&PDB-ENSP_mappings:8bay.B&PDB-ENSP_mappings:8bay.C&PDB-ENSP_mappings:8hb9.AAA&PDB-ENSP_mappings:8hb9.BBB&PDB-ENSP_mappings:8hb9.CCC&PDB-ENSP_mappings:8hb9.DDD&PDB-ENSP_mappings:8t7d.A&PDB-ENSP_mappings:8t7d.B&PDB-ENSP_mappings:8t7d.C&PDB-ENSP_mappings:8t7d.D&PDB-ENSP_mappings:8t7n.A&PDB-ENSP_mappings:8t7n.B&PDB-ENSP_mappings:8t7o.A&PDB-ENSP_mappings:8t7o.B&PDB-ENSP_mappings:8vh9.A&PDB-ENSP_mappings:8vh9.B&PDB-ENSP_mappings:8vha.A&PDB-ENSP_mappings:8vha.B&PDB-ENSP_mappings:8vha.C&PDB-ENSP_mappings:8vha.D&PDB-ENSP_mappings:8vhb.A&PDB-ENSP_mappings:8vhb.B&PDB-ENSP_mappings:8vhb.C&PDB-ENSP_mappings:8vhb.D&PDB-ENSP_mappings:8vhc.A&PDB-ENSP_mappings:8vhc.B&PDB-ENSP_mappings:8vhd.A&PDB-ENSP_mappings:8vhd.B&PDB-ENSP_mappings:8vhd.C&PDB-ENSP_mappings:8vhd.D&PDB-ENSP_mappings:8vhe.A&PDB-ENSP_mappings:8vhe.B&PDB-ENSP_mappings:8vhe.C&PDB-ENSP_mappings:8vhe.D&AFDB-ENSP_mappings:AF-O75874-F1&Pfam:PF00180&PIRSF:PIRSF000108&PANTHER:PTHR11822&SMART:SM01329&Superfamily:SSF53659&NCBIFAM:TIGR00127			0.0493	0.0893	0.0447	0.0069	0.0477	0.044	0.0528	0.08074	0.03746	0.08195	0.01179	0.02765	0.04776	0.05457	0.05994	0.04805	0.05948	0.08065	0.008772	0.05748	0.09285	0.01005	0.02328	0.04795	0.05675	0.06055	0.04068	0.09285	gnomADg_ASJ	benign	0&1&1	1&1&1	24033266&24728327&26599207&33053772&31085772&29973652&29487696						FAIL	15	11	9	-24	0.00	0.04	0.00	0.00	IDH1	0.421	8.2900e-01	134520	0.06251	0.05003	0.04932	138259	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000002.12:g.208243593C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000539328&SCV001869727&SCV005240875	single_nucleotide_variant	SO:0001483	ClinGen:CA160063&UniProtKB:O75874																																																																																																																																															31,28	17,17	14,11	0/1	12,19,11,17	ACA	0.00	0.00	0.00			12,19,10,18	31.92		0.4745762711864407
GRCh38	IDH1	D12_12345_1234556_Thyroid_S9	p.Gly105=	ENSP00000260985.2:p.Gly105=	chr2	208248468	208248468.0	G	A	A	208248468	.	G	A	.	PASS	NM_005896	A	synonymous_variant	LOW	IDH1	ENSG00000138413	Transcript	ENST00000345146	protein_coding	4/10		c.315C>T	538	315	105	G	ggC/ggT	rs11554137&COSV61616039		-1		SNV	HGNC	HGNC:5382	YES	MANE_Select	NM_005896.4		1	P1	CCDS2381.1	ENSP00000260985	O75874.233	A0A024R3Y6.24	UPI000012D1B4			1			PDB-ENSP_mappings:1t09.A&PDB-ENSP_mappings:1t09.B&PDB-ENSP_mappings:1t0l.A&PDB-ENSP_mappings:1t0l.B&PDB-ENSP_mappings:1t0l.C&PDB-ENSP_mappings:1t0l.D&Gene3D:3.40.718.10&PDB-ENSP_mappings:3inm.A&PDB-ENSP_mappings:3inm.B&PDB-ENSP_mappings:3inm.C&PDB-ENSP_mappings:3map.A&PDB-ENSP_mappings:3map.B&PDB-ENSP_mappings:3mar.A&PDB-ENSP_mappings:3mar.B&PDB-ENSP_mappings:3mas.A&PDB-ENSP_mappings:3mas.B&PDB-ENSP_mappings:4i3k.A&PDB-ENSP_mappings:4i3k.B&PDB-ENSP_mappings:4i3l.A&PDB-ENSP_mappings:4i3l.B&PDB-ENSP_mappings:4kzo.A&PDB-ENSP_mappings:4kzo.B&PDB-ENSP_mappings:4kzo.C&PDB-ENSP_mappings:4l03.A&PDB-ENSP_mappings:4l03.B&PDB-ENSP_mappings:4l03.C&PDB-ENSP_mappings:4l04.A&PDB-ENSP_mappings:4l04.B&PDB-ENSP_mappings:4l04.C&PDB-ENSP_mappings:4l04.D&PDB-ENSP_mappings:4l04.E&PDB-ENSP_mappings:4l04.F&PDB-ENSP_mappings:4l06.A&PDB-ENSP_mappings:4l06.B&PDB-ENSP_mappings:4l06.C&PDB-ENSP_mappings:4l06.D&PDB-ENSP_mappings:4l06.E&PDB-ENSP_mappings:4l06.F&PDB-ENSP_mappings:4umx.A&PDB-ENSP_mappings:4umx.B&PDB-ENSP_mappings:4umy.A&PDB-ENSP_mappings:4umy.B&PDB-ENSP_mappings:4xrx.A&PDB-ENSP_mappings:4xrx.B&PDB-ENSP_mappings:4xs3.A&PDB-ENSP_mappings:4xs3.B&PDB-ENSP_mappings:5de1.A&PDB-ENSP_mappings:5de1.B&PDB-ENSP_mappings:5k10.A&PDB-ENSP_mappings:5k10.B&PDB-ENSP_mappings:5k11.A&PDB-ENSP_mappings:5k11.B&PDB-ENSP_mappings:5l57.A&PDB-ENSP_mappings:5l58.A&PDB-ENSP_mappings:5lge.A&PDB-ENSP_mappings:5lge.B&PDB-ENSP_mappings:5lge.C&PDB-ENSP_mappings:5lge.D&PDB-ENSP_mappings:5sun.A&PDB-ENSP_mappings:5sun.B&PDB-ENSP_mappings:5svf.A&PDB-ENSP_mappings:5svf.B&PDB-ENSP_mappings:5svf.C&PDB-ENSP_mappings:5svf.D&PDB-ENSP_mappings:5tqh.A&PDB-ENSP_mappings:5tqh.B&PDB-ENSP_mappings:5tqh.C&PDB-ENSP_mappings:5tqh.D&PDB-ENSP_mappings:5yfm.A&PDB-ENSP_mappings:5yfm.B&PDB-ENSP_mappings:5yfm.C&PDB-ENSP_mappings:5yfn.A&PDB-ENSP_mappings:5yfn.B&PDB-ENSP_mappings:6adg.A&PDB-ENSP_mappings:6adg.B&PDB-ENSP_mappings:6adg.C&PDB-ENSP_mappings:6b0z.A&PDB-ENSP_mappings:6b0z.B&PDB-ENSP_mappings:6b0z.C&PDB-ENSP_mappings:6b0z.D&PDB-ENSP_mappings:6bkx.A&PDB-ENSP_mappings:6bkx.B&PDB-ENSP_mappings:6bkx.C&PDB-ENSP_mappings:6bky.A&PDB-ENSP_mappings:6bky.B&PDB-ENSP_mappings:6bky.C&PDB-ENSP_mappings:6bky.D&PDB-ENSP_mappings:6bky.E&PDB-ENSP_mappings:6bky.F&PDB-ENSP_mappings:6bkz.A&PDB-ENSP_mappings:6bkz.B&PDB-ENSP_mappings:6bl0.A&PDB-ENSP_mappings:6bl0.B&PDB-ENSP_mappings:6bl0.C&PDB-ENSP_mappings:6bl1.A&PDB-ENSP_mappings:6bl1.B&PDB-ENSP_mappings:6bl1.C&PDB-ENSP_mappings:6bl2.A&PDB-ENSP_mappings:6bl2.B&PDB-ENSP_mappings:6bl2.C&PDB-ENSP_mappings:6io0.A&PDB-ENSP_mappings:6io0.B&PDB-ENSP_mappings:6o2y.A&PDB-ENSP_mappings:6o2y.B&PDB-ENSP_mappings:6o2y.C&PDB-ENSP_mappings:6o2z.A&PDB-ENSP_mappings:6o2z.B&PDB-ENSP_mappings:6pay.A&PDB-ENSP_mappings:6pay.B&PDB-ENSP_mappings:6pay.C&PDB-ENSP_mappings:6pay.D&PDB-ENSP_mappings:6q6f.A&PDB-ENSP_mappings:6q6f.B&PDB-ENSP_mappings:6u4j.A&PDB-ENSP_mappings:6u4j.B&PDB-ENSP_mappings:6vei.A&PDB-ENSP_mappings:6vei.B&PDB-ENSP_mappings:6vg0.A&PDB-ENSP_mappings:6vg0.B&PDB-ENSP_mappings:6vg0.C&PDB-ENSP_mappings:7pjm.A&PDB-ENSP_mappings:7pjm.B&PDB-ENSP_mappings:7pjm.C&PDB-ENSP_mappings:7pjn.A&PDB-ENSP_mappings:7pjn.B&PDB-ENSP_mappings:7pjn.C&PDB-ENSP_mappings:7pjn.D&PDB-ENSP_mappings:8bay.A&PDB-ENSP_mappings:8bay.B&PDB-ENSP_mappings:8bay.C&PDB-ENSP_mappings:8hb9.AAA&PDB-ENSP_mappings:8hb9.BBB&PDB-ENSP_mappings:8hb9.CCC&PDB-ENSP_mappings:8hb9.DDD&PDB-ENSP_mappings:8t7d.A&PDB-ENSP_mappings:8t7d.B&PDB-ENSP_mappings:8t7d.C&PDB-ENSP_mappings:8t7d.D&PDB-ENSP_mappings:8t7n.A&PDB-ENSP_mappings:8t7n.B&PDB-ENSP_mappings:8t7o.A&PDB-ENSP_mappings:8t7o.B&PDB-ENSP_mappings:8vh9.A&PDB-ENSP_mappings:8vh9.B&PDB-ENSP_mappings:8vha.A&PDB-ENSP_mappings:8vha.B&PDB-ENSP_mappings:8vha.C&PDB-ENSP_mappings:8vha.D&PDB-ENSP_mappings:8vhb.A&PDB-ENSP_mappings:8vhb.B&PDB-ENSP_mappings:8vhb.C&PDB-ENSP_mappings:8vhb.D&PDB-ENSP_mappings:8vhc.A&PDB-ENSP_mappings:8vhc.B&PDB-ENSP_mappings:8vhd.A&PDB-ENSP_mappings:8vhd.B&PDB-ENSP_mappings:8vhd.C&PDB-ENSP_mappings:8vhd.D&PDB-ENSP_mappings:8vhe.A&PDB-ENSP_mappings:8vhe.B&PDB-ENSP_mappings:8vhe.C&PDB-ENSP_mappings:8vhe.D&AFDB-ENSP_mappings:AF-O75874-F1&Pfam:PF00180&PIRSF:PIRSF000108&PANTHER:PTHR11822&SMART:SM01329&Superfamily:SSF53659&NCBIFAM:TIGR00127			0.0569	0.1172	0.0447	0.0069	0.0477	0.045	0.05397	0.1058	0.03897	0.08222	0.01186	0.02769	0.04976	0.05514	0.0619	0.04844	0.0665	0.105	0.008772	0.05996	0.09303	0.01006	0.02348	0.05137	0.0568	0.06493	0.04108	0.1172	AFR	benign	0&1	1&1	24033266&25553291&20368538&21647152&21791467&21873548&23184331&24532263&24606602&24868540&26992216&28218607&28246275&29423539&29535392&30052515&32368160&33904417&36011350&20946881&28067407&33809750&31165048&34188585&24968698&25324972&31413655&23176617&21242187&20171178&33193845&27721426&33887545&31085772&29622865&22966788&20130071&32612806&35372066&23146058&22566607&24466377&34946913&36740223&35477782&37973912						FAIL	2	-45	2	-45	0.00	0.00	0.18	0.07	IDH1		8.2900e-01	402961	0.07104	0.05240	0.05691	389478	not_provided&not_specified		MedGen:C3661900&MedGen:CN169374		NC_000002.12:g.208248468G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000539329&SCV001833559&SCV005240877	single_nucleotide_variant	SO:0001483	ClinGen:CA2079054		IDH1:3417	SO:0001819&synonymous_variant										1	11554137																											109					0.954							171.09	v6.1	Unknown		True	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancer types including acute myeloid leukemia and gliomas.	False	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IDH1 ENSP00000260985.2:G105= mutant UNKNOWN.	False	The IDH1 ENSP00000260985.2:g105= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	209113192						True	False	False	Unknown								False	False		IDH1, a cell metabolism enzyme, is recurrently mutated in various cancer types including acute myeloid leukemia and gliomas.	The IDH1 ENSP00000260985.2:g105= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IDH1 ENSP00000260985.2:G105= mutant UNKNOWN.						v6.1	02/04/2019		GRCh38	IDH1	3417.0	ENSP00000260985.2:G105=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IDH1"",""entrezGeneId"":3417,""alteration"":""ENSP00000260985.2:G105="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IDH1, a cell metabolism enzyme, is recurrently mutated in various cancer types including acute myeloid leukemia and gliomas."",""variantSummary"":""The IDH1 ENSP00000260985.2:g105= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IDH1 ENSP00000260985.2:G105= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/04/2019""}"	True	True	False	Unknown		Unknown																						49,55	17,27	32,28	0/1	25,24,25,30	TGC	0.00	0.00	0.00			23,26,25,30	38.5		0.5288461538461539
GRCh38	ERBB4	D12_12345_1234556_Thyroid_S9	p.Val1065=	ENSP00000342235.4:p.Val1065=	chr2	211387139	211387139.0	T	C	C	211387139	.	T	C	.	PASS	NM_005235	C	synonymous_variant	LOW	ERBB4	ENSG00000178568	Transcript	ENST00000342788	protein_coding	27/28		c.3195A>G	3467	3195	1065	V	gtA/gtG	rs3748962&COSV61463116		-1		SNV	HGNC	HGNC:3432	YES	MANE_Select	NM_005235.3		1	P4	CCDS2394.1	ENSP00000342235	Q15303.245		UPI00000499DF	Q15303-1		1			PIRSF:PIRSF000619&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q15303-F1			0.2230	0.0756	0.2983	0.2887	0.2992	0.2229	0.3262	0.08762	0.2602	0.3297	0.2758	0.3537	0.3163	0.3419	0.3152	0.2648	0.2606	0.0999	0.2868	0.2554	0.3305	0.3119	0.3524	0.2925	0.3377	0.2647	0.2583	0.3537	gnomADe_FIN	benign	0&1	1&1	28225484&17598910&28425244&20600594&29453196&23301017&38149095						FAIL	-8	5	5	7	0.00	0.02	0.00	0.00	ERBB4		3.5700e-01	1210024	0.25273	0.29535	0.22304	1199893	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000002.12:g.211387139T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001911607&SCV002406995&SCV005087744&SCV005241062	single_nucleotide_variant	SO:0001483	ClinGen:CA2087490		ERBB4:2066	SO:0001819&synonymous_variant										1	3748962																											518					0.998							247.48	v6.1	Unknown		True	ERBB4, a receptor tyrosine kinase, is altered at low to moderate frequencies in various cancer types, most frequently in melanoma and lung cancer.	False	07/23/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB4 ENSP00000342235.4:V1065= mutant UNKNOWN.	False	The ERBB4 ENSP00000342235.4:v1065= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	212251864						True	False	False	Unknown								False	False		ERBB4, a receptor tyrosine kinase, is altered at low to moderate frequencies in various cancer types, most frequently in melanoma and lung cancer.	The ERBB4 ENSP00000342235.4:v1065= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB4 ENSP00000342235.4:V1065= mutant UNKNOWN.						v6.1	07/23/2019		GRCh38	ERBB4	2066.0	ENSP00000342235.4:V1065=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ERBB4"",""entrezGeneId"":2066,""alteration"":""ENSP00000342235.4:V1065="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ERBB4, a receptor tyrosine kinase, is altered at low to moderate frequencies in various cancer types, most frequently in melanoma and lung cancer."",""variantSummary"":""The ERBB4 ENSP00000342235.4:v1065= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ERBB4 ENSP00000342235.4:V1065= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2019""}"	True	True	False	Unknown		Unknown																						280,237	147,106	133,131	0/1	137,143,137,100	ATA	.	.	.			78,202,76,161	26.95		0.4584139264990329
GRCh38	ERBB4	D12_12345_1234556_Thyroid_S9			chr2	211420614	211420618.0	AAAAG	A	A	211420614	.	AAAAG	A	.	PASS	NM_005235	-	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	ERBB4	ENSG00000178568	Transcript	ENST00000342788	protein_coding		24/27	c.2965-7_2965-4del						rs60420993		-1		deletion	HGNC	HGNC:3432	YES	MANE_Select	NM_005235.3		1	P4	CCDS2394.1	ENSP00000342235	Q15303.245		UPI00000499DF	Q15303-1		1						0.1384	0.413	0.0663	0.0694	0.0169	0.0143	0.02826	0.3538	0.08676	0.01266	0.07003	0.005549	0.03615	0.01633	0.04053	0.01693	0.1156	0.3516	0	0.06903	0.01182	0.07625	0.0048	0.03401	0.0178	0.08578	0.0189	0.413	AFR			1	26919099						FAIL	-21	-3	-3	-39	0.00	0.01	0.00	0.00	ERBB4		3.5700e-01	1209952				1199894	not_provided&not_specified&ERBB4-related_disorder		MedGen:C3661900&MedGen:CN169374&.		NC_000002.12:g.211420616AAGA[1]	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001857842&SCV002403327	Microsatellite	SO:0000289	ClinGen:CA2087566		ERBB4:2066	SO:0001627&intron_variant										1	60420993																											56					0.929							247.79													chr2	212285339																																																	True	True	False	Unknown		Unknown																						25,27	15,14	10,13	0/1	15,10,10,17	TAA						13,12,9,18	33.54		0.5192307692307693
GRCh38	BARD1	D12_12345_1234556_Thyroid_S9	p.K650T	ENSP00000260947.4:p.Lys650Thr	chr2	214730463	214730463.0	T	G	G	214730463	.	T	G	.	PASS	NM_000465	G	missense_variant	MODERATE	BARD1	ENSG00000138376	Transcript	ENST00000260947	protein_coding	10/11		c.1949A>C	2063	1949	650	K/T	aAg/aCg	rs876659021&COSV53610550		-1		SNV	HGNC	HGNC:952	YES	MANE_Select	NM_000465.4		1	P2	CCDS2397.1	ENSP00000260947	Q99728.233		UPI000013D11D	Q99728-1		1	deleterious(0.03)	possibly_damaging(0.544)	PDB-ENSP_mappings:2nte.A&PDB-ENSP_mappings:2nte.B&PDB-ENSP_mappings:2r1z.A&PDB-ENSP_mappings:2r1z.B&Gene3D:3.40.50.10190&PDB-ENSP_mappings:3fa2.A&PDB-ENSP_mappings:3fa2.B&PDB-ENSP_mappings:6m14.A&PDB-ENSP_mappings:6m14.B&PDB-ENSP_mappings:7e8i.K&PDB-ENSP_mappings:7lyc.N&AFDB-ENSP_mappings:AF-Q99728-F1&PROSITE_profiles:PS50172&PANTHER:PTHR24171&Superfamily:SSF52113&Superfamily:SSF52113																																uncertain_significance	0&1	1&1							FAIL	45	23	-17	0	0.00	0.00	0.00	0.00	BARD1	0.019	1.0870e+00	479131				472520	Familial_cancer_of_breast&Hereditary_cancer-predisposing_syndrome		MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000002.12:g.214730463T>G	criteria_provided&_multiple_submitters&_no_conflicts	Uncertain_significance			SCV000660843&SCV005844788	single_nucleotide_variant	SO:0001483	ClinGen:CA350451180		BARD1:580	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	876659021																											125					0.944							244.2	v6.1	Unknown		True	BARD1, a tumor suppressor involved in the DNA damage response, is altered by mutation in breast and ovarian cancers.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BARD1 ENSP00000260947.4:K650T mutant UNKNOWN.	False	The BARD1 ENSP00000260947.4:k650t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	215595187						True	False	False	Unknown								False	False		BARD1, a tumor suppressor involved in the DNA damage response, is altered by mutation in breast and ovarian cancers.	The BARD1 ENSP00000260947.4:k650t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BARD1 ENSP00000260947.4:K650T mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	BARD1	580.0	ENSP00000260947.4:K650T			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BARD1"",""entrezGeneId"":580,""alteration"":""ENSP00000260947.4:K650T"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BARD1, a tumor suppressor involved in the DNA damage response, is altered by mutation in breast and ovarian cancers."",""variantSummary"":""The BARD1 ENSP00000260947.4:k650t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BARD1 ENSP00000260947.4:K650T mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						115,3	59,3	56,0	0/1	59,56,1,2	CTT	.	.	.			57,58,1,2	6.38		0.025423728813559324
GRCh38	BARD1	D12_12345_1234556_Thyroid_S9	p.V507M	ENSP00000260947.4:p.Val507Met	chr2	214767531	214767531.0	C	T	T	214767531	.	C	T	.	PASS	NM_000465	T	missense_variant	MODERATE	BARD1	ENSG00000138376	Transcript	ENST00000260947	protein_coding	6/11		c.1519G>A	1633	1519	507	V/M	Gtg/Atg	rs2070094&CM034384&COSV53610001		-1		SNV	HGNC	HGNC:952	YES	MANE_Select	NM_000465.4		1	P2	CCDS2397.1	ENSP00000260947	Q99728.233		UPI000013D11D	Q99728-1		1	tolerated(0.1)	benign(0.019)	Gene3D:1.25.40.20&PDB-ENSP_mappings:3c5r.A&PDB-ENSP_mappings:3c5r.B&PDB-ENSP_mappings:7e8i.K&PDB-ENSP_mappings:7lyc.N&AFDB-ENSP_mappings:AF-Q99728-F1&Pfam:PF12796&PROSITE_profiles:PS50088&PROSITE_profiles:PS50297&PANTHER:PTHR24171&SMART:SM00248&Superfamily:SSF48403			0.3662	0.3608	0.3069	0.3433	0.3976	0.407	0.3664	0.3671	0.2978	0.4063	0.3578	0.4717	0.385	0.3603	0.365	0.4066	0.3713	0.3712	0.2626	0.3186	0.4172	0.3719	0.4674	0.4422	0.3639	0.379	0.4119	0.4717	gnomADe_FIN	benign&benign/likely_benign	0&1&1	1&1&1	25741868&23222812&29458332&19412175&19482343&25785002&29879995&33623049&35084806&14550946&23966609&33240400&35768791&17399677&37645774&37561379&38920653						FAIL	-2	14	-47	-49	0.00	0.00	0.00	0.00	BARD1	0.108	1.0870e+00	140757	0.28064	0.37833	0.36621	150471	Familial_cancer_of_breast&Hereditary_cancer-predisposing_syndrome&not_provided&not_specified		MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MedGen:CN169374		NC_000002.12:g.214767531C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000172729&SCV000292077&SCV000304410&SCV000427212&SCV000602628&SCV001718573&SCV001835864&SCV005258299&SCV005405338	single_nucleotide_variant	SO:0001483	ClinGen:CA163499&UniProtKB:Q99728																																																																																																																																															45,30	19,14	26,16	0|1	16,29,13,17	ACA	0.00	0.00	0.00		215632255	22,23,15,15	16.96		0.4
GRCh38	BARD1	D12_12345_1234556_Thyroid_S9	p.His506=	ENSP00000260947.4:p.His506=	chr2	214767532	214767532.0	A	G	G	214767532	.	A	G	.	PASS	NM_000465	G	synonymous_variant	LOW	BARD1	ENSG00000138376	Transcript	ENST00000260947	protein_coding	6/11		c.1518T>C	1632	1518	506	H	caT/caC	rs2070093&COSV53617490		-1		SNV	HGNC	HGNC:952	YES	MANE_Select	NM_000465.4		1	P2	CCDS2397.1	ENSP00000260947	Q99728.233		UPI000013D11D	Q99728-1		1			Gene3D:1.25.40.20&PDB-ENSP_mappings:3c5r.A&PDB-ENSP_mappings:3c5r.B&PDB-ENSP_mappings:7e8i.K&PDB-ENSP_mappings:7lyc.N&AFDB-ENSP_mappings:AF-Q99728-F1&Pfam:PF12796&PROSITE_profiles:PS50088&PROSITE_profiles:PS50297&PANTHER:PTHR24171&SMART:SM00248&Superfamily:SSF48403			0.7706	0.5545	0.7594	0.9484	0.8181	0.8384	0.8077	0.5838	0.8077	0.8238	0.9402	0.8912	0.7558	0.8038	0.7906	0.8413	0.7556	0.5994	0.7566	0.7537	0.8288	0.9488	0.8994	0.7653	0.8049	0.7396	0.8392	0.9488	gnomADg_EAS	benign	0&1	1&1	25741868&24033266&19536092&35084806&17399677						FAIL	13	-11	-48	46	0.00	0.00	0.00	0.00	BARD1		1.0870e+00	183704	0.71382	0.81342	0.77057	181790	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_breast_ovarian_cancer_syndrome&Familial_cancer_of_breast		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535		NC_000002.12:g.214767532A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212690&SCV000304409&SCV000427213&SCV000537319&SCV000538392&SCV000602625&SCV000999980&SCV001835315&SCV002505113&SCV002801169&SCV004016348&SCV005241569&SCV005405335&SCV006311450	single_nucleotide_variant	SO:0001483	ClinGen:CA186180		BARD1:580	SO:0001619&non-coding_transcript_variant&SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	2070093																											77					0.987							245.93	v6.1	Unknown		True	BARD1, a tumor suppressor involved in the DNA damage response, is altered by mutation in breast and ovarian cancers.	False	06/11/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BARD1 ENSP00000260947.4:H506= mutant UNKNOWN.	False	The BARD1 ENSP00000260947.4:h506= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	215632256						True	False	False	Unknown								False	False		BARD1, a tumor suppressor involved in the DNA damage response, is altered by mutation in breast and ovarian cancers.	The BARD1 ENSP00000260947.4:h506= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BARD1 ENSP00000260947.4:H506= mutant UNKNOWN.						v6.1	06/11/2024		GRCh38	BARD1	580.0	ENSP00000260947.4:H506=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BARD1"",""entrezGeneId"":580,""alteration"":""ENSP00000260947.4:H506="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BARD1, a tumor suppressor involved in the DNA damage response, is altered by mutation in breast and ovarian cancers."",""variantSummary"":""The BARD1 ENSP00000260947.4:h506= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BARD1 ENSP00000260947.4:H506= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/11/2024""}"	True	True	False	Unknown		Unknown																						47,29	20,14	27,15	0|1	18,29,13,16	CAT	.	.	.		215632255	23,24,14,15	14.28		0.3815789473684211
GRCh38	BARD1	D12_12345_1234556_Thyroid_S9	p.R378S	ENSP00000260947.4:p.Arg378Ser	chr2	214780740	214780740.0	C	G	G	214780740	.	C	G	.	PASS	NM_000465	G	missense_variant	MODERATE	BARD1	ENSG00000138376	Transcript	ENST00000260947	protein_coding	4/11		c.1134G>C	1248	1134	378	R/S	agG/agC	rs2229571&CM076014&COSV53612030		-1		SNV	HGNC	HGNC:952	YES	MANE_Select	NM_000465.4		1	P2	CCDS2397.1	ENSP00000260947	Q99728.233		UPI000013D11D	Q99728-1		1	tolerated(0.39)	benign(0.015)	AFDB-ENSP_mappings:AF-Q99728-F1&PANTHER:PTHR24171&MobiDB_lite:mobidb-lite			0.4593	0.379	0.4914	0.3413	0.6412	0.4796	0.5862	0.3935	0.4196	0.5762	0.3568	0.6918	0.5267	0.6113	0.5639	0.4859	0.53	0.3984	0.5615	0.4691	0.5861	0.373	0.6824	0.5952	0.6117	0.537	0.4817	0.6918	gnomADe_FIN	benign	0&1&1	1&1&1	25741868&23554684&23222812&29458332&19412175&19482343&23056176&25785002&29879995&31258718&32708251&33623049&35084806&30071039&17028982&30976110&23966609&33603458&18059179&35650591&33240400&35768791&37645774&37561379&38920653						FAIL	-43	-33	-43	26	0.00	0.00	0.01	0.00	BARD1	0.111	1.0870e+00	142769	0.53183	0.54870	0.45927	152483	BARD1-related_cancer_predisposition&not_specified&Hereditary_cancer-predisposing_syndrome&Hereditary_breast_ovarian_cancer_syndrome&not_provided&Familial_cancer_of_breast		MONDO:MONDO:0700267&MedGen:CN377756&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MedGen:C3661900&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535		NC_000002.12:g.214780740C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000187237&SCV000292073&SCV000304407&SCV000427216&SCV000602626&SCV000632933&SCV001845574&SCV002505125&SCV002799314&SCV004016352&SCV005241571&SCV005405311&SCV005919010&SCV006311447	single_nucleotide_variant	SO:0001483	ClinGen:CA169361&UniProtKB:Q99728																																																																																																																																															43,46	16,24	27,22	0/1	21,22,18,28	TCC	.	.	.			24,19,20,26	36.8		0.5168539325842697
GRCh38	BARD1	D12_12345_1234556_Thyroid_S9	p.P24S	ENSP00000260947.4:p.Pro24Ser	chr2	214809500	214809500.0	G	A	A	214809500	.	G	A	.	PASS	NM_000465	A	missense_variant	MODERATE	BARD1	ENSG00000138376	Transcript	ENST00000260947	protein_coding	1/11		c.70C>T	184	70	24	P/S	Ccc/Tcc	rs1048108&CM076015&COSV53608734		-1		SNV	HGNC	HGNC:952	YES	MANE_Select	NM_000465.4		1	P2	CCDS2397.1	ENSP00000260947	Q99728.233		UPI000013D11D	Q99728-1		1	tolerated(0.11)	benign(0.055)	AFDB-ENSP_mappings:AF-Q99728-F1&MobiDB_lite:mobidb-lite			0.3313	0.1929	0.4006	0.3313	0.3946	0.4039	0.3658	0.2061	0.4253	0.4179	0.3487	0.4203	0.3307	0.3621	0.3597	0.4127	0.3327	0.2121	0.3513	0.3861	0.4357	0.3606	0.4036	0.3562	0.3699	0.3425	0.4086	0.4357	gnomADg_ASJ	benign	0&1&1	1&1&1	25741868&23554684&21514219&23222812&29484706&29458332&19412175&19482343&23056176&24293394&25785002&29879995&30132831&31123171&31258718&32708251&33623049&35084806&23966609&34094541&35768791&37561379&38920653						FAIL	36	-41	2	31	0.00	0.00	0.00	0.00	BARD1	0.260	1.0870e+00	183698	0.30314	0.43768	0.33127	181856	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_cancer_of_breast		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535		NC_000002.12:g.214809500G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212668&SCV000292076&SCV000304412&SCV000427227&SCV000602627&SCV000633057&SCV001856682&SCV004016356&SCV005241580&SCV005405374&SCV006311455	single_nucleotide_variant	SO:0001483	ClinGen:CA186160&UniProtKB:Q99728																																																																																																																																															377,371	187,196	190,175	0/1	181,196,169,202	GGC	0.00	0.00	0.00			157,220,166,205	47.92		0.4959893048128342
GRCh38	OBSL1	D12_12345_1234556_Thyroid_S9			chr2	219567292	219567292.0	G	A	A	219567292	.	G	A	.	PASS		A	upstream_gene_variant	MODIFIER	OBSL1	ENSG00000124006	Transcript	ENST00000604031	protein_coding									rs61732787&COSV54714308&COSV54727111	4780	-1	cds_start_NF	SNV	HGNC	HGNC:29092					2			ENSP00000475126		S4R463.52	UPI0003335028			1						0.1717	0.0454	0.2017	0.1151	0.2425	0.3067	0.2391	0.07972	0.1691	0.3002	0.1304	0.2407	0.262	0.2448	0.2362	0.2948	0.1932	0.08504	0.0956	0.1787	0.2949	0.1222	0.2461	0.2347	0.2468	0.2261	0.3045	0.3067	SAS	benign	0&1&1	1&1&1							FAIL	15	34	-16	-19	0.00	0.00	0.00	0.00	OBSL1			334517	0.19590	0.24860	0.17173	284847	3M_syndrome_2&not_provided		MONDO:MONDO:0013039&MedGen:C2752041&OMIM:612921&Orphanet:2616&MedGen:C3661900		NC_000002.12:g.219567292G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000427838&SCV001722115&SCV001864911&SCV002029266&SCV005240460	single_nucleotide_variant	SO:0001483	ClinGen:CA2131422		OBSL1:23363	SO:0001819&synonymous_variant										1	61732787																											934					0.998							246.96	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr2	220432014						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	OBSL1		ENSP00000289656.3:F193=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""OBSL1"",""entrezGeneId"":null,""alteration"":""ENSP00000289656.3:F193="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						468,464	217,215	251,249	0/1	232,236,250,214	GGA	0.00	0.00	0.00			251,217,237,227	52.69		0.4978540772532189
GRCh38	INHA	D12_12345_1234556_Thyroid_S9	p.Ala177=	ENSP00000243786.2:p.Ala177=	chr2	219574956	219574956.0	C	T	T	219574956	.	C	T	.	PASS	NM_002191	T	synonymous_variant	LOW	INHA	ENSG00000123999	Transcript	ENST00000243786	protein_coding	2/2		c.531C>T	596	531	177	A	gcC/gcT	rs12720063&COSV54715323		1		SNV	HGNC	HGNC:6065	YES	MANE_Select	NM_002191.4		1	P1	CCDS2444.1	ENSP00000243786	P05111.211		UPI000002C8C6						AFDB-ENSP_mappings:AF-P05111-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF037328&PANTHER:PTHR11848			0.1534	0.0809	0.2464	0.2103	0.1968	0.0818	0.1978	0.1079	0.2494	0.1751	0.169	0.1968	0.1626	0.2087	0.1882	0.09426	0.1763	0.1128	0.1967	0.2346	0.1892	0.1937	0.1959	0.1565	0.2026	0.1774	0.09337	0.2494	gnomADe_AMR	benign	0&1	1&1	25111790&25528498						FAIL	10	-49	-34	37	0.00	0.00	0.00	0.00	INHA		6.8600e-01	3055288	0.17384	0.18123	0.15335	3206445	INHA-related_disorder		.		NC_000002.12:g.219574956C>T	no_assertion_criteria_provided	Benign			SCV004778762	single_nucleotide_variant	SO:0001483	ClinGen:CA2132001		INHA:3623	SO:0001819&synonymous_variant										1	12720063																											1016					0.99							246.63	v6.1	Unknown		True	INHA, a regulator of gonadal hormone secretion, is altered by mutation in various cancer types.	False	08/14/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INHA ENSP00000243786.2:A177= mutant UNKNOWN.	False	The INHA ENSP00000243786.2:a177= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	220439678						True	False	False	Unknown								False	False		INHA, a regulator of gonadal hormone secretion, is altered by mutation in various cancer types.	The INHA ENSP00000243786.2:a177= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INHA ENSP00000243786.2:A177= mutant UNKNOWN.						v6.1	08/14/2019		GRCh38	INHA	3623.0	ENSP00000243786.2:A177=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""INHA"",""entrezGeneId"":3623,""alteration"":""ENSP00000243786.2:A177="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""INHA, a regulator of gonadal hormone secretion, is altered by mutation in various cancer types."",""variantSummary"":""The INHA ENSP00000243786.2:a177= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with INHA ENSP00000243786.2:A177= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/14/2019""}"	True	True	False	Unknown		Unknown																						488,518	259,289	229,229	0/1	253,235,270,248	CCG	0.00	0.00	0.00			238,250,253,265	63.02		0.5149105367793241
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222202200	222202200.0	C	G	G	222202200	.	C	G	.	PASS	NM_181458	G	splice_polypyrimidine_tract_variant&intron_variant	LOW	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-10G>C						rs2855268		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.0719	0.059	0.121	0	0.173	0.0245	0.1304	0.08093	0.09772	0.1922	0.0001581	0.1153	0.1822	0.1436	0.1327	0.03724	0.1157	0.07924	0.0614	0.1445	0.1878	0.0001935	0.1184	0.1565	0.1416	0.1488	0.03319	0.1922	gnomADe_ASJ	benign		1	25741868&24033266&23751107&34910505						FAIL	-10	-9	-39	-9	0.00	0.00	0.00	0.00	PAX3		4.0900e-01	226998	0.12312		0.07188	228928	not_provided&not_specified&Waardenburg_syndrome&Craniofacial-deafness-hand_syndrome		MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0018094&MedGen:C3266898&OMIM:PS193500&Orphanet:3440&MONDO:MONDO:0007395&MedGen:C1852510&OMIM:122880&Orphanet:1529		NC_000002.12:g.222202200C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000269614&SCV000316718&SCV000427892&SCV000427893&SCV000717165&SCV002401760&SCV005240501	single_nucleotide_variant	SO:0001483	ClinGen:CA2135471		PAX3:5077	SO:0001627&intron_variant										1	2855268																											732					0.986							244.13													chr2	223066919																																																	True	True	False	Unknown		Unknown																						360,362	191,188	169,174	0/1	193,167,191,171	ACA	.	.	.			120,240,137,225	50.83		0.5013850415512465
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222203567	222203567.0	G	A	A	222203567	.	G	A	.	PASS	NM_181458	A	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-1377C>T						rs7559271		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.4659	0.447	0.4236	0.3889	0.6024	0.4601											0.5437	0.4611	0.7577	0.4181	0.5482	0.3677	0.6269	0.585	0.6251	0.5213	0.4726	0.7577	gnomADg_AMI			1	27560520&24914781&31025105&29921221&27193062&22341974&23028347&28053980&33983923&35399580&27560833&32670926&23843775						FAIL	-6	-25	30	-4	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											96					1							234.05													chr2	223068286																																																	True	True	False	Unknown		Unknown																						53,43	24,22	29,21	0/1	23,30,26,17	AGA	0.00	0.00	0.00			24,29,17,26	29.61		0.4479166666666667
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222204102	222204102.0	A	T	T	222204102	.	A	T	.	PASS	NM_181458	T	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-1912T>A						rs7588737&COSV60586244		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.1889	0.0666	0.2219	0.1151	0.4175	0.1718											0.3019	0.1089	0.6495	0.2254	0.3185	0.09282	0.4759	0.3345	0.4274	0.2978	0.1973	0.6495	gnomADg_AMI		0&1	0&1							FAIL	-36	35	3	13	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											72					0.972							242.46													chr2	223068821																																																	True	True	False	Unknown		Unknown																						39,31	24,12	15,19	0/1	20,19,14,17	TAA	.	.	.			21,18,19,12	27.82		0.44285714285714284
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222204360	222204360.0	T	C	C	222204360	.	T	C	.	PASS	NM_181458	C	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-2170A>G						rs2033806		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.9349	0.9297	0.9352	0.999	0.9155	0.8957											0.9171	0.9231	0.8816	0.9414	0.8864	0.9992	0.9492	0.8844	0.9018	0.9153	0.878	0.9992	gnomADg_EAS										FAIL	42	21	1	41	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											101					0.911							238.91													chr2	223069079																																																	True	True	False	Unknown		Unknown																						0,92	0,46	0,46	0/1	0,0,49,43	ATA	.	.	.			0,0,47,45	64.65		1.0
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222204906	222204906.0	T	C	C	222204906	.	T	C	.	PASS	NM_181458	C	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-2716A>G						rs13017777		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.2638	0.0696	0.415	0.1319	0.492	0.32											0.3714	0.1236	0.6513	0.4018	0.3547	0.1054	0.548	0.3639	0.5088	0.3654	0.3337	0.6513	gnomADg_AMI			1	30531825						FAIL	-1	-44	1	37	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											89					0.978							245.65													chr2	223069625																																																	True	True	False	Unknown		Unknown																						42,45	24,17	18,28	0/1	18,24,29,16	ATT	.	.	.			20,22,21,24	36.73		0.5172413793103449
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222205149	222205149.0	T	C	C	222205149	.	T	C	.	PASS	NM_181458	C	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-2959A>G						rs34364313		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.1885	0.0658	0.2219	0.1141	0.4175	0.1718											0.301	0.1075	0.6491	0.2253	0.3193	0.09161	0.4758	0.3367	0.4268	0.2972	0.1968	0.6491	gnomADg_AMI										FAIL	36	-19	36	25	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											80					0.975							245.19													chr2	223069868																																																	True	True	False	Unknown		Unknown																						41,37	20,15	21,22	0/1	21,20,20,17	TTA	.	.	.			16,25,22,15	32.43		0.47435897435897434
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222206138	222206139.0	AT	A	A	222206138	.	AT	A	.	PASS	NM_181458	-	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-3949del						rs11366818		-1		deletion	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1																						0.1205	0.08764	0.06208	0.1472	0.1919	0.001774	0.1279	0.1528	0.1444	0.155	0.03392	0.1919	gnomADg_ASJ										FAIL	41	22	-45	-2	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											133					0.729							230.47													chr2	223070857																																																	True	True	False	Unknown		Unknown																						48,49	24,27	24,22	0/1	24,24,35,14	AAT						24,24,25,24	29.92		0.5051546391752577
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222207300	222207300.0	T	A	A	222207300	.	T	A	.	PASS	NM_181458	A	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-5110A>T						rs2855266		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.0719	0.0598	0.121	0	0.172	0.0245											0.1163	0.08025	0.0614	0.144	0.1865	0.0001929	0.1184	0.1497	0.1425	0.1498	0.03273	0.1865	gnomADg_ASJ			1	34560273&31763980&33692830						FAIL	-8	-21	-8	-46	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											115					0.965							239.22													chr2	223072019																																																	True	True	False	Unknown		Unknown																						61,50	36,24	25,26	0/1	33,28,21,29	TTG	.	.	.			36,25,27,23	29.82		0.45045045045045046
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222208003	222208005.0	GTA	G	G	222208003	.	GTA	G	.	PASS	NM_181458	-	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-5815_1174-5814del						rs71408506		-1		deletion	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.2404	0.1301	0.268	0.1806	0.4433	0.2229											0.3005	0.1076	0.649	0.2288	0.3194	0.09089	0.4793	0.3262	0.4236	0.2986	0.1969	0.649	gnomADg_AMI										FAIL	30	-9	-12	32	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											79					0.861							226.19													chr2	223072722																																																	True	True	False	Unknown		Unknown																						34,34	20,24	14,10	0/1	13,21,17,17	TGT						15,19,19,15	27.33		0.5
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222208301	222208302.0	AT	A	A	222208301	.	AT	A	.	PASS	NM_181458	-	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-6112del						rs34691906		-1		deletion	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.1931	0.0764	0.2248	0.1151	0.4175	0.1779											0.3042	0.1145	0.6538	0.2293	0.3195	0.09274	0.4798	0.3493	0.4267	0.3022	0.202	0.6538	gnomADg_AMI										FAIL	10	2	36	-28	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											69					0.739							240.3													chr2	223073020																																																	True	True	False	Unknown		Unknown																						26,25	15,12	11,13	0/1	14,12,15,10	TAT						15,11,10,15	29.11		0.49019607843137253
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222209696	222209729.0	CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	C	C	222209696	.	CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	C	.	PASS	NM_181458	-	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-7539_1174-7507del						rs546468709		-1		deletion	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1																						0.2646	0.1903	0.1368	0.3564	0.3246	0.0008606	0.4736	0.3364	0.2809	0.3214	0.1372	0.4736	gnomADg_FIN																					4.0900e-01																																																											265					0.506							176.03													chr2	223074415																																																	True	True	False	Unknown		Unknown																						65,69	31,44	34,25	0/1	28,37,42,27	ACA						40,25,35,34	37.82		0.5149253731343284
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222209932	222209932.0	A	G	G	222209932	.	A	G	.	PASS	NM_181458	G	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-7742T>C						rs7588554		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.1879	0.0658	0.2205	0.1111	0.4185	0.1718											0.3002	0.1062	0.6516	0.2263	0.3178	0.08951	0.4752	0.3435	0.4258	0.2966	0.1972	0.6516	gnomADg_AMI										FAIL	-45	-49	-2	2	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											232					0.991							246.87													chr2	223074651																																																	True	True	False	Unknown		Unknown																						134,96	71,49	63,47	0/1	76,58,55,41	AAC	.	.	.			63,71,42,54	19.3		0.41739130434782606
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222210352	222210352.0	C	T	T	222210352	.	C	T	.	PASS	NM_181458	T	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-8162G>A						rs35887641		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.1879	0.0658	0.2205	0.1111	0.4185	0.1718											0.3006	0.1075	0.6538	0.2266	0.3179	0.08959	0.4757	0.3435	0.4256	0.2966	0.1978	0.6538	gnomADg_AMI										FAIL	-6	-1	-12	-1	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											117					0.974							241.18													chr2	223075071																																																	True	True	False	Unknown		Unknown																						51,63	28,23	23,40	0/1	23,28,29,34	GCT	0.00	0.00	0.00			28,23,33,30	41.8		0.5526315789473685
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222210549	222210549.0	C	T	T	222210549	.	C	T	.	PASS	NM_181458	T	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1174-8359G>A						rs7565552		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.1881	0.0658	0.2205	0.1111	0.4185	0.1728											0.3006	0.1075	0.6524	0.2264	0.3178	0.08975	0.4747	0.3459	0.4258	0.2972	0.1986	0.6524	gnomADg_AMI				19142206						FAIL	-41	-8	-8	-28	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											164					0.945							228.71													chr2	223075268																																																	True	True	False	Unknown		Unknown																						84,71	46,31	38,40	0/1	42,42,38,33	CCT	0.00	0.00	0.00			42,42,40,31	30.72		0.45806451612903226
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222214625	222214625.0	G	A	A	222214625	.	G	A	.	PASS	NM_181458	A	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1173+5515C>T						rs6730989		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.0912	0.1316	0.1225	0	0.173	0.0245											0.136	0.1467	0.06057	0.1537	0.1909	0.0001932	0.1186	0.1633	0.1432	0.1605	0.03278	0.1909	gnomADg_ASJ										FAIL	-11	-9	29	-9	0.00	0.00	0.00	0.02	PAX3		4.0900e-01																																																											97					1							238.36													chr2	223079344																																																	True	True	False	Unknown		Unknown																						49,48	21,24	28,24	0/1	16,33,20,28	TGG	0.00	0.00	0.00			28,21,20,28	34.98		0.4948453608247423
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222215473	222215473.0	G	A	A	222215473	.	G	A	.	PASS	NM_181458	A	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1173+4667C>T						rs2578449		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.0847	0.1067	0.1225	0	0.173	0.0245											0.1292	0.1229	0.0614	0.1515	0.191	0.0001932	0.1184	0.1633	0.1432	0.1562	0.03243	0.191	gnomADg_ASJ										FAIL	-20	-6	-47	-12	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											163					0.81							230													chr2	223080192																																																	True	True	False	Unknown		Unknown																						73,59	33,24	40,35	0/1	33,40,32,27	GGA	0.00	0.00	0.00			53,20,43,16	29.14		0.44696969696969696
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222217612	222217612.0	C	T	T	222217612	.	C	T	.	PASS	NM_181458	T	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1173+2528G>A						rs1978859		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.2464	0.0764	0.2752	0.2768	0.3549	0.3129											0.4674	0.3455	0.2788	0.4982	0.5319	0.4962	0.4781	0.5139	0.4895	0.5008	0.5339	0.5339	gnomADg_SAS										FAIL	-2	1	-13	1	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											163					0.81							229.71													chr2	223082331																																																	True	True	False	Unknown		Unknown																						66,66	27,31	39,35	0|1	33,33,38,28	ACG	0.00	0.00	0.00		223082331	28,38,27,39	29.66		0.5
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222217628	222217632.0	C	CAGTT	CAGTT	222217628	.	C	CAGTT	.	PASS	NM_181458	AGTT	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1173+2511_1173+2512insAACT						rs5838936		-1		insertion	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.9605	0.9599	0.9481	0.9911	0.9513	0.9479											0.9702	0.9917	0.8888	0.9706	0.9735	0.9994	0.9687	0.9694	0.9546	0.9725	0.9861	0.9994	gnomADg_EAS																					4.0900e-01																																																											158					0.848							232.1													chr2	223082347																																																	True	True	False	Unknown		Unknown																						0,134	0,63	0,71	0|1	0,0,76,58	TCA					223082331	0,0,57,77	56.47		1.0
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222217807	222217807.0	G	C	C	222217807	.	G	C	.	PASS	NM_181458	C	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1173+2333C>G						rs1978860		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.6965	0.8048	0.7637	0.4077	0.8499	0.6421											0.8061	0.8156	0.8257	0.7752	0.7689	0.3817	0.8192	0.7891	0.8503	0.7991	0.651	0.8503	gnomADg_NFE				22341974						FAIL	22	21	22	-33	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											101					1							236.92													chr2	223082526																																																	True	True	False	Unknown		Unknown																						0,101	0,47	0,54	0/1	0,0,47,54	AGA	.	.	.			0,0,57,44	64.68		1.0
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222218360	222218360.0	T	C	C	222218360	.	T	C	.	PASS	NM_181458	C	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		7/8	c.1173+1780A>G						rs2253377		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						0.9818	0.9985	0.9669	1	0.9583	0.9755											0.9639	0.9909	0.8893	0.9679	0.9562	0.9994	0.9614	0.9626	0.9448	0.965	0.9754	1	EAS										FAIL	-1	-48	17	-1	0.00	0.00	0.00	0.00	PAX3		4.0900e-01																																																											112					0.946							238.41													chr2	223083079																																																	True	True	False	Unknown		Unknown																						0,106	0,46	0,60	0/1	0,0,44,62	ATT	.	.	.			0,0,52,54	64.69		1.0
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9			chr2	222293933	222293934.0	GT	G	G	222293933	.	GT	G	.	PASS	NM_181458	-	intron_variant	MODIFIER	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding		4/8	c.586+233del						rs10712898		-1		deletion	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1						1.0000	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	AFR&AMR&EAS&EUR&SAS&gnomADe_AFR&gnomADe_AMR&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_REMAINING&gnomADe_SAS&gnomADg_AFR&gnomADg_AMI&gnomADg_AMR&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_REMAINING&gnomADg_SAS	benign		1							FAIL	-10	-50	25	20	0.00	0.00	0.00	0.00	PAX3		4.0900e-01	1269208				1260351	not_provided		MedGen:C3661900		NC_000002.12:g.222293935del	criteria_provided&_single_submitter	Benign			SCV001900020	Deletion	SO:0000159	ClinGen:CA66340302		PAX3:5077	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant										1	10712898																											460					0.935							242.08													chr2	223158652																																																	True	True	False	Unknown		Unknown																						0,430	0,224	0,206	0/1	0,0,223,207	GGT						0,0,257,173	63.48		1.0
GRCh38	PAX3	D12_12345_1234556_Thyroid_S9	p.Gly43=	ENSP00000375922.3:p.Gly43=	chr2	222297170	222297170.0	A	G	G	222297170	.	A	G	.	PASS	NM_181458	G	synonymous_variant	LOW	PAX3	ENSG00000135903	Transcript	ENST00000392070	protein_coding	2/9		c.129T>C	512	129	43	G	ggT/ggC	rs12623857&COSV108047236		-1		SNV	HGNC	HGNC:8617	YES	MANE_Select	NM_181458.4		1	P4	CCDS42825.1	ENSP00000375922	P23760.238		UPI00001A8BEF	P23760-7		1			Prints:PR00027&SMART:SM00351&PANTHER:PTHR45636&Superfamily:SSF46689&PROSITE_profiles:PS51057&Gene3D:1.10.10.10&Pfam:PF00292&CDD:cd00131&AFDB-ENSP_mappings:AF-P23760-F1			0.9044	0.8351	0.9063	0.998	0.8459	0.9601	0.8571	0.8364	0.932	0.9255	0.9998	0.8334	0.9486	0.8407	0.8738	0.9516	0.8559	0.8374	0.6242	0.9116	0.924	0.9996	0.8294	0.932	0.8393	0.8889	0.9532	0.9998	gnomADe_EAS	benign	0&1	1&1	25741868&24033266&17149730						FAIL	23	-18	23	2	0.00	0.06	0.00	0.00	PAX3		4.0900e-01	195432	0.84653	0.88715	0.90435	192593	Waardenburg_syndrome_type_1&Waardenburg_syndrome_type_3&Craniofacial-deafness-hand_syndrome&Waardenburg_syndrome&not_specified&not_provided		MONDO:MONDO:0008670&MedGen:C1847800&OMIM:193500&Orphanet:894&MONDO:MONDO:0007862&MedGen:C0079661&OMIM:148820&Orphanet:3440&Orphanet:896&MONDO:MONDO:0007395&MedGen:C1852510&OMIM:122880&Orphanet:1529&MONDO:MONDO:0018094&MedGen:C3266898&OMIM:PS193500&Orphanet:3440&MedGen:CN169374&MedGen:C3661900		NC_000002.12:g.222297170A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000227582&SCV000269608&SCV000316719&SCV000427910&SCV000427911&SCV000717032&SCV002029391&SCV002029392&SCV002029393&SCV002408806&SCV005240509	single_nucleotide_variant	SO:0001483	ClinGen:CA201739		PAX3:5077	SO:0001819&synonymous_variant										1	12623857																											1120					0.995							246.91	v6.1	Unknown		True	PAX3, a transcription factor, is altered by chromosomal translocation in rhabdomyosarcoma.	False	11/17/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX3 ENSP00000375922.3:G43= mutant UNKNOWN.	False	The PAX3 ENSP00000375922.3:g43= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr2	223161889						True	False	False	Unknown								False	False		PAX3, a transcription factor, is altered by chromosomal translocation in rhabdomyosarcoma.	The PAX3 ENSP00000375922.3:g43= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX3 ENSP00000375922.3:G43= mutant UNKNOWN.						v6.1	11/17/2023		GRCh38	PAX3	5077.0	ENSP00000375922.3:G43=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PAX3"",""entrezGeneId"":5077,""alteration"":""ENSP00000375922.3:G43="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PAX3, a transcription factor, is altered by chromosomal translocation in rhabdomyosarcoma."",""variantSummary"":""The PAX3 ENSP00000375922.3:g43= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX3 ENSP00000375922.3:G43= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/17/2023""}"	True	True	False	Unknown		Unknown																						1,1113	0,500	1,613	0/1	0,1,575,538	CAC	.	.	.			1,0,524,589	64.73		0.9991023339317774
GRCh38	CUL3	D12_12345_1234556_Thyroid_S9			chr2	224497818		G	<INS>	<INS>	224497818	MantaINS:7886:0:0:0:3:0	G	<INS>	.	PASS	NM_003590	insertion	feature_elongation&coding_sequence_variant	HIGH	CUL3	ENSG00000036257	Transcript	ENST00000264414	protein_coding	12/16			1995	1641	547					-1		insertion	HGNC	HGNC:2553	YES	MANE_Select	NM_003590.5		1	P1	CCDS2462.1	ENSP00000264414	Q13618.227		UPI0000001C83	Q13618-1		1			Gene3D:3.30.230.130&PDB-ENSP_mappings:8gq6.C&PDB-ENSP_mappings:8gq6.F&PDB-ENSP_mappings:8h33.C&PDB-ENSP_mappings:8h33.F&PDB-ENSP_mappings:8h33.H&PDB-ENSP_mappings:8h33.I&PDB-ENSP_mappings:8h34.C&PDB-ENSP_mappings:8h34.F&PDB-ENSP_mappings:8h34.H&PDB-ENSP_mappings:8h34.I&PDB-ENSP_mappings:8h34.M&PDB-ENSP_mappings:8h34.O&PDB-ENSP_mappings:8h35.C&PDB-ENSP_mappings:8h35.F&PDB-ENSP_mappings:8h35.H&PDB-ENSP_mappings:8h35.I&PDB-ENSP_mappings:8h35.M&PDB-ENSP_mappings:8h35.O&PDB-ENSP_mappings:8h35.T&PDB-ENSP_mappings:8h35.V&PDB-ENSP_mappings:8h36.C&PDB-ENSP_mappings:8h36.F&PDB-ENSP_mappings:8h37.C&PDB-ENSP_mappings:8h37.F&PDB-ENSP_mappings:8h37.M&PDB-ENSP_mappings:8h37.O&PDB-ENSP_mappings:8h38.L&PDB-ENSP_mappings:8h3a.L&PDB-ENSP_mappings:8h3f.L&PDB-ENSP_mappings:8h3q.C&PDB-ENSP_mappings:8h3r.C&PDB-ENSP_mappings:8h3r.F&PDB-ENSP_mappings:8k8t.C&PDB-ENSP_mappings:8k8t.D&PDB-ENSP_mappings:8k9i.C&PDB-ENSP_mappings:8khp.C&PDB-ENSP_mappings:8khp.D&AFDB-ENSP_mappings:AF-Q13618-F1&Pfam:PF00888&PROSITE_profiles:PS50069&PANTHER:PTHR11932&SMART:SM00182&Superfamily:SSF75632																																																																																																												0,69		0,69							69	CTGTCGACCACTGTGTTTGGCTAAGTAGAACCTTCAGTAAATCAAACCAGGTTTTAGAAAATCAAACAA		CTGTCGACCACTGTGTTTGGCTAAGTAGAACCTTCAGTAAATCAAACCAGGTTTTAGAAAATCAAACAAGACAAAATTACTATACATTTATGATCA																chr2	225362535	CCAACTATGTGGTCAATTTTGGAATAGGTGTGGTGTGGTGCTGAAAAAAATGTATATT			INS																																													True	True	False	Unknown		Unknown																															0,1				0,2	
GRCh38	CUL3	D12_12345_1234556_Thyroid_S9			chr2	224569728	224569728.0	A	G	G	224569728	.	A	G	.	PASS	NM_003590	G	intron_variant	MODIFIER	CUL3	ENSG00000036257	Transcript	ENST00000264414	protein_coding		1/15	c.67-11872T>C						rs10498163&COSV52361378		-1		SNV	HGNC	HGNC:2553	YES	MANE_Select	NM_003590.5		1	P1	CCDS2462.1	ENSP00000264414	Q13618.227		UPI0000001C83	Q13618-1		1						0.2809	0.1596	0.3516	0.3651	0.33	0.2577	0.3065	0.1607	0.3026	0.3612	0.2777	0.2791	0.3314	0.3143	0.3063	0.2437	0.2864	0.1769	0.4363	0.3333	0.3732	0.3228	0.3008	0.4041	0.3324	0.2892	0.2623	0.4363	gnomADg_AMI	benign	0&1	1&1	27922606						FAIL	15	-46	-39	49	0.00	0.00	0.01	0.00	CUL3		3.6500e-01	504910		0.29993	0.28095	496687	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000002.12:g.224569728A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000711864&SCV001937927&SCV005242736	single_nucleotide_variant	SO:0001483	ClinGen:CA2140323		CUL3:8452	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	10498163																											72					0.972							234.29													chr2	225434445																																																	True	True	False	Unknown		Unknown																						38,32	23,13	15,19	0/1	23,15,17,15	CAT	.	.	.			22,16,14,18	30.65		0.45714285714285713
GRCh38	LINC01937	D12_12345_1234556_Thyroid_S9			chr2	238654938	238654938.0	G	C	C	238654938	.	G	C	.	PASS		C	intron_variant&non_coding_transcript_variant	MODIFIER	LINC01937	ENSG00000234279	Transcript	ENST00000653335	lncRNA		2/2	n.193+84122G>C						rs907100		1		SNV	HGNC	HGNC:52760	YES																			0.5883	0.8064	0.3732	0.5655	0.4483	0.6135											0.5392	0.7633	0.4077	0.4376	0.4677	0.5437	0.4272	0.4422	0.4461	0.5118	0.5789	0.8064	AFR				26691610&29121662&33406744&34721519&30483659&21611176&31226582&19083859&19948332&19083839&19948333																																																																												517					0.998							246.96													chr2	239563579																																																	True	False	False	Unknown		Unknown																						0,516	0,258	0,258	0|1	0,0,242,274	TGA	.	.	.		239563579	0,0,242,274	57.73		1.0
GRCh38	LINC01937	D12_12345_1234556_Thyroid_S9			chr2	238654956	238654956.0	G	A	A	238654956	.	G	A	.	PASS		A	intron_variant&non_coding_transcript_variant	MODIFIER	LINC01937	ENSG00000234279	Transcript	ENST00000653335	lncRNA		2/2	n.193+84140G>A						rs11689319		1		SNV	HGNC	HGNC:52760	YES																			0.1901	0.0938	0.1715	0.1319	0.2982	0.2822											0.226	0.1224	0.2765	0.1905	0.322	0.117	0.2946	0.2551	0.2858	0.2517	0.2638	0.322	gnomADg_ASJ				19083839																																																																												508					0.998							247.27													chr2	239563597																																																	True	False	False	Unknown		Unknown																						0,507	0,256	0,251	0|1	0,0,256,251	GGG	0.00	0.00	0.00		239563579	0,0,227,280	57.73		1.0
GRCh38	HDAC4	D12_12345_1234556_Thyroid_S9			chr2	239346630		A	[chr13:24669053[A	[chr13:24669053[A	239346630	MantaBND:8048:0:1:0:0:0:1	A	[chr13:24669053[A	.	PASS	NM_001378414	.A	feature_truncation&intron_variant	HIGH	HDAC4	ENSG00000068024	Transcript	ENST00000543185	protein_coding		2/26									-1		chromosome_breakpoint	HGNC	HGNC:14063	YES	MANE_Select	NM_001378414.1		5	A1	CCDS92981.1	ENSP00000440481		A0A7I2SVS4.16	UPI000387C768			1																																																																																																														3			0,5							5	CACTC			MantaBND:8048:0:1:0:0:0:0	1														chr2	240268325				BND																																													True	True	False	Unknown		Unknown																															0,1				1,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr20	4466836	4466836.0	A	C	C	4466836	.	A	C	.	PASS		C	intergenic_variant	MODIFIER														rs1031825				SNV																						0.5547	0.4085	0.6902	0.5278	0.7048	0.5297											0.6253	0.4663	0.6611	0.6998	0.6441	0.5101	0.7132	0.6644	0.7019	0.6359	0.5576	0.7132	gnomADg_FIN				26691610&28341840&29121662&33406744&30483659&24997319&32451905&28155888&19083859&27570235&22851935&35318655&37239431&19948332&19948333&38522119																																																																												91					0.956							239.42													chr20	4447483																																																	True	False	False	Unknown		Unknown																						37,50	21,22	16,28	0/1	21,16,28,22	AAC	.	.	.			19,18,24,26	41.68		0.5747126436781609
GRCh38	PAK5	D12_12345_1234556_Thyroid_S9	p.Ile709=	ENSP00000322957.5:p.Ile709=	chr20	9539495	9539495.0	G	A	A	9539495	.	G	A	.	PASS	NM_177990	A	synonymous_variant	LOW	PAK5	ENSG00000101349	Transcript	ENST00000353224	protein_coding	10/10		c.2127C>T	2603	2127	709	I	atC/atT	rs12329540&COSV62022294		-1		SNV	HGNC	HGNC:15916	YES	MANE_Select	NM_177990.4		1	P1	CCDS13107.1	ENSP00000322957	Q9P286.221		UPI0000035BAD						Gene3D:1.10.510.10&PDB-ENSP_mappings:2f57.A&PDB-ENSP_mappings:2f57.B&PDB-ENSP_mappings:8c12.AAA&AFDB-ENSP_mappings:AF-Q9P286-F1&PANTHER:PTHR45832&CDD:cd06658			0.0429	0.0015	0.0735	0	0.1322	0.0297	0.1433	0.02235	0.0524	0.05062	7.557e-05	0.1612	0.02621	0.1679	0.1147	0.03206	0.1042	0.02742	0.2336	0.07568	0.0519	0.0001929	0.1652	0.03061	0.1633	0.08222	0.02903	0.2336	gnomADg_AMI		0&1	0&1																		3.2900e-01																																																											413					0.993							246.16	v6.1	Unknown		True	PAK5, a serine/threonine kinase, is altered by mutation in various cancer types, including melanoma and lung cancers.	False	11/25/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAK5 ENSP00000322957.5:I709= mutant UNKNOWN.	False	The PAK5 ENSP00000322957.5:i709= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr20	9520142						True	False	False	Unknown								False	False		PAK5, a serine/threonine kinase, is altered by mutation in various cancer types, including melanoma and lung cancers.	The PAK5 ENSP00000322957.5:i709= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAK5 ENSP00000322957.5:I709= mutant UNKNOWN.						v6.1	11/25/2019		GRCh38	PAK5	57144.0	ENSP00000322957.5:I709=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PAK5"",""entrezGeneId"":57144,""alteration"":""ENSP00000322957.5:I709="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PAK5, a serine/threonine kinase, is altered by mutation in various cancer types, including melanoma and lung cancers."",""variantSummary"":""The PAK5 ENSP00000322957.5:i709= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAK5 ENSP00000322957.5:I709= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/25/2019""}"	True	True	False	Unknown		Unknown																						229,181	111,78	118,103	0/1	126,103,86,95	CGA	0.00	0.00	0.00			110,119,95,86	21.83		0.44146341463414634
GRCh38	ZNF217	D12_12345_1234556_Thyroid_S9	p.D889G	ENSP00000360526.2:p.Asp889Gly	chr20	53576098	53576098.0	T	C	C	53576098	.	T	C	.	PASS	NM_006526	C	missense_variant	MODERATE	ZNF217	ENSG00000171940	Transcript	ENST00000371471	protein_coding	4/6		c.2666A>G	3092	2666	889	D/G	gAc/gGc	rs34323943&COSV56593639		-1		SNV	HGNC	HGNC:13009	YES	MANE_Select	NM_006526.3		5	P1	CCDS13443.1	ENSP00000360526	O75362.204		UPI000013C323				tolerated(0.21)	benign(0)	PANTHER:PTHR45925&AFDB-ENSP_mappings:AF-O75362-F1			0.0869	0.0023	0.0951	0.0833	0.1203	0.1646	0.1108	0.01625	0.07638	0.07557	0.05081	0.1417	0.1668	0.1127	0.1076	0.1585	0.08794	0.01939	0.09211	0.0897	0.08184	0.07504	0.1369	0.1327	0.1173	0.09074	0.1645	0.1668	gnomADe_MID		0&1	0&1							FAIL	-1	-4	-35	-6	0.00	0.00	0.00	0.00	ZNF217	0.134	2.3700e-01																																																											1184					0.998							246.44	v6.1	Unknown		True	ZNF217, a transcription factor, is altered by amplification in various cancers.	False	11/21/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ZNF217 ENSP00000360526.2:D889G mutant UNKNOWN.	False	The ZNF217 ENSP00000360526.2:d889g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr20	52192637						True	False	False	Unknown								False	False		ZNF217, a transcription factor, is altered by amplification in various cancers.	The ZNF217 ENSP00000360526.2:d889g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ZNF217 ENSP00000360526.2:D889G mutant UNKNOWN.						v6.1	11/21/2023		GRCh38	ZNF217	7764.0	ENSP00000360526.2:D889G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ZNF217"",""entrezGeneId"":7764,""alteration"":""ENSP00000360526.2:D889G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ZNF217, a transcription factor, is altered by amplification in various cancers."",""variantSummary"":""The ZNF217 ENSP00000360526.2:d889g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ZNF217 ENSP00000360526.2:D889G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/21/2023""}"	True	True	False	Unknown		Unknown																						598,584	264,285	334,299	0/1	281,317,283,301	GTC	.	.	.			295,303,300,284	53.61		0.494077834179357
GRCh38	AURKA	D12_12345_1234556_Thyroid_S9	p.I57V	ENSP00000379251.3:p.Ile57Val	chr20	56386407	56386407.0	T	C	C	56386407	.	T	C	.	PASS	NM_198437	C	missense_variant	MODERATE	AURKA	ENSG00000087586	Transcript	ENST00000395915	protein_coding	3/9		c.169A>G	222	169	57	I/V	Att/Gtt	rs1047972&CM051389&COSV100452806		-1		SNV	HGNC	HGNC:11393	YES	MANE_Select	NM_198437.3		1	P1	CCDS13451.1	ENSP00000379251	O14965.248		UPI000013C70F			1	tolerated_low_confidence(1)	benign(0)	AFDB-ENSP_mappings:AF-O14965-F1&PANTHER:PTHR24350&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.8498	0.8298	0.8948	0.877	0.8181	0.8497	0.8438	0.8343	0.9115	0.8584	0.8708	0.8101	0.8355	0.8405	0.8471	0.8578	0.8445	0.838	0.8923	0.8874	0.8652	0.8804	0.8102	0.8844	0.8385	0.8557	0.8554	0.9115	gnomADe_AMR	benign	0&1&1	1&1&1	21514219&18854777&16465622&21050672&35637613&27270838&31521144&34465813&29678897&31636670&25328151&28152093&28155045&29333101&31031846&32231728&33050100&33967624&29122619&28906374&25124567&28424560&31871591&35201446&25253995&26925658&28903390&25452806&30777875&34337875&30093449&24722014&34758846&16412566&37565930&24598702&35961696						FAIL	3	-32	-13	3	0.03	0.00	0.00	0.00	AURKA	0.031	5.2800e-01	3059051	0.83777	0.84819	0.84984	3196767	AURKA-related_disorder		.		NC_000020.11:g.56386407T>C	no_assertion_criteria_provided	Benign			SCV004795994	single_nucleotide_variant	SO:0001483	ClinGen:CA9917486		AURKA:6790&LOC126863064:126863064	SO:0001583&missense_variant										1	1047972																											609					0.989							121.42	v6.1	Unknown		True	AURKA, an intracellular kinase, is altered by mutation, amplification or overexpression in various cancer types including breast and colorectal cancers.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKA ENSP00000379251.3:I57V mutant UNKNOWN.	False	The AURKA ENSP00000379251.3:i57v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr20	54961463						True	False	False	Unknown								False	False		AURKA, an intracellular kinase, is altered by mutation, amplification or overexpression in various cancer types including breast and colorectal cancers.	The AURKA ENSP00000379251.3:i57v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKA ENSP00000379251.3:I57V mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	AURKA	6790.0	ENSP00000379251.3:I57V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""AURKA"",""entrezGeneId"":6790,""alteration"":""ENSP00000379251.3:I57V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""AURKA, an intracellular kinase, is altered by mutation, amplification or overexpression in various cancer types including breast and colorectal cancers."",""variantSummary"":""The AURKA ENSP00000379251.3:i57v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AURKA ENSP00000379251.3:I57V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						277,325	137,151	140,174	0/1	139,138,166,159	ATG	.	.	.			137,140,134,191	40.35		0.5398671096345515
GRCh38		D12_12345_1234556_Thyroid_S9			chr21	15313279	15313279.0	A	G	G	15313279	.	A	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000300143	Transcript	ENST00000769434	lncRNA		3/3	n.387-1925A>G						rs722098		1		SNV			YES																			0.5028	0.8419	0.4669	0.5427	0.1869	0.3538											0.393	0.749	0.2303	0.4366	0.2513	0.5323	0.2912	0.2517	0.1858	0.3521	0.3457	0.8419	AFR				21273692&15660291&21754915&21976407&26522768&26691610&29121662&33406744&34721519&21611176&20850402&19083859&24362753&27294018&17035394&22812491&19948332&19480843																																																																												69					0.986							243.12													chr21	16685598																																																	True	False	False	Unknown		Unknown																						39,29	15,17	24,12	0/1	22,17,12,17	GAT	.	.	.			18,21,12,17	27.51		0.4264705882352941
GRCh38		D12_12345_1234556_Thyroid_S9			chr21	25933100		T	[chr10:85370662[T	[chr10:85370662[T	25933100	MantaBND:11363:0:1:0:0:0:0	T	[chr10:85370662[T	.	PASS		.T	upstream_gene_variant	MODIFIER		ENSG00000233783	Transcript	ENST00000786111	lncRNA										979	1		chromosome_breakpoint			YES																																																																																																																											6			0,5							5	CTTTT			MantaBND:11363:0:1:0:0:0:1	0														chr21	27305413				BND																																													True	False	False	Unknown		Unknown																															1,1				3,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr21	27235844	27235844.0	A	G	G	27235844	.	A	G	.	PASS		G	downstream_gene_variant	MODIFIER		ENSG00000296857	Transcript	ENST00000743057	lncRNA									rs2830795	3010	1		SNV																						0.2831	0.1112	0.2579	0.5198	0.2893	0.2832											0.2376	0.125	0.182	0.2547	0.3919	0.5194	0.1986	0.2857	0.2769	0.263	0.268	0.5198	EAS				26522768&26691610&29121662&33406744&34721519&33857205&22851935&34302344&32884502&37239431&19948332&19083752																																																																												111					1							248.34													chr21	28608163																																																	True	False	False	Unknown		Unknown																						0,111	0,64	0,47	0/1	0,0,58,53	GAG	.	.	.			0,0,45,66	64.7		1.0
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38380033	38380033.0	G	A	A	38380033	.	G	A	.	PASS	NM_182918	A	downstream_gene_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding									rs2836352	3	-1		SNV	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.1797	0.0613	0.134	0.1925	0.1948	0.3436	0.1909	0.07663	0.1511	0.1693	0.1558	0.1301	0.1956	0.1915	0.2008	0.2935	0.1626	0.08892	0.2648	0.1501	0.1631	0.2008	0.17	0.1361	0.1942	0.1701	0.3124	0.3436	SAS										FAIL	5	-8	4	-1	0.00	0.00	0.00	0.00	ERG																																																													344					0.983							247.36													chr21	39751955																																																	True	True	False	Unknown		Unknown																						177,161	81,73	96,88	0/1	96,81,70,91	TGT	0.00	0.00	0.00			122,55,112,49	34.69		0.47633136094674555
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38380751	38380751.0	C	T	T	38380751	.	C	T	.	PASS	NM_182918	T	3_prime_UTR_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding	10/10		c.*2652G>A	4189					rs6517463		-1		SNV	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.3834	0.4811	0.2839	0.4127	0.2813	0.3967	0.2546	0.466	0.3136	0.2392	0.3485	0.2575	0.2888	0.2445	0.285	0.3469	0.3213	0.4534	0.3451	0.2971	0.2297	0.4198	0.2522	0.25	0.2509	0.3171	0.3691	0.4811	AFR										FAIL	-6	36	-5	45	0.00	0.00	0.00	0.00	ERG		2.3400e-01																																																											173					0.896							237.03													chr21	39752673																																																	True	True	False	Unknown		Unknown																						72,83	32,33	40,50	0/1	35,37,41,42	ACT	0.00	0.00	0.00			35,37,49,34	41.9		0.535483870967742
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38380799	38380804.0	GAATAT	G	G	38380799	.	GAATAT	G	.	PASS	NM_182918	-	3_prime_UTR_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding	10/10		c.*2599_*2603del	4136-4140					rs10546014&COSV55728528		-1		deletion	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.3834	0.4811	0.2839	0.4127	0.2813	0.3967	0.2545	0.4661	0.315	0.2392	0.348	0.2575	0.2885	0.2443	0.2848	0.3465	0.32	0.451	0.3425	0.2961	0.2297	0.4163	0.2505	0.2483	0.2504	0.3168	0.368	0.4811	AFR		0&1	0&1																		2.3400e-01																																																											192					0.948							243.82													chr21	39752721																																																	True	True	False	Unknown		Unknown																						79,103	40,45	39,58	0/1	33,46,51,52	TGA						36,43,49,54	46.79		0.5659340659340659
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38381424	38381424.0	A	C	C	38381424	.	A	C	.	PASS	NM_182918	C	3_prime_UTR_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding	10/10		c.*1979T>G	3516					rs2836353		-1		SNV	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.1771	0.059	0.1311	0.1935	0.1909	0.3384	0.1879	0.07636	0.1436	0.1561	0.1494	0.1303	0.1907	0.1895	0.1943	0.288	0.1595	0.08645	0.2664	0.1481	0.1486	0.2005	0.1597	0.1361	0.192	0.1701	0.3065	0.3384	SAS										FAIL	-1	-34	-34	4	0.00	0.00	0.00	0.00	ERG		2.3400e-01																																																											282					0.996							245.63													chr21	39753346																																																	True	True	False	Unknown		Unknown																						124,157	51,69	73,88	0/1	74,50,81,76	GAT	.	.	.			55,69,63,94	51.89		0.5587188612099644
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38381453	38381453.0	T	C	C	38381453	.	T	C	.	PASS	NM_182918	C	3_prime_UTR_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding	10/10		c.*1950A>G	3487					rs2836354		-1		SNV	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.3894	0.4834	0.2911	0.4147	0.2932	0.4049	0.2666	0.4686	0.324	0.2417	0.3516	0.2651	0.2975	0.2571	0.2968	0.354	0.329	0.4555	0.3469	0.3044	0.2326	0.4238	0.2593	0.2551	0.2628	0.3256	0.375	0.4834	AFR										FAIL	29	-12	-43	20	0.00	0.00	0.00	0.00	ERG		2.3400e-01																																																											249					0.996							245.67													chr21	39753375																																																	True	True	False	Unknown		Unknown																						102,146	41,70	61,76	0/1	55,47,78,68	GTG	.	.	.			38,64,56,90	47.03		0.5887096774193549
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38471160	38471160.0	G	A	A	38471160	.	G	A	.	PASS	NM_182918	A	intron_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding		1/9	c.19-25539C>T						rs2836427		-1		SNV	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.1352	0.0817	0.1124	0.251	0.1083	0.1319											0.118	0.08406	0.01206	0.139	0.08329	0.2697	0.09261	0.06463	0.1293	0.1098	0.1285	0.2697	gnomADg_EAS			1	32888494						FAIL	-33	-35	39	-3	0.00	0.00	0.00	0.00	ERG		2.3400e-01																																																											186					0.984							244.79													chr21	39843083																																																	True	True	False	Unknown		Unknown																						99,84	48,51	51,33	0/1	45,54,45,39	AGT	0.00	0.00	0.00			42,57,38,46	30.73		0.45901639344262296
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38471469	38471469.0	C	T	T	38471469	.	C	T	.	PASS	NM_182918	T	intron_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding		1/9	c.19-25848G>A						rs9977083		-1		SNV	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.7648	0.6687	0.817	0.8681	0.7744	0.7413	1							1	1		0.7583	0.6934	0.6476	0.7736	0.8232	0.8894	0.7473	0.7721	0.7849	0.7703	0.7464	1	gnomADe_NFE&gnomADe_REMAINING										FAIL	-29	28	-5	-32	0.00	0.00	0.00	0.00	ERG		2.3400e-01																																																											128					0.984							243.17													chr21	39843392																																																	True	True	False	Unknown		Unknown																						0,126	0,69	0,57	0/1	0,0,62,64	ACA	0.00	0.00	0.00			0,0,63,63	64.71		1.0
GRCh38	ERG	D12_12345_1234556_Thyroid_S9			chr21	38498386	38498386.0	G	A	A	38498386	.	G	A	.	PASS	NM_182918	A	5_prime_UTR_variant	MODIFIER	ERG	ENSG00000157554	Transcript	ENST00000288319	protein_coding	1/10		c.-6C>T	92					rs2836441		-1		SNV	HGNC	HGNC:3446	YES	MANE_Select	NM_182918.4		1	P4	CCDS13658.1	ENSP00000288319	P11308.230		UPI0000074389	P11308-4		1						0.8908	0.9546	0.8444	0.8442	0.8887	0.8875	0.8606	0.9462	0.8105	0.9368	0.8062	0.8997	0.929	0.8551	0.8744	0.8876	0.8843	0.9444	0.9868	0.823	0.9372	0.8121	0.9005	0.9456	0.8592	0.8949	0.8909	0.9868	gnomADg_AMI			1	32467347&27863252						FAIL	-14	7	50	-23	0.00	0.00	0.00	0.04	ERG		2.3400e-01																																																											184					0.967							246.85													chr21	39870310																																																	True	True	False	Unknown		Unknown																						83,95	37,50	46,45	0/1	41,42,51,44	CGA	0.00	0.00	0.00			49,34,58,37	43.3		0.5337078651685393
GRCh38	TMPRSS2	D12_12345_1234556_Thyroid_S9			chr21	41507982	41507982.0	C	A	A	41507982	.	C	A	.	PASS	NM_005656	A	intron_variant	MODIFIER	TMPRSS2	ENSG00000184012	Transcript	ENST00000332149	protein_coding		1/13	c.-57+99G>T						rs75603675&COSV59827803		-1		SNV	HGNC	HGNC:11876	YES	MANE_Select	NM_005656.4		1	P1	CCDS33564.1	ENSP00000330330	O15393.210		UPI0000049921	O15393-1		1						0.2438	0.295	0.2723	0.0169	0.4046	0.2229	0.3835	0.3387	0.2774	0.3615	0.008322	0.3938	0.3839	0.4073	0.3586	0.2487	0.3592	0.3296	0.5121	0.3138	0.3752	0.01432	0.3923	0.4178	0.4142	0.3545	0.2397	0.5121	gnomADg_AMI	benign	0&1	1&1	35327350&35793369&35987511&33101356&32410502&32664879&34588322&35811452&32691890&35636966&35963158&37055652&36146782&33358483&33655087&33966626&36457338&32867305&35337605&30680235&34223911&34530086&34230933&35580180&37240057&35714803&34016183&34341784&33707363&35386063&34425415&34402498&33375616&33143053&34248311&36532428&34339474&35939103&34001248&32861340&35022007&34553696&37809329&37452704&37795240&37567834&38754620&38420467&38601158						FAIL	-17	0	-32	1	0.00	0.00	0.01	0.00	TMPRSS2		9.9100e-01	1273671		0.35752	0.24381	1264217	not_provided		MedGen:C3661900		NC_000021.9:g.41507982C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001902460&SCV005310656	single_nucleotide_variant	SO:0001483	ClinGen:CA10034943		TMPRSS2:7113&LOC117134604:117134604	SO:0001583&missense_variant&SO:0001627&intron_variant										1	75603675																											384					0.995							245.62													chr21	42879909																																																	True	True	False	Unknown		Unknown																						187,195	105,96	82,99	0/1	89,98,92,103	ACC	0.00	0.00	0.00			93,94,89,106	46.05		0.5104712041884817
GRCh38		D12_12345_1234556_Thyroid_S9			chr21	42186887	42186887.0	T	C	C	42186887	.	T	C	.	PASS		C	intergenic_variant	MODIFIER														rs221956				SNV																						0.6342	0.6505	0.647	0.5853	0.6899	0.5961											0.6675	0.6509	0.6579	0.6623	0.6202	0.5819	0.6264	0.6463	0.6984	0.6703	0.6104	0.6984	gnomADg_NFE				26691610&29121662&33406744&33857205&33546406																																																																												773					0.978							241.59													chr21	43606997																																																	True	False	False	Unknown		Unknown																						0,756	0,424	0,332	0/1	0,0,394,362	ATT	.	.	.			0,0,412,344	64.73		1.0
GRCh38	ICOSLG	D12_12345_1234556_Thyroid_S9			chr21	44229895	44229895.0	A	G	G	44229895	.	A	G	.	PASS	NM_015259	G	intron_variant	MODIFIER	ICOSLG	ENSG00000160223	Transcript	ENST00000407780	protein_coding		6/6	c.898+159T>C						rs4568033&COSV60263272		-1		SNV	HGNC	HGNC:17087	YES	MANE_Select	NM_015259.6		1	A2	CCDS42952.1	ENSP00000384432	O75144.205	A0N0L8.140	UPI0000049DCB	O75144-1								0.7069	0.7988	0.6744	0.5774	0.7018	0.7444	0.04145	0.3541	0.046	0.05486	0.09563	0.02322	0.0428	0.007776	0.06084	0.3072	0.09273	0.3163	0	0.03779	0.03285	0.02077	0.002024	0.08421	0.006977	0.06667	0.1976	0.7988	AFR		0&1	0&1							FAIL	27	-15	-42	8	0.00	0.00	0.00	0.01	ICOSLG																																																													957					0.998							247.03													chr21	45649778																																																	True	True	False	Unknown		Unknown																						490,465	232,246	258,219	0/1	256,234,244,221	CAT	.	.	.			240,250,233,232	44.11		0.4869109947643979
GRCh38	ICOSLG	D12_12345_1234556_Thyroid_S9			chr21	44229965	44229965.0	T	C	C	44229965	.	T	C	.	PASS	NM_015259	C	intron_variant	MODIFIER	ICOSLG	ENSG00000160223	Transcript	ENST00000407780	protein_coding		6/6	c.898+89A>G						rs13052840&COSV60263420		-1		SNV	HGNC	HGNC:17087	YES	MANE_Select	NM_015259.6		1	A2	CCDS42952.1	ENSP00000384432	O75144.205	A0N0L8.140	UPI0000049DCB	O75144-1								0.6228	0.6188	0.6744	0.5665	0.7117	0.5583	0.0698	0.1666	0.1183	0.04523	0.161	0.1589	0.02475	0.05795	0.0686	0.07767	0.02855	0.0463	0.04412	0.02188	0.006208	0.02955	0.03409	0.005618	0.02152	0.02643	0.01641	0.7117	EUR		0&1	0&1							FAIL	-1	-4	-1	-3	0.10	0.01	0.00	0.00	ICOSLG																																																													861					0.997							247.33													chr21	45649848																																																	True	True	False	Unknown		Unknown																						451,407	223,218	228,189	0/1	250,201,209,198	TTT	.	.	.			232,219,210,197	33.89		0.47435897435897434
GRCh38	LZTR1	D12_12345_1234556_Thyroid_S9	p.Lys70=	ENSP00000496779.1:p.Lys70=	chr22	20983036	20983036.0	G	A	A	20983036	.	G	A	.	PASS	NM_006767	A	synonymous_variant	LOW	LZTR1	ENSG00000099949	Transcript	ENST00000646124	protein_coding	2/21		c.210G>A	285	210	70	K	aaG/aaA	rs13054014&COSV53147463		1		SNV	HGNC	HGNC:6742	YES	MANE_Select	NM_006767.4			P1	CCDS33606.1	ENSP00000496779	Q8N653.174	A0A384NL67.24	UPI000013C695			1			Gene3D:2.120.10.80&Superfamily:SSF117281&PANTHER:PTHR46376&AFDB-ENSP_mappings:AF-Q8N653-F1			0.2851	0.2443	0.3444	0.2014	0.2594	0.411	0.2675	0.2495	0.4012	0.2233	0.2049	0.248	0.231	0.2615	0.2663	0.3394	0.2666	0.2524	0.2303	0.3329	0.2163	0.2114	0.2465	0.2021	0.2657	0.2656	0.342	0.411	SAS	benign	0&1	1&1	29469822						FAIL	8	-3	-9	9	0.00	0.01	0.00	0.00	LZTR1		1.9970e+00	379392	0.26234	0.28495	0.28514	378707	not_specified&Hereditary_cancer-predisposing_syndrome&Cardiovascular_phenotype&not_provided		MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN230736&MedGen:C3661900		NC_000022.11:g.20983036G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000516280&SCV001363694&SCV001365804&SCV001727274&SCV002729758&SCV005276926	single_nucleotide_variant	SO:0001483	ClinGen:CA10118311		LZTR1:8216	SO:0001819&synonymous_variant										1	13054014																											642					0.997							247.26	v6.1	Unknown		True	LZTR1, a ubiquitin ligase adaptor protein, is recurrently altered by mutation in glioblastoma, Noonan syndrome, and schwannomatosis.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LZTR1 ENSP00000496779.1:K70= mutant UNKNOWN.	False	The LZTR1 ENSP00000496779.1:k70= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr22	21337325						True	False	False	Unknown								False	False		LZTR1, a ubiquitin ligase adaptor protein, is recurrently altered by mutation in glioblastoma, Noonan syndrome, and schwannomatosis.	The LZTR1 ENSP00000496779.1:k70= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LZTR1 ENSP00000496779.1:K70= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	LZTR1	8216.0	ENSP00000496779.1:K70=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""LZTR1"",""entrezGeneId"":8216,""alteration"":""ENSP00000496779.1:K70="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""LZTR1, a ubiquitin ligase adaptor protein, is recurrently altered by mutation in glioblastoma, Noonan syndrome, and schwannomatosis."",""variantSummary"":""The LZTR1 ENSP00000496779.1:k70= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with LZTR1 ENSP00000496779.1:K70= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						368,272	200,135	168,137	0/1	175,193,124,148	AGC	0.00	0.00	0.00			183,185,151,121	12.37		0.425
GRCh38	BCR	D12_12345_1234556_Thyroid_S9	p.N796S	ENSP00000303507.8:p.Asn796Ser	chr22	23285182	23285182.0	A	G	G	23285182	.	A	G	.	PASS	NM_004327	G	missense_variant	MODERATE	BCR	ENSG00000186716	Transcript	ENST00000305877	protein_coding	10/23		c.2387A>G	2839	2387	796	N/S	aAt/aGt	rs140504&CM057927&COSV59932309		1		SNV	HGNC	HGNC:1014	YES	MANE_Select	NM_004327.4		1	P1	CCDS13806.1	ENSP00000303507	P11274.254		UPI000016A088	P11274-1		1	tolerated_low_confidence(0.7)	benign(0)	PDB-ENSP_mappings:5oc7.A&PDB-ENSP_mappings:5oc7.D&Coiled-coils_(Ncoils):Coil&PANTHER:PTHR23182&CDD:cd13367&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00233&Superfamily:SSF50729&Gene3D:2.30.29.30&PROSITE_profiles:PS50003&AFDB-ENSP_mappings:AF-P11274-F1			0.7937	0.9501	0.8573	0.5377	0.8748	0.7178	0.8336	0.9402	0.8223	0.8812	0.5147	0.8442	0.8531	0.849	0.8204	0.7337	0.857	0.936	0.7248	0.853	0.8859	0.5186	0.8451	0.8733	0.8468	0.8543	0.7271	0.9501	AFR	benign	0&1&1	1&1&1	32747715&27748288&17822820&15866548&18082628						FAIL	-1	-7	19	17	0.00	0.00	0.00	0.00	BCR	0.098	6.0800e-01	1182413	0.87736	0.81864	0.79373	1173454	not_provided		MedGen:C3661900		NC_000022.11:g.23285182A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001757876&SCV005276992	single_nucleotide_variant	SO:0001483	ClinGen:CA10142571		BCR:613	SO:0001583&missense_variant										1	140504																											628					0.995							247.22	v6.1	Unknown		True	BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies.	False	07/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:N796S mutant UNKNOWN.	False	The BCR ENSP00000303507.8:n796s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr22	23627369						True	False	False	Unknown								False	False		BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies.	The BCR ENSP00000303507.8:n796s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:N796S mutant UNKNOWN.						v6.1	07/23/2018		GRCh38	BCR	613.0	ENSP00000303507.8:N796S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCR"",""entrezGeneId"":613,""alteration"":""ENSP00000303507.8:N796S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies."",""variantSummary"":""The BCR ENSP00000303507.8:n796s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:N796S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2018""}"	True	True	False	Unknown		Unknown																						0,625	0,275	0,350	0/1	0,0,339,286	AAT	.	.	.			0,0,257,368	64.73		1.0
GRCh38	BCR	D12_12345_1234556_Thyroid_S9			chr22	23290146	23290146.0	G	A	A	23290146	.	G	A	.	PASS	NM_004327	A	intron_variant	MODIFIER	BCR	ENSG00000186716	Transcript	ENST00000305877	protein_coding		13/22	c.2708-193G>A						rs140506		1		SNV	HGNC	HGNC:1014	YES	MANE_Select	NM_004327.4		1	P1	CCDS13806.1	ENSP00000303507	P11274.254		UPI000016A088	P11274-1		1						0.9898	0.9977	0.9899	1	0.9652	0.9939	0.9641	0.9912	0.989	0.9557	0.9999	0.9686	0.9814	0.952	0.9644	0.9873	0.9712	0.9907	0.9055	0.9863	0.9574	1	0.9709	0.9898	0.9536	0.9773	0.9917	1	EAS&gnomADg_EAS				37302352						FAIL	26	1	37	1	0.00	0.01	0.01	0.00	BCR		6.0800e-01																																																											651					0.997							246.23													chr22	23632333																																																	True	True	False	Unknown		Unknown																						0,649	0,349	0,300	0/1	0,0,305,344	AGC	0.00	0.00	0.00			0,0,337,312	64.73		1.0
GRCh38	BCR	D12_12345_1234556_Thyroid_S9			chr22	23290478	23290478.0	C	A	A	23290478	.	C	A	.	PASS	NM_004327	A	intron_variant	MODIFIER	BCR	ENSG00000186716	Transcript	ENST00000305877	protein_coding		14/22	c.2782+65C>A						rs131677&COSV59935579		1		SNV	HGNC	HGNC:1014	YES	MANE_Select	NM_004327.4		1	P1	CCDS13806.1	ENSP00000303507	P11274.254		UPI000016A088	P11274-1		1						0.6903	0.9017	0.7536	0.4048	0.7644	0.5777	0.7182	0.8884	0.7322	0.7693	0.3993	0.782	0.7765	0.7295	0.7106	0.6056	0.7637	0.8803	0.6068	0.7642	0.7667	0.3866	0.7829	0.7857	0.731	0.7692	0.6025	0.9017	AFR		0&1	0&1							FAIL	25	-8	5	10	0.00	0.00	0.00	0.00	BCR		6.0800e-01																																																											940					0.998							245.22													chr22	23632665																																																	True	True	False	Unknown		Unknown																						0,938	0,428	0,510	0/1	0,0,465,473	TCA	0.00	0.00	0.00			0,0,491,447	64.73		1.0
GRCh38	BCR	D12_12345_1234556_Thyroid_S9			chr22	23291065	23291065.0	G	A	A	23291065	.	G	A	.	PASS	NM_004327	A	intron_variant	MODIFIER	BCR	ENSG00000186716	Transcript	ENST00000305877	protein_coding		14/22	c.2782+652G>A						rs131678		1		SNV	HGNC	HGNC:1014	YES	MANE_Select	NM_004327.4		1	P1	CCDS13806.1	ENSP00000303507	P11274.254		UPI000016A088	P11274-1		1						0.7911	0.7973	0.8012	0.9663	0.6958	0.6933	0.6675	1	0.7288	1	1	0.8333		0.6431	0.6667	0.5741	0.7441	0.7739	0.6784	0.7926	0.6178	0.97	0.8216	0.6701	0.6969	0.7249	0.7034	1	gnomADe_AFR&gnomADe_ASJ&gnomADe_EAS										FAIL	2	-39	-39	-7	0.00	0.00	0.00	0.00	BCR		6.0800e-01																																																											403					1							204.5													chr22	23633252																																																	True	True	False	Unknown		Unknown																						0,403	0,185	0,218	0/1	0,0,195,208	CGG	0.00	0.00	0.00			0,0,233,170	64.73		1.0
GRCh38	BCR	D12_12345_1234556_Thyroid_S9	p.A1204G	ENSP00000303507.8:p.Ala1204Gly	chr22	23314599	23314599.0	C	G	G	23314599	.	C	G	.	PASS	NM_004327	G	missense_variant	MODERATE	BCR	ENSG00000186716	Transcript	ENST00000305877	protein_coding	22/23		c.3611C>G	4063	3611	1204	A/G	gCc/gGc	rs56265970&COSV59925974		1		SNV	HGNC	HGNC:1014	YES	MANE_Select	NM_004327.4		1	P1	CCDS13806.1	ENSP00000303507	P11274.254		UPI000016A088	P11274-1		1	deleterious_low_confidence(0)	possibly_damaging(0.624)	PANTHER:PTHR23182&CDD:cd04387&Phobius:CYTOPLASMIC_DOMAIN&SMART:SM00324&Superfamily:SSF48350&Gene3D:1.10.555.10&Pfam:PF00620&PROSITE_profiles:PS50238&AFDB-ENSP_mappings:AF-P11274-F1			0.0300	0.0401	0.0231	0.0208	0.0209	0.0399	0.0009793	0.002586	0.0001604	0.0003141	0.0001782	5.676e-05	0.001259	0.001071	0.000977	0.0007846	6.572e-06	0	0	0	0	0	0	0	1.47e-05	0	0	0.0401	AFR		0&1	0&1	35040003						FAIL	-47	-34	-1	4	0.00	0.00	0.00	0.00	BCR	0.250	6.0800e-01																																																											823					0.981							90.78	v6.1	Unknown		True	BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies.	False	07/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:A1204G mutant UNKNOWN.	False	The BCR ENSP00000303507.8:a1204g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr22	23656786						True	False	False	Unknown								False	False		BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies.	The BCR ENSP00000303507.8:a1204g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:A1204G mutant UNKNOWN.						v6.1	07/23/2018		GRCh38	BCR	613.0	ENSP00000303507.8:A1204G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCR"",""entrezGeneId"":613,""alteration"":""ENSP00000303507.8:A1204G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies."",""variantSummary"":""The BCR ENSP00000303507.8:a1204g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:A1204G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2018""}"	True	True	False	Unknown		Unknown																						790,17	391,11	399,6	0|1	409,381,9,8	GCC	.	.	.		23656786	444,346,9,8	3.19		0.021065675340768277
GRCh38	BCR	D12_12345_1234556_Thyroid_S9	p.Thr1205=	ENSP00000303507.8:p.Thr1205=	chr22	23314603	23314603.0	G	A	A	23314603	.	G	A	.	PASS	NM_004327	A	synonymous_variant	LOW	BCR	ENSG00000186716	Transcript	ENST00000305877	protein_coding	22/23		c.3615G>A	4067	3615	1205	T	acG/acA	rs56365112&COSV59925978		1		SNV	HGNC	HGNC:1014	YES	MANE_Select	NM_004327.4		1	P1	CCDS13806.1	ENSP00000303507	P11274.254		UPI000016A088	P11274-1		1			PANTHER:PTHR23182&CDD:cd04387&Phobius:CYTOPLASMIC_DOMAIN&SMART:SM00324&Superfamily:SSF48350&Gene3D:1.10.555.10&Pfam:PF00620&PROSITE_profiles:PS50238&AFDB-ENSP_mappings:AF-P11274-F1									0.001034	0.003207	0.0002292	0.0003533	0.0001782	5.676e-05	0.00126	0.001109	0.001028	0.0008932	0.0003421	0.001183	0	6.569e-05	0	0	0	0	2.941e-05	0	0	0.003207	gnomADe_AFR		0&1	0&1							FAIL	2	37	2	0	0.05	0.00	0.00	0.00	BCR		6.0800e-01																																																											829					0.982							89.6	v6.1	Unknown		True	BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies.	False	07/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:T1205= mutant UNKNOWN.	False	The BCR ENSP00000303507.8:t1205= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr22	23656790						True	False	False	Unknown								False	False		BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies.	The BCR ENSP00000303507.8:t1205= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:T1205= mutant UNKNOWN.						v6.1	07/23/2018		GRCh38	BCR	613.0	ENSP00000303507.8:T1205=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCR"",""entrezGeneId"":613,""alteration"":""ENSP00000303507.8:T1205="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCR, a signaling molecule, is recurrently altered by chromosomal rearrangement in chronic myeloid leukemia and other hematopoietic malignancies."",""variantSummary"":""The BCR ENSP00000303507.8:t1205= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCR ENSP00000303507.8:T1205= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2018""}"	True	True	False	Unknown		Unknown																						797,17	398,11	399,6	0|1	392,405,9,8	CGG	0.00	0.00	1.00		23656786	447,350,11,6	3.3		0.020884520884520884
GRCh38	LMCD1-AS1	D12_12345_1234556_Thyroid_S9			chr3	8575021	8575023.0	A	AAG	AAG	8575021	.	A	AAG	.	PASS		AG	intron_variant&non_coding_transcript_variant	MODIFIER	LMCD1-AS1	ENSG00000227110	Transcript	ENST00000819960	lncRNA		4/4	n.848-1149_848-1148dup						rs2308242		-1		insertion	HGNC	HGNC:44477																				0.7270	0.6089	0.7767	0.745	0.7972	0.7607											0.7503	0.6461	0.8967	0.8014	0.7739	0.7554	0.8184	0.7925	0.7878	0.7576	0.7492	0.8967	gnomADg_AMI				33801242																																																																												680					0.978							244.53													chr3	8616707																																																	True	False	False	Unknown		Unknown																						320,345	164,168	156,177	0/1	146,174,185,160	AAA						186,134,184,161	56.79		0.518796992481203
GRCh38	FANCD2	D12_12345_1234556_Thyroid_S9	p.Val374=	ENSP00000502379.1:p.Val374=	chr3	10043852	10043852.0	A	G	G	10043852	.	A	G	.	PASS	NM_001018115	G	synonymous_variant	LOW	FANCD2	ENSG00000144554	Transcript	ENST00000675286	protein_coding	14/44		c.1122A>G	1192	1122	374	V	gtA/gtG	rs34046352&COSV55037937		1		SNV	HGNC	HGNC:3585	YES	MANE_Select	NM_001018115.3			P2	CCDS33696.1	ENSP00000502379	Q9BXW9.198		UPI000006CD51	Q9BXW9-2		1			PDB-ENSP_mappings:6vaa.B&PDB-ENSP_mappings:6vad.B&PDB-ENSP_mappings:6vae.B&PDB-ENSP_mappings:6vaf.B&PDB-ENSP_mappings:7ay1.B&PDB-ENSP_mappings:7kzq.V&PDB-ENSP_mappings:7kzr.V&PDB-ENSP_mappings:7kzs.V&PDB-ENSP_mappings:7kzt.V&PDB-ENSP_mappings:7kzv.V&PDB-ENSP_mappings:7zf1.B&PDB-ENSP_mappings:8a9j.B&PDB-ENSP_mappings:8a9k.B&PANTHER:PTHR32086&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF14631&CDD:cd11721&AFDB-ENSP_mappings:AF-Q9BXW9-F1									0.09981	0.3005	0.1231	0.1166	0.04706	0.1066	0.1214	0.09062	0.1172	0.1306	0.193	0.3353	0.2352	0.1406	0.1415	0.06032	0.1081	0.113	0.1482	0.1705	0.1477	0.3353	gnomADg_AFR	benign	0&1	1&1	25741868						FAIL	8	-23	12	-3	0.00	0.00	0.00	0.00	FANCD2		7.7700e-01	257065		0.12393		250831	Fanconi_anemia_complementation_group_A&Fanconi_anemia_complementation_group_D2&not_provided&Hereditary_breast_ovarian_cancer_syndrome&not_specified&Fanconi_anemia		MONDO:MONDO:0009215&MedGen:C3469521&OMIM:227650&Orphanet:84&MONDO:MONDO:0009214&MedGen:C3160738&OMIM:227646&Orphanet:84&MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MedGen:CN169374&MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84		NC_000003.12:g.10043852A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000305855&SCV000439467&SCV000603567&SCV000752016&SCV001136293&SCV001832741&SCV002070977&SCV002505190&SCV004017630&SCV005238714	single_nucleotide_variant	SO:0001483	ClinGen:CA2249503		FANCD2:2177&LOC107303338:107303338	SO:0001819&synonymous_variant										1	34046352																											75					0.653							54.45	v6.1	Unknown		True	FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:V374= mutant UNKNOWN.	False	The FANCD2 ENSP00000502379.1:v374= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	10085536						True	False	False	Unknown								False	False		FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia.	The FANCD2 ENSP00000502379.1:v374= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:V374= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	FANCD2	2177.0	ENSP00000502379.1:V374=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FANCD2"",""entrezGeneId"":2177,""alteration"":""ENSP00000502379.1:V374="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia."",""variantSummary"":""The FANCD2 ENSP00000502379.1:v374= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:V374= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						40,9	20,5	20,4	0/1	19,21,4,5	TAT	.	.	.			17,23,0,9	10.16		0.1836734693877551
GRCh38	FANCD2	D12_12345_1234556_Thyroid_S9	p.Ser390=	ENSP00000502379.1:p.Ser390=	chr3	10046615	10046615.0	C	T	T	10046615	.	C	T	.	PASS	NM_001018115	T	synonymous_variant	LOW	FANCD2	ENSG00000144554	Transcript	ENST00000675286	protein_coding	15/44		c.1170C>T	1240	1170	390	S	agC/agT	rs112887807&COSV55040833		1		SNV	HGNC	HGNC:3585	YES	MANE_Select	NM_001018115.3			P2	CCDS33696.1	ENSP00000502379	Q9BXW9.198		UPI000006CD51	Q9BXW9-2		1			PDB-ENSP_mappings:6vaa.B&PDB-ENSP_mappings:6vad.B&PDB-ENSP_mappings:6vae.B&PDB-ENSP_mappings:6vaf.B&PDB-ENSP_mappings:7ay1.B&PDB-ENSP_mappings:7kzq.V&PDB-ENSP_mappings:7kzr.V&PDB-ENSP_mappings:7kzs.V&PDB-ENSP_mappings:7kzt.V&PDB-ENSP_mappings:7kzv.V&PDB-ENSP_mappings:7zf1.B&PDB-ENSP_mappings:8a9j.B&PDB-ENSP_mappings:8a9k.B&PANTHER:PTHR32086&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF14631&CDD:cd11721&AFDB-ENSP_mappings:AF-Q9BXW9-F1									0.3644	0.4162	0.2618	0.3775	0.3054	0.4416	0.401	0.3734	0.3771	0.2174	0.4578	0.4776	0.4392	0.4184	0.4547	0.4073	0.4613	0.4615	0.4615	0.4518	0.4065	0.4776	gnomADg_AFR	benign&likely_benign	0&1	1&1							FAIL	13	0	-35	20	0.00	0.16	0.00	0.00	FANCD2		7.7700e-01	342261		0.43038		291535	Fanconi_anemia&Hereditary_breast_ovarian_cancer_syndrome&not_provided&Fanconi_anemia_complementation_group_D2		MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MedGen:C3661900&MONDO:MONDO:0009214&MedGen:C3160738&OMIM:227646&Orphanet:84		NC_000003.12:g.10046615C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000439470&SCV000603575&SCV000751969&SCV002505193&SCV005262577	single_nucleotide_variant	SO:0001483	ClinGen:CA2249538		FANCD2:2177&LOC107303338:107303338	SO:0001819&synonymous_variant										1	112887807																											138					0.884							136.49	v6.1	Unknown		True	FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:S390= mutant UNKNOWN.	False	The FANCD2 ENSP00000502379.1:s390= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	10088299						True	False	False	Unknown								False	False		FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia.	The FANCD2 ENSP00000502379.1:s390= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:S390= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	FANCD2	2177.0	ENSP00000502379.1:S390=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FANCD2"",""entrezGeneId"":2177,""alteration"":""ENSP00000502379.1:S390="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia."",""variantSummary"":""The FANCD2 ENSP00000502379.1:s390= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:S390= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						100,22	42,13	58,9	0|1	47,53,11,11	GCA	0.00	0.00	1.00		10088299	51,49,12,10	4.71		0.18032786885245902
GRCh38	FANCD2	D12_12345_1234556_Thyroid_S9	p.Thr393=	ENSP00000502379.1:p.Thr393=	chr3	10046624	10046624.0	T	C	C	10046624	.	T	C	.	PASS	NM_001018115	C	synonymous_variant	LOW	FANCD2	ENSG00000144554	Transcript	ENST00000675286	protein_coding	15/44		c.1179T>C	1249	1179	393	T	acT/acC	rs72492998&COSV55032659		1		SNV	HGNC	HGNC:3585	YES	MANE_Select	NM_001018115.3			P2	CCDS33696.1	ENSP00000502379	Q9BXW9.198		UPI000006CD51	Q9BXW9-2		1			PDB-ENSP_mappings:6vaa.B&PDB-ENSP_mappings:6vad.B&PDB-ENSP_mappings:6vae.B&PDB-ENSP_mappings:6vaf.B&PDB-ENSP_mappings:7ay1.B&PDB-ENSP_mappings:7kzq.V&PDB-ENSP_mappings:7kzr.V&PDB-ENSP_mappings:7kzs.V&PDB-ENSP_mappings:7kzt.V&PDB-ENSP_mappings:7kzv.V&PDB-ENSP_mappings:7zf1.B&PDB-ENSP_mappings:8a9j.B&PDB-ENSP_mappings:8a9k.B&PANTHER:PTHR32086&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF14631&CDD:cd11721&AFDB-ENSP_mappings:AF-Q9BXW9-F1									0.3844	0.4322	0.2866	0.393	0.3148	0.447	0.4127	0.3937	0.3938	0.2536	0.4585	0.478	0.4405	0.4197	0.4559	0.4085	0.4618	0.4624	0.4621	0.4517	0.4088	0.478	gnomADg_AFR	benign&likely_benign	0&1	1&1							FAIL	-9	24	-9	24	0.05	0.00	0.00	0.00	FANCD2		7.7700e-01	342262		0.43314		291537	Fanconi_anemia&Fanconi_anemia_complementation_group_A&Hereditary_breast_ovarian_cancer_syndrome&not_provided&Fanconi_anemia_complementation_group_D2		MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MONDO:MONDO:0009215&MedGen:C3469521&OMIM:227650&Orphanet:84&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MedGen:C3661900&MONDO:MONDO:0009214&MedGen:C3160738&OMIM:227646&Orphanet:84		NC_000003.12:g.10046624T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000439471&SCV000603576&SCV000751970&SCV001136297&SCV002505195&SCV005262578	single_nucleotide_variant	SO:0001483	ClinGen:CA2249542		FANCD2:2177&LOC107303338:107303338	SO:0001819&synonymous_variant										1	72492998																											139					0.863							122.04	v6.1	Unknown		True	FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia.	False	10/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:T393= mutant UNKNOWN.	False	The FANCD2 ENSP00000502379.1:t393= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	10088308						True	False	False	Unknown								False	False		FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia.	The FANCD2 ENSP00000502379.1:t393= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:T393= mutant UNKNOWN.						v6.1	10/22/2018		GRCh38	FANCD2	2177.0	ENSP00000502379.1:T393=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FANCD2"",""entrezGeneId"":2177,""alteration"":""ENSP00000502379.1:T393="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FANCD2, a tumor suppressor and DNA repair protein, is infrequently altered in cancer. Germline mutations of FANCD2 are associated with the cancer predisposition syndrome Fanconi Anemia."",""variantSummary"":""The FANCD2 ENSP00000502379.1:t393= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCD2 ENSP00000502379.1:T393= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/22/2018""}"	True	True	False	Unknown		Unknown																						97,23	44,13	53,10	0|1	45,52,10,13	CTC	.	.	.		10088299	40,57,12,11	4.32		0.19166666666666668
GRCh38	FANCD2	D12_12345_1234556_Thyroid_S9	p.P714L	ENSP00000502379.1:p.Pro714Leu	chr3	10064848	10064848.0	C	T	T	10064848	.	C	T	.	PASS	NM_001018115	T	missense_variant	MODERATE	FANCD2	ENSG00000144554	Transcript	ENST00000675286	protein_coding	23/44		c.2141C>T	2211	2141	714	P/L	cCg/cTg	rs3864017&COSV55033303		1		SNV	HGNC	HGNC:3585	YES	MANE_Select	NM_001018115.3			P2	CCDS33696.1	ENSP00000502379	Q9BXW9.198		UPI000006CD51	Q9BXW9-2		1	tolerated(0.27)	benign(0)	PDB-ENSP_mappings:6vaa.B&PDB-ENSP_mappings:6vad.B&PDB-ENSP_mappings:6vae.B&PDB-ENSP_mappings:6vaf.B&PDB-ENSP_mappings:7ay1.B&PDB-ENSP_mappings:7kzq.V&PDB-ENSP_mappings:7kzr.V&PDB-ENSP_mappings:7kzs.V&PDB-ENSP_mappings:7kzt.V&PDB-ENSP_mappings:7kzv.V&PDB-ENSP_mappings:7zf1.B&PDB-ENSP_mappings:8a9j.B&PDB-ENSP_mappings:8a9k.B&PANTHER:PTHR32086&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF14631&CDD:cd11721&AFDB-ENSP_mappings:AF-Q9BXW9-F1									0.1447	0.27	0.1463	0.1485	0.05138	0.1212	0.1475	0.1438	0.1468	0.1649	0.1881	0.2837	0.2682	0.1427	0.1522	0.06252	0.122	0.125	0.1625	0.1682	0.1615	0.2837	gnomADg_AFR	benign&benign/likely_benign	0&1	1&1	25741868&24728327&26822197&32107087						FAIL	14	-22	28	-4	0.00	0.00	0.00	0.00	FANCD2		7.7700e-01	134315		0.15449		138054	not_provided&Fanconi_anemia_complementation_group_A&Hereditary_breast_ovarian_cancer_syndrome&not_specified&Fanconi_anemia&Fanconi_anemia_complementation_group_D2		MedGen:C3661900&MONDO:MONDO:0009215&MedGen:C3469521&OMIM:227650&Orphanet:84&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MedGen:CN169374&MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MONDO:MONDO:0009214&MedGen:C3160738&OMIM:227646&Orphanet:84		NC_000003.12:g.10064848C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000305866&SCV000439587&SCV000603566&SCV000752015&SCV001136301&SCV001901112&SCV001933108&SCV002050736&SCV002070982&SCV002505221&SCV002529486&SCV004017632&SCV005264511	single_nucleotide_variant	SO:0001483	ClinGen:CA159448&UniProtKB:Q9BXW9																																																																																																																																															89,17	45,10	44,7	0/1	57,32,12,5	CCG	0.00	0.00	1.00			45,44,11,6	10.32		0.16037735849056603
GRCh38	MLH1	D12_12345_1234556_Thyroid_S9			chr3	36997280	36997280.0	C	T	T	36997280	.	C	T	.	PASS	NM_000249	T	intron_variant	MODIFIER	MLH1	ENSG00000076242	Transcript	ENST00000231790	protein_coding		2/18	c.207+571C>T						rs9852378		1		SNV	HGNC	HGNC:7127	YES	MANE_Select	NM_000249.4		1	P1	CCDS2663.1	ENSP00000231790	P40692.246		UPI0000000C7E	P40692-1		1						0.3087	0.4168	0.379	0.0754	0.4404	0.2178	0.3822	0.3125	0.3338	0.3	0.08491	0	0.5	0.4391	0.377	0.2291	0.4064	0.3873	0.5374	0.4133	0.4059	0.07841	0.3672	0.3562	0.4586	0.3878	0.2388	0.5374	gnomADg_AMI	benign		1	34594420						FAIL	0	20	-16	20	0.00	0.00	0.00	0.01	MLH1		6.3900e-01	90024			0.30871	95498	Lynch_syndrome&not_provided		MONDO:MONDO:0005835&MedGen:C4552100&Orphanet:144&MedGen:C3661900		NC_000003.12:g.36997280C>T	reviewed_by_expert_panel	Benign			SCV000106504	single_nucleotide_variant	SO:0001483	ClinGen:CA008449		MLH1:4292	SO:0001623&5_prime_UTR_variant&SO:0001627&intron_variant										1	9852378																											202					0.921							230.39													chr3	37038771																																																	True	True	False	Unknown		Unknown																						103,83	52,39	51,44	0/1	56,47,43,40	ACG	0.00	0.00	0.00			51,52,39,44	27.96		0.44623655913978494
GRCh38	MLH1	D12_12345_1234556_Thyroid_S9	p.I219V	ENSP00000231790.3:p.Ile219Val	chr3	37012077	37012077.0	A	G	G	37012077	.	A	G	.	PASS	NM_000249	G	missense_variant	MODERATE	MLH1	ENSG00000076242	Transcript	ENST00000231790	protein_coding	8/19		c.655A>G	685	655	219	I/V	Atc/Gtc	rs1799977&CM970958&COSV51613800		1		SNV	HGNC	HGNC:7127	YES	MANE_Select	NM_000249.4		1	P1	CCDS2663.1	ENSP00000231790	P40692.246		UPI0000000C7E	P40692-1		1	tolerated(0.44)	benign(0.062)	Gene3D:3.30.565.10&PDB-ENSP_mappings:4p7a.A&AFDB-ENSP_mappings:AF-P40692-F1&Pfam:PF01119&PANTHER:PTHR10073&SMART:SM01340&Superfamily:SSF54211&Superfamily:SSF55874&NCBIFAM:TIGR00585&CDD:cd03483			0.1296	0.0386	0.1686	0.0258	0.325	0.1309	0.29	0.07566	0.1715	0.2916	0.03741	0.2953	0.2603	0.3237	0.2622	0.1356	0.2265	0.07953	0.4262	0.2216	0.2783	0.02762	0.2891	0.2483	0.3245	0.2275	0.126	0.4262	gnomADg_AMI	benign	0&1&1	1&1&1	25741868&24033266&24728327&23946381&25491747&18414213&26811195&23757202&24086368&24491308&17267408&22594646&18701435&20150366&21700777&17119116&18830263&27608007&22703879&29458332&19781088&20149637&24039736&26900293&29664240&28206966&29616133&32957448&24278394&19389263&31175773&24689082&18523027&31374908&25938433&21093899&19930554&20805886&22740958&17374836&32756484&12624141&19029193&24292105&32749112&34868194&20967208&28749454&23913011&17870204&18723338&19203531&19665066&20056646&20063070&20473912&20860725&21156845&22136435&22174852&25986311&26275295&29190978&22294770&16963262&20864636&26761715&29963112&23313170&35870994&37182709&32205469&23852586&24084575&30861523&37296718&23755158&25703993&28934397&31398342&21908578&31660093&31031852&21566726&22763379&31607598&29394274&35379994&29063235&31779681&25437057&26103898&36976737&25596266&34628594&27566557&29341452&23626689&34997843&27630279&31160353&37919876&30283143&38303633&39125905						FAIL	20	-50	18	14	0.00	0.00	0.00	0.01	MLH1	0.292	6.3900e-01	36557	0.24296	0.23254	0.12959	45219	Hereditary_nonpolyposis_colorectal_neoplasms&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Lynch_syndrome&Colorectal_cancer&_hereditary_nonpolyposis&_type_2&Lynch_syndrome_1&Muir-Torr_syndrome&Malignant_tumor_of_breast		MeSH:D003123&MedGen:C0009405&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0005835&MedGen:C4552100&Orphanet:144&MONDO:MONDO:0012249&MedGen:C1333991&OMIM:609310&Orphanet:144&MONDO:MONDO:0007356&MedGen:C2936783&OMIM:120435&Orphanet:144&MONDO:MONDO:0008018&MedGen:C1321489&OMIM:158320&Orphanet:587&MONDO:MONDO:0007254&MedGen:C0006142		NC_000003.12:g.37012077A>G	reviewed_by_expert_panel	Benign			SCV000106807	single_nucleotide_variant	SO:0001483	ClinGen:CA011410&UniProtKB:P40692																																																																																																																																															30,28	13,13	17,15	0/1	15,15,12,16	CAT	.	.	.			12,18,9,19	32.58		0.4827586206896552
GRCh38		D12_12345_1234556_Thyroid_S9			chr3	41094730	41094741.0	C	CCAACCTGGATT	CCAACCTGGATT	41094730	.	C	CCAACCTGGATT	.	PASS		CAACCTGGATT	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000305067	Transcript	ENST00000808368	lncRNA		2/6	n.394+1819_394+1820insAATCCAGGTTG						rs2067235		-1		insertion			YES																			0.4040	0.3623	0.4207	0.3601	0.5368	0.3569											0.4823	0.395	0.522	0.4345	0.4146	0.3592	0.5905	0.3707	0.5517	0.4839	0.3482	0.5905	gnomADg_FIN				23690203&36292568																																																																												282					0.972							235.37													chr3	41136221																																																	True	False	False	Unknown		Unknown																						142,132	71,62	71,70	0/1	93,49,66,66	GCC						64,78,58,74	34.38		0.48175182481751827
GRCh38	SETD2	D12_12345_1234556_Thyroid_S9	p.Asn1155=	ENSP00000386759.3:p.Asn1155=	chr3	47121171	47121171.0	A	G	G	47121171	.	A	G	.	PASS	NM_014159	G	synonymous_variant	LOW	SETD2	ENSG00000181555	Transcript	ENST00000409792	protein_coding	3/21		c.3465T>C	3654	3465	1155	N	aaT/aaC	rs6767907&COSV57430115		-1		SNV	HGNC	HGNC:18420	YES	MANE_Select	NM_014159.7		5	P3	CCDS2749.2	ENSP00000386759	Q9BYW2.194		UPI00017E10FB	Q9BYW2-1		1			MobiDB_lite:mobidb-lite&PANTHER:PTHR46711&AFDB-ENSP_mappings:AF-Q9BYW2-F1			0.6783	0.7837	0.6816	0.6577	0.6074	0.6278	0.6083	0.7592	0.7416	0.5899	0.7065	0.6254	0.5312	0.5958	0.6102	0.5955	0.6531	0.7574	0.4207	0.6652	0.5929	0.6852	0.6297	0.5205	0.5989	0.6291	0.604	0.7837	AFR	benign	0&1	1&1	30922329&28663576						FAIL	-28	23	4	2	0.00	0.00	0.00	0.00	SETD2		1.7600e-01	586533	0.64478	0.63430	0.67831	576751	Luscan-Lumish_syndrome&not_provided		MONDO:MONDO:0014791&MedGen:C4085873&OMIM:616831&Orphanet:597738&MedGen:C3661900		NC_000003.12:g.47121171A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000843771&SCV001718275&SCV001883906&SCV002055137&SCV005241844	single_nucleotide_variant	SO:0001483	ClinGen:CA2363378		SETD2:29072	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	6767907																											88					0.966							242.38	v6.1	Unknown		True	SETD2, an H3K36 trimethylase, is altered in a variety of cancer types.	False	11/21/2022	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SETD2 ENSP00000386759.3:N1155= mutant UNKNOWN.	False	The SETD2 ENSP00000386759.3:n1155= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	47162661						True	False	False	Unknown								False	False		SETD2, an H3K36 trimethylase, is altered in a variety of cancer types.	The SETD2 ENSP00000386759.3:n1155= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SETD2 ENSP00000386759.3:N1155= mutant UNKNOWN.						v6.1	11/21/2022		GRCh38	SETD2	29072.0	ENSP00000386759.3:N1155=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SETD2"",""entrezGeneId"":29072,""alteration"":""ENSP00000386759.3:N1155="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SETD2, an H3K36 trimethylase, is altered in a variety of cancer types."",""variantSummary"":""The SETD2 ENSP00000386759.3:n1155= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SETD2 ENSP00000386759.3:N1155= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/21/2022""}"	True	True	False	Unknown		Unknown																						30,55	12,39	18,16	0/1	15,15,25,30	GAT	.	.	.			15,15,25,30	44.42		0.6470588235294118
GRCh38	RHOA	D12_12345_1234556_Thyroid_S9			chr3	49395968	49395968.0	C	T	T	49395968	.	C	T	.	PASS	NM_001664	T	intron_variant	MODIFIER	RHOA	ENSG00000067560	Transcript	ENST00000418115	protein_coding		1/4	c.-3+15852G>A						rs4855879		-1		SNV	HGNC	HGNC:667	YES	MANE_Select	NM_001664.4		1	P1	CCDS2795.1	ENSP00000400175	P61586.216	A0A024R324.72	UPI0000046824			1						0.9750	0.91	0.9928	1	0.999	1											0.9821	0.9372	1	0.9941	1	1	1	1	0.9998	0.9901	0.9998	1	EAS&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID										FAIL	-2	28	-2	-22	0.00	0.00	0.00	0.00	RHOA		4.3300e-01																																																											129					0.977							245.96													chr3	49433401																																																	True	True	False	Unknown		Unknown																						0,126	0,46	0,80	0/1	0,0,66,60	CCA	0.00	0.00	0.00			0,0,76,50	64.71		1.0
GRCh38	MST1	D12_12345_1234556_Thyroid_S9	p.Pro326=	ENSP00000414287.2:p.Pro326=	chr3	49686351	49686351.0	C	A	A	49686351	.	C	A	.	PASS	NM_020998	A	synonymous_variant	LOW	MST1	ENSG00000173531	Transcript	ENST00000449682	protein_coding	8/18		c.978G>T	1761	978	326	P	ccG/ccT	rs9713651&COSV56535754		-1		SNV	HGNC	HGNC:7380	YES	MANE_Select	NM_020998.4		1	P1	CCDS33757.2	ENSP00000414287		G3XAK1.112	UPI0000EE2A31			1			Gene3D:2.40.20.10&AFDB-ENSP_mappings:AF-G3XAK1-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00051&PIRSF:PIRSF001152&PIRSF:PIRSF500185&PROSITE_profiles:PS50070&SMART:SM00130&Superfamily:SSF57440&CDD:cd00108									0.5114	0.3366	0.6637	0.4281	0.9392	0.4882	0.4677	0.4857	0.5174	0.6624	0.5012	0.3564	0.592	0.629	0.4016	0.943	0.4826	0.4519	0.518	0.4969	0.7028	0.943	gnomADg_EAS	likely_benign	0&1	1&1							FAIL	-44	20	-13	-38	0.00	0.00	0.00	0.03	MST1		9.5100e-01	769273	0.37820			698177	not_provided		MedGen:C3661900		NC_000003.12:g.49686351C>A	criteria_provided&_multiple_submitters&_no_conflicts	Likely_benign			SCV001094461&SCV005261412	single_nucleotide_variant	SO:0001483	ClinGen:CA2403001		MST1:4485	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant&SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	9713651																											715					0.783							50	v6.1	Unknown		True	MST1, an intracellular kinase, is infrequently altered in various cancer types.	False	08/27/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1 ENSP00000414287.2:P326= mutant UNKNOWN.	False	The MST1 ENSP00000414287.2:p326= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	49723784						True	False	False	Unknown								False	False		MST1, an intracellular kinase, is infrequently altered in various cancer types.	The MST1 ENSP00000414287.2:p326= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1 ENSP00000414287.2:P326= mutant UNKNOWN.						v6.1	08/27/2019		GRCh38	MST1	4485.0	ENSP00000414287.2:P326=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MST1"",""entrezGeneId"":4485,""alteration"":""ENSP00000414287.2:P326="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MST1, an intracellular kinase, is infrequently altered in various cancer types."",""variantSummary"":""The MST1 ENSP00000414287.2:p326= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1 ENSP00000414287.2:P326= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/27/2019""}"	True	True	False	Unknown		Unknown																						308,252	152,126	156,126	0/1	159,149,123,129	GCG	0.00	0.00	0.00			153,155,123,129	19.74		0.45
GRCh38	MST1	D12_12345_1234556_Thyroid_S9	p.Pro153=	ENSP00000414287.2:p.Pro153=	chr3	49687375	49687375.0	T	C	C	49687375	.	T	C	.	PASS	NM_020998	C	synonymous_variant	LOW	MST1	ENSG00000173531	Transcript	ENST00000449682	protein_coding	4/18		c.459A>G	1242	459	153	P	ccA/ccG	rs3020779&COSV108101641		-1		SNV	HGNC	HGNC:7380	YES	MANE_Select	NM_020998.4		1	P1	CCDS33757.2	ENSP00000414287		G3XAK1.112	UPI0000EE2A31			1			Gene3D:2.40.20.10&AFDB-ENSP_mappings:AF-G3XAK1-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00051&PIRSF:PIRSF001152&PIRSF:PIRSF500185&PROSITE_profiles:PS50070&PANTHER:PTHR24261&SMART:SM00130&Superfamily:SSF57440&CDD:cd00108			0.8602	0.7095	0.8573	0.9871	0.834	0.9622	0.8386	0.7257	0.9054	0.8522	0.997	0.9003	0.7807	0.8226	0.8359	0.9442	0.818	0.7328	0.7989	0.8578	0.8502	0.9913	0.9107	0.7517	0.8236	0.8094	0.9439	0.997	gnomADe_EAS		0&1	0&1							FAIL	20	-13	-11	42	0.00	0.00	0.01	0.00	MST1		9.5100e-01																																																											810					0.972							82.24	v6.1	Unknown		True	MST1, an intracellular kinase, is infrequently altered in various cancer types.	False	08/27/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1 ENSP00000414287.2:P153= mutant UNKNOWN.	False	The MST1 ENSP00000414287.2:p153= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	49724808						True	False	False	Unknown								False	False		MST1, an intracellular kinase, is infrequently altered in various cancer types.	The MST1 ENSP00000414287.2:p153= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1 ENSP00000414287.2:P153= mutant UNKNOWN.						v6.1	08/27/2019		GRCh38	MST1	4485.0	ENSP00000414287.2:P153=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MST1"",""entrezGeneId"":4485,""alteration"":""ENSP00000414287.2:P153="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MST1, an intracellular kinase, is infrequently altered in various cancer types."",""variantSummary"":""The MST1 ENSP00000414287.2:p153= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1 ENSP00000414287.2:P153= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/27/2019""}"	True	True	False	Unknown		Unknown																						429,358	207,174	222,184	0/1	210,219,178,180	TTG	.	.	.			206,223,180,178	20.77		0.4548919949174079
GRCh38	MST1	D12_12345_1234556_Thyroid_S9			chr3	49688595	49688595.0	T	C	C	49688595	.	T	C	.	PASS	NM_020998	C	splice_donor_region_variant&intron_variant	LOW	MST1	ENSG00000173531	Transcript	ENST00000449682	protein_coding		1/17	c.94+3A>G						rs62262685&COSV106058525		-1		SNV	HGNC	HGNC:7380	YES	MANE_Select	NM_020998.4		1	P1	CCDS33757.2	ENSP00000414287		G3XAK1.112	UPI0000EE2A31			1												0.2765	0.3764	0.3947	0.2645	0.2494	0.3582	0.3165	0.2576	0.2671	0.338	0.2212	0.2957	0.1605	0.1994	0.1832	0.2106	0.2228	0.15	0.1849	0.2169	0.1846	0.3947	gnomADe_AMR		0&1	0&1							FAIL	3	11	10	3	0.00	0.00	0.00	0.13	MST1		9.5100e-01																																																											854					0.76							69.6													chr3	49726028																																																	True	True	False	Unknown		Unknown																						564,85	278,39	286,46	0/1	296,268,38,47	TTA	.	.	.			366,198,36,49	11.37		0.13097072419106318
GRCh38	MST1R	D12_12345_1234556_Thyroid_S9	p.R1335G	ENSP00000296474.3:p.Arg1335Gly	chr3	49887507	49887507.0	T	C	C	49887507	.	T	C	.	PASS	NM_002447	C	missense_variant	MODERATE	MST1R	ENSG00000164078	Transcript	ENST00000296474	protein_coding	20/20		c.4003A>G	4267	4003	1335	R/G	Aga/Gga	rs1062633&COSV56566222		-1		SNV	HGNC	HGNC:7381	YES	MANE_Select	NM_002447.4		1	P2	CCDS2807.1	ENSP00000296474	Q04912.230		UPI000159688A	Q04912-1		1	tolerated(0.62)	benign(0)	Gene3D:1.10.510.10&PDB-ENSP_mappings:3pls.A&PDB-ENSP_mappings:8zkd.A&AFDB-ENSP_mappings:AF-Q04912-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF07714&PIRSF:PIRSF000617&PROSITE_profiles:PS50011&PANTHER:PTHR24416&SMART:SM00219&Superfamily:SSF56112&CDD:cd05058			0.4191	0.7443	0.3761	0.1438	0.498	0.2127	0.4748	0.6834	0.3032	0.4053	0.1533	0.3904	0.4242	0.5114	0.4673	0.2409	0.5083	0.6778	0.5352	0.3979	0.3937	0.1419	0.3836	0.4728	0.5022	0.5038	0.2348	0.7443	AFR	benign	0&1	1&1	21543897&29531956&27798627&28672935&21504591&37878672&37164063&36974753						FAIL	47	-2	-17	-2	0.00	0.00	0.00	0.00	MST1R	0.111	9.8500e-01	3058886	0.56289	0.41797	0.41913	3200502	MST1R-related_disorder		.		NC_000003.12:g.49887507T>C	no_assertion_criteria_provided	Benign			SCV004793437	single_nucleotide_variant	SO:0001483	ClinGen:CA2408390		MST1R:4486	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	1062633																											886					0.995							246.51	v6.1	Unknown		True	MST1R, a receptor tyrosine kinase, is altered by overexpression and mutation in various cancer types.	False	08/28/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1R ENSP00000296474.3:R1335G mutant UNKNOWN.	False	The MST1R ENSP00000296474.3:r1335g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	49924940						True	False	False	Unknown								False	False		MST1R, a receptor tyrosine kinase, is altered by overexpression and mutation in various cancer types.	The MST1R ENSP00000296474.3:r1335g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1R ENSP00000296474.3:R1335G mutant UNKNOWN.						v6.1	08/28/2019		GRCh38	MST1R	4486.0	ENSP00000296474.3:R1335G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MST1R"",""entrezGeneId"":4486,""alteration"":""ENSP00000296474.3:R1335G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MST1R, a receptor tyrosine kinase, is altered by overexpression and mutation in various cancer types."",""variantSummary"":""The MST1R ENSP00000296474.3:r1335g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1R ENSP00000296474.3:R1335G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/28/2019""}"	True	True	False	Unknown		Unknown																						0,882	0,474	0,408	0/1	0,0,461,421	CTG	.	.	.			0,0,403,479	64.73		1.0
GRCh38	MST1R	D12_12345_1234556_Thyroid_S9	p.Q523R	ENSP00000296474.3:p.Gln523Arg	chr3	49898669	49898669.0	T	C	C	49898669	.	T	C	.	PASS	NM_002447	C	missense_variant	MODERATE	MST1R	ENSG00000164078	Transcript	ENST00000296474	protein_coding	4/20		c.1568A>G	1832	1568	523	Q/R	cAa/cGa	rs2230590&COSV56566654		-1		SNV	HGNC	HGNC:7381	YES	MANE_Select	NM_002447.4		1	P2	CCDS2807.1	ENSP00000296474	Q04912.230		UPI000159688A	Q04912-1		1	tolerated(0.77)	benign(0)	Gene3D:3.30.1680.10&PDB-ENSP_mappings:4fww.A&PDB-ENSP_mappings:4qt8.A&PDB-ENSP_mappings:4qt8.B&AFDB-ENSP_mappings:AF-Q04912-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000617&Superfamily:SSF103575&CDD:cd11279			0.4165	0.7368	0.3761	0.1429	0.497	0.2117	0.4746	0.6758	0.3026	0.4052	0.1531	0.3902	0.4239	0.5114	0.4667	0.2409	0.5065	0.6705	0.5374	0.3978	0.3937	0.143	0.3837	0.4728	0.5022	0.5043	0.234	0.7368	AFR	benign	0&1	1&1	21543897&37047000&27798627&34385509&29273807&21504591&36581621&37700350&38072966&37878672&39192095						FAIL	19	-46	0	11	0.00	0.00	0.00	0.01	MST1R	0.026	9.8500e-01	1237612	0.56059	0.41718	0.41653	1229232	not_provided&MST1R-related_disorder		MedGen:C3661900&.		NC_000003.12:g.49898669T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001849055&SCV005304057	single_nucleotide_variant	SO:0001483	ClinGen:CA2409185		MST1R:4486	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	2230590																											774					0.999							247.08	v6.1	Unknown		True	MST1R, a receptor tyrosine kinase, is altered by overexpression and mutation in various cancer types.	False	08/28/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1R ENSP00000296474.3:Q523R mutant UNKNOWN.	False	The MST1R ENSP00000296474.3:q523r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	49936102						True	False	False	Unknown								False	False		MST1R, a receptor tyrosine kinase, is altered by overexpression and mutation in various cancer types.	The MST1R ENSP00000296474.3:q523r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1R ENSP00000296474.3:Q523R mutant UNKNOWN.						v6.1	08/28/2019		GRCh38	MST1R	4486.0	ENSP00000296474.3:Q523R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MST1R"",""entrezGeneId"":4486,""alteration"":""ENSP00000296474.3:Q523R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MST1R, a receptor tyrosine kinase, is altered by overexpression and mutation in various cancer types."",""variantSummary"":""The MST1R ENSP00000296474.3:q523r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MST1R ENSP00000296474.3:Q523R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/28/2019""}"	True	True	False	Unknown		Unknown																						0,773	0,377	0,396	0/1	0,0,365,408	TTG	.	.	.			0,0,311,462	64.73		1.0
GRCh38	PBRM1	D12_12345_1234556_Thyroid_S9	p.Pro1567=	ENSP00000516722.1:p.Pro1567=	chr3	52550771	52550771.0	T	C	C	52550771	.	T	C	.	PASS	NM_001405607	C	synonymous_variant	LOW	PBRM1	ENSG00000163939	Transcript	ENST00000707071	protein_coding	30/32		c.4701A>G	4881	4701	1567	P	ccA/ccG	rs2251219&COSV56259388		-1		SNV	HGNC	HGNC:30064	YES	MANE_Select	NM_001405607.1			P1		ENSP00000516722		A0A9L9PXL4.6	UPI000387D000			1			PANTHER:PTHR16062			0.3231	0.1452	0.4654	0.4296	0.4195	0.2536	0.3861	0.1646	0.5199	0.462	0.479	0.4029	0.4056	0.3936	0.3693	0.2413	0.3423	0.175	0.4583	0.4645	0.4501	0.4302	0.3923	0.432	0.4015	0.3704	0.2399	0.5199	gnomADe_AMR		0&1	1&1	21085053&21438146&22005930&23507081&21042317&25505091&26228411&20081856&20848240&20940148&22560537&25897833&26658939&31723243&26338991&26599540&28465436&27562178&35974141&29912442&23453885&35079000&22801476&23967141&34887591&35590387&37443018						FAIL	46	31	18	-1	0.00	0.00	0.00	0.00	PBRM1																																																													544					0.993							246.69	v6.1	Unknown		True	PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:P1567= mutant UNKNOWN.	False	The PBRM1 ENSP00000516722.1:p1567= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	52584787						True	False	False	Unknown								False	False		PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	The PBRM1 ENSP00000516722.1:p1567= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:P1567= mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PBRM1	55193.0	ENSP00000516722.1:P1567=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PBRM1"",""entrezGeneId"":55193,""alteration"":""ENSP00000516722.1:P1567="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma."",""variantSummary"":""The PBRM1 ENSP00000516722.1:p1567= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:P1567= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						279,261	136,123	143,138	0/1	144,135,137,124	CTG	.	.	.			119,160,107,154	38.24		0.48333333333333334
GRCh38	PBRM1	D12_12345_1234556_Thyroid_S9	p.Pro1214=	ENSP00000516722.1:p.Pro1214=	chr3	52576635	52576635.0	T	A	A	52576635	.	T	A	.	PASS	NM_001405607	A	synonymous_variant	LOW	PBRM1	ENSG00000163939	Transcript	ENST00000707071	protein_coding	24/32		c.3642A>T	3822	3642	1214	P	ccA/ccT	rs17264436&COSV56259420		-1		SNV	HGNC	HGNC:30064	YES	MANE_Select	NM_001405607.1			P1		ENSP00000516722		A0A9L9PXL4.6	UPI000387D000			1			Gene3D:2.30.30.490&Pfam:PF01426&PROSITE_profiles:PS51038&PANTHER:PTHR16062&SMART:SM00439&CDD:cd04717			0.3161	0.1483	0.4582	0.4276	0.4165	0.2239	0.3791	0.1644	0.5156	0.4601	0.4761	0.401	0.3991	0.3872	0.3626	0.2144	0.3382	0.1753	0.4582	0.4594	0.449	0.4277	0.3899	0.4286	0.3956	0.367	0.2171	0.5156	gnomADe_AMR		0&1	1&1	25003827&24886551&35974141						FAIL	-5	-2	-5	-2	0.01	0.06	0.00	0.00	PBRM1																																																													102					0.931							238.92	v6.1	Unknown		True	PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:P1214= mutant UNKNOWN.	False	The PBRM1 ENSP00000516722.1:p1214= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	52610651						True	False	False	Unknown								False	False		PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	The PBRM1 ENSP00000516722.1:p1214= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:P1214= mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PBRM1	55193.0	ENSP00000516722.1:P1214=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PBRM1"",""entrezGeneId"":55193,""alteration"":""ENSP00000516722.1:P1214="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma."",""variantSummary"":""The PBRM1 ENSP00000516722.1:p1214= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:P1214= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						53,42	25,15	28,27	0/1	23,30,22,20	CTG	.	.	.			29,24,15,27	28.87		0.4421052631578947
GRCh38	PBRM1	D12_12345_1234556_Thyroid_S9	p.V993I	ENSP00000516722.1:p.Val993Ile	chr3	52589103	52589103.0	C	T	T	52589103	.	C	T	.	PASS	NM_001405607	T	missense_variant	MODERATE	PBRM1	ENSG00000163939	Transcript	ENST00000707071	protein_coding	20/32		c.2977G>A	3157	2977	993	V/I	Gtc/Atc	rs375687372&COSV56259441		-1		SNV	HGNC	HGNC:30064	YES	MANE_Select	NM_001405607.1			P1		ENSP00000516722		A0A9L9PXL4.6	UPI000387D000			1	deleterious_low_confidence(0)	benign(0.015)	Gene3D:2.30.30.490&Pfam:PF01426&PROSITE_profiles:PS51038&PANTHER:PTHR16062&SMART:SM00439&CDD:cd04717									0.0003497	5.977e-05	0.000179	0	0	1.872e-05	0	0.000439	0.0001822	1.16e-05	0.0001183	9.654e-05	0	0.000131	0	0	0	0	0.0001764	0	0	0.000439	gnomADe_NFE		0&1	0&1							FAIL	-3	23	-33	1	0.00	0.00	0.00	0.00	PBRM1																																																													151					0.987							245.82	v6.1	Unknown		True	PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:V993I mutant UNKNOWN.	False	The PBRM1 ENSP00000516722.1:v993i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	52623119						True	False	False	Unknown								False	False		PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	The PBRM1 ENSP00000516722.1:v993i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:V993I mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PBRM1	55193.0	ENSP00000516722.1:V993I			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PBRM1"",""entrezGeneId"":55193,""alteration"":""ENSP00000516722.1:V993I"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma."",""variantSummary"":""The PBRM1 ENSP00000516722.1:v993i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:V993I mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						70,79	42,41	28,38	0/1	37,33,42,37	ACG	0.00	0.00	0.00			33,37,32,47	41.3		0.5302013422818792
GRCh38	PBRM1	D12_12345_1234556_Thyroid_S9	p.Thr752=	ENSP00000516722.1:p.Thr752=	chr3	52609669	52609669.0	T	C	C	52609669	.	T	C	.	PASS	NM_001405607	C	synonymous_variant	LOW	PBRM1	ENSG00000163939	Transcript	ENST00000707071	protein_coding	18/32		c.2256A>G	2436	2256	752	T	acA/acG	rs3755806&COSV56259469		-1		SNV	HGNC	HGNC:30064	YES	MANE_Select	NM_001405607.1			P1		ENSP00000516722		A0A9L9PXL4.6	UPI000387D000			1			Gene3D:1.20.920.10&Pfam:PF00439&PROSITE_patterns:PS00633&PROSITE_profiles:PS50014&SMART:SM00297&Superfamily:SSF47370&CDD:cd05515			0.3225	0.1483	0.4611	0.4276	0.4215	0.2495	0.3865	0.1658	0.5194	0.4621	0.4765	0.4028	0.4057	0.3943	0.3673	0.2401	0.3425	0.1766	0.4593	0.4628	0.4515	0.4286	0.3924	0.432	0.4014	0.3689	0.2377	0.5194	gnomADe_AMR		0&1	1&1	17903307&23070075&35974141&29658973						FAIL	32	-32	5	39	0.00	0.00	0.01	0.00	PBRM1																																																													60					1							240.28	v6.1	Unknown		True	PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	False	04/03/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:T752= mutant UNKNOWN.	False	The PBRM1 ENSP00000516722.1:t752= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	52643685						True	False	False	Unknown								False	False		PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma.	The PBRM1 ENSP00000516722.1:t752= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:T752= mutant UNKNOWN.						v6.1	04/03/2017		GRCh38	PBRM1	55193.0	ENSP00000516722.1:T752=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PBRM1"",""entrezGeneId"":55193,""alteration"":""ENSP00000516722.1:T752="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PBRM1 encodes a tumor suppressor and component of the SWI/SNF chromatin-remodeling complex. Inactivating mutations of PBRM1 are frequently found in renal carcinoma."",""variantSummary"":""The PBRM1 ENSP00000516722.1:t752= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PBRM1 ENSP00000516722.1:T752= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/03/2017""}"	True	True	False	Unknown		Unknown																						31,29	13,14	18,15	0/1	19,12,14,15	ATG	.	.	.			17,14,17,12	32.7		0.48333333333333334
GRCh38	PBRM1	D12_12345_1234556_Thyroid_S9			chr3	52662122		T	<INS>	<INS>	52662122	MantaINS:8717:1:1:2:7:0	T	<INS>	.	PASS	NM_001405607	insertion	intron_variant	MODIFIER	PBRM1	ENSG00000163939	Transcript	ENST00000707071	protein_coding		5/31									-1		insertion	HGNC	HGNC:30064	YES	MANE_Select	NM_001405607.1			P1		ENSP00000516722		A0A9L9PXL4.6	UPI000387D000			1																																																																																																															0,75		0,75							75	ACACACTTACTCCTTCAGTCACTGTGCCCTGATTGTCTTGCCCATCTTCATCATCATCTTCGTCATCTGCTTCTC		ACACACTTACTCCTTCAGTCACTGTGCCCTGATTGTCTTGCCCATCTTCATCATCATCTTCGTCATCTGCTTCTCTCTCTCTCTCTCTCCCCCCGCCCTGTCTGTTTCTCTCTGTCTCC																chr3	52696138	CTGTTTTCCAGAACATCTGCCCTTCCAGAGCACCAGTTGCACTAAAAGCCCAACAAGAGCC			INS																																													True	True	False	Unknown		Unknown																															1,3				0,6	
GRCh38	PBRM1	D12_12345_1234556_Thyroid_S9			chr3	52679658		G	<INS>	<INS>	52679658	MantaINS:5899:1:1:0:3:0	G	<INS>	.	PASS	NM_001405607	insertion	feature_elongation&coding_sequence_variant	HIGH	PBRM1	ENSG00000163939	Transcript	ENST00000707071	protein_coding	2/32			233	53	18					-1		insertion	HGNC	HGNC:30064	YES	MANE_Select	NM_001405607.1			P1		ENSP00000516722		A0A9L9PXL4.6	UPI000387D000			1			MobiDB_lite:mobidb-lite																																																																																																												0,56		0,56							56	TCCCCGCTGACACTGCTGGAAGGGGAGGTAGCTCTTCTTCTCTTGGAACCCATGGA		TCCCCGCTGACACTGCTGGAAGGGGAGGTAGCTCTTCTTCTCTTGGAACCCATGGATACTGACTGTAGAATTATCTGAGCC																chr3	52713674	ATCGAATAAAATTGATTGAAATCATCATCCAATGGAATCGAATGGTATCATTGAATGGAATCGAATGGAATCATCATCAAAA			INS																																													True	True	False	Unknown		Unknown																															2,1				1,2	
GRCh38	MITF	D12_12345_1234556_Thyroid_S9			chr3	69965271	69965271.0	C	T	T	69965271	.	C	T	.	PASS	NM_000248	T	3_prime_UTR_variant	MODIFIER	MITF	ENSG00000187098	Transcript	ENST00000394351	protein_coding	9/9		c.*23C>T	1414					rs746168511&COSV58832766		1		SNV	HGNC	HGNC:7105		MANE_Plus_Clinical		NM_000248.4	1		CCDS2913.1	ENSP00000377880	O75030.226		UPI000002ADFF	O75030-9		1												2.955e-05	2.995e-05	8.959e-05	0	2.535e-05	1.882e-05	0.0001744	2.892e-05	3.329e-05	1.162e-05	1.314e-05	4.826e-05	0	0	0	0	0	0	0	0	0	0.0001744	gnomADe_MID	uncertain_significance	0&1	1&1							FAIL	-31	31	-28	26	0.00	0.00	0.00	0.00	MITF		4.9100e-01	346503				292697	Waardenburg_syndrome_type_2A&Tietz_syndrome		MONDO:MONDO:0008671&MedGen:C1860339&OMIM:193510&Orphanet:3440&MONDO:MONDO:0007077&MedGen:C0391816&OMIM:103500&Orphanet:42665		NC_000003.12:g.69965271C>T	criteria_provided&_single_submitter	Uncertain_significance			SCV000445944&SCV000445945	single_nucleotide_variant	SO:0001483	ClinGen:CA10617338		MITF:4286	SO:0001624&3_prime_UTR_variant										1	746168511																											662					0.998							246.53													chr3	70014422																																																	True	True	False	Unknown		Unknown																						331,330	180,184	151,146	0/1	161,170,154,176	TCG	0.00	0.00	0.00			102,229,110,220	48.35		0.49924357034795763
GRCh38		D12_12345_1234556_Thyroid_S9			chr3	72446626	72446626.0	C	G	G	72446626	.	C	G	.	PASS		G	downstream_gene_variant	MODIFIER		ENSG00000305376	Transcript	ENST00000810668	lncRNA									rs13066407	2246	-1		SNV			YES																			0.9808	0.9304	0.9942	1	1	1	0.9938	0.9379	0.9966	0.9992	0.9437	0.9999	0.9983	0.9992	0.9934	0.999	0.98	0.9386	1	0.9951	0.9994	0.939	0.9999	1	0.9991	0.9853	0.9973	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_MID																																																																																459					0.989							246.72													chr3	72495777																																																	True	False	False	Unknown		Unknown																						0,454	0,199	0,255	0/1	0,0,215,239	CCG	.	.	.			0,0,184,270	64.73		1.0
GRCh38	ROBO2	D12_12345_1234556_Thyroid_S9			chr3	76001848		A	[chr15:55721134[A	[chr15:55721134[A	76001848	MantaBND:14821:0:1:0:0:0:1	A	[chr15:55721134[A	.	PASS		.A	feature_truncation&intron_variant	HIGH	ROBO2	ENSG00000185008	Transcript	ENST00000696630	protein_coding		2/29									1		chromosome_breakpoint	HGNC	HGNC:10250							CCDS93314.1	ENSP00000512767		A0A8Q3SIW8.11	UPI0007DC5F41			1																																																																																																														2			0,5							5	AATTA			MantaBND:14821:0:1:0:0:0:0	3														chr3	76050999				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	EPHA3	D12_12345_1234556_Thyroid_S9	p.Lys800=	ENSP00000337451.2:p.Lys800=	chr3	89449278	89449278.0	G	A	A	89449278	.	G	A	.	PASS	NM_005233	A	synonymous_variant	LOW	EPHA3	ENSG00000044524	Transcript	ENST00000336596	protein_coding	14/17		c.2400G>A	2528	2400	800	K	aaG/aaA	rs1398197&COSV60692555		1		SNV	HGNC	HGNC:3387	YES	MANE_Select	NM_005233.6		1	P1	CCDS2922.1	ENSP00000337451	P29320.234	A0A140VJJ0.50	UPI0000163BE4	P29320-1		1			Gene3D:1.10.510.10&PDB-ENSP_mappings:2gsf.A&PDB-ENSP_mappings:2qo2.A&PDB-ENSP_mappings:2qo7.A&PDB-ENSP_mappings:2qo9.A&PDB-ENSP_mappings:2qob.A&PDB-ENSP_mappings:2qoc.A&PDB-ENSP_mappings:2qod.A&PDB-ENSP_mappings:2qof.A&PDB-ENSP_mappings:2qoi.A&PDB-ENSP_mappings:2qok.A&PDB-ENSP_mappings:2qol.A&PDB-ENSP_mappings:2qon.A&PDB-ENSP_mappings:2qoo.A&PDB-ENSP_mappings:2qoq.A&PDB-ENSP_mappings:3dzq.A&PDB-ENSP_mappings:3fxx.A&PDB-ENSP_mappings:3fy2.A&PDB-ENSP_mappings:4g2f.A&PDB-ENSP_mappings:4gk2.A&PDB-ENSP_mappings:4gk3.A&PDB-ENSP_mappings:4gk4.A&PDB-ENSP_mappings:4p4c.A&PDB-ENSP_mappings:4p5q.A&PDB-ENSP_mappings:4p5z.A&PDB-ENSP_mappings:4twn.A&PDB-ENSP_mappings:4two.A&PDB-ENSP_mappings:6in0.A&AFDB-ENSP_mappings:AF-P29320-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF07714&PIRSF:PIRSF000666&PROSITE_profiles:PS50011&PANTHER:PTHR46877&SMART:SM00219&Superfamily:SSF56112&CDD:cd05066			0.1126	0.2625	0.0879	0.0516	0.0457	0.0593	0.05749	0.2445	0.04894	0.07893	0.04247	0.03427	0.09228	0.05096	0.07246	0.07548	0.1052	0.2329	0.08882	0.07809	0.08506	0.04685	0.03672	0.06803	0.05225	0.1028	0.07498	0.2625	AFR	benign	0&1	1&1	29932736						FAIL	11	-44	48	18	0.00	0.00	0.00	0.00	EPHA3		5.0800e-01	3056783	0.11541	0.07125	0.11262	3199709	EPHA3-related_disorder		.		NC_000003.12:g.89449278G>A	no_assertion_criteria_provided	Benign			SCV004786202	single_nucleotide_variant	SO:0001483	ClinGen:CA2502835		EPHA3:2042	SO:0001819&synonymous_variant										1	1398197																											99					0.949							246.49	v6.1	Unknown		True	EPHA3, a receptor tyrosine kinase, is altered in various cancer types including skin and lung cancers.	False	02/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA3 ENSP00000337451.2:K800= mutant UNKNOWN.	False	The EPHA3 ENSP00000337451.2:k800= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	89498428						True	False	False	Unknown								False	False		EPHA3, a receptor tyrosine kinase, is altered in various cancer types including skin and lung cancers.	The EPHA3 ENSP00000337451.2:k800= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA3 ENSP00000337451.2:K800= mutant UNKNOWN.						v6.1	02/22/2018		GRCh38	EPHA3	2042.0	ENSP00000337451.2:K800=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EPHA3"",""entrezGeneId"":2042,""alteration"":""ENSP00000337451.2:K800="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EPHA3, a receptor tyrosine kinase, is altered in various cancer types including skin and lung cancers."",""variantSummary"":""The EPHA3 ENSP00000337451.2:k800= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA3 ENSP00000337451.2:K800= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/22/2018""}"	True	True	False	Unknown		Unknown																						53,41	28,21	25,20	0/1	26,27,16,25	AGT	0.00	0.00	0.00			27,26,18,23	27.93		0.43617021276595747
GRCh38	EPHA3	D12_12345_1234556_Thyroid_S9	p.W924R	ENSP00000337451.2:p.Trp924Arg	chr3	89472543	89472543.0	T	C	C	89472543	.	T	C	.	PASS	NM_005233	C	missense_variant	MODERATE	EPHA3	ENSG00000044524	Transcript	ENST00000336596	protein_coding	16/17		c.2770T>C	2898	2770	924	W/R	Tgg/Cgg	rs35124509&COSV60708046		1		SNV	HGNC	HGNC:3387	YES	MANE_Select	NM_005233.6		1	P1	CCDS2922.1	ENSP00000337451	P29320.234	A0A140VJJ0.50	UPI0000163BE4	P29320-1		1	tolerated_low_confidence(0.56)	benign(0)	Gene3D:1.10.150.50&PDB-ENSP_mappings:2gsf.A&PDB-ENSP_mappings:2qo2.A&PDB-ENSP_mappings:2qo7.A&PDB-ENSP_mappings:2qo9.A&PDB-ENSP_mappings:2qob.A&PDB-ENSP_mappings:2qoc.A&PDB-ENSP_mappings:2qod.A&PDB-ENSP_mappings:2qof.A&PDB-ENSP_mappings:2qoi.A&PDB-ENSP_mappings:2qok.A&PDB-ENSP_mappings:2qol.A&PDB-ENSP_mappings:2qon.A&PDB-ENSP_mappings:2qoo.A&PDB-ENSP_mappings:2qoq.A&PDB-ENSP_mappings:3dzq.A&PDB-ENSP_mappings:3fxx.A&PDB-ENSP_mappings:3fy2.A&PDB-ENSP_mappings:4g2f.A&PDB-ENSP_mappings:4gk2.A&PDB-ENSP_mappings:4gk3.A&PDB-ENSP_mappings:4gk4.A&PDB-ENSP_mappings:4p4c.A&PDB-ENSP_mappings:4p5q.A&PDB-ENSP_mappings:4p5z.A&PDB-ENSP_mappings:4twn.A&PDB-ENSP_mappings:4two.A&AFDB-ENSP_mappings:AF-P29320-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF07647&PIRSF:PIRSF000666&PROSITE_profiles:PS50105&PANTHER:PTHR46877&SMART:SM00454&Superfamily:SSF47769			0.3912	0.674	0.3732	0.2163	0.3976	0.1953	0.3838	0.6466	0.324	0.3499	0.1663	0.4875	0.3346	0.3937	0.3842	0.2336	0.4475	0.6322	0.2412	0.3624	0.3611	0.1978	0.5006	0.3231	0.3886	0.4311	0.2288	0.674	AFR		0&1	1&1	34944636&34560273&33875891&35505052&32665545&35393594&34929384&35164939&34910505&37591828&38438384&38811844						FAIL	-20	-21	30	-21	0.00	0.00	0.00	0.09	EPHA3	0.295	5.0800e-01																																																											84					0.988							247.84	v6.1	Unknown		True	EPHA3, a receptor tyrosine kinase, is altered in various cancer types including skin and lung cancers.	False	02/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA3 ENSP00000337451.2:W924R mutant UNKNOWN.	False	The EPHA3 ENSP00000337451.2:w924r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	89521693						True	False	False	Unknown								False	False		EPHA3, a receptor tyrosine kinase, is altered in various cancer types including skin and lung cancers.	The EPHA3 ENSP00000337451.2:w924r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA3 ENSP00000337451.2:W924R mutant UNKNOWN.						v6.1	02/22/2018		GRCh38	EPHA3	2042.0	ENSP00000337451.2:W924R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EPHA3"",""entrezGeneId"":2042,""alteration"":""ENSP00000337451.2:W924R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EPHA3, a receptor tyrosine kinase, is altered in various cancer types including skin and lung cancers."",""variantSummary"":""The EPHA3 ENSP00000337451.2:w924r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA3 ENSP00000337451.2:W924R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/22/2018""}"	True	True	False	Unknown		Unknown																						41,42	23,24	18,18	0/1	22,19,18,24	CTG	.	.	.			18,23,22,20	35.62		0.5060240963855421
GRCh38		D12_12345_1234556_Thyroid_S9			chr3	110582178	110582178.0	C	T	T	110582178	.	C	T	.	PASS		T	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000304514	Transcript	ENST00000804115	lncRNA		1/1	n.149+3028C>T						rs2399334		1		SNV																						0.6044	0.4849	0.6398	0.6508	0.5964	0.7014											0.5754	0.4889	0.6178	0.5813	0.4695	0.6478	0.6178	0.6497	0.6103	0.5956	0.6928	0.7014	SAS																																																																																103					0.913							222.29													chr3	110301025																																																	True	False	False	Unknown		Unknown																						0,94	0,50	0,44	0/1	0,0,56,38	ACT	0.00	0.00	0.00			0,0,56,38	64.66		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr3	110582215	110582215.0	G	T	T	110582215	.	G	T	.	PASS		T	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000304514	Transcript	ENST00000804115	lncRNA		1/1	n.149+3065G>T						rs2399333		1		SNV																						0.6218	0.534	0.647	0.6468	0.6163	0.7025											0.6019	0.5345	0.6443	0.5909	0.5092	0.6458	0.6356	0.6327	0.6338	0.614	0.6981	0.7025	SAS																																																																																142					0.93							224.1													chr3	110301062																																																	True	False	False	Unknown		Unknown																						0,132	0,68	0,64	0/1	0,0,80,52	CGT	0.00	0.00	0.00			0,0,80,52	64.72		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr3	110582279	110582279.0	T	G	G	110582279	.	T	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000304514	Transcript	ENST00000804115	lncRNA		1/1	n.149+3129T>G						rs2399332		1		SNV																						0.6516	0.5741	0.6599	0.6964	0.6213	0.7352											0.6225	0.5744	0.6504	0.5994	0.5453	0.6934	0.6436	0.6497	0.6445	0.6294	0.7232	0.7352	SAS				26691610&29121662&33406744&34721519&31226582&24997319&25955683&32451905&20942902&38774862																																																																												136					0.868							225.12													chr3	110301126																																																	True	False	False	Unknown		Unknown																						0,118	0,66	0,52	0/1	0,0,71,47	TTT	.	.	.			0,0,57,61	64.47		1.0
GRCh38	GSK3B	D12_12345_1234556_Thyroid_S9			chr3	119905776		A	<INS>	<INS>	119905776	MantaINS:1845:1:1:0:10:0	A	<INS>	.	PASS	NM_001146156	insertion	feature_elongation&coding_sequence_variant	HIGH	GSK3B	ENSG00000082701	Transcript	ENST00000264235	protein_coding	7/11			1804	791	264					-1		insertion	HGNC	HGNC:4617	YES	MANE_Select	NM_001146156.2		1	A1	CCDS54628.1	ENSP00000264235	P49841.267	Q6FI27.165	UPI000004DAA4	P49841-1		1			Gene3D:1.10.510.10&PDB-ENSP_mappings:1gng.A&PDB-ENSP_mappings:1gng.B&PDB-ENSP_mappings:1h8f.A&PDB-ENSP_mappings:1h8f.B&PDB-ENSP_mappings:1i09.A&PDB-ENSP_mappings:1i09.B&PDB-ENSP_mappings:1j1b.A&PDB-ENSP_mappings:1j1b.B&PDB-ENSP_mappings:1j1c.A&PDB-ENSP_mappings:1j1c.B&PDB-ENSP_mappings:1o9u.A&PDB-ENSP_mappings:1pyx.A&PDB-ENSP_mappings:1pyx.B&PDB-ENSP_mappings:1q3d.A&PDB-ENSP_mappings:1q3d.B&PDB-ENSP_mappings:1q3w.A&PDB-ENSP_mappings:1q3w.B&PDB-ENSP_mappings:1q41.A&PDB-ENSP_mappings:1q41.B&PDB-ENSP_mappings:1q4l.A&PDB-ENSP_mappings:1q4l.B&PDB-ENSP_mappings:1q5k.A&PDB-ENSP_mappings:1q5k.B&PDB-ENSP_mappings:1r0e.A&PDB-ENSP_mappings:1r0e.B&PDB-ENSP_mappings:1uv5.A&PDB-ENSP_mappings:2jld.A&PDB-ENSP_mappings:2jld.B&PDB-ENSP_mappings:2o5k.A&PDB-ENSP_mappings:2ow3.A&PDB-ENSP_mappings:2ow3.B&PDB-ENSP_mappings:3du8.A&PDB-ENSP_mappings:3du8.B&PDB-ENSP_mappings:3f7z.A&PDB-ENSP_mappings:3f7z.B&PDB-ENSP_mappings:3f88.A&PDB-ENSP_mappings:3f88.B&PDB-ENSP_mappings:3gb2.A&PDB-ENSP_mappings:3i4b.A&PDB-ENSP_mappings:3i4b.B&PDB-ENSP_mappings:3l1s.A&PDB-ENSP_mappings:3l1s.B&PDB-ENSP_mappings:3m1s.A&PDB-ENSP_mappings:3m1s.B&PDB-ENSP_mappings:3pup.A&PDB-ENSP_mappings:3pup.B&PDB-ENSP_mappings:3q3b.A&PDB-ENSP_mappings:3q3b.B&PDB-ENSP_mappings:3say.A&PDB-ENSP_mappings:3say.B&PDB-ENSP_mappings:3sd0.A&PDB-ENSP_mappings:3sd0.B&PDB-ENSP_mappings:3zdi.A&PDB-ENSP_mappings:3zrk.A&PDB-ENSP_mappings:3zrk.B&PDB-ENSP_mappings:3zrl.A&PDB-ENSP_mappings:3zrl.B&PDB-ENSP_mappings:3zrm.A&PDB-ENSP_mappings:3zrm.B&PDB-ENSP_mappings:4acc.A&PDB-ENSP_mappings:4acc.B&PDB-ENSP_mappings:4acd.A&PDB-ENSP_mappings:4acd.B&PDB-ENSP_mappings:4acg.A&PDB-ENSP_mappings:4acg.B&PDB-ENSP_mappings:4ach.A&PDB-ENSP_mappings:4ach.B&PDB-ENSP_mappings:4afj.A&PDB-ENSP_mappings:4afj.B&PDB-ENSP_mappings:4b7t.A&PDB-ENSP_mappings:4dit.A&PDB-ENSP_mappings:4iq6.A&PDB-ENSP_mappings:4iq6.B&PDB-ENSP_mappings:4j1r.A&PDB-ENSP_mappings:4j1r.B&PDB-ENSP_mappings:4j1r.C&PDB-ENSP_mappings:4j1r.D&PDB-ENSP_mappings:4j71.A&PDB-ENSP_mappings:4j71.B&PDB-ENSP_mappings:4nm0.A&PDB-ENSP_mappings:4nm3.A&PDB-ENSP_mappings:4nm5.A&PDB-ENSP_mappings:4nm7.A&PDB-ENSP_mappings:4ptc.A&PDB-ENSP_mappings:4ptc.B&PDB-ENSP_mappings:4pte.A&PDB-ENSP_mappings:4pte.B&PDB-ENSP_mappings:4ptg.A&PDB-ENSP_mappings:4ptg.B&PDB-ENSP_mappings:5f94.A&PDB-ENSP_mappings:5f94.B&PDB-ENSP_mappings:5f95.A&PDB-ENSP_mappings:5f95.B&PDB-ENSP_mappings:5hln.A&PDB-ENSP_mappings:5hln.B&PDB-ENSP_mappings:5hlp.A&PDB-ENSP_mappings:5hlp.B&PDB-ENSP_mappings:5k5n.A&PDB-ENSP_mappings:5k5n.B&PDB-ENSP_mappings:5kpk.A&PDB-ENSP_mappings:5kpk.B&PDB-ENSP_mappings:5kpl.A&PDB-ENSP_mappings:5kpl.B&PDB-ENSP_mappings:5kpm.A&PDB-ENSP_mappings:5kpm.B&PDB-ENSP_mappings:5oy4.A&PDB-ENSP_mappings:5oy4.B&PDB-ENSP_mappings:5t31.A&PDB-ENSP_mappings:5t31.B&PDB-ENSP_mappings:6b8j.A&PDB-ENSP_mappings:6gjo.A&PDB-ENSP_mappings:6gjo.B&PDB-ENSP_mappings:6gn1.A&PDB-ENSP_mappings:6gn1.B&PDB-ENSP_mappings:6h0u.A&PDB-ENSP_mappings:6h0u.B&PDB-ENSP_mappings:6hk3.A&PDB-ENSP_mappings:6hk3.B&PDB-ENSP_mappings:6hk4.A&PDB-ENSP_mappings:6hk4.B&PDB-ENSP_mappings:6hk7.A&PDB-ENSP_mappings:6tcu.A&PDB-ENSP_mappings:6v6l.A&PDB-ENSP_mappings:6y9r.A&PDB-ENSP_mappings:6y9s.A&PDB-ENSP_mappings:6y9s.B&PDB-ENSP_mappings:7b6f.A&PDB-ENSP_mappings:7oy5.A&PDB-ENSP_mappings:7oy5.B&PDB-ENSP_mappings:7sxh.A&PDB-ENSP_mappings:7sxj.A&PDB-ENSP_mappings:7u2z.A&PDB-ENSP_mappings:7u2z.B&PDB-ENSP_mappings:7u31.A&PDB-ENSP_mappings:7u31.B&PDB-ENSP_mappings:7u33.A&PDB-ENSP_mappings:7u33.B&PDB-ENSP_mappings:7u36.A&PDB-ENSP_mappings:7u36.B&PDB-ENSP_mappings:7z1f.A&PDB-ENSP_mappings:7z1f.B&PDB-ENSP_mappings:7z1g.A&PDB-ENSP_mappings:8auz.A&PDB-ENSP_mappings:8auz.B&PDB-ENSP_mappings:8av1.A&PDB-ENSP_mappings:8av1.B&PDB-ENSP_mappings:8djc.A&PDB-ENSP_mappings:8djc.B&PDB-ENSP_mappings:8djd.A&PDB-ENSP_mappings:8djd.B&PDB-ENSP_mappings:8dje.A&PDB-ENSP_mappings:8dje.B&PDB-ENSP_mappings:8ff8.A&PDB-ENSP_mappings:8ff8.B&PDB-ENSP_mappings:8xn6.A&PDB-ENSP_mappings:8xn6.B&AFDB-ENSP_mappings:AF-P49841-F1&Pfam:PF00069&PROSITE_profiles:PS50011&PANTHER:PTHR24057&SMART:SM00220&Superfamily:SSF56112&CDD:cd14137																																																																																																												0,92		0,92							92	TCCACACCACTATCCCCTGGAAATATTGGTTGTCCTAGTAACAGCTCAGCCAACACACAGCCAGCAGACCATACATCTAAAGAGAAAAGAAA		TCCACACCACTATCCCCTGGAAATATTGGTTGTCCTAGTAACAGCTCAGCCAACACACAGCCAGCAGACCATACATCTAAAGAGAAAAGAAAGGTTCACCTCTGTGAGATGAATGCACACATCACAAAGTAGTTTCTCAGATTGCTTCTGTCTAG																chr3	119624623	ATTCGATTATGATTCATTTCGTGTTCATTCTATGGTTCCACAGGTTTCCATTCGTG			INS																																													True	True	False	Unknown		Unknown																															1,0				0,4	
GRCh38	GATA2	D12_12345_1234556_Thyroid_S9	p.Thr188=	ENSP00000345681.2:p.Thr188=	chr3	128486034	128486034.0	C	G	G	128486034	.	C	G	.	PASS	NM_032638	G	synonymous_variant	LOW	GATA2	ENSG00000179348	Transcript	ENST00000341105	protein_coding	3/6		c.564G>C	912	564	188	T	acG/acC	rs34870876&COSV62003138		-1		SNV	HGNC	HGNC:4171	YES	MANE_Select	NM_032638.5		1	P1	CCDS3049.1	ENSP00000345681	P23769.210		UPI00000730CD	P23769-1		1			AFDB-ENSP_mappings:AF-P23769-F1&PIRSF:PIRSF003027&PANTHER:PTHR10071&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.0186	0.0008	0.0288	0	0.0586	0.0133	0.0541	0.007912	0.01501	0.01119	0.0001784	0.09107	0.006634	0.06138	0.04429	0.02367	0.0396	0.01006	0.07965	0.02345	0.008111	0.0001946	0.09178	0.006803	0.0588	0.0351	0.02174	0.09178	gnomADg_FIN	benign	0&1	1&1	25741868&34641967						FAIL	6	-44	-34	-3	0.08	0.00	0.00	0.00	GATA2		3.3500e-01	257566	0.04014		0.01857	250902	not_provided&not_specified&Deafness-lymphedema-leukemia_syndrome&Monocytopenia_with_susceptibility_to_infections&Inborn_genetic_diseases		MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0013540&MedGen:C3279664&OMIM:614038&Orphanet:3226&MONDO:MONDO:0013607&MedGen:C3280030&OMIM:614172&Orphanet:228423&MeSH:D030342&MedGen:C0950123		NC_000003.12:g.128486034C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306841&SCV000440693&SCV000554443&SCV000702963&SCV001858513&SCV002506309&SCV005301744&SCV005596753	single_nucleotide_variant	SO:0001483	ClinGen:CA2600002		GATA2:2624	SO:0001819&synonymous_variant										1	34870876																											841					0.992							243.97	v6.1	Unknown		True	GATA2, a transcription factor, is recurrently mutated in hematological malignancies and various solid tumors.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA2 ENSP00000345681.2:T188= mutant UNKNOWN.	False	The GATA2 ENSP00000345681.2:t188= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	128204877						True	False	False	Unknown								False	False		GATA2, a transcription factor, is recurrently mutated in hematological malignancies and various solid tumors.	The GATA2 ENSP00000345681.2:t188= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA2 ENSP00000345681.2:T188= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	GATA2	2624.0	ENSP00000345681.2:T188=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GATA2"",""entrezGeneId"":2624,""alteration"":""ENSP00000345681.2:T188="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GATA2, a transcription factor, is recurrently mutated in hematological malignancies and various solid tumors."",""variantSummary"":""The GATA2 ENSP00000345681.2:t188= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA2 ENSP00000345681.2:T188= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						416,418	208,210	208,208	0/1	217,199,185,233	CCG	.	.	.			253,163,245,173	53.27		0.5011990407673861
GRCh38	GATA2	D12_12345_1234556_Thyroid_S9	p.Pro5=	ENSP00000345681.2:p.Pro5=	chr3	128487017	128487017.0	G	C	C	128487017	.	G	C	.	PASS	NM_032638	C	synonymous_variant	LOW	GATA2	ENSG00000179348	Transcript	ENST00000341105	protein_coding	2/6		c.15C>G	363	15	5	P	ccC/ccG	rs1573858&COSV62003056		-1		SNV	HGNC	HGNC:4171	YES	MANE_Select	NM_032638.5		1	P1	CCDS3049.1	ENSP00000345681	P23769.210		UPI00000730CD	P23769-1		1			AFDB-ENSP_mappings:AF-P23769-F1&PIRSF:PIRSF003027			0.7099	0.8222	0.7046	0.6944	0.664	0.6247	0.6339	0.7932	0.7119	0.7525	0.6413	0.5376	0.7784	0.6224	0.661	0.6734	0.6813	0.7857	0.7626	0.7182	0.7324	0.7022	0.5309	0.7705	0.6285	0.6924	0.6558	0.8222	AFR	benign	0&1	1&1	25741868&24033266&31672593&34641967&36806681&34638133&33831168&37595058						FAIL	9	37	-37	9	0.00	0.00	0.00	0.00	GATA2		3.3500e-01	257563	0.69339	0.69432	0.70986	250906	Monocytopenia_with_susceptibility_to_infections&not_specified&Inborn_genetic_diseases&Deafness-lymphedema-leukemia_syndrome&not_provided		MONDO:MONDO:0013607&MedGen:C3280030&OMIM:614172&Orphanet:228423&MedGen:CN169374&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0013540&MedGen:C3279664&OMIM:614038&Orphanet:3226&MedGen:C3661900		NC_000003.12:g.128487017G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000306836&SCV000440698&SCV000539225&SCV000702962&SCV001728581&SCV001933738&SCV001933739&SCV001944929&SCV002049329&SCV004102608&SCV005301749&SCV005596750	single_nucleotide_variant	SO:0001483	ClinGen:CA2600126		GATA2:2624	SO:0001819&synonymous_variant										1	1573858																											410					0.998							248.18	v6.1	Unknown		True	GATA2, a transcription factor, is recurrently mutated in hematological malignancies and various solid tumors.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA2 ENSP00000345681.2:P5= mutant UNKNOWN.	False	The GATA2 ENSP00000345681.2:p5= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	128205860						True	False	False	Unknown								False	False		GATA2, a transcription factor, is recurrently mutated in hematological malignancies and various solid tumors.	The GATA2 ENSP00000345681.2:p5= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA2 ENSP00000345681.2:P5= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	GATA2	2624.0	ENSP00000345681.2:P5=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GATA2"",""entrezGeneId"":2624,""alteration"":""ENSP00000345681.2:P5="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GATA2, a transcription factor, is recurrently mutated in hematological malignancies and various solid tumors."",""variantSummary"":""The GATA2 ENSP00000345681.2:p5= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA2 ENSP00000345681.2:P5= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						217,192	108,92	109,100	0/1	98,119,104,88	CGG	.	.	.			71,146,62,130	32.34		0.46943765281173594
GRCh38	EPHB1	D12_12345_1234556_Thyroid_S9	p.Ser145=	ENSP00000381097.3:p.Ser145=	chr3	134951682	134951682.0	C	T	T	134951682	.	C	T	.	PASS	NM_004441	T	synonymous_variant	LOW	EPHB1	ENSG00000154928	Transcript	ENST00000398015	protein_coding	3/16		c.435C>T	807	435	145	S	agC/agT	rs7644369&COSV67660842		1		SNV	HGNC	HGNC:3392	YES	MANE_Select	NM_004441.5		1	P1	CCDS46921.1	ENSP00000381097	P54762.230		UPI000012A07E	P54762-1					Gene3D:2.60.120.260&Pfam:PF01404&PIRSF:PIRSF000666&PANTHER:PTHR46877&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd10476&PROSITE_profiles:PS51550&SMART:SM00615&Superfamily:SSF49785&AFDB-ENSP_mappings:AF-P54762-F1			0.4814	0.6377	0.5692	0.2123	0.4394	0.5286	0.4492	0.6266	0.5225	0.5388	0.1587	0.3595	0.5641	0.447	0.4571	0.5194	0.4887	0.6069	0.4242	0.5179	0.5259	0.1983	0.3431	0.5748	0.4508	0.5033	0.5193	0.6377	AFR		0&1	0&1	21763378&26437399&37103689						FAIL	10	-7	-27	36	0.00	0.00	0.00	0.07	EPHB1		4.4100e-01																																																											788					0.995							246.72	v6.1	Unknown		True	EPHB1, a receptor tyrosine kinase, is altered by mutation in various cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHB1 ENSP00000381097.3:S145= mutant UNKNOWN.	False	The EPHB1 ENSP00000381097.3:s145= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	134670524						True	False	False	Unknown								False	False		EPHB1, a receptor tyrosine kinase, is altered by mutation in various cancer types.	The EPHB1 ENSP00000381097.3:s145= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHB1 ENSP00000381097.3:S145= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	EPHB1	2047.0	ENSP00000381097.3:S145=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EPHB1"",""entrezGeneId"":2047,""alteration"":""ENSP00000381097.3:S145="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EPHB1, a receptor tyrosine kinase, is altered by mutation in various cancer types."",""variantSummary"":""The EPHB1 ENSP00000381097.3:s145= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHB1 ENSP00000381097.3:S145= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						397,387	192,198	205,189	0/1	179,218,184,203	GCT	0.00	0.00	0.00			166,231,197,190	46.97		0.49362244897959184
GRCh38	EPHB1	D12_12345_1234556_Thyroid_S9	p.Tyr600=	ENSP00000381097.3:p.Tyr600=	chr3	135179900	135179900.0	C	T	T	135179900	.	C	T	.	PASS	NM_004441	T	synonymous_variant	LOW	EPHB1	ENSG00000154928	Transcript	ENST00000398015	protein_coding	10/16		c.1800C>T	2172	1800	600	Y	taC/taT	rs1042787&COSV67654940		1		SNV	HGNC	HGNC:3392	YES	MANE_Select	NM_004441.5		1	P1	CCDS46921.1	ENSP00000381097	P54762.230		UPI000012A07E	P54762-1					Gene3D:3.30.200.20&PIRSF:PIRSF000666&Pfam:PF14575&PANTHER:PTHR46877&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P54762-F1			0.5379	0.5166	0.5	0.7282	0.3797	0.5603	0.4216	0.4984	0.5015	0.3187	0.7178	0.321	0.3232	0.4049	0.4257	0.5266	0.442	0.502	0.3835	0.4842	0.3243	0.7049	0.3066	0.3129	0.3983	0.43	0.5326	0.7282	EAS		0&1	0&1							FAIL	-3	-31	-2	45	0.00	0.01	0.00	0.00	EPHB1		4.4100e-01																																																											310					0.981							246.03	v6.1	Unknown		True	EPHB1, a receptor tyrosine kinase, is altered by mutation in various cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHB1 ENSP00000381097.3:Y600= mutant UNKNOWN.	False	The EPHB1 ENSP00000381097.3:y600= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	134898742						True	False	False	Unknown								False	False		EPHB1, a receptor tyrosine kinase, is altered by mutation in various cancer types.	The EPHB1 ENSP00000381097.3:y600= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHB1 ENSP00000381097.3:Y600= mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	EPHB1	2047.0	ENSP00000381097.3:Y600=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EPHB1"",""entrezGeneId"":2047,""alteration"":""ENSP00000381097.3:Y600="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EPHB1, a receptor tyrosine kinase, is altered by mutation in various cancer types."",""variantSummary"":""The EPHB1 ENSP00000381097.3:y600= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHB1 ENSP00000381097.3:Y600= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						188,116	99,55	89,61	0/1	92,96,57,59	ACG	0.00	0.00	0.00			93,95,64,52	11.9		0.3815789473684211
GRCh38	PIK3CB	D12_12345_1234556_Thyroid_S9			chr3	138692372	138692372.0	A	G	G	138692372	.	A	G	.	PASS	NM_006219	G	intron_variant	MODIFIER	PIK3CB	ENSG00000051382	Transcript	ENST00000674063	protein_coding		14/23	c.1893-1229T>C						rs361055		-1		SNV	HGNC	HGNC:8976	YES	MANE_Select	NM_006219.3			P1	CCDS3104.1	ENSP00000501150	P42338.215		UPI0000046842			1						0.5889	0.2042	0.6671	0.9821	0.5467	0.6912											0.5079	0.2588	0.4561	0.6373	0.5181	0.9832	0.6751	0.5136	0.5573	0.5256	0.6649	0.9832	gnomADg_EAS										FAIL	4	-4	-35	2	0.00	0.00	0.00	0.00	PIK3CB		3.1900e-01																																																											153					0.922							230.94													chr3	138411214																																																	True	True	False	Unknown		Unknown																						72,69	30,31	42,38	0/1	44,28,35,34	CAT	.	.	.			22,50,25,44	35.46		0.48936170212765956
GRCh38	PIK3CB	D12_12345_1234556_Thyroid_S9			chr3	138707586	138707586.0	T	C	C	138707586	.	T	C	.	PASS	NM_006219	C	intron_variant	MODIFIER	PIK3CB	ENSG00000051382	Transcript	ENST00000674063	protein_coding		10/23	c.1400-297A>G						rs361084		-1		SNV	HGNC	HGNC:8976	YES	MANE_Select	NM_006219.3			P1	CCDS3104.1	ENSP00000501150	P42338.215		UPI0000046842			1						0.6825	0.5749	0.6816	0.9841	0.5189	0.6861	0.5386	0.5448	0.6925	0.4742	0.9845	0.6612	0.4822	0.5275	0.5633	0.6376	0.5769	0.5549	0.4561	0.6418	0.4816	0.9847	0.6632	0.4796	0.5331	0.5562	0.6579	0.9847	gnomADg_EAS				20508983						FAIL	0	29	45	-44	0.00	0.00	0.00	0.00	PIK3CB		3.1900e-01																																																											84					0.94							238.39													chr3	138426428																																																	True	True	False	Unknown		Unknown																						40,39	19,20	21,19	0/1	19,21,18,21	CTC	.	.	.			22,18,13,26	34.18		0.4936708860759494
GRCh38	ATR	D12_12345_1234556_Thyroid_S9	p.Gln2625=	ENSP00000343741.4:p.Gln2625=	chr3	142449489	142449489.0	C	T	T	142449489	.	C	T	.	PASS	NM_001184	T	synonymous_variant	LOW	ATR	ENSG00000175054	Transcript	ENST00000350721	protein_coding	47/47		c.7875G>A	7904	7875	2625	Q	caG/caA	rs1802904&COSV99377126		-1		SNV	HGNC	HGNC:882	YES	MANE_Select	NM_001184.4		1	P1	CCDS3124.1	ENSP00000343741	Q13535.213		UPI0000031A31	Q13535-1		1			PDB-ENSP_mappings:5yz0.A&PDB-ENSP_mappings:5yz0.B&PROSITE_profiles:PS51190&SMART:SM01343&SMART:SM00146&Pfam:PF02260&PANTHER:PTHR11139&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13535-F1			0.9163	0.9856	0.8084	0.9266	0.8658	0.9407	0.8689	0.9738	0.7652	0.7749	0.9076	0.8102	0.8609	0.868	0.8761	0.9354	0.8866	0.9696	0.8392	0.8056	0.7837	0.9289	0.8043	0.8435	0.8665	0.8737	0.9392	0.9856	AFR	benign&benign/likely_benign	0&1	1&1	24033266&18414213&23757202&17010193&23844225&32724790						FAIL	22	-1	-32	32	0.00	0.00	0.00	0.00	ATR		5.1800e-01	93669	0.89782	0.86461	0.91633	99572	not_provided&Familial_cutaneous_telangiectasia_and_oropharyngeal_predisposition_cancer_syndrome&Seckel_syndrome_1&Hereditary_cancer-predisposing_syndrome&not_specified		MedGen:C3661900&MONDO:MONDO:0013806&MedGen:C3281203&OMIM:614564&Orphanet:313846&MONDO:MONDO:0008869&MedGen:C4551474&OMIM:210600&Orphanet:808&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374		NC_000003.12:g.142449489C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000111483&SCV000192411&SCV000441390&SCV000538376&SCV000697788&SCV001729232&SCV001775060&SCV001944573&SCV004015468&SCV005257849&SCV006311428	single_nucleotide_variant	SO:0001483	ClinGen:CA147190		ATR:545	SO:0001819&synonymous_variant										1	1802904																											100					0.96							243.67	v6.1	Unknown		True	ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:Q2625= mutant UNKNOWN.	False	The ATR ENSP00000343741.4:q2625= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	142168331						True	False	False	Unknown								False	False		ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	The ATR ENSP00000343741.4:q2625= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:Q2625= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ATR	545.0	ENSP00000343741.4:Q2625=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ATR"",""entrezGeneId"":545,""alteration"":""ENSP00000343741.4:Q2625="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types."",""variantSummary"":""The ATR ENSP00000343741.4:q2625= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:Q2625= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,96	0,51	0,45	0/1	0,0,48,48	CCT	0.00	0.00	0.00			0,0,53,43	64.66		1.0
GRCh38	ATR	D12_12345_1234556_Thyroid_S9	p.Tyr1736=	ENSP00000343741.4:p.Tyr1736=	chr3	142503442	142503442.0	A	G	G	142503442	.	A	G	.	PASS	NM_001184	G	synonymous_variant	LOW	ATR	ENSG00000175054	Transcript	ENST00000350721	protein_coding	30/47		c.5208T>C	5237	5208	1736	Y	taT/taC	rs2227931&COSV63386201		-1		SNV	HGNC	HGNC:882	YES	MANE_Select	NM_001184.4		1	P1	CCDS3124.1	ENSP00000343741	Q13535.213		UPI0000031A31	Q13535-1		1			PDB-ENSP_mappings:5yz0.A&PDB-ENSP_mappings:5yz0.B&PROSITE_profiles:PS51189&Superfamily:SSF48452&Superfamily:SSF48371&Gene3D:1.25.40.10&PANTHER:PTHR11139&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13535-F1			0.3125	0.2073	0.353	0.3542	0.3917	0.3016	0.3889	0.1939	0.3209	0.4575	0.3239	0.3827	0.3919	0.409	0.3806	0.2612	0.342	0.2037	0.5793	0.3538	0.4496	0.3537	0.3808	0.4422	0.4118	0.3714	0.2717	0.5793	gnomADg_AMI	benign&likely_benign	0&1	1&1	18414213&21085059&17010193&32597209&38813106						FAIL	11	-26	11	22	0.20	0.00	0.00	0.00	ATR		5.1800e-01	157992	0.34957	0.36398	0.31250	167839	Hereditary_cancer-predisposing_syndrome&not_specified&Familial_cutaneous_telangiectasia_and_oropharyngeal_predisposition_cancer_syndrome&not_provided&Seckel_syndrome_1		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MONDO:MONDO:0013806&MedGen:C3281203&OMIM:614564&Orphanet:313846&MedGen:C3661900&MONDO:MONDO:0008869&MedGen:C4551474&OMIM:210600&Orphanet:808		NC_000003.12:g.142503442A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000192395&SCV000441420&SCV000697786&SCV001729234&SCV001902916&SCV003801477&SCV003801478&SCV004015479&SCV005257869&SCV006311433	single_nucleotide_variant	SO:0001483	ClinGen:CA171367		ATR:545	SO:0001819&synonymous_variant										1	2227931																											112					0.973							242.67	v6.1	Unknown		True	ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:Y1736= mutant UNKNOWN.	False	The ATR ENSP00000343741.4:y1736= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	142222284						True	False	False	Unknown								False	False		ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	The ATR ENSP00000343741.4:y1736= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:Y1736= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ATR	545.0	ENSP00000343741.4:Y1736=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ATR"",""entrezGeneId"":545,""alteration"":""ENSP00000343741.4:Y1736="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types."",""variantSummary"":""The ATR ENSP00000343741.4:y1736= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:Y1736= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,109	0,54	0,55	0/1	0,0,60,49	GAT	.	.	.			0,0,49,60	64.69		1.0
GRCh38	ATR	D12_12345_1234556_Thyroid_S9	p.R635Q	ENSP00000343741.4:p.Arg635Gln	chr3	142556557	142556557.0	C	T	T	142556557	.	C	T	.	PASS	NM_001184	T	missense_variant	MODERATE	ATR	ENSG00000175054	Transcript	ENST00000350721	protein_coding	9/47		c.1904G>A	1933	1904	635	R/Q	cGa/cAa	rs202162034&COSV63386230		-1		SNV	HGNC	HGNC:882	YES	MANE_Select	NM_001184.4		1	P1	CCDS3124.1	ENSP00000343741	Q13535.213		UPI0000031A31	Q13535-1		1	tolerated_low_confidence(0.56)	benign(0)	PDB-ENSP_mappings:5yz0.A&PDB-ENSP_mappings:5yz0.B&Superfamily:SSF48371&Gene3D:1.25.10.10&PANTHER:PTHR11139&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13535-F1									0.000535	5.974e-05	0.0001342	0.0001914	5.04e-05	0	0.0008669	0.0006637	0.0003808	1.16e-05	0.0002498	0.000169	0	6.549e-05	0.0002882	0	0	0	0.0004116	0.0004785	0	0.0008669	gnomADe_MID	uncertain_significance&likely_benign	0&1	1&1							FAIL	-31	18	-2	10	0.07	0.21	0.00	0.00	ATR	0.084	5.1800e-01	900024	0.00023	0.00026		888105	ATR-related_disorder&Seckel_syndrome_1&Familial_cutaneous_telangiectasia_and_oropharyngeal_predisposition_cancer_syndrome&not_provided&Inborn_genetic_diseases&not_specified		.&MONDO:MONDO:0008869&MedGen:C4551474&OMIM:210600&Orphanet:808&MONDO:MONDO:0013806&MedGen:C3281203&OMIM:614564&Orphanet:313846&MedGen:C3661900&MeSH:D030342&MedGen:C0950123&MedGen:CN169374		NC_000003.12:g.142556557C>T	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(8)&Likely_benign(1)		SCV001305584&SCV001385378&SCV002048472&SCV002071014&SCV002722663&SCV003834502&SCV004111503&SCV005078182&SCV005662772	single_nucleotide_variant	SO:0001483	ClinGen:CA2650470		ATR:545	SO:0001583&missense_variant										1	202162034																											68					1							246.46	v6.1	Unknown		True	ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:R635Q mutant UNKNOWN.	False	The ATR ENSP00000343741.4:r635q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	142275399						True	False	False	Unknown								False	False		ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	The ATR ENSP00000343741.4:r635q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:R635Q mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ATR	545.0	ENSP00000343741.4:R635Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ATR"",""entrezGeneId"":545,""alteration"":""ENSP00000343741.4:R635Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types."",""variantSummary"":""The ATR ENSP00000343741.4:r635q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:R635Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						37,31	20,15	17,16	0/1	13,24,12,19	TCG	0.00	0.00	0.00			18,19,16,15	30.52		0.45588235294117646
GRCh38	ATR	D12_12345_1234556_Thyroid_S9	p.Asp605=	ENSP00000343741.4:p.Asp605=	chr3	142558694	142558694.0	A	G	G	142558694	.	A	G	.	PASS	NM_001184	G	synonymous_variant	LOW	ATR	ENSG00000175054	Transcript	ENST00000350721	protein_coding	8/47		c.1815T>C	1844	1815	605	D	gaT/gaC	rs2227929&COSV63386203		-1		SNV	HGNC	HGNC:882	YES	MANE_Select	NM_001184.4		1	P1	CCDS3124.1	ENSP00000343741	Q13535.213		UPI0000031A31	Q13535-1		1			PDB-ENSP_mappings:5yz0.A&PDB-ENSP_mappings:5yz0.B&Superfamily:SSF48371&Gene3D:1.25.10.10&PANTHER:PTHR11139&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13535-F1			0.3107	0.2042	0.3516	0.3552	0.3867	0.3016	0.386	0.1942	0.3218	0.4499	0.3251	0.3774	0.3922	0.4054	0.3787	0.2622	0.3375	0.2016	0.5526	0.3524	0.442	0.3542	0.3722	0.4388	0.4053	0.3719	0.2718	0.5526	gnomADg_AMI	benign	0&1	1&1	18414213&21085059&17010193						FAIL	-13	1	-49	41	0.00	0.00	0.00	0.04	ATR		5.1800e-01	157966	0.34576	0.35160	0.31070	167813	Hereditary_cancer-predisposing_syndrome&not_provided&not_specified&Familial_cutaneous_telangiectasia_and_oropharyngeal_predisposition_cancer_syndrome&Seckel_syndrome_1		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0013806&MedGen:C3281203&OMIM:614564&Orphanet:313846&MONDO:MONDO:0008869&MedGen:C4551474&OMIM:210600&Orphanet:808		NC_000003.12:g.142558694A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000192369&SCV000202208&SCV000441450&SCV001729235&SCV001847397&SCV003801841&SCV003801842&SCV004015523&SCV005303013&SCV006311431	single_nucleotide_variant	SO:0001483	ClinGen:CA171342		ATR:545	SO:0001819&synonymous_variant										1	2227929																											195					0.969							246.16	v6.1	Unknown		True	ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:D605= mutant UNKNOWN.	False	The ATR ENSP00000343741.4:d605= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	142277536						True	False	False	Unknown								False	False		ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	The ATR ENSP00000343741.4:d605= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:D605= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ATR	545.0	ENSP00000343741.4:D605=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ATR"",""entrezGeneId"":545,""alteration"":""ENSP00000343741.4:D605="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types."",""variantSummary"":""The ATR ENSP00000343741.4:d605= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:D605= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,189	0,102	0,87	0/1	0,0,94,95	CAT	.	.	.			0,0,73,116	64.72		1.0
GRCh38	ATR	D12_12345_1234556_Thyroid_S9	p.Gly592=	ENSP00000343741.4:p.Gly592=	chr3	142558733	142558733.0	A	T	T	142558733	.	A	T	.	PASS	NM_001184	T	synonymous_variant	LOW	ATR	ENSG00000175054	Transcript	ENST00000350721	protein_coding	8/47		c.1776T>A	1805	1776	592	G	ggT/ggA	rs2227930&COSV63383320		-1		SNV	HGNC	HGNC:882	YES	MANE_Select	NM_001184.4		1	P1	CCDS3124.1	ENSP00000343741	Q13535.213		UPI0000031A31	Q13535-1		1			PDB-ENSP_mappings:5yz0.A&PDB-ENSP_mappings:5yz0.B&Superfamily:SSF48371&Gene3D:1.25.10.10&PANTHER:PTHR11139&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13535-F1			0.5980	0.8533	0.5058	0.4732	0.5865	0.4591	0.5716	0.8046	0.4627	0.5609	0.4444	0.5478	0.563	0.5855	0.5743	0.4334	0.6265	0.7943	0.6787	0.5332	0.5605	0.465	0.5394	0.6062	0.5866	0.6255	0.4434	0.8533	AFR	benign&benign/likely_benign	0&1	1&1	24033266&18414213&17010193&27863252&32888493&29403010						FAIL	43	2	-50	2	0.05	0.00	0.00	0.34	ATR		5.1800e-01	157965	0.66300	0.55292	0.59804	167812	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_cutaneous_telangiectasia_and_oropharyngeal_predisposition_cancer_syndrome&Seckel_syndrome_1		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0013806&MedGen:C3281203&OMIM:614564&Orphanet:313846&MONDO:MONDO:0008869&MedGen:C4551474&OMIM:210600&Orphanet:808		NC_000003.12:g.142558733A>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000192368&SCV000202209&SCV000441452&SCV000538378&SCV000697779&SCV001729236&SCV001751843&SCV001775062&SCV004015534&SCV005260844&SCV006311420	single_nucleotide_variant	SO:0001483	ClinGen:CA171340		ATR:545	SO:0001819&synonymous_variant										1	2227930																											167					0.952							245.17	v6.1	Unknown		True	ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:G592= mutant UNKNOWN.	False	The ATR ENSP00000343741.4:g592= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	142277575						True	False	False	Unknown								False	False		ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types.	The ATR ENSP00000343741.4:g592= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:G592= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ATR	545.0	ENSP00000343741.4:G592=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ATR"",""entrezGeneId"":545,""alteration"":""ENSP00000343741.4:G592="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ATR, a tumor suppressor involved in DNA damage repair, is mutated in various cancer types."",""variantSummary"":""The ATR ENSP00000343741.4:g592= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATR ENSP00000343741.4:G592= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						0,159	0,87	0,72	0/1	0,0,82,77	TAC	.	.	.			0,0,64,95	64.72		1.0
GRCh38	ATR	D12_12345_1234556_Thyroid_S9	p.K297N	ENSP00000343741.4:p.Lys297Asn	chr3	142562511	142562511.0	C	G	G	142562511	.	C	G	.	PASS	NM_001184	G	missense_variant	MODERATE	ATR	ENSG00000175054	Transcript	ENST00000350721	protein_coding	4/47		c.891G>C	920	891	297	K/N	aaG/aaC	rs2229033&COSV63384505		-1		SNV	HGNC	HGNC:882	YES	MANE_Select	NM_001184.4		1	P1	CCDS3124.1	ENSP00000343741	Q13535.213		UPI0000031A31	Q13535-1		1	tolerated(0.36)	benign(0.041)	PDB-ENSP_mappings:5yz0.A&PDB-ENSP_mappings:5yz0.B&Superfamily:SSF48371&PANTHER:PTHR11139&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13535-F1			0.0030	0.0015	0.0058	0	0.0089	0	0.01252	0.001974	0.00564	0.01773	2.52e-05	0.01286	0.01058	0.01425	0.01189	0.002308	0.009844	0.002262	0.01096	0.005489	0.01499	0	0.01349	0.003401	0.01606	0.008979	0.0008275	0.01773	gnomADe_ASJ	benign&benign/likely_benign	0&1	1&1	25741868&18414213&22792358&23313170						FAIL	-29	46	46	0	0.00	0.00	0.00	0.00	ATR	0.097	5.1800e-01	158005	0.01184		0.00300	167852	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_cutaneous_telangiectasia_and_oropharyngeal_predisposition_cancer_syndrome&Seckel_syndrome_1		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0013806&MedGen:C3281203&OMIM:614564&Orphanet:313846&MONDO:MONDO:0008869&MedGen:C4551474&OMIM:210600&Orphanet:808		NC_000003.12:g.142562511C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000192412&SCV000266995&SCV000730060&SCV001159512&SCV001308660&SCV001720445&SCV002544839&SCV003801935&SCV003801936&SCV004016079&SCV005260846&SCV006311424	single_nucleotide_variant	SO:0001483	ClinGen:CA171382&UniProtKB:Q13535																																																																																																																																															46,46	27,20	19,26	0/1	27,19,23,23	GCT	.	.	.			28,18,23,23	35.33		0.5
GRCh38	ATR	D12_12345_1234556_Thyroid_S9	p.M211T	ENSP00000343741.4:p.Met211Thr	chr3	142562770	142562770.0	A	G	G	142562770	.	A	G	.	PASS	NM_001184	G	missense_variant	MODERATE	ATR	ENSG00000175054	Transcript	ENST00000350721	protein_coding	4/47		c.632T>C	661	632	211	M/T	aTg/aCg	rs2227928&COSV63383325		-1		SNV	HGNC	HGNC:882	YES	MANE_Select	NM_001184.4		1	P1	CCDS3124.1	ENSP00000343741	Q13535.213		UPI0000031A31	Q13535-1		1	tolerated(0.84)	benign(0)	PDB-ENSP_mappings:5yz0.A&PDB-ENSP_mappings:5yz0.B&PANTHER:PTHR11139&Phobius:TRANSMEMBRANE&AFDB-ENSP_mappings:AF-Q13535-F1			0.5974	0.8517	0.5058	0.4732	0.5865	0.4581	0.5724	0.8018	0.4639	0.5616	0.4444	0.548	0.5637	0.5862	0.5749	0.4347	0.6256	0.7907	0.6791	0.5336	0.5603	0.4644	0.5387	0.6054	0.5871	0.6251	0.443	0.8517	AFR	benign&benign/likely_benign	0&1	1&1	24033266&22938532&18414213&26743341&23757202&18191955&28415781&18551366&28238063&26920143&17010193&32597209&23313170&36233089&22767148&27905519&36969849&34594039						FAIL	-37	-40	-1	40	0.00	0.00	0.00	0.00	ATR	0.089	5.1800e-01	93668	0.66231	0.55398	0.59744	99571	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_cutaneous_telangiectasia_and_oropharyngeal_predisposition_cancer_syndrome&Seckel_syndrome_1		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0013806&MedGen:C3281203&OMIM:614564&Orphanet:313846&MONDO:MONDO:0008869&MedGen:C4551474&OMIM:210600&Orphanet:808		NC_000003.12:g.142562770A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000111482&SCV000192403&SCV000441457&SCV000538379&SCV001729237&SCV001775063&SCV001861027&SCV004015567&SCV005260848&SCV006311421	single_nucleotide_variant	SO:0001483	ClinGen:CA147188&UniProtKB:Q13535																																																																																																																																															0,90	0,46	0,44	0/1	0,0,44,46	CAT	.	.	.			0,0,44,46	64.64		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr3	151080811		T	[chr1:64619402[T	[chr1:64619402[T	151080811	MantaBND:4637:0:1:0:0:0:0	T	[chr1:64619402[T	.	PASS		.T	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH		ENSG00000306422	Transcript	ENST00000818311	lncRNA		1/2									-1		chromosome_breakpoint																																																																																																																														1			0,9							9	TTCTGTTTT			MantaBND:4637:0:1:0:0:0:1	0														chr3	150798598				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	LINC01994	D12_12345_1234556_Thyroid_S9			chr3	182437646		C	[chr6:47007909[C	[chr6:47007909[C	182437646	MantaBND:9113:0:1:0:0:0:0	C	[chr6:47007909[C	.	PASS		.C	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	LINC01994	ENSG00000241098	Transcript	ENST00000715741	lncRNA		3/6									-1		chromosome_breakpoint	HGNC	HGNC:52827																																																																																																																												1			0,10							10	TTTTTAATGC			MantaBND:9113:0:1:0:0:0:1	2														chr3	182155434				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38	DCUN1D1	D12_12345_1234556_Thyroid_S9	p.Ala106=	ENSP00000292782.4:p.Ala106=	chr3	182963952	182963952.0	C	T	T	182963952	.	C	T	.	PASS	NM_020640	T	synonymous_variant	LOW	DCUN1D1	ENSG00000043093	Transcript	ENST00000292782	protein_coding	3/7		c.318G>A	367	318	106	A	gcG/gcA	rs4859146&COSV53044616		-1		SNV	HGNC	HGNC:18184	YES	MANE_Select	NM_020640.4		1	P1	CCDS3240.1	ENSP00000292782	Q96GG9.173		UPI0000073D68						Gene3D:1.10.238.10&PDB-ENSP_mappings:3tdu.A&PDB-ENSP_mappings:3tdu.B&PDB-ENSP_mappings:3tdz.A&PDB-ENSP_mappings:3tdz.B&PDB-ENSP_mappings:4p5o.E&PDB-ENSP_mappings:4p5o.F&PDB-ENSP_mappings:5ufi.A&PDB-ENSP_mappings:5ufi.B&PDB-ENSP_mappings:5ufi.C&PDB-ENSP_mappings:5ufi.D&PDB-ENSP_mappings:5v83.A&PDB-ENSP_mappings:5v86.A&PDB-ENSP_mappings:5v88.A&PDB-ENSP_mappings:6b5q.A&PDB-ENSP_mappings:6b5q.B&PDB-ENSP_mappings:6bg3.A&PDB-ENSP_mappings:6bg5.A&PDB-ENSP_mappings:6p5v.A&PDB-ENSP_mappings:6p5w.A&PDB-ENSP_mappings:6xol.A&PDB-ENSP_mappings:6xom.A&PDB-ENSP_mappings:6xon.A&PDB-ENSP_mappings:6xoo.A&PDB-ENSP_mappings:6xop.A&PDB-ENSP_mappings:6xoq.A&PDB-ENSP_mappings:7kwa.A&PDB-ENSP_mappings:8or2.F&PDB-ENSP_mappings:8or3.F&AFDB-ENSP_mappings:AF-Q96GG9-F1&PROSITE_profiles:PS51229&PANTHER:PTHR12281			0.6130	0.7322	0.7017	0.2738	0.7425	0.6053	0.7382	0.7446	0.6667	0.6359	0.2289	0.7705	0.6689	0.7705	0.7175	0.6213	0.7274	0.7431	0.8516	0.6822	0.6309	0.2626	0.7717	0.6803	0.7687	0.715	0.6102	0.8516	gnomADg_AMI		0&1	0&1	22654721&25239657&19473369						FAIL	-7	25	17	-23	0.00	0.00	0.00	0.00	DCUN1D1		5.2900e-01																																																											84					0.964							130.09	v6.1	Unknown		True	DCUN1D1, a component of an E3 ligases complex, is amplified in squamous cell carcinomas.	False	02/13/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DCUN1D1 ENSP00000292782.4:A106= mutant UNKNOWN.	False	The DCUN1D1 ENSP00000292782.4:a106= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	182681740						True	False	False	Unknown								False	False		DCUN1D1, a component of an E3 ligases complex, is amplified in squamous cell carcinomas.	The DCUN1D1 ENSP00000292782.4:a106= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DCUN1D1 ENSP00000292782.4:A106= mutant UNKNOWN.						v6.1	02/13/2019		GRCh38	DCUN1D1	54165.0	ENSP00000292782.4:A106=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DCUN1D1"",""entrezGeneId"":54165,""alteration"":""ENSP00000292782.4:A106="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DCUN1D1, a component of an E3 ligases complex, is amplified in squamous cell carcinomas."",""variantSummary"":""The DCUN1D1 ENSP00000292782.4:a106= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DCUN1D1 ENSP00000292782.4:A106= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/13/2019""}"	True	True	False	Unknown		Unknown																						0,81	0,38	0,43	0/1	0,0,39,42	ACG	0.00	0.00	0.00			0,0,36,45	64.59		1.0
GRCh38	KLHL6	D12_12345_1234556_Thyroid_S9	p.Asn437=	ENSP00000341342.3:p.Asn437=	chr3	183494118	183494118.0	A	G	G	183494118	.	A	G	.	PASS	NM_130446	G	synonymous_variant	LOW	KLHL6	ENSG00000172578	Transcript	ENST00000341319	protein_coding	5/7		c.1311T>C	1364	1311	437	N	aaT/aaC	rs1520101&COSV58066416		-1		SNV	HGNC	HGNC:18653	YES	MANE_Select	NM_130446.4		1	P1	CCDS3245.2	ENSP00000341342	Q8WZ60.179		UPI0000169CB9						Gene3D:2.120.10.80&AFDB-ENSP_mappings:AF-Q8WZ60-F1&Pfam:PF24681&PIRSF:PIRSF037037&PANTHER:PTHR24412&SMART:SM00612&Superfamily:SSF117281			0.6979	0.8722	0.5793	0.8006	0.4771	0.6677	0.5042	0.8217	0.6049	0.5282	0.8129	0.3969	0.6597	0.47	0.5486	0.6448	0.5919	0.8109	0.5308	0.595	0.519	0.7875	0.3865	0.7041	0.4737	0.598	0.6568	0.8722	AFR		0&1	0&1							FAIL	11	-39	-32	45	0.00	0.00	0.01	0.00	KLHL6		9.2900e-01																																																											226					0.991							244.01	v6.1	Unknown		True	KLHL6, an E3 ligase, is infrequently altered in cancer.	False	08/29/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLHL6 ENSP00000341342.3:N437= mutant UNKNOWN.	False	The KLHL6 ENSP00000341342.3:n437= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	183211906						True	False	False	Unknown								False	False		KLHL6, an E3 ligase, is infrequently altered in cancer.	The KLHL6 ENSP00000341342.3:n437= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLHL6 ENSP00000341342.3:N437= mutant UNKNOWN.						v6.1	08/29/2023		GRCh38	KLHL6	89857.0	ENSP00000341342.3:N437=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KLHL6"",""entrezGeneId"":89857,""alteration"":""ENSP00000341342.3:N437="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KLHL6, an E3 ligase, is infrequently altered in cancer."",""variantSummary"":""The KLHL6 ENSP00000341342.3:n437= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLHL6 ENSP00000341342.3:N437= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/29/2023""}"	True	True	False	Unknown		Unknown																						114,110	59,53	55,57	0/1	57,57,55,55	CAT	.	.	.			66,48,62,48	37.16		0.49107142857142855
GRCh38	ETV5	D12_12345_1234556_Thyroid_S9			chr3	186046674	186046674.0	G	A	A	186046674	.	G	A	.	PASS	NM_004454	A	3_prime_UTR_variant	MODIFIER	ETV5	ENSG00000244405	Transcript	ENST00000306376	protein_coding	13/13		c.*1965C>T	3722					rs4686724&COSV60500331		-1		SNV	HGNC	HGNC:3494	YES	MANE_Select	NM_004454.3		1	P1	CCDS33906.1	ENSP00000306894	P41161.197		UPI000012A175	P41161-1		1						0.9938	0.9781	0.9971	1	1	1	0.547	0.5187	0.5479	0.5515	0.5494	0.6857	0.5357	0.5477	0.5453	0.5562	0.8474	0.7318	0.8467	0.8762	0.8808	0.8812	0.9194	0.8864	0.8872	0.856	0.8579	1	EAS&EUR&SAS		0&1	0&1							FAIL	-27	-10	-27	22	0.00	0.00	0.00	0.00	ETV5		2.3300e-01																																																											371					0.806							226.47													chr3	185764463																																																	True	True	False	Unknown		Unknown																						83,216	48,107	35,109	0/1	38,45,108,108	AGA	0.00	0.00	0.00			51,32,113,103	41.91		0.7224080267558528
GRCh38	ETV5	D12_12345_1234556_Thyroid_S9			chr3	186047791	186047792.0	G	GT	GT	186047791	.	G	GT	.	PASS	NM_004454	T	3_prime_UTR_variant	MODIFIER	ETV5	ENSG00000244405	Transcript	ENST00000306376	protein_coding	13/13		c.*847dup	2604-2605					rs5855080		-1		insertion	HGNC	HGNC:3494	YES	MANE_Select	NM_004454.3		1	P1	CCDS33906.1	ENSP00000306894	P41161.197		UPI000012A175	P41161-1		1						0.5609	0.6717	0.5706	0.3135	0.7137	0.502	0.642	0.6474	0.6014	0.6062	0.3613	0.6281	0.6004	0.7108	0.6627	0.5171	0.6664	0.6534	0.6107	0.6345	0.6233	0.3293	0.6529	0.551	0.7238	0.6616	0.5108	0.7238	gnomADg_NFE										FAIL	-41	-45	-41	33	0.00	0.00	0.00	0.00	ETV5		2.3300e-01																																																											640					0.875							241.88													chr3	185765580																																																	True	True	False	Unknown		Unknown																						2,558	2,286	0,272	0/1	0,2,274,284	TGT						0,2,226,332	63.24		0.9964285714285714
GRCh38	BCL6	D12_12345_1234556_Thyroid_S9	p.Cys604=	ENSP00000384371.2:p.Cys604=	chr3	187725526	187725526.0	G	A	A	187725526	.	G	A	.	PASS	NM_001706	A	synonymous_variant	LOW	BCL6	ENSG00000113916	Transcript	ENST00000406870	protein_coding	8/10		c.1812C>T	1920	1812	604	C	tgC/tgT	rs61732778&COSV51650391&COSV51652282		-1		SNV	HGNC	HGNC:1001	YES	MANE_Select	NM_001706.5		1	P1	CCDS3289.1	ENSP00000384371	P41182.235		UPI000012682C	P41182-1		1			PDB-ENSP_mappings:2en2.A&SMART:SM00355&PROSITE_profiles:PS50157&PROSITE_patterns:PS00028&Superfamily:SSF57667&Gene3D:3.30.160.60&Pfam:PF00096&AFDB-ENSP_mappings:AF-P41182-F1			0.0683	0.0726	0.0432	0.0903	0.0736	0.0521	0.07071	0.06275	0.03405	0.04438	0.06963	0.08601	0.06768	0.07343	0.06918	0.05812	0.0704	0.06435	0.005482	0.04933	0.04296	0.09202	0.08547	0.07143	0.07805	0.06623	0.05882	0.09202	gnomADg_EAS		0&1&1	1&1&1	34021172&33097823&34989438&35831902&30595370&34594039&36502284&38538606&37277458&39134668&38965376						FAIL	16	-28	-27	-21	0.00	0.00	0.00	0.00	BCL6		2.2100e-01																																																											1083					0.995							244.45	v6.1	Unknown		True	BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.	False	02/06/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6 ENSP00000384371.2:C604= mutant UNKNOWN.	False	The BCL6 ENSP00000384371.2:c604= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	187443314						True	False	False	Unknown								False	False		BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.	The BCL6 ENSP00000384371.2:c604= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6 ENSP00000384371.2:C604= mutant UNKNOWN.						v6.1	02/06/2019		GRCh38	BCL6	604.0	ENSP00000384371.2:C604=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCL6"",""entrezGeneId"":604,""alteration"":""ENSP00000384371.2:C604="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas."",""variantSummary"":""The BCL6 ENSP00000384371.2:c604= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6 ENSP00000384371.2:C604= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/06/2019""}"	True	True	False	Unknown		Unknown																						550,528	318,272	232,256	0/1	277,273,224,304	CGC	0.00	0.00	0.00			271,279,248,280	48.15		0.4897959183673469
GRCh38	BCL6	D12_12345_1234556_Thyroid_S9	p.Asn387=	ENSP00000384371.2:p.Asn387=	chr3	187729244	187729244.0	G	A	A	187729244	.	G	A	.	PASS	NM_001706	A	synonymous_variant	LOW	BCL6	ENSG00000113916	Transcript	ENST00000406870	protein_coding	5/10		c.1161C>T	1269	1161	387	N	aaC/aaT	rs1056932&COSV51649553		-1		SNV	HGNC	HGNC:1001	YES	MANE_Select	NM_001706.5		1	P1	CCDS3289.1	ENSP00000384371	P41182.235		UPI000012682C	P41182-1		1			PANTHER:PTHR24394&AFDB-ENSP_mappings:AF-P41182-F1			0.5653	0.1104	0.7536	0.7956	0.672	0.6994	0.6511	0.1596	0.7694	0.7025	0.8244	0.6896	0.6944	0.6525	0.6451	0.6457	0.5391	0.1839	0.8015	0.7016	0.7099	0.7992	0.7014	0.7245	0.6516	0.5972	0.6553	0.8244	gnomADe_EAS		0&1	1&1	21658613&23940558&20299965&22347493&19336552&15102677&16264183&33863951&31562340&35831902						FAIL	-31	6	6	-18	0.00	0.00	0.00	0.00	BCL6		2.2100e-01																																																											1221					0.994							246.21	v6.1	Unknown		True	BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.	False	02/06/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6 ENSP00000384371.2:N387= mutant UNKNOWN.	False	The BCL6 ENSP00000384371.2:n387= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr3	187447032						True	False	False	Unknown								False	False		BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.	The BCL6 ENSP00000384371.2:n387= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6 ENSP00000384371.2:N387= mutant UNKNOWN.						v6.1	02/06/2019		GRCh38	BCL6	604.0	ENSP00000384371.2:N387=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""BCL6"",""entrezGeneId"":604,""alteration"":""ENSP00000384371.2:N387="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas."",""variantSummary"":""The BCL6 ENSP00000384371.2:n387= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6 ENSP00000384371.2:N387= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/06/2019""}"	True	True	False	Unknown		Unknown																						634,580	311,252	323,328	0/1	301,333,297,283	GGT	0.00	0.00	0.00			316,318,271,309	37.25		0.47775947281713343
GRCh38		D12_12345_1234556_Thyroid_S9			chr3	191088319	191088319.0	T	C	C	191088319	.	T	C	.	PASS		C	non_coding_transcript_exon_variant	MODIFIER		ENSG00000309795	Transcript	ENST00000843942	lncRNA	2/2		n.437T>C	437					rs1355366		1		SNV																						0.4046	0.5983	0.2651	0.1597	0.4394	0.4581											0.4447	0.562	0.4317	0.3098	0.4107	0.1495	0.4043	0.3435	0.433	0.4223	0.478	0.5983	AFR				26691610&29121662&33406744&34721519&33857205&29923375&32195283&30483616&19083859&31745634&27294018&19948332&38774862																																																																												105					0.952							237.16													chr3	190806108																																																	True	False	False	Unknown		Unknown																						45,55	14,31	31,24	0/1	26,19,27,28	CTC	.	.	.			21,24,25,30	40.62		0.55
GRCh38	ATP13A4	D12_12345_1234556_Thyroid_S9			chr3	193489591	193489591.0	T	C	C	193489591	.	T	C	.	PASS		C	intron_variant&non_coding_transcript_variant	MODIFIER	ATP13A4	ENSG00000127249	Transcript	ENST00000490925	retained_intron		7/20	n.846+139A>G						rs6444724&COSV55075785		-1		SNV	HGNC	HGNC:25422					1															0.4667	0.5325	0.4798	0.4663	0.3817	0.456	0.4064	0.5123	0.5118	0.3677	0.4094	0.3422	0.4267	0.3964	0.4084	0.4446	0.4323	0.5065	0.3775	0.479	0.3625	0.438	0.3477	0.4558	0.3926	0.4182	0.4506	0.5325	AFR		0&1	0&1	23771752&26522768&26691610&29121662&33406744&34721519&33857205&31745634&27294018&38605929&38774862						FAIL	50	-24	0	34	0.00	0.00	0.00	0.00	ATP13A4																																																													137					0.905							237.3													chr3	193207380																																																	True	False	False	Unknown		Unknown																						65,59	32,31	33,28	0/1	33,32,31,28	CTG	.	.	.			38,27,23,36	33.32		0.47580645161290325
GRCh38	TFRC	D12_12345_1234556_Thyroid_S9			chr3	196055305	196055305.0	C	T	T	196055305	.	C	T	.	PASS	NM_001128148	T	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	TFRC	ENSG00000072274	Transcript	ENST00000360110	protein_coding		16/18	c.1678-4G>A						rs419068&COSV64056245		-1		SNV	HGNC	HGNC:11763	YES	MANE_Select	NM_001128148.3		1	P2	CCDS3312.1	ENSP00000353224	P02786.264		UPI0000049ADE			1						0.2981	0.2927	0.3285	0.1597	0.3489	0.3742	0.3168	0.3078	0.2718	0.3836	0.2001	0.3791	0.2474	0.316	0.3032	0.3629	0.3147	0.3111	0.4625	0.2815	0.3767	0.1724	0.3682	0.2687	0.3205	0.2917	0.3472	0.4625	gnomADg_AMI	benign	0&1	1&1	25741868						FAIL	-49	-11	28	-25	0.00	0.02	0.00	0.00	TFRC		4.8900e-01	1237075	0.19091	0.32015	0.29812	1226199	TFRC-related_combined_immunodeficiency&not_provided&not_specified		MONDO:MONDO:0014760&MedGen:C5568133&OMIM:616740&Orphanet:476113&MedGen:C3661900&MedGen:CN169374		NC_000003.12:g.196055305C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001851744&SCV002098880&SCV004102105&SCV004380368&SCV005305719	single_nucleotide_variant	SO:0001483	ClinGen:CA2777798		TFRC:7037	SO:0001627&intron_variant										1	419068																											68					1							247.06													chr3	195782176																																																	True	False	False	Unknown		Unknown																						0,68	0,34	0,34	0|1	0,0,37,31	GCA	0.00	0.00	0.00		195782176	0,0,27,41	50.46		1.0
GRCh38	TFRC	D12_12345_1234556_Thyroid_S9			chr3	196055306	196055306.0	A	G	G	196055306	.	A	G	.	PASS	NM_001128148	G	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	TFRC	ENSG00000072274	Transcript	ENST00000360110	protein_coding		16/18	c.1678-5T>C						rs366268		-1		SNV	HGNC	HGNC:11763	YES	MANE_Select	NM_001128148.3		1	P2	CCDS3312.1	ENSP00000353224	P02786.264		UPI0000049ADE			1						0.2983	0.2935	0.3285	0.1597	0.3489	0.3742	0.3168	0.3091	0.2718	0.3837	0.2001	0.3791	0.2473	0.316	0.3031	0.3629	0.315	0.3121	0.4625	0.2817	0.3767	0.1726	0.3675	0.2687	0.3205	0.2912	0.3474	0.4625	gnomADg_AMI	benign		1	25741868						FAIL	13	-5	27	-26	0.04	0.01	0.00	0.00	TFRC		4.8900e-01	1230584	0.19330	0.32029	0.29832	1219289	TFRC-related_combined_immunodeficiency&not_specified&not_provided		MONDO:MONDO:0014760&MedGen:C5568133&OMIM:616740&Orphanet:476113&MedGen:CN169374&MedGen:C3661900		NC_000003.12:g.196055306A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001842032&SCV002098881&SCV003331579&SCV004102106&SCV005305720	single_nucleotide_variant	SO:0001483	ClinGen:CA2777799		TFRC:7037	SO:0001627&intron_variant										1	366268																											67					1							248.22													chr3	195782177																																																	True	False	False	Unknown		Unknown																						0,67	0,33	0,34	0|1	0,0,38,29	CAA	.	.	.		195782176	0,0,26,41	50.45		1.0
GRCh38	TFRC	D12_12345_1234556_Thyroid_S9			chr3	196069703	196069703.0	A	T	T	196069703	.	A	T	.	PASS	NM_001128148	T	intron_variant	MODIFIER	TFRC	ENSG00000072274	Transcript	ENST00000360110	protein_coding		6/18	c.688-135T>A						rs3827556		-1		SNV	HGNC	HGNC:11763	YES	MANE_Select	NM_001128148.3		1	P2	CCDS3312.1	ENSP00000353224	P02786.264		UPI0000049ADE			1						0.1064	0.0061	0.1354	0.1538	0.0875	0.1922	0.09661	0.01607	0.1033	0.09765	0.2043	0.1611	0.03716	0.07369	0.08375	0.143	0.0708	0.01638	0.0318	0.08644	0.08785	0.1683	0.1565	0.01701	0.07453	0.05693	0.1491	0.2043	gnomADe_EAS				31134135						FAIL	-49	-6	-43	-48	0.00	0.00	0.00	0.00	TFRC		4.8900e-01																																																											84					0.976							236.06													chr3	195796574																																																	True	False	False	Unknown		Unknown																						49,33	21,17	28,16	0/1	21,28,19,14	AAA	.	.	.			31,18,17,16	23.66		0.4024390243902439
GRCh38	FGFR3	D12_12345_1234556_Thyroid_S9			chr4	1795376	1795376.0	C	A	A	1795376	.	C	A	.	PASS	NM_000142	A	intron_variant	MODIFIER	FGFR3	ENSG00000068078	Transcript	ENST00000440486	protein_coding		2/17	c.109+1333C>A						rs538286822		1		SNV	HGNC	HGNC:3690	YES	MANE_Select	NM_000142.5		5	P4	CCDS3353.1	ENSP00000414914	P22607.265		UPI000012A72C	P22607-1		1						0.0004	0.0008	0	0	0.001	0											0.003949	0.002533	0	0.0006539	0	0	0.0007553	0	0.006951	0.001892	0.000208	0.006951	gnomADg_NFE										FAIL	27	7	27	-24	0.00	0.00	0.00	0.00	FGFR3		4.5800e-01																																																											118					0.983							239.75													chr4	1797103																																																	True	True	False	Unknown		Unknown																						55,61	26,30	29,31	0/1	24,31,34,27	CCC	0.00	0.00	0.00			25,30,21,40	38.98		0.5258620689655172
GRCh38	FGFR3	D12_12345_1234556_Thyroid_S9			chr4	1803569	1803569.0	G	A	A	1803569	.	G	A	.	PASS	NM_000142	A	intron_variant	MODIFIER	FGFR3	ENSG00000068078	Transcript	ENST00000440486	protein_coding		7/17	c.931-123G>A						rs3135883		1		SNV	HGNC	HGNC:3690	YES	MANE_Select	NM_000142.5		5	P4	CCDS3353.1	ENSP00000414914	P22607.265		UPI000012A72C	P22607-1		1						0.9249	0.7572	0.9712	1	0.9692	0.9959	0.9706	0.78	0.9807	0.9887	1	0.9523	0.978	0.9743	0.9633	0.9845	0.9221	0.7872	0.9715	0.9678	0.9882	1	0.9548	0.9694	0.9737	0.9423	0.9874	1	EAS&gnomADe_EAS&gnomADg_EAS	benign		1	30258940						FAIL	12	39	-8	-16	0.00	0.01	0.00	0.00	FGFR3		4.5800e-01	680177			0.92492	660600	not_provided		MedGen:C3661900		NC_000004.12:g.1803569G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000981823&SCV005306460	single_nucleotide_variant	SO:0001483	ClinGen:CA11887137		FGFR3:2261	SO:0001627&intron_variant										1	3135883																											740					0.997							246.59													chr4	1805296																																																	True	True	False	Unknown		Unknown																						0,738	0,344	0,394	0/1	0,0,353,385	GGT	0.00	0.00	0.00			0,0,403,335	64.73		1.0
GRCh38	FGFR3	D12_12345_1234556_Thyroid_S9	p.Thr651=	ENSP00000414914.2:p.Thr651=	chr4	1806167	1806167.0	G	A	A	1806167	.	G	A	.	PASS	NM_000142	A	synonymous_variant	LOW	FGFR3	ENSG00000068078	Transcript	ENST00000440486	protein_coding	14/18		c.1953G>A	2228	1953	651	T	acG/acA	rs7688609&COSV99600161		1		SNV	HGNC	HGNC:3690	YES	MANE_Select	NM_000142.5		5	P4	CCDS3353.1	ENSP00000414914	P22607.265		UPI000012A72C	P22607-1		1			PDB-ENSP_mappings:4k33.A&PDB-ENSP_mappings:6lvm.A&PDB-ENSP_mappings:6pnx.A&PDB-ENSP_mappings:6pnx.B&PDB-ENSP_mappings:7dhl.A&PDB-ENSP_mappings:8udt.A&PDB-ENSP_mappings:8udt.B&PDB-ENSP_mappings:8udt.C&PDB-ENSP_mappings:8udu.A&PDB-ENSP_mappings:8udu.B&PDB-ENSP_mappings:8udv.A&PDB-ENSP_mappings:8udv.B&PDB-ENSP_mappings:8udv.C&PANTHER:PTHR24416&Superfamily:SSF56112&Gene3D:1.10.510.10&Pfam:PF07714&PIRSF:PIRSF000628&Phobius:CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50011&SMART:SM00219&AFDB-ENSP_mappings:AF-P22607-F1			0.9561	0.8381	0.9914	1	1	1	0.9959	0.8572	0.993	1	1	1	0.9957	0.9998	0.9902	0.9995	0.9604	0.861	1	0.9884	1	1	1	0.9932	0.9996	0.9773	0.9992	1	EAS&EUR&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN	benign&likely_benign	0&1	1&1	30305059&32368160&21264207&19855393&30258940&37273678&29977536						FAIL	-49	-2	8	6	0.00	0.00	0.00	0.00	FGFR3		4.5800e-01	873164	0.95508	0.98731	0.95607	861287	not_provided&Squamous_cell_lung_carcinoma&not_specified		MedGen:C3661900&Human_Phenotype_Ontology:HP:0030359&MONDO:MONDO:0005097&MedGen:C0149782&MedGen:CN169374		NC_000004.12:g.1806167G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002507545&SCV005299383	single_nucleotide_variant	SO:0001483	ClinGen:CA2810632		FGFR3:2261	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										3	7688609																											773					1							245.29	v6.1	Unknown		True	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	False	01/10/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR3 ENSP00000414914.2:T651= mutant UNKNOWN.	False	The FGFR3 ENSP00000414914.2:t651= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	1807894						True	False	False	Unknown								False	False		FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The FGFR3 ENSP00000414914.2:t651= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR3 ENSP00000414914.2:T651= mutant UNKNOWN.						v6.1	01/10/2017		GRCh38	FGFR3	2261.0	ENSP00000414914.2:T651=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGFR3"",""entrezGeneId"":2261,""alteration"":""ENSP00000414914.2:T651="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer."",""variantSummary"":""The FGFR3 ENSP00000414914.2:t651= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR3 ENSP00000414914.2:T651= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/10/2017""}"	True	True	False	Unknown		Unknown																						0,773	0,394	0,379	0/1	0,0,386,387	CGA	0.00	0.00	0.00			0,0,365,408	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr4	10967435	10967435.0	T	A	A	10967435	.	T	A	.	PASS		A	intergenic_variant	MODIFIER														rs2046361				SNV																						0.4307	0.5877	0.3386	0.4127	0.3429	0.3926											0.3866	0.5397	0.5526	0.3705	0.3563	0.4109	0.2214	0.3435	0.3181	0.3816	0.4155	0.5877	AFR				26522768&26691610&28341840&29121662&33406744&34721519&19083859&19948332																																																																												83					0.928							245.96													chr4	10969059																																																	True	False	False	Unknown		Unknown																						36,41	20,22	16,19	0/1	20,16,22,19	ATT	.	.	.			20,16,17,24	37.42		0.5324675324675324
GRCh38		D12_12345_1234556_Thyroid_S9			chr4	19038300		C	[chr2:103381891[C	[chr2:103381891[C	19038300	MantaBND:182:0:1:0:0:0:0	C	[chr2:103381891[C	.	PASS		.C	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH		ENSG00000301657	Transcript	ENST00000780679	lncRNA		2/2									-1		chromosome_breakpoint			YES																																																																																																																											4			0,5							5	TACCA			MantaBND:182:0:1:0:0:0:1	1														chr4	19039923				BND																																													True	False	False	Unknown		Unknown																															1,1				4,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr4	19930744		A	[chr12:33545095[A	[chr12:33545095[A	19930744	MantaBND:181:0:1:0:0:0:1	A	[chr12:33545095[A	.	PASS		.A	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH		ENSG00000248515	Transcript	ENST00000819375	lncRNA		2/2									1		chromosome_breakpoint																																																																																																																														0			0,4							4	CAAA			MantaBND:181:0:1:0:0:0:0	1														chr4	19932367				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr4	33763657		C	[chr6:53470562[C	[chr6:53470562[C	33763657	MantaBND:412:0:1:0:0:0:0	C	[chr6:53470562[C	.	PASS																																																																																																																																																				1			0,7							7	TCTCACC			MantaBND:412:0:1:0:0:0:1	1														chr4	33765279				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38	PALLD	D12_12345_1234556_Thyroid_S9			chr4	168742464	168742464.0	T	G	G	168742464	.	T	G	.	PASS		G	intron_variant	MODIFIER	PALLD	ENSG00000129116	Transcript	ENST00000649826	protein_coding		1/2	c.343+30541T>G						rs6811238		1	cds_start_NF&cds_end_NF	SNV	HGNC	HGNC:17068								ENSP00000497440		A0A3B3ISX8.28	UPI000E6E9017			1						0.5585	0.5492	0.4683	0.6171	0.504	0.6309											0.5278	0.5512	0.5888	0.5016	0.4856	0.6275	0.4384	0.5034	0.5217	0.4967	0.6176	0.6309	SAS				23771752&26691610&29121662&30735000&33406744&27294018&33546406&38605929						FAIL	0	38	0	-13	0.00	0.01	0.00	0.00	PALLD		6.9000e-01																																																											91					0.978							241.34													chr4	169663615																																																	True	False	False	Unknown		Unknown																						0,89	0,38	0,51	0/1	0,0,50,39	GTG	.	.	.			0,0,39,50	64.64		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.Ser4367=	ENSP00000406229.2:p.Ser4367=	chr4	186595726	186595726.0	A	G	G	186595726	.	A	G	.	PASS	NM_005245	G	synonymous_variant	LOW	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	26/27		c.13101T>C	13312	13101	4367	S	tcT/tcC	rs1298865&COSV71672634		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1			Phobius:CYTOPLASMIC_DOMAIN&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.4918	0.7118	0.5317	0.5724	0.3698	0.2086	0.3772	0.6762	0.5782	0.4589	0.6464	0.3844	0.4061	0.3563	0.3959	0.2589	0.4736	0.6674	0.3084	0.526	0.4571	0.6095	0.3923	0.4626	0.3647	0.4497	0.2614	0.7118	AFR	benign	0&1	1&1	19126244&24023550&33462482						FAIL	30	-16	-37	-48	0.00	0.00	0.00	0.00	FAT1		5.7100e-01	1273862	0.45409	0.42118	0.49181	1263328	not_provided		MedGen:C3661900		NC_000004.12:g.186595726A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001903533&SCV002333143&SCV005306688	single_nucleotide_variant	SO:0001483	ClinGen:CA3164666		FAT1:2195	SO:0001819&synonymous_variant										1	1298865																											734					0.996							247.71	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S4367= mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:s4367= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187516880						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:s4367= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S4367= mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:S4367=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:S4367="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:s4367= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S4367= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						338,393	176,194	162,199	0/1	163,175,194,199	GAG	.	.	.			143,195,197,196	56.05		0.5376196990424077
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.K4059N	ENSP00000406229.2:p.Lys4059Asn	chr4	186598052	186598052.0	C	G	G	186598052	.	C	G	.	PASS	NM_005245	G	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	23/27		c.12177G>C	12388	12177	4059	K/N	aaG/aaC	rs1280097&COSV107530399		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.10.25.10&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50026&SMART:SM00179&SMART:SM00181&Superfamily:SSF57196&CDD:cd00054			0.9974	1	0.9971	1	0.996	0.9928	0.9942	0.9992	0.9976	0.9961	1	0.996	0.9915	0.9936	0.9939	0.9953	0.9957	0.9989	0.9989	0.9969	0.9951	1	0.9968	0.9932	0.9929	0.9948	0.9967	1	AFR&EAS&gnomADe_EAS&gnomADg_EAS	benign	0&1	1&1							FAIL	-41	40	32	-1	0.00	0.01	0.00	0.00	FAT1	0.265	5.7100e-01	1180023	0.99521	0.99534	0.99740	1169037	not_provided		MedGen:C3661900		NC_000004.12:g.186598052C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001753968&SCV002376483&SCV005306695	single_nucleotide_variant	SO:0001483	ClinGen:CA3164916		FAT1:2195	SO:0001583&missense_variant										1	1280097																											108					0.972							243.39	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:K4059N mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:k4059n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187519206						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:k4059n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:K4059N mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:K4059N			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:K4059N"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:k4059n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:K4059N mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,105	0,55	0,50	0/1	0,0,55,50	GCT	.	.	.			0,0,53,52	64.69		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.S3554A	ENSP00000406229.2:p.Ser3554Ala	chr4	186603866	186603866.0	A	C	C	186603866	.	A	C	.	PASS	NM_005245	C	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	19/27		c.10660T>G	10871	10660	3554	S/A	Tct/Gct	rs2637777&COSV106065552&COSV71673371		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(0.54)	benign(0)	Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF49313			0.5128	0.7844	0.5389	0.5774	0.3688	0.2086	0.3807	0.7455	0.5818	0.4576	0.6494	0.3817	0.4077	0.3584	0.4009	0.2594	0.4929	0.7334	0.3073	0.5316	0.4559	0.6141	0.3887	0.4558	0.3663	0.4687	0.2626	0.7844	AFR	benign	0&1&1	1&1&1	21085053&19893579&17938632&30657779&24023550						FAIL	12	-13	-21	-13	0.00	0.00	0.00	0.00	FAT1	0.039	5.7100e-01	1268969	0.47160		0.51278	1261400	not_provided		MedGen:C3661900		NC_000004.12:g.186603866A>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001899720&SCV002331644&SCV005306705	single_nucleotide_variant	SO:0001483	ClinGen:CA3165297		FAT1:2195&LOC126807254:126807254	SO:0001583&missense_variant										1	2637777																											480					0.998							244.81	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S3554A mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:s3554a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187525020						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:s3554a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S3554A mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:S3554A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:S3554A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:s3554a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S3554A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						224,255	124,138	100,117	0/1	102,122,128,127	GAG	.	.	.			96,128,121,134	56.06		0.5323590814196242
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.Asn3121=	ENSP00000406229.2:p.Asn3121=	chr4	186613209	186613209.0	G	A	A	186613209	.	G	A	.	PASS	NM_005245	A	synonymous_variant	LOW	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	13/27		c.9363C>T	9574	9363	3121	N	aaC/aaT	rs2249916&COSV71675358		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1			Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50268&SMART:SM00112&Superfamily:SSF49313&Superfamily:SSF49313&CDD:cd11304			0.6114	0.7398	0.6571	0.6657	0.5805	0.3814	0.5793	0.7061	0.6742	0.6196	0.6892	0.5876	0.5904	0.5755	0.5867	0.4559	0.6192	0.6964	0.5982	0.6544	0.6099	0.6742	0.5975	0.5822	0.5765	0.6094	0.4523	0.7398	AFR	benign	0&1	1&1							FAIL	2	16	12	-17	0.00	0.00	0.00	0.00	FAT1		5.7100e-01	1281026	0.62221	0.59129	0.61142	1271744	not_provided		MedGen:C3661900		NC_000004.12:g.186613209G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001911623&SCV002406965&SCV005302799	single_nucleotide_variant	SO:0001483	ClinGen:CA3165650		FAT1:2195	SO:0001819&synonymous_variant										1	2249916																											1064					0.996							245.46	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:N3121= mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:n3121= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187534363						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:n3121= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:N3121= mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:N3121=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:N3121="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:n3121= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:N3121= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,1060	0,525	0,535	0|1	0,0,503,557	CGT	0.00	0.00	0.00		187534363	0,0,468,592	57.73		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.Asp3117=	ENSP00000406229.2:p.Asp3117=	chr4	186613221	186613221.0	A	G	G	186613221	.	A	G	.	PASS	NM_005245	G	synonymous_variant	LOW	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	13/27		c.9351T>C	9562	9351	3117	D	gaT/gaC	rs2249917&COSV71672930		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1			Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50268&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.4179	0.5446	0.4683	0.2808	0.4702	0.2986	0.4508	0.5413	0.5027	0.4761	0.3011	0.4466	0.4348	0.4585	0.4501	0.3557	0.4668	0.531	0.4711	0.4824	0.4636	0.2836	0.4548	0.4418	0.4493	0.4558	0.3432	0.5446	AFR	benign	0&1	1&1							FAIL	49	1	4	0	0.00	0.00	0.00	0.00	FAT1		5.7100e-01	1286546	0.47329	0.44077	0.41793	1276383	not_provided		MedGen:C3661900		NC_000004.12:g.186613221A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001938277&SCV002331647&SCV005302800	single_nucleotide_variant	SO:0001483	ClinGen:CA3165654		FAT1:2195	SO:0001819&synonymous_variant										1	2249917																											1010					1							245.53	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:D3117= mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:d3117= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187534375						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:d3117= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:D3117= mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:D3117=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:D3117="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:d3117= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:D3117= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,1010	0,502	0,508	0|1	0,0,476,534	CAT	.	.	.		187534363	0,0,450,560	57.73		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.Ala2968=	ENSP00000406229.2:p.Ala2968=	chr4	186617176	186617176.0	G	A	A	186617176	.	G	A	.	PASS	NM_005245	A	synonymous_variant	LOW	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	11/27		c.8904C>T	9115	8904	2968	A	gcC/gcT	rs1280099&COSV71672932		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1			Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.4161	0.5424	0.4683	0.2808	0.4662	0.2965	0.4475	0.5392	0.5018	0.476	0.3006	0.4465	0.4343	0.4545	0.4467	0.3539	0.4659	0.5308	0.478	0.4809	0.4625	0.2834	0.4587	0.4456	0.4471	0.4558	0.3429	0.5424	AFR	benign	0&1	1&1							FAIL	22	10	-16	-27	0.00	0.00	0.00	0.00	FAT1		5.7100e-01	1239825	0.47547	0.43983	0.41613	1228947	not_provided		MedGen:C3661900		NC_000004.12:g.186617176G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001848672&SCV002408212&SCV005302808	single_nucleotide_variant	SO:0001483	ClinGen:CA3165783		FAT1:2195&LOC126807255:126807255	SO:0001819&synonymous_variant										1	1280099																											115					1							244.43	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:A2968= mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:a2968= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187538330						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:a2968= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:A2968= mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:A2968=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:A2968="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:a2968= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:A2968= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,115	0,55	0,60	0/1	0,0,62,53	CGG	0.00	0.00	0.00			0,0,60,55	64.7		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.Q2933P	ENSP00000406229.2:p.Gln2933Pro	chr4	186617788	186617788.0	T	G	G	186617788	.	T	G	.	PASS	NM_005245	G	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	10/27		c.8798A>C	9009	8798	2933	Q/P	cAa/cCa	rs1280098&COSV71672137&COSV71674342&COSV71675402		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&Superfamily:SSF49313&CDD:cd11304			0.5921	0.7655	0.6037	0.631	0.5467	0.3558	0.5439	0.7105	0.6118	0.5765	0.6248	0.5274	0.5678	0.5412	0.5578	0.4302	0.5914	0.6992	0.5703	0.6104	0.5703	0.6306	0.5301	0.5616	0.5408	0.5935	0.427	0.7655	AFR	benign	0&1&1&1	1&1&1&1							FAIL	-3	24	-2	20	0.00	0.00	0.00	0.01	FAT1	0.139	5.7100e-01	1230564	0.62337		0.59205	1219269	not_provided		MedGen:C3661900		NC_000004.12:g.186617788T>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001842004&SCV002337720&SCV005302811	single_nucleotide_variant	SO:0001483	ClinGen:CA3165818		FAT1:2195&LOC126807255:126807255	SO:0001583&missense_variant										1	1280098																											135					0.948							243.97	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:Q2933P mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:q2933p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187538942						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:q2933p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:Q2933P mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:Q2933P			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:Q2933P"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:q2933p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:Q2933P mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,128	0,70	0,58	0/1	0,0,56,72	TTG	.	.	.			0,0,64,64	64.71		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.I2718V	ENSP00000406229.2:p.Ile2718Val	chr4	186618434	186618434.0	T	C	C	186618434	.	T	C	.	PASS	NM_005245	C	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	10/27		c.8152A>G	8363	8152	2718	I/V	Att/Gtt	rs3733406&COSV71674310		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(0.22)	benign(0.011)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.0571	0.0696	0.049	0.0268	0.0905	0.0429	0.06823	0.07127	0.04069	0.0753	0.03411	0.08763	0.07871	0.07003	0.0678	0.0593	0.06861	0.06664	0.04496	0.05953	0.07205	0.02882	0.08869	0.1258	0.07221	0.07467	0.058	0.1258	gnomADg_MID	benign	0&1	1&1	35279875						FAIL	17	46	17	7	0.00	0.00	0.00	0.00	FAT1	0.099	5.7100e-01	1282850	0.07243		0.05711	1271419	not_provided		MedGen:C3661900		NC_000004.12:g.186618434T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001913876&SCV002331651&SCV005302814	single_nucleotide_variant	SO:0001483	ClinGen:CA3165926		FAT1:2195	SO:0001583&missense_variant										1	3733406																											77					0.974							243.49	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:I2718V mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:i2718v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187539588						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:i2718v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:I2718V mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:I2718V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:I2718V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:i2718v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:I2718V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						40,35	26,15	14,20	0/1	20,20,21,14	ATA	.	.	.			18,22,13,22	31.63		0.4666666666666667
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.Pro2248=	ENSP00000406229.2:p.Pro2248=	chr4	186619842	186619842.0	C	T	T	186619842	.	C	T	.	PASS	NM_005245	T	synonymous_variant	LOW	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	10/27		c.6744G>A	6955	6744	2248	P	ccG/ccA	rs11931107&COSV104437728		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1			Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.0423	0.0424	0.0317	0.0278	0.0676	0.0389	0.05785	0.04606	0.03168	0.0665	0.03403	0.08638	0.06657	0.0588	0.0565	0.05479	0.05489	0.0438	0.04496	0.04422	0.06394	0.02771	0.08787	0.102	0.06048	0.0586	0.05285	0.102	gnomADg_MID	benign	0&1	1&1							FAIL	-2	-10	-9	0	0.00	0.00	0.00	0.00	FAT1		5.7100e-01	1227435	0.05604	0.05678	0.04233	1216119	not_provided		MedGen:C3661900		NC_000004.12:g.186619842C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001835043&SCV002404096&SCV005302821	single_nucleotide_variant	SO:0001483	ClinGen:CA3166192		FAT1:2195	SO:0001819&synonymous_variant										1	11931107																											844					0.999							247.29	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:P2248= mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:p2248= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187540996						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:p2248= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:P2248= mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:P2248=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:P2248="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:p2248= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:P2248= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						422,421	200,196	222,225	0/1	231,191,201,220	CCG	0.00	0.00	0.00			211,211,220,201	52.02		0.49940688018979834
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.H1273R	ENSP00000406229.2:p.His1273Arg	chr4	186636739	186636739.0	T	C	C	186636739	.	T	C	.	PASS	NM_005245	C	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	5/27		c.3818A>G	4029	3818	1273	H/R	cAc/cGc	rs328418&COSV71672989		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&Superfamily:SSF49313&CDD:cd11304			0.6458	0.8729	0.647	0.6786	0.5586	0.3937	0.56	0.8247	0.6753	0.6259	0.6969	0.5659	0.6006	0.5468	0.5775	0.4667	0.6372	0.8095	0.5969	0.6505	0.6197	0.679	0.5784	0.5646	0.5495	0.6207	0.4637	0.8729	AFR	benign	0&1	1&1	37577398						FAIL	-39	-9	6	-1	0.00	0.00	0.00	0.00	FAT1	0.154	5.7100e-01	1236097	0.63376	0.58761	0.64577	1225217	not_provided		MedGen:C3661900		NC_000004.12:g.186636739T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001843763&SCV002405780&SCV005302838	single_nucleotide_variant	SO:0001483	ClinGen:CA3166897		FAT1:2195	SO:0001583&missense_variant										1	328418																											886					0.997							245.09	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:H1273R mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:h1273r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187557893						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:h1273r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:H1273R mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:H1273R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:H1273R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:h1273r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:H1273R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,883	0,457	0,426	0/1	0,0,452,431	GTG	.	.	.			0,0,410,473	64.73		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9			chr4	186663617	186663617.0	C	G	G	186663617	.	C	G	.	PASS	NM_005245	G	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding		2/26	c.3266-4G>C						rs172903		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1						0.9834	0.9992	0.9611	1	0.9553	0.9898	0.9553	0.9922	0.9709	0.9664	0.9999	0.9688	0.9713	0.9488	0.9578	0.9842	0.9672	0.99	0.9485	0.9566	0.9686	1	0.9724	0.9626	0.9517	0.9598	0.984	1	EAS&gnomADg_EAS	benign		1							FAIL	-13	-15	-33	1	0.00	0.00	0.00	0.00	FAT1		5.7100e-01	1183172	0.96249	0.96732	0.98343	1171251	not_provided		MedGen:C3661900		NC_000004.12:g.186663617C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001758895&SCV002377278&SCV005302844	single_nucleotide_variant	SO:0001483	ClinGen:CA3167055		FAT1:2195	SO:0001627&intron_variant										1	172903																											87					0.908							237.82													chr4	187584771																																																	True	True	False	Unknown		Unknown																						0,79	0,45	0,34	0/1	0,0,38,41	ACA	.	.	.			0,0,30,49	64.58		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.R1064G	ENSP00000406229.2:p.Arg1064Gly	chr4	186706638	186706638.0	T	C	C	186706638	.	T	C	.	PASS	NM_005245	C	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	2/27		c.3190A>G	3401	3190	1064	R/G	Aga/Gga	rs11939575&COSV71672014		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.7458	0.907	0.7176	0.5	0.7803	0.7658	0.7753	0.8966	0.6735	0.8112	0.4877	0.7523	0.8067	0.7845	0.7724	0.7987	0.7997	0.8908	0.833	0.7333	0.8153	0.5157	0.7376	0.8129	0.7899	0.802	0.784	0.907	AFR	benign	0&1	1&1							FAIL	2	-2	34	12	0.00	0.00	0.00	0.00	FAT1	0.123	5.7100e-01	1244700	0.82722	0.76090	0.74581	1235938	not_provided		MedGen:C3661900		NC_000004.12:g.186706638T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001863340&SCV002333158&SCV005302848	single_nucleotide_variant	SO:0001483	ClinGen:CA3167090		FAT1:2195	SO:0001583&missense_variant										1	11939575																											234					1							243.49	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:R1064G mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:r1064g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187627792						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:r1064g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:R1064G mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:R1064G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:R1064G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:r1064g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:R1064G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,234	0,141	0,93	0/1	0,0,132,102	CTG	.	.	.			0,0,123,111	64.73		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.V862L	ENSP00000406229.2:p.Val862Leu	chr4	186707244	186707244.0	C	G	G	186707244	.	C	G	.	PASS	NM_005245	G	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	2/27		c.2584G>C	2795	2584	862	V/L	Gtt/Ctt	rs1877731&COSV71672016		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&PANTHER:PTHR24026&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.6891	0.7035	0.6974	0.502	0.7753	0.7679	0.7696	0.7118	0.6641	0.8103	0.4879	0.7522	0.7897	0.7834	0.7589	0.8022	0.7494	0.7183	0.8322	0.7117	0.8151	0.515	0.738	0.8027	0.7885	0.7625	0.7869	0.8322	gnomADg_AMI	benign	0&1	1&1							FAIL	-7	-32	-7	1	0.00	0.00	0.00	0.00	FAT1	0.101	5.7100e-01	1273384	0.77552		0.68910	1263933	not_provided		MedGen:C3661900		NC_000004.12:g.186707244C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001901260&SCV002331713&SCV005302851	single_nucleotide_variant	SO:0001483	ClinGen:CA3167234		FAT1:2195	SO:0001583&missense_variant										1	1877731																											744					0.999							245.02	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:V862L mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:v862l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187628398						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:v862l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:V862L mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:V862L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:V862L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:v862l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:V862L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,743	0,375	0,368	0/1	0,0,373,370	ACA	.	.	.			0,0,339,404	64.73		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.F614L	ENSP00000406229.2:p.Phe614Leu	chr4	186707986	186707986.0	G	C	C	186707986	.	G	C	.	PASS	NM_005245	C	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	2/27		c.1842C>G	2053	1842	614	F/L	ttC/ttG	rs367863&COSV71672018		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(1)	benign(0)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50268&PANTHER:PTHR24026&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.6905	0.708	0.6974	0.502	0.7773	0.7669	0.7703	0.7241	0.6642	0.8108	0.4879	0.7524	0.7888	0.784	0.7601	0.8019	0.7535	0.7323	0.8341	0.7125	0.8147	0.5142	0.738	0.7959	0.789	0.7666	0.7866	0.8341	gnomADg_AMI	benign	0&1	1&1							FAIL	39	-6	39	-24	0.00	0.00	0.00	0.00	FAT1	0.086	5.7100e-01	1227896	0.78008	0.74757	0.69050	1215288	not_provided		MedGen:C3661900		NC_000004.12:g.186707986G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001837308&SCV002377292&SCV005302854	single_nucleotide_variant	SO:0001483	ClinGen:CA3167375		FAT1:2195	SO:0001583&missense_variant										1	367863																											195					0.974							243.57	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:F614L mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:f614l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187629140						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:f614l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:F614L mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:F614L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:F614L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:f614l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:F614L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,190	0,101	0,89	0/1	0,0,110,80	AGA	.	.	.			0,0,111,79	64.72		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.Asn495=	ENSP00000406229.2:p.Asn495=	chr4	186708343	186708343.0	G	A	A	186708343	.	G	A	.	PASS	NM_005245	A	synonymous_variant	LOW	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	2/27		c.1485C>T	1696	1485	495	N	aaC/aaT	rs458021&COSV71672020		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1			Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&PROSITE_profiles:PS50268&PANTHER:PTHR24026&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.4219	0.2859	0.5692	0.2242	0.6461	0.4744	0.6136	0.3389	0.544	0.6248	0.2202	0.6359	0.5544	0.6473	0.5808	0.5131	0.5376	0.3511	0.6846	0.5628	0.6362	0.2402	0.6218	0.5822	0.6513	0.5484	0.4847	0.6846	gnomADg_AMI	benign	0&1	1&1							FAIL	-43	-18	8	-2	0.00	0.00	0.00	0.00	FAT1		5.7100e-01	1265703	0.56177	0.56436	0.42192	1257327	not_provided		MedGen:C3661900		NC_000004.12:g.186708343G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001892625&SCV002374723&SCV005302855	single_nucleotide_variant	SO:0001483	ClinGen:CA3167458		FAT1:2195	SO:0001819&synonymous_variant										1	458021																											699					0.997							245.74	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:N495= mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:n495= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187629497						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:n495= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:N495= mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:N495=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:N495="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:n495= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:N495= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,697	0,364	0,333	0/1	0,0,352,345	CGT	0.00	0.00	0.00			0,0,323,374	64.73		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.V482I	ENSP00000406229.2:p.Val482Ile	chr4	186708384	186708384.0	C	T	T	186708384	.	C	T	.	PASS	NM_005245	T	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	2/27		c.1444G>A	1655	1444	482	V/I	Gtc/Atc	rs3733413&COSV106065588&COSV71672022&COSV71672959		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(0.1)	benign(0.094)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00028&Prints:PR00205&PROSITE_profiles:PS50268&PANTHER:PTHR24026&Superfamily:SSF49313&CDD:cd11304			0.3389	0.1581	0.4798	0.1399	0.5765	0.4438	0.5475	0.2117	0.4549	0.5824	0.131	0.5043	0.5114	0.5845	0.5176	0.479	0.4475	0.2279	0.6579	0.4708	0.5948	0.1498	0.491	0.5272	0.5801	0.4806	0.4502	0.6579	gnomADg_AMI	benign	0&1&1&1	1&1&1&1							FAIL	-8	44	-43	1	0.00	0.00	0.00	0.00	FAT1	0.120	5.7100e-01	1288685	0.46072		0.33886	1278517	not_provided		MedGen:C3661900		NC_000004.12:g.186708384C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001937173&SCV002464320&SCV005302856	single_nucleotide_variant	SO:0001483	ClinGen:CA3167466		FAT1:2195	SO:0001583&missense_variant										1	3733413																											618					0.987							243.57	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:V482I mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:v482i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187629538						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:v482i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:V482I mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:V482I			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:V482I"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:v482i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:V482I mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,610	0,327	0,283	0/1	0,0,285,325	ACA	0.00	0.00	0.00			0,0,290,320	64.73		1.0
GRCh38	FAT1	D12_12345_1234556_Thyroid_S9	p.S404R	ENSP00000406229.2:p.Ser404Arg	chr4	186708616	186708616.0	A	C	C	186708616	.	A	C	.	PASS	NM_005245	C	missense_variant	MODERATE	FAT1	ENSG00000083857	Transcript	ENST00000441802	protein_coding	2/27		c.1212T>G	1423	1212	404	S/R	agT/agG	rs3733414&COSV71672025		-1		SNV	HGNC	HGNC:3595	YES	MANE_Select	NM_005245.4		5	P1	CCDS47177.1	ENSP00000406229	Q14517.211		UPI000051946B			1	tolerated_low_confidence(0.13)	benign(0.033)	Gene3D:2.60.40.60&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50268&PANTHER:PTHR24026&SMART:SM00112&Superfamily:SSF49313&CDD:cd11304			0.3990	0.2073	0.5677	0.2242	0.6441	0.4663	0.6117	0.2666	0.5408	0.6247	0.2206	0.6366	0.5499	0.6477	0.5766	0.5084	0.5175	0.2816	0.6842	0.5554	0.6365	0.2411	0.622	0.5816	0.6514	0.5341	0.479	0.6842	gnomADg_AMI	benign	0&1	1&1	19126244&29748316						FAIL	-31	48	42	16	0.00	0.00	0.00	0.01	FAT1	0.137	5.7100e-01	1288791	0.54316	0.55758	0.39896	1278623	not_provided		MedGen:C3661900		NC_000004.12:g.186708616A>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001937303&SCV002440838&SCV005302857	single_nucleotide_variant	SO:0001483	ClinGen:CA3167507		FAT1:2195	SO:0001583&missense_variant										1	3733414																											203					1							245.56	v6.1	Unknown		True	FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	False	02/15/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S404R mutant UNKNOWN.	False	The FAT1 ENSP00000406229.2:s404r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr4	187629770						True	False	False	Unknown								False	False		FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types.	The FAT1 ENSP00000406229.2:s404r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S404R mutant UNKNOWN.						v6.1	02/15/2018		GRCh38	FAT1	2195.0	ENSP00000406229.2:S404R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FAT1"",""entrezGeneId"":2195,""alteration"":""ENSP00000406229.2:S404R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FAT1, a tumor suppressor and transmembrane protein, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The FAT1 ENSP00000406229.2:s404r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FAT1 ENSP00000406229.2:S404R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/15/2018""}"	True	True	False	Unknown		Unknown																						0,203	0,98	0,105	0/1	0,0,100,103	TAC	.	.	.			0,0,101,102	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr4	189396926	189396926.0	C	G	G	189396926	.	C	G	.	PASS		G	intergenic_variant	MODIFIER														rs1979255				SNV																						0.6082	0.6581	0.5519	0.5774	0.6481	0.5716											0.6397	0.6727	0.587	0.5807	0.7158	0.5566	0.547	0.7397	0.6523	0.6573	0.5987	0.7397	gnomADg_MID				26691610&29121662&33406744&18466599&30483659&33857205&32195283&25955683&25763762&19083859&27294018&19948332																																																																												232					0.991							243.41													chr4	190318080																																																	True	False	False	Unknown		Unknown																						135,95	64,54	71,41	0/1	75,60,46,49	TCA	.	.	.			54,81,35,60	18.23		0.41304347826086957
GRCh38	SDHA	D12_12345_1234556_Thyroid_S9	p.Pro297=	ENSP00000264932.6:p.Pro297=	chr5	230996	230996.0	T	C	C	230996	.	T	C	.	PASS	NM_004168	C	synonymous_variant	LOW	SDHA	ENSG00000073578	Transcript	ENST00000264932	protein_coding	7/15		c.891T>C	927	891	297	P	ccT/ccC	rs1126417&COSV53767683		1		SNV	HGNC	HGNC:10680	YES	MANE_Select	NM_004168.4		1	P1	CCDS3853.1	ENSP00000264932	P31040.244		UPI0000000C2C	P31040-1		1			Gene3D:3.50.50.60&PDB-ENSP_mappings:6vax.A&PDB-ENSP_mappings:6vax.C&PDB-ENSP_mappings:8dyd.A&PDB-ENSP_mappings:8dye.A&PDB-ENSP_mappings:8gs8.A&AFDB-ENSP_mappings:AF-P31040-F1&Pfam:PF00890&PANTHER:PTHR11632&Superfamily:SSF51905&Superfamily:SSF56425&NCBIFAM:TIGR01812&NCBIFAM:TIGR01816&PIRSF:PIRSF000171			0.6534	0.7874	0.6902	0.3363	0.7475	0.6759	0.742	0.7837	0.6586	0.6963	0.3482	0.7621	0.6257	0.7645	0.7218	0.6834	0.7405	0.782	0.8311	0.7092	0.704	0.3363	0.7511	0.585	0.7576	0.7341	0.6738	0.8311	gnomADg_AMI	benign	0&1	1&1	25741868&24033266&20398431						FAIL	5	-8	30	4	0.00	0.00	0.00	0.00	SDHA		7.8600e-01	130283	0.76869	0.70783	0.65335	135730	Mitochondrial_complex_II_deficiency&_nuclear_type_1&Pheochromocytoma/paraganglioma_syndrome_5&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Dilated_cardiomyopathy_1GG&Hereditary_pheochromocytoma-paraganglioma&Leigh_syndrome&Neurodegeneration_with_ataxia_and_late-onset_optic_atrophy		MONDO:MONDO:0100294&MedGen:C5700310&OMIM:252011&Orphanet:3208&MONDO:MONDO:0013602&MedGen:C3279992&OMIM:614165&Orphanet:29072&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0013339&MedGen:C3150898&OMIM:613642&Orphanet:154&MONDO:MONDO:0017366&MedGen:C1708353&OMIM:PS168000&Orphanet:29072&MONDO:MONDO:0009723&MedGen:C2931891&OMIM:256000&Orphanet:506&MONDO:MONDO:0031006&MedGen:C5543254&OMIM:619259		NC_000005.10:g.230996T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212855&SCV000310006&SCV000457016&SCV000457017&SCV000457018&SCV000540297&SCV000886090&SCV001716505&SCV001763149&SCV001763150&SCV001763151&SCV001944490&SCV004015372&SCV005302880&SCV006089816&SCV006099404	single_nucleotide_variant	SO:0001483	ClinGen:CA155160		SDHA:6389	SO:0001819&synonymous_variant										1	1126417																											824					0.985							159.38	v6.1	Unknown		True	SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:P297= mutant UNKNOWN.	False	The SDHA ENSP00000264932.6:p297= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	231111						True	False	False	Unknown								False	False		SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers.	The SDHA ENSP00000264932.6:p297= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:P297= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	SDHA	6389.0	ENSP00000264932.6:P297=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SDHA"",""entrezGeneId"":6389,""alteration"":""ENSP00000264932.6:P297="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers."",""variantSummary"":""The SDHA ENSP00000264932.6:p297= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:P297= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						417,395	206,217	211,178	0/1	201,216,195,200	CTA	.	.	.			164,253,151,244	42.32		0.48645320197044334
GRCh38	SDHA	D12_12345_1234556_Thyroid_S9	p.Leu435=	ENSP00000264932.6:p.Leu435=	chr5	236472	236472.0	G	T	T	236472	.	G	T	.	PASS	NM_004168	T	synonymous_variant	LOW	SDHA	ENSG00000073578	Transcript	ENST00000264932	protein_coding	10/15		c.1305G>T	1341	1305	435	L	ctG/ctT	rs35964044&COSV53772863		1		SNV	HGNC	HGNC:10680	YES	MANE_Select	NM_004168.4		1	P1	CCDS3853.1	ENSP00000264932	P31040.244		UPI0000000C2C	P31040-1		1			Gene3D:3.50.50.60&PDB-ENSP_mappings:6vax.A&PDB-ENSP_mappings:6vax.C&PDB-ENSP_mappings:8dyd.A&PDB-ENSP_mappings:8dye.A&PDB-ENSP_mappings:8gs8.A&AFDB-ENSP_mappings:AF-P31040-F1&Pfam:PF00890&PANTHER:PTHR11632&Superfamily:SSF51905&NCBIFAM:TIGR01812&NCBIFAM:TIGR01816&PIRSF:PIRSF000171			0.0152	0.0008	0.0231	0	0.0288	0.0307	0.01634	0.002988	0.01031	0.04665	5.039e-05	0.0369	0.03733	0.01485	0.02009	0.02533	0.01542	0.002573	0	0.01836	0.04666	0.000193	0.03689	0.0102	0.01815	0.02268	0.02505	0.04666	gnomADg_ASJ	uncertain_significance&benign	0&1	1&1	25741868						FAIL	-36	-44	30	-1	0.00	0.00	0.00	0.00	SDHA		7.8600e-01	224954	0.01461		0.01518	226823	Mitochondrial_complex_II_deficiency&_nuclear_type_1&Pheochromocytoma/paraganglioma_syndrome_5&Neurodegeneration_with_ataxia_and_late-onset_optic_atrophy&Dilated_cardiomyopathy_1GG&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_pheochromocytoma-paraganglioma&Leigh_syndrome		MONDO:MONDO:0100294&MedGen:C5700310&OMIM:252011&Orphanet:3208&MONDO:MONDO:0013602&MedGen:C3279992&OMIM:614165&Orphanet:29072&MONDO:MONDO:0031006&MedGen:C5543254&OMIM:619259&MONDO:MONDO:0013339&MedGen:C3150898&OMIM:613642&Orphanet:154&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0017366&MedGen:C1708353&OMIM:PS168000&Orphanet:29072&MONDO:MONDO:0009723&MedGen:C2931891&OMIM:256000&Orphanet:506		NC_000005.10:g.236472G>T	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(1)&Benign(13)		SCV000266803&SCV000309987&SCV000457031&SCV000457032&SCV000457033&SCV000664454&SCV000724562&SCV002046445&SCV002550447&SCV003800523&SCV004015374&SCV005902015&SCV006058712&SCV006089863	single_nucleotide_variant	SO:0001483	ClinGen:CA358583		SDHA:6389	SO:0001819&synonymous_variant										1	35964044																											826					0.904							77.58	v6.1	Unknown		True	SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:L435= mutant UNKNOWN.	False	The SDHA ENSP00000264932.6:l435= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	236587						True	False	False	Unknown								False	False		SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers.	The SDHA ENSP00000264932.6:l435= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:L435= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	SDHA	6389.0	ENSP00000264932.6:L435=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SDHA"",""entrezGeneId"":6389,""alteration"":""ENSP00000264932.6:L435="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers."",""variantSummary"":""The SDHA ENSP00000264932.6:l435= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:L435= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						375,372	211,183	164,189	0/1	187,188,195,177	TGT	0.00	0.00	0.00			237,138,228,144	48.87		0.4979919678714859
GRCh38	SDHA	D12_12345_1234556_Thyroid_S9	p.A660G	ENSP00000264932.6:p.Ala660Gly	chr5	256404	256404.0	C	G	G	256404	.	C	G	.	PASS	NM_004168	G	missense_variant	MODERATE	SDHA	ENSG00000073578	Transcript	ENST00000264932	protein_coding	15/15		c.1979C>G	2015	1979	660	A/G	gCc/gGc	rs191412461		1		SNV	HGNC	HGNC:10680	YES	MANE_Select	NM_004168.4		1	P1	CCDS3853.1	ENSP00000264932	P31040.244		UPI0000000C2C	P31040-1		1	deleterious_low_confidence(0.01)	benign(0.208)	Gene3D:4.10.80.40&PDB-ENSP_mappings:6vax.A&PDB-ENSP_mappings:6vax.C&PDB-ENSP_mappings:8dyd.A&PDB-ENSP_mappings:8dye.A&PDB-ENSP_mappings:8gs8.A&AFDB-ENSP_mappings:AF-P31040-F1&Pfam:PF02910&PANTHER:PTHR11632&Superfamily:SSF46977&NCBIFAM:TIGR01816			0.0010	0	0.0072	0	0	0	0.0001752	0	0.0004026	0	0	0	0.0001736	0.0001998	0.0002486	0	0.0001641	0.0001202	0	0.0004573	0	0	0	0.003401	0.0001764	0	0	0.0072	AMR	benign/likely_benign&uncertain_significance&_likely_benign&uncertain_significance&benign&likely_benign		1							FAIL	0	30	-1	30	0.00	0.00	0.00	0.00	SDHA	0.590	7.8600e-01	239660	0.00008	0.00012	0.00100	239848	SDHA-related_disorder&Hereditary_cancer-predisposing_syndrome&Pheochromocytoma/paraganglioma_syndrome_5&Mitochondrial_complex_II_deficiency&_nuclear_type_1&not_provided&Hereditary_pheochromocytoma-paraganglioma&Leigh_syndrome		.&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MONDO:MONDO:0013602&MedGen:C3279992&OMIM:614165&Orphanet:29072&MONDO:MONDO:0100294&MedGen:C5700310&OMIM:252011&Orphanet:3208&MedGen:C3661900&MONDO:MONDO:0017366&MedGen:C1708353&OMIM:PS168000&Orphanet:29072&MONDO:MONDO:0009723&MedGen:C2931891&OMIM:256000&Orphanet:506		NC_000005.10:g.256404C>G	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(8)&Benign(2)&Likely_benign(3)		SCV000288127&SCV000674932&SCV001154364&SCV001319630&SCV001319631&SCV001319632&SCV001811315&SCV002527740&SCV003819236&SCV004018614&SCV004220293&SCV005410664&SCV005876388	single_nucleotide_variant	SO:0001483	ClinGen:CA3173479		SDHA:6389	SO:0001583&missense_variant										1	191412461																											218					0.968							104.15	v6.1	Unknown		True	SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:A660G mutant UNKNOWN.	False	The SDHA ENSP00000264932.6:a660g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	256519						True	False	False	Unknown								False	False		SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers.	The SDHA ENSP00000264932.6:a660g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:A660G mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	SDHA	6389.0	ENSP00000264932.6:A660G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SDHA"",""entrezGeneId"":6389,""alteration"":""ENSP00000264932.6:A660G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers."",""variantSummary"":""The SDHA ENSP00000264932.6:a660g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHA ENSP00000264932.6:A660G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						109,102	62,64	47,38	0/1	54,55,43,59	GCC	.	.	.			45,64,45,57	35.55		0.4834123222748815
GRCh38	MIR4457	D12_12345_1234556_Thyroid_S9			chr5	1305964		T	[chr2:112394286[T	[chr2:112394286[T	1305964	MantaBND:6898:0:1:0:0:0:1	T	[chr2:112394286[T	.	PASS		.T	downstream_gene_variant	MODIFIER	MIR4457	ENSG00000263670	Transcript	ENST00000580663	miRNA										3345	-1		chromosome_breakpoint	HGNC	HGNC:41554	YES																																																																																																																											2			0,10							10	GGGTTTTGAG			MantaBND:6898:0:1:0:0:0:0	2														chr5	1306079				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	RN7SKP73	D12_12345_1234556_Thyroid_S9			chr5	5124999	5125003.0	C	CGTGT	CGTGT	5124999	.	C	CGTGT	.	PASS		GTGT	upstream_gene_variant	MODIFIER	RN7SKP73	ENSG00000223007	Transcript	ENST00000411075	misc_RNA									rs2307526	1046	1		insertion	HGNC	HGNC:45797	YES																			0.6130	0.6248	0.6873	0.376	0.6531	0.7474											0.6422	0.6251	0.8176	0.6672	0.5763	0.3985	0.7449	0.625	0.6457	0.6263	0.72	0.8176	gnomADg_AMI				33801242																																																																												132					0.97							241.1													chr5	5125112																																																	True	False	False	Unknown		Unknown																						62,66	25,28	37,38	0/1	39,23,36,30	ACG						30,32,30,36	37.21		0.515625
GRCh38		D12_12345_1234556_Thyroid_S9			chr5	17374789	17374789.0	A	G	G	17374789	.	A	G	.	PASS		G	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000249199	Transcript	ENST00000790821	lncRNA		1/2	n.194+669T>C						rs159606		-1		SNV			YES																			0.6562	0.6558	0.6225	0.6359	0.6213	0.7372											0.6463	0.6528	0.5231	0.5947	0.6332	0.6467	0.6543	0.7211	0.6494	0.6432	0.7238	0.7372	SAS				26522768&26691610&29121662&33406744&34721519&33857205&27294018																																																																												87					0.851							234.84													chr5	17374898																																																	True	False	False	Unknown		Unknown																						1,73	0,35	1,38	0/1	0,1,36,37	CAT	.	.	.			1,0,34,39	47.22		0.9864864864864865
GRCh38	IL7R	D12_12345_1234556_Thyroid_S9	p.I66T	ENSP00000306157.3:p.Ile66Thr	chr5	35860966	35860966.0	T	C	C	35860966	.	T	C	.	PASS	NM_002185	C	missense_variant	MODERATE	IL7R	ENSG00000168685	Transcript	ENST00000303115	protein_coding	2/8		c.197T>C	284	197	66	I/T	aTc/aCc	rs1494558&CM1111762&COSV57405776		1		SNV	HGNC	HGNC:6024	YES	MANE_Select	NM_002185.5		1	P1	CCDS3911.1	ENSP00000306157	P16871.224		UPI000013E861	P16871-1		1	tolerated(0.18)	benign(0)	PDB-ENSP_mappings:3di2.B&PDB-ENSP_mappings:3di2.D&PDB-ENSP_mappings:3di3.B&PDB-ENSP_mappings:3up1.A&PDB-ENSP_mappings:3up1.B&PDB-ENSP_mappings:5j11.B&PDB-ENSP_mappings:6p50.C&PDB-ENSP_mappings:6p67.G&PDB-ENSP_mappings:6p67.I&PDB-ENSP_mappings:6p67.J&PDB-ENSP_mappings:6p67.K&PDB-ENSP_mappings:7opb.A&PDB-ENSP_mappings:7opb.B&PDB-ENSP_mappings:7opb.C&PANTHER:PTHR23037&Pfam:PF18447&Gene3D:2.60.40.1870&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P16871-F1			0.5998	0.7625	0.5418	0.4256	0.6978	0.5	0.6565	0.7535	0.5061	0.6298	0.4229	0.7318	0.6024	0.6767	0.6444	0.5164	0.6726	0.7518	0.7971	0.5625	0.6379	0.4192	0.7359	0.6301	0.6712	0.6416	0.5085	0.7971	gnomADg_AMI	benign	0&1&1	1&1&1	25741868&24033266&24728327&24309190&31623129&33246355&21949827&21875636&27051588&28537236&18204446&23973891&22377791&9843216&21326139&23692589&31817502&30342817&30377306&32894076&30123216&24770783&30026549&22977631&34236279&35280415&31673011&28863244&24250851&28435278&30214228&33810367&30381825&16890764&10899029&37564647&38577257&38674437						FAIL	24	-2	19	24	0.00	0.00	0.00	0.00	IL7R	0.091	9.8100e-01	14839		0.62787	0.59984	29878	not_provided&not_specified&Immunodeficiency_104		MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0012163&MedGen:C5676890&OMIM:608971		NC_000005.10:g.35860966T>C	reviewed_by_expert_panel	Benign			SCV004242291	single_nucleotide_variant	SO:0001483	ClinGen:CA124390&OMIM:146661.0001		IL7R:3575	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	1494558																											80					0.938							242.35	v6.1	Unknown		True	IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:I66T mutant UNKNOWN.	False	The IL7R ENSP00000306157.3:i66t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	35861068						True	False	False	Unknown								False	False		IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.	The IL7R ENSP00000306157.3:i66t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:I66T mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	IL7R	3575.0	ENSP00000306157.3:I66T			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IL7R"",""entrezGeneId"":3575,""alteration"":""ENSP00000306157.3:I66T"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia."",""variantSummary"":""The IL7R ENSP00000306157.3:i66t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:I66T mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						0,75	0,38	0,37	0/1	0,0,43,32	ATC	.	.	.			0,0,34,41	64.54		1.0
GRCh38	IL7R	D12_12345_1234556_Thyroid_S9	p.V138I	ENSP00000306157.3:p.Val138Ile	chr5	35871088	35871088.0	G	A	A	35871088	.	G	A	.	PASS	NM_002185	A	missense_variant	MODERATE	IL7R	ENSG00000168685	Transcript	ENST00000303115	protein_coding	4/8		c.412G>A	499	412	138	V/I	Gtc/Atc	rs1494555&CM088536&COSV57406117		1		SNV	HGNC	HGNC:6024	YES	MANE_Select	NM_002185.5		1	P1	CCDS3911.1	ENSP00000306157	P16871.224		UPI000013E861	P16871-1		1	tolerated(0.38)	benign(0)	PDB-ENSP_mappings:3di2.B&PDB-ENSP_mappings:3di2.D&PDB-ENSP_mappings:3di3.B&PDB-ENSP_mappings:3up1.A&PDB-ENSP_mappings:3up1.B&PDB-ENSP_mappings:5j11.B&PDB-ENSP_mappings:6p50.C&PDB-ENSP_mappings:6p67.G&PDB-ENSP_mappings:6p67.I&PDB-ENSP_mappings:6p67.J&PDB-ENSP_mappings:6p67.K&PDB-ENSP_mappings:7opb.A&PDB-ENSP_mappings:7opb.B&PDB-ENSP_mappings:7opb.C&PANTHER:PTHR23037&Gene3D:2.60.40.10&Pfam:PF00041&PROSITE_profiles:PS50853&Superfamily:SSF49265&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P16871-F1			0.6669	0.9312	0.562	0.4812	0.7038	0.5378	0.6674	0.8827	0.5152	0.6432	0.4791	0.7402	0.6335	0.6801	0.6632	0.5544	0.7136	0.8709	0.7982	0.5796	0.6531	0.4762	0.7438	0.6429	0.6761	0.6866	0.5433	0.9312	AFR	benign	0&1&1	1&1&1	25741868&24033266&17705862&24728327&17327408&18633131&19066394&22113576&33246355&21244681&16449530&18687755&19356949&20952689&22180854&22609637&28537236&18204446&30392849&32111053&31354347&9843216&21326139&23692589&29484785&31817502&30123216&19231135&24770783&22649007&19825846&22977631&24391818&22471460&35280415&36698400&31673011&28863244&24250851&19505916&30214228&36341446&36883100&30030270&26686208&37108754&19523791&10899029&37564647&38577257						FAIL	13	-32	-10	-6	0.00	0.00	0.00	0.00	IL7R	0.228	9.8100e-01	14840		0.65193	0.66693	29879	not_specified&not_provided&Immunodeficiency_104		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0012163&MedGen:C5676890&OMIM:608971		NC_000005.10:g.35871088G>A	reviewed_by_expert_panel	Benign			SCV004242294	single_nucleotide_variant	SO:0001483	ClinGen:CA124393&OMIM:146661.0002		IL7R:3575	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	1494555																											183					0.978							234.75	v6.1	Unknown		True	IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:V138I mutant UNKNOWN.	False	The IL7R ENSP00000306157.3:v138i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	35871190						True	False	False	Unknown								False	False		IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.	The IL7R ENSP00000306157.3:v138i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:V138I mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	IL7R	3575.0	ENSP00000306157.3:V138I			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IL7R"",""entrezGeneId"":3575,""alteration"":""ENSP00000306157.3:V138I"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia."",""variantSummary"":""The IL7R ENSP00000306157.3:v138i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:V138I mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						0,179	0,99	0,80	0/1	0,0,84,95	CGT	0.00	0.00	0.00			0,0,78,101	64.72		1.0
GRCh38	IL7R	D12_12345_1234556_Thyroid_S9	p.I356V	ENSP00000306157.3:p.Ile356Val	chr5	35876172	35876172.0	A	G	G	35876172	.	A	G	.	PASS	NM_002185	G	missense_variant	MODERATE	IL7R	ENSG00000168685	Transcript	ENST00000303115	protein_coding	8/8		c.1066A>G	1153	1066	356	I/V	Atc/Gtc	rs3194051&CM058270&COSV57411124		1		SNV	HGNC	HGNC:6024	YES	MANE_Select	NM_002185.5		1	P1	CCDS3911.1	ENSP00000306157	P16871.224		UPI000013E861	P16871-1		1	tolerated(0.53)	benign(0.083)	PANTHER:PTHR23037&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P16871-F1			0.2208	0.348	0.1816	0.0625	0.2823	0.1769	0.2545	0.3422	0.1584	0.272	0.07067	0.2934	0.2923	0.2639	0.2454	0.2075	0.2768	0.3419	0.3399	0.2209	0.2643	0.07281	0.2882	0.3129	0.2689	0.2713	0.1969	0.348	AFR	benign	0&1&1	1&1&1	24033266&24728327&21297633&28487959&23818875&32760600&21875636&17554260&24911414&18204446&19956108&19359276&30392849&26123260&19221116&32111053&18563381&25236396&29742149&35907923&28446795&23692589&31817502&15674389&17660816&19231135&24770783&34469753&23610432&21400209&22191464&31673011&26508701&36341446&22410365&21938017&19523791&20832869&38577257&38160309&38612837						FAIL	-2	14	-4	-7	0.00	0.00	0.00	0.00	IL7R	0.019	9.8100e-01	134533	0.29317	0.24446	0.22085	138272	not_specified&Immunodeficiency_104&not_provided		MedGen:CN169374&MONDO:MONDO:0012163&MedGen:C5676890&OMIM:608971&MedGen:C3661900		NC_000005.10:g.35876172A>G	reviewed_by_expert_panel	Benign			SCV004810394	single_nucleotide_variant	SO:0001483	ClinGen:CA160114		IL7R:3575	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	3194051																											670					0.997							246.36	v6.1	Unknown		True	IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:I356V mutant UNKNOWN.	False	The IL7R ENSP00000306157.3:i356v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	35876274						True	False	False	Unknown								False	False		IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.	The IL7R ENSP00000306157.3:i356v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:I356V mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	IL7R	3575.0	ENSP00000306157.3:I356V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""IL7R"",""entrezGeneId"":3575,""alteration"":""ENSP00000306157.3:I356V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia."",""variantSummary"":""The IL7R ENSP00000306157.3:i356v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R ENSP00000306157.3:I356V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						1,667	1,345	0,322	0/1	0,1,343,324	CAT	.	.	.			0,1,337,330	64.73		0.9985029940119761
GRCh38	RICTOR	D12_12345_1234556_Thyroid_S9	p.Ser1058=	ENSP00000349959.3:p.Ser1058=	chr5	38950674	38950674.0	G	A	A	38950674	.	G	A	.	PASS	NM_152756	A	synonymous_variant	LOW	RICTOR	ENSG00000164327	Transcript	ENST00000357387	protein_coding	31/38		c.3174C>T	3196	3174	1058	S	agC/agT	rs2115949&COSV108116186		-1		SNV	HGNC	HGNC:28611	YES	MANE_Select	NM_152756.5		1	P4	CCDS34148.1	ENSP00000349959	Q6R327.172		UPI00003529F3	Q6R327-1					PDB-ENSP_mappings:6zwm.E&PDB-ENSP_mappings:6zwm.F&PDB-ENSP_mappings:6zwo.F&PDB-ENSP_mappings:7pe7.E&PDB-ENSP_mappings:7pe7.F&PDB-ENSP_mappings:7pe8.E&PDB-ENSP_mappings:7pe9.E&PDB-ENSP_mappings:7tzo.E&PDB-ENSP_mappings:7tzo.F&AFDB-ENSP_mappings:AF-Q6R327-F1&PANTHER:PTHR13298			0.9495	0.9085	0.9741	0.9881	0.9861	0.91	0.9757	0.9085	0.9746	0.9889	0.9908	0.9925	0.9735	0.9807	0.9736	0.9174	0.9592	0.9092	0.9737	0.9697	0.989	0.9915	0.9919	0.966	0.9807	0.9702	0.9187	0.9925	gnomADe_FIN		0&1	0&1							FAIL	12	46	2	-13	0.00	0.00	0.00	0.00	RICTOR		3.0500e-01																																																											111					0.991							236.64	v6.1	Unknown		True	RICTOR, a core component of the oncogenic mTOR2 complex, is altered by amplification or mutation in various cancer types.	False	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RICTOR ENSP00000349959.3:S1058= mutant UNKNOWN.	False	The RICTOR ENSP00000349959.3:s1058= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	38950776						True	False	False	Unknown								False	False		RICTOR, a core component of the oncogenic mTOR2 complex, is altered by amplification or mutation in various cancer types.	The RICTOR ENSP00000349959.3:s1058= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RICTOR ENSP00000349959.3:S1058= mutant UNKNOWN.						v6.1	02/04/2019		GRCh38	RICTOR	253260.0	ENSP00000349959.3:S1058=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RICTOR"",""entrezGeneId"":253260,""alteration"":""ENSP00000349959.3:S1058="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RICTOR, a core component of the oncogenic mTOR2 complex, is altered by amplification or mutation in various cancer types."",""variantSummary"":""The RICTOR ENSP00000349959.3:s1058= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RICTOR ENSP00000349959.3:S1058= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/04/2019""}"	True	True	False	Unknown		Unknown																						0,110	0,52	0,58	0/1	0,0,59,51	TGC	0.00	0.00	0.00			0,0,53,57	64.69		1.0
GRCh38	RICTOR	D12_12345_1234556_Thyroid_S9	p.S837F	ENSP00000349959.3:p.Ser837Phe	chr5	38955694	38955694.0	G	A	A	38955694	.	G	A	.	PASS	NM_152756	A	missense_variant	MODERATE	RICTOR	ENSG00000164327	Transcript	ENST00000357387	protein_coding	26/38		c.2510C>T	2532	2510	837	S/F	tCc/tTc	rs2043112&COSV57117211		-1		SNV	HGNC	HGNC:28611	YES	MANE_Select	NM_152756.5		1	P4	CCDS34148.1	ENSP00000349959	Q6R327.172		UPI00003529F3	Q6R327-1			deleterious_low_confidence(0.02)	benign(0.003)	PDB-ENSP_mappings:5zcs.E&PDB-ENSP_mappings:5zcs.F&PDB-ENSP_mappings:6zwm.E&PDB-ENSP_mappings:6zwm.F&PDB-ENSP_mappings:6zwo.F&PDB-ENSP_mappings:7pe7.E&PDB-ENSP_mappings:7pe7.F&PDB-ENSP_mappings:7pe8.E&PDB-ENSP_mappings:7pe9.E&PDB-ENSP_mappings:7tzo.E&PDB-ENSP_mappings:7tzo.F&AFDB-ENSP_mappings:AF-Q6R327-F1&Pfam:PF14663&PANTHER:PTHR13298&SMART:SM01303&Superfamily:SSF48371&Superfamily:SSF48371			0.3638	0.2648	0.3631	0.4494	0.4284	0.3436	0.3953	0.2812	0.3782	0.4274	0.4932	0.4662	0.3225	0.3992	0.3831	0.3138	0.3773	0.2897	0.3465	0.3876	0.4242	0.4734	0.4677	0.3129	0.4086	0.3614	0.342	0.4932	gnomADe_EAS		0&1	1&1	28117391&23251661&29992529&34281267&33581239&25765185&36255006&30205378&26484159						FAIL	-23	2	2	-4	0.00	0.00	0.00	0.00	RICTOR	0.049	3.0500e-01																																																											68					0.971							244.36	v6.1	Unknown		True	RICTOR, a core component of the oncogenic mTOR2 complex, is altered by amplification or mutation in various cancer types.	False	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RICTOR ENSP00000349959.3:S837F mutant UNKNOWN.	False	The RICTOR ENSP00000349959.3:s837f mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	38955796						True	False	False	Unknown								False	False		RICTOR, a core component of the oncogenic mTOR2 complex, is altered by amplification or mutation in various cancer types.	The RICTOR ENSP00000349959.3:s837f mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RICTOR ENSP00000349959.3:S837F mutant UNKNOWN.						v6.1	02/04/2019		GRCh38	RICTOR	253260.0	ENSP00000349959.3:S837F			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RICTOR"",""entrezGeneId"":253260,""alteration"":""ENSP00000349959.3:S837F"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RICTOR, a core component of the oncogenic mTOR2 complex, is altered by amplification or mutation in various cancer types."",""variantSummary"":""The RICTOR ENSP00000349959.3:s837f mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RICTOR ENSP00000349959.3:S837F mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/04/2019""}"	True	True	False	Unknown		Unknown																						35,31	17,20	18,11	0/1	17,18,16,15	GGA	0.00	0.00	0.00			13,22,13,18	31.75		0.4696969696969697
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44311666	44311666.0	C	T	T	44311666	.	C	T	.	PASS	NM_004465	T	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.326-1136G>A						rs1448035		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.3079	0.3464	0.4697	0.1796	0.3151	0.2658											0.3201	0.3336	0.3293	0.4134	0.2963	0.1699	0.3058	0.2993	0.3085	0.3284	0.2783	0.4697	AMR				19137569						FAIL	-2	25	3	-29	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											58					0.948							246.96													chr5	44311768																																																	True	True	False	Unknown		Unknown																						37,18	21,10	16,8	0/1	16,21,5,13	TCA	0.00	0.00	0.00			20,17,13,5	16.6		0.32727272727272727
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44313180	44313180.0	G	T	T	44313180	.	G	T	.	PASS	NM_004465	T	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.326-2650C>A						rs1839090		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.5286	0.739	0.5749	0.5387	0.335	0.3998											0.4556	0.683	0.3487	0.5199	0.3239	0.5101	0.3393	0.3836	0.3295	0.4345	0.3998	0.739	AFR				24265547						FAIL	-2	-3	1	-6	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											80					0.925							238.54													chr5	44313282																																																	True	True	False	Unknown		Unknown																						43,31	24,13	19,18	0/1	15,28,20,11	TGG	0.00	0.00	0.00			20,23,16,15	26.43		0.4189189189189189
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44313201	44313201.0	T	C	C	44313201	.	T	C	.	PASS	NM_004465	C	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.326-2671A>G						rs1839091		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.4679	0.2466	0.4251	0.4613	0.666	0.6002											0.5394	0.299	0.6513	0.479	0.6767	0.4888	0.6608	0.619	0.6706	0.5637	0.6004	0.6767	gnomADg_ASJ										FAIL	45	46	-25	46	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											74					0.946							239.15													chr5	44313303																																																	True	True	False	Unknown		Unknown																						31,39	14,20	17,19	0/1	17,14,21,18	GTA	.	.	.			16,15,16,23	38.72		0.5571428571428572
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44328727	44328727.0	A	C	C	44328727	.	A	C	.	PASS	NM_004465	C	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.326-18197T>G						rs13165847		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.4956	0.3442	0.4323	0.4653	0.665	0.6022											0.5641	0.3854	0.6524	0.4849	0.6883	0.4926	0.6601	0.6224	0.6707	0.5754	0.602	0.6883	gnomADg_ASJ										FAIL	-19	44	1	-48	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											389					0.995							241.55													chr5	44328829																																																	True	True	False	Unknown		Unknown																						191,196	90,106	101,90	0/1	96,95,92,104	CAC	.	.	.			81,110,90,106	44.69		0.5064599483204134
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44347689	44347689.0	C	T	T	44347689	.	C	T	.	PASS	NM_004465	T	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.326-37159G>A						rs12657059		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.2596	0.1679	0.4524	0.1835	0.3151	0.2679											0.2782	0.1896	0.3282	0.3968	0.2917	0.177	0.304	0.2911	0.3071	0.3048	0.2786	0.4524	AMR										FAIL	-6	-8	-4	-8	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											63					0.984							243.26													chr5	44347791																																																	True	True	False	Unknown		Unknown																						30,32	13,11	17,21	0/1	17,13,17,15	GCA	0.00	0.00	0.00			18,12,16,16	35.23		0.5161290322580645
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44355224	44355224.0	T	C	C	44355224	.	T	C	.	PASS	NM_004465	C	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.325+33134A>G						rs1374968		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.9794	0.9236	0.9986	1	0.999	1											0.9822	0.9381	1	0.9937	0.9994	1	1	0.9966	0.9998	0.9895	0.9998	1	EAS&SAS&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN										FAIL	48	-16	-34	-3	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											88					0.977							245.56													chr5	44355326																																																	True	True	False	Unknown		Unknown																						0,86	0,44	0,42	0/1	0,0,39,47	ATG	.	.	.			0,0,39,47	64.62		1.0
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44355261	44355261.0	T	C	C	44355261	.	T	C	.	PASS	NM_004465	C	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.325+33097A>G						rs1374967		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.6532	0.6354	0.4611	0.7153	0.6809	0.7209											0.6607	0.6434	0.6721	0.5263	0.6976	0.7051	0.6719	0.7041	0.691	0.6486	0.7088	0.7209	SAS										FAIL	11	-2	-17	-8	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											85					0.941							243.58													chr5	44355363																																																	True	True	False	Unknown		Unknown																						40,40	20,20	20,20	0/1	23,17,24,16	ATG	.	.	.			17,23,22,18	34.86		0.5
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44361683	44361683.0	C	T	T	44361683	.	C	T	.	PASS	NM_004465	T	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.325+26675G>A						rs339507		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.9788	0.9213	0.9986	1	0.999	1											0.9819	0.9371	1	0.9935	0.9994	1	1	0.9966	0.9997	0.989	0.9998	1	EAS&SAS&gnomADg_AMI&gnomADg_EAS&gnomADg_FIN										FAIL	-20	24	-20	23	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											94					0.947							228.78													chr5	44361785																																																	True	True	False	Unknown		Unknown																						0,89	0,38	0,51	0/1	0,0,44,45	ACT	0.00	0.00	0.00			0,0,49,40	64.64		1.0
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44362667	44362667.0	C	T	T	44362667	.	C	T	.	PASS	NM_004465	T	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.325+25691G>A						rs1482672&COSV52935510		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.4673	0.2368	0.4179	0.4673	0.663	0.6125											0.5354	0.2863	0.6531	0.4751	0.665	0.4925	0.6625	0.6122	0.6702	0.5554	0.6087	0.6702	gnomADg_NFE		0&1	0&1	24265547						FAIL	-50	-25	9	5	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											110					0.936							236.08													chr5	44362769																																																	True	True	False	Unknown		Unknown																						51,52	30,24	21,28	0/1	28,23,25,27	TCT	0.00	0.00	0.00			27,24,31,21	36.25		0.5048543689320388
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44376958	44376958.0	G	A	A	44376958	.	G	A	.	PASS	NM_004465	A	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.325+11400C>T						rs1384449		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.7194	0.6914	0.6066	0.7232	0.7992	0.7515											0.7554	0.7112	0.7533	0.6749	0.8036	0.7103	0.7703	0.8163	0.7972	0.7673	0.7754	0.8163	gnomADg_MID				22074045&24265547&31687416						FAIL	-50	-2	16	47	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											113					0.947							232.78													chr5	44377060																																																	True	True	False	Unknown		Unknown																						0,107	0,48	0,59	0|1	0,0,58,49	CGC	0.00	0.00	0.00		44377060	0,0,55,52	57.69		1.0
GRCh38	FGF10	D12_12345_1234556_Thyroid_S9			chr5	44376981	44376981.0	G	T	T	44376981	.	G	T	.	PASS	NM_004465	T	intron_variant	MODIFIER	FGF10	ENSG00000070193	Transcript	ENST00000264664	protein_coding		1/2	c.325+11377C>A						rs2929854		-1		SNV	HGNC	HGNC:3666	YES	MANE_Select	NM_004465.2		1	P1	CCDS3950.1	ENSP00000264664	O15520.197	A0A7U3JW18.11	UPI000004065F			1						0.9988	0.9955	1	1	1	1											0.9992	0.997	1	0.9998	1	1	1	1	1	0.9991	1	1	AMR&EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_SAS										FAIL	3	-7	3	21	0.00	0.00	0.00	0.00	FGF10		2.6700e-01																																																											124					0.944							235.83													chr5	44377083																																																	True	True	False	Unknown		Unknown																						0,117	0,54	0,63	0|1	0,0,68,49	AGA	0.00	0.00	0.00		44377060	0,0,61,56	57.7		1.0
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.Tyr486=	ENSP00000257430.4:p.Tyr486=	chr5	112827157	112827157.0	T	C	C	112827157	.	T	C	.	PASS	NM_000038	C	synonymous_variant	LOW	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	12/16		c.1458T>C	1517	1458	486	Y	taT/taC	rs2229992&CM990152&COSV57321592		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			Gene3D:1.25.10.10&PDB-ENSP_mappings:3au3.A&PDB-ENSP_mappings:3nmw.A&PDB-ENSP_mappings:3nmw.B&PDB-ENSP_mappings:3nmx.A&PDB-ENSP_mappings:3nmx.B&PDB-ENSP_mappings:3nmx.C&PDB-ENSP_mappings:3nmz.A&PDB-ENSP_mappings:3nmz.B&PDB-ENSP_mappings:3qhe.A&PDB-ENSP_mappings:3qhe.C&PDB-ENSP_mappings:3t7u.A&PDB-ENSP_mappings:3t7u.B&PDB-ENSP_mappings:4yje.A&PDB-ENSP_mappings:4yjl.A&PDB-ENSP_mappings:4yjl.B&PDB-ENSP_mappings:4yjl.C&PDB-ENSP_mappings:4yjl.D&PDB-ENSP_mappings:4yjl.E&PDB-ENSP_mappings:4yjl.F&PDB-ENSP_mappings:4yk6.A&PDB-ENSP_mappings:5b6g.A&PDB-ENSP_mappings:5iz6.A&PDB-ENSP_mappings:5iz8.A&PDB-ENSP_mappings:5iz8.B&PDB-ENSP_mappings:5iz9.A&PDB-ENSP_mappings:5iza.A&PDB-ENSP_mappings:5z8h.A&PDB-ENSP_mappings:7f6m.A&PDB-ENSP_mappings:7f7o.A&PDB-ENSP_mappings:8gsj.A&PANTHER:PTHR12607&SMART:SM00185&Superfamily:SSF48371			0.5100	0.1619	0.6671	0.6647	0.5795	0.638	0.5868	0.1889	0.6896	0.5641	0.7126	0.5167	0.5526	0.5909	0.5726	0.6385	0.4819	0.2063	0.6305	0.6226	0.5496	0.6709	0.4806	0.585	0.5859	0.5123	0.6462	0.7126	gnomADe_EAS	benign&other	0&1&1	1&1&1	25741868&20844743&25324626&23757202&17267408&23940558&22532847&27217144&29434720&18708403&16569251&20333795&20510605&21995949&27028212&27087319&15768050&17221838&18849522&21279955&29050326&20685668&9487968&20434453&26092435&22528324&31383941&30809121&26511139&28010732&33352971&31018568&35422484&24666523&24403877&35477782&36828923&38135866						FAIL	-38	24	-4	-28	0.00	0.00	0.00	0.00	APC		3.2100e-01	42238	0.46217	0.57798	0.50998	51408	APC-Associated_Polyposis_Disorders&Hepatocellular_carcinoma&Desmoid_disease&_hereditary&Neoplasm_of_stomach&Familial_adenomatous_polyposis_1&Carcinoma_of_colon&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_colorectal_cancer		MedGen:CN239210&Human_Phenotype_Ontology:HP:0001402&Human_Phenotype_Ontology:HP:0002899&Human_Phenotype_Ontology:HP:0003007&Human_Phenotype_Ontology:HP:0006750&MONDO:MONDO:0007256&MedGen:C2239176&OMIM:114550&Orphanet:88673&MedGen:C1851124&OMIM:135290&Orphanet:873&Human_Phenotype_Ontology:HP:0006753&MONDO:MONDO:0021085&MedGen:C0038356&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&MONDO:MONDO:0002032&MedGen:C0699790&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0023113&MedGen:CN280943		NC_000005.10:g.112827157T>C	reviewed_by_expert_panel	Benign			SCV003836582	single_nucleotide_variant	SO:0001483	ClinGen:CA005169		APC:324	SO:0001819&synonymous_variant										1	2229992																											106					1							246.19	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:Y486= mutant UNKNOWN.	False	The APC ENSP00000257430.4:y486= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112162854						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:y486= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:Y486= mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:Y486=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:Y486="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:y486= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:Y486= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Unknown		Unknown																						64,42	32,15	32,27	0/1	33,31,26,16	ATG	.	.	.			27,37,15,27	21.31		0.39622641509433965
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.Ala545=	ENSP00000257430.4:p.Ala545=	chr5	112828864	112828864.0	G	A	A	112828864	.	G	A	.	PASS	NM_000038	A	synonymous_variant	LOW	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	14/16		c.1635G>A	1694	1635	545	A	gcG/gcA	rs351771&COSV57321606		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			Gene3D:1.25.10.10&PDB-ENSP_mappings:3au3.A&PDB-ENSP_mappings:3nmw.A&PDB-ENSP_mappings:3nmw.B&PDB-ENSP_mappings:3nmx.A&PDB-ENSP_mappings:3nmx.B&PDB-ENSP_mappings:3nmx.C&PDB-ENSP_mappings:3nmz.A&PDB-ENSP_mappings:3nmz.B&PDB-ENSP_mappings:3qhe.A&PDB-ENSP_mappings:3qhe.C&PDB-ENSP_mappings:3t7u.A&PDB-ENSP_mappings:3t7u.B&PDB-ENSP_mappings:4yje.A&PDB-ENSP_mappings:4yjl.A&PDB-ENSP_mappings:4yjl.B&PDB-ENSP_mappings:4yjl.C&PDB-ENSP_mappings:4yjl.D&PDB-ENSP_mappings:4yjl.E&PDB-ENSP_mappings:4yjl.F&PDB-ENSP_mappings:4yk6.A&PDB-ENSP_mappings:5b6g.A&PDB-ENSP_mappings:5iz6.A&PDB-ENSP_mappings:5iz8.A&PDB-ENSP_mappings:5iz8.B&PDB-ENSP_mappings:5iz9.A&PDB-ENSP_mappings:5iza.A&PDB-ENSP_mappings:5z8h.A&PDB-ENSP_mappings:7f6m.A&PDB-ENSP_mappings:7f7o.A&PDB-ENSP_mappings:8gsj.A&Coiled-coils_(Ncoils):Coil&Pfam:PF00514&PANTHER:PTHR12607&SMART:SM00185&Superfamily:SSF48371			0.6661	0.5166	0.7161	0.8165	0.5994	0.7464	0.6275	0.5182	0.7262	0.5809	0.8399	0.5725	0.6148	0.6163	0.6328	0.7099	0.6014	0.5342	0.614	0.6687	0.566	0.8189	0.5363	0.6327	0.6126	0.61	0.7321	0.8399	gnomADe_EAS	benign&other	0&1	1&1	25741868&20844743&23757202&23940558&27217144&24078348&16569251&20333795&21995949&27028212&27087319&14616385&18849522&34967580&33352971&35075162&27081525&35477782&36828923&38135866						FAIL	3	12	3	33	0.00	0.00	0.00	0.00	APC		3.2100e-01	42239	0.58643	0.64811	0.66613	51409	APC-Associated_Polyposis_Disorders&Hereditary_cancer-predisposing_syndrome&not_provided&not_specified&Familial_adenomatous_polyposis_1&Carcinoma_of_colon&Familial_colorectal_cancer		MedGen:CN239210&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&MONDO:MONDO:0002032&MedGen:C0699790&MONDO:MONDO:0023113&MedGen:CN280943		NC_000005.10:g.112828864G>A	reviewed_by_expert_panel	Benign			SCV003836588	single_nucleotide_variant	SO:0001483	ClinGen:CA005411		APC:324	SO:0001819&synonymous_variant										1	351771																											161					0.95							240.62	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:A545= mutant UNKNOWN.	False	The APC ENSP00000257430.4:a545= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112164561						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:a545= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:A545= mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:A545=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:A545="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:a545= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:A545= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Unknown		Unknown																						86,67	39,31	47,36	0/1	41,45,30,37	CGA	0.00	0.00	0.00			50,36,42,25	27.07		0.43790849673202614
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.Pro1442=	ENSP00000257430.4:p.Pro1442=	chr5	112839920	112839920.0	T	A	A	112839920	.	T	A	.	PASS	NM_000038	A	synonymous_variant	LOW	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	16/16		c.4326T>A	4385	4326	1442	P	ccT/ccA	rs67622085&COSV104567212&COSV57332204		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			PDB-ENSP_mappings:1th1.C&PDB-ENSP_mappings:1th1.D&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.0056	0.0023	0.013	0	0.0129	0.0031	0.01131	0.001852	0.005211	0.004439	7.557e-05	0.006964	0.003121	0.01348	0.009653	0.001913	0.007363	0.003184	0	0.006813	0.005187	0	0.005781	0.0102	0.01141	0.008988	0.001456	0.01348	gnomADe_NFE	benign	0&1&1	1&1&1	25741868&15133491&15122587&16843107&35866738						FAIL	-48	11	27	11	0.00	0.00	0.00	0.00	APC		3.2100e-01	132705	0.01007	0.00810	0.00559	136453	APC-Associated_Polyposis_Disorders&Desmoid_disease&_hereditary&Familial_adenomatous_polyposis_1&Hepatocellular_carcinoma&Colorectal_cancer&Gastric_adenocarcinoma_and_proximal_polyposis_of_the_stomach&Gastric_cancer&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Carcinoma_of_colon		MedGen:CN239210&MedGen:C1851124&OMIM:135290&Orphanet:873&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&Human_Phenotype_Ontology:HP:0001402&Human_Phenotype_Ontology:HP:0002899&Human_Phenotype_Ontology:HP:0003007&Human_Phenotype_Ontology:HP:0006750&MONDO:MONDO:0007256&MedGen:C2239176&OMIM:114550&Orphanet:88673&MONDO:MONDO:0005575&MedGen:C0346629&OMIM:114500&MONDO:MONDO:0017790&MedGen:C4749917&OMIM:619182&Orphanet:314022&Human_Phenotype_Ontology:HP:0012126&MONDO:MONDO:0001056&MeSH:D013274&MedGen:C0024623&OMIM:613659&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0002032&MedGen:C0699790		NC_000005.10:g.112839920T>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000153860&SCV000187018&SCV000301594&SCV000452010&SCV000602525&SCV000609170&SCV000681660&SCV001897989&SCV002532004&SCV002550622&SCV002812591&SCV002819241&SCV004017505&SCV004930999&SCV005219828	single_nucleotide_variant	SO:0001483	ClinGen:CA009438		APC:324	SO:0001819&synonymous_variant										1	67622085																											280					0.836							216.22	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:P1442= mutant UNKNOWN.	False	The APC ENSP00000257430.4:p1442= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112175617						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:p1442= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:P1442= mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:P1442=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:P1442="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:p1442= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:P1442= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Unknown		Unknown																						110,124	59,66	51,58	0/1	56,54,65,59	CTC	.	.	.			55,55,61,63	45.35		0.5299145299145299
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.Thr1493=	ENSP00000257430.4:p.Thr1493=	chr5	112840073	112840073.0	G	A	A	112840073	.	G	A	.	PASS	NM_000038	A	synonymous_variant	LOW	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	16/16		c.4479G>A	4538	4479	1493	T	acG/acA	rs41115&CD108356&COSV57321403&COSV57381675		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			PDB-ENSP_mappings:1t08.C&PDB-ENSP_mappings:1th1.C&PDB-ENSP_mappings:1th1.D&PDB-ENSP_mappings:1v18.B&Pfam:PF05923			0.6655	0.5174	0.7161	0.8165	0.5994	0.7423	0.6275	0.5203	0.7266	0.582	0.8403	0.5728	0.6137	0.6163	0.6328	0.7091	0.6016	0.5346	0.6167	0.6692	0.5674	0.8196	0.5367	0.6327	0.6126	0.6097	0.7306	0.8403	gnomADe_EAS	benign&other	0&1&1&1	1&1&1&1	25741868&20844743&23757202&23940558&14724163&27217144&16569251&19777185&20333795&20510605&21995949&24861525&27028212&27087319&27898031&26092435&35866738&33790997&34967580&28010732&27245242&33352971&25490678&37273678&37232746&27081525&28243320&35477782&38135866						FAIL	2	36	-39	0	0.00	0.00	0.00	0.00	APC		3.2100e-01	42242	0.58622	0.64857	0.66554	51412	APC-Associated_Polyposis_Disorders&Colorectal_cancer&Gastric_cancer&Hepatocellular_carcinoma&Familial_adenomatous_polyposis_1&Gastric_adenocarcinoma_and_proximal_polyposis_of_the_stomach&Desmoid_disease&_hereditary&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_colorectal_cancer&Carcinoma_of_colon		MedGen:CN239210&MONDO:MONDO:0005575&MedGen:C0346629&OMIM:114500&Human_Phenotype_Ontology:HP:0012126&MONDO:MONDO:0001056&MeSH:D013274&MedGen:C0024623&OMIM:613659&Human_Phenotype_Ontology:HP:0001402&Human_Phenotype_Ontology:HP:0002899&Human_Phenotype_Ontology:HP:0003007&Human_Phenotype_Ontology:HP:0006750&MONDO:MONDO:0007256&MedGen:C2239176&OMIM:114550&Orphanet:88673&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&MONDO:MONDO:0017790&MedGen:C4749917&OMIM:619182&Orphanet:314022&MedGen:C1851124&OMIM:135290&Orphanet:873&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0023113&MedGen:CN280943&MONDO:MONDO:0002032&MedGen:C0699790		NC_000005.10:g.112840073G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000058711&SCV000109824&SCV000212682&SCV000301595&SCV000452013&SCV000602515&SCV000647520&SCV000681669&SCV001847829&SCV002808339&SCV004017438&SCV006311398	single_nucleotide_variant	SO:0001483	ClinGen:CA009580		APC:324	SO:0001819&synonymous_variant										1	41115																											77					0.948							235.73	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:T1493= mutant UNKNOWN.	False	The APC ENSP00000257430.4:t1493= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112175770						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:t1493= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:T1493= mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:T1493=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:T1493="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:t1493= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:T1493= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Unknown		Unknown																						29,44	12,25	17,19	0/1	13,16,28,16	CGG	0.00	0.00	0.00			14,15,27,17	42.01		0.6027397260273972
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.Gly1678=	ENSP00000257430.4:p.Gly1678=	chr5	112840628	112840628.0	G	A	A	112840628	.	G	A	.	PASS	NM_000038	A	synonymous_variant	LOW	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	16/16		c.5034G>A	5093	5034	1678	G	ggG/ggA	rs42427&COSV57321627		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			Pfam:PF16634&MobiDB_lite:mobidb-lite			0.6667	0.5189	0.7176	0.8165	0.6024	0.7423	0.6322	0.5219	0.7291	0.5825	0.8403	0.574	0.6155	0.622	0.6362	0.7092	0.6047	0.5361	0.6143	0.6745	0.5672	0.8195	0.537	0.6327	0.6176	0.6118	0.7302	0.8403	gnomADe_EAS	benign&other	0&1	1&1	25741868&20844743&25324626&23757202&23940558&14724163&18547414&27217144&23251617&24980784&16569251&20333795&20510605&15768050&17221838&26173102&33790997&30809121&34967580&28010732&27081525&24403877&35477782&16169467&38135866						FAIL	-25	44	10	44	0.00	0.00	0.00	0.00	APC		3.2100e-01	42243	0.59013	0.65140	0.66673	51413	APC-Associated_Polyposis_Disorders&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_adenomatous_polyposis_1&Carcinoma_of_colon&Familial_colorectal_cancer		MedGen:CN239210&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&MONDO:MONDO:0002032&MedGen:C0699790&MONDO:MONDO:0023113&MedGen:CN280943		NC_000005.10:g.112840628G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000109825&SCV000212683&SCV000301596&SCV000452019&SCV000602516&SCV000647553&SCV000681702&SCV001739108&SCV004017449&SCV006311393	single_nucleotide_variant	SO:0001483	ClinGen:CA009852		APC:324	SO:0001819&synonymous_variant										1	42427																											110					0.891							227.54	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:G1678= mutant UNKNOWN.	False	The APC ENSP00000257430.4:g1678= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112176325						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:g1678= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:G1678= mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:G1678=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:G1678="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:g1678= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:G1678= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Unknown		Unknown																						48,50	19,16	29,34	0/1	21,27,28,22	GGG	0.00	0.00	0.00			26,22,20,30	36.55		0.5102040816326531
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.Ser1756=	ENSP00000257430.4:p.Ser1756=	chr5	112840862	112840862.0	T	G	G	112840862	.	T	G	.	PASS	NM_000038	G	synonymous_variant	LOW	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	16/16		c.5268T>G	5327	5268	1756	S	tcT/tcG	rs866006&COSV57321636&COSV57325918		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			Pfam:PF16635&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.6669	0.5197	0.7161	0.8165	0.6004	0.7454	0.6291	0.5213	0.7272	0.5912	0.8404	0.5737	0.6163	0.6179	0.6348	0.7099	0.6028	0.5352	0.614	0.6693	0.5741	0.8193	0.5364	0.6327	0.6147	0.6127	0.7307	0.8404	gnomADe_EAS	benign&other	0&1&1	1&1&1	25741868&20844743&23757202&23940558&11818965&27217144&16569251&20333795&21995949&27087319&14616385&27081525&35477782&38135866						FAIL	31	25	31	23	0.00	0.00	0.00	0.00	APC		3.2100e-01	42245	0.58799		0.66693	51415	APC-Associated_Polyposis_Disorders&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_adenomatous_polyposis_1&Carcinoma_of_colon&Familial_colorectal_cancer		MedGen:CN239210&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&MONDO:MONDO:0002032&MedGen:C0699790&MONDO:MONDO:0023113&MedGen:CN280943		NC_000005.10:g.112840862T>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000109826&SCV000212684&SCV000301599&SCV000452024&SCV000602518&SCV000647567&SCV000681723&SCV001753688&SCV004017461&SCV006311395	single_nucleotide_variant	SO:0001483	ClinGen:CA010004		APC:324	SO:0001819&synonymous_variant										1	866006																											127					0.961							233.26	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:S1756= mutant UNKNOWN.	False	The APC ENSP00000257430.4:s1756= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112176559						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:s1756= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:S1756= mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:S1756=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:S1756="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:s1756= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:S1756= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Unknown		Unknown																						57,65	26,31	31,34	0/1	26,31,40,25	CTT	.	.	.			37,20,34,31	40.12		0.5327868852459017
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.V1822D	ENSP00000257430.4:p.Val1822Asp	chr5	112841059	112841059.0	T	A	A	112841059	.	T	A	.	PASS	NM_000038	A	missense_variant	MODERATE	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	16/16		c.5465T>A	5524	5465	1822	V/D	gTc/gAc	rs459552&CM990164&COSV57321643		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1	tolerated_low_confidence(1)	benign(0)	Pfam:PF16635&MobiDB_lite:mobidb-lite			0.8654	0.9909	0.8184	0.9008	0.7654	0.7955	0.7767	0.9612	0.8275	0.7661	0.9044	0.6946	0.7882	0.7678	0.7891	0.7793	0.8201	0.9566	0.7818	0.812	0.7612	0.9022	0.669	0.8231	0.7613	0.8152	0.7935	0.9909	AFR	benign&other	0&1&1	1&1&1	25741868&26451011&20357209&20844743&24728327&23946381&21819567&30337837&23757202&25372392&18992263&23940558&14724163&32708070&22703879&29458332&20149637&24039736&27217144&31485167&19453261&19619005&24078348&18708403&24980784&16569251&20333795&20510605&21995949&27028212&27087319&17221838&14616385&11221825&17556698&18375958&20301519&23159591&23576677&25941542&28410400&31723073&19888426&26809274&29963112&30239722&25653542&22528324&34967580&28010732&26213617&33240400&33769591&23516639&29273807&32053874&27081525&31406247&36224396&25243319&18343606&36581621&38135866&38356597						FAIL	-22	-2	34	-2	0.00	0.00	0.00	0.00	APC	0.190	3.2100e-01	21030	0.82626	0.79810	0.86542	33882	Classic_or_attenuated_familial_adenomatous_polyposis&APC-Associated_Polyposis_Disorders&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_multiple_polyposis_syndrome&Familial_adenomatous_polyposis_1&Familial_colorectal_cancer		MONDO:MONDO:0021057&MedGen:CN372698&MedGen:CN239210&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0021055&MedGen:C0032580&OMIM:PS175100&Orphanet:733&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&MONDO:MONDO:0023113&MedGen:CN280943		NC_000005.10:g.112841059T>A	reviewed_by_expert_panel	Benign			SCV003836607	single_nucleotide_variant	SO:0001483	ClinGen:CA010422&UniProtKB:P25054																																																																																																																																															58,39	24,21	34,18	0/1	34,24,26,13	GTC	.	.	.			34,24,22,17	22.9		0.4020618556701031
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.Pro1960=	ENSP00000257430.4:p.Pro1960=	chr5	112841474	112841474.0	G	A	A	112841474	.	G	A	.	PASS	NM_000038	A	synonymous_variant	LOW	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	16/16		c.5880G>A	5939	5880	1960	P	ccG/ccA	rs465899&COSV57321652		1		SNV	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			Pfam:PF05923			0.6665	0.5212	0.7161	0.8165	0.5994	0.7423	0.6276	0.525	0.7266	0.582	0.8404	0.5727	0.6157	0.6163	0.633	0.7086	0.6028	0.5384	0.6154	0.6696	0.5675	0.8207	0.5372	0.6327	0.6129	0.6102	0.7302	0.8404	gnomADe_EAS	benign&other	0&1	1&1	25741868&20844743&25324626&23757202&27217144&16569251&20333795&27087319&15768050&17221838&14616385&25941542&33790997&30809121&28010732&25250560&27081525&24403877&35477782&38135866						FAIL	2	39	2	0	0.00	0.00	0.00	0.00	APC		3.2100e-01	42247	0.58691	0.64881	0.66653	51417	APC-Associated_Polyposis_Disorders&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Familial_adenomatous_polyposis_1&Carcinoma_of_colon&Familial_colorectal_cancer		MedGen:CN239210&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0021056&MedGen:C2713442&OMIM:175100&MONDO:MONDO:0002032&MedGen:C0699790&MONDO:MONDO:0023113&MedGen:CN280943		NC_000005.10:g.112841474G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000109829&SCV000212685&SCV000301602&SCV000452031&SCV000602519&SCV000647613&SCV000681767&SCV001843799&SCV004017483&SCV006311396	single_nucleotide_variant	SO:0001483	ClinGen:CA010770		APC:324	SO:0001819&synonymous_variant										1	465899																											112					0.938							236.4	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:P1960= mutant UNKNOWN.	False	The APC ENSP00000257430.4:p1960= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112177171						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:p1960= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:P1960= mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:P1960=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:P1960="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:p1960= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:P1960= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Unknown		Unknown																						58,47	32,24	26,23	0/1	24,34,29,18	CGG	0.00	0.00	0.00			32,26,24,23	29.71		0.44761904761904764
GRCh38	APC	D12_12345_1234556_Thyroid_S9	p.N2723IlefsTer	ENSP00000257430.4:p.Asn2723IlefsTer17	chr5	112843761	112843763.0	A	ATT	ATT	112843761	.	A	ATT	.	PASS	NM_000038	TT	frameshift_variant	HIGH	APC	ENSG00000134982	Transcript	ENST00000257430	protein_coding	16/16		c.8167_8168insTT	8226-8227	8167-8168	2723	N/IX	aac/aTTac			1		insertion	HGNC	HGNC:583	YES	MANE_Select	NM_000038.6		5	P1	CCDS4107.1	ENSP00000257430	P25054.270		UPI000013CF60	P25054-1		1			Pfam:PF05937																																																				3.2100e-01																																																											80					0.95							243	v6.1	Unknown		True	APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	False	06/04/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:N2723Ifs*17 mutant UNKNOWN.	False	The APC ENSP00000257430.4:n2723ifs*17 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	112179458						True	False	False	Unknown								False	False		APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The APC ENSP00000257430.4:n2723ifs*17 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:N2723Ifs*17 mutant UNKNOWN.						v6.1	06/04/2024		GRCh38	APC	324.0	ENSP00000257430.4:N2723Ifs*17			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""APC"",""entrezGeneId"":324,""alteration"":""ENSP00000257430.4:N2723Ifs*17"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer."",""variantSummary"":""The APC ENSP00000257430.4:n2723ifs*17 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with APC ENSP00000257430.4:N2723Ifs*17 mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""06/04/2024""}"	True	True	False	Likely Loss-of-function	11062151;15561772;11257105	Likely Oncogenic																						71,5	37,5	34,0	0|1	41,30,2,3	GAA					112179458	31,40,2,3	3.64		0.06578947368421052
GRCh38	SPOCK1	D12_12345_1234556_Thyroid_S9			chr5	137297649	137297649.0	G	A	A	137297649	.	G	A	.	PASS		A	intron_variant&non_coding_transcript_variant	MODIFIER	SPOCK1	ENSG00000152377	Transcript	ENST00000635347	protein_coding_CDS_not_defined		1/6	n.150+15779C>T						rs13182883&COSV56442857		-1		SNV	HGNC	HGNC:11251					5															0.4157	0.5265	0.3876	0.4504	0.328	0.3405											0.3861	0.4701	0.2533	0.3864	0.3943	0.4488	0.2681	0.3299	0.3493	0.3989	0.3912	0.5265	AFR		0&1	0&1	23771752&29121662&33406744&31745634&27294018&33382772&33546406&16360294						FAIL	-24	-4	3	-40	0.00	0.00	0.00	0.00	SPOCK1																																																													373					0.989							241.65													chr5	136633338																																																	True	False	False	Unknown		Unknown																						242,127	99,55	143,72	0/1	118,124,64,63	CGA	0.00	0.00	0.00			125,117,72,55	11.8		0.34417344173441733
GRCh38	FGF1	D12_12345_1234556_Thyroid_S9			chr5	142619851	142619852.0	G	GA	GA	142619851	.	G	GA	.	PASS	NM_000800	A	intron_variant	MODIFIER	FGF1	ENSG00000113578	Transcript	ENST00000337706	protein_coding		1/3	c.-34-5691dup						rs150910782		-1		insertion	HGNC	HGNC:3665	YES	MANE_Select	NM_000800.5		2	P1	CCDS4275.1	ENSP00000338548	P05230.252	A0A7U3JVZ2.14	UPI00000411BE	P05230-1								0.2081	0.09	0.3429	0.0744	0.3569	0.2566											0.3137	0.1606	0.409	0.3654	0.2832	0.09004	0.3876	0.3037	0.3957	0.325	0.2871	0.409	gnomADg_AMI										FAIL	-46	36	16	-8	0.00	0.01	0.00	0.00	FGF1		1.0410e+00																																																											504					0.875							232.01													chr5	141999416																																																	True	True	False	Unknown		Unknown																						253,188	128,99	125,89	0/1	144,109,97,91	CGA						145,108,98,90	24.81		0.42630385487528344
GRCh38	FGF1	D12_12345_1234556_Thyroid_S9			chr5	142630815	142630815.0	G	A	A	142630815	.	G	A	.	PASS	NM_000800	A	intron_variant	MODIFIER	FGF1	ENSG00000113578	Transcript	ENST00000337706	protein_coding		1/3	c.-34-16654C>T						rs249921		-1		SNV	HGNC	HGNC:3665	YES	MANE_Select	NM_000800.5		2	P1	CCDS4275.1	ENSP00000338548	P05230.252	A0A7U3JVZ2.14	UPI00000411BE	P05230-1								0.7007	0.8389	0.7017	0.494	0.7396	0.6861											0.7652	0.8322	0.8546	0.7143	0.7712	0.4892	0.778	0.7449	0.7596	0.7398	0.6886	0.8546	gnomADg_AMI																					1.0410e+00																																																											680					0.981							243.41													chr5	142010380																																																	True	True	False	Unknown		Unknown																						347,320	182,183	165,137	0/1	186,161,173,147	AGC	0.00	0.00	0.00			155,192,142,178	36.99		0.47976011994003
GRCh38	FGF1	D12_12345_1234556_Thyroid_S9			chr5	142638295	142638295.0	C	T	T	142638295	.	C	T	.	PASS	NM_000800	T	intron_variant	MODIFIER	FGF1	ENSG00000113578	Transcript	ENST00000337706	protein_coding		1/3	c.-34-24134G>A						rs152528		-1		SNV	HGNC	HGNC:3665	YES	MANE_Select	NM_000800.5		2	P1	CCDS4275.1	ENSP00000338548	P05230.252	A0A7U3JVZ2.14	UPI00000411BE	P05230-1								0.2336	0.0446	0.2608	0.2619	0.3767	0.2935											0.2821	0.09827	0.4123	0.3026	0.2928	0.2255	0.2988	0.2687	0.3886	0.2735	0.285	0.4123	gnomADg_AMI			1	32999326&21348951&23912956																	1.0410e+00																																																											680					0.987							239.38													chr5	142017860																																																	True	True	False	Unknown		Unknown																						330,341	185,178	145,163	0/1	172,158,171,170	ACC	0.00	0.00	0.00			171,159,174,167	53.38		0.5081967213114754
GRCh38	FGF1	D12_12345_1234556_Thyroid_S9			chr5	142656345	142656346.0	T	TA	TA	142656345	.	T	TA	.	PASS	NM_000800	A	intron_variant	MODIFIER	FGF1	ENSG00000113578	Transcript	ENST00000337706	protein_coding		1/3	c.-35+29611dup						rs11393714		-1		insertion	HGNC	HGNC:3665	YES	MANE_Select	NM_000800.5		2	P1	CCDS4275.1	ENSP00000338548	P05230.252	A0A7U3JVZ2.14	UPI00000411BE	P05230-1								0.1577	0.3623	0.1311	0.1339	0.0467	0.0389											0.1237	0.3182	0.05934	0.1234	0.03806	0.1381	0.04954	0.1586	0.02756	0.1033	0.04146	0.3623	AFR																					1.0410e+00																																																											92					0.88							245.54													chr5	142035910																																																	True	True	False	Unknown		Unknown																						36,45	19,22	17,23	0/1	19,17,17,28	TTA						22,14,22,23	39.8		0.5555555555555556
GRCh38	FGF1	D12_12345_1234556_Thyroid_S9			chr5	142666543	142666544.0	C	CA	CA	142666543	.	C	CA	.	PASS	NM_000800	A	intron_variant	MODIFIER	FGF1	ENSG00000113578	Transcript	ENST00000337706	protein_coding		1/3	c.-35+19413dup						rs111227134		-1		insertion	HGNC	HGNC:3665	YES	MANE_Select	NM_000800.5		2	P1	CCDS4275.1	ENSP00000338548	P05230.252	A0A7U3JVZ2.14	UPI00000411BE	P05230-1								0.2532	0.4743	0.2723	0.1429	0.2306	0.0777											0.2835	0.4533	0.3789	0.2683	0.2149	0.1382	0.238	0.2397	0.2186	0.255	0.09299	0.4743	AFR																					1.0410e+00																																																											87					0.805							235.68													chr5	142046108																																																	True	True	False	Unknown		Unknown																						2,68	0,32	2,36	0/1	0,2,34,34	ACA						2,0,40,28	60		0.9714285714285714
GRCh38	FGF1	D12_12345_1234556_Thyroid_S9			chr5	142666611	142666611.0	A	G	G	142666611	.	A	G	.	PASS	NM_000800	G	intron_variant	MODIFIER	FGF1	ENSG00000113578	Transcript	ENST00000337706	protein_coding		1/3	c.-35+19346T>C						rs73284579		-1		SNV	HGNC	HGNC:3665	YES	MANE_Select	NM_000800.5		2	P1	CCDS4275.1	ENSP00000338548	P05230.252	A0A7U3JVZ2.14	UPI00000411BE	P05230-1								0.0839	0.1263	0.1066	0.123	0.0408	0.0143											0.06278	0.1189	0.06689	0.09537	0.04061	0.1161	0.04879	0.1531	0.02308	0.05393	0.02299	0.1531	gnomADg_MID																					1.0410e+00																																																											133					0.925							238.17													chr5	142046176																																																	True	True	False	Unknown		Unknown																						55,68	29,34	26,34	0/1	19,36,38,30	TAA	.	.	.			29,26,36,32	42.46		0.5528455284552846
GRCh38	FGF1	D12_12345_1234556_Thyroid_S9			chr5	142666618	142666618.0	G	T	T	142666618	.	G	T	.	PASS	NM_000800	T	intron_variant	MODIFIER	FGF1	ENSG00000113578	Transcript	ENST00000337706	protein_coding		1/3	c.-35+19339C>A						rs67197778		-1		SNV	HGNC	HGNC:3665	YES	MANE_Select	NM_000800.5		2	P1	CCDS4275.1	ENSP00000338548	P05230.252	A0A7U3JVZ2.14	UPI00000411BE	P05230-1								0.2496	0.4652	0.268	0.1419	0.2296	0.0767											0.2808	0.4466	0.3794	0.2675	0.215	0.1379	0.2371	0.2313	0.2171	0.2531	0.08952	0.4652	AFR																					1.0410e+00																																																											143					0.958							240.86													chr5	142046183																																																	True	True	False	Unknown		Unknown																						0,137	0,67	0,70	0/1	0,0,59,78	AGA	0.00	0.00	0.00			0,0,77,60	64.72		1.0
GRCh38	CSF1R	D12_12345_1234556_Thyroid_S9	p.Thr242=	ENSP00000501699.1:p.Thr242=	chr5	150078115	150078115.0	G	A	A	150078115	.	G	A	.	PASS	NM_001288705	A	synonymous_variant	LOW	CSF1R	ENSG00000182578	Transcript	ENST00000675795	protein_coding	4/21		c.726C>T	853	726	242	T	acC/acT	rs2228422&CM153945&COSV53827656		-1		SNV	HGNC	HGNC:2433	YES	MANE_Select	NM_001288705.3			P1	CCDS4302.1	ENSP00000501699	P07333.245		UPI000004984A	P07333-1		1			Gene3D:2.60.40.10&PDB-ENSP_mappings:4dkd.C&PDB-ENSP_mappings:4liq.E&PDB-ENSP_mappings:4wrl.A&PDB-ENSP_mappings:4wrl.C&PDB-ENSP_mappings:4wrm.A&AFDB-ENSP_mappings:AF-P07333-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00047&PIRSF:PIRSF000615&PIRSF:PIRSF500947&PROSITE_profiles:PS50835&PANTHER:PTHR24416&SMART:SM00408&SMART:SM00409&Superfamily:SSF48726&CDD:cd20936			0.3874	0.2799	0.366	0.2113	0.5457	0.5665	0.5434	0.3192	0.4145	0.4907	0.2162	0.695	0.4254	0.5624	0.5148	0.5523	0.4789	0.3213	0.4845	0.4238	0.4954	0.2189	0.7061	0.3912	0.5674	0.437	0.5525	0.7061	gnomADg_FIN	benign	0&1&1	1&1&1	24528583&25913741&23889897&20574656						FAIL	-18	-4	36	-3	0.00	0.01	0.00	0.06	CSF1R		4.8500e-01	352165	0.48070	0.51531	0.38738	302347	Brain_abnormalities&_neurodegeneration&_and_dysosteosclerosis&Hereditary_diffuse_leukoencephalopathy_with_spheroids&not_provided		MONDO:MONDO:0032772&MedGen:C5193117&OMIM:618476&MONDO:MONDO:0030796&MedGen:C3711381&OMIM:PS221820&Orphanet:313808&MedGen:C3661900		NC_000005.10:g.150078115G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000455254&SCV000744825&SCV001730296&SCV001876363&SCV001876364	single_nucleotide_variant	SO:0001483	ClinGen:CA3507098		CSF1R:1436&LOC111188154:111188154	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	2228422																											806					0.998							246.83	v6.1	Unknown		True	CSF1R, a cytokine receptor, is altered in various cancer types.	False	02/07/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CSF1R ENSP00000501699.1:T242= mutant UNKNOWN.	False	The CSF1R ENSP00000501699.1:t242= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	149457678						True	False	False	Unknown								False	False		CSF1R, a cytokine receptor, is altered in various cancer types.	The CSF1R ENSP00000501699.1:t242= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CSF1R ENSP00000501699.1:T242= mutant UNKNOWN.						v6.1	02/07/2018		GRCh38	CSF1R	1436.0	ENSP00000501699.1:T242=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CSF1R"",""entrezGeneId"":1436,""alteration"":""ENSP00000501699.1:T242="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CSF1R, a cytokine receptor, is altered in various cancer types."",""variantSummary"":""The CSF1R ENSP00000501699.1:t242= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CSF1R ENSP00000501699.1:T242= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/07/2018""}"	True	True	False	Unknown		Unknown																						0,804	0,384	0,420	0/1	0,0,434,370	TGG	0.00	0.00	0.00			0,0,470,334	64.73		1.0
GRCh38	CSF1R	D12_12345_1234556_Thyroid_S9	p.Pro28=	ENSP00000501699.1:p.Pro28=	chr5	150080990	150080990.0	A	G	G	150080990	.	A	G	.	PASS	NM_001288705	G	synonymous_variant	LOW	CSF1R	ENSG00000182578	Transcript	ENST00000675795	protein_coding	2/21		c.84T>C	211	84	28	P	ccT/ccC	rs216123&COSV53831811		-1		SNV	HGNC	HGNC:2433	YES	MANE_Select	NM_001288705.3			P1	CCDS4302.1	ENSP00000501699	P07333.245		UPI000004984A	P07333-1		1			Gene3D:2.60.40.10&PDB-ENSP_mappings:4dkd.C&PDB-ENSP_mappings:4liq.E&PDB-ENSP_mappings:4wrl.A&PDB-ENSP_mappings:4wrl.C&PDB-ENSP_mappings:4wrm.A&AFDB-ENSP_mappings:AF-P07333-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000615&PIRSF:PIRSF500947&PROSITE_profiles:PS50835&SMART:SM00409&Superfamily:SSF48726			0.3353	0.2587	0.353	0.0893	0.5527	0.456	0.532	0.2879	0.3643	0.4769	0.1112	0.6987	0.4826	0.5616	0.4964	0.4675	0.4614	0.2982	0.4671	0.3902	0.4865	0.1005	0.7093	0.432	0.5649	0.4415	0.468	0.7093	gnomADg_FIN	benign	0&1	1&1	29434720&23889897&18059179						FAIL	34	29	-27	35	0.00	0.00	0.00	0.00	CSF1R		4.8500e-01	352179	0.47370	0.48718	0.33526	302657	Brain_abnormalities&_neurodegeneration&_and_dysosteosclerosis&not_provided&Hereditary_diffuse_leukoencephalopathy_with_spheroids		MONDO:MONDO:0032772&MedGen:C5193117&OMIM:618476&MedGen:C3661900&MONDO:MONDO:0030796&MedGen:C3711381&OMIM:PS221820&Orphanet:313808		NC_000005.10:g.150080990A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000455268&SCV000744829&SCV001731759&SCV001876365&SCV001876366&SCV001947379	single_nucleotide_variant	SO:0001483	ClinGen:CA3507286		CSF1R:1436	SO:0001619&non-coding_transcript_variant&SO:0001623&5_prime_UTR_variant&SO:0001819&synonymous_variant										1	216123																											1073					0.998							246.48	v6.1	Unknown		True	CSF1R, a cytokine receptor, is altered in various cancer types.	False	02/07/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CSF1R ENSP00000501699.1:P28= mutant UNKNOWN.	False	The CSF1R ENSP00000501699.1:p28= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	149460553						True	False	False	Unknown								False	False		CSF1R, a cytokine receptor, is altered in various cancer types.	The CSF1R ENSP00000501699.1:p28= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CSF1R ENSP00000501699.1:P28= mutant UNKNOWN.						v6.1	02/07/2018		GRCh38	CSF1R	1436.0	ENSP00000501699.1:P28=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CSF1R"",""entrezGeneId"":1436,""alteration"":""ENSP00000501699.1:P28="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CSF1R, a cytokine receptor, is altered in various cancer types."",""variantSummary"":""The CSF1R ENSP00000501699.1:p28= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CSF1R ENSP00000501699.1:P28= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/07/2018""}"	True	True	False	Unknown		Unknown																						0,1071	0,505	0,566	0/1	0,0,529,542	CAG	.	.	.			0,0,521,550	64.73		1.0
GRCh38	PDGFRB	D12_12345_1234556_Thyroid_S9			chr5	150113909	150113909.0	C	T	T	150113909	.	C	T	.	PASS	NM_002609	T	3_prime_UTR_variant	MODIFIER	PDGFRB	ENSG00000113721	Transcript	ENST00000261799	protein_coding	23/23		c.*1854G>A	5630					rs1864973		-1		SNV	HGNC	HGNC:8804	YES	MANE_Select	NM_002609.4		1	P1	CCDS4303.1	ENSP00000261799	P09619.263		UPI0000131791	P09619-1		1						0.9980	0.9992	0.9986	1	0.994	0.998	0.9956	0.9997	0.9972	0.9937	1	1	0.9797	0.9949	0.9932	0.9971	0.9963	0.9992	1	0.992	0.9931	1	0.9995	0.983	0.995	0.9953	0.9956	1	EAS&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_EAS										FAIL	-31	-37	4	-31	0.00	0.00	0.00	0.00	PDGFRB		5.0400e-01																																																											470					0.991							247.62													chr5	149493472																																																	True	True	False	Unknown		Unknown																						0,466	0,217	0,249	0/1	0,0,235,231	TCA	0.00	0.00	0.00			0,0,216,250	64.73		1.0
GRCh38	SGCD	D12_12345_1234556_Thyroid_S9			chr5	156235245	156235253.0	G	GCCTACTGA	GCCTACTGA	156235245	.	G	GCCTACTGA	.	PASS		CCTACTGA	intron_variant	MODIFIER	SGCD	ENSG00000170624	Transcript	ENST00000517913	protein_coding		3/9	c.-43-94288_-43-94287insCTACTGAC						rs11281372		1		insertion	HGNC	HGNC:10807					5		CCDS47326.1	ENSP00000429378	Q92629.201		UPI000014A6BA	Q92629-3		1					1	0.6158	0.6831	0.5317	0.6974	0.5736	0.544											0.605	0.653	0.6493	0.5516	0.6148	0.6879	0.5398	0.5621	0.5958	0.6018	0.5345	0.6974	EAS																					1.2990e+00																																																											50					1							234.93													chr5	155662255																																																	True	False	False	Unknown		Unknown																						0,50	0,26	0,24	0/1	0,0,26,24	GGC						0,0,22,28	62.82		1.0
GRCh38	GABRA6	D12_12345_1234556_Thyroid_S9	p.Ser3=	ENSP00000274545.5:p.Ser3=	chr5	161685998	161685998.0	G	A	A	161685998	.	G	A	.	PASS	NM_000811	A	synonymous_variant	LOW	GABRA6	ENSG00000145863	Transcript	ENST00000274545	protein_coding	1/9		c.9G>A	278	9	3	S	tcG/tcA	rs13188991&COSV50878128		1		SNV	HGNC	HGNC:4080	YES	MANE_Select	NM_000811.3		1	P1	CCDS4356.1	ENSP00000274545	Q16445.201		UPI000013DA14						AFDB-ENSP_mappings:AF-Q16445-F1&Prints:PR01619&Phobius:SIGNAL_PEPTIDE&Phobius:SIGNAL_PEPTIDE_N_REGION&Cleavage_site_(Signalp):SignalP-noTM			0.0992	0.0083	0.1124	0.0655	0.2664	0.0757	0.235	0.04139	0.1139	0.2943	0.06723	0.2638	0.2094	0.2609	0.2243	0.09007	0.1772	0.04608	0.1835	0.1598	0.2844	0.07402	0.2678	0.2347	0.2558	0.1725	0.08496	0.2943	gnomADe_ASJ	benign	0&1	1&1	29135068						FAIL	39	-19	26	29	0.00	0.00	0.00	0.01	GABRA6		1.1840e+00	1169909	0.18768		0.09924	1154983	Childhood_absence_epilepsy&GABRA6-related_disorder		MONDO:MONDO:0010826&MedGen:C4281785&OMIM:PS600131&Orphanet:64280&.		NC_000005.10:g.161685998G>A	criteria_provided&_single_submitter	Benign			SCV001731152	single_nucleotide_variant	SO:0001483	ClinGen:CA3543724		GABRA6:2559	SO:0001819&synonymous_variant										1	13188991																											98					0.969							244.81	v6.1	Unknown		True	GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	False	12/08/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:S3= mutant UNKNOWN.	False	The GABRA6 ENSP00000274545.5:s3= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	161113004						True	False	False	Unknown								False	False		GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	The GABRA6 ENSP00000274545.5:s3= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:S3= mutant UNKNOWN.						v6.1	12/08/2023		GRCh38	GABRA6	2559.0	ENSP00000274545.5:S3=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GABRA6"",""entrezGeneId"":2559,""alteration"":""ENSP00000274545.5:S3="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer."",""variantSummary"":""The GABRA6 ENSP00000274545.5:s3= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:S3= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/08/2023""}"	True	True	False	Unknown		Unknown																						51,44	27,18	24,26	0/1	22,29,23,21	CGT	0.00	0.00	0.00			28,23,25,19	31.47		0.4631578947368421
GRCh38	GABRA6	D12_12345_1234556_Thyroid_S9	p.Ala317=	ENSP00000274545.5:p.Ala317=	chr5	161692065	161692065.0	G	T	T	161692065	.	G	T	.	PASS	NM_000811	T	synonymous_variant	LOW	GABRA6	ENSG00000145863	Transcript	ENST00000274545	protein_coding	8/9		c.951G>T	1220	951	317	A	gcG/gcT	rs12522663&COSV99194042		1		SNV	HGNC	HGNC:4080	YES	MANE_Select	NM_000811.3		1	P1	CCDS4356.1	ENSP00000274545	Q16445.201		UPI000013DA14						Gene3D:1.20.58.390&AFDB-ENSP_mappings:AF-Q16445-F1&Pfam:PF02932&Prints:PR00253&PANTHER:PTHR18945&Superfamily:SSF90112&NCBIFAM:TIGR00860&Transmembrane_helices:TMhelix&Phobius:TRANSMEMBRANE&CDD:cd19052			0.9683	0.8911	0.9813	0.999	0.999	1	0.9969	0.8975	0.993	1	1	1	0.9939	0.9997	0.9925	0.9998	0.9703	0.8982	1	0.9869	1	1	1	0.9932	0.9995	0.9787	0.999	1	SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN	benign	0&1	1&1							FAIL	10	-28	-37	-3	0.00	0.00	0.00	0.00	GABRA6		1.1840e+00	1169910	0.96548	0.99022	0.96825	1154984	Childhood_absence_epilepsy		MONDO:MONDO:0010826&MedGen:C4281785&OMIM:PS600131&Orphanet:64280		NC_000005.10:g.161692065G>T	criteria_provided&_single_submitter	Benign			SCV001731153	single_nucleotide_variant	SO:0001483	ClinGen:CA3544056		GABRA6:2559	SO:0001819&synonymous_variant										1	12522663																											101					0.99							242.8	v6.1	Unknown		True	GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	False	12/08/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:A317= mutant UNKNOWN.	False	The GABRA6 ENSP00000274545.5:a317= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	161119071						True	False	False	Unknown								False	False		GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	The GABRA6 ENSP00000274545.5:a317= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:A317= mutant UNKNOWN.						v6.1	12/08/2023		GRCh38	GABRA6	2559.0	ENSP00000274545.5:A317=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GABRA6"",""entrezGeneId"":2559,""alteration"":""ENSP00000274545.5:A317="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer."",""variantSummary"":""The GABRA6 ENSP00000274545.5:a317= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:A317= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/08/2023""}"	True	True	False	Unknown		Unknown																						0,100	0,53	0,47	0/1	0,0,47,53	CGC	0.00	0.00	0.00			0,0,44,56	64.67		1.0
GRCh38	GABRA6	D12_12345_1234556_Thyroid_S9	p.Ala335=	ENSP00000274545.5:p.Ala335=	chr5	161692119	161692119.0	C	G	G	161692119	.	C	G	.	PASS	NM_000811	G	synonymous_variant	LOW	GABRA6	ENSG00000145863	Transcript	ENST00000274545	protein_coding	8/9		c.1005C>G	1274	1005	335	A	gcC/gcG	rs13184586&COSV50877703		1		SNV	HGNC	HGNC:4080	YES	MANE_Select	NM_000811.3		1	P1	CCDS4356.1	ENSP00000274545	Q16445.201		UPI000013DA14						Gene3D:1.20.58.390&AFDB-ENSP_mappings:AF-Q16445-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF02932&Prints:PR01619&Superfamily:SSF90112&NCBIFAM:TIGR00860&CDD:cd19052			0.4012	0.3351	0.3732	0.3185	0.5736	0.4182	0.542	0.3622	0.351	0.5351	0.3111	0.5436	0.4905	0.572	0.5223	0.4481	0.4785	0.3601	0.4297	0.4268	0.5256	0.3039	0.5526	0.483	0.5666	0.4502	0.4299	0.5736	EUR	benign	0&1	1&1	24786987&27245092&29018204						FAIL	-11	16	-3	-46	0.00	0.00	0.00	0.00	GABRA6		1.1840e+00	1169911	0.48808	0.48544	0.40116	1154985	Childhood_absence_epilepsy&GABRA6-related_disorder		MONDO:MONDO:0010826&MedGen:C4281785&OMIM:PS600131&Orphanet:64280&.		NC_000005.10:g.161692119C>G	criteria_provided&_single_submitter	Benign			SCV001731154	single_nucleotide_variant	SO:0001483	ClinGen:CA3544070		GABRA6:2559	SO:0001819&synonymous_variant										1	13184586																											108					0.954							238.49	v6.1	Unknown		True	GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	False	12/08/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:A335= mutant UNKNOWN.	False	The GABRA6 ENSP00000274545.5:a335= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	161119125						True	False	False	Unknown								False	False		GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	The GABRA6 ENSP00000274545.5:a335= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:A335= mutant UNKNOWN.						v6.1	12/08/2023		GRCh38	GABRA6	2559.0	ENSP00000274545.5:A335=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GABRA6"",""entrezGeneId"":2559,""alteration"":""ENSP00000274545.5:A335="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer."",""variantSummary"":""The GABRA6 ENSP00000274545.5:a335= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:A335= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/08/2023""}"	True	True	False	Unknown		Unknown																						50,53	21,31	29,22	0/1	20,30,32,21	CCA	.	.	.			25,25,22,31	37.56		0.5145631067961165
GRCh38	GABRA6	D12_12345_1234556_Thyroid_S9	p.Val448=	ENSP00000274545.5:p.Val448=	chr5	161701755	161701755.0	C	G	G	161701755	.	C	G	.	PASS	NM_000811	G	synonymous_variant	LOW	GABRA6	ENSG00000145863	Transcript	ENST00000274545	protein_coding	9/9		c.1344C>G	1613	1344	448	V	gtC/gtG	rs4277944&COSV99194043		1		SNV	HGNC	HGNC:4080	YES	MANE_Select	NM_000811.3		1	P1	CCDS4356.1	ENSP00000274545	Q16445.201		UPI000013DA14						Gene3D:1.20.58.390&AFDB-ENSP_mappings:AF-Q16445-F1&Phobius:NON_CYTOPLASMIC_DOMAIN									0.9966	0.8889	0.9924	1	1	1	0.9931	0.9997	0.992	0.9998	0.9679	0.8896	1	0.9863	1	1	1	0.9897	0.9995	0.9768	0.999	1	gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN	benign	0&1	1&1							FAIL	-3	50	-3	-33	0.00	0.00	0.00	0.00	GABRA6		1.1840e+00	1169912	0.96202			1154987	Childhood_absence_epilepsy		MONDO:MONDO:0010826&MedGen:C4281785&OMIM:PS600131&Orphanet:64280		NC_000005.10:g.161701755C>G	criteria_provided&_single_submitter	Benign			SCV001731155	single_nucleotide_variant	SO:0001483	ClinGen:CA3544171		GABRA6:2559	SO:0001819&synonymous_variant										1	4277944																											75					0.947							246.33	v6.1	Unknown		True	GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	False	12/08/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:V448= mutant UNKNOWN.	False	The GABRA6 ENSP00000274545.5:v448= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	161128761						True	False	False	Unknown								False	False		GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer.	The GABRA6 ENSP00000274545.5:v448= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:V448= mutant UNKNOWN.						v6.1	12/08/2023		GRCh38	GABRA6	2559.0	ENSP00000274545.5:V448=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""GABRA6"",""entrezGeneId"":2559,""alteration"":""ENSP00000274545.5:V448="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""GABRA6, a subunit of the GABA-A receptor, is infrequently altered in cancer."",""variantSummary"":""The GABRA6 ENSP00000274545.5:v448= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GABRA6 ENSP00000274545.5:V448= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/08/2023""}"	True	True	False	Unknown		Unknown																						0,71	0,38	0,33	0/1	0,0,33,38	TCA	.	.	.			0,0,32,39	64.5		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr5	171660961	171660965.0	AGTAG	A	A	171660961	.	AGTAG	A	.	PASS		-	intergenic_variant	MODIFIER														rs5873274				deletion																						0.4463	0.4644	0.4366	0.369	0.5338	0.4182											0.4938	0.4662	0.4341	0.4628	0.48	0.3695	0.5131	0.5379	0.5267	0.4957	0.4723	0.5379	gnomADg_MID																																																																																500					0.972							246.72													chr5	171087965																																																	True	False	False	Unknown		Unknown																						265,221	133,104	132,117	0/1	138,127,111,110	AAG						110,155,96,125	24.5		0.4547325102880658
GRCh38		D12_12345_1234556_Thyroid_S9			chr5	175351675	175351675.0	A	G	G	175351675	.	A	G	.	PASS		G	downstream_gene_variant	MODIFIER		ENSG00000306776	Transcript	ENST00000820936	lncRNA									rs251934	3593	1		SNV																						0.2678	0.205	0.3516	0.123	0.4135	0.2924											0.3385	0.2322	0.3542	0.3432	0.3826	0.1296	0.4133	0.381	0.4069	0.3701	0.2825	0.4135	EUR				26522768&26691610&29121662&33406744&32195283&23648204&19083859&31745634&27294018&36134022&19948332																																																																												474					0.994							246.51													chr5	174778678																																																	True	False	False	Unknown		Unknown																						219,252	116,125	103,127	0/1	104,115,117,135	CAT	.	.	.			109,110,126,126	56.1		0.535031847133758
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9			chr5	177086246	177086246.0	C	G	G	177086246	.	C	G	.	PASS	NM_213647	G	upstream_gene_variant	MODIFIER	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding									rs640180	669	1		SNV	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1						0.8532	0.7466	0.8473	1	0.7694	0.9366											0.7917	0.7496	0.7346	0.8114	0.7895	0.999	0.849	0.7381	0.7802	0.7786	0.9283	1	EAS				21472143																																																																												329					1							247.34													chr5	176513247																																																	True	True	False	Unknown		Unknown																						189,140	78,78	111,62	0/1	84,105,68,72	GCC	.	.	.			97,92,74,66	18.12		0.425531914893617
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9			chr5	177088590	177088591.0	A	AC	AC	177088590	.	A	AC	.	PASS	NM_213647	C	intron_variant	MODIFIER	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding		1/17	c.-53-958dup						rs11429362		1		insertion	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1					2	0.8528	0.7451	0.8473	1	0.7684	0.9376	0.8267	0.7629	0.8378	0.7796	0.9996	0.7857	0.7051	0.7738	0.8003	0.9327	0.7923	0.7511	0.7341	0.812	0.7897	0.999	0.8489	0.7347	0.7803	0.7811	0.9285	1	EAS										FAIL	-48	19	28	-4	0.00	0.00	0.00	0.00	FGFR4		8.8400e-01																																																											912					0.968							248.12													chr5	176515591																																																	True	True	False	Unknown		Unknown																						431,452	195,218	236,234	0/1	234,197,233,219	CAC						216,215,223,229	59.16		0.5118912797281994
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9			chr5	177088865	177088866.0	AG	A	A	177088865	.	AG	A	.	PASS	NM_213647	-	intron_variant	MODIFIER	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding		1/17	c.-53-684del						rs11332088		1		deletion	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1						0.8069	0.6286	0.8271	1	0.7396	0.9039											0.7463	0.6605	0.7029	0.7888	0.7664	0.9985	0.8174	0.6939	0.7482	0.7462	0.8934	1	EAS										FAIL	-12	2	39	0	0.17	0.00	0.03	0.00	FGFR4		8.8400e-01																																																											647					0.977							242.95													chr5	176515866																																																	True	True	False	Unknown		Unknown																						339,293	161,137	178,156	0/1	199,140,162,131	TAG						167,172,144,149	26.87		0.46360759493670883
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9			chr5	177090135	177090139.0	C	CGTGT	CGTGT	177090135	.	C	CGTGT	.	PASS	NM_213647	GTGT	intron_variant	MODIFIER	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding		2/17	c.92-238_92-235dup						rs59390048		1		insertion	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1					20	0.7730	0.5666	0.8026	0.9702	0.7286	0.8732	0.4857	0.4241	0.4969	0.482	0.5454	0.5018	0.4657	0.48	0.4829	0.4908	0.7097	0.5951	0.6667	0.7587	0.7512	0.9677	0.7716	0.6399	0.7278	0.7108	0.8506	0.9702	EAS																					8.8400e-01																																																											777					0.616							223.07													chr5	176517136																																																	True	True	False	Unknown		Unknown																						298,181	140,86	158,95	0/1	147,151,84,97	GCG						129,169,61,120	21.52		0.3778705636743215
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9	p.Arg54=	ENSP00000292408.4:p.Arg54=	chr5	177090460	177090460.0	T	G	G	177090460	.	T	G	.	PASS	NM_213647	G	synonymous_variant	LOW	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding	3/18		c.162T>G	378	162	54	R	cgT/cgG	rs446382&COSV52802425		1		SNV	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1			Gene3D:2.60.40.10&AFDB-ENSP_mappings:AF-P22455-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000628&SMART:SM00408&SMART:SM00409&Superfamily:SSF48726			0.7760	0.5756	0.8084	0.9772	0.6899	0.9049	0.7431	0.6085	0.8341	0.7153	0.9782	0.7553	0.6623	0.7244	0.7432	0.8883	0.7117	0.6121	0.6989	0.7544	0.7261	0.9756	0.7608	0.6224	0.7219	0.7016	0.9005	0.9782	gnomADe_EAS	benign	0&1	1&1	24200957						FAIL	-8	-6	35	-6	0.00	0.00	0.00	0.02	FGFR4		8.8400e-01	3061016	0.68323	0.76467	0.77596	3197432	FGFR4-related_disorder		.		NC_000005.10:g.177090460T>G	no_assertion_criteria_provided	Benign			SCV004797095	single_nucleotide_variant	SO:0001483	ClinGen:CA3575922		FGFR4:2264	SO:0001819&synonymous_variant										1	446382																											953					0.996							246.41	v6.1	Unknown		True	FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types.	False	07/23/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:R54= mutant UNKNOWN.	False	The FGFR4 ENSP00000292408.4:r54= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	176517461						True	False	False	Unknown								False	False		FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types.	The FGFR4 ENSP00000292408.4:r54= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:R54= mutant UNKNOWN.						v6.1	07/23/2019		GRCh38	FGFR4	2264.0	ENSP00000292408.4:R54=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGFR4"",""entrezGeneId"":2264,""alteration"":""ENSP00000292408.4:R54="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types."",""variantSummary"":""The FGFR4 ENSP00000292408.4:r54= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:R54= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2019""}"	True	True	False	Unknown		Unknown																						469,480	226,225	243,255	0/1	223,246,256,224	GTC	.	.	.			234,235,241,239	58.2		0.505795574288725
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9	p.P136L	ENSP00000292408.4:p.Pro136Leu	chr5	177090796	177090796.0	C	T	T	177090796	.	C	T	.	PASS	NM_213647	T	missense_variant	MODERATE	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding	4/18		c.407C>T	623	407	136	P/L	cCc/cTc	rs376618&COSV99448701		1		SNV	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1	tolerated_low_confidence(0.38)	benign(0)	AFDB-ENSP_mappings:AF-P22455-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF000628&PANTHER:PTHR24416&MobiDB_lite:mobidb-lite			0.8073	0.6301	0.8271	1	0.7396	0.9039	0.7723	0.661	0.856	0.7555	0.9993	0.811	0.6909	0.7547	0.7764	0.8787	0.7467	0.6614	0.7044	0.7883	0.7669	0.9985	0.8179	0.6939	0.7483	0.7469	0.8934	1	EAS	benign&likely_benign	0&1	1&1	24200957&21487324&20691689&21396369&24146310&24548884&22271411&21656577&18762813&19500394&33017009&22610000&22523086&21653700&30258940&24288432						FAIL	10	-35	29	33	0.00	0.00	0.02	0.00	FGFR4	0.180	8.8400e-01	1679938	0.72105	0.79499	0.80731	1671852	Classic_Hodgkin_lymphoma&FGFR4-related_disorder		Human_Phenotype_Ontology:HP:0012189&MONDO:MONDO:0009348&MedGen:C0019829&OMIM:236000&Orphanet:391&.		NC_000005.10:g.177090796C>T	criteria_provided&_single_submitter	Likely_benign			SCV002507274	single_nucleotide_variant	SO:0001483	ClinGen:CA3575987		FGFR4:2264	SO:0001583&missense_variant										3	376618																											824					0.998							245.41	v6.1	Unknown		True	FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types.	False	07/23/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:P136L mutant UNKNOWN.	False	The FGFR4 ENSP00000292408.4:p136l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	176517797						True	False	False	Unknown								False	False		FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types.	The FGFR4 ENSP00000292408.4:p136l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:P136L mutant UNKNOWN.						v6.1	07/23/2019		GRCh38	FGFR4	2264.0	ENSP00000292408.4:P136L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGFR4"",""entrezGeneId"":2264,""alteration"":""ENSP00000292408.4:P136L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types."",""variantSummary"":""The FGFR4 ENSP00000292408.4:p136l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:P136L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2019""}"	True	True	False	Unknown		Unknown																						430,392	217,208	213,184	0/1	210,220,176,216	CCC	0.00	0.00	0.00			215,215,194,198	35.77		0.4768856447688564
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9	p.Arg234=	ENSP00000292408.4:p.Arg234=	chr5	177091783	177091783.0	C	T	T	177091783	.	C	T	.	PASS	NM_213647	T	synonymous_variant	LOW	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding	6/18		c.702C>T	918	702	234	R	cgC/cgT	rs452885&COSV52807660		1		SNV	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1			Gene3D:2.60.40.10&PDB-ENSP_mappings:6j6y.A&PDB-ENSP_mappings:6j6y.D&PDB-ENSP_mappings:7ysw.C&PDB-ENSP_mappings:7ysw.E&AFDB-ENSP_mappings:AF-P22455-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF07679&PIRSF:PIRSF000628&PROSITE_profiles:PS50835&PANTHER:PTHR24416&SMART:SM00409&Superfamily:SSF48726&CDD:cd05857			0.8071	0.6293	0.8271	1	0.7396	0.9039	0.7723	0.6611	0.856	0.7553	0.9993	0.8109	0.6905	0.7547	0.7764	0.8787	0.7465	0.6614	0.7029	0.7884	0.7664	0.9985	0.8176	0.6939	0.7482	0.7457	0.8937	1	EAS	benign	0&1	1&1	24200957						FAIL	-27	-6	-27	25	0.00	0.00	0.07	0.00	FGFR4		8.8400e-01	3060679	0.72113	0.79485	0.80711	3197096	FGFR4-related_disorder		.		NC_000005.10:g.177091783C>T	no_assertion_criteria_provided	Benign			SCV004796583	single_nucleotide_variant	SO:0001483	ClinGen:CA3576093		FGFR4:2264	SO:0001819&synonymous_variant										1	452885																											1001					0.996							247.11	v6.1	Unknown		True	FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types.	False	07/23/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:R234= mutant UNKNOWN.	False	The FGFR4 ENSP00000292408.4:r234= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	176518784						True	False	False	Unknown								False	False		FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types.	The FGFR4 ENSP00000292408.4:r234= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:R234= mutant UNKNOWN.						v6.1	07/23/2019		GRCh38	FGFR4	2264.0	ENSP00000292408.4:R234=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FGFR4"",""entrezGeneId"":2264,""alteration"":""ENSP00000292408.4:R234="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FGFR4, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification at low frequencies in various cancer types."",""variantSummary"":""The FGFR4 ENSP00000292408.4:r234= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR4 ENSP00000292408.4:R234= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2019""}"	True	True	False	Unknown		Unknown																						522,475	245,220	277,255	0/1	270,252,250,225	GCT	0.00	0.00	0.00			249,273,221,254	35.6		0.4764292878635908
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9			chr5	177095727	177095727.0	C	T	T	177095727	.	C	T	.	PASS	NM_213647	T	splice_donor_region_variant&intron_variant	LOW	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding		13/17	c.1821+4C>T						rs42409&COSV99448713		1		SNV	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1						0.7019	0.3722	0.7637	0.9742	0.663	0.863	0.707	0.4107	0.8044	0.6743	0.9776	0.7217	0.6	0.693	0.699	0.8471	0.6354	0.4246	0.6667	0.7121	0.687	0.974	0.7294	0.5651	0.6878	0.6358	0.8597	0.9776	gnomADe_EAS	benign	0&1	1&1							FAIL	-40	-39	-40	2	0.00	0.00	0.06	0.00	FGFR4		8.8400e-01	3059127	0.59842	0.72795	0.70188	3196843	FGFR4-related_disorder		.		NC_000005.10:g.177095727C>T	no_assertion_criteria_provided	Benign			SCV004793263	single_nucleotide_variant	SO:0001483	ClinGen:CA3576562		FGFR4:2264	SO:0001627&intron_variant										1	42409																											844					0.998							245.45													chr5	176522728																																																	True	True	False	Unknown		Unknown																						431,411	242,217	189,194	0/1	223,208,196,215	ACA	0.00	0.00	0.00			218,213,188,223	44.01		0.48812351543942994
GRCh38	FGFR4	D12_12345_1234556_Thyroid_S9			chr5	177099958	177099958.0	C	T	T	177099958	.	C	T	.	PASS	NM_213647	T	downstream_gene_variant	MODIFIER	FGFR4	ENSG00000160867	Transcript	ENST00000292408	protein_coding										1814	1		SNV	HGNC	HGNC:3691	YES	MANE_Select	NM_213647.3		1	P2	CCDS4410.1	ENSP00000292408	P22455.242		UPI000012A72D	P22455-1		1																																																																																																																		742					0.827							201.23													chr5	176526959																																																	True	True	False	Unknown		Unknown																						608,6	294,3	314,3	0/1	320,288,1,5	TCT	0.00	0.00	1.00			270,338,2,4	9.86		0.009771986970684038
GRCh38	NSD1	D12_12345_1234556_Thyroid_S9	p.L395GlyfsTer	ENSP00000395929.2:p.Leu395GlyfsTer20	chr5	177204237	177204250.0	AGCTACCTGTCCTT	A	A	177204237	.	AGCTACCTGTCCTT	A	.	PASS	NM_022455	-	frameshift_variant	HIGH	NSD1	ENSG00000165671	Transcript	ENST00000439151	protein_coding	4/23		c.1182_1194del	1379-1391	1182-1194	394-398	ELPVL/X	gaGCTACCTGTCCTT/ga			1		deletion	HGNC	HGNC:14234	YES	MANE_Select	NM_022455.5		1	P2	CCDS4412.1	ENSP00000395929	Q96L73.209		UPI000006F9C6	Q96L73-1		1			Gene3D:2.30.30.140&AFDB-ENSP_mappings:AF-Q96L73-F1&Pfam:PF00855&Superfamily:SSF63748&CDD:cd20161																																																				1.4400e-01																																																											185					0.978							242.46	v6.1	Unknown		True	NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia.	False	12/01/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:L395Gfs*20 mutant UNKNOWN.	False	The NSD1 ENSP00000395929.2:l395gfs*20 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	176631238						True	False	False	Unknown								False	False		NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia.	The NSD1 ENSP00000395929.2:l395gfs*20 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:L395Gfs*20 mutant UNKNOWN.						v6.1	12/01/2025		GRCh38	NSD1	64324.0	ENSP00000395929.2:L395Gfs*20			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NSD1"",""entrezGeneId"":64324,""alteration"":""ENSP00000395929.2:L395Gfs*20"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia."",""variantSummary"":""The NSD1 ENSP00000395929.2:l395gfs*20 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:L395Gfs*20 mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/01/2025""}"	True	True	False	Likely Loss-of-function	20018718;29176703	Likely Oncogenic																						176,5	84,5	92,0	0/1	92,84,2,3	GAG						102,74,2,3	10.64		0.027624309392265192
GRCh38	NSD1	D12_12345_1234556_Thyroid_S9	p.Leu2277=	ENSP00000395929.2:p.Leu2277=	chr5	177294197	177294197.0	T	C	C	177294197	.	T	C	.	PASS	NM_022455	C	synonymous_variant	LOW	NSD1	ENSG00000165671	Transcript	ENST00000439151	protein_coding	23/23		c.6829T>C	7026	6829	2277	L	Ttg/Ctg	rs28580074&COSV61770055		1		SNV	HGNC	HGNC:14234	YES	MANE_Select	NM_022455.5		1	P2	CCDS4412.1	ENSP00000395929	Q96L73.209		UPI000006F9C6	Q96L73-1		1			AFDB-ENSP_mappings:AF-Q96L73-F1&PANTHER:PTHR22884&MobiDB_lite:mobidb-lite			0.7714	0.9251	0.7839	0.4871	0.8807	0.7352	0.86	0.9296	0.7744	0.8852	0.4899	0.8142	0.8837	0.8827	0.8495	0.7816	0.8633	0.9226	0.943	0.827	0.8862	0.4895	0.8121	0.9116	0.8767	0.8732	0.752	0.943	gnomADg_AMI	benign	0&1	1&1	25741868&23757202&32708070&18001468&27834868						FAIL	-48	14	-26	-12	0.00	0.00	0.00	0.00	NSD1		1.4400e-01	96073	0.89897		0.77137	101967	Sotos_syndrome&Inborn_genetic_diseases&not_provided&not_specified		MONDO:MONDO:0019349&MedGen:C0175695&OMIM:117550&Orphanet:821&MeSH:D030342&MedGen:C0950123&MedGen:C3661900&MedGen:CN169374		NC_000005.10:g.177294197T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000114084&SCV000314077&SCV000846072&SCV001728674&SCV002029456	single_nucleotide_variant	SO:0001483	ClinGen:CA149212		NSD1:64324	SO:0001819&synonymous_variant										1	28580074																											1070					1							247.08	v6.1	Unknown		True	NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia.	False	12/01/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:L2277= mutant UNKNOWN.	False	The NSD1 ENSP00000395929.2:l2277= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	176721198						True	False	False	Unknown								False	False		NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia.	The NSD1 ENSP00000395929.2:l2277= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:L2277= mutant UNKNOWN.						v6.1	12/01/2025		GRCh38	NSD1	64324.0	ENSP00000395929.2:L2277=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NSD1"",""entrezGeneId"":64324,""alteration"":""ENSP00000395929.2:L2277="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia."",""variantSummary"":""The NSD1 ENSP00000395929.2:l2277= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:L2277= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/01/2025""}"	True	True	False	Unknown		Unknown																						0,1070	0,571	0,499	0/1	0,0,533,537	ATT	.	.	.			0,0,538,532	64.73		1.0
GRCh38	NSD1	D12_12345_1234556_Thyroid_S9	p.Gly2301=	ENSP00000395929.2:p.Gly2301=	chr5	177294271	177294271.0	G	C	C	177294271	.	G	C	.	PASS	NM_022455	C	synonymous_variant	LOW	NSD1	ENSG00000165671	Transcript	ENST00000439151	protein_coding	23/23		c.6903G>C	7100	6903	2301	G	ggG/ggC	rs11740250&COSV61770866		1		SNV	HGNC	HGNC:14234	YES	MANE_Select	NM_022455.5		1	P2	CCDS4412.1	ENSP00000395929	Q96L73.209		UPI000006F9C6	Q96L73-1		1			AFDB-ENSP_mappings:AF-Q96L73-F1&PANTHER:PTHR22884&MobiDB_lite:mobidb-lite			0.1080	0.0106	0.1455	0	0.2475	0.181	0.2173	0.03336	0.1039	0.3256	0.0006045	0.245	0.2386	0.2315	0.2086	0.2186	0.1674	0.04018	0.244	0.1471	0.3169	0.001927	0.2551	0.2551	0.2372	0.1787	0.1969	0.3256	gnomADe_ASJ	benign	0&1	1&1	25741868&18414213&23757202&18001468						FAIL	33	39	-18	-1	0.00	0.00	0.00	0.00	NSD1		1.4400e-01	96074	0.18007	0.19145	0.10803	101968	Inborn_genetic_diseases&Sotos_syndrome&not_provided&not_specified		MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0019349&MedGen:C0175695&OMIM:117550&Orphanet:821&MedGen:C3661900&MedGen:CN169374		NC_000005.10:g.177294271G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000114085&SCV000194279&SCV000314078&SCV000846184&SCV001938798&SCV002029467&SCV002407999	single_nucleotide_variant	SO:0001483	ClinGen:CA149215		NSD1:64324	SO:0001819&synonymous_variant										1	11740250																											1068					1							247.87	v6.1	Unknown		True	NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia.	False	12/01/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:G2301= mutant UNKNOWN.	False	The NSD1 ENSP00000395929.2:g2301= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	176721272						True	False	False	Unknown								False	False		NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia.	The NSD1 ENSP00000395929.2:g2301= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:G2301= mutant UNKNOWN.						v6.1	12/01/2025		GRCh38	NSD1	64324.0	ENSP00000395929.2:G2301=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NSD1"",""entrezGeneId"":64324,""alteration"":""ENSP00000395929.2:G2301="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NSD1, a transcription factor and histone methyltransferase, is frequently altered by translocation in pediatric acute myeloid leukemia."",""variantSummary"":""The NSD1 ENSP00000395929.2:g2301= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NSD1 ENSP00000395929.2:G2301= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/01/2025""}"	True	True	False	Unknown		Unknown																						540,528	297,283	243,245	0/1	268,272,267,261	GGT	.	.	.			285,255,282,246	52.04		0.4943820224719101
GRCh38	DDX41	D12_12345_1234556_Thyroid_S9	p.Arg400=	ENSP00000330349.8:p.Arg400=	chr5	177513383	177513383.0	G	A	A	177513383	.	G	A	.	PASS	NM_016222	A	synonymous_variant	LOW	DDX41	ENSG00000183258	Transcript	ENST00000330503	protein_coding	11/17		c.1200C>T	1216	1200	400	R	cgC/cgT	rs335438&COSV57250806		-1		SNV	HGNC	HGNC:18674	YES	MANE_Select	NM_016222.4		1	P1	CCDS4427.1	ENSP00000330349	Q9UJV9.224		UPI0000125164			1			PDB-ENSP_mappings:5gvr.A&PDB-ENSP_mappings:5h1y.A&PDB-ENSP_mappings:5h1y.B&PDB-ENSP_mappings:8c6j.CD&Superfamily:SSF52540&PANTHER:PTHR47958&SMART:SM00487&Gene3D:3.40.50.300&AFDB-ENSP_mappings:AF-Q9UJV9-F1			0.3864	0.4539	0.3199	0.2063	0.4712	0.4407	0.4469	0.4703	0.295	0.4044	0.1753	0.453	0.4119	0.4624	0.4343	0.4626	0.4425	0.4583	0.4638	0.3632	0.3994	0.1893	0.4699	0.415	0.4664	0.4342	0.4634	0.4712	EUR	benign	0&1	1&1	34641967						FAIL	38	23	21	-38	0.00	0.00	0.00	0.02	DDX41		7.6800e-01	1278531	0.46086	0.41981	0.38638	1267112	not_provided&DDX41-related_hematologic_malignancy_predisposition_syndrome&Inborn_genetic_diseases		MedGen:C3661900&MONDO:MONDO:0014809&MedGen:C4225174&OMIM:616871&Orphanet:488647&MeSH:D030342&MedGen:C0950123		NC_000005.10:g.177513383G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001907226&SCV002049233&SCV003333685&SCV005563842	single_nucleotide_variant	SO:0001483	ClinGen:CA3584868		DDX41:51428	SO:0001819&synonymous_variant										1	335438																											749					1							246.4	v6.1	Unknown		True	DDX41, an RNA helicase involved in innate immunity, is recurrently altered by mutation in hematopoietic malignancies.	False	11/03/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DDX41 ENSP00000330349.8:R400= mutant UNKNOWN.	False	The DDX41 ENSP00000330349.8:r400= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	176940384						True	False	False	Unknown								False	False		DDX41, an RNA helicase involved in innate immunity, is recurrently altered by mutation in hematopoietic malignancies.	The DDX41 ENSP00000330349.8:r400= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DDX41 ENSP00000330349.8:R400= mutant UNKNOWN.						v6.1	11/03/2025		GRCh38	DDX41	51428.0	ENSP00000330349.8:R400=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""DDX41"",""entrezGeneId"":51428,""alteration"":""ENSP00000330349.8:R400="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""DDX41, an RNA helicase involved in innate immunity, is recurrently altered by mutation in hematopoietic malignancies."",""variantSummary"":""The DDX41 ENSP00000330349.8:r400= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DDX41 ENSP00000330349.8:R400= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/03/2025""}"	True	True	False	Unknown		Unknown																						402,347	209,180	193,167	0/1	208,194,171,176	CGC	0.00	0.00	0.00			223,179,194,153	26.79		0.46328437917222964
GRCh38	DDX41	D12_12345_1234556_Thyroid_S9			chr5	177513870	177513870.0	G	C	C	177513870	.	G	C	.	PASS	NM_016222	C	intron_variant	MODIFIER	DDX41	ENSG00000183258	Transcript	ENST00000330503	protein_coding		9/16	c.936-23C>G						rs335439		-1		SNV	HGNC	HGNC:18674	YES	MANE_Select	NM_016222.4		1	P1	CCDS4427.1	ENSP00000330349	Q9UJV9.224		UPI0000125164			1						0.9706	0.8933	0.9928	1	0.999	1	0.9972	0.9032	0.9937	1	1	1	0.9944	0.9999	0.9934	0.9997	0.9721	0.9036	1	0.9882	1	1	1	0.9932	0.9996	0.9806	0.9998	1	EAS&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN	benign		1	34641967						FAIL	28	-3	28	-3	0.01	0.09	0.00	0.00	DDX41		7.6800e-01	1274299	0.96685	0.99080	0.97065	1262474	not_provided		MedGen:C3661900		NC_000005.10:g.177513870G>C	criteria_provided&_single_submitter	Benign			SCV001904895	single_nucleotide_variant	SO:0001483	ClinGen:CA3584948		DDX41:51428	SO:0001627&intron_variant										1	335439																											861					0.999							246.55													chr5	176940871																																																	True	True	False	Unknown		Unknown																						0,860	0,444	0,416	0/1	0,0,429,431	TGA	.	.	.			0,0,377,483	64.73		1.0
GRCh38	FLT4	D12_12345_1234556_Thyroid_S9	p.R1324L	ENSP00000261937.6:p.Arg1324Leu	chr5	180603313	180603313.0	C	A	A	180603313	.	C	A	.	PASS	NM_182925	A	missense_variant	MODERATE	FLT4	ENSG00000037280	Transcript	ENST00000261937	protein_coding	30/30		c.3971G>T	4026	3971	1324	R/L	cGg/cTg	rs307821&COSV56098908&COSV56108334&COSV56119874		-1		SNV	HGNC	HGNC:3767	YES	MANE_Select	NM_182925.5		1	P1	CCDS4457.1	ENSP00000261937	P35916.235		UPI00001488E7	P35916-2		1	tolerated_low_confidence(0.47)	benign(0)	Low_complexity_(Seg):seg&MobiDB_lite:mobidb-lite&Phobius:CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P35916-F1									0.09851	0.05255	0.04708	0.101	0.0003528	0.09255	0.06437	0.1105	0.08821	0.04648	0.08062	0.05134	0.2967	0.06115	0.1112	0.0005778	0.08603	0.08844	0.1067	0.07467	0.04077	0.2967	gnomADg_AMI	benign	0&1&1&1	1&1&1&1	25741868&23462807&33762959&26830973&22015057&26254278&28978162&29787601&29290970&30401688&22212486&26063633&30651923&33447413&31921657&31032317&24337833&26816714&28326244&34367064&26614032&36135186&23026828&25100134&23024706&35267558						FAIL	21	-34	2	-19	0.00	0.00	0.00	0.00	FLT4	0.068	2.6500e-01	263057	0.08951			251880	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000005.10:g.180603313C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000316817&SCV001757228	single_nucleotide_variant	SO:0001483	ClinGen:CA3605611		FLT4:2324	SO:0001583&missense_variant										1	307821																											778					0.995							248.47	v6.1	Unknown		True	FLT4, a receptor tyrosine kinase, is infrequently altered by mutation in a variety of cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT4 ENSP00000261937.6:R1324L mutant UNKNOWN.	False	The FLT4 ENSP00000261937.6:r1324l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr5	180030313						True	False	False	Unknown								False	False		FLT4, a receptor tyrosine kinase, is infrequently altered by mutation in a variety of cancer types.	The FLT4 ENSP00000261937.6:r1324l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT4 ENSP00000261937.6:R1324L mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	FLT4	2324.0	ENSP00000261937.6:R1324L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FLT4"",""entrezGeneId"":2324,""alteration"":""ENSP00000261937.6:R1324L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FLT4, a receptor tyrosine kinase, is infrequently altered by mutation in a variety of cancer types."",""variantSummary"":""The FLT4 ENSP00000261937.6:r1324l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT4 ENSP00000261937.6:R1324L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						407,367	218,176	189,191	0/1	183,224,180,187	CCG	0.00	0.00	0.00			208,199,205,162	33.79		0.47416020671834624
GRCh38	FLT4	D12_12345_1234556_Thyroid_S9	p.R1146H	ENSP00000261937.6:p.Arg1146His	chr5	180612606	180612606.0	C	T	T	180612606	.	C	T	.	PASS	NM_182925	T	missense_variant	MODERATE	FLT4	ENSG00000037280	Transcript	ENST00000261937	protein_coding	26/30		c.3437G>A	3492	3437	1146	R/H	cGc/cAc	rs1130379&COSV56097140		-1		SNV	HGNC	HGNC:3767	YES	MANE_Select	NM_182925.5		1	P1	CCDS4457.1	ENSP00000261937	P35916.235		UPI00001488E7	P35916-2		1	tolerated(0.15)	benign(0.005)	Superfamily:SSF56112&Pfam:PF07714&PIRSF:PIRSF000615&Gene3D:1.10.510.10&PANTHER:PTHR24416&PROSITE_profiles:PS50011&CDD:cd05102&Phobius:CYTOPLASMIC_DOMAIN&SMART:SM00219&AFDB-ENSP_mappings:AF-P35916-F1			0.0341	0.003	0.0288	0	0.1173	0.0297	0.09658	0.01512	0.03711	0.08677	0.0003275	0.1258	0.0879	0.1091	0.08358	0.0364	0.07143	0.01911	0.1831	0.04586	0.07761	0.0003865	0.1213	0.06463	0.1079	0.06682	0.03237	0.1831	gnomADg_AMI	benign	0&1	1&1	25741868&22404826&37065486						FAIL	-27	5	5	-34	0.01	0.07	0.00	0.00	FLT4	0.094	2.6500e-01	263050	0.07343	0.07575	0.03415	251887	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000005.10:g.180612606C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000316810&SCV001865119	single_nucleotide_variant	SO:0001483	ClinGen:CA3605822&UniProtKB:P35916																																																																																																																																															277,266	154,144	123,122	0/1	143,134,121,145	GCG	0.00	0.00	0.00			118,159,99,167	41.34		0.48987108655616945
GRCh38	FLT4	D12_12345_1234556_Thyroid_S9	p.H890Q	ENSP00000261937.6:p.His890Gln	chr5	180619344	180619344.0	G	C	C	180619344	.	G	C	.	PASS	NM_182925	C	missense_variant	MODERATE	FLT4	ENSG00000037280	Transcript	ENST00000261937	protein_coding	19/30		c.2670C>G	2725	2670	890	H/Q	caC/caG	rs448012&COSV56098125		-1		SNV	HGNC	HGNC:3767	YES	MANE_Select	NM_182925.5		1	P1	CCDS4457.1	ENSP00000261937	P35916.235		UPI00001488E7	P35916-2		1	deleterious(0.02)	benign(0.294)	Superfamily:SSF56112&Pfam:PF07714&Gene3D:3.30.200.20&PIRSF:PIRSF000615&PANTHER:PTHR24416&PROSITE_profiles:PS50011&CDD:cd05102&Phobius:CYTOPLASMIC_DOMAIN&SMART:SM00219&AFDB-ENSP_mappings:AF-P35916-F1			0.5827	0.5144	0.7464	0.497	0.6531	0.5746	0.6298	0.5374	0.7486	0.5801	0.4935	0.7046	0.5806	0.6362	0.6165	0.5687	0.6122	0.5424	0.6969	0.6969	0.5676	0.4929	0.7045	0.6007	0.6338	0.6186	0.5782	0.7486	gnomADe_AMR	benign	0&1	1&1	25741868&24033266&26830973&22015057&19924384&28978162&30401688&28123542&25239121&34944636&25530832&37065486&31032317&35756188&28326244&23026828&25100134						FAIL	20	6	-1	-11	0.01	0.01	0.00	0.00	FLT4	0.310	2.6500e-01	263039	0.59701	0.62474	0.58267	251898	Hereditary_lymphedema_type_I&not_specified&Congenital_heart_defects&_multiple_types&_7&not_provided		MONDO:MONDO:0007919&MedGen:C1704423&OMIM:153100&Orphanet:79452&MedGen:CN169374&MONDO:MONDO:0032913&MedGen:C5394062&OMIM:618780&MedGen:C3661900		NC_000005.10:g.180619344G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000316798&SCV000539181&SCV001880962&SCV001933510&SCV001933511	single_nucleotide_variant	SO:0001483	ClinGen:CA3606153&UniProtKB:P35916																																																																																																																																															0,529	0,261	0,268	0/1	0,0,261,268	GGT	.	.	.			0,0,281,248	64.73		1.0
GRCh38	FLT4	D12_12345_1234556_Thyroid_S9			chr5	180619426	180619448.0	C	CTGGCCGCTTAGCTAAGGCACAG	CTGGCCGCTTAGCTAAGGCACAG	180619426	.	C	CTGGCCGCTTAGCTAAGGCACAG	.	PASS	NM_182925	TGGCCGCTTAGCTAAGGCACAG	intron_variant	MODIFIER	FLT4	ENSG00000037280	Transcript	ENST00000261937	protein_coding		18/29	c.2648-61_2648-60insCTGTGCCTTAGCTAAGCGGCCA						rs70973949&COSV107246960		-1		insertion	HGNC	HGNC:3767	YES	MANE_Select	NM_182925.5		1	P1	CCDS4457.1	ENSP00000261937	P35916.235		UPI00001488E7	P35916-2		1						0.6316	0.5121	0.781	0.5536	0.7256	0.6708	0.7022	0.5432	0.7779	0.6833	0.5631	0.7507	0.6194	0.7126	0.6897	0.6624	0.6754	0.5647	0.7407	0.7526	0.6806	0.5584	0.7554	0.6463	0.7206	0.6927	0.6736	0.781	AMR	benign	0&1	1&1																		2.6500e-01	1229608	0.59511		0.63159	1220862	not_provided		MedGen:C3661900		NC_000005.10:g.180619426_180619427insTGGCCGCTTAGCTAAGGCACAG	criteria_provided&_single_submitter	Benign			SCV001837913	Insertion	SO:0000667	ClinGen:CA3606197		FLT4:2324	SO:0001627&intron_variant										1	70973949																											381					0.979							205.65													chr5	180046426																																																	True	True	False	Unknown		Unknown																						0,373	0,175	0,198	0/1	0,0,208,165	ACC						0,0,230,143	63.48		1.0
GRCh38	FLT4	D12_12345_1234556_Thyroid_S9			chr5	180619492	180619494.0	CAG	C	C	180619492	.	CAG	C	.	PASS	NM_182925	-	intron_variant	MODIFIER	FLT4	ENSG00000037280	Transcript	ENST00000261937	protein_coding		18/29	c.2648-128_2648-127del						rs35078045		-1		deletion	HGNC	HGNC:3767	YES	MANE_Select	NM_182925.5		1	P1	CCDS4457.1	ENSP00000261937	P35916.235		UPI00001488E7	P35916-2		1						0.6552	0.5825	0.7882	0.5665	0.7107	0.6933	0.6753	0.5759	0.7689	0.6606	0.5714	0.7419	0.6262	0.6754	0.6734	0.6683	0.6708	0.5955	0.7336	0.7417	0.656	0.5621	0.7426	0.6497	0.6968	0.6803	0.68	0.7882	AMR			1							FAIL	-39	45	-37	45	0.00	0.01	0.00	0.00	FLT4		2.6500e-01	1277383				1265963	not_provided		MedGen:C3661900		NC_000005.10:g.180619493AG[1]	criteria_provided&_single_submitter	Benign			SCV001908279	Microsatellite	SO:0000289	ClinGen:CA3606228		FLT4:2324	SO:0001627&intron_variant										1	35078045																											643					0.994							245.24													chr5	180046492																																																	True	True	False	Unknown		Unknown																						0,639	0,337	0,302	0/1	0,0,328,311	GCA						0,0,348,291	63.48		1.0
GRCh38	FLT4	D12_12345_1234556_Thyroid_S9	p.T494A	ENSP00000261937.6:p.Thr494Ala	chr5	180624003	180624003.0	T	C	C	180624003	.	T	C	.	PASS	NM_182925	C	missense_variant	MODERATE	FLT4	ENSG00000037280	Transcript	ENST00000261937	protein_coding	11/30		c.1480A>G	1535	1480	494	T/A	Acg/Gcg	rs307826&COSV56108373		-1		SNV	HGNC	HGNC:3767	YES	MANE_Select	NM_182925.5		1	P1	CCDS4457.1	ENSP00000261937	P35916.235		UPI00001488E7	P35916-2		1	tolerated(0.29)	benign(0.009)	PDB-ENSP_mappings:4bsj.A&Superfamily:SSF48726&Pfam:PF22971&Gene3D:2.60.40.10&PIRSF:PIRSF000615&PIRSF:PIRSF000615&PANTHER:PTHR24416&PROSITE_profiles:PS50835&Phobius:NON_CYTOPLASMIC_DOMAIN&SMART:SM00409&AFDB-ENSP_mappings:AF-P35916-F1			0.0529	0.0151	0.0605	0	0.1074	0.0971	0.1081	0.02611	0.05658	0.1124	0.000529	0.08995	0.09518	0.1195	0.09871	0.0863	0.08122	0.02889	0.3044	0.07003	0.12	0.001157	0.08454	0.08844	0.1165	0.08412	0.07697	0.3044	gnomADg_AMI	benign	0&1	1&1	25741868&28117391&22404826&23462807&22175024&33762959&30621627&30385613&26830973&25695485&22015057&20223440&19924384&26254278&28978162&29787601&29290970&30401688&27668980&22212486&26063633&30651923&23788753&33447413&31921657&31032317&28404979&29742281&24337833&25120953&26816714&28326244&34367064&27747094&26614032&36135186&23026828&25100134&23024706&35267558						FAIL	42	-6	-46	7	0.00	0.00	0.00	0.00	FLT4	0.125	2.6500e-01	263028	0.09127		0.05292	251908	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000005.10:g.180624003T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000316787&SCV001847888	single_nucleotide_variant	SO:0001483	ClinGen:CA3606707&UniProtKB:P35916																																																																																																																																															406,389	213,205	193,184	0/1	204,202,163,226	GTG	.	.	.			215,191,185,204	44.16		0.48930817610062893
GRCh38	FLT4	D12_12345_1234556_Thyroid_S9	p.N149D	ENSP00000261937.6:p.Asn149Asp	chr5	180630293	180630293.0	T	C	C	180630293	.	T	C	.	PASS	NM_182925	C	missense_variant	MODERATE	FLT4	ENSG00000037280	Transcript	ENST00000261937	protein_coding	4/30		c.445A>G	500	445	149	N/D	Aac/Gac	rs34221241&COSV56097170		-1		SNV	HGNC	HGNC:3767	YES	MANE_Select	NM_182925.5		1	P1	CCDS4457.1	ENSP00000261937	P35916.235		UPI00001488E7	P35916-2		1	tolerated(0.22)	benign(0.003)	PDB-ENSP_mappings:4bsk.A&Gene3D:2.60.40.10&Pfam:PF21339&PIRSF:PIRSF000615&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-P35916-F1			0.0389	0.0045	0.0331	0.001	0.1243	0.0409	0.09431	0.0152	0.039	0.06651	0.0002771	0.1191	0.08773	0.1062	0.08129	0.04657	0.07036	0.01903	0.1502	0.04985	0.0625	0.0005792	0.1182	0.06122	0.1056	0.06866	0.04167	0.1502	gnomADg_AMI	benign	0&1	1&1	25741868&29875488&35078996&36168886&38412862						FAIL	44	-5	-16	4	0.02	0.16	0.03	0.00	FLT4	0.064	2.6500e-01	263062	0.07186	0.07510	0.03894	251930	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000005.10:g.180630293T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000316822&SCV001846909	single_nucleotide_variant	SO:0001483	ClinGen:CA3607107&UniProtKB:P35916																																																																																																																																															364,362	176,168	188,194	0/1	200,164,179,183	TTG	.	.	.			178,186,179,183	49.23		0.4986225895316804
GRCh38	HIVEP1	D12_12345_1234556_Thyroid_S9			chr6	12059721	12059721.0	G	A	A	12059721	.	G	A	.	PASS		A	intron_variant	MODIFIER	HIVEP1	ENSG00000095951	Transcript	ENST00000714232	protein_coding		3/9	c.-567+8253G>A						rs13218440		1		SNV	HGNC	HGNC:4920						A2		ENSP00000519513			UPI001FB172A0									0.4123	0.4107	0.3876	0.4236	0.4085	0.4243											0.4035	0.4106	0.3451	0.4091	0.4588	0.4305	0.3812	0.3707	0.395	0.4227	0.4304	0.4588	gnomADg_ASJ				23771752&26522768&26691610&29121662&33406744&34721519&33857205&24406457&31745634&27294018&33950286&29615764&33546406&16360294&38774862						FAIL	-8	1	46	-1	0.00	0.00	0.00	0.00	HIVEP1																																																													419					1							247.15													chr6	12059954																																																	True	False	False	Unknown		Unknown																						213,206	114,131	99,75	0/1	108,105,118,88	GGG	0.00	0.00	0.00			121,92,129,77	40.29		0.4916467780429594
GRCh38	E2F3	D12_12345_1234556_Thyroid_S9			chr6	20442967	20442968.0	C	CA	CA	20442967	.	C	CA	.	PASS	NM_001949	A	intron_variant	MODIFIER	E2F3	ENSG00000112242	Transcript	ENST00000346618	protein_coding		1/6	c.394-36866dup						rs60258972		1		insertion	HGNC	HGNC:3115	YES	MANE_Select	NM_001949.5		1		CCDS4545.1	ENSP00000262904	O00716.208		UPI0000129AC2	O00716-1							13	0.8173	0.7595	0.8617	0.8323	0.8211	0.8446											0.8761	0.8166	0.9446	0.9145	0.8425	0.9331	0.8196	0.8958	0.9038	0.8889	0.9261	0.9446	gnomADg_AMI										FAIL	48	49	10	11	0.00	0.00	0.00	0.00	E2F3		3.9300e-01																																																											212					0.901							225.99													chr6	20443198																																																	True	True	False	Unknown		Unknown																						56,135	32,75	24,60	0/1	32,24,74,61	TCA						48,8,110,25	40.7		0.7068062827225131
GRCh38	E2F3	D12_12345_1234556_Thyroid_S9			chr6	20447062	20447062.0	A	G	G	20447062	.	A	G	.	PASS	NM_001949	G	intron_variant	MODIFIER	E2F3	ENSG00000112242	Transcript	ENST00000346618	protein_coding		1/6	c.394-32784A>G						rs4712499		1		SNV	HGNC	HGNC:3115	YES	MANE_Select	NM_001949.5		1		CCDS4545.1	ENSP00000262904	O00716.208		UPI0000129AC2	O00716-1								0.9820	0.997	0.9784	1	0.9503	0.9785											0.968	0.9915	0.9572	0.9684	0.9453	1	0.9628	0.9626	0.9521	0.9674	0.9838	1	EAS&gnomADg_EAS										FAIL	1	49	-11	49	0.00	0.00	0.00	0.00	E2F3		3.9300e-01																																																											185					1							244.66													chr6	20447293																																																	True	True	False	Unknown		Unknown																						0,185	0,87	0,98	0/1	0,0,87,98	AAG	.	.	.			0,0,91,94	64.72		1.0
GRCh38	E2F3	D12_12345_1234556_Thyroid_S9			chr6	20461071	20461071.0	T	C	C	20461071	.	T	C	.	PASS	NM_001949	C	intron_variant	MODIFIER	E2F3	ENSG00000112242	Transcript	ENST00000346618	protein_coding		1/6	c.394-18775T>C						rs9465755		1		SNV	HGNC	HGNC:3115	YES	MANE_Select	NM_001949.5		1		CCDS4545.1	ENSP00000262904	O00716.208		UPI0000129AC2	O00716-1								0.6114	0.4433	0.7651	0.5169	0.7614	0.6728											0.682	0.5137	0.8714	0.6995	0.6279	0.5321	0.7489	0.6828	0.7793	0.6795	0.6791	0.8714	gnomADg_AMI										FAIL	-14	13	1	-15	0.00	0.00	0.00	0.00	E2F3		3.9300e-01																																																											331					0.961							238.93													chr6	20461302																																																	True	True	False	Unknown		Unknown																						0,318	0,141	0,177	0/1	0,0,174,144	ATA	.	.	.			0,0,137,181	64.73		1.0
GRCh38	E2F3	D12_12345_1234556_Thyroid_S9			chr6	20472957		A	<INS>	<INS>	20472957	MantaINS:8856:1:1:0:8:0	A	<INS>	.	PASS	NM_001949	insertion	intron_variant	MODIFIER	E2F3	ENSG00000112242	Transcript	ENST00000346618	protein_coding		1/6									1		insertion	HGNC	HGNC:3115	YES	MANE_Select	NM_001949.5		1		CCDS4545.1	ENSP00000262904	O00716.208		UPI0000129AC2	O00716-1																																																																																																																	0,58		0,58							58	ATAGAAAAGTGTGTGTTTTGCTACGATTTATGGGAAAAACTTTTTAAAGATGGGATGG		ATAGAAAAGTGTGTGTTTTGCTACGATTTATGGGAAAAACTTTTTAAAGATGGGATGGAATGGAATGGAATACAATGCAATAGAATAGAATAGAATGGAATTAAATCAACTCCCTTGTGGAATAAAAGGGAA																chr6	20473188	TTGGAAACGGGAGTATCTTC			INS																																													True	True	False	Unknown		Unknown																															2,0				3,4	
GRCh38	H3C1	D12_12345_1234556_Thyroid_S9	p.Arg73=	ENSP00000480826.2:p.Arg73=	chr6	26020708	26020708.0	C	T	T	26020708	.	C	T	.	PASS	NM_003529	T	synonymous_variant	LOW	H3C1	ENSG00000275714	Transcript	ENST00000613854	protein_coding	1/1		c.219C>T	258	219	73	R	cgC/cgT	rs2229766		1		SNV	HGNC	HGNC:4766	YES	MANE_Select	NM_003529.3			P1	CCDS4570.1	ENSP00000480826	P68431.203		UPI00000003C7						PDB-ENSP_mappings:2cv5.A&PDB-ENSP_mappings:2cv5.E&PDB-ENSP_mappings:3afa.A&PDB-ENSP_mappings:3afa.E&PDB-ENSP_mappings:3ayw.A&PDB-ENSP_mappings:3ayw.E&PDB-ENSP_mappings:3aze.A&PDB-ENSP_mappings:3aze.E&PDB-ENSP_mappings:3azf.A&PDB-ENSP_mappings:3azf.E&PDB-ENSP_mappings:3azg.A&PDB-ENSP_mappings:3azg.E&PDB-ENSP_mappings:3azh.A&PDB-ENSP_mappings:3azh.E&PDB-ENSP_mappings:3azi.A&PDB-ENSP_mappings:3azi.E&PDB-ENSP_mappings:3azj.A&PDB-ENSP_mappings:3azj.E&PDB-ENSP_mappings:3azk.A&PDB-ENSP_mappings:3azk.E&PDB-ENSP_mappings:3azl.A&PDB-ENSP_mappings:3azl.E&PDB-ENSP_mappings:3azm.A&PDB-ENSP_mappings:3azm.E&PDB-ENSP_mappings:3azn.A&PDB-ENSP_mappings:3azn.E&PDB-ENSP_mappings:3w96.A&PDB-ENSP_mappings:3w96.E&PDB-ENSP_mappings:3w97.A&PDB-ENSP_mappings:3w97.E&PDB-ENSP_mappings:3w98.A&PDB-ENSP_mappings:3w98.E&PDB-ENSP_mappings:3w99.A&PDB-ENSP_mappings:3w99.E&PDB-ENSP_mappings:3wa9.A&PDB-ENSP_mappings:3wa9.E&PDB-ENSP_mappings:3waa.A&PDB-ENSP_mappings:3waa.E&PDB-ENSP_mappings:3wkj.A&PDB-ENSP_mappings:3wkj.E&PDB-ENSP_mappings:3x1s.A&PDB-ENSP_mappings:3x1s.E&PDB-ENSP_mappings:3x1t.A&PDB-ENSP_mappings:3x1t.E&PDB-ENSP_mappings:3x1u.A&PDB-ENSP_mappings:3x1u.E&PDB-ENSP_mappings:3x1v.A&PDB-ENSP_mappings:3x1v.E&PDB-ENSP_mappings:4ym5.A&PDB-ENSP_mappings:4ym5.E&PDB-ENSP_mappings:4ym6.A&PDB-ENSP_mappings:4ym6.E&PDB-ENSP_mappings:4z2m.G&PDB-ENSP_mappings:4z2m.I&PDB-ENSP_mappings:5av5.A&PDB-ENSP_mappings:5av5.E&PDB-ENSP_mappings:5av6.A&PDB-ENSP_mappings:5av6.E&PDB-ENSP_mappings:5av8.A&PDB-ENSP_mappings:5av8.E&PDB-ENSP_mappings:5av9.A&PDB-ENSP_mappings:5av9.E&PDB-ENSP_mappings:5avb.A&PDB-ENSP_mappings:5avb.E&PDB-ENSP_mappings:5avc.A&PDB-ENSP_mappings:5avc.E&PDB-ENSP_mappings:5b24.A&PDB-ENSP_mappings:5b24.E&PDB-ENSP_mappings:5b2i.A&PDB-ENSP_mappings:5b2i.E&PDB-ENSP_mappings:5b2j.A&PDB-ENSP_mappings:5b2j.E&PDB-ENSP_mappings:5b31.A&PDB-ENSP_mappings:5b31.E&PDB-ENSP_mappings:5c3i.B&PDB-ENSP_mappings:5c3i.F&PDB-ENSP_mappings:5c3i.J&PDB-ENSP_mappings:5c3i.N&PDB-ENSP_mappings:5c3i.R&PDB-ENSP_mappings:5c3i.V&PDB-ENSP_mappings:5cpi.A&PDB-ENSP_mappings:5cpi.E&PDB-ENSP_mappings:5cpj.A&PDB-ENSP_mappings:5cpj.E&PDB-ENSP_mappings:5cpk.A&PDB-ENSP_mappings:5cpk.E&PDB-ENSP_mappings:5gse.A&PDB-ENSP_mappings:5gse.E&PDB-ENSP_mappings:5gse.K&PDB-ENSP_mappings:5gse.O&PDB-ENSP_mappings:5gsu.A&PDB-ENSP_mappings:5gsu.E&PDB-ENSP_mappings:5gt0.A&PDB-ENSP_mappings:5gt0.E&PDB-ENSP_mappings:5gt3.A&PDB-ENSP_mappings:5gt3.E&PDB-ENSP_mappings:5gtc.A&PDB-ENSP_mappings:5gtc.E&PDB-ENSP_mappings:5jrg.A&PDB-ENSP_mappings:5jrg.E&PDB-ENSP_mappings:5xf3.A&PDB-ENSP_mappings:5xf3.E&PDB-ENSP_mappings:5xf4.A&PDB-ENSP_mappings:5xf4.E&PDB-ENSP_mappings:5xf5.A&PDB-ENSP_mappings:5xf5.E&PDB-ENSP_mappings:5y0c.A&PDB-ENSP_mappings:5y0c.E&PDB-ENSP_mappings:5y0d.A&PDB-ENSP_mappings:5y0d.E&PDB-ENSP_mappings:5z23.A&PDB-ENSP_mappings:5z23.E&PDB-ENSP_mappings:5z30.A&PDB-ENSP_mappings:5z30.E&PDB-ENSP_mappings:5zbx.A&PDB-ENSP_mappings:5zbx.E&PDB-ENSP_mappings:6hkt.A&PDB-ENSP_mappings:6hkt.E&PDB-ENSP_mappings:6hkt.K&PDB-ENSP_mappings:6hkt.O&PDB-ENSP_mappings:6hkt.U&PDB-ENSP_mappings:6hkt.Y&PDB-ENSP_mappings:6hkt.a&PDB-ENSP_mappings:6hkt.e&PDB-ENSP_mappings:6hkt.k&PDB-ENSP_mappings:6hkt.o&PDB-ENSP_mappings:6hkt.u&PDB-ENSP_mappings:6hkt.y&PDB-ENSP_mappings:6hts.I&PDB-ENSP_mappings:6hts.M&PDB-ENSP_mappings:6ipu.A&PDB-ENSP_mappings:6ipu.E&PDB-ENSP_mappings:6iq4.A&PDB-ENSP_mappings:6iq4.E&PDB-ENSP_mappings:6jou.A&PDB-ENSP_mappings:6jou.E&PDB-ENSP_mappings:6jr0.A&PDB-ENSP_mappings:6jr0.E&PDB-ENSP_mappings:6jr1.A&PDB-ENSP_mappings:6jr1.E&PDB-ENSP_mappings:6jxd.A&PDB-ENSP_mappings:6jxd.E&PDB-ENSP_mappings:6k1i.A&PDB-ENSP_mappings:6k1i.E&PDB-ENSP_mappings:6k1j.A&PDB-ENSP_mappings:6k1j.E&PDB-ENSP_mappings:6k1k.A&PDB-ENSP_mappings:6k1k.E&PDB-ENSP_mappings:6ke9.A&PDB-ENSP_mappings:6ke9.E&PDB-ENSP_mappings:6kvd.A&PDB-ENSP_mappings:6kvd.E&PDB-ENSP_mappings:6l49.K&PDB-ENSP_mappings:6l49.O&PDB-ENSP_mappings:6l49.S&PDB-ENSP_mappings:6l49.W&PDB-ENSP_mappings:6l4a.A&PDB-ENSP_mappings:6l4a.E&PDB-ENSP_mappings:6l4a.K&PDB-ENSP_mappings:6l4a.O&PDB-ENSP_mappings:6l4a.S&PDB-ENSP_mappings:6l4a.W&PDB-ENSP_mappings:6l9h.A&PDB-ENSP_mappings:6l9h.E&PDB-ENSP_mappings:6l9z.A&PDB-ENSP_mappings:6l9z.E&PDB-ENSP_mappings:6l9z.K&PDB-ENSP_mappings:6l9z.O&PDB-ENSP_mappings:6la2.A&PDB-ENSP_mappings:6la2.E&PDB-ENSP_mappings:6la2.K&PDB-ENSP_mappings:6la2.O&PDB-ENSP_mappings:6la2.U&PDB-ENSP_mappings:6la2.Y&PDB-ENSP_mappings:6la2.e&PDB-ENSP_mappings:6la2.i&PDB-ENSP_mappings:6la8.A&PDB-ENSP_mappings:6la8.E&PDB-ENSP_mappings:6la8.K&PDB-ENSP_mappings:6la8.O&PDB-ENSP_mappings:6la9.A&PDB-ENSP_mappings:6la9.E&PDB-ENSP_mappings:6la9.K&PDB-ENSP_mappings:6la9.O&PDB-ENSP_mappings:6lab.A&PDB-ENSP_mappings:6lab.E&PDB-ENSP_mappings:6lab.K&PDB-ENSP_mappings:6lab.O&PDB-ENSP_mappings:6le9.A&PDB-ENSP_mappings:6le9.E&PDB-ENSP_mappings:6ler.A&PDB-ENSP_mappings:6ler.E&PDB-ENSP_mappings:6ler.K&PDB-ENSP_mappings:6ler.O&PDB-ENSP_mappings:6m3v.A&PDB-ENSP_mappings:6m3v.E&PDB-ENSP_mappings:6m3v.K&PDB-ENSP_mappings:6m3v.O&PDB-ENSP_mappings:6m44.A&PDB-ENSP_mappings:6m44.E&PDB-ENSP_mappings:6m44.K&PDB-ENSP_mappings:6m44.O&PDB-ENSP_mappings:6m4d.A&PDB-ENSP_mappings:6m4d.E&PDB-ENSP_mappings:6m4g.A&PDB-ENSP_mappings:6m4g.E&PDB-ENSP_mappings:6m4h.A&PDB-ENSP_mappings:6m4h.E&PDB-ENSP_mappings:6r8y.A&PDB-ENSP_mappings:6r8y.E&PDB-ENSP_mappings:6r8z.A&PDB-ENSP_mappings:6r8z.E&PDB-ENSP_mappings:6r90.A&PDB-ENSP_mappings:6r90.E&PDB-ENSP_mappings:6r91.A&PDB-ENSP_mappings:6r91.E&PDB-ENSP_mappings:6r92.A&PDB-ENSP_mappings:6r92.E&PDB-ENSP_mappings:6r93.A&PDB-ENSP_mappings:6r93.E&PDB-ENSP_mappings:6r94.A&PDB-ENSP_mappings:6r94.E&PDB-ENSP_mappings:6t90.A&PDB-ENSP_mappings:6t90.E&PDB-ENSP_mappings:6t93.A&PDB-ENSP_mappings:6t93.E&PDB-ENSP_mappings:6upk.A&PDB-ENSP_mappings:6upk.E&PDB-ENSP_mappings:6upl.A&PDB-ENSP_mappings:6upl.E&PDB-ENSP_mappings:6usj.A&PDB-ENSP_mappings:6usj.E&PDB-ENSP_mappings:6usj.K&PDB-ENSP_mappings:6usj.O&PDB-ENSP_mappings:6v2k.A&PDB-ENSP_mappings:6v2k.E&PDB-ENSP_mappings:6v92.a&PDB-ENSP_mappings:6v92.e&PDB-ENSP_mappings:6yov.A&PDB-ENSP_mappings:6yov.E&PDB-ENSP_mappings:7bwd.A&PDB-ENSP_mappings:7bwd.E&PDB-ENSP_mappings:7c0m.A&PDB-ENSP_mappings:7c0m.E&PDB-ENSP_mappings:7c0m.a&PDB-ENSP_mappings:7c0m.e&PDB-ENSP_mappings:7ccq.A&PDB-ENSP_mappings:7ccq.E&PDB-ENSP_mappings:7ccr.A&PDB-ENSP_mappings:7ccr.E&PDB-ENSP_mappings:7ccr.L&PDB-ENSP_mappings:7ccr.P&PDB-ENSP_mappings:7cow.A&PDB-ENSP_mappings:7cow.E&PDB-ENSP_mappings:7cow.K&PDB-ENSP_mappings:7cow.O&PDB-ENSP_mappings:7d1z.A&PDB-ENSP_mappings:7d1z.E&PDB-ENSP_mappings:7dbp.A&PDB-ENSP_mappings:7dbp.E&PDB-ENSP_mappings:7e8d.A&PDB-ENSP_mappings:7e8d.E&PDB-ENSP_mappings:7k5x.A&PDB-ENSP_mappings:7k5x.E&PDB-ENSP_mappings:7k5y.A&PDB-ENSP_mappings:7k5y.E&PDB-ENSP_mappings:7k60.A&PDB-ENSP_mappings:7k60.E&PDB-ENSP_mappings:7k61.A&PDB-ENSP_mappings:7k61.E&PDB-ENSP_mappings:7k63.A&PDB-ENSP_mappings:7k63.E&PDB-ENSP_mappings:7lya.A&PDB-ENSP_mappings:7lya.E&PDB-ENSP_mappings:7lyb.A&PDB-ENSP_mappings:7lyb.E&PDB-ENSP_mappings:7lyc.A&PDB-ENSP_mappings:7lyc.E&PDB-ENSP_mappings:7nl0.A&PDB-ENSP_mappings:7nl0.E&PDB-ENSP_mappings:7scy.A&PDB-ENSP_mappings:7scy.E&PDB-ENSP_mappings:7scz.A&PDB-ENSP_mappings:7scz.E&PDB-ENSP_mappings:7u0g.A&PDB-ENSP_mappings:7u0g.E&PDB-ENSP_mappings:7u0i.A&PDB-ENSP_mappings:7u0i.E&PDB-ENSP_mappings:7u0j.A&PDB-ENSP_mappings:7u0j.E&PDB-ENSP_mappings:7v6q.B&PDB-ENSP_mappings:7v6q.F&PDB-ENSP_mappings:7v90.A&PDB-ENSP_mappings:7v90.E&PDB-ENSP_mappings:7v96.A&PDB-ENSP_mappings:7v96.E&PDB-ENSP_mappings:7v96.K&PDB-ENSP_mappings:7v96.O&PDB-ENSP_mappings:7v9c.A&PDB-ENSP_mappings:7v9c.E&PDB-ENSP_mappings:7v9c.K&PDB-ENSP_mappings:7v9c.O&PDB-ENSP_mappings:7v9j.A&PDB-ENSP_mappings:7v9j.E&PDB-ENSP_mappings:7v9j.K&PDB-ENSP_mappings:7v9j.O&PDB-ENSP_mappings:7v9j.S&PDB-ENSP_mappings:7v9j.W&PDB-ENSP_mappings:7v9k.A&PDB-ENSP_mappings:7v9k.E&PDB-ENSP_mappings:7v9k.K&PDB-ENSP_mappings:7v9k.O&PDB-ENSP_mappings:7v9k.S&PDB-ENSP_mappings:7v9k.W&PDB-ENSP_mappings:7v9k.a&PDB-ENSP_mappings:7v9k.e&PDB-ENSP_mappings:7v9s.A&PDB-ENSP_mappings:7v9s.E&PDB-ENSP_mappings:7v9s.K&PDB-ENSP_mappings:7v9s.O&PDB-ENSP_mappings:7v9s.S&PDB-ENSP_mappings:7v9s.W&PDB-ENSP_mappings:7va4.A&PDB-ENSP_mappings:7va4.E&PDB-ENSP_mappings:7va4.K&PDB-ENSP_mappings:7va4.O&PDB-ENSP_mappings:7va4.S&PDB-ENSP_mappings:7va4.W&PDB-ENSP_mappings:7va4.a&PDB-ENSP_mappings:7va4.e&PDB-ENSP_mappings:7vz4.A&PDB-ENSP_mappings:7vz4.E&PDB-ENSP_mappings:7w9v.A&PDB-ENSP_mappings:7w9v.E&PDB-ENSP_mappings:7x57.A&PDB-ENSP_mappings:7x57.C&PDB-ENSP_mappings:7x57.E&PDB-ENSP_mappings:7x57.G&PDB-ENSP_mappings:7x58.A&PDB-ENSP_mappings:7x58.C&PDB-ENSP_mappings:7x58.E&PDB-ENSP_mappings:7x58.G&PDB-ENSP_mappings:7xd1.A&PDB-ENSP_mappings:7xd1.E&PDB-ENSP_mappings:7xvl.A&PDB-ENSP_mappings:7xvl.E&PDB-ENSP_mappings:7xvl.K&PDB-ENSP_mappings:7xvl.O&PDB-ENSP_mappings:7xvl.U&PDB-ENSP_mappings:7xvl.Y&PDB-ENSP_mappings:7xvl.e&PDB-ENSP_mappings:7xvl.i&PDB-ENSP_mappings:7xvm.A&PDB-ENSP_mappings:7xvm.E&PDB-ENSP_mappings:7xvm.K&PDB-ENSP_mappings:7xvm.O&PDB-ENSP_mappings:7xx5.A&PDB-ENSP_mappings:7xx5.E&PDB-ENSP_mappings:7xx5.K&PDB-ENSP_mappings:7xx5.O&PDB-ENSP_mappings:7xx6.A&PDB-ENSP_mappings:7xx6.E&PDB-ENSP_mappings:7xx6.K&PDB-ENSP_mappings:7xx6.O&PDB-ENSP_mappings:7xx6.U&PDB-ENSP_mappings:7xx6.Y&PDB-ENSP_mappings:7xx6.e&PDB-ENSP_mappings:7xx6.i&PDB-ENSP_mappings:7xzx.A&PDB-ENSP_mappings:7xzx.E&PDB-ENSP_mappings:7xzy.A&PDB-ENSP_mappings:7xzy.E&PDB-ENSP_mappings:7xzz.A&PDB-ENSP_mappings:7xzz.E&PDB-ENSP_mappings:7y00.A&PDB-ENSP_mappings:7y00.E&PDB-ENSP_mappings:7y5u.D&PDB-ENSP_mappings:7y5v.D&PDB-ENSP_mappings:7y5v.I&PDB-ENSP_mappings:7y5w.A&PDB-ENSP_mappings:7y5w.C&PDB-ENSP_mappings:7y5w.E&PDB-ENSP_mappings:7y5w.G&PDB-ENSP_mappings:7y60.A&PDB-ENSP_mappings:7y60.C&PDB-ENSP_mappings:7y60.E&PDB-ENSP_mappings:7y60.G&PDB-ENSP_mappings:7y61.A&PDB-ENSP_mappings:7y61.C&PDB-ENSP_mappings:7y61.E&PDB-ENSP_mappings:7y61.G&PDB-ENSP_mappings:7y8r.A&PDB-ENSP_mappings:7y8r.E&PDB-ENSP_mappings:7yoz.A&PDB-ENSP_mappings:7yoz.C&PDB-ENSP_mappings:7yoz.E&PDB-ENSP_mappings:7yoz.G&PDB-ENSP_mappings:7yqk.A&PDB-ENSP_mappings:7yqk.E&PDB-ENSP_mappings:7zi4.I&PDB-ENSP_mappings:7zi4.M&PDB-ENSP_mappings:8dk5.A&PDB-ENSP_mappings:8dk5.E&PDB-ENSP_mappings:8evg.A&PDB-ENSP_mappings:8evg.E&PDB-ENSP_mappings:8evh.A&PDB-ENSP_mappings:8evh.E&PDB-ENSP_mappings:8evi.A&PDB-ENSP_mappings:8evi.E&PDB-ENSP_mappings:8evj.A&PDB-ENSP_mappings:8evj.E&PDB-ENSP_mappings:8grm.A&PDB-ENSP_mappings:8grm.E&PDB-ENSP_mappings:8gui.A&PDB-ENSP_mappings:8gui.E&PDB-ENSP_mappings:8guj.A&PDB-ENSP_mappings:8guj.E&PDB-ENSP_mappings:8guk.A&PDB-ENSP_mappings:8guk.E&PDB-ENSP_mappings:8h0v.a&PDB-ENSP_mappings:8h0v.e&PDB-ENSP_mappings:8h0w.a&PDB-ENSP_mappings:8h0w.e&PDB-ENSP_mappings:8h1t.A&PDB-ENSP_mappings:8h1t.E&PDB-ENSP_mappings:8hag.A&PDB-ENSP_mappings:8hag.E&PDB-ENSP_mappings:8hah.A&PDB-ENSP_mappings:8hah.E&PDB-ENSP_mappings:8hai.A&PDB-ENSP_mappings:8hai.E&PDB-ENSP_mappings:8haj.A&PDB-ENSP_mappings:8haj.E&PDB-ENSP_mappings:8hak.A&PDB-ENSP_mappings:8hak.E&PDB-ENSP_mappings:8hal.A&PDB-ENSP_mappings:8hal.E&PDB-ENSP_mappings:8ham.A&PDB-ENSP_mappings:8ham.E&PDB-ENSP_mappings:8han.A&PDB-ENSP_mappings:8han.E&PDB-ENSP_mappings:8he5.a&PDB-ENSP_mappings:8he5.e&PDB-ENSP_mappings:8ieg.E&PDB-ENSP_mappings:8ieg.K&PDB-ENSP_mappings:8iej.E&PDB-ENSP_mappings:8iej.K&PDB-ENSP_mappings:8ihl.A&PDB-ENSP_mappings:8ihl.E&PDB-ENSP_mappings:8ihl.K&PDB-ENSP_mappings:8ihl.M&PDB-ENSP_mappings:8ihl.Q&PDB-ENSP_mappings:8ihl.U&PDB-ENSP_mappings:8iqf.D&PDB-ENSP_mappings:8iqf.I&PDB-ENSP_mappings:8iqg.D&PDB-ENSP_mappings:8j6s.A&PDB-ENSP_mappings:8j6s.C&PDB-ENSP_mappings:8j6s.E&PDB-ENSP_mappings:8j6s.G&PDB-ENSP_mappings:8j6t.A&PDB-ENSP_mappings:8j6t.C&PDB-ENSP_mappings:8j6t.E&PDB-ENSP_mappings:8j6t.G&PDB-ENSP_mappings:8jbx.A&PDB-ENSP_mappings:8jbx.E&PDB-ENSP_mappings:8jcc.A&PDB-ENSP_mappings:8jcc.E&PDB-ENSP_mappings:8jcd.A&PDB-ENSP_mappings:8jcd.E&PDB-ENSP_mappings:8jhf.A&PDB-ENSP_mappings:8jhf.E&PDB-ENSP_mappings:8jhg.A&PDB-ENSP_mappings:8jhg.E&PDB-ENSP_mappings:8jl9.A&PDB-ENSP_mappings:8jl9.E&PDB-ENSP_mappings:8jla.A&PDB-ENSP_mappings:8jla.E&PDB-ENSP_mappings:8jnd.A&PDB-ENSP_mappings:8jnd.E&PDB-ENSP_mappings:8jne.A&PDB-ENSP_mappings:8jne.E&PDB-ENSP_mappings:8jnf.A&PDB-ENSP_mappings:8jnf.E&PDB-ENSP_mappings:8off.Ca&PDB-ENSP_mappings:8off.Cb&PDB-ENSP_mappings:8oo7.M&PDB-ENSP_mappings:8oo7.Q&PDB-ENSP_mappings:8ooa.M&PDB-ENSP_mappings:8ooa.Q&PDB-ENSP_mappings:8oop.M&PDB-ENSP_mappings:8oop.Q&PDB-ENSP_mappings:8oos.M&PDB-ENSP_mappings:8oos.Q&PDB-ENSP_mappings:8osj.A&PDB-ENSP_mappings:8osj.E&PDB-ENSP_mappings:8osk.A&PDB-ENSP_mappings:8osk.E&PDB-ENSP_mappings:8osl.A&PDB-ENSP_mappings:8osl.E&PDB-ENSP_mappings:8ots.A&PDB-ENSP_mappings:8ots.E&PDB-ENSP_mappings:8ott.A&PDB-ENSP_mappings:8ott.E&PDB-ENSP_mappings:8ox0.A&PDB-ENSP_mappings:8ox0.E&PDB-ENSP_mappings:8ox1.A&PDB-ENSP_mappings:8ox1.E&PDB-ENSP_mappings:8q36.AAA&PDB-ENSP_mappings:8q36.EEE&PDB-ENSP_mappings:8q3e.AAA&PDB-ENSP_mappings:8q3e.EEE&PDB-ENSP_mappings:8q3m.AAA&PDB-ENSP_mappings:8q3m.EEE&PDB-ENSP_mappings:8q3x.AAA&PDB-ENSP_mappings:8q3x.EEE&PDB-ENSP_mappings:8qkt.AAA&PDB-ENSP_mappings:8qkt.EEE&PDB-ENSP_mappings:8qkt.KKK&PDB-ENSP_mappings:8qkt.OOO&PDB-ENSP_mappings:8smw.A&PDB-ENSP_mappings:8smw.E&PDB-ENSP_mappings:8smx.A&PDB-ENSP_mappings:8smx.E&PDB-ENSP_mappings:8smy.A&PDB-ENSP_mappings:8smy.E&PDB-ENSP_mappings:8smz.A&PDB-ENSP_mappings:8smz.E&PDB-ENSP_mappings:8sn0.A&PDB-ENSP_mappings:8sn0.E&PDB-ENSP_mappings:8sn1.A&PDB-ENSP_mappings:8sn1.E&PDB-ENSP_mappings:8sn2.A&PDB-ENSP_mappings:8sn2.E&PDB-ENSP_mappings:8sn3.A&PDB-ENSP_mappings:8sn3.E&PDB-ENSP_mappings:8sn4.A&PDB-ENSP_mappings:8sn4.E&PDB-ENSP_mappings:8sn5.A&PDB-ENSP_mappings:8sn5.E&PDB-ENSP_mappings:8sn6.A&PDB-ENSP_mappings:8sn6.E&PDB-ENSP_mappings:8sn7.A&PDB-ENSP_mappings:8sn7.E&PDB-ENSP_mappings:8sn8.A&PDB-ENSP_mappings:8sn8.E&PDB-ENSP_mappings:8sn9.A&PDB-ENSP_mappings:8sn9.E&PDB-ENSP_mappings:8sna.A&PDB-ENSP_mappings:8sna.E&PDB-ENSP_mappings:8sps.A&PDB-ENSP_mappings:8sps.E&PDB-ENSP_mappings:8spu.A&PDB-ENSP_mappings:8spu.E&PDB-ENSP_mappings:8syp.A&PDB-ENSP_mappings:8syp.E&PDB-ENSP_mappings:8txv.A&PDB-ENSP_mappings:8txv.E&PDB-ENSP_mappings:8txw.A&PDB-ENSP_mappings:8txw.E&PDB-ENSP_mappings:8txx.A&PDB-ENSP_mappings:8txx.E&PDB-ENSP_mappings:8u13.A&PDB-ENSP_mappings:8u13.E&PDB-ENSP_mappings:8u14.A&PDB-ENSP_mappings:8u14.E&PDB-ENSP_mappings:8upf.A&PDB-ENSP_mappings:8upf.E&PDB-ENSP_mappings:8vfx.A&PDB-ENSP_mappings:8vfx.E&PDB-ENSP_mappings:8vfy.A&PDB-ENSP_mappings:8vfy.E&PDB-ENSP_mappings:8vfz.A&PDB-ENSP_mappings:8vfz.E&PDB-ENSP_mappings:8vg0.A&PDB-ENSP_mappings:8vg0.E&PDB-ENSP_mappings:8vg1.A&PDB-ENSP_mappings:8vg1.E&PDB-ENSP_mappings:8vg2.A&PDB-ENSP_mappings:8vg2.E&PDB-ENSP_mappings:8w9d.a&PDB-ENSP_mappings:8w9d.e&PDB-ENSP_mappings:8w9e.a&PDB-ENSP_mappings:8w9e.e&PDB-ENSP_mappings:8w9f.a&PDB-ENSP_mappings:8w9f.e&PDB-ENSP_mappings:8wg5.A&PDB-ENSP_mappings:8wg5.E&PDB-ENSP_mappings:8x15.C&PDB-ENSP_mappings:8x15.G&PDB-ENSP_mappings:8x19.C&PDB-ENSP_mappings:8x19.G&PDB-ENSP_mappings:8x1c.C&PDB-ENSP_mappings:8x1c.G&PDB-ENSP_mappings:8xbt.A&PDB-ENSP_mappings:8xbt.E&PDB-ENSP_mappings:8xbu.A&PDB-ENSP_mappings:8xbu.E&PDB-ENSP_mappings:8xbw.E&PDB-ENSP_mappings:8ybj.A&PDB-ENSP_mappings:8ybj.E&PDB-ENSP_mappings:8ybk.A&PDB-ENSP_mappings:8ybk.E&PDB-ENSP_mappings:8yjf.C&PDB-ENSP_mappings:8yjf.E&PDB-ENSP_mappings:8yjm.C&PDB-ENSP_mappings:8yjm.E&PDB-ENSP_mappings:8yti.A&PDB-ENSP_mappings:8yti.E&PDB-ENSP_mappings:8yti.K&PDB-ENSP_mappings:8yti.O&PDB-ENSP_mappings:8yv8.A&PDB-ENSP_mappings:8yv8.E&PDB-ENSP_mappings:9fgq.A&PDB-ENSP_mappings:9fgq.E&PDB-ENSP_mappings:9fh9.A&PDB-ENSP_mappings:9fh9.E&Superfamily:SSF47113&Prints:PR00622&PROSITE_patterns:PS00959&Pfam:PF00125&Gene3D:1.10.20.10&PANTHER:PTHR11426&SMART:SM00428&AFDB-ENSP_mappings:AF-P68431-F1			0.0120	0.0015	0.0187	0	0.0318	0.0133	0.0404	0.006093	0.01894	0.02717	0.0005542	0.01503	0.04993	0.04705	0.03757	0.01847	0.02573	0.008247	0.009868	0.01869	0.02711	0.002124	0.01186	0.04422	0.0427	0.0241	0.01697	0.04993	gnomADe_MID																					1.9610e+00																																																											1111					0.998							246.99	v6.1	Unknown		True	The H3C1 gene encodes H3.1, an H3 histone variant.	False	09/14/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3C1 ENSP00000480826.2:R73= mutant UNKNOWN.	False	The H3C1 ENSP00000480826.2:r73= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	26020936						True	False	False	Unknown								False	False		The H3C1 gene encodes H3.1, an H3 histone variant.	The H3C1 ENSP00000480826.2:r73= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3C1 ENSP00000480826.2:R73= mutant UNKNOWN.						v6.1	09/14/2017		GRCh38	H3C1	8350.0	ENSP00000480826.2:R73=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""H3C1"",""entrezGeneId"":8350,""alteration"":""ENSP00000480826.2:R73="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""The H3C1 gene encodes H3.1, an H3 histone variant."",""variantSummary"":""The H3C1 ENSP00000480826.2:r73= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3C1 ENSP00000480826.2:R73= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/14/2017""}"	True	True	False	Unknown		Unknown																						560,549	296,306	264,243	0/1	259,301,262,287	GCG	0.00	0.00	0.00			285,275,261,288	53.28		0.4950405770964833
GRCh38	H3C1	D12_12345_1234556_Thyroid_S9			chr6	26026371	26026371.0	G	C	C	26026371	.	G	C	.	PASS		C	downstream_gene_variant	MODIFIER	H3C1	ENSG00000275714	Transcript	ENST00000850876	protein_coding									rs2032449	4884	1		SNV	HGNC	HGNC:4766						P1	CCDS4570.1	ENSP00000520960			UPI00000003C7									0.3944	0.1316	0.4524	0.7123	0.3956	0.3793											0.3558	0.1882	0.4758	0.4082	0.3176	0.7056	0.4048	0.2671	0.4103	0.3745	0.382	0.7123	EAS																																																																																779					0.999							247.08													chr6	26026599																																																	True	True	False	Unknown		Unknown																						375,403	199,201	176,202	0/1	180,195,197,206	AGA	.	.	.			194,181,201,202	60.44		0.5179948586118251
GRCh38	H3C3	D12_12345_1234556_Thyroid_S9			chr6	26043836	26043836.0	G	A	A	26043836	.	G	A	.	PASS	NM_003531	A	upstream_gene_variant	MODIFIER	H3C3	ENSG00000287080	Transcript	ENST00000612966	protein_coding									rs11751732	1548	1		SNV	HGNC	HGNC:4768	YES	MANE_Select	NM_003531.3			P1	CCDS4576.1	ENSP00000484658	P68431.203		UPI00000003C7									0.1933	0.3472	0.1571	0.0734	0.1342	0.1953											0.1939	0.3113	0.1308	0.1612	0.2696	0.08327	0.104	0.2295	0.1476	0.2081	0.2049	0.3472	AFR																																																																																299					0.98							246.96													chr6	26044064																																																	True	True	False	Unknown		Unknown																						145,148	81,63	64,85	0/1	84,61,62,86	TGG	0.00	0.00	0.00			80,65,81,67	42.04		0.5051194539249146
GRCh38	H3C3	D12_12345_1234556_Thyroid_S9	p.Cys97=	ENSP00000484658.2:p.Cys97=	chr6	26045701	26045701.0	T	C	C	26045701	.	T	C	.	PASS	NM_003531	C	synonymous_variant	LOW	H3C3	ENSG00000287080	Transcript	ENST00000612966	protein_coding	1/1		c.291T>C	318	291	97	C	tgT/tgC	rs3752416&COSV63551327		1		SNV	HGNC	HGNC:4768	YES	MANE_Select	NM_003531.3			P1	CCDS4576.1	ENSP00000484658	P68431.203		UPI00000003C7						Gene3D:1.10.20.10&PDB-ENSP_mappings:2cv5.A&PDB-ENSP_mappings:2cv5.E&PDB-ENSP_mappings:3afa.A&PDB-ENSP_mappings:3afa.E&PDB-ENSP_mappings:3ayw.A&PDB-ENSP_mappings:3ayw.E&PDB-ENSP_mappings:3aze.A&PDB-ENSP_mappings:3aze.E&PDB-ENSP_mappings:3azf.A&PDB-ENSP_mappings:3azf.E&PDB-ENSP_mappings:3azg.A&PDB-ENSP_mappings:3azg.E&PDB-ENSP_mappings:3azh.A&PDB-ENSP_mappings:3azh.E&PDB-ENSP_mappings:3azi.A&PDB-ENSP_mappings:3azi.E&PDB-ENSP_mappings:3azj.A&PDB-ENSP_mappings:3azj.E&PDB-ENSP_mappings:3azk.A&PDB-ENSP_mappings:3azk.E&PDB-ENSP_mappings:3azl.A&PDB-ENSP_mappings:3azl.E&PDB-ENSP_mappings:3azm.A&PDB-ENSP_mappings:3azm.E&PDB-ENSP_mappings:3azn.A&PDB-ENSP_mappings:3azn.E&PDB-ENSP_mappings:3w96.A&PDB-ENSP_mappings:3w96.E&PDB-ENSP_mappings:3w97.A&PDB-ENSP_mappings:3w97.E&PDB-ENSP_mappings:3w98.A&PDB-ENSP_mappings:3w98.E&PDB-ENSP_mappings:3w99.A&PDB-ENSP_mappings:3w99.E&PDB-ENSP_mappings:3wa9.A&PDB-ENSP_mappings:3wa9.E&PDB-ENSP_mappings:3waa.A&PDB-ENSP_mappings:3waa.E&PDB-ENSP_mappings:3wkj.A&PDB-ENSP_mappings:3wkj.E&PDB-ENSP_mappings:3x1s.A&PDB-ENSP_mappings:3x1s.E&PDB-ENSP_mappings:3x1t.A&PDB-ENSP_mappings:3x1t.E&PDB-ENSP_mappings:3x1u.A&PDB-ENSP_mappings:3x1u.E&PDB-ENSP_mappings:3x1v.A&PDB-ENSP_mappings:3x1v.E&PDB-ENSP_mappings:4ym5.A&PDB-ENSP_mappings:4ym5.E&PDB-ENSP_mappings:4ym6.A&PDB-ENSP_mappings:4ym6.E&PDB-ENSP_mappings:4z2m.G&PDB-ENSP_mappings:4z2m.I&PDB-ENSP_mappings:5av5.A&PDB-ENSP_mappings:5av5.E&PDB-ENSP_mappings:5av6.A&PDB-ENSP_mappings:5av6.E&PDB-ENSP_mappings:5av8.A&PDB-ENSP_mappings:5av8.E&PDB-ENSP_mappings:5av9.A&PDB-ENSP_mappings:5av9.E&PDB-ENSP_mappings:5avb.A&PDB-ENSP_mappings:5avb.E&PDB-ENSP_mappings:5avc.A&PDB-ENSP_mappings:5avc.E&PDB-ENSP_mappings:5b24.A&PDB-ENSP_mappings:5b24.E&PDB-ENSP_mappings:5b2i.A&PDB-ENSP_mappings:5b2i.E&PDB-ENSP_mappings:5b2j.A&PDB-ENSP_mappings:5b2j.E&PDB-ENSP_mappings:5b31.A&PDB-ENSP_mappings:5b31.E&PDB-ENSP_mappings:5c3i.B&PDB-ENSP_mappings:5c3i.F&PDB-ENSP_mappings:5c3i.J&PDB-ENSP_mappings:5c3i.N&PDB-ENSP_mappings:5c3i.R&PDB-ENSP_mappings:5c3i.V&PDB-ENSP_mappings:5cpi.A&PDB-ENSP_mappings:5cpi.E&PDB-ENSP_mappings:5cpj.A&PDB-ENSP_mappings:5cpj.E&PDB-ENSP_mappings:5cpk.A&PDB-ENSP_mappings:5cpk.E&PDB-ENSP_mappings:5gse.A&PDB-ENSP_mappings:5gse.E&PDB-ENSP_mappings:5gse.K&PDB-ENSP_mappings:5gse.O&PDB-ENSP_mappings:5gsu.A&PDB-ENSP_mappings:5gsu.E&PDB-ENSP_mappings:5gt0.A&PDB-ENSP_mappings:5gt0.E&PDB-ENSP_mappings:5gt3.A&PDB-ENSP_mappings:5gt3.E&PDB-ENSP_mappings:5gtc.A&PDB-ENSP_mappings:5gtc.E&PDB-ENSP_mappings:5jrg.A&PDB-ENSP_mappings:5jrg.E&PDB-ENSP_mappings:5xf3.A&PDB-ENSP_mappings:5xf3.E&PDB-ENSP_mappings:5xf4.A&PDB-ENSP_mappings:5xf4.E&PDB-ENSP_mappings:5xf5.A&PDB-ENSP_mappings:5xf5.E&PDB-ENSP_mappings:5y0c.A&PDB-ENSP_mappings:5y0c.E&PDB-ENSP_mappings:5y0d.A&PDB-ENSP_mappings:5y0d.E&PDB-ENSP_mappings:5z30.A&PDB-ENSP_mappings:5z30.E&PDB-ENSP_mappings:6hkt.A&PDB-ENSP_mappings:6hkt.E&PDB-ENSP_mappings:6hkt.K&PDB-ENSP_mappings:6hkt.O&PDB-ENSP_mappings:6hkt.U&PDB-ENSP_mappings:6hkt.Y&PDB-ENSP_mappings:6hkt.a&PDB-ENSP_mappings:6hkt.e&PDB-ENSP_mappings:6hkt.k&PDB-ENSP_mappings:6hkt.o&PDB-ENSP_mappings:6hkt.u&PDB-ENSP_mappings:6hkt.y&PDB-ENSP_mappings:6hts.I&PDB-ENSP_mappings:6hts.M&PDB-ENSP_mappings:6ipu.A&PDB-ENSP_mappings:6ipu.E&PDB-ENSP_mappings:6iq4.A&PDB-ENSP_mappings:6iq4.E&PDB-ENSP_mappings:6jou.A&PDB-ENSP_mappings:6jou.E&PDB-ENSP_mappings:6jr0.A&PDB-ENSP_mappings:6jr0.E&PDB-ENSP_mappings:6jr1.A&PDB-ENSP_mappings:6jr1.E&PDB-ENSP_mappings:6jxd.A&PDB-ENSP_mappings:6jxd.E&PDB-ENSP_mappings:6k1i.A&PDB-ENSP_mappings:6k1i.E&PDB-ENSP_mappings:6k1j.A&PDB-ENSP_mappings:6k1j.E&PDB-ENSP_mappings:6k1k.A&PDB-ENSP_mappings:6k1k.E&PDB-ENSP_mappings:6ke9.A&PDB-ENSP_mappings:6ke9.E&PDB-ENSP_mappings:6kvd.A&PDB-ENSP_mappings:6kvd.E&PDB-ENSP_mappings:6l49.K&PDB-ENSP_mappings:6l49.O&PDB-ENSP_mappings:6l49.S&PDB-ENSP_mappings:6l49.W&PDB-ENSP_mappings:6l4a.A&PDB-ENSP_mappings:6l4a.E&PDB-ENSP_mappings:6l4a.K&PDB-ENSP_mappings:6l4a.O&PDB-ENSP_mappings:6l4a.S&PDB-ENSP_mappings:6l4a.W&PDB-ENSP_mappings:6l9h.A&PDB-ENSP_mappings:6l9h.E&PDB-ENSP_mappings:6l9z.A&PDB-ENSP_mappings:6l9z.E&PDB-ENSP_mappings:6l9z.K&PDB-ENSP_mappings:6l9z.O&PDB-ENSP_mappings:6la2.A&PDB-ENSP_mappings:6la2.E&PDB-ENSP_mappings:6la2.K&PDB-ENSP_mappings:6la2.O&PDB-ENSP_mappings:6la2.U&PDB-ENSP_mappings:6la2.Y&PDB-ENSP_mappings:6la2.e&PDB-ENSP_mappings:6la2.i&PDB-ENSP_mappings:6la8.A&PDB-ENSP_mappings:6la8.E&PDB-ENSP_mappings:6la8.K&PDB-ENSP_mappings:6la8.O&PDB-ENSP_mappings:6la9.A&PDB-ENSP_mappings:6la9.E&PDB-ENSP_mappings:6la9.K&PDB-ENSP_mappings:6la9.O&PDB-ENSP_mappings:6lab.A&PDB-ENSP_mappings:6lab.E&PDB-ENSP_mappings:6lab.K&PDB-ENSP_mappings:6lab.O&PDB-ENSP_mappings:6le9.A&PDB-ENSP_mappings:6le9.E&PDB-ENSP_mappings:6ler.A&PDB-ENSP_mappings:6ler.E&PDB-ENSP_mappings:6ler.K&PDB-ENSP_mappings:6ler.O&PDB-ENSP_mappings:6m3v.A&PDB-ENSP_mappings:6m3v.E&PDB-ENSP_mappings:6m3v.K&PDB-ENSP_mappings:6m3v.O&PDB-ENSP_mappings:6m44.A&PDB-ENSP_mappings:6m44.E&PDB-ENSP_mappings:6m44.K&PDB-ENSP_mappings:6m44.O&PDB-ENSP_mappings:6m4d.A&PDB-ENSP_mappings:6m4d.E&PDB-ENSP_mappings:6m4g.A&PDB-ENSP_mappings:6m4g.E&PDB-ENSP_mappings:6m4h.A&PDB-ENSP_mappings:6m4h.E&PDB-ENSP_mappings:6r8y.A&PDB-ENSP_mappings:6r8y.E&PDB-ENSP_mappings:6r8z.A&PDB-ENSP_mappings:6r8z.E&PDB-ENSP_mappings:6r90.A&PDB-ENSP_mappings:6r90.E&PDB-ENSP_mappings:6r91.A&PDB-ENSP_mappings:6r91.E&PDB-ENSP_mappings:6r92.A&PDB-ENSP_mappings:6r92.E&PDB-ENSP_mappings:6r93.A&PDB-ENSP_mappings:6r93.E&PDB-ENSP_mappings:6r94.A&PDB-ENSP_mappings:6r94.E&PDB-ENSP_mappings:6t90.A&PDB-ENSP_mappings:6t90.E&PDB-ENSP_mappings:6t93.A&PDB-ENSP_mappings:6t93.E&PDB-ENSP_mappings:6upk.A&PDB-ENSP_mappings:6upk.E&PDB-ENSP_mappings:6upl.A&PDB-ENSP_mappings:6upl.E&PDB-ENSP_mappings:6usj.A&PDB-ENSP_mappings:6usj.E&PDB-ENSP_mappings:6usj.K&PDB-ENSP_mappings:6usj.O&PDB-ENSP_mappings:6v2k.A&PDB-ENSP_mappings:6v2k.E&PDB-ENSP_mappings:6v92.a&PDB-ENSP_mappings:6v92.e&PDB-ENSP_mappings:6yov.A&PDB-ENSP_mappings:6yov.E&PDB-ENSP_mappings:7bwd.A&PDB-ENSP_mappings:7bwd.E&PDB-ENSP_mappings:7c0m.A&PDB-ENSP_mappings:7c0m.E&PDB-ENSP_mappings:7c0m.a&PDB-ENSP_mappings:7c0m.e&PDB-ENSP_mappings:7ccq.A&PDB-ENSP_mappings:7ccq.E&PDB-ENSP_mappings:7ccr.A&PDB-ENSP_mappings:7ccr.E&PDB-ENSP_mappings:7ccr.L&PDB-ENSP_mappings:7ccr.P&PDB-ENSP_mappings:7cow.A&PDB-ENSP_mappings:7cow.E&PDB-ENSP_mappings:7cow.K&PDB-ENSP_mappings:7cow.O&PDB-ENSP_mappings:7d1z.A&PDB-ENSP_mappings:7d1z.E&PDB-ENSP_mappings:7dbp.A&PDB-ENSP_mappings:7dbp.E&PDB-ENSP_mappings:7e8d.A&PDB-ENSP_mappings:7e8d.E&PDB-ENSP_mappings:7k5x.A&PDB-ENSP_mappings:7k5x.E&PDB-ENSP_mappings:7k5y.A&PDB-ENSP_mappings:7k5y.E&PDB-ENSP_mappings:7k60.A&PDB-ENSP_mappings:7k60.E&PDB-ENSP_mappings:7k61.A&PDB-ENSP_mappings:7k61.E&PDB-ENSP_mappings:7k63.A&PDB-ENSP_mappings:7k63.E&PDB-ENSP_mappings:7lya.A&PDB-ENSP_mappings:7lya.E&PDB-ENSP_mappings:7lyb.A&PDB-ENSP_mappings:7lyb.E&PDB-ENSP_mappings:7lyc.A&PDB-ENSP_mappings:7lyc.E&PDB-ENSP_mappings:7nl0.A&PDB-ENSP_mappings:7nl0.E&PDB-ENSP_mappings:7scy.A&PDB-ENSP_mappings:7scy.E&PDB-ENSP_mappings:7scz.A&PDB-ENSP_mappings:7scz.E&PDB-ENSP_mappings:7u0g.A&PDB-ENSP_mappings:7u0g.E&PDB-ENSP_mappings:7u0i.A&PDB-ENSP_mappings:7u0i.E&PDB-ENSP_mappings:7u0j.A&PDB-ENSP_mappings:7u0j.E&PDB-ENSP_mappings:7v6q.B&PDB-ENSP_mappings:7v6q.F&PDB-ENSP_mappings:7v90.A&PDB-ENSP_mappings:7v90.E&PDB-ENSP_mappings:7v96.A&PDB-ENSP_mappings:7v96.E&PDB-ENSP_mappings:7v96.K&PDB-ENSP_mappings:7v96.O&PDB-ENSP_mappings:7v9c.A&PDB-ENSP_mappings:7v9c.E&PDB-ENSP_mappings:7v9c.K&PDB-ENSP_mappings:7v9c.O&PDB-ENSP_mappings:7v9j.A&PDB-ENSP_mappings:7v9j.E&PDB-ENSP_mappings:7v9j.K&PDB-ENSP_mappings:7v9j.O&PDB-ENSP_mappings:7v9j.S&PDB-ENSP_mappings:7v9j.W&PDB-ENSP_mappings:7v9k.A&PDB-ENSP_mappings:7v9k.E&PDB-ENSP_mappings:7v9k.K&PDB-ENSP_mappings:7v9k.O&PDB-ENSP_mappings:7v9k.S&PDB-ENSP_mappings:7v9k.W&PDB-ENSP_mappings:7v9k.a&PDB-ENSP_mappings:7v9k.e&PDB-ENSP_mappings:7v9s.A&PDB-ENSP_mappings:7v9s.E&PDB-ENSP_mappings:7v9s.K&PDB-ENSP_mappings:7v9s.O&PDB-ENSP_mappings:7v9s.S&PDB-ENSP_mappings:7v9s.W&PDB-ENSP_mappings:7va4.A&PDB-ENSP_mappings:7va4.E&PDB-ENSP_mappings:7va4.K&PDB-ENSP_mappings:7va4.O&PDB-ENSP_mappings:7va4.S&PDB-ENSP_mappings:7va4.W&PDB-ENSP_mappings:7va4.a&PDB-ENSP_mappings:7va4.e&PDB-ENSP_mappings:7vz4.A&PDB-ENSP_mappings:7vz4.E&PDB-ENSP_mappings:7w9v.A&PDB-ENSP_mappings:7w9v.E&PDB-ENSP_mappings:7x57.A&PDB-ENSP_mappings:7x57.C&PDB-ENSP_mappings:7x57.E&PDB-ENSP_mappings:7x57.G&PDB-ENSP_mappings:7x58.A&PDB-ENSP_mappings:7x58.C&PDB-ENSP_mappings:7x58.E&PDB-ENSP_mappings:7x58.G&PDB-ENSP_mappings:7xd1.A&PDB-ENSP_mappings:7xd1.E&PDB-ENSP_mappings:7xvl.A&PDB-ENSP_mappings:7xvl.E&PDB-ENSP_mappings:7xvl.K&PDB-ENSP_mappings:7xvl.O&PDB-ENSP_mappings:7xvl.U&PDB-ENSP_mappings:7xvl.Y&PDB-ENSP_mappings:7xvl.e&PDB-ENSP_mappings:7xvl.i&PDB-ENSP_mappings:7xvm.A&PDB-ENSP_mappings:7xvm.E&PDB-ENSP_mappings:7xvm.K&PDB-ENSP_mappings:7xvm.O&PDB-ENSP_mappings:7xx5.A&PDB-ENSP_mappings:7xx5.E&PDB-ENSP_mappings:7xx5.K&PDB-ENSP_mappings:7xx5.O&PDB-ENSP_mappings:7xx6.A&PDB-ENSP_mappings:7xx6.E&PDB-ENSP_mappings:7xx6.K&PDB-ENSP_mappings:7xx6.O&PDB-ENSP_mappings:7xx6.U&PDB-ENSP_mappings:7xx6.Y&PDB-ENSP_mappings:7xx6.e&PDB-ENSP_mappings:7xx6.i&PDB-ENSP_mappings:7xzx.A&PDB-ENSP_mappings:7xzx.E&PDB-ENSP_mappings:7xzy.A&PDB-ENSP_mappings:7xzy.E&PDB-ENSP_mappings:7xzz.A&PDB-ENSP_mappings:7xzz.E&PDB-ENSP_mappings:7y00.A&PDB-ENSP_mappings:7y00.E&PDB-ENSP_mappings:7y5u.D&PDB-ENSP_mappings:7y5v.D&PDB-ENSP_mappings:7y5v.I&PDB-ENSP_mappings:7y5w.A&PDB-ENSP_mappings:7y5w.C&PDB-ENSP_mappings:7y5w.E&PDB-ENSP_mappings:7y5w.G&PDB-ENSP_mappings:7y60.A&PDB-ENSP_mappings:7y60.C&PDB-ENSP_mappings:7y60.E&PDB-ENSP_mappings:7y60.G&PDB-ENSP_mappings:7y61.A&PDB-ENSP_mappings:7y61.C&PDB-ENSP_mappings:7y61.E&PDB-ENSP_mappings:7y61.G&PDB-ENSP_mappings:7y8r.A&PDB-ENSP_mappings:7y8r.E&PDB-ENSP_mappings:7yoz.A&PDB-ENSP_mappings:7yoz.C&PDB-ENSP_mappings:7yoz.E&PDB-ENSP_mappings:7yoz.G&PDB-ENSP_mappings:7yqk.A&PDB-ENSP_mappings:7yqk.E&PDB-ENSP_mappings:7zi4.I&PDB-ENSP_mappings:7zi4.M&PDB-ENSP_mappings:8dk5.A&PDB-ENSP_mappings:8dk5.E&PDB-ENSP_mappings:8evg.A&PDB-ENSP_mappings:8evg.E&PDB-ENSP_mappings:8evh.A&PDB-ENSP_mappings:8evh.E&PDB-ENSP_mappings:8evi.A&PDB-ENSP_mappings:8evi.E&PDB-ENSP_mappings:8evj.A&PDB-ENSP_mappings:8evj.E&PDB-ENSP_mappings:8grm.A&PDB-ENSP_mappings:8grm.E&PDB-ENSP_mappings:8gui.A&PDB-ENSP_mappings:8gui.E&PDB-ENSP_mappings:8guj.A&PDB-ENSP_mappings:8guj.E&PDB-ENSP_mappings:8guk.A&PDB-ENSP_mappings:8guk.E&PDB-ENSP_mappings:8h0v.a&PDB-ENSP_mappings:8h0v.e&PDB-ENSP_mappings:8h0w.a&PDB-ENSP_mappings:8h0w.e&PDB-ENSP_mappings:8h1t.A&PDB-ENSP_mappings:8h1t.E&PDB-ENSP_mappings:8hag.A&PDB-ENSP_mappings:8hag.E&PDB-ENSP_mappings:8hah.A&PDB-ENSP_mappings:8hah.E&PDB-ENSP_mappings:8hai.A&PDB-ENSP_mappings:8hai.E&PDB-ENSP_mappings:8haj.A&PDB-ENSP_mappings:8haj.E&PDB-ENSP_mappings:8hak.A&PDB-ENSP_mappings:8hak.E&PDB-ENSP_mappings:8hal.A&PDB-ENSP_mappings:8hal.E&PDB-ENSP_mappings:8ham.A&PDB-ENSP_mappings:8ham.E&PDB-ENSP_mappings:8han.A&PDB-ENSP_mappings:8han.E&PDB-ENSP_mappings:8he5.a&PDB-ENSP_mappings:8he5.e&PDB-ENSP_mappings:8ieg.E&PDB-ENSP_mappings:8ieg.K&PDB-ENSP_mappings:8iej.E&PDB-ENSP_mappings:8iej.K&PDB-ENSP_mappings:8ihl.A&PDB-ENSP_mappings:8ihl.E&PDB-ENSP_mappings:8ihl.K&PDB-ENSP_mappings:8ihl.M&PDB-ENSP_mappings:8ihl.Q&PDB-ENSP_mappings:8ihl.U&PDB-ENSP_mappings:8iqf.D&PDB-ENSP_mappings:8iqf.I&PDB-ENSP_mappings:8iqg.D&PDB-ENSP_mappings:8j6s.A&PDB-ENSP_mappings:8j6s.C&PDB-ENSP_mappings:8j6s.E&PDB-ENSP_mappings:8j6s.G&PDB-ENSP_mappings:8j6t.A&PDB-ENSP_mappings:8j6t.C&PDB-ENSP_mappings:8j6t.E&PDB-ENSP_mappings:8j6t.G&PDB-ENSP_mappings:8jbx.A&PDB-ENSP_mappings:8jbx.E&PDB-ENSP_mappings:8jcc.A&PDB-ENSP_mappings:8jcc.E&PDB-ENSP_mappings:8jcd.A&PDB-ENSP_mappings:8jcd.E&PDB-ENSP_mappings:8jhf.A&PDB-ENSP_mappings:8jhf.E&PDB-ENSP_mappings:8jhg.A&PDB-ENSP_mappings:8jhg.E&PDB-ENSP_mappings:8jl9.A&PDB-ENSP_mappings:8jl9.E&PDB-ENSP_mappings:8jla.A&PDB-ENSP_mappings:8jla.E&PDB-ENSP_mappings:8jnd.A&PDB-ENSP_mappings:8jnd.E&PDB-ENSP_mappings:8jne.A&PDB-ENSP_mappings:8jne.E&PDB-ENSP_mappings:8jnf.A&PDB-ENSP_mappings:8jnf.E&PDB-ENSP_mappings:8off.Ca&PDB-ENSP_mappings:8off.Cb&PDB-ENSP_mappings:8oo7.M&PDB-ENSP_mappings:8oo7.Q&PDB-ENSP_mappings:8ooa.M&PDB-ENSP_mappings:8ooa.Q&PDB-ENSP_mappings:8oop.M&PDB-ENSP_mappings:8oop.Q&PDB-ENSP_mappings:8oos.M&PDB-ENSP_mappings:8oos.Q&PDB-ENSP_mappings:8osj.A&PDB-ENSP_mappings:8osj.E&PDB-ENSP_mappings:8osk.A&PDB-ENSP_mappings:8osk.E&PDB-ENSP_mappings:8osl.A&PDB-ENSP_mappings:8osl.E&PDB-ENSP_mappings:8ots.A&PDB-ENSP_mappings:8ots.E&PDB-ENSP_mappings:8ott.A&PDB-ENSP_mappings:8ott.E&PDB-ENSP_mappings:8ox0.A&PDB-ENSP_mappings:8ox0.E&PDB-ENSP_mappings:8ox1.A&PDB-ENSP_mappings:8ox1.E&PDB-ENSP_mappings:8q36.AAA&PDB-ENSP_mappings:8q36.EEE&PDB-ENSP_mappings:8q3e.AAA&PDB-ENSP_mappings:8q3e.EEE&PDB-ENSP_mappings:8q3m.AAA&PDB-ENSP_mappings:8q3m.EEE&PDB-ENSP_mappings:8q3x.AAA&PDB-ENSP_mappings:8q3x.EEE&PDB-ENSP_mappings:8qkt.AAA&PDB-ENSP_mappings:8qkt.EEE&PDB-ENSP_mappings:8qkt.KKK&PDB-ENSP_mappings:8qkt.OOO&PDB-ENSP_mappings:8smw.A&PDB-ENSP_mappings:8smw.E&PDB-ENSP_mappings:8smx.A&PDB-ENSP_mappings:8smx.E&PDB-ENSP_mappings:8smy.A&PDB-ENSP_mappings:8smy.E&PDB-ENSP_mappings:8smz.A&PDB-ENSP_mappings:8smz.E&PDB-ENSP_mappings:8sn0.A&PDB-ENSP_mappings:8sn0.E&PDB-ENSP_mappings:8sn1.A&PDB-ENSP_mappings:8sn1.E&PDB-ENSP_mappings:8sn2.A&PDB-ENSP_mappings:8sn2.E&PDB-ENSP_mappings:8sn3.A&PDB-ENSP_mappings:8sn3.E&PDB-ENSP_mappings:8sn4.A&PDB-ENSP_mappings:8sn4.E&PDB-ENSP_mappings:8sn5.A&PDB-ENSP_mappings:8sn5.E&PDB-ENSP_mappings:8sn6.A&PDB-ENSP_mappings:8sn6.E&PDB-ENSP_mappings:8sn7.A&PDB-ENSP_mappings:8sn7.E&PDB-ENSP_mappings:8sn8.A&PDB-ENSP_mappings:8sn8.E&PDB-ENSP_mappings:8sn9.A&PDB-ENSP_mappings:8sn9.E&PDB-ENSP_mappings:8sna.A&PDB-ENSP_mappings:8sna.E&PDB-ENSP_mappings:8sps.A&PDB-ENSP_mappings:8sps.E&PDB-ENSP_mappings:8spu.A&PDB-ENSP_mappings:8spu.E&PDB-ENSP_mappings:8syp.A&PDB-ENSP_mappings:8syp.E&PDB-ENSP_mappings:8txv.A&PDB-ENSP_mappings:8txv.E&PDB-ENSP_mappings:8txw.A&PDB-ENSP_mappings:8txw.E&PDB-ENSP_mappings:8txx.A&PDB-ENSP_mappings:8txx.E&PDB-ENSP_mappings:8u13.A&PDB-ENSP_mappings:8u13.E&PDB-ENSP_mappings:8u14.A&PDB-ENSP_mappings:8u14.E&PDB-ENSP_mappings:8upf.A&PDB-ENSP_mappings:8upf.E&PDB-ENSP_mappings:8vfx.A&PDB-ENSP_mappings:8vfx.E&PDB-ENSP_mappings:8vfy.A&PDB-ENSP_mappings:8vfy.E&PDB-ENSP_mappings:8vfz.A&PDB-ENSP_mappings:8vfz.E&PDB-ENSP_mappings:8vg0.A&PDB-ENSP_mappings:8vg0.E&PDB-ENSP_mappings:8vg1.A&PDB-ENSP_mappings:8vg1.E&PDB-ENSP_mappings:8vg2.A&PDB-ENSP_mappings:8vg2.E&PDB-ENSP_mappings:8w9d.a&PDB-ENSP_mappings:8w9d.e&PDB-ENSP_mappings:8w9e.a&PDB-ENSP_mappings:8w9e.e&PDB-ENSP_mappings:8w9f.a&PDB-ENSP_mappings:8w9f.e&PDB-ENSP_mappings:8wg5.A&PDB-ENSP_mappings:8wg5.E&PDB-ENSP_mappings:8x15.C&PDB-ENSP_mappings:8x15.G&PDB-ENSP_mappings:8x19.C&PDB-ENSP_mappings:8x19.G&PDB-ENSP_mappings:8x1c.C&PDB-ENSP_mappings:8x1c.G&PDB-ENSP_mappings:8xbt.A&PDB-ENSP_mappings:8xbt.E&PDB-ENSP_mappings:8xbu.A&PDB-ENSP_mappings:8xbu.E&PDB-ENSP_mappings:8xbw.E&PDB-ENSP_mappings:8ybj.A&PDB-ENSP_mappings:8ybj.E&PDB-ENSP_mappings:8ybk.A&PDB-ENSP_mappings:8ybk.E&PDB-ENSP_mappings:8yjf.C&PDB-ENSP_mappings:8yjf.E&PDB-ENSP_mappings:8yjm.C&PDB-ENSP_mappings:8yjm.E&PDB-ENSP_mappings:8yti.A&PDB-ENSP_mappings:8yti.E&PDB-ENSP_mappings:8yti.K&PDB-ENSP_mappings:8yti.O&PDB-ENSP_mappings:8yv8.A&PDB-ENSP_mappings:8yv8.E&PDB-ENSP_mappings:9fgq.A&PDB-ENSP_mappings:9fgq.E&PDB-ENSP_mappings:9fh9.A&PDB-ENSP_mappings:9fh9.E&AFDB-ENSP_mappings:AF-P68431-F1&Pfam:PF00125&Prints:PR00622&PANTHER:PTHR11426&SMART:SM00428&Superfamily:SSF47113			0.7053	0.7133	0.6902	0.8423	0.6531	0.6176	0.685	0.7206	0.6494	0.6987	0.8553	0.6689	0.6328	0.6839	0.6948	0.6278	0.6888	0.7188	0.6165	0.6708	0.6878	0.8484	0.6747	0.6122	0.6699	0.7089	0.6236	0.8553	gnomADe_EAS		0&1	0&1																		1.9520e+00																																																											1262					0.999							202.05	v6.1	Unknown		True	H3C3, a histone variant, is recurrently altered by mutation in various pediatric cancers, including pediatric glioblastoma.	False	08/11/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3C3 ENSP00000484658.2:C97= mutant UNKNOWN.	False	The H3C3 ENSP00000484658.2:c97= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	26045929						True	False	False	Unknown								False	False		H3C3, a histone variant, is recurrently altered by mutation in various pediatric cancers, including pediatric glioblastoma.	The H3C3 ENSP00000484658.2:c97= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3C3 ENSP00000484658.2:C97= mutant UNKNOWN.						v6.1	08/11/2025		GRCh38	H3C3	8352.0	ENSP00000484658.2:C97=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""H3C3"",""entrezGeneId"":8352,""alteration"":""ENSP00000484658.2:C97="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""H3C3, a histone variant, is recurrently altered by mutation in various pediatric cancers, including pediatric glioblastoma."",""variantSummary"":""The H3C3 ENSP00000484658.2:c97= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H3C3 ENSP00000484658.2:C97= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/11/2025""}"	True	True	False	Unknown		Unknown																						0,1261	0,627	0,634	0/1	0,0,646,615	GTG	.	.	.			0,0,576,685	64.73		1.0
GRCh38	H1-2	D12_12345_1234556_Thyroid_S9	p.Ser36=	ENSP00000339566.3:p.Ser36=	chr6	26056321	26056321.0	A	G	G	26056321	.	A	G	.	PASS	NM_005319	G	synonymous_variant	LOW	H1-2	ENSG00000187837	Transcript	ENST00000343677	protein_coding	1/1		c.108T>C	150	108	36	S	tcT/tcC	rs10425&COSV59191826		-1		SNV	HGNC	HGNC:4716	YES	MANE_Select	NM_005319.4			P1	CCDS4577.1	ENSP00000339566	P16403.225		UPI0000001BD9						PDB-ENSP_mappings:8h0v.u&PDB-ENSP_mappings:8h0w.u&SMART:SM00526&Prints:PR00624&CDD:cd00073&Superfamily:SSF46785&PROSITE_profiles:PS51504&Gene3D:1.10.10.10&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P16403-F1			0.7608	0.9281	0.6744	0.8552	0.6372	0.6258	0.6765	0.9053	0.6466	0.6692	0.8948	0.6658	0.6611	0.666	0.6935	0.6358	0.7298	0.8927	0.6418	0.6726	0.6529	0.8612	0.6725	0.6395	0.6545	0.7308	0.6308	0.9281	AFR		0&1	0&1	35124268&31447881																	1.7260e+00																																																											1219					0.998							247.9	v6.1	Unknown		True	H1-2, a histone variant, is infrequently altered by mutation in various cancer types.	False	08/07/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H1-2 ENSP00000339566.3:S36= mutant UNKNOWN.	False	The H1-2 ENSP00000339566.3:s36= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	26056549						True	False	False	Unknown								False	False		H1-2, a histone variant, is infrequently altered by mutation in various cancer types.	The H1-2 ENSP00000339566.3:s36= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H1-2 ENSP00000339566.3:S36= mutant UNKNOWN.						v6.1	08/07/2019		GRCh38	H1-2	3006.0	ENSP00000339566.3:S36=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""H1-2"",""entrezGeneId"":3006,""alteration"":""ENSP00000339566.3:S36="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""H1-2, a histone variant, is infrequently altered by mutation in various cancer types."",""variantSummary"":""The H1-2 ENSP00000339566.3:s36= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with H1-2 ENSP00000339566.3:S36= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/07/2019""}"	True	True	False	Unknown		Unknown																						0,1217	0,600	0,617	0/1	0,0,598,619	CAG	.	.	.			0,0,603,614	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.L10V	ENSP00000366005.5:p.Leu10Val	chr6	29942581	29942581.0	C	G	G	29942581	.	C	G	.	PASS	NM_002116	G	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	1/8		c.28C>G	50	28	10	L/V	Ctc/Gtc	rs1143146&COSV65136471		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.04)	benign(0.003)	PDB-ENSP_mappings:5w1w.C&PDB-ENSP_mappings:5w1w.H&PDB-ENSP_mappings:5w1w.M&PDB-ENSP_mappings:5w1w.R&Low_complexity_(Seg):seg&Phobius:SIGNAL_PEPTIDE_H_REGION&Phobius:SIGNAL_PEPTIDE&SignalP_GRAM_POSITIVE:SignalP-TM&Cleavage_site_(Signalp):SignalP-noTM&AFDB-ENSP_mappings:AF-P04439-F1			0.5054	0.4743	0.5965	0.5397	0.5119	0.4407	0.05603	0.07542	0.1568	0.1549	0.2733	0.0897	0.06972	0.03783	0.0817	0.1118	0.1534	0.1588	0.139	0.181	0.2095	0.1495	0.1112	0.22	0.1506	0.1468	0.1215	0.5965	AMR		0&1	1&1	28955865&35743738&36609529&32888494						FAIL	-47	-36	45	41	0.00	0.00	0.00	0.00	HLA-A	0.017	1.9760e+00																																																											959					0.997							153.26	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L10V mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:l10v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910358						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:l10v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L10V mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:L10V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:L10V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:l10v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L10V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						461,495	229,241	232,254	0|1	245,216,232,263	CCT	.	.	.		29910358	229,232,272,223	55.84		0.5177824267782427
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.S14L	ENSP00000366005.5:p.Ser14Leu	chr6	29942594	29942594.0	C	T	T	29942594	.	C	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	1/8		c.41C>T	63	41	14	S/L	tCg/tTg	rs2230954&COSV65136854		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.05)	benign(0.003)	Low_complexity_(Seg):seg&Phobius:SIGNAL_PEPTIDE_H_REGION&Phobius:SIGNAL_PEPTIDE&PANTHER:PTHR16675&SignalP_GRAM_POSITIVE:SignalP-TM&Cleavage_site_(Signalp):SignalP-noTM&AFDB-ENSP_mappings:AF-P04439-F1									0.03175	0.06509	0.06605	0.0447	0.05388	0.04293	0.04209	0.02589	0.03938	0.05862	0.06506	0.08679	0.05502	0.07475	0.06352	0.06744	0.04008	0.08416	0.05201	0.07088	0.09242	0.09242	gnomADg_SAS		0&1	0&1	27766139&19774073						FAIL	-3	23	32	43	0.00	0.00	0.00	0.00	HLA-A	0.050	1.9760e+00	1727031	0.12606	0.12151		1781398		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29942594C>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				2230954					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					965					0.992							153.21	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S14L mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:s14l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910371						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:s14l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S14L mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:S14L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:S14L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:s14l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S14L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						504,453	231,227	273,226	0/1	244,260,246,207	TCG	0.00	0.00	0.00			253,251,220,233	32.73		0.47335423197492166
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Ala16=	ENSP00000366005.5:p.Ala16=	chr6	29942601	29942601.0	C	T	T	29942601	.	C	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	1/8		c.48C>T	70	48	16	A	gcC/gcT	rs41546314&COSV65136481		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			Low_complexity_(Seg):seg&Phobius:SIGNAL_PEPTIDE_H_REGION&Phobius:SIGNAL_PEPTIDE&PANTHER:PTHR16675&SignalP_GRAM_POSITIVE:SignalP-TM&Cleavage_site_(Signalp):SignalP-noTM&AFDB-ENSP_mappings:AF-P04439-F1			0.2444	0.1755	0.3357	0.2917	0.3141	0.1524	0.01191	0.008818	0.01934	0.02051	0.03714	0.02142	0.01015	0.009873	0.016	0.01485	0.02743	0.01705	0.05192	0.02092	0.01905	0.03287	0.02885	0.02	0.03691	0.0155	0.01631	0.3357	AMR		0&1	1&1	30837455						FAIL	16	25	25	23	0.00	0.00	0.00	0.00	HLA-A		1.9760e+00																																																											982					0.991							151.81	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A16= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:a16= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910378						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:a16= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A16= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:A16=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:A16="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:a16= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A16= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						448,525	225,236	223,289	0|1	224,224,257,268	CCC	0.00	0.00	0.00		29910358	215,233,260,265	45.59		0.539568345323741
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Ser26=	ENSP00000366005.5:p.Ser26=	chr6	29942761	29942761.0	C	T	T	29942761	.	C	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.78C>T	100	78	26	S	tcC/tcT	rs1136657&COSV65137424		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.009496	0.006659	0.01864	0.01202	0.02132	0.01397	0.008165	0.007961	0.01296	0.01657	0.01228	0.006546	0.01852	0.009628	0.007331	0.01529	0.009894	0.01163	0.0174	0.006645	0.008615	0.02132	gnomADe_EAS		0&1	0&1							FAIL	12	-4	11	-29	0.05	0.03	0.00	0.00	HLA-A		1.9760e+00																																																											685					0.931							100.79	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S26= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:s26= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910538						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:s26= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S26= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:S26=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:S26="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:s26= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S26= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						315,323	172,170	143,153	0/1	167,148,174,149	CCC	0.00	0.00	0.00			194,121,201,122	44.57		0.5062695924764891
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Ala48=	ENSP00000366005.5:p.Ala48=	chr6	29942827	29942827.0	C	A	A	29942827	.	C	A	.	PASS	NM_002116	A	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.144C>A	166	144	48	A	gcC/gcA	rs12721675&COSV65136488		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.3824	0.4425	0.4597	0.3899	0.3807	0.2403	0.09048	0.2749	0.2022	0.1428	0.2385	0.08227	0.1634	0.06932	0.1263	0.1334	0.2367	0.3844	0.09036	0.2799	0.2083	0.2492	0.07743	0.2696	0.1573	0.2524	0.1978	0.4597	AMR		0&1	0&1							FAIL	2	25	2	23	0.33	0.04	0.00	0.00	HLA-A		1.9760e+00																																																											1073					0.91							125.87	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A48= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:a48= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910604						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:a48= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A48= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:A48=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:A48="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:a48= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A48= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						513,463	267,229	246,234	0/1	262,251,222,241	CCG	0.00	0.00	0.00			310,203,254,209	33.69		0.47438524590163933
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Phe60=	ENSP00000366005.5:p.Phe60=	chr6	29942863	29942863.0	C	T	T	29942863	.	C	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.180C>T	202	180	60	F	ttC/ttT	rs3173429&COSV65139538&COSV65140273		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.0671	0.0976	0.0821	0.0198	0.0805	0.0501	0.04385	0.08541	0.03834	0.03828	0.003887	0.04519	0.06202	0.04421	0.0477	0.04078	0.06466	0.09135	0.08896	0.05886	0.05152	0.009336	0.05091	0.04274	0.05773	0.06101	0.04244	0.0976	AFR		0&1&1	0&1&1							FAIL	6	-11	-13	22	0.09	0.01	0.00	0.00	HLA-A		1.9760e+00	1727042	0.08315		0.06709	1781409		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29942863C>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001819&synonymous_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				3173429					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					1195					0.907							150.2	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:F60= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:f60= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910640						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:f60= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:F60= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:F60=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:F60="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:f60= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:F60= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						595,489	287,251	308,238	0/1	276,319,253,236	TCG	0.00	0.00	0.00			298,297,249,240	14.8		0.4511070110701107
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Gly80=	ENSP00000366005.5:p.Gly80=	chr6	29942923	29942923.0	G	T	T	29942923	.	G	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.240G>T	262	240	80	G	ggG/ggT	rs1059452&COSV105311073&COSV65136989		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.06454	0.02922	0.07477	0.02987	0.03446	0.0329	0.02784	0.07267	0.04848	0.03264	0.007574	0.004453	0.01042	0.008392	0.005243	0.006684	0.006777	0.01562	0.01002	0.003221	0.007246	0.07477	gnomADe_AMR		0&1&1	0&1&1							FAIL	-10	-5	-2	5	0.00	0.00	0.00	0.00	HLA-A		1.9760e+00																																																											1010					0.908							172.27	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G80= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:g80= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910700						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:g80= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G80= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:G80=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:G80="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:g80= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G80= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						470,447	238,198	232,249	0|1	223,247,230,217	GGC	0.00	0.00	0.00		29910700	219,251,201,246	15.75		0.48745910577971646
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Q86E	ENSP00000366005.5:p.Gln86Glu	chr6	29942939	29942939.0	C	G	G	29942939	.	C	G	.	PASS	NM_002116	G	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.256C>G	278	256	86	Q/E	Cag/Gag	rs1059455&COSV65136733		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.69)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.3924	0.3048	0.4986	0.4851	0.4175	0.3139	0.1759	0.1555	0.2602	0.1356	0.1836	0.08623	0.1401	0.1803	0.1601	0.1646	0.02979	0.03258	0.03186	0.03737	0.03938	0.03697	0.01595	0.02532	0.02797	0.02314	0.02709	0.4986	AMR		0&1	0&1	36389712						FAIL	-21	3	14	5	0.00	0.00	0.00	0.00	HLA-A	0.063	1.9760e+00																																																											880					0.918							171.26	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q86E mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:q86e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910716						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:q86e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q86E mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:Q86E			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:Q86E"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:q86e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q86E mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						408,400	207,181	201,219	0|1	182,226,200,200	CCA	.	.	.		29910700	181,227,183,217	19.23		0.49504950495049505
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Q86R	ENSP00000366005.5:p.Gln86Arg	chr6	29942940	29942940.0	A	G	G	29942940	.	A	G	.	PASS	NM_002116	G	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.257A>G	279	257	86	Q/R	cAg/cGg	rs1064588&COSV65137030&COSV65138857		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(1)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.3944	0.4425	0.4323	0.3839	0.3509	0.3579	0.2704	0.4008	0.4267	0.3821	0.3671	0.1737	0.2676	0.2513	0.2763	0.3495	0.2139	0.3543	0.03125	0.2917	0.289	0.2212	0.04943	0.2899	0.1291	0.2273	0.2477	0.4425	AFR		0&1&1	0&1&1	36389712						FAIL	-22	2	-27	19	0.00	0.00	0.00	0.00	HLA-A	0.023	1.9760e+00																																																											876					0.922							171.21	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q86R mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:q86r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910717						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:q86r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q86R mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:Q86R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:Q86R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:q86r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q86R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						405,403	206,182	199,221	0|1	187,218,204,199	CAG	.	.	.		29910700	180,225,187,216	23.03		0.49876237623762376
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.N90K	ENSP00000366005.5:p.Asn90Lys	chr6	29942953	29942953.0	T	A	A	29942953	.	T	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.270T>A	292	270	90	N/K	aaT/aaA	rs199474436&COSV65137266		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.33)	benign(0.001)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.3946	0.3003	0.5086	0.4891	0.4215	0.316	0.1788	0.1505	0.2738	0.1412	0.1515	0.07891	0.1395	0.184	0.1632	0.1713	0.02579	0.03487	0.02094	0.03195	0.02745	0.04115	0.01039	0.03488	0.02235	0.03409	0.03861	0.5086	AMR		0&1	0&1	35743738						FAIL	-35	7	-4	0	0.00	0.00	0.00	0.00	HLA-A	0.080	1.9760e+00																																																											824					0.913							172.34	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:N90K mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:n90k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910730						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:n90k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:N90K mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:N90K			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:N90K"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:n90k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:N90K mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						357,395	179,180	178,215	0|1	157,200,199,196	ATG	.	.	.		29910700	165,192,182,213	21.96		0.5252659574468085
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Q94H	ENSP00000366005.5:p.Gln94His	chr6	29942965	29942965.0	G	C	C	29942965	.	G	C	.	PASS	NM_002116	C	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.282G>C	304	282	94	Q/H	caG/caC	rs78306866&COSV65140297		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.53)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.6807	0.6634	0.7133	0.6706	0.6899	0.682	0.5992	0.6275	0.6844	0.6481	0.5868	0.333	0.5999	0.6028	0.5956	0.6392	0.414	0.5688	0.2818	0.463	0.4315	0.2799	0.1398	0.4688	0.3506	0.4247	0.4212	0.7133	AMR		0&1	0&1							FAIL	7	1	7	-6	0.00	0.00	0.00	0.00	HLA-A	0.044	1.9760e+00	1727050	0.63827		0.68071	1781417		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29942965G>C	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				78306866					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					742					0.931							168.96	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q94H mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:q94h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910742						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:q94h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q94H mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:Q94H			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:Q94H"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:q94h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:Q94H mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,691	0,335	0,356	0/1	0,0,335,356	AGT	.	.	.			0,0,337,354	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.D98H	ENSP00000366005.5:p.Asp98His	chr6	29942975	29942975.0	G	C	C	29942975	.	G	C	.	PASS	NM_002116	C	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	2/8		c.292G>C	314	292	98	D/H	Gac/Cac	rs1136683&COSV65138671		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.53)	benign(0.007)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.2280	0.1778	0.3012	0.2966	0.3141	0.0849	0.05423	0.02755	0.07922	0.03229	0.01695	0.02127	0.02642	0.06176	0.03972	0.01894	0.003827	0.002575	0.01036	0.003905	0.001884	0.006287	0.003777	0	0.004894	0.002	0.0007924	0.3141	EUR		0&1	0&1							FAIL	-9	42	47	-22	0.00	0.00	0.00	0.00	HLA-A	0.023	1.9760e+00																																																											721					0.938							164.87	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D98H mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:d98h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29910752						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:d98h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D98H mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:D98H			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:D98H"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:d98h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D98H mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						252,424	121,196	131,228	0|1	114,138,226,198	TGA	.	.	.		29910700	115,137,212,212	13.91		0.6272189349112426
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.I121M	ENSP00000366005.5:p.Ile121Met	chr6	29943287	29943287.0	A	G	G	29943287	.	A	G	.	PASS	NM_002116	G	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.363A>G	385	363	121	I/M	atA/atG	rs1136695&COSV65136818		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.12)	benign(0.038)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.6611	0.6467	0.768	0.6865	0.6292	0.6115	0.1401	0.1761	0.3631	0.2263	0.4411	0.1511	0.1731	0.09891	0.1798	0.3577	0.1476	0.2021	0.06154	0.1844	0.1577	0.1794	0.05946	0.1406	0.1192	0.1461	0.2637	0.768	AMR		0&1	0&1							FAIL	-19	-2	44	2	0.03	0.02	0.00	0.00	HLA-A	0.032	1.9760e+00	1727017	0.48639	0.55408	0.66114	1781384		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943287A>G	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1136695					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					800					0.991							108.95	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:I121M mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:i121m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911064						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:i121m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:I121M mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:I121M			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:I121M"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:i121m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:I121M mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,793	0,353	0,440	0/1	0,0,388,405	TAA	.	.	.			0,0,456,337	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.S129P	ENSP00000366005.5:p.Ser129Pro	chr6	29943309	29943309.0	T	C	C	29943309	.	T	C	.	PASS	NM_002116	C	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.385T>C	407	385	129	S/P	Tcg/Ccg	rs1136700&COSV65136992		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(1)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1aqd.C&PDB-ENSP_mappings:1aqd.F&PDB-ENSP_mappings:1aqd.I&PDB-ENSP_mappings:1aqd.L&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4ov5.C&PDB-ENSP_mappings:4ov5.F&PDB-ENSP_mappings:4ov5.I&PDB-ENSP_mappings:4ov5.L&PDB-ENSP_mappings:4ov5.O&PDB-ENSP_mappings:4ov5.R&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.3027	0.289	0.1599	0.3264	0.2803	0.4213	0.2584	0.1353	0.1873	0.3571	0.4736	0.1242	0.2573	0.2427	0.2771	0.4631	0.1713	0.127	0.2537	0.1049	0.2121	0.516	0.06353	0.2447	0.2114	0.1557	0.3296	0.516	gnomADg_EAS		0&1	0&1							FAIL	-24	33	22	-2	0.02	0.05	0.00	0.00	HLA-A	0.042	1.9760e+00	1727018	0.31947	0.34756	0.30272	1781385		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943309T>C	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1136700					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					894					0.993							105.11	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S129P mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:s129p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911086						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:s129p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S129P mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:S129P			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:S129P"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:s129p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S129P mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						422,466	197,207	225,259	0|1	224,198,244,222	GTC	.	.	.		29911086	235,187,225,241	41.48		0.5247747747747747
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.G131W	ENSP00000366005.5:p.Gly131Trp	chr6	29943315	29943315.0	G	T	T	29943315	.	G	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.391G>T	413	391	131	G/W	Ggg/Tgg	rs1136702&COSV65137531		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.03)	benign(0.009)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1aqd.C&PDB-ENSP_mappings:1aqd.F&PDB-ENSP_mappings:1aqd.I&PDB-ENSP_mappings:1aqd.L&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4ov5.C&PDB-ENSP_mappings:4ov5.F&PDB-ENSP_mappings:4ov5.I&PDB-ENSP_mappings:4ov5.L&PDB-ENSP_mappings:4ov5.O&PDB-ENSP_mappings:4ov5.R&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.2444	0.1747	0.3357	0.2887	0.3181	0.1524	0.002121	0.002093	0.005753	0.003117	0.005118	0.001394	0.001129	0.001778	0.002165	0.003568	0.001188	0.0008306	0	0.0004511	0.002655	0.001783	0.0002094	0	0.001764	0	0	0.3357	AMR		0&1	0&1	30123242&37394533						FAIL	27	45	16	-26	0.08	0.01	0.00	0.00	HLA-A	0.160	1.9760e+00																																																											911					0.991							104.8	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G131W mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:g131w mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911092						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:g131w mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G131W mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:G131W			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:G131W"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:g131w mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G131W mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						468,435	215,204	253,231	0|1	245,223,216,219	CGG	0.00	0.00	0.00		29911092	232,236,233,202	25.71		0.48172757475083056
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.F133L	ENSP00000366005.5:p.Phe133Leu	chr6	29943321	29943321.0	T	C	C	29943321	.	T	C	.	PASS	NM_002116	C	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.397T>C	419	397	133	F/L	Ttc/Ctc	rs1059488		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(1)	benign(0.015)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1aqd.C&PDB-ENSP_mappings:1aqd.F&PDB-ENSP_mappings:1aqd.I&PDB-ENSP_mappings:1aqd.L&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4ov5.C&PDB-ENSP_mappings:4ov5.F&PDB-ENSP_mappings:4ov5.I&PDB-ENSP_mappings:4ov5.L&PDB-ENSP_mappings:4ov5.O&PDB-ENSP_mappings:4ov5.R&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.0413	0.0779	0.0245	0.005	0.0417	0.0409	0.01078	0.03751	0.01462	0.014	0.002359	0.01116	0.01752	0.008861	0.01445	0.01919	0.03191	0.06107	0.03681	0.02296	0.02091	0.001733	0.0106	0.009091	0.02045	0.02156	0.02469	0.0779	AFR										FAIL	-36	21	10	-32	0.00	0.05	0.00	0.00	HLA-A	0.046	1.9760e+00	1727019	0.05194	0.04237	0.04133	1781386		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943321T>C	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1059488					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					946					0.992							105.36	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:F133L mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:f133l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911098						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:f133l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:F133L mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:F133L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:F133L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:f133l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:F133L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						446,492	211,234	235,258	0|1	239,207,271,221	CTT	.	.	.		29911086	248,198,237,255	41.42		0.5245202558635395
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.R138Q	ENSP00000366005.5:p.Arg138Gln	chr6	29943337	29943337.0	G	A	A	29943337	.	G	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.413G>A	435	413	138	R/Q	cGg/cAg	rs3173420&COSV65137272&COSV65142056		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.24)	benign(0.001)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1aqd.C&PDB-ENSP_mappings:1aqd.F&PDB-ENSP_mappings:1aqd.I&PDB-ENSP_mappings:1aqd.L&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4ov5.C&PDB-ENSP_mappings:4ov5.F&PDB-ENSP_mappings:4ov5.I&PDB-ENSP_mappings:4ov5.L&PDB-ENSP_mappings:4ov5.O&PDB-ENSP_mappings:4ov5.R&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.6498	0.7352	0.7003	0.6766	0.5895	0.5327	0.06546	0.1371	0.1604	0.14	0.4451	0.05472	0.09432	0.0381	0.08458	0.2142	0.09374	0.155	0.06522	0.09853	0.1054	0.1606	0.03929	0.1395	0.06344	0.07942	0.1355	0.7352	AFR		0&1&1	1&1&1	35743738&32888494						FAIL	2	44	-6	-48	0.36	0.00	0.00	0.00	HLA-A	0.047	1.9760e+00	1727020	0.50430		0.64976	1781387		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943337G>A	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				3173420					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					957					0.971							103.66	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R138Q mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:r138q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911114						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:r138q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R138Q mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:R138Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:R138Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:r138q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R138Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,929	0,443	0,486	0/1	0,0,486,443	CGG	0.00	0.00	0.00			0,0,460,469	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Arg138=	ENSP00000366005.5:p.Arg138=	chr6	29943338	29943338.0	G	C	C	29943338	.	G	C	.	PASS	NM_002116	C	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.414G>C	436	414	138	R	cgG/cgC	rs1059498&COSV65139979&COSV65146061		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1aqd.C&PDB-ENSP_mappings:1aqd.F&PDB-ENSP_mappings:1aqd.I&PDB-ENSP_mappings:1aqd.L&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4ov5.C&PDB-ENSP_mappings:4ov5.F&PDB-ENSP_mappings:4ov5.I&PDB-ENSP_mappings:4ov5.L&PDB-ENSP_mappings:4ov5.O&PDB-ENSP_mappings:4ov5.R&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.4169	0.3646	0.536	0.497	0.4344	0.3027	0.01319	0.02524	0.05154	0.02572	0.05792	0.008055	0.02425	0.008161	0.01769	0.03996	0.01148	0.01445	0.0102	0.007499	0.01349	0.03118	0.00333	0.02273	0.01093	0.01342	0.01276	0.536	AMR		0&1&1	0&1&1							FAIL	-2	4	16	-7	0.00	0.05	0.00	0.00	HLA-A		1.9760e+00																																																											952					0.971							103.75	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R138= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:r138= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911115						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:r138= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R138= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:R138=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:R138="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:r138= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R138= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						504,420	244,196	260,224	0|1	264,240,226,194	GGC	.	.	.		29911092	256,248,208,212	4.62		0.45454545454545453
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Leu150=	ENSP00000366005.5:p.Leu150=	chr6	29943372	29943372.0	C	T	T	29943372	.	C	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.448C>T	470	448	150	L	Ctg/Ttg	rs1059506&COSV65138946&COSV65139875		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.1564	0.1891	0.1527	0.1438	0.1143	0.1708	0.1018	0.1307	0.1503	0.1323	0.2906	0.05187	0.09826	0.09343	0.1046	0.1367	0.08098	0.12	0.05263	0.1081	0.08704	0.102	0.03455	0.08333	0.0609	0.07692	0.1161	0.2906	gnomADe_EAS		0&1&1	0&1&1							FAIL	9	-30	8	1	0.01	0.00	0.00	0.00	HLA-A		1.9760e+00	1727021	0.13791	0.13351	0.15635	1781388		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943372C>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001819&synonymous_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1059506					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					1039					0.948							91.07	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L150= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:l150= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911149						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:l150= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L150= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:L150=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:L150="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:l150= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L150= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						426,559	205,280	221,279	0/1	223,203,287,272	CCT	0.00	0.00	0.00			210,216,300,259	42.06		0.5675126903553299
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.N151K	ENSP00000366005.5:p.Asn151Lys	chr6	29943377	29943377.0	C	A	A	29943377	.	C	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.453C>A	475	453	151	N/K	aaC/aaA	rs1059509&CM1618077&COSV65137229		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0)	benign(0.011)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.4585	0.4009	0.5922	0.502	0.4672	0.3875	0.07808	0.08731	0.2969	0.05935	0.0665	0.1121	0.0867	0.06306	0.07719	0.1591	0.04419	0.04127	0.02128	0.07053	0.04253	0.04565	0.02844	0.02128	0.04312	0.02117	0.1037	0.5922	AMR		0&1&1	0&1&1	37394533						FAIL	2	4	2	3	0.10	0.01	0.00	0.00	HLA-A	0.074	1.9760e+00																																																											1046					0.943							91.2	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:N151K mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:n151k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911154						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:n151k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:N151K mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:N151K			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:N151K"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:n151k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:N151K mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						558,428	275,207	283,221	0/1	280,278,232,196	ACG	0.00	0.00	0.00			299,259,213,215	11.7		0.4340770791075051
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.K168Q	ENSP00000366005.5:p.Lys168Gln	chr6	29943426	29943426.0	A	C	C	29943426	.	A	C	.	PASS	NM_002116	C	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.502A>C	524	502	168	K/Q	Aag/Cag	rs1059517&CM994738&COSV65138341		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(1)	benign(0.035)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.3391	0.5673	0.2853	0.2143	0.2356	0.3037	0.1991	0.6219	0.3287	0.3182	0.4071	0.06314	0.3071	0.1681	0.2569	0.2423	0.2313	0.529	0.03571	0.2742	0.2043	0.2589	0.02723	0.3636	0.1118	0.3	0.1744	0.6219	gnomADe_AFR		0&1&1	0&1&1	21108794&34650566						FAIL	3	-45	34	7	0.00	0.00	0.00	0.00	HLA-A	0.025	1.9760e+00	1727022			0.33906	1781389		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943426A>C	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1059517					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					1014					0.91							86.3	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:K168Q mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:k168q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911203						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:k168q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:K168Q mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:K168Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:K168Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:k168q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:K168Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						427,496	217,242	210,254	0/1	208,219,246,250	CAA	.	.	.			240,187,234,262	37.58		0.5373781148429035
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.R169H	ENSP00000366005.5:p.Arg169His	chr6	29943430	29943430.0	G	A	A	29943430	.	G	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.506G>A	528	506	169	R/H	cGc/cAc	rs1059520&COSV65137241		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.02)	benign(0.003)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.03076	0.03065	0.1342	0.02741	0.01432	0.03294	0.02447	0.02291	0.02814	0.0777	0.008359	0.009693	0	0.01059	0.005092	0.01049	0.0056	0.009615	0.00812	0.001639	0.009278	0.1342	gnomADe_AMR		0&1	0&1	24947555						FAIL	-49	-10	3	-1	0.00	0.00	0.00	0.00	HLA-A	0.056	1.9760e+00																																																											1031					0.912							85.64	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R169H mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:r169h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911207						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:r169h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R169H mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:R169H			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:R169H"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:r169h mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:R169H mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						496,444	235,226	261,218	0|1	235,261,220,224	CGC	0.00	0.00	0.00		29911190	238,258,242,202	18.39		0.4723404255319149
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.H175R	ENSP00000366005.5:p.His175Arg	chr6	29943448	29943448.0	A	G	G	29943448	.	A	G	.	PASS	NM_002116	G	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.524A>G	546	524	175	H/R	cAt/cGt	rs1059536&COSV65139057		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.66)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.2564	0.4607	0.232	0.1617	0.165	0.1892	0.1404	0.4404	0.2544	0.2089	0.3117	0.05094	0.2088	0.1179	0.1798	0.1895	0.1546	0.3607	0.01852	0.1873	0.1345	0.2161	0.02065	0.1863	0.07686	0.1983	0.1476	0.4607	AFR		0&1	0&1	34650566						FAIL	-28	2	36	12	0.00	0.00	0.01	0.00	HLA-A	0.202	1.9760e+00	1727023		0.17707	0.25639	1781390		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943448A>G	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1059536					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					1048					0.894							83.91	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:H175R mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:h175r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911225						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:h175r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:H175R mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:H175R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:H175R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:h175r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:H175R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						531,406	255,185	276,221	0/1	242,289,211,195	CAT	.	.	.			302,229,180,226	11.93		0.43329775880469584
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.E176V	ENSP00000366005.5:p.Glu176Val	chr6	29943451	29943451.0	A	T	T	29943451	.	A	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.527A>T	549	527	176	E/V	gAg/gTg	rs9256983&COSV65136508&COSV65136602&COSV65137155&COSV65139076		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.88)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.5980	0.5885	0.7334	0.5893	0.5865	0.5358	0.1567	0.2011	0.3987	0.2468	0.4342	0.09551	0.3004	0.122	0.1755	0.345	0.1055	0.1412	0.04365	0.1678	0.2035	0.1791	0.03167	0.2179	0.08098	0.1079	0.2455	0.7334	AMR		0&1&1&1&1	1&1&1&1&1	28928442						FAIL	11	-31	33	1	0.00	0.00	0.00	0.00	HLA-A	0.144	1.9760e+00	1727024			0.59804	1781391		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943451A>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				9256983					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					1040					0.892							84.48	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E176V mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:e176v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911228						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:e176v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E176V mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:E176V			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:E176V"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:e176v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E176V mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						60,868	22,412	38,456	0/1	23,37,410,458	GAG	.	.	.			59,1,406,462	41.91		0.9353448275862069
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Leu184=	ENSP00000366005.5:p.Leu184=	chr6	29943476	29943476.0	G	A	A	29943476	.	G	A	.	PASS	NM_002116	A	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.552G>A	574	552	184	L	ctG/ctA	rs199474562		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.0006354	0.0003373	0.0004201	0.001025	5.737e-05	0.0007291	0.0003794	0.0007036	0.0005699	0.0001942	0.0004518	5.624e-05	0	0.001117	0.001531	0	0.0003779	0	0.000615	0	0	0.001531	gnomADg_ASJ										FAIL	2	8	4	8	0.00	0.00	0.00	0.03	HLA-A		1.9760e+00																																																											1013					0.883							84.34	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L184= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:l184= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911253						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:l184= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L184= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:L184=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:L184="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:l184= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L184= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						837,57	383,28	454,29	0|1	396,441,35,22	TGG	0.00	0.00	1.00		29911253	410,427,50,7	3.55		0.06375838926174497
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.D185E	ENSP00000366005.5:p.Asp185Glu	chr6	29943479	29943479.0	T	G	G	29943479	.	T	G	.	PASS	NM_002116	G	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.555T>G	577	555	185	D/E	gaT/gaG	rs1059542&COSV65143681		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(1)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.9257	0.9342	0.9078	0.9841	0.8479	0.9468	0.6725	0.8462	0.8255	0.7836	0.9798	0.321	0.7264	0.6378	0.7211	0.8905	0.5823	0.7577	0.4628	0.5937	0.6719	0.9143	0.1745	0.7195	0.5048	0.6537	0.7015	0.9841	EAS		0&1	0&1							FAIL	1	27	-46	5	0.00	0.00	0.00	0.08	HLA-A	0.036	1.9760e+00	1727025	0.85964		0.92572	1781392		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29943479T>G	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1059542					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					1026					0.878							84.45	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D185E mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:d185e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911256						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:d185e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D185E mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:D185E			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:D185E"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:d185e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D185E mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,901	0,413	0,488	0/1	0,0,433,468	ATG	.	.	.			0,0,459,442	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.V189E	ENSP00000366005.5:p.Val189Glu	chr6	29943490	29943490.0	T	A	A	29943490	.	T	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.566T>A	588	566	189	V/E	gTg/gAg	rs61760919&COSV106112940		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.01)	probably_damaging(0.991)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.000707	0.0002232	0.0004854	0.001693	8.884e-05	0.001412	0.0008601	0.0007079	0.0009356	0.000406	0.001612	0.0001385	0.002475	0.001585	0.003456	0	0.001394	0	0.002405	0.006276	0.002268	0.006276	gnomADg_REMAINING		0&1	0&1							FAIL	2	16	-10	-6	0.00	0.00	0.00	0.11	HLA-A	0.159	1.9760e+00																																																											1074					0.877							89.95	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:V189E mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:v189e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911267						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:v189e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:V189E mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:V189E			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:V189E"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:v189e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:V189E mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						851,91	377,43	474,48	0|1	431,420,48,43	GTG	.	.	.		29911253	401,450,74,17	3.76		0.09660297239915075
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.G199R	ENSP00000366005.5:p.Gly199Arg	chr6	29943519	29943519.0	G	A	A	29943519	.	G	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.595G>A	617	595	199	G/R	Ggg/Agg	rs41559916&COSV65137603		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0)	probably_damaging(1)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tmc.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Prints:PR01638&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.03672	0.04344	0.04359	0.03522	0.05322	0.0506	0.07271	0.03664	0.03845	0.01725	0.06461	0.08589	0.09893	0.04666	0.0445	0.05504	0.0373	0.04	0.06354	0.05556	0.02719	0.09893	gnomADg_AMI		0&1	0&1							FAIL	2	-13	18	-35	0.00	0.00	0.00	0.02	HLA-A	0.172	1.9760e+00																																																											1100					0.909							102.17	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G199R mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:g199r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911296						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:g199r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G199R mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:G199R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:G199R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:g199r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G199R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						714,286	311,133	403,153	0/1	372,342,154,132	CGG	0.00	0.00	1.00			313,401,161,125	11.7		0.286
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.T202M	ENSP00000366005.5:p.Thr202Met	chr6	29943529	29943529.0	C	T	T	29943529	.	C	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.605C>T	627	605	202	T/M	aCg/aTg	rs9391665&COSV65137610		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.05)	benign(0.025)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Pfam:PF00129&Gene3D:3.30.500.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF54452&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.03405	0.0291	0.03966	0.03429	0.05428	0.04466	0.06454	0.03435	0.03518	0.0155	0.05356	0.0617	0.06842	0.04341	0.0379	0.05744	0.03202	0.03205	0.05709	0.04021	0.01632	0.06842	gnomADg_AMI		0&1	0&1							FAIL	-23	-45	-45	49	0.00	0.00	0.01	0.00	HLA-A	0.118	1.9760e+00																																																											1098					0.918							112.79	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T202M mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:t202m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911306						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:t202m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T202M mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:T202M			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:T202M"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:t202m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T202M mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						828,180	370,85	458,95	0|1	424,404,99,81	ACG	0.00	0.00	1.00		29911306	366,462,84,96	4.76		0.17857142857142858
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9			chr6	29943541	29943542.0	CG	C	C	29943541	.	CG	C	.	PASS	NM_002116	-	frameshift_variant&splice_region_variant	HIGH	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.619+1del	640	618	206	T/X	acG/ac	rs776875561&COSV105311080&COSV65140152		1		deletion	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1		2							0.004788	0.01656	0.004137	0.004685	0.000426	0.007399	0.008683	0.004508	0.005741	0.003501	0.0125	0.02363	0.01705	0.007383	0.009857	0.001509	0.006116	0.01	0.008924	0.01155	0.00897	0.02363	gnomADg_AFR		0&1&1	0&1&1							FAIL	-35	10	2	37	0.00	0.00	0.01	0.00	HLA-A		1.9760e+00																																																											1043					0.918							119.07													chr6	29911318																																																	True	True	False	Unknown		Unknown																						836,121	374,57	462,64	0|1	453,383,56,65	ACG					29911318	327,509,54,67	3.53		0.12643678160919541
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Thr206=	ENSP00000366005.5:p.Thr206=	chr6	29943542	29943542.0	G	T	T	29943542	.	G	T	.	PASS	NM_002116	T	splice_region_variant&synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.618G>T	640	618	206	T	acG/acT	rs41554520&COSV105311080&COSV65140152		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.3487	0.3016	0.3596	0.35	0.3463	0.1777	0.3251	0.361	0.3281	0.2987	0.2484	0.2709	0.1887	0.2794	0.2901	0.3192	0.1428	0.274	0.2316	0.2362	0.3421	0.361	gnomADe_NFE		0&1&1	0&1&1							FAIL	9	-36	-2	1	0.00	0.00	0.00	0.04	HLA-A		1.9760e+00																																																											1038					0.934							119.52	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T206= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:t206= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911319						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:t206= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T206= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:T206=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:T206="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:t206= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T206= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						789,180	350,85	439,95	0|1	386,403,100,80	CGG	0.00	0.00	1.00		29911306	317,472,61,119	4.71		0.18575851393188855
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.D207Y	ENSP00000366005.5:p.Asp207Tyr	chr6	29943543	29943543.0	G	T	T	29943543	.	G	T	.	PASS	NM_002116	T	missense_variant&splice_region_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	3/8		c.619G>T	641	619	207	D/Y	Gac/Tac	rs62687162&COSV65138570&COSV99060793&CS087969		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0)	probably_damaging(0.998)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1									0.004904	0.01711	0.004165	0.004773	0.0004194	0.007469	0.00906	0.004625	0.005813	0.003616	0.01228	0.02339	0.01887	0.007103	0.009557	0.001475	0.006065	0.009615	0.008724	0.01122	0.008699	0.02339	gnomADg_AFR		0&1&1&1	0&1&1&1	37588055						PASS	-37	0	-2	0	0.00	0.00	0.01	0.83	HLA-A	0.198	1.9760e+00																																																											1034					0.934							119.8	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D207Y mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:d207y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911320						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:d207y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D207Y mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:D207Y			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:D207Y"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:d207y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:D207Y mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						845,121	377,57	468,64	0|1	438,407,60,61	GGG	0.00	0.00	1.00		29911318	322,523,56,65	4.65		0.12525879917184266
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.H216Y	ENSP00000366005.5:p.His216Tyr	chr6	29944148	29944148.0	C	T	T	29944148	.	C	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	4/8		c.646C>T	668	646	216	H/Y	Cac/Tac	rs77235917&COSV65142495		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0)	benign(0.28)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PROSITE_profiles:PS50835&Superfamily:SSF48726&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.0507	0.0386	0.0749	0.0218	0.0785	0.0511	0.06105	0.037	0.05153	0.05827	0.007044	0.03709	0.06576	0.06673	0.05995	0.04129	0.0215	0.01385	0.0256	0.02489	0.03084	0.00734	0.01706	0.01471	0.02705	0.02199	0.01051	0.0785	EUR		0&1	0&1							FAIL	21	-26	-32	31	0.04	0.04	0.00	0.00	HLA-A	0.063	1.9760e+00																																																											772					0.734							40.7	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:H216Y mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:h216y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911925						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:h216y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:H216Y mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:H216Y			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:H216Y"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:h216y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:H216Y mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						324,243	159,128	165,115	0/1	152,172,122,121	CCA	0.00	0.00	0.00			209,115,151,92	13.72		0.42857142857142855
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Glu222=	ENSP00000366005.5:p.Glu222=	chr6	29944168	29944168.0	G	A	A	29944168	.	G	A	.	PASS	NM_002116	A	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	4/8		c.666G>A	688	666	222	E	gaG/gaA	rs12721753&COSV65137003		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Pfam:PF07654&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PROSITE_profiles:PS50835&Superfamily:SSF48726&PANTHER:PTHR16675&SMART:SM00407&AFDB-ENSP_mappings:AF-P04439-F1									0.0007702	0.0005086	0.001557	0.001244	0.001427	0.0006413	0.0005435	0.0006194	0.0009812	0.002016	0.001532	0.001053	0	0.001294	0.001667	0.002744	0.001468	0	0.001825	0.0007463	0.001239	0.002744	gnomADg_EAS		0&1	0&1							FAIL	2	1	11	1	0.12	0.08	0.00	0.00	HLA-A		1.9760e+00																																																											687					0.689							35.91	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E222= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:e222= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911945						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:e222= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E222= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:E222=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:E222="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:e222= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E222= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						436,37	220,19	216,18	0/1	227,209,19,18	AGG	0.00	0.00	1.00			221,215,31,6	6.02		0.07822410147991543
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.G231S	ENSP00000366005.5:p.Gly231Ser	chr6	29944193	29944193.0	G	A	A	29944193	.	G	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	4/8		c.691G>A	713	691	231	G/S	Ggc/Agc	rs9260180&COSV65137221		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.02)	benign(0.005)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Pfam:PF07654&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PROSITE_profiles:PS50835&Superfamily:SSF48726&PANTHER:PTHR16675&SMART:SM00407&AFDB-ENSP_mappings:AF-P04439-F1									0.03748	0.1154	0.137	0.09361	0.1723	0.02114	0.04976	0.02191	0.05592	0.09899	0.09135	0.187	0.01068	0.1333	0.1377	0.1217	0.01742	0.1605	0.04579	0.09924	0.1052	0.187	gnomADg_AFR		0&1	0&1							FAIL	-24	36	2	-14	0.01	0.00	0.00	0.00	HLA-A	0.140	1.9760e+00	1727033		0.05933		1781400		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29944193G>A	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				9260180					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					612					0.636							33.16	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G231S mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:g231s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29911970						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:g231s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G231S mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:G231S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:G231S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:g231s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:G231S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						270,119	147,55	123,64	0/1	136,134,68,51	GGG	0.00	0.00	0.00			69,201,22,97	5.36		0.3059125964010283
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.A270S	ENSP00000366005.5:p.Ala270Ser	chr6	29944310	29944310.0	G	T	T	29944310	.	G	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	4/8		c.808G>T	830	808	270	A/S	Gct/Tct	rs1059632&CM1618078&COSV65136926		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.02)	benign(0.011)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Pfam:PF07654&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PROSITE_profiles:PS50835&Superfamily:SSF48726&PANTHER:PTHR16675&SMART:SM00407&AFDB-ENSP_mappings:AF-P04439-F1									0.07156	0.1961	0.1722	0.1498	0.1948	0.04033	0.1128	0.05301	0.08575	0.1479	0.09471	0.1889	0.009677	0.1285	0.1483	0.1127	0.01966	0.1181	0.05253	0.1005	0.1185	0.1961	gnomADe_AFR		0&1&1	0&1&1							FAIL	-26	-34	-8	44	0.00	0.00	0.00	0.00	HLA-A	0.044	1.9760e+00	1727035		0.18615		1781402		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29944310G>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1059632					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					678					0.5							48.8	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A270S mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:a270s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912087						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:a270s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A270S mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:A270S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:A270S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:a270s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A270S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						182,157	72,76	110,81	0/1	75,107,76,81	GGC	0.00	0.00	0.00			135,47,129,28	30.69		0.4631268436578171
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.E277Q	ENSP00000366005.5:p.Glu277Gln	chr6	29944331	29944331.0	G	C	C	29944331	.	G	C	.	PASS	NM_002116	C	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	4/8		c.829G>C	851	829	277	E/Q	Gag/Cag	rs2231095&COSV65136521		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.04)	benign(0)	PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Pfam:PF07654&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PROSITE_profiles:PS50835&Superfamily:SSF48726&PANTHER:PTHR16675&SMART:SM00407&AFDB-ENSP_mappings:AF-P04439-F1			0.4487	0.5129	0.4856	0.4167	0.4344	0.3834	0.1582	0.2752	0.3413	0.2364	0.2703	0.1424	0.1708	0.1344	0.1627	0.2267	0.1491	0.266	0.03682	0.193	0.2046	0.1744	0.03855	0.2027	0.08847	0.1563	0.1644	0.5129	AFR		0&1	0&1							FAIL	3	-47	-29	36	0.00	0.00	0.00	0.01	HLA-A	0.128	1.9760e+00	1727036			0.44868	1781403		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29944331G>C	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				2231095					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					800					0.545							52.53	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E277Q mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:e277q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912108						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:e277q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E277Q mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:E277Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:E277Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:e277q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:E277Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						16,420	6,181	10,239	0/1	10,6,187,233	AGA	.	.	.			0,16,336,84	41.91		0.963302752293578
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Leu290=	ENSP00000366005.5:p.Leu290=	chr6	29944370	29944370.0	C	T	T	29944370	.	C	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	4/8		c.868C>T	890	868	290	L	Ctg/Ttg	rs1059686&COSV65136529		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:1akj.A&PDB-ENSP_mappings:1ao7.A&PDB-ENSP_mappings:1b0g.A&PDB-ENSP_mappings:1b0g.D&PDB-ENSP_mappings:1b0r.A&PDB-ENSP_mappings:1bd2.A&PDB-ENSP_mappings:1duy.A&PDB-ENSP_mappings:1duy.D&PDB-ENSP_mappings:1duz.A&PDB-ENSP_mappings:1duz.D&PDB-ENSP_mappings:1eey.A&PDB-ENSP_mappings:1eey.D&PDB-ENSP_mappings:1eez.A&PDB-ENSP_mappings:1eez.D&PDB-ENSP_mappings:1hhg.A&PDB-ENSP_mappings:1hhg.D&PDB-ENSP_mappings:1hhh.A&PDB-ENSP_mappings:1hhi.A&PDB-ENSP_mappings:1hhi.D&PDB-ENSP_mappings:1hhj.A&PDB-ENSP_mappings:1hhj.D&PDB-ENSP_mappings:1hhk.A&PDB-ENSP_mappings:1hhk.D&PDB-ENSP_mappings:1hla.A&PDB-ENSP_mappings:1hsb.A&PDB-ENSP_mappings:1i1f.A&PDB-ENSP_mappings:1i1f.D&PDB-ENSP_mappings:1i1y.A&PDB-ENSP_mappings:1i1y.D&PDB-ENSP_mappings:1i4f.A&PDB-ENSP_mappings:1i7r.A&PDB-ENSP_mappings:1i7r.D&PDB-ENSP_mappings:1i7t.A&PDB-ENSP_mappings:1i7t.D&PDB-ENSP_mappings:1i7u.A&PDB-ENSP_mappings:1i7u.D&PDB-ENSP_mappings:1im3.A&PDB-ENSP_mappings:1im3.E&PDB-ENSP_mappings:1im3.I&PDB-ENSP_mappings:1im3.M&PDB-ENSP_mappings:1jf1.A&PDB-ENSP_mappings:1jht.A&PDB-ENSP_mappings:1lp9.A&PDB-ENSP_mappings:1lp9.H&PDB-ENSP_mappings:1oga.A&PDB-ENSP_mappings:1p7q.A&PDB-ENSP_mappings:1q94.A&PDB-ENSP_mappings:1q94.D&PDB-ENSP_mappings:1qew.A&PDB-ENSP_mappings:1qr1.A&PDB-ENSP_mappings:1qr1.D&PDB-ENSP_mappings:1qrn.A&PDB-ENSP_mappings:1qse.A&PDB-ENSP_mappings:1qsf.A&PDB-ENSP_mappings:1qvo.A&PDB-ENSP_mappings:1qvo.D&PDB-ENSP_mappings:1s8d.A&PDB-ENSP_mappings:1s9w.A&PDB-ENSP_mappings:1s9x.A&PDB-ENSP_mappings:1s9y.A&PDB-ENSP_mappings:1t1w.A&PDB-ENSP_mappings:1t1x.A&PDB-ENSP_mappings:1t1y.A&PDB-ENSP_mappings:1t1z.A&PDB-ENSP_mappings:1t20.A&PDB-ENSP_mappings:1t21.A&PDB-ENSP_mappings:1t22.A&PDB-ENSP_mappings:1tvb.A&PDB-ENSP_mappings:1tvb.D&PDB-ENSP_mappings:1tvh.A&PDB-ENSP_mappings:1tvh.D&PDB-ENSP_mappings:1w72.A&PDB-ENSP_mappings:1w72.D&PDB-ENSP_mappings:1x7q.A&PDB-ENSP_mappings:2av1.A&PDB-ENSP_mappings:2av1.D&PDB-ENSP_mappings:2av7.A&PDB-ENSP_mappings:2av7.D&PDB-ENSP_mappings:2bck.A&PDB-ENSP_mappings:2bck.D&PDB-ENSP_mappings:2bnq.A&PDB-ENSP_mappings:2bnr.A&PDB-ENSP_mappings:2c7u.A&PDB-ENSP_mappings:2c7u.D&PDB-ENSP_mappings:2clr.A&PDB-ENSP_mappings:2clr.D&PDB-ENSP_mappings:2f53.A&PDB-ENSP_mappings:2f54.A&PDB-ENSP_mappings:2f54.F&PDB-ENSP_mappings:2git.A&PDB-ENSP_mappings:2git.D&PDB-ENSP_mappings:2gj6.A&PDB-ENSP_mappings:2gt9.A&PDB-ENSP_mappings:2gt9.D&PDB-ENSP_mappings:2gtw.A&PDB-ENSP_mappings:2gtw.D&PDB-ENSP_mappings:2gtz.A&PDB-ENSP_mappings:2gtz.D&PDB-ENSP_mappings:2guo.A&PDB-ENSP_mappings:2guo.D&PDB-ENSP_mappings:2hla.A&PDB-ENSP_mappings:2hn7.A&PDB-ENSP_mappings:2j8u.A&PDB-ENSP_mappings:2j8u.H&PDB-ENSP_mappings:2jcc.A&PDB-ENSP_mappings:2jcc.H&PDB-ENSP_mappings:2p5e.A&PDB-ENSP_mappings:2p5w.A&PDB-ENSP_mappings:2pye.A&PDB-ENSP_mappings:2uwe.A&PDB-ENSP_mappings:2uwe.H&PDB-ENSP_mappings:2v2w.A&PDB-ENSP_mappings:2v2w.D&PDB-ENSP_mappings:2v2x.A&PDB-ENSP_mappings:2v2x.D&PDB-ENSP_mappings:2vlj.A&PDB-ENSP_mappings:2vlk.A&PDB-ENSP_mappings:2vll.A&PDB-ENSP_mappings:2vll.D&PDB-ENSP_mappings:2vlr.A&PDB-ENSP_mappings:2vlr.F&PDB-ENSP_mappings:2x4n.A&PDB-ENSP_mappings:2x4n.D&PDB-ENSP_mappings:2x4o.A&PDB-ENSP_mappings:2x4o.D&PDB-ENSP_mappings:2x4p.A&PDB-ENSP_mappings:2x4p.D&PDB-ENSP_mappings:2x4q.A&PDB-ENSP_mappings:2x4q.D&PDB-ENSP_mappings:2x4r.A&PDB-ENSP_mappings:2x4r.D&PDB-ENSP_mappings:2x4s.A&PDB-ENSP_mappings:2x4s.D&PDB-ENSP_mappings:2x4t.A&PDB-ENSP_mappings:2x4t.D&PDB-ENSP_mappings:2x4u.A&PDB-ENSP_mappings:2x4u.D&PDB-ENSP_mappings:2x70.A&PDB-ENSP_mappings:2x70.D&PDB-ENSP_mappings:2xpg.A&PDB-ENSP_mappings:3bgm.A&PDB-ENSP_mappings:3bh8.A&PDB-ENSP_mappings:3bh9.A&PDB-ENSP_mappings:3bhb.A&PDB-ENSP_mappings:3bo8.A&PDB-ENSP_mappings:3d25.A&PDB-ENSP_mappings:3d39.A&PDB-ENSP_mappings:3d3v.A&PDB-ENSP_mappings:3fqn.A&PDB-ENSP_mappings:3fqr.A&PDB-ENSP_mappings:3fqt.A&PDB-ENSP_mappings:3fqu.A&PDB-ENSP_mappings:3fqw.A&PDB-ENSP_mappings:3fqx.A&PDB-ENSP_mappings:3ft2.A&PDB-ENSP_mappings:3ft3.A&PDB-ENSP_mappings:3ft4.A&PDB-ENSP_mappings:3giv.A&PDB-ENSP_mappings:3giv.D&PDB-ENSP_mappings:3gjf.A&PDB-ENSP_mappings:3gjf.D&PDB-ENSP_mappings:3gsn.H&PDB-ENSP_mappings:3gso.A&PDB-ENSP_mappings:3gsq.A&PDB-ENSP_mappings:3gsr.A&PDB-ENSP_mappings:3gsu.A&PDB-ENSP_mappings:3gsv.A&PDB-ENSP_mappings:3gsw.A&PDB-ENSP_mappings:3gsx.A&PDB-ENSP_mappings:3h7b.A&PDB-ENSP_mappings:3h7b.D&PDB-ENSP_mappings:3h9h.A&PDB-ENSP_mappings:3h9h.D&PDB-ENSP_mappings:3h9s.A&PDB-ENSP_mappings:3hae.A&PDB-ENSP_mappings:3hae.D&PDB-ENSP_mappings:3hae.J&PDB-ENSP_mappings:3hae.P&PDB-ENSP_mappings:3hla.A&PDB-ENSP_mappings:3hpj.A&PDB-ENSP_mappings:3hpj.D&PDB-ENSP_mappings:3i6g.A&PDB-ENSP_mappings:3i6g.D&PDB-ENSP_mappings:3i6k.A&PDB-ENSP_mappings:3i6k.E&PDB-ENSP_mappings:3i6l.D&PDB-ENSP_mappings:3ixa.A&PDB-ENSP_mappings:3ixa.D&PDB-ENSP_mappings:3kla.A&PDB-ENSP_mappings:3kla.D&PDB-ENSP_mappings:3mgo.A&PDB-ENSP_mappings:3mgo.D&PDB-ENSP_mappings:3mgo.G&PDB-ENSP_mappings:3mgo.J&PDB-ENSP_mappings:3mgt.A&PDB-ENSP_mappings:3mgt.D&PDB-ENSP_mappings:3mgt.G&PDB-ENSP_mappings:3mgt.J&PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mrb.A&PDB-ENSP_mappings:3mrc.A&PDB-ENSP_mappings:3mrd.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:3myj.A&PDB-ENSP_mappings:3myj.D&PDB-ENSP_mappings:3nfn.A&PDB-ENSP_mappings:3o3a.A&PDB-ENSP_mappings:3o3a.D&PDB-ENSP_mappings:3o3b.A&PDB-ENSP_mappings:3o3b.D&PDB-ENSP_mappings:3o3d.A&PDB-ENSP_mappings:3o3d.D&PDB-ENSP_mappings:3o3e.A&PDB-ENSP_mappings:3o3e.D&PDB-ENSP_mappings:3pwj.A&PDB-ENSP_mappings:3pwj.D&PDB-ENSP_mappings:3pwl.A&PDB-ENSP_mappings:3pwl.D&PDB-ENSP_mappings:3pwn.A&PDB-ENSP_mappings:3pwn.D&PDB-ENSP_mappings:3pwp.A&PDB-ENSP_mappings:3qdg.A&PDB-ENSP_mappings:3qdj.A&PDB-ENSP_mappings:3qdm.A&PDB-ENSP_mappings:3qeq.A&PDB-ENSP_mappings:3qfd.A&PDB-ENSP_mappings:3qfd.D&PDB-ENSP_mappings:3qfj.A&PDB-ENSP_mappings:3qzw.A&PDB-ENSP_mappings:3qzw.D&PDB-ENSP_mappings:3rew.A&PDB-ENSP_mappings:3rew.D&PDB-ENSP_mappings:3rl1.A&PDB-ENSP_mappings:3rl2.A&PDB-ENSP_mappings:3utq.A&PDB-ENSP_mappings:3uts.A&PDB-ENSP_mappings:3uts.F&PDB-ENSP_mappings:3utt.A&PDB-ENSP_mappings:3utt.F&PDB-ENSP_mappings:3v5d.A&PDB-ENSP_mappings:3v5d.D&PDB-ENSP_mappings:3v5h.A&PDB-ENSP_mappings:3v5h.D&PDB-ENSP_mappings:3v5k.A&PDB-ENSP_mappings:3v5k.D&PDB-ENSP_mappings:3vxm.A&PDB-ENSP_mappings:3vxn.A&PDB-ENSP_mappings:3vxo.A&PDB-ENSP_mappings:3vxo.D&PDB-ENSP_mappings:3vxp.A&PDB-ENSP_mappings:3vxp.D&PDB-ENSP_mappings:3vxr.A&PDB-ENSP_mappings:3vxs.A&PDB-ENSP_mappings:3vxu.A&PDB-ENSP_mappings:3vxu.F&PDB-ENSP_mappings:3w0w.A&PDB-ENSP_mappings:3wl9.A&PDB-ENSP_mappings:3wlb.A&PDB-ENSP_mappings:4e5x.A&PDB-ENSP_mappings:4e5x.D&PDB-ENSP_mappings:4eup.A&PDB-ENSP_mappings:4eup.D&PDB-ENSP_mappings:4f7m.A&PDB-ENSP_mappings:4f7m.D&PDB-ENSP_mappings:4f7p.A&PDB-ENSP_mappings:4f7t.A&PDB-ENSP_mappings:4f7t.D&PDB-ENSP_mappings:4ftv.A&PDB-ENSP_mappings:4gkn.A&PDB-ENSP_mappings:4gkn.D&PDB-ENSP_mappings:4gks.A&PDB-ENSP_mappings:4gks.D&PDB-ENSP_mappings:4hwz.A&PDB-ENSP_mappings:4hx1.A&PDB-ENSP_mappings:4i48.A&PDB-ENSP_mappings:4i4w.A&PDB-ENSP_mappings:4jfd.A&PDB-ENSP_mappings:4jfe.A&PDB-ENSP_mappings:4jff.A&PDB-ENSP_mappings:4jfo.A&PDB-ENSP_mappings:4jfo.D&PDB-ENSP_mappings:4jfp.A&PDB-ENSP_mappings:4jfp.D&PDB-ENSP_mappings:4jfq.A&PDB-ENSP_mappings:4jfq.D&PDB-ENSP_mappings:4k7f.A&PDB-ENSP_mappings:4k7f.D&PDB-ENSP_mappings:4l29.A&PDB-ENSP_mappings:4l29.C&PDB-ENSP_mappings:4l29.E&PDB-ENSP_mappings:4l29.G&PDB-ENSP_mappings:4l29.I&PDB-ENSP_mappings:4l29.K&PDB-ENSP_mappings:4l29.M&PDB-ENSP_mappings:4l29.O&PDB-ENSP_mappings:4l29.Q&PDB-ENSP_mappings:4l29.S&PDB-ENSP_mappings:4l29.U&PDB-ENSP_mappings:4l29.W&PDB-ENSP_mappings:4l29.Y&PDB-ENSP_mappings:4l29.a&PDB-ENSP_mappings:4l3c.A&PDB-ENSP_mappings:4l3c.C&PDB-ENSP_mappings:4l3c.E&PDB-ENSP_mappings:4l3c.G&PDB-ENSP_mappings:4l3c.I&PDB-ENSP_mappings:4l3c.K&PDB-ENSP_mappings:4l3c.M&PDB-ENSP_mappings:4l3c.O&PDB-ENSP_mappings:4l3c.Q&PDB-ENSP_mappings:4l3c.S&PDB-ENSP_mappings:4l3c.U&PDB-ENSP_mappings:4l3c.W&PDB-ENSP_mappings:4l3c.Y&PDB-ENSP_mappings:4l3c.a&PDB-ENSP_mappings:4l3e.A&PDB-ENSP_mappings:4mj5.A&PDB-ENSP_mappings:4mj6.A&PDB-ENSP_mappings:4mnq.A&PDB-ENSP_mappings:4n8v.A&PDB-ENSP_mappings:4n8v.D&PDB-ENSP_mappings:4nnx.A&PDB-ENSP_mappings:4nny.A&PDB-ENSP_mappings:4no0.A&PDB-ENSP_mappings:4no2.A&PDB-ENSP_mappings:4no3.A&PDB-ENSP_mappings:4no5.A&PDB-ENSP_mappings:4nqv.A&PDB-ENSP_mappings:4nqv.C&PDB-ENSP_mappings:4nqv.E&PDB-ENSP_mappings:4nqv.G&PDB-ENSP_mappings:4nqv.I&PDB-ENSP_mappings:4nqv.K&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4qok.A&PDB-ENSP_mappings:4u6x.A&PDB-ENSP_mappings:4u6y.A&PDB-ENSP_mappings:4uq2.A&PDB-ENSP_mappings:4uq2.C&PDB-ENSP_mappings:4uq3.A&PDB-ENSP_mappings:4uq3.C&PDB-ENSP_mappings:4wj5.A&PDB-ENSP_mappings:4wj5.D&PDB-ENSP_mappings:4wu5.A&PDB-ENSP_mappings:4wu5.D&PDB-ENSP_mappings:4wu7.A&PDB-ENSP_mappings:4wu7.D&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:5brz.A&PDB-ENSP_mappings:5bs0.A&PDB-ENSP_mappings:5c07.A&PDB-ENSP_mappings:5c07.F&PDB-ENSP_mappings:5c08.A&PDB-ENSP_mappings:5c08.F&PDB-ENSP_mappings:5c09.A&PDB-ENSP_mappings:5c09.F&PDB-ENSP_mappings:5c0a.A&PDB-ENSP_mappings:5c0a.F&PDB-ENSP_mappings:5c0b.A&PDB-ENSP_mappings:5c0b.F&PDB-ENSP_mappings:5c0c.A&PDB-ENSP_mappings:5c0c.F&PDB-ENSP_mappings:5c0d.A&PDB-ENSP_mappings:5c0e.A&PDB-ENSP_mappings:5c0f.A&PDB-ENSP_mappings:5c0g.A&PDB-ENSP_mappings:5c0i.A&PDB-ENSP_mappings:5c0j.A&PDB-ENSP_mappings:5d2l.A&PDB-ENSP_mappings:5d2l.C&PDB-ENSP_mappings:5d2l.G&PDB-ENSP_mappings:5d2l.M&PDB-ENSP_mappings:5d2n.A&PDB-ENSP_mappings:5d2n.H&PDB-ENSP_mappings:5d9s.A&PDB-ENSP_mappings:5ddh.A&PDB-ENSP_mappings:5e00.A&PDB-ENSP_mappings:5e6i.C&PDB-ENSP_mappings:5e6i.I&PDB-ENSP_mappings:5e6i.M&PDB-ENSP_mappings:5e6i.R&PDB-ENSP_mappings:5e9d.A&PDB-ENSP_mappings:5e9d.F&PDB-ENSP_mappings:5enw.A&PDB-ENSP_mappings:5eot.A&PDB-ENSP_mappings:5eu3.A&PDB-ENSP_mappings:5eu4.A&PDB-ENSP_mappings:5eu4.D&PDB-ENSP_mappings:5eu5.A&PDB-ENSP_mappings:5eu6.A&PDB-ENSP_mappings:5euo.A&PDB-ENSP_mappings:5euo.C&PDB-ENSP_mappings:5f7d.A&PDB-ENSP_mappings:5f9j.A&PDB-ENSP_mappings:5fa3.A&PDB-ENSP_mappings:5fa4.A&PDB-ENSP_mappings:5fdw.A&PDB-ENSP_mappings:5grd.A&PDB-ENSP_mappings:5grg.A&PDB-ENSP_mappings:5gsd.A&PDB-ENSP_mappings:5hga.A&PDB-ENSP_mappings:5hga.D&PDB-ENSP_mappings:5hgb.A&PDB-ENSP_mappings:5hgb.D&PDB-ENSP_mappings:5hgb.G&PDB-ENSP_mappings:5hgb.J&PDB-ENSP_mappings:5hgd.A&PDB-ENSP_mappings:5hgd.D&PDB-ENSP_mappings:5hgh.A&PDB-ENSP_mappings:5hhm.A&PDB-ENSP_mappings:5hhm.F&PDB-ENSP_mappings:5hhn.A&PDB-ENSP_mappings:5hho.A&PDB-ENSP_mappings:5hhp.A&PDB-ENSP_mappings:5hhq.A&PDB-ENSP_mappings:5hyj.A&PDB-ENSP_mappings:5hyj.F&PDB-ENSP_mappings:5iro.A&PDB-ENSP_mappings:5iro.E&PDB-ENSP_mappings:5iro.I&PDB-ENSP_mappings:5iro.M&PDB-ENSP_mappings:5iro.Q&PDB-ENSP_mappings:5iro.U&PDB-ENSP_mappings:5isz.A&PDB-ENSP_mappings:5jhd.A&PDB-ENSP_mappings:5jhd.F&PDB-ENSP_mappings:5jzi.A&PDB-ENSP_mappings:5jzi.F&PDB-ENSP_mappings:5men.A&PDB-ENSP_mappings:5meo.A&PDB-ENSP_mappings:5mep.A&PDB-ENSP_mappings:5mep.D&PDB-ENSP_mappings:5meq.A&PDB-ENSP_mappings:5mer.A&PDB-ENSP_mappings:5mer.D&PDB-ENSP_mappings:5n1y.A&PDB-ENSP_mappings:5n6b.A&PDB-ENSP_mappings:5n6b.D&PDB-ENSP_mappings:5nht.H&PDB-ENSP_mappings:5nme.A&PDB-ENSP_mappings:5nme.F&PDB-ENSP_mappings:5nmf.A&PDB-ENSP_mappings:5nmf.F&PDB-ENSP_mappings:5nmg.A&PDB-ENSP_mappings:5nmg.F&PDB-ENSP_mappings:5nmh.A&PDB-ENSP_mappings:5nmk.A&PDB-ENSP_mappings:5nqk.H&PDB-ENSP_mappings:5swq.A&PDB-ENSP_mappings:5tez.A&PDB-ENSP_mappings:5wjl.A&PDB-ENSP_mappings:5wjl.D&PDB-ENSP_mappings:5wjl.G&PDB-ENSP_mappings:5wjn.A&PDB-ENSP_mappings:5wjn.D&PDB-ENSP_mappings:5wjn.G&PDB-ENSP_mappings:5wkf.A&PDB-ENSP_mappings:5wkf.F&PDB-ENSP_mappings:5wkh.A&PDB-ENSP_mappings:5wkh.F&PDB-ENSP_mappings:5wsh.A&PDB-ENSP_mappings:5wwi.A&PDB-ENSP_mappings:5wwj.A&PDB-ENSP_mappings:5wwj.C&PDB-ENSP_mappings:5wwu.A&PDB-ENSP_mappings:5wxc.A&PDB-ENSP_mappings:5wxc.C&PDB-ENSP_mappings:5wxd.A&PDB-ENSP_mappings:5xov.A&PDB-ENSP_mappings:5xov.D&PDB-ENSP_mappings:5yxn.C&PDB-ENSP_mappings:5yxu.C&PDB-ENSP_mappings:5yxu.E&PDB-ENSP_mappings:6am5.A&PDB-ENSP_mappings:6amt.A&PDB-ENSP_mappings:6amt.D&PDB-ENSP_mappings:6amu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6d78.A&PDB-ENSP_mappings:6d7g.A&PDB-ENSP_mappings:6dkp.A&PDB-ENSP_mappings:6e1i.A&PDB-ENSP_mappings:6ei2.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6eqa.A&PDB-ENSP_mappings:6eqb.A&PDB-ENSP_mappings:6ewa.A&PDB-ENSP_mappings:6ewa.E&PDB-ENSP_mappings:6ewc.A&PDB-ENSP_mappings:6ewc.E&PDB-ENSP_mappings:6ewo.A&PDB-ENSP_mappings:6ewo.E&PDB-ENSP_mappings:6g3j.A&PDB-ENSP_mappings:6g3j.D&PDB-ENSP_mappings:6g3k.A&PDB-ENSP_mappings:6g3k.D&PDB-ENSP_mappings:6j1w.A&PDB-ENSP_mappings:6j29.A&PDB-ENSP_mappings:6j2a.A&PDB-ENSP_mappings:6joz.A&PDB-ENSP_mappings:6jp3.A&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6nca.A&PDB-ENSP_mappings:6nca.B&PDB-ENSP_mappings:6nca.C&PDB-ENSP_mappings:6nca.D&PDB-ENSP_mappings:6nca.E&PDB-ENSP_mappings:6nca.F&PDB-ENSP_mappings:6nca.G&PDB-ENSP_mappings:6nca.H&PDB-ENSP_mappings:6nca.I&PDB-ENSP_mappings:6nca.J&PDB-ENSP_mappings:6nca.K&PDB-ENSP_mappings:6nca.L&PDB-ENSP_mappings:6nca.M&PDB-ENSP_mappings:6nca.N&PDB-ENSP_mappings:6nca.O&PDB-ENSP_mappings:6nca.P&PDB-ENSP_mappings:6nca.Q&PDB-ENSP_mappings:6nca.R&PDB-ENSP_mappings:6nca.S&PDB-ENSP_mappings:6nca.T&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6opd.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:6ptb.A&PDB-ENSP_mappings:6ptb.D&PDB-ENSP_mappings:6pte.A&PDB-ENSP_mappings:6pte.E&PDB-ENSP_mappings:6pte.H&PDB-ENSP_mappings:6pte.K&PDB-ENSP_mappings:6q3k.A&PDB-ENSP_mappings:6q3s.A&PDB-ENSP_mappings:6r2l.A&PDB-ENSP_mappings:6rp9.A&PDB-ENSP_mappings:6rp9.F&PDB-ENSP_mappings:6rpa.A&PDB-ENSP_mappings:6rpb.A&PDB-ENSP_mappings:6rpb.F&PDB-ENSP_mappings:6rpb.K&PDB-ENSP_mappings:6rpb.P&PDB-ENSP_mappings:6rsy.A&PDB-ENSP_mappings:6rsy.F&PDB-ENSP_mappings:6ss7.A&PDB-ENSP_mappings:6ss7.D&PDB-ENSP_mappings:6ss8.A&PDB-ENSP_mappings:6ss8.D&PDB-ENSP_mappings:6ss9.A&PDB-ENSP_mappings:6ss9.D&PDB-ENSP_mappings:6ssa.A&PDB-ENSP_mappings:6ssa.D&PDB-ENSP_mappings:6ssa.G&PDB-ENSP_mappings:6ssa.J&PDB-ENSP_mappings:7l1b.A&PDB-ENSP_mappings:7l1c.A&PDB-ENSP_mappings:7l1d.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7rk7.A&PDB-ENSP_mappings:7rm4.A&PDB-ENSP_mappings:7rm4.F&PDB-ENSP_mappings:7rm4.K&PDB-ENSP_mappings:7rm4.P&PDB-ENSP_mappings:7rrg.A&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Pfam:PF07654&Phobius:NON_CYTOPLASMIC_DOMAIN&CDD:cd21026&PROSITE_profiles:PS50835&Superfamily:SSF48726&PANTHER:PTHR16675&SMART:SM00407&AFDB-ENSP_mappings:AF-P04439-F1									0.1123	0.0856	0.2114	0.09783	0.04992	0.1016	0.05481	0.1165	0.09017	0.08262	0.002782	0.002476	0.001754	0.002479	0.003613	0.003654	0.00295	0	0.002965	0.00312	0.002092	0.2114	gnomADe_AMR		0&1	0&1							FAIL	-3	-30	-3	27	0.00	0.00	0.03	0.02	HLA-A		1.9760e+00																																																											1035					0.707							61.88	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L290= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:l290= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912147						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:l290= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L290= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:L290=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:L290="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:l290= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L290= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						362,370	172,157	190,213	0/1	188,174,164,206	TCT	0.00	0.00	0.00			238,124,263,107	43.55		0.505464480874317
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.L300P	ENSP00000366005.5:p.Leu300Pro	chr6	29944503	29944503.0	T	C	C	29944503	.	T	C	.	PASS	NM_002116	C	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	5/8		c.899T>C	921	899	300	L/P	cTg/cCg	rs1136903&COSV104688033&COSV65136543		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(1)	benign(0)	PDB-ENSP_mappings:3mr9.A&PDB-ENSP_mappings:3mre.A&PDB-ENSP_mappings:3mrf.A&PDB-ENSP_mappings:3mrg.A&PDB-ENSP_mappings:3mrh.A&PDB-ENSP_mappings:3mri.A&PDB-ENSP_mappings:3mrj.A&PDB-ENSP_mappings:3mrk.A&PDB-ENSP_mappings:3mrl.A&PDB-ENSP_mappings:3mrm.A&PDB-ENSP_mappings:3mrn.A&PDB-ENSP_mappings:3mro.A&PDB-ENSP_mappings:3mrp.A&PDB-ENSP_mappings:3mrq.A&PDB-ENSP_mappings:3mrr.A&PDB-ENSP_mappings:4nqx.A&PDB-ENSP_mappings:4nqx.C&PDB-ENSP_mappings:4nqx.E&PDB-ENSP_mappings:4nqx.G&PDB-ENSP_mappings:4nqx.I&PDB-ENSP_mappings:4nqx.K&PDB-ENSP_mappings:4wuu.A&PDB-ENSP_mappings:6apn.A&PDB-ENSP_mappings:6apn.B&PDB-ENSP_mappings:6at9.A&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:6mpp.A&PDB-ENSP_mappings:6o9b.A&PDB-ENSP_mappings:6o9c.A&PDB-ENSP_mappings:6pbh.A&PDB-ENSP_mappings:7mle.A&PDB-ENSP_mappings:7phr.H&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7stf.A&PDB-ENSP_mappings:7uc5.A&PDB-ENSP_mappings:7uc5.D&PDB-ENSP_mappings:8dvg.A&Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR16675&AFDB-ENSP_mappings:AF-P04439-F1			0.6863	0.7307	0.7738	0.6885	0.6342	0.6155	0.1611	0.39	0.5588	0.2861	0.5904	0.1433	0.2953	0.1016	0.2016	0.3426	0.2633	0.4232	0.09259	0.3859	0.316	0.3797	0.07761	0.3654	0.1595	0.302	0.3117	0.7738	AMR		0&1&1	0&1&1	32964195&32256020&37979960						FAIL	-3	11	25	-37	0.03	0.01	0.00	0.00	HLA-A	0.051	1.9760e+00	1727037	0.63637		0.68630	1781404		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29944503T>C	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1136903					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					718					0.989							115.03	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L300P mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:l300p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912280						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:l300p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L300P mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:L300P			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:L300P"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:l300p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L300P mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,710	0,346	0,364	0/1	0,0,351,359	CTG	.	.	.			0,0,425,285	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.L318F	ENSP00000366005.5:p.Leu318Phe	chr6	29944556	29944556.0	C	T	T	29944556	.	C	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	5/8		c.952C>T	974	952	318	L/F	Ctt/Ttt	rs3179982&COSV65136547&COSV65137006		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(0.05)	benign(0)	PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:7qpd.M&Low_complexity_(Seg):seg&Phobius:TRANSMEMBRANE&PANTHER:PTHR16675&Transmembrane_helices:TMhelix&AFDB-ENSP_mappings:AF-P04439-F1			0.5353	0.6044	0.6023	0.4881	0.5229	0.456	0.06101	0.1856	0.2477	0.1472	0.3193	0.0406	0.1187	0.03323	0.08936	0.1516	0.127	0.2497	0.008097	0.1818	0.1665	0.1733	0.02062	0.1736	0.06631	0.1608	0.1506	0.6044	AFR		0&1&1	0&1&1							FAIL	7	-42	-7	35	0.00	0.00	0.00	0.00	HLA-A	0.008	1.9760e+00	1727039	0.48601	0.52522	0.53534	1781406		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29944556C>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				3179982					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					918					0.971							100.21	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L318F mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:l318f mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912333						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:l318f mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L318F mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:L318F			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:L318F"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:l318f mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:L318F mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,891	0,428	0,463	0/1	0,0,457,434	CCT	0.00	0.00	0.00			0,0,416,475	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Ala329=	ENSP00000366005.5:p.Ala329=	chr6	29944591	29944591.0	C	T	T	29944591	.	C	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	5/8		c.987C>T	1009	987	329	A	gcC/gcT	rs1141891&COSV65136553		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:7qpd.M&Low_complexity_(Seg):seg&Phobius:TRANSMEMBRANE&PANTHER:PTHR16675&Transmembrane_helices:TMhelix&AFDB-ENSP_mappings:AF-P04439-F1			0.6831	0.7216	0.7723	0.6885	0.6322	0.6145	0.1201	0.3017	0.4782	0.2335	0.5358	0.1105	0.2241	0.07068	0.1539	0.2977	0.1594	0.2731	0.05556	0.2246	0.2088	0.2551	0.04824	0.3306	0.102	0.1976	0.1986	0.7723	AMR		0&1	0&1							FAIL	25	-28	0	25	0.00	0.00	0.00	0.05	HLA-A		1.9760e+00	1727044	0.61243	0.64969	0.68311	1781411		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29944591C>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001819&synonymous_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1141891					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					844					0.94							103.55	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A329= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:a329= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912368						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:a329= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A329= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:A329=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:A329="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:a329= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:A329= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,793	0,375	0,418	0/1	0,0,421,372	CCG	0.00	0.00	0.00			0,0,299,494	64.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9			chr6	29944618	29944620.0	T	TGG	TGG	29944618	.	T	TGG	.	PASS	NM_002116	GG	splice_region_variant&intron_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding		5/7	c.1012+3_1012+4dup						rs376806238		1		insertion	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1					2	0.0557	0.0825	0.0677	0.0179	0.0656	0.0399	0.001084	0.002237	0.002863	0.001479	0.004509	0.0002252	0.001344	0.0006393	0.001123	0.004355	0.001031	0.001255	0	0.001649	0.0005807	0.002481	0.0003392	0	0.0008684	0.001992	0.0008278	0.0825	AFR																					1.9760e+00																																																											651					0.853							104.15													chr6	29912395																																																	True	True	False	Unknown		Unknown																						335,220	155,96	180,124	0/1	169,166,122,98	GTG						113,222,36,184	3.12		0.3963963963963964
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Ser343=	ENSP00000366005.5:p.Ser343=	chr6	29945075	29945075.0	T	C	C	29945075	.	T	C	.	PASS	NM_002116	C	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	6/8		c.1029T>C	1051	1029	343	S	agT/agC	rs1137296&COSV65136571		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:4emz.D&PDB-ENSP_mappings:4emz.E&PDB-ENSP_mappings:4en2.D&PDB-ENSP_mappings:4en2.E&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7ux3.Y&PDB-ENSP_mappings:8d4c.P&PDB-ENSP_mappings:8d4c.Y&PDB-ENSP_mappings:8d4d.P&PDB-ENSP_mappings:8d4d.Y&PDB-ENSP_mappings:8d4e.Y&PDB-ENSP_mappings:8d4f.P&PDB-ENSP_mappings:8d4f.Y&PDB-ENSP_mappings:8d4g.P&PDB-ENSP_mappings:8d4g.Y&PDB-ENSP_mappings:8d9r.0&PDB-ENSP_mappings:8d9r.1&PDB-ENSP_mappings:8d9r.2&PDB-ENSP_mappings:8d9r.Y&PDB-ENSP_mappings:8d9r.y&PDB-ENSP_mappings:8d9r.z&PDB-ENSP_mappings:8d9s.0&PDB-ENSP_mappings:8d9s.1&PDB-ENSP_mappings:8d9s.2&PDB-ENSP_mappings:8d9s.Y&PDB-ENSP_mappings:8d9s.y&PDB-ENSP_mappings:8d9s.z&PDB-ENSP_mappings:8d9t.0&PDB-ENSP_mappings:8d9t.1&PDB-ENSP_mappings:8d9t.Y&PDB-ENSP_mappings:8d9t.x&PDB-ENSP_mappings:8d9t.y&PDB-ENSP_mappings:8d9t.z&PDB-ENSP_mappings:8d9u.0&PDB-ENSP_mappings:8d9u.1&PDB-ENSP_mappings:8d9u.Y&PDB-ENSP_mappings:8d9u.x&PDB-ENSP_mappings:8d9u.y&PDB-ENSP_mappings:8d9u.z&PDB-ENSP_mappings:8d9v.P&PDB-ENSP_mappings:8d9v.Y&PDB-ENSP_mappings:8d9w.Y&PDB-ENSP_mappings:8d9w.j&Pfam:PF06623&Phobius:CYTOPLASMIC_DOMAIN&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P04439-F1			0.6865	0.73	0.7752	0.6885	0.6342	0.6166	0.1482	0.2859	0.5753	0.2906	0.5697	0.08725	0.209	0.08979	0.1766	0.3871	0.1158	0.2022	0.05655	0.1368	0.1751	0.2114	0.01738	0.1915	0.07931	0.135	0.1575	0.7752	AMR		0&1	0&1							FAIL	-12	16	16	-16	0.06	0.00	0.07	0.00	HLA-A		1.9760e+00	1727046		0.65635	0.68650	1781413		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29945075T>C	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001819&synonymous_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1137296					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					372					0.68							50.1	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S343= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:s343= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912852						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:s343= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S343= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:S343=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:S343="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:s343= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S343= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						1,252	0,115	1,137	0|1	1,0,114,138	GTT	.	.	.		29912852	0,1,149,103	57.71		0.9960474308300395
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.T345S	ENSP00000366005.5:p.Thr345Ser	chr6	29945079	29945079.0	A	T	T	29945079	.	A	T	.	PASS	NM_002116	T	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	6/8		c.1033A>T	1055	1033	345	T/S	Act/Tct	rs2231119&COSV65136576		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	tolerated_low_confidence(1)	benign(0)	PDB-ENSP_mappings:4emz.D&PDB-ENSP_mappings:4emz.E&PDB-ENSP_mappings:4en2.D&PDB-ENSP_mappings:4en2.E&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7ux3.Y&PDB-ENSP_mappings:8d4c.P&PDB-ENSP_mappings:8d4c.Y&PDB-ENSP_mappings:8d4d.P&PDB-ENSP_mappings:8d4d.Y&PDB-ENSP_mappings:8d4e.Y&PDB-ENSP_mappings:8d4f.P&PDB-ENSP_mappings:8d4f.Y&PDB-ENSP_mappings:8d4g.P&PDB-ENSP_mappings:8d4g.Y&PDB-ENSP_mappings:8d9r.0&PDB-ENSP_mappings:8d9r.1&PDB-ENSP_mappings:8d9r.2&PDB-ENSP_mappings:8d9r.Y&PDB-ENSP_mappings:8d9r.y&PDB-ENSP_mappings:8d9r.z&PDB-ENSP_mappings:8d9s.0&PDB-ENSP_mappings:8d9s.1&PDB-ENSP_mappings:8d9s.2&PDB-ENSP_mappings:8d9s.Y&PDB-ENSP_mappings:8d9s.y&PDB-ENSP_mappings:8d9s.z&PDB-ENSP_mappings:8d9t.0&PDB-ENSP_mappings:8d9t.1&PDB-ENSP_mappings:8d9t.Y&PDB-ENSP_mappings:8d9t.x&PDB-ENSP_mappings:8d9t.y&PDB-ENSP_mappings:8d9t.z&PDB-ENSP_mappings:8d9u.0&PDB-ENSP_mappings:8d9u.1&PDB-ENSP_mappings:8d9u.Y&PDB-ENSP_mappings:8d9u.x&PDB-ENSP_mappings:8d9u.y&PDB-ENSP_mappings:8d9u.z&PDB-ENSP_mappings:8d9v.P&PDB-ENSP_mappings:8d9v.Y&PDB-ENSP_mappings:8d9w.Y&PDB-ENSP_mappings:8d9w.j&Pfam:PF06623&Phobius:CYTOPLASMIC_DOMAIN&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P04439-F1			0.6865	0.73	0.7752	0.6885	0.6342	0.6166	0.146	0.2848	0.5734	0.2878	0.5656	0.08686	0.2075	0.08883	0.1764	0.3818	0.1109	0.1929	0.05556	0.1291	0.1707	0.2011	0.01642	0.1628	0.07734	0.1317	0.1468	0.7752	AMR		0&1	0&1	28955865&32256020&34506591						FAIL	6	-16	40	12	0.00	0.01	0.00	0.02	HLA-A	0.092	1.9760e+00	1727047		0.65631	0.68650	1781414		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29945079A>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				2231119					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					378					0.677							50.59	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T345S mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:t345s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29912856						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:t345s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T345S mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:T345S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:T345S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:t345s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:T345S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,256	0,117	0,139	0|1	0,0,128,128	CAC	.	.	.		29912852	0,0,147,109	57.73		1.0
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.V358M	ENSP00000366005.5:p.Val358Met	chr6	29945260	29945260.0	G	A	A	29945260	.	G	A	.	PASS	NM_002116	A	missense_variant	MODERATE	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	7/8		c.1072G>A	1094	1072	358	V/M	Gtg/Atg	rs1137631&COSV65139698		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1	deleterious_low_confidence(0.01)	benign(0.118)	PDB-ENSP_mappings:4emz.D&PDB-ENSP_mappings:4emz.E&PDB-ENSP_mappings:4en2.D&PDB-ENSP_mappings:4en2.E&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7ux3.Y&PDB-ENSP_mappings:8d4c.P&PDB-ENSP_mappings:8d4c.Y&PDB-ENSP_mappings:8d4d.P&PDB-ENSP_mappings:8d4d.Y&PDB-ENSP_mappings:8d4e.Y&PDB-ENSP_mappings:8d4f.P&PDB-ENSP_mappings:8d4f.Y&PDB-ENSP_mappings:8d4g.P&PDB-ENSP_mappings:8d4g.Y&PDB-ENSP_mappings:8d9r.0&PDB-ENSP_mappings:8d9r.1&PDB-ENSP_mappings:8d9r.2&PDB-ENSP_mappings:8d9r.Y&PDB-ENSP_mappings:8d9r.y&PDB-ENSP_mappings:8d9r.z&PDB-ENSP_mappings:8d9s.0&PDB-ENSP_mappings:8d9s.1&PDB-ENSP_mappings:8d9s.2&PDB-ENSP_mappings:8d9s.Y&PDB-ENSP_mappings:8d9s.y&PDB-ENSP_mappings:8d9s.z&PDB-ENSP_mappings:8d9t.0&PDB-ENSP_mappings:8d9t.1&PDB-ENSP_mappings:8d9t.Y&PDB-ENSP_mappings:8d9t.x&PDB-ENSP_mappings:8d9t.y&PDB-ENSP_mappings:8d9t.z&PDB-ENSP_mappings:8d9u.0&PDB-ENSP_mappings:8d9u.1&PDB-ENSP_mappings:8d9u.Y&PDB-ENSP_mappings:8d9u.x&PDB-ENSP_mappings:8d9u.y&PDB-ENSP_mappings:8d9u.z&PDB-ENSP_mappings:8d9v.P&PDB-ENSP_mappings:8d9v.Y&PDB-ENSP_mappings:8d9w.Y&PDB-ENSP_mappings:8d9w.j&Low_complexity_(Seg):seg&Pfam:PF06623&Phobius:CYTOPLASMIC_DOMAIN&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P04439-F1									0.01121	0.0215	0.01852	0.02755	0.02006	0.005304	0.01193	0.009045	0.01461	0.01913	0.01356	0.0167	0.00813	0.01577	0.03203	0.02108	0.002171	0.02976	0.01126	0.01335	0.02069	0.03203	gnomADg_ASJ		0&1	0&1							FAIL	13	-22	-3	21	0.00	0.08	0.00	0.05	HLA-A	0.099	1.9760e+00	1727048	0.16669	0.15692		1781415		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29945260G>A	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001583&missense_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				1137631					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					621					0.997							129.57	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:V358M mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:v358m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29913037						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:v358m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:V358M mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:V358M			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:V358M"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:v358m mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:V358M mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						319,300	149,174	170,126	0/1	144,175,130,170	TGT	0.00	0.00	0.00			164,155,136,164	39.42		0.48465266558966075
GRCh38	HLA-A	D12_12345_1234556_Thyroid_S9	p.Ser359=	ENSP00000366005.5:p.Ser359=	chr6	29945265	29945265.0	C	T	T	29945265	.	C	T	.	PASS	NM_002116	T	synonymous_variant	LOW	HLA-A	ENSG00000206503	Transcript	ENST00000376809	protein_coding	7/8		c.1077C>T	1099	1077	359	S	tcC/tcT	rs14288		1		SNV	HGNC	HGNC:4931	YES	MANE_Select	NM_002116.8			P2	CCDS34373.1	ENSP00000366005	P04439.218	B1PKY1.140	UPI000008AB1D	P04439-1		1			PDB-ENSP_mappings:4emz.D&PDB-ENSP_mappings:4emz.E&PDB-ENSP_mappings:4en2.D&PDB-ENSP_mappings:4en2.E&PDB-ENSP_mappings:6eny.F&PDB-ENSP_mappings:7qpd.M&PDB-ENSP_mappings:7ux3.Y&PDB-ENSP_mappings:8d4c.P&PDB-ENSP_mappings:8d4c.Y&PDB-ENSP_mappings:8d4d.P&PDB-ENSP_mappings:8d4d.Y&PDB-ENSP_mappings:8d4e.Y&PDB-ENSP_mappings:8d4f.P&PDB-ENSP_mappings:8d4f.Y&PDB-ENSP_mappings:8d4g.P&PDB-ENSP_mappings:8d4g.Y&PDB-ENSP_mappings:8d9r.0&PDB-ENSP_mappings:8d9r.1&PDB-ENSP_mappings:8d9r.2&PDB-ENSP_mappings:8d9r.Y&PDB-ENSP_mappings:8d9r.y&PDB-ENSP_mappings:8d9r.z&PDB-ENSP_mappings:8d9s.0&PDB-ENSP_mappings:8d9s.1&PDB-ENSP_mappings:8d9s.2&PDB-ENSP_mappings:8d9s.Y&PDB-ENSP_mappings:8d9s.y&PDB-ENSP_mappings:8d9s.z&PDB-ENSP_mappings:8d9t.0&PDB-ENSP_mappings:8d9t.1&PDB-ENSP_mappings:8d9t.Y&PDB-ENSP_mappings:8d9t.x&PDB-ENSP_mappings:8d9t.y&PDB-ENSP_mappings:8d9t.z&PDB-ENSP_mappings:8d9u.0&PDB-ENSP_mappings:8d9u.1&PDB-ENSP_mappings:8d9u.Y&PDB-ENSP_mappings:8d9u.x&PDB-ENSP_mappings:8d9u.y&PDB-ENSP_mappings:8d9u.z&PDB-ENSP_mappings:8d9v.P&PDB-ENSP_mappings:8d9v.Y&PDB-ENSP_mappings:8d9w.Y&PDB-ENSP_mappings:8d9w.j&Low_complexity_(Seg):seg&Pfam:PF06623&Phobius:CYTOPLASMIC_DOMAIN&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-P04439-F1			0.9257	0.9342	0.9078	0.9841	0.8479	0.9468	0.7234	0.8733	0.921	0.8615	0.9923	0.5238	0.7931	0.6639	0.7881	0.915	0.7712	0.8649	0.7147	0.8263	0.8191	0.9809	0.3542	0.8827	0.7134	0.8189	0.8875	0.9923	gnomADe_EAS										FAIL	8	-27	16	20	0.00	0.00	0.00	0.00	HLA-A		1.9760e+00	1727049	0.84376	0.87955	0.92572	1781416		Vancomycin_response		MedGen:CN297638	NC_000006.12:g.29945265C>T	no_classification_for_the_single_variant	no_classification_for_the_single_variant		1723892:drug_response		single_nucleotide_variant	SO:0001483			HLA-A:3105	SO:0001819&synonymous_variant					no_classification_for_the_single_variant		no_classification_for_the_single_variant				14288					no_classification_for_the_single_variant	no_classification_for_the_single_variant																					587					0.998							134.42	v6.1	Unknown		True	HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	False	11/11/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S359= mutant UNKNOWN.	False	The HLA-A ENSP00000366005.5:s359= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	29913042						True	False	False	Unknown								False	False		HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer.	The HLA-A ENSP00000366005.5:s359= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S359= mutant UNKNOWN.						v6.1	11/11/2019		GRCh38	HLA-A	3105.0	ENSP00000366005.5:S359=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""HLA-A"",""entrezGeneId"":3105,""alteration"":""ENSP00000366005.5:S359="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""HLA-A, an MHC class I component involved in the presentation of antigens to the immune system, is infrequently altered in cancer."",""variantSummary"":""The HLA-A ENSP00000366005.5:s359= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HLA-A ENSP00000366005.5:S359= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/11/2019""}"	True	True	False	Unknown		Unknown																						0,586	0,312	0,274	0/1	0,0,258,328	CCC	0.00	0.00	0.00			0,0,268,318	64.73		1.0
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.Ser1296=	ENSP00000364163.3:p.Ser1296=	chr6	32201368	32201368.0	G	A	A	32201368	.	G	A	.	PASS	NM_004557	A	synonymous_variant	LOW	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	22/30		c.3888C>T	4027	3888	1296	S	tcC/tcT	rs8192574&COSV66681539		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1					Low_complexity_(Seg):seg&SMART:SM01338&PIRSF:PIRSF002279&Gene3D:3.30.70.3310&Prints:PR01987&PANTHER:PTHR45836&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q99466-F1			0.0100	0.0045	0.0058	0	0.0388	0.001	0.04283	0.006249	0.003777	0.005753	2.527e-05	0.02695	0.002114	0.05233	0.03729	0.0002952	0.02318	0.008371	0.04167	0.006794	0.006336	0.0001933	0.02626	0.003401	0.03985	0.01087	0.0008285	0.05233	gnomADe_NFE		0&1	0&1							FAIL	2	33	10	44	0.00	0.00	0.00	0.00	NOTCH4		8.6600e-01																																																											975					1							248.46	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:S1296= mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:s1296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32169145						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:s1296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:S1296= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:S1296=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:S1296="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:s1296= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:S1296= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						501,474	249,236	252,238	0/1	253,248,232,242	GGG	0.00	0.00	0.00			243,258,244,230	43.77		0.48615384615384616
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.Gly989=	ENSP00000364163.3:p.Gly989=	chr6	32204288	32204288.0	T	G	G	32204288	.	T	G	.	PASS	NM_004557	G	synonymous_variant	LOW	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	19/30		c.2967A>C	3106	2967	989	G	ggA/ggC	rs1044506		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1					SMART:SM00181&SMART:SM00179&PIRSF:PIRSF002279&Pfam:PF00008&Gene3D:2.10.25.10&CDD:cd00054&PROSITE_profiles:PS50026&PANTHER:PTHR45836&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57184&AFDB-ENSP_mappings:AF-Q99466-F1			0.9633	0.9924	0.9568	0.9921	0.8907	0.9734	0.8796	0.978	0.9526	0.9713	0.9986	0.8663	0.9424	0.8596	0.8903	0.9757	0.914	0.9731	0.9276	0.9348	0.9703	0.9954	0.8815	0.949	0.864	0.9371	0.9737	0.9986	gnomADe_EAS	benign		1	21098978&21297263&19143815&22096524&37250650&37164013						FAIL	-23	47	-23	-40	0.01	0.00	0.00	0.00	NOTCH4		8.6600e-01	1277124	0.90337	0.91648	0.96326	1266993	not_provided		MedGen:C3661900		NC_000006.12:g.32204288T>G	criteria_provided&_single_submitter	Benign			SCV001906743	single_nucleotide_variant	SO:0001483	ClinGen:CA3739555		NOTCH4:4855	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	1044506																											1110					0.999							247.3	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G989= mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:g989= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32172065						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:g989= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G989= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:G989=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:G989="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:g989= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G989= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						0,1109	0,531	0,578	0/1	0,0,556,553	ATC	.	.	.			0,0,504,605	64.73		1.0
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9			chr6	32216928	32216928.0	G	A	A	32216928	.	G	A	.	PASS	NM_004557	A	intron_variant	MODIFIER	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding		11/29	c.1861+17C>T						rs3134798		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1								0.8245	0.8669	0.6902	0.9137	0.7256	0.8722	0.7446	0.8681	0.6774	0.933	0.9017	0.6307	0.8829	0.7265	0.7701	0.8774	0.7766	0.8602	0.7099	0.7294	0.9305	0.9042	0.6349	0.8946	0.7322	0.8292	0.8768	0.933	gnomADe_ASJ	benign		1	34039391&25268255&35078996						FAIL	17	16	17	4	0.00	0.00	0.02	0.00	NOTCH4		8.6600e-01	1223313	0.76967	0.77231	0.82448	1211135	not_provided		MedGen:C3661900		NC_000006.12:g.32216928G>A	criteria_provided&_single_submitter	Benign			SCV001829446	single_nucleotide_variant	SO:0001483	ClinGen:CA3739864		NOTCH4:4855	SO:0001627&intron_variant										1	3134798																											668					0.985							245.08													chr6	32184705																																																	True	True	False	Unknown		Unknown																						0,658	0,306	0,352	0/1	0,0,321,337	AGT	0.00	0.00	0.00			0,0,371,287	64.73		1.0
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.Gly348=	ENSP00000364163.3:p.Gly348=	chr6	32220520	32220520.0	G	C	C	32220520	.	G	C	.	PASS	NM_004557	C	synonymous_variant	LOW	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	6/30		c.1044C>G	1183	1044	348	G	ggC/ggG	rs423023&COSV66678383&COSV66681385		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1					SMART:SM00181&SMART:SM00179&PIRSF:PIRSF002279&Gene3D:2.10.25.10&Pfam:PF07645&PROSITE_patterns:PS01186&PROSITE_patterns:PS00022&CDD:cd00054&PROSITE_profiles:PS50026&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.3203	0.2413	0.3372	0.2976	0.3996	0.3569	0.3033	0.2153	0.268	0.5014	0.2707	0.3116	0.3964	0.3002	0.3124	0.3339	0.2908	0.2094	0.3805	0.3204	0.5069	0.2245	0.3133	0.4218	0.3196	0.3152	0.3217	0.5069	gnomADg_ASJ	benign	0&1&1	1&1&1	34039391						FAIL	35	44	35	-10	0.00	0.01	0.11	0.00	NOTCH4		8.6600e-01	1222852			0.32029	1211961	not_provided		MedGen:C3661900		NC_000006.12:g.32220520G>C	criteria_provided&_single_submitter	Benign			SCV001827655	single_nucleotide_variant	SO:0001483	ClinGen:CA3740089		NOTCH4:4855	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	423023																											931					0.999							247.28	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G348= mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:g348= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32188297						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:g348= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G348= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:G348=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:G348="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:g348= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G348= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						476,454	242,235	234,219	0/1	242,234,219,235	CGC	.	.	.			242,234,252,202	44.93		0.4881720430107527
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.T320A	ENSP00000364163.3:p.Thr320Ala	chr6	32220606	32220606.0	T	C	C	32220606	.	T	C	.	PASS	NM_004557	C	missense_variant	MODERATE	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	6/30		c.958A>G	1097	958	320	T/A	Acc/Gcc	rs422951&CM133099&COSV66678386		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1			tolerated(1)	benign(0.003)	SMART:SM00181&SMART:SM00179&PIRSF:PIRSF002279&Gene3D:2.10.25.10&Pfam:PF07645&CDD:cd00054&PROSITE_profiles:PS50026&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.3431	0.2958	0.3112	0.2212	0.4553	0.4397	0.4319	0.2994	0.3132	0.5831	0.21	0.4225	0.4408	0.4475	0.4294	0.4061	0.3962	0.3014	0.4572	0.3749	0.5839	0.1939	0.4324	0.4728	0.4563	0.4028	0.411	0.5839	gnomADg_ASJ	benign	0&1&1	1&1&1	21297263&20385819&34640639&31475028&31844038&32771030&25802187&28449694&14729256&31838262&15091315&21654846&22732452&23549433&24948216&25399751&28568708&15710038&29451182&21498463&29282121&23566281&36353205&34039391&18231122&22725956&30122875&37228872&35840665&36817473&39195155						FAIL	-42	-23	1	6	0.00	0.24	0.00	0.00	NOTCH4	0.277	8.6600e-01	1297197	0.40024	0.40354	0.34305	1286986	not_provided		MedGen:C3661900		NC_000006.12:g.32220606T>C	criteria_provided&_single_submitter	Benign			SCV001950510	single_nucleotide_variant	SO:0001483	ClinGen:CA3740103		NOTCH4:4855	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	422951																											882					0.998							248.12	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:T320A mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:t320a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32188383						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:t320a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:T320A mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:T320A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:T320A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:t320a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:T320A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						454,426	214,213	240,213	0/1	241,213,208,218	GTC	.	.	.			229,225,197,229	41.46		0.48409090909090907
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.Gln284=	ENSP00000364163.3:p.Gln284=	chr6	32220826	32220826.0	C	T	T	32220826	.	C	T	.	PASS	NM_004557	T	synonymous_variant	LOW	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	5/30		c.852G>A	991	852	284	Q	caG/caA	rs520803&COSV66678390		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1					SMART:SM00181&SMART:SM00179&PIRSF:PIRSF002279&Pfam:PF00008&Gene3D:2.10.25.10&CDD:cd00054&PROSITE_profiles:PS50026&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.2678	0.208	0.2594	0.1935	0.3519	0.3446	0.3025	0.2175	0.2688	0.5015	0.1902	0.3085	0.3963	0.3024	0.3106	0.3301	0.2905	0.2113	0.3978	0.3222	0.5069	0.1638	0.3138	0.4218	0.3221	0.3156	0.3156	0.5069	gnomADg_ASJ	benign	0&1	1&1	21297263						FAIL	-25	43	30	1	0.00	0.01	0.00	0.00	NOTCH4		8.6600e-01	1279259	0.28410	0.30600	0.26777	1266543	not_provided		MedGen:C3661900		NC_000006.12:g.32220826C>T	criteria_provided&_single_submitter	Benign			SCV001910166	single_nucleotide_variant	SO:0001483	ClinGen:CA3740137		NOTCH4:4855	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	520803																											829					1							246.38	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:Q284= mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:q284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32188603						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:q284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:Q284= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:Q284=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:Q284="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:q284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:Q284= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						423,406	189,211	234,195	0/1	198,225,194,212	ACT	0.00	0.00	0.00			216,207,213,193	45.03		0.4897466827503016
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.D272G	ENSP00000364163.3:p.Asp272Gly	chr6	32220863	32220863.0	T	C	C	32220863	.	T	C	.	PASS	NM_004557	C	missense_variant	MODERATE	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	5/30		c.815A>G	954	815	272	D/G	gAc/gGc	rs520692&COSV66678393		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1			tolerated(0.39)	benign(0.005)	SMART:SM00181&PIRSF:PIRSF002279&Gene3D:2.10.25.10&PROSITE_patterns:PS01186&PROSITE_patterns:PS00022&PROSITE_profiles:PS50026&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.2678	0.208	0.2594	0.1935	0.3519	0.3446	0.3024	0.2175	0.2686	0.501	0.1902	0.3082	0.3961	0.3024	0.3104	0.3299	0.2901	0.2111	0.3962	0.3217	0.5058	0.1639	0.3133	0.4178	0.3217	0.3147	0.3158	0.5058	gnomADg_ASJ	benign	0&1	1&1	29973002&22253750&14729256&32646407&15091315&28568708&16894623&31413635&21498463&36714673&25120811&29500382&37228872&38302106						FAIL	35	6	16	-7	0.00	0.06	0.00	0.00	NOTCH4	0.256	8.6600e-01	1287249	0.28287	0.30581	0.26777	1277082	not_provided		MedGen:C3661900		NC_000006.12:g.32220863T>C	criteria_provided&_single_submitter	Benign			SCV001936231	single_nucleotide_variant	SO:0001483	ClinGen:CA3740140		NOTCH4:4855	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	520692																											876					1							245.89	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:D272G mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:d272g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32188640						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:d272g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:D272G mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:D272G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:D272G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:d272g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:D272G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						444,432	197,218	247,214	0|1	224,220,215,217	GTC	.	.	.		32188640	217,227,207,225	41.1		0.4931506849315068
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.Pro271=	ENSP00000364163.3:p.Pro271=	chr6	32220865	32220865.0	T	C	C	32220865	.	T	C	.	PASS	NM_004557	C	synonymous_variant	LOW	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	5/30		c.813A>G	952	813	271	P	ccA/ccG	rs520688&COSV66678399		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1					SMART:SM00181&PIRSF:PIRSF002279&Pfam:PF00008&Gene3D:2.10.25.10&PROSITE_patterns:PS01186&PROSITE_patterns:PS00022&PROSITE_profiles:PS50026&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.2802	0.2095	0.2594	0.2421	0.3519	0.3558	0.305	0.2174	0.2686	0.5009	0.271	0.3082	0.3964	0.3024	0.3128	0.3341	0.2922	0.2111	0.3954	0.3217	0.5058	0.2242	0.3127	0.4178	0.3216	0.315	0.3205	0.5058	gnomADg_ASJ	benign	0&1	1&1	34039391&36333282&25287876						FAIL	4	33	5	-9	0.05	0.00	0.00	0.00	NOTCH4		8.6600e-01	1289316	0.28341	0.31086	0.28015	1279147	not_provided		MedGen:C3661900		NC_000006.12:g.32220865T>C	criteria_provided&_single_submitter	Benign			SCV001940050	single_nucleotide_variant	SO:0001483	ClinGen:CA3740141		NOTCH4:4855	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	520688																											866					1							246.08	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:P271= mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:p271= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32188642						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:p271= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:P271= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:P271=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:P271="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:p271= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:P271= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						433,433	189,219	244,214	0|1	221,212,231,202	CTG	.	.	.		32188640	211,222,215,218	45.99		0.5
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.Thr174=	ENSP00000364163.3:p.Thr174=	chr6	32221255	32221255.0	T	C	C	32221255	.	T	C	.	PASS	NM_004557	C	synonymous_variant	LOW	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	4/30		c.522A>G	661	522	174	T	acA/acG	rs415929&COSV66678403		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1					SMART:SM00181&SMART:SM00179&PIRSF:PIRSF002279&Pfam:PF00008&Gene3D:2.10.25.10&CDD:cd00054&PROSITE_profiles:PS50026&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.2800	0.2088	0.2594	0.2421	0.3519	0.3558	0.3053	0.218	0.269	0.5015	0.2711	0.3089	0.3975	0.3026	0.3137	0.3345	0.293	0.212	0.3978	0.3224	0.5069	0.2249	0.3135	0.4218	0.3222	0.3165	0.3208	0.5069	gnomADg_ASJ	benign	0&1	1&1	20088021&31838262&28568708&34469753&23637959&34039391&36824606&29500382&25287876&32450446						FAIL	37	-10	1	15	0.00	0.03	0.00	0.00	NOTCH4		8.6600e-01	1281290	0.28348	0.31128	0.27995	1270287	not_provided		MedGen:C3661900		NC_000006.12:g.32221255T>C	criteria_provided&_single_submitter	Benign			SCV001913175	single_nucleotide_variant	SO:0001483	ClinGen:CA3740220		NOTCH4:4855	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	415929																											964					0.997							247.69	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:T174= mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:t174= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32189032						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:t174= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:T174= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:T174=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:T174="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:t174= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:T174= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						479,482	235,235	244,247	0/1	234,245,231,251	ATG	.	.	.			238,241,256,226	56.03		0.5015608740894901
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.K117Q	ENSP00000364163.3:p.Lys117Gln	chr6	32222613	32222613.0	T	G	G	32222613	.	T	G	.	PASS	NM_004557	G	missense_variant	MODERATE	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	3/30		c.349A>C	488	349	117	K/Q	Aag/Cag	rs915894&COSV66678407		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1			tolerated(0.87)	benign(0)	PIRSF:PIRSF002279&Gene3D:2.10.25.10&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.3988	0.3714	0.3285	0.5109	0.3519	0.4182	0.379	0.3759	0.2739	0.3791	0.5051	0.3064	0.3047	0.383	0.3728	0.3737	0.3595	0.3764	0.3279	0.2867	0.3658	0.493	0.3118	0.2993	0.3605	0.3463	0.4057	0.5109	EAS	benign	0&1	1&1	20403199&29973002&32394637&19143815&14729256&15091315&31413635&21498463&26491355&28560257&34039391&37228872&34321204&38027162&38116117&39085889						FAIL	-41	49	18	21	0.00	0.00	0.00	0.00	NOTCH4	0.212	8.6600e-01	1294880	0.37221	0.35843	0.39876	1284676	not_provided		MedGen:C3661900		NC_000006.12:g.32222613T>G	criteria_provided&_single_submitter	Benign			SCV001948305	single_nucleotide_variant	SO:0001483	ClinGen:CA3740275		NOTCH4:4855	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant										1	915894																											1113					0.997							246.66	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:K117Q mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:k117q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32190390						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:k117q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:K117Q mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:K117Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:K117Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:k117q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:K117Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						572,538	257,239	315,299	0|1	274,298,251,287	TTG	.	.	.		32190390	307,265,284,254	36.5		0.4846846846846847
GRCh38	NOTCH4	D12_12345_1234556_Thyroid_S9	p.Gly111=	ENSP00000364163.3:p.Gly111=	chr6	32222629	32222629.0	A	G	G	32222629	.	A	G	.	PASS	NM_004557	G	synonymous_variant	LOW	NOTCH4	ENSG00000204301	Transcript	ENST00000375023	protein_coding	3/30		c.333T>C	472	333	111	G	ggT/ggC	rs443198&CM030916&COSV66678412		-1		SNV	HGNC	HGNC:7884	YES	MANE_Select	NM_004557.4		1	P1	CCDS34420.1	ENSP00000364163	Q99466.231	A0A1U9X983.43	UPI0000130571	Q99466-1					SMART:SM00181&SMART:SM00179&PIRSF:PIRSF002279&Gene3D:2.10.25.10&PROSITE_patterns:PS00022&PROSITE_patterns:PS01186&PROSITE_profiles:PS50026&Phobius:NON_CYTOPLASMIC_DOMAIN&Superfamily:SSF57196&AFDB-ENSP_mappings:AF-Q99466-F1			0.4607	0.4705	0.3775	0.5615	0.3638	0.502	0.3959	0.4693	0.3434	0.4521	0.526	0.2351	0.4089	0.3911	0.4159	0.4641	0.3957	0.4625	0.415	0.3631	0.449	0.5363	0.2393	0.3673	0.3664	0.4068	0.4851	0.5615	EAS	benign	0&1&1	1&1&1	35124268&21779181&20885795&28526340&31838262&27231971&19680446&37065486&34039391&26210123&34258301&36824606&34130729&36724752&38728360						FAIL	-6	33	-6	2	0.00	0.01	0.00	0.03	NOTCH4		8.6600e-01	1293220	0.40397	0.38038	0.46066	1283025	not_provided		MedGen:C3661900		NC_000006.12:g.32222629A>G	criteria_provided&_single_submitter	Benign			SCV001944717	single_nucleotide_variant	SO:0001483	ClinGen:CA3740279		NOTCH4:4855	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	443198																											1118					0.996							246.48	v6.1	Unknown		True	NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G111= mutant UNKNOWN.	False	The NOTCH4 ENSP00000364163.3:g111= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	32190406						True	False	False	Unknown								False	False		NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor.	The NOTCH4 ENSP00000364163.3:g111= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G111= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	NOTCH4	4855.0	ENSP00000364163.3:G111=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH4"",""entrezGeneId"":4855,""alteration"":""ENSP00000364163.3:G111="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH4, a transmembrane receptor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH4 ENSP00000364163.3:g111= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH4 ENSP00000364163.3:G111= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						575,538	258,236	317,302	0|1	271,304,271,267	CAC	.	.	.		32190390	302,273,269,269	35.25		0.4833782569631626
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	35169624	35169941.0	C	CATCCAACCATCATCAACATCACCAACACCGTCACCACCATCACAACCACCACCACCACCATCACAACCACCATCACCCCCACTACCACCACCATTATCATCACCATCACCACCACCACCATCACCAACACATCACAACCACCACCACCACCACCATCACCATCACAACTACCACCACAACCATCACAACCATCACTACCACCATCATAACCAACATCACCACCATCACAACCCCCATCACCACCATCACAACCACCACCATCACAACCACCATCACCACCATCACAACCACCATCACCCCCACTACCACCACCATT	CATCCAACCATCATCAACATCACCAACACCGTCACCACCATCACAACCACCACCACCACCATCACAACCACCATCACCCCCACTACCACCACCATTATCATCACCATCACCACCACCACCATCACCAACACATCACAACCACCACCACCACCACCATCACCATCACAACTACCACCACAACCATCACAACCATCACTACCACCATCATAACCAACATCACCACCATCACAACCCCCATCACCACCATCACAACCACCACCATCACAACCACCATCACCACCATCACAACCACCATCACCCCCACTACCACCACCATT	35169624	MantaINS:8989:0:0:0:0:0	C	CATCCAACCATCATCAACATCACCAACACCGTCACCACCATCACAACCACCACCACCACCATCACAACCACCATCACCCCCACTACCACCACCATTATCATCACCATCACCACCACCACCATCACCAACACATCACAACCACCACCACCACCACCATCACCATCACAACTACCACCACAACCATCACAACCATCACTACCACCATCATAACCAACATCACCACCATCACAACCCCCATCACCACCATCACAACCACCACCATCACAACCACCATCACCACCATCACAACCACCATCACCCCCACTACCACCACCATT	.	PASS		ATCCAACCATCATCAACATCACCAACACCGTCACCACCATCACAACCACCACCACCACCATCACAACCACCATCACCCCCACTACCACCACCATTATCATCACCATCACCACCACCACCATCACCAACACATCACAACCACCACCACCACCACCATCACCATCACAACTACCACCACAACCATCACAACCATCACTACCACCATCATAACCAACATCACCACCATCACAACCCCCATCACCACCATCACAACCACCACCATCACAACCACCATCACCACCATCACAACCACCATCACCCCCACTACCACCACCATT	intergenic_variant	MODIFIER														rs1782229286				insertion																																						0.02656	0.04157	0	0.01429	0	0.03125	0		0.01695	0	0.04	0.04157	gnomADg_AFR																																																																														1M316I	0,3					35169624		3	ATC																		chr6	35137401			316	INS																																													True	False	False	Unknown		Unknown																															0,1				0,48	
GRCh38	FANCE	D12_12345_1234556_Thyroid_S9	p.Pro129=	ENSP00000229769.2:p.Pro129=	chr6	35455885	35455885.0	A	C	C	35455885	.	A	C	.	PASS	NM_021922	C	synonymous_variant	LOW	FANCE	ENSG00000112039	Transcript	ENST00000229769	protein_coding	2/10		c.387A>C	595	387	129	P	ccA/ccC	rs4713867&COSV57690669		1		SNV	HGNC	HGNC:3586	YES	MANE_Select	NM_021922.3		1	P1	CCDS4805.1	ENSP00000229769	Q9HB96.181		UPI000000DB76			1			PDB-ENSP_mappings:7kzp.E&PDB-ENSP_mappings:7kzq.E&PDB-ENSP_mappings:7kzr.E&PDB-ENSP_mappings:7kzs.E&PDB-ENSP_mappings:7kzt.E&PDB-ENSP_mappings:7kzv.E&PANTHER:PTHR32094&AFDB-ENSP_mappings:AF-Q9HB96-F1			0.7780	0.8911	0.817	0.7133	0.6779	0.7669	0.6856	0.877	0.8151	0.7332	0.7072	0.6914	0.7074	0.6671	0.6998	0.7429	0.7431	0.8709	0.5923	0.7667	0.7395	0.6855	0.6956	0.7585	0.6736	0.7417	0.7434	0.8911	AFR	benign	0&1	1&1	25741868&32708070						FAIL	-29	2	-7	-29	0.00	0.00	0.00	0.00	FANCE		9.5700e-01	261435	0.73566		0.77796	252337	not_specified&not_provided&Fanconi_anemia_complementation_group_E		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0010953&MedGen:C3160739&OMIM:600901&Orphanet:84		NC_000006.12:g.35455885A>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000313809&SCV000462661&SCV000603579&SCV001000015&SCV001863518&SCV001933152&SCV004017665	single_nucleotide_variant	SO:0001483	ClinGen:CA3771398		FANCE:2178	SO:0001819&synonymous_variant										1	4713867																											1055					0.999							247.76	v6.1	Unknown		True	FANCE, a DNA repair protein, is infrequently altered in cancer.	False	10/13/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCE ENSP00000229769.2:P129= mutant UNKNOWN.	False	The FANCE ENSP00000229769.2:p129= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	35423662						True	False	False	Unknown								False	False		FANCE, a DNA repair protein, is infrequently altered in cancer.	The FANCE ENSP00000229769.2:p129= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCE ENSP00000229769.2:P129= mutant UNKNOWN.						v6.1	10/13/2023		GRCh38	FANCE	2178.0	ENSP00000229769.2:P129=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FANCE"",""entrezGeneId"":2178,""alteration"":""ENSP00000229769.2:P129="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FANCE, a DNA repair protein, is infrequently altered in cancer."",""variantSummary"":""The FANCE ENSP00000229769.2:p129= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FANCE ENSP00000229769.2:P129= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/13/2023""}"	True	True	False	Unknown		Unknown																						0,1054	0,518	0,536	0/1	0,0,533,521	CAG	.	.	.			0,0,495,559	64.73		1.0
GRCh38	CDKN1A	D12_12345_1234556_Thyroid_S9			chr6	36677919	36677919.0	A	G	G	36677919	.	A	G	.	PASS	NM_000389	G	upstream_gene_variant	MODIFIER	CDKN1A	ENSG00000124762	Transcript	ENST00000244741	protein_coding									rs2395655&COSV55187098	795	1		SNV	HGNC	HGNC:1784	YES	MANE_Select	NM_000389.5		1	P1	CCDS4824.1	ENSP00000244741	P38936.247		UPI0000048F7B			1						0.5276	0.7413	0.3876	0.5486	0.3797	0.4683	0.401	0.6961	0.3413	0.547	0.5496	0.3562	0.5472	0.3821	0.437	0.449	0.4864	0.6856	0.2445	0.4271	0.5562	0.5205	0.3613	0.5816	0.3959	0.5081	0.456	0.7413	AFR		0&1	1&1	17459456&18174243&19258477&20617153&24820515&21145615&26932598&26683024&28862766&18507837&20126416&22291954&23231583&24474449&30660786&35294321&33447070&31554702&24626178&32593486&25837031&26441981&30854807&28993806&36198295&30275531&30595370&37683633&38755535						FAIL	20	-17	-1	14	0.00	0.00	0.00	0.11	CDKN1A																																																													183					0.973							239.32													chr6	36645696																																																	True	True	False	Unknown		Unknown																						75,103	51,51	24,52	0/1	38,37,56,47	GAT	.	.	.			34,41,44,59	48.63		0.5786516853932584
GRCh38	CDKN1A	D12_12345_1234556_Thyroid_S9			chr6	36682788	36682788.0	G	C	C	36682788	.	G	C	.	PASS	NM_000389	C	intron_variant	MODIFIER	CDKN1A	ENSG00000124762	Transcript	ENST00000244741	protein_coding		1/2	c.-5-1309G>C						rs3176345		1		SNV	HGNC	HGNC:1784	YES	MANE_Select	NM_000389.5		1	P1	CCDS4824.1	ENSP00000244741	P38936.247		UPI0000048F7B			1						0.2602	0.3215	0.2522	0.4901	0.0666	0.1452	0.05263			0	0.5			0.03125	0		0.1532	0.261	0.1382	0.2276	0.08065	0.4896	0.06034	0.09524	0.06595	0.1452	0.1242	0.5	gnomADe_EAS										FAIL	17	0	17	-48	0.00	0.00	0.01	0.00	CDKN1A		1.4920e+00																																																											972					0.999							248.8													chr6	36650565																																																	True	True	False	Unknown		Unknown																						470,501	228,275	242,226	0/1	234,236,240,261	GGG	.	.	.			218,252,234,267	62.82		0.5159629248197735
GRCh38	CDKN1A	D12_12345_1234556_Thyroid_S9	p.S31R	ENSP00000244741.6:p.Ser31Arg	chr6	36684194	36684194.0	C	A	A	36684194	.	C	A	.	PASS	NM_000389	A	missense_variant	MODERATE	CDKN1A	ENSG00000124762	Transcript	ENST00000244741	protein_coding	2/3		c.93C>A	183	93	31	S/R	agC/agA	rs1801270&CM940226&COSV55187247		1		SNV	HGNC	HGNC:1784	YES	MANE_Select	NM_000389.5		1	P1	CCDS4824.1	ENSP00000244741	P38936.247		UPI0000048F7B			1	tolerated(1)	benign(0)	Gene3D:4.10.365.10&PDB-ENSP_mappings:6p8h.C&AFDB-ENSP_mappings:AF-P38936-F1&Pfam:PF02234&PANTHER:PTHR46778			0.2562	0.3094	0.2493	0.4881	0.0666	0.1452	0.09367	0.256	0.3323	0.09044	0.4805	0.05574	0.126	0.06526	0.1123	0.1036	0.1492	0.2488	0.1363	0.2247	0.08415	0.4864	0.0601	0.09864	0.06574	0.141	0.1216	0.4881	EAS	benign	0&1&1	1&1&1	21514219&17459456&18174243&19258477&24491308&18805939&18191955&30202817&22655231&27415837&26263974&20452958&24820515&27246533&32293552&28324443&18974877&17293864&23697595&21877955&16111488&21454826&35971775&18507837&20126416&23231583&15878916&19224585&19505915&20433229&24045412&26278624&26846214&31703578&31895498&34743275&35786622&35865244&7655464&8084608&8807325&19237173&19367277&19750108&20127253&20979563&25267570&26289323&27506496&28668478&28718371&29578436&29892419&30544467&31405322&32821748&33481818&34227093&31759353&31909567&28976792&28210099&34295994&35351459&18493234&36632296&37189693&25625488&34078296&33885357&28107433&36691945&32925069&26693075&29503979&24626178&19910837&33230300&32458635&36644456&18694622&32552660&32850701&23642098&31408923&28366820&26328260&27566557&19536170&35563252&25502557&23761956&20708717&26405550&37247280&28323902&17331670&19176223&37667176&37730565&37605254&38540335&38285782&38992585&38846977						FAIL	0	37	21	43	0.00	0.00	0.00	0.00	CDKN1A	0.244	1.4920e+00	17565			0.25619	32604	CIP1/WAF1_TUMOR-ASSOCIATED_POLYMORPHISM_1		.		NC_000006.12:g.36684194C>A	no_assertion_criteria_provided	Benign			SCV000039413	single_nucleotide_variant	SO:0001483	ClinGen:CA127261&OMIM:116899.0001&UniProtKB:P38936																																																																																																																																															618,600	291,297	327,303	0/1	330,288,298,302	GCC	0.00	0.00	0.00			299,319,279,321	52.65		0.49261083743842365
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	40726411		A	]chr16:13587437]A	]chr16:13587437]A	40726411	MantaBND:8899:0:1:0:0:0:0	A	]chr16:13587437]A	.	PASS		.A	downstream_gene_variant	MODIFIER		ENSG00000300353	Transcript	ENST00000771114	lncRNA										1043	1		chromosome_breakpoint			YES																																																																																																																											5			0,4							4	TACG			MantaBND:8899:0:1:0:0:0:1	1														chr6	40694150				BND																																													True	False	False	Unknown		Unknown																															1,1				2,1	
GRCh38	CCND3	D12_12345_1234556_Thyroid_S9	p.S259A	ENSP00000362082.5:p.Ser259Ala	chr6	41936044	41936044.0	A	C	C	41936044	.	A	C	.	PASS	NM_001760	C	missense_variant	MODERATE	CCND3	ENSG00000112576	Transcript	ENST00000372991	protein_coding	5/5		c.775T>G	934	775	259	S/A	Tct/Gct	rs1051130&COSV57827647		-1		SNV	HGNC	HGNC:1585	YES	MANE_Select	NM_001760.5		1	P1	CCDS4863.1	ENSP00000362082	P30281.224		UPI00001275C9	P30281-1		1	tolerated(0.53)	benign(0)	PDB-ENSP_mappings:3g33.B&PDB-ENSP_mappings:3g33.D&PDB-ENSP_mappings:7sj3.B&AFDB-ENSP_mappings:AF-P30281-F1&SMART:SM01332&CDD:cd20578&MobiDB_lite:mobidb-lite			0.5925	0.8487	0.5058	0.504	0.5467	0.4458	0.5498	0.8083	0.4711	0.5621	0.4947	0.5449	0.4763	0.5546	0.5608	0.4496	0.6154	0.8049	0.5187	0.5399	0.5583	0.5228	0.546	0.5612	0.5508	0.5968	0.4564	0.8487	AFR		0&1	0&1	18174243&19258477&20003265&18389087&16111488&18507837&28323902						FAIL	42	7	0	19	0.00	0.00	0.00	0.00	CCND3	0.042	5.4800e-01																																																											896					0.999							248.42	v6.1	Unknown		True	CCND3, a regulator of the cell cycle, is amplified in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCND3 ENSP00000362082.5:S259A mutant UNKNOWN.	False	The CCND3 ENSP00000362082.5:s259a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	41903782						True	False	False	Unknown								False	False		CCND3, a regulator of the cell cycle, is amplified in various cancer types.	The CCND3 ENSP00000362082.5:s259a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCND3 ENSP00000362082.5:S259A mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	CCND3	896.0	ENSP00000362082.5:S259A			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CCND3"",""entrezGeneId"":896,""alteration"":""ENSP00000362082.5:S259A"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CCND3, a regulator of the cell cycle, is amplified in various cancer types."",""variantSummary"":""The CCND3 ENSP00000362082.5:s259a mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CCND3 ENSP00000362082.5:S259A mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						445,450	209,200	236,250	0/1	224,221,228,222	GAG	.	.	.			188,257,198,252	55.29		0.5027932960893855
GRCh38	CCND3	D12_12345_1234556_Thyroid_S9			chr6	41957115	41957115.0	G	A	A	41957115	.	G	A	.	PASS		A	intron_variant	MODIFIER	CCND3	ENSG00000112576	Transcript	ENST00000616010	protein_coding		2/4	c.-174-19721C>T						rs4623235		-1		SNV	HGNC	HGNC:1585					5		CCDS47427.1	ENSP00000484424	P30281.224		UPI000182464B	P30281-4		1						0.4285	0.4433	0.4395	0.4464	0.506	0.3027											0.4816	0.4406	0.4989	0.468	0.5089	0.4555	0.5093	0.4762	0.5159	0.4863	0.336	0.5159	gnomADg_NFE			1	37277458																	1.4030e+00																																																											493					0.974							246.58													chr6	41924853																																																	True	True	False	Unknown		Unknown																						236,244	113,112	123,132	0/1	125,111,130,114	AGT	0.00	0.00	0.00			106,130,96,148	48.3		0.5083333333333333
GRCh38	CCND3	D12_12345_1234556_Thyroid_S9			chr6	41975342	41975342.0	T	C	C	41975342	.	T	C	.	PASS		C	intron_variant	MODIFIER	CCND3	ENSG00000112576	Transcript	ENST00000616010	protein_coding		2/4	c.-174-37948A>G						rs9381104		-1		SNV	HGNC	HGNC:1585					5		CCDS47427.1	ENSP00000484424	P30281.224		UPI000182464B	P30281-4		1						0.7063	0.8343	0.7147	0.6508	0.6551	0.637											0.7167	0.8171	0.8333	0.7298	0.6778	0.6627	0.679	0.6224	0.6693	0.6909	0.6443	0.8343	AFR																					1.4030e+00																																																											796					0.999							248.14													chr6	41943080																																																	True	True	False	Unknown		Unknown																						0,795	0,396	0,399	0/1	0,0,425,370	CTG	.	.	.			0,0,426,369	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	42045304	42045304.0	C	T	T	42045304	.	C	T	.	PASS		T	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR6_D44BQ	enhancer									rs6919122				SNV																						0.5627	0.7526	0.5043	0.5873	0.497	0.3896											0.5825	0.7121	0.5033	0.5153	0.4963	0.5823	0.5219	0.483	0.5479	0.5658	0.3903	0.7526	AFR			1	34282934																																																																												180					0.961							240.05													chr6	42013042																																																	True	False	False	Unknown		Unknown																						0,173	0,91	0,82	0|1	0,0,83,90	TCG	0.00	0.00	0.00		42013042	0,0,65,108	57.72		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	42045311	42045311.0	T	C	C	42045311	.	T	C	.	PASS		C	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR6_D44BQ	enhancer									rs6942118				SNV																						0.6056	0.6195	0.5764	0.5367	0.6769	0.6053											0.6336	0.6137	0.6985	0.6165	0.5594	0.5359	0.6138	0.6395	0.6634	0.6586	0.6165	0.6985	gnomADg_AMI																																																																																184					0.962							239.86													chr6	42013049																																																	True	False	False	Unknown		Unknown																						84,93	37,53	47,40	0|1	38,46,46,47	ATT	.	.	.		42013042	33,51,38,55	35.05		0.5254237288135594
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	42045622	42045622.0	G	T	T	42045622	.	G	T	.	PASS		T	regulatory_region_variant	MODIFIER			RegulatoryFeature	ENSR6_D44BQ	enhancer									rs6458267				SNV																						0.6058	0.5083	0.5389	0.6627	0.5775	0.7556											0.5638	0.5249	0.5198	0.5753	0.5579	0.6573	0.5729	0.5782	0.5651	0.5691	0.7312	0.7556	SAS																																																																																245					0.988							247.73													chr6	42013360																																																	True	False	False	Unknown		Unknown																						117,125	60,56	57,69	0/1	56,61,64,61	GGG	0.00	0.00	0.00			61,56,69,56	43		0.5165289256198347
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	47040163		C	[chr3:182155444[C	[chr3:182155444[C	47040163	MantaBND:9113:0:1:0:0:0:1	C	[chr3:182155444[C	.	PASS		.C	downstream_gene_variant	MODIFIER		ENSG00000305542	Transcript	ENST00000811630	lncRNA										4680	-1		chromosome_breakpoint																																																																																																																														2			0,10							10	ATTAAAAAGA			MantaBND:9113:0:1:0:0:0:0	1														chr6	47007899				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	47853517	47853521.0	A	AGAAG	AGAAG	47853517	.	A	AGAAG	.	PASS		GAAG	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000304494	Transcript	ENST00000803766	lncRNA		1/3	n.123+364_123+367dup						rs2307710		1		insertion																					10	0.6689	0.5446	0.7853	0.749	0.671	0.6697											0.6614	0.5691	0.6652	0.7542	0.6483	0.7825	0.7336	0.6565	0.6759	0.6752	0.6714	0.7853	AMR				33801242																																																																												48					0.896							239.26													chr6	47821253																																																	True	False	False	Unknown		Unknown																						25,18	6,5	19,13	0/1	14,11,10,8	GAG						13,12,7,11	25.56		0.4186046511627907
GRCh38	KILH	D12_12345_1234556_Thyroid_S9			chr6	53605757		G	[chr4:33765286[G	[chr4:33765286[G	53605757	MantaBND:412:0:1:0:0:0:1	G	[chr4:33765286[G	.	PASS		.G	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	KILH	ENSG00000231683	Transcript	ENST00000510846	lncRNA		1/3									-1		chromosome_breakpoint	HGNC	HGNC:56729					4																																																																																																																							1			0,7							7	TGAGAGA			MantaBND:412:0:1:0:0:0:0	1														chr6	53470555				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38	EPHA7	D12_12345_1234556_Thyroid_S9	p.Pro692=	ENSP00000358309.4:p.Pro692=	chr6	93258133	93258133.0	C	T	T	93258133	.	C	T	.	PASS	NM_004440	T	synonymous_variant	LOW	EPHA7	ENSG00000135333	Transcript	ENST00000369303	protein_coding	11/17		c.2076G>A	2294	2076	692	P	ccG/ccA	rs345730		-1		SNV	HGNC	HGNC:3390	YES	MANE_Select	NM_004440.4		1	P3	CCDS5031.1	ENSP00000358309	Q15375.230		UPI0000044771	Q15375-1		1			PDB-ENSP_mappings:2rei.A&PDB-ENSP_mappings:3dko.A&PDB-ENSP_mappings:7eec.A&PDB-ENSP_mappings:7eed.A&PDB-ENSP_mappings:7eef.A&Pfam:PF07714&Gene3D:3.30.200.20&PIRSF:PIRSF000666&CDD:cd05066&SMART:SM00219&Phobius:CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50011&PANTHER:PTHR46877&Superfamily:SSF56112&AFDB-ENSP_mappings:AF-Q15375-F1			0.7312	0.5991	0.6945	0.8165	0.7237	0.8558	0.7172	0.5903	0.6852	0.7425	0.8378	0.7053	0.7729	0.7079	0.7261	0.8369	0.6881	0.6071	0.6316	0.7107	0.7246	0.8091	0.7221	0.7823	0.7056	0.7012	0.8342	0.8558	SAS	benign		1							FAIL	-34	28	37	-34	0.00	0.00	0.00	0.00	EPHA7		2.8200e-01	1331194	0.67830	0.72256	0.73123	1321869	not_provided		MedGen:C3661900		NC_000006.12:g.93258133C>T	criteria_provided&_single_submitter	Benign			SCV002050458	single_nucleotide_variant	SO:0001483	ClinGen:CA3929038		EPHA7:2045	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	345730																											85					1							244.81	v6.1	Unknown		True	EPHA7, a receptor tyrosine kinase, is altered by mutation or deletion in various cancer types, most frequently in skin cancers.	False	02/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA7 ENSP00000358309.4:P692= mutant UNKNOWN.	False	The EPHA7 ENSP00000358309.4:p692= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	93967851						True	False	False	Unknown								False	False		EPHA7, a receptor tyrosine kinase, is altered by mutation or deletion in various cancer types, most frequently in skin cancers.	The EPHA7 ENSP00000358309.4:p692= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA7 ENSP00000358309.4:P692= mutant UNKNOWN.						v6.1	02/22/2018		GRCh38	EPHA7	2045.0	ENSP00000358309.4:P692=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EPHA7"",""entrezGeneId"":2045,""alteration"":""ENSP00000358309.4:P692="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EPHA7, a receptor tyrosine kinase, is altered by mutation or deletion in various cancer types, most frequently in skin cancers."",""variantSummary"":""The EPHA7 ENSP00000358309.4:p692= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA7 ENSP00000358309.4:P692= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/22/2018""}"	True	True	False	Unknown		Unknown																						0,85	0,42	0,43	0/1	0,0,48,37	TCG	0.00	0.00	0.00			0,0,43,42	64.62		1.0
GRCh38	EPHA7	D12_12345_1234556_Thyroid_S9	p.Ser447=	ENSP00000358309.4:p.Ser447=	chr6	93272406	93272406.0	A	G	G	93272406	.	A	G	.	PASS	NM_004440	G	synonymous_variant	LOW	EPHA7	ENSG00000135333	Transcript	ENST00000369303	protein_coding	6/17		c.1341T>C	1559	1341	447	S	agT/agC	rs345713&COSV65194705		-1		SNV	HGNC	HGNC:3390	YES	MANE_Select	NM_004440.4		1	P3	CCDS5031.1	ENSP00000358309	Q15375.230		UPI0000044771	Q15375-1		1			Gene3D:2.60.40.10&PIRSF:PIRSF000666&CDD:cd00063&SMART:SM00060&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50853&PANTHER:PTHR46877&Superfamily:SSF49265&AFDB-ENSP_mappings:AF-Q15375-F1			0.9004	0.9894	0.817	0.8214	0.8926	0.9284	0.8813	0.98	0.7749	0.9394	0.8387	0.847	0.9575	0.8792	0.891	0.9372	0.8999	0.9748	0.8991	0.8465	0.9357	0.8125	0.8518	0.9728	0.8766	0.8872	0.9248	0.9894	AFR		0&1	1&1	36224396						FAIL	17	16	-3	6	0.00	0.00	0.00	0.00	EPHA7		2.8200e-01																																																											90					0.944							233.83	v6.1	Unknown		True	EPHA7, a receptor tyrosine kinase, is altered by mutation or deletion in various cancer types, most frequently in skin cancers.	False	02/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA7 ENSP00000358309.4:S447= mutant UNKNOWN.	False	The EPHA7 ENSP00000358309.4:s447= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	93982124						True	False	False	Unknown								False	False		EPHA7, a receptor tyrosine kinase, is altered by mutation or deletion in various cancer types, most frequently in skin cancers.	The EPHA7 ENSP00000358309.4:s447= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA7 ENSP00000358309.4:S447= mutant UNKNOWN.						v6.1	02/22/2018		GRCh38	EPHA7	2045.0	ENSP00000358309.4:S447=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EPHA7"",""entrezGeneId"":2045,""alteration"":""ENSP00000358309.4:S447="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EPHA7, a receptor tyrosine kinase, is altered by mutation or deletion in various cancer types, most frequently in skin cancers."",""variantSummary"":""The EPHA7 ENSP00000358309.4:s447= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPHA7 ENSP00000358309.4:S447= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/22/2018""}"	True	True	False	Unknown		Unknown																						0,85	0,43	0,42	0/1	0,0,40,45	CAC	.	.	.			0,0,42,43	64.62		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	93827537	93827537.0	T	C	C	93827537	.	T	C	.	PASS		C	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000297836	Transcript	ENST00000751338	lncRNA		1/1	n.724+5725A>G						rs1336071		-1		SNV																						0.5791	0.5893	0.4813	0.5734	0.5338	0.6871											0.5538	0.5758	0.3081	0.514	0.5072	0.5774	0.5168	0.415	0.5518	0.5209	0.6781	0.6871	SAS				23771752&29121662&33406744&34721519&19646946&38774862																																																																												124					0.863							236.53													chr6	94537255																																																	True	False	False	Unknown		Unknown																						0,107	0,62	0,45	0/1	0,0,50,57	ATC	.	.	.			0,0,45,62	64.69		1.0
GRCh38	KLHL32	D12_12345_1234556_Thyroid_S9			chr6	97010244	97010248.0	G	GAAGC	GAAGC	97010244	.	G	GAAGC	.	PASS		AAGC	5_prime_UTR_variant	MODIFIER	KLHL32	ENSG00000186231	Transcript	ENST00000620278	protein_coding	1/9		c.-653_-652insAGCA	46-47					rs2307652		1		insertion	HGNC	HGNC:21221					1		CCDS75495.1	ENSP00000482012		A0A087WYQ8.53	UPI0001EE8C5F								1	0.7133	0.9455	0.6859	0.5724	0.5437	0.7382	0.7				1	0.5		0.8333	0.75		0.6503	0.8902	0.4835	0.672	0.5768	0.6003	0.5231	0.5788	0.526	0.6364	0.6963	1	gnomADe_EAS				23690203&36292568																	1.1300e+00																																																											81					0.951							246.09													chr6	97458120																																																	True	False	False	Unknown		Unknown																						46,31	19,15	27,16	0/1	25,21,15,16	GGA						20,26,15,16	23		0.4025974025974026
GRCh38	FYN	D12_12345_1234556_Thyroid_S9	p.A139delinsGlyMetTer	ENSP00000346671.3:p.Ala139delinsGlyMetTer	chr6	111707949	111707964.0	G	GAGACAGGTTACATTC	GAGACAGGTTACATTC	111707949	.	G	GAGACAGGTTACATTC	.	PASS	NM_002037	AGACAGGTTACATTC	stop_gained&protein_altering_variant	HIGH	FYN	ENSG00000010810	Transcript	ENST00000354650	protein_coding	6/14		c.415_416insGAATGTAACCTGTCT	1022-1023	415-416	139	A/GM*PVS	gct/gGAATGTAACCTGTCTct			-1		insertion	HGNC	HGNC:4037	YES	MANE_Select	NM_002037.5		1	P3	CCDS5094.1	ENSP00000346671	P06241.274		UPI0000141141	P06241-1					PDB-ENSP_mappings:1a0n.B&PDB-ENSP_mappings:1avz.C&PDB-ENSP_mappings:1azg.B&PDB-ENSP_mappings:1efn.A&PDB-ENSP_mappings:1efn.C&PDB-ENSP_mappings:1fyn.A&PDB-ENSP_mappings:1g83.A&PDB-ENSP_mappings:1g83.B&PDB-ENSP_mappings:1m27.C&PDB-ENSP_mappings:1nyf.A&PDB-ENSP_mappings:1nyg.A&PDB-ENSP_mappings:1shf.A&PDB-ENSP_mappings:1shf.B&PDB-ENSP_mappings:1zbj.A&PDB-ENSP_mappings:3h0f.A&PDB-ENSP_mappings:3h0h.A&PDB-ENSP_mappings:3h0i.A&PDB-ENSP_mappings:3h0i.B&PDB-ENSP_mappings:3ua6.A&PDB-ENSP_mappings:3ua6.B&PDB-ENSP_mappings:3ua7.A&PDB-ENSP_mappings:3ua7.B&PDB-ENSP_mappings:3ua7.C&PDB-ENSP_mappings:3ua7.D&PDB-ENSP_mappings:4d8d.A&PDB-ENSP_mappings:4d8d.C&PDB-ENSP_mappings:4eik.A&PDB-ENSP_mappings:4znx.A&PDB-ENSP_mappings:4znx.B&PDB-ENSP_mappings:4znx.C&PDB-ENSP_mappings:4znx.D&PDB-ENSP_mappings:5zau.A&PDB-ENSP_mappings:6edf.A&PDB-ENSP_mappings:6ipy.A&PDB-ENSP_mappings:6ipz.Z&PDB-ENSP_mappings:7a2j.A&PDB-ENSP_mappings:7a2j.B&PDB-ENSP_mappings:7a2k.A&PDB-ENSP_mappings:7a2k.B&PDB-ENSP_mappings:7a2k.C&PDB-ENSP_mappings:7a2k.D&PDB-ENSP_mappings:7a2l.A&PDB-ENSP_mappings:7a2l.B&PDB-ENSP_mappings:7a2m.A&PDB-ENSP_mappings:7a2m.B&PDB-ENSP_mappings:7a2n.A&PDB-ENSP_mappings:7a2n.B&PDB-ENSP_mappings:7a2n.C&PDB-ENSP_mappings:7a2n.D&PDB-ENSP_mappings:7a2o.A&PDB-ENSP_mappings:7a2p.A&PDB-ENSP_mappings:7a2q.A&PDB-ENSP_mappings:7a2r.A&PDB-ENSP_mappings:7a2s.A&PDB-ENSP_mappings:7a2t.A&PDB-ENSP_mappings:7a2u.A&PDB-ENSP_mappings:7a2v.A&PDB-ENSP_mappings:7a2w.A&PDB-ENSP_mappings:7a2x.A&PDB-ENSP_mappings:7a2y.A&PDB-ENSP_mappings:7a2z.A&PDB-ENSP_mappings:7ud6.A&PDB-ENSP_mappings:8kdx.A&CDD:cd12006&Superfamily:SSF50044&PROSITE_profiles:PS50002&PANTHER:PTHR24418&Gene3D:2.30.30.40&SMART:SM00326&Prints:PR00452&AFDB-ENSP_mappings:AF-P06241-F1																																																				2.1500e-01																																																											101					0.931							239.97	v6.1	Unknown		True	FYN, a receptor tyrosine kinase, is altered by mutation in a variety of cancer types including hematologic malignancies and cholangiocarcinomas.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FYN ENSP00000346671.3:A139delinsGM* altered UNKNOWN.	False	The FYN ENSP00000346671.3:a139delinsGMensp00000346671.3:a139delinsgm* alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	112029152						True	False	False	Unknown								False	False		FYN, a receptor tyrosine kinase, is altered by mutation in a variety of cancer types including hematologic malignancies and cholangiocarcinomas.	The FYN ENSP00000346671.3:a139delinsGMensp00000346671.3:a139delinsgm* alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FYN ENSP00000346671.3:A139delinsGM* altered UNKNOWN.						v6.1	07/31/2019		GRCh38	FYN	2534.0	ENSP00000346671.3:A139delinsGM*			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""FYN"",""entrezGeneId"":2534,""alteration"":""ENSP00000346671.3:A139delinsGM*"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""FYN, a receptor tyrosine kinase, is altered by mutation in a variety of cancer types including hematologic malignancies and cholangiocarcinomas."",""variantSummary"":""The FYN ENSP00000346671.3:a139delinsGMensp00000346671.3:a139delinsgm* alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FYN ENSP00000346671.3:A139delinsGM* altered UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						91,3	42,1	49,2	0/1	43,48,1,2	AGC						56,35,3,0	9.86		0.031914893617021274
GRCh38	CCN6	D12_12345_1234556_Thyroid_S9	p.Q56H	ENSP00000357655.4:p.Gln56His	chr6	112061110	112061110.0	G	T	T	112061110	.	G	T	.	PASS	NM_198239	T	missense_variant	MODERATE	CCN6	ENSG00000112761	Transcript	ENST00000368666	protein_coding	2/5		c.168G>T	422	168	56	Q/H	caG/caT	rs1230345&COSV57889411		1		SNV	HGNC	HGNC:12771	YES	MANE_Select	NM_198239.2		1	P1	CCDS5098.1	ENSP00000357655	O95389.179	A0A384NYW3.27	UPI000004E930	O95389-1		1	tolerated(0.36)	benign(0)	AFDB-ENSP_mappings:AF-O95389-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00219&PIRSF:PIRSF036495&PROSITE_profiles:PS51323&PANTHER:PTHR11348&SMART:SM00121&Superfamily:SSF57184&Low_complexity_(Seg):seg			0.2989	0.4705	0.2392	0.3313	0.2465	0.1299	0.2698	0.4642	0.2001	0.3003	0.2986	0.2175	0.2342	0.2776	0.2746	0.1389	0.3134	0.4561	0.2149	0.2314	0.3076	0.3094	0.2087	0.2637	0.2752	0.3085	0.1463	0.4705	AFR	benign	0&1	1&1	27028512&29680248&31754465&32244273&35702583&39156961																0.039	1.0550e+00	355060	0.33615	0.26062	0.29892	301225	Progressive_pseudorheumatoid_dysplasia&not_provided		MONDO:MONDO:0008827&MedGen:C0432215&OMIM:208230&Orphanet:1159&MedGen:C3661900		NC_000006.12:g.112061110G>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000459669&SCV001722279&SCV001850493	single_nucleotide_variant	SO:0001483	ClinGen:CA3963924&UniProtKB:O95389																																																																																																																																															468,435	244,231	224,204	0/1	223,245,201,234	AGC	0.00	0.00	0.00			245,223,223,212	39.78		0.48172757475083056
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	116772391	116772393.0	T	TTC	TTC	116772391	.	T	TTC	.	PASS		TC	intergenic_variant	MODIFIER														rs2307839				insertion																						0.7027	0.7806	0.8084	0.5367	0.7416	0.6534											0.7499	0.7874	0.8037	0.7713	0.8907	0.5472	0.721	0.8401	0.7386	0.7716	0.6739	0.8907	gnomADg_ASJ				33801242																																																																												202					0.941							246.43													chr6	117093554																																																	True	False	False	Unknown		Unknown																						0,190	0,105	0,85	0/1	0,0,98,92	GTT						0,0,99,91	63.48		1.0
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9	p.Arg2077=	ENSP00000357493.3:p.Arg2077=	chr6	117310268	117310268.0	T	G	G	117310268	.	T	G	.	PASS	NM_001378902	G	synonymous_variant	LOW	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding	41/44		c.6229A>C	6515	6229	2077	R	Aga/Cga	rs552183&COSV63850804		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1			Gene3D:1.10.510.10&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF07714&Prints:PR00109&PROSITE_patterns:PS00109&PROSITE_profiles:PS50011&PANTHER:PTHR24416&SMART:SM00219&Superfamily:SSF56112&CDD:cd05044			0.1190	0.1331	0.1052	0.119	0.1451	0.0828	0.124	0.137	0.07702	0.1668	0.1264	0.108	0.1651	0.1262	0.1326	0.102	0.128	0.1403	0.2473	0.09892	0.1706	0.1276	0.1125	0.1395	0.1277	0.1345	0.09412	0.2473	gnomADg_AMI		0&1	0&1							FAIL	2	-25	2	-25	0.01	0.02	0.00	0.00	ROS1		9.9300e-01	3770433				3886584	not_provided		MedGen:C3661900		NC_000006.12:g.117310268T>G	criteria_provided&_single_submitter	Benign			SCV005889851	single_nucleotide_variant	SO:0001483			ROS1:6098	SO:0001819&synonymous_variant										1																												71					0.986							244.83	v6.1	Unknown		True	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	False	04/10/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:R2077= mutant UNKNOWN.	False	The ROS1 ENSP00000357493.3:r2077= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	117631431						True	False	False	Unknown								False	False		ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1 ENSP00000357493.3:r2077= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:R2077= mutant UNKNOWN.						v6.1	04/10/2017		GRCh38	ROS1	6098.0	ENSP00000357493.3:R2077=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ROS1"",""entrezGeneId"":6098,""alteration"":""ENSP00000357493.3:R2077="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer."",""variantSummary"":""The ROS1 ENSP00000357493.3:r2077= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:R2077= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/10/2017""}"	True	True	False	Unknown		Unknown																						39,31	24,19	15,12	0/1	22,17,13,18	CTA	.	.	.			19,20,19,12	29.23		0.44285714285714284
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117318256	117318256.0	T	C	C	117318256	.	T	C	.	PASS	NM_001378902	C	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		37/43	c.5923-4A>G						rs497186&COSV63853023		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.098	0.1032	0.1441	0.1094	0.1202	0.02065	0.07238	0.1767	0.115	0.1065	0.1586	0.1245	0.1248	0.1164	0.09463	0.02368	0.2467	0.08832	0.1777	0.1179	0.1105	0.1361	0.1272	0.1074	0.1105	0.2467	gnomADg_AMI		0&1	0&1							FAIL	-13	-4	5	-16	0.00	0.01	0.00	0.00	ROS1		9.9300e-01	3770434				3886585	not_provided		MedGen:C3661900		NC_000006.12:g.117318256T>C	criteria_provided&_single_submitter	Benign			SCV005889852	single_nucleotide_variant	SO:0001483			ROS1:6098	SO:0001627&intron_variant										1																												103					0.913							223.2													chr6	117639419																																																	True	True	False	Unknown		Unknown																						54,40	28,23	26,17	0/1	31,23,22,18	ATA	.	.	.			29,25,27,13	26.64		0.425531914893617
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117318457	117318457.0	G	T	T	117318457	.	G	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		37/43	c.5923-205C>A						rs501109&COSV104423542		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.098	0.1032	0.1441	0.1094											0.09489	0.02364	0.2456	0.08854	0.1778	0.1185	0.113	0.1361	0.1273	0.1075	0.1108	0.2456	gnomADg_AMI		0&1	0&1							FAIL	10	-39	16	-39	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											95					0.979							242.38													chr6	117639620																																																	True	True	False	Unknown		Unknown																						46,47	25,23	21,24	0/1	26,20,24,23	GGT	0.00	0.00	0.00			25,21,22,25	35.9		0.5053763440860215
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117318625	117318625.0	T	C	C	117318625	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		37/43	c.5923-373A>G						rs493548		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0863	0.0076	0.0951	0.1032	0.1441	0.1094											0.09469	0.02373	0.2467	0.08837	0.1778	0.1185	0.1106	0.1361	0.1272	0.1075	0.1106	0.2467	gnomADg_AMI										FAIL	-1	9	49	-43	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											103					0.951							241.58													chr6	117639788																																																	True	True	False	Unknown		Unknown																						45,53	23,33	22,20	0/1	30,15,26,27	ATT	.	.	.			28,17,28,25	39.54		0.5408163265306123
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117318657	117318657.0	A	G	G	117318657	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		37/43	c.5923-405T>C						rs493451		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1831	0.2269	0.134	0.1835	0.162	0.18											0.1674	0.2189	0.2599	0.1252	0.2281	0.1995	0.112	0.1599	0.1466	0.1692	0.1778	0.2599	gnomADg_AMI										FAIL	16	-10	13	17	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											97					0.948							239.33													chr6	117639820																																																	True	True	False	Unknown		Unknown																						43,49	21,29	22,20	0/1	16,27,26,23	TAA	.	.	.			22,21,26,23	38.4		0.532608695652174
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117319225	117319225.0	G	A	A	117319225	.	G	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		37/43	c.5922+643C>T						rs592757		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.098	0.1032	0.1441	0.1094											0.09468	0.02367	0.2462	0.08845	0.1775	0.118	0.1111	0.1361	0.1272	0.1075	0.1101	0.2462	gnomADg_AMI										FAIL	-5	38	29	-14	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											107					0.991							244.94													chr6	117640388																																																	True	True	False	Unknown		Unknown																						54,52	27,35	27,17	0/1	27,27,29,23	TGA	0.00	0.00	0.00			28,26,30,22	34.79		0.49056603773584906
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117320083	117320083.0	C	A	A	117320083	.	C	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		36/43	c.5760-53G>T						rs2243386&COSV63853919		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0873	0.0098	0.098	0.1032	0.1441	0.1094	0.1228	0.02456	0.07253	0.1781	0.1158	0.1068	0.161	0.1276	0.1275	0.1179	0.09547	0.0264	0.2473	0.08863	0.1773	0.1183	0.111	0.1361	0.1272	0.1082	0.1109	0.2473	gnomADg_AMI		0&1	0&1							FAIL	-21	-4	-21	1	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											146					0.849							229.79													chr6	117641246																																																	True	True	False	Unknown		Unknown																						58,66	28,35	30,31	0/1	34,24,42,24	ACA	0.00	0.00	0.00			34,24,41,25	40.23		0.532258064516129
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117320167	117320167.0	C	T	T	117320167	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		36/43	c.5760-137G>A						rs75236299&COSV104423543		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0873	0.0098	0.098	0.1032	0.1441	0.1094	0.1165	0.02478	0.08302	0.1727	0.1143	0.1068	0.1731	0.1203	0.1198	0.1138	0.09546	0.02646	0.2467	0.08834	0.1777	0.1185	0.1111	0.1361	0.1272	0.1079	0.1105	0.2467	gnomADg_AMI		0&1	0&1							FAIL	-30	-37	36	-36	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											134					0.769							228.95													chr6	117641330																																																	True	True	False	Unknown		Unknown																						51,52	15,27	36,25	0/1	29,22,32,20	ACG	0.00	0.00	0.00			23,28,25,27	36.06		0.5048543689320388
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117320311	117320311.0	G	A	A	117320311	.	G	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		36/43	c.5760-281C>T						rs78240410&COSV63861467		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0873	0.0098	0.098	0.1032	0.1441	0.1094											0.09544	0.02652	0.2451	0.08829	0.1773	0.1179	0.1109	0.1361	0.1272	0.1082	0.1108	0.2451	gnomADg_AMI		0&1	0&1							FAIL	-16	3	-1	-15	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											78					0.974							243.49													chr6	117641474																																																	True	True	False	Unknown		Unknown																						42,34	23,17	19,17	0/1	18,24,20,14	TGT	0.00	0.00	0.00			17,25,17,17	29.67		0.4473684210526316
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117320656	117320656.0	T	G	G	117320656	.	T	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		36/43	c.5759+603A>C						rs543230&COSV63861469		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.098	0.1032	0.1441	0.1094											0.09462	0.02367	0.2473	0.0885	0.1777	0.1179	0.1107	0.1361	0.1271	0.1069	0.1109	0.2473	gnomADg_AMI		0&1	0&1							FAIL	3	4	-20	4	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											117					1							242.84													chr6	117641819																																																	True	True	False	Unknown		Unknown																						64,53	38,29	26,24	0/1	31,33,28,25	ATC	.	.	.			29,35,32,21	30.14		0.452991452991453
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117320907	117320908.0	TA	T	T	117320907	.	TA	T	.	PASS	NM_001378902	-	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		36/43	c.5759+351del						rs147037238		-1		deletion	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0875	0.0098	0.098	0.1032	0.1441	0.1104											0.09538	0.02643	0.2467	0.08827	0.1778	0.1168	0.1109	0.1361	0.1272	0.1084	0.1103	0.2467	gnomADg_AMI										FAIL	4	-37	4	-4	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											194					0.851							233.18													chr6	117642070																																																	True	True	False	Unknown		Unknown																						82,83	38,50	44,33	0/1	47,35,48,35	GTA						51,31,51,32	36.82		0.503030303030303
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117322270	117322270.0	T	C	C	117322270	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5624-876A>G						rs492132&COSV63853923		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1256	0.0673	0.147	0.1528	0.1441	0.1421											0.1147	0.07246	0.2451	0.12	0.1777	0.1795	0.1119	0.1361	0.128	0.1255	0.1367	0.2451	gnomADg_AMI		0&1	0&1	22163003&25387708						FAIL	-31	4	-11	-36	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											113					0.912							237.11													chr6	117643433																																																	True	True	False	Unknown		Unknown																						49,54	25,33	24,21	0/1	26,23,30,24	CTC	.	.	.			28,21,31,23	38.36		0.5242718446601942
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117322496	117322496.0	C	G	G	117322496	.	C	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5624-1102G>C						rs489576&COSV63853926		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1248	0.0658	0.1455	0.1528	0.1441	0.1411											0.1148	0.07274	0.2467	0.1202	0.1777	0.1805	0.1114	0.1327	0.128	0.1256	0.1356	0.2467	gnomADg_AMI		0&1	0&1							FAIL	-27	27	-29	6	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											115					0.913							239													chr6	117643659																																																	True	True	False	Unknown		Unknown																						54,51	26,26	28,25	0/1	31,23,33,18	TCT	.	.	.			23,31,24,27	34.21		0.4857142857142857
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117322734	117322734.0	A	G	G	117322734	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5624-1340T>C						rs3798375&COSV63860856		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1733	0.1604	0.1527	0.0933	0.2028	0.2577											0.2003	0.1759	0.1086	0.1752	0.1646	0.1092	0.1955	0.1156	0.2277	0.1898	0.2639	0.2639	gnomADg_SAS		0&1	0&1							FAIL	49	13	-3	30	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											83					0.892							234.94													chr6	117643897																																																	True	True	False	Unknown		Unknown																						31,43	16,25	15,18	0/1	14,17,25,18	AAT	.	.	.			19,12,33,10	40.78		0.581081081081081
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117322891	117322891.0	T	C	C	117322891	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5623+1441A>G						rs687218&COSV63853930		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.098	0.1032	0.1441	0.1094											0.09458	0.02363	0.2467	0.08834	0.1772	0.1186	0.1104	0.1361	0.1272	0.1056	0.1105	0.2467	gnomADg_AMI		0&1	0&1							FAIL	0	45	1	-36	0.00	0.00	0.00	0.01	ROS1		9.9300e-01																																																											76					0.934							244.75													chr6	117644054																																																	True	True	False	Unknown		Unknown																						41,30	13,17	28,13	0/1	27,14,13,17	GTC	.	.	.			15,26,16,14	26.98		0.4225352112676056
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117322969	117322969.0	C	T	T	117322969	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5623+1363G>A						rs575006&COSV63853934		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.098	0.1032	0.1441	0.1094											0.09467	0.02361	0.2467	0.08861	0.1775	0.1182	0.1109	0.1361	0.1271	0.107	0.1112	0.2467	gnomADg_AMI		0&1	0&1	25323936						FAIL	-33	46	-3	1	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											89					0.921							235.87													chr6	117644132																																																	True	True	False	Unknown		Unknown																						39,43	13,24	26,19	0/1	20,19,19,24	ACA	0.00	0.00	0.00			18,21,22,21	37.08		0.524390243902439
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117323678	117323678.0	C	T	T	117323678	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5623+654G>A						rs568514&COSV63853936		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1246	0.0658	0.1455	0.1528	0.1441	0.1401											0.1149	0.07285	0.2467	0.1204	0.1777	0.1798	0.1113	0.1361	0.128	0.1254	0.1356	0.2467	gnomADg_AMI		0&1	0&1							FAIL	-42	-1	-6	-40	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											101					0.97							245.63													chr6	117644841																																																	True	True	False	Unknown		Unknown																						47,51	24,27	23,24	0|1	23,24,23,28	CCT	0.00	0.00	0.00		117644841	24,23,21,30	30.59		0.5204081632653061
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117323703	117323703.0	T	C	C	117323703	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5623+629A>G						rs546631&COSV63851643		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1929	0.2163	0.17	0.1964	0.161	0.2065											0.1672	0.2048	0.2599	0.1499	0.2203	0.2192	0.1128	0.1565	0.1469	0.172	0.1901	0.2599	gnomADg_AMI		0&1	0&1							FAIL	15	-26	47	3	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											88					0.966							245.99													chr6	117644866																																																	True	True	False	Unknown		Unknown																						47,38	21,20	26,18	0|1	24,23,20,18	TTA	.	.	.		117644841	24,23,16,22	22.37		0.4470588235294118
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117323878	117323878.0	C	T	T	117323878	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5623+454G>A						rs545537&COSV63853941		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1246	0.0658	0.1455	0.1528	0.1441	0.1401											0.1148	0.07269	0.2467	0.1201	0.178	0.1787	0.1116	0.1361	0.128	0.1255	0.1363	0.2467	gnomADg_AMI		0&1	0&1	20353593						FAIL	-18	-1	-18	1	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											188					0.941							228.34													chr6	117645041																																																	True	True	False	Unknown		Unknown																						97,80	47,41	50,39	0/1	58,39,41,39	ACT	0.00	0.00	0.00			52,45,50,30	29.4		0.4519774011299435
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117324076	117324076.0	C	T	T	117324076	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		35/43	c.5623+256G>A						rs543706&COSV63853944		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0865	0.0076	0.098	0.1032	0.1441	0.1084											0.09463	0.02358	0.2467	0.08837	0.1777	0.1177	0.1112	0.137	0.1271	0.1077	0.111	0.2467	gnomADg_AMI		0&1	0&1							FAIL	18	-14	-13	42	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											100					0.98							243.69													chr6	117645239																																																	True	True	False	Unknown		Unknown																						58,40	29,17	29,23	0/1	25,33,19,21	GCC	0.00	0.00	0.00			26,32,22,18	23.83		0.40816326530612246
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117325126	117325126.0	A	G	G	117325126	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		34/43	c.5540-711T>C						rs473006&COSV63853946		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0083	0.098	0.1032	0.1441	0.1084											0.0945	0.02355	0.2434	0.08853	0.1773	0.1174	0.1105	0.1361	0.1271	0.1069	0.1105	0.2434	gnomADg_AMI		0&1	0&1							FAIL	16	-13	16	18	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											101					0.99							243.26													chr6	117646289																																																	True	True	False	Unknown		Unknown																						49,51	25,24	24,27	0/1	22,27,20,31	AAC	.	.	.			18,31,23,28	36.54		0.51
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117325609	117325609.0	T	C	C	117325609	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		34/43	c.5539+615A>G						rs508278&COSV63851645		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1867	0.1929	0.17	0.1964	0.161	0.2065											0.1621	0.1864	0.2588	0.1489	0.2206	0.2195	0.1133	0.1531	0.147	0.1686	0.1908	0.2588	gnomADg_AMI		0&1	0&1							FAIL	25	26	26	16	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											115					0.974							225.35													chr6	117646772																																																	True	True	False	Unknown		Unknown																						63,49	37,32	26,17	0/1	36,27,32,17	GTC	.	.	.			34,29,31,18	27.92		0.4375
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117326089	117326098.0	GATTATATAT	G	G	117326089	.	GATTATATAT	G	.	PASS	NM_001378902	-	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		34/43	c.5539+126_5539+134del						rs201641328		-1		deletion	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1												0.05566	0.0151	0.03892	0.09332	0.06856	0.02803	0.1256	0.0548	0.05741	0.06629	0.1005	0.03426	0.323	0.1426	0.1797	0.1693	0.07328	0.157	0.1091	0.1332	0.1629	0.323	gnomADg_AMI																					9.9300e-01																																																											60					0.75							222.01													chr6	117647252																																																	True	True	False	Unknown		Unknown																						32,13	17,9	15,4	0/1	15,17,7,6	AGA						20,12,5,8	21.2		0.28888888888888886
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117326901	117326901.0	C	T	T	117326901	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		33/43	c.5349-487G>A						rs530713&COSV63853959		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0865	0.0076	0.098	0.1032	0.1441	0.1084											0.09464	0.02358	0.2462	0.08843	0.178	0.1178	0.1114	0.1361	0.1271	0.108	0.1098	0.2462	gnomADg_AMI		0&1	0&1							FAIL	23	10	28	24	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											112					1							239.68													chr6	117648064																																																	True	True	False	Unknown		Unknown																						68,44	30,21	38,23	0/1	39,29,23,21	GCT	0.00	0.00	0.00			33,35,24,20	20.26		0.39285714285714285
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117327177	117327177.0	C	T	T	117327177	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		33/43	c.5349-763G>A						rs528633&COSV63853961		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0865	0.0076	0.098	0.1032	0.1441	0.1084											0.09464	0.02356	0.2473	0.08824	0.1778	0.1178	0.1114	0.1361	0.1272	0.1078	0.1103	0.2473	gnomADg_AMI		0&1	0&1							FAIL	-33	50	33	17	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											168					0.994							237.69													chr6	117648340																																																	True	True	False	Unknown		Unknown																						83,84	37,34	46,50	0/1	35,48,43,41	TCC	0.00	0.00	0.00			45,38,43,41	38.11		0.5029940119760479
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117328010	117328010.0	C	T	T	117328010	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		33/43	c.5348+1319G>A						rs499599&COSV63853964		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0865	0.0076	0.098	0.1032	0.1441	0.1084											0.09468	0.02359	0.2467	0.08859	0.1779	0.1181	0.1111	0.1361	0.1272	0.108	0.1103	0.2467	gnomADg_AMI		0&1	0&1							FAIL	-43	19	12	-8	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											80					0.988							245.94													chr6	117649173																																																	True	True	False	Unknown		Unknown																						41,38	24,20	17,18	0/1	21,20,18,20	TCA	0.00	0.00	0.00			18,23,24,14	32.74		0.4810126582278481
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117328825	117328825.0	T	C	C	117328825	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		33/43	c.5348+504A>G						rs581235&COSV63851422&COSV63855905		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1494	0.1513	0.1571	0.1528	0.1471	0.1401	0.1382	0.147	0.1578	0.1918	0.1792	0.1064	0.174	0.1282	0.1429	0.1442	0.1371	0.1454	0.2467	0.1301	0.1907	0.1799	0.1115	0.1735	0.1298	0.1422	0.137	0.2467	gnomADg_AMI		0&1&1	0&1&1	37933079						FAIL	13	-12	-1	-12	0.00	0.22	0.00	0.00	ROS1		9.9300e-01																																																											91					0.989							244.28													chr6	117649988																																																	True	True	False	Unknown		Unknown																						42,48	24,23	18,25	0/1	23,19,24,24	ATT	.	.	.			17,25,27,21	38.34		0.5333333333333333
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117328968	117328968.0	A	T	T	117328968	.	A	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		33/43	c.5348+361T>A						rs574664&COSV63853970		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.0994	0.1032	0.1441	0.1084											0.09464	0.02368	0.2473	0.08854	0.1777	0.1181	0.1103	0.1361	0.1272	0.107	0.1104	0.2473	gnomADg_AMI		0&1	0&1	23339595						FAIL	-45	-5	-8	-5	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											97					1							241.77													chr6	117650131																																																	True	True	False	Unknown		Unknown																						59,38	32,11	27,27	0/1	32,27,19,19	AAG	.	.	.			35,24,16,22	21.17		0.3917525773195876
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117329637	117329637.0	G	A	A	117329637	.	G	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-191C>T						rs584647&COSV63851656		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1853	0.1876	0.17	0.1964	0.161	0.2065											0.1604	0.1818	0.2599	0.1474	0.2205	0.2175	0.113	0.1531	0.1469	0.1681	0.1882	0.2599	gnomADg_AMI		0&1	0&1							FAIL	50	-31	9	-31	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											661					0.983							227.4													chr6	117650800																																																	True	True	False	Unknown		Unknown																						338,312	169,158	169,154	0/1	184,154,140,172	AGT	0.00	0.00	0.00			197,141,198,114	37.25		0.48
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117330181	117330181.0	A	G	G	117330181	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-735T>C						rs541866&COSV63853975		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0865	0.0076	0.098	0.1032	0.1441	0.1084											0.09471	0.02363	0.2467	0.08834	0.1777	0.1181	0.1109	0.1361	0.1273	0.1068	0.1107	0.2467	gnomADg_AMI		0&1	0&1							FAIL	13	11	13	11	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											1132					0.997							165.96													chr6	117651344																																																	True	True	False	Unknown		Unknown																						573,556	303,292	270,264	0/1	278,295,260,296	AAC	.	.	.			276,297,270,286	49.01		0.4924712134632418
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117330763	117330763.0	T	C	C	117330763	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-1317A>G						rs521645		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.3556	0.382	0.2882	0.2778	0.3638	0.4397											0.3668	0.3895	0.3684	0.3015	0.3931	0.3108	0.3087	0.2755	0.3746	0.3602	0.4427	0.4427	gnomADg_SAS										FAIL	-20	-39	-20	-50	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											532					0.82							143.26													chr6	117651926																																																	True	True	False	Unknown		Unknown																						0,436	0,213	0,223	0/1	0,0,221,215	ATA	.	.	.			0,0,212,224	64.73		1.0
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117331024	117331024.0	T	C	C	117331024	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-1578A>G						rs518987&COSV63853980		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.0994	0.1032	0.1441	0.1084											0.09476	0.02367	0.2467	0.08884	0.1778	0.118	0.1112	0.1361	0.1273	0.1079	0.1104	0.2467	gnomADg_AMI		0&1	0&1							FAIL	12	-11	43	-11	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											153					0.941							195.76													chr6	117652187																																																	True	True	False	Unknown		Unknown																						77,67	30,30	47,37	0/1	47,30,39,28	ATG	.	.	.			30,47,36,31	31.93		0.4652777777777778
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117332132	117332132.0	G	A	A	117332132	.	G	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-2686C>T						rs2128603228		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1																						0	0	0	0	0	0	0	0	0	0	0	0	gnomADg_AFR&gnomADg_AMI&gnomADg_AMR&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_REMAINING&gnomADg_SAS										FAIL	-36	-38	19	43	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											169					0.846							153.47													chr6	117653295																																																	True	True	False	Unknown		Unknown																						139,4	64,2	75,2	0/1	83,56,0,4	AGG	0.00	0.00	1.00			84,55,2,2	11.7		0.027972027972027972
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117332137	117332137.0	T	G	G	117332137	.	T	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-2691A>C						rs1582645034		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1																						0	0	0	0	0	0	0	0	0	0	0	0	gnomADg_AFR&gnomADg_AMI&gnomADg_AMR&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_REMAINING&gnomADg_SAS										FAIL	-45	-41	-35	-11	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											167					0.826							155.2													chr6	117653300																																																	True	True	False	Unknown		Unknown																						130,8	60,3	70,5	0/1	79,51,4,4	TTG	.	.	.			77,53,5,3	10.91		0.057971014492753624
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117332181	117332181.0	A	G	G	117332181	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-2735T>C						rs9489127		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1482	0.1324	0.1239	0.1468	0.161	0.1748											0.139	0.1314	0.2599	0.1161	0.2203	0.1555	0.104	0.1463	0.145	0.1511	0.163	0.2599	gnomADg_AMI										FAIL	-13	33	-30	13	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											133					0.737							153.26													chr6	117653344																																																	True	True	False	Unknown		Unknown																						61,37	28,17	33,20	0/1	42,19,18,19	AAG	.	.	.			29,32,24,13	26.61		0.37755102040816324
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117332417	117332417.0	C	T	T	117332417	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-2971G>A								-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1																																												FAIL	-4	4	36	44	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											134					0.925							166.66													chr6	117653580																																																	True	True	False	Unknown		Unknown																						120,4	52,3	68,1	0/1	83,37,1,3	GCC	0.00	0.00	1.00			51,69,2,2	11.2		0.03225806451612903
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117332737	117332737.0	G	A	A	117332737	.	G	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5231-3291C>T						rs151318180&COSV63861477		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.0994	0.1032	0.1441	0.1084											0.09471	0.02365	0.2467	0.08888	0.1778	0.1178	0.1115	0.137	0.1271	0.1081	0.11	0.2467	gnomADg_AMI		0&1	0&1							FAIL	-17	8	2	-42	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											78					0.949							140.06													chr6	117653900																																																	True	True	False	Unknown		Unknown																						29,45	11,22	18,23	0/1	12,17,24,21	TGA	0.00	0.00	0.00			14,15,17,28	39.04		0.6081081081081081
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117333417	117333417.0	A	G	G	117333417	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+3755T>C						rs147199000&COSV63861482		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0869	0.0076	0.0994	0.1032	0.1451	0.1084											0.09464	0.02357	0.2467	0.08862	0.1777	0.1174	0.1106	0.1301	0.1273	0.1067	0.1102	0.2467	gnomADg_AMI		0&1	0&1							FAIL	29	-14	-9	16	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											78					0.936							113.29													chr6	117654580																																																	True	True	False	Unknown		Unknown																						38,35	21,18	17,17	0/1	20,18,23,12	CAA	.	.	.			23,15,20,15	32.34		0.4794520547945205
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117333837	117333837.0	A	G	G	117333837	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+3335T>C						rs117014103&COSV63853983		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.0994	0.1032	0.1441	0.1084											0.09467	0.02353	0.2467	0.08879	0.1775	0.118	0.1109	0.1361	0.1272	0.1074	0.1103	0.2467	gnomADg_AMI		0&1	0&1							FAIL	5	-41	-44	37	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											76					0.987							174.6													chr6	117655000																																																	True	True	False	Unknown		Unknown																						41,34	21,22	20,12	0/1	25,16,20,14	AAC	.	.	.			23,18,20,14	30.12		0.4533333333333333
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117333977	117333977.0	A	G	G	117333977	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+3195T>C						rs529905597		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0002	0	0	0.001	0	0											1.971e-05	0	0	0	0	0.0005798	0	0	0	0	0	0.001	EAS										FAIL	9	-15	-19	10	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											106					0.981							142.56													chr6	117655140																																																	True	True	False	Unknown		Unknown																						100,4	54,3	46,1	0/1	48,52,1,3	TAT	.	.	.			40,60,2,2	11.48		0.038461538461538464
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117334007	117334007.0	A	G	G	117334007	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+3165T>C						rs2128608149		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1																																												FAIL	-45	-21	-49	21	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											71					0.915							115.16													chr6	117655170																																																	True	True	False	Unknown		Unknown																						61,4	26,4	35,0	0|1	29,32,2,2	AAG	.	.	.		117655170	16,45,2,2	4.34		0.06153846153846154
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117334464	117334464.0	T	C	C	117334464	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+2708A>G						rs117333339&COSV63853988		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.0994	0.1032	0.1441	0.1084											0.09477	0.02362	0.2473	0.08869	0.1778	0.1181	0.1112	0.1361	0.1273	0.1075	0.1107	0.2473	gnomADg_AMI		0&1	0&1							FAIL	-1	-2	44	-2	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											63					0.968							208.38													chr6	117655627																																																	True	True	False	Unknown		Unknown																						40,21	21,14	19,7	0/1	18,22,13,8	GTT	.	.	.			23,17,16,5	17.8		0.3442622950819672
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117334807	117334807.0	G	A	A	117334807	.	G	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+2365C>T						rs145913971		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0867	0.0076	0.0994	0.1032	0.1441	0.1084											0.09472	0.0236	0.2467	0.08885	0.1773	0.1179	0.1112	0.1361	0.1272	0.1079	0.1106	0.2467	gnomADg_AMI										FAIL	-9	15	33	15	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											75					0.933							154.21													chr6	117655970																																																	True	True	False	Unknown		Unknown																						46,24	20,9	26,15	0/1	29,17,12,12	TGG	0.00	0.00	0.00			21,25,11,13	16.25		0.34285714285714286
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117334857	117334857.0	C	T	T	117334857	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+2315G>A						rs141926637&COSV63861489		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0871	0.0076	0.0994	0.1052	0.1441	0.1084											0.09483	0.02368	0.2467	0.08859	0.1777	0.1203	0.1112	0.1361	0.1273	0.1069	0.1105	0.2467	gnomADg_AMI		0&1	0&1							FAIL	-35	-1	43	30	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											58					0.828							152.06													chr6	117656020																																																	True	True	False	Unknown		Unknown																						32,16	15,6	17,10	0/1	16,16,11,5	ACT	0.00	0.00	0.00			17,15,7,9	18.45		0.3333333333333333
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117335176	117335176.0	G	A	A	117335176	.	G	A	.	PASS	NM_001378902	A	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+1996C>T						rs9481702&COSV63851668		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1889	0.1906	0.1715	0.2083	0.161	0.2076											0.1616	0.1834	0.2599	0.148	0.2203	0.2327	0.1136	0.1531	0.147	0.1682	0.1909	0.2599	gnomADg_AMI		0&1	0&1							FAIL	-5	11	19	11	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											114					0.921							169.31													chr6	117656339																																																	True	True	False	Unknown		Unknown																						52,53	26,32	26,21	0/1	23,29,36,17	GGC	0.00	0.00	0.00			35,17,29,24	36.29		0.5047619047619047
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117335392	117335392.0	T	G	G	117335392	.	T	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+1780A>C						rs9385006		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.7580	0.8517	0.7262	0.5694	0.7843	0.8211											0.7866	0.8422	0.6912	0.7707	0.7582	0.5996	0.6866	0.7381	0.7889	0.7697	0.7939	0.8517	AFR										FAIL	-11	44	-1	19	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											67					1							125.53													chr6	117656555																																																	True	True	False	Unknown		Unknown																						0,67	0,36	0,31	0/1	0,0,34,33	GTA	.	.	.			0,0,35,32	64.45		1.0
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117335432	117335432.0	A	G	G	117335432	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+1740T>C						rs9489130		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1508	0.1415	0.1254	0.1468	0.161	0.1748											0.143	0.1408	0.2604	0.1175	0.2203	0.1576	0.1125	0.1531	0.1463	0.1523	0.1643	0.2604	gnomADg_AMI										FAIL	13	-3	-21	2	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											72					0.972							136.28													chr6	117656595																																																	True	True	False	Unknown		Unknown																						35,35	19,24	16,11	0/1	18,17,20,15	CAA	.	.	.			14,21,15,20	34.3		0.5
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117336523	117336523.0	A	G	G	117336523	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+649T>C						rs12199518&COSV63857338		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0909	0.0106	0.1081	0.0933	0.1103	0.1646											0.08612	0.02459	0.01974	0.09974	0.08698	0.1083	0.09359	0.07483	0.1121	0.09272	0.1759	0.1759	gnomADg_SAS		0&1	0&1							FAIL	-39	-15	-38	25	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											77					0.974							202.1													chr6	117657686																																																	True	True	False	Unknown		Unknown																						31,44	15,21	16,23	0/1	15,16,21,23	CAT	.	.	.			11,20,20,24	41.24		0.5866666666666667
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117337030	117337030.0	G	C	C	117337030	.	G	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		32/43	c.5230+142C>G						rs17079053&COSV63853994		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0909	0.0227	0.1009	0.1032	0.1441	0.1084	0.1226	0.03483	0.08508	0.1745	0.1121	0.1061	0.1741	0.1274	0.1265	0.1157	0.09862	0.03685	0.2462	0.0909	0.1779	0.1182	0.1112	0.1395	0.1272	0.112	0.1099	0.2462	gnomADg_AMI		0&1	0&1							FAIL	-12	18	-1	-26	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											103					0.942							238.76													chr6	117658193																																																	True	True	False	Unknown		Unknown																						64,33	24,19	40,14	0/1	34,30,15,18	TGA	.	.	.			26,38,15,18	13.51		0.3402061855670103
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117337842	117337842.0	C	T	T	117337842	.	C	T	.	PASS	NM_001378902	T	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		31/43	c.5062-502G>A						rs1000153		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1735	0.1604	0.1527	0.0952	0.2008	0.2587											0.2007	0.1766	0.1086	0.1765	0.162	0.1102	0.1962	0.1156	0.2277	0.19	0.2647	0.2647	gnomADg_SAS										FAIL	47	2	-29	0	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											137					0.934							238.19													chr6	117659005																																																	True	True	False	Unknown		Unknown																						75,53	35,28	40,25	0|1	40,35,27,26	CCC	0.00	0.00	0.00		117659005	44,31,26,27	16.33		0.4140625
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117337863	117337863.0	A	G	G	117337863	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		31/43	c.5062-523T>C						rs1000154		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.1737	0.1611	0.1527	0.0942	0.2018	0.2587											0.2005	0.1762	0.1086	0.1766	0.1641	0.1101	0.1959	0.1156	0.2277	0.1909	0.2646	0.2646	gnomADg_SAS				32215555						FAIL	26	3	-50	31	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											135					0.933							238.18													chr6	117659026																																																	True	True	False	Unknown		Unknown																						72,54	33,28	39,26	0|1	33,39,29,25	GAA	.	.	.		117659005	36,36,25,29	19.1		0.42857142857142855
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117338690	117338690.0	C	G	G	117338690	.	C	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		31/43	c.5062-1350G>C						rs1894674&COSV63853997		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0909	0.0227	0.1009	0.1032	0.1441	0.1084											0.09856	0.03672	0.2467	0.09069	0.1775	0.1166	0.1114	0.1395	0.1273	0.1119	0.11	0.2467	gnomADg_AMI		0&1	1&1	27903959						FAIL	-30	5	35	5	0.00	0.00	0.00	0.12	ROS1		9.9300e-01																																																											92					0.913							238.87													chr6	117659853																																																	True	True	False	Unknown		Unknown																						45,39	21,27	24,12	0/1	24,21,19,20	GCT	.	.	.			22,23,19,20	31.61		0.4642857142857143
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117340101	117340101.0	T	C	C	117340101	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		31/43	c.5061+1034A>G						rs4145450&COSV63856583		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.9213	0.9175	0.9265	0.9405	0.8986	0.9264											0.9038	0.9156	0.9616	0.9345	0.8995	0.944	0.8565	0.898	0.892	0.9157	0.9185	0.9616	gnomADg_AMI		0&1	0&1							FAIL	36	-14	-12	3	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											75					0.933							234.72													chr6	117661264																																																	True	True	False	Unknown		Unknown																						0,70	0,32	0,38	0/1	0,0,34,36	TTA	.	.	.			0,0,34,36	64.49		1.0
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117340181	117340181.0	T	C	C	117340181	.	T	C	.	PASS	NM_001378902	C	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		31/43	c.5061+954A>G						rs2301486&COSV63854001		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0996	0.0507	0.1095	0.1032	0.1451	0.1084											0.1071	0.05869	0.2451	0.09421	0.1899	0.1176	0.1113	0.1497	0.1313	0.1171	0.1104	0.2451	gnomADg_AMI		0&1	0&1							FAIL	12	-44	-42	19	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											89					0.854							241.95													chr6	117661344																																																	True	True	False	Unknown		Unknown																						35,41	17,18	18,23	0/1	17,18,15,26	TTA	.	.	.			17,18,22,19	37.9		0.5394736842105263
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117340261	117340261.0	A	G	G	117340261	.	A	G	.	PASS	NM_001378902	G	intron_variant	MODIFIER	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		31/43	c.5061+874T>C						rs2301485&COSV63854004		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0875	0.0076	0.1037	0.1032	0.1451	0.1084											0.09712	0.02471	0.2467	0.09039	0.1896	0.1176	0.1109	0.1395	0.1309	0.1093	0.1102	0.2467	gnomADg_AMI		0&1	1&1	27903959						FAIL	19	26	47	2	0.00	0.00	0.00	0.00	ROS1		9.9300e-01																																																											91					0.956							240.41													chr6	117661424																																																	True	True	False	Unknown		Unknown																						33,54	13,27	20,27	0/1	20,13,30,24	CAC	.	.	.			18,15,23,31	44.53		0.6206896551724138
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9	p.G1610SerfsTer	ENSP00000357493.3:p.Gly1610SerfsTer16	chr6	117341450	117341457.0	GCCTTCCA	G	G	117341450	.	GCCTTCCA	G	.	PASS	NM_001378902	-	frameshift_variant	HIGH	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding	30/44		c.4827_4833del	5113-5119	4827-4833	1609-1611	NGR/X	aaTGGAAGG/aa			-1		deletion	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1			Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50853&PANTHER:PTHR24416&SMART:SM00060&Superfamily:SSF49265																																																				9.9300e-01																																																											90					0.911							232.7	v6.1	Unknown		True	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	False	04/10/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:G1610Sfs*16 mutant UNKNOWN.	False	The ROS1 ENSP00000357493.3:g1610sfs*16 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	117662613						True	False	False	Unknown								False	False		ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1 ENSP00000357493.3:g1610sfs*16 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:G1610Sfs*16 mutant UNKNOWN.						v6.1	04/10/2017		GRCh38	ROS1	6098.0	ENSP00000357493.3:G1610Sfs*16			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ROS1"",""entrezGeneId"":6098,""alteration"":""ENSP00000357493.3:G1610Sfs*16"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer."",""variantSummary"":""The ROS1 ENSP00000357493.3:g1610sfs*16 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:G1610Sfs*16 mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/10/2017""}"	True	True	False	Unknown		Unknown																						79,3	47,3	32,0	0/1	33,46,1,2	AGC						35,44,1,2	10.26		0.036585365853658534
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117356920	117356920.0	A	G	G	117356920	.	A	G	.	PASS	NM_001378902	G	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		25/43	c.3840-5T>C						rs2243384&COSV63851401&COSV63855476		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.3946	0.2012	0.3905	0.4762	0.497	0.4693	0.5053	0.23	0.4102	0.5453	0.4258	0.4326	0.5156	0.5267	0.486	0.4629	0.4177	0.2357	0.4429	0.4102	0.5429	0.4664	0.4259	0.5204	0.5149	0.4269	0.4618	0.5453	gnomADe_ASJ		0&1&1	0&1&1							FAIL	-5	-45	-22	40	0.02	0.00	0.00	0.00	ROS1		9.9300e-01	3387835				3546964	not_provided		MedGen:C3661900		NC_000006.12:g.117356920A>G	criteria_provided&_single_submitter	Benign			SCV005431597	single_nucleotide_variant	SO:0001483			ROS1:6098	SO:0001627&intron_variant										1																												60					0.9							242.7													chr6	117678083																																																	True	True	False	Unknown		Unknown																						27,27	14,14	13,13	0/1	13,14,10,17	TAG	.	.	.			6,21,9,18	33.63		0.5
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9			chr6	117366293	117366293.0	G	A	A	117366293	.	G	A	.	PASS	NM_001378902	A	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding		18/43	c.2583-3C>T						rs34245994&COSV104423552		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1						0.0032	0	0.0029	0	0.0129	0.001	0.01201	0.001436	0.002728	0.01233	2.52e-05	0.003833	0.002951	0.0144	0.01263	0.0007887	0.007736	0.002142	0.1064	0.004186	0.01268	0	0.003866	0.003401	0.01212	0.007561	0.0004146	0.1064	gnomADg_AMI	benign	0&1	1&1							FAIL	6	0	6	-3	0.00	0.18	0.00	0.00	ROS1		9.9300e-01	789289	0.00930	0.00750	0.00319	779186	not_provided		MedGen:C3661900		NC_000006.12:g.117366293G>A	criteria_provided&_single_submitter	Benign			SCV001119567	single_nucleotide_variant	SO:0001483	ClinGen:CA3975224		ROS1:6098	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	34245994																											89					0.978							231.29													chr6	117687456																																																	True	True	False	Unknown		Unknown																						37,50	15,28	22,22	0/1	18,19,25,25	TGC	0.00	0.00	0.00			22,15,23,27	41.57		0.5747126436781609
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9	p.R176Q	ENSP00000357493.3:p.Arg176Gln	chr6	117403216	117403216.0	C	T	T	117403216	.	C	T	.	PASS	NM_001378902	T	missense_variant	MODERATE	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding	7/44		c.527G>A	813	527	176	R/Q	cGa/cAa	rs2243380&COSV63853037&COSV63858933		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1	tolerated(0.1)	benign(0.344)	Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50853&SMART:SM00060&Superfamily:SSF49265&CDD:cd00063			0.0501	0.0038	0.0865	0.0407	0.0934	0.0521	0.08107	0.01431	0.05509	0.09393	0.05691	0.07813	0.08298	0.08676	0.0794	0.05665	0.06281	0.01559	0.1681	0.0662	0.09222	0.05476	0.0765	0.09524	0.08663	0.0767	0.05261	0.1681	gnomADg_AMI		0&1&1	0&1&1	21119753&25530832						FAIL	-21	50	-4	12	0.00	0.00	0.00	0.00	ROS1	0.336	9.9300e-01	3387860				3546989	not_provided		MedGen:C3661900		NC_000006.12:g.117403216C>T	criteria_provided&_single_submitter	Benign			SCV005432990	single_nucleotide_variant	SO:0001483			ROS1:6098	SO:0001583&missense_variant										1																												143					0.958							238.84	v6.1	Unknown		True	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	False	04/10/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:R176Q mutant UNKNOWN.	False	The ROS1 ENSP00000357493.3:r176q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	117724379						True	False	False	Unknown								False	False		ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1 ENSP00000357493.3:r176q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:R176Q mutant UNKNOWN.						v6.1	04/10/2017		GRCh38	ROS1	6098.0	ENSP00000357493.3:R176Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ROS1"",""entrezGeneId"":6098,""alteration"":""ENSP00000357493.3:R176Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer."",""variantSummary"":""The ROS1 ENSP00000357493.3:r176q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:R176Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/10/2017""}"	True	True	False	Unknown		Unknown																						80,57	37,21	43,36	0/1	38,42,30,27	TCG	0.00	0.00	0.00			39,41,26,31	23.31		0.41605839416058393
GRCh38	ROS1	D12_12345_1234556_Thyroid_S9	p.Leu110=	ENSP00000357493.3:p.Leu110=	chr6	117404415	117404415.0	T	A	A	117404415	.	T	A	.	PASS	NM_001378902	A	synonymous_variant	LOW	ROS1	ENSG00000047936	Transcript	ENST00000368507	protein_coding	6/44		c.330A>T	616	330	110	L	ctA/ctT	rs2243378&COSV63852338		-1		SNV	HGNC	HGNC:10261	YES	MANE_Select	NM_001378902.1		5	P1	CCDS93994.1	ENSP00000357493		Q5H8Y1.123	UPI0000470AE6			1			Gene3D:2.60.40.10&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS50853&SMART:SM00060&Superfamily:SSF49265			0.6751	0.9244	0.5231	0.5675	0.502	0.7352	0.4964	0.8822	0.4728	0.4067	0.5692	0.6126	0.5314	0.465	0.5221	0.6652	0.6046	0.8658	0.5683	0.4991	0.414	0.5654	0.6196	0.534	0.4752	0.5756	0.6852	0.9244	AFR		0&1	0&1							FAIL	4	-33	4	41	0.00	0.02	0.00	0.00	ROS1		9.9300e-01																																																											213					0.981							247.62	v6.1	Unknown		True	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	False	04/10/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:L110= mutant UNKNOWN.	False	The ROS1 ENSP00000357493.3:l110= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	117725578						True	False	False	Unknown								False	False		ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1 ENSP00000357493.3:l110= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:L110= mutant UNKNOWN.						v6.1	04/10/2017		GRCh38	ROS1	6098.0	ENSP00000357493.3:L110=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ROS1"",""entrezGeneId"":6098,""alteration"":""ENSP00000357493.3:L110="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer."",""variantSummary"":""The ROS1 ENSP00000357493.3:l110= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ROS1 ENSP00000357493.3:L110= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/10/2017""}"	True	True	False	Unknown		Unknown																						107,102	50,40	57,62	0/1	46,61,57,45	GTA	.	.	.			41,66,35,67	36.51		0.4880382775119617
GRCh38	MYB	D12_12345_1234556_Thyroid_S9			chr6	135206205	135206206.0	C	CA	CA	135206205	.	C	CA	.	PASS	NM_001130173	A	intron_variant	MODIFIER	MYB	ENSG00000118513	Transcript	ENST00000341911	protein_coding		15/15	c.2169+2903dup						rs67836018		1		insertion	HGNC	HGNC:7545	YES	MANE_Select	NM_001130173.2		1	A1	CCDS47481.1	ENSP00000339992	P10242.223		UPI000002AE9A	P10242-4		1					22																	0.1971	0.1017	0.3237	0.1776	0.2819	0.2677	0.1188	0.1825	0.2413	0.1885	0.1747	0.3237	gnomADg_AMI										FAIL	48	-23	2	-23	0.00	0.00	0.00	0.00	MYB		4.4300e-01																																																											146					0.699							163.96													chr6	135527343																																																	True	True	False	Unknown		Unknown																						38,64	18,25	20,39	0/1	26,12,38,26	TCA						22,16,39,25	13.67		0.6274509803921569
GRCh38	MYB	D12_12345_1234556_Thyroid_S9			chr6	135213685	135213685.0	T	C	C	135213685	.	T	C	.	PASS	NM_001130173	C	intron_variant	MODIFIER	MYB	ENSG00000118513	Transcript	ENST00000341911	protein_coding		15/15	c.2170-4179T>C						rs210945		1		SNV	HGNC	HGNC:7545	YES	MANE_Select	NM_001130173.2		1	A1	CCDS47481.1	ENSP00000339992	P10242.223		UPI000002AE9A	P10242-4		1						0.9738	0.9955	0.9236	0.9633	0.9891	0.9755											0.9728	0.9944	0.9781	0.9263	0.9317	0.9561	0.9786	0.9524	0.973	0.965	0.9693	0.9955	AFR										FAIL	-43	17	-9	-35	0.00	0.00	0.00	0.00	MYB		4.4300e-01																																																											342					0.994							198.62													chr6	135534823																																																	True	True	False	Unknown		Unknown																						0,340	0,156	0,184	0/1	0,0,174,166	CTA	.	.	.			0,0,170,170	64.73		1.0
GRCh38	MYB	D12_12345_1234556_Thyroid_S9			chr6	135217369	135217370.0	C	CA	CA	135217369	.	C	CA	.	PASS	NM_001130173	A	intron_variant	MODIFIER	MYB	ENSG00000118513	Transcript	ENST00000341911	protein_coding		15/15	c.2170-485dup						rs35138768		1		insertion	HGNC	HGNC:7545	YES	MANE_Select	NM_001130173.2		1	A1	CCDS47481.1	ENSP00000339992	P10242.223		UPI000002AE9A	P10242-4		1					10	0.4169	0.2398	0.4366	0.496	0.5348	0.4397											0.4779	0.2926	0.6757	0.4875	0.5776	0.5254	0.5491	0.5938	0.5607	0.4736	0.5022	0.6757	gnomADg_AMI										FAIL	-28	19	-25	11	0.00	0.00	0.00	0.00	MYB		4.4300e-01																																																											396					0.866							231.36													chr6	135538507																																																	True	True	False	Unknown		Unknown																						54,289	27,131	27,158	0/1	27,27,155,134	TCA						22,32,127,162	41.16		0.8425655976676385
GRCh38	MYB	D12_12345_1234556_Thyroid_S9			chr6	135217454	135217454.0	G	A	A	135217454	.	G	A	.	PASS	NM_001130173	A	intron_variant	MODIFIER	MYB	ENSG00000118513	Transcript	ENST00000341911	protein_coding		15/15	c.2170-410G>A						rs2179308		1		SNV	HGNC	HGNC:7545	YES	MANE_Select	NM_001130173.2		1	A1	CCDS47481.1	ENSP00000339992	P10242.223		UPI000002AE9A	P10242-4		1						0.4413	0.2466	0.451	0.506	0.5696	0.499											0.4766	0.2831	0.6659	0.4782	0.5522	0.5162	0.5591	0.5578	0.5694	0.4668	0.5126	0.6659	gnomADg_AMI				30934900&28134766						FAIL	13	15	-3	-38	0.00	0.00	0.00	0.00	MYB		4.4300e-01																																																											290					0.993							247.67													chr6	135538592																																																	True	True	False	Unknown		Unknown																						0,288	0,136	0,152	0/1	0,0,145,143	TGT	0.00	0.00	0.00			0,0,115,173	64.73		1.0
GRCh38	MYB	D12_12345_1234556_Thyroid_S9			chr6	135217501	135217501.0	A	G	G	135217501	.	A	G	.	PASS	NM_001130173	G	intron_variant	MODIFIER	MYB	ENSG00000118513	Transcript	ENST00000341911	protein_coding		15/15	c.2170-363A>G						rs1013891		1		SNV	HGNC	HGNC:7545	YES	MANE_Select	NM_001130173.2		1	A1	CCDS47481.1	ENSP00000339992	P10242.223		UPI000002AE9A	P10242-4		1						0.6573	0.6074	0.6974	0.62	0.7058	0.6851											0.6866	0.6184	0.7258	0.7011	0.6608	0.6302	0.7256	0.6633	0.7242	0.661	0.6962	0.7258	gnomADg_AMI			1	30934900&28134766&33462482						FAIL	-32	2	19	-50	0.00	0.00	0.00	0.00	MYB		4.4300e-01																																																											216					1							245.77													chr6	135538639																																																	True	True	False	Unknown		Unknown																						0,216	0,109	0,107	0/1	0,0,105,111	CAG	.	.	.			0,0,96,120	64.73		1.0
GRCh38	TNFAIP3	D12_12345_1234556_Thyroid_S9	p.F127C	ENSP00000481570.1:p.Phe127Cys	chr6	137874929	137874929.0	T	G	G	137874929	.	T	G	.	PASS	NM_001270508	G	missense_variant	MODERATE	TNFAIP3	ENSG00000118503	Transcript	ENST00000612899	protein_coding	3/9		c.380T>G	679	380	127	F/C	tTc/tGc	rs2230926&CM083789&COSV52797460		1		SNV	HGNC	HGNC:11896	YES	MANE_Select	NM_001270508.2		5	P1	CCDS5187.1	ENSP00000481570	P21580.228		UPI000000D92D			1	tolerated(0.05)	benign(0.034)	PDB-ENSP_mappings:2vfj.A&PDB-ENSP_mappings:2vfj.B&PDB-ENSP_mappings:2vfj.C&PDB-ENSP_mappings:2vfj.D&Gene3D:3.90.70.80&PDB-ENSP_mappings:3dkb.A&PDB-ENSP_mappings:3dkb.B&PDB-ENSP_mappings:3dkb.C&PDB-ENSP_mappings:3dkb.D&PDB-ENSP_mappings:3dkb.E&PDB-ENSP_mappings:3dkb.F&PDB-ENSP_mappings:3zjd.A&PDB-ENSP_mappings:3zjd.B&PDB-ENSP_mappings:3zje.A&PDB-ENSP_mappings:3zje.B&PDB-ENSP_mappings:3zjf.A&PDB-ENSP_mappings:3zjf.B&PDB-ENSP_mappings:3zjg.A&PDB-ENSP_mappings:3zjg.B&PDB-ENSP_mappings:5lrx.A&PDB-ENSP_mappings:5lrx.C&PDB-ENSP_mappings:5lrx.E&PDB-ENSP_mappings:5lrx.F&PDB-ENSP_mappings:5v3b.A&PDB-ENSP_mappings:5v3b.B&PDB-ENSP_mappings:5v3b.C&PDB-ENSP_mappings:5v3b.D&PDB-ENSP_mappings:5v3b.E&PDB-ENSP_mappings:5v3b.F&PDB-ENSP_mappings:5v3p.A&PDB-ENSP_mappings:5v3p.B&PDB-ENSP_mappings:5v3p.C&PDB-ENSP_mappings:5v3p.D&PDB-ENSP_mappings:5v3p.E&PDB-ENSP_mappings:5v3p.F&AFDB-ENSP_mappings:AF-P21580-F1&Pfam:PF02338&PROSITE_profiles:PS50802&CDD:cd22766			0.1396	0.4092	0.0778	0.0506	0.0239	0.0297	0.04253	0.3672	0.03946	0.04725	0.05819	0.01606	0.05687	0.03333	0.06039	0.03091	0.1265	0.3628	0	0.07315	0.04407	0.043	0.01677	0.05782	0.0313	0.1098	0.03125	0.4092	AFR	benign/likely_benign&not_provided&benign	0&1&1	1&1&1	24728327&27057306&31217170&21060334&23227085&21980439&22087647&23049788&20169177&33287909&20933377&22541939&26663301&28470010&20876667&35382527&24069534&25034154&30206443&30770922&23326239&23049601&25980667&30923465&22753952&24946689&22407130&19169254&21905002&22291604&22640752&33975174&34464884&27338350&23577190&27399966&34306371&21622953&26324017&31530986&34199962&34847931&23393188&25473424&21326317&28639493&28199970&25337792&35107652&27536202&19165918&28526340&19838193&32771030&30813592&22488580&21208380&23911423&20849588&29783072&28095483&19417005&19165919&20483768&24884566&26143186&28296250&28448618&22113471&21336280&19387456&22127930&20822710&19439038&19774492&20112363&20617138&21917936&22402800&22924496&24489017&24971370&25050625&25674272&25806576&26338037&26846592&26986245&27726311&28888761&30529365&30662920&31131138&31300459&31534975&32334614&32406335&34840214&35490943&36096187&20453841&35382378&28702029&31308453&27716397&26683155&33236284&33665595&34253242&33255258&31427375&32664585&24741605&3609609						FAIL	-31	14	-20	18	0.00	0.00	0.00	0.00	TNFAIP3		2.0900e-01	135334	0.14193		0.13958	139073	Autoinflammatory_syndrome&_familial&_Behcet-like_1&not_provided&not_specified		MONDO:MONDO:0800045&MedGen:C4225218&OMIM:616744&Orphanet:476102&Orphanet:674762&MedGen:C3661900&MedGen:CN169374		NC_000006.12:g.137874929T>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV001470929&SCV001646481&SCV001890536&SCV005227767	single_nucleotide_variant	SO:0001483	ClinGen:CA162415&UniProtKB:P21580																																																																																																																																															319,388	142,184	177,204	0/1	162,157,190,198	TTC	.	.	.			155,164,204,184	50.54		0.5487977369165488
GRCh38	ZBTB2	D12_12345_1234556_Thyroid_S9	p.Glu432=	ENSP00000323183.4:p.Glu432=	chr6	151365770	151365770.0	C	T	T	151365770	.	C	T	.	PASS	NM_020861	T	synonymous_variant	LOW	ZBTB2	ENSG00000181472	Transcript	ENST00000325144	protein_coding	3/3		c.1296G>A	1448	1296	432	E	gaG/gaA	rs11155787&COSV57312030		-1		SNV	HGNC	HGNC:20868	YES	MANE_Select	NM_020861.3		1	P1	CCDS5231.1	ENSP00000323183	Q8N680.182		UPI00000728EE						PANTHER:PTHR24394&AFDB-ENSP_mappings:AF-Q8N680-F1			0.4239	0.3517	0.5447	0.2778	0.6382	0.3661	0.6032	0.3802	0.5778	0.5908	0.354	0.6692	0.4563	0.6367	0.5674	0.3833	0.5407	0.3908	0.4211	0.5571	0.589	0.2946	0.6773	0.4422	0.6372	0.5332	0.3788	0.6773	gnomADg_FIN	benign	0&1	1&1	32042192&34594039						FAIL	23	-1	-27	36	0.00	0.00	0.00	0.00	ZBTB2		1.7900e-01	1286394	0.55451	0.54881	0.42392	1276231	not_provided		MedGen:C3661900		NC_000006.12:g.151365770C>T	criteria_provided&_single_submitter	Benign			SCV001938086	single_nucleotide_variant	SO:0001483	ClinGen:CA4050475		ZBTB2:57621	SO:0001819&synonymous_variant										1	11155787																											794					0.991							246.66	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr6	151686905						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	ZBTB2		ENSP00000323183.4:E432=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ZBTB2"",""entrezGeneId"":null,""alteration"":""ENSP00000323183.4:E432="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						422,365	201,195	221,170	0/1	233,189,197,168	CCT	0.00	0.00	0.00			254,168,203,162	26.84		0.46378653113087676
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9			chr6	151857493	151857493.0	C	A	A	151857493	.	C	A	.	PASS	NM_000125	A	intron_variant	MODIFIER	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding		2/7	c.643+14706C>A						rs827418		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1						0.4601	0.6203	0.3343	0.4514	0.3887	0.4151											0.4312	0.5532	0.3794	0.3181	0.4764	0.439	0.3142	0.4126	0.4051	0.4243	0.4112	0.6203	AFR										FAIL	14	43	-47	23	0.00	0.00	0.00	0.00	ESR1		4.5600e-01																																																											599					0.786							235.53													chr6	152178628																																																	True	True	False	Unknown		Unknown																						282,189	144,99	138,90	0/1	141,141,99,90	CCC	0.00	0.00	0.00			161,121,97,92	12.38		0.4012738853503185
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9	p.Arg243=	ENSP00000206249.3:p.Arg243=	chr6	151880740	151880740.0	T	C	C	151880740	.	T	C	.	PASS	NM_000125	C	synonymous_variant	LOW	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding	3/8		c.729T>C	960	729	243	R	cgT/cgC	rs4986934&COSV108024177		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1			PDB-ENSP_mappings:1hcp.A&PDB-ENSP_mappings:1hcq.A&PDB-ENSP_mappings:1hcq.B&PDB-ENSP_mappings:1hcq.E&PDB-ENSP_mappings:1hcq.F&Gene3D:3.30.50.10&PDB-ENSP_mappings:4aa6.A&PDB-ENSP_mappings:4aa6.B&PDB-ENSP_mappings:4aa6.E&PDB-ENSP_mappings:4aa6.F&AFDB-ENSP_mappings:AF-P03372-F1&Pfam:PF00105&PIRSF:PIRSF002527&PIRSF:PIRSF500101&Prints:PR00047&PROSITE_profiles:PS51030&PANTHER:PTHR48092&SMART:SM00399&Superfamily:SSF57716&CDD:cd07171			0.9856	0.997	0.964	1	0.9692	0.9877	0.9617	0.9946	0.9775	0.9404	0.9995	0.9598	0.9819	0.9578	0.965	0.9772	0.9729	0.9936	0.9989	0.9792	0.941	0.9996	0.9558	0.9966	0.9603	0.9768	0.977	1	EAS		0&1	1&1	19319135&15217512&18271972&18990228&30283335&23593326						FAIL	-30	-2	28	-2	0.00	0.00	0.07	0.00	ESR1		4.5600e-01																																																											841					0.996							243.79	v6.1	Unknown		True	ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.	False	07/23/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:R243= mutant UNKNOWN.	False	The ESR1 ENSP00000206249.3:r243= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	152201875						True	False	False	Unknown								False	False		ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.	The ESR1 ENSP00000206249.3:r243= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:R243= mutant UNKNOWN.						v6.1	07/23/2019		GRCh38	ESR1	2099.0	ENSP00000206249.3:R243=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ESR1"",""entrezGeneId"":2099,""alteration"":""ENSP00000206249.3:R243="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers."",""variantSummary"":""The ESR1 ENSP00000206249.3:r243= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:R243= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2019""}"	True	True	False	Unknown		Unknown																						0,838	0,403	0,435	0/1	0,0,410,428	GTA	.	.	.			0,0,459,379	64.73		1.0
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9			chr6	151908930	151908930.0	G	A	A	151908930	.	G	A	.	PASS	NM_000125	A	intron_variant	MODIFIER	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding		3/7	c.760+28159G>A						rs112950253		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1						0.0056	0.0008	0.0144	0	0.0169	0											0.01392	0.003168	0.05824	0.01777	0.0352	0	0.005734	0.02055	0.02085	0.01478	0.004375	0.05824	gnomADg_AMI										FAIL	-34	-13	23	-1	0.00	0.00	0.00	0.00	ESR1		4.5600e-01																																																											131					0.893							242.14													chr6	152230065																																																	True	True	False	Unknown		Unknown																						64,53	33,23	31,30	0/1	34,30,32,21	GGA	0.00	0.00	0.00			29,35,22,31	30		0.452991452991453
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9	p.Pro325=	ENSP00000206249.3:p.Pro325=	chr6	151944387	151944387.0	G	C	C	151944387	.	G	C	.	PASS	NM_000125	C	synonymous_variant	LOW	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding	4/8		c.975G>C	1206	975	325	P	ccG/ccC	rs1801132&CM016108&COSV52782058&COSV52791570		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1			Gene3D:1.10.565.10&PDB-ENSP_mappings:1a52.A&PDB-ENSP_mappings:1a52.B&PDB-ENSP_mappings:1ere.A&PDB-ENSP_mappings:1ere.B&PDB-ENSP_mappings:1ere.C&PDB-ENSP_mappings:1ere.D&PDB-ENSP_mappings:1ere.E&PDB-ENSP_mappings:1ere.F&PDB-ENSP_mappings:1err.A&PDB-ENSP_mappings:1err.B&PDB-ENSP_mappings:1g50.A&PDB-ENSP_mappings:1g50.B&PDB-ENSP_mappings:1g50.C&PDB-ENSP_mappings:1gwq.A&PDB-ENSP_mappings:1gwq.B&PDB-ENSP_mappings:1gwr.A&PDB-ENSP_mappings:1gwr.B&PDB-ENSP_mappings:1l2i.A&PDB-ENSP_mappings:1l2i.B&PDB-ENSP_mappings:1pcg.A&PDB-ENSP_mappings:1pcg.B&PDB-ENSP_mappings:1qkt.A&PDB-ENSP_mappings:1qku.A&PDB-ENSP_mappings:1qku.B&PDB-ENSP_mappings:1qku.C&PDB-ENSP_mappings:1r5k.A&PDB-ENSP_mappings:1r5k.B&PDB-ENSP_mappings:1r5k.C&PDB-ENSP_mappings:1sj0.A&PDB-ENSP_mappings:1uom.A&PDB-ENSP_mappings:1x7e.A&PDB-ENSP_mappings:1x7e.B&PDB-ENSP_mappings:1x7r.A&PDB-ENSP_mappings:1xp1.A&PDB-ENSP_mappings:1xp6.A&PDB-ENSP_mappings:1xp9.A&PDB-ENSP_mappings:1xpc.A&PDB-ENSP_mappings:1xqc.A&PDB-ENSP_mappings:1xqc.B&PDB-ENSP_mappings:1xqc.C&PDB-ENSP_mappings:1xqc.D&PDB-ENSP_mappings:1yim.A&PDB-ENSP_mappings:1yin.A&PDB-ENSP_mappings:1zky.A&PDB-ENSP_mappings:1zky.B&PDB-ENSP_mappings:2ayr.A&PDB-ENSP_mappings:2b1v.A&PDB-ENSP_mappings:2b1v.B&PDB-ENSP_mappings:2b1z.A&PDB-ENSP_mappings:2b1z.B&PDB-ENSP_mappings:2b23.A&PDB-ENSP_mappings:2b23.B&PDB-ENSP_mappings:2bj4.A&PDB-ENSP_mappings:2bj4.B&PDB-ENSP_mappings:2fai.A&PDB-ENSP_mappings:2fai.B&PDB-ENSP_mappings:2g44.A&PDB-ENSP_mappings:2g44.B&PDB-ENSP_mappings:2g5o.A&PDB-ENSP_mappings:2g5o.B&PDB-ENSP_mappings:2i0j.A&PDB-ENSP_mappings:2i0j.B&PDB-ENSP_mappings:2i0j.C&PDB-ENSP_mappings:2i0j.D&PDB-ENSP_mappings:2iog.A&PDB-ENSP_mappings:2iok.A&PDB-ENSP_mappings:2iok.B&PDB-ENSP_mappings:2jf9.A&PDB-ENSP_mappings:2jf9.B&PDB-ENSP_mappings:2jf9.C&PDB-ENSP_mappings:2jfa.A&PDB-ENSP_mappings:2jfa.B&PDB-ENSP_mappings:2ocf.A&PDB-ENSP_mappings:2ouz.A&PDB-ENSP_mappings:2p15.A&PDB-ENSP_mappings:2p15.B&PDB-ENSP_mappings:2pog.A&PDB-ENSP_mappings:2pog.B&PDB-ENSP_mappings:2q6j.A&PDB-ENSP_mappings:2q6j.B&PDB-ENSP_mappings:2q70.A&PDB-ENSP_mappings:2q70.B&PDB-ENSP_mappings:2qa6.A&PDB-ENSP_mappings:2qa6.B&PDB-ENSP_mappings:2qa8.A&PDB-ENSP_mappings:2qa8.B&PDB-ENSP_mappings:2qab.A&PDB-ENSP_mappings:2qab.B&PDB-ENSP_mappings:2qe4.A&PDB-ENSP_mappings:2qe4.B&PDB-ENSP_mappings:2qgt.A&PDB-ENSP_mappings:2qgt.B&PDB-ENSP_mappings:2qgw.A&PDB-ENSP_mappings:2qgw.B&PDB-ENSP_mappings:2qh6.A&PDB-ENSP_mappings:2qh6.B&PDB-ENSP_mappings:2qr9.A&PDB-ENSP_mappings:2qr9.B&PDB-ENSP_mappings:2qse.A&PDB-ENSP_mappings:2qse.B&PDB-ENSP_mappings:2qxm.A&PDB-ENSP_mappings:2qxm.B&PDB-ENSP_mappings:2qxs.A&PDB-ENSP_mappings:2qxs.B&PDB-ENSP_mappings:2qzo.A&PDB-ENSP_mappings:2qzo.B&PDB-ENSP_mappings:2r6w.A&PDB-ENSP_mappings:2r6w.B&PDB-ENSP_mappings:2r6y.A&PDB-ENSP_mappings:2r6y.B&PDB-ENSP_mappings:2yat.A&PDB-ENSP_mappings:2yja.B&PDB-ENSP_mappings:3dt3.A&PDB-ENSP_mappings:3dt3.B&PDB-ENSP_mappings:3erd.A&PDB-ENSP_mappings:3erd.B&PDB-ENSP_mappings:3ert.A&PDB-ENSP_mappings:3hlv.A&PDB-ENSP_mappings:3hlv.B&PDB-ENSP_mappings:3hm1.A&PDB-ENSP_mappings:3hm1.B&PDB-ENSP_mappings:3l03.A&PDB-ENSP_mappings:3l03.B&PDB-ENSP_mappings:3os8.A&PDB-ENSP_mappings:3os8.B&PDB-ENSP_mappings:3os8.C&PDB-ENSP_mappings:3os8.D&PDB-ENSP_mappings:3os9.A&PDB-ENSP_mappings:3os9.B&PDB-ENSP_mappings:3os9.C&PDB-ENSP_mappings:3os9.D&PDB-ENSP_mappings:3osa.A&PDB-ENSP_mappings:3osa.B&PDB-ENSP_mappings:3osa.C&PDB-ENSP_mappings:3osa.D&PDB-ENSP_mappings:3q95.A&PDB-ENSP_mappings:3q95.B&PDB-ENSP_mappings:3uu7.A&PDB-ENSP_mappings:3uu7.B&PDB-ENSP_mappings:3uua.A&PDB-ENSP_mappings:3uua.B&PDB-ENSP_mappings:3uuc.A&PDB-ENSP_mappings:3uuc.B&PDB-ENSP_mappings:3uuc.C&PDB-ENSP_mappings:3uuc.D&PDB-ENSP_mappings:3uud.A&PDB-ENSP_mappings:3uud.B&PDB-ENSP_mappings:4dma.A&PDB-ENSP_mappings:4dma.B&PDB-ENSP_mappings:4iu7.A&PDB-ENSP_mappings:4iu7.B&PDB-ENSP_mappings:4iui.A&PDB-ENSP_mappings:4iui.B&PDB-ENSP_mappings:4iv2.A&PDB-ENSP_mappings:4iv2.B&PDB-ENSP_mappings:4iv4.A&PDB-ENSP_mappings:4iv4.B&PDB-ENSP_mappings:4ivw.A&PDB-ENSP_mappings:4ivw.B&PDB-ENSP_mappings:4ivy.A&PDB-ENSP_mappings:4ivy.B&PDB-ENSP_mappings:4iw6.A&PDB-ENSP_mappings:4iw6.B&PDB-ENSP_mappings:4iw8.A&PDB-ENSP_mappings:4iw8.B&PDB-ENSP_mappings:4iwc.A&PDB-ENSP_mappings:4iwc.B&PDB-ENSP_mappings:4iwf.A&PDB-ENSP_mappings:4iwf.B&PDB-ENSP_mappings:4mg5.A&PDB-ENSP_mappings:4mg5.B&PDB-ENSP_mappings:4mg6.A&PDB-ENSP_mappings:4mg6.B&PDB-ENSP_mappings:4mg7.A&PDB-ENSP_mappings:4mg7.B&PDB-ENSP_mappings:4mg8.A&PDB-ENSP_mappings:4mg8.B&PDB-ENSP_mappings:4mg9.A&PDB-ENSP_mappings:4mg9.B&PDB-ENSP_mappings:4mga.A&PDB-ENSP_mappings:4mga.B&PDB-ENSP_mappings:4mgb.A&PDB-ENSP_mappings:4mgb.B&PDB-ENSP_mappings:4mgc.A&PDB-ENSP_mappings:4mgc.B&PDB-ENSP_mappings:4mgd.A&PDB-ENSP_mappings:4mgd.B&PDB-ENSP_mappings:4pp6.A&PDB-ENSP_mappings:4pp6.B&PDB-ENSP_mappings:4ppp.A&PDB-ENSP_mappings:4ppp.B&PDB-ENSP_mappings:4pps.A&PDB-ENSP_mappings:4pps.B&PDB-ENSP_mappings:4pxm.A&PDB-ENSP_mappings:4pxm.B&PDB-ENSP_mappings:4q13.A&PDB-ENSP_mappings:4q13.B&PDB-ENSP_mappings:4q50.A&PDB-ENSP_mappings:4q50.B&PDB-ENSP_mappings:4q50.C&PDB-ENSP_mappings:4q50.D&PDB-ENSP_mappings:4q50.E&PDB-ENSP_mappings:4q50.F&PDB-ENSP_mappings:4q50.G&PDB-ENSP_mappings:4q50.H&PDB-ENSP_mappings:4tuz.A&PDB-ENSP_mappings:4tuz.B&PDB-ENSP_mappings:4tv1.A&PDB-ENSP_mappings:4tv1.B&PDB-ENSP_mappings:4xi3.A&PDB-ENSP_mappings:4xi3.B&PDB-ENSP_mappings:4xi3.C&PDB-ENSP_mappings:4xi3.D&PDB-ENSP_mappings:4zn7.A&PDB-ENSP_mappings:4zn7.B&PDB-ENSP_mappings:4zn9.A&PDB-ENSP_mappings:4zn9.B&PDB-ENSP_mappings:4znh.A&PDB-ENSP_mappings:4znh.B&PDB-ENSP_mappings:4zns.A&PDB-ENSP_mappings:4zns.B&PDB-ENSP_mappings:4znt.A&PDB-ENSP_mappings:4znt.B&PDB-ENSP_mappings:4znu.A&PDB-ENSP_mappings:4znu.B&PDB-ENSP_mappings:4znv.A&PDB-ENSP_mappings:4znv.B&PDB-ENSP_mappings:4znw.A&PDB-ENSP_mappings:4znw.B&PDB-ENSP_mappings:5aau.A&PDB-ENSP_mappings:5aau.B&PDB-ENSP_mappings:5aav.A&PDB-ENSP_mappings:5aav.B&PDB-ENSP_mappings:5acc.A&PDB-ENSP_mappings:5ak2.A&PDB-ENSP_mappings:5ak2.B&PDB-ENSP_mappings:5di7.A&PDB-ENSP_mappings:5di7.B&PDB-ENSP_mappings:5did.A&PDB-ENSP_mappings:5did.B&PDB-ENSP_mappings:5die.A&PDB-ENSP_mappings:5die.B&PDB-ENSP_mappings:5dig.A&PDB-ENSP_mappings:5dig.B&PDB-ENSP_mappings:5dk9.A&PDB-ENSP_mappings:5dk9.B&PDB-ENSP_mappings:5dkb.A&PDB-ENSP_mappings:5dkb.B&PDB-ENSP_mappings:5dke.A&PDB-ENSP_mappings:5dke.B&PDB-ENSP_mappings:5dkg.A&PDB-ENSP_mappings:5dkg.B&PDB-ENSP_mappings:5dks.A&PDB-ENSP_mappings:5dks.B&PDB-ENSP_mappings:5dl4.A&PDB-ENSP_mappings:5dl4.B&PDB-ENSP_mappings:5dlr.A&PDB-ENSP_mappings:5dlr.B&PDB-ENSP_mappings:5dmc.A&PDB-ENSP_mappings:5dmc.B&PDB-ENSP_mappings:5dmf.A&PDB-ENSP_mappings:5dmf.B&PDB-ENSP_mappings:5dp0.A&PDB-ENSP_mappings:5dp0.B&PDB-ENSP_mappings:5drj.A&PDB-ENSP_mappings:5drj.B&PDB-ENSP_mappings:5drm.A&PDB-ENSP_mappings:5drm.B&PDB-ENSP_mappings:5dtv.A&PDB-ENSP_mappings:5dtv.B&PDB-ENSP_mappings:5du5.A&PDB-ENSP_mappings:5du5.B&PDB-ENSP_mappings:5due.A&PDB-ENSP_mappings:5due.B&PDB-ENSP_mappings:5dug.A&PDB-ENSP_mappings:5dug.B&PDB-ENSP_mappings:5duh.A&PDB-ENSP_mappings:5duh.B&PDB-ENSP_mappings:5dvs.A&PDB-ENSP_mappings:5dvs.B&PDB-ENSP_mappings:5dvv.A&PDB-ENSP_mappings:5dvv.B&PDB-ENSP_mappings:5dwe.A&PDB-ENSP_mappings:5dwe.B&PDB-ENSP_mappings:5dwg.A&PDB-ENSP_mappings:5dwg.B&PDB-ENSP_mappings:5dwi.A&PDB-ENSP_mappings:5dwi.B&PDB-ENSP_mappings:5dwj.A&PDB-ENSP_mappings:5dwj.B&PDB-ENSP_mappings:5dx3.A&PDB-ENSP_mappings:5dx3.B&PDB-ENSP_mappings:5dxb.A&PDB-ENSP_mappings:5dxb.B&PDB-ENSP_mappings:5dxe.A&PDB-ENSP_mappings:5dxe.B&PDB-ENSP_mappings:5dxg.A&PDB-ENSP_mappings:5dxg.B&PDB-ENSP_mappings:5dxk.A&PDB-ENSP_mappings:5dxk.B&PDB-ENSP_mappings:5dxm.A&PDB-ENSP_mappings:5dxm.B&PDB-ENSP_mappings:5dxp.A&PDB-ENSP_mappings:5dxp.B&PDB-ENSP_mappings:5dxq.A&PDB-ENSP_mappings:5dxq.B&PDB-ENSP_mappings:5dxr.A&PDB-ENSP_mappings:5dxr.B&PDB-ENSP_mappings:5dy8.A&PDB-ENSP_mappings:5dy8.B&PDB-ENSP_mappings:5dyb.A&PDB-ENSP_mappings:5dyb.B&PDB-ENSP_mappings:5dyd.A&PDB-ENSP_mappings:5dyd.B&PDB-ENSP_mappings:5dz0.A&PDB-ENSP_mappings:5dz0.B&PDB-ENSP_mappings:5dz1.A&PDB-ENSP_mappings:5dz1.B&PDB-ENSP_mappings:5dz3.A&PDB-ENSP_mappings:5dz3.B&PDB-ENSP_mappings:5dzh.A&PDB-ENSP_mappings:5dzh.B&PDB-ENSP_mappings:5dzi.A&PDB-ENSP_mappings:5dzi.B&PDB-ENSP_mappings:5e0w.A&PDB-ENSP_mappings:5e0w.B&PDB-ENSP_mappings:5e0x.A&PDB-ENSP_mappings:5e0x.B&PDB-ENSP_mappings:5e14.A&PDB-ENSP_mappings:5e14.B&PDB-ENSP_mappings:5e15.A&PDB-ENSP_mappings:5e15.B&PDB-ENSP_mappings:5e19.A&PDB-ENSP_mappings:5e19.B&PDB-ENSP_mappings:5e1c.A&PDB-ENSP_mappings:5e1c.B&PDB-ENSP_mappings:5egv.A&PDB-ENSP_mappings:5egv.B&PDB-ENSP_mappings:5ehj.A&PDB-ENSP_mappings:5ehj.B&PDB-ENSP_mappings:5ei1.A&PDB-ENSP_mappings:5ei1.B&PDB-ENSP_mappings:5eit.A&PDB-ENSP_mappings:5eit.B&PDB-ENSP_mappings:5fqp.A&PDB-ENSP_mappings:5fqr.A&PDB-ENSP_mappings:5fqs.A&PDB-ENSP_mappings:5fqt.A&PDB-ENSP_mappings:5fqv.A&PDB-ENSP_mappings:5gs4.A&PDB-ENSP_mappings:5gtr.A&PDB-ENSP_mappings:5hyr.A&PDB-ENSP_mappings:5hyr.B&PDB-ENSP_mappings:5jmm.A&PDB-ENSP_mappings:5jmm.B&PDB-ENSP_mappings:5kcc.A&PDB-ENSP_mappings:5kcc.B&PDB-ENSP_mappings:5kcd.A&PDB-ENSP_mappings:5kcd.B&PDB-ENSP_mappings:5kce.A&PDB-ENSP_mappings:5kce.B&PDB-ENSP_mappings:5kcf.A&PDB-ENSP_mappings:5kcf.B&PDB-ENSP_mappings:5kct.A&PDB-ENSP_mappings:5kct.B&PDB-ENSP_mappings:5kcu.A&PDB-ENSP_mappings:5kcu.B&PDB-ENSP_mappings:5kcw.A&PDB-ENSP_mappings:5kcw.B&PDB-ENSP_mappings:5kd9.A&PDB-ENSP_mappings:5kd9.B&PDB-ENSP_mappings:5kr9.A&PDB-ENSP_mappings:5kr9.B&PDB-ENSP_mappings:5kra.A&PDB-ENSP_mappings:5kra.B&PDB-ENSP_mappings:5kra.E&PDB-ENSP_mappings:5kra.F&PDB-ENSP_mappings:5krc.A&PDB-ENSP_mappings:5krc.B&PDB-ENSP_mappings:5krf.A&PDB-ENSP_mappings:5krf.B&PDB-ENSP_mappings:5krh.A&PDB-ENSP_mappings:5krh.B&PDB-ENSP_mappings:5kri.A&PDB-ENSP_mappings:5kri.B&PDB-ENSP_mappings:5krj.A&PDB-ENSP_mappings:5krj.B&PDB-ENSP_mappings:5krk.A&PDB-ENSP_mappings:5krk.B&PDB-ENSP_mappings:5krl.A&PDB-ENSP_mappings:5krl.B&PDB-ENSP_mappings:5krm.A&PDB-ENSP_mappings:5krm.B&PDB-ENSP_mappings:5kro.A&PDB-ENSP_mappings:5kro.B&PDB-ENSP_mappings:5t1z.A&PDB-ENSP_mappings:5t1z.B&PDB-ENSP_mappings:5t92.A&PDB-ENSP_mappings:5t92.B&PDB-ENSP_mappings:5t97.A&PDB-ENSP_mappings:5t97.B&PDB-ENSP_mappings:5tld.A&PDB-ENSP_mappings:5tld.B&PDB-ENSP_mappings:5tlf.A&PDB-ENSP_mappings:5tlf.B&PDB-ENSP_mappings:5tlg.A&PDB-ENSP_mappings:5tlg.B&PDB-ENSP_mappings:5tll.A&PDB-ENSP_mappings:5tll.B&PDB-ENSP_mappings:5tlm.A&PDB-ENSP_mappings:5tlm.B&PDB-ENSP_mappings:5tlo.A&PDB-ENSP_mappings:5tlo.B&PDB-ENSP_mappings:5tlp.A&PDB-ENSP_mappings:5tlp.B&PDB-ENSP_mappings:5tlt.A&PDB-ENSP_mappings:5tlt.B&PDB-ENSP_mappings:5tlu.A&PDB-ENSP_mappings:5tlu.B&PDB-ENSP_mappings:5tlv.A&PDB-ENSP_mappings:5tlv.B&PDB-ENSP_mappings:5tlx.A&PDB-ENSP_mappings:5tlx.B&PDB-ENSP_mappings:5tly.A&PDB-ENSP_mappings:5tly.B&PDB-ENSP_mappings:5tm1.A&PDB-ENSP_mappings:5tm1.B&PDB-ENSP_mappings:5tm2.A&PDB-ENSP_mappings:5tm2.B&PDB-ENSP_mappings:5tm3.A&PDB-ENSP_mappings:5tm3.B&PDB-ENSP_mappings:5tm4.A&PDB-ENSP_mappings:5tm4.B&PDB-ENSP_mappings:5tm5.A&PDB-ENSP_mappings:5tm5.B&PDB-ENSP_mappings:5tm6.A&PDB-ENSP_mappings:5tm6.B&PDB-ENSP_mappings:5tm7.A&PDB-ENSP_mappings:5tm7.B&PDB-ENSP_mappings:5tm8.A&PDB-ENSP_mappings:5tm8.B&PDB-ENSP_mappings:5tm9.A&PDB-ENSP_mappings:5tm9.B&PDB-ENSP_mappings:5tml.A&PDB-ENSP_mappings:5tml.B&PDB-ENSP_mappings:5tmm.A&PDB-ENSP_mappings:5tmm.B&PDB-ENSP_mappings:5tmo.A&PDB-ENSP_mappings:5tmo.B&PDB-ENSP_mappings:5tmq.A&PDB-ENSP_mappings:5tmq.B&PDB-ENSP_mappings:5tmr.A&PDB-ENSP_mappings:5tmr.B&PDB-ENSP_mappings:5tms.A&PDB-ENSP_mappings:5tms.B&PDB-ENSP_mappings:5tmt.A&PDB-ENSP_mappings:5tmt.B&PDB-ENSP_mappings:5tmu.A&PDB-ENSP_mappings:5tmu.B&PDB-ENSP_mappings:5tmv.A&PDB-ENSP_mappings:5tmv.B&PDB-ENSP_mappings:5tmw.A&PDB-ENSP_mappings:5tmw.B&PDB-ENSP_mappings:5tmz.A&PDB-ENSP_mappings:5tmz.B&PDB-ENSP_mappings:5tn1.A&PDB-ENSP_mappings:5tn1.B&PDB-ENSP_mappings:5tn3.A&PDB-ENSP_mappings:5tn3.B&PDB-ENSP_mappings:5tn4.A&PDB-ENSP_mappings:5tn4.B&PDB-ENSP_mappings:5tn5.A&PDB-ENSP_mappings:5tn5.B&PDB-ENSP_mappings:5tn6.A&PDB-ENSP_mappings:5tn6.B&PDB-ENSP_mappings:5tn7.A&PDB-ENSP_mappings:5tn7.B&PDB-ENSP_mappings:5tn8.A&PDB-ENSP_mappings:5tn8.B&PDB-ENSP_mappings:5tn9.A&PDB-ENSP_mappings:5tn9.B&PDB-ENSP_mappings:5tn9.C&PDB-ENSP_mappings:5tn9.D&PDB-ENSP_mappings:5tnb.A&PDB-ENSP_mappings:5tnb.B&PDB-ENSP_mappings:5tnb.C&PDB-ENSP_mappings:5tnb.D&PDB-ENSP_mappings:5u2b.A&PDB-ENSP_mappings:5u2b.B&PDB-ENSP_mappings:5u2b.C&PDB-ENSP_mappings:5u2b.D&PDB-ENSP_mappings:5u2b.E&PDB-ENSP_mappings:5u2b.F&PDB-ENSP_mappings:5u2d.A&PDB-ENSP_mappings:5u2d.B&PDB-ENSP_mappings:5ufw.A&PDB-ENSP_mappings:5ufw.B&PDB-ENSP_mappings:5ufx.A&PDB-ENSP_mappings:5ufx.B&PDB-ENSP_mappings:5w9c.A&PDB-ENSP_mappings:5w9c.B&PDB-ENSP_mappings:5w9c.C&PDB-ENSP_mappings:5w9c.D&PDB-ENSP_mappings:5w9d.A&PDB-ENSP_mappings:5w9d.B&PDB-ENSP_mappings:5wgd.A&PDB-ENSP_mappings:5wgd.B&PDB-ENSP_mappings:5wgq.A&PDB-ENSP_mappings:5wgq.B&PDB-ENSP_mappings:6b0f.A&PDB-ENSP_mappings:6b0f.B&PDB-ENSP_mappings:6c42.A&PDB-ENSP_mappings:6c42.B&PDB-ENSP_mappings:6cbz.A&PDB-ENSP_mappings:6cbz.B&PDB-ENSP_mappings:6chw.A&PDB-ENSP_mappings:6chz.A&PDB-ENSP_mappings:6czn.A&PDB-ENSP_mappings:6czn.B&PDB-ENSP_mappings:6d0f.A&PDB-ENSP_mappings:6d0f.B&PDB-ENSP_mappings:6df6.A&PDB-ENSP_mappings:6df6.B&PDB-ENSP_mappings:6df6.C&PDB-ENSP_mappings:6df6.D&PDB-ENSP_mappings:6dfn.A&PDB-ENSP_mappings:6dfn.B&PDB-ENSP_mappings:6dfn.C&PDB-ENSP_mappings:6dfn.D&PDB-ENSP_mappings:6iar.A&PDB-ENSP_mappings:6owc.A&PDB-ENSP_mappings:6owc.B&PDB-ENSP_mappings:6pet.A&PDB-ENSP_mappings:6pet.B&PDB-ENSP_mappings:6pet.C&PDB-ENSP_mappings:6pet.D&PDB-ENSP_mappings:6pfm.A&PDB-ENSP_mappings:6pfm.D&PDB-ENSP_mappings:6pit.A&PDB-ENSP_mappings:6pit.B&PDB-ENSP_mappings:6psj.A&PDB-ENSP_mappings:6psj.B&PDB-ENSP_mappings:6sbo.A&PDB-ENSP_mappings:6sbo.B&PDB-ENSP_mappings:6sq0.A&PDB-ENSP_mappings:6sq0.B&PDB-ENSP_mappings:6suo.A&PDB-ENSP_mappings:6suo.B&PDB-ENSP_mappings:6v87.A&PDB-ENSP_mappings:6v87.B&PDB-ENSP_mappings:6v8t.A&PDB-ENSP_mappings:6v8t.B&PDB-ENSP_mappings:6vgh.A&PDB-ENSP_mappings:6vgh.B&PDB-ENSP_mappings:6vjd.A&PDB-ENSP_mappings:6vjd.B&PDB-ENSP_mappings:6vjd.C&PDB-ENSP_mappings:6vjd.D&PDB-ENSP_mappings:6vpf.A&PDB-ENSP_mappings:6vpf.B&PDB-ENSP_mappings:6vpf.C&PDB-ENSP_mappings:6vpf.D&PDB-ENSP_mappings:6wok.A&PDB-ENSP_mappings:6wok.B&PDB-ENSP_mappings:6wok.C&PDB-ENSP_mappings:6wok.D&PDB-ENSP_mappings:6zoq.A&PDB-ENSP_mappings:6zoq.B&PDB-ENSP_mappings:6zor.A&PDB-ENSP_mappings:6zor.B&PDB-ENSP_mappings:6zos.A&PDB-ENSP_mappings:6zos.B&PDB-ENSP_mappings:7jhd.A&PDB-ENSP_mappings:7jhd.B&PDB-ENSP_mappings:7kbs.A&PDB-ENSP_mappings:7kbs.B&PDB-ENSP_mappings:7msa.A&PDB-ENSP_mappings:7msa.B&PDB-ENSP_mappings:7msa.C&PDB-ENSP_mappings:7msa.D&PDB-ENSP_mappings:7n9o.A&PDB-ENSP_mappings:7n9o.B&PDB-ENSP_mappings:7n9o.C&PDB-ENSP_mappings:7n9o.D&PDB-ENSP_mappings:7ndo.A&PDB-ENSP_mappings:7ndo.B&PDB-ENSP_mappings:7nel.A&PDB-ENSP_mappings:7nel.B&PDB-ENSP_mappings:7nfb.A&PDB-ENSP_mappings:7nfb.B&PDB-ENSP_mappings:7qvj.A&PDB-ENSP_mappings:7qvj.B&PDB-ENSP_mappings:7qvl.A&PDB-ENSP_mappings:7qvl.B&PDB-ENSP_mappings:7r62.A&PDB-ENSP_mappings:7rke.A&PDB-ENSP_mappings:7rke.B&PDB-ENSP_mappings:7rnm.A&PDB-ENSP_mappings:7rnm.B&PDB-ENSP_mappings:7rrx.A&PDB-ENSP_mappings:7rrx.B&PDB-ENSP_mappings:7rrx.C&PDB-ENSP_mappings:7rrx.D&PDB-ENSP_mappings:7rry.A&PDB-ENSP_mappings:7rry.B&PDB-ENSP_mappings:7rry.C&PDB-ENSP_mappings:7rry.D&PDB-ENSP_mappings:7rrz.A&PDB-ENSP_mappings:7rrz.B&PDB-ENSP_mappings:7rrz.C&PDB-ENSP_mappings:7rrz.D&PDB-ENSP_mappings:7rs0.A&PDB-ENSP_mappings:7rs0.B&PDB-ENSP_mappings:7rs0.C&PDB-ENSP_mappings:7rs0.D&PDB-ENSP_mappings:7rs1.A&PDB-ENSP_mappings:7rs1.B&PDB-ENSP_mappings:7rs1.C&PDB-ENSP_mappings:7rs1.D&PDB-ENSP_mappings:7rs2.A&PDB-ENSP_mappings:7rs2.B&PDB-ENSP_mappings:7rs2.C&PDB-ENSP_mappings:7rs2.D&PDB-ENSP_mappings:7rs3.A&PDB-ENSP_mappings:7rs3.B&PDB-ENSP_mappings:7rs3.C&PDB-ENSP_mappings:7rs3.D&PDB-ENSP_mappings:7rs4.A&PDB-ENSP_mappings:7rs4.B&PDB-ENSP_mappings:7rs4.C&PDB-ENSP_mappings:7rs4.D&PDB-ENSP_mappings:7rs7.A&PDB-ENSP_mappings:7rs7.B&PDB-ENSP_mappings:7rs7.C&PDB-ENSP_mappings:7rs7.D&PDB-ENSP_mappings:7rs8.A&PDB-ENSP_mappings:7rs8.B&PDB-ENSP_mappings:7rs8.C&PDB-ENSP_mappings:7rs8.D&PDB-ENSP_mappings:7rs9.A&PDB-ENSP_mappings:7rs9.B&PDB-ENSP_mappings:7rs9.C&PDB-ENSP_mappings:7rs9.D&PDB-ENSP_mappings:7sfo.A&PDB-ENSP_mappings:7sfo.B&PDB-ENSP_mappings:7t2x.A&PDB-ENSP_mappings:7t2x.B&PDB-ENSP_mappings:7te7.A&PDB-ENSP_mappings:7uj7.A&PDB-ENSP_mappings:7uj7.B&PDB-ENSP_mappings:7uj7.C&PDB-ENSP_mappings:7uj7.D&PDB-ENSP_mappings:7uj8.A&PDB-ENSP_mappings:7uj8.B&PDB-ENSP_mappings:7ujc.A&PDB-ENSP_mappings:7ujc.B&PDB-ENSP_mappings:7ujf.A&PDB-ENSP_mappings:7ujf.B&PDB-ENSP_mappings:7ujf.C&PDB-ENSP_mappings:7ujf.D&PDB-ENSP_mappings:7ujm.A&PDB-ENSP_mappings:7ujm.B&PDB-ENSP_mappings:7ujm.C&PDB-ENSP_mappings:7ujm.D&PDB-ENSP_mappings:7ujo.A&PDB-ENSP_mappings:7ujo.B&PDB-ENSP_mappings:7ujo.C&PDB-ENSP_mappings:7ujo.D&PDB-ENSP_mappings:7ujw.A&PDB-ENSP_mappings:7ujw.B&PDB-ENSP_mappings:7ujw.C&PDB-ENSP_mappings:7ujw.D&PDB-ENSP_mappings:7ujy.A&PDB-ENSP_mappings:7ujy.B&PDB-ENSP_mappings:7ujy.C&PDB-ENSP_mappings:7ujy.D&PDB-ENSP_mappings:7wnv.A&PDB-ENSP_mappings:7wnv.B&PDB-ENSP_mappings:7wnv.C&PDB-ENSP_mappings:7wnv.D&PDB-ENSP_mappings:7y8f.A&PDB-ENSP_mappings:7y8f.B&PDB-ENSP_mappings:7y8g.A&PDB-ENSP_mappings:7y8g.B&PDB-ENSP_mappings:7ymk.A&PDB-ENSP_mappings:7ymk.B&PDB-ENSP_mappings:8du6.A&PDB-ENSP_mappings:8du6.B&PDB-ENSP_mappings:8du8.A&PDB-ENSP_mappings:8du8.B&PDB-ENSP_mappings:8du9.A&PDB-ENSP_mappings:8du9.B&PDB-ENSP_mappings:8dub.A&PDB-ENSP_mappings:8dub.B&PDB-ENSP_mappings:8duc.A&PDB-ENSP_mappings:8dud.A&PDB-ENSP_mappings:8dug.A&PDB-ENSP_mappings:8dug.B&PDB-ENSP_mappings:8duh.A&PDB-ENSP_mappings:8duh.B&PDB-ENSP_mappings:8dui.A&PDB-ENSP_mappings:8dui.B&PDB-ENSP_mappings:8duk.A&PDB-ENSP_mappings:8duk.B&PDB-ENSP_mappings:8duk.C&PDB-ENSP_mappings:8duk.D&PDB-ENSP_mappings:8dus.A&PDB-ENSP_mappings:8dus.B&PDB-ENSP_mappings:8dus.E&PDB-ENSP_mappings:8dus.F&PDB-ENSP_mappings:8dus.G&PDB-ENSP_mappings:8dus.H&PDB-ENSP_mappings:8dv5.A&PDB-ENSP_mappings:8dv5.B&PDB-ENSP_mappings:8dv7.A&PDB-ENSP_mappings:8dv7.B&PDB-ENSP_mappings:8dv8.A&PDB-ENSP_mappings:8dv8.B&PDB-ENSP_mappings:8dvb.A&PDB-ENSP_mappings:8dvb.B&PDB-ENSP_mappings:8ev1.A&PDB-ENSP_mappings:8ev1.B&PDB-ENSP_mappings:8ev2.A&PDB-ENSP_mappings:8ev2.B&PDB-ENSP_mappings:8vyt.A&PDB-ENSP_mappings:8vyt.B&PDB-ENSP_mappings:8vyt.C&PDB-ENSP_mappings:8vyt.D&PDB-ENSP_mappings:8vyx.A&PDB-ENSP_mappings:8vyx.B&PDB-ENSP_mappings:8vyx.C&PDB-ENSP_mappings:8vyx.D&PDB-ENSP_mappings:8vz0.A&PDB-ENSP_mappings:8vz0.B&PDB-ENSP_mappings:8vz0.C&PDB-ENSP_mappings:8vz0.D&PDB-ENSP_mappings:8vz1.A&PDB-ENSP_mappings:8vz1.B&PDB-ENSP_mappings:8vz1.C&PDB-ENSP_mappings:8vz1.D&PDB-ENSP_mappings:8vzp.A&PDB-ENSP_mappings:8vzp.B&PDB-ENSP_mappings:8vzp.C&PDB-ENSP_mappings:8vzp.D&PDB-ENSP_mappings:8vzq.A&PDB-ENSP_mappings:8vzq.B&PDB-ENSP_mappings:8vzq.C&PDB-ENSP_mappings:8vzq.D&PDB-ENSP_mappings:8w03.A&PDB-ENSP_mappings:8w03.B&PDB-ENSP_mappings:8w03.C&PDB-ENSP_mappings:8w03.D&PDB-ENSP_mappings:8w07.A&PDB-ENSP_mappings:8w07.B&PDB-ENSP_mappings:8w07.C&PDB-ENSP_mappings:8w07.D&PDB-ENSP_mappings:9bqe.A&PDB-ENSP_mappings:9bqe.B&PDB-ENSP_mappings:9bu1.A&PDB-ENSP_mappings:9bu1.B&AFDB-ENSP_mappings:AF-P03372-F1&PIRSF:PIRSF002527&PIRSF:PIRSF500101&PROSITE_profiles:PS51843&PANTHER:PTHR48092&Superfamily:SSF48508&CDD:cd06949			0.7177	0.9342	0.7291	0.498	0.7893	0.5695	0.7516	0.9068	0.6961	0.8011	0.5014	0.7358	0.7486	0.7693	0.7462	0.6066	0.7887	0.8974	0.852	0.7439	0.7981	0.4969	0.7246	0.8095	0.7769	0.7909	0.5917	0.9342	AFR		0&1&1&1	1&1&1&1	19693267&20357209&21708280&21514219&28652652&19218192&15113403&15157284&18787887&20099281&30214429&25315199&27070141&24218030&35848345&20959426&27546373&23719583&28178648&22259677&26608979&20616674&19319135&18450649&20304699&19941161&18053221&21760950&25116933&20148360&18511131&18680103&18350145&17268813&19654868&15268889&16292600&23567436&21528353&19760036&18062975&15217512&16504171&17116097&17609999&18271972&18445666&18636479&18990228&19175383&19194457&19375130&19673915&19884274&20046055&20109228&20172949&20383761&21429951&22011627&22222969&22324545&22511967&22808109&22993654&24395301&25200861&25228414&26302681&26434778&28808214&31562548&32854465&33099762&33281037&35182276&18678289&26370976&26590813&29636617&28617822&34545128&16280269&18980759&29228205&32407592&23429186&20429621&32399466&31321026&23894347&28199202&23593326&28424560&25066711&28036262&29890676&31616008&32046629&36302831&23805288&31975979&23917948&24784887&23577061&17599809&33451133&28705582&23574728&26334887&25815259&24004806&24177593&3547778						FAIL	30	-32	-30	14	0.00	0.00	0.02	0.00	ESR1		4.5600e-01																																																											1156					1							246.47	v6.1	Unknown		True	ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.	False	07/23/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:P325= mutant UNKNOWN.	False	The ESR1 ENSP00000206249.3:p325= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	152265522						True	False	False	Unknown								False	False		ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.	The ESR1 ENSP00000206249.3:p325= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:P325= mutant UNKNOWN.						v6.1	07/23/2019		GRCh38	ESR1	2099.0	ENSP00000206249.3:P325=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ESR1"",""entrezGeneId"":2099,""alteration"":""ENSP00000206249.3:P325="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers."",""variantSummary"":""The ESR1 ENSP00000206249.3:p325= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:P325= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2019""}"	True	True	False	Unknown		Unknown																						601,555	292,269	309,286	0/1	305,296,297,258	CGA	.	.	.			310,291,267,288	39.64		0.4801038062283737
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9			chr6	151966005	151966006.0	GT	G	G	151966005	.	GT	G	.	PASS	NM_000125	-	intron_variant	MODIFIER	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding		4/7	c.1096+21499del						rs71713368		1		deletion	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1					1	0.7244	0.8396	0.804	0.5387	0.8419	0.5828											0.8056	0.8167	0.8648	0.84	0.8488	0.5377	0.7696	0.8973	0.8269	0.822	0.6101	0.8973	gnomADg_MID										FAIL	-27	-47	48	-34	0.00	0.00	0.00	0.00	ESR1		4.5600e-01																																																											117					0.915							231.38													chr6	152287140																																																	True	True	False	Unknown		Unknown																						56,51	26,30	30,21	0|1	26,30,28,23	AGT					152287140	34,22,25,26	25.24		0.4766355140186916
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9			chr6	151966008	151966008.0	G	C	C	151966008	.	G	C	.	PASS	NM_000125	C	intron_variant	MODIFIER	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding		4/7	c.1096+21500G>C						rs63741360		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1						0.7246	0.8404	0.804	0.5387	0.8419	0.5828											0.806	0.8169	0.8648	0.8404	0.8488	0.5382	0.7698	0.8973	0.8274	0.8227	0.6111	0.8973	gnomADg_MID										FAIL	-30	-34	-50	45	0.00	0.00	0.00	0.00	ESR1		4.5600e-01																																																											117					0.915							231.11													chr6	152287143																																																	True	True	False	Unknown		Unknown																						55,52	25,30	30,22	0|1	25,30,28,24	TGC	.	.	.		152287140	35,20,24,28	27.23		0.48598130841121495
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9			chr6	152042056	152042056.0	G	A	A	152042056	.	G	A	.	PASS	NM_000125	A	intron_variant	MODIFIER	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding		5/7	c.1236-18935G>A						rs2982728		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1						0.4874	0.5983	0.2406	0.5933	0.339	0.5562											0.4183	0.596	0.3692	0.2514	0.2754	0.5985	0.4011	0.3095	0.3361	0.3898	0.5548	0.5985	gnomADg_EAS										FAIL	13	-38	-36	29	0.00	0.00	0.00	0.00	ESR1		4.5600e-01																																																											136					0.993							172.32													chr6	152363191																																																	True	True	False	Unknown		Unknown																						82,53	37,25	45,28	0/1	43,39,26,27	CGC	0.00	0.00	0.00			32,50,22,31	18.53		0.3925925925925926
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9			chr6	152061259	152061259.0	C	G	G	152061259	.	C	G	.	PASS	NM_000125	G	intron_variant	MODIFIER	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding		6/7	c.1369+135C>G						rs9341017		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1						0.0090	0.0015	0.013	0.001	0.0219	0.0112	0.02504	0.005151	0.01696	0.06934	2.987e-05	0.00852	0.03311	0.02946	0.0265	0.01158	0.01939	0.005631	0.02083	0.01654	0.0585	0.0001928	0.00688	0.02721	0.03002	0.02604	0.01329	0.06934	gnomADe_ASJ	likely_benign		1							FAIL	1	16	-1	28	0.00	0.00	0.00	0.00	ESR1		4.5600e-01	1219496			0.00899	1209474	not_provided		MedGen:C3661900		NC_000006.12:g.152061259C>G	criteria_provided&_single_submitter	Likely_benign			SCV001824228	single_nucleotide_variant	SO:0001483	ClinGen:CA150439572		ESR1:2099	SO:0001627&intron_variant										1	9341017																											61					0.967							240.82													chr6	152382394																																																	True	True	False	Unknown		Unknown																						30,29	13,6	17,23	0/1	17,13,12,17	ACC	.	.	.			20,10,19,10	33.28		0.4915254237288136
GRCh38	ESR1	D12_12345_1234556_Thyroid_S9	p.Thr594=	ENSP00000206249.3:p.Thr594=	chr6	152098960	152098960.0	G	A	A	152098960	.	G	A	.	PASS	NM_000125	A	synonymous_variant	LOW	ESR1	ENSG00000091831	Transcript	ENST00000206249	protein_coding	8/8		c.1782G>A	2013	1782	594	T	acG/acA	rs2228480&CM056948&COSV52780915		1		SNV	HGNC	HGNC:3467	YES	MANE_Select	NM_000125.4		1	P1	CCDS5234.1	ENSP00000206249	P03372.293	G4XH65.94	UPI000004A328	P03372-1		1			PDB-ENSP_mappings:2ocf.A&PDB-ENSP_mappings:4jc3.B&PDB-ENSP_mappings:4jdd.B&PDB-ENSP_mappings:5n10.C&PDB-ENSP_mappings:5n10.D&PDB-ENSP_mappings:5n10.F&PDB-ENSP_mappings:6hhp.B&PDB-ENSP_mappings:6hkb.B&PDB-ENSP_mappings:6hkf.B&PDB-ENSP_mappings:6hmu.B&PDB-ENSP_mappings:6tjm.B&PDB-ENSP_mappings:6tl3.B&PDB-ENSP_mappings:7b9m.B&PDB-ENSP_mappings:7b9r.B&PDB-ENSP_mappings:7b9t.B&PDB-ENSP_mappings:7ba3.B&PDB-ENSP_mappings:7ba5.B&PDB-ENSP_mappings:7ba6.B&PDB-ENSP_mappings:7ba7.B&PDB-ENSP_mappings:7ba8.B&PDB-ENSP_mappings:7ba9.B&PDB-ENSP_mappings:7baa.B&PDB-ENSP_mappings:7bab.B&PDB-ENSP_mappings:7nfw.B&PDB-ENSP_mappings:7niz.B&PDB-ENSP_mappings:7opw.B&PDB-ENSP_mappings:7oq7.B&PDB-ENSP_mappings:7oq8.B&PDB-ENSP_mappings:7pwt.B&PDB-ENSP_mappings:7pwz.B&PDB-ENSP_mappings:8afn.B&PDB-ENSP_mappings:8ai0.B&PDB-ENSP_mappings:8alr.B&PDB-ENSP_mappings:8alt.B&PDB-ENSP_mappings:8alv.B&PDB-ENSP_mappings:8alw.B&PDB-ENSP_mappings:8am7.B&PDB-ENSP_mappings:8anf.B&PDB-ENSP_mappings:8aoy.B&PDB-ENSP_mappings:8aps.B&PDB-ENSP_mappings:8aq1.B&PDB-ENSP_mappings:8aqc.B&PDB-ENSP_mappings:8aqe.B&PDB-ENSP_mappings:8aqz.B&PDB-ENSP_mappings:8ar4.B&PDB-ENSP_mappings:8ar5.B&PDB-ENSP_mappings:8arg.B&PDB-ENSP_mappings:8aro.B&PDB-ENSP_mappings:8arq.B&PDB-ENSP_mappings:8arr.B&PDB-ENSP_mappings:8arw.B&PDB-ENSP_mappings:8arx.B&PDB-ENSP_mappings:8ary.B&PDB-ENSP_mappings:8arz.B&PDB-ENSP_mappings:8as1.B&PDB-ENSP_mappings:8at9.B&PDB-ENSP_mappings:8atp.B&PDB-ENSP_mappings:8au2.B&PDB-ENSP_mappings:8aus.B&PDB-ENSP_mappings:8auy.B&PDB-ENSP_mappings:8av3.B&PDB-ENSP_mappings:8av4.B&PDB-ENSP_mappings:8av7.B&PDB-ENSP_mappings:8av8.B&PDB-ENSP_mappings:8awg.B&PDB-ENSP_mappings:8axe.B&PDB-ENSP_mappings:8axu.B&PDB-ENSP_mappings:8aze.B&PDB-ENSP_mappings:8b39.B&PDB-ENSP_mappings:8bwj.B&PDB-ENSP_mappings:8bwx.B&PDB-ENSP_mappings:8bwz.B&PDB-ENSP_mappings:8bx0.B&PDB-ENSP_mappings:8bx3.B&PDB-ENSP_mappings:8bx4.B&PDB-ENSP_mappings:8bxi.B&PDB-ENSP_mappings:8bxm.B&PDB-ENSP_mappings:8bxn.B&PDB-ENSP_mappings:8bxo.B&PDB-ENSP_mappings:8bxq.B&PDB-ENSP_mappings:8bxs.B&PDB-ENSP_mappings:8by9.B&PDB-ENSP_mappings:8byb.B&PDB-ENSP_mappings:8byc.B&PDB-ENSP_mappings:8byd.B&PDB-ENSP_mappings:8bye.B&PDB-ENSP_mappings:8byf.B&PDB-ENSP_mappings:8byg.B&PDB-ENSP_mappings:8byo.B&PDB-ENSP_mappings:8byy.B&PDB-ENSP_mappings:8byz.B&PDB-ENSP_mappings:8bz0.B&PDB-ENSP_mappings:8bz9.B&PDB-ENSP_mappings:8bza.B&PDB-ENSP_mappings:8bzb.B&PDB-ENSP_mappings:8bzc.B&PDB-ENSP_mappings:8bzd.B&PDB-ENSP_mappings:8bze.B&PDB-ENSP_mappings:8bzf.B&PDB-ENSP_mappings:8bzg.B&PDB-ENSP_mappings:8bzh.B&PDB-ENSP_mappings:8bzt.B&PDB-ENSP_mappings:8bzw.B&PDB-ENSP_mappings:8c04.B&PDB-ENSP_mappings:8c0k.B&PDB-ENSP_mappings:8c42.B&PDB-ENSP_mappings:8c4f.B&PDB-ENSP_mappings:8c4g.B&AFDB-ENSP_mappings:AF-P03372-F1&Pfam:PF12743&PIRSF:PIRSF500101			0.1887	0.1452	0.2378	0.2014	0.175	0.2137	0.1897	0.1499	0.2648	0.1403	0.1923	0.1857	0.1112	0.19	0.1792	0.1905	0.179	0.1536	0.1099	0.2306	0.1312	0.2057	0.1827	0.08562	0.1839	0.1624	0.1898	0.2648	gnomADe_AMR	risk_factor&benign&likely_benign	0&1&1	1&1&1	20734064&19693267&20357209&21708280&28652652&20729390&25111588&33893823&15113403&15157284&32185656&30214429&27070141&29241914&35848345&20959426&24587880&19094228&21869864&21092186&22549291&24721264&28394528&29434720&30870275&20375995&26608979&19319135&20304699&19941161&25116933&27717337&19654868&35285722&15268889&19760036&16504171&17609999&18636479&19175383&20046055&20172949&20383761&21429951&22511967&22993654&24395301&31562548&33281037&35182276&18385916&26590813&29636617&18424448&18627768&19519176&19636371&19860576&19926619&20128071&28109853&28707126&33452979&33808990&30636932&27542969&32407811&31759353&35452412&18980759&34088265&29458346&20429621&31544208&26550281&33467215&36262248&34671317&27225751&23894347&36495498&28424560&36661054&35267063&31450692&29890676&36276944&36354656&32046629&23805288&35393538&27196727&15380041&35654312&24784887&22224819&24403849&33451133&28487205&29129999&23574728&26334887&23761956&29299489&24004806&24052609&35477782&17498544&16213680&19036616&18164902&17509487&15133719&3753099						FAIL	-40	0	-40	0	0.00	0.00	0.03	0.01	ESR1		4.5600e-01	1263746	0.17200	0.18928	0.18870	1251073	Migraine_with_or_without_aura&_susceptibility_to&not_provided&ESR1-related_disorder&Estrogen_resistance_syndrome&Migraine_with_or_without_aura&_susceptibility_to&_1&Familial_cancer_of_breast&Myocardial_infarction&_susceptibility_to		MONDO:MONDO:0100246&MedGen:CN300932&OMIM:PS157300&MedGen:C3661900&.&MONDO:MONDO:0014148&MedGen:C3809250&OMIM:615363&Orphanet:785&MONDO:MONDO:0008000&MedGen:C3887485&OMIM:157300&MONDO:MONDO:0016419&MedGen:C0346153&OMIM:114480&Orphanet:227535&MONDO:MONDO:0012039&MedGen:C1832662&OMIM:608446		NC_000006.12:g.152098960G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV001890571&SCV002796516	single_nucleotide_variant	SO:0001483	ClinGen:CA4052546&OMIM:133430.0005		ESR1:2099	SO:0001624&3_prime_UTR_variant&SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	2228480																											892					0.993							247.52	v6.1	Unknown		True	ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.	False	07/23/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:T594= mutant UNKNOWN.	False	The ESR1 ENSP00000206249.3:t594= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	152420095						True	False	False	Unknown								False	False		ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.	The ESR1 ENSP00000206249.3:t594= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:T594= mutant UNKNOWN.						v6.1	07/23/2019		GRCh38	ESR1	2099.0	ENSP00000206249.3:T594=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ESR1"",""entrezGeneId"":2099,""alteration"":""ENSP00000206249.3:T594="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers."",""variantSummary"":""The ESR1 ENSP00000206249.3:t594= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 ENSP00000206249.3:T594= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/23/2019""}"	True	True	False	Unknown		Unknown																						475,411	262,216	213,195	0/1	231,244,208,203	CGG	0.00	0.00	0.00			212,263,171,240	26		0.463882618510158
GRCh38	SYNE1	D12_12345_1234556_Thyroid_S9			chr6	152434466		C	[chr7:24971112[C	[chr7:24971112[C	152434466	MantaBND:9745:0:1:0:0:0:0	C	[chr7:24971112[C	.	PASS		.C	feature_truncation&intron_variant	HIGH	SYNE1	ENSG00000131018	Transcript	ENST00000673281	protein_coding		32/33									-1	cds_end_NF	chromosome_breakpoint	HGNC	HGNC:17089								ENSP00000500893		A0A5F9ZI52.20	UPI00123452D7			1																																																																																																														0			0,7							7	TGTTTCT			MantaBND:9745:0:1:0:0:0:1	3														chr6	152755601				BND																																													True	False	False	Unknown		Unknown																															1,1				1,2	
GRCh38	ARID1B	D12_12345_1234556_Thyroid_S9	p.Gln204=	ENSP00000490491.2:p.Gln204=	chr6	156778292	156778292.0	A	G	G	156778292	.	A	G	.	PASS	NM_001374828	G	synonymous_variant	LOW	ARID1B	ENSG00000049618	Transcript	ENST00000636930	protein_coding	1/20		c.612A>G	915	612	204	Q	caA/caG	rs78253128&COSV51649851&COSV51656192		1		SNV	HGNC	HGNC:18040	YES	MANE_Select	NM_001374828.1		2	A2	CCDS87459.2	ENSP00000490491	Q8NFD5.198	A0A6Q8NVI4.19	UPI00125CB504	Q8NFD5-3		1			AFDB-ENSP_mappings:AF-Q8NFD5-F1&Coiled-coils_(Ncoils):Coil&Phobius:NON_CYTOPLASMIC_DOMAIN&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.0425	0.121	0.0259	0.0129	0.0089	0.0133	0.004263	0.005375	0.003822	0.001572	0.0008916	0.01003	0.002172	0.004461	0.004295	0.0007261	0.004821	0.005707	0	0.005071	0.001172	0.000607	0.00737	0.003497	0.004838	0.002475	0.0004193	0.121	AFR	benign/likely_benign&benign	0&1&1	1&1&1	18414213						FAIL	-38	-41	13	36	0.00	0.00	0.00	0.00	ARID1B		2.0500e-01	126328	0.00030	0.00230	0.04253	131860	not_specified&Coffin-Siris_syndrome_1&Inborn_genetic_diseases&not_provided		MedGen:CN169374&MONDO:MONDO:0007617&MedGen:C3281201&OMIM:135900&Orphanet:1465&MeSH:D030342&MedGen:C0950123&MedGen:C3661900		NC_000006.12:g.156778292A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000147830&SCV000847681&SCV001832085&SCV002054212&SCV002432280&SCV005226195	single_nucleotide_variant	SO:0001483	ClinGen:CA151054		ARID1B:57492&LOC115308161:115308161	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	78253128																											894					0.779							204.45	v6.1	Unknown		True	ARID1B, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation or deletion in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1B ENSP00000490491.2:Q204= mutant UNKNOWN.	False	The ARID1B ENSP00000490491.2:q204= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	157099426						True	False	False	Unknown								False	False		ARID1B, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation or deletion in various cancer types.	The ARID1B ENSP00000490491.2:q204= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1B ENSP00000490491.2:Q204= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ARID1B	57492.0	ENSP00000490491.2:Q204=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ARID1B"",""entrezGeneId"":57492,""alteration"":""ENSP00000490491.2:Q204="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ARID1B, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The ARID1B ENSP00000490491.2:q204= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1B ENSP00000490491.2:Q204= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						445,251	241,127	204,124	0/1	203,242,119,132	AAC	.	.	.			213,232,101,150	11.8		0.36063218390804597
GRCh38	ARID1B	D12_12345_1234556_Thyroid_S9	p.Ala794=	ENSP00000490491.2:p.Ala794=	chr6	157084796	157084796.0	G	A	A	157084796	.	G	A	.	PASS	NM_001374828	A	synonymous_variant	LOW	ARID1B	ENSG00000049618	Transcript	ENST00000636930	protein_coding	5/20		c.2382G>A	2685	2382	794	A	gcG/gcA	rs3734441&COSV51659621		1		SNV	HGNC	HGNC:18040	YES	MANE_Select	NM_001374828.1		2	A2	CCDS87459.2	ENSP00000490491	Q8NFD5.198	A0A6Q8NVI4.19	UPI00125CB504	Q8NFD5-3		1			AFDB-ENSP_mappings:AF-Q8NFD5-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR12656&MobiDB_lite:mobidb-lite			0.4952	0.2806	0.6254	0.5734	0.5239	0.5828	0.5231	0.3335	0.6034	0.6063	0.571	0.392	0.5492	0.5245	0.5201	0.5707	0.473	0.3401	0.6828	0.558	0.589	0.5529	0.3862	0.6096	0.5245	0.4986	0.5845	0.6828	gnomADg_AMI	benign	0&1	1&1	18414213&23300646						FAIL	18	-4	-22	-5	0.00	0.00	0.00	0.00	ARID1B		2.0500e-01	126320	0.47263	0.51904	0.49521	131852	not_specified&Inborn_genetic_diseases&Coffin-Siris_syndrome_1&not_provided		MedGen:CN169374&MeSH:D030342&MedGen:C0950123&MONDO:MONDO:0007617&MedGen:C3281201&OMIM:135900&Orphanet:1465&MedGen:C3661900		NC_000006.12:g.157084796G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000147822&SCV000846132&SCV001775269&SCV001903703&SCV002464279	single_nucleotide_variant	SO:0001483	ClinGen:CA151040		ARID1B:57492	SO:0001623&5_prime_UTR_variant&SO:0001819&synonymous_variant										1	3734441																											1259					0.995							247.99	v6.1	Unknown		True	ARID1B, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation or deletion in various cancer types.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1B ENSP00000490491.2:A794= mutant UNKNOWN.	False	The ARID1B ENSP00000490491.2:a794= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr6	157405930						True	False	False	Unknown								False	False		ARID1B, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation or deletion in various cancer types.	The ARID1B ENSP00000490491.2:a794= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1B ENSP00000490491.2:A794= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	ARID1B	57492.0	ENSP00000490491.2:A794=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ARID1B"",""entrezGeneId"":57492,""alteration"":""ENSP00000490491.2:A794="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ARID1B, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation or deletion in various cancer types."",""variantSummary"":""The ARID1B ENSP00000490491.2:a794= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1B ENSP00000490491.2:A794= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						640,613	346,331	294,282	0/1	335,305,304,309	CGT	0.00	0.00	0.00			321,319,268,345	49.79		0.48922585794094176
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	157238417	157238509.0	GA	AGTGGTGATGATGGTAAAGATGAGGGTGATAGTGGTGATGGTGATGAGGGTGGCGGTGATGGTTGTGAGGATGAGTGTGATGGTGATGATGG	AGTGGTGATGATGGTAAAGATGAGGGTGATAGTGGTGATGGTGATGAGGGTGGCGGTGATGGTTGTGAGGATGAGTGTGATGGTGATGATGG	157238417	MantaINS:9801:0:0:0:2:0	GA	AGTGGTGATGATGGTAAAGATGAGGGTGATAGTGGTGATGGTGATGAGGGTGGCGGTGATGGTTGTGAGGATGAGTGTGATGGTGATGATGG	.	PASS		AGTGGTGATGATGGTAAAGATGAGGGTGATAGTGGTGATGGTGATGAGGGTGGCGGTGATGGTTGTGAGGATGAGTGTGATGGTGATGATGG	upstream_gene_variant	MODIFIER		ENSG00000295864	Transcript	ENST00000733291	lncRNA										2245	1		indel																																																																																																																																1M92I2D						157238418																					chr6	157641214		True	92	INS																																													True	False	False	Unknown		Unknown																															1,0				28,40	
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	157238573	157238856.0	G	<INS>	<INS>	157238573	MantaDUP:TANDEM:9801:0:1:0:0:0	G	<INS>	.	PASS		insertion	upstream_gene_variant	MODIFIER		ENSG00000295864	Transcript	ENST00000733291	lncRNA										1807	1		insertion																																																																																																																															-52,52		-47,47				283					True																	chr6	157641060		True	283	INS																																													True	False	False	Unknown		Unknown																															4,5					
GRCh38	MAP3K4	D12_12345_1234556_Thyroid_S9	p.R157H	ENSP00000375986.4:p.Arg157His	chr6	161048742	161048742.0	G	A	A	161048742	.	G	A	.	PASS	NM_005922	A	missense_variant	MODERATE	MAP3K4	ENSG00000085511	Transcript	ENST00000392142	protein_coding	3/27		c.470G>A	633	470	157	R/H	cGt/cAt	rs4559074&CM1616147&COSV104538709		1		SNV	HGNC	HGNC:6856	YES	MANE_Select	NM_005922.4		1	A2	CCDS34565.1	ENSP00000375986	Q9Y6R4.214		UPI00004574E1	Q9Y6R4-1			tolerated_low_confidence(1)	benign(0)	AFDB-ENSP_mappings:AF-Q9Y6R4-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF19431&PANTHER:PTHR48016			0.9842	1	0.9712	0.995	0.9563	0.9898	0.9569	0.9934	0.9689	0.9934	0.9953	0.9137	0.9901	0.9521	0.966	0.9876	0.9665	0.9915	0.9978	0.9751	0.9945	0.9975	0.9144	0.9932	0.9514	0.9712	0.9892	1	AFR		0&1&1	1&1&1	20624154&33462484						FAIL	10	-1	-44	10	0.00	0.00	0.00	0.02	MAP3K4	0.127	4.3700e-01																																																											114					0.974							227.04	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr6	161469774						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	MAP3K4		ENSP00000375986.4:R157H			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAP3K4"",""entrezGeneId"":null,""alteration"":""ENSP00000375986.4:R157H"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						0,111	0,55	0,56	0/1	0,0,57,54	CGT	0.00	0.00	0.00			0,0,53,58	64.7		1.0
GRCh38	MAP3K4	D12_12345_1234556_Thyroid_S9	p.A1199del	ENSP00000375986.4:p.Ala1199del	chr6	161098318	161098321.0	CCTG	C	C	161098318	.	CCTG	C	.	PASS	NM_005922	-	inframe_deletion	MODERATE	MAP3K4	ENSG00000085511	Transcript	ENST00000392142	protein_coding	17/27		c.3596_3598del	3729-3731	3566-3568	1189-1190	PA/P	cCTGct/cct	rs5881391		1		deletion	HGNC	HGNC:6856	YES	MANE_Select	NM_005922.4		1	A2	CCDS34565.1	ENSP00000375986	Q9Y6R4.214		UPI00004574E1	Q9Y6R4-1					AFDB-ENSP_mappings:AF-Q9Y6R4-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF19431&PANTHER:PTHR48016&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg		30							0.6346	0.6371	0.6272	0.6207	0.6213	0.6336	0.7297	0.6371	0.6294	0.6145	0.9464	0.9659	0.9868	0.9673	0.9726	0.9903	0.881	0.9897	0.9317	0.9547	0.9818	0.9903	gnomADg_EAS										FAIL	-46	-40	-19	-40	0.00	0.00	0.00	0.00	MAP3K4		4.3700e-01																																																											1065					0.706							226.04	v6.1	Unknown		False		False	01/29/2026	Unknown	MUTATION		False		chr6	161519350						False	False	False	Unknown								False	False										v6.1	01/29/2026		GRCh38	MAP3K4		ENSP00000375986.4:A1199del			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAP3K4"",""entrezGeneId"":null,""alteration"":""ENSP00000375986.4:A1199del"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":false,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":"""",""variantSummary"":"""",""tumorTypeSummary"":"""",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/29/2026""}"	True	False	False	Unknown		Unknown																						2,750	0,414	2,336	0/1	1,1,379,371	CCC						1,1,399,351	62.06		0.9973404255319149
GRCh38	PRKN	D12_12345_1234556_Thyroid_S9	p.V380L	ENSP00000355865.1:p.Val380Leu	chr6	161386823	161386823.0	C	G	G	161386823	.	C	G	.	PASS	NM_004562	G	missense_variant	MODERATE	PRKN	ENSG00000185345	Transcript	ENST00000366898	protein_coding	10/12		c.1138G>C	1236	1138	380	V/L	Gta/Cta	rs1801582&CM032983&COSV58214160		-1		SNV	HGNC	HGNC:8607	YES	MANE_Select	NM_004562.3		1	P1	CCDS5281.1	ENSP00000355865	O60260.230	X5DR79.68	UPI00003673FE	O60260-1		1	tolerated(0.8)	benign(0)	Gene3D:2.20.25.20&PDB-ENSP_mappings:2jmo.A&PDB-ENSP_mappings:4bm9.A&PDB-ENSP_mappings:4i1f.A&PDB-ENSP_mappings:4i1h.A&PDB-ENSP_mappings:5c1z.A&PDB-ENSP_mappings:5c1z.B&PDB-ENSP_mappings:5c23.A&PDB-ENSP_mappings:5c23.B&PDB-ENSP_mappings:5c9v.A&PDB-ENSP_mappings:5n2w.A&PDB-ENSP_mappings:5n38.A&PDB-ENSP_mappings:6glc.A&PDB-ENSP_mappings:6hue.A&PDB-ENSP_mappings:6hue.B&PDB-ENSP_mappings:6n13.B&PDB-ENSP_mappings:8jwv.A&AFDB-ENSP_mappings:AF-O60260-F1&PIRSF:PIRSF037880&PROSITE_profiles:PS51873			0.1721	0.177	0.1643	0.0853	0.173	0.2597	0.1683	0.1705	0.1216	0.2212	0.07438	0.1508	0.1546	0.1658	0.1684	0.2625	0.1691	0.1774	0.239	0.1587	0.2219	0.08462	0.1511	0.1156	0.1644	0.1937	0.2686	0.2686	gnomADg_SAS	benign	0&1&1	1&1&1	25741868&21738487&31681140&33574311&29992529&12975291&20301651&22361577&10319889&14639672&16793319&29706348&34281267&32399466&33519679&36255006&25887117&33343949&33617468&30510423&19351622&30034773&31308240&32345713&34440451&32856414&15261877&20506312&21188226&18321758&37626726&39088078																0.281	1.1700e+00	41221	0.17577		0.17212	49645	not_provided&Autosomal_recessive_juvenile_Parkinson_disease_2&Ovarian_neoplasm&Lung_cancer&not_specified		MedGen:C3661900&MONDO:MONDO:0010820&MedGen:C1868675&OMIM:600116&Orphanet:2828&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267&MONDO:MONDO:0008903&MedGen:C0242379&OMIM:211980&MedGen:CN169374		NC_000006.12:g.161386823C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000224957&SCV000310473&SCV000461687&SCV001721326&SCV002811292&SCV005091802	single_nucleotide_variant	SO:0001483	ClinGen:CA200721&UniProtKB:O60260																																																																																																																																															283,260	147,133	136,127	0/1	152,131,141,119	ACG	.	.	.			106,177,128,132	36.22		0.47882136279926335
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	164624257	164624257.0	C	T	T	164624257	.	C	T	.	PASS		T	intergenic_variant	MODIFIER														rs1390470				SNV																						0.9934	0.9796	0.9914	1	1	1											0.9943	0.9843	1	0.9915	1	1	0.9999	0.9796	0.9991	0.9915	0.9998	1	EAS&EUR&SAS&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS																																																																																102					0.931							238.54													chr6	165045290																																																	True	False	False	Unknown		Unknown																						1,94	0,44	1,50	0/1	1,0,53,41	ACA	0.00	0.00	0.00			0,1,53,41	51.91		0.9894736842105263
GRCh38		D12_12345_1234556_Thyroid_S9			chr6	164624301	164624301.0	G	T	T	164624301	.	G	T	.	PASS		T	intergenic_variant	MODIFIER														rs727811				SNV																						0.4878	0.202	0.4611	0.6369	0.5845	0.6401											0.4684	0.2691	0.6264	0.4663	0.5017	0.6652	0.5215	0.4592	0.5534	0.4981	0.5988	0.6652	gnomADg_EAS				26522768&26691610&29121662&33406744&19668368&18716610&22749789&19083859&24362753&32375366&27294018&19948332&20457083&38774862																																																																												118					0.949							239.42													chr6	165045334																																																	True	False	False	Unknown		Unknown																						59,53	31,28	28,25	0/1	26,33,31,22	TGT	0.00	0.00	0.00			36,23,26,27	32.84		0.4732142857142857
GRCh38	CARD11	D12_12345_1234556_Thyroid_S9	p.Arg1092=	ENSP00000380150.4:p.Arg1092=	chr7	2906827	2906827.0	T	C	C	2906827	.	T	C	.	PASS	NM_032415	C	synonymous_variant	LOW	CARD11	ENSG00000198286	Transcript	ENST00000396946	protein_coding	25/25		c.3276A>G	3602	3276	1092	R	cgA/cgG	rs1124581&COSV67797057		-1		SNV	HGNC	HGNC:16393	YES	MANE_Select	NM_032415.7		1	P1	CCDS5336.2	ENSP00000380150	Q9BXL7.195		UPI00003FED38			1			Gene3D:3.40.50.300&AFDB-ENSP_mappings:AF-Q9BXL7-F1&PANTHER:PTHR14559&Superfamily:SSF52540			0.5964	0.7012	0.5274	0.6508	0.4742	0.5736	0.4994	0.6629	0.5007	0.4571	0.6042	0.4138	0.4919	0.492	0.505	0.5446	0.544	0.6696	0.4989	0.5278	0.4527	0.6373	0.4123	0.5204	0.4884	0.5421	0.5655	0.7012	AFR	not_provided&benign	0&1	1&1	25741868&24033266						FAIL	47	11	36	11	0.00	0.01	0.00	0.00	CARD11		3.6400e-01	402477	0.54659	0.51631	0.59645	389742	Severe_combined_immunodeficiency_due_to_CARD11_deficiency&Immunodeficiency_11b_with_atopic_dermatitis&BENTA_disease&not_specified&not_provided		MONDO:MONDO:0014081&MedGen:C3554686&OMIM:615206&Orphanet:357237&MONDO:MONDO:0054697&MedGen:C4539957&OMIM:617638&MONDO:MONDO:0014645&MedGen:C4551967&OMIM:616452&Orphanet:464336&MedGen:CN169374&MedGen:C3661900		NC_000007.14:g.2906827T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000538572&SCV001727008&SCV001775827&SCV001775828&SCV001775829&SCV004101914	single_nucleotide_variant	SO:0001483	ClinGen:CA4131761		CARD11:84433	SO:0001819&synonymous_variant										1	1124581																											709					0.999							246.88	v6.1	Unknown		True	CARD11, a scaffolding protein, is altered in various cancer types including skin cancer and diffuse large B-cell lymphoma.	False	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CARD11 ENSP00000380150.4:R1092= mutant UNKNOWN.	False	The CARD11 ENSP00000380150.4:r1092= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	2946461						True	False	False	Unknown								False	False		CARD11, a scaffolding protein, is altered in various cancer types including skin cancer and diffuse large B-cell lymphoma.	The CARD11 ENSP00000380150.4:r1092= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CARD11 ENSP00000380150.4:R1092= mutant UNKNOWN.						v6.1	01/31/2018		GRCh38	CARD11	84433.0	ENSP00000380150.4:R1092=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CARD11"",""entrezGeneId"":84433,""alteration"":""ENSP00000380150.4:R1092="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CARD11, a scaffolding protein, is altered in various cancer types including skin cancer and diffuse large B-cell lymphoma."",""variantSummary"":""The CARD11 ENSP00000380150.4:r1092= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CARD11 ENSP00000380150.4:R1092= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/31/2018""}"	True	True	False	Unknown		Unknown																						373,335	201,168	172,167	0/1	180,193,166,169	GTC	.	.	.			154,219,133,202	33.04		0.4731638418079096
GRCh38	SDK1	D12_12345_1234556_Thyroid_S9			chr7	4270685	4270685.0	G	A	A	4270685	.	G	A	.	PASS		A	downstream_gene_variant	MODIFIER	SDK1	ENSG00000146555	Transcript	ENST00000476701	retained_intron									rs6950322	1685	1		SNV	HGNC	HGNC:19307					1															0.3193	0.3268	0.2795	0.3343	0.3588	0.2812											0.3319	0.3089	0.2275	0.2755	0.301	0.3132	0.4817	0.3231	0.3443	0.2976	0.2824	0.4817	gnomADg_FIN																																																																																452					1							247.29													chr7	4310317																																																	True	False	False	Unknown		Unknown																						229,223	124,111	105,112	0/1	105,124,113,110	GGA	0.00	0.00	0.00			126,103,121,102	41.7		0.49336283185840707
GRCh38	SDK1	D12_12345_1234556_Thyroid_S9			chr7	4270733	4270733.0	C	T	T	4270733	.	C	T	.	PASS		T	downstream_gene_variant	MODIFIER	SDK1	ENSG00000146555	Transcript	ENST00000476701	retained_intron									rs6955448	1733	1		SNV	HGNC	HGNC:19307					1															0.3193	0.326	0.2795	0.3353	0.3588	0.2812											0.3312	0.3067	0.2275	0.2758	0.3007	0.3126	0.4808	0.3265	0.3443	0.2974	0.2828	0.4808	gnomADg_FIN				26691610&28341840&29121662&30735000&33406744&34721519&30483659&33857205&32451905&27294018&33382772&35601485&37239431&33546406&38522119																																																																												418					0.99							247.36													chr7	4310365																																																	True	False	False	Unknown		Unknown																						221,193	109,100	112,93	0/1	111,110,104,89	ACG	0.00	0.00	0.00			115,106,91,102	31.15		0.46618357487922707
GRCh38	SDK1	D12_12345_1234556_Thyroid_S9			chr7	4270765	4270765.0	C	T	T	4270765	.	C	T	.	PASS		T	downstream_gene_variant	MODIFIER	SDK1	ENSG00000146555	Transcript	ENST00000476701	retained_intron									rs6955464	1765	1		SNV	HGNC	HGNC:19307					1															0.3221	0.3366	0.281	0.3343	0.3588	0.2812											0.3351	0.3207	0.2264	0.2768	0.3007	0.3133	0.4812	0.3185	0.3441	0.2991	0.2838	0.4812	gnomADg_FIN																																																																																350					0.989							246.25													chr7	4310397																																																	True	False	False	Unknown		Unknown																						203,143	101,79	102,64	0/1	93,110,61,82	CCG	0.00	0.00	0.00			87,116,55,88	14.09		0.41329479768786126
GRCh38	PMS2	D12_12345_1234556_Thyroid_S9	p.Ser260=	ENSP00000265849.7:p.Ser260=	chr7	5997349	5997349.0	G	C	C	5997349	.	G	C	.	PASS	NM_000535	C	synonymous_variant	LOW	PMS2	ENSG00000122512	Transcript	ENST00000265849	protein_coding	7/15		c.780C>G	810	780	260	S	tcC/tcG	rs1805319&CD136761&COSV56223185		-1		SNV	HGNC	HGNC:9122	YES	MANE_Select	NM_000535.7		1	P4	CCDS5343.1	ENSP00000265849	P54278.230		UPI000013D696	P54278-1		1			PDB-ENSP_mappings:1ea6.A&PDB-ENSP_mappings:1ea6.B&PDB-ENSP_mappings:1h7s.A&PDB-ENSP_mappings:1h7s.B&PDB-ENSP_mappings:1h7u.A&PDB-ENSP_mappings:1h7u.B&Gene3D:3.30.230.10&PDB-ENSP_mappings:6mfq.A&PDB-ENSP_mappings:6mfq.B&PDB-ENSP_mappings:7rcb.A&PDB-ENSP_mappings:7rcb.B&PDB-ENSP_mappings:7rci.A&PDB-ENSP_mappings:7rci.B&PDB-ENSP_mappings:7rck.A&PDB-ENSP_mappings:7rck.B&AFDB-ENSP_mappings:AF-P54278-F1&PANTHER:PTHR10073&SMART:SM01340&Superfamily:SSF54211&NCBIFAM:TIGR00585&CDD:cd03484			0.8313	0.8555	0.7478	0.879	0.836	0.8037	0.8131	0.842	0.6619	0.8349	0.93	0.7979	0.8412	0.8135	0.8227	0.8159	0.8168	0.8433	0.8987	0.7361	0.8487	0.9144	0.7944	0.8605	0.8122	0.8177	0.8124	0.93	gnomADe_EAS	benign	0&1&1	1&1&1	25741868&23757202&16619239&32708070&26900293&15256438&8993976&16472587&20205264&182681&19132747&34247610&38260514&38284451&38877099						FAIL	47	19	-23	19	0.00	0.00	0.01	0.01	PMS2		8.9800e-01	36693	0.82377		0.83127	45354	not_specified&not_provided&Lynch_syndrome&Mismatch_repair_cancer_syndrome_4&Lynch_syndrome_4&Endometrial_carcinoma&Hereditary_nonpolyposis_colorectal_neoplasms&Hereditary_cancer-predisposing_syndrome		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0005835&MedGen:C4552100&Orphanet:144&MONDO:MONDO:0030843&MedGen:C5436817&OMIM:619101&MONDO:MONDO:0013699&MedGen:C1838333&OMIM:614337&Orphanet:144&Human_Phenotype_Ontology:HP:0012114&MONDO:MONDO:0002447&MedGen:C0476089&OMIM:608089&MeSH:D003123&MedGen:C0009405&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000007.14:g.5997349G>C	reviewed_by_expert_panel	Benign			SCV000108381	single_nucleotide_variant	SO:0001483	ClinGen:CA012812		PMS2:5395	SO:0001619&non-coding_transcript_variant&SO:0001623&5_prime_UTR_variant&SO:0001819&synonymous_variant										1	1805319																											178					0.972							244.43	v6.1	Unknown		True	PMS2, an endonuclease involved in DNA repair, is altered in various cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PMS2 ENSP00000265849.7:S260= mutant UNKNOWN.	False	The PMS2 ENSP00000265849.7:s260= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	6036980						True	False	False	Unknown								False	False		PMS2, an endonuclease involved in DNA repair, is altered in various cancers.	The PMS2 ENSP00000265849.7:s260= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PMS2 ENSP00000265849.7:S260= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	PMS2	5395.0	ENSP00000265849.7:S260=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PMS2"",""entrezGeneId"":5395,""alteration"":""ENSP00000265849.7:S260="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PMS2, an endonuclease involved in DNA repair, is altered in various cancers."",""variantSummary"":""The PMS2 ENSP00000265849.7:s260= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PMS2 ENSP00000265849.7:S260= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						0,173	0,82	0,91	0/1	0,0,90,83	CGG	.	.	.			0,0,95,78	64.72		1.0
GRCh38	PMS2	D12_12345_1234556_Thyroid_S9			chr7	5997426	5997427.0	GA	G	G	5997426	.	GA	G	.	PASS	NM_000535	-	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	PMS2	ENSG00000122512	Transcript	ENST00000265849	protein_coding		6/14	c.706-4del						rs60794673		-1		deletion	HGNC	HGNC:9122	YES	MANE_Select	NM_000535.7		1	P4	CCDS5343.1	ENSP00000265849	P54278.230		UPI000013D696	P54278-1		1						0.4531	0.4024	0.4553	0.4931	0.4533	0.4785	0.4	0.3476	0.3861	0.4355	0.4746	0.4144	0.4533	0.3934	0.406	0.4259	0.4475	0.3388	0.4207	0.4557	0.5239	0.7053	0.4633	0.5113	0.4752	0.4549	0.536	0.7053	gnomADg_EAS	uncertain_significance&benign&likely_benign		1	25741868&24033266&33240400						FAIL	-11	-30	-47	-23	0.00	0.00	0.00	0.00	PMS2		8.9800e-01	218461				215366	not_provided&Hereditary_nonpolyposis_colorectal_neoplasms&Lynch_syndrome&Lynch_syndrome_4&not_specified&Breast_and/or_ovarian_cancer&Hereditary_cancer-predisposing_syndrome&Ovarian_neoplasm		MedGen:C3661900&MeSH:D003123&MedGen:C0009405&MONDO:MONDO:0005835&MedGen:C4552100&Orphanet:144&MONDO:MONDO:0013699&MedGen:C1838333&OMIM:614337&Orphanet:144&MedGen:CN169374&MedGen:CN221562&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&Human_Phenotype_Ontology:HP:0100615&MONDO:MONDO:0021068&MeSH:D010051&MedGen:C0919267		NC_000007.14:g.5997443del	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000257705&SCV000257707&SCV000540065&SCV000663426&SCV000691102&SCV000745197&SCV001137318&SCV001439935&SCV001470605&SCV001729530&SCV001911041&SCV002042815&SCV002568042&SCV006107623	Deletion	SO:0000159	ClinGen:CA277892		PMS2:5395	SO:0001627&intron_variant										1	60794673																											156					0.731							235.68													chr7	6037057																																																	True	True	False	Unknown		Unknown																						58,56	28,26	30,30	0/1	32,26,34,22	TGA						22,36,24,32	28.8		0.49122807017543857
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13891557	13891557.0	G	A	A	13891557	.	G	A	.	PASS	NM_004956	A	3_prime_UTR_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	14/14		c.*4309C>T	6131					rs9785000		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.8013	0.9153	0.7478	0.7212	0.7614	0.8088	0.759	0.8913	0.7356	0.7605	0.7104	0.7931	0.6925	0.7587	0.7739	0.7936	0.7947	0.8884	0.7099	0.7567	0.7396	0.7308	0.8016	0.7211	0.7526	0.7895	0.8165	0.9153	AFR										FAIL	30	13	50	-29	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											108					0.991							241.84													chr7	13931182																																																	True	True	False	Unknown		Unknown																						0,107	0,62	0,45	0/1	0,0,55,52	TGT	0.00	0.00	0.00			0,0,54,53	64.69		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13892357	13892357.0	T	A	A	13892357	.	T	A	.	PASS	NM_004956	A	3_prime_UTR_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	14/14		c.*3509A>T	5331					rs4721286		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.8153	0.9637	0.7507	0.7212	0.7614	0.8129	0.7618	0.9293	0.7436	0.7604	0.7093	0.7931	0.7	0.7595	0.7797	0.796	0.8053	0.9261	0.7115	0.76	0.7398	0.7284	0.8003	0.7279	0.7528	0.7956	0.8171	0.9637	AFR										FAIL	-42	-35	37	14	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											138					0.949							235.96													chr7	13931982																																																	True	True	False	Unknown		Unknown																						0,131	0,62	0,69	0/1	0,0,73,58	GTT	.	.	.			0,0,58,73	64.72		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13892976	13892976.0	C	T	T	13892976	.	C	T	.	PASS	NM_004956	T	3_prime_UTR_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	14/14		c.*2890G>A	4712					rs28557435		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.6346	0.4879	0.6787	0.5645	0.7247	0.7812	0.6833	0.5246	0.6796	0.7246	0.55	0.7143	0.6714	0.7199	0.6907	0.7659	0.6585	0.5197	0.7113	0.6922	0.7042	0.5823	0.766	0.6781	0.7118	0.6829	0.7834	0.7834	gnomADg_SAS										FAIL	-32	-50	-3	13	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											100					0.97							234.77													chr7	13932601																																																	True	True	False	Unknown		Unknown																						0,97	0,49	0,48	0/1	0,0,45,52	ACG	0.00	0.00	0.00			0,0,53,44	64.67		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13893281	13893281.0	A	G	G	13893281	.	A	G	.	PASS	NM_004956	G	3_prime_UTR_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	14/14		c.*2585T>C	4407					rs73068138		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.0234	0	0.0231	0.001	0.0537	0.047	0.04411	0.00725	0.0282	0.02125	8.961e-05	0.08621	0.01235	0.05938	0.05078	0.04755	0.03965	0.01022	0.05482	0.0249	0.02305	0.00116	0.06623	0.02721	0.06012	0.03119	0.04799	0.08621	gnomADe_FIN										FAIL	22	23	23	2	0.01	0.00	0.00	0.00	ETV1		6.5800e-01																																																											196					0.944							235.49													chr7	13932906																																																	True	True	False	Unknown		Unknown																						101,84	50,43	51,41	0/1	44,57,44,40	CAG	.	.	.			53,48,55,29	29.73		0.4540540540540541
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13894733	13894733.0	A	T	T	13894733	.	A	T	.	PASS	NM_004956	T	3_prime_UTR_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	14/14		c.*1133T>A	2955					rs3735343&COSV54151354		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.2640	0.0923	0.3184	0.246	0.3628	0.3742	0.3374	0.1277	0.339	0.2942	0.2625	0.3554	0.1983	0.3778	0.3248	0.3392	0.303	0.1311	0.4123	0.3411	0.2856	0.2695	0.3982	0.1599	0.3821	0.2938	0.3801	0.4123	gnomADg_AMI		0&1	0&1							FAIL	-6	-38	5	10	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											72					0.986							241.29													chr7	13934358																																																	True	True	False	Unknown		Unknown																						0,71	0,34	0,37	0/1	0,0,35,36	GAG	.	.	.			0,0,36,35	64.5		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13895063	13895063.0	A	G	G	13895063	.	A	G	.	PASS	NM_004956	G	3_prime_UTR_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	14/14		c.*803T>C	2625					rs3735344		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3530	0.3691	0.3703	0.247	0.3976	0.3824	0.3808	0.3787	0.3824	0.3253	0.2627	0.405	0.2163	0.415	0.3824	0.3545	0.399	0.3848	0.4143	0.3878	0.3159	0.2705	0.4298	0.1905	0.4215	0.3709	0.3922	0.4298	gnomADg_FIN										FAIL	23	-48	-30	15	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											116					0.991							244.47													chr7	13934688																																																	True	True	False	Unknown		Unknown																						2,113	0,61	2,52	0/1	2,0,63,50	CAT	.	.	.			0,2,57,56	41.91		0.9826086956521739
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13907980	13907981.0	G	GT	GT	13907980	.	G	GT	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		11/13	c.941-1382dup						rs55959792		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3089	0.2882	0.3055	0.2202	0.3787	0.3589	0.378	0.3074	0.3246	0.2667	0.2426	0.393	0.2398	0.4025	0.3654	0.3738	0.3566	0.3057	0.4132	0.3413	0.2801	0.2473	0.3853	0.1939	0.3986	0.3264	0.3732	0.4132	gnomADg_AMI										FAIL	-38	6	-4	-37	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											102					0.833							235.46													chr7	13947605																																																	True	True	False	Unknown		Unknown																						2,83	0,47	2,36	0/1	1,1,49,34	AGT						1,1,41,42	57.97		0.9764705882352941
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13908554	13908554.0	G	A	A	13908554	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		11/13	c.940+1078C>T						rs2237293		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.6971	0.8011	0.6354	0.6617	0.6262	0.7096											0.6695	0.7608	0.5879	0.6399	0.5528	0.6522	0.6831	0.4966	0.6249	0.6418	0.7196	0.8011	AFR										FAIL	48	-3	48	-33	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											89					0.966							236.76													chr7	13948179																																																	True	True	False	Unknown		Unknown																						0,86	0,47	0,39	0/1	0,0,38,48	TGT	0.00	0.00	0.00			0,0,45,41	64.62		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13909094	13909094.0	T	C	C	13909094	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		11/13	c.940+538A>G						rs2072167		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3956	0.4697	0.3329	0.376	0.3728	0.3834											0.403	0.4437	0.411	0.3633	0.3058	0.39	0.3931	0.2254	0.3973	0.3624	0.3933	0.4697	AFR			1	26314407&36224396						FAIL	-1	30	-1	30	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											106					0.726							228.96													chr7	13948719																																																	True	True	False	Unknown		Unknown																						0,77	0,30	0,47	0/1	0,0,35,42	ATT	.	.	.			0,0,56,21	64.56		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13934938	13934938.0	G	A	A	13934938	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		8/13	c.554+770C>T						rs35638429&COSV54137286		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.2943	0.1589	0.281	0.4157	0.328	0.3272											0.2783	0.1634	0.1996	0.2753	0.3291	0.3997	0.3501	0.3129	0.3219	0.3196	0.3344	0.4157	EAS		0&1	0&1							FAIL	-18	27	43	-27	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											131					0.962							236.28													chr7	13974563																																																	True	True	False	Unknown		Unknown																						0,126	0,67	0,59	0/1	0,0,61,65	AGG	0.00	0.00	0.00			0,0,56,70	64.71		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13936144	13936144.0	A	G	G	13936144	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.366-248T>C						rs17167675&COSV54137299		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3161	0.1589	0.3487	0.4236	0.3489	0.3609											0.303	0.1712	0.2072	0.3251	0.3706	0.4059	0.3627	0.3299	0.3526	0.3449	0.3767	0.4236	EAS		0&1	0&1							FAIL	-1	-40	10	32	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											199					0.995							241.1													chr7	13975769																																																	True	True	False	Unknown		Unknown																						0,198	0,97	0,101	0/1	0,0,100,98	CAT	.	.	.			0,0,83,115	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13936633	13936633.0	G	T	T	13936633	.	G	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.366-737C>A						rs17167676&COSV54137307		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3031	0.1248	0.3429	0.4147	0.3439	0.3589											0.2914	0.1413	0.2039	0.3179	0.3637	0.3985	0.3661	0.3197	0.3473	0.3363	0.3737	0.4147	EAS		0&1	0&1							FAIL	-2	6	1	-25	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											246					0.996							247.71													chr7	13976258																																																	True	True	False	Unknown		Unknown																						0,245	0,105	0,140	0/1	0,0,98,147	AGG	0.00	0.00	0.00			0,0,138,107	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13937041	13937042.0	CA	C	C	13937041	.	CA	C	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.366-1146del						rs145484724		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3029	0.1248	0.3444	0.4127	0.3439	0.3589											0.2947	0.144	0.2094	0.3221	0.3644	0.4024	0.3773	0.3298	0.3489	0.3427	0.3752	0.4127	EAS										FAIL	-3	-7	-3	44	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											395					0.924							197.8													chr7	13976666																																																	True	True	False	Unknown		Unknown																						3,362	2,173	1,189	0/1	2,1,203,159	TCA						1,2,148,214	62.06		0.9917808219178083
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13937208	13937208.0	T	G	G	13937208	.	T	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.366-1312A>C						rs77089697&COSV54137315		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.2851	0.0575	0.3386	0.4167	0.3439	0.3589											0.278	0.09393	0.2081	0.3145	0.3641	0.4002	0.3641	0.3129	0.3477	0.3278	0.3742	0.4167	EAS		0&1	0&1							FAIL	24	20	-14	3	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											240					1							246.53													chr7	13976833																																																	True	True	False	Unknown		Unknown																						0,240	0,122	0,118	0/1	0,0,125,115	ATA	.	.	.			0,0,103,137	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13937370	13937370.0	C	A	A	13937370	.	C	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.366-1474G>T						rs3801096&COSV54137324		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3011	0.1248	0.3429	0.4137	0.338	0.3558											0.2853	0.1396	0.1813	0.3155	0.3604	0.3985	0.3599	0.3197	0.3375	0.3327	0.3675	0.4137	EAS		0&1	0&1							FAIL	-17	45	10	-21	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											121					0.975							242.66													chr7	13976995																																																	True	True	False	Unknown		Unknown																						0,118	0,65	0,53	0/1	0,0,47,71	ACA	0.00	0.00	0.00			0,0,54,64	64.71		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13938381	13938381.0	A	C	C	13938381	.	A	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.365+736T>G						rs12536599&COSV54137340		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3167	0.1672	0.3473	0.4206	0.3459	0.3599											0.302	0.1736	0.2072	0.3244	0.3641	0.4022	0.364	0.3265	0.3498	0.3441	0.3746	0.4206	EAS		0&1	0&1							FAIL	-1	-32	1	36	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											232					1							247.48													chr7	13978006																																																	True	True	False	Unknown		Unknown																						0,232	0,102	0,130	0/1	0,0,118,114	AAT	.	.	.			0,0,104,128	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13939020	13939020.0	C	T	T	13939020	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.365+97G>A						rs3801098&COSV54137351		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3153	0.1657	0.3458	0.4177	0.3449	0.3599	0.3446	0.1596	0.341	0.3538	0.3963	0.3623	0.3521	0.3426	0.3519	0.3846	0.2992	0.1713	0.2031	0.3224	0.3638	0.3996	0.3608	0.3231	0.3461	0.3395	0.3745	0.4177	EAS		0&1	0&1							FAIL	-43	-26	-10	-26	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											93					1							243.53													chr7	13978645																																																	True	True	False	Unknown		Unknown																						0,93	0,55	0,38	0|1	0,0,53,40	ACG	0.00	0.00	0.00		13978630	0,0,41,52	50.65		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13939023	13939023.0	T	A	A	13939023	.	T	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		7/13	c.365+94A>T						rs3801099&COSV54137356		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3151	0.1657	0.3458	0.4177	0.3439	0.3599	0.3423	0.1577	0.3401	0.3522	0.3959	0.3609	0.3501	0.3401	0.3495	0.3838	0.299	0.1711	0.2031	0.3223	0.3641	0.3992	0.36	0.3231	0.3461	0.3395	0.3745	0.4177	EAS		0&1	0&1							FAIL	-43	-22	2	-29	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											93					1							244.37													chr7	13978648																																																	True	True	False	Unknown		Unknown																						0,93	0,53	0,40	0|1	0,0,40,53	TTA	.	.	.		13978630	0,0,44,49	50.65		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9	p.S100G	ENSP00000405327.1:p.Ser100Gly	chr7	13939184	13939184.0	T	C	C	13939184	.	T	C	.	PASS	NM_004956	C	missense_variant	MODERATE	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	7/14		c.298A>G	686	298	100	S/G	Agc/Ggc	rs9639168&COSV54136900		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1	tolerated(0.31)	benign(0)	AFDB-ENSP_mappings:AF-P50549-F1&Pfam:PF04621			0.3193	0.18	0.3458	0.4187	0.3439	0.3609	0.3448	0.1785	0.3549	0.358	0.4023	0.3561	0.3536	0.3425	0.3533	0.3893	0.3053	0.1916	0.2077	0.325	0.363	0.4024	0.3523	0.3231	0.3477	0.3455	0.375	0.4187	EAS		0&1	0&1	28672935&27775552						FAIL	30	-2	-49	41	0.00	0.00	0.00	0.00	ETV1	0.135	6.5800e-01																																																											104					0.942							234.33	v6.1	Unknown		True	ETV1, a transcription factor, is altered by chromosomal rearrangement or overexpression in various cancer types.	False	02/14/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV1 ENSP00000405327.1:S100G mutant UNKNOWN.	False	The ETV1 ENSP00000405327.1:s100g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	13978809						True	False	False	Unknown								False	False		ETV1, a transcription factor, is altered by chromosomal rearrangement or overexpression in various cancer types.	The ETV1 ENSP00000405327.1:s100g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV1 ENSP00000405327.1:S100G mutant UNKNOWN.						v6.1	02/14/2018		GRCh38	ETV1	2115.0	ENSP00000405327.1:S100G			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ETV1"",""entrezGeneId"":2115,""alteration"":""ENSP00000405327.1:S100G"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ETV1, a transcription factor, is altered by chromosomal rearrangement or overexpression in various cancer types."",""variantSummary"":""The ETV1 ENSP00000405327.1:s100g mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV1 ENSP00000405327.1:S100G mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/14/2018""}"	True	True	False	Unknown		Unknown																						0,98	0,49	0,49	0/1	0,0,51,47	CTG	.	.	.			0,0,50,48	64.67		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13939600	13939600.0	G	A	A	13939600	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-354C>T						rs9639169		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3141	0.1657	0.3458	0.4127	0.3429	0.3609											0.299	0.171	0.2072	0.3224	0.3626	0.3958	0.3601	0.3276	0.3461	0.3431	0.375	0.4127	EAS										FAIL	-20	19	28	-37	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											103					0.981							240.51													chr7	13979225																																																	True	True	False	Unknown		Unknown																						0,101	0,48	0,53	0|1	0,0,47,54	AGA	0.00	0.00	0.00		13979225	0,0,48,53	57.68		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13939601	13939601.0	A	C	C	13939601	.	A	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-355T>G						rs9639170		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3141	0.1657	0.3458	0.4127	0.3429	0.3609											0.2988	0.171	0.2072	0.3224	0.3626	0.3956	0.3597	0.3253	0.346	0.3425	0.3752	0.4127	EAS										FAIL	18	-21	-2	-21	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											100					0.99							239.91													chr7	13979226																																																	True	True	False	Unknown		Unknown																						0,99	0,47	0,52	0|1	0,0,48,51	GAT	.	.	.		13979225	0,0,48,51	57.67		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13939953	13939953.0	C	T	T	13939953	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-707G>A						rs73276816		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3143	0.1657	0.3458	0.4137	0.3439	0.3599											0.3001	0.1721	0.2072	0.3228	0.3635	0.3991	0.3638	0.3231	0.3469	0.3428	0.3753	0.4137	EAS										FAIL	-45	40	37	-22	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											245					0.984							247.51													chr7	13979578																																																	True	True	False	Unknown		Unknown																						0,241	0,128	0,113	0/1	0,0,132,109	ACA	0.00	0.00	0.00			0,0,149,92	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13939986	13939986.0	G	A	A	13939986	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-740C>T						rs17167681		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3143	0.1657	0.3458	0.4137	0.3439	0.3599											0.3003	0.1724	0.2072	0.3231	0.3641	0.3981	0.3651	0.3231	0.3471	0.3425	0.3753	0.4137	EAS										FAIL	39	28	45	4	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											311					0.99							247													chr7	13979611																																																	True	True	False	Unknown		Unknown																						0,308	0,166	0,142	0/1	0,0,148,160	CGT	0.00	0.00	0.00			0,0,198,110	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13940104	13940104.0	G	A	A	13940104	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-858C>T						rs12532909		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3141	0.1657	0.3458	0.4127	0.3439	0.3599											0.3002	0.1726	0.2077	0.3226	0.3635	0.3985	0.3644	0.3185	0.3471	0.3427	0.3743	0.4127	EAS										FAIL	-3	40	41	-27	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											443					0.971							194.49													chr7	13979729																																																	True	True	False	Unknown		Unknown																						0,430	0,203	0,227	0/1	0,0,218,212	CGG	0.00	0.00	0.00			0,0,201,229	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13940363	13940372.0	AAAAAAAAAG	A	A	13940363	.	AAAAAAAAAG	A	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-1126_236-1118del						rs150976778		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3155	0.1679	0.3458	0.4167	0.3459	0.3579											0.2884	0.1639	0.2031	0.3072	0.3621	0.3859	0.31	0.3015	0.3403	0.3217	0.3659	0.4167	EAS																					6.5800e-01																																																											384					0.857							155.51													chr7	13979988																																																	True	True	False	Unknown		Unknown																						84,245	41,100	43,145	0/1	45,39,130,115	AAA						42,42,121,124	40.66		0.7446808510638298
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13940530	13940530.0	C	T	T	13940530	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-1284G>A						rs9639171		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3143	0.1657	0.3458	0.4137	0.3439	0.3599											0.3003	0.1722	0.2077	0.3226	0.3634	0.4	0.3637	0.3231	0.3473	0.3431	0.3749	0.4137	EAS										FAIL	11	-1	30	11	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											290					0.983							243.73													chr7	13980155																																																	True	True	False	Unknown		Unknown																						0,285	0,123	0,162	0/1	0,0,151,134	TCT	0.00	0.00	0.00			0,0,119,166	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13941638	13941638.0	A	G	G	13941638	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-2392T>C						rs12538878		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3257	0.1831	0.3458	0.4375	0.3449	0.3691											0.3085	0.1922	0.2072	0.3267	0.3638	0.427	0.3647	0.3265	0.3494	0.346	0.386	0.4375	EAS										FAIL	-1	-27	40	-27	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											407					1							212.06													chr7	13981263																																																	True	True	False	Unknown		Unknown																						0,407	0,181	0,226	0/1	0,0,207,200	AAT	.	.	.			0,0,217,190	64.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13941863	13941887.0	GAATAAATAAATAAATAAATAAATA	G	G	13941863	.	GAATAAATAAATAAATAAATAAATA	G	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-2641_236-2618del						rs111978808		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1																						0.307	0.178	0.208	0.3323	0.3658	0.402	0.3864	0.3345	0.3505	0.3486	0.3874	0.402	gnomADg_EAS																					6.5800e-01																																																											578					0.718							202.6													chr7	13981488																																																	True	True	False	Unknown		Unknown																						0,415	0,208	0,207	0/1	0,0,208,207	CGA						0,0,179,236	61.11		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13941948	13941948.0	C	G	G	13941948	.	C	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-2702G>C						rs1029519		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3157	0.1664	0.3501	0.4117	0.3479	0.3609											0.3014	0.1721	0.2059	0.326	0.3643	0.3955	0.3674	0.3276	0.3484	0.3443	0.3762	0.4117	EAS										FAIL	-12	-1	34	-21	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											531					0.989							233.91													chr7	13981573																																																	True	True	False	Unknown		Unknown																						0,525	0,277	0,248	0|1	0,0,247,278	TCT	.	.	.		13981573	0,0,293,232	57.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13941957	13941957.0	G	C	C	13941957	.	G	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-2711C>G						rs76540524		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3157	0.1664	0.3501	0.4117	0.3479	0.3609											0.3005	0.1712	0.2059	0.3249	0.3638	0.395	0.3634	0.3231	0.3482	0.3433	0.3761	0.4117	EAS										FAIL	1	-10	1	-8	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											513					0.99							238.46													chr7	13981582																																																	True	True	False	Unknown		Unknown																						0,508	0,258	0,250	0|1	0,0,252,256	AGG	.	.	.		13981573	0,0,280,228	57.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13942020	13942025.0	CTTTTT	C	C	13942020	.	CTTTTT	C	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-2779_236-2775del						rs560415338		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5501	0.5197	0.5663	0.5357	0.5358	0.6094											0.3123	0.203	0.1836	0.3543	0.3588	0.4165	0.3939	0.375	0.3354	0.3594	0.3885	0.6094	SAS																					6.5800e-01																																																											284					0.63							184.81													chr7	13981645																																																	True	True	False	Unknown		Unknown																						46,133	18,64	28,69	0/1	16,30,86,47	TCT						28,18,57,76	37.71		0.7430167597765364
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13942123	13942123.0	A	G	G	13942123	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-2877T>C						rs75025125		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3187	0.1823	0.3473	0.4127	0.3449	0.3589											0.3142	0.1992	0.2086	0.349	0.3675	0.4054	0.3895	0.3626	0.349	0.3585	0.3784	0.4127	EAS										FAIL	37	-12	-11	-23	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											82					1							77.52													chr7	13981748																																																	True	True	False	Unknown		Unknown																						0,82	0,48	0,34	0/1	0,0,36,46	CAC	.	.	.			0,0,4,78	64.6		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13942357	13942358.0	TA	T	T	13942357	.	TA	T	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-3112del						rs76326420		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3085	0.1725	0.3458	0.4127	0.34	0.3262											0.3007	0.1856	0.2061	0.3215	0.3634	0.3958	0.3575	0.3027	0.3437	0.3397	0.3484	0.4127	EAS										FAIL	4	-34	-34	3	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											534					0.979							225.96													chr7	13981982																																																	True	True	False	Unknown		Unknown																						0,523	0,246	0,277	0/1	0,0,265,258	TTA						0,0,236,287	63.48		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13942421	13942421.0	C	T	T	13942421	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-3175G>A						rs73276821		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3291	0.1815	0.3458	0.496	0.3429	0.3303											0.3062	0.1899	0.2061	0.3264	0.3621	0.4833	0.3663	0.3027	0.3438	0.3449	0.3518	0.496	EAS										FAIL	-7	-1	18	-5	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											420					0.936							192.37													chr7	13982046																																																	True	True	False	Unknown		Unknown																						0,393	0,178	0,215	0|1	0,0,209,184	ACT	0.00	0.00	0.00		13982046	0,0,158,235	57.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13942435	13942435.0	A	G	G	13942435	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-3189T>C						rs75346686		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3167	0.1838	0.3458	0.4385	0.341	0.3252											0.3035	0.1901	0.2066	0.3264	0.3621	0.4267	0.3586	0.3027	0.3436	0.3404	0.3502	0.4385	EAS										FAIL	-40	-15	-19	4	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											390					0.931							180.24													chr7	13982060																																																	True	True	False	Unknown		Unknown																						0,363	0,168	0,195	0|1	0,0,205,158	GAT	.	.	.		13982046	0,0,144,219	57.73		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13942795	13942795.0	A	C	C	13942795	.	A	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-3549T>G						rs28615403		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3698	0.2912	0.3588	0.5238	0.3489	0.3466											0.3426	0.2982	0.2072	0.3372	0.39	0.5174	0.3747	0.3333	0.3492	0.371	0.3704	0.5238	EAS										FAIL	1	2	1	2	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											97					1							243.09													chr7	13982420																																																	True	True	False	Unknown		Unknown																						0,97	0,46	0,51	0/1	0,0,57,40	AAC	.	.	.			0,0,50,47	64.67		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13943744	13943744.0	T	A	A	13943744	.	T	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-4498A>T						rs11981205		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7808	0.6725	0.7695	0.9315	0.7366	0.8252											0.7448	0.6898	0.7687	0.7518	0.8318	0.9334	0.8001	0.7891	0.7419	0.7754	0.8298	0.9334	gnomADg_EAS										FAIL	2	30	-15	-43	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											163					0.969							225.85													chr7	13983369																																																	True	True	False	Unknown		Unknown																						1,157	1,85	0,72	0/1	0,1,80,77	ATA	.	.	.			0,1,70,87	64.72		0.9936708860759493
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13944250	13944250.0	C	T	T	13944250	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-5004G>A						rs2079329		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.9189	0.9123	0.8617	0.994	0.8728	0.9387											0.8922	0.9076	0.9035	0.8723	0.9499	0.9938	0.8769	0.9388	0.8754	0.9086	0.9316	0.994	EAS										FAIL	-2	36	36	-7	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											85					0.976							228.29													chr7	13983875																																																	True	True	False	Unknown		Unknown																						0,83	0,39	0,44	0/1	0,0,41,42	CCG	0.00	0.00	0.00			0,0,39,44	64.6		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13945443	13945444.0	AT	A	A	13945443	.	AT	A	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-6198del						rs77650876		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.3572	0.2731	0.3573	0.4286	0.3569	0.3978											0.335	0.2636	0.2091	0.3406	0.3998	0.4179	0.3816	0.3438	0.3567	0.364	0.4005	0.4286	EAS										FAIL	-38	-20	4	-37	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											104					0.75							228.08													chr7	13985068																																																	True	True	False	Unknown		Unknown																						13,65	7,35	6,30	0/1	9,4,35,30	GAT						5,8,29,36	46.35		0.8333333333333334
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13948622	13948622.0	G	C	C	13948622	.	G	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-9376C>G						rs6461058		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.8844	0.7958	0.8501	0.996	0.8648	0.9335											0.8617	0.8126	0.9055	0.8597	0.9179	0.9953	0.8738	0.9184	0.871	0.8852	0.9277	0.996	EAS										FAIL	-1	17	1	-17	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											85					0.929							237.58													chr7	13988247																																																	True	True	False	Unknown		Unknown																						0,79	0,34	0,45	0/1	0,0,39,40	AGT	.	.	.			0,0,34,45	64.58		1.0
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13948898	13948898.0	C	A	A	13948898	.	C	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-9652G>T						rs725964		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.2766	0.0303	0.3314	0.4048	0.3419	0.3712											0.2718	0.07208	0.2072	0.3119	0.3625	0.3928	0.3665	0.3061	0.3471	0.325	0.3874	0.4048	EAS			1	32121467						FAIL	-10	14	-9	-25	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											96					0.938							243.09													chr7	13988523																																																	True	True	False	Unknown		Unknown																						1,89	1,47	0,42	0/1	1,0,45,44	ACC	0.00	0.00	0.00			1,0,43,46	50.05		0.9888888888888889
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13949587	13949587.0	T	C	C	13949587	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-10341A>G						rs905572590		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1																																												FAIL	-38	9	1	9	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											260					0.904							217.56													chr7	13989212																																																	True	True	False	Unknown		Unknown																						222,13	94,7	128,6	0/1	115,107,6,7	ATA	.	.	.			93,129,4,9	11.52		0.05531914893617021
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13955563	13955565.0	GCC	G	G	13955563	.	GCC	G	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.236-16319_236-16318del								-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1																																												FAIL	-13	24	-7	-22	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											115					0.852							240.14													chr7	13995188																																																	True	True	False	Unknown		Unknown																						94,4	35,4	59,0	0/1	50,44,2,2	AGC						37,57,2,2	6.14		0.04081632653061224
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13973594	13973594.0	A	G	G	13973594	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+3833T>C						rs1476622		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7646	0.9758	0.7752	0.6736	0.7058	0.6258											0.7816	0.9352	0.822	0.7681	0.6746	0.7056	0.7716	0.7313	0.7149	0.7512	0.6316	0.9758	AFR										FAIL	28	-3	28	29	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											135					0.956							237.79													chr7	14013219																																																	True	True	False	Unknown		Unknown																						65,64	37,29	28,35	0/1	36,29,37,27	TAA	.	.	.			40,25,32,32	36.16		0.49612403100775193
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13973703	13973703.0	A	T	T	13973703	.	A	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+3724T>A						rs1476621		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7434	0.8971	0.7767	0.6716	0.7058	0.6247											0.7625	0.8706	0.8216	0.7636	0.6702	0.7013	0.7716	0.7089	0.7136	0.74	0.6315	0.8971	AFR										FAIL	14	-18	3	24	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											109					0.872							237.85													chr7	14013328																																																	True	True	False	Unknown		Unknown																						48,47	22,23	26,24	0/1	26,22,24,23	TAA	.	.	.			22,26,18,29	35.24		0.49473684210526314
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13973827	13973827.0	G	A	A	13973827	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+3600C>T						rs7808321		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7774	0.9818	0.8127	0.6696	0.7515	0.6135											0.8156	0.949	0.8462	0.8153	0.7759	0.7005	0.7699	0.8027	0.7654	0.8006	0.6273	0.9818	AFR										FAIL	-14	-42	-14	-42	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											100					0.95							245.5													chr7	14013452																																																	True	True	False	Unknown		Unknown																						42,53	26,29	16,24	0/1	18,24,25,28	CGG	0.00	0.00	0.00			22,20,23,30	40.86		0.5578947368421052
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13973979	13973979.0	C	T	T	13973979	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+3448G>A						rs2282868		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7792	0.9803	0.8084	0.6696	0.7435	0.636											0.8164	0.9479	0.8618	0.8117	0.7866	0.7009	0.7818	0.8129	0.7648	0.7987	0.646	0.9803	AFR										FAIL	44	0	-10	-5	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											65					0.969							242.8													chr7	14013604																																																	True	True	False	Unknown		Unknown																						29,34	18,15	11,19	0/1	15,14,20,14	TCC	0.00	0.00	0.00			12,17,13,21	36.93		0.5396825396825397
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13975590	13975591.0	G	GA	GA	13975590	.	G	GA	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+1836dup						rs368323645		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1																						0.5041	0.4216	0.6135	0.5781	0.3988	0.5941	0.5096	0.4333	0.5378	0.508	0.4238	0.6135	gnomADg_AMI										FAIL	33	-35	4	33	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											535					0.789							195.93													chr7	14015215																																																	True	True	False	Unknown		Unknown																						241,181	116,84	125,97	0/1	130,111,109,72	AGA						153,88,108,73	17.81		0.42890995260663506
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13975693	13975693.0	T	A	A	13975693	.	T	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+1734A>T						rs2282867		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7085	0.8359	0.7666	0.5863	0.7078	0.6217											0.7565	0.8298	0.8492	0.7737	0.7486	0.6152	0.7619	0.7603	0.7265	0.7392	0.6302	0.8492	gnomADg_AMI			1	32888493&32888494&30595370&34594039						FAIL	16	46	47	36	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											460					0.85							233.03													chr7	14015318																																																	True	True	False	Unknown		Unknown																						202,189	100,87	102,102	0/1	101,101,108,81	GTG	.	.	.			95,107,102,87	37.18		0.4833759590792839
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13977314	13977314.0	T	C	C	13977314	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+113A>G						rs2074670		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5575	0.6475	0.6282	0.5734	0.5417	0.3855	0.5351	0.6248	0.628	0.3546	0.6291	0.6038	0.4624	0.5337	0.5234	0.426	0.5683	0.6215	0.6634	0.6195	0.3666	0.5991	0.6071	0.4932	0.5361	0.5498	0.426	0.6634	gnomADg_AMI										FAIL	24	-2	43	9	0.01	0.00	0.00	0.00	ETV1		6.5800e-01																																																											197					0.904							239.46													chr7	14016939																																																	True	True	False	Unknown		Unknown																						86,92	51,48	35,44	0/1	56,30,53,39	GTG	.	.	.			63,23,63,29	40.56		0.5168539325842697
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13977382	13977382.0	C	T	T	13977382	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+45G>A						rs2066977&COSV54144115		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5555	0.643	0.6282	0.5724	0.5417	0.3824	0.5291	0.6254	0.6494	0.3612	0.6258	0.6052	0.4665	0.5267	0.522	0.4339	0.5674	0.6198	0.6634	0.6196	0.3671	0.5964	0.6064	0.4966	0.5355	0.5494	0.425	0.6634	gnomADg_AMI		0&1	0&1							FAIL	-44	-46	36	48	0.03	0.00	0.00	0.00	ETV1		6.5800e-01																																																											270					0.744							221.8													chr7	14017007																																																	True	True	False	Unknown		Unknown																						111,90	63,41	48,49	0|1	64,47,48,42	ACC	0.00	0.00	0.00		14017007	50,61,45,45	21.04		0.44776119402985076
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13977383	13977383.0	C	G	G	13977383	.	C	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		6/13	c.235+44G>C						rs2066976&COSV54144126		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5557	0.643	0.6282	0.5724	0.5427	0.3824	0.5302	0.6262	0.6513	0.3623	0.6263	0.6054	0.4678	0.5278	0.5228	0.4354	0.5676	0.6201	0.6634	0.6196	0.3675	0.5963	0.606	0.4932	0.5356	0.5504	0.4254	0.6634	gnomADg_AMI		0&1	0&1							FAIL	-45	-47	47	-26	0.01	0.00	0.00	0.00	ETV1		6.5800e-01																																																											266					0.752							221.38													chr7	14017008																																																	True	True	False	Unknown		Unknown																						109,91	61,42	48,49	0|1	62,47,50,41	CCA	.	.	.		14017007	42,67,45,46	21.66		0.455
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13977501	13977502.0	T	TA	TA	13977501	.	T	TA	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-22dup						rs5882424		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5549	0.6415	0.6282	0.5704	0.5408	0.3845	0.5185	0.6143	0.6395	0.3553	0.6211	0.6028	0.4422	0.5158	0.5105	0.4253	0.5682	0.621	0.6634	0.6198	0.3664	0.5993	0.6067	0.4932	0.5363	0.55	0.4246	0.6634	gnomADg_AMI										FAIL	-26	-21	-21	-45	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											205					0.649							230.83													chr7	14017126																																																	True	True	False	Unknown		Unknown																						58,75	28,35	30,40	0/1	27,31,39,36	TTA						31,27,37,38	41.45		0.5639097744360902
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13978519	13978519.0	C	T	T	13978519	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-1039G>A						rs12531288		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5885	0.7625	0.6354	0.5714	0.5427	0.3845											0.5968	0.7218	0.6641	0.6311	0.3673	0.5976	0.6064	0.5034	0.5354	0.5712	0.4251	0.7625	AFR										FAIL	-2	-32	-2	-32	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											76					1							245.69													chr7	14018144																																																	True	True	False	Unknown		Unknown																						41,35	23,17	18,18	0|1	22,19,21,14	TCA	0.00	0.00	0.00		14018144	22,19,15,20	24.04		0.4605263157894737
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13978531	13978531.0	G	A	A	13978531	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-1051C>T						rs9969142		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.4734	0.4856	0.6095	0.4335	0.506	0.3681											0.5026	0.4859	0.6564	0.5973	0.35	0.4347	0.5493	0.4793	0.5027	0.5071	0.3976	0.6564	gnomADg_AMI										FAIL	35	-44	11	-14	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											77					1							248.13													chr7	14018156																																																	True	True	False	Unknown		Unknown																						44,33	26,16	18,17	0|1	23,21,24,9	CGT	0.00	0.00	0.00		14018144	27,17,13,20	20.65		0.42857142857142855
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13978576	13978576.0	C	T	T	13978576	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-1096G>A						rs7802610		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7175	0.8714	0.7622	0.5774	0.7157	0.6237											0.7611	0.8436	0.8484	0.7807	0.7679	0.6015	0.757	0.7979	0.727	0.7493	0.6319	0.8714	AFR										FAIL	-6	29	11	-32	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											94					1							247.54													chr7	14018201																																																	True	True	False	Unknown		Unknown																						45,49	23,27	22,22	0/1	27,18,28,21	ACG	0.00	0.00	0.00			25,20,24,25	37.47		0.5212765957446809
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13978735	13978735.0	G	T	T	13978735	.	G	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-1255C>A						rs7806670		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5783	0.7284	0.6311	0.5714	0.5427	0.3814											0.5849	0.6836	0.6626	0.6257	0.3668	0.5978	0.6066	0.5034	0.5338	0.5598	0.4248	0.7284	AFR										FAIL	4	-31	-48	6	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											67					0.985							249.09													chr7	14018360																																																	True	True	False	Unknown		Unknown																						39,27	17,13	22,14	0/1	23,16,14,13	AGA	0.00	0.00	0.00			13,26,12,15	25.61		0.4090909090909091
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13978869	13978869.0	C	T	T	13978869	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-1389G>A						rs7806587		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7175	0.8714	0.7622	0.5784	0.7157	0.6227											0.7609	0.8431	0.8484	0.7798	0.7676	0.6017	0.7562	0.8	0.727	0.7493	0.6307	0.8714	AFR				30049619						FAIL	-13	41	33	-50	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											136					1							239.4													chr7	14018494																																																	True	True	False	Unknown		Unknown																						76,60	44,38	32,22	0/1	41,35,29,31	ACG	0.00	0.00	0.00			47,29,39,21	28.03		0.4411764705882353
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13979617	13979617.0	A	G	G	13979617	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-2137T>C						rs2214683		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7470	0.9766	0.7723	0.5784	0.7157	0.6247											0.7884	0.9396	0.8462	0.7889	0.762	0.6026	0.7562	0.7979	0.7272	0.7671	0.6333	0.9766	AFR			1	32888493						FAIL	43	-8	-36	2	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											110					0.955							237.27													chr7	14019242																																																	True	True	False	Unknown		Unknown																						48,57	26,31	22,26	0/1	22,26,27,30	CAT	.	.	.			30,18,31,26	40.2		0.5428571428571428
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13979823	13979823.0	T	C	C	13979823	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-2343A>G						rs4721288		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5545	0.6377	0.6268	0.5724	0.5417	0.3855											0.5669	0.616	0.6634	0.6203	0.3669	0.5978	0.6073	0.4932	0.5362	0.5488	0.4248	0.6634	gnomADg_AMI										FAIL	-28	-30	-28	-6	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											91					0.934							236.62													chr7	14019448																																																	True	True	False	Unknown		Unknown																						45,40	28,23	17,17	0/1	17,28,21,19	TTC	.	.	.			26,19,18,22	32.44		0.47058823529411764
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13979915	13979915.0	G	T	T	13979915	.	G	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-2435C>A						rs4721289		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5321	0.5598	0.621	0.5714	0.5408	0.3824											0.5486	0.5525	0.6626	0.6146	0.3673	0.598	0.6075	0.483	0.5357	0.5365	0.4254	0.6626	gnomADg_AMI										FAIL	15	24	-4	-31	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											147					0.918							219.37													chr7	14019540																																																	True	True	False	Unknown		Unknown																						61,74	32,43	29,31	0/1	32,29,32,42	TGG	0.00	0.00	0.00			25,36,39,35	42.8		0.5481481481481482
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13981061	13981061.0	T	C	C	13981061	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-3581A>G						rs10255497		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5377	0.5673	0.6225	0.5833	0.5427	0.3855											0.5503	0.5549	0.6648	0.6157	0.3665	0.6028	0.6174	0.4897	0.5359	0.5367	0.4259	0.6648	gnomADg_AMI										FAIL	-21	43	12	43	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											118					0.975							240.42													chr7	14020686																																																	True	True	False	Unknown		Unknown																						53,62	21,39	32,23	0/1	20,33,34,28	CTC	.	.	.			26,27,35,27	40.46		0.5391304347826087
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13981470	13981470.0	G	A	A	13981470	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-3990C>T						rs4721290		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.4754	0.4887	0.6095	0.4375	0.507	0.3691											0.5038	0.4856	0.6542	0.5992	0.3491	0.436	0.5593	0.4688	0.5034	0.5081	0.3998	0.6542	gnomADg_AMI										FAIL	-17	-24	43	-40	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											86					0.965							238.67													chr7	14021095																																																	True	True	False	Unknown		Unknown																						52,31	24,11	28,20	0|1	27,25,16,15	GGA	0.00	0.00	0.00		14021095	35,17,20,11	12.14		0.37349397590361444
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13981496	13981496.0	C	G	G	13981496	.	C	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-4016G>C						rs4721291		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5633	0.6649	0.6297	0.5774	0.5427	0.3855											0.5731	0.6372	0.6604	0.6223	0.3662	0.5977	0.6157	0.4862	0.5358	0.551	0.426	0.6649	AFR										FAIL	-43	24	13	37	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											104					0.885							216.35													chr7	14021121																																																	True	True	False	Unknown		Unknown																						64,28	29,10	35,18	0|1	33,31,14,14	ACA	.	.	.		14021095	46,18,18,10	5.04		0.30434782608695654
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13981544	13981548.0	T	TATAC	TATAC	13981544	.	T	TATAC	.	PASS	NM_004956	ATAC	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-4065_182-4064insGTAT						rs68083019		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5339	0.5628	0.6182	0.5754	0.5417	0.3845											0.495	0.499	0.5982	0.5764	0.3247	0.5458	0.5215	0.4007	0.4834	0.4842	0.3703	0.6182	AMR																					6.5800e-01																																																											171					0.871							216.54													chr7	14021169																																																	True	True	False	Unknown		Unknown																						86,63	47,29	39,34	0/1	44,42,37,26	ATA						63,23,47,16	22.22		0.4228187919463087
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13981708	13981708.0	T	G	G	13981708	.	T	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-4228A>C						rs4721292		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5547	0.652	0.6239	0.5694	0.5358	0.3783											0.572	0.6356	0.6619	0.622	0.3663	0.5941	0.6134	0.4932	0.5346	0.5505	0.426	0.6619	gnomADg_AMI										FAIL	-20	-13	-12	34	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											157					0.975							237.41													chr7	14021333																																																	True	True	False	Unknown		Unknown																						92,61	43,22	49,39	0|1	52,40,32,29	TTT	.	.	.		14021333	35,57,27,34	11.71		0.39869281045751637
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13981709	13981709.0	T	C	C	13981709	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.182-4229A>G						rs4721293		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5545	0.6513	0.6239	0.5694	0.5358	0.3783											0.572	0.6357	0.6619	0.622	0.3659	0.594	0.6135	0.4932	0.5346	0.55	0.4263	0.6619	gnomADg_AMI										FAIL	0	-14	-21	33	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											146					0.973							236.07													chr7	14021334																																																	True	True	False	Unknown		Unknown																						83,59	40,22	43,37	0|1	36,47,30,29	TTC	.	.	.		14021333	35,48,25,34	15.97		0.4154929577464789
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13982061	13982061.0	C	T	T	13982061	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+4577G>A						rs10244180		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5337	0.5643	0.621	0.5774	0.5328	0.3865											0.5417	0.5526	0.6641	0.6082	0.3613	0.5992	0.6146	0.4623	0.5211	0.5323	0.4229	0.6641	gnomADg_AMI										FAIL	46	1	-31	1	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											101					1							236.93													chr7	14021686																																																	True	True	False	Unknown		Unknown																						54,47	19,25	35,22	0/1	29,25,23,24	ACC	0.00	0.00	0.00			26,28,25,22	31.77		0.46534653465346537
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13982740	13982740.0	G	A	A	13982740	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+3898C>T						rs7791209		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5166	0.4939	0.6196	0.5774	0.5417	0.3855											0.5329	0.4927	0.6663	0.6098	0.3676	0.601	0.6197	0.4796	0.5361	0.5296	0.425	0.6663	gnomADg_AMI										FAIL	-14	31	2	-16	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											74					1							244.62													chr7	14022365																																																	True	True	False	Unknown		Unknown																						43,31	19,14	24,17	0/1	24,19,15,16	CGT	0.00	0.00	0.00			24,19,8,23	26.45		0.4189189189189189
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13982819	13982819.0	A	G	G	13982819	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+3819T>C						rs7790949&COSV54144131		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5637	0.6664	0.6297	0.5774	0.5427	0.3855											0.5731	0.6341	0.6648	0.6232	0.3674	0.5998	0.6178	0.4932	0.5364	0.5523	0.4255	0.6664	AFR		0&1	0&1							FAIL	16	2	-17	2	0.04	0.00	0.00	0.00	ETV1		6.5800e-01																																																											82					0.976							246.41													chr7	14022444																																																	True	True	False	Unknown		Unknown																						44,36	24,16	20,20	0/1	26,18,20,16	TAA	.	.	.			24,20,18,18	28.55		0.45
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13982897	13982897.0	A	G	G	13982897	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+3741T>C						rs7790991&COSV54150405		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5637	0.6664	0.6297	0.5774	0.5427	0.3855											0.5731	0.6344	0.6634	0.6225	0.3665	0.5998	0.6181	0.4897	0.5363	0.5512	0.4258	0.6664	AFR		0&1	0&1							FAIL	23	-31	-29	46	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											71					1							248.07													chr7	14022522																																																	True	True	False	Unknown		Unknown																						40,31	23,12	17,19	0/1	21,19,17,14	TAA	.	.	.			20,20,18,13	28.56		0.43661971830985913
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13983618	13983618.0	T	C	C	13983618	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+3020A>G						rs3801103		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5643	0.6672	0.6297	0.5833	0.5427	0.3814											0.5679	0.6301	0.6637	0.6195	0.365	0.5988	0.593	0.493	0.5339	0.546	0.4216	0.6672	AFR										FAIL	-33	4	-41	4	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											106					0.83							233.36													chr7	14023243																																																	True	True	False	Unknown		Unknown																						46,42	24,21	22,21	0/1	25,21,24,18	CTG	.	.	.			29,17,21,21	33.07		0.4772727272727273
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13983621	13983622.0	C	CT	CT	13983621	.	C	CT	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+3016dup						rs34955846		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5643	0.6664	0.6297	0.5833	0.5427	0.3824											0.5699	0.6316	0.6659	0.6226	0.3693	0.6047	0.6014	0.4929	0.5345	0.5505	0.4276	0.6664	AFR										FAIL	-5	1	0	1	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											100					0.64							235.37													chr7	14023246																																																	True	True	False	Unknown		Unknown																						41,23	21,14	20,9	0/1	20,21,14,9	ACT						24,17,13,10	23.9		0.359375
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13983666	13983666.0	G	T	T	13983666	.	G	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2972C>A						rs3801104		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5639	0.6664	0.6297	0.5823	0.5427	0.3814											0.5726	0.635	0.6663	0.6231	0.3671	0.606	0.6085	0.5036	0.5375	0.5495	0.4255	0.6664	AFR										FAIL	-18	33	-3	-44	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											103					0.874							235.83													chr7	14023291																																																	True	True	False	Unknown		Unknown																						49,41	32,21	17,20	0|1	28,21,20,21	TGC	0.00	0.00	0.00		14023291	21,28,24,17	23.67		0.45555555555555555
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13983681	13983681.0	A	G	G	13983681	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2957T>C						rs116912390		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.0094	0.0008	0.0187	0	0.0268	0.0061											0.02136	0.005742	0.04057	0.0269	0.0188	0	0.008117	0.01736	0.03381	0.02527	0.01005	0.04057	gnomADg_AMI										FAIL	18	-8	45	-5	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											100					0.9							239.82													chr7	14023306																																																	True	True	False	Unknown		Unknown																						48,42	28,21	20,21	0|1	25,23,23,19	AAT	.	.	.		14023291	23,25,20,22	24.78		0.4666666666666667
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13983714	13983715.0	T	TA	TA	13983714	.	T	TA	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2923dup						rs35601993		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5549	0.674	0.6282	0.5506	0.5278	0.3742											0.5737	0.6454	0.6648	0.6218	0.3682	0.5993	0.5989	0.486	0.5355	0.554	0.423	0.674	AFR										FAIL	11	-11	11	12	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											90					0.878							243.52													chr7	14023339																																																	True	True	False	Unknown		Unknown																						43,36	22,15	21,21	0/1	20,23,23,13	TTA						25,18,12,24	29.06		0.45569620253164556
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13983837	13983837.0	A	G	G	13983837	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2801T>C						rs3801105		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5641	0.6664	0.6297	0.5833	0.5427	0.3814											0.573	0.6348	0.6634	0.6231	0.3667	0.6012	0.6178	0.4897	0.5359	0.5509	0.4238	0.6664	AFR										FAIL	-9	-37	-20	27	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											127					1							241.24													chr7	14023462																																																	True	True	False	Unknown		Unknown																						68,59	40,34	28,25	0/1	34,34,30,29	TAT	.	.	.			40,28,33,26	31.79		0.4645669291338583
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13984024	13984024.0	A	C	C	13984024	.	A	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2614T>G						rs1319410		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5647	0.6694	0.6311	0.5813	0.5427	0.3814											0.5742	0.6383	0.6634	0.6232	0.3666	0.602	0.6177	0.4932	0.5362	0.5521	0.4241	0.6694	AFR										FAIL	-41	-15	-9	-15	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											114					0.904							234.46													chr7	14023649																																																	True	True	False	Unknown		Unknown																						66,37	34,16	32,21	0/1	40,26,20,17	AAA	.	.	.			32,34,13,24	15.79		0.3592233009708738
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13984182	13984182.0	C	G	G	13984182	.	C	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2456G>C						rs765982		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.7692	0.9811	0.7767	0.6349	0.7227	0.6636											0.7952	0.9451	0.8502	0.793	0.7657	0.6489	0.7682	0.7959	0.7297	0.7737	0.668	0.9811	AFR			1	32888494						FAIL	-11	26	-25	-33	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											79					1							247.27													chr7	14023807																																																	True	True	False	Unknown		Unknown																						44,35	26,17	18,18	0/1	23,21,16,19	GCG	.	.	.			21,23,16,19	29.17		0.4430379746835443
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13984548	13984548.0	G	A	A	13984548	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2090C>T						rs765981		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5641	0.6664	0.6297	0.5833	0.5427	0.3814											0.5735	0.6347	0.6634	0.6235	0.3671	0.6016	0.6201	0.4932	0.5365	0.5514	0.4236	0.6664	AFR										FAIL	45	-19	20	-20	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											117					0.974							243.49													chr7	14024173																																																	True	True	False	Unknown		Unknown																						55,59	22,29	33,30	0/1	24,31,28,31	CGT	0.00	0.00	0.00			33,22,20,39	38.01		0.5175438596491229
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13984606	13984606.0	C	T	T	13984606	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+2032G>A						rs765980		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5641	0.6664	0.6297	0.5833	0.5427	0.3814											0.5735	0.6349	0.6634	0.6233	0.3667	0.6029	0.6196	0.4897	0.5364	0.5514	0.4241	0.6664	AFR										FAIL	-2	1	3	-38	0.00	0.00	0.00	0.01	ETV1		6.5800e-01																																																											95					0.958							246.2													chr7	14024231																																																	True	True	False	Unknown		Unknown																						50,41	21,24	29,17	0/1	27,23,23,18	ACG	0.00	0.00	0.00			30,20,16,25	29.97		0.45054945054945056
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13984755	13984755.0	C	T	T	13984755	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+1883G>A						rs2282866		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5647	0.6664	0.6297	0.5843	0.5427	0.3834											0.5729	0.6343	0.6626	0.6228	0.3668	0.6036	0.6175	0.4932	0.5358	0.5513	0.4234	0.6664	AFR										FAIL	-49	-1	-1	5	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											112					1							246.44													chr7	14024380																																																	True	True	False	Unknown		Unknown																						72,40	34,16	38,24	0|1	29,43,21,19	ACT	0.00	0.00	0.00		14024380	39,33,19,21	7.13		0.35714285714285715
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13984771	13984771.0	A	T	T	13984771	.	A	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+1867T>A						rs2282865		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5647	0.6664	0.6297	0.5843	0.5427	0.3834											0.5731	0.6345	0.6634	0.6227	0.3671	0.6038	0.6178	0.4897	0.536	0.5504	0.4245	0.6664	AFR										FAIL	-48	-6	-17	39	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											104					0.99							246.48													chr7	14024396																																																	True	True	False	Unknown		Unknown																						58,45	26,19	32,26	0|1	24,34,23,22	GAT	.	.	.		14024380	30,28,21,24	21.02		0.4368932038834951
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13984913	13984917.0	CAAGT	C	C	13984913	.	CAAGT	C	.	PASS	NM_004956	-	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+1721_181+1724del						rs66641803		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1																						0.5679	0.6289	0.6588	0.6192	0.3654	0.5964	0.6045	0.4861	0.5328	0.5462	0.4187	0.6588	gnomADg_AMI										FAIL	-16	1	-48	30	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											135					0.785							215.6													chr7	14024538																																																	True	True	False	Unknown		Unknown																						50,56	28,26	22,30	0/1	23,27,29,27	ACA						23,27,31,25	37.39		0.5283018867924528
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13985242	13985242.0	G	A	A	13985242	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+1396C>T						rs10235014		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5645	0.6664	0.6297	0.5833	0.5437	0.3824											0.5731	0.6345	0.6634	0.6227	0.3668	0.6022	0.6188	0.4932	0.536	0.5498	0.425	0.6664	AFR										FAIL	-26	13	2	-34	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											107					0.991							244.04													chr7	14024867																																																	True	True	False	Unknown		Unknown																						59,47	21,28	38,19	0/1	31,28,17,30	TGT	0.00	0.00	0.00			27,32,24,23	28.89		0.44339622641509435
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13985692	13985692.0	A	G	G	13985692	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+946T>C						rs2214684		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5645	0.6664	0.6282	0.5833	0.5437	0.3834											0.573	0.6344	0.663	0.6227	0.3672	0.603	0.6177	0.4932	0.5361	0.5501	0.4246	0.6664	AFR										FAIL	-30	41	-13	41	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											108					0.963							240.71													chr7	14025317																																																	True	True	False	Unknown		Unknown																						60,44	31,26	29,18	0/1	30,30,23,21	AAT	.	.	.			37,23,27,17	25.93		0.4230769230769231
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13985744	13985744.0	T	C	C	13985744	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+894A>G						rs3801107		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5062	0.5651	0.611	0.4454	0.5089	0.4121											0.5237	0.5502	0.6557	0.6052	0.3499	0.4416	0.5597	0.483	0.5038	0.5151	0.434	0.6557	gnomADg_AMI										FAIL	-11	8	-11	8	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											114					0.947							235.79													chr7	14025369																																																	True	True	False	Unknown		Unknown																						54,54	28,27	26,27	0/1	24,30,23,31	ATG	.	.	.			28,26,28,26	35.99		0.5
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13985786	13985786.0	T	G	G	13985786	.	T	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+852A>C						rs3801108		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5649	0.6687	0.6282	0.5833	0.5437	0.3824											0.5735	0.6362	0.6634	0.6231	0.3671	0.6023	0.6187	0.4932	0.536	0.5507	0.4235	0.6687	AFR										FAIL	21	-34	-34	33	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											117					0.915							237.82													chr7	14025411																																																	True	True	False	Unknown		Unknown																						56,51	23,28	33,23	0/1	29,27,23,28	ATT	.	.	.			20,36,24,27	33.19		0.4766355140186916
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13985849	13985849.0	A	G	G	13985849	.	A	G	.	PASS	NM_004956	G	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+789T>C						rs3801109		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5643	0.6664	0.6282	0.5833	0.5437	0.3824											0.5729	0.635	0.6626	0.6226	0.3666	0.602	0.6171	0.4932	0.5358	0.5506	0.4236	0.6664	AFR										FAIL	26	14	31	-35	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											95					0.979							243.16													chr7	14025474																																																	True	True	False	Unknown		Unknown																						49,44	26,20	23,24	0/1	20,29,21,23	AAG	.	.	.			21,28,17,27	32.57		0.4731182795698925
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13986015	13986015.0	G	A	A	13986015	.	G	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+623C>T						rs3801110&COSV54151512		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5753	0.7073	0.6282	0.5833	0.5447	0.3824	0.5051	0.6475	0.6128	0.3419	0.6244	0.5995	0.4587	0.4982	0.5054	0.4212	0.5822	0.6668	0.6648	0.6247	0.3664	0.6036	0.6177	0.4932	0.5363	0.5562	0.4245	0.7073	AFR		0&1	0&1							FAIL	49	-28	6	-22	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											127					0.906							235.44													chr7	14025640																																																	True	True	False	Unknown		Unknown																						61,54	31,26	30,28	0/1	26,35,27,27	AGC	0.00	0.00	0.00			28,33,27,27	32.4		0.46956521739130436
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13986102	13986102.0	C	T	T	13986102	.	C	T	.	PASS	NM_004956	T	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+536G>A						rs3823704&COSV54148588		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5637	0.6664	0.6282	0.5804	0.5447	0.3814	0.5274	0.6352	0.637	0.3576	0.6195	0.6102	0.4695	0.5254	0.5195	0.4289	0.5731	0.6354	0.6626	0.6229	0.3671	0.5968	0.618	0.4932	0.536	0.5517	0.4237	0.6664	AFR		0&1	0&1							FAIL	14	12	14	12	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											92					0.978							240.75													chr7	14025727																																																	True	True	False	Unknown		Unknown																						48,42	18,15	30,27	0/1	29,19,23,19	GCA	0.00	0.00	0.00			15,33,16,26	31.82		0.4666666666666667
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13986141	13986141.0	T	A	A	13986141	.	T	A	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		5/13	c.181+497A>T						rs10215655&COSV54148253		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5641	0.6672	0.6282	0.5813	0.5437	0.3824	0.531	0.6411	0.6486	0.359	0.6226	0.6118	0.4688	0.5285	0.5221	0.4325	0.5734	0.6361	0.6634	0.6226	0.3671	0.5997	0.6188	0.4728	0.5361	0.5508	0.4244	0.6672	AFR		0&1	0&1							FAIL	-18	41	18	-25	0.00	0.00	0.00	0.07	ETV1		6.5800e-01																																																											95					0.989							235.99													chr7	14025766																																																	True	True	False	Unknown		Unknown																						50,44	18,19	32,25	0/1	23,27,25,19	GTG	.	.	.			19,31,18,26	32.02		0.46808510638297873
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13988242	13988244.0	G	GCA	GCA	13988242	.	G	GCA	.	PASS	NM_004956	CA	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		3/13	c.46-71_46-70dup						rs59844225		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.4782	0.4849	0.5591	0.5268	0.493	0.3466	0.3885	0.4191	0.4631	0.2904	0.4702	0.4682	0.3767	0.3786	0.3913	0.336	0.5397	0.5538	0.6634	0.606	0.3573	0.5968	0.6072	0.483	0.5186	0.5312	0.4175	0.6634	gnomADg_AMI																					6.5800e-01																																																											155					0.6							223.05													chr7	14027867																																																	True	True	False	Unknown		Unknown																						56,37	28,19	28,18	0/1	34,22,24,13	CGC						32,24,20,17	24.65		0.3978494623655914
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13988366	13988366.0	T	C	C	13988366	.	T	C	.	PASS	NM_004956	C	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		3/13	c.46-193A>G						rs6977237		-1		SNV	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5695	0.6846	0.6254	0.5883	0.5427	0.3824	0.5341	0.6562	0.6388	0.3567	0.6372	0.6121	0.4735	0.5284	0.5266	0.4316	0.5773	0.6511	0.6667	0.6221	0.3661	0.6061	0.6172	0.4932	0.5355	0.5537	0.4233	0.6846	AFR			1	36224396&30038396						FAIL	47	-23	-23	-1	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											88					0.977							237.32													chr7	14027991																																																	True	True	False	Unknown		Unknown																						43,43	24,23	19,20	0/1	19,24,20,23	GTT	.	.	.			18,25,26,17	35.1		0.5
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13988620	13988621.0	G	GA	GA	13988620	.	G	GA	.	PASS	NM_004956	A	intron_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding		3/13	c.45+387dup						rs11460974		-1		insertion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5937	0.8313	0.6484	0.4573	0.5557	0.4131	0.5686	0.7089	0.6349	0.5765	0.449	0.5769	0.5999	0.5702	0.562	0.5105	0.7228	0.8579	0.8387	0.7487	0.7203	0.4444	0.6268	0.7235	0.6854	0.6968	0.5627	0.8579	gnomADg_AFR										FAIL	22	24	33	24	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											282					0.532							206.84													chr7	14028245																																																	True	True	False	Unknown		Unknown																						84,66	36,32	48,34	0/1	48,36,40,26	AGA						32,52,28,38	32.31		0.44
GRCh38	ETV1	D12_12345_1234556_Thyroid_S9			chr7	13989082	13989083.0	TA	T	T	13989082	.	TA	T	.	PASS	NM_004956	-	5_prime_UTR_variant	MODIFIER	ETV1	ENSG00000006468	Transcript	ENST00000430479	protein_coding	3/14		c.-31del	358					rs140879246&COSV54138676		-1		deletion	HGNC	HGNC:3490	YES	MANE_Select	NM_004956.5		1	P1	CCDS55088.1	ENSP00000405327	P50549.202		UPI000012A26E	P50549-1		1						0.5164	0.6967	0.5778	0.4891	0.4911	0.2832	0.4824	0.6724	0.6101	0.3188	0.5098	0.4977	0.3931	0.4858	0.4744	0.3388	0.5384	0.6634	0.6465	0.5838	0.3123	0.5033	0.4958	0.4144	0.4874	0.5104	0.3322	0.6967	AFR		0&1	0&1							FAIL	33	49	8	49	0.00	0.00	0.00	0.00	ETV1		6.5800e-01																																																											102					0.922							245.25													chr7	14028707																																																	True	True	False	Unknown		Unknown																						53,41	24,21	29,20	0/1	22,31,26,15	GTA						29,24,22,19	26.87		0.43617021276595747
GRCh38	OSBPL3	D12_12345_1234556_Thyroid_S9			chr7	24931486		G	[chr6:152755608[G	[chr6:152755608[G	24931486	MantaBND:9745:0:1:0:0:0:1	G	[chr6:152755608[G	.	PASS		.G	feature_truncation&intron_variant	HIGH	OSBPL3	ENSG00000070882	Transcript	ENST00000415952	protein_coding		1/2									-1	cds_end_NF	chromosome_breakpoint	HGNC	HGNC:16370					4			ENSP00000411249		C9J8P4.76	UPI0001881473																																																																																																																	3			0,7							7	AAACAGA			MantaBND:9745:0:1:0:0:0:0	0														chr7	24971105				BND																																													True	False	False	Unknown		Unknown																															1,1				1,2	
GRCh38	INHBA	D12_12345_1234556_Thyroid_S9			chr7	41695436	41695436.0	C	T	T	41695436	.	C	T	.	PASS	NM_002192	T	intron_variant	MODIFIER	INHBA	ENSG00000122641	Transcript	ENST00000242208	protein_coding		2/2	c.388+4551G>A						rs2237432		-1		SNV	HGNC	HGNC:6066	YES	MANE_Select	NM_002192.4		1	P1	CCDS5464.1	ENSP00000242208	P08476.237	A4D1W7.147	UPI000012D421			1						0.7127	0.8169	0.6066	0.5893	0.7803	0.7045											0.7544	0.8069	0.818	0.6141	0.6817	0.6	0.8402	0.7041	0.7598	0.727	0.7039	0.8402	gnomADg_FIN			1	18413775&21222045&32970737&35361970						FAIL	33	0	-26	4	0.00	0.00	0.00	0.00	INHBA		1.6600e-01																																																											66					0.955							244.55													chr7	41735034																																																	True	True	False	Unknown		Unknown																						34,29	12,16	22,13	0/1	14,20,16,13	CCC	0.00	0.00	0.00			16,18,13,16	30.87		0.4603174603174603
GRCh38	CAMK2B	D12_12345_1234556_Thyroid_S9			chr7	44254776		T	<INS>	<INS>	44254776	MantaINS:10224:0:0:0:3:0	T	<INS>	.	PASS		insertion	intron_variant&NMD_transcript_variant	MODIFIER	CAMK2B	ENSG00000058404	Transcript	ENST00000700291	nonsense_mediated_decay		3/18									-1	cds_start_NF	insertion	HGNC	HGNC:1461								ENSP00000514922		A0A8V8TQ13.10	UPI0020B09A9A			1																																																																																																															0,4		0,4							4	ACCA		ACCATCATCACCAACCACCATCACCATCACCACCACCATCACCACCAACCACCATCACCATCACCACCACCATCACCA																chr7	44294375	ACCATCACTGCCACCACCACCATCATCACTATCACCATCACCACCATCACACCATTACCATTATCATCACCACC			INS																																													True	False	False	Unknown		Unknown																															0,2				0,14	
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55105075	55105075.0	T	C	C	55105075	.	T	C	.	PASS	NM_005228	C	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		1/27	c.89-37211T>C						rs2110290		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.3952	0.2277	0.3718	0.7163	0.333	0.3712											0.3247	0.2423	0.42	0.3742	0.284	0.7058	0.4041	0.3299	0.3196	0.2972	0.3913	0.7163	EAS				23251617&25396734						FAIL	-35	25	34	-19	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											124					0.976							239.64													chr7	55172768																																																	True	True	False	Unknown		Unknown																						68,53	34,29	34,24	0/1	29,39,29,24	GTT	.	.	.			33,35,23,30	27.81		0.4380165289256198
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55117085	55117085.0	A	G	G	55117085	.	A	G	.	PASS	NM_005228	G	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		1/27	c.89-25201A>G						rs73135268		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.0527	0.0363	0.0504	0	0.1004	0.0818											0.06917	0.03871	0.03728	0.06773	0.1366	0.002316	0.04521	0.1837	0.09135	0.08065	0.09353	0.1837	gnomADg_MID										FAIL	-3	2	-18	2	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											133					0.94							241.92													chr7	55184778																																																	True	True	False	Unknown		Unknown																						64,61	34,26	30,35	0/1	38,26,27,34	CAG	.	.	.			32,32,28,33	34.94		0.488
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55153962	55153962.0	G	A	A	55153962	.	G	A	.	PASS	NM_005228	A	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		6/27	c.748-49G>A						rs4947986&COSV51773953		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.3207	0.0726	0.3401	0.6498	0.2813	0.3436	0.2874	0.09012	0.3452	0.2244	0.6701	0.2785	0.2545	0.2756	0.2893	0.3354	0.2455	0.09763	0.3004	0.3295	0.2247	0.6503	0.2744	0.2925	0.2741	0.272	0.3459	0.6701	gnomADe_EAS	benign	0&1	1&1	20197289&26906551&25396734&34680968&33935511&34501555&20446891&23778325&27613841&26261317&26202599&32450446						FAIL	28	49	6	28	0.02	0.00	0.00	0.00	EGFR		4.7500e-01	1248590	0.21744	0.30217	0.32069	1238959	not_provided		MedGen:C3661900		NC_000007.14:g.55153962G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001868006&SCV005268217	single_nucleotide_variant	SO:0001483	ClinGen:CA4265343		EGFR:1956	SO:0001627&intron_variant										1	4947986																											1168					0.994							246.66													chr7	55221655																																																	True	True	False	Unknown		Unknown																						594,567	327,303	267,264	0/1	298,296,309,258	CGC	0.00	0.00	0.00			317,277,295,272	47.6		0.4883720930232558
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55156097	55156097.0	T	C	C	55156097	.	T	C	.	PASS	NM_005228	C	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		8/27	c.1006+151T>C						rs3735059&COSV51818638		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.5942	0.829	0.5663	0.3542	0.5507	0.589	0.5711	0.794	0.5829	0.6457	0.3241	0.5333	0.6372	0.5754	0.5885	0.6015	0.6271	0.7895	0.5285	0.5714	0.644	0.3514	0.5293	0.6088	0.5799	0.6128	0.5947	0.829	AFR	benign	0&1	1&1	19026460						FAIL	-18	19	2	-39	0.00	0.00	0.03	0.00	EGFR		4.7500e-01	1268274			0.59425	1258184	not_provided		MedGen:C3661900		NC_000007.14:g.55156097T>C	criteria_provided&_single_submitter	Benign			SCV001897167	single_nucleotide_variant	SO:0001483	ClinGen:CA12649123		EGFR:1956&LOC126860048:126860048	SO:0001627&intron_variant										1	3735059																											1009					0.995							245.65													chr7	55223790																																																	True	True	False	Unknown		Unknown																						509,495	233,215	276,280	0/1	247,262,240,255	CTA	.	.	.			309,200,288,207	49.75		0.49302788844621515
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55161850	55161850.0	T	C	C	55161850	.	T	C	.	PASS	NM_005228	C	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		13/27	c.1631+219T>C						rs3752651&COSV51773959		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.1290	0.0666	0.1585	0.1379	0.2028	0.1074											0.1513	0.07377	0.2747	0.1755	0.1696	0.1143	0.1206	0.2177	0.1997	0.1773	0.1163	0.2747	gnomADg_AMI	benign	0&1	1&1	22662167&19190167&27437777&28938685&29156842&30026459&32712352&22199994&34721579&23912956&23778325&27613841&24319539						FAIL	37	23	-14	-16	0.00	0.00	0.00	0.00	EGFR		4.7500e-01	1225850			0.12899	1214532	not_provided		MedGen:C3661900		NC_000007.14:g.55161850T>C	criteria_provided&_single_submitter	Benign			SCV001834255	single_nucleotide_variant	SO:0001483	ClinGen:CA12692718		EGFR:1956	SO:0001627&intron_variant										1	3752651																											219					0.995							247.42													chr7	55229543																																																	True	True	False	Unknown		Unknown																						107,111	45,54	62,57	0/1	61,46,52,59	CTA	.	.	.			33,74,41,70	40.7		0.5091743119266054
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9	p.Ala613=	ENSP00000275493.2:p.Ala613=	chr7	55165396	55165396.0	C	T	T	55165396	.	C	T	.	PASS	NM_005228	T	synonymous_variant	LOW	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding	15/28		c.1839C>T	2100	1839	613	A	gcC/gcT	rs17290169&COSV51776666		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1			PDB-ENSP_mappings:1ivo.A&PDB-ENSP_mappings:1ivo.B&PDB-ENSP_mappings:1nql.A&PDB-ENSP_mappings:1yy9.A&PDB-ENSP_mappings:3b2v.A&PDB-ENSP_mappings:3njp.A&PDB-ENSP_mappings:3njp.B&PDB-ENSP_mappings:3qwq.A&PDB-ENSP_mappings:4kro.A&PDB-ENSP_mappings:4krp.A&PDB-ENSP_mappings:4uip.A&PDB-ENSP_mappings:4uv7.A&PDB-ENSP_mappings:5xwd.A&PDB-ENSP_mappings:6aru.A&PDB-ENSP_mappings:7om4.A&PDB-ENSP_mappings:7syd.A&PDB-ENSP_mappings:7syd.B&PDB-ENSP_mappings:7sye.A&PDB-ENSP_mappings:7sye.B&PDB-ENSP_mappings:7sz0.A&PDB-ENSP_mappings:7sz0.B&PDB-ENSP_mappings:7sz1.A&PDB-ENSP_mappings:7sz1.B&PDB-ENSP_mappings:7sz5.A&PDB-ENSP_mappings:7sz5.B&PDB-ENSP_mappings:7sz7.A&PDB-ENSP_mappings:7sz7.B&PDB-ENSP_mappings:8hgo.A&PDB-ENSP_mappings:8hgp.A&PDB-ENSP_mappings:8hgs.A&PDB-ENSP_mappings:8hgs.B&PDB-ENSP_mappings:8ukv.A&PDB-ENSP_mappings:8ukv.B&PDB-ENSP_mappings:8ukw.A&PDB-ENSP_mappings:8ukw.B&PDB-ENSP_mappings:8ukx.A&Superfamily:SSF57184&PANTHER:PTHR24416&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF14843&Gene3D:2.10.220.10&PIRSF:PIRSF000619&AFDB-ENSP_mappings:AF-P00533-F1			0.0421	0.0696	0.0389	0.001	0.0666	0.0245	0.05476	0.0582	0.04437	0.07205	0.0007053	0.05636	0.08865	0.05742	0.05737	0.03914	0.05438	0.05353	0.005482	0.04803	0.08554	0.001738	0.05712	0.1224	0.05946	0.06297	0.03937	0.1224	gnomADg_MID	benign	0&1	1&1	24033266&17956637&36873279&33874989&36347915&29660021						FAIL	41	-4	-13	41	0.00	0.00	0.00	0.01	EGFR		4.7500e-01	360461	0.05805		0.04213	303212	not_specified&not_provided&EGFR-related_lung_cancer&Lung_cancer&Hereditary_cancer-predisposing_syndrome		MedGen:CN169374&MedGen:C3661900&MedGen:CN130014&MONDO:MONDO:0008903&MedGen:C0242379&OMIM:211980&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000007.14:g.55165396C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000539078&SCV001717764&SCV001915323&SCV004017420&SCV005270515&SCV005579545	single_nucleotide_variant	SO:0001483	ClinGen:CA4265711		EGFR:1956	SO:0001819&synonymous_variant										1	17290169																											1165					0.994							246.27	v6.1	Unknown		True	EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:A613= mutant UNKNOWN.	False	The EGFR ENSP00000275493.2:a613= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	55233089						True	False	False	Unknown								False	False		EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others.	The EGFR ENSP00000275493.2:a613= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:A613= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	EGFR	1956.0	ENSP00000275493.2:A613=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EGFR"",""entrezGeneId"":1956,""alteration"":""ENSP00000275493.2:A613="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others."",""variantSummary"":""The EGFR ENSP00000275493.2:a613= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:A613= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						566,592	276,280	290,312	0/1	251,315,306,286	CCG	0.00	0.00	0.00			257,309,292,300	63.63		0.5112262521588946
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55165492	55165492.0	C	T	T	55165492	.	C	T	.	PASS	NM_005228	T	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		15/27	c.1880+55C>T						rs17290183&COSV51776706		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.0421	0.0696	0.0389	0.001	0.0666	0.0245	0.05461	0.05799	0.04444	0.07226	0.0003592	0.05604	0.09095	0.05719	0.0569	0.03922	0.05442	0.05371	0.005482	0.04809	0.08564	0.001735	0.05726	0.1224	0.05944	0.06238	0.03954	0.1224	gnomADg_MID	benign	0&1	1&1	34648354						FAIL	31	39	-44	39	0.00	0.00	0.00	0.14	EGFR		4.7500e-01	1229994			0.04213	1219960	not_provided		MedGen:C3661900		NC_000007.14:g.55165492C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001839575&SCV005270526	single_nucleotide_variant	SO:0001483	ClinGen:CA12563285		EGFR:1956	SO:0001627&intron_variant										1	17290183																											1052					0.998							246.85													chr7	55233185																																																	True	True	False	Unknown		Unknown																						506,544	269,271	237,273	0/1	269,237,271,273	TCA	0.00	0.00	0.00			254,252,252,292	63.42		0.518095238095238
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55166621	55166662.0	G	GTGAGGAGGTGGGAGTCACAGTGGTGGTGGTGTTGATGGTGA	GTGAGGAGGTGGGAGTCACAGTGGTGGTGGTGTTGATGGTGA	55166621	.	G	GTGAGGAGGTGGGAGTCACAGTGGTGGTGGTGTTGATGGTGA	.	PASS	NM_005228	TGAGGAGGTGGGAGTCACAGTGGTGGTGGTGTTGATGGTGA	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		15/27	c.1880+1224_1880+1225insATGAGGAGGTGGGAGTCACAGTGGTGGTGGTGTTGATGGTG						rs55715636		1		insertion	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1					40																	0.09264	0.0453	0.1955	0.1075	0.1113	0.05125	0.06305	0.1492	0.127	0.1111	0.04568	0.1955	gnomADg_AMI																					4.7500e-01																																																											1049					0.471							123.93													chr7	55234314																																																	True	True	False	Unknown		Unknown																						203,291	81,111	122,180	0/1	117,86,144,147	GGT						101,102,156,135	40.43		0.5890688259109311
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55169081	55169081.0	A	G	G	55169081	.	A	G	.	PASS	NM_005228	G	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		15/27	c.1881-2094A>G						rs845550		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.9321	0.8964	0.9352	1	0.8847	0.9571											0.902	0.9023	0.8593	0.9279	0.9287	0.9996	0.846	0.932	0.8914	0.9182	0.9633	1	EAS										FAIL	-27	-26	-27	-7	0.00	0.00	0.01	0.00	EGFR		4.7500e-01																																																											704					0.98							235.73													chr7	55236774																																																	True	True	False	Unknown		Unknown																						0,690	0,347	0,343	0/1	0,0,344,346	GAA	.	.	.			0,0,311,379	64.73		1.0
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55169103	55169103.0	C	T	T	55169103	.	C	T	.	PASS	NM_005228	T	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		15/27	c.1881-2072C>T						rs10081281		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.6128	0.4924	0.5144	0.879	0.4722	0.7157											0.4867	0.4638	0.4102	0.4831	0.5568	0.8823	0.494	0.5704	0.4513	0.4956	0.7133	0.8823	gnomADg_EAS										FAIL	14	19	4	-49	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											689					0.943							214.43													chr7	55236796																																																	True	True	False	Unknown		Unknown																						449,201	223,107	226,94	0/1	235,214,91,110	TCT	0.00	0.00	0.00			195,254,89,112	11.8		0.30923076923076925
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55169169	55169169.0	T	C	C	55169169	.	T	C	.	PASS	NM_005228	C	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		15/27	c.1881-2006T>C						rs1815156		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.5158	0.5809	0.464	0.5764	0.4294	0.4908											0.4635	0.5307	0.3767	0.4485	0.5213	0.6042	0.4043	0.5103	0.4192	0.4667	0.5131	0.6042	gnomADg_EAS										FAIL	-47	27	26	-8	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											348					0.991							164.78													chr7	55236862																																																	True	True	False	Unknown		Unknown																						175,170	95,80	80,90	0/1	81,94,88,82	TTG	.	.	.			49,126,32,138	39.54		0.4927536231884058
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55169590	55169590.0	A	G	G	55169590	.	A	G	.	PASS	NM_005228	G	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		15/27	c.1881-1585A>G						rs845551		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.6569	0.5265	0.8098	0.631	0.7654	0.6401											0.7118	0.584	0.7982	0.7863	0.8311	0.6285	0.6787	0.7755	0.7793	0.7441	0.6627	0.8311	gnomADg_ASJ				34680968&26305006						FAIL	45	25	-11	30	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											453					0.967							244.5													chr7	55237283																																																	True	True	False	Unknown		Unknown																						209,229	91,108	118,121	0/1	99,110,114,115	GAG	.	.	.			131,78,121,108	52.13		0.5228310502283106
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55170394	55170394.0	C	T	T	55170394	.	C	T	.	PASS	NM_005228	T	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		15/27	c.1881-781C>T						rs10258429&COSV51800626		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.1124	0.2398	0.049	0.0496	0.0736	0.09	0.07938	0.209	0.05067	0.05204	0.04882	0.07244	0.0586	0.07709	0.07784	0.1026	0.1082	0.2022	0.03289	0.06651	0.05472	0.05656	0.07624	0.06463	0.0744	0.09612	0.09528	0.2398	AFR	benign	0&1	1&1	28762371&36873279&27776352						FAIL	25	4	-23	4	0.00	0.00	0.00	0.00	EGFR		4.7500e-01	1241373	0.11748	0.08298	0.11242	1233430	not_provided		MedGen:C3661900		NC_000007.14:g.55170394C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001859401&SCV005270537	single_nucleotide_variant	SO:0001483	ClinGen:CA4265796		EGFR:1956	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	10258429																											892					0.999							247.46													chr7	55238087																																																	True	True	False	Unknown		Unknown																						477,414	241,209	236,205	0/1	247,230,200,214	ACC	0.00	0.00	0.00			297,180,259,155	26.35		0.46464646464646464
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55175089	55175089.0	T	C	C	55175089	.	T	C	.	PASS	NM_005228	C	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2283+269T>C						rs712831		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.6725	0.5582	0.8141	0.6329	0.7734	0.6636											0.7333	0.6177	0.8103	0.7938	0.842	0.6382	0.7505	0.7653	0.791	0.7543	0.682	0.842	gnomADg_ASJ	benign		1							FAIL	2	33	2	-46	0.00	0.00	0.06	0.00	EGFR		4.7500e-01	1273426			0.67252	1263975	not_provided		MedGen:C3661900		NC_000007.14:g.55175089T>C	criteria_provided&_single_submitter	Benign			SCV001902146	single_nucleotide_variant	SO:0001483	ClinGen:CA12508231		EGFR:1956	SO:0001627&intron_variant										1	712831																											390					0.992							241.1													chr7	55242782																																																	True	True	False	Unknown		Unknown																						192,195	84,98	108,97	0/1	84,108,106,89	ATG	.	.	.			88,104,97,98	44.02		0.5038759689922481
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55176061	55176061.0	A	G	G	55176061	.	A	G	.	PASS	NM_005228	G	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2283+1241A>G						rs9692301&COSV51773967		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.1957	0.1732	0.3285	0.0109	0.2903	0.2249											0.26	0.1905	0.4405	0.3461	0.2775	0.01619	0.2052	0.2653	0.3086	0.2694	0.2314	0.4405	gnomADg_AMI		0&1	0&1	23251617&25396734&24319539						FAIL	1	2	-25	-33	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											118					0.992							244.32													chr7	55243754																																																	True	True	False	Unknown		Unknown																						77,40	41,23	36,17	0/1	44,33,24,16	AAG	.	.	.			34,43,23,17	12.63		0.3418803418803419
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55176787	55176787.0	A	G	G	55176787	.	A	G	.	PASS	NM_005228	G	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2283+1967A>G						rs56015951		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.1953	0.1717	0.3285	0.0109	0.2903	0.2249											0.2601	0.1897	0.4394	0.3453	0.2784	0.01645	0.2	0.2626	0.3085	0.2695	0.2318	0.4394	gnomADg_AMI										FAIL	-19	-35	-1	-3	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											113					0.991							249.67													chr7	55244480																																																	True	True	False	Unknown		Unknown																						60,52	22,24	38,28	0/1	34,26,32,20	TAT	.	.	.			16,44,18,34	31.56		0.4642857142857143
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55176937	55176937.0	C	A	A	55176937	.	C	A	.	PASS	NM_005228	A	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2283+2117C>A						rs10046549&COSV51773975		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.2025	0.1974	0.3285	0.0119	0.2913	0.2249											0.2694	0.2175	0.4379	0.3519	0.2788	0.01769	0.2018	0.2626	0.3094	0.2763	0.2343	0.4379	gnomADg_AMI		0&1	0&1							FAIL	-2	48	-3	9	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											209					0.99							231.28													chr7	55244630																																																	True	True	False	Unknown		Unknown																						114,93	67,53	47,40	0/1	65,49,55,38	TCT	0.00	0.00	0.00			88,26,75,18	27.21		0.4492753623188406
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55179184	55179184.0	A	G	G	55179184	.	A	G	.	PASS	NM_005228	G	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2284-2109A>G						rs62457093&COSV51773989		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.1649	0.0998	0.3055	0.0089	0.2883	0.1871											0.2317	0.127	0.3553	0.3068	0.2562	0.01156	0.2049	0.2619	0.2985	0.245	0.2014	0.3553	gnomADg_AMI		0&1	0&1							FAIL	47	26	19	-18	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											833					0.994							247.67													chr7	55246877																																																	True	True	False	Unknown		Unknown																						411,417	199,205	212,212	0/1	217,194,221,196	TAA	.	.	.			175,236,169,248	54.6		0.5036231884057971
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55179839	55179839.0	C	T	T	55179839	.	C	T	.	PASS	NM_005228	T	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2284-1454C>T						rs845557		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.7839	0.8162	0.8573	0.6498	0.8509	0.7577	0.7778					0.75		0.875	0.6667		0.8353	0.8104	0.8432	0.854	0.8946	0.6624	0.8262	0.8333	0.8618	0.836	0.778	0.8946	gnomADg_ASJ										FAIL	9	26	17	8	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											375					0.973							214.7													chr7	55247532																																																	True	True	False	Unknown		Unknown																						0,365	0,178	0,187	0/1	0,0,186,179	ACT	0.00	0.00	0.00			0,0,189,176	64.73		1.0
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55179895	55179895.0	G	A	A	55179895	.	G	A	.	PASS	NM_005228	A	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2284-1398G>A						rs845558&COSV51773998		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.3331	0.553	0.4164	0.0208	0.4016	0.228	0.125					0		0.2	0		0.4267	0.5088	0.4482	0.4384	0.3705	0.02471	0.325	0.3767	0.4355	0.4233	0.2558	0.553	AFR		0&1	0&1	23251617&30827726&24319539						FAIL	-47	0	-39	-5	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											517					0.992							245.54													chr7	55247588																																																	True	True	False	Unknown		Unknown																						245,268	134,141	111,127	0/1	131,114,128,140	GGT	0.00	0.00	0.00			140,105,161,107	54.64		0.5224171539961013
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55179917	55179917.0	C	T	T	55179917	.	C	T	.	PASS	NM_005228	T	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2284-1376C>T						rs17290392&COSV51791019		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.1396	0.2383	0.098	0.0516	0.1193	0.1472	0.1667					0.25		0.1818	0		0.1539	0.2467	0.1261	0.1198	0.1316	0.05198	0.09064	0.1599	0.1245	0.1509	0.148	0.25	gnomADe_FIN		0&1	0&1	28039167						FAIL	44	48	-27	47	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											590					0.995							245.09													chr7	55247610																																																	True	True	False	Unknown		Unknown																						300,287	158,163	142,124	0/1	160,140,132,155	ACT	0.00	0.00	0.00			184,116,178,109	41.35		0.4889267461669506
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55180538	55180538.0	A	G	G	55180538	.	A	G	.	PASS	NM_005228	G	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2284-755A>G						rs12532468		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.4974	0.6044	0.5994	0.2242	0.6074	0.4489	0.5201	0.5	0.4167		0.5			0.5323	0.5	0.5	0.5692	0.5884	0.5757	0.6032	0.6622	0.2123	0.4619	0.6803	0.5938	0.5926	0.4832	0.6803	gnomADg_MID										FAIL	-13	49	48	-36	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											1022					0.997							247.67													chr7	55248231																																																	True	True	False	Unknown		Unknown																						1,1018	1,488	0,530	0/1	1,0,507,511	CAC	.	.	.			1,0,457,561	64.73		0.9990186457311089
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55180795	55180795.0	G	A	A	55180795	.	G	A	.	PASS	NM_005228	A	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2284-498G>A						rs13243364		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.4784	0.587	0.5677	0.1706	0.6074	0.453	0.5371	0.559	0.5674	0.6683	0.1376	0.4819	0.5902	0.5718	0.5627	0.5159	0.56	0.5659	0.5769	0.5793	0.6666	0.1629	0.462	0.6884	0.596	0.5846	0.4838	0.6884	gnomADg_MID										FAIL	31	44	31	44	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											1147					0.999							246.61													chr7	55248488																																																	True	True	False	Unknown		Unknown																						0,1146	0,574	0,572	0/1	0,0,583,563	CGG	0.00	0.00	0.00			0,0,587,559	64.73		1.0
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55181094	55181094.0	T	C	C	55181094	.	T	C	.	PASS	NM_005228	C	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		19/27	c.2284-199T>C						rs10241326		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1						0.4954	0.6415	0.5706	0.1815	0.6083	0.4519	0.5553	0.6015	0.5649	0.669	0.1613	0.471	0.655	0.5993	0.5661	0.5117	0.5715	0.6038	0.5747	0.5827	0.6669	0.1788	0.4616	0.6849	0.5963	0.5908	0.4851	0.6849	gnomADg_MID	benign		1	19201048						FAIL	-6	27	32	46	0.00	0.00	0.00	0.00	EGFR		4.7500e-01	1276464			0.49541	1267632	not_provided		MedGen:C3661900		NC_000007.14:g.55181094T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001909232&SCV005271099	single_nucleotide_variant	SO:0001483	ClinGen:CA12508236		EGFR:1956&EGFR-AS1:100507500	SO:0001619&non-coding_transcript_variant&SO:0001627&intron_variant										1	10241326																											1038					0.991							247.63													chr7	55248787																																																	True	True	False	Unknown		Unknown																						0,1029	0,553	0,476	0/1	0,0,473,556	CTC	.	.	.			0,0,491,538	64.73		1.0
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9	p.Gln787=	ENSP00000275493.2:p.Gln787=	chr7	55181370	55181370.0	G	A	A	55181370	.	G	A	.	PASS	NM_005228	A	synonymous_variant	LOW	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding	20/28		c.2361G>A	2622	2361	787	Q	caG/caA	rs1050171&CM067987&COSV51769407		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1			PDB-ENSP_mappings:1m14.A&PDB-ENSP_mappings:1m17.A&PDB-ENSP_mappings:1xkk.A&PDB-ENSP_mappings:2eb2.A&PDB-ENSP_mappings:2eb3.A&PDB-ENSP_mappings:2gs2.A&PDB-ENSP_mappings:2gs6.A&PDB-ENSP_mappings:2gs7.A&PDB-ENSP_mappings:2gs7.B&PDB-ENSP_mappings:2itn.A&PDB-ENSP_mappings:2ito.A&PDB-ENSP_mappings:2itp.A&PDB-ENSP_mappings:2itq.A&PDB-ENSP_mappings:2itt.A&PDB-ENSP_mappings:2itu.A&PDB-ENSP_mappings:2itv.A&PDB-ENSP_mappings:2itw.A&PDB-ENSP_mappings:2itx.A&PDB-ENSP_mappings:2ity.A&PDB-ENSP_mappings:2itz.A&PDB-ENSP_mappings:2j5e.A&PDB-ENSP_mappings:2j5f.A&PDB-ENSP_mappings:2j6m.A&PDB-ENSP_mappings:2jit.A&PDB-ENSP_mappings:2jit.B&PDB-ENSP_mappings:2jiu.A&PDB-ENSP_mappings:2jiu.B&PDB-ENSP_mappings:2jiv.A&PDB-ENSP_mappings:2jiv.B&PDB-ENSP_mappings:2rf9.A&PDB-ENSP_mappings:2rf9.B&PDB-ENSP_mappings:2rfd.A&PDB-ENSP_mappings:2rfd.B&PDB-ENSP_mappings:2rfe.A&PDB-ENSP_mappings:2rfe.B&PDB-ENSP_mappings:2rfe.C&PDB-ENSP_mappings:2rfe.D&PDB-ENSP_mappings:2rgp.A&PDB-ENSP_mappings:3bel.A&PDB-ENSP_mappings:3gop.A&PDB-ENSP_mappings:3gt8.A&PDB-ENSP_mappings:3gt8.B&PDB-ENSP_mappings:3gt8.C&PDB-ENSP_mappings:3gt8.D&PDB-ENSP_mappings:3ika.A&PDB-ENSP_mappings:3ika.B&PDB-ENSP_mappings:3lzb.A&PDB-ENSP_mappings:3lzb.B&PDB-ENSP_mappings:3lzb.C&PDB-ENSP_mappings:3lzb.D&PDB-ENSP_mappings:3lzb.E&PDB-ENSP_mappings:3lzb.F&PDB-ENSP_mappings:3lzb.G&PDB-ENSP_mappings:3lzb.H&PDB-ENSP_mappings:3poz.A&PDB-ENSP_mappings:3ug1.A&PDB-ENSP_mappings:3ug2.A&PDB-ENSP_mappings:3vjn.A&PDB-ENSP_mappings:3vjo.A&PDB-ENSP_mappings:3w2o.A&PDB-ENSP_mappings:3w2p.A&PDB-ENSP_mappings:3w2q.A&PDB-ENSP_mappings:3w2r.A&PDB-ENSP_mappings:3w2s.A&PDB-ENSP_mappings:3w32.A&PDB-ENSP_mappings:3w33.A&PDB-ENSP_mappings:4g5j.A&PDB-ENSP_mappings:4g5p.A&PDB-ENSP_mappings:4g5p.B&PDB-ENSP_mappings:4hjo.A&PDB-ENSP_mappings:4i1z.A&PDB-ENSP_mappings:4i20.A&PDB-ENSP_mappings:4i21.A&PDB-ENSP_mappings:4i21.B&PDB-ENSP_mappings:4i22.A&PDB-ENSP_mappings:4i23.A&PDB-ENSP_mappings:4i24.A&PDB-ENSP_mappings:4i24.B&PDB-ENSP_mappings:4jq7.A&PDB-ENSP_mappings:4jq8.A&PDB-ENSP_mappings:4jr3.A&PDB-ENSP_mappings:4jrv.A&PDB-ENSP_mappings:4li5.A&PDB-ENSP_mappings:4ll0.A&PDB-ENSP_mappings:4ll0.B&PDB-ENSP_mappings:4lqm.A&PDB-ENSP_mappings:4lrm.A&PDB-ENSP_mappings:4lrm.B&PDB-ENSP_mappings:4lrm.C&PDB-ENSP_mappings:4lrm.D&PDB-ENSP_mappings:4lrm.E&PDB-ENSP_mappings:4r3p.A&PDB-ENSP_mappings:4r3r.A&PDB-ENSP_mappings:4r5s.A&PDB-ENSP_mappings:4riw.B&PDB-ENSP_mappings:4riw.D&PDB-ENSP_mappings:4rix.B&PDB-ENSP_mappings:4rix.D&PDB-ENSP_mappings:4riy.B&PDB-ENSP_mappings:4riy.D&PDB-ENSP_mappings:4rj4.A&PDB-ENSP_mappings:4rj5.A&PDB-ENSP_mappings:4rj6.A&PDB-ENSP_mappings:4rj7.A&PDB-ENSP_mappings:4rj8.A&PDB-ENSP_mappings:4tks.A&PDB-ENSP_mappings:4wd5.A&PDB-ENSP_mappings:4wd5.B&PDB-ENSP_mappings:4wkq.A&PDB-ENSP_mappings:4wrg.A&PDB-ENSP_mappings:4zau.A&PDB-ENSP_mappings:4zjv.A&PDB-ENSP_mappings:4zjv.B&PDB-ENSP_mappings:4zse.A&PDB-ENSP_mappings:4zse.B&PDB-ENSP_mappings:4zse.C&PDB-ENSP_mappings:4zse.D&PDB-ENSP_mappings:5c8k.A&PDB-ENSP_mappings:5c8m.A&PDB-ENSP_mappings:5c8n.A&PDB-ENSP_mappings:5cal.A&PDB-ENSP_mappings:5can.A&PDB-ENSP_mappings:5cao.A&PDB-ENSP_mappings:5cap.A&PDB-ENSP_mappings:5caq.A&PDB-ENSP_mappings:5cas.A&PDB-ENSP_mappings:5cau.A&PDB-ENSP_mappings:5cav.A&PDB-ENSP_mappings:5cnn.A&PDB-ENSP_mappings:5cnn.B&PDB-ENSP_mappings:5cno.A&PDB-ENSP_mappings:5cno.B&PDB-ENSP_mappings:5cno.X&PDB-ENSP_mappings:5czh.A&PDB-ENSP_mappings:5czi.A&PDB-ENSP_mappings:5d41.A&PDB-ENSP_mappings:5d41.B&PDB-ENSP_mappings:5edp.A&PDB-ENSP_mappings:5edq.A&PDB-ENSP_mappings:5edr.A&PDB-ENSP_mappings:5em5.A&PDB-ENSP_mappings:5em6.A&PDB-ENSP_mappings:5em7.A&PDB-ENSP_mappings:5em8.A&PDB-ENSP_mappings:5fed.A&PDB-ENSP_mappings:5fee.A&PDB-ENSP_mappings:5feq.A&PDB-ENSP_mappings:5gmp.A&PDB-ENSP_mappings:5gnk.A&PDB-ENSP_mappings:5gty.A&PDB-ENSP_mappings:5gty.B&PDB-ENSP_mappings:5gty.C&PDB-ENSP_mappings:5gty.D&PDB-ENSP_mappings:5gty.E&PDB-ENSP_mappings:5gty.F&PDB-ENSP_mappings:5gty.G&PDB-ENSP_mappings:5gty.H&PDB-ENSP_mappings:5gtz.A&PDB-ENSP_mappings:5hcx.A&PDB-ENSP_mappings:5hcy.A&PDB-ENSP_mappings:5hcz.A&PDB-ENSP_mappings:5hg5.A&PDB-ENSP_mappings:5hg7.A&PDB-ENSP_mappings:5hg8.A&PDB-ENSP_mappings:5hg9.A&PDB-ENSP_mappings:5hib.A&PDB-ENSP_mappings:5hic.A&PDB-ENSP_mappings:5j9y.A&PDB-ENSP_mappings:5j9z.A&PDB-ENSP_mappings:5jeb.A&PDB-ENSP_mappings:5u8l.A&PDB-ENSP_mappings:5ug8.A&PDB-ENSP_mappings:5ug9.A&PDB-ENSP_mappings:5uga.A&PDB-ENSP_mappings:5ugb.A&PDB-ENSP_mappings:5ugc.A&PDB-ENSP_mappings:5uwd.A&PDB-ENSP_mappings:5x26.A&PDB-ENSP_mappings:5x27.A&PDB-ENSP_mappings:5x28.A&PDB-ENSP_mappings:5x2a.A&PDB-ENSP_mappings:5x2a.B&PDB-ENSP_mappings:5x2a.C&PDB-ENSP_mappings:5x2a.D&PDB-ENSP_mappings:5x2c.A&PDB-ENSP_mappings:5x2c.B&PDB-ENSP_mappings:5x2f.A&PDB-ENSP_mappings:5x2f.B&PDB-ENSP_mappings:5x2f.C&PDB-ENSP_mappings:5x2f.D&PDB-ENSP_mappings:5x2k.A&PDB-ENSP_mappings:5xdk.A&PDB-ENSP_mappings:5xdl.A&PDB-ENSP_mappings:5xgm.A&PDB-ENSP_mappings:5xgn.A&PDB-ENSP_mappings:5xgn.B&PDB-ENSP_mappings:5y25.A&PDB-ENSP_mappings:5y9t.A&PDB-ENSP_mappings:5yu9.A&PDB-ENSP_mappings:5yu9.B&PDB-ENSP_mappings:5yu9.C&PDB-ENSP_mappings:5yu9.D&PDB-ENSP_mappings:5zto.A&PDB-ENSP_mappings:5zwj.A&PDB-ENSP_mappings:6d8e.A&PDB-ENSP_mappings:6duk.A&PDB-ENSP_mappings:6duk.B&PDB-ENSP_mappings:6duk.C&PDB-ENSP_mappings:6duk.D&PDB-ENSP_mappings:6duk.E&PDB-ENSP_mappings:6duk.F&PDB-ENSP_mappings:6jrj.A&PDB-ENSP_mappings:6jrk.A&PDB-ENSP_mappings:6jrx.A&PDB-ENSP_mappings:6jwl.A&PDB-ENSP_mappings:6jx0.A&PDB-ENSP_mappings:6jx4.A&PDB-ENSP_mappings:6jxt.A&PDB-ENSP_mappings:6jz0.A&PDB-ENSP_mappings:6lub.A&PDB-ENSP_mappings:6lud.A&PDB-ENSP_mappings:6p1d.A&PDB-ENSP_mappings:6p1d.B&PDB-ENSP_mappings:6p1d.C&PDB-ENSP_mappings:6p1d.D&PDB-ENSP_mappings:6p1l.A&PDB-ENSP_mappings:6p1l.B&PDB-ENSP_mappings:6p1l.C&PDB-ENSP_mappings:6p1l.D&PDB-ENSP_mappings:6p8q.A&PDB-ENSP_mappings:6p8q.B&PDB-ENSP_mappings:6p8q.C&PDB-ENSP_mappings:6p8q.D&PDB-ENSP_mappings:6s89.A&PDB-ENSP_mappings:6s8a.A&PDB-ENSP_mappings:6s9b.A&PDB-ENSP_mappings:6s9c.A&PDB-ENSP_mappings:6s9d.A&PDB-ENSP_mappings:6tfu.A&PDB-ENSP_mappings:6tfu.B&PDB-ENSP_mappings:6tfv.A&PDB-ENSP_mappings:6tfv.B&PDB-ENSP_mappings:6tfw.A&PDB-ENSP_mappings:6tfw.B&PDB-ENSP_mappings:6tfy.A&PDB-ENSP_mappings:6tfy.B&PDB-ENSP_mappings:6tfz.A&PDB-ENSP_mappings:6tfz.B&PDB-ENSP_mappings:6tg0.A&PDB-ENSP_mappings:6tg0.B&PDB-ENSP_mappings:6tg1.A&PDB-ENSP_mappings:6tg1.B&PDB-ENSP_mappings:6v5n.A&PDB-ENSP_mappings:6v5n.B&PDB-ENSP_mappings:6v5n.C&PDB-ENSP_mappings:6v5n.D&PDB-ENSP_mappings:6v5p.A&PDB-ENSP_mappings:6v5p.B&PDB-ENSP_mappings:6v5p.C&PDB-ENSP_mappings:6v5p.D&PDB-ENSP_mappings:6v66.A&PDB-ENSP_mappings:6v66.B&PDB-ENSP_mappings:6v66.C&PDB-ENSP_mappings:6v66.D&PDB-ENSP_mappings:6v6k.A&PDB-ENSP_mappings:6v6k.B&PDB-ENSP_mappings:6v6k.C&PDB-ENSP_mappings:6v6k.D&PDB-ENSP_mappings:6v6k.E&PDB-ENSP_mappings:6v6k.F&PDB-ENSP_mappings:6v6k.G&PDB-ENSP_mappings:6v6k.H&PDB-ENSP_mappings:6v6o.A&PDB-ENSP_mappings:6v6o.B&PDB-ENSP_mappings:6v6o.C&PDB-ENSP_mappings:6v6o.D&PDB-ENSP_mappings:6v6o.E&PDB-ENSP_mappings:6v6o.F&PDB-ENSP_mappings:6v6o.G&PDB-ENSP_mappings:6v6o.H&PDB-ENSP_mappings:6vh4.A&PDB-ENSP_mappings:6vhn.A&PDB-ENSP_mappings:6vhp.A&PDB-ENSP_mappings:6wa2.A&PDB-ENSP_mappings:6wa2.B&PDB-ENSP_mappings:6wa2.C&PDB-ENSP_mappings:6wa2.D&PDB-ENSP_mappings:6wak.A&PDB-ENSP_mappings:6wak.B&PDB-ENSP_mappings:6wak.C&PDB-ENSP_mappings:6wak.D&PDB-ENSP_mappings:6wxn.A&PDB-ENSP_mappings:6wxn.B&PDB-ENSP_mappings:6wxn.C&PDB-ENSP_mappings:6wxn.D&PDB-ENSP_mappings:6xl4.A&PDB-ENSP_mappings:6xl4.B&PDB-ENSP_mappings:6xl4.C&PDB-ENSP_mappings:6xl4.D&PDB-ENSP_mappings:6z4b.A&PDB-ENSP_mappings:6z4b.B&PDB-ENSP_mappings:6z4d.A&PDB-ENSP_mappings:6z4d.B&PDB-ENSP_mappings:7a2a.A&PDB-ENSP_mappings:7a2a.B&PDB-ENSP_mappings:7a6i.A&PDB-ENSP_mappings:7a6j.A&PDB-ENSP_mappings:7a6j.B&PDB-ENSP_mappings:7a6k.A&PDB-ENSP_mappings:7a6k.B&PDB-ENSP_mappings:7a6k.C&PDB-ENSP_mappings:7a6k.D&PDB-ENSP_mappings:7aei.A&PDB-ENSP_mappings:7aem.A&PDB-ENSP_mappings:7b85.A&PDB-ENSP_mappings:7er2.A&PDB-ENSP_mappings:7jxi.A&PDB-ENSP_mappings:7jxi.B&PDB-ENSP_mappings:7jxi.C&PDB-ENSP_mappings:7jxi.D&PDB-ENSP_mappings:7jxk.A&PDB-ENSP_mappings:7jxk.B&PDB-ENSP_mappings:7jxk.C&PDB-ENSP_mappings:7jxk.D&PDB-ENSP_mappings:7jxk.E&PDB-ENSP_mappings:7jxk.F&PDB-ENSP_mappings:7jxl.A&PDB-ENSP_mappings:7jxl.B&PDB-ENSP_mappings:7jxl.C&PDB-ENSP_mappings:7jxl.D&PDB-ENSP_mappings:7jxm.A&PDB-ENSP_mappings:7jxm.B&PDB-ENSP_mappings:7jxm.C&PDB-ENSP_mappings:7jxm.D&PDB-ENSP_mappings:7jxp.A&PDB-ENSP_mappings:7jxp.B&PDB-ENSP_mappings:7jxp.C&PDB-ENSP_mappings:7jxp.D&PDB-ENSP_mappings:7jxp.E&PDB-ENSP_mappings:7jxp.F&PDB-ENSP_mappings:7jxq.A&PDB-ENSP_mappings:7jxq.B&PDB-ENSP_mappings:7jxq.C&PDB-ENSP_mappings:7jxq.D&PDB-ENSP_mappings:7jxw.A&PDB-ENSP_mappings:7jxw.B&PDB-ENSP_mappings:7jxw.C&PDB-ENSP_mappings:7jxw.D&PDB-ENSP_mappings:7k1h.A&PDB-ENSP_mappings:7k1h.B&PDB-ENSP_mappings:7k1h.C&PDB-ENSP_mappings:7k1h.D&PDB-ENSP_mappings:7k1h.E&PDB-ENSP_mappings:7k1h.F&PDB-ENSP_mappings:7k1i.A&PDB-ENSP_mappings:7kxz.A&PDB-ENSP_mappings:7ky0.A&PDB-ENSP_mappings:7ky0.B&PDB-ENSP_mappings:7ky0.C&PDB-ENSP_mappings:7ky0.D&PDB-ENSP_mappings:7lg8.A&PDB-ENSP_mappings:7lg8.B&PDB-ENSP_mappings:7lg8.C&PDB-ENSP_mappings:7lg8.D&PDB-ENSP_mappings:7lgs.A&PDB-ENSP_mappings:7lgs.B&PDB-ENSP_mappings:7lgs.C&PDB-ENSP_mappings:7lgs.D&PDB-ENSP_mappings:7ltx.A&PDB-ENSP_mappings:7ltx.B&PDB-ENSP_mappings:7ltx.C&PDB-ENSP_mappings:7ltx.D&PDB-ENSP_mappings:7oxb.A&PDB-ENSP_mappings:7si1.A&PDB-ENSP_mappings:7syd.A&PDB-ENSP_mappings:7syd.B&PDB-ENSP_mappings:7sye.A&PDB-ENSP_mappings:7sye.B&PDB-ENSP_mappings:7sz0.A&PDB-ENSP_mappings:7sz0.B&PDB-ENSP_mappings:7sz1.A&PDB-ENSP_mappings:7sz1.B&PDB-ENSP_mappings:7sz5.A&PDB-ENSP_mappings:7sz5.B&PDB-ENSP_mappings:7sz7.A&PDB-ENSP_mappings:7sz7.B&PDB-ENSP_mappings:7t4i.A&PDB-ENSP_mappings:7t4j.A&PDB-ENSP_mappings:7t4j.B&PDB-ENSP_mappings:7tvd.A&PDB-ENSP_mappings:7u98.A&PDB-ENSP_mappings:7u98.B&PDB-ENSP_mappings:7u98.C&PDB-ENSP_mappings:7u98.D&PDB-ENSP_mappings:7u99.A&PDB-ENSP_mappings:7u9a.A&PDB-ENSP_mappings:7ukv.A&PDB-ENSP_mappings:7ukw.A&PDB-ENSP_mappings:7ukw.B&PDB-ENSP_mappings:7ukw.C&PDB-ENSP_mappings:7ukw.D&PDB-ENSP_mappings:7vra.A&PDB-ENSP_mappings:7vre.A&PDB-ENSP_mappings:7zym.A&PDB-ENSP_mappings:7zyn.A&PDB-ENSP_mappings:7zyp.A&PDB-ENSP_mappings:7zyq.A&PDB-ENSP_mappings:7zyq.B&PDB-ENSP_mappings:8a27.A&PDB-ENSP_mappings:8a2a.A&PDB-ENSP_mappings:8a2b.A&PDB-ENSP_mappings:8a2d.A&PDB-ENSP_mappings:8d73.A&PDB-ENSP_mappings:8d73.B&PDB-ENSP_mappings:8d76.A&PDB-ENSP_mappings:8d76.B&PDB-ENSP_mappings:8dsw.A&PDB-ENSP_mappings:8eme.A&PDB-ENSP_mappings:8eme.B&PDB-ENSP_mappings:8f1h.A&PDB-ENSP_mappings:8f1w.A&PDB-ENSP_mappings:8f1w.B&PDB-ENSP_mappings:8f1w.C&PDB-ENSP_mappings:8f1w.D&PDB-ENSP_mappings:8f1x.A&PDB-ENSP_mappings:8f1y.A&PDB-ENSP_mappings:8f1z.A&PDB-ENSP_mappings:8fv3.A&PDB-ENSP_mappings:8fv3.B&PDB-ENSP_mappings:8fv3.C&PDB-ENSP_mappings:8fv3.D&PDB-ENSP_mappings:8fv4.A&PDB-ENSP_mappings:8fv4.B&PDB-ENSP_mappings:8fv4.C&PDB-ENSP_mappings:8fv4.D&PDB-ENSP_mappings:8g63.A&PDB-ENSP_mappings:8gb4.A&PDB-ENSP_mappings:8gb4.B&PDB-ENSP_mappings:8gb4.C&PDB-ENSP_mappings:8gb4.D&PDB-ENSP_mappings:8gk5.A&PDB-ENSP_mappings:8gk5.B&PDB-ENSP_mappings:8gk5.C&PDB-ENSP_mappings:8gk5.D&PDB-ENSP_mappings:8h7x.A&PDB-ENSP_mappings:8h7x.B&PDB-ENSP_mappings:8hv1.A&PDB-ENSP_mappings:8hv2.A&PDB-ENSP_mappings:8hv3.A&PDB-ENSP_mappings:8hv4.A&PDB-ENSP_mappings:8hv5.A&PDB-ENSP_mappings:8hv6.A&PDB-ENSP_mappings:8hv7.A&PDB-ENSP_mappings:8hv8.A&PDB-ENSP_mappings:8hv9.A&PDB-ENSP_mappings:8hva.A&PDB-ENSP_mappings:8hy7.A&PDB-ENSP_mappings:8kfq.A&PDB-ENSP_mappings:8pnz.A&PDB-ENSP_mappings:8po0.A&PDB-ENSP_mappings:8po1.A&PDB-ENSP_mappings:8po2.A&PDB-ENSP_mappings:8po2.B&PDB-ENSP_mappings:8po2.D&PDB-ENSP_mappings:8po3.A&PDB-ENSP_mappings:8po4.A&PDB-ENSP_mappings:8po4.B&PDB-ENSP_mappings:8sc7.A&PDB-ENSP_mappings:8tjl.A&PDB-ENSP_mappings:8to3.A&PDB-ENSP_mappings:8to3.B&PDB-ENSP_mappings:8to3.C&PDB-ENSP_mappings:8to3.D&PDB-ENSP_mappings:8to4.A&PDB-ENSP_mappings:8to4.B&PDB-ENSP_mappings:8to4.C&PDB-ENSP_mappings:8to4.D&PDB-ENSP_mappings:8wd4.A&Transmembrane_helices:TMhelix&SMART:SM00219&Superfamily:SSF56112&CDD:cd05108&PANTHER:PTHR24416&PROSITE_profiles:PS50011&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF07714&Gene3D:3.30.200.20&PIRSF:PIRSF000619&AFDB-ENSP_mappings:AF-P00533-F1			0.4327	0.4175	0.5519	0.1825	0.6074	0.4468	0.5626	0.3998	0.5568	0.6666	0.1617	0.4705	0.6115	0.5888	0.5502	0.5075	0.5142	0.412	0.5695	0.5541	0.6613	0.177	0.461	0.6531	0.5939	0.5503	0.4803	0.6666	gnomADe_ASJ	benign&likely_benign	0&1&1	1&1&1	25741868&34449663&30305059&32368160&29434720&23251617&19563658&31906817&28043105&23790025&17956637&17875215&30026459&17409930&23244191&23450128&26666825&26762143&26870997&27750395&32362623&33888812&19201048&28674394&23675485&26376646&31938054&33911638&27365368&27304188&22426987&27431322&24594201&23207070&26290189&23925389&30348712&21869887&21457545&31370270&36169894&36347915&24838331&24454509&30274976&27895798&24934485&29977536&23555641&27776352&35387120&25411647&29660021&35477782&38025894&39234105						FAIL	13	1	13	1	0.00	0.00	0.00	0.00	EGFR		4.7500e-01	45271	0.54244	0.52278	0.43271	54438	Inflammatory_skin_and_bowel_disease&_neonatal&_2&not_provided&not_specified&Lung_carcinoma&Lung_cancer&Squamous_cell_lung_carcinoma&Hereditary_cancer-predisposing_syndrome&EGFR-related_lung_cancer		MONDO:MONDO:0014481&MedGen:C4015130&OMIM:616069&Orphanet:294023&MedGen:C3661900&MedGen:CN169374&MONDO:MONDO:0005138&MedGen:C0684249&MONDO:MONDO:0008903&MedGen:C0242379&OMIM:211980&Human_Phenotype_Ontology:HP:0030359&MONDO:MONDO:0005097&MedGen:C0149782&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN130014		NC_000007.14:g.55181370G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000062099&SCV000310914&SCV001137367&SCV001721333&SCV001875965&SCV001894635&SCV004017419&SCV005023110&SCV005271122&SCV005895482	single_nucleotide_variant	SO:0001483	ClinGen:CA135896		EGFR:1956&EGFR-AS1:100507500	SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										3	1050171																											1214					0.999							246.32	v6.1	Unknown		True	EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:Q787= mutant UNKNOWN.	False	The EGFR ENSP00000275493.2:q787= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	55249063						True	False	False	Unknown								False	False		EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others.	The EGFR ENSP00000275493.2:q787= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:Q787= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	EGFR	1956.0	ENSP00000275493.2:Q787=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EGFR"",""entrezGeneId"":1956,""alteration"":""ENSP00000275493.2:Q787="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others."",""variantSummary"":""The EGFR ENSP00000275493.2:q787= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:Q787= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						0,1213	0,676	0,537	0/1	0,0,608,605	AGC	0.00	0.00	0.00			0,0,583,630	64.73		1.0
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9	p.Thr903=	ENSP00000275493.2:p.Thr903=	chr7	55198724	55198724.0	T	C	C	55198724	.	T	C	.	PASS	NM_005228	C	synonymous_variant	LOW	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding	23/28		c.2709T>C	2970	2709	903	T	acT/acC	rs1140475&COSV51770428		1		SNV	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1			PDB-ENSP_mappings:1m14.A&PDB-ENSP_mappings:1m17.A&PDB-ENSP_mappings:1xkk.A&PDB-ENSP_mappings:2eb2.A&PDB-ENSP_mappings:2eb3.A&PDB-ENSP_mappings:2gs2.A&PDB-ENSP_mappings:2gs6.A&PDB-ENSP_mappings:2gs7.A&PDB-ENSP_mappings:2gs7.B&PDB-ENSP_mappings:2itn.A&PDB-ENSP_mappings:2ito.A&PDB-ENSP_mappings:2itp.A&PDB-ENSP_mappings:2itq.A&PDB-ENSP_mappings:2itt.A&PDB-ENSP_mappings:2itu.A&PDB-ENSP_mappings:2itv.A&PDB-ENSP_mappings:2itw.A&PDB-ENSP_mappings:2itx.A&PDB-ENSP_mappings:2ity.A&PDB-ENSP_mappings:2itz.A&PDB-ENSP_mappings:2j5e.A&PDB-ENSP_mappings:2j5f.A&PDB-ENSP_mappings:2j6m.A&PDB-ENSP_mappings:2jit.A&PDB-ENSP_mappings:2jit.B&PDB-ENSP_mappings:2jiu.A&PDB-ENSP_mappings:2jiu.B&PDB-ENSP_mappings:2jiv.A&PDB-ENSP_mappings:2jiv.B&PDB-ENSP_mappings:2rf9.A&PDB-ENSP_mappings:2rf9.B&PDB-ENSP_mappings:2rfd.A&PDB-ENSP_mappings:2rfd.B&PDB-ENSP_mappings:2rfe.A&PDB-ENSP_mappings:2rfe.B&PDB-ENSP_mappings:2rfe.C&PDB-ENSP_mappings:2rfe.D&PDB-ENSP_mappings:2rgp.A&PDB-ENSP_mappings:3bel.A&PDB-ENSP_mappings:3gop.A&PDB-ENSP_mappings:3gt8.A&PDB-ENSP_mappings:3gt8.B&PDB-ENSP_mappings:3gt8.C&PDB-ENSP_mappings:3gt8.D&PDB-ENSP_mappings:3ika.A&PDB-ENSP_mappings:3ika.B&PDB-ENSP_mappings:3lzb.A&PDB-ENSP_mappings:3lzb.B&PDB-ENSP_mappings:3lzb.C&PDB-ENSP_mappings:3lzb.D&PDB-ENSP_mappings:3lzb.E&PDB-ENSP_mappings:3lzb.F&PDB-ENSP_mappings:3lzb.G&PDB-ENSP_mappings:3lzb.H&PDB-ENSP_mappings:3poz.A&PDB-ENSP_mappings:3ug1.A&PDB-ENSP_mappings:3ug2.A&PDB-ENSP_mappings:3vjn.A&PDB-ENSP_mappings:3vjo.A&PDB-ENSP_mappings:3w2o.A&PDB-ENSP_mappings:3w2p.A&PDB-ENSP_mappings:3w2q.A&PDB-ENSP_mappings:3w2r.A&PDB-ENSP_mappings:3w2s.A&PDB-ENSP_mappings:3w32.A&PDB-ENSP_mappings:3w33.A&PDB-ENSP_mappings:4g5j.A&PDB-ENSP_mappings:4g5p.A&PDB-ENSP_mappings:4g5p.B&PDB-ENSP_mappings:4hjo.A&PDB-ENSP_mappings:4i1z.A&PDB-ENSP_mappings:4i20.A&PDB-ENSP_mappings:4i21.A&PDB-ENSP_mappings:4i21.B&PDB-ENSP_mappings:4i22.A&PDB-ENSP_mappings:4i23.A&PDB-ENSP_mappings:4i24.A&PDB-ENSP_mappings:4i24.B&PDB-ENSP_mappings:4jq7.A&PDB-ENSP_mappings:4jq8.A&PDB-ENSP_mappings:4jr3.A&PDB-ENSP_mappings:4jrv.A&PDB-ENSP_mappings:4li5.A&PDB-ENSP_mappings:4ll0.A&PDB-ENSP_mappings:4ll0.B&PDB-ENSP_mappings:4lqm.A&PDB-ENSP_mappings:4lrm.A&PDB-ENSP_mappings:4lrm.B&PDB-ENSP_mappings:4lrm.C&PDB-ENSP_mappings:4lrm.D&PDB-ENSP_mappings:4lrm.E&PDB-ENSP_mappings:4r3p.A&PDB-ENSP_mappings:4r3r.A&PDB-ENSP_mappings:4r5s.A&PDB-ENSP_mappings:4riw.B&PDB-ENSP_mappings:4riw.D&PDB-ENSP_mappings:4rix.B&PDB-ENSP_mappings:4rix.D&PDB-ENSP_mappings:4riy.B&PDB-ENSP_mappings:4riy.D&PDB-ENSP_mappings:4rj4.A&PDB-ENSP_mappings:4rj5.A&PDB-ENSP_mappings:4rj6.A&PDB-ENSP_mappings:4rj7.A&PDB-ENSP_mappings:4rj8.A&PDB-ENSP_mappings:4tks.A&PDB-ENSP_mappings:4wd5.A&PDB-ENSP_mappings:4wd5.B&PDB-ENSP_mappings:4wkq.A&PDB-ENSP_mappings:4wrg.A&PDB-ENSP_mappings:4zau.A&PDB-ENSP_mappings:4zjv.A&PDB-ENSP_mappings:4zjv.B&PDB-ENSP_mappings:4zse.A&PDB-ENSP_mappings:4zse.B&PDB-ENSP_mappings:4zse.C&PDB-ENSP_mappings:4zse.D&PDB-ENSP_mappings:5c8k.A&PDB-ENSP_mappings:5c8m.A&PDB-ENSP_mappings:5c8n.A&PDB-ENSP_mappings:5cal.A&PDB-ENSP_mappings:5can.A&PDB-ENSP_mappings:5cao.A&PDB-ENSP_mappings:5cap.A&PDB-ENSP_mappings:5caq.A&PDB-ENSP_mappings:5cas.A&PDB-ENSP_mappings:5cau.A&PDB-ENSP_mappings:5cav.A&PDB-ENSP_mappings:5cnn.A&PDB-ENSP_mappings:5cnn.B&PDB-ENSP_mappings:5cno.A&PDB-ENSP_mappings:5cno.B&PDB-ENSP_mappings:5cno.X&PDB-ENSP_mappings:5czh.A&PDB-ENSP_mappings:5czi.A&PDB-ENSP_mappings:5d41.A&PDB-ENSP_mappings:5d41.B&PDB-ENSP_mappings:5edp.A&PDB-ENSP_mappings:5edq.A&PDB-ENSP_mappings:5edr.A&PDB-ENSP_mappings:5em5.A&PDB-ENSP_mappings:5em6.A&PDB-ENSP_mappings:5em7.A&PDB-ENSP_mappings:5em8.A&PDB-ENSP_mappings:5fed.A&PDB-ENSP_mappings:5fee.A&PDB-ENSP_mappings:5feq.A&PDB-ENSP_mappings:5gmp.A&PDB-ENSP_mappings:5gnk.A&PDB-ENSP_mappings:5gty.A&PDB-ENSP_mappings:5gty.B&PDB-ENSP_mappings:5gty.C&PDB-ENSP_mappings:5gty.D&PDB-ENSP_mappings:5gty.E&PDB-ENSP_mappings:5gty.F&PDB-ENSP_mappings:5gty.G&PDB-ENSP_mappings:5gty.H&PDB-ENSP_mappings:5gtz.A&PDB-ENSP_mappings:5hcx.A&PDB-ENSP_mappings:5hcy.A&PDB-ENSP_mappings:5hcz.A&PDB-ENSP_mappings:5hg5.A&PDB-ENSP_mappings:5hg7.A&PDB-ENSP_mappings:5hg8.A&PDB-ENSP_mappings:5hg9.A&PDB-ENSP_mappings:5hib.A&PDB-ENSP_mappings:5hic.A&PDB-ENSP_mappings:5j9y.A&PDB-ENSP_mappings:5j9z.A&PDB-ENSP_mappings:5jeb.A&PDB-ENSP_mappings:5u8l.A&PDB-ENSP_mappings:5ug8.A&PDB-ENSP_mappings:5ug9.A&PDB-ENSP_mappings:5uga.A&PDB-ENSP_mappings:5ugb.A&PDB-ENSP_mappings:5ugc.A&PDB-ENSP_mappings:5uwd.A&PDB-ENSP_mappings:5x26.A&PDB-ENSP_mappings:5x27.A&PDB-ENSP_mappings:5x28.A&PDB-ENSP_mappings:5x2a.A&PDB-ENSP_mappings:5x2a.B&PDB-ENSP_mappings:5x2a.C&PDB-ENSP_mappings:5x2a.D&PDB-ENSP_mappings:5x2c.A&PDB-ENSP_mappings:5x2c.B&PDB-ENSP_mappings:5x2f.A&PDB-ENSP_mappings:5x2f.B&PDB-ENSP_mappings:5x2f.C&PDB-ENSP_mappings:5x2f.D&PDB-ENSP_mappings:5x2k.A&PDB-ENSP_mappings:5xdk.A&PDB-ENSP_mappings:5xdl.A&PDB-ENSP_mappings:5xgm.A&PDB-ENSP_mappings:5xgn.A&PDB-ENSP_mappings:5xgn.B&PDB-ENSP_mappings:5y25.A&PDB-ENSP_mappings:5y9t.A&PDB-ENSP_mappings:5yu9.A&PDB-ENSP_mappings:5yu9.B&PDB-ENSP_mappings:5yu9.C&PDB-ENSP_mappings:5yu9.D&PDB-ENSP_mappings:5zto.A&PDB-ENSP_mappings:5zwj.A&PDB-ENSP_mappings:6d8e.A&PDB-ENSP_mappings:6duk.A&PDB-ENSP_mappings:6duk.B&PDB-ENSP_mappings:6duk.C&PDB-ENSP_mappings:6duk.D&PDB-ENSP_mappings:6duk.E&PDB-ENSP_mappings:6duk.F&PDB-ENSP_mappings:6jrj.A&PDB-ENSP_mappings:6jrk.A&PDB-ENSP_mappings:6jrx.A&PDB-ENSP_mappings:6jwl.A&PDB-ENSP_mappings:6jx0.A&PDB-ENSP_mappings:6jx4.A&PDB-ENSP_mappings:6jxt.A&PDB-ENSP_mappings:6jz0.A&PDB-ENSP_mappings:6lub.A&PDB-ENSP_mappings:6lud.A&PDB-ENSP_mappings:6p1d.A&PDB-ENSP_mappings:6p1d.B&PDB-ENSP_mappings:6p1d.C&PDB-ENSP_mappings:6p1d.D&PDB-ENSP_mappings:6p1l.A&PDB-ENSP_mappings:6p1l.B&PDB-ENSP_mappings:6p1l.C&PDB-ENSP_mappings:6p1l.D&PDB-ENSP_mappings:6p8q.A&PDB-ENSP_mappings:6p8q.B&PDB-ENSP_mappings:6p8q.C&PDB-ENSP_mappings:6p8q.D&PDB-ENSP_mappings:6s89.A&PDB-ENSP_mappings:6s8a.A&PDB-ENSP_mappings:6s9b.A&PDB-ENSP_mappings:6s9c.A&PDB-ENSP_mappings:6s9d.A&PDB-ENSP_mappings:6tfu.A&PDB-ENSP_mappings:6tfu.B&PDB-ENSP_mappings:6tfv.A&PDB-ENSP_mappings:6tfv.B&PDB-ENSP_mappings:6tfw.A&PDB-ENSP_mappings:6tfw.B&PDB-ENSP_mappings:6tfy.A&PDB-ENSP_mappings:6tfy.B&PDB-ENSP_mappings:6tfz.A&PDB-ENSP_mappings:6tfz.B&PDB-ENSP_mappings:6tg0.A&PDB-ENSP_mappings:6tg0.B&PDB-ENSP_mappings:6tg1.A&PDB-ENSP_mappings:6tg1.B&PDB-ENSP_mappings:6v5n.A&PDB-ENSP_mappings:6v5n.B&PDB-ENSP_mappings:6v5n.C&PDB-ENSP_mappings:6v5n.D&PDB-ENSP_mappings:6v5p.A&PDB-ENSP_mappings:6v5p.B&PDB-ENSP_mappings:6v5p.C&PDB-ENSP_mappings:6v5p.D&PDB-ENSP_mappings:6v66.A&PDB-ENSP_mappings:6v66.B&PDB-ENSP_mappings:6v66.C&PDB-ENSP_mappings:6v66.D&PDB-ENSP_mappings:6v6k.A&PDB-ENSP_mappings:6v6k.B&PDB-ENSP_mappings:6v6k.C&PDB-ENSP_mappings:6v6k.D&PDB-ENSP_mappings:6v6k.E&PDB-ENSP_mappings:6v6k.F&PDB-ENSP_mappings:6v6k.G&PDB-ENSP_mappings:6v6k.H&PDB-ENSP_mappings:6v6o.A&PDB-ENSP_mappings:6v6o.B&PDB-ENSP_mappings:6v6o.C&PDB-ENSP_mappings:6v6o.D&PDB-ENSP_mappings:6v6o.E&PDB-ENSP_mappings:6v6o.F&PDB-ENSP_mappings:6v6o.G&PDB-ENSP_mappings:6v6o.H&PDB-ENSP_mappings:6vh4.A&PDB-ENSP_mappings:6vhn.A&PDB-ENSP_mappings:6vhp.A&PDB-ENSP_mappings:6wa2.A&PDB-ENSP_mappings:6wa2.B&PDB-ENSP_mappings:6wa2.C&PDB-ENSP_mappings:6wa2.D&PDB-ENSP_mappings:6wak.A&PDB-ENSP_mappings:6wak.B&PDB-ENSP_mappings:6wak.C&PDB-ENSP_mappings:6wak.D&PDB-ENSP_mappings:6wxn.A&PDB-ENSP_mappings:6wxn.B&PDB-ENSP_mappings:6wxn.C&PDB-ENSP_mappings:6wxn.D&PDB-ENSP_mappings:6xl4.A&PDB-ENSP_mappings:6xl4.B&PDB-ENSP_mappings:6xl4.C&PDB-ENSP_mappings:6xl4.D&PDB-ENSP_mappings:6z4b.A&PDB-ENSP_mappings:6z4b.B&PDB-ENSP_mappings:6z4d.A&PDB-ENSP_mappings:6z4d.B&PDB-ENSP_mappings:7a2a.A&PDB-ENSP_mappings:7a2a.B&PDB-ENSP_mappings:7a6i.A&PDB-ENSP_mappings:7a6j.A&PDB-ENSP_mappings:7a6j.B&PDB-ENSP_mappings:7a6k.A&PDB-ENSP_mappings:7a6k.B&PDB-ENSP_mappings:7a6k.C&PDB-ENSP_mappings:7a6k.D&PDB-ENSP_mappings:7aei.A&PDB-ENSP_mappings:7aem.A&PDB-ENSP_mappings:7b85.A&PDB-ENSP_mappings:7er2.A&PDB-ENSP_mappings:7jxi.A&PDB-ENSP_mappings:7jxi.B&PDB-ENSP_mappings:7jxi.C&PDB-ENSP_mappings:7jxi.D&PDB-ENSP_mappings:7jxk.A&PDB-ENSP_mappings:7jxk.B&PDB-ENSP_mappings:7jxk.C&PDB-ENSP_mappings:7jxk.D&PDB-ENSP_mappings:7jxk.E&PDB-ENSP_mappings:7jxk.F&PDB-ENSP_mappings:7jxl.A&PDB-ENSP_mappings:7jxl.B&PDB-ENSP_mappings:7jxl.C&PDB-ENSP_mappings:7jxl.D&PDB-ENSP_mappings:7jxm.A&PDB-ENSP_mappings:7jxm.B&PDB-ENSP_mappings:7jxm.C&PDB-ENSP_mappings:7jxm.D&PDB-ENSP_mappings:7jxp.A&PDB-ENSP_mappings:7jxp.B&PDB-ENSP_mappings:7jxp.C&PDB-ENSP_mappings:7jxp.D&PDB-ENSP_mappings:7jxp.E&PDB-ENSP_mappings:7jxp.F&PDB-ENSP_mappings:7jxq.A&PDB-ENSP_mappings:7jxq.B&PDB-ENSP_mappings:7jxq.C&PDB-ENSP_mappings:7jxq.D&PDB-ENSP_mappings:7jxw.A&PDB-ENSP_mappings:7jxw.B&PDB-ENSP_mappings:7jxw.C&PDB-ENSP_mappings:7jxw.D&PDB-ENSP_mappings:7k1h.A&PDB-ENSP_mappings:7k1h.B&PDB-ENSP_mappings:7k1h.C&PDB-ENSP_mappings:7k1h.D&PDB-ENSP_mappings:7k1h.E&PDB-ENSP_mappings:7k1h.F&PDB-ENSP_mappings:7k1i.A&PDB-ENSP_mappings:7kxz.A&PDB-ENSP_mappings:7ky0.A&PDB-ENSP_mappings:7ky0.B&PDB-ENSP_mappings:7ky0.C&PDB-ENSP_mappings:7ky0.D&PDB-ENSP_mappings:7lg8.A&PDB-ENSP_mappings:7lg8.B&PDB-ENSP_mappings:7lg8.C&PDB-ENSP_mappings:7lg8.D&PDB-ENSP_mappings:7lgs.A&PDB-ENSP_mappings:7lgs.B&PDB-ENSP_mappings:7lgs.C&PDB-ENSP_mappings:7lgs.D&PDB-ENSP_mappings:7ltx.A&PDB-ENSP_mappings:7ltx.B&PDB-ENSP_mappings:7ltx.C&PDB-ENSP_mappings:7ltx.D&PDB-ENSP_mappings:7oxb.A&PDB-ENSP_mappings:7si1.A&PDB-ENSP_mappings:7syd.A&PDB-ENSP_mappings:7syd.B&PDB-ENSP_mappings:7sye.A&PDB-ENSP_mappings:7sye.B&PDB-ENSP_mappings:7sz0.A&PDB-ENSP_mappings:7sz0.B&PDB-ENSP_mappings:7sz1.A&PDB-ENSP_mappings:7sz1.B&PDB-ENSP_mappings:7sz5.A&PDB-ENSP_mappings:7sz5.B&PDB-ENSP_mappings:7sz7.A&PDB-ENSP_mappings:7sz7.B&PDB-ENSP_mappings:7t4i.A&PDB-ENSP_mappings:7t4j.A&PDB-ENSP_mappings:7t4j.B&PDB-ENSP_mappings:7tvd.A&PDB-ENSP_mappings:7u98.A&PDB-ENSP_mappings:7u98.B&PDB-ENSP_mappings:7u98.C&PDB-ENSP_mappings:7u98.D&PDB-ENSP_mappings:7u99.A&PDB-ENSP_mappings:7u9a.A&PDB-ENSP_mappings:7ukv.A&PDB-ENSP_mappings:7ukw.A&PDB-ENSP_mappings:7ukw.B&PDB-ENSP_mappings:7ukw.C&PDB-ENSP_mappings:7ukw.D&PDB-ENSP_mappings:7vra.A&PDB-ENSP_mappings:7vre.A&PDB-ENSP_mappings:7zym.A&PDB-ENSP_mappings:7zyn.A&PDB-ENSP_mappings:7zyp.A&PDB-ENSP_mappings:7zyq.A&PDB-ENSP_mappings:7zyq.B&PDB-ENSP_mappings:8a27.A&PDB-ENSP_mappings:8a2a.A&PDB-ENSP_mappings:8a2b.A&PDB-ENSP_mappings:8a2d.A&PDB-ENSP_mappings:8d73.A&PDB-ENSP_mappings:8d73.B&PDB-ENSP_mappings:8d76.A&PDB-ENSP_mappings:8d76.B&PDB-ENSP_mappings:8dsw.A&PDB-ENSP_mappings:8eme.A&PDB-ENSP_mappings:8eme.B&PDB-ENSP_mappings:8f1h.A&PDB-ENSP_mappings:8f1w.A&PDB-ENSP_mappings:8f1w.B&PDB-ENSP_mappings:8f1w.C&PDB-ENSP_mappings:8f1w.D&PDB-ENSP_mappings:8f1x.A&PDB-ENSP_mappings:8f1y.A&PDB-ENSP_mappings:8f1z.A&PDB-ENSP_mappings:8fv3.A&PDB-ENSP_mappings:8fv3.B&PDB-ENSP_mappings:8fv3.C&PDB-ENSP_mappings:8fv3.D&PDB-ENSP_mappings:8fv4.A&PDB-ENSP_mappings:8fv4.B&PDB-ENSP_mappings:8fv4.C&PDB-ENSP_mappings:8fv4.D&PDB-ENSP_mappings:8g63.A&PDB-ENSP_mappings:8gb4.A&PDB-ENSP_mappings:8gb4.B&PDB-ENSP_mappings:8gb4.C&PDB-ENSP_mappings:8gb4.D&PDB-ENSP_mappings:8gk5.A&PDB-ENSP_mappings:8gk5.B&PDB-ENSP_mappings:8gk5.C&PDB-ENSP_mappings:8gk5.D&PDB-ENSP_mappings:8h7x.A&PDB-ENSP_mappings:8h7x.B&PDB-ENSP_mappings:8hv1.A&PDB-ENSP_mappings:8hv2.A&PDB-ENSP_mappings:8hv3.A&PDB-ENSP_mappings:8hv4.A&PDB-ENSP_mappings:8hv5.A&PDB-ENSP_mappings:8hv6.A&PDB-ENSP_mappings:8hv7.A&PDB-ENSP_mappings:8hv8.A&PDB-ENSP_mappings:8hv9.A&PDB-ENSP_mappings:8hva.A&PDB-ENSP_mappings:8hy7.A&PDB-ENSP_mappings:8kfq.A&PDB-ENSP_mappings:8pnz.A&PDB-ENSP_mappings:8po0.A&PDB-ENSP_mappings:8po1.A&PDB-ENSP_mappings:8po2.A&PDB-ENSP_mappings:8po2.B&PDB-ENSP_mappings:8po2.D&PDB-ENSP_mappings:8po3.A&PDB-ENSP_mappings:8po4.A&PDB-ENSP_mappings:8po4.B&PDB-ENSP_mappings:8sc7.A&PDB-ENSP_mappings:8tjl.A&PDB-ENSP_mappings:8to3.A&PDB-ENSP_mappings:8to3.B&PDB-ENSP_mappings:8to3.C&PDB-ENSP_mappings:8to3.D&PDB-ENSP_mappings:8to4.A&PDB-ENSP_mappings:8to4.B&PDB-ENSP_mappings:8to4.C&PDB-ENSP_mappings:8to4.D&PDB-ENSP_mappings:8wd4.A&SMART:SM00219&Superfamily:SSF56112&CDD:cd05108&PANTHER:PTHR24416&PROSITE_profiles:PS50011&Phobius:CYTOPLASMIC_DOMAIN&Prints:PR00109&Pfam:PF07714&Gene3D:1.10.510.10&PIRSF:PIRSF000619&AFDB-ENSP_mappings:AF-P00533-F1			0.9167	0.9281	0.8963	0.9196	0.8907	0.9397	0.8789	0.929	0.8934	0.8995	0.9382	0.8843	0.9197	0.8691	0.8831	0.9365	0.8966	0.9261	0.9134	0.8983	0.892	0.9326	0.8843	0.9082	0.8746	0.8913	0.937	0.9397	SAS	benign	0&1	1&1	32708070&19372140&31906817&17956637&25396734&22199994&26550313&24319539&33911638&22426987&36873279&21869887&28783046&36347915&32547536&24454509&26909593&23555641&27776352&22536362&36765720&38785976						FAIL	-7	31	8	-6	0.00	0.00	0.00	0.00	EGFR		4.7500e-01	1166017	0.88905		0.91673	1155740	Inflammatory_skin_and_bowel_disease&_neonatal&_2&EGFR-related_lung_cancer&not_provided		MONDO:MONDO:0014481&MedGen:C4015130&OMIM:616069&Orphanet:294023&MedGen:CN130014&MedGen:C3661900		NC_000007.14:g.55198724T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001721334&SCV001875967&SCV005271221	single_nucleotide_variant	SO:0001483	ClinGen:CA4266167		EGFR:1956	SO:0001819&synonymous_variant										1	1140475																											641					0.997							246.39	v6.1	Unknown		True	EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:T903= mutant UNKNOWN.	False	The EGFR ENSP00000275493.2:t903= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	55266417						True	False	False	Unknown								False	False		EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others.	The EGFR ENSP00000275493.2:t903= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:T903= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	EGFR	1956.0	ENSP00000275493.2:T903=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EGFR"",""entrezGeneId"":1956,""alteration"":""ENSP00000275493.2:T903="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others."",""variantSummary"":""The EGFR ENSP00000275493.2:t903= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR ENSP00000275493.2:T903= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						0,639	0,320	0,319	0/1	0,0,330,309	CTG	.	.	.			0,0,409,230	64.73		1.0
GRCh38	EGFR	D12_12345_1234556_Thyroid_S9			chr7	55204803	55204805.0	TAC	T	T	55204803	.	TAC	T	.	PASS	NM_005228	-	intron_variant	MODIFIER	EGFR	ENSG00000146648	Transcript	ENST00000275493	protein_coding		27/27	c.3272-446_3272-445del						rs142265202		1		deletion	HGNC	HGNC:3236	YES	MANE_Select	NM_005228.5		1	P1	CCDS5514.1	ENSP00000275493	P00533.293		UPI000003E750	P00533-1		1					6	0.1781	0.0393	0.3386	0.0853	0.2664	0.2566											0.2289	0.08102	0.2595	0.3602	0.312	0.09229	0.2055	0.4062	0.2786	0.2664	0.2839	0.4062	gnomADg_MID										FAIL	7	-37	-4	23	0.00	0.00	0.00	0.00	EGFR		4.7500e-01																																																											346					0.717							221.43													chr7	55272496																																																	True	True	False	Unknown		Unknown																						136,112	63,61	73,51	0/1	82,54,69,43	ATA						75,61,64,48	25.64		0.45161290322580644
GRCh38		D12_12345_1234556_Thyroid_S9			chr7	65614429		C	<INS>	<INS>	65614429	MantaINS:10336:0:0:0:2:0	C	<INS>	.	PASS		insertion	upstream_gene_variant	MODIFIER		ENSG00000230386	Transcript	ENST00000515547	unprocessed_pseudogene										2652	1		insertion			YES																																																																																																																												0,17		0,17							17	CTTCTTCCTCCTCCTCC		CTTCTTCCTCCTCCTCCCTCCTCCTCCTCCCTCTTCCTCCTCCTCCCTCTTCCTCCTCCCTCTTCCTCCTCCTCCTCCTCTCCTTCTCCTTCTCCTTCT																chr7	65079342	CCTCCTCCCTCTTCCTCCTCCCTCTTCCTCCTCCTCCCTCTTCCTCCTCCTCCCTCTTCCTCCTCTTT			INS																																													True	False	False	Unknown		Unknown																															0,1				0,13	
GRCh38	MAGI2	D12_12345_1234556_Thyroid_S9	p.Pro1443=	ENSP00000346151.4:p.Pro1443=	chr7	78019354	78019354.0	G	C	C	78019354	.	G	C	.	PASS	NM_012301	C	synonymous_variant	LOW	MAGI2	ENSG00000187391	Transcript	ENST00000354212	protein_coding	22/22		c.4329C>G	4676	4329	1443	P	ccC/ccG	rs13438302&COSV107443863		-1		SNV	HGNC	HGNC:18957	YES	MANE_Select	NM_012301.4		1	P4	CCDS5594.1	ENSP00000346151	Q86UL8.197		UPI00001615D2	Q86UL8-1		1			AFDB-ENSP_mappings:AF-Q86UL8-F1&MobiDB_lite:mobidb-lite			0.4123	0.4387	0.3833	0.628	0.1968	0.3967	0.2271	0.4268	0.3988	0.2779	0.6518	0.2483	0.236	0.1912	0.2613	0.354	0.297	0.4224	0.2113	0.3198	0.2775	0.6395	0.2744	0.2655	0.191	0.2636	0.3726	0.6518	gnomADe_EAS	benign	0&1	1&1	18414213&23757202&22894909						FAIL	50	-3	-43	24	0.00	0.00	0.00	0.00	MAGI2		3.6900e-01	95514	0.18467	0.34185	0.41234	101413	Nephrotic_syndrome_15&not_provided&not_specified		MONDO:MONDO:0033262&MedGen:C4539896&OMIM:617609&MedGen:C3661900&MedGen:CN169374		NC_000007.14:g.78019354G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000113472&SCV000151795&SCV001750989&SCV002014089&SCV002446122&SCV005087631&SCV005268370	single_nucleotide_variant	SO:0001483	ClinGen:CA148583		MAGI2:9863	SO:0001819&synonymous_variant										1	13438302																											87					1							240.57	v6.1	Unknown		True	MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	False	11/21/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:P1443= mutant UNKNOWN.	False	The MAGI2 ENSP00000346151.4:p1443= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	77648671						True	False	False	Unknown								False	False		MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	The MAGI2 ENSP00000346151.4:p1443= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:P1443= mutant UNKNOWN.						v6.1	11/21/2024		GRCh38	MAGI2	9863.0	ENSP00000346151.4:P1443=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAGI2"",""entrezGeneId"":9863,""alteration"":""ENSP00000346151.4:P1443="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MAGI2, a membrane-associated guanylate kinase, is altered in various cancers."",""variantSummary"":""The MAGI2 ENSP00000346151.4:p1443= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:P1443= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/21/2024""}"	True	True	False	Unknown		Unknown																						51,36	24,13	27,23	0/1	30,21,18,18	TGG	.	.	.			21,30,17,19	25.24		0.41379310344827586
GRCh38	MAGI2	D12_12345_1234556_Thyroid_S9	p.Pro1423=	ENSP00000346151.4:p.Pro1423=	chr7	78019414	78019414.0	C	G	G	78019414	.	C	G	.	PASS	NM_012301	G	synonymous_variant	LOW	MAGI2	ENSG00000187391	Transcript	ENST00000354212	protein_coding	22/22		c.4269G>C	4616	4269	1423	P	ccG/ccC	rs2960452&COSV62634115		-1		SNV	HGNC	HGNC:18957	YES	MANE_Select	NM_012301.4		1	P4	CCDS5594.1	ENSP00000346151	Q86UL8.197		UPI00001615D2	Q86UL8-1		1			AFDB-ENSP_mappings:AF-Q86UL8-F1&PANTHER:PTHR10316&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.3876	0.4244	0.3818	0.5575	0.1889	0.3712	0.2053	0.4205	0.3727	0.2772	0.5931	0.2256	0.2494	0.1847	0.2504	0.3377	0.283	0.4037	0.2105	0.3095	0.2729	0.5603	0.243	0.2572	0.1843	0.2549	0.3526	0.5931	gnomADe_EAS	benign	0&1	1&1	18414213&23757202						FAIL	-37	-10	50	-36	0.00	0.00	0.00	0.00	MAGI2		3.6900e-01	95513		0.50000	0.38758	101412	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000007.14:g.78019414C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000113471&SCV000151794&SCV001909270&SCV002451513&SCV005268381	single_nucleotide_variant	SO:0001483	ClinGen:CA148581		MAGI2:9863	SO:0001819&synonymous_variant										1	2960452																											31					1							240.41	v6.1	Unknown		True	MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	False	11/21/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:P1423= mutant UNKNOWN.	False	The MAGI2 ENSP00000346151.4:p1423= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	77648731						True	False	False	Unknown								False	False		MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	The MAGI2 ENSP00000346151.4:p1423= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:P1423= mutant UNKNOWN.						v6.1	11/21/2024		GRCh38	MAGI2	9863.0	ENSP00000346151.4:P1423=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAGI2"",""entrezGeneId"":9863,""alteration"":""ENSP00000346151.4:P1423="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MAGI2, a membrane-associated guanylate kinase, is altered in various cancers."",""variantSummary"":""The MAGI2 ENSP00000346151.4:p1423= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:P1423= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/21/2024""}"	True	True	False	Unknown		Unknown																						9,22	5,8	4,14	0/1	6,3,12,10	CCG	.	.	.			6,3,8,14	40.34		0.7096774193548387
GRCh38	MAGI2	D12_12345_1234556_Thyroid_S9	p.Leu1119=	ENSP00000346151.4:p.Leu1119=	chr7	78127263	78127263.0	T	C	C	78127263	.	T	C	.	PASS	NM_012301	C	synonymous_variant	LOW	MAGI2	ENSG00000187391	Transcript	ENST00000354212	protein_coding	19/22		c.3357A>G	3704	3357	1119	L	ctA/ctG	rs2074641&COSV62664428&COSV62668799		-1		SNV	HGNC	HGNC:18957	YES	MANE_Select	NM_012301.4		1	P4	CCDS5594.1	ENSP00000346151	Q86UL8.197		UPI00001615D2	Q86UL8-1		1			AFDB-ENSP_mappings:AF-Q86UL8-F1&PANTHER:PTHR10316&MobiDB_lite:mobidb-lite			0.7865	0.9228	0.7205	0.5714	0.8698	0.7853	0.8568	0.9134	0.7074	0.8019	0.5937	0.8765	0.8011	0.8785	0.8443	0.7694	0.8568	0.9082	0.6941	0.7681	0.7947	0.589	0.8704	0.7857	0.8759	0.8469	0.7635	0.9228	AFR	benign	0&1&1	1&1&1							FAIL	12	-12	-32	-35	0.00	0.00	0.00	0.00	MAGI2		3.6900e-01	129565	0.88398	0.82481	0.78654	135011	not_specified&Nephrotic_syndrome_15&not_provided		MedGen:CN169374&MONDO:MONDO:0033262&MedGen:C4539896&OMIM:617609&MedGen:C3661900		NC_000007.14:g.78127263T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000842701&SCV001914920&SCV002014090&SCV002407655&SCV005087292&SCV005268414	single_nucleotide_variant	SO:0001483	ClinGen:CA153642		MAGI2:9863	SO:0001819&synonymous_variant										1	2074641																											1093					0.995							248.26	v6.1	Unknown		True	MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	False	11/21/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:L1119= mutant UNKNOWN.	False	The MAGI2 ENSP00000346151.4:l1119= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	77756580						True	False	False	Unknown								False	False		MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	The MAGI2 ENSP00000346151.4:l1119= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:L1119= mutant UNKNOWN.						v6.1	11/21/2024		GRCh38	MAGI2	9863.0	ENSP00000346151.4:L1119=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAGI2"",""entrezGeneId"":9863,""alteration"":""ENSP00000346151.4:L1119="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MAGI2, a membrane-associated guanylate kinase, is altered in various cancers."",""variantSummary"":""The MAGI2 ENSP00000346151.4:l1119= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:L1119= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/21/2024""}"	True	True	False	Unknown		Unknown																						0,1088	0,457	0,631	0/1	0,0,555,533	GTA	.	.	.			0,0,570,518	64.73		1.0
GRCh38	MAGI2	D12_12345_1234556_Thyroid_S9	p.Ser1071=	ENSP00000346151.4:p.Ser1071=	chr7	78127407	78127407.0	C	T	T	78127407	.	C	T	.	PASS	NM_012301	T	synonymous_variant	LOW	MAGI2	ENSG00000187391	Transcript	ENST00000354212	protein_coding	19/22		c.3213G>A	3560	3213	1071	S	tcG/tcA	rs7812015&COSV62650317&COSV62664437		-1		SNV	HGNC	HGNC:18957	YES	MANE_Select	NM_012301.4		1	P4	CCDS5594.1	ENSP00000346151	Q86UL8.197		UPI00001615D2	Q86UL8-1		1			AFDB-ENSP_mappings:AF-Q86UL8-F1&PANTHER:PTHR10316&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite			0.7863	0.9228	0.7205	0.5714	0.8688	0.7853	0.8568	0.9132	0.7074	0.8024	0.5937	0.8787	0.802	0.8786	0.8443	0.7695	0.8567	0.9082	0.6934	0.768	0.7949	0.5887	0.8701	0.7857	0.8759	0.8463	0.7643	0.9228	AFR	benign	0&1&1	1&1&1							FAIL	-2	3	4	-14	0.00	0.08	0.00	0.00	MAGI2		3.6900e-01	129564	0.88398	0.82440	0.78634	135010	not_specified&Nephrotic_syndrome_15&not_provided		MedGen:CN169374&MONDO:MONDO:0033262&MedGen:C4539896&OMIM:617609&MedGen:C3661900		NC_000007.14:g.78127407C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000842700&SCV001880951&SCV002014091&SCV002466008&SCV005087294&SCV005268425	single_nucleotide_variant	SO:0001483	ClinGen:CA153640		MAGI2:9863	SO:0001819&synonymous_variant										1	7812015																											665					0.997							245.07	v6.1	Unknown		True	MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	False	11/21/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:S1071= mutant UNKNOWN.	False	The MAGI2 ENSP00000346151.4:s1071= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	77756724						True	False	False	Unknown								False	False		MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	The MAGI2 ENSP00000346151.4:s1071= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:S1071= mutant UNKNOWN.						v6.1	11/21/2024		GRCh38	MAGI2	9863.0	ENSP00000346151.4:S1071=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAGI2"",""entrezGeneId"":9863,""alteration"":""ENSP00000346151.4:S1071="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MAGI2, a membrane-associated guanylate kinase, is altered in various cancers."",""variantSummary"":""The MAGI2 ENSP00000346151.4:s1071= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:S1071= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/21/2024""}"	True	True	False	Unknown		Unknown																						0,663	0,307	0,356	0/1	0,0,331,332	CCG	0.00	0.00	0.00			0,0,239,424	64.73		1.0
GRCh38	MAGI2	D12_12345_1234556_Thyroid_S9	p.Lys338=	ENSP00000346151.4:p.Lys338=	chr7	78489792	78489792.0	C	T	T	78489792	.	C	T	.	PASS	NM_012301	T	synonymous_variant	LOW	MAGI2	ENSG00000187391	Transcript	ENST00000354212	protein_coding	6/22		c.1014G>A	1361	1014	338	K	aaG/aaA	rs3735442&COSV62640934		-1		SNV	HGNC	HGNC:18957	YES	MANE_Select	NM_012301.4		1	P4	CCDS5594.1	ENSP00000346151	Q86UL8.197		UPI00001615D2	Q86UL8-1		1			AFDB-ENSP_mappings:AF-Q86UL8-F1&PANTHER:PTHR10316&Low_complexity_(Seg):seg			0.3231	0.4864	0.2334	0.2321	0.2952	0.2883	0.3032	0.4369	0.2034	0.3086	0.2389	0.2889	0.3848	0.3052	0.3144	0.3013	0.3269	0.4269	0.1099	0.2566	0.313	0.2268	0.2829	0.3912	0.3019	0.3229	0.2944	0.4864	AFR	benign	0&1	1&1	18720471						FAIL	48	-1	-31	-28	0.00	0.00	0.00	0.00	MAGI2		3.6900e-01	129557	0.34546	0.29420	0.32308	135003	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000007.14:g.78489792C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000842693&SCV001858537&SCV002401238&SCV005087729&SCV005269032	single_nucleotide_variant	SO:0001483	ClinGen:CA153628		MAGI2:9863	SO:0001819&synonymous_variant										1	3735442																											87					0.897							229.93	v6.1	Unknown		True	MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	False	11/21/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:K338= mutant UNKNOWN.	False	The MAGI2 ENSP00000346151.4:k338= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	78119109						True	False	False	Unknown								False	False		MAGI2, a membrane-associated guanylate kinase, is altered in various cancers.	The MAGI2 ENSP00000346151.4:k338= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:K338= mutant UNKNOWN.						v6.1	11/21/2024		GRCh38	MAGI2	9863.0	ENSP00000346151.4:K338=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MAGI2"",""entrezGeneId"":9863,""alteration"":""ENSP00000346151.4:K338="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MAGI2, a membrane-associated guanylate kinase, is altered in various cancers."",""variantSummary"":""The MAGI2 ENSP00000346151.4:k338= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAGI2 ENSP00000346151.4:K338= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/21/2024""}"	True	True	False	Unknown		Unknown																						41,37	18,23	23,14	0/1	25,16,16,21	CCT	0.00	0.00	0.00			20,21,20,17	32.53		0.47435897435897434
GRCh38	HGF	D12_12345_1234556_Thyroid_S9			chr7	81717369	81717369.0	T	C	C	81717369	.	T	C	.	PASS	NM_000601	C	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	HGF	ENSG00000019991	Transcript	ENST00000222390	protein_coding		10/17	c.1272-4A>G						rs1800793		-1		SNV	HGNC	HGNC:4893	YES	MANE_Select	NM_000601.6		1	P4	CCDS5597.1	ENSP00000222390	P14210.258		UPI000000D92B	P14210-1		1						0.7983	0.6657	0.8429	0.8839	0.8012	0.8548	0.7994	0.6601	0.8707	0.8648	0.8824	0.7911	0.8506	0.7913	0.8017	0.863	0.7691	0.6678	0.7346	0.8371	0.8607	0.8576	0.7803	0.9007	0.7945	0.7932	0.8713	0.9007	gnomADg_MID	benign&likely_benign		1	25741868&24033266&21724856&19360663&20005573&20122738&23513043&15064106						FAIL	13	-4	-29	-24	0.03	0.04	0.00	0.00	HGF		4.7100e-01	43607	0.75304		0.79832	52776	not_provided&Nonsyndromic_Hearing_Loss&_Mixed&Autosomal_recessive_nonsyndromic_hearing_loss_39&not_specified		MedGen:C3661900&MedGen:CN239440&MONDO:MONDO:0012003&MedGen:C1842342&OMIM:608265&Orphanet:90636&MedGen:CN169374		NC_000007.14:g.81717369T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000060206&SCV000305367&SCV000470110&SCV000716976&SCV000743168&SCV001934141&SCV002408243&SCV005227978	single_nucleotide_variant	SO:0001483	ClinGen:CA132815		HGF:3082	SO:0001627&intron_variant										1	1800793																											85					0.941							242.8													chr7	81346685																																																	True	True	False	Unknown		Unknown																						0,80	0,35	0,45	0/1	0,0,45,35	GTG	.	.	.			0,0,46,34	64.58		1.0
GRCh38	CDK6	D12_12345_1234556_Thyroid_S9			chr7	92648001	92648001.0	G	A	A	92648001	.	G	A	.	PASS	NM_001145306	A	intron_variant	MODIFIER	CDK6	ENSG00000105810	Transcript	ENST00000424848	protein_coding		5/7	c.647+23425C>T						rs73232024&COSV56009076		-1		SNV	HGNC	HGNC:1777	YES	MANE_Select	NM_001145306.2		1	P1	CCDS5628.1	ENSP00000397087	Q00534.238		UPI00001108FA			1						0.1348	0.0545	0.2046	0.0218	0.3111	0.1288											0.2044	0.08168	0.3279	0.2058	0.3365	0.02029	0.2451	0.3673	0.281	0.2476	0.136	0.3673	gnomADg_MID		0&1	1&1	34469753						FAIL	38	3	38	6	0.00	0.00	0.00	0.00	CDK6		4.1200e-01																																																											73					1							242.56													chr7	92277315																																																	True	True	False	Unknown		Unknown																						40,33	20,13	20,20	0/1	16,24,15,18	AGC	0.00	0.00	0.00			24,16,19,14	30.16		0.4520547945205479
GRCh38	CDK6	D12_12345_1234556_Thyroid_S9			chr7	92685635		G	<INS>	<INS>	92685635	MantaINS:3157:1:1:0:2:0	G	<INS>	.	PASS	NM_001145306	insertion	intron_variant	MODIFIER	CDK6	ENSG00000105810	Transcript	ENST00000424848	protein_coding		4/7									-1		insertion	HGNC	HGNC:1777	YES	MANE_Select	NM_001145306.2		1	P1	CCDS5628.1	ENSP00000397087	Q00534.238		UPI00001108FA			1																																																																																																															0,92		0,92							92	CCCCAACAGACTGGACTAAAAGTTAAAATGGAGTCACTTATGCTCACCAAACCAAAACTGGGTAAATCAGGAGAGACAGAGAAGTCAAAAGA		CCCCAACAGACTGGACTAAAAGTTAAAATGGAGTCACTTATGCTCACCAAACCAAAACTGGGTAAATCAGGAGAGACAGAGAAGTCAAAAGAACGCAAACGAGAACGAGAAAGAGAGAGGGAAG																chr7	92314949	CACACACACCTTATATACCCCCCAACACACACACACACACACCTTATATACCCAACACACACACACGCACACACCTTATATACC			INS																																													True	True	False	Unknown		Unknown																															0,0				0,2	
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9			chr7	102104313	102104314.0	G	GT	GT	102104313	.	G	GT	.	PASS	NM_001913	T	intron_variant	MODIFIER	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding		5/22	c.440-12dup						rs371174192		1		insertion	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1					11	0.3570	0.4478	0.4121	0.0952	0.4165	0.4039	0.4424	0.4654	0.4178	0.4771	0.1323	0.4129	0.4864	0.4509	0.442	0.4448	0.47	0.4956	0.3653	0.4766	0.5641	0.05706	0.4513	0.5445	0.4838	0.4788	0.457	0.5641	gnomADg_ASJ										FAIL	25	0	-21	-5	0.00	0.00	0.00	0.00	CUX1		5.5500e-01																																																											100					0.87							243.48													chr7	101747593																																																	True	True	False	Unknown		Unknown																						49,38	26,23	23,15	0/1	28,21,21,17	GGT						33,16,24,14	26.25		0.4367816091954023
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9			chr7	102111780	102111780.0	A	G	G	102111780	.	A	G	.	PASS	NM_001913	G	splice_donor_region_variant&intron_variant	LOW	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding		7/22	c.640+6A>G						rs9655774&COSV52891009		1		SNV	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1						0.1573	0.0961	0.2133	0.0208	0.2763	0.2188	0.2696	0.1316	0.2326	0.2613	0.01477	0.2737	0.2088	0.2896	0.2505	0.2206	0.2274	0.1335	0.216	0.2228	0.2781	0.01949	0.2775	0.2381	0.2916	0.2334	0.2193	0.2916	gnomADg_NFE	benign	0&1	1&1							FAIL	-25	16	-1	-6	0.00	0.00	0.01	0.01	CUX1		5.5500e-01	1255427	0.23827	0.24255	0.15735	1245359	Global_developmental_delay_with_or_without_impaired_intellectual_development&not_provided		MONDO:MONDO:0032680&MedGen:C5193032&OMIM:618330&MedGen:C3661900		NC_000007.14:g.102111780A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001876443&SCV005268291	single_nucleotide_variant	SO:0001483	ClinGen:CA4410526		CUX1:1523	SO:0001627&intron_variant										1	9655774																											915					0.999							246.85													chr7	101755060																																																	True	True	False	Unknown		Unknown																						466,448	235,213	231,235	0/1	252,214,244,204	GAT	.	.	.			201,265,185,263	46.33		0.49015317286652077
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9	p.Pro379=	ENSP00000484760.2:p.Pro379=	chr7	102193869	102193869.0	G	A	A	102193869	.	G	A	.	PASS	NM_001913	A	synonymous_variant	LOW	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding	13/23		c.1137G>A	1161	1137	379	P	ccG/ccA	rs2230104&COSV52891026		1		SNV	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1			PANTHER:PTHR14043&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13948-F1			0.2985	0.3646	0.2738	0.0675	0.3857	0.3753	0.3718	0.372	0.2969	0.3794	0.07184	0.3429	0.457	0.387	0.361	0.3712	0.3615	0.3674	0.3209	0.3132	0.4003	0.06988	0.3501	0.4828	0.3909	0.3582	0.36	0.4828	gnomADg_MID	benign	0&1	1&1							FAIL	22	-27	-27	21	0.00	0.00	0.00	0.01	CUX1		5.5500e-01	1255430	0.38759	0.35381	0.29852	1245362	Global_developmental_delay_with_or_without_impaired_intellectual_development&not_provided		MONDO:MONDO:0032680&MedGen:C5193032&OMIM:618330&MedGen:C3661900		NC_000007.14:g.102193869G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001876446&SCV005268294	single_nucleotide_variant	SO:0001483	ClinGen:CA4410740		CUX1:1523	SO:0001819&synonymous_variant										1	2230104																											1052					0.999							245.18	v6.1	Unknown		True	CUX1, a transcription factor, is frequently altered in several cancers types by deletion, mutation or translocation.	False	08/03/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUX1 ENSP00000484760.2:P379= mutant UNKNOWN.	False	The CUX1 ENSP00000484760.2:p379= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	101837149						True	False	False	Unknown								False	False		CUX1, a transcription factor, is frequently altered in several cancers types by deletion, mutation or translocation.	The CUX1 ENSP00000484760.2:p379= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUX1 ENSP00000484760.2:P379= mutant UNKNOWN.						v6.1	08/03/2018		GRCh38	CUX1	1523.0	ENSP00000484760.2:P379=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CUX1"",""entrezGeneId"":1523,""alteration"":""ENSP00000484760.2:P379="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CUX1, a transcription factor, is frequently altered in several cancers types by deletion, mutation or translocation."",""variantSummary"":""The CUX1 ENSP00000484760.2:p379= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUX1 ENSP00000484760.2:P379= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/03/2018""}"	True	True	False	Unknown		Unknown																						0,1051	0,536	0,515	0/1	0,0,539,512	CGT	0.00	0.00	0.00			0,0,544,507	64.73		1.0
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9			chr7	102201571	102201571.0	A	G	G	102201571	.	A	G	.	PASS	NM_001913	G	intron_variant	MODIFIER	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding		14/22	c.1255+5968A>G						rs60987662&COSV52891045		1		SNV	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1						0.3167	0.4206	0.2824	0.0784	0.3837	0.3773	0.3703	0.4244	0.299	0.3802	0.07995	0.3455	0.4603	0.3826	0.3641	0.3715	0.3776	0.4207	0.3208	0.3235	0.4017	0.08075	0.3564	0.483	0.3895	0.3738	0.3604	0.483	gnomADg_MID	benign	0&1	1&1	37298077&36653534						FAIL	-41	22	42	22	0.00	0.00	0.00	0.00	CUX1		5.5500e-01	1255431	0.40035	0.35703	0.31669	1245363	Global_developmental_delay_with_or_without_impaired_intellectual_development&not_provided		MONDO:MONDO:0032680&MedGen:C5193032&OMIM:618330&MedGen:C3661900		NC_000007.14:g.102201571A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001876447&SCV005268296	single_nucleotide_variant	SO:0001483	ClinGen:CA4411021		CUX1:1523	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	60987662																											1072					0.993							244.53													chr7	101844851																																																	True	True	False	Unknown		Unknown																						0,1065	0,626	0,439	0/1	0,0,540,525	CAC	.	.	.			0,0,531,534	64.73		1.0
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9			chr7	102248841	102248841.0	G	A	A	102248841	.	G	A	.	PASS	NM_001913	A	intron_variant	MODIFIER	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding		14/22	c.1256-24525G>A						rs410825&COSV52891057		1		SNV	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1						0.5445	0.3147	0.5	0.9097	0.4901	0.5665	0.4624	0.3221	0.5278	0.4065	0.9077	0.5549	0.4295	0.4495	0.4692	0.531	0.4395	0.3341	0.4056	0.475	0.3682	0.8945	0.5326	0.3662	0.4465	0.446	0.5388	0.9097	EAS	benign	0&1	1&1							FAIL	-26	39	-1	38	0.00	0.00	0.00	0.00	CUX1		5.5500e-01	1249567		0.70000	0.54453	1241192	not_provided		MedGen:C3661900		NC_000007.14:g.102248841G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001867159&SCV005268299	single_nucleotide_variant	SO:0001483	ClinGen:CA4411514		CUX1:1523	SO:0001627&intron_variant&SO:0001819&synonymous_variant										1	410825																											134					1							247.55													chr7	101892121																																																	True	True	False	Unknown		Unknown																						65,69	28,40	37,29	0/1	28,37,35,34	CGC	0.00	0.00	0.00			47,18,56,13	38.63		0.5149253731343284
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9	p.A464T	ENSP00000484760.2:p.Ala464Thr	chr7	102274250	102274250.0	G	A	A	102274250	.	G	A	.	PASS	NM_001913	A	missense_variant	MODERATE	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding	16/23		c.1390G>A	1414	1390	464	A/T	Gct/Act	rs803064&COSV52922844		1		SNV	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1	tolerated_low_confidence(0.59)	benign(0.006)	Pfam:PF08172&PANTHER:PTHR14043&Phobius:NON_CYTOPLASMIC_DOMAIN&AFDB-ENSP_mappings:AF-Q13948-F1			0.5591	0.6172	0.5072	0.498	0.5358	0.6043	0.5613	0.6007	0.5799	0.5585	0.4694	0.53	0.4962	0.5634	0.5561	0.5795	0.5626	0.5935	0.6393	0.5202	0.5818	0.494	0.515	0.5238	0.5635	0.5431	0.5798	0.6393	gnomADg_AMI	benign	0&1	1&1	35581205																	5.5500e-01	1255432	0.57497	0.56850	0.55911	1245364	not_provided&Global_developmental_delay_with_or_without_impaired_intellectual_development		MedGen:C3661900&MONDO:MONDO:0032680&MedGen:C5193032&OMIM:618330		NC_000007.14:g.102274250G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001876448&SCV005268300	single_nucleotide_variant	SO:0001483	ClinGen:CA4411641		CUX1:1523	SO:0001583&missense_variant										1	803064																											940					0.998							247.1	v6.1	Unknown		True	CUX1, a transcription factor, is frequently altered in several cancers types by deletion, mutation or translocation.	False	08/03/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUX1 ENSP00000484760.2:A464T mutant UNKNOWN.	False	The CUX1 ENSP00000484760.2:a464t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	101917521						True	False	False	Unknown								False	False		CUX1, a transcription factor, is frequently altered in several cancers types by deletion, mutation or translocation.	The CUX1 ENSP00000484760.2:a464t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUX1 ENSP00000484760.2:A464T mutant UNKNOWN.						v6.1	08/03/2018		GRCh38	CUX1	1523.0	ENSP00000484760.2:A464T			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""CUX1"",""entrezGeneId"":1523,""alteration"":""ENSP00000484760.2:A464T"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""CUX1, a transcription factor, is frequently altered in several cancers types by deletion, mutation or translocation."",""variantSummary"":""The CUX1 ENSP00000484760.2:a464t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CUX1 ENSP00000484760.2:A464T mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/03/2018""}"	True	True	False	Unknown		Unknown																						0,938	0,482	0,456	0/1	0,0,447,491	CGC	0.00	0.00	0.00			0,0,481,457	64.73		1.0
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9			chr7	102280022	102280023.0	T	TC	TC	102280022	.	T	TC	.	PASS	NM_001913	C	splice_polypyrimidine_tract_variant&intron_variant	LOW	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding		18/22	c.1681-12dup						rs3831764		1		insertion	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1					3	0.7318	0.9773	0.6585	0.5159	0.7217	0.6851																						0.9773	AFR	benign		1																		5.5500e-01	1255433				1245365	Global_developmental_delay_with_or_without_impaired_intellectual_development		MONDO:MONDO:0032680&MedGen:C5193032&OMIM:618330		NC_000007.14:g.102280025dup	criteria_provided&_single_submitter	Benign			SCV001876449	Duplication	SO:1000035	ClinGen:CA163417641		CUX1:1523	SO:0001627&intron_variant										1	3831764																											743					0.978							246.1													chr7	101923315																																																	True	True	False	Unknown		Unknown																						1,726	1,416	0,310	0/1	0,1,364,362	CTC						0,1,428,298	63.48		0.9986244841815681
GRCh38	CUX1	D12_12345_1234556_Thyroid_S9			chr7	102282795	102282795.0	G	T	T	102282795	.	G	T	.	PASS	NM_001913	T	intron_variant	MODIFIER	CUX1	ENSG00000257923	Transcript	ENST00000622516	protein_coding		22/22	c.1967+19G>T						rs73712454&COSV52926438&COSV99477190		1		SNV	HGNC	HGNC:2557		MANE_Plus_Clinical		NM_001913.5	1		CCDS5720.1	ENSP00000484760	Q13948.160		UPI00001A95D5	Q13948-1		1						0.2043	0.0651	0.2795	0.1885	0.3052	0.2515	0.2886	0.09375	0.3606	0.2791	0.1455	0.2431	0.231	0.3049	0.2728	0.2271	0.2225	0.0919	0.2239	0.2667	0.2836	0.1531	0.2043	0.2587	0.2964	0.2346	0.2057	0.3606	gnomADe_AMR		0&1&1	0&1&1																		5.5500e-01																																																											435					0.995							246.22													chr7	101926087																																																	True	True	False	Unknown		Unknown																						235,198	124,113	111,85	0/1	109,126,84,114	GGC	0.00	0.00	0.00			46,189,7,191	26.96		0.45727482678983833
GRCh38	PIK3CG	D12_12345_1234556_Thyroid_S9	p.Pro324=	ENSP00000419260.1:p.Pro324=	chr7	106868533	106868533.0	A	G	G	106868533	.	A	G	.	PASS	NM_001282426	G	synonymous_variant	LOW	PIK3CG	ENSG00000105851	Transcript	ENST00000496166	protein_coding	2/11		c.972A>G	1129	972	324	P	ccA/ccG	rs849389&COSV108203239		1		SNV	HGNC	HGNC:8978	YES	MANE_Select	NM_001282426.2		1	P1	CCDS5739.1	ENSP00000419260	P48736.226		UPI00000746B8						PDB-ENSP_mappings:1e8y.A&PDB-ENSP_mappings:1e8z.A&PDB-ENSP_mappings:1he8.A&PDB-ENSP_mappings:2a4z.A&PDB-ENSP_mappings:2a5u.A&PDB-ENSP_mappings:2chw.A&PDB-ENSP_mappings:2chx.A&PDB-ENSP_mappings:2chz.A&PDB-ENSP_mappings:2v4l.A&PDB-ENSP_mappings:3apc.A&PDB-ENSP_mappings:3apd.A&PDB-ENSP_mappings:3apf.A&PDB-ENSP_mappings:3csf.A&PDB-ENSP_mappings:3cst.A&PDB-ENSP_mappings:3dbs.A&PDB-ENSP_mappings:3dpd.A&PDB-ENSP_mappings:3ene.A&PDB-ENSP_mappings:3ibe.A&PDB-ENSP_mappings:3l08.A&PDB-ENSP_mappings:3l13.A&PDB-ENSP_mappings:3l16.A&PDB-ENSP_mappings:3l17.A&PDB-ENSP_mappings:3l54.A&PDB-ENSP_mappings:3lj3.A&PDB-ENSP_mappings:3mjw.A&PDB-ENSP_mappings:3ml8.A&PDB-ENSP_mappings:3ml9.A&PDB-ENSP_mappings:3nzs.A&PDB-ENSP_mappings:3nzu.A&PDB-ENSP_mappings:3oaw.A&PDB-ENSP_mappings:3p2b.A&PDB-ENSP_mappings:3pre.A&PDB-ENSP_mappings:3prz.A&PDB-ENSP_mappings:3ps6.A&PDB-ENSP_mappings:3qaq.A&PDB-ENSP_mappings:3qar.A&PDB-ENSP_mappings:3qjz.A&PDB-ENSP_mappings:3qk0.A&PDB-ENSP_mappings:3r7q.A&PDB-ENSP_mappings:3r7r.A&PDB-ENSP_mappings:3s2a.A&PDB-ENSP_mappings:3sd5.A&PDB-ENSP_mappings:3t8m.A&PDB-ENSP_mappings:3tjp.A&PDB-ENSP_mappings:3tl5.A&PDB-ENSP_mappings:3zvv.A&PDB-ENSP_mappings:3zw3.A&PDB-ENSP_mappings:4anu.A&PDB-ENSP_mappings:4anv.A&PDB-ENSP_mappings:4anw.A&PDB-ENSP_mappings:4anx.A&PDB-ENSP_mappings:4aof.A&PDB-ENSP_mappings:4dk5.A&PDB-ENSP_mappings:4ezj.A&PDB-ENSP_mappings:4ezk.A&PDB-ENSP_mappings:4ezl.A&PDB-ENSP_mappings:4f1s.A&PDB-ENSP_mappings:4fa6.A&PDB-ENSP_mappings:4fad.A&PDB-ENSP_mappings:4fhj.A&PDB-ENSP_mappings:4fhk.A&PDB-ENSP_mappings:4fjy.A&PDB-ENSP_mappings:4fjz.A&PDB-ENSP_mappings:4flh.A&PDB-ENSP_mappings:4ful.A&PDB-ENSP_mappings:4g11.A&PDB-ENSP_mappings:4gb9.A&PDB-ENSP_mappings:4hle.A&PDB-ENSP_mappings:4hvb.A&PDB-ENSP_mappings:4j6i.A&PDB-ENSP_mappings:4kz0.A&PDB-ENSP_mappings:4kzc.A&PDB-ENSP_mappings:4ps3.A&PDB-ENSP_mappings:4ps7.A&PDB-ENSP_mappings:4ps8.A&PDB-ENSP_mappings:4urk.A&PDB-ENSP_mappings:4wwn.A&PDB-ENSP_mappings:4wwo.A&PDB-ENSP_mappings:4wwp.A&PDB-ENSP_mappings:4xx5.A&PDB-ENSP_mappings:4xz4.A&PDB-ENSP_mappings:5eds.A&PDB-ENSP_mappings:5g2n.A&PDB-ENSP_mappings:5g55.A&PDB-ENSP_mappings:5jha.A&PDB-ENSP_mappings:5jhb.A&PDB-ENSP_mappings:5kae.A&PDB-ENSP_mappings:5oq4.A&PDB-ENSP_mappings:5t23.A&PDB-ENSP_mappings:6aud.A&PDB-ENSP_mappings:6c1s.A&PDB-ENSP_mappings:6fh5.A&PDB-ENSP_mappings:6gq7.A&PDB-ENSP_mappings:6t3b.A&PDB-ENSP_mappings:6t3c.A&PDB-ENSP_mappings:6xrl.A&PDB-ENSP_mappings:6xrm.A&PDB-ENSP_mappings:6xrn.A&PDB-ENSP_mappings:7jwe.A&PDB-ENSP_mappings:7jwz.A&PDB-ENSP_mappings:7jx0.A&PDB-ENSP_mappings:7kke.A&PDB-ENSP_mappings:7mez.A&PDB-ENSP_mappings:7z61.A&PDB-ENSP_mappings:8dp0.A&PDB-ENSP_mappings:8sc8.A&PANTHER:PTHR10048&AFDB-ENSP_mappings:AF-P48736-F1			0.9395	0.8608	0.9582	0.995	0.9553	0.9591	0.95	0.8455	0.9715	0.9739	0.9985	0.9615	0.9208	0.9504	0.9476	0.941	0.9284	0.8592	0.9339	0.953	0.9709	0.9965	0.9655	0.8776	0.9505	0.9352	0.9463	0.9985	gnomADe_EAS	benign	0&1	1&1	32324875						FAIL	-37	-21	-21	-24	0.00	0.00	0.00	0.00	PIK3CG		6.5600e-01	2688530	0.91742		0.93950	2849567	not_specified		MedGen:CN169374		NC_000007.14:g.106868533A>G	criteria_provided&_single_submitter	Benign			SCV004234166	single_nucleotide_variant	SO:0001483	ClinGen:CA4429283		PIK3CG:5294	SO:0001819&synonymous_variant										1	849389																											1140					0.997							246.05	v6.1	Unknown		True	PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	False	03/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:P324= mutant UNKNOWN.	False	The PIK3CG ENSP00000419260.1:p324= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	106508978						True	False	False	Unknown								False	False		PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	The PIK3CG ENSP00000419260.1:p324= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:P324= mutant UNKNOWN.						v6.1	03/17/2017		GRCh38	PIK3CG	5294.0	ENSP00000419260.1:P324=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3CG"",""entrezGeneId"":5294,""alteration"":""ENSP00000419260.1:P324="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others."",""variantSummary"":""The PIK3CG ENSP00000419260.1:p324= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:P324= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/17/2017""}"	True	True	False	Unknown		Unknown																						2,1135	0,544	2,591	0|1	0,2,591,544	CAC	.	.	.		106508978	2,0,558,577	57.73		0.9982409850483729
GRCh38	PIK3CG	D12_12345_1234556_Thyroid_S9	p.Asp327=	ENSP00000419260.1:p.Asp327=	chr7	106868542	106868542.0	T	C	C	106868542	.	T	C	.	PASS	NM_001282426	C	synonymous_variant	LOW	PIK3CG	ENSG00000105851	Transcript	ENST00000496166	protein_coding	2/11		c.981T>C	1138	981	327	D	gaT/gaC	rs849390&COSV105275905&COSV108203240		1		SNV	HGNC	HGNC:8978	YES	MANE_Select	NM_001282426.2		1	P1	CCDS5739.1	ENSP00000419260	P48736.226		UPI00000746B8						PDB-ENSP_mappings:1e8y.A&PDB-ENSP_mappings:1e8z.A&PDB-ENSP_mappings:1he8.A&PDB-ENSP_mappings:2a4z.A&PDB-ENSP_mappings:2a5u.A&PDB-ENSP_mappings:2chw.A&PDB-ENSP_mappings:2chx.A&PDB-ENSP_mappings:2chz.A&PDB-ENSP_mappings:2v4l.A&PDB-ENSP_mappings:3apc.A&PDB-ENSP_mappings:3apd.A&PDB-ENSP_mappings:3apf.A&PDB-ENSP_mappings:3csf.A&PDB-ENSP_mappings:3cst.A&PDB-ENSP_mappings:3dbs.A&PDB-ENSP_mappings:3dpd.A&PDB-ENSP_mappings:3ene.A&PDB-ENSP_mappings:3ibe.A&PDB-ENSP_mappings:3l08.A&PDB-ENSP_mappings:3l13.A&PDB-ENSP_mappings:3l16.A&PDB-ENSP_mappings:3l17.A&PDB-ENSP_mappings:3l54.A&PDB-ENSP_mappings:3lj3.A&PDB-ENSP_mappings:3mjw.A&PDB-ENSP_mappings:3ml8.A&PDB-ENSP_mappings:3ml9.A&PDB-ENSP_mappings:3nzs.A&PDB-ENSP_mappings:3nzu.A&PDB-ENSP_mappings:3oaw.A&PDB-ENSP_mappings:3p2b.A&PDB-ENSP_mappings:3pre.A&PDB-ENSP_mappings:3prz.A&PDB-ENSP_mappings:3ps6.A&PDB-ENSP_mappings:3qaq.A&PDB-ENSP_mappings:3qar.A&PDB-ENSP_mappings:3qjz.A&PDB-ENSP_mappings:3qk0.A&PDB-ENSP_mappings:3r7q.A&PDB-ENSP_mappings:3r7r.A&PDB-ENSP_mappings:3s2a.A&PDB-ENSP_mappings:3sd5.A&PDB-ENSP_mappings:3t8m.A&PDB-ENSP_mappings:3tjp.A&PDB-ENSP_mappings:3tl5.A&PDB-ENSP_mappings:3zvv.A&PDB-ENSP_mappings:3zw3.A&PDB-ENSP_mappings:4anu.A&PDB-ENSP_mappings:4anv.A&PDB-ENSP_mappings:4anw.A&PDB-ENSP_mappings:4anx.A&PDB-ENSP_mappings:4aof.A&PDB-ENSP_mappings:4dk5.A&PDB-ENSP_mappings:4ezj.A&PDB-ENSP_mappings:4ezk.A&PDB-ENSP_mappings:4ezl.A&PDB-ENSP_mappings:4f1s.A&PDB-ENSP_mappings:4fa6.A&PDB-ENSP_mappings:4fad.A&PDB-ENSP_mappings:4fhj.A&PDB-ENSP_mappings:4fhk.A&PDB-ENSP_mappings:4fjy.A&PDB-ENSP_mappings:4fjz.A&PDB-ENSP_mappings:4flh.A&PDB-ENSP_mappings:4ful.A&PDB-ENSP_mappings:4g11.A&PDB-ENSP_mappings:4gb9.A&PDB-ENSP_mappings:4hle.A&PDB-ENSP_mappings:4hvb.A&PDB-ENSP_mappings:4j6i.A&PDB-ENSP_mappings:4kz0.A&PDB-ENSP_mappings:4kzc.A&PDB-ENSP_mappings:4ps3.A&PDB-ENSP_mappings:4ps7.A&PDB-ENSP_mappings:4ps8.A&PDB-ENSP_mappings:4urk.A&PDB-ENSP_mappings:4wwn.A&PDB-ENSP_mappings:4wwo.A&PDB-ENSP_mappings:4wwp.A&PDB-ENSP_mappings:4xx5.A&PDB-ENSP_mappings:4xz4.A&PDB-ENSP_mappings:5eds.A&PDB-ENSP_mappings:5g2n.A&PDB-ENSP_mappings:5g55.A&PDB-ENSP_mappings:5jha.A&PDB-ENSP_mappings:5jhb.A&PDB-ENSP_mappings:5kae.A&PDB-ENSP_mappings:5oq4.A&PDB-ENSP_mappings:5t23.A&PDB-ENSP_mappings:6aud.A&PDB-ENSP_mappings:6c1s.A&PDB-ENSP_mappings:6fh5.A&PDB-ENSP_mappings:6gq7.A&PDB-ENSP_mappings:6t3b.A&PDB-ENSP_mappings:6t3c.A&PDB-ENSP_mappings:6xrl.A&PDB-ENSP_mappings:6xrm.A&PDB-ENSP_mappings:6xrn.A&PDB-ENSP_mappings:7jwe.A&PDB-ENSP_mappings:7jwz.A&PDB-ENSP_mappings:7jx0.A&PDB-ENSP_mappings:7kke.A&PDB-ENSP_mappings:7mez.A&PDB-ENSP_mappings:7z61.A&PDB-ENSP_mappings:8dp0.A&PDB-ENSP_mappings:8sc8.A&PANTHER:PTHR10048&AFDB-ENSP_mappings:AF-P48736-F1			0.9409	0.8616	0.9597	0.997	0.9563	0.9611	0.9515	0.8459	0.9718	0.9756	0.9988	0.962	0.9208	0.9522	0.9487	0.9412	0.9298	0.8599	0.9339	0.9539	0.9735	0.9975	0.966	0.8776	0.9527	0.9371	0.9467	0.9988	gnomADe_EAS	benign	0&1&1	1&1&1							FAIL	-46	-30	46	-30	0.00	0.00	0.00	0.00	PIK3CG		6.5600e-01	2688531	0.91873	0.95017	0.94089	2849568	not_specified		MedGen:CN169374		NC_000007.14:g.106868542T>C	criteria_provided&_single_submitter	Benign			SCV004234177	single_nucleotide_variant	SO:0001483	ClinGen:CA4429285		PIK3CG:5294	SO:0001819&synonymous_variant										1	849390																											1140					0.997							245.96	v6.1	Unknown		True	PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	False	03/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:D327= mutant UNKNOWN.	False	The PIK3CG ENSP00000419260.1:d327= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	106508987						True	False	False	Unknown								False	False		PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	The PIK3CG ENSP00000419260.1:d327= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:D327= mutant UNKNOWN.						v6.1	03/17/2017		GRCh38	PIK3CG	5294.0	ENSP00000419260.1:D327=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3CG"",""entrezGeneId"":5294,""alteration"":""ENSP00000419260.1:D327="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others."",""variantSummary"":""The PIK3CG ENSP00000419260.1:d327= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:D327= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/17/2017""}"	True	True	False	Unknown		Unknown																						0,1137	0,552	0,585	0|1	0,0,608,529	ATG	.	.	.		106508978	0,0,573,564	57.73		1.0
GRCh38	PIK3CG	D12_12345_1234556_Thyroid_S9	p.S442Y	ENSP00000419260.1:p.Ser442Tyr	chr7	106868886	106868886.0	C	A	A	106868886	.	C	A	.	PASS	NM_001282426	A	missense_variant	MODERATE	PIK3CG	ENSG00000105851	Transcript	ENST00000496166	protein_coding	2/11		c.1325C>A	1482	1325	442	S/Y	tCc/tAc	rs17847825&COSV63249331&COSV63252855		1		SNV	HGNC	HGNC:8978	YES	MANE_Select	NM_001282426.2		1	P1	CCDS5739.1	ENSP00000419260	P48736.226		UPI00000746B8				deleterious(0.02)	possibly_damaging(0.752)	PDB-ENSP_mappings:1e8y.A&PDB-ENSP_mappings:1e8z.A&PDB-ENSP_mappings:1he8.A&PDB-ENSP_mappings:2a4z.A&PDB-ENSP_mappings:2a5u.A&PDB-ENSP_mappings:2chw.A&PDB-ENSP_mappings:2chx.A&PDB-ENSP_mappings:2chz.A&PDB-ENSP_mappings:2v4l.A&PDB-ENSP_mappings:3apc.A&PDB-ENSP_mappings:3apd.A&PDB-ENSP_mappings:3apf.A&PDB-ENSP_mappings:3csf.A&PDB-ENSP_mappings:3cst.A&PDB-ENSP_mappings:3dbs.A&PDB-ENSP_mappings:3dpd.A&PDB-ENSP_mappings:3ene.A&PDB-ENSP_mappings:3ibe.A&PDB-ENSP_mappings:3l08.A&PDB-ENSP_mappings:3l13.A&PDB-ENSP_mappings:3l16.A&PDB-ENSP_mappings:3l17.A&PDB-ENSP_mappings:3l54.A&PDB-ENSP_mappings:3lj3.A&PDB-ENSP_mappings:3mjw.A&PDB-ENSP_mappings:3ml8.A&PDB-ENSP_mappings:3ml9.A&PDB-ENSP_mappings:3nzs.A&PDB-ENSP_mappings:3nzu.A&PDB-ENSP_mappings:3oaw.A&PDB-ENSP_mappings:3p2b.A&PDB-ENSP_mappings:3pre.A&PDB-ENSP_mappings:3prz.A&PDB-ENSP_mappings:3ps6.A&PDB-ENSP_mappings:3qaq.A&PDB-ENSP_mappings:3qar.A&PDB-ENSP_mappings:3qjz.A&PDB-ENSP_mappings:3qk0.A&PDB-ENSP_mappings:3r7q.A&PDB-ENSP_mappings:3r7r.A&PDB-ENSP_mappings:3s2a.A&PDB-ENSP_mappings:3sd5.A&PDB-ENSP_mappings:3t8m.A&PDB-ENSP_mappings:3tjp.A&PDB-ENSP_mappings:3tl5.A&PDB-ENSP_mappings:3zvv.A&PDB-ENSP_mappings:3zw3.A&PDB-ENSP_mappings:4anu.A&PDB-ENSP_mappings:4anv.A&PDB-ENSP_mappings:4anw.A&PDB-ENSP_mappings:4anx.A&PDB-ENSP_mappings:4aof.A&PDB-ENSP_mappings:4dk5.A&PDB-ENSP_mappings:4ezj.A&PDB-ENSP_mappings:4ezk.A&PDB-ENSP_mappings:4ezl.A&PDB-ENSP_mappings:4f1s.A&PDB-ENSP_mappings:4fa6.A&PDB-ENSP_mappings:4fad.A&PDB-ENSP_mappings:4fhj.A&PDB-ENSP_mappings:4fhk.A&PDB-ENSP_mappings:4fjy.A&PDB-ENSP_mappings:4fjz.A&PDB-ENSP_mappings:4flh.A&PDB-ENSP_mappings:4ful.A&PDB-ENSP_mappings:4g11.A&PDB-ENSP_mappings:4gb9.A&PDB-ENSP_mappings:4hle.A&PDB-ENSP_mappings:4hvb.A&PDB-ENSP_mappings:4j6i.A&PDB-ENSP_mappings:4kz0.A&PDB-ENSP_mappings:4kzc.A&PDB-ENSP_mappings:4ps3.A&PDB-ENSP_mappings:4ps7.A&PDB-ENSP_mappings:4ps8.A&PDB-ENSP_mappings:4urk.A&PDB-ENSP_mappings:4wwn.A&PDB-ENSP_mappings:4wwo.A&PDB-ENSP_mappings:4wwp.A&PDB-ENSP_mappings:4xx5.A&PDB-ENSP_mappings:4xz4.A&PDB-ENSP_mappings:5eds.A&PDB-ENSP_mappings:5g2n.A&PDB-ENSP_mappings:5g55.A&PDB-ENSP_mappings:5jha.A&PDB-ENSP_mappings:5jhb.A&PDB-ENSP_mappings:5kae.A&PDB-ENSP_mappings:5oq4.A&PDB-ENSP_mappings:5t23.A&PDB-ENSP_mappings:6aud.A&PDB-ENSP_mappings:6c1s.A&PDB-ENSP_mappings:6fh5.A&PDB-ENSP_mappings:6gq7.A&PDB-ENSP_mappings:6t3b.A&PDB-ENSP_mappings:6t3c.A&PDB-ENSP_mappings:6xrl.A&PDB-ENSP_mappings:6xrm.A&PDB-ENSP_mappings:6xrn.A&PDB-ENSP_mappings:7jwe.A&PDB-ENSP_mappings:7jwz.A&PDB-ENSP_mappings:7jx0.A&PDB-ENSP_mappings:7kke.A&PDB-ENSP_mappings:7mez.A&PDB-ENSP_mappings:7z61.A&PDB-ENSP_mappings:8dp0.A&PDB-ENSP_mappings:8sc8.A&Low_complexity_(Seg):seg&Pfam:PF00792&Gene3D:2.60.40.150&Superfamily:SSF49562&SMART:SM00142&CDD:cd08399&PANTHER:PTHR10048&PROSITE_profiles:PS51547&AFDB-ENSP_mappings:AF-P48736-F1			0.1160	0.0068	0.0476	0.1925	0.1103	0.2393	0.1121	0.02154	0.04774	0.1366	0.1752	0.1186	0.182	0.1049	0.1173	0.2247	0.08544	0.02229	0.07895	0.06651	0.132	0.1772	0.113	0.1497	0.1036	0.1021	0.231	0.2393	SAS	benign	0&1&1	1&1&1	29097255&29867955&26491355&33821232&33671828&24625924&39245801						FAIL	18	-28	-19	2	0.00	0.00	0.00	0.00	PIK3CG	0.346	6.5600e-01	1270269	0.07966	0.11761	0.11601	1258881	not_provided		MedGen:C3661900		NC_000007.14:g.106868886C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001900149&SCV005271090	single_nucleotide_variant	SO:0001483	ClinGen:CA4429358		PIK3CG:5294	SO:0001583&missense_variant										1	17847825																											941					1							247.52	v6.1	Unknown		True	PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	False	03/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:S442Y mutant UNKNOWN.	False	The PIK3CG ENSP00000419260.1:s442y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	106509331						True	False	False	Unknown								False	False		PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	The PIK3CG ENSP00000419260.1:s442y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:S442Y mutant UNKNOWN.						v6.1	03/17/2017		GRCh38	PIK3CG	5294.0	ENSP00000419260.1:S442Y			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3CG"",""entrezGeneId"":5294,""alteration"":""ENSP00000419260.1:S442Y"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others."",""variantSummary"":""The PIK3CG ENSP00000419260.1:s442y mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:S442Y mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/17/2017""}"	True	True	False	Unknown		Unknown																						487,454	259,255	228,199	0/1	226,261,234,220	TCC	0.00	0.00	0.00			250,237,231,223	40.45		0.4824654622741764
GRCh38	PIK3CG	D12_12345_1234556_Thyroid_S9	p.Asp950=	ENSP00000419260.1:p.Asp950=	chr7	106884244	106884244.0	C	T	T	106884244	.	C	T	.	PASS	NM_001282426	T	synonymous_variant	LOW	PIK3CG	ENSG00000105851	Transcript	ENST00000496166	protein_coding	9/11		c.2850C>T	3007	2850	950	D	gaC/gaT	rs2230460&COSV63247876		1		SNV	HGNC	HGNC:8978	YES	MANE_Select	NM_001282426.2		1	P1	CCDS5739.1	ENSP00000419260	P48736.226		UPI00000746B8						PDB-ENSP_mappings:1e8y.A&PDB-ENSP_mappings:1e8z.A&PDB-ENSP_mappings:1he8.A&PDB-ENSP_mappings:2a4z.A&PDB-ENSP_mappings:2a5u.A&PDB-ENSP_mappings:2chw.A&PDB-ENSP_mappings:2chx.A&PDB-ENSP_mappings:2chz.A&PDB-ENSP_mappings:2v4l.A&PDB-ENSP_mappings:3apc.A&PDB-ENSP_mappings:3apd.A&PDB-ENSP_mappings:3apf.A&PDB-ENSP_mappings:3csf.A&PDB-ENSP_mappings:3cst.A&PDB-ENSP_mappings:3dbs.A&PDB-ENSP_mappings:3dpd.A&PDB-ENSP_mappings:3ene.A&PDB-ENSP_mappings:3ibe.A&PDB-ENSP_mappings:3l08.A&PDB-ENSP_mappings:3l13.A&PDB-ENSP_mappings:3l16.A&PDB-ENSP_mappings:3l17.A&PDB-ENSP_mappings:3l54.A&PDB-ENSP_mappings:3lj3.A&PDB-ENSP_mappings:3mjw.A&PDB-ENSP_mappings:3ml8.A&PDB-ENSP_mappings:3ml9.A&PDB-ENSP_mappings:3nzs.A&PDB-ENSP_mappings:3nzu.A&PDB-ENSP_mappings:3oaw.A&PDB-ENSP_mappings:3p2b.A&PDB-ENSP_mappings:3pre.A&PDB-ENSP_mappings:3prz.A&PDB-ENSP_mappings:3ps6.A&PDB-ENSP_mappings:3qaq.A&PDB-ENSP_mappings:3qar.A&PDB-ENSP_mappings:3qjz.A&PDB-ENSP_mappings:3qk0.A&PDB-ENSP_mappings:3r7q.A&PDB-ENSP_mappings:3r7r.A&PDB-ENSP_mappings:3s2a.A&PDB-ENSP_mappings:3sd5.A&PDB-ENSP_mappings:3t8m.A&PDB-ENSP_mappings:3tjp.A&PDB-ENSP_mappings:3tl5.A&PDB-ENSP_mappings:3zvv.A&PDB-ENSP_mappings:3zw3.A&PDB-ENSP_mappings:4anu.A&PDB-ENSP_mappings:4anv.A&PDB-ENSP_mappings:4anw.A&PDB-ENSP_mappings:4anx.A&PDB-ENSP_mappings:4aof.A&PDB-ENSP_mappings:4dk5.A&PDB-ENSP_mappings:4ezj.A&PDB-ENSP_mappings:4ezk.A&PDB-ENSP_mappings:4ezl.A&PDB-ENSP_mappings:4f1s.A&PDB-ENSP_mappings:4fa6.A&PDB-ENSP_mappings:4fad.A&PDB-ENSP_mappings:4fhj.A&PDB-ENSP_mappings:4fhk.A&PDB-ENSP_mappings:4fjy.A&PDB-ENSP_mappings:4fjz.A&PDB-ENSP_mappings:4flh.A&PDB-ENSP_mappings:4ful.A&PDB-ENSP_mappings:4g11.A&PDB-ENSP_mappings:4gb9.A&PDB-ENSP_mappings:4hle.A&PDB-ENSP_mappings:4hvb.A&PDB-ENSP_mappings:4j6i.A&PDB-ENSP_mappings:4kz0.A&PDB-ENSP_mappings:4kzc.A&PDB-ENSP_mappings:4ps3.A&PDB-ENSP_mappings:4ps7.A&PDB-ENSP_mappings:4ps8.A&PDB-ENSP_mappings:4urk.A&PDB-ENSP_mappings:4wwn.A&PDB-ENSP_mappings:4wwo.A&PDB-ENSP_mappings:4wwp.A&PDB-ENSP_mappings:4xx5.A&PDB-ENSP_mappings:4xz4.A&PDB-ENSP_mappings:5eds.A&PDB-ENSP_mappings:5g2n.A&PDB-ENSP_mappings:5g55.A&PDB-ENSP_mappings:5jha.A&PDB-ENSP_mappings:5jhb.A&PDB-ENSP_mappings:5kae.A&PDB-ENSP_mappings:5oq4.A&PDB-ENSP_mappings:5t23.A&PDB-ENSP_mappings:6aud.A&PDB-ENSP_mappings:6c1s.A&PDB-ENSP_mappings:6fh5.A&PDB-ENSP_mappings:6gq7.A&PDB-ENSP_mappings:6t3b.A&PDB-ENSP_mappings:6t3c.A&PDB-ENSP_mappings:6xrl.A&PDB-ENSP_mappings:6xrm.A&PDB-ENSP_mappings:6xrn.A&PDB-ENSP_mappings:7jwe.A&PDB-ENSP_mappings:7jwz.A&PDB-ENSP_mappings:7jx0.A&PDB-ENSP_mappings:7kke.A&PDB-ENSP_mappings:7mez.A&PDB-ENSP_mappings:7z61.A&PDB-ENSP_mappings:8dp0.A&PDB-ENSP_mappings:8sc8.A&PROSITE_patterns:PS00916&Pfam:PF00454&Gene3D:1.10.1070.11&Superfamily:SSF56112&SMART:SM00146&CDD:cd00894&PANTHER:PTHR10048&PROSITE_profiles:PS50290&AFDB-ENSP_mappings:AF-P48736-F1			0.1186	0.0144	0.0504	0.1925	0.1123	0.2382	0.1124	0.02835	0.04943	0.1361	0.1745	0.1297	0.1843	0.1044	0.1184	0.2247	0.08859	0.02785	0.07709	0.06947	0.1319	0.1778	0.1265	0.1497	0.1044	0.1028	0.2316	0.2382	SAS		0&1	0&1	29097255&29867955&33821232&33671828&39245801						FAIL	-9	-49	26	22	0.00	0.01	0.00	0.00	PIK3CG		6.5600e-01																																																											80					1							244.03	v6.1	Unknown		True	PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	False	03/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:D950= mutant UNKNOWN.	False	The PIK3CG ENSP00000419260.1:d950= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	106524689						True	False	False	Unknown								False	False		PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others.	The PIK3CG ENSP00000419260.1:d950= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:D950= mutant UNKNOWN.						v6.1	03/17/2017		GRCh38	PIK3CG	5294.0	ENSP00000419260.1:D950=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PIK3CG"",""entrezGeneId"":5294,""alteration"":""ENSP00000419260.1:D950="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PIK3CG encodes a kinase involved in modulation of the extracellular signal. Inactivating mutations of PIK3CG are found in uterine, endometrial, skin and lung cancers, among others."",""variantSummary"":""The PIK3CG ENSP00000419260.1:d950= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CG ENSP00000419260.1:D950= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/17/2017""}"	True	True	False	Unknown		Unknown																						40,40	23,22	17,18	0/1	17,23,20,20	ACA	0.00	0.00	0.00			16,24,16,24	34.86		0.5
GRCh38	IMMP2L	D12_12345_1234556_Thyroid_S9			chr7	111299927	111299931.0	CAAGT	C	C	111299927	.	CAAGT	C	.	PASS		-	intron_variant&non_coding_transcript_variant	MODIFIER	IMMP2L	ENSG00000184903	Transcript	ENST00000489381	protein_coding_CDS_not_defined		1/3	n.180+90640_180+90643del						rs1611048		-1		deletion	HGNC	HGNC:14598					5															0.6084	0.6596	0.5389	0.5625	0.5119	0.7352											0.5437	0.632	0.3576	0.5847	0.6171	0.5476	0.4582	0.5959	0.4795	0.5785	0.7064	0.7352	SAS				23690203&36292568						FAIL	43	-4	32	1	0.00	0.00	0.00	0.00	IMMP2L																																																													90					0.944							246.33													chr7	110939983																																																	True	False	False	Unknown		Unknown																						45,40	26,19	19,21	0/1	21,24,22,18	ACA						20,25,15,25	30.95		0.47058823529411764
GRCh38	MET	D12_12345_1234556_Thyroid_S9			chr7	116795714	116795714.0	C	T	T	116795714	.	C	T	.	PASS		T	3_prime_UTR_variant&NMD_transcript_variant	MODIFIER	MET	ENSG00000105976	Transcript	ENST00000436117	nonsense_mediated_decay	19/20		c.*1463C>T	4154					rs41736&COSV59255908		1		SNV	HGNC	HGNC:7029					1			ENSP00000410980	P08581.277		UPI0002065103	P08581-3		1						0.3522	0.034	0.464	0.4673	0.4414	0.4928	0.4411	0.08698	0.5098	0.4904	0.4896	0.3993	0.4267	0.4474	0.438	0.4525	0.348	0.1002	0.3055	0.4432	0.4873	0.4696	0.3817	0.4116	0.4479	0.3845	0.4535	0.5098	gnomADe_AMR	benign	0&1	1&1	25741868&23757202&32022527&19252927&21543897&34203389&17053076&19002214&22383989&25203738&31213837&21970370&25416047&27813498&18059179&19500853&22104167						FAIL	38	-32	0	-47	0.00	0.00	0.00	0.00	MET		4.6600e-01	93574	0.32350	0.42284	0.35224	99478	Renal_cell_carcinoma&Autosomal_recessive_nonsyndromic_hearing_loss_97&not_specified&Papillary_renal_cell_carcinoma_type_1&not_provided&Hereditary_cancer-predisposing_syndrome		Human_Phenotype_Ontology:HP:0005584&Human_Phenotype_Ontology:HP:0006720&MONDO:MONDO:0005086&MeSH:D002292&MedGen:C0007134&Orphanet:217071&MONDO:MONDO:0014739&MedGen:C4084709&OMIM:616705&Orphanet:90636&MedGen:CN169374&Human_Phenotype_Ontology:HP:0011797&MedGen:C1336839&OMIM:605074&Orphanet:47044&MedGen:C3661900&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000007.14:g.116795714C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000111374&SCV000213437&SCV000306715&SCV000466459&SCV000513600&SCV000623442&SCV000697660&SCV002014199&SCV004015831&SCV005273294&SCV005442080&SCV005895134&SCV006099415	single_nucleotide_variant	SO:0001483	ClinGen:CA147089		MET:4233	SO:0001819&synonymous_variant										1	41736																											121					1							246.98	v6.1	Unknown		True	MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:D1304= mutant UNKNOWN.	False	The MET ENSP00000317272.6:d1304= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	116435768						True	False	False	Unknown								False	False		MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types.	The MET ENSP00000317272.6:d1304= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:D1304= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	MET	4233.0	ENSP00000317272.6:D1304=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MET"",""entrezGeneId"":4233,""alteration"":""ENSP00000317272.6:D1304="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types."",""variantSummary"":""The MET ENSP00000317272.6:d1304= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:D1304= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						69,52	38,25	31,27	0/1	35,34,29,23	ACG	0.00	0.00	0.00			32,37,16,36	26.45		0.4297520661157025
GRCh38	MET	D12_12345_1234556_Thyroid_S9			chr7	116795968	116795968.0	G	A	A	116795968	.	G	A	.	PASS		A	3_prime_UTR_variant&NMD_transcript_variant	MODIFIER	MET	ENSG00000105976	Transcript	ENST00000436117	nonsense_mediated_decay	20/20		c.*1622G>A	4313					rs2023748&COSV59255937		1		SNV	HGNC	HGNC:7029					1			ENSP00000410980	P08581.277		UPI0002065103	P08581-3		1						0.3538	0.034	0.4697	0.4673	0.4433	0.4949	0.4444	0.08772	0.5106	0.4904	0.4896	0.3994	0.4281	0.4514	0.4413	0.4549	0.35	0.1009	0.307	0.4444	0.487	0.4703	0.382	0.4116	0.4513	0.3863	0.4562	0.5106	gnomADe_AMR	benign	0&1	1&1	25741868&23613720&23757202&32022527&21543897&17053076&20011629&22383989&21970370&29062608						FAIL	-1	-46	-18	-7	0.00	0.00	0.00	0.00	MET		4.6600e-01	93575	0.32250		0.35383	99479	Renal_cell_carcinoma&Autosomal_recessive_nonsyndromic_hearing_loss_97&Hereditary_cancer-predisposing_syndrome&not_specified&Papillary_renal_cell_carcinoma_type_1&not_provided		Human_Phenotype_Ontology:HP:0005584&Human_Phenotype_Ontology:HP:0006720&MONDO:MONDO:0005086&MeSH:D002292&MedGen:C0007134&Orphanet:217071&MONDO:MONDO:0014739&MedGen:C4084709&OMIM:616705&Orphanet:90636&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&Human_Phenotype_Ontology:HP:0011797&MedGen:C1336839&OMIM:605074&Orphanet:47044&MedGen:C3661900		NC_000007.14:g.116795968G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000111375&SCV000213438&SCV000306716&SCV000466460&SCV000513601&SCV000623448&SCV000697661&SCV002014200&SCV004015832&SCV005273295&SCV005895129&SCV006099418	single_nucleotide_variant	SO:0001483	ClinGen:CA147092		MET:4233	SO:0001819&synonymous_variant										1	2023748																											107					0.981							241.98	v6.1	Unknown		True	MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:A1357= mutant UNKNOWN.	False	The MET ENSP00000317272.6:a1357= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	116436022						True	False	False	Unknown								False	False		MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types.	The MET ENSP00000317272.6:a1357= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:A1357= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	MET	4233.0	ENSP00000317272.6:A1357=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MET"",""entrezGeneId"":4233,""alteration"":""ENSP00000317272.6:A1357="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types."",""variantSummary"":""The MET ENSP00000317272.6:a1357= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:A1357= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						64,41	35,18	29,23	0/1	27,37,21,20	CGA	0.00	0.00	0.00			32,32,20,21	20.34		0.3904761904761905
GRCh38	MET	D12_12345_1234556_Thyroid_S9			chr7	116796043	116796043.0	G	A	A	116796043	.	G	A	.	PASS		A	3_prime_UTR_variant&NMD_transcript_variant	MODIFIER	MET	ENSG00000105976	Transcript	ENST00000436117	nonsense_mediated_decay	20/20		c.*1697G>A	4388					rs41737&COSV59255944		1		SNV	HGNC	HGNC:7029					1			ENSP00000410980	P08581.277		UPI0002065103	P08581-3		1						0.3546	0.0356	0.4726	0.4673	0.4433	0.4949	0.4445	0.08952	0.5108	0.4904	0.4896	0.3994	0.4279	0.4514	0.4414	0.455	0.3506	0.1028	0.3055	0.4451	0.487	0.4714	0.3823	0.4116	0.4514	0.3866	0.4557	0.5108	gnomADe_AMR	benign	0&1	1&1	25741868&23757202&32022527&21543897&17053076&22383989&21970370&29062608						FAIL	23	-1	42	-1	0.00	0.00	0.00	0.00	MET		4.6600e-01	93576	0.32105	0.42478	0.35463	99480	not_provided&Renal_cell_carcinoma&Autosomal_recessive_nonsyndromic_hearing_loss_97&Papillary_renal_cell_carcinoma_type_1&not_specified&Hereditary_cancer-predisposing_syndrome		MedGen:C3661900&Human_Phenotype_Ontology:HP:0005584&Human_Phenotype_Ontology:HP:0006720&MONDO:MONDO:0005086&MeSH:D002292&MedGen:C0007134&Orphanet:217071&MONDO:MONDO:0014739&MedGen:C4084709&OMIM:616705&Orphanet:90636&Human_Phenotype_Ontology:HP:0011797&MedGen:C1336839&OMIM:605074&Orphanet:47044&MedGen:CN169374&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162		NC_000007.14:g.116796043G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000111376&SCV000213439&SCV000306718&SCV000466464&SCV000513602&SCV000623449&SCV000697663&SCV002014201&SCV004015833&SCV005273296&SCV005895130&SCV006099419	single_nucleotide_variant	SO:0001483	ClinGen:CA147095		MET:4233	SO:0001819&synonymous_variant										1	41737																											68					0.971							244.32	v6.1	Unknown		True	MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types.	False	11/08/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:P1382= mutant UNKNOWN.	False	The MET ENSP00000317272.6:p1382= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	116436097						True	False	False	Unknown								False	False		MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types.	The MET ENSP00000317272.6:p1382= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:P1382= mutant UNKNOWN.						v6.1	11/08/2024		GRCh38	MET	4233.0	ENSP00000317272.6:P1382=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""MET"",""entrezGeneId"":4233,""alteration"":""ENSP00000317272.6:P1382="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""MET, a receptor tyrosine kinase, is recurrently altered by mutation or amplification in various cancer types."",""variantSummary"":""The MET ENSP00000317272.6:p1382= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET ENSP00000317272.6:P1382= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/08/2024""}"	True	True	False	Unknown		Unknown																						40,26	19,13	21,13	0/1	21,19,16,10	CGT	0.00	0.00	0.00			18,22,11,15	23.77		0.3939393939393939
GRCh38	SMO	D12_12345_1234556_Thyroid_S9	p.Gly388=	ENSP00000249373.3:p.Gly388=	chr7	129206487	129206487.0	G	C	C	129206487	.	G	C	.	PASS	NM_005631	C	synonymous_variant	LOW	SMO	ENSG00000128602	Transcript	ENST00000249373	protein_coding	6/12		c.1164G>C	1683	1164	388	G	ggG/ggC	rs2228617&COSV50829466		1		SNV	HGNC	HGNC:11119	YES	MANE_Select	NM_005631.5		1	P1	CCDS5811.1	ENSP00000249373	Q99835.220		UPI0000050447			1			Gene3D:1.20.1070.10&PDB-ENSP_mappings:4jkv.A&PDB-ENSP_mappings:4jkv.B&PDB-ENSP_mappings:4n4w.A&PDB-ENSP_mappings:4o9r.A&PDB-ENSP_mappings:4qim.A&PDB-ENSP_mappings:4qin.A&PDB-ENSP_mappings:5l7d.A&PDB-ENSP_mappings:5l7d.B&PDB-ENSP_mappings:5l7i.A&PDB-ENSP_mappings:5l7i.B&PDB-ENSP_mappings:5v56.A&PDB-ENSP_mappings:5v56.B&PDB-ENSP_mappings:5v57.A&PDB-ENSP_mappings:5v57.B&PDB-ENSP_mappings:6ot0.R&PDB-ENSP_mappings:6xbj.R&PDB-ENSP_mappings:6xbk.R&PDB-ENSP_mappings:6xbl.R&PDB-ENSP_mappings:6xbm.R&PDB-ENSP_mappings:7zi0.A&PDB-ENSP_mappings:7zi0.B&AFDB-ENSP_mappings:AF-Q99835-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF01534&PROSITE_profiles:PS50261&PANTHER:PTHR11309&SMART:SM01330&CDD:cd15030			0.7562	0.6687	0.7896	0.7718	0.8231	0.7658	0.825	0.6837	0.728	0.8753	0.7451	0.807	0.8786	0.8401	0.8198	0.7687	0.7865	0.6911	0.9561	0.745	0.8752	0.7543	0.8241	0.8844	0.8439	0.8162	0.7677	0.9561	gnomADg_AMI	benign	0&1	1&1	24033266&30334169&27236920&25189937&23826113&28833756						FAIL	-23	22	-9	-5	0.00	0.00	0.00	0.00	SMO		7.0600e-01	403462	0.78964	0.79749	0.75619	389787	not_provided&Hamartoma_of_hypothalamus&not_specified		MedGen:C3661900&Human_Phenotype_Ontology:HP:0002444&MONDO:MONDO:0009436&MedGen:C0342418&OMIM:241800&MedGen:CN169374		NC_000007.14:g.129206487G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000540390&SCV001868947&SCV002057484&SCV005267738	single_nucleotide_variant	SO:0001483	ClinGen:CA4479316		SMO:6608	SO:0001819&synonymous_variant										1	2228617																											909					0.998							247.04	v6.1	Unknown		True	SMO, a G-protein coupled receptor, is mutated in various cancers including basal cell carcinoma and medulloblastoma.	False	04/19/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMO ENSP00000249373.3:G388= mutant UNKNOWN.	False	The SMO ENSP00000249373.3:g388= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	128846328						True	False	False	Unknown								False	False		SMO, a G-protein coupled receptor, is mutated in various cancers including basal cell carcinoma and medulloblastoma.	The SMO ENSP00000249373.3:g388= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMO ENSP00000249373.3:G388= mutant UNKNOWN.						v6.1	04/19/2017		GRCh38	SMO	6608.0	ENSP00000249373.3:G388=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SMO"",""entrezGeneId"":6608,""alteration"":""ENSP00000249373.3:G388="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SMO, a G-protein coupled receptor, is mutated in various cancers including basal cell carcinoma and medulloblastoma."",""variantSummary"":""The SMO ENSP00000249373.3:g388= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SMO ENSP00000249373.3:G388= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/19/2017""}"	True	True	False	Unknown		Unknown																						0,907	0,406	0,501	0/1	0,0,452,455	GGA	.	.	.			0,0,449,458	64.73		1.0
GRCh38	PTN	D12_12345_1234556_Thyroid_S9			chr7	137345033	137345033.0	G	A	A	137345033	.	G	A	.	PASS		A	upstream_gene_variant	MODIFIER	PTN	ENSG00000105894	Transcript	ENST00000699293	protein_coding										1265	-1		SNV	HGNC	HGNC:9630							CCDS94211.1	ENSP00000514273		A0A8V8TNI1.10	UPI0000D4CB67																																																																																																																					208					0.971							231.19													chr7	137029779																																																	True	False	False	Unknown		Unknown																						199,3	110,3	89,0	0/1	113,86,1,2	TGT	0.00	0.00	1.00			98,101,1,2	5.43		0.01485148514851485
GRCh38	DGKI	D12_12345_1234556_Thyroid_S9			chr7	137724078		G	[chr2:180119845[G	[chr2:180119845[G	137724078	MantaBND:7511:0:1:0:0:0:1	G	[chr2:180119845[G	.	PASS	NM_001321708	.G	feature_truncation&intron_variant	HIGH	DGKI	ENSG00000157680	Transcript	ENST00000614521	protein_coding		1/32									-1		chromosome_breakpoint	HGNC	HGNC:2855	YES	MANE_Select	NM_001321708.2		5	P3	CCDS94212.1	ENSP00000479053		A0A087WV00.62	UPI0003E66EDB																																																																																																																	2			0,11							11	AGAGAGACAGT			MantaBND:7511:0:1:0:0:0:0	5														chr7	137408824				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr7	139041404		G	[chr1:173410484[G	[chr1:173410484[G	139041404	MantaBND:2404:0:1:0:0:0:0	G	[chr1:173410484[G	.	PASS		.G	downstream_gene_variant	MODIFIER		ENSG00000304140	Transcript	ENST00000799995	lncRNA										4455	1		chromosome_breakpoint																																																																																																																														1			0,4							4	GAGA			MantaBND:2404:0:1:0:0:0:1	2														chr7	138726150				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38	BRAF	D12_12345_1234556_Thyroid_S9			chr7	140788414	140788432.0	AATGAAGTATTATGCAGCT	A	A	140788414	.	AATGAAGTATTATGCAGCT	A	.	PASS	NM_004333	-	intron_variant	MODIFIER	BRAF	ENSG00000157764	Transcript	ENST00000646891	protein_coding		8/17	c.1141-848_1141-831del								-1		deletion	HGNC	HGNC:1097	YES	MANE_Select	NM_004333.6			P4	CCDS5863.1	ENSP00000493543	P15056.261		UPI000013DF26			1																																																							2.4500e-01																																																											176					0.977							245.53													chr7	140488214																																																	True	True	False	Unknown		Unknown																						169,3	61,2	108,1	0/1	89,80,3,0	TAA						95,74,2,1	6.53		0.01744186046511628
GRCh38	EZH2	D12_12345_1234556_Thyroid_S9	p.D185H	ENSP00000320147.2:p.Asp185His	chr7	148828812	148828812.0	C	G	G	148828812	.	C	G	.	PASS	NM_004456	G	missense_variant	MODERATE	EZH2	ENSG00000106462	Transcript	ENST00000320356	protein_coding	6/20		c.553G>C	688	553	185	D/H	Gac/Cac	rs2302427&CM162254&COSV57449162		-1		SNV	HGNC	HGNC:3527	YES	MANE_Select	NM_004456.5		1	P4	CCDS5891.1	ENSP00000320147	Q15910.221	A0A090N8E9.66	UPI000006D77C	Q15910-2		1	deleterious_low_confidence(0)	possibly_damaging(0.614)	AFDB-ENSP_mappings:AF-Q15910-F1&Pfam:PF18118&PANTHER:PTHR45747&SMART:SM00717&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.0799	0.0038	0.0461	0.2063	0.0696	0.0869	0.07488	0.01195	0.03678	0.09989	0.1213	0.09587	0.09105	0.07489	0.08107	0.07157	0.06209	0.01381	0.05263	0.05092	0.09476	0.1729	0.09423	0.08844	0.07725	0.07346	0.08177	0.2063	EAS	benign	0&1&1	1&1&1	25741868&24728327&18414213&19567509&29104488&24179546&29497317&32748461&30214282&24691023&29212262&35813302&35870994&32272438&36695247&34206082&29479874&26807327&26693053&24040354&28833756&38764053						FAIL	-19	44	18	-38	0.00	0.00	0.00	0.00	EZH2	0.454	2.7200e-01	134224	0.06036	0.07864	0.07987	137963	not_specified&not_provided&Weaver_syndrome		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0010193&MedGen:C0265210&OMIM:277590&Orphanet:3447		NC_000007.14:g.148828812C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000168398&SCV000193125&SCV000231687&SCV000310393&SCV001730075&SCV005272828	single_nucleotide_variant	SO:0001483	ClinGen:CA159195&UniProtKB:Q15910																																																																																																																																															46,72	22,45	24,27	0/1	24,22,34,38	TCA	.	.	.			22,24,37,35	46.22		0.6101694915254238
GRCh38	EZH2	D12_12345_1234556_Thyroid_S9			chr7	148846601	148846602.0	TA	T	T	148846601	.	TA	T	.	PASS	NM_004456	-	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	EZH2	ENSG00000106462	Transcript	ENST00000320356	protein_coding		2/19	c.118-4del						rs3214332		-1		deletion	HGNC	HGNC:3527	YES	MANE_Select	NM_004456.5		1	P4	CCDS5891.1	ENSP00000320147	Q15910.221	A0A090N8E9.66	UPI000006D77C	Q15910-2		1						0.7612	0.9569	0.7839	0.6974	0.67	0.6401	0.6757	0.892	0.7084	0.679	0.6594	0.6197	0.7354	0.6715	0.6854	0.6628	0.7513	0.9238	0.7053	0.7492	0.6812	0.67	0.5992	0.7789	0.6865	0.7326	0.6619	0.9569	AFR	benign&likely_benign		1	18414213						FAIL	-5	-14	-3	3	0.02	0.03	0.00	0.00	EZH2		2.7200e-01	210966				207472	not_specified&not_provided&Weaver_syndrome		MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0010193&MedGen:C0265210&OMIM:277590&Orphanet:3447		NC_000007.14:g.148846612del	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000247331&SCV000288557&SCV001866732&SCV001933619&SCV002803209	Deletion	SO:0000159	ClinGen:CA208858		EZH2:2146	SO:0001627&intron_variant										1	3214332																											58					0.862							245.7													chr7	148543693																																																	True	True	False	Unknown		Unknown																						2,48	1,28	1,20	0/1	0,2,26,22	TTA						1,1,20,28	59.04		0.96
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.Gln2895=	ENSP00000262189.6:p.Gln2895=	chr7	152176768	152176768.0	C	T	T	152176768	.	C	T	.	PASS	NM_170606	T	synonymous_variant	LOW	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	38/59		c.8685G>A	8902	8685	2895	Q	caG/caA	rs6464211&COSV51370950		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1			PANTHER:PTHR45888			0.3828	0.7549	0.2392	0.3016	0.17	0.2843	0.184	0.7154	0.2334	0.2379	0.3034	0.2641	0.2481	0.1483	0.2168	0.2641	0.3312	0.6939	0.05263	0.2312	0.2412	0.307	0.2771	0.2687	0.1566	0.295	0.2717	0.7549	AFR	benign	0&1	1&1	31872004&26818916&35409657&24706189&23991983&33255693						FAIL	-2	-1	-27	0	0.00	0.00	0.00	0.00	KMT2C		2.0200e-01	1166982	0.34123	0.24936	0.38279	1155632	not_provided&Kleefstra_syndrome_2		MedGen:C3661900&MONDO:MONDO:0054701&MedGen:C4540395&OMIM:617768		NC_000007.14:g.152176768C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001723955&SCV001910839&SCV001981142&SCV005273456	single_nucleotide_variant	SO:0001483	ClinGen:CA4579638		KMT2C:58508	SO:0001819&synonymous_variant										1	6464211																											176					0.983							236.61	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:Q2895= mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:q2895= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151873853						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:q2895= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:Q2895= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:Q2895=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:Q2895="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:q2895= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:Q2895= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						86,87	31,40	55,47	0/1	43,43,42,45	CCT	0.00	0.00	0.00			36,50,39,48	38.26		0.5028901734104047
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.L1572GlnfsTer	ENSP00000262189.6:p.Leu1572GlnfsTer95	chr7	152187793	152187798.0	A	ATGCTT	ATGCTT	152187793	.	A	ATGCTT	.	PASS	NM_170606	TGCTT	frameshift_variant	HIGH	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	32/59		c.4714_4715insAAGCA	4931-4932	4714-4715	1572	L/QAX	ctc/cAAGCAtc			-1		insertion	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1			PANTHER:PTHR45888&Low_complexity_(Seg):seg																																																				2.0200e-01																																																											119					0.966							240.64	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:L1572Qfs*95 mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:l1572qfs*95 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151884878						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:l1572qfs*95 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:L1572Qfs*95 mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:L1572Qfs*95			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:L1572Qfs*95"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:l1572qfs*95 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:L1572Qfs*95 mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Likely Loss-of-function	30108106;25537518;23259788;19433796	Likely Oncogenic																						112,3	57,1	55,2	0/1	47,65,1,2	GAG						60,52,1,2	8.76		0.02608695652173913
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9			chr7	152202910		A	<INS>	<INS>	152202910	MantaINS:748:1:1:0:3:0	A	<INS>	.	PASS	NM_170606	insertion	intron_variant	MODIFIER	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding		26/58									-1		insertion	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1																																																																																																															0,89		0,89							89	AATAATGTAAAGCAAAATATTACTTGTAAATAGGCAGGGAAAGTTTCTTCAAGCTTATTTTTCCTTTTTCGGTATCTCTTCTTTATTTT		AATAATGTAAAGCAAAATATTACTTGTAAATAGGCAGGGAAAGTTTCTTCAAGCTTATTTTTCCTTTTTCGGTATCTCTTCTTTATTTTCTCAGTGAAATAGGAAGCAAGCTCATAAAAAGGGAAGAAATCACGAAGGATTAAGGAAGGA																chr7	151899995	TTTTTTATTTGTTTACCACCTTAAATGTGTTGTT			INS																																													True	True	False	Unknown		Unknown																															0,0				0,4	
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.R909K	ENSP00000262189.6:p.Arg909Lys	chr7	152235860	152235860.0	C	T	T	152235860	.	C	T	.	PASS	NM_170606	T	missense_variant	MODERATE	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	16/59		c.2726G>A	2943	2726	909	R/K	aGg/aAg	rs199504848&COSV51276261		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1	deleterious_low_confidence(0)	probably_damaging(0.954)	PANTHER:PTHR45888&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg									0.2059	0.08625	0.09739	0.1882	0.2445	0.1937	0.1959	0.2225	0.2205	0.1053	0.42	0.3432	0.4876	0.4353	0.4395	0.396	0.4405	0.4639	0.4528	0.425	0.4008	0.4876	gnomADg_AMI		0&1	1&1	39030589						FAIL	4	-43	4	0	0.00	0.00	0.02	0.00	KMT2C	0.430	2.0200e-01	3764529				1784557	Kleefstra_syndrome_2		MONDO:MONDO:0054701&MedGen:C4540395&OMIM:617768		NC_000007.14:g.152235860C>T	no_classification_provided	not_provided			SCV005870978	single_nucleotide_variant	SO:0001483			KMT2C:58508	SO:0001583&missense_variant										0																												1393					0.701							46.29	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:R909K mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:r909k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151932945						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:r909k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:R909K mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:R909K			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:R909K"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:r909k mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:R909K mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						904,73	500,41	404,32	0|1	485,419,40,33	CCT	0.00	0.00	1.00		151932945	517,387,34,39	4.79		0.07471852610030706
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.P860S	ENSP00000262189.6:p.Pro860Ser	chr7	152238781	152238781.0	G	A	A	152238781	.	G	A	.	PASS	NM_170606	A	missense_variant	MODERATE	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	15/59		c.2578C>T	2795	2578	860	P/S	Cca/Tca	rs112515611&COSV51278267		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1	deleterious_low_confidence(0)	probably_damaging(0.995)	PANTHER:PTHR45888&MobiDB_lite:mobidb-lite									0	0	0	0	0	0	0	0	0	0												0	gnomADe_AFR&gnomADe_AMR&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_REMAINING&gnomADe_SAS	uncertain_significance	0&1	1&1							FAIL	45	-42	-15	45	0.04	0.00	0.00	0.00	KMT2C	0.296	2.0200e-01	1192209				1182238	not_specified		MedGen:CN169374		NC_000007.14:g.152238781G>A	criteria_provided&_single_submitter	Uncertain_significance			SCV001774495	single_nucleotide_variant	SO:0001483	ClinGen:CA169245012		KMT2C:58508	SO:0001583&missense_variant										1	112515611																											143					0.657							49.37	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P860S mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:p860s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151935866						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:p860s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P860S mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:P860S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:P860S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:p860s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P860S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						83,11	37,4	46,7	0/1	41,42,7,4	GGG	0.00	0.00	1.00			39,44,6,5	11.79		0.11702127659574468
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.W858L	ENSP00000262189.6:p.Trp858Leu	chr7	152238786	152238786.0	C	A	A	152238786	.	C	A	.	PASS	NM_170606	A	missense_variant	MODERATE	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	15/59		c.2573G>T	2790	2573	858	W/L	tGg/tTg	rs111493987&COSV51367709		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1	deleterious_low_confidence(0)	probably_damaging(0.98)	PANTHER:PTHR45888&MobiDB_lite:mobidb-lite									0	0	0	0	0	0	0	0	0	0												0	gnomADe_AFR&gnomADe_AMR&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_REMAINING&gnomADe_SAS	uncertain_significance&pathogenic	0&1	1&1	33373444&28955865						FAIL	-9	40	17	-20	0.06	0.20	0.00	0.00	KMT2C	0.518	2.0200e-01	1192208				1182239	Kleefstra_syndrome_2&not_specified&Autism&_susceptiblity_to		MONDO:MONDO:0054701&MedGen:C4540395&OMIM:617768&MedGen:CN169374&MONDO:MONDO:0020836&MedGen:CN301178&OMIM:PS209850		NC_000007.14:g.152238786C>A	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Pathogenic(1)&Uncertain_significance(2)		SCV001774494&SCV004009703&SCV005438779	single_nucleotide_variant	SO:0001483	ClinGen:CA169245016		KMT2C:58508	SO:0001583&missense_variant										33	111493987																											136					0.662							45.87	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:W858L mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:w858l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151935871						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:w858l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:W858L mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:W858L			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:W858L"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:w858l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:W858L mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						80,10	35,3	45,7	0/1	47,33,5,5	CCA	0.00	0.00	1.00			34,46,8,2	9.11		0.1111111111111111
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.Thr852=	ENSP00000262189.6:p.Thr852=	chr7	152238803	152238803.0	T	A	A	152238803	.	T	A	.	PASS	NM_170606	A	synonymous_variant	LOW	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	15/59		c.2556A>T	2773	2556	852	T	acA/acT	rs113632846&COSV51368066		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1			PANTHER:PTHR45888&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite																																	0&1	0&1							FAIL	23	-26	0	33	0.04	0.00	0.00	0.00	KMT2C		2.0200e-01																																																											127					0.677							45.68	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:T852= mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:t852= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151935888						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:t852= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:T852= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:T852=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:T852="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:t852= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:T852= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						79,7	34,3	45,4	0/1	45,34,5,2	CTG	.	.	.			34,45,3,4	9.05		0.08139534883720931
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.G838S	ENSP00000262189.6:p.Gly838Ser	chr7	152247922	152247922.0	C	T	T	152247922	.	C	T	.	PASS	NM_170606	T	missense_variant	MODERATE	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	14/59		c.2512G>A	2729	2512	838	G/S	Ggt/Agt	rs2479172&COSV51279050		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1	deleterious_low_confidence(0)	probably_damaging(0.998)	PANTHER:PTHR45888&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite									6.861e-07	3.013e-05	0	0	0	0	0	0	0	0	0.002692	0.0055	0.002457	0.001946	0.0009416	0.001701	0.002161	0.004202	0.001339	0.003348	0.006517	0.006517	gnomADg_SAS		0&1	0&1	26204995&36596842&36613967						FAIL	-2	-5	36	-20	0.00	0.00	0.01	0.16	KMT2C	0.448	2.0200e-01																																																											106					0.83							69.6	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:G838S mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:g838s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151945007						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:g838s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:G838S mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:G838S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:G838S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:g838s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:G838S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						73,15	40,7	33,8	0/1	34,39,11,4	CCA	0.00	0.00	1.00			55,18,9,6	10.97		0.17045454545454544
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.Y816*	ENSP00000262189.6:p.Tyr816Ter	chr7	152247986	152247987.0	G	GT	GT	152247986	.	G	GT	.	PASS	NM_170606	T	stop_gained&frameshift_variant	HIGH	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	14/59		c.2447dup	2664-2665	2447-2448	816	Y/*	tac/taAc	rs150073007		-1		insertion	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1			PANTHER:PTHR45888									0.4916	0.4955	0.4952	0.4888	0.4998	0.4915	0.4909	0.4905	0.4918	0.4985	0.4946	0.4965	0.4989	0.4945	0.4934	0.5	0.4932	0.4891	0.4932	0.4925	0.4979	0.5	gnomADg_EAS	benign&likely_benign		1	25741868&24033266&35280415&26014803&36874103&38111036						FAIL	40	-8	-24	-28	0.00	0.00	0.00	0.01	KMT2C		2.0200e-01	403020		0.49007		390552	not_specified&Intellectual_disability		MedGen:CN169374&Human_Phenotype_Ontology:HP:0000730&Human_Phenotype_Ontology:HP:0001249&Human_Phenotype_Ontology:HP:0001267&Human_Phenotype_Ontology:HP:0001286&Human_Phenotype_Ontology:HP:0002122&Human_Phenotype_Ontology:HP:0002192&Human_Phenotype_Ontology:HP:0002316&Human_Phenotype_Ontology:HP:0002382&Human_Phenotype_Ontology:HP:0002386&Human_Phenotype_Ontology:HP:0002402&Human_Phenotype_Ontology:HP:0002458&Human_Phenotype_Ontology:HP:0002482&Human_Phenotype_Ontology:HP:0002499&Human_Phenotype_Ontology:HP:0002543&Human_Phenotype_Ontology:HP:0003767&Human_Phenotype_Ontology:HP:0006833&Human_Phenotype_Ontology:HP:0007154&Human_Phenotype_Ontology:HP:0007176&Human_Phenotype_Ontology:HP:0007180&MONDO:MONDO:0001071&MeSH:D008607&MedGen:C3714756		NC_000007.14:g.152247987dup	criteria_provided&_single_submitter	Benign			SCV000539482	Duplication	SO:1000035	ClinGen:CA4581220		KMT2C:58508	SO:0001587&nonsense										5	150073007																											368					0.625							65.41	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:Y816* mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:y816* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151945071						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:y816* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:Y816* mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:Y816*			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:Y816*"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:y816* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:Y816* mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Likely Loss-of-function	30108106;25537518;23259788;19433796	Likely Oncogenic																						147,83	63,41	84,42	0/1	70,77,42,41	TGT						78,69,46,37	10.19		0.36086956521739133
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.Ser806=	ENSP00000262189.6:p.Ser806=	chr7	152248016	152248016.0	G	C	C	152248016	.	G	C	.	PASS	NM_170606	C	synonymous_variant	LOW	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	14/59		c.2418C>G	2635	2418	806	S	tcC/tcG	rs3896406&COSV51275152		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1			PANTHER:PTHR45888									0.3027	0.2076	0.256	0.1846	0.08256	0.1506	0.2296	0.3419	0.2375	0.1621	0.004181	0.0005542	0	0.002757	0.006105	0.005428	0.0009459	0.01748	0.007144	0.005238	0.002285	0.3419	gnomADe_NFE	benign	0&1	1&1							FAIL	10	-38	5	6	0.00	0.00	0.00	0.00	KMT2C		2.0200e-01	1596664		0.41587		1633747	not_provided		MedGen:C3661900		NC_000007.14:g.152248016G>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002407609&SCV005273488	single_nucleotide_variant	SO:0001483	ClinGen:CA4581238		KMT2C:58508	SO:0001819&synonymous_variant										1	3896406																											474					0.572							54.94	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:S806= mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:s806= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151945101						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:s806= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:S806= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:S806=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:S806="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:s806= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:S806= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						195,76	86,35	109,41	0/1	99,96,34,42	AGG	.	.	.			84,111,39,37	10.89		0.28044280442804426
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.Pro377=	ENSP00000262189.6:p.Pro377=	chr7	152265091	152265091.0	T	A	A	152265091	.	T	A	.	PASS	NM_170606	A	synonymous_variant	LOW	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	8/59		c.1131A>T	1348	1131	377	P	ccA/ccT	rs62478356&COSV51276727		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1			PDB-ENSP_mappings:2ysm.A&Gene3D:3.30.40.10&Pfam:PF00628&PROSITE_profiles:PS50016&PROSITE_profiles:PS50089&PANTHER:PTHR45888&SMART:SM00184&SMART:SM00249&Superfamily:SSF57903&CDD:cd15509									0.3489	0.08824	0.3586	0.2691	0.1146	0.2751	0.3237	0.381	0.2953	0.2325	0.03065	0.00898	0.02335	0.03155	0.02876	0.01646	0.06548	0.01119	0.04251	0.04277	0.01614	0.381	gnomADe_NFE	benign	0&1	1&1	31188922						FAIL	-14	38	44	-13	0.01	0.00	0.00	0.00	KMT2C		2.0200e-01	1166983		0.45537		1155638	not_provided		MedGen:C3661900		NC_000007.14:g.152265091T>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001723956&SCV005273495	single_nucleotide_variant	SO:0001483	ClinGen:CA4581584		KMT2C:58508&LOC123956272:123956272	SO:0001819&synonymous_variant										1	62478356																											456					0.548							38.2	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P377= mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:p377= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151962176						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:p377= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P377= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:P377=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:P377="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:p377= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P377= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						178,72	70,33	108,39	0/1	86,92,31,41	ATG	.	.	.			104,74,44,28	3.81		0.288
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.Pro335=	ENSP00000262189.6:p.Pro335=	chr7	152273712	152273712.0	A	T	T	152273712	.	A	T	.	PASS	NM_170606	T	synonymous_variant	LOW	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	7/59		c.1005T>A	1222	1005	335	P	ccT/ccA	rs141993954&COSV51329402		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1			PANTHER:PTHR45888									0.002578	0.0009532	0.0009247	0.004004	0.001549	0.002206	0.002309	0.002494	0.002538	0.005699	0.0008614	0.000703	0	0.0008798	0.002159	0.001004	0.0007965	0	0.0008053	0.001482	0.002001	0.005699	gnomADe_SAS	benign	0&1	1&1	28522829						FAIL	50	19	-7	-5	0.00	0.00	0.00	0.00	KMT2C		2.0200e-01	1638599	0.01730	0.04340		1624285	not_provided		MedGen:C3661900		NC_000007.14:g.152273712A>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV002452660&SCV005273497	single_nucleotide_variant	SO:0001483	ClinGen:CA169231543		KMT2C:58508	SO:0001819&synonymous_variant										1	141993954																											308					0.76							47.3	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P335= mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:p335= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151970797						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:p335= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P335= mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:P335=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:P335="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:p335= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P335= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						214,20	100,8	114,12	0/1	97,117,9,11	CAG	.	.	.			131,83,13,7	10.14		0.08547008547008547
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.T316S	ENSP00000262189.6:p.Thr316Ser	chr7	152273771	152273771.0	T	A	A	152273771	.	T	A	.	PASS	NM_170606	A	missense_variant	MODERATE	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	7/59		c.946A>T	1163	946	316	T/S	Acc/Tcc	rs10454320&CM156680&COSV51279497		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1	deleterious_low_confidence(0.01)	possibly_damaging(0.48)	Gene3D:3.30.40.10&Pfam:PF13771&PROSITE_profiles:PS51805&PANTHER:PTHR45888&SMART:SM00249&CDD:cd15696									0.4905	0.4919	0.4853	0.4751	0.4596	0.4827	0.4858	0.492	0.4825	0.4958	0.4054	0.4346	0.3589	0.3414	0.4278	0.297	0.3573	0.1075	0.4222	0.381	0.3468	0.4958	gnomADe_SAS		0&1&1	0&1&1	26014803&26204995&26480299						FAIL	-40	8	32	3	0.00	0.01	0.00	0.00	KMT2C	0.145	2.0200e-01																																																											519					0.723							42.15	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:T316S mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:t316s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151970856						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:t316s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:T316S mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:T316S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:T316S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:t316s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:T316S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						74,301	30,134	44,167	0/1	38,36,163,138	GTG	.	.	.			44,30,114,187	40.27		0.8026666666666666
GRCh38	KMT2C	D12_12345_1234556_Thyroid_S9	p.P309S	ENSP00000262189.6:p.Pro309Ser	chr7	152273792	152273792.0	G	A	A	152273792	.	G	A	.	PASS	NM_170606	A	missense_variant	MODERATE	KMT2C	ENSG00000055609	Transcript	ENST00000262189	protein_coding	7/59		c.925C>T	1142	925	309	P/S	Cct/Tct	rs138627563&COSV51275341		-1		SNV	HGNC	HGNC:13726	YES	MANE_Select	NM_170606.3		1	P2	CCDS5931.1	ENSP00000262189	Q8NEZ4.205		UPI0000141B9F	Q8NEZ4-1		1	deleterious_low_confidence(0)	probably_damaging(0.999)	Gene3D:3.30.40.10&Pfam:PF13771&PROSITE_profiles:PS51805&PANTHER:PTHR45888&SMART:SM00249&CDD:cd15696																																uncertain_significance	0&1	1&1							FAIL	-13	47	11	5	0.31	0.00	0.00	0.00	KMT2C	0.562	2.0200e-01	1120223		0.11133		1109121	Tip-toe_gait		Human_Phenotype_Ontology:HP:0002394&Human_Phenotype_Ontology:HP:0030051&Human_Phenotype_Ontology:HP:0040083&MedGen:C0427144		NC_000007.14:g.152273792G>A	no_assertion_criteria_provided	Uncertain_significance			SCV001653523	single_nucleotide_variant	SO:0001483	ClinGen:CA169231566		KMT2C:58508	SO:0001583&missense_variant										0	138627563																											436					0.702							40.76	v6.1	Unknown		True	KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	False	08/22/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P309S mutant UNKNOWN.	False	The KMT2C ENSP00000262189.6:p309s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr7	151970877						True	False	False	Unknown								False	False		KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies.	The KMT2C ENSP00000262189.6:p309s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P309S mutant UNKNOWN.						v6.1	08/22/2018		GRCh38	KMT2C	58508.0	ENSP00000262189.6:P309S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KMT2C"",""entrezGeneId"":58508,""alteration"":""ENSP00000262189.6:P309S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KMT2C, a tumor suppressor and histone methyltransferase, is altered in various solid and hematologic malignancies."",""variantSummary"":""The KMT2C ENSP00000262189.6:p309s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KMT2C ENSP00000262189.6:P309S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""08/22/2018""}"	True	True	False	Unknown		Unknown																						259,47	111,23	148,24	0/1	129,130,31,16	GGA	0.00	0.00	1.00			101,158,21,26	6.52		0.15359477124183007
GRCh38		D12_12345_1234556_Thyroid_S9			chr7	156198119	156198119.0	T	C	C	156198119	.	T	C	.	PASS		C	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000295268	Transcript	ENST00000728934	lncRNA		2/3	n.215+1947T>C						rs737681		1		SNV			YES																			0.6400	0.4955	0.6988	0.8631	0.6103	0.5941											0.5952	0.5132	0.6502	0.6736	0.5404	0.8484	0.6531	0.551	0.6005	0.5737	0.6201	0.8631	EAS				26691610&29121662&33406744&19083859&35627269&27294018&19948332																																																																												1128					0.997							246.2													chr7	155990813																																																	True	False	False	Unknown		Unknown																						558,567	298,304	260,263	0/1	289,269,265,302	CTT	.	.	.			253,305,260,307	60.75		0.504
GRCh38		D12_12345_1234556_Thyroid_S9			chr8	19232269	19232273.0	T	TAAGG	TAAGG	19232269	.	T	TAAGG	.	PASS		AAGG	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000253557	Transcript	ENST00000807969	lncRNA		1/1	n.145+3191_145+3194dup						rs2308072		-1		insertion																						0.4357	0.6278	0.3213	0.3978	0.4712	0.2597											0.4867	0.584	0.4667	0.3574	0.402	0.384	0.5141	0.3878	0.4797	0.4691	0.2899	0.6278	AFR				23690203&36292568																																																																												228					0.934							246.25													chr8	19089779																																																	True	False	False	Unknown		Unknown																						114,99	52,49	62,50	0/1	62,52,49,50	CTA						42,72,39,60	30.43		0.4647887323943662
GRCh38		D12_12345_1234556_Thyroid_S9			chr8	28553555	28553555.0	T	C	C	28553555	.	T	C	.	PASS		C	intron_variant&non_coding_transcript_variant	MODIFIER		ENSG00000290005	Transcript	ENST00000728995	lncRNA		1/2	n.166-2046A>G						rs10092491		-1		SNV																						0.6156	0.5976	0.6138	0.6528	0.5934	0.6258											0.5854	0.5858	0.7033	0.5946	0.6431	0.6461	0.6134	0.5986	0.5657	0.5919	0.6378	0.7033	gnomADg_AMI				23771752&26522768&26691610&29121662&33406744&34721519&27294018&32999068&37239431&33546406																																																																												196					0.98							246.01													chr8	28411072																																																	True	False	False	Unknown		Unknown																						84,108	40,47	44,61	0/1	51,33,55,53	GTT	.	.	.			47,37,62,46	48.27		0.5625
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9			chr8	31863691	31863691.0	C	T	T	31863691	.	C	T	.	PASS		T	intron_variant	MODIFIER	NRG1	ENSG00000157168	Transcript	ENST00000652698	protein_coding		1/11	c.37+224260C>T						rs1383890		1		SNV	HGNC	HGNC:7997						A2	CCDS94272.1	ENSP00000499008		A0A494C1F8.30	UPI0001A47185			1						0.6615	0.5431	0.5965	0.8899	0.5974	0.6984											0.6021	0.5789	0.6604	0.5944	0.5138	0.8776	0.6696	0.585	0.5835	0.5725	0.7081	0.8899	EAS			1	35835914																	3.5900e-01																																																											181					0.906							236.37													chr8	31721207																																																	True	True	False	Unknown		Unknown																						77,87	49,55	28,32	0/1	47,30,35,52	TCA	0.00	0.00	0.00			55,22,47,40	42.11		0.5304878048780488
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9			chr8	32327120		A	<INS>	<INS>	32327120	MantaINS:2698:1:1:0:4:0	A	<INS>	.	PASS		insertion	intron_variant	MODIFIER	NRG1	ENSG00000157168	Transcript	ENST00000652698	protein_coding		1/11									1		insertion	HGNC	HGNC:7997						A2	CCDS94272.1	ENSP00000499008		A0A494C1F8.30	UPI0001A47185			1																																																																																																															0,75		0,75							75	GCAGTGTGGGGCTGGCACAGAGATGAAAGAAAGAAGAGGTTCCTCCCTGGTTTCTGTTTATTTGAACCTGAATCA		GCAGTGTGGGGCTGGCACAGAGATGAAAGAAAGAAGAGGTTCCTCCCTGGTTTCTGTTTATTTGAACCTGAATCAAAGAGAATGGAAACAAATGG																chr8	32184636	GAAAGTTCACGATGGAACAGTCTGAATGACGAGTCTTTGTCACAGGGAGAGGGCACAGG			INS																																													True	True	False	Unknown		Unknown																															1,2				0,6	
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9			chr8	32548461	32548461.0	T	C	C	32548461	.	T	C	.	PASS	NM_013964	C	5_prime_UTR_variant	MODIFIER	NRG1	ENSG00000157168	Transcript	ENST00000405005	protein_coding	1/12		c.-266T>C	151					rs7820838		1		SNV	HGNC	HGNC:7997	YES	MANE_Select	NM_013964.5		1	A2	CCDS6085.1	ENSP00000384620	Q02297.249		UPI000013DED6	Q02297-1		1						0.7656	0.7648	0.8545	0.7837	0.8121	0.637	0.7786	0.7541	0.8641	0.76	0.8657	0.8065	0.7288	0.7799	0.7686	0.6574	0.7849	0.762	0.8399	0.8659	0.7686	0.7986	0.8238	0.7241	0.7827	0.7898	0.6577	0.8659	gnomADg_AMR			1	19199244&29121253&22574178&26634245&28604730&20718829&18282690																	4.7500e-01																																																											687					0.997							245.5													chr8	32405979																																																	True	True	False	Unknown		Unknown																						0,685	0,322	0,363	0/1	0,0,364,321	GTG	.	.	.			0,0,215,470	64.73		1.0
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9	p.R38Q	ENSP00000384620.2:p.Arg38Gln	chr8	32595840	32595840.0	G	A	A	32595840	.	G	A	.	PASS	NM_013964	A	missense_variant	MODERATE	NRG1	ENSG00000157168	Transcript	ENST00000405005	protein_coding	2/12		c.113G>A	529	113	38	R/Q	cGa/cAa	rs3924999&CM054795&COSV55177787		1		SNV	HGNC	HGNC:7997	YES	MANE_Select	NM_013964.5		1	A2	CCDS6085.1	ENSP00000384620	Q02297.249		UPI000013DED6	Q02297-1		1	deleterious_low_confidence(0.01)	benign(0.115)	PDB-ENSP_mappings:7sjl.A&MobiDB_lite:mobidb-lite&PROSITE_profiles:PS50835&CDD:cd05895&Phobius:CYTOPLASMIC_DOMAIN&Superfamily:SSF48726&Gene3D:2.60.40.10&PANTHER:PTHR11100&AFDB-ENSP_mappings:AF-Q02297-F1			0.3852	0.0666	0.3746	0.7589	0.3767	0.4468	0.4025	0.09955	0.4313	0.3525	0.7744	0.3419	0.339	0.4008	0.4022	0.4095	0.3214	0.1125	0.2807	0.3703	0.3471	0.7714	0.3483	0.3265	0.39	0.3579	0.4262	0.7744	gnomADe_EAS	benign	0&1&1	1&1&1	25324626&21728034&27236031&25529856&18478032&17598910&24976857&26748513&26756273&31156712&32710539&19199244&28855605&19521112&23429840&20638435&23489597&23360725&21035784&22574178&12874607&16219117&28094814&17631867&19394386&19545856&20157235&20182055&20497232&21745728&22467496&29310728&31944381&33279967&33770628&18466881&22183611&23524320&33193575&18466879&26305006&36742238&25106628&26346124&33217458&35528795&20718829&23028568&23319876&29225331&24883238&28993723&24991953&23715299&17996908&19954751&17408693&19782967&18282690&17300918&15276238&18420180&16730337&36566681&37441552&38577257&38029052&39123493&39062492																0.042	4.7500e-01	3059329	0.30678	0.39128	0.38518	3197045	NRG1-related_disorder		.		NC_000008.11:g.32595840G>A	no_assertion_criteria_provided	Benign			SCV004797815	single_nucleotide_variant	SO:0001483	ClinGen:CA4705476		NRG1:3084	SO:0001583&missense_variant&SO:0001623&5_prime_UTR_variant										1	3924999																											83					0.94							245.07	v6.1	Unknown		True	NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers.	False	07/15/2022	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 ENSP00000384620.2:R38Q mutant UNKNOWN.	False	The NRG1 ENSP00000384620.2:r38q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	32453358						True	False	False	Unknown								False	False		NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers.	The NRG1 ENSP00000384620.2:r38q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 ENSP00000384620.2:R38Q mutant UNKNOWN.						v6.1	07/15/2022		GRCh38	NRG1	3084.0	ENSP00000384620.2:R38Q			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NRG1"",""entrezGeneId"":3084,""alteration"":""ENSP00000384620.2:R38Q"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers."",""variantSummary"":""The NRG1 ENSP00000384620.2:r38q mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 ENSP00000384620.2:R38Q mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/15/2022""}"	True	True	False	Unknown		Unknown																						40,38	21,22	19,16	0/1	22,18,20,18	CGA	0.00	0.00	0.00			19,21,22,16	33.63		0.48717948717948717
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9			chr8	32595957		T	<INS>	<INS>	32595957	MantaINS:3303:1:1:0:10:0	T	<INS>	.	PASS	NM_013964	insertion	feature_elongation&coding_sequence_variant	HIGH	NRG1	ENSG00000157168	Transcript	ENST00000405005	protein_coding	2/12			647	231	77					1		insertion	HGNC	HGNC:7997	YES	MANE_Select	NM_013964.5		1	A2	CCDS6085.1	ENSP00000384620	Q02297.249		UPI000013DED6	Q02297-1		1			PDB-ENSP_mappings:7sjl.A&PROSITE_profiles:PS50835&CDD:cd05895&Phobius:CYTOPLASMIC_DOMAIN&Superfamily:SSF48726&Gene3D:2.60.40.10&Pfam:PF07679&PANTHER:PTHR11100&SMART:SM00408&SMART:SM00409&AFDB-ENSP_mappings:AF-Q02297-F1																																																																																																												0,35		0,35							35	GAATCGAAAAAACAAACCACAAAATATCAAGATAC		GAATCGAAAAAACAAACCACAAAATATCAAGATACCAAAACAGATATATAGACCAATGGAACAGAACAGAGGCCTCGGAAATAACACCAC																chr8	32453475	CATCAAGCTACCAATGCCTTTCTTCACAGAATTGGAAAAAACTACTTTAAAGCTCATATG			INS																																													True	True	False	Unknown		Unknown																															4,4				38,0	
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9	p.K91IlefsTer	ENSP00000384620.2:p.Lys91IlefsTer25	chr8	32595998	32596000.0	A	ATT	ATT	32595998	.	A	ATT	.	PASS	NM_013964	TT	frameshift_variant	HIGH	NRG1	ENSG00000157168	Transcript	ENST00000405005	protein_coding	2/12		c.271_272insTT	687-688	271-272	91	K/IX	aag/aTTag			1		insertion	HGNC	HGNC:7997	YES	MANE_Select	NM_013964.5		1	A2	CCDS6085.1	ENSP00000384620	Q02297.249		UPI000013DED6	Q02297-1		1			PDB-ENSP_mappings:7sjl.A&Low_complexity_(Seg):seg&PROSITE_profiles:PS50835&CDD:cd05895&Phobius:CYTOPLASMIC_DOMAIN&Superfamily:SSF48726&Gene3D:2.60.40.10&Pfam:PF07679&PANTHER:PTHR11100&SMART:SM00408&SMART:SM00409&AFDB-ENSP_mappings:AF-Q02297-F1																																																				4.7500e-01																																																											132					0.811							219.85	v6.1	Unknown		True	NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers.	False	07/15/2022	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 ENSP00000384620.2:K91Ifs*25 mutant UNKNOWN.	False	The NRG1 ENSP00000384620.2:k91ifs*25 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	32453516						True	False	False	Unknown								False	False		NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers.	The NRG1 ENSP00000384620.2:k91ifs*25 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 ENSP00000384620.2:K91Ifs*25 mutant UNKNOWN.						v6.1	07/15/2022		GRCh38	NRG1	3084.0	ENSP00000384620.2:K91Ifs*25			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NRG1"",""entrezGeneId"":3084,""alteration"":""ENSP00000384620.2:K91Ifs*25"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers."",""variantSummary"":""The NRG1 ENSP00000384620.2:k91ifs*25 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 ENSP00000384620.2:K91Ifs*25 mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/15/2022""}"	True	True	False	Unknown		Unknown																						104,3	57,3	47,0	0/1	54,50,2,1	AAA						37,67,2,1	9.47		0.028037383177570093
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9			chr8	32648114	32648114.0	G	C	C	32648114	.	G	C	.	PASS	NM_013964	C	intron_variant	MODIFIER	NRG1	ENSG00000157168	Transcript	ENST00000405005	protein_coding		5/11	c.502+31229G>C						rs35641374&COSV55157546		1		SNV	HGNC	HGNC:7997	YES	MANE_Select	NM_013964.5		1	A2	CCDS6085.1	ENSP00000384620	Q02297.249		UPI000013DED6	Q02297-1		1						0.0301	0.0401	0.0245	0	0.0179	0.0644	0.01839	0.03769	0.02538	0.03822	0.0002771	0.003557	0.1139	0.0141	0.02638	0.06214	0.02384	0.0337	0.001099	0.02818	0.0438	0.0005789	0.004617	0.102	0.01717	0.04967	0.0605	0.1139	gnomADe_MID	likely_benign	0&1	1&1	19521112&22574178&30180823&33193575&34475833																	4.7500e-01	218702	0.02061	0.02489	0.03015	215383	not_provided&not_specified		MedGen:C3661900&MedGen:CN169374		NC_000008.11:g.32648114G>C	criteria_provided&_multiple_submitters&_no_conflicts	Likely_benign			SCV000258067&SCV005223370	single_nucleotide_variant	SO:0001483	ClinGen:CA249080		NRG1:3084	SO:0001583&missense_variant&SO:0001627&intron_variant										1	35641374																											1008					0.996							247.67													chr8	32505633																																																	True	True	False	Unknown		Unknown																						497,507	242,276	255,231	0/1	249,248,248,259	TGT	.	.	.			252,245,257,250	59.2		0.5049800796812749
GRCh38	NRG1	D12_12345_1234556_Thyroid_S9			chr8	32728474	32728474.0	A	G	G	32728474	.	A	G	.	PASS	NM_013964	G	intron_variant	MODIFIER	NRG1	ENSG00000157168	Transcript	ENST00000405005	protein_coding		6/11	c.632+396A>G						rs11785668		1		SNV	HGNC	HGNC:7997	YES	MANE_Select	NM_013964.5		1	A2	CCDS6085.1	ENSP00000384620	Q02297.249		UPI000013DED6	Q02297-1		1						0.0455	0.0817	0.0274	0.002	0.0308	0.0695	0.03019	0.08447	0.02846	0.08835	0.00138	0.02174	0.1012	0.02762	0.04043	0.06188	0.04579	0.07728	0	0.04303	0.09198	0.003669	0.0211	0.09184	0.03054	0.06717	0.06105	0.1012	gnomADe_MID																					4.7500e-01																																																											137					0.912							243.44													chr8	32585992																																																	True	True	False	Unknown		Unknown																						63,62	30,31	33,31	0/1	25,38,29,33	CAG	.	.	.			34,29,32,30	35.95		0.496
GRCh38	ADGRA2	D12_12345_1234556_Thyroid_S9	p.Gly1113=	ENSP00000406367.2:p.Gly1113=	chr8	37841677	37841677.0	C	G	G	37841677	.	C	G	.	PASS	NM_032777	G	synonymous_variant	LOW	ADGRA2	ENSG00000020181	Transcript	ENST00000412232	protein_coding	19/19		c.3339C>G	3725	3339	1113	G	ggC/ggG	rs4976898&COSV55102516		1		SNV	HGNC	HGNC:17849	YES	MANE_Select	NM_032777.10		1	P1	CCDS6097.2	ENSP00000406367	Q96PE1.192		UPI00004AE50D	Q96PE1-1					AFDB-ENSP_mappings:AF-Q96PE1-F1&Phobius:CYTOPLASMIC_DOMAIN&PANTHER:PTHR45930&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.7983	0.8472	0.7522	0.8889	0.7117	0.7607	0.7163	0.8246	0.7938	0.6256	0.9118	0.7853	0.5638	0.7032	0.7096	0.7309	0.7519	0.821	0.7237	0.7458	0.6092	0.8955	0.79	0.5411	0.7048	0.7152	0.7402	0.9118	gnomADe_EAS		0&1	0&1							FAIL	27	16	-28	-15	0.00	0.00	0.00	0.00	ADGRA2		9.4300e-01																																																											323					0.994							245.82	v6.1	Unknown		True	ADGRA2, an adhesion G protein-coupled receptor, is infrequently altered in cancer.	False	09/03/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ADGRA2 ENSP00000406367.2:G1113= mutant UNKNOWN.	False	The ADGRA2 ENSP00000406367.2:g1113= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	37699195						True	False	False	Unknown								False	False		ADGRA2, an adhesion G protein-coupled receptor, is infrequently altered in cancer.	The ADGRA2 ENSP00000406367.2:g1113= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ADGRA2 ENSP00000406367.2:G1113= mutant UNKNOWN.						v6.1	09/03/2024		GRCh38	ADGRA2	25960.0	ENSP00000406367.2:G1113=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ADGRA2"",""entrezGeneId"":25960,""alteration"":""ENSP00000406367.2:G1113="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ADGRA2, an adhesion G protein-coupled receptor, is infrequently altered in cancer."",""variantSummary"":""The ADGRA2 ENSP00000406367.2:g1113= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ADGRA2 ENSP00000406367.2:G1113= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/03/2024""}"	True	True	False	Unknown		Unknown																						160,161	70,93	90,68	0/1	77,83,84,77	GCC	.	.	.			89,71,116,45	41.09		0.5015576323987538
GRCh38	ADGRA2	D12_12345_1234556_Thyroid_S9	p.Gly1220=	ENSP00000406367.2:p.Gly1220=	chr8	37841998	37841998.0	C	T	T	37841998	.	C	T	.	PASS	NM_032777	T	synonymous_variant	LOW	ADGRA2	ENSG00000020181	Transcript	ENST00000412232	protein_coding	19/19		c.3660C>T	4046	3660	1220	G	ggC/ggT	rs7010546&COSV55104307		1		SNV	HGNC	HGNC:17849	YES	MANE_Select	NM_032777.10		1	P1	CCDS6097.2	ENSP00000406367	Q96PE1.192		UPI00004AE50D	Q96PE1-1					AFDB-ENSP_mappings:AF-Q96PE1-F1&Phobius:CYTOPLASMIC_DOMAIN&PANTHER:PTHR45930&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg			0.4641	0.3048	0.5144	0.6716	0.4165	0.4785	0.4094	0.3022	0.5261	0.3353	0.7238	0.4553	0.2564	0.3958	0.3995	0.4719	0.3947	0.311	0.4857	0.4628	0.3273	0.6789	0.4676	0.2226	0.3952	0.3854	0.4768	0.7238	gnomADe_EAS		0&1	0&1							FAIL	15	42	-2	-9	0.00	0.00	0.00	0.00	ADGRA2		9.4300e-01																																																											441					1							247.65	v6.1	Unknown		True	ADGRA2, an adhesion G protein-coupled receptor, is infrequently altered in cancer.	False	09/03/2024	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ADGRA2 ENSP00000406367.2:G1220= mutant UNKNOWN.	False	The ADGRA2 ENSP00000406367.2:g1220= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	37699516						True	False	False	Unknown								False	False		ADGRA2, an adhesion G protein-coupled receptor, is infrequently altered in cancer.	The ADGRA2 ENSP00000406367.2:g1220= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ADGRA2 ENSP00000406367.2:G1220= mutant UNKNOWN.						v6.1	09/03/2024		GRCh38	ADGRA2	25960.0	ENSP00000406367.2:G1220=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ADGRA2"",""entrezGeneId"":25960,""alteration"":""ENSP00000406367.2:G1220="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ADGRA2, an adhesion G protein-coupled receptor, is infrequently altered in cancer."",""variantSummary"":""The ADGRA2 ENSP00000406367.2:g1220= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ADGRA2 ENSP00000406367.2:G1220= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""09/03/2024""}"	True	True	False	Unknown		Unknown																						216,225	98,103	118,122	0/1	105,111,115,110	GCA	0.00	0.00	0.00			105,111,107,118	47.91		0.5102040816326531
GRCh38	KAT6A	D12_12345_1234556_Thyroid_S9	p.Gln1657_Pro1661dup	ENSP00000265713.2:p.Gln1657_Pro1661dup	chr8	41933237	41933252.0	C	CGGCTGTGGCTGCTGT	CGGCTGTGGCTGCTGT	41933237	.	C	CGGCTGTGGCTGCTGT	.	PASS	NM_006766	GGCTGTGGCTGCTGT	inframe_insertion	MODERATE	KAT6A	ENSG00000083168	Transcript	ENST00000265713	protein_coding	17/17		c.4968_4982dup	5394-5395	4982-4983	1661	P/PQQPQP	ccg/ccACAGCAGCCACAGCCg	rs750049486		-1		insertion	HGNC	HGNC:13013	YES	MANE_Select	NM_006766.5		1	P1	CCDS6124.1	ENSP00000265713	Q92794.227		UPI000013D666			1			AFDB-ENSP_mappings:AF-Q92794-F1&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg									0.001076	0.0001241	0.0004322	4.066e-05	2.719e-05	2.517e-05	0.0002244	0.001317	0.0006871	0.000137	0.0006253	0.0001688	0	0.0004586	0	0	0	0	0.001179	0.0004771	0	0.001317	gnomADe_NFE	uncertain_significance&benign&likely_benign		1																		8.3000e-02	587892				579397	Inborn_genetic_diseases&KAT6A-related_disorder&not_provided		MeSH:D030342&MedGen:C0950123&.&MedGen:C3661900		NC_000008.11:g.41933240_41933254dup	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(1)&Benign(1)&Likely_benign(3)		SCV000846648&SCV001900152&SCV002454221&SCV003715090&SCV004157538	Duplication	SO:1000035	ClinGen:CA4729389		KAT6A:7994	SO:0001821&inframe_insertion										1	750049486																											1026					0.789							230.74	v6.1	Unknown		True	KAT6A, a histone acetyltransferase, is recurrently altered by translocation in acute myeloid leukemia.	False	02/07/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KAT6A ENSP00000265713.2:Q1657_P1661dup altered UNKNOWN.	False	The KAT6A ENSP00000265713.2:q1657_p1661dup alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	41790755						True	False	False	Unknown								False	False		KAT6A, a histone acetyltransferase, is recurrently altered by translocation in acute myeloid leukemia.	The KAT6A ENSP00000265713.2:q1657_p1661dup alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KAT6A ENSP00000265713.2:Q1657_P1661dup altered UNKNOWN.						v6.1	02/07/2019		GRCh38	KAT6A	7994.0	ENSP00000265713.2:Q1657_P1661dup			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""KAT6A"",""entrezGeneId"":7994,""alteration"":""ENSP00000265713.2:Q1657_P1661dup"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""KAT6A, a histone acetyltransferase, is recurrently altered by translocation in acute myeloid leukemia."",""variantSummary"":""The KAT6A ENSP00000265713.2:q1657_p1661dup alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KAT6A ENSP00000265713.2:Q1657_P1661dup altered UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""02/07/2019""}"	True	True	False	Unknown		Unknown																						426,384	185,157	241,227	0/1	223,203,209,175	GCG						188,238,202,182	30.29		0.4740740740740741
GRCh38	PRKDC	D12_12345_1234556_Thyroid_S9	p.I3434T	ENSP00000313420.3:p.Ile3434Thr	chr8	47798394	47798394.0	A	G	G	47798394	.	A	G	.	PASS	NM_006904	G	missense_variant	MODERATE	PRKDC	ENSG00000253729	Transcript	ENST00000314191	protein_coding	73/86		c.10301T>C	10311	10301	3434	I/T	aTt/aCt	rs7830743&CM1213050&COSV58047120		-1		SNV	HGNC	HGNC:9413	YES	MANE_Select	NM_006904.7		1	P1	CCDS75735.1	ENSP00000313420	P78527.240		UPI0000013593	P78527-1		1	tolerated_low_confidence(0.35)	benign(0)	PDB-ENSP_mappings:5luq.A&PDB-ENSP_mappings:5luq.B&PDB-ENSP_mappings:5w1r.A&PDB-ENSP_mappings:5y3r.C&PDB-ENSP_mappings:6zfp.A&PDB-ENSP_mappings:6zh2.A&PDB-ENSP_mappings:6zh4.A&PDB-ENSP_mappings:6zh6.A&PDB-ENSP_mappings:6zh8.A&PDB-ENSP_mappings:6zha.A&PDB-ENSP_mappings:6zhe.A&PDB-ENSP_mappings:6zhe.F&PDB-ENSP_mappings:7k0y.A&PDB-ENSP_mappings:7k10.A&PDB-ENSP_mappings:7k11.A&PDB-ENSP_mappings:7k19.A&PDB-ENSP_mappings:7k1b.A&PDB-ENSP_mappings:7k1j.A&PDB-ENSP_mappings:7k1k.A&PDB-ENSP_mappings:7k1n.A&PDB-ENSP_mappings:7lt3.C&PDB-ENSP_mappings:7lt3.L&PDB-ENSP_mappings:7nfc.A&PDB-ENSP_mappings:7nfc.F&PDB-ENSP_mappings:7nfe.A&PDB-ENSP_mappings:7otm.A&PDB-ENSP_mappings:7otp.A&PDB-ENSP_mappings:7otv.A&PDB-ENSP_mappings:7otw.A&PDB-ENSP_mappings:7oty.A&PDB-ENSP_mappings:7sgl.A&PDB-ENSP_mappings:7su3.A&PDB-ENSP_mappings:7sud.A&PDB-ENSP_mappings:7tyr.A&PDB-ENSP_mappings:7z87.A&PDB-ENSP_mappings:7z88.A&PDB-ENSP_mappings:8bh3.A&PDB-ENSP_mappings:8bh3.S&PDB-ENSP_mappings:8bhv.A&PDB-ENSP_mappings:8bhv.F&PDB-ENSP_mappings:8bhy.A&PDB-ENSP_mappings:8bhy.S&PDB-ENSP_mappings:8bot.A&PDB-ENSP_mappings:8bot.F&PDB-ENSP_mappings:8bot.S&PDB-ENSP_mappings:8ez9.C&PDB-ENSP_mappings:8ez9.L&PDB-ENSP_mappings:8eza.C&PDB-ENSP_mappings:8eza.L&PDB-ENSP_mappings:8ezb.C&PDB-ENSP_mappings:8ezb.L&Pfam:PF02259&PROSITE_profiles:PS51189&PANTHER:PTHR11139			0.1845	0.3086	0.2608	0.0804	0.0547	0.2035	0.07162	0.2888	0.306	0.09232	0.08841	0.03871	0.09607	0.05	0.08613	0.1559	0.1332	0.2717	0.1923	0.2128	0.09101	0.08398	0.03223	0.09524	0.04963	0.1368	0.1636	0.3086	AFR	benign&benign/likely_benign	0&1&1	1&1&1	18401594&28324443&18413776&23697595&21877955&23108991&35003222&23183621&37287874&31350979&36312587&38892180						FAIL	3	-12	-21	-12	0.01	0.17	0.00	0.00	PRKDC	0.075	1.8300e-01	379415	0.12059	0.13740	0.18450	371887	not_provided&Severe_combined_immunodeficiency_due_to_DNA-PKcs_deficiency&not_specified		MedGen:C3661900&MONDO:MONDO:0014423&MedGen:C4014833&OMIM:615966&Orphanet:317425&MedGen:CN169374		NC_000008.11:g.47798394A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign/Likely_benign			SCV000516356&SCV001730374&SCV002050712&SCV004233485&SCV005223523	single_nucleotide_variant	SO:0001483	ClinGen:CA4739340		PRKDC:5591	SO:0001583&missense_variant										1	7830743																											76					1							235.3	v6.1	Unknown		True	PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers.	False	12/11/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:I3434T mutant UNKNOWN.	False	The PRKDC ENSP00000313420.3:i3434t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	48710955						True	False	False	Unknown								False	False		PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers.	The PRKDC ENSP00000313420.3:i3434t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:I3434T mutant UNKNOWN.						v6.1	12/11/2023		GRCh38	PRKDC	5591.0	ENSP00000313420.3:I3434T			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PRKDC"",""entrezGeneId"":5591,""alteration"":""ENSP00000313420.3:I3434T"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers."",""variantSummary"":""The PRKDC ENSP00000313420.3:i3434t mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:I3434T mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/11/2023""}"	True	True	False	Unknown		Unknown																						43,33	25,20	18,13	0/1	21,22,17,16	AAT	.	.	.			19,24,6,27	28.21		0.4342105263157895
GRCh38	PRKDC	D12_12345_1234556_Thyroid_S9	p.L1244ProfsTer	ENSP00000313420.3:p.Leu1244ProfsTer42	chr8	47893255	47893256.0	A	AG	AG	47893255	.	A	AG	.	PASS	NM_006904	G	frameshift_variant	HIGH	PRKDC	ENSG00000253729	Transcript	ENST00000314191	protein_coding	31/86		c.3730dup	3740-3741	3730-3731	1244	L/PX	ctt/cCtt	rs11411516		-1		insertion	HGNC	HGNC:9413	YES	MANE_Select	NM_006904.7		1	P1	CCDS75735.1	ENSP00000313420	P78527.240		UPI0000013593	P78527-1		1			PDB-ENSP_mappings:5luq.A&PDB-ENSP_mappings:5luq.B&PDB-ENSP_mappings:5w1r.A&PDB-ENSP_mappings:5y3r.C&PDB-ENSP_mappings:6zfp.A&PDB-ENSP_mappings:6zh2.A&PDB-ENSP_mappings:6zh4.A&PDB-ENSP_mappings:6zh6.A&PDB-ENSP_mappings:6zh8.A&PDB-ENSP_mappings:6zha.A&PDB-ENSP_mappings:6zhe.A&PDB-ENSP_mappings:6zhe.F&PDB-ENSP_mappings:7k0y.A&PDB-ENSP_mappings:7k10.A&PDB-ENSP_mappings:7k11.A&PDB-ENSP_mappings:7k19.A&PDB-ENSP_mappings:7k1b.A&PDB-ENSP_mappings:7k1j.A&PDB-ENSP_mappings:7k1k.A&PDB-ENSP_mappings:7k1n.A&PDB-ENSP_mappings:7lt3.C&PDB-ENSP_mappings:7lt3.L&PDB-ENSP_mappings:7nfc.A&PDB-ENSP_mappings:7nfc.F&PDB-ENSP_mappings:7nfe.A&PDB-ENSP_mappings:7otm.A&PDB-ENSP_mappings:7otp.A&PDB-ENSP_mappings:7otv.A&PDB-ENSP_mappings:7otw.A&PDB-ENSP_mappings:7oty.A&PDB-ENSP_mappings:7sgl.A&PDB-ENSP_mappings:7su3.A&PDB-ENSP_mappings:7sud.A&PDB-ENSP_mappings:7tyr.A&PDB-ENSP_mappings:7z87.A&PDB-ENSP_mappings:7z88.A&PDB-ENSP_mappings:8bh3.A&PDB-ENSP_mappings:8bh3.S&PDB-ENSP_mappings:8bhv.A&PDB-ENSP_mappings:8bhv.F&PDB-ENSP_mappings:8bhy.A&PDB-ENSP_mappings:8bhy.S&PDB-ENSP_mappings:8bot.A&PDB-ENSP_mappings:8bot.F&PDB-ENSP_mappings:8bot.S&PDB-ENSP_mappings:8ez9.C&PDB-ENSP_mappings:8ez9.L&PDB-ENSP_mappings:8eza.C&PDB-ENSP_mappings:8eza.L&PDB-ENSP_mappings:8ezb.C&PDB-ENSP_mappings:8ezb.L&Pfam:PF20502&PANTHER:PTHR11139&Superfamily:SSF48371																																benign		1	35003222																	1.8300e-01	1168284				1155979	Severe_combined_immunodeficiency_due_to_DNA-PKcs_deficiency		MONDO:MONDO:0014423&MedGen:C4014833&OMIM:615966&Orphanet:317425		NC_000008.11:g.47893257dup	criteria_provided&_single_submitter	Benign			SCV001727107	Duplication	SO:1000035	ClinGen:CA176152485		PRKDC:5591	SO:0001589&frameshift_variant										1	11411516																											1033					0.981							247.3	v6.1	Unknown		True	PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers.	False	12/11/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:L1244Pfs*42 mutant UNKNOWN.	False	The PRKDC ENSP00000313420.3:l1244pfs*42 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	48805816						True	False	False	Unknown								False	False		PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers.	The PRKDC ENSP00000313420.3:l1244pfs*42 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:L1244Pfs*42 mutant UNKNOWN.						v6.1	12/11/2023		GRCh38	PRKDC	5591.0	ENSP00000313420.3:L1244Pfs*42			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PRKDC"",""entrezGeneId"":5591,""alteration"":""ENSP00000313420.3:L1244Pfs*42"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers."",""variantSummary"":""The PRKDC ENSP00000313420.3:l1244pfs*42 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:L1244Pfs*42 mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/11/2023""}"	True	True	False	Likely Loss-of-function	31055244	Likely Oncogenic																						1,1012	0,469	1,543	0/1	0,1,523,489	AAG						1,0,442,570	63.48		0.9990128331688055
GRCh38	PRKDC	D12_12345_1234556_Thyroid_S9	p.M333I	ENSP00000313420.3:p.Met333Ile	chr8	47939665	47939665.0	C	T	T	47939665	.	C	T	.	PASS	NM_006904	T	missense_variant	MODERATE	PRKDC	ENSG00000253729	Transcript	ENST00000314191	protein_coding	11/86		c.999G>A	1009	999	333	M/I	atG/atA	rs8178017&COSV104628405		-1		SNV	HGNC	HGNC:9413	YES	MANE_Select	NM_006904.7		1	P1	CCDS75735.1	ENSP00000313420	P78527.240		UPI0000013593	P78527-1		1	deleterious_low_confidence(0.01)	benign(0.001)	Gene3D:1.25.10.10&PDB-ENSP_mappings:5luq.A&PDB-ENSP_mappings:5luq.B&PDB-ENSP_mappings:5w1r.A&PDB-ENSP_mappings:5y3r.C&PDB-ENSP_mappings:6zfp.A&PDB-ENSP_mappings:6zh2.A&PDB-ENSP_mappings:6zh4.A&PDB-ENSP_mappings:6zh6.A&PDB-ENSP_mappings:6zh8.A&PDB-ENSP_mappings:6zha.A&PDB-ENSP_mappings:6zhe.A&PDB-ENSP_mappings:6zhe.F&PDB-ENSP_mappings:7k0y.A&PDB-ENSP_mappings:7k10.A&PDB-ENSP_mappings:7k11.A&PDB-ENSP_mappings:7k19.A&PDB-ENSP_mappings:7k1b.A&PDB-ENSP_mappings:7k1j.A&PDB-ENSP_mappings:7k1k.A&PDB-ENSP_mappings:7k1n.A&PDB-ENSP_mappings:7lt3.C&PDB-ENSP_mappings:7lt3.L&PDB-ENSP_mappings:7nfc.A&PDB-ENSP_mappings:7nfc.F&PDB-ENSP_mappings:7nfe.A&PDB-ENSP_mappings:7otm.A&PDB-ENSP_mappings:7otp.A&PDB-ENSP_mappings:7otv.A&PDB-ENSP_mappings:7otw.A&PDB-ENSP_mappings:7oty.A&PDB-ENSP_mappings:7sgl.A&PDB-ENSP_mappings:7su3.A&PDB-ENSP_mappings:7sud.A&PDB-ENSP_mappings:7tyr.A&PDB-ENSP_mappings:7z87.A&PDB-ENSP_mappings:7z88.A&PDB-ENSP_mappings:8bh3.A&PDB-ENSP_mappings:8bh3.S&PDB-ENSP_mappings:8bhv.A&PDB-ENSP_mappings:8bhv.F&PDB-ENSP_mappings:8bhy.A&PDB-ENSP_mappings:8bhy.S&PDB-ENSP_mappings:8bot.A&PDB-ENSP_mappings:8bot.F&PDB-ENSP_mappings:8bot.S&PDB-ENSP_mappings:8ez9.C&PDB-ENSP_mappings:8ez9.L&PDB-ENSP_mappings:8eza.C&PDB-ENSP_mappings:8eza.L&PDB-ENSP_mappings:8ezb.C&PDB-ENSP_mappings:8ezb.L&Pfam:PF20500&PANTHER:PTHR11139&Superfamily:SSF48371			0.0174	0.0023	0.0403	0	0.0497	0.0061	0.03992	0.006645	0.02706	0.1145	0.000101	0.0285	0.05391	0.04358	0.04424	0.01013	0.03068	0.007532	0.01868	0.03228	0.1187	0.0003861	0.02658	0.07143	0.04395	0.04545	0.009344	0.1187	gnomADg_ASJ	benign&likely_benign	0&1	1&1	34046847						FAIL	-19	32	-1	4	0.00	0.00	0.00	0.00	PRKDC	0.132	1.8300e-01	379752	0.03261	0.03247	0.01737	369977	not_specified&Severe_combined_immunodeficiency_due_to_DNA-PKcs_deficiency&not_provided		MedGen:CN169374&MONDO:MONDO:0014423&MedGen:C4014833&OMIM:615966&Orphanet:317425&MedGen:C3661900		NC_000008.11:g.47939665C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000517119&SCV000655405&SCV005265549	single_nucleotide_variant	SO:0001483	ClinGen:CA4741852		PRKDC:5591	SO:0001583&missense_variant										1	8178017																											83					0.988							245.23	v6.1	Unknown		True	PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers.	False	12/11/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:M333I mutant UNKNOWN.	False	The PRKDC ENSP00000313420.3:m333i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	48852225						True	False	False	Unknown								False	False		PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers.	The PRKDC ENSP00000313420.3:m333i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:M333I mutant UNKNOWN.						v6.1	12/11/2023		GRCh38	PRKDC	5591.0	ENSP00000313420.3:M333I			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PRKDC"",""entrezGeneId"":5591,""alteration"":""ENSP00000313420.3:M333I"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PRKDC, a catalytic subunit of the DNA-dependent serine/threonine protein kinase, is recurrently altered by mutation in various cancers."",""variantSummary"":""The PRKDC ENSP00000313420.3:m333i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PRKDC ENSP00000313420.3:M333I mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""12/11/2023""}"	True	True	False	Unknown		Unknown																						37,45	21,27	16,18	0/1	22,15,24,21	GCA	0.00	0.00	0.00			16,21,24,21	39.08		0.5487804878048781
GRCh38	ST18	D12_12345_1234556_Thyroid_S9			chr8	52276161		A	<INS>	<INS>	52276161	MantaINS:10173:0:0:0:4:0	A	<INS>	.	PASS		insertion	intron_variant	MODIFIER	ST18	ENSG00000147488	Transcript	ENST00000699087	protein_coding		2/27									-1		insertion	HGNC	HGNC:18695						P1	CCDS6149.1	ENSP00000514122	O60284.162		UPI0000046C30																																																																																																																		0,7		0,7							7	CATACCA		CATACCACATACACACCACACAGGCAAACTACACACCACACACACCAAACACACACCACATACACACACCCTATACATACCACACACACACACAAACCACATGCACACCACACATAGCCCATACACAC																chr8	53188721	ACACAACATACCACATGCACACACACCACACATACCACACAGG			INS																																													True	False	False	Unknown		Unknown																															0,1				0,17	
GRCh38	PREX2	D12_12345_1234556_Thyroid_S9	p.Lys33=	ENSP00000288368.4:p.Lys33=	chr8	67952493	67952493.0	G	A	A	67952493	.	G	A	.	PASS	NM_024870	A	synonymous_variant	LOW	PREX2	ENSG00000046889	Transcript	ENST00000288368	protein_coding	1/40		c.99G>A	448	99	33	K	aaG/aaA	rs61753697&COSV55767087		1		SNV	HGNC	HGNC:22950	YES	MANE_Select	NM_024870.4		1	P1	CCDS6201.1	ENSP00000288368	Q70Z35.159		UPI0000375435	Q70Z35-1		1			Pfam:PF00621&Gene3D:1.20.900.10&SMART:SM00325&PROSITE_profiles:PS50010&CDD:cd00160&Superfamily:SSF48065&AFDB-ENSP_mappings:AF-Q70Z35-F1			0.3133	0.0499	0.366	0.5228	0.3062	0.4233	0.3135	0.07909	0.3633	0.2322	0.5391	0.2632	0.2325	0.3109	0.306	0.3769	0.2507	0.09049	0.2018	0.3233	0.2388	0.5229	0.2547	0.1986	0.3018	0.2631	0.4002	0.5391	gnomADe_EAS	benign	0&1	1&1							FAIL	31	-12	-25	15	0.00	0.00	0.02	0.00	PREX2		6.5100e-01	3060181	0.23039	0.35988	0.31330	3218086	PREX2-related_disorder		.		NC_000008.11:g.67952493G>A	no_assertion_criteria_provided	Benign			SCV004798807	single_nucleotide_variant	SO:0001483	ClinGen:CA4773166		PREX2:80243	SO:0001819&synonymous_variant										1	61753697																											830					0.999							247.37	v6.1	Unknown		True	PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K33= mutant UNKNOWN.	False	The PREX2 ENSP00000288368.4:k33= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	68864728						True	False	False	Unknown								False	False		PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	The PREX2 ENSP00000288368.4:k33= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K33= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PREX2	80243.0	ENSP00000288368.4:K33=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PREX2"",""entrezGeneId"":80243,""alteration"":""ENSP00000288368.4:K33="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas."",""variantSummary"":""The PREX2 ENSP00000288368.4:k33= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K33= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						436,393	216,167	220,226	0/1	220,216,196,197	AGA	0.00	0.00	0.00			230,206,208,185	33.77		0.47406513872135103
GRCh38	PREX2	D12_12345_1234556_Thyroid_S9	p.Arg399=	ENSP00000288368.4:p.Arg399=	chr8	68055931	68055931.0	C	A	A	68055931	.	C	A	.	PASS	NM_024870	A	synonymous_variant	LOW	PREX2	ENSG00000046889	Transcript	ENST00000288368	protein_coding	10/40		c.1195C>A	1544	1195	399	R	Cga/Aga	rs1434774&COSV55751403		1		SNV	HGNC	HGNC:22950	YES	MANE_Select	NM_024870.4		1	P1	CCDS6201.1	ENSP00000288368	Q70Z35.159		UPI0000375435	Q70Z35-1		1			PANTHER:PTHR22829&Gene3D:1.10.10.10&Pfam:PF00610&SMART:SM00049&PROSITE_profiles:PS50186&CDD:cd04439&Superfamily:SSF46785&AFDB-ENSP_mappings:AF-Q70Z35-F1			0.5617	0.8865	0.4755	0.2688	0.5239	0.5245	0.502	0.8497	0.4523	0.425	0.2717	0.5938	0.4401	0.4978	0.5071	0.5204	0.5884	0.8341	0.6527	0.4969	0.4353	0.2495	0.603	0.3878	0.4976	0.5404	0.5112	0.8865	AFR	benign	0&1	1&1							FAIL	2	-22	0	43	0.00	0.00	0.00	0.25	PREX2		6.5100e-01	1274701	0.60272	0.50657	0.56170	1265237	not_provided&PREX2-related_disorder		MedGen:C3661900&.		NC_000008.11:g.68055931C>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001901636&SCV005268497	single_nucleotide_variant	SO:0001483	ClinGen:CA4773525		PREX2:80243	SO:0001819&synonymous_variant										1	1434774																											224					0.969							238.73	v6.1	Unknown		True	PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:R399= mutant UNKNOWN.	False	The PREX2 ENSP00000288368.4:r399= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	68968166						True	False	False	Unknown								False	False		PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	The PREX2 ENSP00000288368.4:r399= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:R399= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PREX2	80243.0	ENSP00000288368.4:R399=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PREX2"",""entrezGeneId"":80243,""alteration"":""ENSP00000288368.4:R399="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas."",""variantSummary"":""The PREX2 ENSP00000288368.4:r399= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:R399= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						108,109	42,49	66,60	0|1	61,47,59,50	CCG	0.00	0.00	0.00		68968166	45,63,57,52	32.43		0.5023041474654378
GRCh38	PREX2	D12_12345_1234556_Thyroid_S9	p.Lys400=	ENSP00000288368.4:p.Lys400=	chr8	68055936	68055936.0	G	A	A	68055936	.	G	A	.	PASS	NM_024870	A	synonymous_variant	LOW	PREX2	ENSG00000046889	Transcript	ENST00000288368	protein_coding	10/40		c.1200G>A	1549	1200	400	K	aaG/aaA	rs1434775&COSV55751423&COSV55756707		1		SNV	HGNC	HGNC:22950	YES	MANE_Select	NM_024870.4		1	P1	CCDS6201.1	ENSP00000288368	Q70Z35.159		UPI0000375435	Q70Z35-1		1			PANTHER:PTHR22829&Gene3D:1.10.10.10&Pfam:PF00610&SMART:SM00049&PROSITE_profiles:PS50186&CDD:cd04439&Superfamily:SSF46785&AFDB-ENSP_mappings:AF-Q70Z35-F1			0.5617	0.8865	0.4755	0.2688	0.5239	0.5245	0.502	0.8484	0.4523	0.425	0.2716	0.5938	0.4401	0.4978	0.507	0.5204	0.5878	0.8329	0.6527	0.4964	0.4348	0.2491	0.6011	0.3793	0.4976	0.5404	0.5108	0.8865	AFR	benign	0&1&1	1&1&1							FAIL	3	-27	43	38	0.00	0.00	0.00	0.05	PREX2		6.5100e-01	1253695	0.60234	0.50641	0.56170	1243632	PREX2-related_disorder&not_provided		.&MedGen:C3661900		NC_000008.11:g.68055936G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001873484&SCV005268498	single_nucleotide_variant	SO:0001483	ClinGen:CA4773526		PREX2:80243	SO:0001819&synonymous_variant										1	1434775																											237					0.97							237.91	v6.1	Unknown		True	PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K400= mutant UNKNOWN.	False	The PREX2 ENSP00000288368.4:k400= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	68968171						True	False	False	Unknown								False	False		PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	The PREX2 ENSP00000288368.4:k400= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K400= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PREX2	80243.0	ENSP00000288368.4:K400=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PREX2"",""entrezGeneId"":80243,""alteration"":""ENSP00000288368.4:K400="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas."",""variantSummary"":""The PREX2 ENSP00000288368.4:k400= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K400= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						113,117	46,54	67,63	0|1	65,48,60,57	AGA	0.00	0.00	0.00		68968166	50,63,59,58	33.87		0.508695652173913
GRCh38	PREX2	D12_12345_1234556_Thyroid_S9	p.Gly606=	ENSP00000288368.4:p.Gly606=	chr8	68080778	68080778.0	A	G	G	68080778	.	A	G	.	PASS	NM_024870	G	synonymous_variant	LOW	PREX2	ENSG00000046889	Transcript	ENST00000288368	protein_coding	17/40		c.1818A>G	2167	1818	606	G	ggA/ggG	rs12682458&COSV55762986		1		SNV	HGNC	HGNC:22950	YES	MANE_Select	NM_024870.4		1	P1	CCDS6201.1	ENSP00000288368	Q70Z35.159		UPI0000375435	Q70Z35-1		1			PANTHER:PTHR22829&Gene3D:2.30.42.10&SMART:SM00228&PROSITE_profiles:PS50106&Superfamily:SSF50156&Superfamily:SSF46785&AFDB-ENSP_mappings:AF-Q70Z35-F1			0.5240	0.5318	0.4524	0.4722	0.5696	0.5706	0.532	0.52	0.4183	0.5543	0.4581	0.5362	0.5294	0.5376	0.5229	0.5551	0.5328	0.5309	0.4657	0.4837	0.5595	0.4553	0.5208	0.535	0.551	0.5213	0.5561	0.5706	SAS	benign	0&1	1&1							FAIL	-1	-32	-1	32	0.00	0.01	0.00	0.00	PREX2		6.5100e-01	3060741	0.54047	0.52439	0.52396	3197158	PREX2-related_disorder		.		NC_000008.11:g.68080778A>G	no_assertion_criteria_provided	Benign			SCV004796092	single_nucleotide_variant	SO:0001483	ClinGen:CA4773751		PREX2:80243	SO:0001819&synonymous_variant										1	12682458																											123					0.951							244.15	v6.1	Unknown		True	PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:G606= mutant UNKNOWN.	False	The PREX2 ENSP00000288368.4:g606= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	68993013						True	False	False	Unknown								False	False		PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	The PREX2 ENSP00000288368.4:g606= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:G606= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PREX2	80243.0	ENSP00000288368.4:G606=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PREX2"",""entrezGeneId"":80243,""alteration"":""ENSP00000288368.4:G606="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas."",""variantSummary"":""The PREX2 ENSP00000288368.4:g606= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:G606= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						68,49	36,22	32,27	0|1	36,32,28,21	GAT	.	.	.		68993013	38,30,33,16	17.71		0.4188034188034188
GRCh38	PREX2	D12_12345_1234556_Thyroid_S9	p.Leu607=	ENSP00000288368.4:p.Leu607=	chr8	68080779	68080779.0	T	C	C	68080779	.	T	C	.	PASS	NM_024870	C	synonymous_variant	LOW	PREX2	ENSG00000046889	Transcript	ENST00000288368	protein_coding	17/40		c.1819T>C	2168	1819	607	L	Tta/Cta	rs12680555&COSV55770460		1		SNV	HGNC	HGNC:22950	YES	MANE_Select	NM_024870.4		1	P1	CCDS6201.1	ENSP00000288368	Q70Z35.159		UPI0000375435	Q70Z35-1		1			PANTHER:PTHR22829&Gene3D:2.30.42.10&SMART:SM00228&PROSITE_profiles:PS50106&Superfamily:SSF50156&AFDB-ENSP_mappings:AF-Q70Z35-F1			0.5240	0.5318	0.4524	0.4722	0.5696	0.5706	0.5321	0.52	0.4187	0.5543	0.4582	0.5362	0.5294	0.5377	0.5229	0.5553	0.5327	0.5308	0.4645	0.4834	0.5594	0.4548	0.5213	0.535	0.5509	0.5213	0.5561	0.5706	SAS	benign	0&1	1&1							FAIL	-33	-13	31	-2	0.00	0.00	0.00	0.00	PREX2		6.5100e-01	3061030	0.54062	0.52443	0.52396	3197446	PREX2-related_disorder		.		NC_000008.11:g.68080779T>C	no_assertion_criteria_provided	Benign			SCV004797122	single_nucleotide_variant	SO:0001483	ClinGen:CA4773752		PREX2:80243	SO:0001819&synonymous_variant										1	12680555																											123					0.951							244.15	v6.1	Unknown		True	PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:L607= mutant UNKNOWN.	False	The PREX2 ENSP00000288368.4:l607= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	68993014						True	False	False	Unknown								False	False		PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	The PREX2 ENSP00000288368.4:l607= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:L607= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PREX2	80243.0	ENSP00000288368.4:L607=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PREX2"",""entrezGeneId"":80243,""alteration"":""ENSP00000288368.4:L607="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas."",""variantSummary"":""The PREX2 ENSP00000288368.4:l607= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:L607= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						67,50	35,22	32,28	0|1	38,29,26,24	ATT	.	.	.		68993013	34,33,36,14	19.17		0.42735042735042733
GRCh38	PREX2	D12_12345_1234556_Thyroid_S9			chr8	68105349	68105349.0	G	T	T	68105349	.	G	T	.	PASS	NM_024870	T	intron_variant	MODIFIER	PREX2	ENSG00000046889	Transcript	ENST00000288368	protein_coding		23/39	c.2716-2760G>T						rs35559159		1		SNV	HGNC	HGNC:22950	YES	MANE_Select	NM_024870.4		1	P1	CCDS6201.1	ENSP00000288368	Q70Z35.159		UPI0000375435	Q70Z35-1		1						0.0048	0.0015	0.0072	0	0.0129	0.0041	0.01834	0.002739	0.01087	0.004288	0	0.007167	0.004176	0.02154	0.01606	0.002778	0.01163	0.003397	0.008772	0.01638	0.004325	0	0.005842	0.006803	0.01841	0.01185	0.002911	0.02154	gnomADe_NFE	benign		1							FAIL	33	1	31	-5	0.00	0.00	0.00	0.00	PREX2		6.5100e-01	3056944	0.01284	0.01229	0.00479	3199870	PREX2-related_disorder		.		NC_000008.11:g.68105349G>T	no_assertion_criteria_provided	Benign			SCV004789796	single_nucleotide_variant	SO:0001483	ClinGen:CA4774194		PREX2:80243	SO:0001583&missense_variant&SO:0001627&intron_variant										1	35559159																											113					0.991							242.28													chr8	69017584																																																	True	True	False	Unknown		Unknown																						52,60	31,28	21,32	0/1	25,27,21,39	AGG	0.00	0.00	0.00			28,24,29,31	39.92		0.5357142857142857
GRCh38	PREX2	D12_12345_1234556_Thyroid_S9	p.Lys1294=	ENSP00000288368.4:p.Lys1294=	chr8	68134174	68134174.0	G	A	A	68134174	.	G	A	.	PASS	NM_024870	A	synonymous_variant	LOW	PREX2	ENSG00000046889	Transcript	ENST00000288368	protein_coding	32/40		c.3882G>A	4231	3882	1294	K	aaG/aaA	rs3793379&COSV55772588		1		SNV	HGNC	HGNC:22950	YES	MANE_Select	NM_024870.4		1	P1	CCDS6201.1	ENSP00000288368	Q70Z35.159		UPI0000375435	Q70Z35-1		1			PANTHER:PTHR22829&AFDB-ENSP_mappings:AF-Q70Z35-F1			0.1210	0.0212	0.2003	0.1865	0.1153	0.138	0.134	0.02912	0.184	0.1318	0.1729	0.1817	0.1259	0.1314	0.1337	0.1372	0.1132	0.03357	0.1079	0.169	0.1249	0.1972	0.2118	0.1667	0.1252	0.1112	0.1382	0.2118	gnomADg_FIN	benign	0&1	1&1							FAIL	-38	-17	35	-5	0.00	0.00	0.00	0.00	PREX2		6.5100e-01	1274446	0.10080	0.13340	0.12101	1262621	PREX2-related_disorder&not_provided		.&MedGen:C3661900		NC_000008.11:g.68134174G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001901316&SCV005268502	single_nucleotide_variant	SO:0001483	ClinGen:CA4774609		PREX2:80243	SO:0001819&synonymous_variant										1	3793379																											157					0.962							245.89	v6.1	Unknown		True	PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	False	03/28/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K1294= mutant UNKNOWN.	False	The PREX2 ENSP00000288368.4:k1294= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	69046409						True	False	False	Unknown								False	False		PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas.	The PREX2 ENSP00000288368.4:k1294= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K1294= mutant UNKNOWN.						v6.1	03/28/2017		GRCh38	PREX2	80243.0	ENSP00000288368.4:K1294=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PREX2"",""entrezGeneId"":80243,""alteration"":""ENSP00000288368.4:K1294="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PREX2, a positive mediator of RAC1 GTPase, is predominantly mutated in melanomas."",""variantSummary"":""The PREX2 ENSP00000288368.4:k1294= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PREX2 ENSP00000288368.4:K1294= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""03/28/2017""}"	True	True	False	Unknown		Unknown																						83,68	39,35	44,33	0/1	48,35,27,41	AGG	0.00	0.00	0.00			38,45,28,40	29.4		0.4503311258278146
GRCh38	EYA1	D12_12345_1234556_Thyroid_S9			chr8	71256517		A	[chr18:72009534[A	[chr18:72009534[A	71256517	MantaBND:13411:0:1:0:0:0:1	A	[chr18:72009534[A	.	PASS		.A	feature_truncation&intron_variant	HIGH	EYA1	ENSG00000104313	Transcript	ENST00000647540	protein_coding		13/19									-1		chromosome_breakpoint	HGNC	HGNC:3519						P4	CCDS34906.1	ENSP00000494438	Q99502.196		UPI000012A3B3	Q99502-1		1																																																																																																														2			0,12							12	ATAGATGTTGCC			MantaBND:13411:0:1:0:0:0:0	1														chr8	72168752				BND																																													True	False	False	Unknown		Unknown																															0,1				1,2	
GRCh38	CASC9	D12_12345_1234556_Thyroid_S9			chr8	75233536		A	[chr1:51973454[A	[chr1:51973454[A	75233536	MantaBND:4529:0:1:0:0:0:0	A	[chr1:51973454[A	.	PASS		.A	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	CASC9	ENSG00000249395	Transcript	ENST00000676364	lncRNA		1/2									-1		chromosome_breakpoint	HGNC	HGNC:48906	YES																																																																																																																											2			0,5							5	CATCA			MantaBND:4529:0:1:0:0:0:1	0														chr8	76145771				BND																																													True	False	False	Unknown		Unknown																															0,1				0,2	
GRCh38		D12_12345_1234556_Thyroid_S9			chr8	75606442	75606446.0	T	TACTG	TACTG	75606442	.	T	TACTG	.	PASS		ACTG	intergenic_variant	MODIFIER														rs10675097				insertion																						0.5972	0.8865	0.4496	0.3671	0.6213	0.5235											0.666	0.839	0.6696	0.497	0.6013	0.3977	0.7295	0.5856	0.6228	0.6448	0.5314	0.8865	AFR																																																																																72					0.986							245.5													chr8	76518677																																																	True	False	False	Unknown		Unknown																						47,24	23,11	24,13	0/1	25,22,12,12	TTA						17,30,17,7	14.47		0.3380281690140845
GRCh38	NBN	D12_12345_1234556_Thyroid_S9	p.Pro672=	ENSP00000265433.4:p.Pro672=	chr8	89946194	89946194.0	T	C	C	89946194	.	T	C	.	PASS	NM_002485	C	synonymous_variant	LOW	NBN	ENSG00000104320	Transcript	ENST00000265433	protein_coding	13/16		c.2016A>G	2122	2016	672	P	ccA/ccG	rs1061302&COSV55371426		-1		SNV	HGNC	HGNC:7652	YES	MANE_Select	NM_002485.5		1	P1	CCDS6249.1	ENSP00000265433	O60934.202		UPI0000073BF4			1			PDB-ENSP_mappings:8bah.C&AFDB-ENSP_mappings:AF-O60934-F1&PIRSF:PIRSF011869&PANTHER:PTHR12162			0.3528	0.2156	0.3761	0.4673	0.3062	0.4519	0.3311	0.2279	0.3531	0.3119	0.479	0.3618	0.3367	0.3191	0.3359	0.4279	0.3081	0.2301	0.2648	0.3415	0.3075	0.4515	0.3524	0.2774	0.3216	0.3254	0.4376	0.479	gnomADe_EAS	benign	0&1	1&1	25741868&24033266&20386703&32461785&20004634&19523210&20478923&20571895&29416357&19393077&24166361&30799775&26402912&35637613&33403820&28402931&21908578&30272267&28647780&22864661&27936167&19917125&24396275&28288557						FAIL	6	-43	6	30	0.04	0.00	0.00	0.00	NBN		1.0570e+00	183696	0.28419	0.34505	0.35284	182835	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Acute_lymphoid_leukemia&Hereditary_breast_ovarian_cancer_syndrome&Microcephaly&_normal_intelligence_and_immunodeficiency		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&Human_Phenotype_Ontology:HP:0004803&Human_Phenotype_Ontology:HP:0005555&Human_Phenotype_Ontology:HP:0006721&MONDO:MONDO:0004967&MedGen:C0023449&OMIM:613065&Orphanet:513&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MONDO:MONDO:0009623&MedGen:C0398791&OMIM:251260&Orphanet:647		NC_000008.11:g.89946194T>C	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212660&SCV000309100&SCV000475288&SCV000539863&SCV000634266&SCV001748574&SCV001839234&SCV002048405&SCV002505280&SCV004016035&SCV004233238&SCV005271446&SCV005880915&SCV006311102	single_nucleotide_variant	SO:0001483	ClinGen:CA186154		NBN:4683	SO:0001819&synonymous_variant										1	1061302																											73					0.959							244.88	v6.1	Unknown		True	NBN, a DNA repair protein, is altered by mutation and amplification in various cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:P672= mutant UNKNOWN.	False	The NBN ENSP00000265433.4:p672= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	90958422						True	False	False	Unknown								False	False		NBN, a DNA repair protein, is altered by mutation and amplification in various cancers.	The NBN ENSP00000265433.4:p672= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:P672= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	NBN	4683.0	ENSP00000265433.4:P672=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NBN"",""entrezGeneId"":4683,""alteration"":""ENSP00000265433.4:P672="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NBN, a DNA repair protein, is altered by mutation and amplification in various cancers."",""variantSummary"":""The NBN ENSP00000265433.4:p672= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:P672= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						0,70	0,35	0,35	0/1	0,0,29,41	ATG	.	.	.			0,0,32,38	64.49		1.0
GRCh38	NBN	D12_12345_1234556_Thyroid_S9	p.Asp399=	ENSP00000265433.4:p.Asp399=	chr8	89955483	89955483.0	A	G	G	89955483	.	A	G	.	PASS	NM_002485	G	synonymous_variant	LOW	NBN	ENSG00000104320	Transcript	ENST00000265433	protein_coding	10/16		c.1197T>C	1303	1197	399	D	gaT/gaC	rs709816&COSV55371961		-1		SNV	HGNC	HGNC:7652	YES	MANE_Select	NM_002485.5		1	P1	CCDS6249.1	ENSP00000265433	O60934.202		UPI0000073BF4			1			PDB-ENSP_mappings:8bah.C&AFDB-ENSP_mappings:AF-O60934-F1&PIRSF:PIRSF011869&PANTHER:PTHR12162&MobiDB_lite:mobidb-lite			0.6086	0.8533	0.5548	0.6647	0.341	0.5337	0.3985	0.7851	0.5742	0.3537	0.6814	0.4375	0.3915	0.3587	0.4247	0.5121	0.5094	0.7683	0.3114	0.5222	0.3473	0.6486	0.433	0.3503	0.361	0.4919	0.5239	0.8533	AFR	benign	0&1	1&1	25741868&24033266&20003265&20386703&19276285&32461785&16091150&21987080&16620382&19523210&20478923&20571895&22933979&25542228&28610420&29416357&35164849&24166361&30799775&28356832&35637613&36139526&26045716&26064273&30272267&36976737&28647780&26101473&25176580&22864661&27936167&19917125&24396275&28288557&25755792						FAIL	-9	-46	-46	2	0.00	0.00	0.01	0.00	NBN		1.0570e+00	183701	0.49031	0.46759	0.60863	182857	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Acute_lymphoid_leukemia&Hereditary_breast_ovarian_cancer_syndrome&Microcephaly&_normal_intelligence_and_immunodeficiency		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&Human_Phenotype_Ontology:HP:0004803&Human_Phenotype_Ontology:HP:0005555&Human_Phenotype_Ontology:HP:0006721&MONDO:MONDO:0004967&MedGen:C0023449&OMIM:613065&Orphanet:513&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MONDO:MONDO:0009623&MedGen:C0398791&OMIM:251260&Orphanet:647		NC_000008.11:g.89955483A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212686&SCV000224910&SCV000309097&SCV000475295&SCV000539865&SCV000634202&SCV000885814&SCV001748576&SCV001759292&SCV002505293&SCV004016038&SCV004233047&SCV005271448&SCV005880921&SCV006311093	single_nucleotide_variant	SO:0001483	ClinGen:CA186171		NBN:4683	SO:0001819&synonymous_variant										1	709816																											91					0.945							239.73	v6.1	Unknown		True	NBN, a DNA repair protein, is altered by mutation and amplification in various cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:D399= mutant UNKNOWN.	False	The NBN ENSP00000265433.4:d399= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	90967711						True	False	False	Unknown								False	False		NBN, a DNA repair protein, is altered by mutation and amplification in various cancers.	The NBN ENSP00000265433.4:d399= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:D399= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	NBN	4683.0	ENSP00000265433.4:D399=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NBN"",""entrezGeneId"":4683,""alteration"":""ENSP00000265433.4:D399="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NBN, a DNA repair protein, is altered by mutation and amplification in various cancers."",""variantSummary"":""The NBN ENSP00000265433.4:d399= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:D399= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						0,86	0,47	0,39	0/1	0,0,44,42	CAT	.	.	.			0,0,47,39	64.62		1.0
GRCh38	NBN	D12_12345_1234556_Thyroid_S9	p.E185Q	ENSP00000265433.4:p.Glu185Gln	chr8	89978251	89978251.0	C	G	G	89978251	.	C	G	.	PASS	NM_002485	G	missense_variant	MODERATE	NBN	ENSG00000104320	Transcript	ENST00000265433	protein_coding	5/16		c.553G>C	659	553	185	E/Q	Gag/Cag	rs1805794&CM034886&COSV55371261&COSV55372457&COSV55375647		-1		SNV	HGNC	HGNC:7652	YES	MANE_Select	NM_002485.5		1	P1	CCDS6249.1	ENSP00000265433	O60934.202		UPI0000073BF4			1	tolerated(1)	benign(0)	Gene3D:3.40.50.10190&PDB-ENSP_mappings:8bah.C&AFDB-ENSP_mappings:AF-O60934-F1&PIRSF:PIRSF011869&PANTHER:PTHR12162			0.3570	0.2307	0.3761	0.4673	0.3062	0.453	0.3315	0.2364	0.3537	0.3121	0.4791	0.3619	0.3375	0.3192	0.3366	0.428	0.3105	0.2374	0.2664	0.3419	0.3082	0.4516	0.3532	0.2789	0.3219	0.3287	0.4372	0.4791	gnomADe_EAS	benign	0&1&1&1&1	1&1&1&1&1	25741868&24033266&20734064&24728327&34711928&28827732&32728337&23284679&18191955&26514363&16465622&16857995&18701435&19109789&19124499&20150366&21129811&21700777&23720673&31584889&20386703&18830263&29458332&32957448&19276285&24062231&22300735&31374908&18579371&18768505&23719583&20805886&19584272&21927616&35312585&19706757&29732392&32014908&18638378&25178586&19367277&29963112&33800431&21647442&20004634&19523210&20478923&20571895&22933979&25542228&28610420&29416357&35164849&19393077&24166361&30799775&24113799&26998278&12917199&21166880&21656575&22413803&22430443&23283743&23381647&23979977&25073514&26493193&27845421&28356832&28476809&29433451&32234891&35207542&24382701&24093751&35637613&28345844&34295994&32778093&36632296&36139526&28402931&26622786&21908578&30197789&26064273&20975951&21864546&22631660&26974709&35639187&26622944&22070649&34990726&24594932&26101473&25176580&21215087&22864661&27936167&19917125&24396275&34926254&18394656&22313875&17991492&22245109&15921821&19022265&37894339&37954025&37610496&3871871						FAIL	2	33	-33	-31	0.00	0.00	0.00	0.00	NBN	0.103	1.0570e+00	134876	0.28656	0.34527	0.35703	138615	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_breast_ovarian_cancer_syndrome&Acute_lymphoid_leukemia&Microcephaly&_normal_intelligence_and_immunodeficiency		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&Human_Phenotype_Ontology:HP:0004803&Human_Phenotype_Ontology:HP:0005555&Human_Phenotype_Ontology:HP:0006721&MONDO:MONDO:0004967&MedGen:C0023449&OMIM:613065&Orphanet:513&MONDO:MONDO:0009623&MedGen:C0398791&OMIM:251260&Orphanet:647		NC_000008.11:g.89978251C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212661&SCV000231034&SCV000309102&SCV000475299&SCV000539866&SCV000611719&SCV000634318&SCV001158777&SCV001748580&SCV001856898&SCV002505314&SCV004016040&SCV004233240&SCV005264901&SCV005880919&SCV006311095	single_nucleotide_variant	SO:0001483	ClinGen:CA160987&UniProtKB:O60934																																																																																																																																															0,74	0,35	0,39	0/1	0,0,35,39	TCA	.	.	.			0,0,34,40	64.53		1.0
GRCh38	NBN	D12_12345_1234556_Thyroid_S9	p.Leu34=	ENSP00000265433.4:p.Leu34=	chr8	89982791	89982791.0	C	T	T	89982791	.	C	T	.	PASS	NM_002485	T	synonymous_variant	LOW	NBN	ENSG00000104320	Transcript	ENST00000265433	protein_coding	2/16		c.102G>A	208	102	34	L	ctG/ctA	rs1063045&COSV55371979		-1		SNV	HGNC	HGNC:7652	YES	MANE_Select	NM_002485.5		1	P1	CCDS6249.1	ENSP00000265433	O60934.202		UPI0000073BF4			1			Gene3D:2.60.200.20&PDB-ENSP_mappings:8bah.C&AFDB-ENSP_mappings:AF-O60934-F1&Pfam:PF00498&PIRSF:PIRSF011869&PROSITE_profiles:PS50006&PANTHER:PTHR12162&SMART:SM00240&Superfamily:SSF49879&CDD:cd22667			0.3792	0.3124	0.3818	0.4673	0.3062	0.4519	0.3361	0.3178	0.3584	0.3183	0.4795	0.362	0.3437	0.3222	0.344	0.4293	0.3328	0.3137	0.2664	0.3518	0.3146	0.4511	0.3536	0.2891	0.322	0.3472	0.4374	0.4795	gnomADe_EAS	benign	0&1	1&1	25741868&24033266&20386703&19276285&21987080&20004634&17496786&19523210&20478923&19393077&30799775&26402912&35637613&24645271&18059179&22864661&27936167&19917125&24396275&15921821						FAIL	-16	18	34	-38	0.00	0.00	0.00	0.00	NBN		1.0570e+00	183697	0.31316	0.35272	0.37919	182905	Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Acute_lymphoid_leukemia&Hereditary_breast_ovarian_cancer_syndrome&Microcephaly&_normal_intelligence_and_immunodeficiency		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&Human_Phenotype_Ontology:HP:0004803&Human_Phenotype_Ontology:HP:0005555&Human_Phenotype_Ontology:HP:0006721&MONDO:MONDO:0004967&MedGen:C0023449&OMIM:613065&Orphanet:513&MONDO:MONDO:0003582&MeSH:D061325&MedGen:C0677776&Orphanet:145&MONDO:MONDO:0009623&MedGen:C0398791&OMIM:251260&Orphanet:647		NC_000008.11:g.89982791C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000212662&SCV000309094&SCV000475302&SCV000539867&SCV000634194&SCV001748581&SCV001940516&SCV002048670&SCV002505319&SCV004016041&SCV004233206&SCV005264908&SCV005880920&SCV006311096	single_nucleotide_variant	SO:0001483	ClinGen:CA186157		NBN:4683	SO:0001623&5_prime_UTR_variant&SO:0001819&synonymous_variant										1	1063045																											92					0.967							245.53	v6.1	Unknown		True	NBN, a DNA repair protein, is altered by mutation and amplification in various cancers.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:L34= mutant UNKNOWN.	False	The NBN ENSP00000265433.4:l34= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	90995019						True	False	False	Unknown								False	False		NBN, a DNA repair protein, is altered by mutation and amplification in various cancers.	The NBN ENSP00000265433.4:l34= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:L34= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	NBN	4683.0	ENSP00000265433.4:L34=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NBN"",""entrezGeneId"":4683,""alteration"":""ENSP00000265433.4:L34="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NBN, a DNA repair protein, is altered by mutation and amplification in various cancers."",""variantSummary"":""The NBN ENSP00000265433.4:l34= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NBN ENSP00000265433.4:L34= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						0,89	0,50	0,39	0/1	0,0,44,45	TCA	0.00	0.00	0.00			0,0,51,38	64.64		1.0
GRCh38	RAD21	D12_12345_1234556_Thyroid_S9	p.Ala480=	ENSP00000297338.2:p.Ala480=	chr8	116851978	116851978.0	A	G	G	116851978	.	A	G	.	PASS	NM_006265	G	synonymous_variant	LOW	RAD21	ENSG00000164754	Transcript	ENST00000297338	protein_coding	11/14		c.1440T>C	1638	1440	480	A	gcT/gcC	rs1050838&COSV52055885		-1		SNV	HGNC	HGNC:9811	YES	MANE_Select	NM_006265.3		1	P1	CCDS6321.1	ENSP00000297338	O60216.207		UPI0000133018			1			PDB-ENSP_mappings:6qnx.B&PDB-ENSP_mappings:6wg3.C&PDB-ENSP_mappings:6wge.C&PDB-ENSP_mappings:7w1m.C&PDB-ENSP_mappings:7zjs.B&PDB-ENSP_mappings:7zjs.D&AFDB-ENSP_mappings:AF-O60216-F1&PANTHER:PTHR12585&MobiDB_lite:mobidb-lite			0.1332	0.0076	0.2536	0.1696	0.1501	0.1626	0.1688	0.02761	0.2494	0.2172	0.1677	0.167	0.1843	0.166	0.1652	0.2065	0.136	0.03153	0.0943	0.211	0.2248	0.1736	0.1696	0.1837	0.1662	0.1365	0.1993	0.2536	AMR	benign	0&1	1&1	25741868&18414213&19276285						FAIL	17	-17	-26	-34	0.00	0.00	0.00	0.02	RAD21		3.4100e-01	159805	0.12410	0.17277	0.13319	168582	Cornelia_de_Lange_syndrome_4&not_specified&not_provided&Mungan_syndrome&Inborn_genetic_diseases		MONDO:MONDO:0013864&MedGen:C3553517&OMIM:614701&Orphanet:199&MedGen:CN169374&MedGen:C3661900&Gene:100126595&MONDO:MONDO:0012657&MedGen:C1969653&OMIM:611376&MeSH:D030342&MedGen:C0950123		NC_000008.11:g.116851978A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000194753&SCV000311442&SCV000728786&SCV000846221&SCV001725353&SCV002033412&SCV002033413&SCV005267982	single_nucleotide_variant	SO:0001483	ClinGen:CA173309		RAD21:5885	SO:0001819&synonymous_variant										1	1050838																											121					0.926							195.61	v6.1	Unknown		True	RAD21 encodes a protein involved in DNA repair and chromosome segregation. Germline mutations of RAD21 are associated with an increased risk of developing breast cancer.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RAD21 ENSP00000297338.2:A480= mutant UNKNOWN.	False	The RAD21 ENSP00000297338.2:a480= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	117864217						True	False	False	Unknown								False	False		RAD21 encodes a protein involved in DNA repair and chromosome segregation. Germline mutations of RAD21 are associated with an increased risk of developing breast cancer.	The RAD21 ENSP00000297338.2:a480= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RAD21 ENSP00000297338.2:A480= mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	RAD21	5885.0	ENSP00000297338.2:A480=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RAD21"",""entrezGeneId"":5885,""alteration"":""ENSP00000297338.2:A480="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RAD21 encodes a protein involved in DNA repair and chromosome segregation. Germline mutations of RAD21 are associated with an increased risk of developing breast cancer."",""variantSummary"":""The RAD21 ENSP00000297338.2:a480= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RAD21 ENSP00000297338.2:A480= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						47,65	23,33	24,32	0/1	21,26,37,28	CAG	.	.	.			31,16,33,32	44.29		0.5803571428571429
GRCh38	TNFRSF11B	D12_12345_1234556_Thyroid_S9			chr8	118935561	118935566.0	ACTTTC	A	A	118935561	.	ACTTTC	A	.	PASS		-	intron_variant&NMD_transcript_variant	MODIFIER	TNFRSF11B	ENSG00000164761	Transcript	ENST00000517352	nonsense_mediated_decay		1/4	c.31-2266_31-2262del						rs3081400		-1		deletion	HGNC	HGNC:11909					1			ENSP00000427924		E5RFV7.73	UPI0001E8F749			1						0.3245	0.2201	0.5	0.2282	0.4483	0.3129											0.3801	0.2567	0.6449	0.4117	0.3293	0.2473	0.4407	0.2789	0.452	0.3783	0.3301	0.6449	gnomADg_AMI				23690203&22124616&36292568																																																																												7					1							224.89													chr8	119947800																																																	True	False	False	Unknown		Unknown																						0,7	0,4	0,3	0/1	0,0,5,2	AAC						0,0,2,5	50.86		1.0
GRCh38	FER1L6-AS2	D12_12345_1234556_Thyroid_S9			chr8	124128250		T	[chr5:82376749[T	[chr5:82376749[T	124128250	MantaBND:13562:0:1:0:0:0:0	T	[chr5:82376749[T	.	PASS		.T	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	FER1L6-AS2	ENSG00000253868	Transcript	ENST00000844077	lncRNA		1/1									-1		chromosome_breakpoint	HGNC	HGNC:26534																																																																																																																												6			0,7							7	TTTACAA			MantaBND:13562:0:1:0:0:0:1	0														chr8	125140491				BND																																													True	False	False	Unknown		Unknown																															1,1				1,2	
GRCh38	MYC	D12_12345_1234556_Thyroid_S9			chr8	127739656	127739657.0	AT	A	A	127739656	.	AT	A	.	PASS	NM_002467	-	intron_variant	MODIFIER	MYC	ENSG00000136997	Transcript	ENST00000621592	protein_coding		2/2	c.802+650del						rs5894898		1		deletion	HGNC	HGNC:7553	YES	MANE_Select	NM_002467.6		1	P4	CCDS6359.2	ENSP00000478887	P01106.274		UPI0000576839	P01106-2		1					12	0.2656	0.4032	0.2349	0.2232	0.2078	0.2045											0.2563	0.377	0.2456	0.2214	0.3259	0.2226	0.1939	0.3333	0.2022	0.2605	0.2022	0.4032	AFR										FAIL	2	29	37	-12	0.00	0.00	0.00	0.00	MYC		1.2800e-01																																																											281					0.776							238.18													chr8	128751902																																																	True	True	False	Unknown		Unknown																						127,91	59,48	68,43	0/1	76,51,38,53	AAT						52,75,39,52	15.98		0.41743119266055045
GRCh38	MYC	D12_12345_1234556_Thyroid_S9			chr8	127745331	127745331.0	T	A	A	127745331	.	T	A	.	PASS	NM_002467	A	downstream_gene_variant	MODIFIER	MYC	ENSG00000136997	Transcript	ENST00000621592	protein_coding									rs7465622	2380	1		SNV	HGNC	HGNC:7553	YES	MANE_Select	NM_002467.6		1	P4	CCDS6359.2	ENSP00000478887	P01106.274		UPI0000576839	P01106-2		1						0.9838	0.9992	1	0.9266	1	0.9939											0.9966	0.9983	1	0.9991	1	0.9303	0.9994	1	0.9996	0.9953	0.9942	1	AMR&EUR&gnomADg_AMI&gnomADg_ASJ&gnomADg_MID																																																																																915					0.983							164.15													chr8	128757577																																																	True	True	False	Unknown		Unknown																						0,899	0,432	0,467	0/1	0,0,448,451	CTC	.	.	.			0,0,471,428	64.73		1.0
GRCh38	FAM135B	D12_12345_1234556_Thyroid_S9			chr8	138386873	138386873.0	C	T	T	138386873	.	C	T	.	PASS		T	intron_variant	MODIFIER	FAM135B	ENSG00000147724	Transcript	ENST00000520380	protein_coding		1/3	c.-19-18871G>A						rs2056277		-1	cds_end_NF	SNV	HGNC	HGNC:28029					3			ENSP00000428017		E5RFQ7.60	UPI0001E8F53D			1						0.1579	0.112	0.1571	0.121	0.2406	0.1738											0.2089	0.1312	0.2473	0.1817	0.3023	0.1296	0.2446	0.2257	0.2592	0.2296	0.1763	0.3023	gnomADg_ASJ				26522768&26691610&29121662&33406744&34721519&19083859&27294018&36134022&37239431&19948332						FAIL	-2	-32	48	43	0.00	0.00	0.00	0.00	FAM135B		6.7700e-01																																																											97					0.938							232.61													chr8	139399116																																																	True	False	False	Unknown		Unknown																						53,38	17,14	36,24	0/1	25,28,23,15	ACG	0.00	0.00	0.00			23,30,13,25	25.6		0.4175824175824176
GRCh38		D12_12345_1234556_Thyroid_S9			chr8	142432222		G	<INS>	<INS>	142432222	MantaINS:13637:0:0:0:4:0	G	<INS>	.	PASS		insertion	intergenic_variant	MODIFIER																		insertion																																																																																																																															0,1		0,1							1	C		CCACCTTCACCCCCAACACCACTACCATCACCACCGTCACCTTCACCATCATCCCCCGTAACCACCACCATTACCATCACCACAATAACTA																chr8	143513583	TATAACCATCACCACCATCCCTACCATCACCCTACCACCACCATCACAACCACCACCATTACTGCCACCTCCACCACCATCATCAC			INS																																													True	False	False	Unknown		Unknown																															0,3				0,11	
GRCh38		D12_12345_1234556_Thyroid_S9			chr8	142935422		T	<INS>	<INS>	142935422	MantaINS:13635:0:0:0:3:0	T	<INS>	.	PASS		insertion	feature_elongation&non_coding_transcript_exon_variant	HIGH		ENSG00000294287	Transcript	ENST00000722513	lncRNA	2/2			342							1		insertion			YES																																																																																																																												0,6		0,6							6	CACTGT		CACTGTCACCACCACCACCACCACACCCATCACCACCACCACCACCACACCCATCAG																chr8	144016838	ATCACCACCGTCATCACCACCACCACACCTATCATCACCACACCCATCACCACCATCATCACCACCATCATCATTATCACCACCATCATCATCACCACCATCATCACCAC			INS																																													True	False	False	Unknown		Unknown																															0,2				0,8	
GRCh38		D12_12345_1234556_Thyroid_S9			chr8	143574584	143574584.0	T	C	C	143574584	.	T	C	.	PASS		C	upstream_gene_variant	MODIFIER		ENSG00000279605	Transcript	ENST00000623257	TEC									rs4606077	3774	1		SNV			YES																			0.6663	0.5734	0.6758	0.755	0.7594	0.5982	0.7311	0.6094	0.7308	0.6812	0.7124	0.7076	0.6912	0.7619	0.7234	0.633	0.7078	0.6112	0.7423	0.7367	0.6844	0.7328	0.7094	0.6293	0.7655	0.7051	0.6199	0.7655	gnomADg_NFE			1	29121662&33406744&30483616&27294018&37304287&33067605																																																																												652					0.997							246.42													chr8	144656754																																																	True	False	False	Unknown		Unknown																						0,650	0,358	0,292	0/1	0,0,312,338	CTA	.	.	.			0,0,352,298	64.73		1.0
GRCh38		D12_12345_1234556_Thyroid_S9			chr8	143574595	143574595.0	G	A	A	143574595	.	G	A	.	PASS		A	upstream_gene_variant	MODIFIER		ENSG00000279605	Transcript	ENST00000623257	TEC									rs1869434	3763	1		SNV			YES																			0.6621	0.562	0.6744	0.754	0.7594	0.5941	0.7306	0.6004	0.7292	0.6811	0.7124	0.707	0.6874	0.7619	0.7224	0.6319	0.705	0.6016	0.7423	0.7359	0.6846	0.7329	0.7091	0.6224	0.7655	0.7042	0.619	0.7655	gnomADg_NFE																																																																																680					0.997							247.03													chr8	144656765																																																	True	False	False	Unknown		Unknown																						0,678	0,378	0,300	0/1	0,0,345,333	CGG	0.00	0.00	0.00			0,0,363,315	64.73		1.0
GRCh38	RECQL4	D12_12345_1234556_Thyroid_S9	p.Leu1043=	ENSP00000482313.2:p.Leu1043=	chr8	144512253	144512253.0	A	G	G	144512253	.	A	G	.	PASS	NM_004260	G	synonymous_variant	LOW	RECQL4	ENSG00000160957	Transcript	ENST00000617875	protein_coding	18/21		c.3127T>C	3176	3127	1043	L	Ttg/Ctg	rs4925828&COSV56741332		-1		SNV	HGNC	HGNC:9949	YES	MANE_Select	NM_004260.4		1	P1	CCDS75804.1	ENSP00000482313	O94761.211		UPI0000E5E124			1			PDB-ENSP_mappings:5lst.A&PANTHER:PTHR13710&AFDB-ENSP_mappings:AF-O94761-F1			0.9461	0.9924	0.928	0.7966	0.998	0.9969	0.9889	0.996	0.9089	1	0.7325	0.9964	0.9969	0.9997	0.9883	0.9985	0.9858	0.9942	1	0.9524	1	0.7874	0.9977	1	0.9995	0.9887	0.9971	1	gnomADe_ASJ&gnomADg_AMI&gnomADg_ASJ&gnomADg_MID	benign	0&1	1&1	32708070						FAIL	10	-15	-45	-23	0.01	0.00	0.00	0.00	RECQL4		1.5190e+00	167573	0.99841	0.97283	0.94609	178005	Rapadilino_syndrome&Baller-Gerold_syndrome&Rothmund-Thomson_syndrome_type_2&not_specified&not_provided		MONDO:MONDO:0009955&MedGen:C1849453&OMIM:266280&Orphanet:3021&MONDO:MONDO:0009039&MedGen:C0265308&OMIM:218600&Orphanet:1225&MONDO:MONDO:0016369&MedGen:C5203410&OMIM:268400&Orphanet:221016&MedGen:CN169374&MedGen:C3661900		NC_000008.11:g.144512253A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000203397&SCV001729429&SCV002033499&SCV002033500&SCV002033501&SCV005270312	single_nucleotide_variant	SO:0001483	ClinGen:CA180368		RECQL4:9401	SO:0001819&synonymous_variant										1	4925828																											801					0.999							247.04	v6.1	Unknown		True	RECQL4 encodes a DNA helicase that is involved in DNA replication and repair. Germline mutations of RECQL4 are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes and predispose to osteosarcomas, among other cancers.	False	01/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RECQL4 ENSP00000482313.2:L1043= mutant UNKNOWN.	False	The RECQL4 ENSP00000482313.2:l1043= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	145737636						True	False	False	Unknown								False	False		RECQL4 encodes a DNA helicase that is involved in DNA replication and repair. Germline mutations of RECQL4 are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes and predispose to osteosarcomas, among other cancers.	The RECQL4 ENSP00000482313.2:l1043= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RECQL4 ENSP00000482313.2:L1043= mutant UNKNOWN.						v6.1	01/17/2017		GRCh38	RECQL4	9401.0	ENSP00000482313.2:L1043=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RECQL4"",""entrezGeneId"":9401,""alteration"":""ENSP00000482313.2:L1043="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RECQL4 encodes a DNA helicase that is involved in DNA replication and repair. Germline mutations of RECQL4 are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes and predispose to osteosarcomas, among other cancers."",""variantSummary"":""The RECQL4 ENSP00000482313.2:l1043= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RECQL4 ENSP00000482313.2:L1043= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/17/2017""}"	True	True	False	Unknown		Unknown																						0,800	0,417	0,383	0/1	0,0,398,402	AAG	.	.	.			0,0,429,371	64.73		1.0
GRCh38	RECQL4	D12_12345_1234556_Thyroid_S9	p.S92P	ENSP00000482313.2:p.Ser92Pro	chr8	144517130	144517130.0	A	G	G	144517130	.	A	G	.	PASS	NM_004260	G	missense_variant	MODERATE	RECQL4	ENSG00000160957	Transcript	ENST00000617875	protein_coding	4/21		c.274T>C	323	274	92	S/P	Tct/Cct	rs2721190&COSV52881402		-1		SNV	HGNC	HGNC:9949	YES	MANE_Select	NM_004260.4		1	P1	CCDS75804.1	ENSP00000482313	O94761.211		UPI0000E5E124			1	tolerated(1)	benign(0)	MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Pfam:PF11719&AFDB-ENSP_mappings:AF-O94761-F1			0.9433	0.9781	0.9222	0.8065	0.998	0.9959	0.9893	0.9845	0.9076	1	0.7579	0.9963	0.996	0.9997	0.9888	0.9985	0.983	0.9832	1	0.9493	1	0.8036	0.9977	1	0.9995	0.9858	0.9969	1	gnomADe_ASJ&gnomADg_AMI&gnomADg_ASJ&gnomADg_MID	benign	0&1	1&1	24728327&32708070&25653542						FAIL	9	-10	0	2	0.00	0.00	0.00	0.00	RECQL4		1.5190e+00	135161	0.99517	0.97332	0.94329	138900	Rapadilino_syndrome&Baller-Gerold_syndrome&Rothmund-Thomson_syndrome_type_2&not_specified&not_provided		MONDO:MONDO:0009955&MedGen:C1849453&OMIM:266280&Orphanet:3021&MONDO:MONDO:0009039&MedGen:C0265308&OMIM:218600&Orphanet:1225&MONDO:MONDO:0016369&MedGen:C5203410&OMIM:268400&Orphanet:221016&MedGen:CN169374&MedGen:C3661900		NC_000008.11:g.144517130A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000203398&SCV001729433&SCV002033522&SCV002033523&SCV002033524&SCV005270344	single_nucleotide_variant	SO:0001483	ClinGen:CA161879		RECQL4:9401	SO:0001583&missense_variant										1	2721190																											719					0.993							248.12	v6.1	Unknown		True	RECQL4 encodes a DNA helicase that is involved in DNA replication and repair. Germline mutations of RECQL4 are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes and predispose to osteosarcomas, among other cancers.	False	01/17/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RECQL4 ENSP00000482313.2:S92P mutant UNKNOWN.	False	The RECQL4 ENSP00000482313.2:s92p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr8	145742514						True	False	False	Unknown								False	False		RECQL4 encodes a DNA helicase that is involved in DNA replication and repair. Germline mutations of RECQL4 are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes and predispose to osteosarcomas, among other cancers.	The RECQL4 ENSP00000482313.2:s92p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RECQL4 ENSP00000482313.2:S92P mutant UNKNOWN.						v6.1	01/17/2017		GRCh38	RECQL4	9401.0	ENSP00000482313.2:S92P			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""RECQL4"",""entrezGeneId"":9401,""alteration"":""ENSP00000482313.2:S92P"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""RECQL4 encodes a DNA helicase that is involved in DNA replication and repair. Germline mutations of RECQL4 are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes and predispose to osteosarcomas, among other cancers."",""variantSummary"":""The RECQL4 ENSP00000482313.2:s92p mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with RECQL4 ENSP00000482313.2:S92P mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/17/2017""}"	True	True	False	Unknown		Unknown																						0,714	0,349	0,365	0/1	0,0,331,383	GAC	.	.	.			0,0,346,368	64.73		1.0
GRCh38	JAK2	D12_12345_1234556_Thyroid_S9	p.D686N	ENSP00000371067.4:p.Asp686Asn	chr9	5078369	5078369.0	G	A	A	5078369	.	G	A	.	PASS	NM_004972	A	missense_variant	MODERATE	JAK2	ENSG00000096968	Transcript	ENST00000381652	protein_coding	16/25		c.2056G>A	2523	2056	686	D/N	Gac/Aac	rs2130590644		1		SNV	HGNC	HGNC:6192	YES	MANE_Select	NM_004972.4		1	P1	CCDS6457.1	ENSP00000371067	O60674.243		UPI000012DA9E			1	deleterious_low_confidence(0.01)	benign(0.265)	PDB-ENSP_mappings:4fvp.A&PDB-ENSP_mappings:4fvq.A&PDB-ENSP_mappings:4fvr.A&PDB-ENSP_mappings:5i4n.A&PDB-ENSP_mappings:5usz.A&PDB-ENSP_mappings:5ut0.A&PDB-ENSP_mappings:5ut1.A&PDB-ENSP_mappings:5ut2.A&PDB-ENSP_mappings:5ut3.A&PDB-ENSP_mappings:5ut4.A&PDB-ENSP_mappings:5ut5.A&PDB-ENSP_mappings:5ut6.A&PDB-ENSP_mappings:5wij.A&PDB-ENSP_mappings:5wik.B&PDB-ENSP_mappings:5wil.A&PDB-ENSP_mappings:5wim.A&PDB-ENSP_mappings:5win.A&PDB-ENSP_mappings:6brw.A&PDB-ENSP_mappings:6bs0.A&PDB-ENSP_mappings:6bss.A&PDB-ENSP_mappings:6d2i.A&PDB-ENSP_mappings:6d2i.B&PDB-ENSP_mappings:6g3c.A&PDB-ENSP_mappings:6g3c.B&PDB-ENSP_mappings:6m9h.A&PDB-ENSP_mappings:6oav.A&PDB-ENSP_mappings:6obb.A&PDB-ENSP_mappings:6obf.A&PDB-ENSP_mappings:6obl.A&PDB-ENSP_mappings:6occ.A&PDB-ENSP_mappings:6xjk.A&PDB-ENSP_mappings:7f7w.A&PDB-ENSP_mappings:7f7w.B&PDB-ENSP_mappings:7jyo.A&PDB-ENSP_mappings:7jyq.A&PDB-ENSP_mappings:7t0p.A&PDB-ENSP_mappings:7t0p.B&PDB-ENSP_mappings:7t1t.A&PDB-ENSP_mappings:8b8n.A&PDB-ENSP_mappings:8b8u.A&PDB-ENSP_mappings:8b8u.B&PDB-ENSP_mappings:8b99.A&PDB-ENSP_mappings:8b9e.A&PDB-ENSP_mappings:8b9h.A&PDB-ENSP_mappings:8ba2.A&PDB-ENSP_mappings:8ba3.A&PDB-ENSP_mappings:8ba4.A&PDB-ENSP_mappings:8ba4.B&PDB-ENSP_mappings:8bab.A&PDB-ENSP_mappings:8bak.A&PDB-ENSP_mappings:8c08.A&PDB-ENSP_mappings:8c08.B&PDB-ENSP_mappings:8c09.A&PDB-ENSP_mappings:8c0a.A&PDB-ENSP_mappings:8c0a.B&PDB-ENSP_mappings:8ex0.A&PDB-ENSP_mappings:8ex1.A&PDB-ENSP_mappings:8ex2.A&PIRSF:PIRSF000636&Gene3D:1.10.510.10&Pfam:PF07714&SMART:SM00219&PANTHER:PTHR45807&PROSITE_profiles:PS50011&CDD:cd05078&Superfamily:SSF56112&AFDB-ENSP_mappings:AF-O60674-F1																																									FAIL	5	-7	-37	36	0.00	0.01	0.00	0.00	JAK2	0.368	8.4800e-01																																																											88					0.989							244.69	v6.1	Unknown		True	JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematologic malignancies.	False	10/05/2021	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2 ENSP00000371067.4:D686N mutant UNKNOWN.	False	The JAK2 ENSP00000371067.4:d686n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	5078369						True	False	False	Unknown								False	False		JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematologic malignancies.	The JAK2 ENSP00000371067.4:d686n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2 ENSP00000371067.4:D686N mutant UNKNOWN.						v6.1	10/05/2021		GRCh38	JAK2	3717.0	ENSP00000371067.4:D686N			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""JAK2"",""entrezGeneId"":3717,""alteration"":""ENSP00000371067.4:D686N"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematologic malignancies."",""variantSummary"":""The JAK2 ENSP00000371067.4:d686n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2 ENSP00000371067.4:D686N mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""10/05/2021""}"	True	True	False	Unknown		Unknown																						84,3	42,2	42,1	0/1	42,42,2,1	AGA	0.00	0.00	1.00			42,42,3,0	10.74		0.034482758620689655
GRCh38	PDCD1LG2	D12_12345_1234556_Thyroid_S9	p.F229S	ENSP00000380855.3:p.Phe229Ser	chr9	5557672	5557672.0	T	C	C	5557672	.	T	C	.	PASS	NM_025239	C	missense_variant	MODERATE	PDCD1LG2	ENSG00000197646	Transcript	ENST00000397747	protein_coding	5/7		c.686T>C	973	686	229	F/S	tTc/tCc	rs7854303&COSV107511955		1		SNV	HGNC	HGNC:18731	YES	MANE_Select	NM_025239.4		1	P1	CCDS6465.1	ENSP00000380855	Q9BQ51.175		UPI0000050EF2	Q9BQ51-1		1	tolerated(1)	benign(0)	PDB-ENSP_mappings:8j3v.A&AFDB-ENSP_mappings:AF-Q9BQ51-F1&PANTHER:PTHR25466&Transmembrane_helices:TMhelix&Phobius:TRANSMEMBRANE&Low_complexity_(Seg):seg			0.9978	0.9947	0.9971	1	0.998	1	0.9994	0.9964	0.9972	1	1	1	0.9948	0.9996	0.9982	0.9999	0.9984	0.9967	1	0.9965	1	1	1	0.9796	0.9994	0.9962	1	1	EAS&SAS&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADg_AMI&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_SAS		0&1	0&1	22039410&36138231&33142805&26295610						FAIL	4	27	-49	27	0.00	0.01	0.00	0.00	PDCD1LG2	0.029	1.5160e+00																																																											473					0.975							243.53	v6.1	Unknown		True	PDCD1LG2, a ligand of T-cell receptors involved in immune suppression, is overexpressed in various cancer types.	False	01/16/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDCD1LG2 ENSP00000380855.3:F229S mutant UNKNOWN.	False	The PDCD1LG2 ENSP00000380855.3:f229s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	5557672						True	False	False	Unknown								False	False		PDCD1LG2, a ligand of T-cell receptors involved in immune suppression, is overexpressed in various cancer types.	The PDCD1LG2 ENSP00000380855.3:f229s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDCD1LG2 ENSP00000380855.3:F229S mutant UNKNOWN.						v6.1	01/16/2019		GRCh38	PDCD1LG2	80380.0	ENSP00000380855.3:F229S			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PDCD1LG2"",""entrezGeneId"":80380,""alteration"":""ENSP00000380855.3:F229S"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PDCD1LG2, a ligand of T-cell receptors involved in immune suppression, is overexpressed in various cancer types."",""variantSummary"":""The PDCD1LG2 ENSP00000380855.3:f229s mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDCD1LG2 ENSP00000380855.3:F229S mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/16/2019""}"	True	True	False	Unknown		Unknown																						0,461	0,227	0,234	0/1	0,0,225,236	TTC	.	.	.			0,0,179,282	64.73		1.0
GRCh38	PTPRD	D12_12345_1234556_Thyroid_S9	p.Gly1418=	ENSP00000370593.3:p.Gly1418=	chr9	8389364	8389364.0	C	G	G	8389364	.	C	G	.	PASS	NM_002839	G	synonymous_variant	LOW	PTPRD	ENSG00000153707	Transcript	ENST00000381196	protein_coding	37/46		c.4254G>C	5276	4254	1418	G	ggG/ggC	rs2279776&COSV61928282		-1		SNV	HGNC	HGNC:9668	YES	MANE_Select	NM_002839.4		5	P1	CCDS43786.1	ENSP00000370593	P23468.233		UPI0000132990	P23468-1		1			Gene3D:3.90.190.10&AFDB-ENSP_mappings:AF-P23468-F1&Phobius:CYTOPLASMIC_DOMAIN&Pfam:PF00102&PROSITE_profiles:PS50055&PANTHER:PTHR46957&SMART:SM00194&Superfamily:SSF52799&CDD:cd14624			0.5563	0.6195	0.451	0.6329	0.4354	0.591	0.4485	0.5899	0.4894	0.4596	0.6185	0.4908	0.5161	0.4248	0.4666	0.5525	0.4982	0.5825	0.6407	0.4901	0.4639	0.6588	0.4923	0.517	0.4328	0.4877	0.565	0.6588	gnomADg_EAS	benign	0&1	1&1	27229762&27035118&23069849&36755664&24518026						FAIL	34	-34	-17	1	0.00	0.00	0.00	0.00	PTPRD		2.0400e-01	1225000	0.48470	0.49917	0.55631	1216267	not_provided		MedGen:C3661900		NC_000009.12:g.8389364C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001835241&SCV005273767	single_nucleotide_variant	SO:0001483	ClinGen:CA4983419		PTPRD:5789	SO:0001819&synonymous_variant										1	2279776																											69					1							244.58	v6.1	Unknown		True	PTPRD, a tumor suppressor and receptor protein tyrosine phosphatase, is altered by mutation or deletion in various cancer types including skin and lung cancers.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRD ENSP00000370593.3:G1418= mutant UNKNOWN.	False	The PTPRD ENSP00000370593.3:g1418= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	8389364						True	False	False	Unknown								False	False		PTPRD, a tumor suppressor and receptor protein tyrosine phosphatase, is altered by mutation or deletion in various cancer types including skin and lung cancers.	The PTPRD ENSP00000370593.3:g1418= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRD ENSP00000370593.3:G1418= mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	PTPRD	5789.0	ENSP00000370593.3:G1418=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRD"",""entrezGeneId"":5789,""alteration"":""ENSP00000370593.3:G1418="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRD, a tumor suppressor and receptor protein tyrosine phosphatase, is altered by mutation or deletion in various cancer types including skin and lung cancers."",""variantSummary"":""The PTPRD ENSP00000370593.3:g1418= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRD ENSP00000370593.3:G1418= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						34,35	23,14	11,21	0/1	16,18,17,18	ACC	.	.	.			19,15,12,23	34.96		0.5072463768115942
GRCh38	PTPRD	D12_12345_1234556_Thyroid_S9	p.R995C	ENSP00000370593.3:p.Arg995Cys	chr9	8485834	8485834.0	G	A	A	8485834	.	G	A	.	PASS	NM_002839	A	missense_variant	MODERATE	PTPRD	ENSG00000153707	Transcript	ENST00000381196	protein_coding	28/46		c.2983C>T	4005	2983	995	R/C	Cgt/Tgt	rs35929428&CM136299&COSV61938804		-1		SNV	HGNC	HGNC:9668	YES	MANE_Select	NM_002839.4		5	P1	CCDS43786.1	ENSP00000370593	P23468.233		UPI0000132990	P23468-1		1	deleterious_low_confidence(0.02)	benign(0)	Gene3D:2.60.40.10&AFDB-ENSP_mappings:AF-P23468-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00041&PROSITE_profiles:PS50853&SMART:SM00060&Superfamily:SSF49265&CDD:cd00063			0.0775	0.0053	0.0951	0.0784	0.0964	0.1421	0.09185	0.01858	0.08846	0.08212	0.09539	0.1028	0.06783	0.09103	0.09108	0.1292	0.07373	0.02035	0.1513	0.08506	0.07719	0.08411	0.108	0.07143	0.09216	0.08302	0.1308	0.1513	gnomADg_AMI	benign	0&1&1	1&1&1	28497593&27035118&30363591&30564000&26181631&33923295&30648269&36000237&36755664						FAIL	-19	23	10	4	0.00	0.00	0.00	0.06	PTPRD	0.139	2.0400e-01	3055817	0.06881		0.07748	3221932	PTPRD-related_disorder		.		NC_000009.12:g.8485834G>A	no_assertion_criteria_provided	Benign			SCV004794575	single_nucleotide_variant	SO:0001483	ClinGen:CA4983951		PTPRD:5789&LOC126860578:126860578	SO:0001583&missense_variant&SO:0001627&intron_variant										1	35929428																											95					1							245.39	v6.1	Unknown		True	PTPRD, a tumor suppressor and receptor protein tyrosine phosphatase, is altered by mutation or deletion in various cancer types including skin and lung cancers.	False	04/23/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRD ENSP00000370593.3:R995C mutant UNKNOWN.	False	The PTPRD ENSP00000370593.3:r995c mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	8485834						True	False	False	Unknown								False	False		PTPRD, a tumor suppressor and receptor protein tyrosine phosphatase, is altered by mutation or deletion in various cancer types including skin and lung cancers.	The PTPRD ENSP00000370593.3:r995c mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRD ENSP00000370593.3:R995C mutant UNKNOWN.						v6.1	04/23/2018		GRCh38	PTPRD	5789.0	ENSP00000370593.3:R995C			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PTPRD"",""entrezGeneId"":5789,""alteration"":""ENSP00000370593.3:R995C"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PTPRD, a tumor suppressor and receptor protein tyrosine phosphatase, is altered by mutation or deletion in various cancer types including skin and lung cancers."",""variantSummary"":""The PTPRD ENSP00000370593.3:r995c mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTPRD ENSP00000370593.3:R995C mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/23/2018""}"	True	True	False	Unknown		Unknown																						55,40	25,25	30,15	0/1	26,29,23,17	CGT	0.00	0.00	0.00			26,29,22,18	25.95		0.42105263157894735
GRCh38	HMGN2P16	D12_12345_1234556_Thyroid_S9			chr9	15592736		A	[chr17:48231219[A	[chr17:48231219[A	15592736	MantaBND:10143:0:1:0:0:0:1	A	[chr17:48231219[A	.	PASS		.A	downstream_gene_variant	MODIFIER	HMGN2P16	ENSG00000231376	Transcript	ENST00000456802	processed_pseudogene										4122	1		chromosome_breakpoint	HGNC	HGNC:31330	YES																																																																																																																											1			0,6							6	GGAGGG			MantaBND:10143:0:1:0:0:0:0	2														chr9	15592734				BND																																													True	False	False	Unknown		Unknown																															0,2				0,2	
GRCh38	PLIN2	D12_12345_1234556_Thyroid_S9			chr9	19139965		A	[chr20:23781023[A	[chr20:23781023[A	19139965	MantaBND:11825:0:1:0:0:0:1	A	[chr20:23781023[A	.	PASS		.A	feature_truncation&intron_variant&non_coding_transcript_variant	HIGH	PLIN2	ENSG00000147872	Transcript	ENST00000494753	protein_coding_CDS_not_defined		1/1									-1		chromosome_breakpoint	HGNC	HGNC:248					2																																																																																																																							3			0,5							5	AGAGC			MantaBND:11825:0:1:0:0:0:0	3														chr9	19139963				BND																																													True	False	False	Unknown		Unknown																															0,0				0,3	
GRCh38	MLLT3	D12_12345_1234556_Thyroid_S9			chr9	20360748		G	<INS>	<INS>	20360748	MantaINS:6871:1:1:0:3:0	G	<INS>	.	PASS	NM_004529	insertion	feature_elongation&coding_sequence_variant	HIGH	MLLT3	ENSG00000171843	Transcript	ENST00000380338	protein_coding	8/11			1667	1424	475					-1		insertion	HGNC	HGNC:7136	YES	MANE_Select	NM_004529.4		1	P4	CCDS6494.1	ENSP00000369695	P42568.195	A0A0S2Z448.45	UPI00002111CB	P42568-1		1			Gene3D:1.20.1270.290&AFDB-ENSP_mappings:AF-P42568-F1&PANTHER:PTHR47827&MobiDB_lite:mobidb-lite																																																																																																												0,43		0,43							43	TTGTTGGTTTTTAGTAAGGGTGGTGGAGGTTCGTGATGTAGGG		TTGTTGGTTTTTAGTAAGGGTGGTGGAGGTTCGTGATGTAGGGTTGTTGAATTTTGTCAAAGGCCTTTTCTGCATCTATTGAGATAATCATGTGGTTTTTGTCTTTGGTT																chr9	20360746	CTCCTCTTGTTGAATTGATCCCTTTACCATTATGTAATGGCCTTCTTTGTCTCTTTTGATCT			INS																																													True	True	False	Unknown		Unknown																															4,2				8,1	
GRCh38	CDKN2A	D12_12345_1234556_Thyroid_S9			chr9	21968653	21968653.0	G	C	C	21968653	.	G	C	.	PASS	NM_000077	C	intron_variant	MODIFIER	CDKN2A	ENSG00000147889	Transcript	ENST00000304494	protein_coding		2/2	c.458-411C>G						rs111532782&COSV58695475		-1		SNV	HGNC	HGNC:1787	YES	MANE_Select	NM_000077.5		1	P2	CCDS6510.1	ENSP00000307101	P42771.244	K7PML8.75	UPI0000047FDA	P42771-1		1						0.0010	0	0	0	0.004	0.001	0.008344	0.0013	0.001714	0.0003596	0	0.001035	0.002995	0.009785	0.008161	0.00443	0.005119	0.001659	0.02083	0.002156	0.0008641	0	0.001035	0.003401	0.0092	0.004257	0.001863	0.02083	gnomADg_AMI		0&1	0&1							FAIL	10	-13	-12	-15	0.00	0.00	0.05	0.00	CDKN2A		7.9100e-01																																																											1204					0.998							248.14													chr9	21968652																																																	True	True	False	Unknown		Unknown																						580,622	303,311	277,311	0/1	306,274,312,310	TGA	.	.	.			295,285,319,303	63.95		0.5174708818635607
GRCh38	CDKN2B	D12_12345_1234556_Thyroid_S9			chr9	22012052	22012052.0	T	C	C	22012052	.	T	C	.	PASS	NM_004936	C	upstream_gene_variant	MODIFIER	CDKN2B	ENSG00000147883	Transcript	ENST00000276925	protein_coding									rs13298881	2747	-1		SNV	HGNC	HGNC:1788	YES	MANE_Select	NM_004936.4		1	P1	CCDS6512.1	ENSP00000276925	P42772.201	K7PPU3.87	UPI000012743C	P42772-1		1						0.0473	0.0363	0.0735	0	0.1213	0.0164	0.08246	0.0375	0.07683	0.08189	6.982e-05	0.06994	0.1114	0.105	0.08787	0.02683	0.07626	0.03857	0.177	0.08792	0.08127	0.0005785	0.0643	0.1565	0.1056	0.09138	0.02361	0.177	gnomADg_AMI			1	19258477&24875940&19819472&21270820&23816148&37947095																																																																												324					0.991							248.14													chr9	22012051																																																	True	True	False	Unknown		Unknown																						166,155	73,82	93,73	0/1	88,78,79,76	ATT	.	.	.			89,77,90,65	36.42		0.48286604361370716
GRCh38	LINGO2	D12_12345_1234556_Thyroid_S9			chr9	27985940	27985940.0	C	T	T	27985940	.	C	T	.	PASS		T	intron_variant	MODIFIER	LINGO2	ENSG00000174482	Transcript	ENST00000698404	protein_coding		8/8	c.-36+26415G>A						rs7041158		-1	cds_end_NF	SNV	HGNC	HGNC:21207								ENSP00000513699		A0A8V8TNG1.10	UPI0020B05DA8									0.3770	0.4274	0.353	0.3264	0.4046	0.3497											0.3741	0.4034	0.3731	0.356	0.3807	0.3408	0.4298	0.3014	0.3559	0.3503	0.3599	0.4298	gnomADg_FIN				26691610&29121662&33406744&30483659&33857205&32451905&31745634&27294018&37239431&33546406&38522119						FAIL	-3	31	41	-50	0.00	0.00	0.00	0.00	LINGO2																																																													74					0.973							243.78													chr9	27985938																																																	True	False	False	Unknown		Unknown																						37,35	15,17	22,18	0/1	16,21,19,16	TCT	0.00	0.00	0.00			20,17,13,22	33.73		0.4861111111111111
GRCh38	FANCG	D12_12345_1234556_Thyroid_S9	p.R513Q	ENSP00000367910.4:p.Arg513Gln	chr9	35075025	35075025.0	C	T	T	35075025	.	C	T	.	PASS	NM_004629	T	missense_variant	MODERATE	FANCG	ENSG00000221829	Transcript	ENST00000378643	protein_coding	12/14		c.1538G>A	1956	1538	513	R/Q	cGg/cAg	rs17885240&COSV62720716		-1		SNV	HGNC	HGNC:3588	YES	MANE_Select	NM_004629.2		1	P2	CCDS6574.1	ENSP00000367910	O15287.217	Q53XM5.147	UPI0000000CB4			1	tolerated(0.05)	benign(0.005)	Gene3D:1.25.40.10&PDB-ENSP_mappings:7kzp.G&PDB-ENSP_mappings:7kzp.H&PDB-ENSP_mappings:7kzq.G&PDB-ENSP_mappings:7kzq.H&PDB-ENSP_mappings:7kzr.G&PDB-ENSP_mappings:7kzr.H&PDB-ENSP_mappings:7kzs.G&PDB-ENSP_mappings:7kzs.H&PDB-ENSP_mappings:7kzt.G&PDB-ENSP_mappings:7kzt.H&PDB-ENSP_mappings:7kzv.G&PDB-ENSP_mappings:7kzv.H&AFDB-ENSP_mappings:AF-O15287-F1&PANTHER:PTHR15254&Superfamily:SSF48452&Low_complexity_(Seg):seg			0.0030	0.0015	0	0	0.0129	0	0.01034	0.001732	0.002146	0.006887	0	0.02194	0.003992	0.01176	0.007318	0.0008232	0.00826	0.002021	0	0.001896	0.008065	0	0.03159	0	0.01122	0.007561	0.0006211	0.03159	gnomADg_FIN	uncertain_significance&_benign&_likely_benign&benign&likely_benign&benign/likely_benign	0&1	1&1	25741868&24728327						FAIL	-39	34	-11	31	0.01	0.01	0.00	0.00	FANCG	0.016	1.0500e+00	134361	0.00715	0.00876	0.00300	138100	Inclusion_Body_Myopathy&_Dominant&Amyotrophic_Lateral_Sclerosis&_Dominant&FANCG-related_disorder&not_specified&not_provided&Fanconi_anemia&Fanconi_anemia_complementation_group_G		MedGen:CN239244&MedGen:CN239175&.&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0019391&MeSH:D005199&MedGen:C0015625&OMIM:PS227650&Orphanet:84&MONDO:MONDO:0013565&MedGen:C3469527&OMIM:614082&Orphanet:84		NC_000009.12:g.35075025C>T	criteria_provided&_conflicting_classifications	Conflicting_classifications_of_pathogenicity	Uncertain_significance(1)&Benign(6)&Likely_benign(4)		SCV000288623&SCV000484369&SCV000484370&SCV000594705&SCV001330891&SCV001653325&SCV001834775&SCV003844910&SCV004017686&SCV004157696&SCV004812750	single_nucleotide_variant	SO:0001483	ClinGen:CA159600&UniProtKB:O15287																																																																																																																																															526,462	266,250	260,212	0/1	263,263,215,247	CCG	0.00	0.00	0.00			255,271,219,243	28.24		0.4676113360323887
GRCh38	PAX5	D12_12345_1234556_Thyroid_S9	p.Tyr370=	ENSP00000350844.4:p.Tyr370=	chr9	36840626	36840626.0	G	A	A	36840626	.	G	A	.	PASS	NM_016734	A	synonymous_variant	LOW	PAX5	ENSG00000196092	Transcript	ENST00000358127	protein_coding	10/10		c.1110C>T	1347	1110	370	Y	taC/taT	rs3780135&COSV63910740		-1		SNV	HGNC	HGNC:8619	YES	MANE_Select	NM_016734.3		1	P1	CCDS6607.1	ENSP00000350844	Q02548.210		UPI000013136C	Q02548-1		1			AFDB-ENSP_mappings:AF-Q02548-F1&Pfam:PF12403&Low_complexity_(Seg):seg			0.7420	0.3275	0.8415	0.8899	0.9473	0.8681	0.9242	0.3639	0.8683	0.8878	0.8979	0.9512	0.8471	0.9505	0.8919	0.8611	0.7782	0.3871	0.8958	0.8639	0.8865	0.8921	0.9541	0.8367	0.9472	0.8259	0.8489	0.9541	gnomADg_FIN	benign&not_provided	0&1	1&1	24728327&21813177&31565544&30214228						FAIL	-9	10	10	-1	0.00	0.02	0.00	0.00	PAX5		3.6100e-01	134998	0.76312	0.86867	0.74201	138737	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000009.12:g.36840626G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001872198&SCV003201893&SCV005265644	single_nucleotide_variant	SO:0001483	ClinGen:CA161360		PAX5:5079	SO:0001583&missense_variant&SO:0001619&non-coding_transcript_variant&SO:0001819&synonymous_variant										1	3780135																											983					0.998							247.15	v6.1	Unknown		True	PAX5, a transcription factor, is frequently rearranged in lymphomas and leukemias.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX5 ENSP00000350844.4:Y370= mutant UNKNOWN.	False	The PAX5 ENSP00000350844.4:y370= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	36840623						True	False	False	Unknown								False	False		PAX5, a transcription factor, is frequently rearranged in lymphomas and leukemias.	The PAX5 ENSP00000350844.4:y370= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX5 ENSP00000350844.4:Y370= mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	PAX5	5079.0	ENSP00000350844.4:Y370=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""PAX5"",""entrezGeneId"":5079,""alteration"":""ENSP00000350844.4:Y370="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""PAX5, a transcription factor, is frequently rearranged in lymphomas and leukemias."",""variantSummary"":""The PAX5 ENSP00000350844.4:y370= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX5 ENSP00000350844.4:Y370= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						0,981	0,485	0,496	0/1	0,0,511,470	AGT	0.00	0.00	0.00			0,0,457,524	64.73		1.0
GRCh38	IGFBPL1	D12_12345_1234556_Thyroid_S9			chr9	38406791	38406795.0	A	ATTAT	ATTAT	38406791	.	A	ATTAT	.	PASS	NM_001007563	TTAT	3_prime_UTR_variant	MODIFIER	IGFBPL1	ENSG00000137142	Transcript	ENST00000377694	protein_coding	5/5		c.*2432_*2435dup	3302-3303					rs16402		-1		insertion	HGNC	HGNC:20081	YES	MANE_Select	NM_001007563.3		2	P1	CCDS35017.1	ENSP00000366923	Q8WX77.158		UPI000006F856									0.6865	0.6392	0.7406	0.7272	0.7028	0.6534											0.689	0.6604	0.8051	0.7111	0.7465	0.7443	0.6307	0.7585	0.701	0.7042	0.6889	0.8051	gnomADg_AMI				33801242																	1.6660e+00																																																											228					0.952							247.19													chr9	38406788																																																	True	False	False	Unknown		Unknown																						114,103	53,56	61,47	0/1	60,54,49,54	AAT						69,45,50,53	32.53		0.47465437788018433
GRCh38		D12_12345_1234556_Thyroid_S9			chr9	68699505	68699508.0	C	CCTT	CCTT	68699505	.	C	CCTT	.	PASS		CTT	downstream_gene_variant	MODIFIER		ENSG00000300573	Transcript	ENST00000772790	lncRNA									rs2067294	3023	-1		insertion			YES																			0.7580	0.8729	0.6614	0.7946	0.6571	0.7372											0.7146	0.8473	0.6189	0.6864	0.6252	0.7903	0.6116	0.7483	0.6541	0.7348	0.7316	0.8729	AFR				33801242																																																																												129					0.899							237.04													chr9	71314421																																																	True	False	False	Unknown		Unknown																						0,116	0,61	0,55	0/1	0,0,71,45	TCC						0,0,58,58	63.45		1.0
GRCh38	GNAQ	D12_12345_1234556_Thyroid_S9			chr9	77728671	77728672.0	G	GA	GA	77728671	.	G	GA	.	PASS	NM_002072	A	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	GNAQ	ENSG00000156052	Transcript	ENST00000286548	protein_coding		5/6	c.736-5dup						rs5898555		-1		insertion	HGNC	HGNC:4390	YES	MANE_Select	NM_002072.5		1	P1	CCDS6658.1	ENSP00000286548	P50148.216	A0A024R240.65	UPI000006D0FB			1						0.3720	0.3026	0.4366	0.38	0.4583	0.3231	0.4558	0.3722	0.4447	0.4484	0.3872	0.4453	0.4633	0.4642	0.4491	0.4329	0.6237	0.4827	0.745	0.6786	0.6663	0.4395	0.6419	0.6884	0.7035	0.6373	0.6043	0.745	gnomADg_AMI	benign		1							FAIL	-4	-8	-7	-16	0.00	0.00	0.00	0.00	GNAQ		8.1800e-01	768309				777831	not_specified&not_provided		MedGen:CN169374&MedGen:C3661900		NC_000009.12:g.77728685dup	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001093356&SCV001855404&SCV006104677	Duplication	SO:1000035	ClinGen:CA5094561		GNAQ:2776	SO:0001627&intron_variant										1	5898555																											125					0.696							201.57													chr9	80343587																																																	True	True	False	Unknown		Unknown																						54,33	30,20	24,13	0/1	29,25,17,16	GGA						21,33,14,19	8.94		0.3793103448275862
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84668501	84668501.0	C	A	A	84668501	.	C	A	.	PASS	NM_006180	A	upstream_gene_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding									rs1187323	1228	1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.7857	0.7769	0.8314	0.7877	0.8201	0.728	0.5							0.5			0.8028	0.7951	0.8838	0.8103	0.7854	0.7937	0.835	0.7789	0.8047	0.8103	0.7523	0.8838	gnomADg_AMI				21178826&26462037&20014955&23315174&26641254&29867348&37047730&23570887&30728786&36721715&19376528																																																																												808					0.999							246.24													chr9	87283416																																																	True	True	False	Unknown		Unknown																						0,807	0,404	0,403	0/1	0,0,420,387	CCG	0.00	0.00	0.00			0,0,493,314	64.73		1.0
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84670680	84670680.0	C	G	G	84670680	.	C	G	.	PASS	NM_006180	G	5_prime_UTR_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding	2/19		c.-69C>G	464					rs1187325&COSV52861221		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.4958	0.2731	0.5663	0.5764	0.5845	0.5726	0.5632	0.3047	0.6476	0.5617	0.5838	0.6257	0.4824	0.5647	0.5498	0.5686	0.5011	0.3116	0.433	0.5668	0.5617	0.5841	0.6349	0.4524	0.5674	0.5028	0.5786	0.6476	gnomADe_AMR	benign	0&1	1&1	24831852&17200667						FAIL	4	6	-13	6	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01	1295965			0.49581	1285760	not_provided		MedGen:C3661900		NC_000009.12:g.84670680C>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001947943&SCV005269172	single_nucleotide_variant	SO:0001483	ClinGen:CA12960635		NTRK2:4915	SO:0001623&5_prime_UTR_variant										1	1187325																											1069					0.998							248.54													chr9	87285595																																																	True	True	False	Unknown		Unknown																						538,529	255,241	283,288	0/1	247,291,260,269	CCG	.	.	.			262,276,294,235	53.3		0.4957825679475164
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84742536	84742536.0	C	T	T	84742536	.	C	T	.	PASS	NM_006180	T	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		10/18	c.1195+609C>T						rs17326762&COSV99460224		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.0186	0.0015	0.0648	0.003	0.0308	0.0123											0.02542	0.006907	0.1198	0.04584	0.01584	0.0001933	0.03244	0.006803	0.03334	0.02129	0.01203	0.1198	gnomADg_AMI		0&1	0&1							FAIL	-1	-29	-2	49	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											600					0.995							245.66													chr9	87357451																																																	True	True	False	Unknown		Unknown																						362,235	191,109	171,126	0/1	182,180,121,114	GCG	0.00	0.00	0.00			169,193,101,134	11.8		0.3936348408710218
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84742816	84742816.0	T	C	C	84742816	.	T	C	.	PASS	NM_006180	C	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		10/18	c.1195+889T>C						rs10868226		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.5745	0.3064	0.6441	0.6746	0.6819	0.6738											0.5792	0.3516	0.5612	0.6198	0.6603	0.6749	0.7338	0.5357	0.6616	0.5982	0.693	0.7338	gnomADg_FIN										FAIL	6	30	-34	-32	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											315					0.844							174.58													chr9	87357731																																																	True	True	False	Unknown		Unknown																						125,141	61,63	64,78	0/1	61,64,84,57	TTC	.	.	.			49,76,18,123	49.03		0.5300751879699248
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84742993	84742994.0	GT	G	G	84742993	.	GT	G	.	PASS	NM_006180	-	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		10/18	c.1195+1070del						rs66492219		1		deletion	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1					3	0.5775	0.3064	0.6513	0.6766	0.6879	0.6759											0.5772	0.3524	0.5625	0.6154	0.6624	0.6763	0.7291	0.5646	0.6624	0.5954	0.6821	0.7291	gnomADg_FIN										FAIL	19	-18	43	-12	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											338					0.932							181.54													chr9	87357908																																																	True	True	False	Unknown		Unknown																						160,155	83,72	77,83	0/1	80,80,80,75	GGT						87,73,89,66	37.49		0.49206349206349204
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84743749	84743749.0	T	C	C	84743749	.	T	C	.	PASS	NM_006180	C	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		10/18	c.1196-1224T>C						rs11140746&COSV99451871		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.5108	0.0666	0.6282	0.6766	0.6879	0.6748											0.5199	0.1559	0.5625	0.5916	0.6616	0.6758	0.727	0.5476	0.6616	0.5539	0.6824	0.727	gnomADg_FIN		0&1	0&1							FAIL	-27	17	18	-30	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											118					0.958							242.14													chr9	87358664																																																	True	True	False	Unknown		Unknown																						62,51	36,21	26,30	0/1	30,32,24,27	ATG	.	.	.			34,28,24,27	29.93		0.45132743362831856
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84744655	84744655.0	G	A	A	84744655	.	G	A	.	PASS	NM_006180	A	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		10/18	c.1196-318G>A						rs113722236		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.0194	0.0567	0.0058	0.004	0.0119	0.002											0.01947	0.04786	0.009868	0.00694	0	0.003667	0.01116	0	0.01021	0.0109	0.001456	0.0567	AFR	benign		1							FAIL	29	30	-22	31	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01	1278566			0.01937	1267146	not_provided		MedGen:C3661900		NC_000009.12:g.84744655G>A	criteria_provided&_single_submitter	Benign			SCV001907265	single_nucleotide_variant	SO:0001483	ClinGen:CA195752544		NTRK2:4915	SO:0001627&intron_variant										1	113722236																											348					0.989							245.96													chr9	87359570																																																	True	True	False	Unknown		Unknown																						173,171	78,74	95,97	0/1	85,88,88,83	CGT	0.00	0.00	0.00			110,63,95,76	40.91		0.49709302325581395
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84811058	84811058.0	G	A	A	84811058	.	G	A	.	PASS	NM_006180	A	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-49982G>A						rs1047896&COSV99451989		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.8632	0.8722	0.8401	0.9216	0.7952	0.8773	0.7901	0.8501	0.8745	0.7846	0.9301	0.792	0.7991	0.7838	0.7997	0.8429	0.8258	0.8523	0.9209	0.8634	0.7961	0.9176	0.8191	0.8048	0.7945	0.8076	0.8488	0.9301	gnomADe_EAS		0&1	0&1	26959740&28941407&32894097&37745409						FAIL	23	-1	-3	-18	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											81					0.975							245.35													chr9	87425973																																																	True	True	False	Unknown		Unknown																						0,79	0,39	0,40	0/1	0,0,44,35	TGT	0.00	0.00	0.00			0,0,34,45	64.57		1.0
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84811367	84811368.0	TG	T	T	84811367	.	TG	T	.	PASS	NM_006180	-	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-49669del						rs201203220		1		deletion	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1					3	0.0252	0.0015	0.0951	0.005	0.0368	0.0164	0.03648	0.003356	0.09758	0.02087	0.0009362	0.04412	0.004735	0.03856	0.03146	0.01766	0.03276	0.007913	0.1195	0.08317	0.01556	0.003471	0.05649	0.006803	0.03635	0.02599	0.01617	0.1195	gnomADg_AMI										FAIL	-9	0	4	16	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											226					0.735							231.56													chr9	87426282																																																	True	True	False	Unknown		Unknown																						82,84	35,36	47,48	0/1	46,36,38,46	TTG						31,51,30,54	37.24		0.5060240963855421
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84813704	84813704.0	G	A	A	84813704	.	G	A	.	PASS	NM_006180	A	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-47336G>A						rs45596934&COSV99460433		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.0256	0.0015	0.0937	0.005	0.0378	0.0184	0.03821	0.003711	0.1006	0.02077	0.0008659	0.0503	0.007116	0.04036	0.03312	0.0201	0.03384	0.008336	0.1195	0.08654	0.01586	0.002894	0.05632	0.0102	0.03761	0.02938	0.01722	0.1195	gnomADg_AMI		0&1	0&1	19844206&23272319						FAIL	-16	10	-12	-16	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											235					0.974							232.94													chr9	87428619																																																	True	True	False	Unknown		Unknown																						119,110	77,54	42,56	0/1	54,65,57,53	CGT	0.00	0.00	0.00			64,55,47,63	34.99		0.48034934497816595
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84813892	84813892.0	C	T	T	84813892	.	C	T	.	PASS	NM_006180	T	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-47148C>T						rs138535351&COSV99460434		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.0248	0.0015	0.0922	0.005	0.0368	0.0164	0.03645	0.003259	0.09832	0.02063	0.0008039	0.04242	0.004739	0.03854	0.03142	0.0176	0.03279	0.007926	0.1195	0.08378	0.01586	0.002701	0.05588	0.006803	0.03637	0.02704	0.0162	0.1195	gnomADg_AMI		0&1	0&1	28235201&37745409						FAIL	18	16	-38	-7	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											114					0.991							243.08													chr9	87428807																																																	True	True	False	Unknown		Unknown																						66,47	38,23	28,24	0|1	26,40,27,20	TCA	0.00	0.00	0.00		87428807	36,30,25,22	17.39		0.415929203539823
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84813893	84813893.0	A	G	G	84813893	.	A	G	.	PASS	NM_006180	G	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-47147A>G						rs74356179&COSV99460438		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.0248	0.0015	0.0922	0.005	0.0368	0.0164	0.03648	0.003259	0.09849	0.02066	0.0008046	0.04242	0.004739	0.03856	0.03145	0.01766	0.0328	0.007921	0.1195	0.08387	0.01586	0.002703	0.05568	0.006803	0.03639	0.02749	0.01618	0.1195	gnomADg_AMI		0&1	0&1	28235201&37745409						FAIL	-4	2	-42	3	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											114					0.991							243.08													chr9	87428808																																																	True	True	False	Unknown		Unknown																						67,46	38,23	29,23	0|1	27,40,25,21	CAA	.	.	.		87428807	38,29,24,22	15.82		0.40707964601769914
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84813951	84813951.0	C	T	T	84813951	.	C	T	.	PASS	NM_006180	T	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-47089C>T						rs1627784&COSV99451990		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.6941	0.6354	0.6772	0.7083	0.6968	0.7679	0.6926	0.6099	0.7182	0.6364	0.7153	0.7202	0.6621	0.6938	0.6867	0.7549	0.6839	0.6207	0.7818	0.6931	0.6508	0.6998	0.7411	0.6837	0.7064	0.6602	0.7542	0.7818	gnomADg_AMI		0&1	0&1	26959740&17720314&37745409&39004388						FAIL	-14	-43	0	36	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											137					1							244.13													chr9	87428866																																																	True	True	False	Unknown		Unknown																						0,137	0,71	0,66	0/1	0,0,70,67	CCG	0.00	0.00	0.00			0,0,82,55	64.72		1.0
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84814375	84814375.0	A	G	G	84814375	.	A	G	.	PASS	NM_006180	G	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-46665A>G						rs1624327&COSV99451992		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.7534	0.6589	0.6859	0.87	0.7237	0.8395	0.7137	0.635	0.7167	0.6782	0.8786	0.7246	0.7424	0.711	0.7175	0.7994	0.7101	0.6434	0.7149	0.7191	0.6948	0.8651	0.7452	0.7517	0.7255	0.7032	0.8058	0.8786	gnomADe_EAS		0&1	0&1	26959740&19844206&17200667&28550723&28863320&34016088&32894097&24802768&37745409&39004388&23272319						FAIL	-1	20	-15	8	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											630					0.987							242.58													chr9	87429290																																																	True	True	False	Unknown		Unknown																						276,346	131,141	145,205	0/1	141,135,182,164	CAT	.	.	.			120,156,133,213	48.55		0.5562700964630225
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84815606	84815606.0	T	A	A	84815606	.	T	A	.	PASS	NM_006180	A	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		12/18	c.1397-45434T>A						rs7816&COSV99451994		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.7913	0.6997	0.7925	0.875	0.7644	0.8558	0.7547	0.6657	0.8151	0.6951	0.8756	0.7695	0.7522	0.7542	0.7544	0.8167	0.7541	0.6802	0.8344	0.8076	0.713	0.8675	0.8013	0.7619	0.7676	0.7378	0.8232	0.8756	gnomADe_EAS		0&1	0&1	26959740&29028593&18179783&37763162						FAIL	36	13	-28	44	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											90					0.989							245.03													chr9	87430521																																																	True	True	False	Unknown		Unknown																						0,89	0,39	0,50	0/1	0,0,51,38	ATT	.	.	.			0,0,27,62	64.64		1.0
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84862359	84862359.0	T	G	G	84862359	.	T	G	.	PASS	NM_006180	G	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1444+1272T>G						rs10116287&COSV99452779		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.1114	0.0325	0.085	0.2212	0.1511	0.0828											0.1146	0.03734	0.2303	0.102	0.1914	0.2207	0.1941	0.1701	0.1403	0.131	0.08168	0.2303	gnomADg_AMI		0&1	0&1							FAIL	33	-42	-23	-19	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											340					0.982							238.6													chr9	87477274																																																	True	True	False	Unknown		Unknown																						162,172	76,76	86,96	0/1	85,77,84,88	TTG	.	.	.			55,107,68,104	45.87		0.5149700598802395
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84863220	84863220.0	A	C	C	84863220	.	A	C	.	PASS	NM_006180	C	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1444+2133A>C						rs7048015&COSV99453599		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.3317	0.4932	0.3818	0.256	0.1839	0.3078											0.2844	0.4636	0.2368	0.332	0.1622	0.2458	0.1755	0.1667	0.1918	0.2665	0.2921	0.4932	AFR		0&1	0&1							FAIL	21	-39	-31	20	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											256					0.984							243.54													chr9	87478135																																																	True	True	False	Unknown		Unknown																						135,117	66,60	69,57	0/1	63,72,64,53	AAC	.	.	.			54,81,47,70	31.48		0.4642857142857143
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84864190	84864190.0	G	A	A	84864190	.	G	A	.	PASS	NM_006180	A	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1445-3053G>A						rs10868232&COSV99452049		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.8646	0.9168	0.879	0.7431	0.8579	0.9162											0.8665	0.9166	0.8969	0.8762	0.8046	0.729	0.8184	0.7671	0.8525	0.8513	0.906	0.9168	AFR		0&1	0&1	31527397						FAIL	-15	0	27	-1	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											74					0.932							240.52													chr9	87479105																																																	True	True	False	Unknown		Unknown																						0,69	0,38	0,31	0/1	0,0,32,37	GGG	0.00	0.00	0.00			0,0,35,34	64.47		1.0
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84864422	84864422.0	A	G	G	84864422	.	A	G	.	PASS	NM_006180	G	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1445-2821A>G						rs7021820&COSV99452050		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.3335	0.4932	0.3833	0.255	0.1869	0.3139											0.2919	0.4652	0.2374	0.3356	0.1626	0.2483	0.1813	0.1701	0.2045	0.2726	0.3043	0.4932	AFR		0&1	0&1							FAIL	1	17	-1	-27	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											199					0.889							225.94													chr9	87479337																																																	True	True	False	Unknown		Unknown																						88,89	49,43	39,46	0/1	45,43,54,35	AAT	.	.	.			36,52,44,45	38.41		0.5028248587570622
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84864491	84864491.0	A	G	G	84864491	.	A	G	.	PASS	NM_006180	G	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1445-2752A>G						rs11140791&COSV99452784		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.1100	0.031	0.0836	0.2212	0.1501	0.0798											0.1147	0.0377	0.2303	0.1024	0.1912	0.2197	0.1938	0.1667	0.1405	0.1313	0.08133	0.2303	gnomADg_AMI		0&1	0&1							FAIL	1	27	1	-30	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											200					0.945							232.48													chr9	87479406																																																	True	True	False	Unknown		Unknown																						105,84	46,45	59,39	0/1	59,46,42,42	AAC	.	.	.			48,57,49,35	27.52		0.4444444444444444
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84864736	84864744.0	CTTTTTTTT	C	C	84864736	.	CTTTTTTTT	C	.	PASS	NM_006180	-	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1445-2492_1445-2485del						rs71369154		1		deletion	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1					14																	0.005314	0.00122	0	0.02226	0	0	0.05894	0	0.003848	0.00731	0.0007153	0.05894	gnomADg_FIN																					1.2300e-01																																																											364					0.555							176.63													chr9	87479651																																																	True	True	False	Unknown		Unknown																						93,109	57,59	36,50	0/1	55,38,60,49	TCT						45,48,50,59	42.44		0.5396039603960396
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84865568	84865568.0	A	C	C	84865568	.	A	C	.	PASS	NM_006180	C	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1445-1675A>C						rs79355269&COSV99452787		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.1098	0.031	0.0836	0.2202	0.1501	0.0798											0.1145	0.03754	0.2285	0.1022	0.1911	0.2198	0.1936	0.1667	0.1402	0.1316	0.08143	0.2285	gnomADg_AMI		0&1	0&1							FAIL	-16	-10	27	-10	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											182					0.934							232.46													chr9	87480483																																																	True	True	False	Unknown		Unknown																						102,68	60,35	42,33	0/1	53,49,34,34	CAC	.	.	.			51,51,33,35	17.81		0.4
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84866937	84866937.0	G	A	A	84866937	.	G	A	.	PASS	NM_006180	A	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		13/18	c.1445-306G>A						rs10868233&COSV99452789		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.1102	0.031	0.0836	0.2222	0.1501	0.0798											0.1142	0.0374	0.2072	0.1014	0.1915	0.2201	0.1946	0.1667	0.1399	0.13	0.08091	0.2222	EAS	benign	0&1	1&1							FAIL	-44	43	2	40	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01	1227426			0.11022	1216110	not_provided		MedGen:C3661900		NC_000009.12:g.84866937G>A	criteria_provided&_single_submitter	Benign			SCV001835032	single_nucleotide_variant	SO:0001483	ClinGen:CA12990749		NTRK2:4915	SO:0001627&intron_variant										1	10868233																											109					0.945							233.44													chr9	87481852																																																	True	True	False	Unknown		Unknown																						43,60	21,23	22,37	0/1	26,17,31,29	TGA	0.00	0.00	0.00			24,19,24,36	43.68		0.5825242718446602
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84872704	84872710.0	GTATCCT	G	G	84872704	.	GTATCCT	G	.	PASS	NM_006180	-	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		14/18	c.1633+5275_1633+5280del								1		deletion	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1					1																																																		1.2300e-01																																																											159					0.767							223.62													chr9	87487619																																																	True	True	False	Unknown		Unknown																						108,14	55,6	53,8	0/1	64,44,9,5	TGT						47,61,7,7	10.64		0.11475409836065574
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84872726	84872726.0	T	G	G	84872726	.	T	G	.	PASS	NM_006180	G	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		14/18	c.1633+5295T>G						rs2075911497		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1												0	0	0	0	0	0	0	0	0	0												0	gnomADe_AFR&gnomADe_AMR&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_REMAINING&gnomADe_SAS										FAIL	1	26	-5	-29	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											164					0.738							223.31													chr9	87487641																																																	True	True	False	Unknown		Unknown																						115,6	54,3	61,3	0/1	66,49,3,3	TTT	.	.	.			47,68,2,4	3.66		0.049586776859504134
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84873606	84873606.0	G	A	A	84873606	.	G	A	.	PASS	NM_006180	A	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		14/18	c.1633+6175G>A						rs3780633		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.0449	0.0008	0.0677	0.0913	0.006	0.0808	0.006328	0.003862	0.05837	0.003806	0.1148	0.009259	0.009232	0.003202	0.01085	0.05353	0.01453	0.002987	0	0.05369	0.001728	0.09613	0.01678	0.01701	0.003646	0.01466	0.06268	0.1148	gnomADe_EAS										FAIL	-46	1	50	-1	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											164					1							244.82													chr9	87488521																																																	True	True	False	Unknown		Unknown																						102,62	50,34	52,28	0/1	52,50,27,35	AGT	0.00	0.00	0.00			56,46,27,35	14.14		0.3780487804878049
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84874870	84874870.0	G	C	C	84874870	.	G	C	.	PASS	NM_006180	C	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		14/18	c.1633+7439G>C						rs9969765		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.4383	0.5174	0.4669	0.4762	0.336	0.3773	0.3468	0.5017	0.4169	0.3573	0.5158	0.3375	0.3401	0.3385	0.3706	0.3612	0.4054	0.5008	0.4671	0.4374	0.3547	0.4681	0.3756	0.3367	0.3445	0.4034	0.3704	0.5174	AFR			1	19844206&20124106&23750220&35361970						FAIL	14	-14	5	47	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											83					1							245.28													chr9	87489785																																																	True	True	False	Unknown		Unknown																						0,83	0,33	0,50	0/1	0,0,43,40	GGA	.	.	.			0,0,43,40	64.6		1.0
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84874933	84874933.0	C	G	G	84874933	.	C	G	.	PASS	NM_006180	G	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		14/18	c.1633+7502C>G						rs9969761&COSV105872179		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.1050	0.0923	0.0922	0.1786	0.0109	0.1524	0.01449	0.1038	0.0753	0.003962	0.1878	0.009375	0.01556	0.006541	0.03035	0.1152	0.05031	0.09921	0	0.07206	0.001728	0.1841	0.01761	0.03401	0.008087	0.03883	0.1349	0.1878	gnomADe_EAS		0&1	0&1							FAIL	-44	25	-44	37	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											117					0.983							241.09													chr9	87489848																																																	True	True	False	Unknown		Unknown																						64,51	33,25	31,26	0/1	35,29,30,21	TCT	.	.	.			42,22,32,19	28.77		0.4434782608695652
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84875340	84875340.0	C	T	T	84875340	.	C	T	.	PASS	NM_006180	T	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		14/18	c.1633+7909C>T						rs9969767		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.1050	0.093	0.0922	0.1786	0.0109	0.1513	0.01469	0.1051	0.07514	0.004057	0.188	0.009036	0.01582	0.006581	0.03031	0.115	0.05015	0.09929	0	0.07217	0.001729	0.1804	0.01761	0.03401	0.0081	0.03799	0.1337	0.188	gnomADe_EAS										FAIL	50	-42	0	16	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											141					0.972							243.8													chr9	87490255																																																	True	True	False	Unknown		Unknown																						78,59	34,24	44,35	0/1	43,35,31,28	ACG	0.00	0.00	0.00			31,47,26,33	26.13		0.4306569343065693
GRCh38	NTRK2	D12_12345_1234556_Thyroid_S9			chr9	84877113	84877113.0	T	C	C	84877113	.	T	C	.	PASS	NM_006180	C	intron_variant	MODIFIER	NTRK2	ENSG00000148053	Transcript	ENST00000277120	protein_coding		14/18	c.1633+9682T>C						rs6559833&COSV99452063		1		SNV	HGNC	HGNC:8032	YES	MANE_Select	NM_006180.6		1	P3	CCDS6671.1	ENSP00000277120	Q16620.243		UPI000006FA0D	Q16620-4		1						0.3345	0.4917	0.3847	0.2579	0.1849	0.319	0.2178	0.4739	0.3259	0.1669	0.2551	0.1807	0.1552	0.2088	0.2403	0.2912	0.2925	0.4677	0.2357	0.336	0.1636	0.2486	0.1808	0.1701	0.2043	0.2723	0.3056	0.4917	AFR		0&1	0&1							FAIL	-45	50	-6	11	0.00	0.00	0.00	0.00	NTRK2		1.2300e-01																																																											130					0.992							243.14													chr9	87492028																																																	True	True	False	Unknown		Unknown																						67,62	38,30	29,32	0/1	39,28,31,31	CTT	.	.	.			32,35,37,25	34.13		0.4806201550387597
GRCh38	SYK	D12_12345_1234556_Thyroid_S9	p.Gln43=	ENSP00000364907.4:p.Gln43=	chr9	90844027	90844027.0	G	A	A	90844027	.	G	A	.	PASS	NM_003177	A	synonymous_variant	LOW	SYK	ENSG00000165025	Transcript	ENST00000375754	protein_coding	2/14		c.129G>A	245	129	43	Q	caG/caA	rs35758162&COSV65327289		1		SNV	HGNC	HGNC:11491	YES	MANE_Select	NM_003177.7		1	P3	CCDS6688.1	ENSP00000364907	P43405.250		UPI000012E0DD	P43405-1		1			PDB-ENSP_mappings:1a81.A&PDB-ENSP_mappings:1a81.C&PDB-ENSP_mappings:1a81.E&PDB-ENSP_mappings:1a81.G&PDB-ENSP_mappings:1a81.I&PDB-ENSP_mappings:1a81.K&Gene3D:3.30.505.10&PDB-ENSP_mappings:4fl2.A&PDB-ENSP_mappings:4fl3.A&PDB-ENSP_mappings:7q5t.AAA&PDB-ENSP_mappings:7q5t.BBB&PDB-ENSP_mappings:7q5t.CCC&PDB-ENSP_mappings:7q5t.DDD&PDB-ENSP_mappings:7q5t.EEE&PDB-ENSP_mappings:7q5t.FFF&PDB-ENSP_mappings:7q5u.AAA&PDB-ENSP_mappings:7q5u.BBB&PDB-ENSP_mappings:7q5u.CCC&PDB-ENSP_mappings:7q5u.DDD&PDB-ENSP_mappings:7q5u.EEE&PDB-ENSP_mappings:7q5u.FFF&PDB-ENSP_mappings:7q5w.AAA&PDB-ENSP_mappings:7q5w.BBB&PDB-ENSP_mappings:7q5w.CCC&PDB-ENSP_mappings:7q5w.DDD&PDB-ENSP_mappings:7q5w.EEE&PDB-ENSP_mappings:7q5w.FFF&PDB-ENSP_mappings:7q63.AAA&PDB-ENSP_mappings:7q63.BBB&PDB-ENSP_mappings:7q63.CCC&PDB-ENSP_mappings:7sa7.A&PDB-ENSP_mappings:7sa7.B&PDB-ENSP_mappings:7sa7.C&PDB-ENSP_mappings:7sa7.D&PDB-ENSP_mappings:7sa7.E&PDB-ENSP_mappings:7sa7.F&AFDB-ENSP_mappings:AF-P43405-F1&Pfam:PF00017&PIRSF:PIRSF000604&PROSITE_profiles:PS50001&SMART:SM00252&Superfamily:SSF55550&CDD:cd09938			0.1110	0.1067	0.1138	0.0159	0.168	0.1544	0.188	0.1214	0.09942	0.2186	0.009613	0.1285	0.2356	0.2033	0.1808	0.1747	0.1603	0.1184	0.2445	0.1376	0.2142	0.01275	0.1177	0.2415	0.2041	0.1645	0.1667	0.2445	gnomADg_AMI		0&1	0&1							FAIL	3	1	3	1	0.00	0.02	0.00	0.00	SYK		3.0200e-01																																																											1184					0.997							246.96	v6.1	Unknown		True	SYK encodes a tyrosine kinase involved in signal transduction. Upregulation of SYK is found in lymphomas, leukemias and select epithelial tumors.	False	01/18/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SYK ENSP00000364907.4:Q43= mutant UNKNOWN.	False	The SYK ENSP00000364907.4:q43= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	93606309						True	False	False	Unknown								False	False		SYK encodes a tyrosine kinase involved in signal transduction. Upregulation of SYK is found in lymphomas, leukemias and select epithelial tumors.	The SYK ENSP00000364907.4:q43= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SYK ENSP00000364907.4:Q43= mutant UNKNOWN.						v6.1	01/18/2017		GRCh38	SYK	6850.0	ENSP00000364907.4:Q43=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""SYK"",""entrezGeneId"":6850,""alteration"":""ENSP00000364907.4:Q43="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""SYK encodes a tyrosine kinase involved in signal transduction. Upregulation of SYK is found in lymphomas, leukemias and select epithelial tumors."",""variantSummary"":""The SYK ENSP00000364907.4:q43= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SYK ENSP00000364907.4:Q43= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""01/18/2017""}"	True	True	False	Unknown		Unknown																						0,1181	0,591	0,590	0/1	0,0,597,584	AGA	0.00	0.00	0.00			0,0,651,530	64.73		1.0
GRCh38	HSD17B3	D12_12345_1234556_Thyroid_S9			chr9	96235628	96235637.0	ATCTTTGTGG	A	A	96235628	.	ATCTTTGTGG	A	.	PASS		-	intron_variant&NMD_transcript_variant	MODIFIER	HSD17B3	ENSG00000130948	Transcript	ENST00000650005	nonsense_mediated_decay		8/8	c.*173-67_*173-59del						rs3831056		-1		deletion	HGNC	HGNC:5212								ENSP00000498121		A0A0S2Z413.37	UPI00071F8B86			1						0.4157	0.298	0.4265	0.4643	0.5	0.4305	0.473	0.3093	0.4135	0.3854	0.4733	0.5068	0.3825	0.4846	0.4605	0.453	0.4339	0.3181	0.4676	0.4412	0.3937	0.4822	0.4988	0.3448	0.4902	0.4278	0.4536	0.5068	gnomADe_FIN	benign		1																			1220642				1212330	not_provided		MedGen:C3661900		NC_000009.12:g.96235634_96235642del	criteria_provided&_single_submitter	Benign			SCV001828522	Deletion	SO:0000159	ClinGen:CA196609324		HSD17B3:3293&SLC35D2-HSD17B3:127748585	SO:0001627&intron_variant										1	3831056																											363					0.884							245.66													chr9	98997910																																																	True	False	False	Unknown		Unknown																						213,108	106,49	107,59	0/1	109,104,54,54	CAT						76,137,29,79	10.64		0.3364485981308411
GRCh38		D12_12345_1234556_Thyroid_S9			chr9	102823911	102823915.0	C	CAATT	CAATT	102823911	.	C	CAATT	.	PASS		AATT	intergenic_variant	MODIFIER														rs2307580				insertion																						0.5128	0.7458	0.4582	0.5159	0.497	0.2495											0.5557	0.7151	0.4321	0.4687	0.4612	0.5109	0.538	0.398	0.5103	0.5201	0.3056	0.7458	AFR				33801242																																																																												51					0.922							243.45													chr9	105586193																																																	True	False	False	Unknown		Unknown																						28,19	17,10	11,9	0/1	13,15,7,12	TCA						16,12,8,11	24.75		0.40425531914893614
GRCh38	KLF4	D12_12345_1234556_Thyroid_S9			chr9	107487224	107487224.0	C	T	T	107487224	.	C	T	.	PASS	NM_004235	T	intron_variant	MODIFIER	KLF4	ENSG00000136826	Transcript	ENST00000374672	protein_coding		3/4	c.1100-32G>A						rs2236599&COSV65928618		-1		SNV	HGNC	HGNC:6348	YES	MANE_Select	NM_004235.6		1	P1	CCDS6770.2	ENSP00000363804	O43474.215		UPI0000375189	O43474-1		1						0.1402	0.0091	0.1758	0.2927	0.1948	0.0787	0.1811	0.0277	0.1866	0.2411	0.2745	0.2665	0.1536	0.184	0.1864	0.08392	0.1509	0.03623	0.1993	0.1664	0.2478	0.2809	0.2715	0.1871	0.1872	0.1703	0.08704	0.2927	EAS		0&1	0&1	26689941&34090531&31393228&26692521&26934576&22767148&35283014						FAIL	-17	-34	-46	-34	0.00	0.03	0.00	0.00	KLF4		6.9800e-01																																																											1030					0.997							247.67													chr9	110249505																																																	True	True	False	Unknown		Unknown																						483,544	223,251	260,293	0/1	234,249,273,271	TCC	0.00	0.00	0.00			242,241,280,264	59.24		0.5296981499513145
GRCh38		D12_12345_1234556_Thyroid_S9			chr9	124119169	124119169.0	C	T	T	124119169	.	C	T	.	PASS		T	downstream_gene_variant	MODIFIER		ENSG00000296076	Transcript	ENST00000736082	lncRNA									rs1463729	2545	-1		SNV																						0.5857	0.7716	0.562	0.4841	0.5994	0.4417											0.6191	0.7394	0.7654	0.5777	0.5513	0.4683	0.6155	0.5884	0.5811	0.6061	0.4493	0.7716	AFR				26522768&26691610&29121662&33406744&33857205&20360305&25763762&19083859&27294018&19948332																																																																												730					0.999							246.11													chr9	126881448																																																	True	False	False	Unknown		Unknown																						376,353	176,178	200,175	0/1	203,173,190,163	ACG	0.00	0.00	0.00			181,195,193,160	40.34		0.4842249657064472
GRCh38		D12_12345_1234556_Thyroid_S9			chr9	126205784	126205784.0	C	T	T	126205784	.	C	T	.	PASS		T	intergenic_variant	MODIFIER														rs1360288				SNV																						0.3243	0.2133	0.2435	0.379	0.338	0.4611											0.3044	0.233	0.4471	0.2788	0.2821	0.3594	0.2859	0.3151	0.3408	0.3219	0.4479	0.4611	SAS				26691610&29121662&33406744&34721519&33857205&19083859&19948332																																																																												854					0.996							246.26													chr9	128968063																																																	True	False	False	Unknown		Unknown																						430,421	214,200	216,221	0/1	211,219,209,212	ACA	0.00	0.00	0.00			205,225,192,229	48.92		0.49471210340775557
GRCh38	ABL1	D12_12345_1234556_Thyroid_S9			chr9	130835417	130835417.0	T	C	C	130835417	.	T	C	.	PASS	NM_005157	C	5_prime_UTR_variant	MODIFIER	ABL1	ENSG00000097007	Transcript	ENST00000318560	protein_coding	1/11		c.-30T>C	164					rs7866590&COSV100583376		1		SNV	HGNC	HGNC:76	YES	MANE_Select	NM_005157.6		1		CCDS35166.1	ENSP00000323315	P00519.286		UPI000013D6D4	P00519-1		1						0.9968	0.9992	0.9928	1	0.9911	0.999	0.9866	0.9978	0.992	0.9964	1	0.9887	0.9807	0.9845	0.988	0.9973	0.99	0.9965	1	0.9855	0.9948	1	0.9893	0.9829	0.9855	0.9922	0.9979	1	EAS&gnomADe_EAS&gnomADg_AMI&gnomADg_EAS		0&1	0&1							FAIL	-12	-3	31	-2	0.00	0.00	0.00	0.00	ABL1		1.9000e-01																																																											416					0.995							243.03													chr9	133710804																																																	True	True	False	Unknown		Unknown																						0,414	0,193	0,221	0|1	0,0,197,217	GTT	.	.	.		133710804	0,0,312,102	57.73		1.0
GRCh38	ABL1	D12_12345_1234556_Thyroid_S9			chr9	130835432	130835433.0	T	TC	TC	130835432	.	T	TC	.	PASS	NM_005157	C	5_prime_UTR_variant	MODIFIER	ABL1	ENSG00000097007	Transcript	ENST00000318560	protein_coding	1/11		c.-15_-14insC	179-180					rs11433463&COSV100583377		1		insertion	HGNC	HGNC:76	YES	MANE_Select	NM_005157.6		1		CCDS35166.1	ENSP00000323315	P00519.286		UPI000013D6D4	P00519-1		1						1.0000	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.9995	1	1	AFR&AMR&EAS&EUR&SAS&gnomADe_AFR&gnomADe_AMR&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_REMAINING&gnomADe_SAS&gnomADg_AFR&gnomADg_AMI&gnomADg_AMR&gnomADg_ASJ&gnomADg_EAS&gnomADg_FIN&gnomADg_MID&gnomADg_NFE&gnomADg_SAS		0&1	0&1							FAIL	-27	15	38	-17	0.00	0.00	0.00	0.00	ABL1		1.9000e-01																																																											530					1							243.81													chr9	133710819																																																	True	True	False	Unknown		Unknown																						0,530	0,244	0,286	0|1	0,0,267,263	GTG					133710804	0,0,373,157	56.48		1.0
GRCh38	ABL1	D12_12345_1234556_Thyroid_S9	p.Pro1108=	ENSP00000323315.5:p.Pro1108=	chr9	130885614	130885614.0	A	G	G	130885614	.	A	G	.	PASS	NM_005157	G	synonymous_variant	LOW	ABL1	ENSG00000097007	Transcript	ENST00000318560	protein_coding	11/11		c.3324A>G	3517	3324	1108	P	ccA/ccG	rs1056171&COSV59323964		1		SNV	HGNC	HGNC:76	YES	MANE_Select	NM_005157.6		1		CCDS35166.1	ENSP00000323315	P00519.286		UPI000013D6D4	P00519-1		1			Gene3D:1.20.120.330&PDB-ENSP_mappings:1zzp.A&AFDB-ENSP_mappings:AF-P00519-F1&Pfam:PF08919&SMART:SM00808			0.6542	0.882	0.6974	0.5952	0.4881	0.547	0.4911	0.8363	0.7248	0.4993	0.5915	0.4895	0.5758	0.4639	0.5218	0.5114	0.5945	0.822	0.446	0.6617	0.5052	0.5997	0.47	0.585	0.4702	0.5781	0.5419	0.882	AFR	benign	0&1	1&1							FAIL	13	2	-5	-50	0.00	0.00	0.00	0.00	ABL1		1.9000e-01	1301303	0.58488		0.65415	1291586	not_provided		MedGen:C3661900		NC_000009.12:g.130885614A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001982123&SCV002371373&SCV005316554	single_nucleotide_variant	SO:0001483	ClinGen:CA5285907		ABL1:25	SO:0001819&synonymous_variant										1	1056171																											970					0.997							247.58	v6.1	Unknown		True	ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.	False	11/09/2020	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ABL1 ENSP00000323315.5:P1108= mutant UNKNOWN.	False	The ABL1 ENSP00000323315.5:p1108= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	133761001						True	False	False	Unknown								False	False		ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.	The ABL1 ENSP00000323315.5:p1108= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ABL1 ENSP00000323315.5:P1108= mutant UNKNOWN.						v6.1	11/09/2020		GRCh38	ABL1	25.0	ENSP00000323315.5:P1108=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""ABL1"",""entrezGeneId"":25,""alteration"":""ENSP00000323315.5:P1108="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia."",""variantSummary"":""The ABL1 ENSP00000323315.5:p1108= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ABL1 ENSP00000323315.5:P1108= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""11/09/2020""}"	True	True	False	Unknown		Unknown																						470,497	229,233	241,264	0/1	238,232,240,257	CAG	.	.	.			225,245,232,265	62.4		0.5139607032057911
GRCh38	TSC1	D12_12345_1234556_Thyroid_S9	p.S450R	ENSP00000298552.3:p.Ser450Arg	chr9	132906821	132906821.0	T	G	G	132906821	.	T	G	.	PASS	NM_000368	G	missense_variant	MODERATE	TSC1	ENSG00000165699	Transcript	ENST00000298552	protein_coding	14/23		c.1348A>C	1565	1348	450	S/R	Agc/Cgc			-1		SNV	HGNC	HGNC:12362	YES	MANE_Select	NM_000368.5		1	P4	CCDS6956.1	ENSP00000298552	Q92574.219	X5D9D2.65	UPI000013773E	Q92574-1		1	tolerated(0.07)	benign(0.318)	PDB-ENSP_mappings:7dl2.C&PDB-ENSP_mappings:7dl2.D&Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR15154&Pfam:PF04388&MobiDB_lite:mobidb-lite&AFDB-ENSP_mappings:AF-Q92574-F1																																									FAIL	11	-34	-42	-6	0.01	0.00	0.00	0.00	TSC1	0.144	2.2700e-01																																																											153					0.98							244.48	v6.1	Unknown		True	TSC1, a scaffold protein, is frequently altered by mutation in bladder cancer.	False	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TSC1 ENSP00000298552.3:S450R mutant UNKNOWN.	False	The TSC1 ENSP00000298552.3:s450r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	135782208						True	False	False	Unknown								False	False		TSC1, a scaffold protein, is frequently altered by mutation in bladder cancer.	The TSC1 ENSP00000298552.3:s450r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TSC1 ENSP00000298552.3:S450R mutant UNKNOWN.						v6.1	04/15/2025		GRCh38	TSC1	7248.0	ENSP00000298552.3:S450R			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""TSC1"",""entrezGeneId"":7248,""alteration"":""ENSP00000298552.3:S450R"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""TSC1, a scaffold protein, is frequently altered by mutation in bladder cancer."",""variantSummary"":""The TSC1 ENSP00000298552.3:s450r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TSC1 ENSP00000298552.3:S450R mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/15/2025""}"	True	True	False	Unknown		Unknown																						146,4	69,2	77,2	0/1	76,70,3,1	CTG	.	.	.			53,93,1,3	11.24		0.02666666666666667
GRCh38		D12_12345_1234556_Thyroid_S9			chr9	134525459	134525459.0	A	G	G	134525459	.	A	G	.	PASS		G	downstream_gene_variant	MODIFIER		ENSG00000297129	Transcript	ENST00000745709	lncRNA									rs7037930	4892	-1		SNV			YES																			0.7726	0.7769	0.7925	0.8145	0.6859	0.7986											0.7258	0.7604	0.7769	0.7654	0.7682	0.8048	0.5861	0.7823	0.7038	0.7467	0.7812	0.8145	EAS																																																																																953					0.996							247.82													chr9	137417305																																																	True	False	False	Unknown		Unknown																						519,430	276,237	243,193	0/1	261,258,207,223	CAA	.	.	.			280,239,226,204	17.62		0.45310853530031614
GRCh38	NOTCH1	D12_12345_1234556_Thyroid_S9	p.Asp2185=	ENSP00000498587.1:p.Asp2185=	chr9	136497184	136497184.0	G	A	A	136497184	.	G	A	.	PASS	NM_017617	A	synonymous_variant	LOW	NOTCH1	ENSG00000148400	Transcript	ENST00000651671	protein_coding	34/34		c.6555C>T	6817	6555	2185	D	gaC/gaT	rs2229974&COSV53025449&COSV53025460		-1		SNV	HGNC	HGNC:7881	YES	MANE_Select	NM_017617.5			P1	CCDS43905.1	ENSP00000498587	P46531.259		UPI0000210F68			1			AFDB-ENSP_mappings:AF-P46531-F1&Phobius:CYTOPLASMIC_DOMAIN&PIRSF:PIRSF002279&MobiDB_lite:mobidb-lite			0.6951	0.6278	0.6542	0.9494	0.5775	0.6738	0.5733	0.6205	0.7141	0.5313	0.9094	0.5205	0.5532	0.5487	0.5887	0.68	0.5942	0.6205	0.4238	0.6488	0.532	0.9393	0.5118	0.5136	0.5522	0.5806	0.6856	0.9494	EAS	benign	0&1&1	1&1&1	23021489&23102684&29383147&28246602&16729972&37471354						FAIL	-47	-24	24	-28	0.00	0.00	0.00	0.00	NOTCH1		2.1700e-01	286141	0.58127	0.61873	0.69509	270378	Aortic_valve_disease_1&Adams-Oliver_syndrome_5&not_provided&Familial_thoracic_aortic_aneurysm_and_aortic_dissection&not_specified		MONDO:MONDO:0024523&MedGen:C3887892&OMIM:109730&MONDO:MONDO:0014459&MedGen:C4014970&OMIM:616028&Orphanet:974&MedGen:C3661900&MONDO:MONDO:0019625&MedGen:C4707243&OMIM:PS607086&Orphanet:91387&MedGen:CN169374		NC_000009.12:g.136497184G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000339458&SCV000519072&SCV000738279&SCV001728841&SCV002026837&SCV002026838&SCV003928454&SCV005323727	single_nucleotide_variant	SO:0001483	ClinGen:CA5339874		NOTCH1:4851	SO:0001819&synonymous_variant										1	2229974																											871					1							247.33	v6.1	Unknown		True	NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:D2185= mutant UNKNOWN.	False	The NOTCH1 ENSP00000498587.1:d2185= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	139391636						True	False	False	Unknown								False	False		NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	The NOTCH1 ENSP00000498587.1:d2185= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:D2185= mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	NOTCH1	4851.0	ENSP00000498587.1:D2185=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH1"",""entrezGeneId"":4851,""alteration"":""ENSP00000498587.1:D2185="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH1 ENSP00000498587.1:d2185= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:D2185= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						0,871	0,425	0,446	0/1	0,0,460,411	CGT	0.00	0.00	0.00			0,0,432,439	64.73		1.0
GRCh38	NOTCH1	D12_12345_1234556_Thyroid_S9	p.Asp1698=	ENSP00000498587.1:p.Asp1698=	chr9	136503255	136503255.0	G	A	A	136503255	.	G	A	.	PASS	NM_017617	A	synonymous_variant	LOW	NOTCH1	ENSG00000148400	Transcript	ENST00000651671	protein_coding	27/34		c.5094C>T	5356	5094	1698	D	gaC/gaT	rs10521&COSV53025038		-1		SNV	HGNC	HGNC:7881	YES	MANE_Select	NM_017617.5			P1	CCDS43905.1	ENSP00000498587	P46531.259		UPI0000210F68			1			Gene3D:3.30.70.3310&PDB-ENSP_mappings:3eto.A&PDB-ENSP_mappings:3eto.B&PDB-ENSP_mappings:3i08.B&PDB-ENSP_mappings:3i08.D&PDB-ENSP_mappings:3l95.X&PDB-ENSP_mappings:3l95.Y&AFDB-ENSP_mappings:AF-P46531-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF07684&PIRSF:PIRSF002279&PANTHER:PTHR45836&SMART:SM01339			0.5535	0.5552	0.5115	0.9018	0.4046	0.3753	0.389	0.5187	0.5711	0.3397	0.8412	0.3918	0.3779	0.3616	0.4139	0.3859	0.4381	0.5159	0.2352	0.4847	0.3308	0.8751	0.3944	0.381	0.3667	0.4241	0.3803	0.9018	EAS	benign	0&1	1&1	23578328&23102684&29383147&27259248&22225590&16729972&36951273						FAIL	-20	32	41	-15	0.00	0.00	0.00	0.00	NOTCH1		2.1700e-01	384696	0.40804	0.44425	0.55351	370210	Adams-Oliver_syndrome_5&not_specified&Familial_thoracic_aortic_aneurysm_and_aortic_dissection&Aortic_valve_disease_1&not_provided		MONDO:MONDO:0014459&MedGen:C4014970&OMIM:616028&Orphanet:974&MedGen:CN169374&MONDO:MONDO:0019625&MedGen:C4707243&OMIM:PS607086&Orphanet:91387&MONDO:MONDO:0024523&MedGen:C3887892&OMIM:109730&MedGen:C3661900		NC_000009.12:g.136503255G>A	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000525650&SCV000738280&SCV001717331&SCV002554335&SCV002554336&SCV003928446&SCV004563052&SCV005323745	single_nucleotide_variant	SO:0001483	ClinGen:CA5340444		NOTCH1:4851	SO:0001819&synonymous_variant										1	10521																											931					1							247.23	v6.1	Unknown		True	NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:D1698= mutant UNKNOWN.	False	The NOTCH1 ENSP00000498587.1:d1698= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	139397707						True	False	False	Unknown								False	False		NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	The NOTCH1 ENSP00000498587.1:d1698= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:D1698= mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	NOTCH1	4851.0	ENSP00000498587.1:D1698=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH1"",""entrezGeneId"":4851,""alteration"":""ENSP00000498587.1:D1698="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH1 ENSP00000498587.1:d1698= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:D1698= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						0,931	0,416	0,515	0/1	0,0,449,482	CGT	0.00	0.00	0.00			0,0,478,453	64.73		1.0
GRCh38	NOTCH1	D12_12345_1234556_Thyroid_S9			chr9	136510809	136510809.0	C	T	T	136510809	.	C	T	.	PASS	NM_017617	T	splice_region_variant&splice_polypyrimidine_tract_variant&intron_variant	LOW	NOTCH1	ENSG00000148400	Transcript	ENST00000651671	protein_coding		16/33	c.2588-4G>A						rs3125001&COSV53031458		-1		SNV	HGNC	HGNC:7881	YES	MANE_Select	NM_017617.5			P1	CCDS43905.1	ENSP00000498587	P46531.259		UPI0000210F68			1						0.5855	0.6952	0.513	0.872	0.4284	0.3548	0.4039	0.6552	0.5781	0.4209	0.8237	0.4613	0.4435	0.3711	0.4395	0.3816	0.4881	0.646	0.273	0.5091	0.4117	0.8554	0.4649	0.4388	0.378	0.4811	0.3742	0.872	EAS	benign	0&1	1&1	21085059&23578328&23102684&16729972&38689001						FAIL	-4	-9	-9	-31	0.00	0.27	0.00	0.00	NOTCH1		2.1700e-01	281108	0.45492		0.58546	265345	Adams-Oliver_syndrome_5&Aortic_valve_disease_1&not_provided&Familial_thoracic_aortic_aneurysm_and_aortic_dissection&not_specified		MONDO:MONDO:0014459&MedGen:C4014970&OMIM:616028&Orphanet:974&MONDO:MONDO:0024523&MedGen:C3887892&OMIM:109730&MedGen:C3661900&MONDO:MONDO:0019625&MedGen:C4707243&OMIM:PS607086&Orphanet:91387&MedGen:CN169374		NC_000009.12:g.136510809C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000331368&SCV000524786&SCV000738274&SCV001728842&SCV002026852&SCV002026853&SCV003928456&SCV005323776	single_nucleotide_variant	SO:0001483	ClinGen:CA5341232		NOTCH1:4851	SO:0001627&intron_variant										1	3125001																											502					1							249.32													chr9	139405261																																																	True	True	False	Unknown		Unknown																						250,252	127,120	123,132	0/1	129,121,134,118	GCG	0.00	0.00	0.00			88,162,90,162	45.87		0.50199203187251
GRCh38	NOTCH1	D12_12345_1234556_Thyroid_S9	p.Asn755=	ENSP00000498587.1:p.Asn755=	chr9	136513480	136513480.0	A	G	G	136513480	.	A	G	.	PASS	NM_017617	G	synonymous_variant	LOW	NOTCH1	ENSG00000148400	Transcript	ENST00000651671	protein_coding	14/34		c.2265T>C	2527	2265	755	N	aaT/aaC	rs2229971&COSV53032670&COSV53109899		-1		SNV	HGNC	HGNC:7881	YES	MANE_Select	NM_017617.5			P1	CCDS43905.1	ENSP00000498587	P46531.259		UPI0000210F68			1			Gene3D:2.10.25.10&AFDB-ENSP_mappings:AF-P46531-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF002279&PROSITE_profiles:PS50026&SMART:SM00179&Superfamily:SSF57184&Superfamily:SSF57196&CDD:cd00054			0.5278	0.6997	0.4784	0.7768	0.335	0.272	0.3243	0.6319	0.549	0.2312	0.7652	0.4253	0.2439	0.2895	0.3451	0.2908	0.4267	0.6243	0.2429	0.4613	0.2292	0.7805	0.4328	0.2993	0.2948	0.3794	0.2864	0.7805	gnomADg_EAS	benign	0&1&1	1&1&1	30328613&23578328&23102684&29383147&36951273&39048597						FAIL	-4	-44	-19	-2	0.00	0.00	0.00	0.00	NOTCH1		2.1700e-01	384703	0.39746	0.39770	0.52776	370782	Familial_thoracic_aortic_aneurysm_and_aortic_dissection&not_provided&Adams-Oliver_syndrome_5&Aortic_valve_disease_1&not_specified		MONDO:MONDO:0019625&MedGen:C4707243&OMIM:PS607086&Orphanet:91387&MedGen:C3661900&MONDO:MONDO:0014459&MedGen:C4014970&OMIM:616028&Orphanet:974&MONDO:MONDO:0024523&MedGen:C3887892&OMIM:109730&MedGen:CN169374		NC_000009.12:g.136513480A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000525662&SCV000738284&SCV001717332&SCV002554969&SCV002554970&SCV003928453&SCV005323782	single_nucleotide_variant	SO:0001483	ClinGen:CA5341428		NOTCH1:4851	SO:0001819&synonymous_variant										1	2229971																											822					0.996							246.9	v6.1	Unknown		True	NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:N755= mutant UNKNOWN.	False	The NOTCH1 ENSP00000498587.1:n755= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	139407932						True	False	False	Unknown								False	False		NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	The NOTCH1 ENSP00000498587.1:n755= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:N755= mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	NOTCH1	4851.0	ENSP00000498587.1:N755=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH1"",""entrezGeneId"":4851,""alteration"":""ENSP00000498587.1:N755="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH1 ENSP00000498587.1:n755= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:N755= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						411,408	207,187	204,221	0/1	191,220,202,206	CAT	.	.	.			225,186,193,215	50.7		0.4981684981684982
GRCh38	NOTCH1	D12_12345_1234556_Thyroid_S9	p.Pro284=	ENSP00000498587.1:p.Pro284=	chr9	136519456	136519456.0	C	T	T	136519456	.	C	T	.	PASS	NM_017617	T	synonymous_variant	LOW	NOTCH1	ENSG00000148400	Transcript	ENST00000651671	protein_coding	5/34		c.852G>A	1114	852	284	P	ccG/ccA	rs2229975&COSV53027901		-1		SNV	HGNC	HGNC:7881	YES	MANE_Select	NM_017617.5			P1	CCDS43905.1	ENSP00000498587	P46531.259		UPI0000210F68			1			Gene3D:2.10.25.10&PDB-ENSP_mappings:5fm9.A&PDB-ENSP_mappings:5fma.A&PDB-ENSP_mappings:5fma.B&AFDB-ENSP_mappings:AF-P46531-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&Pfam:PF00008&PIRSF:PIRSF002279&PROSITE_patterns:PS00022&PROSITE_profiles:PS50026&SMART:SM00179&SMART:SM00181&Superfamily:SSF57196&CDD:cd00054			0.1222	0.087	0.0793	0.0962	0.1163	0.2331	0.1382	0.1078	0.08828	0.212	0.05736	0.1015	0.17	0.1351	0.1387	0.2508	0.1266	0.106	0.1623	0.1119	0.2177	0.06741	0.09593	0.1463	0.1371	0.1309	0.2592	0.2592	gnomADg_SAS	benign	0&1	1&1	23578328&23102684&35288444						FAIL	-5	-13	-17	-13	0.00	0.00	0.00	0.00	NOTCH1		2.1700e-01	384692	0.12514	0.13700	0.12220	370282	Familial_thoracic_aortic_aneurysm_and_aortic_dissection&not_provided&Adams-Oliver_syndrome_5&Aortic_valve_disease_1&not_specified		MONDO:MONDO:0019625&MedGen:C4707243&OMIM:PS607086&Orphanet:91387&MedGen:C3661900&MONDO:MONDO:0014459&MedGen:C4014970&OMIM:616028&Orphanet:974&MONDO:MONDO:0024523&MedGen:C3887892&OMIM:109730&MedGen:CN169374		NC_000009.12:g.136519456C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000525643&SCV000738277&SCV001728845&SCV002555108&SCV002555110&SCV003928442&SCV005323801	single_nucleotide_variant	SO:0001483	ClinGen:CA5342024		NOTCH1:4851	SO:0001819&synonymous_variant										1	2229975																											660					1							248.66	v6.1	Unknown		True	NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:P284= mutant UNKNOWN.	False	The NOTCH1 ENSP00000498587.1:p284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	139413908						True	False	False	Unknown								False	False		NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	The NOTCH1 ENSP00000498587.1:p284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:P284= mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	NOTCH1	4851.0	ENSP00000498587.1:P284=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH1"",""entrezGeneId"":4851,""alteration"":""ENSP00000498587.1:P284="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH1 ENSP00000498587.1:p284= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:P284= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						342,318	186,182	156,136	0/1	174,168,154,164	GCG	0.00	0.00	0.00			210,132,190,128	38.14		0.4818181818181818
GRCh38	NOTCH1	D12_12345_1234556_Thyroid_S9	p.Asn104=	ENSP00000498587.1:p.Asn104=	chr9	136523808	136523808.0	A	G	G	136523808	.	A	G	.	PASS	NM_017617	G	synonymous_variant	LOW	NOTCH1	ENSG00000148400	Transcript	ENST00000651671	protein_coding	3/34		c.312T>C	574	312	104	N	aaT/aaC	rs4489420&COSV53027593		-1		SNV	HGNC	HGNC:7881	YES	MANE_Select	NM_017617.5			P1	CCDS43905.1	ENSP00000498587	P46531.259		UPI0000210F68			1			Gene3D:2.10.25.10&AFDB-ENSP_mappings:AF-P46531-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PIRSF:PIRSF002279&PROSITE_profiles:PS50026&SMART:SM00179&Superfamily:SSF57196&CDD:cd00054			0.7400	0.9523	0.6037	0.8363	0.505	0.6922	0.5112	0.8967	0.6583	0.5112	0.8457	0.5895	0.5131	0.4659	0.5437	0.646	0.6267	0.8826	0.4561	0.595	0.5124	0.8404	0.5992	0.5034	0.473	0.5697	0.6654	0.9523	AFR	benign	0&1	1&1	29434720&28568708&23578328&23102684&29383147&16729972&36951273						FAIL	48	-36	-7	47	0.00	0.00	0.00	0.00	NOTCH1		2.1700e-01	286142	0.60867	0.59705	0.74002	270379	Aortic_valve_disease_1&Adams-Oliver_syndrome_5&Familial_thoracic_aortic_aneurysm_and_aortic_dissection&not_provided&not_specified		MONDO:MONDO:0024523&MedGen:C3887892&OMIM:109730&MONDO:MONDO:0014459&MedGen:C4014970&OMIM:616028&Orphanet:974&MONDO:MONDO:0019625&MedGen:C4707243&OMIM:PS607086&Orphanet:91387&MedGen:C3661900&MedGen:CN169374		NC_000009.12:g.136523808A>G	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000339459&SCV000518321&SCV000738282&SCV001728846&SCV002026868&SCV002026869&SCV003928445&SCV005323804	single_nucleotide_variant	SO:0001483	ClinGen:CA5342208		NOTCH1:4851	SO:0001819&synonymous_variant										1	4489420																											825					0.999							246.64	v6.1	Unknown		True	NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	False	04/13/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:N104= mutant UNKNOWN.	False	The NOTCH1 ENSP00000498587.1:n104= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	139418260						True	False	False	Unknown								False	False		NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.	The NOTCH1 ENSP00000498587.1:n104= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:N104= mutant UNKNOWN.						v6.1	04/13/2017		GRCh38	NOTCH1	4851.0	ENSP00000498587.1:N104=			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""NOTCH1"",""entrezGeneId"":4851,""alteration"":""ENSP00000498587.1:N104="",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor."",""variantSummary"":""The NOTCH1 ENSP00000498587.1:n104= mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 ENSP00000498587.1:N104= mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""04/13/2017""}"	True	True	False	Unknown		Unknown																						1,823	1,368	0,455	0/1	1,0,403,420	CAT	.	.	.			1,0,408,415	64.73		0.9987864077669902
GRCh38	EGFL7	D12_12345_1234556_Thyroid_S9	p.V153I	ENSP00000307843.7:p.Val153Ile	chr9	136670216	136670216.0	G	A	A	136670216	.	G	A	.	PASS	NM_016215	A	missense_variant	MODERATE	EGFL7	ENSG00000172889	Transcript	ENST00000308874	protein_coding	8/11		c.457G>A	1002	457	153	V/I	Gtc/Atc	rs2297538&COSV58247698		1		SNV	HGNC	HGNC:20594	YES	MANE_Select	NM_016215.5		1	P1	CCDS7002.1	ENSP00000307843	Q9UHF1.181		UPI0000036A42				tolerated(0.44)	benign(0.007)	Phobius:NON_CYTOPLASMIC_DOMAIN&PANTHER:PTHR14949&PROSITE_patterns:PS01187&Superfamily:SSF57196&Superfamily:SSF57184&Pfam:PF14670&Gene3D:2.10.25.10&SMART:SM00179&SMART:SM00181&AFDB-ENSP_mappings:AF-Q9UHF1-F1			0.1683	0.2073	0.1945	0.1349	0.2087	0.09	0.1934	0.22	0.2021	0.2372	0.1013	0.1558	0.2286	0.2028	0.2018	0.1009	0.1997	0.216	0.193	0.2136	0.245	0.1149	0.1469	0.2551	0.2049	0.2476	0.09503	0.2551	gnomADg_MID		0&1	0&1	34488676&31911328&35494025&35087281&35923305						FAIL	-31	-6	22	15	0.00	0.00	0.01	0.00	EGFL7	0.010	1.7970e+00																																																											797					0.997							247.31	v6.1	Unknown		True	EGFL7, a secreted pro-angiogenic factor, is infrequently mutated in various cancer types.	False	07/31/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFL7 ENSP00000307843.7:V153I mutant UNKNOWN.	False	The EGFL7 ENSP00000307843.7:v153i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr9	139564668						True	False	False	Unknown								False	False		EGFL7, a secreted pro-angiogenic factor, is infrequently mutated in various cancer types.	The EGFL7 ENSP00000307843.7:v153i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFL7 ENSP00000307843.7:V153I mutant UNKNOWN.						v6.1	07/31/2019		GRCh38	EGFL7	51162.0	ENSP00000307843.7:V153I			UNKNOWN							Unknown				"{""query"":{""id"":null,""referenceGenome"":""GRCh38"",""hugoSymbol"":""EGFL7"",""entrezGeneId"":51162,""alteration"":""ENSP00000307843.7:V153I"",""alterationType"":null,""svType"":null,""tumorType"":""UNKNOWN"",""consequence"":null,""proteinStart"":null,""proteinEnd"":null,""hgvs"":null,""hgvsInfo"":null,""canonicalTranscript"":null},""geneExist"":true,""variantExist"":false,""alleleExist"":false,""oncogenic"":""Unknown"",""mutationEffect"":{""knownEffect"":""Unknown"",""description"":"""",""citations"":{""pmids"":[],""abstracts"":[]}},""highestSensitiveLevel"":null,""highestResistanceLevel"":null,""highestDiagnosticImplicationLevel"":null,""highestPrognosticImplicationLevel"":null,""highestFdaLevel"":null,""otherSignificantSensitiveLevels"":[],""otherSignificantResistanceLevels"":[],""VUS"":false,""hotspot"":false,""exon"":null,""geneSummary"":""EGFL7, a secreted pro-angiogenic factor, is infrequently mutated in various cancer types."",""variantSummary"":""The EGFL7 ENSP00000307843.7:v153i mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown."",""tumorTypeSummary"":""There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFL7 ENSP00000307843.7:V153I mutant UNKNOWN."",""prognosticSummary"":"""",""diagnosticSummary"":"""",""diagnosticImplications"":[],""prognosticImplications"":[],""treatments"":[],""dataVersion"":""v6.1"",""lastUpdate"":""07/31/2019""}"	True	True	False	Unknown		Unknown																						391,404	185,193	206,211	0/1	216,175,193,211	CGT	0.00	0.00	0.00			204,187,218,186	56.46		0.5081761006289308
GRCh38	MT-RNR1	D12_12345_1234556_Thyroid_S9			chrM	4132		G	<INS>	<INS>	4132	MantaINS:1151:0:0:0:9:0	G	<INS>	.	PASS		insertion	downstream_gene_variant	MODIFIER	MT-RNR1	ENSG00000211459	Transcript	ENST00000389680	Mt_rRNA										2532	1		insertion	HGNC	HGNC:7470	YES													1																																																																																																															0,113		0,113							113	CATACCCCCGATTCCGCTACGACCAACTCATACACCTCCTATGAAAAAACTTCCTACCACTCACCCTAGCATTACTTATATGATATGTCTCCATACCCATTACAATCTCCAGC		CATACCCCCGATTCCGCTACGACCAACTCATACACCTCCTATGAAAAAACTTCCTACCACTCACCCTAGCATTACTTATATGATATGTCTCCATACCCATTACAATCTCCAGCCTGGGCGACAGAGCAAGACTCCA																chrM	4133	AACTGTATAAATCTTTACA			INS																																													True	False	False	Unknown		Unknown																															0,0				0,5	
GRCh38	AR	D12_12345_1234556_Thyroid_S9			chrX	67689329	67689329.0	C	G	G	67689329	.	C	G	.	PASS	NM_000044	G	intron_variant	MODIFIER	AR	ENSG00000169083	Transcript	ENST00000374690	protein_coding		3/7	c.1885+3203C>G						rs5919409		1		SNV	HGNC	HGNC:644	YES	MANE_Select	NM_000044.6		1	P1	CCDS14387.1	ENSP00000363822	P10275.302		UPI0000167B08	P10275-1		1						0.8832	0.675	0.9447	0.9974	0.9426	0.9443											0.8663	0.6938	0.9	0.9477	0.9503	0.9988	0.9348	0.9116	0.9235	0.906	0.9406	0.9988	gnomADg_EAS										FAIL	7	3	-34	-20	0.00	0.00	0.00	0.00	AR																																																													46					1							243.21													chrX	66909171																																																	True	True	False	Unknown		Unknown																						0,46	0,23	0,23	0/1	0,0,18,28	TCA	.	.	.			0,0,23,23	63.91		1.0
GRCh38	HDAC8	D12_12345_1234556_Thyroid_S9			chrX	72327360		T	T[chr13:81251699[	T[chr13:81251699[	72327360	MantaBND:2462:0:1:0:0:0:1	T	T[chr13:81251699[	.	PASS		T.	downstream_gene_variant	MODIFIER	HDAC8	ENSG00000147099	Transcript	ENST00000650604	protein_coding										2207	-1		chromosome_breakpoint	HGNC	HGNC:13315								ENSP00000497105		A0A3B3IS37.29	UPI000E6EEF5C			1																																																																																																														0			0,9							9	TGATTTTCT			MantaBND:2462:0:1:0:0:0:0	2														chrX	71547210				BND																																													True	False	False	Unknown		Unknown																															0,2				0,2	
